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Message from Kathleen Sebelius
Secretary of Health and Human Services
 Tobacco use imposes enormous public health and financial costs on this nation —costs that 
are completely avoidable. Until we end tobacco use, more people will become addicted, more people will 
become sick, more families will be devastated by the loss of loved ones, and the nation will continue 
to incur damaging medical and lost productivity costs. Now is the time to fully implement proven and 
effective interventions that reduce tobacco-caused death and disease and to help end this public health 
epidemic once and for all.
 Cigarettes are responsible for approximately 443,000 deaths—one in every five deaths—each year 
in the United States. The chronic diseases caused by tobacco use lead the causes of death and disability 
in the United States and unnecessarily strain our health care system. The economic burden of cigarette 
use includes more than $193 billion annually in health care costs and loss of productivity.
 We can prevent the staggering toll that tobacco takes on individuals, families, and communities. 
This new Surgeon General’s report focuses on cigarettes and cigarette smoke to provide further 
evidence on how cigarettes cause addiction and premature death. It identifies better approaches to 
helping people stop smoking and brings to light new ideas for how to lower the incidence of smoking-
caused disease.
 Twenty years of successful state efforts show that the more states invest in tobacco control 
programs, the greater the reductions in smoking, and the longer states maintain such programs, the 
greater and faster the impact. The largest impacts come when we increase tobacco prices, ban smoking 
in public places, offer affordable and accessible cessation treatments and services, and combine media 
campaigns with other initiatives. We have outlined a level of state investment in comprehensive 
tobacco control and prevention efforts that, if implemented, would result in an estimated five million 
fewer smokers over the next five years. Hundreds of thousands of premature deaths caused by tobacco 
use could be prevented, and many fewer of the nations’ children would be deprived by premature 
death of their aunts, uncles, parents, and grandparents. Importantly, in 2009 the U.S. Food and Drug 
Administration received statutory authority to regulate tobacco products. This has the potential to lead 
to even greater progress in reducing morbidity and mortality from tobacco use.
 Tobacco prevention and control efforts need to be commensurate with the harm caused by tobacco 
use. Otherwise, tobacco use will remain the largest cause of preventable illness and death in our nation 
for decades to come. When we help Americans quit tobacco use and prevent our youth from ever 
starting, we all benefit. Now is the time for comprehensive public health and regulatory approaches to 
tobacco control. We have the knowledge and tools to largely eliminate tobacco caused disease. If we 





In 1964, the first Surgeon General’s report on the effects of smoking on health was released.  In 
the nearly 50 years since, extensive data from thousands of studies have consistently substantiated the 
devastating effects of smoking on the lives of millions of Americans. Yet today in the United States, 
tobacco use remains the single largest preventable cause of death and disease for both men and women. 
Now, this 2010 report of the Surgeon General explains beyond a shadow of a doubt how tobacco smoke 
causes disease, validates earlier findings, and expands and strengthens the science base. Armed with 
this irrefutable data, the time has come to mount a full-scale assault on the tobacco epidemic. 
More than 1,000 people are killed every day by cigarettes, and one-half of all long-term smokers 
are killed by smoking-related diseases. A large proportion of these deaths are from early heart attacks, 
chronic lung diseases, and cancers. For every person who dies from tobacco use, another 20 Americans 
continue to suffer with at least one serious tobacco-related illness. But the harmful effects of smok-
ing do not end with the smoker. Every year, thousands of nonsmokers die from heart disease and lung 
cancer, and hundreds of thousands of children suffer from respiratory infections because of exposure 
to secondhand smoke. There is no risk-free level of exposure to tobacco smoke, and there is no safe 
tobacco product. 
This new Surgeon General’s report describes in detail the ways tobacco smoke damages every 
organ in the body and causes disease and death. We must build on our successes and more effectively 
educate people about the health risks of tobacco use, prevent youth from ever using tobacco products, 
expand access to proven cessation treatments and services, and reduce exposure to secondhand smoke. 
Putting laws and other restrictions in place, including making tobacco products progressively less 
affordable, will ultimately lead to our goal of a healthier America by reducing the devastating effects 
of smoking. 
The Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration 
(FDA), and other federal agencies are diligently working toward this goal by implementing and sup-
porting policies and regulations that strengthen our resolve to end the tobacco epidemic. CDC has 
incorporated the World Health Organization’s MPOWER approach into its actions at the local, state, 
and national levels. MPOWER consists of six key interventions proven to reduce tobacco use that can 
prevent millions of deaths. CDC, along with federal, state, and local partners, is committed to monitor-
ing the tobacco epidemic and prevention policies; protecting people from secondhand smoke where 
they live, work, and play; offering quit assistance to current smokers; warning about the dangers of 
tobacco; enforcing comprehensive restrictions on tobacco advertising, promotion, and sponsorship; 
and raising taxes and prices on tobacco products.
In 2009, the Family Smoking Prevention and Tobacco Control Act was enacted, giving FDA 
explicit regulatory authority over tobacco products to protect and promote the health of the American 
public. Among other things, this historic legislation gave the agency the authority to require compa-
nies to reveal all of the ingredients in tobacco products—including the amount of nicotine—and to 
prohibit the sale of tobacco products labeled as “light,” “mild,” or “low.” Further, with this new regula-
tory mandate, FDA will regulate tobacco advertising and require manufacturers to use more effective 
warning labels, as well as restrict the access of young people to their products. FDA will also assess and 
regulate modified risk products, taking into account the impact their availability and marketing has on 
initiation and cessation of tobacco use.
Reducing the tremendous toll of disease, disability, and death caused by tobacco use in the United 
States is an urgent need and a shared responsibility. All public health agencies need to partner together 
to develop common strategies to combat the dangers of smoking and tobacco use and defeat this 
epidemic for good.
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This 2010 Surgeon General’s report represents another important step in the developing recogni-
tion, both in this nation and around the world, that tobacco use is devastating to public health. Past 
investments in research and in comprehensive tobacco control programs—combined with the findings 
presented by this new report—provide the foundation, evidence, and impetus to increase the urgency 
of our actions to end the epidemic of tobacco use.
Thomas R. Frieden, M.D., M.P.H.             
  
  
        
        
Margaret A. Hamburg, M.D.
Commissioner of Food and Drugs
U.S. Food and Drug Administration
Director      
Centers for Disease Control and Prevention  
and 
Administrator 
Agency for Toxic Substances and Disease Registry
iii
Preface
from the Surgeon General,
United States Public Health Service
In 1964, the Surgeon General released a landmark report on the dangers of smoking. During the 
intervening 45 years, 29 Surgeon General’s reports have documented the overwhelming and conclusive 
biologic, epidemiologic, behavioral, and pharmacologic evidence that tobacco use is deadly. Our newest 
report, How Tobacco Smoke Causes Disease, is a comprehensive, scientific discussion of how main-
stream and secondhand smoke exposures damage the human body. Decades of research have enabled 
scientists to identify the specific mechanisms of smoking-related diseases and to characterize them in 
great detail. Those biologic processes of cigarette smoke and disease are the focus of this report. 
One-third of people who have ever tried smoking become daily smokers. This report investi-
gates how and why smokers become addicted and documents how nicotine compares with heroin and 
cocaine in its hold on users and its effects on the brain. The way tobacco is grown, mixed, and processed 
today has made cigarettes more addictive than ever before. Because of this, the majority of smokers who 
try to quit on their own typically require many attempts. It is imperative that we use this information to 
prevent initiation, make tobacco products less addictive, and provide access to treatments and services 
to help smokers quit successfully. 
This new report also substantiates the evidence that there is no safe level of exposure to cigarette 
smoke. When individuals inhale cigarette smoke, either directly or secondhand, they are inhaling more 
than 7,000 chemicals: hundreds of these are hazardous, and at least 69 are known to cause cancer. The 
chemicals are rapidly absorbed by cells in the body and produce disease-causing cellular changes. This 
report explains those changes and identifies the mechanisms by which the major classes of the chemi-
cals in cigarette smoke contribute to specific disease processes. In addition, the report discusses how 
chemicals in cigarette smoke impair the immune system and cause the kind of cellular damage that 
leads to cancer and other diseases. Insight is provided as to why smokers are far more likely to suffer 
from chronic disease than are nonsmokers.
By learning how tobacco smoke causes disease, we learn more about how chemicals harm cells, 
how genes may make us susceptible, and how tobacco users become addicted to nicotine. The answers 
to these questions will help us to more effectively prevent tobacco addiction and treat tobacco-caused 
disease. Understanding the complexity of genetic, biochemical, and other influences discussed in this 
report offers the promise of reducing the disease burden from tobacco use through earlier detection 
and better treatment; however, even with all of the science presented here, it currently remains true 
that the only proven strategies to reduce the risks of tobacco-caused disease are preventing initiation, 
facilitating cessation, and eliminating exposure to secondhand smoke. 
My priority as Surgeon General is the health of the American people. Although we have made great 
strides in tobacco control, more than 440,000 deaths each year are caused by smoking and exposure to 
secondhand smoke. The cost to the nation is tremendous: a staggering amount is spent on medical care 
and lost productivity.  But most importantly there is  immeasurable cost in human suffering and loss. 
In 1964, Surgeon General Luther Terry called for “appropriate remedial actions” to address the 
adverse effects of smoking. With this report, the devastating effects of smoking have been character-
ized in great detail and the need for appropriate remedial action is even more apparent. The harmful 
effects of tobacco smoke do not end with the users of tobacco. There is no safe level of exposure to 
tobacco smoke. Every inhalation of tobacco smoke exposes our children, our families, and our loved 
ones to dangerous chemicals that can damage their bodies and result in life-threatening diseases such 
as cancer and heart disease. And, although not a focus of this report, we know that smokeless tobacco 
causes cancer and has other adverse health effects. The science is now clear that “appropriate remedial 
actions” include protecting everyone in the country from having to breathe secondhand smoke; mak-
ing all tobacco products progressively less affordable; expanding access to proven cessation treatments 
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and services; taking actions at the federal, state, and local levels to counteract the influence of tobacco 
advertising, promotions, and sponsorship; and ensuring that all adults and children clearly understand 
that the result of tobacco use is addiction, suffering, reduced quality of life, and all too often, early 
death. Forty-five years after Surgeon General Terry called on this nation to act, I say, if not now, when? 
The health of our nation depends on it. 
      Regina Benjamin, M.D., M.B.A.
      Surgeon General
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Introduction
Since the first of the series in 1964, reports of the 
Surgeon General have provided definitive syntheses of the 
evidence on smoking and health. The topics have ranged 
widely, including comprehensive coverage of the health 
effects of active and passive smoking (U.S. Department 
of Health, Education, and Welfare [USDHEW] 1979; U.S. 
Department of Health and Human Services [USDHHS] 
1986, 2004, 2006), the impact of tobacco control policies 
(USDHHS 2000), and addiction (USDHHS 1988). A goal of 
these reports has been to synthesize available evidence for 
reaching conclusions on causality that have public health 
implications. In reaching conclusions on causation, the 
reports have followed a model that originated with the 
1964 report: compilation of all relevant lines of scientific 
evidence, critical assessment of the evidence, evaluation 
of the strength of evidence by using guidelines for evi-
dence evaluation, and a summary conclusion on causation 
(USDHEW 1964; USDHHS 2004). The 2004 Surgeon Gen-
eral’s report provides a review of this approach and gives 
a set of ordered categories for classifying the strength of 
evidence for causality that was used in the 2004 and 2006 
reports on active and involuntary smoking, respectively 
(Table 1.1). The Surgeon General’s reports have established 
a long list of health consequences and diseases caused by 
tobacco use and exposure to tobacco smoke (Figure 1.1).
This report considers the biologic and behavioral 
mechanisms that may underlie the pathogenicity of 
tobacco smoke. Many Surgeon General’s reports have 
considered research findings on mechanisms in assessing 
the biologic plausibility of associations observed in epi-
demiologic studies. Mechanisms of disease are important 
because they may provide plausibility, which is one of the 
guideline criteria for assessing evidence on causation. The 
1964 report, for example, gave extensive consideration to 
the presence of carcinogens in tobacco smoke and the find-
ings of animal models (USDHEW 1964). This new report, 
however, specifically reviews the evidence on the poten-
tial mechanisms by which smoking causes diseases and 
considers whether a mechanism is likely to be operative 
in the production of human disease by tobacco smoke. 
This evidence is important to understand how smoking 
causes disease, to identify those who may be particularly 
susceptible, and to assess the potential risks of tobacco 
products. In addition, this evidence is relevant to achiev-
ing the tobacco-related goals and objectives in the Healthy 
People initiative—the nation’s disease prevention and 
health promotion agenda—and to developing the inter-
ventions for our nation’s tobacco cessation targets for the 
year 2020 (USDHHS 2009).
In the planning of this report, the diseases and other 
adverse outcomes causally linked to smoking served to 
define the scope of issues considered in each of the chap-
ters. Because sufficient biologic plausibility had been 
established in prior reports for all causal conclusions, the 
evidence on biologic and behavioral mechanisms reviewed 
in this report complements and supports the causal con-
clusions established earlier. The report is not focused on 
whether the evidence supports the plausibility of a causal 
association of smoking with a particular disease. In fact, 
most of the diseases and other adverse outcomes con-
sidered in this report have long been causally linked to 
smoking. This report focuses on the health consequences 
caused by exposure to tobacco smoke and does not 
review the evidence on the mechanisms of how smokeless 
tobacco causes disease.
The determination of whether a particular mecha-
nism figures in the causation of disease by tobacco smoke 
has potential implications for prevention, diagnosis, and 
treatment. A general schema for the causation of disease 
by tobacco smoke is provided in Figure 1.2. The assump-
tion is that disease may be a consequence of one or more 
pathways, each possibly having one or more component 
mechanisms. The figure shows multiple pathways, each 
comprised potentially of multiple mechanisms. Moreover, 
the same mechanism might figure into several different 
pathways. For example, mutations of genes are likely to 
Table 1.1 Four-level hierarchy for classifying the strength of causal inferences from available evidence
Level 1 Evidence is sufficient to infer a causal relationship
Level 2 Evidence is suggestive but not sufficient to infer a causal relationship
Level 3 Evidence is inadequate to infer the presence or absence of a causal relationship (which encompasses 
evidence that is sparse, of poor quality, or conflicting)
Level 4 Evidence is suggestive of no causal relationship
Source: U.S. Department of Health and Human Services 2004, 2006.
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figure into several different pathways for the causation of 
cancer. As a complex mixture with many different toxic 
components, tobacco smoke is likely to act through mul-
tiple pathways in causing disease, and multiple genes may 
be involved. Genes may modulate the activity of these 
pathways, and there may also be connections between the 
pathways. Other environmental factors may act through 
the same pathways as tobacco smoke or through differ-
ent pathways and, thereby, augment the contribution of 
smoking to disease incidence. For example, the combined 
effects of smoking and radon may contribute to causing 
lung cancer (National Research Council 1998). 
Pathways and mechanisms by which active and pas-
sive smoking contribute to causation of cardiovascular 
disease are illustrated in Figure 1.3 (Ambrose and Barua 
2004). This depiction of cigarette components in the “tar 
phase” and “gas phase” shows their action through several 
interacting pathways, indicating a role for genetic as well 
as other factors.
The characterization of mechanisms by which 
smoking causes disease could lead to applications of this 
knowledge to public health by (1) assessing tobacco prod-
ucts for their potential to cause injury through a partic-
ular mechanism, (2) developing biomarkers of injury to 
identify smokers at early stages of disease development, 
(3) identifying persons at risk on a genetic basis through 
the operation of a particular mechanism, (4) providing 
a basis for preventive therapies that block or reverse the 
underlying process of injury, and (5) identifying the con-
tribution of smoking to causation of diseases with mul-
tiple etiologic factors. Consequently, research continues 
on the mechanisms by which smoking causes disease, 
even though the evidence has long been sufficient to 
infer that active smoking and exposure to secondhand 
smoke cause numerous diseases (USDHHS 2004, 2006). 
In addition, the resulting understanding of mechanisms 
is likely to prove applicable to diseases caused not only by 
Figure 1.1 The health consequences causally linked to smoking and exposure to secondhand smoke
Source: USDHHS 2004, 2006.
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Figure 1.2 General schema for the causation of 
disease by tobacco smoke
Note: M = disease mechanisms; P = disease pathways.
smoking but by other agents that may act through some 
of the same mechanisms. 
This report is written at a time when new research 
methods have facilitated exploration of the mechanisms 
by which smoking causes disease at a depth not previ-
ously possible. With the powerful methods of molecular 
and cellular research, disease pathogenesis can now be 
studied at the molecular level, and animal models can be 
developed to explore specific pathways of injury. Conse-
quently, the range of evidence considered in this report is 
broad, coming from clinical studies, animal models, and 
in vitro systems. The coverage extends from research at 
the molecular level to population-level biomarker studies. 
Evaluation of Evidence on 
Mechanisms of Disease Production
Approaches for evaluation and synthesis of evidence 
on mechanisms have not been previously proposed in 
Surgeon General’s reports, although substantial emphasis 
has been placed on biologic mechanisms. The 1964 report 
indicated that three lines of evidence would be reviewed: 
animal experiments, clinical and autopsy studies, and 
population studies. It further commented on the essential 
nature of all three lines of evidence in reaching conclu-
sions on causality. That report and subsequent reports of 
the Surgeon General, however, have given only general 
guidance on assessing biologic plausibility (USDHEW 
1964; USDHHS 2004). The 1964 report used the term 
“coherence of the association” as one of the criteria for 
causality (Table 1.2). In addressing lung cancer, the report 
stated: “A final criterion for the appraisal of causal sig-
nificance of an association is its coherence with known 
facts in the natural history and biology of the disease” 
(USDHEW 1964, p. 185).
The 1982 report of the Surgeon General noted:
Coherence is clearly established when the actual 
mechanism of disease production is defined. 
Coherence exists, nonetheless, although of a 
lesser magnitude, when there is enough evidence 
to support a plausible mechanism, but not a 
detailed understanding of each step in the chain 
of events by which a given etiologic agent pro-
duces disease (USDHHS 1982, p. 20).
The 2004 report discussed coherence, plausibility, 
and analogy together, commenting:
Although the original definitions of these criteria 
were subtly different, in practice they have been 
treated essentially as one idea: that a proposed 
causal relationship not violate known scientific 
principles, and that it be consistent with experi-
mentally demonstrated biologic mechanisms and 
other relevant data, such as ecologic patterns of 
disease…. In addition, if biologic understanding 
can be used to set aside explanations other than 
a causal association, it offers further support for 
causality. Together, these criteria can serve both 
to support a causal claim (by supporting the pro-
posed mechanism) or refute it (by showing that 
the proposed mechanism is unlikely) (USDHHS 
2004, p. 22).
Hill (1965) listed both plausibility and coherence 
among his nine criteria but did not offer a sharp distinction 
between the two. He commented on the linkage of the 
concept of plausibility to the contemporary state of knowl-
edge, and his views of coherence were largely consistent 
with statements in the 1964 Surgeon General’s report. 
Current evidence on mechanisms of disease causa-
tion raises issues that could not have been anticipated at 
the time of the 1964 report. With advances in laboratory 
research over the last several decades, researchers are 
challenged to interpret molecular and cellular evidence on 
mechanisms and causation. The need for new approaches 
to interpret such evidence has been recognized in several 
research areas including infectious diseases and cancer. 
Approaches have been proposed by agencies and research-
ers that assess carcinogens.
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Figure 1.3 Potential pathways and mechanisms for cardiovascular dysfunction mediated by cigarette smoking 
Source: Ambrose and Barua 2004. Reprinted with permission from Elsevier, © 2004.
Note: The bold boxes and arrows in the flow diagram represent the probable central mechanisms in the complex pathophysiology 
of atherothrombotic disease mediated by cigarette smoking. H2O2 = hydrogen peroxide; METC = mitochondrial electron transport 
chain; NADPH = reduced nicotinamide adenine dinucleotide phosphate; NO = nitric oxide; NOS = nitric oxide synthase; 
O 2  = superoxide anion; ONOO  = peroxynitrite.. - -
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In infectious disease research, the arrival of molec-
ular techniques for studying microbes led to a recogni-
tion that extensions of Koch’s postulates were needed 
to accommodate this new type of information (Falkow 
1988; Fredericks and Relman 1996). Falkow (1988) pro-
posed “molecular Koch’s postulates” for considering the 
role of specific microbial genes in pathogenicity. Freder-
icks and Relman (1996) listed seven criteria for evaluat-
ing whether a disease could be attributed to a putatively 
identified pathogen, found by sequence-based methods. 
They emphasized that “coherence and plausibility are 
important” (p. 30). Pagano and colleagues (2004) also 
acknowledged the complexities of causally linking cancer 
to infectious agents. 
Research has broadened and increased the literature 
on mechanisms of carcinogenesis and has contributed to 
a similar rationale for developing approaches to review 
information on mechanisms. Approaches have been 
proposed by the International Agency for Research on 
Cancer (IARC) and the U.S. Environmental Protection 
Agency (EPA). 
In the preamble to its monographs on carcinoge-
nicity, IARC describes its approach for characterizing 
the strength of evidence regarding mechanisms relevant 
to the agent being evaluated (IARC 2006). For animal 
experiments, IARC offers a four-level classification of the 
strength of evidence, which parallels the categories of 
the 2004 Surgeon General’s report: sufficient evidence 
of carcinogenicity, limited evidence of carcinogenicity, 
inadequate evidence of carcinogenicity, and evidence 
suggesting lack of carcinogenicity. The strength of evi-
dence on mechanisms is described with terms such as 
“weak,” “moderate,” or “strong.” The IARC working group 
preparing the monographs is also charged with assessing 
whether the mechanism is operative in humans. Guid-
ance is given for evaluating the role of a mechanism in 
experimental animals. Emphasis is placed on consistency 
across experimental systems and on biologic plausibility 
and coherence. 
EPA covers the identification of a “mode of action” 
in its Guidelines for Carcinogen Risk Assessment (USEPA 
2005). Mode of action refers to the process by which an 
agent causes disease but at a less detailed and specific 
level than is intended by mechanism of action. In these 
guidelines, EPA modified the Hill (1965) criteria, offer-
ing its framework for evaluating evidence on mode of 
action. The steps for evaluating a hypothesized mode of 
action include (1) description of the hypothesized mode of 
action, (2) discussion of the experimental support for this 
mode of action, (3) consideration of the possibility of other 
modes of action, and (4) conclusions about the hypoth-
esized mode of action. In regard to evaluating the experi-
mental support, the Guidelines list strength, consistency, 
and specificity of association as considerations. The find-
ing of dose-response is given weight as is proper temporal 
ordering. Finally, the Guidelines call for biologic plausibil-
ity and coherence: “It is important that the hypothesized 
mode of action and the events that are part of it be based 
on contemporaneous understanding of the biology of can-
cer to be accepted” (pp. 2–46). Standard descriptors for 
the strength of evidence are not mentioned. 
Mechanisms of Action: Necessary, 
Sufficient, or Neither
For many of the diseases caused by smoking, mul-
tiple mechanisms are likely to be involved. For example, 
study results indicate that general and specific DNA injury 
and repair processes contribute to carcinogenesis. Causal 
agents have been classified as “necessary,” “sufficient,” 
or “neither necessary nor sufficient” (Rothman 1976). A 
necessary cause is requisite for occurrence of the disease; 
Table 1.2 Causal criteria
1964 Report of the Advisory Committee to the U.S. Surgeon General 
1. Consistency of the association
2. Strength of the association
3. Specificity of the association
4. Temporal relationship of the association
5.   Coherence of the association










Source: U.S. Department of Health, Education, and Welfare 1964; Hill 1965.
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severe acute respiratory syndrome (SARS), for example, 
cannot occur without infection with the SARS coronavi-
rus. Exposure to a sufficient cause is invariably followed 
by occurrence of the disease. For chronic diseases, many 
causal factors are in the category “neither necessary nor 
sufficient”; cigarette smoking, for example, does not cause 
lung cancer in all smokers, and some cases occur among 
lifetime nonsmokers. 
A similar formulation of “necessary” and “suffi-
cient” might be extended to considering the mechanisms 
of disease production. If there is only one pathway to a 
disease, and a particular mechanism is included in that 
pathway, then the mechanism is required for the develop-
ment of the disease and would be considered “necessary.” 
A mechanism that is a component of one or more but not 
all pathways would be considered “sufficient.” Applica-
tion of this type of classification would require a depth 
of understanding of the interplay of mechanisms that has 
not been reached for the pathogenesis of most diseases 
caused by tobacco smoking. Consequently, the chapters of 
this report largely address mechanisms of disease causa-
tion one by one without placing them into categories of 
necessary, sufficient, or neither. 
Description of Evidence on 
Mechanisms of Disease Production
Because evidence related to mechanisms of dis-
eases caused by smoking is still evolving, this report uses 
a descriptive approach in reviewing and presenting the 
evidence. The chapters are based on review of the most 
relevant studies at the time they were written. A summary 
is given on the basis of the strength of evidence for each 
mechanism considered. 
As for causal inference in regard to smoking and 
disease, the finding that a particular mechanism plays 
a role in the production of disease by smoking has 
implications. The finding could point to a biomarker indi-
cating that the pathway is active, or it could indicate the 
possibility of new preventive therapies to obviate the par-
ticular pathway.
Scientific Basis of the Report
The statements and conclusions throughout this 
report are documented by citation of studies published 
in the scientific literature. For the most part, this report 
cites peer-reviewed journal articles, including reviews that 
integrate findings from numerous studies, and books by 
recognized experts. When a study has been accepted for 
publication but the publication has not yet been issued, 
owing to the delay between acceptance and final publica-
tion, the study is referred to as “in press.” This report also 
refers, on occasion, to unpublished research such as a pre-
sentation at a professional meeting or a personal commu-
nication from the researcher. These personal references 
are to acknowledge experts whose research is in progress. 
Development of the Report
This report of the Surgeon General was prepared by 
the Office on Smoking and Health, National Center for 
Chronic Disease Prevention and Health Promotion, Cen-
ters for Disease Control and Prevention, USDHHS. Initial 
chapters were written by 64 experts selected because of 
their knowledge of and familiarity with the topics pre-
sented here. These contributions are summarized in 
seven chapters evaluated by more than 30 peer review-
ers. The entire manuscript was then sent to more than 
20 scientists and other experts, who examined it for sci-
entific integrity. After each review cycle, the drafts were 
revised by the editors on the basis of the reviewers’ com-
ments. Subsequently, the report was reviewed by various 
institutes and agencies within USDHHS. Publication lags, 
even short ones, prevent an up-to-the-minute inclusion 
of all recently published articles and data. Therefore, by 
the time the public reads this report, additional studies or 
data may have been published. 
Throughout this report, genes are represented by 
their abbreviations in italics. In many cases, proteins 
and enzymes related to these genes have the same abbre-
viation, presented in roman type. Definitions, alternative 
genetic symbols, related proteins and enzymes, and poly-
morphisms and variant genotypes are listed alphabetically 
by gene abbreviation in the table at the end of this report, 
“Definitions and Alternative Nomenclature of Genetic 
Symbols Used in This Report.” 
On June 22, 2009, President Barack Obama signed 
into law legislation granting authority to the U.S. 
Food and Drug Administration to regulate all tobacco 
products (Family Smoking Prevention and Tobacco 
Control Act 2009 [Public Law 111-31]). Terms used 
in this report reflect terms in the scientific literature 
and may not meet the definitions under the Tobacco 
Control Act.
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Major Conclusions
The scientific evidence supports the following major 
conclusions:
1. The evidence on the mechanisms by which smoking 
causes disease indicates that there is no risk-free level 
of exposure to tobacco smoke. 
2. Inhaling the complex chemical mixture of combus-
tion compounds in tobacco smoke causes adverse 
health outcomes, particularly cancer and cardiovas-
cular and pulmonary diseases, through mechanisms 
that include DNA damage, inflammation, and oxida-
tive stress. 
3. Through multiple defined mechanisms, the risk and 
severity of many adverse health outcomes caused by 
smoking are directly related to the duration and level 
of exposure to tobacco smoke.
4. Sustained use and long-term exposures to tobacco 
smoke are due to the powerfully addicting effects 
of tobacco products, which are mediated by diverse 
actions of nicotine and perhaps other compounds, at 
multiple types of nicotinic receptors in the brain. 
5. Low levels of exposure, including exposures to sec-
ondhand tobacco smoke, lead to a rapid and sharp 
increase in endothelial dysfunction and inflamma-
tion, which are implicated in acute cardiovascular 
events and thrombosis.
6. There is insufficient evidence that product modifica-
tion strategies to lower emissions of specific toxicants 
in tobacco smoke reduce risk for the major adverse 
health outcomes.
Chapter Conclusions
Chapter 2. The Changing Cigarette
1.  The evidence indicates that changing cigarette 
designs over the last five decades, including filtered, 
low-tar, and “light” variations, have not reduced over-
all disease risk among smokers and may have hin-
dered prevention and cessation efforts.
2.  There is insufficient evidence to determine whether 
novel tobacco products reduce individual and popula-
tion health risks. 
3.  The overall health of the public could be harmed if 
the introduction of novel tobacco products encour-
ages tobacco use among people who would otherwise 
be unlikely to use a tobacco product or delays cessa-
tion among persons who would otherwise quit using 
tobacco altogether.
Chapter 3. Chemistry and 
Toxicology of Cigarette Smoke and 
Biomarkers of Exposure and Harm
1. In spite of uncertainties concerning whether par-
ticular cigarette smoke constituents are responsible 
for specific adverse health outcomes, there is broad 
scientific agreement that several of the major classes 
of chemicals in the combustion emissions of burned 
tobacco are toxic and carcinogenic.
2. The design characteristics of cigarettes, including 
ventilation features, filters, and paper porosity, have 
a significant influence on the levels of toxic and carci-
nogenic chemicals in the inhaled smoke.
3. The different types of tobacco lamina (e.g., bright, 
burley, or oriental) that are combined to produce a 
specific tobacco blend have a significant influence on 
the levels of toxic and carcinogenic chemicals in the 
combustion emissions of burned tobacco.
4. There is no available cigarette machine-smoking 
method that can be used to accurately predict doses of 
the chemical constituents of tobacco smoke received 
when using tobacco products.
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5. Tobacco-specific biomarkers (nicotine and its metab-
olites and the tobacco-specific nitrosamines) have 
been validated as quantitative measures of exposure 
to tobacco smoke among smokers of cigarettes of 
similar design who do not use other tobacco-contain-
ing products.
6. Although biomarkers of potential harm exist for most 
tobacco-related diseases, many are not specific to 
tobacco and levels are also influenced by diet, occupa-
tion, or other lifestyle or environmental factors.
Chapter 4. Nicotine Addiction:  
Past and Present
1. Nicotine is the key chemical compound that causes 
and sustains the powerful addicting effects of com-
mercial tobacco products.
2. The powerful addicting effects of commercial tobacco 
products are mediated by diverse actions of nicotine 
at multiple types of nicotinic receptors in the brain.
3. Evidence is suggestive that there may be psychoso-
cial, biologic, and genetic determinants associated 
with different trajectories observed among popula-
tion subgroups as they move from experimentation to 
heavy smoking.
4. Inherited genetic variation in genes such as CYP2A6 
contributes to the differing patterns of smoking 
behavior and smoking cessation. 
5. Evidence is consistent that individual differences in 
smoking histories and severity of withdrawal symp-
toms are related to successful recovery from nicotine 
addiction.
Chapter 5. Cancer
1. The doses of cigarette smoke carcinogens resulting 
from inhalation of tobacco smoke are reflected in lev-
els of these carcinogens or their metabolites in the 
urine of smokers. Certain biomarkers are associated 
with exposure to specific cigarette smoke carcinogens, 
such as urinary metabolites of the tobacco-specific 
nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone and hemoglobin adducts of aro- 
matic amines. 
2. The metabolic activation of cigarette smoke carcino-
gens by cytochrome P-450 enzymes has a direct effect 
on the formation of DNA adducts.
3. There is consistent evidence that a combination of 
polymorphisms in the CYP1A1 and GSTM1 genes 
leads to higher DNA adduct levels in smokers and 
higher relative risks for lung cancer than in those 
smokers without this genetic profile.
4. Carcinogen exposure and resulting DNA damage 
observed in smokers results directly in the numerous 
cytogenetic changes present in lung cancer.
5. Smoking increases the frequency of DNA adducts of 
cigarette smoke carcinogens such as benzo[a]pyrene 
and tobacco-specific nitrosamines in the lung and 
other organs.
6. Exposure to cigarette smoke carcinogens leads to 
DNA damage and subsequent mutations in TP53 and 
KRAS in lung cancer. 
7. There is consistent evidence that smoking leads to the 
presence of promoter methylation of key tumor sup-
pressor genes such as P16 in lung cancer and other 
smoking-caused cancers. 
8. There is consistent evidence that smoke constituents 
such as nicotine and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone can activate signal transduction 
pathways directly through receptor-mediated events, 
allowing the survival of damaged epithelial cells that 
would normally die. 
9. There is consistent evidence for an inherited sus-
ceptibility of lung cancer with some less common 
genotypes unrelated to a familial clustering of smok- 
ing behaviors. 
10.  Smoking cessation remains the only proven strategy 
for reducing the pathogenic processes leading to can-
cer in that the specific contribution of many tobacco 
carcinogens, alone or in combination, to the develop-
ment of cancer has not been identified.
Chapter 6. Cardiovascular Diseases 
1. There is a nonlinear dose response between expo-
sure to tobacco smoke and cardiovascular risk, with 
a sharp increase at low levels of exposure (including 
exposures from secondhand smoke or infrequent 
cigarette smoking) and a shallower dose-response 
relationship as the number of cigarettes smoked per 
day increases.
2. Cigarette smoking leads to endothelial injury and 
dysfunction in both coronary and peripheral arter-
ies. There is consistent evidence that oxidizing 
chemicals and nicotine are responsible for endothe- 
lial dysfunction.
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3. Tobacco smoke exposure leads to an increased risk 
of thrombosis, a major factor in the pathogenesis of 
smoking-induced cardiovascular events.
4. Cigarette smoking produces a chronic inflamma-
tory state that contributes to the atherogenic disease 
processes and elevates levels of biomarkers of 
inflammation, known powerful predictors of cardio-
vascular events.
5. Cigarette smoking produces an atherogenic lipid pro-
file, primarily due to an increase in triglycerides and a 
decrease in high-density lipoprotein cholesterol.
6. Smoking cessation reduces the risk of cardiovascular 
morbidity and mortality for smokers with or without 
coronary heart disease.
7. The use of nicotine or other medications to facilitate 
smoking cessation in people with known cardiovas-
cular disease produces far less risk than the risk of 
continued smoking.
8. The evidence to date does not establish that a reduc-
tion of cigarette consumption (that is, smoking fewer 
cigarettes per day) reduces the risks of cardiovascu-
lar disease.
9. Cigarette smoking produces insulin resistance and 
chronic inflammation, which can accelerate macro-
vascular and microvascular complications, including 
nephropathy.
Chapter 7. Pulmonary Diseases
1. Oxidative stress from exposure to tobacco smoke has 
a role in the pathogenetic process leading to chronic 
obstructive pulmonary disease.
2. Protease-antiprotease imbalance has a role in the 
pathogenesis of emphysema.
3. Inherited genetic variation in genes such as SER-
PINA3 is involved in the pathogenesis of tobacco-
caused chronic obstructive pulmonary disease.
4. Smoking cessation remains the only proven strategy 
for reducing the pathogenetic processes leading to 
chronic obstructive pulmonary disease.
Chapter 8. Reproductive and  
Developmental Effects 
1. There is consistent evidence that links smoking in 
men to chromosome changes or DNA damage in 
sperm (germ cells), affecting male fertility, pregnancy 
viability, and anomalies in offspring.
2. There is consistent evidence for association of peri-
conceptional smoking to cleft lip with or without 
cleft palate. 
3. There is consistent evidence that increases in follicle-
stimulating hormone levels and decreases in estrogen 
and progesterone are associated with cigarette smok-
ing in women, at least in part due to effects of nicotine 
on the endocrine system. 
4. There is consistent evidence that maternal smoking 
leads to transient increases in maternal heart rate and 
blood pressure (primarily diastolic), probably medi-
ated by the release of norepinephrine and epinephrine 
into the circulatory system.
5. There is consistent evidence that links maternal 
smoking to interference in the physiological transfor-
mation of spiral arteries and thickening of the villous 
membrane in forming the placenta; placental prob-
lems could lead to fetal loss, preterm delivery, or low 
birth weight.
6. There is consistent evidence of the presence of histo-
pathologic changes in the fetus from maternal smok-
ing, particularly in the lung and brain.
7. There is consistent evidence that suggests smoking 
leads to immunosuppressive effects, including dys-
regulation of the inflammatory response, that may 
lead to miscarriage and preterm delivery. 
8. There is consistent evidence that suggests a role 
for polycyclic aromatic hydrocarbons from tobacco 
smoke in the adverse effects of maternal smoking on a 
variety of reproductive and developmental endpoints.
9. There is consistent evidence that tobacco smoke 
exposure leads to diminished oviductal functioning, 
which could impair fertilization. 
10. There is consistent evidence that links prenatal 
smoke exposure and genetic variations in metaboliz-
ing enzymes such as GSTT1 with increased risk of 
adverse pregnancy outcomes such as lowered birth 
weight and reduced gestation.
11. There is consistent evidence that genetic polymor-
phisms, such as variants in transforming growth fac-
tor-alpha, modify the risks of oral clefting in offspring 
related to maternal smoking.
12. There is consistent evidence that carbon monoxide 
leads to birth weight deficits and may play a role in 
neurologic deficits (cognitive and neurobehavioral 
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Introduction
growing public awareness of the health hazards of tobacco 
use, primarily through reducing machine-measured tar and 
nicotine content (NCI 1996). However, evidence now dem-
onstrates that these modifications did not reduce the risk 
of cigarette smoking and in addition may have undermined 
efforts to prevent tobacco use and promote cessation 
(NCI 2001). In recent years, a range of new products have 
been introduced and marketed to smokers as an alterna-
tive to conventional cigarettes, sometimes accompanied 
by messages, explicit or implied, that they offer reduced 
exposure to toxic substances or risk of disease (Peder-
son and Nelson 2007). The focus of this chapter is on the 
health consequences of changes in cigarette design over 
time. Coverage of novel cigarette products is not intended 
to be comprehensive or current, because this market is 
rapidly evolving.
Cigarettes are the most common form of tobacco 
used in most of the world (World Health Organization 
[WHO] 2006) and cause 443,000 deaths in the United 
States each year (U.S. Department of Health and Human 
Services [USDHHS] 1986, 1988; National Cancer Institute 
[NCI] 1997; Centers for Disease Control and Prevention 
[CDC] 2008). The primary short- and long-range strate-
gies for reducing deaths associated with tobacco use are 
cessation and prevention, respectively, along with reduc-
tion of secondhand smoke exposure (Warner et al. 1998; 
USDHHS 2000; Stratton et al. 2001; WHO 2003a). Another 
concept that has been considered is changing the ciga-
rette itself to make it less toxic. The concept of modify-
ing conventional cigarettes to be potentially less harmful 
is not new. Beginning in the 1950s, the tobacco industry 
embarked on efforts to modify cigarettes in response to 
Cigarette Design Changes over the Years
The history of tobacco product design and mar-
keting has been discussed elsewhere and need not be 
repeated (Reynolds and Shachtman 1989; Goodman 1993, 
2004; Hilts 1996; Kluger 1996; Tate 1999; Brandt 2007). 
However, the tobacco industry’s internal memoranda and 
other documents make it clear that the core concept and 
function of the cigarette has changed little since its inven-
tion in the early part of the nineteenth century; namely, 
it is a tobacco-derived product for delivering nicotine 
to the user (University of California at San Francisco 
[UCSF] 2008). 
By the early 1950s, mounting scientific evidence 
began to implicate cigarette smoking in the develop-
ment of serious respiratory, heart, and neoplastic diseases 
(Royal College of Physicians of London 1962; U.S. Depart-
ment of Health, Education, and Welfare [USDHEW] 1964). 
This evidence created a new force in cigarette design that 
has remained prominent to this day: to design cigarettes 
that could be marketed as addressing the health concerns 
of both cigarette smokers and health professionals by re-
ducing toxicants (Slade and Henningfield 1998; Stratton 
et al. 2001). Early efforts to reduce toxicants focused on 
efforts to reduce the overall tar (e.g., total particulate mat-
ter minus nicotine and water content) and nicotine yields 
of cigarettes.
The first major design change to reduce tar and nic-
otine yields was the introduction of filters in the 1950s. 
Before 1950, only 0.6 percent of cigarettes were filtered, 
but the increasing lay press coverage of the potential 
dangers of smoking led to an explosion of filter development 
and marketing. By 1960, filtered cigarettes represented 51 
percent of the cigarette market (USDHHS 1989).  By 2005, 
they represented 99 percent of the market. Major design 
efforts to reduce machine-measured tar and nicotine 
yields continued throughout the 1960s and 1970s with the 
introduction of “light” and low-tar cigarettes. Efforts to 
further reduce machine-measured tar and nicotine yields 
included the use of porous cigarette paper, reconstituted 
tobacco, filter tip ventilation, and the use of expanded 
tobacco (Hoffmann et al. 1996). 
The initial focus on reduction of tar and nicotine 
yields was supported by early case-control studies sug-
gesting that cancer risks were reduced by increased use of 
filters and decreased machine-measured tar delivery, and 
laboratory studies appeared to confirm this dose-response 
relationship. This research led to the seemingly reasonable 
conclusion that cigarettes with lower machine-measured 
tar and nicotine might pose fewer hazards, assuming that 
smokers did not increase the number of cigarettes they 
smoked per day or otherwise change their smoking behav-
iors (USDHEW 1967, 1969, 1971, 1974; USDHHS 1981; 
Stratton et al. 2001). Thus, it was widely accepted that 
declining tar and nicotine levels could lead to decreased 
disease risk. The concept that reduced exposure to 
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toxicants could  reduce disease risk was supported 
by previous Surgeon General’s reports (USDHEW 
1969). In 1966, the U.S. Public Health Service rec-
ommended “the progressive reduction of the ‘tar’ 
and nicotine content of cigarette smoke” (USDHEW 
1966, p. 2), and the Federal Trade Commission (FTC) 
announced that it would generally permit cigarette com-
panies to make marketing claims about tar and nicotine 
yields as long as those statements were based on a uni-
form machine-based test method for measuring tar and 
nicotine yields, subsequently known as “the FTC method” 
(Peeler 1996; Pillsbury 1996). 
Efforts to reduce tar and nicotine yields as measured 
on the basis of machine-smoking conditions were success-
ful. The sales-weighted deliveries in U.S. cigarette smoke 
decreased from 38 milligrams (mg) of tar and 2.7 mg of 
nicotine in 1954 to 12 mg of tar and 0.95 mg of nicotine 
in 1993 (Hoffmann et al. 1996). Machine measurements 
of tar have shown little change since then, and machine 
measurements of nicotine delivery have remained at 
approximately 0.9 mg per cigarette since 1981 (Federal 
Register 1995, 1996; Slade et al. 1995; Hurt and Robertson 
1998; Kessler 2001).
Unfortunately, with the accrual and evaluation of 
additional data, the evidence today does not demonstrate 
that efforts to lower machine-measured tar and nicotine 
yields actually decreased the health risks of smoking, pri-
marily because these changes did not reduce smokers’ 
actual exposure to tobacco toxicants (NCI 2001; USDHHS 
2004). Indeed, to the extent that filters and other efforts 
to reduce machine-measured tar and nicotine reduced 
smokers’ health concerns, and thereby delayed quitting 
and/or increased cigarette use, they may have contributed 
to an overall increase in cigarette-caused mortality (Strat-
ton et al. 2001). 
As mentioned above, for example, the first effort to 
change the design of cigarettes was the addition of the fil-
ter. In theory, use of filter technologies can remove sub-
stantial amounts of a wide variety of toxicants (Browne 
1990; Hoffmann and Hoffmann 1997). In fact, however, 
evidence on the ability of filters to reduce harm is not 
clear (Slade 1993; NCI 2001; Stratton et al. 2001). And, 
some novel filter designs may introduce new toxicants 
such as asbestos (Slade 1993), carbon (Pauly et al. 1997), 
and glass (Pauly et al. 1998). The wide variation in filter 
technology across brands and over time precludes general 
conclusions about whether filters increased or decreased 
exposure of smokers to toxicants. 
Similarly, a variety of design features made it pos-
sible for cigarette smokers to compensate, that is, easily 
ingest severalfold higher amounts of tar and nicotine than 
the yields obtained when using the machine-based FTC 
method (Djordjevic et al. 2000; NCI 2001; Stratton et al. 
2001; WHO 2003c). Most important was the introduction 
of ventilation holes in the cigarette filters, which allowed 
smoke to escape during machine testing. In the 1980s, 
research ers discovered that smokers covered these venti-
lation holes with their fingers, negating the effect of the 
holes in reducing smoke exposure (Kozlowski et al. 1980, 
2002, 2006). Moreover, subsequent research demonstrated 
that the use of ventilation holes produced higher levels of 
free-base nicotine, which led to a more addictive product 
as well as deeper lung inhalation of cooler and less harsh 
smoke (Stratton et al. 2001; Pankow et al. 2003a,b; Watson 
et al. 2004). Driven by nicotine addiction and enabled by 
cigarettes that delivered smoother, cooler smoke diluted 
by ambient air, smokers could easily compensate for 
reduced delivery of nicotine by increasing smoke intake 
per cigarette and per day, thus maintaining high levels of 
disease risk (NCI 2001; Thun and Burns 2001). 
Tobacco industry documents, many of which are 
available at the Legacy Tobacco Documents Library at 
UCSF, clearly demonstrate that at least by the mid-1970s 
the tobacco industry well understood the importance of 
creating health reassurance messages in order to alleviate 
health concerns, and that one important method of doing 
so was through claims of low deliveries of tar. For example, 
a 1977 British American Tobacco marketing report con-
cluded, “All work in this area should be directed towards 
providing consumer reassurance (emphasis in original)
about cigarettes and the smoking habit. This can be pro-
vided in different ways, e.g. by claimed low deliveries, by 
the perception of low deliveries and by the perception of 
‘mildness’” (Short 1977, p. 3). At the same time, tobacco 
company documents also clearly demonstrate that the 
industry understood that smokers would not achieve the 
claimed deliveries because of smoker compensation. For 
example, a 1975 Philip Morris memo noted: “In effect, the 
Marlboro 85 smokers in this study did not achieve any 
reduction in smoke intake by smoking a cigarette (Marl-
boro Lights) normally considered lower in delivery” 
(Goodman 1975, p. 3). 
In contrast to industry awareness, the various ways 
that cigarettes were physically modified and the nature 
and level of compensation in response to design changes 
were not well understood by parties outside of the tobacco 
industry itself. Public health officials had little basis 
to anticipate the degree to which manufacturers could 
design cigarettes to allow smokers to draw more smoke 
and nicotine from cigarettes than was represented by 
machine-measured yields of tar and nicotine (NCI 2001; 
Parascan dola 2005).
It was not until the turn of the twenty-first century 
that it became increasingly clear that no relationship 
existed between machine-measured tar and nicotine levels 
and risks for most categories of cigarette-related diseases. 
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In 1994, an expert committee convened by NCI concluded: 
“The smoking of cigarettes with lower machine-measured 
yields has a small effect in reducing the risk of cancer 
caused by smoking, no effect on the risk of cardiovascular 
diseases, and an uncertain effect on the risk of pulmonary 
disease” (NCI 1996, p. vi). Moreover, whereas squamous 
cell carcinomas had been the predominant form of lung 
cancer, by the late twentieth century adenocar cinoma 
of the lung was becoming increasingly common, pre-
sumably reflecting deeper inhalation of smoke that was 
facilitated by ventilated filters as well as other factors 
such as changes in agricultural practices, tobacco curing, 
and cigarette manufacturing processes that could lead to 
increased concentrations of tobacco-specific nitrosamines 
(NCI 2001; Stratton et al. 2001) (see Chapter 5, “Cancer”). 
By 2001, NCI concluded that “measurements of tar and 
nicotine yields using the FTC method do not offer smok-
ers meaningful information on the amount of tar and 
nicotine they will receive from a cigarette” (NCI 2001, 
p. 10). The 2001 review also concluded that the evidence 
“…does not indicate a benefit to public health from 
changes in cigarette design and manufacturing over the 
last fifty years” (NCI 2001, p. 10). Today, there is a scien-
tific consensus that changes in cigarette designs from the 
1950s to the 1980s to reduce machine-measured tar yields 
did not result in decreased morbidity and mortality (NCI 
2001; Thun and Burns 2001). In sum, it took decades to 
recognize that changes to reduce machine-measured tar 
and nicotine yields in cigarettes did not have a measurable 
beneficial impact on public health (NCI 2001). In 2008, 
FTC rescinded its 1966 guidance that generally permitted 
statements concerning tar and nicotine yield if they were 
based on the Cambridge filter method (sometimes called 
the FTC method) (FTC 2008).
Other changes during the past 50 years have 
included efforts that potentially have made cigarettes 
more addicting through the use of flavors, chemical 
treatments to alter the smell and appearance of cigarette 
smoke, methods to mask noxious sensory effects, and con-
trol of the nicotine dose (see Chapter 4, “Nicotine Addic-
tion: Past and Present”). These approaches included new 
types of filters, tobacco blends, and ingredients; cigarette 
ventilation; control of pH; and efforts to reduce various 
volatile organic compounds in tobacco and smoke. These 
product modifications have the potential to increase the 
risk of addiction by contributing to increased risk of ini-
tiating use of the product, increased ease of smoke inha-
lation, decreased noxiousness of the smoke, and possibly 
increased brain nicotine exposure (WHO 2007; Chapter 4, 
“Nicotine Addiction: Past and Present”). 
New Cigarette Products
Cigarette smoke contains more than 7,000 chemi-
cals, including at least 69 known carcinogens and many 
other toxicants implicated in major diseases (Inter-
national Agency for Research on Cancer [IARC] 2004; 
Borgerding and Klus 2005; Rodgman and Perfetti 
2009), and because the potency of toxicants and mecha-
nisms of action differ, reducing concentrations of indi-
vidual toxicants might have only a negligible effect on 
disease risk from smoking (Fowles and Dybing 2003; 
Pankow et al. 2007; Burns et al. 2008). Despite these chal-
lenges, Brown & Williamson (acquired by R.J. Reynolds 
in 2004), Vector Tobacco, and Philip Morris have all 
developed cigarettes that purport to deliver lower levels 
of specific toxicants (e.g., carcinogenic nitrosamines) as 
determined by standard machine-smoking methods. This 
reduction in toxicant levels has been accomplished by use 
of new technologies in tobacco curing and/or by adding car-
bon or other materials to cigarette filters (Hoffmann et al. 
2001; IARC 2004). However, the extent to which exposure 
to toxicants is actually reduced in smokers is not known 
because reduced machine-measured yields of toxicants do 
not necessarily reflect actual human exposure. A smoker 
who switches to a brand with lower machine-measured 
toxicants may smoke these cigarettes in a more intense 
fashion or may consume more cigarettes per day than 
previously. Either change could result in greater human 
exposure to toxicants and no decrease in risk of disease.
For example, Brown & Williamson introduced 
Advance as a new cigarette with the claim that levels of 
tobacco-specific nitrosamines (TSNAs) were 70 percent 
lower than those in leading “light” brands (Star Scientific 
2005). Preliminary laboratory studies of cigarette smokers 
provide mixed evidence for the possibility that use of this 
cigarette substitute would result in reduced exposure to 
tobacco toxicants (Breland et al. 2002, 2003). Omni, man-
ufactured by Vector Tobacco, is a conventional cigarette 
for which the marketers claimed lower levels of carcino-
genic polycyclic aromatic hydrocarbons, nitrosamines, 
and catechols (Vector Group 2001). Preliminary studies 
in which Omni is smoked instead of the smokers’ usual 
brand of cigarettes provide little evidence for reduced 





the addictive threshold. The test market ended in 1991 
when Philip Morris withdrew the product from the mar-
ket. Quest was a low-nicotine cigarette developed by Vec-
tor Tobacco (Rose and Behm 2004; Vector Tobacco 2004). 
Three products were available: (1) a cigarette with 0.6 
mg of nicotine and 10 mg of tar per cigarette, as deter-
mined by FTC machine measurements; (2) a cigarette 
with 0.3 mg of nicotine and 10 mg of tar per cigarette; 
and (3) a “nicotine-free” cigarette with no more than 
0.05 mg of nicotine and 10 mg of tar per cigarette (Vec-
tor Tobacco 2004). It was unclear how long and how 
often smokers would use the “nicotine-free” version rather 
than versions that contained higher levels of nicotine and 
whether the two versions with nicotine would hinder the 
desire and ability to stop smoking. 
In theory, gradually reducing the content and yield 
of nicotine in cigarettes over a period of many years, 
using design features that make compensation difficult or 
impossible, might lessen smokers’ dependence on nico-
tine. Low-nicotine cigarettes have also been proposed as 
a method to prevent new smokers (primarily youth) from 
ever establishing nicotine dependence (Benowitz and 
Henningfield 1994; Henningfield et al. 1998; Benowitz 
et al. 2007; Zeller et al. 2009). However, the potential 
role of nicotine analogues in maintaining addiction is 
poorly understood.
A commercial cigarette with very low nicotine 
content was introduced in test markets in 1989 under 
the brand name Next (Butschky et al. 1995). The nico-
tine content of Next appeared to be lower than the levels 
hypothesized by Benowitz and Henningfield (1994) to be 
Cigarette-Like Products
In 1988, R.J. Reynolds launched a new era of novel 
products with Premier, a nicotine-delivering product 
similar in size and appearance to a conventional cigarette 
but consisting of an aluminum canister that contained 
alumina beads impregnated with glycerin, propylene gly-
col, and a nicotine-rich tobacco extract (Slade 1993; Slade 
and Henningfield 1998). Heat from a carbon fuel element 
vaporized material adjacent to the alumina beads, and 
these vapors condensed into more proximal segments to 
form the aerosol that was puffed and inhaled by the con-
sumer (Slade and Henningfield 1998). Compared with 
conventional cigarettes, Premier delivered similar doses 
of nicotine, higher levels of carbon monoxide (CO), and 
reduced levels of many other toxicants (WHO 2001). Pre-
mier was test marketed in the United States in 1988 but 
was soon withdrawn because of poor sales (Slade and 
Henningfield 1998).
More recently, tobacco companies have developed 
several other novel cigarette-like products that deliver 
nicotine to the consumer (Stratton et al. 2001; Slade 
et al. 2002). Eclipse (R.J. Reynolds) uses a technology 
similar to that developed for Premier (Slade and Hen-
ningfield 1998; Slade et al. 2002): the heat source is 
a carbon fuel element, and nicotine and glycerin are 
vaporized from an aluminum-lined chamber filled 
with what the manufacturer described as “highly 
processed tobacco” and mixed with glycerin. Both 
human and machine-testing data indicate that these prod-
ucts provide no clear benefit to users over conventional 
cigarettes. A report commissioned by the Commonwealth 
of Massachusetts Department of Public Health found that 
intensive machine smoking of Eclipse delivered levels of 
key lung and cancer-causing toxicants (e.g., acrolein, CO) 
similar to, or higher than, those from two commercial 
cigarette brands (Labstat 2000). A complication in evalu-
ating the toxicity of Eclipse is that several prototypes were 
test marketed (Slade et al. 2002). It is not clear whether 
changes not disclosed by the manufacturer account for 
the variability across studies (Stapleton et al. 1998; Lee et 
al. 2004; Breland et al. 2006). Nonetheless, it appears that 
vol unteers who had been exposed to Eclipse (Shiffman et 
al. 2004; Hughes et al. 2005) or had heard of it believed it 
to be less harmful than conventional cigarettes. Further-
more, concerns have been raised that Eclipse and Premier 
could be modified to deliver other drugs, including illicit 
drugs (Cone and Henningfield 1989; Steckley et al. 2002).
Accord (Philip Morris) consists of a specially 
designed “cigarette” used in combination with an igni-
tion system (Slade and Henningfield 1998). The handheld, 
battery-operated, microchip-controlled product heats 
a cigarette-like tobacco roll when it is puffed (Slade and 
Henningfield 1998). Although actual-use studies of Accord 
have not been performed, preliminary laboratory studies 
with volunteers suggest the possibility that actual human 
exposure to nicotine and toxicants might substantially 
exceed that predicted by Philip Morris’ tests (Buchhalter 
et al. 2001; Breland et al. 2002; Philip Morris USA 2005). 
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6 to 22 percent and average daily consumption by up to 
14 percent among smokers compared with workers sub-
ject to minimal or no restrictions (Farrelly et al. 1999; 
NCI 2000; USDHHS 2000; Bonnie et al. 2007). Products 
that enable nicotine consumption in the workplace and 
other places could reverse these potential reductions in 
smoking prevalence through use of one product in the 
workplace and continued smoking outside, that is, dual 
product use (Henningfield et al. 2002; European Commis-
sion 2007). Moreover, the dual use of tobacco products is 
likely to result in greater exposure to toxicants than does 
use of either product type alone (Henningfield et al. 2002).
Balancing the risks and benefits of new cigarette 
products is challenging because of the diversity of prod-
ucts, their associated potential risks and benefits on the 
multitude of tobacco-related diseases, and the dearth of 
empirical data on their effects. The 2001 Institute of Medi-
cine (IOM) report (Stratton et al. 2001) and a report from 
the University of Minnesota Transdisciplinary Tobacco Use 
Research Center raised a series of questions about these 
and similar products (Hughes 2000; Stratton et al. 2001; 
Hatsukami and Hecht 2005; Hatsukami et al. 2005). WHO 
developed similar scientific questions, as well as recom-
mendations for research and product testing (WHO 2003d, 
2004a, 2006, 2007). Although all the questions raised by 
these organizations merit consideration, the following 
questions are a critical starting point for evaluating new 
cigarette or cigarette-like products:
	 •	 Does	 use	 of	 the	 product	 decrease	 individual	 and	
population exposure to the harmful substances in 
tobacco smoke?
	 •	 Is	this	decreased	exposure	associated	with	a	decrease	
in individual and population risk of disease?
	 •	 Are	 there	 surrogate	 indicators	 of	 disease	 risk	 that	
could be measured in a timeframe of sufficient 
duration for product evaluation?
	 •	 What	are	the	public	health	implications	of	products	
that may reduce exposure to toxicants in tobacco 
smoke? Specifically, do these products increase ini-
tiation of tobacco use, decrease cessation, promote 
relapse among those who have quit, or lead to dual 
product use?
The health consequences of new cigarette products 
have not been demonstrated in scientific studies. The 
challenges include a need for development and valida-
tion of testing methods for new products (WHO 2004b). 
Extended nonlaboratory studies under natural condi-
tions with a broader range of biomarkers of toxicants are 
required to determine whether novel products result in 
overall reduction of exposure to toxicants, and still longer 
and more extensive studies would be required to deter-
mine whether or not the disease risk of the individual or 
population harm are decreased (WHO 2004a, 2007; Hatsu-
kami et al. 2007). For example, products delivering lower 
levels of nitrosamines might theoretically reduce cancer 
risks, but because many of these products still deliver nic-
otine and CO, cardiovascular risks may remain unchanged 
or may even increase. In addition, if TSNAs are removed, 
other potent carcinogens may sustain overall high levels 
of exposure to carcinogens (Fowles and Dybing 2003). 
There are substantial risks that the marketing of 
novel cigarettes could lead to increased tobacco use in 
current smokers, relapse in former smokers, and initia-
tion in those who never smoked, particularly youth (Hen-
ningfield et al. 2003; Hatsukami et al. 2004a, 2005). For 
example, in a survey of 1,000 current cigarette smokers 
and 499 former smokers older than 18 years of age, 91 
percent thought Eclipse was safer than regular cigarettes, 
24 percent believed Eclipse was completely safe, and 
57.4 percent were interested in using the product (Shiff-
man et al. 2004). Interest was greatest among those who 
were contemplating smoking cessation, and exposure 
to Eclipse’s claims was followed by a reduced interest in 
cessation. Those interested in using Eclipse included 6.2 
percent of all former smokers and 15.2 percent of young 
adults 18 through 25 years of age who had stopped smok-
ing within the past two years. Further extending these 
findings, Hamilton and colleagues (2004) found that 
advertisements for light cigarettes were perceived to im-
ply that their use is healthier than use of regular ciga-
rettes, partly because consumers wrongly believed that 
the advertisements must be approved and endorsed by a 
government agency.
In addition, products designed or marketed to 
be used in places where smoking is not allowed may 
defeat public health efforts to reduce smoking rates. For 
example, studies have found that having a 100-percent 
smoke-free workplace reduced smoking prevalence by 
Surgeon General’s Report
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2007, or modified after that date) to submit an application 
containing specified manufacturing and ingredient infor-
mation, as well as studies of the product’s health risks, for 
FDA review. After reviewing the application, the agency 
will issue an order either permitting the product to be 
marketed or denying its marketing according to specified 
bases for its action. New tobacco products determined by 
FDA to be substantially equivalent to products already on 
the market as of February 15, 2007, are not required to 
undergo premarket review.
Section 911 provides that “modified risk tobacco 
products” may only be marketed if FDA determines, 
after reviewing a product application, that the product will 
significantly reduce the risk of tobacco-related disease to 
individual users, and benefit the health of the population 
as a whole, taking into account the impact on both users 
and nonusers of tobacco products. Section 911 recognizes 
so-called special rule products, which also require pre-
market approval. Such products may be marketed for up 
to five years (subject to renewal) if the agency determines 
that the applicant has met specified criteria, the applicant 
agrees to conduct certain postmarket surveillance and 
studies, and other specified findings regarding the relative 
harm of the product are made. Under this section, FDA 
must issue guidance or regulations on the scientific evi-
dence required for the assessment and ongoing review of 
modified-risk tobacco products in consultation with IOM.
On June 22, 2009, President Barack Obama signed 
into law the Family Smoking Prevention and Tobacco 
Control Act (Public Law 111-31). The Tobacco Control 
Act grants the U.S. Food and Drug Administration (FDA) 
the authority to regulate tobacco products to protect the 
public’s health and recognizes FDA as the primary federal 
regulatory authority with respect to the manufacture, 
marketing, and distribution of tobacco products. Key ele-
ments of the act include, among other things, creation 
of a new Center for Tobacco Products, prohibition of the 
sale of cigarettes containing certain characterizing fla-
vors, the requirement that manufacturers and importers 
report to FDA the ingredients and additives in their prod-
ucts, strengthened warning labels with graphic images of 
the adverse effects of cigarette use, and oversight of the 
tobacco industry’s efforts to develop and market potential 
reduced-exposure tobacco products. The Tobacco Control 
Act also requires FDA to reissue the agency’s 1996 regula-
tion aimed at reducing young people’s access to tobacco 
products and curbing the appeal of tobacco to the young. 
Although some provisions of the act went into effect 
shortly after the statute was enacted, such as the ban on 
flavored cigarettes, others will be implemented over time.
Sections 910 and 911 of the Tobacco Control Act 
provide that premarket review of certain tobacco products 
by FDA is required before the products may be marketed. 
Section 910 requires manufacturers of new tobacco prod-
ucts (those not commercially marketed as of February 15, 
Summary
To reduce smoking-attributable death and disease, 
public health efforts since the 1964 Surgeon General’s 
report on smoking and health have focused on reduc-
ing the prevalence of tobacco use. Reduced prevalence 
has been achieved through efforts to prevent tobacco use 
and promote cessation; this effort has been termed one of 
the “ten great public health achievements of the twenti-
eth century” (CDC 1999). At the time the adverse effects 
of smoking were being recognized, the tobacco industry 
developed cigarettes with low machine-measured yields 
of tar and nicotine, and public health authorities encour-
aged consumers to select them (Peeler 1996; Shopland 
2001). Unfortunately, it took public health researchers 
and federal authorities many years to discover what the 
tobacco industry knew much earlier: the health benefits 
of reductions of tar and nicotine intakes were negligible 
at best for persons using these products (Federal Register 
1995, 1996; NCI 2001; WHO 2001; U.S. v. Philip Morris No. 
449 F. Supp. 2d 1, 430–75 [D.D.C. 2006]). In 2001, an NCI 
report concluded: “There is no convincing evidence that 
changes in cigarette design between 1950 and the mid 1980s 
have resulted in an important decrease in the disease bur-
den caused by cigarette use either for smokers as a group 
or for the entire population” (NCI 2001, p. 146). Thus, by 
the twenty-first century, it was apparent that five decades 
of evolving cigarette design had not reduced overall disease 
risk among smokers, and new designs were used by the 
tobacco industry as a tool to undermine prevention and 
cessation efforts (NCI 2001; Stratton et al. 2001; WHO 
2001, 2003a,b,c; USDHHS 2004). 
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Similarly, informative and comprehensive scientific 
evaluations do not exist for any of the other new prod-
ucts developed ostensibly to reduce toxicants in cigarette 
smoke. This lack of data limits any conclusions that can be 
drawn about potential health risks or benefits.
The well-documented risks of cigarette design 
changes must be weighed against any potential benefits 
(Stratton et al. 2001). As this chapter makes clear, sub-
stantial risks may be associated with new tobacco prod-
ucts: (1) smokers who might have otherwise stopped 
smoking may continue to smoke because of perceived 
reduction in risk with use of new products; (2) former 
smokers may resume smoking because of perceived reduc-
tion in risk with use of new products; and (3) nonsmokers, 
particularly youth, may start to use new products because 
of their perceived safety. The theoretical benefit of ciga-
rette design changes is to reduce exposure to toxicants suf-
ficiently to reduce the risk of disease and death. However, 
if these products are used by persons otherwise unlikely 
to use a tobacco product, which would undermine efforts 
to prevent tobacco use, or if the products delay cessation 
among persons who would otherwise stop using tobacco, 
the overall health of the population would be harmed. 
There is little doubt that new tobacco products will 
continue to be developed. Consequently, there is a criti-
cal need to conduct independent research on the design, 
composition, and health effects of new cigarette products 
and to put in place a comprehensive surveillance sys-
tem to understand consumers’ knowledge, attitudes, and 
behaviors regarding these products.
Conclusions
1.  The evidence indicates that changing cigarette 
designs over the last five decades, including filtered, 
low-tar, and “light” variations, have not reduced over-
all disease risk among smokers and may have hin-
dered prevention and cessation efforts.
2.  There is insufficient evidence to determine whether 
novel tobacco products reduce individual and popula-
tion health risks. 
3.  The overall health of the public could be harmed if 
the introduction of novel tobacco products encour-
ages tobacco use among people who would otherwise 
be unlikely to use a tobacco product or delays cessa-
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Introduction
The section on “Biomarkers” offers an overview of 
in vitro and in vivo data on genotoxicity and cytotoxic-
ity and a review of the literature on animal bioassays, in 
addition to general concepts of biomarkers of exposure, 
of biologically effective dose, and of potential harm, as an 
introduction to more detailed descriptions of biomarkers 
in subsequent chapters of this Surgeon General’s report.
Cigarette smoke is a complex mixture of chemical 
compounds that are bound to aerosol particles or are free 
in the gas phase. Chemical compounds in tobacco can be 
distilled into smoke or can react to form other constitu-
ents that are then distilled to smoke. Researchers have 
estimated that cigarette smoke has 7,357 chemical com-
pounds from many different classes (Rodgman and Perfetti 
2009). In assessing the nature of tobacco smoke, scientists 
must consider chemical composition, concentrations of 
components, particle size, and particle charge (Dube and 
Green 1982). These characteristics vary with the cigarette 
design and the chemical nature of the product.
Fowles and Dybing (2003) suggested an approach to 
identify the chemical components in tobacco smoke with 
the greatest potential for toxic effects. They considered 
the risk for cancer, cardiovascular disease, and heart dis-
ease. Using this approach, these investigators found that 
1,3-butadiene presented by far the most significant cancer 
risk; acrolein and acetaldehyde had the greatest potential 
to be respiratory irritants; and cyanide, arsenic, and the 
cresols were the primary sources of cardiovascular risk. 
Other chemical classes of concern include other met-
als, N-nitrosamines, and polycyclic aromatic hydrocar-
bons (PAHs). This evaluation, along with the Hoffmann 
list of biologically active chemicals (Hoffmann and Hoff-
mann 1998), was used to select the chemicals reviewed in 
this chapter. Other chemical components with potential 
for harm will be identified as analysis of tobacco smoke 
becomes more complete and cigarette design and addi-
tives change.
This chapter summarizes the state of knowledge 
about the chemistry and toxicology of cigarette smoke and 
provides data relevant to the evaluations and conclusions 
presented in the disease-specific chapters of this report. 
The literature reviewed in this chapter is limited to manu-
factured cigarettes and does not include publications on 
handmade (“roll your own”) cigarettes or other products 
that contain nicotine. The next section, “Chemistry,” 
includes a brief description of technologies used by cig-
arette manufacturers in a limited number of cigarette 
brands marketed as “reduced-exposure” or “lower-yield” 
products. These commercial products have not been met 
with widespread consumer acceptance. The following sec-
tion, “Biomarkers,” focuses on the manufactured tobacco- 
burning cigarette consumed by the majority of smokers in 
the United States and elsewhere. 
The section on “Chemistry” describes the chemi-
cal components of cigarette smoke and addresses aspects 
of product design that alter the components of cigarette 
smoke and factors affecting delivery of smoke to the 
smoker. In most cases, the data reported for chemical 
levels in mainstream smoke were derived under standard 
smoking conditions described by the U.S. Federal Trade 
Commission (FTC) and the International Organization 
for Standardization (ISO). These standard conditions are 
puff volume of 35 milliliters (mL), two-second puff dura-
tion, one-minute puff frequency, and butt length defined 
as either 23 millimeters (mm) for nonfilter cigarettes or 
the length of the filter overwrap paper plus 3 mm. When 
alternative smoking regimens are used, levels of poten-
tially harmful substances in smoke emissions usually 
differ from those measured under standard conditions. 
(For more details, see “Delivery of Chemical Constituents 
into Tobacco Smoke” later in this chapter.) When people 
smoke, they do not use the puff volume and puff frequency 
programmed into smoking machines, and smoking hab-
its vary significantly from person to person and cigarette 
to cigarette. Consequently, actual exposures to and doses 
of components of smoke cannot be derived from values 




during puffing (Johnson et al. 1973b; Perfetti et al. 1998). 
Thus, the way the cigarette is smoked (e.g., puff volume 
and time between puffs) can alter the relative levels of 
mainstream and sidestream smoke (Perfetti et al. 1998). 
In addition, the ratio of the levels of chemical com-
ponents in sidestream smoke to their levels in mainstream 
smoke can be altered by differences among cigarettes 
(Perfetti et al. 1998). These differences are related to the 
tobacco blend or type, the tobacco preparation (e.g., cut 
width, additives, and moisture level), the dimensions of 
the cigarette, the weight of the tobacco rod, the porosity 
of the paper, the presence of a filter, and the type of filter. 
Studies using a machine that simulates human smoking 
have determined that the change in the ratio of sidestream 
to mainstream smoke components after introducing a fil-
ter and ventilation primarily resulted from a decrease in 
the amount of mainstream smoke, because the amount 
of sidestream smoke does not change substantially with 
alterations in cigarette design (Perfetti et al. 1998). 
Examination of chemicals with similar properties revealed 
that those with a low boiling point had higher ratios of 
levels in sidestream smoke to levels in mainstream smoke 
and that compounds with a high boiling point had lower 
ratios (Sakuma et al. 1984). Studies indicate that compared 
with mainstream smoke collected under standard FTC/
ISO smoking parameters, sidestream smoke has higher 
levels of PAHs (Grimmer et al. 1987; Evans et al. 1993); 
nitrosamines (Brunnemann et al. 1977a, 1980; Hoffmann 
et al. 1979a; Rühl et al. 1980); aza-arenes (Dong et al. 1978; 
Grimmer et al. 1987); aromatic amines (Patrianakos and 
Hoffmann 1979); carbon monoxide (CO) (Hoffmann et al. 
1979b; Rickert et al. 1984); nicotine (Rickert et al. 1984; 
Pakhale et al. 1997); ammonia (Brunnemann and Hoff-
mann 1975); pyridine (Johnson et al. 1973b; Brunnemann 
et al. 1978; Sakuma et al. 1984); and the gas phase com-
ponents 1,3-butadiene, acrolein, isoprene, benzene, and 
toluene (Brunnemann et al. 1990). With increased puffing 
intensity, the toxicant ratios of sidestream to mainstream 
smoke decrease (Borgerding et al. 2000).
The increase in the amount of tobacco burned 
during smoldering compared with tobacco burned dur-
ing puffing is not the only factor influencing differences 
in the chemical content of sidestream and mainstream 
smoke. The burning conditions that generate sidestream 
and mainstream smoke also differ (Guerin 1987). Tem-
peratures reach 900°C during a puff and fall to about 
400°C between puffs (Guerin 1987). Puffing burns the 
tobacco on the periphery of the cigarette, and tobacco in 
Phases of Tobacco Smoke
Smoke from a burning cigarette is a “concentrated 
aerosol of liquid particles suspended in an atmosphere 
consisting mainly of nitrogen, oxygen, carbon monoxide 
and carbon dioxide” (Guerin 1980, p. 201). Researchers 
have also described cigarette smoke as a “lightly charged, 
highly concentrated matrix of submicron particles con-
tained in a gas with each particle being a multicomposi-
tional collection of compounds arising from distillation, 
pyrolysis, and combustion of tobacco” (Dube and Green 
1982, p. 42). Tobacco smoke is a complex and dynamic 
chemical mixture. Researchers have analyzed whole 
smoke or used chemical and physical means to sepa-
rately examine the gas and particulate portions of tobacco 
smoke. The gas phase is defined as the portion of smoke 
that passes through a glass fiber filter of specified physi-
cal parameters, and the particulate phase refers to all 
matter captured by the glass fiber filter (Pillsbury 1969). 
Standard methods for analysis of tobacco smoke sepa-
rate the two phases by using Cambridge glass fiber filters 
designed to collect aerosol particles of 0.3 micrometers 
(µm) or larger with an efficiency not less than 99 percent 
(Pillsbury 1969). Although these separate phases are an 
artificial construct, they are useful for describing the 
results of analysis of the components of cigarette smoke 
typically obtained by machine smoking. When people 
smoke cigarettes, the continuum of physical character-
istics in smoke does not include the differentiation into 
specific fractions. The diameter of cigarette smoke par-
ticles constantly changes, and as the particles coalesce 
after their formation, they grow in diameter. However, in 
diluted smoke, loss of a volatile chemical matrix or other 
components may cause particles to shrink and changes in 
the particle size may alter the relative amounts of certain 
chemicals in the gas and particle phases (Guerin 1980). 
Smoke formation occurs when the cigarette is lit 
and a puff is taken or when the cigarette smolders between 
puffs. Mainstream smoke is released from the butt end 
of the burning cigarette during puffing, and sidestream 
smoke emanates from the burning cigarette coal when it 
smolders (Guerin 1980). The air in the immediate vicin-
ity of an active smoker contains a mixture of sidestream 
smoke, exhaled mainstream smoke, and any smoke that 
passes through the porous paper surrounding the tobacco 
(Löfroth 1989). A greater quantity of sidestream smoke 
is generated when the amount of tobacco burned dur-
ing smoldering increases relative to the amount burned 
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the core burns between puffs (Johnson 1977; Hoffmann 
et al. 1979a). Thus, mainstream smoke depends on the 
chemical composition of the combustible portion of the 
cigarette near the periphery of the rod, whereas chemi-
cals at higher concentrations in the central portion of 
the rod have higher levels in sidestream smoke than in 
mainstream smoke (Johnson 1977). Sidestream smoke 
is produced during conditions with less available oxygen 
(Guerin et al. 1987) and higher alkalinity and water con-
tent than those for mainstream smoke (Brunnemann and 
Hoffmann 1974; Adams et al. 1987; Guerin 1987). Ammo-
nia levels are significantly higher in sidestream smoke, 
resulting in a more alkaline pH (Adams et al. 1987). Thus, 
the composition and levels of chemical species in main-
stream smoke differ from those in sidestream smoke. 
Levels of some compounds are higher in mainstream 
smoke than in sidestream smoke, and this difference may 
reflect chemical influences that are more complex than 
just changes in puff frequency. For example, mainstream 
smoke contains considerably more cyanide than side-
stream smoke does (Johnson et al. 1973b; Brunnemann 
et al. 1977a; Norman et al. 1983). Sakuma and colleagues 
(1983) measured a series of semivolatile compounds in 
tobacco smoke and found that levels of phenol, cresol, 
xylenols, guiacol, formic acid, and acetic acid were higher 
in sidestream smoke, whereas levels of catechol and 
hydroquinone were higher in mainstream smoke. 
Individual chemical constituents may be found 
in the particulate phase, the gas phase, or both (Guerin 
1980). As cigarette smoke dissipates, chemicals may pass 
between the particulate and gas phases (Löfroth 1989). 
The gas phase contains gases and chemical constituents 
that are sufficiently volatile to remain in the gas phase 
long enough to pass through the Cambridge glass fiber 
filter (Guerin 1980), but as the filter becomes wet dur-
ing the first puffs, hydrophilic compounds tend to adhere 
to it. The gas phase of cigarette smoke includes nitro-
gen (N2), oxygen (O2), carbon dioxide (CO2), CO, acetal-
dehyde, methane, hydrogen cyanide (HCN), nitric acid, 
acetone, acrolein, ammonia, methanol, hydrogen sulfide 
(H2S), hydrocarbons, gas phase nitrosamines, and car-
bonyl compounds (Borgerding and Klus 2005; Rodgman 
and Perfetti 2009). Constituents in the particulate phase 
include carboxylic acids, phenols, water, humectants, 
nicotine, terpenoids, paraffin waxes, tobacco-specific 
nitrosamines (TSNAs), PAHs, and catechols. Mainstream 
smoke contains only a small amount of nicotine in the 
gas phase (Johnson et al. 1973b; Pakhale et al. 1997), but 
the fraction of nicotine in the gas phase is higher in side-
stream smoke because of the higher pH (Johnson et al. 
1973b; Brunnemann and Hoffmann 1974; Adams et al. 
1987; Pakhale et al. 1997). Brunnemann and colleagues 
(1977b) studied both mainstream and sidestream smoke 
and found that the gas phase of mainstream smoke con-
tained more cyanide than did the particulate phase. John-
son and colleagues (1973b), however, showed that in 
sidestream smoke, cyanide is present almost exclusively in 
the particulate phase. Guerin (1980) concluded that both 
formaldehyde and cyanide may be present in both phases, 
and Spincer and Chard (1971) found formaldehyde in both 
the particulate and gas phases. The PAHs in the gas phase 
were only 1 percent of total PAHs, and the PAH distribu-
tion between gas and particulate phases varied with the 
boiling point of the PAHs (Grimmer et al. 1987). Because 
physical and chemical changes occur after tobacco smoke 
is drawn from the cigarette, some of the reported differ-
ences in PAH levels could result from differences in mea-
surement techniques.
In summary, cigarette smoke is a complex and 
dynamic system. The concentration of smoke and the time 
after it leaves the cigarette can cause changes in particle 
size that may alter the relative amounts of certain chemi-
cals in the gas and particle phases. Also, specific proper-
ties of the tobacco, the physical design of the cigarette, 
and the machine-smoking method that is employed to 
generate mainstream smoke for analyes can have a sig-
nificant impact on the levels of both mainstream and side- 
stream emissions.
Nicotine and Free Nicotine
The tobacco leaf contains many alkaloid chemicals; 
nicotine is the most abundant. Nicotine content varies, 
among other factors, by the leaf position on the tobacco 
stalk and also by the blend or leaf type used in a given 
cigarette or cigar (Tso 1990; Kozlowski et al. 2001). Plants 
such as tobacco that are characterized by high alkaloid 
content often possess a natural pharmacologic defense 
against microorganisms, insects, and vertebrates. For 
example, nicotine is toxic to many insects and, for many 
years, has been extracted from tobacco for use as a com-
mercial pesticide (Domino 1999). Nicotine is addictive in 
humans because a portion of the nicotine molecule is sim-
ilar to acetylcholine, an important brain neurotransmitter 
(Brody et al. 2006). 
The alkaloids in tobacco leaf include anatabine, 
anabasine, nornicotine, N-methylanabasine, anabaseine, 
nicotine, nicotine N’-oxide, myosmine, β-nicotyrine, 
cotinine, and 2,3′-bipyridyl (Figure 3.1). In commercial 
tobacco products, nicotine concentrations range from 6 
to 18 milligrams per gram (mg/g) (0.6 to 1.8 percent 
by weight) (International Agency for Research on Can-
cer [IARC] 2004; Counts et al. 2005). Together, the sum 
of the concentrations of anatabine, anabasine, and nor-
nicotine equals approximately 5 percent of the nicotine 
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concentration (Jacob et al. 1999). Many minor tobacco 
alkaloids are pharmacologically active in humans in one or 
more ways. Clark and colleagues (1965) observed that some 
of these alkaloids had physiological effects in a variety of 
animal tests. Lefevre (1989) reviewed the evidence and con-
cluded that anabasine and nornicotine had demonstrated 
effects on smooth muscle fiber, blood pressure, and enzyme 
inhibition. The literature on potentially addictive prop-
erties of these minor alkaloids is limited. S(-)-nicotine, 
which is present in the tobacco leaf, is structurally simi-
lar to forms of several minor alkaloids also found in the 
tobacco leaf, such as S(-)-N-methylanabasine (Figure 3.2). 
Moreover, Dwoskin and colleagues (1995) reported that in 
the rat, anatabine, anabasine, N-methylanabasine, anaba-
seine, and nornicotine all release dopamine from striatal 
brain tissue. Overall, it is likely that some of the minor 
tobacco alkaloids could (1) be addictive if delivered 
alone at sufficiently high levels and (2) act together with 
nicotine during tobacco use to generate effects that are 
difficult to discern because nicotine levels are so much 
higher. In addition to addictiveness, both nicotine and 
minor secondary amine alkaloids are precursors of carci-
nogenic TSNAs (IARC 2004, 2007).
The unprotonated nicotine molecule contains two 
nitrogen atoms with basic properties. The unproton-
ated nicotine molecule can thus add one proton to form 
a monoprotonated species or two protons to form the 
diprotonated species (Figure 3.3) (Brunnemann and Hoff-
mann 1974). The first proton added to nicotine attaches 
predominantly to the nitrogen on the five-membered 
(pyrrolidine) ring, because that nitrogen is significantly 
more basic than the nitrogen on the six-membered (pyri-
dine) ring. Although protonated nicotine is not volatile, 
unprotonated nicotine is volatile and is able to enter the 
gas phase and readily pass into lipid membranes. Unpro-
tonated nicotine is therefore free of the limitations that 
Figure 3.1 Tobacco alkaloids
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come with carrying an ionic charge, and the scientific 
literature and tobacco industry documents frequently 
refer to nicotine in this form as both “free nicotine” and 
“free-base nicotine.” In the tobacco plant and in the dried 
leaf, nicotine largely exists in its ionic forms; otherwise, it 
would be rapidly lost to the surrounding atmosphere.
In water or in the droplets of particulate matter in 
tobacco smoke, the distribution of nicotine among its 
three forms depends on the pH of the solution. Increas-
ing acidity of the solution increases the fraction of proton-
ated molecules; conversely, increasing basicity increases 
the fraction in the unprotonated (free base) form (Figure 
3.3). Because all forms of nicotine are highly soluble in 
water, all of the nicotine entering the respiratory tract 
from one puff of tobacco smoke easily dissolves in lung 
fluids and blood. However, because unprotonated nicotine 
from tobacco smoke particles is volatile, whereas proton-
ated nicotine is not, a higher percentage of unprotonated 
nicotine in a puff results in a higher rate of nicotine depo-
sition in the respiratory tract (Pankow 2001; Henningfield 
et al. 2004). The exact nature and effects of the increased 
rate of deposition depends on the chemical composition 
and the size of particles in the tobacco smoke, as well as 
topographic characteristics of smoking, such as puff size 
and duration and depth of inhalation. Increased rates of 
deposition in the respiratory tract lead to increased rates 
of nicotine delivery to the brain, which intensify the 
addictive properties of a drug (Henningfield et al. 2004). 
The conventional view has been that a sample of par-
ticulate matter from tobacco smoke is not usually so 
acidic that the diprotonated form becomes important. In 
water at room temperature, the approximate dividing line 
between dominance by protonated forms or by the unpro-
tonated form is a pH of 8 (González et al. 1980). At higher 
pH, the fraction of unprotonated nicotine (αfb) is greater 
than the fraction of protonated nicotine (Pankow 2001). 
At pH 8, the two fractions are present in equal percent-
ages. At any lower pH, the fraction of protonated nicotine 
is greater. 
Because a typical sample of particulate matter from 
tobacco smoke collected from a cigarette or cigar is mostly 
nonaqueous liquid, it is not possible to take conventional 
pH measurements to determine nicotine distribution 
between the monoprotonated and unprotonated forms 
(Pankow 2001). However, it is possible to measure the 
concentration of unprotonated nicotine in a sample of 
tobacco smoke particulate (cp,u), because that level pro-
duces a directly proportional concentration of unpro-
tonated nicotine in the gas phase, which is measurable 
(Pankow et al. 1997, 2003; Watson et al. 2004). Measur-
ing the concentration of nicotine in a sample of tobacco 
smoke in the particulate phase (cp,t) allows calculation of 
the fraction of unprotonated nicotine: αfb = cp,u/cp,t (Pan-
kow et al. 2003). To simplify the discussion of αfb values 
in tobacco smoke, Pankow (2001) introduced the term 
“effective pH” (pHeff), which refers to the pH needed in 
water to obtain the αfb value in a sample of particulate 
matter from smoke. Reported values of αfb for smoke from 
commercial cigarettes at 20oC were 0.006 to 0.36 (Pan-
kow et al. 2003; Watson et al. 2004), which corresponds to 
pHeff values at 20
oC in the range of 5.8 to 7.8.
Figure 3.2 Structures of nicotine and minor  
alkaloid S(-)-N-methylanabasine in  
tobacco leaf
Figure 3.3 Three forms of nicotine
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The fraction αfb for particulate matter in tobacco 
smoke is important because the rapidity with which 
inhaled nicotine from tobacco smoke evaporates from 
the particulate phase and deposits on the linings of the 
respiratory tract is directly proportional to the αfb 
value for the smoke (Pankow et al. 2003). According to 
numerous tobacco industry documents, increasing levels 
of unprotonated nicotine in tobacco smoke was known 
to increase smoke “strength,” “impact,” “kick,” and/or 
“harshness” (Backhurst 1965; Dunn 1973; Teague 1974; 
Ingebrethsen and Lyman 1991). Because of similar mech-
anisms, nicotine replacement therapy delivering gaseous 
nicotine caused throat irritation at delivery levels per puff 
that were similar to those reached by smoking a cigarette 
rated by using the FTC regimen at approximately 1 mg of 
total nicotine delivery; thus, cigarette design is focused on 
a balance between smoke “impact” and irritation. Some 
researchers have suggested that the irritation and harsh-
ness of smoke at higher pH makes it harder for smokers to 
inhale this smoke into the lungs (Brunnemann and Hoff-
mann 1974).
The value of αfb for particulate matter in each puff 
of smoke from one brand of cigarette or cigar strongly 
depends on the overall proportion of acids to bases in the 
puff (Pankow et al. 1997). As already noted, nicotine itself 
is a base. The natural acids in tobacco smoke (e.g., formic 
acid, acetic acid, and propionic acid) can protonate nico-
tine and tend to reduce αfb from its maximum of 1.0. The 
natural bases (e.g., ammonia) tend to neutralize the acids 
and keep more nicotine in the unprotonated form.
Variability in the acid-base nature of commer-
cially available tobacco leaf is considerable. Flue-cured 
(“bright”) tobacco is typically viewed as producing acidic 
smoke. Air-cured (“burley”) tobacco is typically viewed as 
producing basic smoke. Simple adjustment of the tobacco 
blend can therefore produce a considerable range of acid 
or base content in tobacco smoke. In acidic smoke, αfb can 
be 0.01 or lower (e.g., 1-percent unprotonated nicotine), 
and in basic smoke, the αfb can be relatively high (e.g., 
0.36 [36-percent unprotonated nicotine]) (Pankow et al. 
2003; Watson et al. 2004). 
Tobacco additives that are bases increase αfb values 
in mainstream smoke, and these additives are discussed 
extensively in tobacco industry documents (Henning-
field et al. 2004). The documents reveal that a variety of 
basic additives have been considered, including ammonia 
and ammonia precursors. Conversely, some manufactur-
ers also were interested in reducing harshness to a mini-
mum and investigated acidic additives such as levulinic 
acid as “smoothing” agents. In that context, the natu-
ral basicity of a specific blend and the harshness of the 
smoke can be reduced by acidic additives such as levulinic 
acid, which tend to reduce αfb (Guess 1980; Stewart and 
Lawrence 1988).
In summary, nicotine in cigarette smoke exists in 
either a protonated or unprotonated form, depending on a 
number of factors, including the presence of natural acids 
and bases, the tobacco blend, tip ventilation, and the use 
of additives. Cigarette design ensures that the smoke has 
enough unprotonated nicotine to rapidly transfer nicotine 
into the body but not so much of it as to be too harsh for 
the smoker to continue to smoke.
N-Nitrosamines
N-nitrosamines are a class of chemical compounds 
containing a nitroso group attached to an amine nitro-
gen. There are two types of nitrosamines in tobacco 
and tobacco smoke: volatile and nonvolatile, includ-
ing TSNAs (Hoffmann et al. 1981; Tricker et al. 1991; 
Spiegelhalder and Bartsch 1996; IARC 2007). The 
volatile nitrosamines include N-nitrosodimethylamine, 
N-nitrosoethylmethylamine, N-nitrosodiethylamine, 
N-nitro-sopyrrolidine, and N-nitrosomorpholine. The 
nonvolatile nitrosamines are 4-(N-nitroso-N-methyl-
amino)butyric acid, N-nitrosopipecolic acid, N-nitroso-
sarcosine, 3-(N-nitroso-N-methylamino)propionic acid, 
N-nitrosoproline, and N-nitrosodiethanolamine. The 
nonvolatile TSNAs (Figure 3.4) have been examined 
extensively in tobacco and tobacco smoke. They include 
N’-nitrosonornicotine (NNN), 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK), N’-nitrosoanatabine 
(NATB), and N’-nitrosoanabasine (NAB). The levels of 
nitrosamines in tobacco products are higher than are 
those in other consumer products, such as cooked bacon 
and beer (Hecht and Hoffmann 1988), and smokers are 
exposed to higher levels of TSNAs than of the other nitro-
samines (Hoffmann et al. 1981; IARC 2007).
Studies have been conducted to identify precursors 
of nitrosamines and to determine the conditions required 
for their formation in tobacco. The primary intent of this 
research was to identify ways to reduce nitrosamine lev-
els in tobacco and tobacco smoke. Secondary and tertiary 
amines in tobacco, including the alkaloids, react with 
nitrosating agents to form N-nitrosamines (Hecht and 
Hoffmann 1988). Hecht and colleagues (1978) showed 
that both nicotine and nornicotine can react with sodium 
nitrite under controlled conditions to form carcino-
genic NNN and NNK, but nicotine is considered more 
important because of its higher level in tobacco products. 
TSNAs are not present at trace levels in freshly harvested 
tobacco, but they are predominantly formed during pro-
cessing, curing, and storage (Hoffmann et al. 1974, 1981; 
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Chamberlain et al. 1984; Andersen and Kemp 1985; Bhide 
et al. 1987; Djordjevic et al. 1989; Fischer et al. 1989b; 
Fisher 2000a). Aerobic bacteria play a major role in TSNA 
formation in air-cured tobacco (Hecht et al. 1975; Hoff-
mann et al. 1981; Parsons et al. 1986). In flue-cured 
tobacco, the curing conditions alter levels of nitrosamines 
(Fisher 2000a). Before the late 1960s and early 1970s, 
direct-fire curing in the United States did not produce 
high levels of TSNAs. When propane gas was introduced 
as the combustion source (Fisher 2000a), nitrogen oxides 
from the exhaust gases in tobacco barns reacted with alka-
loids in the tobacco plant to form TSNAs. Hoffmann and 
colleagues (Hoffmann et al. 1981; Brunnemann and Hoff-
mann 1991) also revealed that N-nitrosodiethanolamine is 
formed from the diethanolamine used in the formulation 
of maleic hydrazide, which is applied to regulate suckers 
on tobacco plants.
Volatile nitrosamines are found primarily in the gas 
phase of tobacco smoke, and TSNAs are almost exclusively 
found in the particulate phase (Guerin 1980). Researchers 
suggest that about one-half of the nitrosamines in tobacco 
smoke are transferred unchanged from the tobacco to the 
smoke and that the remainder is formed from pyrosynthe-
sis during smoking (Hoffmann et al. 1977; Adams et al. 
1983). Other researchers have concluded that almost all 
TSNAs are transferred directly from the tobacco (Fischer 
et al. 1990b).
It is difficult to determine whether TSNAs are 
pyrosynthesized or transferred intact, because the most 
important factors in nitrosamine formation such as con-
centrations of preformed TSNA in tobacco or their pre-
cursor, as well as chemical and physical processes during 
smoking, could affect either mechanism. Morie and Sloan 
(1973) reported that the nitrate and amine content in 
tobacco determined the amount of N-nitrosodimethyl-
amine formed in tobacco smoke. This finding has been 
widely duplicated by researchers looking at other nitrosa-
mines (Hecht et al. 1975; Brunnemann et al. 1977a, 1983; 
Hoffmann et al. 1981; Adams et al. 1983, 1984; Fischer et 
al. 1989b; Tricker et al. 1991; Atawodi et al. 1995; Spie-
gelhalder and Bartsch 1996). Other factors that influ-
ence nitrate concentrations in tobacco can also indirectly 
influence nitrosamine concentrations. Because TSNA 
content is strongly influenced by the use of stems that are 
naturally high in TSNAs in the cigarette rod, the increased 
use of stems leads to higher nitrosamines in the smoke 
(Brunnemann et al. 1983). Researchers have also found 
that the use of nitrogen fertilizer can contribute to the 
concentration of nitrosamines in tobacco and ultimately 
in the smoke (Johnson and Rhoades 1972; Tso et al. 1975; 
Brunnemann et al. 1977a; Chamberlain et al. 1984, 1986). 
Other influential factors identified were tobacco growth 
conditions, storage times, storage temperatures (Ander-
sen et al. 1982; Andersen and Kemp 1985), and the stalk 
positions from which the tobacco leaves are harvested 
(Chamberlain et al. 1986).
Another factor contributing to nitrosamine concen-
trations in tobacco is the type of tobacco used (Johnson 
Figure 3.4 Tobacco-specific nitrosamines
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and Rhoades 1972; Brunnemann et al. 1983; Fischer et 
al. 1989b,c). Oriental tobaccos are lowest in both nitrates 
and TSNAs (Fischer et al. 1989b), whereas burley tobacco 
contains the highest TSNA concentrations (Fischer et 
al. 1989b,c). The nitrosamine concentrations in bright 
tobacco are between those in oriental and burley and 
depend on the curing practices described earlier (Tso et al. 
1975; Hoffmann et al. 1979a). The TSNA concentrations 
are higher in blended cigarettes than in those made from 
bright tobacco, because burley is included in the blend 
(Fischer et al. 1990a). In most tobaccos, NNN concentra-
tions exceed NNK concentrations (Fischer et al. 1989b), 
but in bright tobacco, NNK concentrations exceed those 
of NNN (Fischer et al. 1989b, 1990a).
The preformed concentration of nitrosamines in 
tobacco leaves and stems is a major determinant of the 
levels in tobacco smoke (Fischer et al. 1990c; Spiegelhal-
der and Bartsch 1996). However, for cigarettes that have 
the same concentrations of nitrosamines in the tobacco, 
the nitrosamine levels in the smoke were largely deter-
mined by the degree of ventilation and the use of cellu-
lose-acetate filter tips in the cigarette. After examining 
machine-generated smoke, by the FTC/ISO method, from 
cigarettes containing the same type of tobacco, whether 
blended or bright only, researchers found that nitrosamine 
levels are correlated with tar delivery, which is primarily 
a function of filter ventilation (Adams et al. 1987; Fischer 
et al. 1990a). However, studies of cigarettes with different 
blends of tobacco have shown that tar is not an accurate 
measure of nitrosamine levels (Fischer et al. 1989c; Spie-
gelhalder and Bartsch 1996; Counts et al. 2004). Studies 
have also shown that cellulose-acetate filter tips remove 
both volatile nitrosamines and TSNAs (Morie and Sloan 
1973; Brunnemann et al. 1980; Rühl et al. 1980; Hoffmann 
et al. 1981). These findings indicate the importance of 
measuring TSNA levels in smoke, rather than using mea-
sured levels of tar or nicotine to predict levels of TSNAs in 
smoke on the basis of an average relationship between tar 
or nicotine and TSNAs. 
Nitrosamine levels measured in the tobacco and the 
smoke from cigarettes that were purchased around the 
world vary widely because of the differences cited above. 
Historically, the ranges of levels of NNN (2 to 12,454 
nanograms [ng] per cigarette), NAB+NATB (109 to 1,033 
ng), and NNK (55 to 10,745 ng) in cigarette tobacco were 
wide (Hoffmann et al. 1974; Fischer et al. 1989b, 1990a,c; 
Tricker et al. 1991; Atawodi et al. 1995; IARC 2004, 2007). 
More recent analyses have given more consistent results 
that depend on the blend of tobacco (NNN + NNK: 87 to 
1,900 ng/g) (Ashley et al. 2003). Levels in mainstream 
tobacco smoke, as reported by the FTC/ISO machine-
smoking method, have been reported at an order of mag-
nitude lower than those in tobacco (NNN = 4 to 1,353 ng 
generated per cigarette); NAB+NATB = 10 to 82 ng; and 
NNK = 5 to 1,749 ng (Fischer et al. 1989b, 1990a,c; Tricker 
et al. 1991; Atawodi et al. 1995; Mitacek et al. 1999). 
Using the ISO, Massachusetts (MDPH; 45-mL puff 
volume, 30-second puff interval, 50 percent of ventilation 
holes blocked) and Canadian Intense (CAN; 55-mL puff 
volume, 30-second puff interval, 100 percent of ventila-
tion holes blocked) smoking regimens, Counts and col-
leagues (2005) reported the levels of TSNAs in mainstream 
smoke from Philip Morris cigarettes sold internationally. 
The investigators found that in mainstream smoke, NNN 
levels were 5.0 to 195.3 ng generated per cigarette for ISO, 
16.3 to 374.2 ng for MDPH, and 20.6 to 410.6 ng for CAN. 
NNK levels were 12.4 to 107.8 ng generated per cigarette 
for ISO, 25.8 to 206.6 ng for MDPH, and 39.1 to 263.0 ng 
for CAN. NATB levels were 8.0 to 160.4 ng generated per 
cigarette for ISO, 31.9 to 295.3 ng for MDPH, and 43.5 to 
345.1 ng for CAN.
The combined levels of NNN and NNK reported by 
Wu and associates (2005) are in good agreement with the 
ranges reported by Counts and colleagues (2005). This 
finding suggests that the more advanced analytical meth-
ods used in these later studies yielded more accurate mea-
sures for current cigarettes than did previous measures. 
Levels of volatile nitrosamines in mainstream tobacco 
smoke are typically lower than those of the TSNAs 
(dimethylnitrosamine = 0.1 to 97 ng generated per 
cigarette; methylethylnitrosamine = 0.1 to 9.1 ng; and 
N-nitrosopyrrolidine = 1.5 to 64.5 ng) (Brunnemann et al. 
1977a, 1980; Adams et al. 1987). 
Ashley and colleagues (2003) compared TSNA con-
centrations in tobacco from Marlboro cigarettes with 
those in locally popular, non-U.S. brands of cigarettes in 
13 countries. For most of the countries, TSNA concentra-
tions in the tobacco from Marlboro cigarettes were higher 
than those in tobacco from locally popular brands from 
that country. TSNA concentrations varied widely (20-fold 
overall) between and within brands from the same coun-
try and differed significantly from country to country. This 
study confirmed earlier work showing wide variations in 
TSNA levels in tobacco and smoke from products within a 
country and between countries (Hecht et al. 1975; Fischer 
et al. 1990c; Spiegelhalder and Bartsch 1996; Gray et al. 
2000). The basic findings from this study were confirmed 
by work from Wu and colleagues (2005), who examined 
combined levels of NNN and NNK in the mainstream 
smoke from cigarettes from the same 13 countries and 
also found a wide variation in this matrix.
Identification of growing, curing, and blending 
practices that alter nitrosamine levels in tobacco and 
smoke have led researchers to agree that low TSNA lev-
els in smoke can be achieved by using particular varieties 
of tobacco and carefully controlling the factors leading to 
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formation and transfer of TSNAs from tobacco into smoke 
(Brunnemann et al. 1977a; Hoffmann et al. 1977; Hecht 
et al. 1978; Rühl et al. 1980; Andersen and Kemp 1985; 
Hecht and Hoffmann 1988; Fischer et al. 1990c; Spiegel-
halder and Bartsch 1996; Mitacek et al. 1999; Ashley et al. 
2003; Burns et al. 2008). To reduce TSNAs, tobacco curing 
in the United States is undergoing a transition, and nitro-
samine levels may change as curing and blending prac-
tices change (Counts et al. 2004; O’Connor et al. 2008). 
In summary, nitrosamines are found in tobacco and 
tobacco smoke at high levels compared with other con-
sumer products. The levels of these compounds, which are 
formed during tobacco processing, curing, and storage, 
can be minimized by breeding and selecting tobacco lines 
with lower propensity for TSNA formation, and limiting 
the use of nitrogen fertilizer, the levels of nitrogen oxides 
in the atmosphere during curing, the amount of burley 
tobacco in the blend, and storage times. The impact of dif-
ferent practices is clearly seen by the wide global range of 
TSNA levels in tobacco and smoke. 
Polycyclic Aromatic Hydrocarbons
PAHs are chemical compounds with two or more 
condensed aromatic and other cyclic rings of carbon and 
hydrogen atoms (Douben 2003). Recent studies (Rodg-
man and Perfetti 2006) have identified at least 539 PAHs in 
tobacco smoke. The U.S. Environmental Protection Agency 
(EPA) has identified 16 priority environmental PAHs on 
the basis of evidence that they cause or may cause can-
cer: acenaphthylene, acenaphthene, anthracene, benz[a]
anthracene, benzo[a]pyrene (B[a]P), benzo[b]fluoran-
thene (B[b]F), benzo[k]fluoranthene (B[k]F), benzo[g,h,i]
perylene, chrysene, dibenz[a,h]anthracene, fluoranthene, 
fluorene, indeno[1,2,3-cd]pyrene, naphthalene, phenan-
threne, and pyrene (Figure 3.5) (USEPA 1980, 1986). The 
16 PAHs, which have two to six fused rings and molecu-
lar weights of 128 to 278, were detected in the particulate 
matter of tobacco smoke (IARC 1986, 2004; Ding et al. 
2006, 2007). PAHs range from highly volatile to relatively 
nonvolatile, and their distribution in the particulate and 
gas phases of tobacco smoke varies with the boiling point 
(Grimmer et al. 1987). However, the gas phase contained 
only an estimated 1 percent of the total PAHs found in 
tobacco smoke. The composition of PAHs in mainstream 
smoke is different from that in sidestream smoke (Grim-
mer et al. 1987), and the lipophilic characteristics range 
from moderate to high (Douben 2003).
PAHs are formed by incomplete combustion of 
natural organic matter such as wood, petroleum, and 
tobacco and are found throughout the environment 
(Evans et al. 1993; Douben 2003). In the burning cone 
at the tip of the tobacco rod, various pyrolysis reactions 
occur to form methylidyne (CH) radicals that are precur-
sors to the pyrosynthesis of PAHs. Hoffmann and Wynder 
(1967) were the first to show that adding nitrate to tobacco 
reduced B[a]P levels. During smoking, nitrates form O2 and 
nitric oxide (NO), which intercept radicals and reduce 
PAH levels (Johnson et al. 1973a; Hoffmann and Hoffmann 
1997). Other researchers also reported that the presence 
of nitrate in tobacco decreases B[a]P levels in the smoke 
(Torikai et al. 2005). The pyrolytic conditions also favor 
the formation of PAHs from certain isoprenoids such as 
solanesol (IARC 1986), although other findings have dis-
agreed with this assessment (Torikai et al. 2005). B[a]P is 
the most widely known and studied PAH (IARC 2004). 
Differences in tobacco type can affect levels of PAHs 
in the smoke. Flue-cured (bright) or sun-cured (oriental) 
tobaccos have lower nitrate content than does air-cured 
(burley) tobacco. Pyrosynthesis of PAHs generates higher 
PAH levels in smoke from cigarettes made exclusively 
with flue-cured or sun-cured tobaccos than in smoke 
from cigarettes made with burley tobaccos (Hoffmann 
and Hoffmann 1997; Ding et al. 2005). Cigarettes made 
from reconstituted tobacco with cellulose fiber as an 
additive yield significantly reduced PAH levels. Evans 
and colleagues (1993) measured PAHs in mainstream 
and sidestream smoke and found that B[a]P, B[b]F, and 
B[k]F levels are related to tar yields in cigarette smoke 
that result from differences in cigarette ventilation.
Some studies reported the levels of B[a]P alone as a 
surrogate for the total PAH content. Ding and colleagues 
(2005) observed that total PAH levels in mainstream 
smoke from commercial cigarette brands varied from 1 to 
1.6 µg generated per cigarette under FTC machine-smok-
ing conditions. In the same study, individual PAHs ranged 
from less than 10 ng generated per cigarette (B[k]F) to 
approximately 500 ng (naphthalene) (Ding et al. 2005). 
Other researchers reported levels of B[b]F at 10.4 ng, 
B[k]F at 5.1 ng, and B[a]P at 13.4 ng generated per cig-
arette (Evans et al. 1993). In four of five brands tested, 
B[a]P concentrations in cigarette tar were about 0.5 ng/
mg of tar (Tomkins et al. 1985). Kaiserman and Rickert 
(1992) reported the levels of B[a]P in smoke from 35 
brands of Canadian cigarettes by using the ISO method; 
mean levels were 3.36 to 28.39 ng generated per cigarette. 
Although B[a]P levels were linearly related to declared tar 
values, the tar values and the B[a]P levels did not change 
at the same relative rate. In a study of PAHs in mainstream 
smoke from cigarettes from 14 countries, Ding and col-
leagues (2006) showed a significant global variation in lev-
els. They also demonstrated an inverse relationship with 
TSNA levels at high PAH and low TSNA levels, possibly as 
a result of differences in nitrate levels.
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Figure 3.5 Priority environmental polycyclic aromatic hydrocarbons
In summary, PAHs result from the burning of bio-
logic material, so they are present in the smoke from 
any form of burning tobacco. Factors that can affect PAH 
levels in tobacco smoke include the type of tobacco and 
its nitrate content. Because of divergent pyrosynthetic 
mechanisms, factors that increase the nitrate content of 
tobacco decrease PAH levels but may increase TSNA levels 
in cigarette smoke. However, a substantial reduction in 
PAH levels in cigarette smoke will be a challenge as long 
as tobacco smoke is generated from burning tobacco.
Volatile Compounds Including 
Aldehydes
When a cigarette is smoked, chemicals partition 
between the particulate and gas phases on the basis of phys-
ical properties including volatility and solubility (Hoff-
mann and Hoffmann 1997). Complete partitioning of any 
chemical to the gas phase of cigarette smoke is generally 
limited to the gaseous products of combustion, such as the 
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oxides of nitrogen, carbon, and sulfur, and the extremely 
volatile low-molecular-weight organic compounds. There 
are between 400 and 500 volatile gases and other com-
pounds in the gas phase (Hoffmann and Hoffmann 1997). 
The nearly complete combustion of the cigarette tobacco 
filler generates an effluent stream of gaseous chemicals 
residing almost exclusively in the gas phase portion of 
mainstream cigarette smoke. These chemicals, on the 
basis of weight, account for most of the mainstream 
smoke. In order by prevalence, these chemicals include 
N2, O2, CO2, CO, nitrogen oxides, and the sulfur-contain-
ing gaseous compounds.
CO and CO2 result from the combustion of tobacco. 
Other than N2 and O2, CO and CO2 are the most abundant 
compounds in mainstream cigarette smoke, represent-
ing nearly 15 percent of the weight of the gas phase. CO2 
levels (approximately 50 mg generated per cigarette) are 
more abundant than are CO levels (approximately 20 mg), 
as determined by the FTC machine-smoking method.
Nitrogen oxide gases are formed by the combus-
tion of nitrogen-containing amino acids and proteins in 
the tobacco leaf (Hoffmann and Hoffmann 1997). Main-
stream cigarette smoke contains mostly NO with traces of 
nitrogen dioxide (NO2) and nitrous oxide. The formation 
of nitrogen oxides is amplified by combustion with nitrate 
salts, and the amount formed is directly related to the 
nitrate concentration of the tobacco leaf (MacKown et al. 
1999). The mainstream cigarette smoke contains approxi-
mately 500 µg of NO generated per cigarette. Although 
fresh smoke contains little NO2, the aging of the smoke 
converts the reactive NO to NO2, which has an estimated 
half-life of 10 minutes (Borland et al. 1985; Rickert et 
al. 1987). These gases react with water and other com-
ponents in cigarette smoke to form nitrate particles and 
acidic constituents.
Sulfur-containing gases result from the combustion 
of sulfur-containing amino acids and proteins (Horton 
and Guerin 1974). In mainstream cigarette smoke, H2S 
is the most abundant of these gases (approximately 85 µg 
generated per cigarette), and both sulfur dioxide and car-
bon disulfide are present in smaller quantities (approxi-
mately 2 µg). 
In addition to the volatile gases, mainstream ciga-
rette smoke contains a wide range of volatile organic com-
pounds (VOCs) (Counts et al. 2005; Polzin et al. 2007). 
The formation of these VOCs results from the incomplete 
combustion of tobacco during and between puffs. The 
generation of VOCs, as well as the previously mentioned 
volatile gases, is directly related to the tar delivery of the 
cigarette, as evidenced by machine smoking under the 
FTC regimen (Hoffmann and Hoffmann 1997; Polzin et 
al. 2007). Therefore, factors altering the yield of tar (e.g., 
tobacco blend, cigarette filter, filter ventilation, paper 
porosity, and tobacco weight) directly affect the yield of 
VOCs. Under certain machine-smoking conditions, the 
use of charcoal filters (Williamson et al. 1965; Counts et 
al. 2005; Laugesen and Fowles 2006; Polzin et al. 2008), 
variations in the temperature in the burning zone, and 
the presence or absence of O2 can substantially alter the 
levels of VOCs generated in cigarette smoke (Torikai et 
al. 2004). The VOCs in mainstream cigarette smoke, as a 
result of their high biologic activity and levels, are among 
the most hazardous chemicals in cigarette smoke (Fowles 
and Dybing 2003; IARC 2004). In developed countries, the 
combined exposure of smokers to mainstream cigarette 
smoke and nonsmokers to secondhand smoke constitutes 
a significant portion of the population’s total exposure 
to certain VOCs. For example, more than one-half of the 
U.S. population’s exposure to benzene is from cigarette 
smoking (U.S. Department of Health and Human Services 
[USDHHS] 2002). The roughly 500 VOCs in the gas phase 
of mainstream cigarette smoke can be subclassified by 
structure. Among the most significant classes are the aro-
matic hydrocarbons, carbonyls, aliphatic hydrocarbons, 
and nitriles. Although other classes of volatile compounds 
(e.g., acids and bases) are present, these four classes of 
VOCs have been the most widely studied, because of their 
biologic activity and overall higher levels.
Aromatics are a class of compounds defined by their 
structural similarity to benzene. These compounds result 
from incomplete combustion of the organic matter of the 
cigarette, most notably sugars and cellulose (Chortyk and 
Schlotzhauer 1973). The most abundant aromatic com-
pounds in mainstream smoke generated from full-flavored 
cigarettes with use of the FTC/ISO smoking regimen are 
toluene (approximately 5 to 80 µg generated per cigarette), 
benzene (approximately 4 to 60 µg), total xylenes (approx-
imately 2 to 20 µg), styrene (approximately 0.5 to 10 µg), 
and ethylbenzene (approximately 1 to 8 µg) (Counts et al. 
2005; Polzin et al. 2007).
Carbonyl compounds include the ketones and 
aldehydes. These compounds are studied because of their 
reactivity and levels, which approach 1 mg generated per 
cigarette. The most prevalent aldehydes in mainstream 
smoke from cigarettes, generated using the ISO regimen, 
are acetaldehyde (approximately 30 to 650 µg generated 
per cigarette), acrolein (approximately 2.5 to 60 µg), and 
formaldehyde (approximately 2 to 50 µg) (Counts et al. 
2005). The most prevalent ketones in mainstream ciga-
rette smoke, generated by using the FTC/ISO smoking 
regimen, are acetone (approximately 50 to 550 µg gener-
ated per cigarette) and 2-butanone (approximately 10 to 
130 µg) (Counts et al. 2005; Polzin et al. 2007). Spincer 
and Chard (1971) identified formaldehyde in both the 
particulate and gas phases of tobacco smoke and found 
that much of the formaldehyde was associated with total 
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particulate matter (TPM). These investigators determined 
that formaldehyde delivery was higher in smoke from 
bright tobacco than in that from burley tobacco. 
On the basis of total mass, hydrocarbons represent 
the largest VOC class in mainstream cigarette smoke 
(Hoffmann and Hoffmann 1997). Both saturated hydrocar-
bons and olefins result from the incomplete combustion 
of cigarette tobacco. The most abundant hydrocarbons in 
cigarette smoke are methane, ethane, and propane, which 
represent nearly 1 percent of the total cigarette effluent. 
Unsaturated hydrocarbons are also present in significant 
quantities in mainstream cigarette smoke, as evidenced by 
using the ISO regimen, but the olefins isoprene (approxi-
mately 70 to 480 µg generated per cigarette) and 1,3-buta-
diene (approximately 6.5 to 55 µg) are the most abundant 
unsaturated hydrocarbons (Counts et al. 2005).
The volatile nitriles, which include compounds such 
as HCN, acetonitrile, and acrylonitrile, are important 
because of their toxic effects. The most abundant nitriles 
in mainstream smoke generated from cigarettes by using 
the ISO regimen are HCN (approximately 3 to 200 µg gen-
erated per cigarette), acetonitrile (approximately 100 µg), 
and acrylonitrile (approximately 1 to 12 µg) (Counts et 
al. 2005).
In summary, cigarette smoke is composed primarily 
of  gaseous and volatile compounds. Thus, levels of these 
compounds are critical in determining the overall toxicity 
of tobacco smoke. Differences in the design of the ciga-
rette can have a substantial effect on the levels determined 
in smoke, which makes the reproducibility of results chal-
lenging, but provides knowledge of possible mechanisms 
to reduce the exposure of smokers.
Heavy Metals
Metals and metalloids are among the many sub-
stances contained in tobacco smoke; they are often loosely 
called “heavy metals” without regard to whether they are 
light- or heavy-mass metals or metalloids. Their chemical 
properties span a wide range. These substances are found 
as pure metals or as metals naturally associated or chemi-
cally bound to other elements that can significantly alter 
the chemical properties of the metals.
Although metals can be deposited on tobacco 
leaves from particles in the air and some fungicides and 
pesticides containing toxic metals have been sprayed on 
tobacco leaves or soils in the past (Frank et al. 1977), 
most of the metals present in plants are absorbed from 
the soil (Schwartz and Hecking 1991; Cheng 2003; Xiao 
et al. 2004a,b). Soils, therefore, including any amend-
ments to the soil, such as sludge, fertilizers, or irrigation 
with polluted water have been the predominant source 
of metals found in tobacco grown in various geographic 
areas (Bache et al. 1985; Mulchi et al. 1987, 1991, 1992; 
Adamu et al. 1989; Bell et al. 1992; Rickert and Kaiserman 
1994; Stephens et al. 2005). Cadmium and lead content in 
tobacco and smoke have been correlated with the con-
tent in the soil in which the tobacco was grown, after 
adjustment for the amendments to the soil (Bache et 
al. 1985; Adamu et al. 1989; Mulchi et al. 1991, 1992; 
Bell et al. 1992; Rickert and Kaiserman 1994; Stephens 
et al. 2005). In addition, Rickert and Kaiserman (1994) 
showed that heavy metals in the air can be important. For 
example, significant changes in the lead concentrations 
in the air between 1974 and 1988 accounted for most of 
the changes in lead levels in tobacco during that period. 
Researchers have associated the mercury content in 
tobacco with environmental factors and soil in geographic 
areas where the tobacco was grown (Rickert and Kai-
serman 1994). Mulchi and colleagues (1992) have also 
suggested that consideration of soil pH is important to 
understanding the relationship between metals in the soil 
and metals in the tobacco leaf. Because of differences in 
the soil, air, and metal uptake by the tobacco plant, the 
metal content of tobaccos varies widely.
Most metals and metalloids are not volatile at room 
temperature. Pure metallic mercury is volatile, but only a 
few forms are volatile at temperatures lower than 100oC. 
The temperature of tobacco that burns at the tip of a ciga-
rette may reach 900oC (Baker 1981). A burning cigarette 
tip is hot enough to volatilize many metals into the gas 
phase, but by the time the smoke is inhaled or rises in a 
plume from the cigarette as secondhand smoke, most of 
the metals have condensed and moved into the particu-
late portion of the smoke aerosol (Baker 1981; Chang et 
al. 2003).
The range of levels of toxic metals found in tobacco 
smoke reflects differences in cigarette manufacturing 
processes, ventilation, additives, concentrations in the 
tobacco, and the efficiency with which the metal transfers 
from the leaf to the smoke. The transfer rate of metals 
from tobacco into smoke also depends on the properties 
of the metal (Krivan et al. 1994). Because tobacco plants 
easily absorb and accumulate cadmium from the soil, 
cadmium is found at relatively high concentrations in 
tobacco leaves. This accumulation, along with the high 
percentage of transfer from the leaves into the smoke 
(Schneider and Krivan 1993), yields high cadmium lev-
els in tobacco smoke (Chiba and Masironi 1992). Kalcher 
and colleagues (1993) developed a model for the behavior 
of metals in mainstream smoke and found that most of 
the cadmium in tobacco smoke is in the particulate phase, 
whereas lead is equally partitioned between the particu-
late and gas phases. Cadmium levels have been reported 
to range from 10 to 250 ng generated per cigarette in the 
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particulate phase (Allen and Vickroy 1976; Bache et al. 
1985; Nitsch et al. 1991; Schneider and Krivan 1993; Kri-
van et al. 1994; Rhoades and White 1997; Csalári and Szán-
tai 2002; Torrence et al. 2002) to a lower level of 1 to 31 
ng in the gas phase (Nitsch et al. 1991). More recent stud-
ies of cadmium levels in particulate matter in smoke from 
commercial cigarettes smoked under FTC/ ISO conditions 
reported a range of 1.6 to 101.0 ng generated per cigarette 
(Counts et al. 2005; Pappas et al. 2006). Not surprisingly, 
Counts et al. (2005) also showed that levels of cadmium in 
smoke generated using more intense smoking regimens 
such as MDPH (12.7 to 178.3 ng generated per cigarette) 
and CAN (43.5 to 197.1 ng generated per cigarette) were 
higher than when using FTC/ISO. This increase was also 
seen with other metals tested. These studies also demon-
strated that changes in cigarette design, such as introduc-
ing filter ventilation, reduces the delivery of metals under 
FTC/ISO smoking conditions. In counterfeit cigarettes, 
levels of cadmium in particulate matter from mainstream 
smoke can be significantly higher, ranging from 40 to 300 
ng generated per cigarette, under FTC smoking condi-
tions (Pappas et al. 2007). 
Lead also transfers well from tobacco to smoke 
(Schneider and Krivan 1993); measurements range 
from 18 to 83 ng generated per cigarette in the partic-
ulate phase (Allen and Vickroy 1976; Nitsch et al. 1991; 
Schneider and Krivan 1993; Krivan et al. 1994; Csalári and 
Szántai 2002; Torrence et al. 2002; Baker et al. 2004) and 
from 6 to 149 ng in the gas phase (Nitsch et al. 1991). 
More recent studies of lead levels in particulate matter in 
smoke from commercial cigarettes smoked under FTC/
ISO conditions reported a range of 4 to 39 ng generated 
per cigarette (Counts et al. 2005; Pappas et al. 2006). Stud-
ies of cigarettes in the United Kingdom have documented 
concentrations of heavy metals in a number of counterfeit 
cigarette brands that were higher than those in domestic 
products (Stephens et al. 2005). These metals included 
arsenic, cadmium, and lead. In counterfeit cigarettes, 
levels of lead in mainstream cigarette smoke can be sig-
nificantly higher, ranging up to 330 ng generated per ciga-
rette, under FTC smoking conditions (Pappas et al. 2007). 
Studies have also found similar levels of nickel in both 
phases: particulate levels range from 1.1 to 78.5 ng gener-
ated per cigarette (Bache et al. 1985; Nitsch et al. 1991; 
Schneider and Krivan 1993; Torjussen et al. 2003), and 
gas phase levels range from 3 to 57 ng (Nitsch et al. 1991).
Tobacco smoke also contains lower levels of other 
metals. The range of levels found in the particulate phase 
includes cobalt, 0.012 to 48.0 ng generated per cigarette; 
arsenic, 1.5 to 21.0 ng; chromium, 1.1 to 1.7 ng; anti-
mony, 0.10 to 0.13 ng; thallium, 0.6 to 2.4 ng; and mer-
cury, 0.46 to 6.5 ng (Allen and Vickroy 1976; Suzuki et 
al. 1976; Nitsch et al. 1991; Schneider and Krivan 1993; 
Krivan et al. 1994; Rhoades and White 1997; Milnerow-
icz et al. 2000; Shaikh et al. 2002; Torrence et al. 2002; 
Baker et al. 2004; Pappas et al. 2006). Gas phase levels de-
pend on the volatility of the metals or metal complexes. 
Cobalt levels range from less than 1 to 10 ng generated per 
cigarette, and mercury levels range from 5.0 to 7.4 ng 
generated per cigarette (Nitsch et al. 1991; Chang et al. 
2002). In a limited analysis, Chang and colleagues (2003) 
found arsenic and antimony in the gas phase but did not 
provide quantitative results.
Studies have identified radioactive elements in 
tobacco and tobacco smoke. Lead 210, a product of 
radioactive decay of radon, was found in tobacco (Peres 
and Hiromoto 2002) and is transported at low levels in 
tobacco smoke (Skwarzec et al. 2001). Most of the lead 
in tobacco smoke is the nonradioactive isotopes. Polo-
nium, an element found only in radioactive forms, is also 
a product of radioactive decay of radon. Some research-
ers have found polonium 210 in tobacco (Skwarzec et al. 
2001; Peres and Hiromoto 2002; Khater 2004), and others 
estimated transfer of 11 to 30 percent of the amount in 
tobacco to tobacco smoke (Ferri and Baratta 1966). The 
presence of a filter and the type of filter used can alter the 
amount of polonium transferred into mainstream smoke; 
some filters remove 33 to 50 percent of the polonium from 
the smoke (Ferri and Baratta 1966). 
In summary, the levels of metals in tobacco smoke 
are primarily a function of their content in the soil in 
which the tobacco is grown, added substances such as fer-
tilizer, and the design of the cigarette. Study findings indi-
cate that (1) growing conditions for tobacco contribute to 
the levels of metals in cigarettes manufactured worldwide 
and (2) some counterfeit cigarettes have higher levels 
of metals than do domestic commercial cigarettes. This 
evidence has proved that tobacco-growing conditions can 
alter the concentrations of metals in cigarette tobacco and 
therefore the levels in the smoke. 
Aromatic Amines
Aromatic amines and their derivatives are used in 
the preparation of dyes, pharmaceuticals, pesticides, and 
plastics (Brougham et al. 1986; Bryant et al. 1994; Cen-
ters for Disease Control and Prevention [CDC] 1994) and 
in the rubber industry as antioxidants and accelerators 
(Parmeggiani 1983). Because of their widespread use, 
aromatic amines are prevalent and may be found as con-
taminants in some color additives, paints, food colors, and 
leather and textile dyes and in the fumes from heating oils 
and fuels. Studies that measured aromatic amines in the 
ambient environment detected their presence and deter-
mined concentrations in air, water, and soil (Birner and 
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Neumann 1988; Del Santo et al. 1991; Ward et al. 1991; 
Skipper et al. 1994; Sabbioni and Beyerbach 1995). Aro-
matic amines consist of at least one hydrocarbon ring and 
one amine-substituted ring, but these agents have diverse 
chemical structures. Chemically, aromatic amines act as 
bases and most exist as solids at room temperature.
Some scientists have suggested that aromatic 
amines are present in unburned tobacco (Schmeltz and 
Hoffmann 1977) and are also formed as combustion prod-
ucts in the particulate phase of tobacco smoke (Patriana-
kos and Hoffmann 1979). Investigators determined levels 
of aromatic amines in both mainstream and sidestream 
smoke (Hoffmann et al. 1969; Patrianakos and Hoffmann 
1979; Grimmer et al. 1987; Luceri et al. 1993; Stabbert et 
al. 2003a). The identified compounds include aniline; 1-, 
2-, 3-, 4-toluidine; 2-, 3-, 4-ethylaniline; 2,3-, 2,4-, 2,5-, 
2,6-dimethylaniline; 1-, 2-naphthylamine; 2-, 3-, 4-ami-
nobiphenyl; and 2-methyl-1-naphthylamine. The most 
commonly studied compounds from this class are shown 
in Figure 3.6. Stabbert and colleagues (2003a) found that 
aromatic amines reside primarily in the particulate phase 
of smoke, except for the more volatile amines such as 
o-toluidine; only 3 percent of o-toluidine was found in the 
gas phase. Studies have reported that sidestream smoke 
contains substantially higher levels of aromatic amines 
than does mainstream smoke, but these levels depend on 
the parameters for puffing the cigarette (Patrianakos and 
Hoffmann 1979; Grimmer et al. 1987; Luceri et al. 1993). 
For mainstream smoke, the levels of aromatic amines 
were reported to be 200 to 1,330 ng generated per ciga-
rette (Luceri et al. 1993; Stabbert et al. 2003a), but stud-
ies have reported much higher levels in sidestream smoke 
(Luceri et al. 1993). More recently, one study reported 
the following levels of aromatic amines in mainstream 
cigarette smoke (Counts et al. 2005). Using the ISO regi-
men, these investigators determined that levels were 3 
to 27 ng generated per cigarette for 1-aminonaphtha-
lene; 2 to 17 ng for 2-aminonaphthalene; 0.6 to 4.2 ng for 
3-aminobiphenyl; and 0.5 to 3.3 ng for 4-aminobiphenyl. 
These levels increased on average by approximately 115 
percent when the MDPH smoking regimen was used and 
by approximately 130 percent under the CAN smok- 
ing regimen.
Levels of aromatic amines in tobacco smoke are 
influenced by both the chemical constituents in the 
tobacco and the chemical and physical processes of the 
burning cigarette. Levels of aromatic amines in smoke 
from cigarettes made with dark tobacco are higher than 
those in cigarettes made from light tobacco (Luceri et al. 
1993). For typical U.S.-blended cigarettes, there is a linear 
correlation between levels of aromatic amines and tar in 
the smoke (Stabbert et al. 2003a). 
Sources of nitrogen in the tobacco also significantly 
influence levels of aromatic amines in tobacco smoke. 
Nitrate is a primary factor in altering the level of aromatic 
amines in tobacco smoke, and its presence is influenced by 
the use of nitrogen fertilizers (Patrianakos and Hoffmann 
1979; Stabbert et al. 2003a). Protein in tobacco is known 
to be a good source of biologic nitrogen, and studies have 
reported that higher nitrogen content from elevated pro-
tein in tobacco increased the yields of 2-naphthylamine 
and 4-aminobiphenyl (Patrianakos and Hoffmann 1979; 
Torikai et al. 2005). Cigarette smoke from bright tobacco 
had lower aromatic amine levels than expected compared 
with the smoke of U.S. blended cigarettes, possibly because 
of the lower nitrogen content in bright tobacco (Stabbert 
et al. 2003a). Combustion temperature is also a factor 
in the generation of aromatic amines in tobacco smoke, 
because lower temperatures yielded lower levels of aro-
matic amines in smoke (Stabbert et al. 2003b). Other 
investigators have suggested that increased cellulose lev-
els in tobacco can decrease aromatic amines in the smoke 
(Torikai et al. 2005), and in another study, cellulose- 
acetate filters removed a substantial portion of aromatic 
amines from mainstream smoke (Luceri et al. 1993).
In summary, it appears that the nitrogen content in 
tobacco, either from protein levels or use of nitrogen fer-
tilizer, is a primary determinant of aromatic amine levels 
in tobacco smoke. The type of tobacco used in the ciga-
rette filler also alters these levels in tobacco smoke. 
Figure 3.6 Commonly studied aromatic amines in tobacco smoke
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Heterocyclic Amines
Heterocyclic amines (HCAs) are a class of chemi-
cal compounds that contain at least one cyclic ring and 
an amine-substituted ring. HCAs act as basic compounds 
because of the amine functional group. HCAs can occur 
in food stuff, such as grilled meats, poultry, fish, and 
tobacco smoke (Sugimura et al. 1977; Sugimura 1997; 
Skog et al. 1998; Murkovic 2004). HCAs are classified in 
two groups: one is produced by the pyrolysis of amino 
acids and proteins through radical reactions, and the 
other is generated by heating mixtures of creatinine, sug-
ars, and amino acids (Sugimura 1997; Murkovic 2004). 
The first group dominates when the pyrolysis temperature 
is high, whereas the second group is predominant at low 
temperatures commonly used to cook meat (Sugimura 








ure 3.7) (Kataoka et al. 1998).
HCAs are not found in unburned tobacco; they are 
present in tobacco smoke as a result of pyrolysis and are 
found in the particulate phase (Manabe and Wada 1990). 
Figure 3.7 Primary heterocyclic amines in tobacco smoke
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The chemical composition of amino acids, protein, sug-
ars, and creatine/creatinine in the tobacco filler influences 
the final HCA levels in the smoke. Other components that 
may alter the pyrolysis of amino acids can also change 
HCA levels in smoke. The usual levels of HCAs in tobacco 
smoke were reported to be 0.3 to 260.0 ng generated per 
cigarette (Hoffmann et al. 2001). Manabe and Wada (1990) 
reported levels of 0.29 to 0.31 ng of Trp-P-1 generated per 
cigarette and 0.51 to 0.66 ng for Trp-P-2 in smoke conden-
sate from five types of cigarettes. Manabe and colleagues 
(1991) determined an average level of 16.4 ng generated 
per cigarette for PhIP in tobacco smoke condensate from 
cigarettes purchased in Japan, the United Kingdom, and 
the United States.
In summary, although HCAs are not specific to 
tobacco products, they are found at levels in tobacco 
smoke particulate that must be considered when assess-
ing the harm from the use of burned tobacco. The con-
centration of nitrogen-containing compounds in tobacco 
influences the levels of HCAs that are found in the smoke, 
and reducing the nitrogen content may be a means of 
reducing HCAs.
Effect of Additives on  
Tobacco Smoke
Chemical additives are introduced into cigarette 
tobacco for a variety of specific purposes, including pH 
adjustment, maintenance of moisture (humectants), ame-
lioration of the harshness of smoke, control of the burn 
rate, and impartation of desirable flavor to the smoke 
(Penn 1997). The taste and flavor of cigarette smoke is 
affected primarily by the tobacco blend and is further 
modified with additives. Specific additives are applied 
to mask the harshness of lower-quality tobacco (World 
Tobacco 2000). Early in the processing of burley and flue-
cured tobaccos, a solution called “casing” is added to the 
shreds of tobacco lamina. The casing is a slurry containing 
humectants (e.g., glycerol and propylene glycol) and fla-
vor ingredients with low volatility (e.g., cocoa, honey, lico-
rice, and fruit extracts) that lend a pleasant aroma. After 
the tobacco is aged, a top-flavoring solution is added to the 
finished cigarette blend. Top flavoring is generally an alco-
hol- or rum-based mixture containing volatile compounds 
(e.g., menthol) and other ingredients (e.g., aromatic com-
pounds, essential oils, and extracts) that are added imme-
diately before packaging (Penn 1997; Fisher 1999).
Even though the specific ingredients added to indi-
vidual cigarette brands are proprietary, a collective list of 
599 additives used in U.S. cigarettes has been published 
on the World Wide Web (Indiana Prevention Resource 
Center 2005). The “599 list” contains individual chemical 
compounds and complex additives, such as essential oils, 
juices, powders, oleoresins, and extracts. Included in the 
list are complex natural extracts and essential oils, such 
as anise, cassia, cedarwood, chocolate, cinnamon, gin-
ger, lavender, licorice, nutmeg, peppermint, valerian, and 
vanilla. The list also includes individual organic chemi-
cal compounds, such as 1-menthol, 3-methyl penta-
noic acid, anethole, β-caryophyllene, caffeine, ethyl 
acetate, γ-decalactone, isoamyl acetate, methyl cinnamate, 
sucrose, and vanillin. The compounds in the 599 list have 
been approved by the U.S. Food and Drug Administration 
as generally recognized as safe for use in foods (Hoffmann 
and Hoffmann 1997). Virtually any material with this 
approval as a food additive is used in cigarette manufactur-
ing (World Tobacco 2000). However, this use is based on 
the broad assumption that additives designated as safe for 
ingestion are safe to burn and inhale in cigarette smoke. 
Because of the detoxifying action of the liver on blood 
coming directly from the digestive tract and the move-
ment of blood from the lungs into the general circulation 
without first passing through the liver, the toxic effects 
associated with ingesting a compound can differ from the 
toxic effects of breathing it. Studies indicated that euge-
nol, a compound found in many natural extracts and used 
as an additive in clove cigarettes, had an LD50 200 times 
lower in Fischer rats when administered intratracheally 
compared with gavage (LaVoie et al. 1986). Although this 
did not simulate inhalation, it did raise concern about 
increased toxicity of this compound to the lung. 
Cigarette tobacco is a complex physicochemical 
mixture containing several types of tobacco and numer-
ous additives (Hoffmann and Hoffmann 1997). The fla-
vor compounds in tobacco can be transferred into the 
smoke by distillation, combustion, or pyrolysis (Green et 
al. 1989). Newly emerging flavored “dessert” cigarettes 
marketed under names such as Midnight Berry, Mandarin 
Mint, and Mocha Taboo (Carpenter et al. 2005) may repre-
sent new sources of exposure to harmful substances, but 
the qualitative and quantitative differences in smoke from 
these cigarettes have not been described.
One of the most common tobacco additives is men-
thol, a monoterpene alcohol (Burdock 1995) first used in 
cigarettes in the mid-1920s (Reynolds 1981) and subse-
quently added to most cigarettes (Eccles 1994). Natural 
sources of menthol include plants in the mint family, 
namely, peppermint (Mentha piperita) and corn mint 
(Mentha arvensis) (Burdock 1995). Flavorants derived 
from natural sources generally contain a mix of com-
pounds, in contrast to flavoring compounds that are 
chemically synthesized. If menthol added to the tobacco 
is derived from natural sources, such as peppermint, 
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constituents such as pulegone may also be present at low 
concentrations. Submicrogram concentrations of pule-
gone (0.024 to 0.29 µg/g) were measured in 12 mentho-
lated brands but were not detected in nonmentholated 
brands (Stanfill and Ashley 1999). Menthol can be added 
on the tobacco, the filter, or the foil pack (Wayne and 
Connolly 2004). Menthol levels in smoke have ranged be-
tween 0.15 and 0.58 mg generated per cigarette for sev-
eral brands (Cantrell 1990). Unlike most nonmentholated 
cigarettes, menthol cigarettes usually contain more flue-
cured and less burley tobacco, along with reconstituted 
tobacco made without added ammonia.
Although they generally are regarded as safe for use 
in foods, certain flavor-related chemicals added to ciga-
rettes and found in cigarette smoke (Stanfill and Ashley 
1999) have known toxic properties. In an analysis of 12 
flavor compounds in tobacco fillers from 68 U.S. cigarette 
brands, concentrations of compounds were 0.0018 to 43.0 
μg/g (Stanfill and Ashley 1999). Also, 62 percent of the 68 
brands contained detectable levels of 1 or more of the 12 
flavor compounds. Piperonal and myristicin were present 
at the highest concentrations. Anethole, myristicin, and 
safrole were found in 20 percent or more of the brands; 
pulegone, piperonal, and methyleugenol were each pres-
ent in at least 10 percent of the brands. In four brands, 
safrole, myristicin, and elemicin were found together, 
which strongly suggests the presence of flavorings such as 
nutmeg or mace (Myristica fragrans) in the tobacco. Cou-
marin is a benzopyrone compound found in the tobacco 
of one menthol brand at a concentration of 0.39 μg/g. 
Pulegone, a monoterpene ketone found in peppermint, 
was present only in mentholated brands. Tentative iden-
tification of other compounds suggested the use of flavor 
agents such as cinnamon and ginger (Stanfill and Ashley 
1999). In addition to tobacco analysis, mainstream smoke 
particulates from several brands were also analyzed for six 
flavor compounds: eugenol, isoeugenol, methyleugenol, 
myristicin, elemicin, and piperonal (Stanfill and Ashley 
2000). Levels of these compounds in the smoke from eight 
U.S. cigarette brands were 0.0066 to 4.21 μg generated per 
cigarette. The measurements suggested that a portion of 
eugenol and isoeugenol in smoke from some cigarettes 
could be a by-product of the burning tobacco. Also, when 
filter ventilation holes in the cigarette were partially or 
fully blocked, the transfer of these compounds from 
tobacco filler to mainstream smoke particulates increased 
twofold to sevenfold.
In summary, the impact of flavor-related additives 
on the toxicity, carcinogenicity, and addictive properties 
of tobacco products has not been thoroughly studied. In 
addition to the known harmful properties of these com-
pounds, they may potentiate the effects of other known 
smoke constituents or alter the way people smoke 
cigarettes. These additives may also increase the initiation 
and continuation of smoking in the population.
Delivery of Chemical Constituents 
into Tobacco Smoke
Various tobacco types are used in the manufacture 
of cigarettes and other tobacco products. Lamina from 
bright, burley, and oriental tobacco varieties, along with 
reconstituted tobacco sheet, is the main filler component 
used in cigarettes (Hoffmann and Hoffmann 1997). In 
addition to lamina, cigarette filler often contains puffed 
or expanded tobacco, tobacco stems, humectants, and 
various flavor additives (Hoffmann and Hoffmann 1997; 
Abdallah 2003a). One tobacco variety such as bright can 
be used, or several varieties can be mixed together in 
products with specific tobacco blends. Most commercial 
cigarettes are constructed primarily from bright tobacco 
or from a blend of mainly bright, burley, and oriental 
tobaccos, usually referred to as an American blend (Browne 
1990). However, a few small geographic areas outside the 
United States (e.g., France) have regional preferences for 
cigarettes made exclusively from dark, air-cured tobacco 
(Akehurst 1981; Tso et al. 1982). Each type of tobacco has 
unique properties that influence packing density (Artho 
et al. 1963), burn rate (Muramatsu 1981), tar and nico-
tine delivery (Griest and Guerin 1977), and flavor and 
aroma (Davis 1976; Enzell 1976; Leffingwell 1976). Bright 
tobacco, also known as flue-cured or Virginia tobacco, has 
lower nitrogen content (i.e., less protein) and higher sugar 
content than do the other varieties. Burley and Maryland 
tobaccos are air cured and typically have higher nicotine 
content but reduced sugar content. 
Sakuma and colleagues (1984) measured the smoke 
components in mainstream and sidestream smoke and 
found that nitrogen-containing compounds were abun-
dant in smoke from burley tobacco, whereas the non-
nitrogen-containing compounds were more abundant 
in smoke from bright and oriental tobaccos. Oriental 
tobacco is often included in blended varieties because of 
its unique aromatic properties (Browne 1990). Cigarettes 
such as light or ultralight varieties that deliver low yields 
of tar and nicotine by FTC/ISO machine measurement 
often contain puffed or expanded tobacco lamina with 
higher “filling power” (Kertsis and Sun 1984; Lewis 1990; 
Kramer 1991), which lowers the density of the tobacco 
rod, thus lowering the amount of tobacco in each ciga-
rette. Several types of reconstituted tobacco sheet are also 
used to manufacture cigarettes (Abdallah 2003b).
Development of reconstituted tobacco was an 
attempt at 100-percent utilization of tobacco (Abdallah 
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2003b). Stems, ribs, and scrap lamina are combined with 
various binders and other additives to form a “reconsti-
tuted” sheet approximating the physical and chemical 
characteristics of a tobacco leaf (Browne 1990; Blackard 
1997; Abdallah 2003b). A common additive in reconsti-
tuted tobacco is diammonium hydrogen phosphate, which 
is used as a pectin release agent that facilitates cross-
linkage to form stable sheet material (Hind and Selig-
man 1967, 1969; Hind 1968). Reconstituted tobacco sheet 
containing this additive selectively adsorbs nicotine from 
surrounding lamina and enriches it in an environment 
abundant in ammonia precursors (Larson at al. 1980). 
The stages of manufacturing a cigarette include 
processing the tobacco lamina and reconstituted tobacco 
materials and slicing them into shreds of a specific cut 
width. Tobacco cut widths vary from approximately 1.5 
mm for a coarse cut to 0.4 mm for a fine cut (Hoffmann 
and Hoffmann 1997). Alternatively, the cut width may 
be expressed in units of cuts per inch, which range from 
approximately 14 to 48. Cigarettes made from fine-cut 
tobacco have faster static burn rates resulting in fewer 
puffs (Resnik et al. 1977). A consequence of using tobacco 
filler with a fine-cut width is that the ratio of filler sur-
face area to void volume increases and may increase the 
efficiency of the tobacco column to filter large aerosol par-
ticles (Keith and Derrick 1960). 
The papers used in cigarettes are generally flax or 
linen fiber and may contain additives (Browne 1990). Salts 
often are added to the cigarette paper as optical whiten-
ers to achieve a target static burn rate and to mask the 
appearance of sidestream smoke (Schur and Rickards 
1960; Owens 1978; Durocher 1984). A key physical prop-
erty of the paper wrapper is its porosity. Papers with high 
porosity facilitate diffusion of gases in and out of the 
tobacco rod (Newsome and Keith 1965; Owen and Reyn-
olds 1967). Volatile smoke constituents such as CO read-
ily diffuse through a porous wrapper, so delivery to the 
smoker is lower than that with less volatile constituents. 
High-porosity papers also permit more O2 to diffuse 
inward, which increases the static burn rate and the air-
flow through the tobacco column that dilutes the smoke. 
A faster-burning cigarette yields fewer puffs, reducing 
tar and nicotine delivery per cigarette (Durocher 1984). 
Porosity of the paper, filler cut width, filter efficiency, 
and tobacco density all make important contributions to 
reduction of pressure drop in the tobacco rod, which is 
a key index related to acceptance by smokers (Norman 
1999). Smokers prefer a cigarette on which they do not 
have to draw too hard because of changes in pressure drop 
as a result of design. A separate but related parameter, fil-
ter pressure drop, is directly related to smoke delivery and 
filter efficiency (Norman 1999). 
In 2006, cigarette lengths generally fell into one 
of four categories in the U.S. market: king-size filter 
cigarettes (79–88 mm; accounting for 62 percent of the 
market); long (94–101 mm; 34 percent of the market); 
ultra long (110–121 mm; 2 percent of the market); and 
regular, nonfilter cigarettes (68–72 mm; 1 percent of the 
market) (FTC 2009). The usual diameter of a conven-
tional cigarette is 7.5 to 8.0 mm (Norman 1999), although 
some “slims” have diameters of 5 to 6 mm. The amount 
of tobacco consumed varies with the circumference of 
the cigarette, and in cigarettes with smaller circumfer-
ence, delivery of constituents in the smoke to the smoker 
decreases accordingly (Ohlemiller et al. 1993). The greater 
surface of the wrapper in long cigarettes increases the 
opportunity for gaseous diffusion out of the cigarette, 
which can (1) reduce delivery of highly volatile constit-
uents of mainstream smoke to the smoker, but increase 
delivery to the nonsmoker and (2) increase the static burn 
rate as more O2 diffuses inward (Moore and Bock 1968). 
However, long cigarettes generally facilitate delivery of 
higher tar and nicotine levels, because more tobacco mass 
is burned.
Before the 1950s, most cigarettes were about 70 mm 
long and unfiltered (Hoffmann and Hoffmann 1997). The 
addition of a filter tip to a cigarette can greatly reduce 
delivery of many chemical constituents of mainstream 
smoke as determined by the FTC/ISO machine-smoking 
method (Fordyce et al. 1961; Williamson et al. 1965). This 
reduction was attributed to filtering of the smoke particu-
late and reducing the amount of tobacco in each cigarette. 
Cost savings are also achieved because the filter material 
is less expensive than the tobacco (Browne 1990). Filters 
provide a firm mouthpiece and permit the smoker to avoid 
direct contact with the tobacco. Cigarettes with modern 
cellulose-acetate filter tips gained about 96 percent of 
the market share by the 1970s (Hoffmann and Hoffmann 
1997). In the United States, cellulose-acetate filter tips are 
the most popular and can selectively remove certain con-
stituents of the smoke, including phenols and alkylphe-
nols (Hoffmann and Wynder 1963; Spears 1963; Baggett 
and Morie 1973; Morie et al. 1975). Typically, a bonding 
agent such as triacetin or glycerol triacetate is used to 
facilitate filter manufacturing (Browne 1990). The filtra-
tion efficiency is proportional to the length, diameter, 
size, and number of fiber strands and the packing density 
of the cigarette (Keith 1975, 1978; Eaker 1990). Flavoring 
agents or other materials can also be incorporated into the 
filter design. 
Extensive research from the 1960s has examined 
the use of activated charcoal in the cigarette filter to 
efficiently remove volatile compounds (Newsome and 
Keith 1965; Williamson et al. 1965; Keith et al. 1966). The 
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addition of activated charcoal significantly reduced levels 
of volatile compounds, such as formaldehyde, cyanide, and 
acrolein (Williamson et al. 1965; Spincer and Chard 1971). 
Charcoal filters reduced the delivery of H2S to mainstream 
smoke (Horton and Guerin 1974). Both cellulose-acetate 
and charcoal filters removed some of the volatile pyridines 
(Brunnemann et al. 1978). Coatings with metallic oxides 
were extremely efficient at removing acidic gases (Keith et 
al. 1966). Filter designs can also be tailored to selectively 
pass and not trap certain classes of targeted compounds. 
For instance, inclusion of alkaline materials in the filter 
inhibits filtration of gaseous nicotine (Browne 1990). 
One key technology used to reduce FTC/ISO 
machine-measured tar and nicotine delivery is the inclu-
sion of microscopic ventilation holes in the paper wrapper 
(Harris 1890) or the filter paper. These holes cause the 
mainstream smoke to become diluted with air (Norman 
1974). Filter ventilation holes are usually located in one or 
more rings about 12 mm from the mouth end of the filter 
(Baker and Lewis 1997). The amount of filter ventilation 
ranges from about 10 percent in some full-flavored variet-
ies to 80 percent in brands measured as having very low 
delivery by using the FTC smoking regimen (CDC 1997). 
Filter ventilation also contributes to control of the burn 
rate (Durocher 1984). The tiny perforations can be made 
by mechanical means, electrostatic sparking, or laser 
ablation. Paper permeability can also be used to increase 
air dilution, although as the cigarette is consumed, this 
effect becomes less important. Delivery of lower levels 
of the constituents of mainstream smoke, as measured 
under FTC machine-smoking conditions, occurs when 
smoke drawn through the cigarette rod mixes and is 
diluted with air drawn through filter ventilation holes. 
Under FTC machine-smoking conditions, filter ventilation 
is highly effective in reducing delivery of chemical con-
stituents (Norman 1974). However, the fingers or lips of 
smokers may cover vent holes when they smoke cigarettes 
and reduce the amount of air available for dilution, which 
results in delivery that is higher than expected (Kozlowski 
et al. 1982, 1996). 
Cigarette smoke is formed by (1) the condensation 
of chemicals formed by the combustion of tobacco, (2) 
pyrolysis and pyrosynthesis, and (3) distillation products 
that form an aerosol in the cooler region directly behind 
the burning coal (Browne 1990). During a puff, the coal 
temperature reaches 800°C to 900°C, and the tempera-
ture of the aerosol drops rapidly to slightly above room 
temperature as it travels down the tobacco rod (Touey and 
Mumpower 1957; Lendvay and Laszlo 1974). As the smoke 
cools, compounds with lower volatility condense first, and 
many of the very volatile gaseous constituents, such as 
CO, remain in the gas phase. The cooler tobacco rod acts 
as a filter itself, and some portions of the smoke condense 
(Dobrowsky 1960) as the smoke is drawn through the 
tobacco column during a puff.
Torikai and colleagues (2004) examined the influ-
ence of the temperature, the pyrolysis environment, and 
the pH of the tobacco leaf on the formation of a wide 
variety of constituents of tobacco smoke. Their findings 
showed that, in general, the yields of the chemical con-
stituents in tobacco smoke that present health concerns 
increased as the temperature increased from 300°C to 
1,000oC, but some compounds (e.g., acrolein and form-
aldehyde) reached their maximum yield at 500oC and the 
yield remained approximately the same at higher tem-
peratures. The presence of O2 in the pyrolysis atmosphere 
increased the yield of acrolein and other volatile organic 
compounds but lowered the levels of cyanide, phenol, and 
1-aminonaphthalene. The pH of the tobacco had a mixed 
effect on the levels of toxic chemicals in tobacco smoke. 
Levels of B[a]P, cyanide, quinoline, resorcinol, and acry-
lonitrile increased with a lower pH, and hydroquinone 
and 1-naphthylamine levels increased with higher pH. 
The effects of the pH and pyrolysis atmosphere combine 
to influence the radical reactions that generate many con-
stituents in tobacco smoke.
In summary, design features of the cigarette have a 
major influence on the yield of the constituents in smoke. 
Altering the tobacco blend, filter type and length, cut 
width, paper porosity, ventilation, and chemical additives 
alters the levels of many constituents of smoke. 
Delivery of Chemicals to Smokers
In addition to cigarette design, the major factors 
that influence the delivery of chemicals to smokers are 
characteristics of puffing (puff volume, duration, and fre-
quency), cigarette length smoked, and blocking air dilu-
tion holes on the filter tips of ventilated cigarettes (e.g., 
with the mouth or fingers). Testing cigarettes by using 
smoking machines or smokers in a laboratory setting can 
elucidate how certain design factors and smoking charac-
teristics can influence the chemical components in smoke. 
However, the results obtained in a laboratory cannot be 
directly applied to populations of smokers because many 
factors influence the way a person smokes each cigarette.
In a laboratory setting, Fischer and colleagues 
(1989a) investigated the influence of smoking param-
eters on the delivery of TSNAs in mainstream smoke for 
six cigarette brands. The research included filter-tipped 
cigarettes with very-low-to-medium ISO/FTC yields of 
constituents of smoke and unfiltered cigarettes with high 
and very high ISO smoke yields. The major finding was 
that the puff profile and duration had no remarkable 
influence on TSNA delivery, but puff volume and frequency 
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significantly increased TSNA yields. The dependency of 
TSNA delivery on the volume of smoke emitted from one 
cigarette (puff volume × number of puffs) was almost lin-
ear up to a total volume of approximately 500 mL. TSNA 
yield was equivalent for the same total volume whether 
the total volume was from a change in puff volume or 
puff frequency. Thus, the total volume drawn through a 
cigarette was the main factor responsible for delivery of 
TSNAs in mainstream smoke.
In another study, average levels of tar, nicotine, and 
CO per liter of smoke and per cigarette were determined 
for 10 brands of cigarettes smoked under 27 machine-
smoking conditions (Rickert et al. 1986). Yields per ciga-
rette were highly variable across smoking conditions, 
because of differences in the total volume of smoke. The 
results of a simple linear regression analysis indicated that 
up to 95 percent of the variation in tar yield per cigarette 
could be explained by variation in the total volume of 
smoke produced per cigarette. Puffing behavior (topogra-
phy), especially the interpuff interval and total smoke vol-
ume per cigarette, which were influenced by puff volume, 
number of puffs, and length of the cigarette smoked, were 
the primary determinants of blood levels of constituents 
of cigarette smoke (Bridges et al. 1990). 
The influence of machine-smoking parameters on 
levels of chemical constituents measured in smoke is well 
illustrated in the work of Counts and colleagues (2005). 
This research was performed according to the ISO, MDPH, 
and CAN regimens described earlier. The study examined 
levels of 44 chemicals emitted in cigarette smoke. Not sur-
prisingly, the more intense smoking regimens resulted in 
higher levels of constituents in cigarette smoke. However, 
in some cases, the emissions of the constituents did not 
maintain their relative levels as a result of different burn-
ing properties of the tobacco under different regimens 
and because of breakthrough in charcoal filters in the 
more intense smoking regimens. Because the intensity of 
smoking changes, the delivery of chemicals to the smoker 
varies and cannot be assessed by using a single smok- 
ing regimen.
In studies of 129 female and 128 male smokers 
of contemporary cigarettes, Melikian and colleagues 
(2007a,b) reported data on smoking topography and 
exposure to toxic substances in mainstream smoke of cig-
arettes that deliver a wide range of nicotine as reported 
by the FTC/ISO method. Exposure was determined by the 
delivered dose and urinary biomarkers. The first study 
focused on whether differences in gender and ethnicity 
affect delivered doses of select toxicants in mainstream 
cigarette smoke, as a result of differences in smoking 
behavior or type of cigarettes smoked (Melikian et al. 
2007b). Smoking topography differed significantly 
between females and males. Compared with men, women 
drew more (13.5 versus 12.0; p = 0.001) but smaller puffs 
(37.6 versus 45.8 mL; p = 0.0001) of shorter duration (1.33 
versus 1.48 seconds; p = 0.002). Women also smoked a 
smaller portion of the cigarettes (36.3-mm butts [40.2 
percent of cigarette length] versus 34.3-mm butts [39.2 
percent of cigarette length]; p = 0.01). Although smoke 
volume per cigarette did not differ between women and 
men (p = 0.06), the daily dose of smoke was significantly 
higher in men (9.3 versus 8.0 liters [L]; p = 0.02), because 
men consume a greater number of cigarettes per day. 
When data were stratified by race, no difference 
was found in puffing characteristics between European 
American and African American female and male smokers, 
except that African American women and men smoked 
equal lengths of the cigarettes (34.5- versus 33.9-mm 
butts; p = 0.93). However, African Americans smoked 
fewer cigarettes, so the daily smoke volume was signifi-
cantly higher among European American smokers (8.61 
versus 7.45 L for women; 10.6 versus 7.8 L for men). The 
emissions of select toxicants per cigarette, as determined 
by use of machine-smoking regimens that mimicked each 
smoker, were consistently greater among male smokers 
than among the female smokers, and they correlated sig-
nificantly with delivered smoke volume per cigarette. The 
geometric means of emissions of nicotine from cigarettes 
were 1.92 mg per cigarette for women versus 2.2 mg for 
men (p = 0.005). Cigarettes smoked by women yielded 
139.5 ng of NNK per cigarette compared with 170.3 ng 
for men (p = 0.0007). B[a]P emissions were 18.0 ng per 
cigarette for women and 20.5 ng for men (p = 0.01). Dif-
ferences between women and men in delivery of toxicants 
in cigarette smoke to the smoker were more profound in 
European Americans than in African Americans. On aver-
age, African American men’s smoking behavior produced 
the highest emissions of select toxicants from cigarettes, 
and European American female smokers received the low-
est amounts of toxicants.
The second study by Melikian and colleagues (2007a) 
investigated urinary concentrations of biomarkers in rela-
tion to levels of select toxicants in mainstream cigarette 
smoke, as determined by using machine-smoking regi-
mens that mimicked the smoking behavior of each smoker. 
In this study of 257 smokers, the researchers determined 
levels of nicotine, NNK, and B[a]P in mainstream smoke 
and concentrations of the respective urinary metabolites: 
cotinine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL), and 1-hydroxypyrene (1-HOP). The smokers were 
assigned to groups according to the FTC yield of toxic 
substances in the cigarettes they smoked: low yield (0.1 
to 0.8 mg of nicotine generated per cigarette, medium 
yield (0.9 to 1.2 mg), and high yield (>1.3 mg). Concentra-
tions of urinary metabolites, expressed per level of par-
ent compound delivered decreased with increased smoke 
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emissions. In smokers of low-, medium-, and high-yield 
cigarettes, as measured by FTC methods, the respective 
ratios of cotinine (nanograms per milligram of creatinine) 
to nicotine (milligrams per day) were 89.4, 77.8, and 57.1 
(low versus high; p = 0.06). Ratios of NNAL (picomoles per 
milligram of creatinine) to NNK (nanograms per day) were 
0.81, 0.55, and 0.57 (low versus high; p = 0.05). Ratios of 
1-HOP (picograms per milligram of creatinine) to B[a]P 
(nanograms per day) were 1.55, 1.13, and 0.97 (low versus 
high; p = 0.008). Similarly, for smokers who consumed 
fewer than 20 cigarettes per day, the means of cotinine 
per unit of delivered nicotine were 3.5-fold higher than 
those for smokers of more than 20 cigarettes per day. Like-
wise, a negative correlation was observed between ratios 
of cotinine to nicotine and delivered doses of nicotine in 
subgroups of smokers who used the identical brand of cig-
arettes, namely a filter-tipped, vented Marlboro (r = -0.59), 
which is a popular brand among European Americans, and 
Newport (r = -0.37), a menthol-flavored cigarette without 
filter-tip vents that is preferred by African Americans. The 
researchers concluded that the intensity of smoking and 
the mouth levels of smoke constituents significantly affect 
the concentrations of urinary biomarkers of exposure and 
should be taken into account in evaluating human expo-
sure to toxic substances in cigarette smoke.
Regarding the influence of cigarette type on urinary 
biomarkers of exposure to toxic substances in mainstream 
smoke, there is a slight difference in puff volume and 
puff frequency among smokers of low-FTC-yield versus 
medium-FTC-yield cigarettes, as measured under FTC 
conditions (Djordjevic et al. 2000). Smokers of low-FTC-
yield brands drew somewhat larger puffs (48.6 versus 44.1 
mL) and inhaled more smoke both per cigarette (615 ver-
sus 523 mL) and daily (9.5 versus 8.2 L). However, delivered 
doses of NNK and B[a]P were marginally higher among 
smokers of medium-yield cigarettes (NNK: 250.9 versus 
186.5 ng per cigarette; B[a]P: 21.4 versus 17.9 ng). On the 
other hand, Hecht and colleagues (2005) found no differ-
ences in urinary biomarkers of exposure to NNK and B[a]P 
among smokers of regular, light, or ultralight cigarettes.
Researchers have also suggested that blocking ven-
tilation holes during smoking can result in increased 
delivery of smoke constituents. For example, when puff 
and inhalation parameters were allowed to vary, partici-
pants took significantly more and larger puffs from ciga-
rettes with unblocked ventilation than from those with 
completely blocked ventilation (Zacny et al. 1986; Swee-
ney et al. 1999). Hoffmann and colleagues (1983) found 
that blocking air-dilution holes in seven brands of com-
mercial filter-tipped cigarettes increased nicotine yields by 
69 percent, tar yields by 51 percent, and CO yields by 147 
percent. Another study examined a cigarette brand with 
tar and nicotine yields of 4.0 and 0.4 mg, respectively, 
under various conditions of machine smoking intended to 
reflect the wide range of smoking behaviors (Rickert et al. 
1983). The researchers studied three levels of five smoking 
parameters (butt length, puff duration, puff interval, puff 
volume, and ventilation occlusion) and the effects on the 
number of puffs and TPM, and they estimated gas phase, 
particulate phase, and total yields of HCN. The HCN and 
TPM yields varied significantly under different smoking 
conditions. Ventilation occlusion had the most pronounced 
effect, accounting for 34 percent of the response variation 
in TPM yields and 42 percent of the response variation in 
total HCN yields.
Comparison of normal lip contact during smoking, 
which partially blocked filter vents, and smoking through 
a cigarette holder, which avoided blocking, showed higher 
nicotine boosts with normal lip contact (Höfer et al. 1991). 
Exposure to other smoke constituents may vary with the 
degree of blocking. Sweeney and colleagues (1999) found 
that blocking the filter vents of cigarettes with ventilation 
levels of at least 66 percent led to significant increases in 
CO exposure. The same manipulation of filter vents in cig-
arettes with filter ventilation levels of 56 percent or lower 
appeared to have negligible consequences for CO exposure. 
In another report, CO exposure from completely blocked 
filter vents was twice as high as from the unblocked vents 
(8.96 versus 4.32 parts per million [ppm]) (Zacny et al. 
1986). Blocking filter vents also resulted in higher CO 
exposure in a study by Höfer and associates (1991). Block-
ing filter ventilation holes is not the only element of smok-
ing topography that influences filter efficiency. More rapid 
or intense puffing increases flow rates, which results in 
less effective filtration, because the smoke passes through 
the tobacco column and filter material more quickly with 
less opportunity for adsorption on the filter’s fibers. This 
smoking behavior also reduced the time for highly volatile 
gaseous materials to diffuse outward through the ciga-
rette’s paper wrapper. 
An “elastic” cigarette is one that shows low levels of 
tar and nicotine when it is tested on a smoking machine 
but can potentially yield higher levels of emissions to 
smokers (Kozlowski et al. 2001). When cigarettes are elas-
tic, smokers can extract as much nicotine as they need by 
changing their pattern of puffing on the cigarette. Analy-
sis of tobacco from commercial American blend cigarettes 
purchased in the United States in 1990 revealed that 
the nicotine content did not differ substantially among 
brands that delivered a wide range of FTC-measured yields 
(Kozlowski et al. 1998). This cigarette design allowed 
delivery of virtually any amount of nicotine, depending 
on puffing behavior. Because there are similar amounts 
of other constituents in tobacco (e.g., TSNAs, metals, 
nitrates, and nitrites), regardless of the FTC ranking of the 
cigarette brand, more intense smoking to obtain a desired 
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dose of nicotine leads to higher exposure to carcinogens. 
Historically, smokers have refused to use brands designed 
to reduce delivery of nicotine. For example, one company 
experimented with a modified cigarette containing denic-
otinized tobacco and a tar yield of 9.3 mg generated per 
cigarette but a nicotine yield of only 0.08 mg, as deter-
mined by using the FTC regimen, but this product was not 
successfully marketed (Rickert 2000).
Not all of the smoke volume delivered in the puff 
is inhaled by the smoker. Some escapes during mouth 
holding before inhalation. The depth of inhalation may be 
important for some smoke constituents but not for oth-
ers, which is not surprising because of the complexity of 
the physics related to particle size that is involved with 
smoking and respiration. Finally, even very brief breath 
holding at peak inspiration can theoretically contrib-
ute to increased diffusion of some smoke constituents 
across alveolar membranes, as the intra-alveolar pres- 
sure increases.
There are considerable individual differences in 
inhalation patterns. In one study, inhaled smoke volume 
was measured by tracing the smoke with an isotope of the 
inert gas krypton (Woodman et al. 1986). The percentage 
of inhaled smoke (total inhaled smoke volume per total 
puff volume) averaged between 46 and 85 percent among 
persons in the study. Neither the mean inhaled smoke vol-
ume per puff nor the total inhaled smoke volume per ciga-
rette was significantly correlated with any of the indices 
for puffing. 
Evidence on the importance of inhalation patterns 
to total smoke exposure is mixed (Woodman et al. 1986; 
Zacny et al. 1987; Zacny and Stitzer 1996). Variations 
in results may be related to the small number of per-
sons tested and to the difficulties inherent in accurately 
capturing the relationship between puffing indices and 
total inhaled smoke. Methods used include pneumogra-
phy  using a mercury strain gauge, whole-body (head and 
arms out) plethysmography, impedance plethysmography, 
inductive plethysmography, and inert gas radiotracers. 
The method most commonly used in U.S. laboratories 
that study smoking is inductive plethysmography, in 
which chest and abdominal expansions are measured by 
bands applied around the rib cage and the abdomen. Sig-
nificant practical limitations include difficulties in accu-
rate calibration of the systems and adequate integration of 
chest and abdominal expansions, especially because men 
tend to have greater abdominal expansion than women do. 
Measurement artifacts created by movement during mea-
surement are another limitation. Studies of the accuracy 
of the systems have shown fair results in adults (Zacny et 
al. 1987). Errors in volume measurements were typically 
approximately 100 mL over a large number of respira-
tory cycles. Unfortunately, the attributes of the systems 
have not been well studied for the puff-by-puff evaluation 
of human smoking behaviors. In addition, the most use-
ful information will come from integrating puff analy-
ses with inhalation parameters on a puff-by-puff basis to 
assess mouth holding and breath holding at peak inha-
lation. Studies such as those cited above have shown 
that mechanical testing regimens cannot mimic the 
way people smoke cigarettes. These findings suggest the 
importance of expressing the levels of toxic constituents 
as a ratio with nicotine or puff volume in the denominator 
(Rickert et al. 1985; Burns et al. 2008).
The size of particles containing chemical species can 
affect their retention in the lung. Cigarette smoke is an 
aerosol formed as the vapors generated in the pyrolysis 
zone cool and condense. Cigarette design has been shown 
to control particle-size distribution in an aerosol, so par-
ticles become easier or more difficult to inhale (Stöber 
1982; Ingebrethsen 1986; McRae 1990; Wayne et al. 2008). 
Burning finer-cut tobacco creates an aerosol with smaller 
particles, which are easier to inhale. Thus, changing the 
filler cut width can change the distribution of particle 
size in the aerosol and the chemistry. Particle size is also 
altered by air dilution. Dilution reduces the aerosol con-
centration and, thus, the coagulation rate. The particle 
size of the smoke is increased by increasing the coagula-
tion rate or by condensing the moisture produced during 
combustion onto the smoke particles. According to Ishizu 
and colleagues (1987), the timed average particle size 
(equivalent diameter) for major chemical components 
in tobacco smoke was 0.03 to 0.5 μm, and constituents 
with higher boiling points tended toward larger particle 
sizes. Very small particles are more likely to be retained 
in the lungs. The overall equivalent diameter of particles 
of crude tar in tobacco smoke was 0.21 μm. Nicotine was 
usually present in small particles (e.g., 0.08 μm). Parti-
cle size influences how fast chemicals are transferred to 
tissue. Particles larger than 0.3 µm are more likely than 
smaller particles to be absorbed in the mouth and throat 
than in the lungs (Wayne et al. 2008).
Accurate measurement of particle size distribution 
in cigarette smoke is important for estimating deposition 
in the lung (Anderson et al. 1989). Most earlier studies 
(1960–1982) reported a median diameter of 0.3 to 0.5 μm, 
including a few ultrafine particles (<0.1 μm). Using the 
electrical aerosol analyzer, Anderson and colleagues (1989) 
reported similar values for median diameter (0.36 to 0.4 
μm) for the particles emitted in smoke from U.S. com-
mercial filter-tipped cigarettes. But, there were also dis-
tinctly smaller particles, with a median diameter of 0.096 
to 0.11 μm. This finding indicated the presence of many 
more ultrafine particles in the smoke than was previously 
recognized. It is notable that the low- and ultralow-yield 
filter-tipped cigarettes Merit and Carlton emitted smaller 
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particles than did the full-flavored Marlboro cigarettes. 
Ultrafine particles are of toxicologic importance because 
their deposition in the respiratory tract was significantly 
higher than that of the 0.3- to 0.5-μm particles. Also, the 
relatively large surface-to-volume ratio of the ultrafine 
particles could facilitate adsorption and delivery of poten-
tially toxic gases to the lung.
An alternative analysis of the impact of particle 
size on deposition in the lung suggested that growth in 
particle size may accelerate deposition in the respiratory 
tract (Martonen and Musante 2000). Because of their 
hygroscopicity, inhaled smoke particles may grow to sev-
eral times their original diameter. This study suggested 
that mainstream cigarette smoke could behave aero-
dynamically as a large cloud (e.g., 20 μm in diameter) 
rather than as submicrometer constituent particles. The 
effect of cloud motion on deposition is pronounced. For 
example, an aerosol with a mass median aerodynamic 
diameter of 0.443 μm and a geometric standard deviation 
of 1.44 would have the following deposition fractions: lung, 
0.14; tracheobronchial, 0.03; and pulmonary, 0.11. When 
cloud motion is simulated, the total deposition is concen-
trated in the tracheobronchial compartment, especially 
in the upper bronchi, and pulmonary deposition is negli-
gible. Cloud motion produces a heterogeneous deposition 
resulting in increased exposure of underlying airway cells 
to toxic and carcinogenic substances. The deposition sites 
correlate with the incidence of cancers in vivo.
Although most of the smoke particles deposit in 
the periphery of the lung, the surface concentrations of 
deposited particles are not significantly greater in the 
periphery than in centrally located airways (Muller et al. 
1990). Concentrations on the surface of the central air-
way are relatively independent of breathing patterns and 
airway geometry. This finding suggests that the effects of 
deposition of particles from cigarette smoke cannot be 
greatly reduced by changing the pattern of smoke inha-
lation. Efforts to manipulate particle size in smoke have 
been described in greater detail in a report by Wayne and 
colleagues (2008). Their study draws on internal tobacco 
company documents to assess industry consideration of 
the role of smoke particle size as a potential controlling 
influence over inhalation patterns and exposure of lungs 
to harmful substances. The researchers reported that 
tobacco manufacturers evaluated manipulation of particle 
size to control physical and sensory attributes of tobacco 
products and to reduce health hazards related to exposure 
to tobacco smoke. Examples of design features of tobacco 
products that relate to potential effects on generation 
of particle size and distribution of particles include puff 
flow rate, tobaccos and experimental blends, combus-
tion, circumference, rod length, and ventilation (Wayne et 
al. 2008).
In summary, smoking behavior (puff volume, 
number of puffs per cigarette, and percentage of ventila-
tion holes blocked) has a major impact on the levels of 
toxic, carcinogenic, and addictive compounds delivered 
to the smoker in cigarette smoke. The puffing patterns 
of smokers vary considerably from person to person. To 
completely understand the effect of specific harmful 
chemical constituents on smokers, further research is 
needed to explore how cigarette design and the chemical 
makeup of cigarettes influence use of the product.
Biomarkers
General Concepts
Accurate prediction of health risks from cigarette 
use is complicated by several factors, including the chemi-
cal complexity of cigarette smoke, significant variations 
among the dose-response relationships for the many dis-
eases associated with exposure to cigarette smoke, quali-
tative and quantitative changes in the dose of cigarette 
smoke received by smokers throughout their smoking 
histories, and the long latencies between the initiation 
of exposure and the onset of some diseases, such as vari-
ous cancers, caused by smoking cigarettes. Prediction is 
also hampered by the ever-changing number and types of 
tobacco products available to consumers, as well as fluc-
tuations in the composition of the products (Stratton et 
al. 2001).
Before the term “biomarker” was coined, biomedical 
researchers used the appearance of unique markers such 
as carcinoembryonic antigens (Burtin et al. 1972) to diag-
nose and monitor cancer or panels of metabolic or physi-
ological risk factors (e.g., serum cholesterol, maternal 
serum α-fetoprotein, and serum angiotensin-converting 
enzyme) to predict the clinical course of adverse effects on 
health. During the 1980s, the National Research Council 
(NRC) issued a series of reports that covered the concep-
tual basis for using biomarkers and reviewing biomarkers 
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related to major organ systems and diseases (Committee 
on Biological Markers of the NRC 1987). In an early com-
prehensive discussion of biomarkers as risk assessment 
tools, Hattis (1986) described their value in characteriz-
ing dose-response relationships, estimating internal dose, 
extrapolating across species, and assessing interindivid-
ual variability (DeCaprio 1997). At about the same time, 
Prignot (1987) published a summary of existing chemi-
cal markers of tobacco exposure that could be used to 
assess individual exposure to tobacco and exposure to sec-
ondhand tobacco smoke as well as to validate successful 
smoking cessation.
In the framework for considering biomarkers pro-
posed by the NRC Committee on Biological Markers 
(1987), a set of still useful definitions was offered. In brief, 
exposure involves contact with the agent of concern. Dose 
refers to the material that enters the body. Internal dose 
refers to the amount of material entering the body, and 
biologically effective dose refers to the amount of the agent 
that reaches the target site(s) within the body. Markers 
of health effects reflect preclinical changes short of those 
reached when clinical disease occurs. Markers of suscepti-
bility are linked to increased risk on exposure. 
The long latency of most diseases caused by ciga-
rette use indicates the need for predictive markers of 
future risk that could identify those people already expe-
riencing preclinical effects of smoking. However, the first 
widely accepted tobacco biomarkers were indicators of 
exposure rather than predictors of disease risk. Breath CO, 
saliva thiocyanate (Jaffe et al. 1981), serum thiocyanate 
(Foulds et al. 1968), and nicotine and nicotine metabolites 
(Watson 1977) were prominent in the early literature for 
assessing exposure to cigarette smoke, and they remain in 
use today.
In comparison with the framework and definitions 
used for exposure and dose generally, a somewhat distinct 
set of terms has been applied to exposure to cigarette 
smoke. The 2001 report, Clearing the Smoke, published 
by the Institute of Medicine defines a biomarker of expo-
sure as a tobacco constituent or metabolite that is mea-
sured in a biologic fluid or tissue and has the potential 
to interact with a biologic macromolecule (Stratton et al. 
2001). The definition notes that such biomarkers are also 
considered as measures of internal dose. A biomarker of 
a biologically effective dose is defined as the amount of a 
tobacco constituent or a metabolite that binds to or alters 
a macromolecule. A biomarker of a biologic event with the 
potential to lead to harm is defined as a measurement of 
an effect attributable to exposure, including early biologic 
effects; alterations in morphology, structure, or function; 
and clinical symptoms consistent with harm. In the more 
general formulation, such biomarkers constitute markers 
of health effects. 
Validated biomarkers of tobacco exposure exist, 
and progress has been made in developing biomarkers of 
biologically effective dose. The biologically effective dose 
represents the net effect of metabolic activation and the 
rate of detoxification in a target biologic tissue or bodily 
fluid. Many tobacco-related toxicants and carcinogens 
are biologically inactive until transformed by metabolic 
enzymes such as cytochrome P-450s into reactive inter-
mediates. Reactive metabolic intermediates bind to mac-
romolecules such as DNA and protein and disrupt their 
normal function. Not all binding to, or alteration of, a 
macromolecule leads to an adverse health effect. Conse-
quently, the amount of material bound to a target mac-
romolecule provides only an estimate of the biologically 
effective dose (Stratton et al. 2001). Polymorphisms of the 
metabolic enzymes may modify the balance of activation 
and detoxification and thus the potency and response of a 
biomarker (Norppa 2003).
Biomarkers of biologic events with the potential to 
lead to harm reflect changes in a cell or in cellular mac-
romolecules that result from exposure to tobacco. These 
biomarkers can range from isolated changes with or with-
out effects on function to events that clearly lead to ill-
ness or are symptoms of illness (e.g., cough). Measurable 
biomarkers of biologic events with the potential to lead to 
harm are relatively nonspecific (Stratton et al. 2001).
Few specific biomarkers have been validated as 
predictors of disease development (Stratton et al. 2001), 
although some studies indicated that DNA and protein 
adduct levels are associated with cancer risk (Hecht 2003). 
The application of biomarkers in tobacco-related disease is 
described in detail throughout this report and discussed 
briefly here.
Biomarkers of Exposure
There are diverse biomarkers of exposure. The least 
intrusive measurements are of chemicals and metabolic 
products in the breath. Levels of exhaled CO, nitric oxide, 
2,5-dimethylfuran, and volatile organic compounds (e.g., 
benzene and toluene) are higher in the breath of smok-
ers than in the breath of nonsmokers (Gordon et al. 2002; 
IARC 2004). One study showed that volatile compounds 
such as benzene and 1,3-butadiene have a short residence 
time in the body and that their concentrations in breath 
were a function of the number of cigarettes smoked and 
the time between when the smoker takes a puff and when 
the breath sample is collected (Gordon et al. 2002). Saliva 
is another biologic material that is readily accessible and 
inexpensive to collect. Cotinine, a metabolite of nicotine 
(Bernert et al. 2000), and thiocyanate, a metabolite of 
cyanide (Prignot 1987), can be measured in saliva; levels 
of both metabolites can be used to distinguish between 
smokers and nonsmokers. 
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serum cotinine and blood cadmium levels correlated with 
the number of cigarettes smoked per day (Telišman et 
al. 1997; Caraballo et al. 1998). The correlation between 
acetonitrile concentrations and the number of cigarettes 
smoked per day was shown to be weak (Houeto et al. 1997).
Markers of tobacco smoke exposure that were mea-
sured in other biologic tissues include PAH compounds 
in lung tissue, B[a]P and TSNAs in cervical mucus (IARC 
2004), and TSNAs in pancreatic juice (Prokopczyk et al. 
2002). Also, researchers observed that pregnant smokers 
had higher placental levels of cadmium than did preg-
nant women who did not smoke (Ronco et al. 2005a,b). In 
another study, cadmium was detected in the seminal fluid 
of smokers at higher levels than in that of nonsmokers, 
and the levels correlated with the number of cigarettes 
smoked per day (Telišman et al. 1997).
Biomarkers of Biologically Effective Dose
For cancer, a common assessment of the biologically 
effective dose is measurement of levels of carcinogen-DNA 
adducts. Strong data from animal experiments and some 
human studies indicate relationships among the levels of 
constituents of tobacco smoke, formation of carcinogen-
DNA adducts, and cancer risk (Stratton et al. 2001). Levels 
of DNA adducts potentially provide the most direct mea-
sure of tobacco-induced DNA damage, and many studies 
reported higher levels in the tissues of smokers than in 
those of nonsmokers (Hecht 2003). In one study, most 
cancers causally associated with tobacco smoking showed 
positive evidence of increased adduct levels (Phillips 2005). 
However, human data on adduct formation suggested 
that saturation may occur at high levels of exposure (i.e., 
>20 cigarettes per day), causing the dose-response curve 
to plateau and reducing the proportional relationship 
between exposure and adduct levels (Godschalk et al. 
2003). Little is known about the temporal variability of 
DNA adducts within a target or surrogate tissue. One 
investigator reported that levels of carcinogen-DNA 
adducts are indicators of carcinogenic hazards but not of 
quantifiable risks (Phillips 2005). 
Carcinogen-DNA adducts can be measured in tar-
get or surrogate tissues. For example, they were mea-
sured in human lung tissue, exfoliated bladder cells, oral 
mucosa, exfoliated oral cells, and cervical cells—all sites 
of tobacco-derived cancers—and in surrogate tissues (e.g., 
carcinogen–peripheral blood lymphocyte DNA adducts) 
(Mancini et al. 1999; Romano et al. 1999; Stratton et al. 
2001). The assumption that levels of DNA adducts in a 
surrogate tissue or cell reflect those in a target tissue has 
principally been supported by studies of animals treated 
with single carcinogens, but results in human biomoni-
toring studies have been mixed (Phillips 2005). 
Urinary compounds are useful markers of the 
uptake and metabolic processing of constituents of ciga-
rette smoke (IARC 2004). Urinary markers of exposure 
to cigarette smoke are nicotine and nicotine metabo-
lites including cotinine; minor tobacco alkaloids such 
as anatabine and anabasine; 1-HOP; 1- and 2-naphthol; 
hydroxyphenanthrenes and phenanthrene dihydrodiols; 
aromatic amines; heterocyclic amines; N-nitrosoproline; 
and NNAL (Hoffmann and Brunnemann 1983; Jacob et 
al. 1999; Hecht 2002; Murphy et al. 2004), thiocyanate 
(Prignot 1987), acetonitrile (Pinggera et al. 2005), and 
methylhippuric acids (Buratti et al. 1999). Nicotine and 
its metabolites and NNAL are specific to tobacco exposure, 
and compounds such as thiocyanate and 1-HOP reflect 
environmental sources of exposure including diet (Van 
Rooij et al. 1994; Sithisarankul et al. 1997; Hecht et al. 
2004). In one study, levels of total NNAL, total cotinine, 
and 1-HOP increased with the number of cigarettes 
smoked per day (Joseph et al. 2005). The highest rates of 
increase were observed at low levels of cigarette use (1 to 
10 cigarettes per day), and levels in urine plateaued at 25 
to 35 cigarettes per day.
Some urinary metabolites provide information on 
metabolic activation and detoxification, as well as the dose 
(Hecht 2002, 2003). Examples are trans,trans-muconic 
acid and S-phenylmercapturic acid (benzene metabolites), 
NNAL and its glucuronides (metabolites of the TSNA 
NNK) (Melikian et al. 1993, 1994; Hecht 2002, 2003), and 
1-HOP (a pyrene metabolite) (Hecht et al. 2004). Studies 
reported that concentrations of urinary 1-HOP glucuro-
nide (Sithisarankul et al. 1997) and total 1-HOP (free and 
conjugated) (Van Rooij et al. 1994) correlated well with the 
number of cigarettes smoked per day. In one study, there 
appeared to be no significant difference in the urinary 
concentration of 1-HOP glucuronide in smokers of ciga-
rettes containing blond (flue-cured) tobacco versus smok-
ers of black (air-cured) tobacco (Sithisarankul et al. 1997). 
Other studies found that in most smokers, more than 80 
percent of the nicotine dose received was accounted for by 
urine content of nicotine, nicotine glucuronide, cotinine, 
cotinine glucuronide, and trans-3’-hydroxycotinine (Ben-
owitz et al. 1994; Davis and Curvall 1999). Total cotinine 
(free and conjugated) is considered the most reliable uri-
nary marker of nicotine exposure (Murphy et al. 2004).
Examination of the blood of smokers shows elevated 
carboxyhemoglobin, thiocyanate, cadmium, acetonitrile, 
2,5-dimethylfuran, VOCs (e.g., benzene, toluene, and 
styrene), the presence of nicotine and its metabolite co-
tinine, and NNAL (Ashley et al. 1996; Houeto et al. 1997; 
IARC 2004). In addition, investigators found a positive 
correlation between carboxyhemoglobin and exhaled CO 
for several hours after smoking (Hopkins et al. 1984), and 
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Additional biomarkers of biologically effective dose 
are (1) protein adducts, in that most carcinogen metabo-
lites that react with DNA also react with proteins, and (2) 
oxidized damage to DNA bases. Protein adducts present 
at higher levels in smokers than in nonsmokers include 
hemoglobin adducts of TSNAs, 3-aminobiphenyl, 4-ami-
nobiphenyl, o-toluidine, p-toluidine, and 2,4-dimethyl-
aniline, as well as adducts from ethylation or methylation 
of the N-terminal valine of hemoglobin (Branner et al. 
1998; Thier et al. 2001; Hecht 2003). The lung tissues 
of smokers have higher levels of acrolein-derived DNA 
lesions, one of which was identified as the mutagenic 
guanine adduct α-hydroxy-2’-deoxyguanosine. This 
lesion blocks DNA replication, potentially leading to G→T 
and G→A base substitution mutations (Yang et al. 2002; 
Zhang et al. 2007; Zaliznyak et al. 2009). The repair prod-
ucts of oxidative DNA lesions are water soluble and are 
generally excreted into urine without further metabo-
lism. Because of extensive and rapid DNA repair, urine 
excretion of the oxidative DNA repair lesions reflects the 
average rate of oxidative DNA damage in all the cells in 
the body (Loft and Poulsen 1998). Levels of 8-hydroxy-2’-
deoxyguanosine (8-OH-dG) (Gackowski et al. 2003) and 
8-nitroguanine (Hsieh et al. 2002), both shown to indi-
cate oxidative DNA damage, were found to be higher in 
the DNA of leukocytes of smokers than in those of non-
smokers. Tobacco smoking was consistently shown to 
increase the urinary excretion rate of 8-OH-dG by 30 to 50 
percent, and levels in urine decreased after smoking ces-
sation (Loft and Poulsen 1998). In addition, both healthy 
smokers and smokers with cancer had urine levels of 
8-hydroxyguanine that were higher than those in healthy 
nonsmokers (Gackowski et al. 2003). The oxidatively 
modified DNA base, 8-hydroxyguanine, is also a marker 
of oxidative stress. There is no epidemiologic evidence 
that high levels of oxidative DNA modification in tissue or 
high levels of oxidatively modified nucleic acid products 
in urine are predictors of cancer development in humans 
(Poulsen 2005).
Many mutagens and carcinogens are metabolically 
activated in vivo to electrophilic forms capable of inter-
action with cellular macromolecules (van Doorn et al. 
1981). One of the mechanisms used by an organism to 
combat electrophilic attack is conjugation of the reactive 
chemical moiety with reduced glutathione, a nucleophile. 
This reaction causes an increase in more polar thioether 
conjugates, which are excreted from the body in urine and 
bile. Urinary thioether concentrations are used as a non-
specific indicator of exposure to alkylating agents. Ciga-
rette smoking was found to cause a dose-related increase 
in the urinary excretion of thioethers. Chemicals present 
in cigarette smoke and excreted in urine as thioethers 
include benzene, styrene, and vinyl chloride (van Doorn 
et al. 1981; Goldstein and Faletto 1993; Fisher 2000b). 
Increased concentrations of alkyladenines and alkylgua-
nines from the reaction of alkylating agents with DNA 
were also observed in the urine of smokers (Hecht 2002). 
All three types of carcinogen biomarkers (thioethers, 
alkyladenines, and alkylguanines) reflect chemical uptake 
and the balance between activation and detoxification 
(Hecht 2003). 
Biomarkers of Biologic Events with the Potential 
to Lead to Harm
Stratton and colleagues (2001) have reviewed a large 
number of biomarkers of biologic events with the poten-
tial to lead to harm. This review and more recent publica-
tions are summarized here. On an organ or system level, 
signs and symptoms of potential biologic events with the 
potential to lead to harm include osteoporosis, cough, 
hyperplasia, dysplasia, abnormal serum lipid concentra-
tions, alterations in levels of blood coagulants, periodontal 
disease, and abnormal results for glucose tolerance tests 
(Stratton et al. 2001). On a molecular level, relevant mea-
surements in target tissues of smokers include changes 
in RNA or protein expression, somatic mutations or loss 
of heterozygosity, alterations in promoter methylation, 
and mitochondrial mutations. In surrogate tissues, bio-
markers of biologic events with the potential to lead to 
harm among smokers include leukocytosis, HPRT muta- 
tions, chromosomal aberrations, and changes in circulat-
ing lymphocytes.
Studies have identified biomarkers of biologic 
events with the potential to lead to harm related to cig-
arette smoking that are addressed in this Surgeon Gen-
eral’s report. For example, a significant association and a 
dose-response relationship were shown for chromosomal 
aberrations induced by B[a]P diol epoxide at locus 3p21.3 
in peripheral blood lymphocytes and for risk of squamous 
cell carcinoma of the head and neck (Zhu et al. 2002). 
Also, study findings suggested the frequency of promoter 
methylation in tumor-suppressor genes (P14, P16, P53) as 
a biomarker for risk of non-small-cell lung cancer among 
current and former smokers and cervical squamous cell 
cancer among smokers (Jarmalaite et al. 2003; Lea et al. 
2004). 
Cigarette smoking is a risk factor for bladder can-
cer. The increased mutagenicity of smokers’ urine was 
first shown in 1977 by testing the brand XAD/acetone-
extractable organics from urine in the Salmonella (Ames 
test) mutagenicity assay (Yamasaki and Ames 1977). Stud-
ies using essentially the same methods confirmed this 
observation (DeMarini 2004). Peak mutagenic activity of 
the urine occurs 4 to 5 hours after the start of smoking 
and decreases to pre-smoking levels in approximately 12 
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to 18 hours (Kado et al. 1985). Findings suggested that the 
mutagens are absorbed rapidly (in 3 to 5 hours).
Urinary mutagenicity generally correlates with the 
number of cigarettes smoked, and the level of urinary 
mutagenicity was found to be similar regardless of the 
tar level of the cigarettes smoked (Tuomisto et al. 1986; 
Kuenemann-Migeot et al. 1996). However, the urine from 
smokers of black tobacco was reported to be twice as 
mutagenic as that from smokers of blond tobacco, which 
correlated with the known increased risk for bladder can-
cer among smokers of black versus blond tobacco (Mala-
veille et al. 1989). In addition, smoking-associated urinary 
mutagenicity correlated with external measures of expo-
sure (e.g., daily intake of chemicals from tobacco smoke) 
and with internal measures of exposure (e.g., urinary 
1-pyrenol) (Pavanello et al. 2002). 
Aromatic amines, heterocyclic amines, and PAHs 
appear to be the chemicals responsible for smoking- 
related urinary mutagenicity, as detected in the Salmo-
nella assay (IARC 2004). Studies showed that urinary 
mutagenicity correlated with the levels of a 4-aminobiphe-
nyl-DNA adduct in exfoliated urothelial cells from smok-
ers (Talaska et al. 1991). Chemical analyses of urine from 
smokers with exceptionally high urinary mutagenicity 
revealed the presence of the mutagen 2-amino-7-naphthol, a 
metabolite of the bladder carcinogen 2-aminonaphthalene 
(β-naphthylamine) (Connor et al. 1983).
Although studies have described several biomark-
ers for risk of cardiovascular disease, no biomarker was 
specific to cigarette smoking. These biomarkers include 
changes in blood lipid concentrations, urine thromboxane 
A2 metabolites, blood F2-isoprostanes, vascular cell adhe-
sion molecule-1, reduced platelet survival, atherosclerosis 
or calcium formation, and possibly elevated blood pres-
sure (Stratton et al. 2001; Cavusoglu et al. 2004; Mor- 
row 2005).
Symptoms and signs of biologic events with the 
potential to lead to harm to the respiratory system 
include late-occurring symptoms (cough, chronic phlegm 
production, wheeze, and shortness of breath) and decre-
ments in pulmonary function, such as a notable decline 
in forced expiratory volume in one second (Carrell 1984; 
Ogushi et al. 1991; Stratton et al. 2001). Other biomark-
ers of biologic events with the potential to lead to harm 
are declines in alveolar neutrophil and macrophage 
counts and declines in neutrophil elastase α1-antipro- 
tease complexes. 
Some of the general markers described here can 
be considered as biomarkers of potential reproductive or 
developmental effects from maternal cigarette smoking 
during pregnancy. Findings in one study indicated that 
increased levels of F2-isoprostane in cord blood may serve 
as a biomarker of oxidative stress (Obwegeser et al. 1999). 
Another study reported biomarkers in cord blood of off-
spring of women who smoked during pregnancy and in 
maternal blood (İşcan et al. 1997). The markers included 
reduced levels of high-density lipoprotein cholesterol 
(HDLc) and apolipoprotein A-I (APO A-I) and elevated 
ratios of total cholesterol to HDLc, low-density lipopro-
tein cholesterol (LDLc) to HDLc, and APO B to APO A-I. 
Proteomics allows study of changes to proteins following 
environmental exposures. A recent comparison of up- and 
downregulated proteins in blood cord sera from the off-
spring of women who smoked during pregnancy with that 
of offspring of nonsmokers suggests that infants exposed 
in utero undergo changes in protein expression simi-
lar to those of smoke-exposed adults and animal models 
(Colquhoun et al. 2009). Among the changes were mark-
ers of inflammation (α2-macroglobulin), altered lipid 
metabolism (APO A-I), and α-fetoprotein, which is associ-
ated with fetal growth retardation (Colquhoun et al. 2009). 
These findings indicate that serum and cord blood lipid 
panels may provide biomarkers of biologic events with the 
potential to lead to harm to fetal metabolism of lipids.
Smoking interferes with absorption of vitamins 
B6, B12, and C and folic acid (Cogswell et al. 2003). 
Study findings indicate that lower plasma concentra-
tions of vitamins (folate and B12) and nitric oxide from 
maternal smoking may result in hyperhomocysteinemia 
in pregnant women, a known risk factor for pregnancy-
induced hypertension, abruptio placentae, and intrauter-
ine growth restriction (Obwegeser et al. 1999; Özerol et 
al. 2004; Steegers-Theunissen et al. 2004). Women who 
smoke during pregnancy have an increased risk of deliver-
ing a low-birth-weight infant (USDHHS 2004). Decreases 
in birth weight were dose related to the number of ciga-
rettes smoked (Abel 1980). Researchers reported that low 
concentrations of maternal serum folate and vitamin B12 
were associated with higher risk of preterm delivery and 
low birth weight, and low-birth-weight infants had signifi-
cantly lower concentrations of vitamins A, B2, E, and folate 
(Navarro et al. 1984; Fréry et al. 1992; Scholl et al. 1996). 
In other studies, placental cadmium levels were strongly 
correlated with birth weight in newborns of mothers who 
smoked (Ronco et al. 2005a). Cotinine concentrations in 
maternal serum and urine were also useful in predicting 
birth weight (Stratton et al. 2001).
In summary, several biomarkers provide an accurate 
assessment of exposure to toxic chemicals in cigarette 
smoke. Still to be determined is how accurately they can 
characterize differences in exposure between tobacco-
burning cigarettes and the variety of potentially reduced-
exposure products introduced into the market during the 
last few years. Biomarkers of biologically effective doses 
for mutagenic and carcinogenic chemicals can provide an 
estimate of the interaction between chemicals in smoke 
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and target biologic tissues or bodily fluids. Genetic poly-
morphisms of the enzymes involved in the metabolic 
activation of the chemicals may influence the net balance 
of activation and detoxification in a target biologic tissue 
and complicate interpretation of the dose-response rela-
tionship between exposure and binding with macromo-
lecular targets. Despite the large number of biomarkers 
of biologic events with the potential to lead to harm, most 
are not specific to exposure to cigarette smoke and require 
additional testing to establish their specificity, sensitivity, 
and reliability when smoking behaviors or product char-
acteristics vary.  In addition, not all biomarkers of biologic 
events with the potential to lead to harm may be sufficient 
for determining population-level effects of the product.
Genotoxicity
Cigarette Smoke Condensate
Condensate from cigarette smoke is mutagenic in 
a variety of systems (DeMarini 1983, 2004; IARC 1986, 
2004). Most studies have used condensate generated from 
the smoke of reference cigarettes such as those available 
from the University of Kentucky, Lexington, Kentucky. 
Researchers using the bacterial Salmonella mutagen-
icity assay reported that the average mutagenicity of 
cigarette smoke condensates prepared from the main-
stream smoke from U.S. commercial cigarettes and K1R4F 
reference cigarettes was not significantly different among 
cigarettes representing more than 70 percent of the U.S. 
market (Steele et al. 1995). These findings suggested that 
such reference cigarettes are acceptable standards for 
comparative mutagenicity of condensates from cigarettes 
purchased typically in the United States. The genotoxicity 
of 10 cigarette smoke condensate samples from a diverse 
set of cigarettes (including the K2R4F reference cigarette) 
and produced under different smoking-machine condi-
tions was studied in four short-term assays: the Salmo-
nella mutagenicity assay in frameshift strains TA98 and 
YG1041, the micronucleus and comet assays in L5178YTk 
± 7.3.2C mouse lymphoma cells, and an assay for chromo-
somal aberrations in CHO-K1 cells (DeMarini et al. 2008). 
All 10 condensate samples were mutagenic in both strains 
of Salmonella and induced micronuclei, and 9 samples 
induced DNA damage or chromosome aberrations. While 
their mutagenic potencies in Salmonella spanned 7-fold 
when expressed as revertants per gram of condensate, they 
spanned 158-fold when expressed as revertants per milli-
gram of nicotine. The range of genotoxic potencies of the 
condensates in the other assays was similar regardless of 
how the data were expressed. The overall conclusion was 
that there was no relation among the genotoxic poten-
cies of the cigarette smoke condensates across the assays 
(DeMarini et al. 2008).
Several lines of evidence indicated that the primary 
sources of mutagenic activity detected in the Salmonella 
mutagenicity assay are aromatic amines and heterocyclic 
amine protein pyrolysate products (IARC 1986). Most of 
this activity resides in the basic or base/neutral fraction 
of the condensates, which contains the aromatic and het-
erocyclic amines. At the molecular level, the mutation 
spectrum of cigarette smoke condensate in the Salmonella 
frameshift strain TA98 was identical to that of the hetero-
cyclic amine Glu-P-1 (DeMarini et al. 1995). The finding 
suggested that this class of compounds is responsible for 
most of the frameshift mutagenic activity of cigarette 
smoke condensate detected in TA98. A frameshift muta-
tion is the insertion into or deletion from DNA of a num-
ber of nucleotides that are not three or multiples of three. 
In contrast, most of the mutations induced by cigarette 
smoke condensate in the base-substitution strain TA100 
were shown to be transversions of GC→TA (78 percent), 
which resembled most closely the mutation spectrum of 
B[a]P, the model PAH (DeMarini et al. 1995). The GC→TA 
transversions, a common class of base substitutions found 
in lung tumors of smokers, were also induced by cigarette 
smoke condensate at the HPRT locus in human B-lym-
phoblastoid MCL-5 cells (Krause et al. 1999).
Study findings indicated that most of the ability of 
cigarette smoke condensate to induce sister chromatid 
exchange (SCE) in mammalian cells may reside in the 
neutral and acidic/neutral fractions, suggesting that this 
activity is attributable to PAHs and acidic compounds, 
such as catechol, hydroquinone, alkylphenols, and benz-
aldehyde (Jansson et al. 1988). 
Nicotine and its metabolites were not mutagenic in 
Salmonella and did not induce SCEs in mammalian cells 
in culture, and nicotine did not produce mutagenic urine 
in rats (Doolittle et al. 1995). Burning tobacco produced 
mutagenic chemicals, and cigarette smoke condensate 
contained a variety of agents exhibiting a wide range of 
toxic effects. Varying the amounts of 300 to 400 ingredi-
ents added to typical commercially blended test cigarettes 
did not alter the inherent mutagenicity or cytotoxicity of 
the resulting condensates or the toxic effects of inhalation 
of the smoke of the resulting cigarettes (Carmines 2002; 
Baker et al. 2004). Many of the pyrolysis products from 
the cigarette ingredients identified as “biologically active” 
were volatile compounds (e.g., benzene, toluene, and sty-
rene) (Baker et al. 2004) and would presumably reside pri-
marily in the gas phase of the cigarette smoke rather than 
in the condensate used in most in vitro assays.
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DNA Damage
Many studies have demonstrated that cigarette 
smoke and its condensate can produce DNA strand breaks 
in rodents, in mammalian cells in culture, or in DNA in 
vitro (IARC 2004). Collectively, results of these studies are 
consistent with the demonstrated clastogenicity (chro-
mosome-breaking ability) of cigarette smoke and conden-
sate and cigarette smoke in experimental systems and in 
humans. Several of these studies (IARC 2004) indicated 
that reactive oxygen or nitrogen species may be the pri-
mary cause of the breaks in DNA strands.
Cytogenetic Effects in Rodents
Exposure of rodents to cigarette smoke by inhala-
tion has generally produced an increased frequency of 
SCE in the bone marrow (IARC 1986). However, such 
exposure produced some negative studies and one positive 
study of induction of chromosomal aberrations in lung 
cells (DeMarini 2004). Nonetheless, this exposure consis-
tently produced micronuclei in bone marrow, peripheral 
blood erythrocytes, and lung cells (IARC 2004). 
Transplacental Effects in Rodents
Mice born to dams exposed to cigarette smoke by 
inhalation during pregnancy had elevated levels of mi-
cronuclei in the liver and peripheral blood (Balansky and 
Blagoeva 1989), and such exposure induced SCEs in the 
liver of fetal mice (Karube et al. 1989). Intraperitoneal 
injection of pregnant Syrian golden hamsters with the 
tobacco carcinogen NNK also induced micronuclei in 
fetal liver (Alaoui-Jamali et al. 1989), and intraperitoneal 
injection of pregnant mice with NNK induced oxidative 
damage, as determined by measurement of concentra-




In general, smoking was shown to increase the fre-
quency of HPRT mutants in peripheral blood lymphocytes 
by approximately 50 percent. However, the increases did 
not reach statistical significance in some studies, probably 
because of the large interindividual variability (DeMarini 
2004). An increase in transversions, in particular GC→TA, 
was noted frequently among smokers (IARC 2004). How-
ever, some analyses found no difference in the mutation 
spectrum at HPRT in smokers and nonsmokers (Curry 
et al. 1999). GC→TA transversions are the primary class 
of base substitution induced by PAHs, and an excess of 
this class of mutation in the HPRT mutation spectrum 
for smokers is consistent with exposure to PAHs in ciga- 
rette smoke.
Genotoxic Effects in Reproductive Tissues 
and Fluids and in Children of Smokers
Lymphocytes from pregnant women who smoked 
either tobacco cigarettes or marijuana cigarettes had 
elevated frequencies of HPRT mutants, as determined by 
the autoradiographic HPRT assay, and analyses of cord 
blood indicated that lymphocytes from the newborns also 
had elevated frequencies of HPRT mutants (IARC 2004; 
DeMarini and Preston 2005). No differences in frequencies 
of HPRT mutants were observed in T lymphocytes from 
newborns of smokers compared with those from newborns 
of nonsmokers, as determined by the T-cell cloning assay. 
However, the mutation spectra for these two groups of 
newborns differed significantly from those for newborns 
of smokers who had an increase in “illegitimate” genomic 
deletions mediated by V(D)J recombinase. These findings 
suggested alteration in the HPRT mutation spectrum and 
possible increase in the frequency of HPRT mutant cells in 
newborns of mothers who smoked compared with those in 
newborns of mothers who did not smoke. Another study 
reported that in utero exposure to cigarette smoke also 
resulted in increases of translocation frequencies in new-
borns (Pluth et al. 2000). Other evidence indicated that 
smoking by the mother may lead to DNA strand breaks in 
lymphocytes of newborns (Şardaş et al. 1995). Amniocytes 
from mothers who smoked may show an increase in chro-
mosomal mutations compared with those from nonsmok-
ers (de la Chica et al. 2005); however, researchers raised 
concerns about this study, such as the lack of exposure 
assessment, the small sample size, and the fact that the 
chromosomal aberrations identified were of the chroma-
tid type, which is a type that could have been formed in 
the petri dish during culturing and were not present in 
the amniotic fluid initially (DeMarini and Preston 2005). 
Reviews indicated that the cervical mucus and 
amniotic fluid of smokers were mutagenic and that cervi-
cal epithelial cells from smokers had higher frequencies of 
micronuclei compared with those from nonsmokers (IARC 
2004). Findings also suggested that smoking may induce 
chromosomal mutations and DNA damage in sperm or 
ova of smokers. The evidence that smoking induced oxida-
tive damage to sperm DNA was found in elevated concen-
trations of 8-OH-dG in sperm DNA of smokers compared 
with that of nonsmokers (Shen et al. 1997). In addition, 
seminal fluid from infertile male smokers showed more 
oxidative damage than did that from infertile nonsmok-
ers (Saleh et al. 2002). Consistent with these observations 
was the finding that sperm from smokers had higher con-
centrations of DNA strand breaks than did sperm from 
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nonsmokers (Potts et al. 1999). Concentrations of DNA 
adducts in sperm, measured by the 32P-postlabeling assay 
were also higher among current smokers than among life-
time nonsmokers (Horak et al. 2003). Collectively, these 
data from studies of humans are consistent with the 
recent demonstration that exposure to cigarette smoke by 
inhalation resulted in germ-cell mutations in male mice 
(Yauk et al. 2007). 
Cytogenetic Effects
Micronuclei. Many studies have examined the 
influence of smoking on the frequency of micronuclei in 
peripheral lymphocytes; the results were mixed (Bonassi 
et al. 2003). A reanalysis of pooled data from 24 databases 
from the Human MicroNucleus international collabora-
tive project showed that smokers did not have an overall 
increase in micronuclei frequency in lymphocytes. How-
ever, a significant increase in micronucleus frequency was 
found in heavy smokers (i.e., those smoking 30 cigarettes 
or more per day) who were not exposed occupationally to 
genotoxic agents. Studies also found elevated micronuclei 
frequencies in the tracheobronchial epithelium of smok-
ers (Lippman et al. 1990).
Sister chromatid exchange. In contrast to fre-
quency of micronuclei, SCE frequencies in peripheral 
lymphocytes are generally higher among smokers than 
among nonsmokers. Numerous studies of SCE frequen-
cies in peripheral lymphocytes showed that cigarette 
smoking induced SCEs, which can then be a confounding 
factor in occupational studies (IARC 2004). The findings 
indicated that of all the cytogenetic endpoints, SCE is the 
most sensitive to the effect of smoking.
Chromosomal aberrations. Studies of large 
populations with use of chromosome banding techniques 
to assess chromosomal aberrations have had mixed 
results. One study reported that the frequency of chromo-
somal aberration was not increased by smoking (Bender 
et al. 1988), and another reported that smoking caused 
a 10- to 20-percent increase in the frequency (Mutation 
Research 1990). Smaller studies and those using 
molecular cytogenetic techniques also had mixed results; 
in some, smoking increased the frequency of chromo-
somal aberrations in peripheral lymphocytes, and in oth-
ers, this finding was not observed (DeMarini 2004). 
Mechanistic considerations include the observa-
tion that smokers had lower concentrations of folate in 
red blood cells than did nonsmokers, which may play a 
role in the higher frequency of chromosomal aberrations 
detected in smokers (Chen et al. 1989). Other studies 
found that exposure of peripheral lymphocytes from smok-
ers to mutagens in vitro resulted in a higher frequency 
of chromosomal aberrations than did similar exposure of 
lymphocytes from nonsmokers (IARC 2004). Collectively, 
findings of these studies suggested that cells of smokers, 
especially males, were less able to repair DNA damage 
and that concentrations of DNA repair enzymes, fragile 
sites in chromosomes, and telomeric associations could 
be affected by recent mutagenic exposures such as smok-
ing (DeMarini 2004). These effects of smoking varied 
among individuals, and were influenced by exposures 
other than smoking. 
A large international study showed that an ele-
vated frequency of chromosomal aberrations in lympho-
cytes predicted cancer risk independently of exposure to 
carcinogens, including cigarette smoke (Bonassi et al. 
2000). However, many studies demonstrated an associa-
tion between smoking and certain genetic changes that 
are specific predictors of various types of tumors. For 
example, lymphocytes of smokers had a higher frequency 
of fragile sites in chromosomes and metaphases with 
extensive breakage, as well as overexpression of fragile 
sites at chromosomal breakpoints associated with can-
cer and oncogene sites on chromosomes (Kao-Shan et al. 
1987). Smoking was associated with chromosomal insta-
bility in lymphocytes as a biomarker for predisposition to 
oral premalignant lesions (Wu et al. 2002). In addition, 
smoking was associated with mutagen sensitivity of lym-
phocytes as a predictor of cancer of the upper aerodigestive 
tract. An analysis of normal bronchial epithelium using 
a molecular cytogenetic technique found a significant 
percentage of trisomy 7 in cancer-free tobacco smokers 
(Lechner et al. 1997). Another study reported a significant 
increase in the loss of heterozygosity involving microsat-
ellite DNA at three specific chromosomal sites containing 
putative tumor-suppressor genes in histologically normal 
bronchial epithelium from long-term smokers (Mao et al. 
1997; Wistuba et al. 1997). The frequency of chromosomal 
aberrations was much higher in lung tumors from smok-
ers (48 percent) than in those from nonsmokers (11 per-
cent), suggesting that lung cancer in smokers is a result 
of genetic alterations distinct from those in nonsmokers 
(Sanchez-Cespedes et al. 2001).
Studies also associated alterations in chromosome 
9 in bladder tumors with cigarette smoking, and 
cytogenetic changes and smoking were associated with 
risk for leukemia and other myelodysplastic syndromes 
(IARC 2004).
DNA strand breaks and oxidative damage. 
A review by DeMarini (2004) reported that lymphocytes, 
buccal cells, and urothelial cells of smokers had higher 
frequencies of DNA strand breaks than those in nonsmok-
ers, as measured by the single-cell gel electrophoresis 
(comet) assay, which detects broken DNA that separates 
from whole nuclear DNA when exposed to an electric 
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current. Oxidative damage measured by concentrations of 
7-hydroxy-8-oxo-2’-deoxyguanosine (8-oxo-dG) (a marker 
of oxidative damage) was elevated in lymphocytes and 
leukocytes, urine, and lung tissue of smokers. In vitro 
studies, including some in human cells, also found that 
cigarette smoke or its components induced DNA or oxi-
dative damage. Collectively, these studies suggested that 
smoking induced oxidative DNA damage.
Mutations in tumors associated with 
smoking. In a review of studies in 2004, IARC noted 
that the TP53 gene was mutated most frequently in lung 
tumors associated with smoking, and the details of this 
observation were reviewed extensively (Pfeifer et al. 2002; 
Pfeifer and Hainaut 2003; IARC 2004). Mutations in the 
TP53 gene were more common in smokers than in non-
smokers, and a direct relationship existed between the fre-
quency of TP53 mutations and the number of cigarettes 
smoked. TP53 mutations were found in preneoplastic 
lesions of the lung, indicating that they were early events 
linked temporally to DNA damage from smoking. 
Among the mutations of the TP53 gene in lung 
tumors of smokers, 30 percent were GC→TA transver-
sions, whereas only 10 percent of the TP53 mutations in 
lung tumors of nonsmokers or in other tumors were of 
this type. The sites at which these mutations occurred in 
the TP53 gene corresponded with the sites of DNA adducts 
remaining after cells were exposed to diol epoxides of PAHs 
and allowed to undergo a period of DNA repair (Smith et 
al. 2000). The mutations in the tumors were targeted at 
methylated CpG sites on chromosomes, and there was 
a bias for most of the mutated guanines of the GC→TA 
mutations to be on the nontranscribed DNA strand in lung 
tumors from smokers, which is attributable to the pref-
erential repair of DNA adducts on the transcribed strand 
(Yoon et al. 2001). 
Mutations in the KRAS gene (codons 12, 13, or 61) 
were shown to occur in approximately 30 percent of lung 
adenocarcinomas of smokers and are primarily GC→TA 
transversions, as seen in the TP53 gene (Gealy et al. 1999). 
As with the TP53 gene, the site at which the majority of 
a particular type of PAH adducts are formed in the KRAS 
gene (the first position of codon 12) corresponded with 
the position where a high frequency of GC→TA trans-
versions occur in lung tumors associated with smoking 
(Tretyakova et al. 2002). Similar to TP53 mutations, KRAS 
mutations occurred early in carcinogenesis of the lung, 
and 66 percent of the mutations in the KRAS gene in 
smoking-associated lung tumors were GC→TA transver-
sions (Keohavong et al. 2001). 
These observations, along with substantially more 
data, suggest that the TP53 and KRAS mutations in lung 
tumors of smokers are due to the direct DNA damage 
resulting from the carcinogens in cigarette smoke, espe-
cially PAHs (Pfeifer and Hainaut 2003). Researchers have 
suggested that other factors, especially selection, may also 
play a role in the observed mutation spectrum in smok-
ing-associated lung tumors (Rodin and Rodin 2005).
Cytotoxicity
Cytotoxicity refers to a specific destructive action 
on cells. The cytotoxicity of cigarette smoke has been 
shown to manifest as several pathological conditions 
including irritation and inflammation, cell prolifera-
tion and hyperplasia, oxidative stress and damage, and 
decreased organ function (Andreoli et al. 2003). Studies 
demonstrated the presence of cytotoxic agents in the gas 
and particulate phases of cigarette smoke, and HCN and 
acrolein were identified as specific cytotoxic agents in the 
gas phase (Thayer and Kensler 1964; Battista 1976a). In 
the particulate phase, nonvolatile and semivolatile frac-
tions, especially semivolatile acidic and neutral fractions, 
were found to demonstrate cytotoxic activity (Curvall et 
al. 1984, 1985; Matsukura et al. 1991). 
Study findings indicate that cytotoxicity may play a 
role in several tobacco-related chronic diseases, including 
emphysema, carcinogenesis, and atherosclerosis (Bom-
bick et al. 1998; Andreoli et al. 2003). For example, injury 
to cells of the respiratory system by cigarette smoke is 
thought to be mediated by smoke-induced inflammation 
and damage from free radicals (Churg and Cherukupalli 
1993). Thus, the usefulness of in vitro cytotoxicity tests 
lies in their ability to measure indicators of cellular injury 
that may correlate with or predict inflammation (Stratton 
et al. 2001). 
Many early cytotoxicity studies focused on damage 
to ciliated organisms (paramecium), clam gill epithelium, 
and animal trachea (Wang 1963; Weiss and Weiss 1964; 
Wynder et al. 1965; Dalhamn 1970; Battista 1976a,b; Don-
nelly et al. 1981a,b; Curvall et al. 1984), as well as cells 
such as adipocytes, macrophages, and human tumor cell 
lines (Thayer and Kensler 1964; Thayer 1976a,b; Drath 
et al. 1981; Curvall et al. 1984, 1985). Ciliatoxicity assays 
measure the time to incapacitation of ciliated cells or the 
time required by ciliated respiratory cells to transport 
inert particles when exposed to cigarette smoke. Impaired 
ciliary function and mucus transport in an intact respira-
tory system precede metaplasia in bronchial epithelium. 
Assays with isolated or cultured cells typically assess inhi-
bition of metabolic activity or cellular growth in the pres-
ence of cigarette smoke or damage to the cell membrane 
(Wynder and Hoffmann 1967).
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Subsequent research on the cytotoxicity of cigarette 
smoke has frequently used the neutral red incorporation 
assay to evaluate smoke from different types of cigarettes 
or tobaccos (Bombick et al. 1997a,b, 1998; Foy et al. 2004). 
This assay is based on the uptake of neutral red dye into the 
lysosomes of viable cells. Injury to the plasma membrane 
or lysosomal membrane was shown to decrease uptake 
and retention of the dye (Babich and Borenfreund 1987). 
One study demonstrated that flue-cured tobacco produced 
smoke condensate that was significantly more cytotoxic in 
the neutral red incorporation assay than was condensate 
from burley tobacco smoke (Bombick et al. 1998). In addi-
tion, no difference was found in the cytotoxicity of smoke 
condensate from reference cigarettes representing com-
mercial ultralow-tar (1R5F), low-tar (1R4F), or unfiltered 
full-flavored (2R1) cigarettes. In contrast, with this assay, 
whole mainstream smoke and the vapor phase of main-
stream smoke from a 2R1 cigarette were more cytotoxic 
than those from a 1R4F cigarette, and those from a 1R4F 
cigarette were more cytotoxic than those from a 1R5F 
cigarette (Bombick et al. 1997a). In addition, sidestream 
smoke (whole smoke and vapor phase) was more cytotoxic 
than mainstream smoke, as determined in the neutral red 
incorporation assay. The same laboratory reported that 
neither a low-nitrogen tobacco blend with a cellulose-
acetate filter (11.6 mg tar in mainstream smoke) nor a 
traditional U.S. tobacco blend with a charcoal filter (10.4 
mg tar in mainstream smoke) reduced the cytotoxicity of 
the condensate of full-flavored, low-tar cigarettes in the 
neutral red incorporation assay (Bombick et al. 1997b). 
In more recent studies, researchers reported that 
heating the tobacco at a low temperature instead of burn-
ing it reduced the cytotoxicity of the smoke, as deter-
mined by the neutral red incorporation assay (Tewes et al. 
2003). However, the reduction was greater in the particu-
late phase than in the gas phase (Patskan and Reininghaus 
2003). Less frequently used in vitro assays for cytotoxicity 
include the dye exclusion assay (Hopkin et al. 1981; Hop-
kin and Evans 1984); the lactate dehydrogenase release 
assay; the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) uptake assay; and the kenacid blue 
binding assay (Putnam et al. 2002). 
Smoking-machine conditions are a determinant of 
the cytotoxicity of cigarette smoke condensate (Foy et al. 
2004; Roemer et al. 2004). Smoke condensates from U.S. 
commercial cigarettes ranging from very low or ultra-
low tar to full flavor as ranked by the FTC/ISO method, 
and also experimental reference cigarettes ranging from 
ultralow tar to low tar to full flavor, demonstrated a higher 
level of cytotoxicity when produced under smoking- 
machine conditions that generated higher smoke yields. 
The increase in cytotoxicity was measured in both the par-
ticulate and the gas phases expressed on a per cigarette 
basis. The increase in cytotoxicity measured in smoke 
produced under more intense smoking conditions was 
greatest for the particulate phase of the full-flavored com-
mercial cigarettes and least for the ultralight varieties. 
This pattern was not as evident for cytotoxicity induced in 
the gas phase (Roemer et al. 2004).
The cytotoxicity of machine-generated mainstream 
smoke from the 2R1 reference cigarette to cultured mouse 
fibroblast L-929 cells was reduced by increasing the age of 
the smoke and the amounts of charcoal in an acetate filter 
(versus acetate alone) (Sonnenfeld et al. 1985). Investiga-
tors showed that cytotoxic effects on lung epithelial cells 
were attributable to oxidants and aldehydes present in 
the volatile phase of the smoke or formed in the cells on 
exposure to the smoke (Hoshino et al. 2001). In one study, 
selective reduction of compounds in the gas phase by an 
activated carbon filter decreased the cytotoxicity of the gas 
phase of the smoke from a commercial cigarette to lung 
epithelial cells (Pouli et al. 2003). (The compounds were 
acetaldehyde, acetone, acetonitrile, acrolein, acrylonitrile, 
benzene, 1,3-butadiene, 2-butanone, 2,5-dimethylfuran, 
ethylbenzene, furan, isobutyraldehyde, isoprene, meth-
acrolein, methanol, 1,3-pentadiene, propionaldehyde, 
propionitrile, toluene, and m-xylene.) However, in other 
research, a decrease in intracellular concentrations of 
reduced glutathione in a human type II–like cultured 
lung cell line (A549) exposed to whole smoke was sig-
nificantly greater than that produced by smoke filtered 
through a Cambridge filter pad (Ritter et al. 2004). This 
finding suggests that chemicals in the particulate phase 
of cigarette smoke produce an immediate depletion of an 
important cellular antioxidant. The A549 cell line has 
been extensively used to study human lung damage by sin-
gle chemicals and complex chemical mixtures. This cell 
line may be more useful for studying substances that are 
active in their administered form, rather than for studying 
those that require biotransformation to reactive metabo-
lites, because some cytochrome P-450 isoforms are not 
expressed in A549 cells (Castell et al. 2005). 
Recent mechanistic studies identified apoptosis 
and necrosis as important mechanisms of cytotoxicity 
of cigarette smoke to cultured mammalian lung cells 
(Hoshino et al. 2001; Piperi et al. 2003; Pouli et al. 2003). 
In one study, the viability of alveolar type 2 A549 cells was 
reduced by smoke extract from a commercial cigarette 
in a time- and concentration-dependent manner, as mea-
sured by the reduction of MTT (Hoshino et al. 2001). In 
another study, the viability of mouse lung LA-4 cells was 
reduced by the gas phase of commercial cigarette smoke 
in a concentration-dependent manner, as measured by 
lactate dehydrogenase leakage and reduced metabolic 
activity (WST-1 assay) (Piperi et al. 2003). In both stud-
ies, apoptosis was seen at low concentrations of smoke 
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and necrosis was seen at higher concentrations. One of 
the studies found that smoke extract increased intracel-
lular oxidative activity (Hoshino et al. 2001). The other 
study observed a dose-dependent reduction in reduced 
cellular glutathione levels (Piperi et al. 2003). In addi-
tion, cells exposed to cigarette smoke showed increased 
protein modification (nitrotyrosine immunoreactivity) 
and activation of mitogen-activated protein kinase path-
ways. Aoshiba and colleagues (2001) reported that toxic 
effects on isolated alveolar macrophages from the smoke 
of an unfiltered commercial cigarette involved oxidative 
stress, an important mediator of cell death through both 
necrosis and apoptosis. This effect was associated with 
accumulation of BAX protein, mitochondrial dysfunction, 
and release of mitochondrial cytochrome c, but it was 
independent of the TP53 gene, FAS, and caspase activa-
tion. Sublethal concentrations of unfiltered extract from 
mainstream smoke from a commercial cigarette pro-
duced evidence of senescence in alveolar epithelial cells—
A549 cells and alveolar type 2 cells isolated from normal 
human lungs. The senescence was characterized by dose- 
and time-dependent increases in β-galactosidase activity, 
changes in cell morphology, accumulation of lipofuscin, 
overexpression of the P21CIP1/WAF1/SDI1 protein, and irre-
versible growth arrest (Tsuji et al. 2004).
Scientists reported that the limitation of past and 
current in vitro tests for cytotoxicity is that the results 
are based on the response of single cell types or isolated 
tissues and do not include the influence of the whole-body 
system on the response (Stratton et al. 2001). However, 
in vitro cytotoxicity assays are useful in determining 
the contribution of different tobacco blends or cigarette 
components (e.g., the filter) to the overall cytotoxicity of 
the smoke and in identifying causative cytotoxic agents 
in smoke and mechanistic pathways. Although in vitro 
assays are not able to replace all conventional animal 
bioassays, they are increasingly seen as alternatives to 
animal testing of drugs and chemicals, in the European 
Union, the United States, and elsewhere (Höfer et al. 2004; 
Interagency Coordinating Committee on the Validation 
of Alternative Methods 2004). Many cellular pathways 
are activated similarly in vitro and in vivo (Devlin et al. 
2005). In 2005, the Canadian government implemented a 
regulation requiring performance of three in vitro tests 
of toxicity (mutagenicity, clastogenicity, and cytotoxic-
ity) on emissions for all cigarettes sold in Canada and that 
the results be reported to the Minister of Health (Canada 
Gazette 2005). Quantitative in vitro dose-response data 
could eliminate the need for use of a large number of 
experimental animals to achieve appropriate statistical 
power in an in vivo study (Parry et al. 2005).
Animal Bioassays
Researchers have tested the carcinogenic ability 
of tar in cigarette smoke in laboratory animals for more 
than nine decades and in animal inhalation studies of 
machine-generated cigarette smoke for more than five 
decades (Wynder and Hoffmann 1967). The first successful 
induction of cancer in a laboratory animal with a tobacco 
product was reported by Wynder and colleagues (1953, 
1957) with the application of cigarette tar to mouse skin. 
They observed a clear dose-response trend between the 
amount of tar applied to the skin of the mice and the per-
centage of animals bearing skin papilloma and carcinoma 
in the test group. Skin-painting studies typically used 
condensate from cigarette smoke produced under stan-
dard FTC or ISO conditions, allowing comparisons among 
studies. More recent studies showed that smoking-ma-
chine conditions influence the measures of in vitro muta-
genicity and cytotoxicity of smoke condensate, expressed 
on a per cigarette or per milligram of tar basis (Roemer 
et al. 2004; Rickert et al. 2007). However, skin-painting 
studies typically focused on product characteristics such 
as tobacco filler, paper, and additives rather than on smoke 
condensate produced under different smoking-machine 
conditions. One study demonstrated that tobacco blend, 
filter type, and flavoring materials are determinants of the 
composition of mainstream smoke, whereas the amount of 
tobacco in the cigarette, the dimensions of the cigarette, 
and the filter type influence smoke yield (Borgerding 
and Klus 2005). Future skin-painting studies will likely 
use condensates produced by different smoking-machine 
conditions, because some countries have begun to man-
date cigarette testing with alternative smoking-machine 
conditions.
The use of experimental animal studies to predict 
cancer risk is more qualitative than quantitative (Stratton 
et al. 2001). Most animals used in laboratory studies with 
smoke are obligate nose breathers. Furthermore, Wynder 
and Hoffman (1967) reported that the respiratory systems 
of laboratory animals differ qualitatively and quantita- 
tively from those of humans in surface area, in the develop- 
ment of mucous membranes, and in having an enhanced 
glandular system that increases the fluid in the nasal 
passages. Despite these limitations, animal studies provide 
information that is not available from in vitro systems 
because animal studies permit the use of an intact host 
system with a full complement of endocrine, hormone, 
and immune effects and hepatic and extrahepatic metabo-
lism (Eaton and Klaassen 2001). Animal studies are often 
used to confirm positive findings or to resolve conflict-
ing results from in vitro assays and to study organ-specific 
effects. Animal studies provide valuable data in terms of 
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biologic plausibility, mechanisms of action, and causality. 
Animal studies of chronic diseases such as cancer can be 
less expensive than human clinical studies, and they also 
allow the use of invasive procedures (Devlin et al. 2005).
The smoke and smoke condensate animal bioassay 
literature is extensive and was reviewed by IARC in 2004. A 
synopsis follows of similar literature with a focus on stud-
ies made available since the publication of that review. 
Dermal Application of Cigarette  
Smoke Condensate
Studies have used mouse skin as the test tissue in 
experiments carried out during the past 35 years, and the 
results from various laboratories have been similar with 
respect to the overall degree of carcinogenic activity of 
cigarette smoke condensate and the major differences in 
activity from cigarettes with different designs. Cigarette 
smoke condensate produces both benign and malignant 
tumors on mouse skin. The induced tumors are usually 
of epidermal origin. The carcinogenic potency of the ciga-
rette smoke condensate depends on the tobacco variety, 
the composition of the cigarette paper, and the presence 
of additives. Subtle differences in smoking techniques, 
storage conditions for cigarette smoke condensate, and 
procedures for animal exposure do not appear to critically 
affect the results (IARC 2004). Researchers also conducted 
a limited number of skin-painting studies in other animal 
species including Syrian golden hamsters (Bernfeld and 
Homburger 1983) and rabbits (Graham et al. 1957).
In early skin-painting experiments with mice, 
researchers examined the tumorigenic activity of smoke 
condensates from reference cigarettes, from cigarettes 
made with different reconstituted tobacco sheets, or from 
mixtures of smoke condensates from reference cigarettes 
and reconstituted tobacco sheets made with 8-percent 
sodium nitrate as a tobacco additive (Dontenwill et al. 
1972). Three preparations were tested: smoke condensate, 
dry smoke condensate without volatile smoke components, 
and condensate from vapor phase smoke. The smoke and 
the dry smoke condensates were equivalent in their ability 
to induce tumors, but the condensate from vapor phase 
smoke was nearly ineffective. The manufacturing process 
used to prepare the reconstituted tobacco sheet was a 
factor in the tumorigenic activity of the smoke conden-
sate. Sodium nitrate reduced the tumorigenic activity of 
smoke condensate when added to the tobacco, to the ref-
erence cigarettes, or to the reconstituted tobacco sheet.
Subsequent studies continued to evaluate refer-
ence and experimental cigarettes constructed of tobacco- 
derived materials in dermal tumor promotion studies with 
female SENCAR mice (Meckley et al. 2004a,b). Cigarette 
smoke condensate from 1R4F reference cigarettes, which 
was applied to the skin of mice three times per week for 
29 weeks, produced significant, dose-dependent increases 
in both the number of tumor-bearing animals and in the 
total number of tumors in mice treated first (initiated) 
with the carcinogen 7,12-dimethylbenz[a]anthracene 
(DMBA). The tumors were papillomas and squamous cell 
carcinomas; papillomas were still progressing toward car-
cinomas at the end of the study. Animals in the high-dose 
group demonstrated treatment-related damage to the 
treated dorsal skin. The damage was described as peeling 
skin, erythema, and sores. The effects on the dorsal skin 
occurred at a lower incidence in the middle-dose group. 
Dose-dependent histologic changes in nonneoplastic skin 
at the treatment site were characterized by increased epi-
dermal thickness (acanthosis) and hyperkeratosis. Sig-
nificant increases were reported in the ratios of organ 
to body weight for the kidneys, liver, and spleen and in 
organ weight and ratios of organ weight to brain weight 
for the liver and spleen in the mid- and high-dose groups 
compared with those for the control group, which was 
initiated with DMBA but not promoted with condensate. 
Histologic examinations revealed an increase in extramed-
ullary hematopoiesis of the spleen in the high-dose group.
To increase the filling power of tobacco, manu-
facturers developed processes to impregnate shredded 
tobacco with volatile materials and then rapidly remove 
them to expand the cellular structure of the leaf, thereby 
reducing the density of the tobacco filler. The expanded 
tobacco was shown to have a high burn rate and irritat-
ing smoke (Browne 1990). The reduced cigarette weight, 
increased filling power, and increased burn rate reduced 
the number of puffs, which, in turn, reduced delivery of 
tar and nicotine (Abdallah 2003a). Expanded tobacco is 
included in commercial cigarettes, and the amount of 
expanded tobacco as a percentage of the tobacco mass 
increases from approximately 15 percent in full-flavored 
cigarettes to 50 percent in ultralight brands (Theophilus 
et al. 2004). Other scientists reported that concentrations 
of most chemicals measured in the smoke of cigarettes 
with puffed, expanded, or freeze-dried tobacco were signif-
icantly reduced compared with those in control cigarettes 
(Hoffmann et al. 2001).
In a study by Theophilus and colleagues (2003b), 
condensates from the smoke of cigarettes constructed with 
100-percent tobacco expanded with dry ice or Freon-11 
(trichlorofluoromethane) produced similar numbers 
of tumor-bearing animals and total tumors in DMBA- 
initiated mice. Animals in the group treated with a low 
dose of condensate from smoke of tobacco expanded with 
Freon had a significantly longer median time to onset of 
tumors and significantly more total tumors than animals 
in the group treated with a low dose of condensate from 
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smoke of tobacco expanded with dry ice. No biologically 
significant nonneoplastic changes were observed in inter-
nal organs or treated dorsal skin. Smoke from the tobacco 
expanded with dry ice contained significantly higher 
concentrations of CO2, acetone, formaldehyde, catechol, 
nitric oxide, and NATB than did smoke from the Freon-
expanded tobacco.
In other research, Theophilus and colleagues 
(2003a) studied smoke from cigarettes constructed with 
100-percent propane-expanded tobacco. They found that 
the smoke had significantly higher concentrations of 
total particulate matter, nicotine, tar, CO, CO2, ammonia, 
catechol, hydroquinone, phenol, p- and m-cresol, nitric 
oxide, NATB, and NNK than did the smoke from Freon- 
expanded tobacco. No biologically significant nonneoplas-
tic differences in internal organs or treated dorsal skin 
were observed among animals treated with condensate 
from cigarettes containing propane-expanded tobacco 
compared with animals treated with condensate from 
cigarettes containing Freon-expanded tobacco. Smoke 
condensates from cigarettes made with Freon- or propane-
expanded tobacco produced similar numbers of tumor-
bearing animals and total tumors in DMBA-initiated mice.
In another study, Theophilus and colleagues (2004) 
treated mice with smoke condensate from cigarettes 
constructed with increasing percentages of expanded 
shredded tobacco stems. In general, there was a pattern 
of increasing numbers of tumor-bearing animals and 
total tumors with increasing doses of tar among groups 
of mice treated with low, medium, or high concentra-
tions of expanded shredded tobacco stems. This pattern 
was not present across these groups at a given tar level. 
The control group treated with condensate from ciga-
rettes without expanded shredded tobacco stems showed 
a dose-dependent increase in the percentage of animals 
with tumors and in the total number of tumors compared 
with DMBA-initiated animals in the solvent (vehicle) con-
trol group not treated with smoke condensate. Cigarettes 
containing expanded shredded tobacco stems produced 
lower concentrations of some chemicals in mainstream 
smoke than did cigarettes that did not contain expanded 
shredded tobacco stems, but the concentrations were not 
consistently reduced in a dose-dependent manner. 
In vivo and in vitro analyses support the hypothesis 
that short-term measures such as cytotoxicity, cellular 
proliferation (hyperplasia), generation of free radicals, and 
inflammation are involved in tumor promotion produced 
by cigarette smoke condensate (Curtin et al. 2004a). Other 
studies found that in addition to promoting tumors, ciga-
rette smoke condensate and its fractions can act as tumor 
initiators, tumor accelerators, and cocarcinogens when 
applied together with other chemicals such as B[a]P and 
complete carcinogens (Wynder and Hoffmann 1961; Hoff-
mann and Wynder 1971; Hecht 2005).
The results from studies of dermal application of 
cigarette smoke condensate suggest a tissue-specific 
response to the chemicals in cigarette smoke that undergo 
covalent binding to DNA. Investigators have detected 
adducts in the skin, lung, heart, kidney, liver, and spleen 
of female ICR mice treated topically with cigarette smoke 
condensate from a commercial U.S.-blended unfiltered 
cigarette (Randerath et al. 1986, 1988; Reddy and Rander-
ath 1990). In one study, dermal application of condensate 
from the smoke of 1R4F reference cigarettes three times 
per week for one or four weeks induced DNA adducts in the 
skin and lung tissue of male CD-1 mice (Lee et al. 1992). 
The relative adduct labeling values in skin were highest 
after one week of exposure and did not increase after four 
weeks. DNA adduct levels in the lung increased between 
one week and four weeks of treatment with condensate. 
Skin adducts declined to less than one-half the values of 
the first week by four weeks after cessation of exposure to 
condensate. In contrast, adduct levels in the lung contin-
ued to increase during the four weeks after cessation of 
exposure. Adduct levels increased with the total amount 
of tar applied weekly. The dose-response relationship was 
especially evident in lung tissue. In another study, treat-
ments three times per week with similar concentrations 
of condensate from 1R4F cigarettes for 29 weeks resulted 
in an increase in DNA adducts in skin and dose- and time-
dependent increases in DNA adducts in lung and heart tis-
sues of female SENCAR mice (Brown et al. 1998).
Inhalation Studies with Cigarette Smoke
Historically, animals have not proven to be good 
models for the type of lung tumors induced by cigarette 
smoke in humans. Inhalation exposure to cigarette smoke 
leads to a reduction in the respiratory rate, and nontrans-
genic animals and animal strains with a low background 
incidence of lung tumors often do not develop an excess 
of lung tumors of any type. Researchers have attempted 
to induce lung cancer by exposure to cigarette smoke in 
several animal species, including rabbits, monkeys, dogs, 
and hamsters and other rodents. Hamsters developed 
laryngeal tumors but not tumors in the lower respiratory 
tract, and dogs developed epidermoid and bronchioloal-
veolar carcinomas (Coggins 2002; IARC 2004; Witschi 
2005). Rodents tended to develop adenomas arising in the 
periphery of the lung rather than bronchial tumors arising 
centrally (Stratton et al. 2001). A study by Hutt and associ-
ates (2005) was the first to describe successful induction 
of lung tumors in mice after a lifetime whole-body expo-
sure to mainstream cigarette smoke. Many animal studies 
used exposure chambers that permit whole-body exposure 
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to cigarette smoke. Modern nose-only exposure tubes 
that allow body heat to dissipate are regarded by some as 
superior to whole-body exposure chambers because they 
eliminate dosing by nonrespiratory routes and allow the 
test concentration delivered to the animal to be closer to 
the concentration delivered to the system, by avoiding loss 
of the test compound on the walls, loss on the skin and 
fur of the animals, sedimentation and impaction of aero-
sol particles in the chamber, and chemical reactivity in 
the chamber (Pauluhn 2005). Table 3.1 contains data on 
lung tumor incidence from studies of carcinogenicity in 
rodents that used inhalation exposure to cigarette smoke. 
Mouse. Witschi and colleagues (1997a) dem-
onstrated that mouse lung tumors developed in the 
peripheral lung as areas of hyperplasia that progress to 
adenocarcinomas. In subsequent research, Witschi and 
colleagues (2002) studied male Balb/c and SWR mice 
exposed to a mixture of 89-percent sidestream smoke and 
Table 3.1 Selected chronic carcinogenicity studies in mice and rats with inhalation exposure to cigarette smoke
Study Strain Gender Concentration
Exposure duration/ 
administration route
Lung tumor incidence 
(%)
Mouse               




Male Average TSP concentration of 122 
mg/m3 from 1R4F reference cigarette 
sidestream/mainstream smoke 
mixture 
6 hours/day,  
5 days/week for  
5 months/whole body




Witschi et al. 
2004
A/J Male Average TSP concentrations of  
176 mg/m3 (high dose),  
120 mg/m3 (medium dose),  
99 mg/m3 (low dose) from 2R4F 
reference cigarette sidestream/
mainstream smoke mixture
6 hours/day,  






Hutt et al. 
2005
B6C3F1 Female Average daily TPM concentration of  
254 ± 27 mg/m3 from a 2R1 reference 
cigarette 
6 hours/day,  
5 days/week for  
30 months/whole body
148/330 (44.8)* 
Controls: 31/326 (9.5)  
Rat                
Dalbey et al. 
1980
F-344 Female 10% smoke concentration from 
unfiltered experimental cigarettes 
(NCI code 16)
8 hours/day, 








Low dose (100 mg/m3 [6%]) and  
high dose (250 mg/m3 [14%]) from  
a 1R3 reference cigarette
6 hours/day,  
5 days/week for up to 
30 months/whole body
Female
  Low: 4/175 (2.3)
  High: 4/81 (4.9)a
  Controls: 0/119 (0)
Male
  Low: 1/178 (0.6)
  High: 5/82 (6.1)
  Controls: 3/118 (2.5)
Note: mg/m3 = milligrams per cubic meter; NCI = National Cancer Institute; TPM = total particulate matter; TSP = total suspended 
particulate. 
aSignificantly different (p <0.05) from controls.
bRespiratory tumors consisted of 8 in the lung (5 adenomas, 2 alveologenic carcinomas, 1 squamous carcinoma) and 2 nasal tumors 
(adenocarcinoma and squamous-cell carcinoma).
*p <0.001.
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11-percent mainstream smoke from 1R4F reference ciga-
rettes (Witschi et al. 2002). As reported in the previous 
studies (Witschi et al. 1997a,b), the investigators included 
a four-month recovery period to increase the development 
of lung tumors. In both strains, they observed increases 
in lung tumor multiplicities (average number of tumors 
per lung) (0.44 ± 0.13 and 0.35 ± 0.14, respectively) and 
lung tumor incidences (number of tumor-bearing mice 
per total number of treated mice) (33% in treated Balb/c 
mice versus 20% in controls and 19% of treated SWR mice 
versus 4% in controls, respectively) (Table 3.1) after expo-
sure to cigarette smoke. Only the lung tumor multiplicity 
in treated SWR mice was statistically different from that 
in SWR controls exposed to air only. These investigators 
found that strain A/J mice were more susceptible to car-
cinogen-induced lung tumors than were Balb/c or SWR 
mice (Witschi et al. 2002). The same exposure regimen 
showed that in male strain A/J mice, the lung tumor mul-
tiplicity was significantly higher among the exposed mice 
than among the air-only controls, and there was a good 
correlation between exposure (average concentration of 
cigarette smoke multiplied by exposure duration) and 
lung tumor multiplicity (Witschi et al. 2002). Prolifera-
tive pulmonary lesions were categorized as focal alveolar 
epithelial hyperplasia, alveolobronchiolar adenomas, and 
alveolobronchiolar adenocarcinomas. Although it was 
possible to achieve a dose-related increase in lung tumor 
multiplicity in A/J mice with this exposure protocol, mice 
exposed to cigarette smoke had fewer adenomas with car-
cinomatous foci or adenocarcinomas (malignant tumors) 
than did air-only controls (Witschi et al. 2002).
In a later study, Witschi and colleagues (2004) used 
a similar exposure regimen with five months of whole-
body exposure to smoke from 2R4F reference cigarettes 
(89-percent sidestream and 11-percent mainstream 
smoke), followed by a four-month recovery period. This 
regimen produced a significant increase in lung tumor 
multiplicity and tumor incidence compared with the 
air-only controls although the response to the high dose 
was slightly less than to the medium dose (Table 3.1) in 
male strain A/J mice. The authors attribute the flat dose- 
response curve to the weak lung carcinogenicity of 
cigarette smoke in mice. The tumors were described as 
bronchioloalveolar adenomas.
Curtin and associates (2004b) studied effects of 
subchronic exposure to mainstream smoke from 1R4F 
reference cigarettes in male RasH2 transgenic mice, which 
carry the human C-HA-RAS oncogene, and A/J mice. 
Mice had whole-body exposure for 20 weeks or nose-only 
exposure for 28 weeks. Results indicated that whole-body 
exposure may be more effective than nose-only exposure 
for inducing statistically significant changes in tumor 
multiplicity and tumor incidence. One concentration of 
cigarette smoke was used in the whole-body experiments, 
and three concentrations were used in the nose-only 
experiments. Both exposure regimens included a 16-week 
recovery period. With whole-body exposure, microscopi-
cally confirmed tumor incidence and tumor multiplicity 
were significantly greater in the exposed animals than in 
the sham-exposed animals in both mouse strains.
Hutt and colleagues (2005) developed a model 
that achieved a 10-fold increase in hyperplastic lesions, 
a 4.6-fold increase in adenomas and papilloma, a 7.25-
fold increase in adenocarcinomas, and a 5-fold increase 
in metastatic pulmonary adenocarcinomas in mice with 
lifetime whole-body exposure to cigarette smoke com-
pared with lesions in air-only sham controls. The B6C3F1 
strain of mice used in this study have low background 
incidence of lung tumors compared with that for A/J mice 
used in other studies. The female mice were exposed to 
mainstream smoke from an unfiltered 2R1 reference ciga-
rette for 30 months. An increase in lung hyperplasia and 
neoplasia was first seen in mice exposed to TPM that died 
spontaneously between 540 and 720 days after the initial 
exposure. At the end of the study, the survival of mice 
exposed to smoke was significantly longer than that of the 
sham-exposed controls possibly because of reduced food 
consumption leading to lower body weight and a lower 
incidence and delayed onset of other types of cancers. 
Animals exposed to TPM also had a statistically significant 
increase in incidence of benign and malignant prolifera-
tive lesions in the nasal cavity. In contrast to other studies 
using a mouse model, this study achieved a significantly 
greater incidence of adenocarcinomas in treated animals 
(67 of 330, 20.3 percent) than in sham-exposed controls (9 
of 326, 2.8 percent).
Rat. Female Fischer-344 (F-344) rats received daily 
nose-only exposure to the smoke of experimental ciga-
rettes for 126 to 128 weeks (7 cigarettes per 8-hour day, 
5 days per week) (Dalbey et al. 1980). The mean delivery 
of smoke particulate from 85-mm unfiltered cigarettes 
(National Cancer Institute, code 16) was 18.4 mg per ciga-
rette. The exposure chamber consisted of holding tubes 
attached to the side of a 350-mL chamber containing a 
mixture of cigarette smoke and room air. The two control 
groups consisted of unexposed and sham-exposed con-
trols. Survival in the smoke-exposed rats was similar to 
that of the two control groups combined. Animals in the 
group exposed to smoke had significantly more tumors 
of the respiratory tract than did the combined control 
groups (Table 3.1). Compared with controls, rats exposed 
to cigarette smoke had significantly fewer tumors in the 
hypophysis, hematopoietic and lymphoid system, uterus, 
and ovary. The number of adrenal tumors and oral tumors 
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in treated animals increased, but the changes did not 
reach statistical significance. Animals exposed to smoke 
also had a significant increase in dermal tumors (subcuta-
neous sarcomas) near ulcers on the front feet from push-
ing against the holding tubes during exposure compared 
with animals in the control groups.
In the same study of lifetime exposure, researchers 
observed nonneoplastic tumors throughout the respira-
tory tract of animals exposed to smoke (Dalbey et al. 1980). 
These lesions included hyperplastic and metaplastic areas 
in the epithelium of the upper airways (nasal turbinates, 
larynx, and trachea) and areas of the lung with focal alveo-
litis (accumulations of pigmented macrophages, alveo-
lar epithelial hyperplasia, and alveolar fibrosis).Lesions 
in control animals were much smaller and less severe. 
Researchers observed fibrosis and thickening of arterioles 
in the papillary muscle of the heart. No other organ sys-
tems showed evidence of smoke-related pathology.
One study also used chronic whole-body exposure 
in an attempt to achieve higher lung doses of cigarette 
smoke in F-344 rats (Mauderly et al. 2004). Low (100 
mg TPM/cubic meter [m3]) and high (250 mg TPM/m3) 
concentrations of mainstream cigarette smoke were used 
for exposures up to 30 months. Cigarette smoke was pro-
duced from unfiltered 1R3 reference cigarettes machine 
puffed twice per minute using a 70-mL, two-second puff 
and then diluted with air cleaned by a high-efficiency 
particulate air filter. Exposure to cigarette smoke sig-
nificantly increased the incidences of nonneoplastic and 
neoplastic, proliferative lung lesions in female rats. Trends 
with exposure for all neoplastic lung lesions were highly 
significant for female rats. No trend with exposure was 
significant for males. Time to first observation of hyper-
plastic lesions was shortened by exposure among female 
but not male rats. Both benign and malignant neoplasms 
were observed earlier in high-exposure female rats than 
in low-exposure female rats. Hyperplastic responses con-
sisted primarily of focal alveolar epithelial hyperplasia. 
Benign neoplasms were bronchioloalveolar adenomas, 
and malignant neoplasms were bronchioloalveolar carci-
nomas. Mean absolute weights of lungs in male and female 
rats exposed to high concentrations of smoke were signifi-
cantly greater than those in animals in the control groups. 
Nonproliferative changes more common in animals in 
high-exposure groups than in low-exposure groups were 
ciliated cuboidal cell metaplasia and squamous metaplasia 
in alveolar ducts. There was no consistent difference by 
sex in development of proliferative nasal lesions, and the 
incidence of nasal cavity neoplasms increased significantly 
in both male and female rats exposed to high concentra-
tions of smoke. Most of the nasal cavity tumors were epi-
thelial in origin, and the benign epithelial tumors were 
adenomas. Histologic changes in the nasal cavity, such 
as squamous metaplasia of transitional and respiratory 
epithelium, mucous cell metaplasia and hyperplasia, and 
inflammatory infiltrates, were more common or more 
severe in the rats exposed to high concentrations of smoke.
Carcinogenicity bioassays should be conducted for 
a major portion of the test animal’s lifetime. Short-term 
(subchronic) exposure studies are primarily performed to 
provide information on target organs of repeated exposure. 
Short-term, nose-only exposures to mainstream smoke 
produced treatment-related histopathologic changes in 
the respiratory tract and in clinical chemistry parameters 
in male and female Sprague-Dawley rats (Coggins et al. 
1989; Ayres et al. 2001; Terpstra et al. 2003). Animals 
exposed to cigarette smoke had significantly more chronic 
active inflammation, epithelial hyperplasia, atrophy of the 
olfactory epithelium, and squamous metaplasia of the na-
sal passages and larynx. Other histopathologic changes 
included increased counts of intra-alveolar brown-gold 
macrophages and bronchial goblet cells. There was a 
dose-dependent trend toward increased severity of the 
effects with increased exposure. Some of the effects such 
as laryngeal squamous metaplasia were not completely 
reversed during a recovery period. 
A U.S.-tobacco-blend cigarette containing the addi-
tive 1-menthol and other conventional processing aids and 
flavoring ingredients was compared with a reference ciga-
rette comprised of a similar tobacco blend in a 13-week 
inhalation study of toxicity in male and female F-344 rats 
(Gaworski et al. 1997). Only one concentration of 1-men-
thol (5,000 ppm) was used. Three dose levels of cigarette 
smoke were tested for each cigarette. Both cigarette vari-
eties produced similar dose-related histologic changes in 
the respiratory tract and increases in ratios of lung weight 
to body weight. The researchers noted that although 
lesions in the trachea and larynx related to cigarette smoke 
were similar in incidence, the degree of the response 
was slightly more severe in some groups of female rats 
exposed to mentholated cigarette smoke than it was in those 
exposed to nonmentholated cigarette smoke.
Theophilus and colleagues (2003a,b, 2004) per-
formed several 13-week nose-only inhalation studies 
with Sprague-Dawley rats to evaluate the toxic effects 
of expanded materials derived from tobacco (Theophi-
lus 2003a,b, 2004). The exposure regimen consisted of 
one hour of exposure per day, five days per week, for 13 
weeks, followed by a 13-week recovery period. Male and 
female rats were exposed to mainstream smoke from ciga-
rettes constructed of 100-percent tobacco expanded with 
dry ice or Freon-11 (Theophilus et al. 2003b) or tobacco 
expanded with propane or Freon-11 (Theophilus et al. 
2003a). Animals exposed to cigarette smoke demonstrated 
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chronic active inflammation and epithelial hyperplasia of 
nasal tissues and ventral squamous metaplasia of the lar-
ynx that appeared to increase in severity with increasing 
doses. Treated animals also had significantly more non-
pigmented macrophages and brown-gold macrophages 
and evidence of chronic active inflammation of the larynx 
than did air-only controls. Most of the histologic changes 
resolved after a 13-week recovery period (Theophilus et 
al. 2003a,b). A separate study was conducted to evalu-
ate the toxic effects of different percentages of expanded 
shredded tobacco stems (Theophilus et al. 2004). Overall, 
exposure to mainstream smoke from cigarettes con-
structed of 9.25-percent, 18.5-percent, or 25-percent 
expanded shredded stems failed to produce signs of 
increased or decreased toxicity relative to the control 
cigarettes that did not contain expanded shredded stems. 
At the highest dose, animals in all the groups exposed to 
expanded shredded stems had significant increases in the 
severity of nonpigmented macrophages in left and apical 
regions of the lung compared with those in unexposed 
animals. Treatment groups with the medium (18.5 per-
cent) and high (25 percent) content of expanded shred-
ded stems also had a significant increase in the severity 
of nonpigmented macrophages and goblet cells in the 
right diaphragmatic region of the lung at the highest dose 
compared with animals treated with smoke from control 
cigarettes containing zero-percent expanded shredded 
stems. Theophilus and colleagues did not describe the 
composition or tobacco blend in the control cigarettes 
or in the cigarettes made with expanded shredded stems. 
They stated that the tobacco blend and cigarette configu-
ration were comparable between test and control ciga-
rettes and that the main difference was the percentage of 
expanded shredded stems in the test cigarettes.
Cardiovascular and Cerebrovascular  
Studies in Animals
Some animal models show promise for studying 
the development of cardiovascular disease induced by 
cigarette smoke. For example, researchers have proposed 
an elastase-perfusion mouse model for aortic aneurysms 
induced by cigarette smoke (Buckley et al. 2004). Another 
example is the cockerel as a model for arteriosclerosis 
(Penn et al. 1983, 1992, 1996; Penn and Snyder 1988). 
Cockerels are sensitive to the plaque-promoting effects of 
chemicals administered by inhalation or injection. Inha-
lation of mainstream cigarette smoke or the vapor phase 
smoke component, 1,3-butadiene, was shown to promote 
plaque development in cockerels, but CO or an injection 
of NNK or solubilized concentrated cigarette smoke con-
densate from an unventilated 2R1 reference cigarette did 
not promote plaque development in cockerels. At high 
doses, intramuscular injections of PAH compounds with 
different carcinogenic potencies also led to arterioscle-
rotic plaque formation. Sidestream smoke was more effec-
tive than mainstream smoke in stimulating aortic plaque 
development in the cockerel model. 
Investigators reported that tissue injury induced 
by oxidative stress, altered serum lipids, increased blood 
pressure, and endothelial damage were other possible 
factors in cardiovascular injury from cigarette smoking 
(Stratton et al. 2001). In another study, inhalation expo-
sure to cigarette smoke produced evidence of oxidative 
stress in the hearts of Balb/c mice (Koul et al. 2003). After 
10 weeks of whole-body exposure for 60 minutes per day 
to the smoke from five commercial filter-tipped cigarettes, 
mice had significantly lower concentrations of glutathione 
and higher concentrations of lipid peroxides, glutathione 
peroxidase, glutathione reductase, and catalase than did 
unexposed mice. Serum triglycerides, total cholesterol, 
LDLc, and the ratio of total cholesterol to HDLc were also 
significantly higher, and HDL and the ratio of HDLc to 
LDLc were significantly lower in the group exposed to 
smoke. Concomitant administration of α-tocopherol pre-
vented some of the smoke-induced changes.
In one study, whole-body exposure to smoke from 
a 2R1 reference cigarette three times per day for 30 days 
resulted in a significant increase in the formation of 
8-oxo-dG, a marker of oxidative damage, in the heart 
tissue of male Sprague-Dawley rats, compared with the 
concentration in unexposed controls (Park et al. 1998). 
Cigarettes were smoked for 15 to 20 minutes to a fixed 
butt length in a 500-mL flask with air pumped into the 
flask. The reduced glutathione content and the oxidative 
state of glutathione in heart tissue were not significantly 
different from those in controls. In another study, whole-
body exposure to low concentrations of cigarette smoke 
resulted in impaired oxidative function in cardiac mito-
chondrial cells; increased intracellular, low-molecular- 
weight iron that can play a role in redox reactions; and 
reduced α-tocopherol during cardiac ischemia and reper-
fusion in female Sprague-Dawley rats (van Jaarsveld et al. 
1992). These findings suggested a mechanism involving 
oxidant radicals. Twice a day for two months, smoke was 
introduced by inserting a lit cigarette into a hole in the 
exposure chamber and allowing smoke to be drawn into 
the chamber for 5 seconds, followed by room air for 55 
seconds. This procedure was repeated until the cigarette 
extinguished (approximately 10 minutes). Carboxyhemo-
globin concentrations in rats exposed to smoke or air were 
not statistically different.
Scientists reported that hepatic uptake of chylo-
microns was significantly lower in Sprague-Dawley rats 
with whole-body exposure to the smoke of two unfiltered, 
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king-size, GPC-brand cigarettes (35 to 40 mL per puff, 
20 puffs per cigarette) than was uptake in sham-exposed 
controls (Pan et al. 1993). Animals were exposed to the 
smoke for 10 minutes, four times per day, for 10 days. 
In addition, more chylomicrons remained in the hearts 
of rats exposed to smoke than in the hearts of controls. 
Hepatic uptake and residence time in heart tissues also 
changed when chylomicrons were administered to unex-
posed animals that had been previously exposed to smoke. 
Smoke exposure increased the thiobarbituric acid reactive 
substance measurement in chylomicrons, a measure of 
lipid peroxidation. In a subsequent series of experiments, 
whole-body exposure to the smoke of two 2R1 reference 
cigarettes (35 to 40 mL per puff, 20 puffs per cigarette) 
for 10 minutes, six times per day, for 10 days, significantly 
increased postprandial serum triglyceride and chylomi-
cron concentrations, decreased hepatic uptake of chy-
lomicron remnants, and increased plasma postheparin 
lipoprotein lipase activity. Hepatic lipase activity was simi-
lar in rats exposed to smoke and controls (Pan et al. 1997). 
In another study, subchronic (14 or 90 days) but not acute 
(1 day) whole-body inhalation exposure to cigarette smoke 
resulted in significantly increased cholesterol, triglycer-
ide, and phospholipid levels in the serum, hearts, aor-
tas, and lungs of male Sprague-Dawley rats (Latha et al. 
1988). Changes in serum lipoproteins included decreases 
in HDLc, triglycerides, and phospholipids and increases 
in LDL and very-low-density lipoprotein cholesterol, tri-
glycerides, and phospholipids. Other alterations in lipid 
metabolism included increased hydroxymethylglutaryl- 
CoA reductase activity, decreased lipoprotein lipase 
activity in heart tissue, and increased lipoprotein lipase in 
adipose tissue. 
Research in male hypercholesterolemic ApoE 
*-/*- mice suggested that five weeks of exposure to 
1R4F cigarette smoke led to an increase in oxidized LDL 
immunoglobulin M (IgM) and antiphosphorylcholine 
IgM antibodies and a decrease in oxidized LDL IgG and 
lymphotoxin-β messenger ribonucleic acid (mRNA) 
expression in the spleen (Tani et al. 2004). Both IgM 
changes were associated with an increase in thickness 
of arterial intima. Animals were acclimated to cigarette 
smoke produced by a vacuum pump until smoke from one 
cigarette per day was tolerated. Mice exposed to cigarette 
smoke had significantly higher serum carboxyhemoglobin 
concentrations than those of air-only controls.
Researchers examined the aortic endothelium from 
male Sprague-Dawley rats by scanning and transmis-
sion electron microscopy after inhalation exposure to the 
smoke of two medium-tar cigarettes (19 mg of tar and 
1.5 mg of nicotine) (Pittilo et al. 1982, 1990). Smoking-
machine conditions were not provided in the descrip-
tion of study methods. Animals were anesthetized before 
exposure. The exposure was repeated 5 days per week dur-
ing a 25-day period. Compared with sham-exposed con-
trols, the rats exposed to smoke demonstrated marked 
morphologic evidence of endothelial damage that 
included increased blebs, microvillus-like projections, 
plasmalemmal vesicles, and Weibel-Palade bodies that 
store von Willebrand factor protein. No endothelial abnor-
malities were seen in rats that received nicotine by subcu-
taneous injections or by continuous subcutaneous pumps. 
These observations suggest that components of cigarette 
smoke other than nicotine are responsible for the endo-
thelial cell changes associated with smoking. Researchers 
reported that male Sprague-Dawley rats with exposure 
to the smoke of five low-nicotine (1 mg) cigarettes for 
20 to 30 minutes per day for four to six weeks had sig-
nificantly higher mean arterial blood pressure after bilat-
eral occlusion of the common carotid artery than did the 
sham-exposed controls (Bennett and Richardson 1990). 
Additionally, the time required to reach a maximum mean 
arterial blood pressure after occlusion was significantly 
less in the animals exposed to cigarette smoke versus the 
sham-exposed controls. Only one smoke concentration 
was used in this study. Using anesthetized, mechanically 
ventilated rats as an in vivo model, researchers showed 
that cigarette smoke produced a biphasic change in the 
diameter of the cerebral arterioles and an increase in mean 
arterial blood pressure in rats (Iida et al. 1998). An initial 
vasoconstriction was seen in animals breathing the smoke 
but not in animals receiving an intravenous infusion of 
nicotine. These findings led researchers to conclude that 
a smoke constituent other than nicotine was responsible 
for the early vascular change. Thromboxane A2 was pro-
posed as the agent responsible for the vasoconstriction. 
Others have determined that cigarette smoking, but not 
the use of transdermal nicotine or smokeless tobacco, 
increased concentrations of thromboxane A2 (Wennmalm 
et al. 1991; Benowitz et al. 1993).
Cardiovascular changes were observed in several 
studies of short-term and lifetime inhalation cigarette 
smoke exposure in rodents. Investigators studied male 
Wistar rats with whole-body exposure to the smoke of 
an unidentified commercial cigarette for 30 days. They 
observed a significant increase in left ventricular systolic 
diameter and a significant reduction in systolic shorten-
ing fraction and ejection fraction compared with those 
in unexposed controls (de Paiva et al. 2003). No change 
in heart rate or heart weight was seen under the expo-
sure conditions of this study. Another study demon-
strated a significant increase in heart weight in female, 
but not male, Sprague-Dawley rats with 13 weeks of daily 
nose-only inhalation exposure to the smoke of a custom-
blended experimental cigarette smoked under FTC condi-
tions (Coggins et al. 1989). Other investigators conducted 
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a 13-week inhalation study of male and female F-344 rats 
exposed to smoke of mentholated or nonmentholated cig-
arettes. Male rats exposed to medium or high doses and 
female rats exposed to high doses of smoke from men-
tholated cigarettes, machine smoked under FTC condi-
tions, developed a significant increase in the ratio of heart 
weight to body weight (Gaworski et al. 1997). Male and 
female rats exposed to high doses of smoke from nonmen-
tholated cigarettes also had a significant increase in car-
diomegaly (high ratio of heart weight to body weight). The 
difference between treated and control animals was no 
longer significant after a six-week recovery period. Dalbey 
and colleagues (1980) observed fibrosis and thickening of 
arterioles in the heart papillary muscle of female F-344 
rats with daily nose-only inhalation exposure for 126 to 
128 weeks to smoke from unfiltered experimental ciga-
rettes. No smoke-related pathologic changes to the large 
vessels were detected from the one concentration of smoke 
(10 percent) that was used.
Studies using dermal applications of smoke con-
densate or inhalation exposure to cigarette smoke dem-
onstrated that chemicals in cigarette smoke underwent 
covalent binding to heart tissue DNA in laboratory animals 
(Randerath et al. 1986, 1988; Reddy and Randerath 1990; 
Brown et al. 1998; Gupta et al. 1999). Studies of cigarette 
smokers showed that the heart tissue contained more 
DNA adducts than that from nonsmokers or former smok-
ers (Van Schooten et al. 1998). They also demonstrated a 
linear relationship between DNA adduct levels and daily 
cigarette smoking. Furthermore, higher DNA adduct 
levels were associated with a higher degree of coronary 
artery disease.
Respiratory Studies in Animals
Exposure to chemicals in cigarette smoke affects 
the function of the respiratory system in laboratory ani-
mals and humans. Notably, exposure to cigarette smoke 
affected airway mucociliary function (Shephard 1978; 
Wanner 1985; Finch et al. 1995). Another researcher 
demonstrated that exposure resulted in a dose-dependent 
inhibition of lung clearance and increased absorption of 
components of the inhaled smoke through the tracheo-
bronchial airways, especially where particle deposition 
occurred and mucociliary clearance was less efficient, spe-
cifically at the ridges within bifurcations and in posterior 
sections of tubular airways (Martonen 1992). Studies have 
shown that the activity of xenobiotic metabolizing (cyto-
chrome P-450) enzymes in human lung tissue is likely 
sufficient to cause in situ activation of pulmonary toxi-
cants (Castell et al. 2005). Species differences in enzyme 
activities have led some to question the use of animal 
data to predict toxic effects in humans from chemicals 
requiring bioactivation to reactive metabolites (Castell et 
al. 2005). Short-term assays to evaluate the components 
of cigarette smoke that impair mucociliary function were 
described in the “Cytotoxicity” section earlier in 
this chapter.
Persistent pulmonary inflammation from repeated 
exposure to cigarette smoke may lead to more severe 
alterations in the structure and function of the lung 
(Stratton et al. 2001). For example, researchers concluded 
that emphysema in cigarette smokers reflects a low-level, 
chronic inflammatory process in the lower respiratory 
tract with an imbalance of protease and antiprotease 
activities leading to the degradation of connective tissue 
(Churg et al. 2002).
Syrian golden hamsters have been used extensively 
to study the pathogenesis of emphysema. They show a pat-
tern of inflammatory airway response and impaired activ-
ity of antioxidants (superoxide dismutase and catalase)—a 
pattern similar to that in humans with repeated expo-
sure to cigarette smoke (Hoidal and Niewoehner 1982; 
McCusker and Hoidal 1990). Rat strains were shown 
to be more resistant to the induction of emphysema by 
exposure to cigarette smoke, but susceptibility in mice 
was strain specific (Groneberg and Chung 2004). Research 
on emphysema induced by cigarette smoke in animals has 
not consistently demonstrated progression of the disease 
(March et al. 1999). In a comparative study of B6C3F1 
mice and F-344 rats, the mouse strain displayed more 
morphometric changes (parenchymal air-space enlarge-
ment, volume density of alveolar air space, and loss of 
alveolar tissue) and significantly more neutrophils within 
inflammatory lesions in the lung. Morphometric differ-
ences in the mice at 13 months were greater than those at 
7 months. This finding suggests that in mice, emphysema 
induced by cigarette smoke may be progressive. Animals 
received a whole-body exposure to the smoke of 2R1 ref-
erence cigarettes that were machine smoked (two 70-mL 
puffs per minute) and diluted with filtered air to achieve 
a chamber concentration of 250 mg of TPM/m3. The 
exposure duration was six hours per day, five days per week. 
The investigators concluded that the type of inflammatory 
response may be a determining factor for differences in 
susceptibility to emphysema induction by cigarette smoke 
among test species. 
Animal models can readily be used to detect and 
quantitate the pulmonary inflammatory response to 
inhaled compounds or mixtures, and the literature in this 
area was reviewed (Stratton et al. 2001; IARC 2004). An 
analysis of bronchoalveolar lavage (BAL) fluid for cellular 
and biochemical indicators of inflammation allows quanti-
tation of the pulmonary inflammatory response of rodents 
to inhaled cigarette smoke (Churg et al. 2002; Shapiro et 
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al. 2003). The differential cell count and the functioning of 
cells obtained by the BAL technique can be used to classify 
the type of inflammatory response, and the biochemical 
content of the BAL fluid can be used to detect release of 
various cytokines and alterations in pulmonary surfactant 
(Stratton et al. 2001; Miller et al. 2002).
Response of inflammatory cells, cytokine profiles, 
enlargement of air space, and mechanical properties of 
the lung (elastance) differed among mouse strains after 
exposure to cigarette smoke (Guerassimov et al. 2004). In 
one study, emphysema-resistant (ICR) and emphysema-
sensitive (C57BL/6) mouse strains showed differences in 
BAL cytokine and chemokine responses following a nose-
only inhalation exposure to 2R1 reference cigarette main-
stream smoke (two-second, 35-mL puff, once per minute) 
for two hours per day for seven days (Obot et al. 2004). 
Test concentrations were achieved by diluting mainstream 
smoke with fresh, conditioned air. There was a significant 
dose response for chemokines and cytokines (KC, JE, 
MIP-1α, MIP-2, RANTES, interleukin (IL)-17, SDF-1β) 
that recruit or activate neutrophils and other cell types in 
ICR mice, and a significant dose-response change in thy-
mus- and activation-regulated chemokines was noted in 
C57BL/6 mice. Other researchers found that in contrast 
to emphysema-resistant ICR mice, emphysema-sensitive 
mouse strains (DBA/2 and C57BL/6J) showed a decrease in 
BAL antioxidant capacity after acute whole-body exposure 
to smoke (five cigarettes in 20 minutes) from a commer-
cial, Virginia-tobacco-type cigarette (Cavarra et al. 2001). 
The animals that had lifetime exposure to the smoke (three 
cigarettes per day for 90 minutes, five days per week, for 
seven months) had decreased lung elastin content and 
developed emphysema. In a study of male ICR mice 
exposed five days per week for two weeks to mainstream 
smoke from commercial, unfiltered, high-tar cigarettes 
(1-second puff of 20-mL volume at 10-second intervals and 
45 puffs per cigarette), the lungs showed evidence of senes-
cence of alveolar epithelial cells (increased β-galactosidase 
activity, lipofuscin accumulation, and P21CIP1/WAF1/SDI1 
protein in type II cells) (Tsuji et al. 2004). The researchers 
proposed that the senescence prohibited lung epithelial 
cells from proliferating and repopulating epithelial cells 
lost to apoptosis during emphysema. 
Bartalesi and associates (2005) also studied whole-
body exposure to cigarette smoke from three commercial, 
filter-tipped, Virginia-tobacco cigarettes per day, five days 
per week, for up to 10 months. This exposure produced 
epithelial cell injury, loss of cilia in the airways, and a 
positive reaction for mouse neutrophil elastase. The find-
ings suggested degradation of lung elastin in emphysema- 
sensitive (C57BL/6J and DBA/2) mouse strains. The 
C57 strain of mice is moderately deficient in serum 
α1-proteinase. Overt emphysema in the C57 strain was 
characterized by disseminated foci of severe emphysema 
interspersed by normal parenchyma. In DBA/2 mice, 
the foci of emphysema were scattered in a network of 
uniformly dilated parenchyma. Other differences were 
a greater fibrotic reaction and faster development of 
emphysema in DBA/2 mice (three months versus six 
months in C57 mice), and more extensive goblet cell 
metaplasia and immunohistochemical reaction for IL-4, 
IL-13, and MUC5AC (a secreted mucin) in C57 mice.
Further research with genetically modified mice 
explored the role of α1-antitrypsin (AAT), elastases, and 
tumor necrosis factor-alpha (TNFα) in emphysema in-
duced by cigarette smoke. In one study, mice deficient 
in AAT (C57BL/6J *pa/*pa [pallid]) developed diffuse, 
panlobular emphysema affecting the entire air space, 
and C57 mice with normal concentrations of AAT devel-
oped more localized centrilobular emphysema (Takubo 
et al. 2002). Other more evident changes in the pallid 
mice with low concentrations of AAT after daily sub-
chronic exposure (six months) to 2R1 cigarette smoke 
were increased T-cell inflammation in the alveolar wall 
and a reduced ability of the lungs to distend under pres-
sure (compliance). Other investigators studied mice 
deficient in NE*-/*- or MMP-12*-/*-. The animals failed 
to develop air-space enlargement after six months of 
exposure to cigarette smoke from an unfiltered reference 
cigarette (Hautamaki et al. 1997; Shapiro et al. 2003). 
The investigators concluded that neutrophil elastase is 
required for recruitment of neutrophils and macrophages 
and for activation of MMP, which solubilizes extracellu-
lar matrix proteins including elastin. Other investigators 
reported that mice deficient in MMP (MMP*-/*-) that had 
a single exposure to the whole smoke of four 2R1 reference 
cigarettes did not show the same early elevations in lavage 
neutrophils, desmosine, or hydroxyproline that are seen 
in mice with normal levels of MMP activity (MMP*+/*+) 
(Churg et al. 2002). In a later study, these investigators 
reported that the absence of TNFα receptors is protective 
against infiltration of inflammatory cells, breakdown of 
lung matrix, and air-space enlargement in mice lacking 
P55 and P75 TNFα receptors (TNFRKO mice) after expo-
sure to whole smoke from four 2R1 reference cigarettes 
five days per week for six months (Churg et al. 2004).
Several studies have shown that subchronic and 
chronic exposure to cigarette smoke produced evidence of 
respiratory tract toxicity that leads to emphysema in rats. 
In one study, the total glutathione, reduced glutathione, 
and protein-bound glutathione content in lung tissue of 
Sprague-Dawley rats with whole-body exposure to smoke 
from 2R1 reference cigarettes for 30 days, three times 
per day, were significantly lower than those in unexposed 
controls (Park et al. 1998). Oxidized glutathione increased 
significantly in rats exposed to smoke. Smoke exposure 
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also produced a treatment-related increase in 8-oxo-dG 
DNA levels in the lungs. Cigarettes were smoked for 15 to 
20 minutes to a fixed butt length in a 500-mL flask with 
air pumped into the flask.
Researchers found increased lung IL-4 and MMP-
12 levels and decreased interferon-γ levels in Wistar rats 
after daily whole-body exposure to the smoke of 20 com-
mercial unfiltered cigarettes six hours per day, five days 
per week, for three and one-half months (Xu et al. 2004). 
The changes were accompanied by pathologic evidence 
of emphysema in the form of inflammation, damage 
to airway epithelium and cilia, reduced mean alveolar 
number, air-space enlargement, and changes in pulmo-
nary function.
Chronic nose-only exposure of female Sprague-
Dawley rats to smoke from 2R1 reference cigarettes twice 
per day significantly reduced the disaturated phosphati-
dylcholine and surfactant protein levels in BAL fluid, but 
not in lung tissues, and significantly increased the albu-
min content of BAL fluid (Subramaniam et al. 1995). The 
researchers also observed increased surface compressibil-
ity and decreased respreading on expansion (respreadabil-
ity index) of organic extracts of the BAL fluid from treated 
rats compared with those for room controls and sham-
treated controls. Total levels of total lung phospholipids 
were not significantly different among the groups.
In selective reviews of the literature, Coggins (1998, 
2002) summarized other nonneoplastic histopathologic 
changes observed in animals exposed to cigarette smoke: 
	 •	 pulmonary	 fibrosis	 in	 C57	 mice	 accompanied	 by	 
accumulation of lymphocytes and macrophages in 
the peribronchiolar and perivascular regions; 
	 •	 alveolar	 fibrosis,	 alveolitis,	 and	 bronchiolitis	 with	
accumulation of macrophages in F-344 rats; 
	 •	 granulomas	in	alveolar	spaces	and	adjacent	intersti-
tial areas of all lobes of the lung in F-344 rats; 
	 •	 perivascular	 or	 peribronchiolar	 accumulation	 of	
lymphoreticular cells, fibrosis and cellular enlarge-
ment of peribronchiolar septa, hyperplasia of type II 
cells and septal fibrosis, and air-space enlargement 
in F-344 rats; 
	 •	 pulmonary	 edema,	 bronchial	 pneumonia,	 pulmo-
nary fibrosis, emphysema, and cor pulmonale in 
beagle dogs that had tracheotomy; and 
	 •	 pleural	thickening,	alveolar	fibrosis,	and	subpleural	
inflammation in beagle dogs without tracheotomy.
Reproductive and Developmental Studies in 
Animals
Fertility and Conception
Animal studies have suggested altered gonadotropin 
release, decreased luteinizing hormone surge, inhibition 
of prolactin release, altered tubal motility, and motility 
and impairment of blastocyst formation and implantation 
as possible mechanisms of fertility impairment among 
smokers (Stratton et al. 2001). In one study, male and 
female Sprague-Dawley rats received nose-only exposure 
to the smoke of 1R4F reference cigarettes (two-second 
puff, one puff per minute, 35-mL puff) for two hours per 
day, seven days per week, for four weeks before and dur-
ing mating for males, and for two weeks before mating, 
during mating, and through gestation day 20 for females 
(Carmines et al. 2003). The investigators observed a sta-
tistically significant decrease in weight of seminal vesicles 
for males exposed to a low concentration or a medium 
concentration of smoke. Weight gains during pregnancy 
and mean uterine weight were significantly reduced in 
the female rats exposed to a high concentration of smoke. 
Fertility and conception endpoints unaffected by exposure 
to smoke were sperm count, motility, and morphology in 
males and corpora lutea, resorptions, implantation sites, 
and mortality in females. In another study, three months 
of whole-body inhalation exposure to mainstream smoke 
for two hours a day from a commercial, filter-tipped, high-
tar cigarette mechanically smoked with a 50-mL syringe 
did not lead to a reduction in uterine weight or estrous 
cycle but did result in decreased estradiol concentration 
in rat uterine tissue compared with that in uterine tis-
sues of sham-exposed control rats (Berstein et al 1999). 
The proliferation index and proportion of uterine tis-
sue cells in S and G2/M phases were increased at three 
weeks of exposure for two hours per day. By three months, 
the differences in values from those of controls were no 
longer statistically different, but they were significantly 
lower than at three weeks, which the investigators attrib-
uted to a decline in the intensity of cell division.
In another study, Wistar rats received whole-body 
exposure to the smoke of a commercial cigarette from 
conception until parturition. Rats were exposed to ciga-
rette smoke six hours per day, five days per week, for 11 
weeks: 6 weeks before mating, 2 weeks during mating, and 
3 weeks during pregnancy (Florek and Marszalek 1999). 
Three concentrations of cigarette smoke were monitored 
by CO concentration, and exposure was assessed by the 
determination of carboxyhemoglobin. Offspring were 
mated to produce two subsequent generations. The 
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researchers observed an apparent dose-dependent reduc-
tion in the mating index, fertility index, and the num-
ber of pregnant rats, but no influence on the duration of 
pregnancy. This exposure regimen also resulted in a dose- 
dependent decrease in the mean number of animals rear-
ing pups on the 21st postnatal day (Florek et al. 1999). 
Researchers reported that the transport of preim-
plantation embryos through the oviduct was retarded in 
golden hamsters with nose-only exposure to mainstream 
or sidestream smoke of unfiltered 2R1 reference cigarettes 
(DiCarlantonio and Talbot 1999). Low, medium, and high 
doses were produced by generating smoke from two, four, 
or six cigarettes. They observed that doses used in the 
study produced serum concentrations of cotinine within 
the range of those in women actively or involuntarily 
exposed to cigarette smoke during pregnancy. Animals 
were exposed to cigarette smoke (one puff per minute, 
35-mL puff) 7 days per week, beginning 14 days before 
mating and continuing through day 3 of pregnancy. In 
females exposed to mainstream smoke, the increased per-
centage of embryos recovered from the oviducts on day 
three of pregnancy was dose dependent. The difference in 
these percentages for the hamsters in the medium- and 
high-dose groups and the control hamsters, who breathed 
only air, was statistically significant. The number of 
embryos retained in the oviducts of hamsters in all three 
groups exposed to sidestream smoke was significantly dif-
ferent from that for controls, but the researchers did not 
observe a dose-dependent pattern. The contraction rate of 
the oviductal muscle also decreased significantly during a 
single exposure to either mainstream or sidestream smoke 
and did not return to initial values during a 25-minute 
recovery period.
Researchers have evaluated the effects of indi-
vidual components of cigarette smoke on reproduction 
in hamster oviducts in vitro. Many components act in a 
dose-response manner and inhibit oviduct function at 
concentrations found in cigarette smoke. Talbot and col-
leagues (1998) showed that cyanide concentrations in 
2R1 cigarette smoke were sufficient to inhibit the cili-
ary beat frequency and time needed for an oocyte cumu-
lus complex to travel through the oviduct to the ostium 
(oocyte cumulus pickup rate) in golden hamsters. Other 
constituents of cigarette smoke (acrolein, formaldehyde, 
phenol, and acetaldehyde) produced these alterations at 
concentrations that were 3 to 50 times higher than the 
corresponding concentrations in the smoke of an experi-
mental 2R1 reference cigarette that was machine smoked 
under a single set of conditions (two-second puff, one puff 
per minute, 40-mL puff). All chemicals acted in a dose- 
dependent manner, and inhibition of the ciliary beat 
frequency for all except acrolein was at least partially 
reversible. The beat frequency of cilia treated with acro-
lein continued to decrease after the chemical was flushed 
out of the perfusion chamber. Tested individually, indole, 
5-methylindole, quinoline, isoquinoline, hydroquinone, 
and substituted phenols (compounds present in the main-
stream smoke of cigarettes), at picomolar to micromolar 
concentrations, inhibited oviductal functioning (ciliary 
beat frequency, oocyte pickup rate, and the contraction 
rate of infundibular smooth muscle) of golden hamster 
oviduct explants. Substitution of an ethyl or methyl group 
greatly increased the potency of the phenolic derivatives 
over that of the parent compound (Riveles et al. 2005). 
A recent study compared follicle loss and markers of 
apoptosis in the ovaries of mice exposed to mainstream 
cigarette smoke or B[a]P (Tuttle et al. 2009). Female 
mice received a nose-only exposure to mainstream smoke 
for eight weeks at a level equal to a pack-a-day habit in 
humans. Compared with mice exposed only to air, smoke-
exposed mice had a significant reduction in the number 
of follicles. There was no increase in apoptotic follicles or 
other markers of cell death in response to cigarette smoke 
exposure. In vitro treatment of cultured ovaries with 
B[a]P did not increase apoptosis. The authors concluded 
that smoke exposure selectively reduced follicles in the 
primordial and transitional stages but that the loss was 
not due to apoptosis (Tuttle et al. 2009).
Fetal Effects
Researchers have demonstrated fetotoxicity from 
cigarette smoke exposure by reporting reduced fetal weight 
in rats and mice exposed during gestation. Reduced fetal 
weight is one of the most reproducible treatment-related 
effects. In utero exposure of fetal Sprague-Dawley rats to 
smoke from a king-size, filter-tipped, commercial ciga-
rette on days 1 through 20 of gestation produced a signifi-
cant reduction in fetal weight (Leichter 1989). For more 
than two hours, the adult female rats were exposed to the 
smoke of 10 lit cigarettes with the burning end of the ciga-
rette placed inside a whole-body-exposure chamber. Litter 
size and placental weights were not different between rats 
exposed to smoke and pair-fed controls given the amount 
of food equal to that consumed by the smoke-exposed 
group. The increase in resorptions of implanted embryos 
in the group exposed to smoke was not significantly dif-
ferent from that in the controls. In a study of mainstream 
smoke from 1R4F cigarettes (two-second puff, one puff 
per minute, 35-mL puff), male Sprague-Dawley rats had 
nose-only exposure for four weeks before and during mat-
ing and female rats had nose-only exposure for two weeks 
before mating, during mating, and through gestation 
day 20 (Carmines et al. 2003). Researchers identified a 
significant decrease in mean fetal weight compared with 
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that of the sham-exposed controls. The number of live and 
dead fetuses was unaffected by smoke exposure. A series 
of experiments with smoke from research cigarettes that 
varied in levels of nicotine, condensate, and CO demon-
strated that the weight and length of fetuses from Sprague- 
Dawley rats was dependent on the intensity and duration 
of smoke inhalation (Reznik and Marquard 1980). All ciga-
rettes were machine smoked with one set of conditions 
(two-second puff, one puff per minute, 35-mL puff). The 
number of exposures per day, the duration of the exposure 
in days, the number of puffs per cigarette, and the volume 
of air used to dilute the smoke were varied to create dif-
ferent exposure groups. The mean fetal weight and length 
decreased with increasing smoke concentrations, and 
fetuses of rats exposed to cigarette smoke two, three, or 
four times a day had significant reductions in weights and 
lengths compared with the fetuses of rats exposed for one 
period per day. Growth retardation was more extensive 
when smoke exposure occurred during the second half of 
pregnancy, but the reduction was less severe in the fetuses 
of rats exposed during the entire pregnancy. These effects 
could not be attributed to the CO concentration in the 
smoke alone, because the effects were more pronounced 
with exposure to the whole smoke than with exposure to 
the gas phase. The number of resorbed fetuses was not 
influenced by smoke exposure.
In one study, mice with the autosomal recessive 
curly-tail gene received nose-only exposure to the main-
stream smoke of a commercial low-tar or high-tar ciga-
rette for 20 minutes, once a day from day zero to day eight 
of pregnancy (Seller et al. 1992). Both cigarette varieties 
were smoked under the same smoking-machine condi-
tions (two-second, 35-mL puff). The scientists observed 
similar levels of increased embryonic loss and retarda-
tion in embryonic development. The decrease in the mean 
somite number in the treated animals compared with that 
in the sham-exposed mice was statistically significant. 
Longer exposures (day 0 through day 17 of pregnancy) to 
smoke from the low-tar cigarettes resulted in a fivefold 
increase in intrauterine embryonic deaths, and live 
embryos weighed significantly less than those from the 
sham-treated group. Differences between the groups 
exposed to smoke from the high- or low-tar cigarettes 
were evident when exposure (10 minutes, three times a 
day) was restricted to days six, seven, and eight of preg-
nancy. The scientists reported that differences between 
the high-tar and low-tar treatment groups disappeared 
when the dose of the smoke from the low-tar cigarettes 
was increased. Weight loss in the treated pregnant mice 
was statistically significant, and weight loss was not dose 
dependent. Findings indicated a dose-response trend in 
the various dosing regimens, and the effect on embryonic 
survival and growth rate from exposure to the smoke of six 
cigarettes was greater than that of two cigarettes.
Curly-tail and C57BL strain mice received nose-only 
exposure on days six, seven, and eight of pregnancy to 
the smoke of a commercial low-tar or high-tar cigarette 
(Bnait and Seller 1995). One set of smoking-machine con-
ditions (two-second puff, one puff per minute, 35-mL puff) 
was used to generate smoke from the low-tar and high-
tar cigarettes, which was puffed over the noses of the test 
animals in individual chambers. Mice in both treatment 
groups were sacrificed on day nine. The embryos were 
removed, and embryonic cells from the fetal plate, sur-
face ectoderm, pericardium, and heart were examined by 
scanning and transmission electron microscopy. In both 
strains, the morphology of the exterior of the neural cells, 
the surface ectoderm, the pericardium, and the heart were 
the same. Cells from embryos of females in the high-tar 
exposure group showed evidence of depressed metabolic 
activity, suggesting anoxic damage that persisted 20 hours 
after the exposure had ceased. In embryos from the low-
tar group, changes were also present but were less marked 
than in embryos of mice in the high-tar group. No change 
occurred in the total cell number or in the number of dead 
cells or alteration in the mitotic index with either type of 
cigarette, but C57BL embryos of mice in the low-tar group 
had a significant reduction in the mitotic index compared 
with embryos of sham-treated controls.
Developmental Effects
Animal studies have suggested that even brief expo-
sures from maternal smoking are detrimental to the very 
early embryo (Bassi et al. 1984; Collins et al. 1985; Lich-
tenbeld and Vidíc 1989; Moessinger 1989; Seller and Bnait 
1995). Prenatal exposure to cigarette smoke resulted in 
impaired growth and maturation of fetal lung, includ-
ing reduced lung volume, lower internal surface area, 
fewer and larger alveoli, decreased lung interstitium and 
parenchymal elastic tissue, increased density of paren-
chymal interstitium, and apparent reduction in synthesis 
of surfactant.
Investigators in one study reported that a single four-
hour, whole-body exposure to smoke from filter-tipped or 
unfiltered cigarettes (one puff per minute, 35-mL puff) 
and a single intranasal administration of cigarette smoke 
condensate induced DNA deletions in fetal C57BL/6J mice 
homozygous for the pink-eyed unstable mutation (Jalili 
et al. 1998). The phenotypic expression of the DNA dele-
tions was development of dark spots on the gray fur of 
the offspring. Spotting frequency did not increase with 
an increase in smoke concentration. The investigators 
reported that chemicals in the particulate phase of 
cigarette smoke that are possibly responsible for the 
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DNA deletions are B[a]P, cadmium, acetamide, aniline, 
o-toluidine, acrylonitrile, and catechol. (For a description 
of transplacental genotoxic effects in rodents, see the sec-
tion on “Genotoxicity” earlier in this chapter.)
Developmental effects from exposure to cigarette 
smoke were further studied in the curly-tail mouse and 
in the C57BL strain, a strain not predisposed to neural 
tube defects (Seller and Bnait 1995). Mice received nose-
only exposure to smoke from commercial low-tar or high-
tar cigarettes from day 0 through day 17. Six cigarettes 
were smoked during each exposure, using one set of 
smoking-machine conditions (two-second, 35-mL puff). 
Mice in both treatment groups were sacrificed on day 18, 
and the embryos were removed and examined for gross 
congenital malformations. Treated mice (low tar and high 
tar) showed significant reduction in number of ossifica-
tion centers in seven regions compared with sham-treated 
controls. Changes were consistently more marked in the 
animals exposed to low tar, but the differences were not 
significantly different from those produced by exposure 
to smoke from the high-tar cigarettes. One rib abnormal-
ity occurred in the C57BL mice, but no major congeni-
tal malformations were observed. In the curly-tail mice, 
a modest increase in the frequency of open spina bifida 
and exencephaly was observed. The researchers proposed 
that although cigarette smoke is not a potent teratogen in 
mice, it may have minor effects in mice that are geneti-
cally predisposed to an abnormality.
In a study of pregnancy-related adverse health 
outcomes from exposure to cigarette smoke, fetuses of 
Sprague-Dawley rats were examined for abnormalities of 
the skull, extremities, and other parts of the body (Reznik 
and Marquard 1980). The exposure regimens varied in 
the number of exposures per day, in the period of expo-
sure during gestation, and in smoke concentrations from 
research cigarettes with different yields of nicotine, con-
densate, and CO. All cigarettes were machine smoked with 
one set of smoking-machine conditions (two-second puff, 
one puff per minute, 35-mL puff). None of the regimens 
produced an increase in malformations. 
A study of developmental toxicity in the fetuses of 
male and female Sprague-Dawley rats exposed to cigarette 
smoke identified an incomplete supraoccipital ossifica-
tion and unossified sternebrae significantly more often in 
smoke-exposed animals than in sham controls (Carmines 
et al. 2003). The number of skeletal variations was dose 
dependent. Fetal external and visceral variations in treated 
animals and controls were not significantly different. The 
exposure regimen consisted of nose-only inhalation for 
two hours per day, seven days per week, for four weeks 
before and during mating for males, and for two weeks 
before mating, during mating, and through gestation 
day 20 for females. Three concentrations of mainstream 
smoke were generated from 1R4F reference cigarettes 
(two-second puff, one puff per minute, 35-mL puff) by 
diluting the smoke with filtered, conditioned air. No deaths 
among male rats were associated with exposure to smoke. 
Occasional diarrhea, salivation, and red material around 
the eyes and nose were noted among male rats exposed 
to smoke and the sham controls. One female rat died of 
causes unrelated to exposure during the study. Females 
exposed to cigarette smoke also had diarrhea, salivation, 
and red material around eyes and nose. The decrease in 
maternal body weight during gestation days 0 through 
20, mean maternal body weight at termination, and mean 
uterine weight in the group exposed to high smoke con-
centration (600 mg TPM/m3) were statistically significant 
compared with those in sham-control female rats. 
In another study, two-day-old pups born to Sprague-
Dawley rats with nose-only daily exposure to mainstream 
cigarette smoke from day 2 to day 22 of pregnancy had 
selective reductions in protein kinase C gamma and delta 
isoforms and neuronal nitric oxide synthase within the 
dorsocaudal brainstem, a region relevant to respiratory 
and other autonomic functions (Hasan et al. 2001). One 
concentration of cigarette smoke exposure (1,000 mL = 
10-mL puff × 10 puffs per cigarette × 10 cigarettes per day 
at hourly intervals) was used in this study.
Other Health Effects
Immune System
Habitual use of cigarettes results in repeated con-
tact with thousands of chemicals. Researchers have shown 
that antigens in tobacco and cigarette smoke are capable 
of stimulating an immune response (Becker et al. 1976; 
Romanski and Broda 1977; Lehrer et al. 1978, 1980; Fran-
cus et al. 1988). Experimental data suggest that nicotine 
itself can affect the immune system, and at least one 
researcher has identified an allergic reaction to nicotine 
in a person exposed to cigarette smoke (Lee et al. 1998; 
McAllister-Sistilli et al. 1998). In addition to nicotine, other 
immunologically active chemicals are found in cigarette 
smoke, including the common additive menthol (Rap-
paport and Hoffman 1941; McGowan 1966; Becker et al. 
1976; Johnson et al. 1990; Mudzinski 1993; Li et al. 1997). 
Research into mechanisms underlying allergic sensitiza-
tion induced by cigarette smoke suggests that exposure to 
cigarette smoke suppresses the normal tolerance to com-
mon inhaled allergenic matter (Moerloose et al. 2006). 
Exposure to ovalbumin, an inert antigen, and mainstream 
smoke from five unfiltered 2R4F reference cigarettes pro-
duced a significant increase in ovalbumin-specific IgE and 
airway inflammation rich in eosinophils and goblet cells 
in male Balb/c mice. In mice exposed to ovalbumin and 
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cigarette smoke, levels of cytokine IFN-γ and thymus and 
activation-regulated chemokine were significantly higher, 
as were the number of dendritic cells, which are special-
ized for antigen capture, migration, and T-cell stimulation; 
activated CD4-positive and CD8-positive T lymphocytes; 
and peribronchial infiltrates with eosinophils. Mice 
exposed only to cigarette smoke did not have increased 
serum IgE, increased total numbers of cells in BAL fluid, 
goblet cell hyperplasia in lung tissue, or increased levels of 
cytokines and chemokines in BAL fluid supernatant.
A body of evidence suggests that exposure to ciga-
rette smoke produces changes in cellular and humoral 
immune function in humans and laboratory animals 
(Johnson et al. 1990). The immune and host defense sys-
tems are highly conserved across species; thus, organs and 
cells of the immune system in humans, mice, and rats are 
similar (Selgrade et al. 1995). However, the effect of ciga-
rette smoke on the immune system depends on the spe-
cies, the duration, and the level of exposure. Short-term, 
low-level exposures generally do not affect the immune 
system or may be stimulatory, whereas long-term expo-
sures (six months or more) or high levels of exposure were 
found to be immunosuppressive (Thomas et al. 1974; Holt 
et al. 1978; Gregson and Prentice 1981; Sopori et al. 1985; 
Johnson et al. 1990). Smoking-related changes in the 
peripheral immune system in humans were observed 
(Stratton et al. 2001). These changes included high white 
blood cell counts; high counts of cytotoxic or suppres-
sor T cells; low counts of inducer or helper T cells; slight 
suppression of T-lymphocyte activity; significantly lower 
activity of natural killer cells; low titers of circulating 
immunoglobulin, except for elevated titers of IgE; and 
increased susceptibility to infection. Researchers observed 
similar effects in animals. More recently, researchers 
reported decreased immune response and resistance to 
transplanted tumor cells in mice with prenatal exposure 
to cigarettes (Ng et al. 2006).
Animals exposed to cigarette smoke for extended 
periods were more susceptible to challenges with tumor 
cells and infectious agents than were unexposed animals 
(Johnson et al. 1990). Scientists studied male C57BL/6J 
mice with 26 weeks of exposure to the smoke of a king-
size, filter-tipped cigarette, with seven to eight minutes 
of exposure to the smoke of 30 cigarettes per day on five 
consecutive days per week and subcutaneous inoculation 
with tumor cells (Chalmer et al. 1975). Tumors in the 
mice had a significantly higher mean volume, which is a 
measure of tumor growth rate, than did unexposed con-
trols. This group also had larger and significantly more 
lung metastases. Animals exposed for only 10 weeks had a 
significantly lower mean tumor volume than did control 
mice. In a study of female C57BL/6 mice, toxic effects to 
the cellular immune system induced by cigarette smoke 
resulted in decreased viral neutralization, which was 
reflected in significant decreases in levels of antibody to 
serum adenovirus and a decrease in activated CD4 T cells 
in the lung after adenovirus administration (Robbins et 
al. 2004). The subchronic daily regimen, which consisted 
of exposure to mainstream smoke from 1R1 or 1R3 refer-
ence cigarettes, also significantly reduced the number of 
dendritic cells in the lung. Exposure inhibited CD4 T-cell 
expansion and maximal activation and reduced numbers 
of activated CD4 and CD8 T cells in response to adenovirus 
administration. Animals exposed to smoke had percent-
ages of lung macrophages, B cells, and CD4 and CD8 cells 
similar to those of controls without exposure to cigarette 
smoke. CD8 cytotoxic T lymphocytes are major effector 
cells involved in immunologically specific tumor destruc-
tion in vivo, and CD4 T cells are essential for controlling 
CD8 T-cell-dependent eradication of tumors (Shiku 2003). 
In another study, tumor cells were injected into 
offspring of female mice exposed to cigarette smoke and 
air-only controls (Ng et al. 2006). Litter size, but not body 
weight of offspring, was significantly reduced by prenatal 
exposure to cigarette smoke. Male offspring injected with 
tumor cells at 5 or 10 weeks of age and female offspring 
injected at 5 weeks had a significant increase in tumor 
incidence compared with that of offspring of mice exposed 
to air only. Tumors grew significantly faster in the male 
offspring with prenatal exposure to cigarette smoke. The 
scientists observed no treatment-related effect on time to 
tumor formation. Activity of cytotoxic T lymphocytes in 
male pups exposed to cigarette smoke was significantly 
reduced, but no effects on natural killer cell activity, 
cytokine levels, histology of lymphoid organs, or subpopu-
lations of immune cells were observed. Scientists studied 
adult mice that were susceptible (A/J strain) or resistant 
(C3H strain) to lung tumors and were exposed to the 
tobacco carcinogen NNK (Razani-Boroujerdi and Sopori 
2007). The findings suggest that differences in immune 
response to chemical carcinogens predicted differences 
in tumor response to the carcinogens. In A/J mice, but 
not in C3H mice, intraperitoneal treatment with NNK 
suppressed anti–sheep red blood cell antibody plaque- 
forming cells; T-cell proliferation induced by concanavalin 
A; and the rise in intracellular calcium induced by anti–
CD3/CD28 antibody. NNK also stimulated a significantly 
higher expression of cyclooxygenase-2 and of α7 nicotinic 
acetylcholine receptors in the lungs of A/J mice than in 
the lungs of C3H mice. The NNK treatments administered 
in this study resulted in lung tumors in all A/J mice but 
not in C3H mice.
Subchronic (14 weeks) exposure to a 6-percent 




cigarettes (two-second puff, one puff per minute, 35-mL 
puff) resulted in increased alveolar macrophage activity in 
Wistar rats (Gregson and Prentice 1981). The macrophage 
activity and the increase in levels of macrophage acid 
phosphatase were dose and time dependent. In a study 
of Sprague-Dawley rats, exposures of 21 or more weeks 
to the mainstream smoke of 2R1 reference cigarettes led 
to significant inhibition of antibody production in lymph 
node cells associated with the lung (Sopori et al. 1989). 
Longer exposures of 35 to 39 weeks significantly reduced 
the plaque-forming response of cells in other lymphoid 
tissues. The plaque-forming response of lymph node cells 
associated with the lung to a T-cell-independent antigen 
was markedly reduced compared with the response of cells 
from control rats. Proliferative responses of lymphoid tis-
sue associated with the lung to T-cell mitogens were unaf-
fected by this exposure, by the relative amounts of T and B 
cells in lymph node cells associated with the lung or in the 
spleen, or by macrophage function in the spleen.
In another study of the immunosuppressive effects 
of exposure to cigarette smoke in female F-344 rats, 
chronic, daily whole-body exposures of up to 30 months 
to mainstream smoke from 1R3 reference cigarettes (two-
second puff, two puffs per minute, 70-mL puff) reduced 
proliferation mediated by T-cell antigen and led to con-
stitutive activation of enzymes involved in activation of 
the T-cell antigen receptor, tyrosine phosphorylase, and 
phospholipase C-γ1 (Kalra et al. 2000). At eight months, 
T-cell proliferation in the spleen was significantly reduced 
in response to anti–CD3 antibody, which directly binds 
the T-cell antigen receptor and causes T-cell prolifera-
tion in the absence of activation of CD28 on T cells. Other 
treatment-related evidence of altered antigen-mediated 
T-cell signaling were depleted calcium stores sensitive to 
inositol-1,4,5-triphosphate and decreased calcium mobi-
lization in spleen cells after ligation of the T-cell anti- 
gen receptor.
Endocrine and Other Effects
Changes in blood glucose were noted in several 
rodent bioassays. Single but not repeated exposure to 
mainstream cigarette smoke produced a significant 
increase in blood glucose levels in anesthetized, mechani-
cally ventilated Sprague-Dawley rats. The smoke was 
inspired through a tracheal cannula (Iida et al. 1998). 
In another study, subchronic nose-only inhalation expo-
sure to the mainstream smoke of mentholated or non-
mentholated cigarettes (two-second puff, one puff per 
minute, 35-mL puff) resulted in a significant decrease in 
blood glucose levels in a high-dose group of F-344 rats 
exposed to smoke from menthol cigarettes or nonmen-
thol cigarettes compared with unexposed control animals 
(Gaworski et al. 1997). Similarly, subchronic nose-only 
exposure to mainstream smoke from 1R4F reference ciga-
rettes (one puff per minute, 35-mL puff) produced a sig-
nificant decrease in glucose level in a high-dose group of 
male Sprague-Dawley rats and in the two groups of female 
rats with highest doses (Terpstra et al. 2003).
Andersson and colleagues (1985) studied acute, 
nose-only, intermittent exposure to smoke from one, 
two, or four unfiltered 1R1 reference cigarettes. This 
exposure resulted in dose-dependent increases in cate-
cholamine utilization in the dopamine and noradrenaline 
nerve terminal systems in the hypothalamus of Sprague-
Dawley male rats. Luteinizing hormone, prolactin, and 
thyroid-stimulating hormone were significantly lower in 
a dose-dependent manner in treated rats than in controls. 
Corticosterone was significantly increased in rats with the 
highest exposure. Follicle-stimulating hormone, adreno-
corticotropic hormone (ACTH), and vasopressin were not 
affected by exposure to cigarette smoke. Treated animals 
received nose-only exposure, but controls were exposed 
only to air. 
In a subsequent study, these investigators reported 
that, in contrast, acute, nose-only continuous exposure of 
male Sprague-Dawley rats to the smoke of one, two, or 
four unfiltered 1R1 reference cigarettes produced smaller 
reductions in catecholamine levels and increases in cat-
echolamine turnover and did not produce an increase in 
dopamine utilization in the median eminence (Andersson 
et al. 1987). The researchers proposed that intermittent 
exposure to cigarette smoke produced stronger euphoric 
and neuroendocrine-related effects than did continuous 
exposure to cigarette smoke. As with male rats, diestrus 
female Sprague-Dawley rats with intermittent 30 minutes 
of nose-only exposure to the smoke of one, two, or four 
unfiltered 1R1 reference cigarettes had decreased cate-
cholamine levels and increased catecholamine utilization 
in hypothalamic and preoptic noradrenaline nerve termi-
nal systems and decreased serum prolactin and lutein-
izing hormone (Andersson et al. 1985). The effects were 
dose and time dependent. In contrast to findings in male 
rats (Andersson et al. 1985), for female rats, exposure to 
cigarette smoke caused lower dopamine and noradrena-
line levels in the median eminence and lower ACTH levels 
(Andersson et al. 1988). Exposure to cigarette smoke did 
not inhibit secretion of the thyroid-stimulating hormone 
in female rats as it did in male rats. Catecholamine levels 
were measured in male Sprague-Dawley rats for 48 hours, 
72 hours, or 7 days after an exposure regimen that con-
sisted of a daily 2-hour exposure to the smoke of two 1R1 
unfiltered reference cigarettes for 10 days (Andersson et 
al. 1989). At 48 hours after exposure, significantly lower 
levels of serum corticosterone and serum prolactin were 
noted and were attributed to maintained activation in 
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dopamine utilization. At 72 hours, serum prolactin levels 
were still significantly lower than those in controls. Brain 
regions of increased catecholamine utilization in rats 
exposed to cigarette smoke decreased with time and were 
absent by seven days after exposure. Levels of ACTH were 
not changed relative to those in controls exposed only 
to air. 
Jansson and colleagues (1992) found that age of 
onset of postnatal endocrine changes varied by the dura-
tion of exposure to cigarette smoke. Male Sprague-Dawley 
rats were exposed daily to the smoke of two 1R1 reference 
cigarettes, beginning on day 1 after birth and continuing 
for 5, 10, or 20 days. The rats were sacrificed 24 hours 
after the 10- or 20-day exposure. Rat pups had a significant 
increase in serum levels of luteinizing hormone compared 
with levels in control pups exposed only to air. Animals 
sacrificed seven months after the 20-day exposure had a 
significant increase in serum prolactin levels. Pups sac-
rificed 24 hours after a 20-day exposure had a significant 
increase in catecholamine utilization in the medial pali-
sade zone of the median eminence and a substantial 
reduction in catecholamine utilization in the parvocellu-
lar and magnocellular parts of the paraventricular hypo-
thalamic nucleus. Changes in catecholamine utilization 
were not seen in animals sacrificed seven months after the 
20-day exposure to cigarette smoke. Serum corticosterone 
levels and dopamine and norepinephrine utilization in 
the hypothalamus were not significantly different for rats 
exposed to smoke and controls.
Other researchers noted statistically significant 
increases in the weight of the adrenal gland relative to body 
weight in Sprague-Dawley rats after subchronic inhala- 
tion exposure to the smoke of 1R4F reference cigarettes 
(one puff per minute, 35-mL puff) (Terpstra et al. 2003). 
Compared with the sham controls, the weight of the left 
adrenal gland increased for males in the two groups with 
the highest doses, whereas females had an increase in 
the weight of the left and right adrenal glands in the two 
groups with the highest doses.
An inverse relationship exists between smoking and 
body weight in humans, and nicotine is believed to be 
the chemical mediator (Chen et al. 2005). Direct nicotine 
administration to humans or animals decreases body 
weight and caloric intake. Scientists designed a study to 
determine the effect of short-term exposure to cigarette 
smoke on appetite control in male Balb/c mice. Inhalation 
exposure to the smoke of three commercial cigarettes a 
day for four days led to a significant decrease in plasma 
concentrations of leptin, a hormone that signals sati-
ety (Chen et al. 2005). Animals exposed to smoke had a 
decrease in mRNA expression of white adipose tissue 
UCP1 (a mitochondrial uncoupling protein involved in en-
ergy metabolism) and an increase in mRNA expression of 
brown adipsose tissue UCP3. Food intake and body weight 
were significantly decreased in the animals exposed to 
smoke compared with those in the sham controls, even 
though plasma concentrations of corticosterone were 
unchanged. Concentrations of hypothalamic neuropeptide 
Y, which stimulates feeding behavior, were not affected by 
the acute exposure regimen. Only one concentration of 
smoke was used in this study, and details on smoking- 
machine conditions were not provided. Other animal 
studies with longer durations of exposure to cigarette 
smoke also documented either weight loss or reduced 
weight gain in treated animals compared with those in 
unexposed controls (Ayres et al. 2001; Carmines et al. 
2003; Witschi et al. 2004).
Summary
This chapter discusses a wide variety of chemicals 
found in cigarette smoke. These chemicals extend across 
a broad spectrum of volatility, lipophilicity, and reactiv-
ity, and include compounds that are known or suspected 
to be carcinogenic, toxic, and addictive. Some of these 
compounds also promote the carcinogenicity, toxicity, or 
addictiveness of the other constituents of cigarette 
smoke. Despite uncertainties about which chemi-
cal constituents are responsible for specific adverse 
health outcomes, there is broad scientific agreement 
about which chemicals in conventional tobacco-burn-
ing cigarettes could be harmful to individuals’ health. 
Less is known about, and research is needed on, the 
potentially harmful chemicals in smoke from new and 
emerging cigarette technologies. Cigarette characteristics 
that influence either nicotine delivery to the smoker or 
smoke constituents that interact with nicotine deserve 
special consideration, because nicotine maintains the 
addiction and thereby leads to ongoing exposures of 
smokers to chemical compounds with known adverse 
health effects.
The levels of the chemical constituents in cigarette 
smoke are influenced by many different factors. The lev-
els of the metals and nitrogen-containing compounds in 
the tobacco are highly influenced by the soil in which it 
is grown and the fertilizers used to promote growth of 
Surgeon General’s Report
78 Chapter 3
the plant. Many of the chemicals of direct concern vary 
with the different types of tobacco (e.g., bright, bur-
ley, or oriental) that are combined to produce a specific 
tobacco blend. Within a type of tobacco, the position of 
the leaf on the stalk can also influence the chemical lev-
els in harvested tobacco leaves that will eventually affect 
the levels in smoke. The inclusion of reconstituted and 
expanded tobacco in cigarette fillers can also alter the 
chemistry of cigarette smoke. After the tobacco is har-
vested, the method of curing and the addition of humec-
tants, sugars, and flavor-related compounds will change 
the chemical composition of the tobacco that goes into 
the cigarette.  Different tobacco blends, filters, filter paper, 
additives, and design innovations employed in cigarette 
manufacturing have a profound influence on the levels of 
toxicants transferred from tobacco into the mainstream 
smoke with every single puff.
It is well documented that cigarettes are not smoked 
with the same puffing profile. The differences in smok-
ing patterns, including the number of puffs, the puff vol-
ume, and whether the smoker blocks the ventilation holes 
greatly influence the delivery of smoke constituents to the 
smoker. An individual smoker consumes each cigarette 
differently, depending on the time of day, on individual 
stress levels, and on the time since the last nicotine use. 
The smoker will change the number of puffs taken, the 
depth of the puff, and the degree to which ventilation 
holes are blocked, depending on the individual circum-
stances occurring at that time. In addition, the rate of 
metabolism of the chemicals after they enter the smoker’s 
body, in addition to other enzymatic and genetic effects, 
can influence how long the chemical species of concern 
remains in the smoker’s system. It is broadly understood 
that there is not a single machine-smoking method that 
can be used to project the levels of chemical constituents 
that are found in the human body.
Validated biomarkers of exposure that correlate with 
dose (the number of cigarettes smoked per day) or that 
provide information on metabolic activation and detoxi-
fication have been reported in the literature. Additional 
research is needed to determine levels of reduction of 
these chemicals in cigarette smoke that would produce 
measurable decreases in the dose delivered to the smoker. 
Although some biomarkers (nicotine and its metabolites 
and the TSNAs) are specific to tobacco exposure, most 
are not specific to tobacco and are influenced by diet, 
occupation, or other environmental factors. Also, although 
biomarkers typically represent only recent exposures, the 
strongest determinant of risk for many diseases (e.g., lung 
cancer) caused by tobacco use is the duration of smok-
ing (IARC 2004). Carcinogen adducts as biomarkers of 
biologically effective doses are the most direct measure 
of tobacco-induced damage at cancer sites in smokers. 
Surrogate measures such as DNA oxidative repair lesions 
in urine and thioether levels respond in a dose-related 
manner to exposure to cigarette smoke and reflect an 
ongoing state of oxidative stress in the body of a smoker. 
Biomarkers of potential harm exist for all major tobacco-
related diseases. The predictive value of these biomarkers 
is lessened by their nonspecific nature. 
In vitro assays using mammalian or bacterial cellu-
lar systems show that cigarette smoke is mutagenic and 
cytotoxic. Genetic damage to the cell and altered metabolic 
activities probably play a role in tobacco-related chronic 
diseases such as cancer and cardiovascular disease. Nota-
bly, oxidative DNA damage and markers of oxidative stress 
are represented by increased levels of oxidatively modi-
fied DNA bases in urine, white blood cells, and lung tis-
sue and by oxidative damage to sperm DNA and seminal 
fluid; increased oxidation of cell membrane lipids (F2- 
isoprostanes) in adult and cord blood; and decreased levels 
of reduced glutathione in lung cells and heart tissue. In 
addition, short-term mutagenicity and cytotoxicity assays 
have led to the identification of several potentially caus-
ative chemical agents in cigarette smoke (e.g., aromatic 
amines and heterocyclic amine protein pyrolysate prod-
ucts in the Salmonella mutagenicity assay and HCN and 
acrolein in cytotoxicity assays). Future in vitro research 
on mutagenicity and cytotoxicity will likely involve ciga-
rette smoke produced under smoking-machine conditions 
that more closely mimic human smoking behavior, rather 
than one standard set of conditions such as the FTC or 
ISO methods.
Many smoking-related effects in humans can be 
reproduced in experimental animals. Some of the most 
promising animal models are those for emphysema and 
cardiovascular disease induced by cigarette smoke. In 
contrast, animals have not proven to be good models for 
the type of lung tumors induced by cigarette smoke in 
humans. In the absence of a widely accepted animal model 
for tobacco carcinogenesis, ample data show that ciga-
rette smoke and its condensate are tumorigenic in several 
animal species and are mutagenic in a variety of systems. 
Current animal studies have attempted to demonstrate a 
dose-response relationship by using either the smoke or 
the condensate from one cigarette type diluted to pro-
duce several concentrations or the smoke or condensate 
from cigarettes from different yield categories. In either 
instance, researchers have used one set of smoking- 
machine conditions to produce the cigarette smoke or 
condensate. Standardized smoking-machine conditions 
such as the FTC or ISO methods are useful for comparisons 
between cigarettes but are less relevant to the exposure 
of human smokers. Future studies will likely incorporate 
alternative smoking-machine conditions required by some 
countries or designed to mimic human smoking patterns.
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In general, an absence of human data requires 
researchers to use the results of experiments with labora-
tory animals and nonanimal systems to estimate human 
risk. The sum of several decades of laboratory research 
lends experimental support to the epidemiologic obser-
vations that cancer, respiratory disease, cardiovascular 
disease, and other adverse health outcomes are caus-
ally related to cigarette smoking. Although some topics 
were not a primary focus of this chapter, of note are the 
instances when sidestream smoke, frequently used as a 
surrogate for environmental tobacco smoke or second-
hand smoke, proved to be more toxic than mainstream 
smoke, which is inhaled directly by the smoker—for 
example, in the neutral red cytotoxicity assay and in the 
development of aortic plaque in the cockerel. Many chem-
icals of concern to public health are present in higher con-
centrations in sidestream smoke, the main contributor to 
secondhand smoke exposure, than in mainstream smoke: 
1,3-butadiene, ammonia, aromatic amines, benzene, 
CO, isoprene, nicotine, nitrosamines, PAHs, pyridine, 
and toluene.
Perhaps the greatest utility of toxicity testing of 
cigarette smoke and condensate comes from the ability to 
explore mechanisms by which tobacco and the constitu-
ents of its smoke cause disease, to identify better biomark-
ers of potential disease risk for use in both clinical and 
population-based studies, and possibly to evaluate the 
relative contribution of cigarette components and design 
features (e.g., additives, tobacco blends, nontobacco com-
ponents, and filter ventilations) to the inherent toxicity 
and addictiveness of the product.
The uncertainties in understanding all of the fac-
tors involved in the delivery and uptake of toxic, carci-
nogenic, and addictive chemicals in cigarette smoke and 
the mechanisms of toxicity induced by cigarette smoke 
should not impede efforts to lower the concentrations 
of these chemicals in cigarette smoke. There are ways to 
lower the concentrations of toxic constituents in cigarette 
smoke, although additional research is needed to deter-
mine the levels of reduction required for achievement of 
measurable and biologically relevant decreases in deliv-
ery of these constituents to the smoker. Such approaches 
include controls over tobacco growing and curing; the 
types of tobacco used in the filler, including the use of 
reconstituted tobacco; the use of additives such as men-
thol; and the design of the cigarette.
Conclusions
1. In spite of uncertainties concerning whether par-
ticular cigarette smoke constituents are responsible 
for specific adverse health outcomes, there is broad 
scientific agreement that several of the major classes 
of chemicals in the combustion emissions of burned 
tobacco are toxic and carcinogenic.
2. The design characteristics of cigarettes, including 
ventilation features, filters, and paper porosity, have 
a significant influence on the levels of toxic and carci-
nogenic chemicals in the inhaled smoke.
3. The different types of tobacco lamina (e.g., bright, 
burley, or oriental) that are combined to produce a 
specific tobacco blend have a significant influence on 
the levels of toxic and carcinogenic chemicals in the 
combustion emissions of burned tobacco.
4. There is no available cigarette machine-smoking 
method that can be used to accurately predict doses of 
the chemical constituents of tobacco smoke received 
when using tobacco products.
5. Tobacco-specific biomarkers (nicotine and its 
metabolites and the tobacco-specific nitrosamines) 
have been validated as quantitative measures of expo-
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Introduction
Nicotine addiction is the fundamental reason that 
individuals persist in using tobacco products, and this 
persistent tobacco use contributes to many diseases 
described in this report. The 1988 report, The Health 
Consequences of Smoking: Nicotine Addiction: A Report 
of the Surgeon General (U.S. Department of Health and 
Human Services [USDHHS] 1988, p. 9), describes the phar-
macologic basis of tobacco addiction and arrives at three 
major conclusions:
1. Cigarettes and other forms of tobacco are addicting.
2. Nicotine is the drug in tobacco that causes addic-
tion.
3. The pharmacologic and behavioral processes that 
determine tobacco addiction are similar to those 
that determine addiction to drugs such as heroin 
and cocaine.
Tobacco addiction remains a substantial problem in 
the United States and worldwide. Of those individuals who 
have ever tried smoking, about one-third become daily 
smokers (USDHHS 1994, p. 67). Of those smokers who 
try to quit, less than 5 percent are successful at any one 
time (Centers for Disease Control and Prevention [CDC] 
2002, 2004). Although not all smokers become nicotine 
dependent, the prevalence of individuals diagnosed as 
nicotine dependent is higher than that for any other sub-
stance abuse disorder (Anthony et al. 1994; CDC 1995b; 
Kandel et al. 1997). Any efforts to reduce tobacco-related 
disease must take into account the addiction potential of 
a tobacco product. 
Since the 1988 Surgeon General’s report was pub-
lished, significant advances have been made in under-
standing the physiological effects of nicotine and the basis 
for addiction:
1. identifying specific genotypes and receptor subtypes 
that may contribute to and play an important role in 
nicotine addiction, 
2. observing sensitivities and responses to nicotine in 
adolescents that might make them more susceptible 
to nicotine addiction than adults are and recogniz-
ing the different trajectories for the development of 
nicotine dependence, 
3. developing a greater awareness of the important role 
of associative learning in addiction, 
4. recognizing the strong associations between smok-
ing and comorbid psychiatric disorders, and 
5. achieving a better understanding of the relapse and 
recovery processes.
The goals of this chapter are to describe these 
advances and their implications and to discuss future 
directions. 
Definition of Nicotine Addiction
The crux of understanding the pathophysiology of 
tobacco addiction and its measurement relies on the iden-
tification of critical characteristics and the definition of 
addiction. This area continues to evolve, and significant 
gaps in research are evident. There is no established 
consensus on criteria for diagnosing nicotine addiction. 
However, researchers have identified several symptoms as 
indicators of addiction. The 1988 Surgeon General’s report 
lists the following general “criteria for drug dependence,” 







– stereotypic patterns of use
– use despite harmful effects
– relapse following abstinence






– pleasant (euphoriant) effects
These criteria are consistent with those for a diag-
nosis of dependence provided in the Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th ed. (DSM-IV) 
(American Psychiatric Association [APA] 2000) and the 
International Classification of Diseases, Tenth Revision 
(ICD-10) (Table 4.1) (World Health Organization [WHO] 
1992). The diagnosis of dependence using these diagnos-
tic systems depends on the person experiencing a specific 
number of these symptoms. The relevance of some of 
these symptoms to nicotine addiction may be question-
able because the DSM criteria are used across different 
drugs of abuse. For example, one symptom of addiction 
is that a great deal of time is spent in activities necessary 
to obtain the substance or recover from its effect. This 
criterion may not be as relevant to the diagnosis of nico-
tine addiction compared with other abused substances. 
Another prominent instrument that researchers have 
used to determine the degree or severity of dependence in 
smokers is the Fagerström Tolerance Questionnaire (FTQ) 
(Fagerström 1978; Fagerström and Schneider 1989), and 
a later, modified version, the Fagerström Test for Nicotine 
Dependence (FTND) (Heatherton et al. 1991). The items 
on these scales, which describe the extent of nicotine 
exposure, the impaired control over use, and the urgency 
for use, are listed in Table 4.2. The first item, time to first 
cigarette after waking, is by itself a stronger predictor of 
relapse than is any other self-report measure of depen-
dence (Baker et al. 2007). The 1988 Surgeon General’s 
report describes the general characteristics and criteria 
for drug dependence, DSM-IV and ICD-10 describe the cri-
teria necessary for diagnosis of dependence, and the FTQ 
and FTND can be used to determine the degree of depen-
dence. The core features across these diagnostic methods 
include (1) repeated and compulsive self-administration; 
(2) impaired control over use (e.g., repeated unsuccess-
ful attempts to stop use or continued use despite known 
harmful consequences); (3) high motivation to seek the 
drug, because of cravings, regulation of affect (e.g., smok-
ing to ease a depressed mood, for relaxation, or for stimu-
lation), or other reasons associated with the psychoactive 
effects of the drug; (4) judgment of greater value from 
Table 4.1 Criteria for substance (nicotine) dependence
DSM-IV ICD-10
A maladaptive pattern of substance use, leading to clinically significant 
impairment or distress, as manifested by 3 or more of the following 
criteria, occurring at any time in the same 12-month period
  
•	 Tolerance—need	increased	amounts	of	substance	to	achieve	desired	
effect, or diminished effect with continued use of same amount
•	 Increased	tolerance








use substance, or recover from its effects
  
•	 Important	social,	occupational,	or	recreational	activities	given	up	or	
reduced because of substance use
•	 Higher	priority	given	to	drug	use	than	to	other	
activities and obligations 
•	 Substance	use	continued	despite	knowledge	of	having	persistent	
or recurrent physical or psychological problem likely to have been 
caused or exacerbated by substance
•	 Persistent	use	despite	harmful	consequences
Source: Adapted from Royal College of Physicians of London 2000 with permission from Royal College of Physicians, © 2000.
Note: DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; ICD-10 = International Classification of Diseases, 
Tenth Revision.
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Table 4.2 Questions, answers, and scoring for Fagerström Test for Nicotine Dependence and Fagerström 
Tolerance Questionnaire
Questions Answers Points
Fagerström Test for Nicotine Dependencea      
How soon after you wake up do you smoke your first cigarette? Within 5 minutes 3
How soon after you wake up do you smoke your first cigarette? 6–30 minutes 2
How soon after you wake up do you smoke your first cigarette? 31–60 minutes 1
How soon after you wake up do you smoke your first cigarette? After 60 minutes 0
Do you find it difficult to refrain from smoking in places where it is 
forbidden (e.g., in church, at the library, in the cinema, etc.)?
Yes 1
Do you find it difficult to refrain from smoking in places where it is forbidden (e.g., in church, at the library, in the cinema, etc.)? No 0
Which cigarette would you hate most to give up? The first one in the morning 1
Which cigarette would you hate most to give up? All others 0
How many cigarettes/day do you smoke? ≤10 0
How many cigarettes/day do you smoke? 11–20 1
How many cigarettes/day do you smoke? 21–30 2
How many cigarettes/day do you smoke? ≥31 3
Do you smoke more frequently during the first hours after waking up than 
during the rest of the day?
Yes 1
Do you smoke more frequently during the first hours after waking up than during the rest of the day? No 0
Do you smoke if you are so ill that you are in bed most of the day? Yes 1
Do you smoke if you are so ill that you are in bed most of the day? No 0
Fagerström Tolerance Questionnaireb      
How soon after you wake up do you smoke your first cigarette? Within 30 minutes 1
How soon after you wake up do you smoke your first cigarette? After 30 minutes 0
Do you find it difficult to refrain from smoking in places where it is 
forbidden (e.g., in church, at the library, in the cinema, etc.)?
Yes 1
Do you find it difficult to refrain from smoking in places where it is forbidden (e.g., in church, at the library, in the cinema, etc.)? No 0
Which cigarette would you hate to give up? The first one in the morning 1
Which cigarette would you hate to give up? Any other 0
How many cigarettes/day do you smoke? ≤15 0
How many cigarettes/day do you smoke? 16–25 1
How many cigarettes/day do you smoke? ≥26 2
Do you smoke more during the morning than during the rest of the day? Yes 1
Do you smoke more during the morning than during the rest of the day? No 0
Do you smoke if you are so ill that you are in bed most of the day? Yes 1
Do you smoke if you are so ill that you are in bed most of the day? No 0
What is the nicotine level of your usual brand of cigarette? ≤0.9 mg 0
What is the nicotine level of your usual brand of cigarette? 1.0–1.2 mg 1
What is the nicotine level of your usual brand of cigarette? ≥1.3 mg 2
Do you inhale? Never 0
Do you inhale? Sometimes 1
Do you inhale? Always 2
Note: mg = milligrams.
aData are from Heatherton et al. 1991.
bData are from Fagerström and Schneider 1989.
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use of the drug over other reinforcers or activities; and 
(5) manifestation of physical dependence, as evidenced by 
withdrawal or tolerance. 
Despite acknowledgment of these core features, the 
current diagnostic criteria for nicotine addiction have cer-
tain limitations. Beginning in 2005, a group of scientists 
have worked to delineate the various issues surrounding 
the measurement of nicotine dependence. The results of 
this work were published in June 2009 (National Cancer 
Institute [NCI] 2009). These issues included the following: 
1. whether nicotine addiction is categorical, dimen-
sional, or emergent (changing over time) and, 
if emergent, whether different aspects of depen-
dence are observed early or late in the process of 
dependence, for example, aspects more related to 
social, sensory, and associational learning versus a 
more physical dimension with a longer duration of 
drug use; 
2. whether nicotine addiction is unidimensional or 
multidimensional and, if multidimensional, whether 
symptoms or dimensions warrant weighting or are 
additive; 
3. whether a threshold of severity or a certain number 
or specific types of symptoms are needed for diagno-
sis of nicotine addiction; 
4. whether motivations or cognitive processes for 
seeking a drug are important components of the 
addiction;
5. whether multiple profiles, patterns, and pathways of 
addiction exist; and 
6. whether the quantity and frequency of use play a 
critical role in addiction.
Other current measures of nicotine addiction or 
tobacco dependence are shown in Table 4.3 that are 
beginning to consider and address some of the limita-
tions of current definitions of addiction and that consider 
nicotine addiction to be comprised of more than one 
phenotype (expression of a trait on the basis of genetic and 
environmental influences). Developing valid measures 
of the various phenotypes of dependence is critical for 
research that (1) examines how these phenotypes are related 
to the trajectory and cessation of smoking behaviors and 
(2) determines whether these phenotypes are related to 
specific neurobiologic measures of addiction or to spe-
cific genes. 
In this chapter, the terms “dependence” and 
“addiction” have been used interchangeably. For some 
disciplines, dependence has been primarily associated 
with physiological manifestations of repeated tobacco use, 
but compulsive drug seeking is typically at the core of 
both the technical term “dependence” and the more gen-
eral term “addiction.” Furthermore, the terms “nicotine 
dependence” and “tobacco dependence” are used inter-
changeably. Nicotine is the drug in tobacco that leads to 
compulsive drug seeking or addiction. However, several 
lines of epidemiologic and laboratory evidence presented 
in this chapter indicate that tobacco-delivered nicotine is 
substantially more addictive than are pure nicotine forms. 
Other tobacco constituents, delivery methods, and pro-
cesses may play a critical supporting role. 
Factors contributing to nicotine or tobacco addic-
tion include the following:
1. the effects of the product itself, including the addic-
tive constituents, their pharmacokinetics and phar-
macodynamics, and the design of the product that 
delivers the addictive constituents (see Chapter 3, 
“Chemistry and Toxicology of Cigarette Smoke and 
Biomarkers of Exposure and Harm”); 
2. the response of the host, including genetic suscepti-
bility and physiological response; and 
3. the environmental setting that determines the 
availability of, accessibility to, and norms for use of 
the product. 
Like the 1988 Surgeon General’s report on nicotine 
addiction, this chapter focuses primarily on the effects of 
the product and the response of the host. 
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Fagerström Test for 
Nicotine Dependence 
(FTND) (Heatherton et 
al. 1991)
Unidimensional and continuous scale that measures behavioral and physiological aspects of addiction 
(e.g., rate of smoking, morning smoking, and difficulty refraining from smoking) and was developed 
to measure physical dependence. Both FTQ and FTND show limited internal consistency (Pomerleau 
et al. 1990; Etter et al. 1999). FTND is a multidimensional scale (≤2 factors) summarized as single 
score (Haddock et al. 1999; Breteler et al. 2004). Adequate test-retest reliability, particularly with 
FTND (Pomerleau et al. 1994). Modestly correlates with levels of carbon monoxide, nicotine, and 
cotinine; weak predictor of withdrawal symptoms (Hughes and Hatsukami et al. 1986; Shiffman et 
al. 2004a; Etter et al. 2005); and modest or weak predictor of treatment outcome (Pinto et al. 1987; 
Silagy et al. 1994; Haddock et al. 1999; Etter et al. 2003a, 2005; Piper et al. 2006). Moderates efficacy 
of nicotine medications (Shiffman and Paton 1999). Does not have incremental value compared with 
measures	of	number	of	cigarettes/day	(Razavi	et	al.	1999;	Dale	et	al.	2001).	A	single	item—time	to	first	
cigarette—is	a	good	predictor	of	cessation	success	and	reflects	a	pattern	of	heavy,	uninterrupted,	and	
automatic smoking (Transdisciplinary Tobacco Use Research Center et al. 2007).
FTQ	was	modified	for	adolescents	(Prokhorov	et	al.	1996,	2000).	One	item	was	eliminated—brand	
of	cigarette	or	number	of	cigarettes	per	day—depending	on	study.	Most	items	were	changed	to	
4-point rating scales. One factor accounted for 41–53% of the variance. Interitem and item-to-total 
score correlations were weak to moderate. Internal consistency was adequate, with good test-retest 
reliability. Modest correlations were observed with amount smoked and between scales for individual 
items (except inhalation item) and cotinine levels.
Stanford Dependence Index is also modified FTQ with only 5 items that are assessed on a 4- to 
6-point scale. This measure was used in adults (Killen et al. 1990) and adolescents (Rojas et al. 1998). 
Adequate test-retest reliability was observed for both populations. In the adolescent population, 
total scores were significantly related to smoking rate, cotinine levels, and self-reported severity of 
withdrawal in past attempts to stop smoking.
Heaviness of Smoking 
Index (Heatherton et al. 
1989) 
Two items from FTQ: time to first cigarette of day and number of cigarettes/day.
Diagnostic and 
Statistical Manual of 
Mental Disorders, 4th ed. 
(DSM-IV) (APA 1994)
Categorical (nicotine dependent and not nicotine dependent) diagnostic resource that measures 
cognitive, behavioral, and physiological aspects of addiction. Criteria are consensus driven rather 
than theory driven and involve pattern of repeated drug use that results in withdrawal, tolerance, 
and compulsive drug taking despite negative consequences. DSM diagnosis is assessed by structured 
and semistructured interviews, such as Diagnostic Interview Schedule (DIS) (Robins et al. 1990) 
or Composite International Diagnostic Interview Substance Abuse Module (Robins et al. 1990). 
DIS results in 2-factor structure (Radzius et al. 2004). Diagnosis of dependence is also made by 
surveys, such as National Comorbidity Survey and National Survey on Drug Use & Health [formerly 
the National Household Survey on Drug Abuse], or by self-reported measures such as Tobacco 
Dependence Screener (TDS) (Kawakami et al. 1999). TDS has a continuous score and acceptable 
internal consistency. DSM-IV diagnoses assessed in epidemiologic surveys are associated with heavier 
smoking and predict persistence in smoking (Breslau et al. 2001). DSM-IV diagnosis is a stronger 
predictor of cessation than FTND, but weaker than number of cigarettes/day (Breslau and Johnson 
2000), and it is poorly correlated with FTND (Moolchan et al. 2002). TDS is associated with number 
of cigarettes/day, carbon monoxide levels, and duration of smoking (Kawakami et al. 1999; Piper 
et al. 2006). Limitation: dichotomous diagnostic classification does not capture dependence that 
varies in degree, assumes unidimensionality, and masks heterogeneity (e.g., diagnosis can be met by 





Hooked on Nicotine 
Checklist (DiFranza et al. 
2002a)
Unidimensional, continuous, 10-item measure to stop smoking theoretically derived on the basis 
of theory of loss of autonomy. Items measure inability to stop smoking, difficulty refraining from 
smoking in prohibited places, craving and need for cigarette, and withdrawal and feeling addicted. 
One-factor solution explains 60% of variance. Strong internal reliability, moderate-to-strong test-
retest reliability of individual items and total score (O’Loughlin et al. 2002), and strong positive 
relationship to maximum frequency of smoking and maximum amount smoked. Weak correlation 
with duration of smoking. Significantly associated (those who endorsed at least 1 item on the scale) 
with failed attempt at smoking cessation, continued smoking until end of follow-up, and progression 
to daily smoking. High rate of symptom endorsement even in persons who ever used tobacco.
Cigarette Dependence 
Scale (CDS) (Etter et al. 
2003a, 2005)
Unidimensional, continuous measure and empirically derived scale (single-factor structure) that 
covers main criteria for DSM-IV and International Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision. Definitions for dependence include compulsion, withdrawal 
symptoms, loss of control, time allocation (the amount of time spent smoking), neglect of other 
activities, and persistence despite harm, but exclude tolerance. This scale has 2 forms, CDS-12 and 
CDS-5, with 12 and 5 items, respectively. Both scales have high test-retest reliability and moderate-to-
strong internal consistency. CDS-12 scores were higher in daily smokers than in occasional smokers 
and were associated with strength of urge to smoke on last attempt to stop smoking and saliva 
cotinine levels. Both CDS-12 and CDS-5 scores decreased with reduction in cigarette smoking, but 
neither scale predicted smoking abstinence at follow-up. In a subsequent study, higher CDS-12 scores 
predicted smoking abstinence at 1 month after cessation. Higher baseline CDS-12 scores weakly 
predicted higher withdrawal ratings at follow-up, with the exception of appetite. Performs better than 
FTND on many of these measures.
Wisconsin Inventory of 
Smoking Dependence 
Motives (WISDM) (Piper 
et al. 2006)
Multidimensional, 68 items with 13 theory-based subscales: (1) affiliative attachment (to smoking);  
(2) automaticity (smoking without awareness or intention); (3) behavioral choice/amelioration 
(smoking despite constraints or alternative reinforcers); (4) cognitive enhancement; (5) craving;  
(6) cue exposure/associative process (reflects basic learning process); (7) loss of control; (8) negative 
reinforcement; (9) positive reinforcement; (10) social/environmental goads (potency of social stimuli 
that model or invite smoking); (11) taste/sensory properties; (12) tolerance; and (13) weight control. 
Identifies motivational dependence process that influences dependence criteria. Some subscales are 
highly correlated, indicating overlapping dimensions. All scales except social/environmental goads 
were weakly to strongly correlated with FTND and moderately to strongly correlated with the TDS. 
Total WISDM score was moderately predictive of number of cigarettes/day and carbon monoxide level, 
with variability of strength of prediction for subscales. Total WISDM score did not significantly predict 
relapse, whereas combination of subscales was predictive (e.g., automaticity, behavioral choice/
amelioration, cognitive enhancement, and negative reinforcement).
Nicotine Dependence 
Syndrome Scale (NDSS) 
(Shiffman et al. 2004a; 
Shiffman and Sayette 
2005)
Multidimensional, theoretically derived scale with 5 subscales: drive (craving and withdrawal, 
withdrawal avoidance, and subjective compulsion to smoke), tolerance (reduced sensitivity to effects 
of smoking), continuity (regularity of smoking rate), stereotypy (rigid patterns of tobacco use), and 
priority (preference for smoking over other reinforcers). Continuous factor scores and single total 
score can be obtained. Most of the reliability and validity testing were not conducted on the final 19 
items that comprise this scale. Internal consistency of subscales is moderate to strong. Test-retest 
is modest to strong. In persons who did not stop smoking, NDSS scores modestly correlated with 
number of cigarettes smoked, difficulty in abstaining, and severity of past withdrawal symptoms. In 
treatment-seeking population, scales are modestly predictive of urges during smoking and during 
abstinence, acute withdrawal symptoms (except negative affect), and cessation outcome. Subscales 
show independent predictive usefulness (e.g., differential correlation with indices of dependence). 
NDSS strongly discriminates nonnicotine-dependent smokers who smoke a maximum of 5 cigarettes/
day (chippers) from regular smokers. Scales also discriminated levels of intake and dependence among 
chippers. Relationship between NDSS remained even when controlled for FTQ score.
Note: Description and results on scales are illustrative and not comprehensive.
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Tobacco Constituents and Pharmacokinetics
Nicotine and Other Tobacco 
Constituents
Tobacco products contain more than 4,000 chemi-
cals, some of which could contribute to dependence. How-
ever, there is little debate that nicotine is a major tobacco 
component responsible for addiction (USDHHS 1988; 
Stolerman and Jarvis 1995; Royal College of Physicians 
of London 2000; Balfour 2004). Nicotine, 3-(1-methyl-
2-pyrrolidinyl)pyridine, is a volatile alkaloid (pKa = 8.5) 
with a molecular weight of 162.23. The absorption and 
renal excretion of nicotine are highly dependent on pH. At 
a high (alkaline) pH, nicotine is in the nonionized state, 
which is associated with the ability to more easily pass 
through lipoprotein membranes (Stratton et al. 2001). 
Nicotine can be rapidly absorbed in the lungs through 
cigarette smoking because of the large surface area of the 
alveoli and small airways and the dissolution of nicotine 
in pulmonary fluid, which has a physiological pH that 
facilitates absorption. Similarly, nicotine from oral prod-
ucts that have an alkaline pH can be readily but more 
gradually absorbed through the oral mucosa. In addi-
tion, nicotine can be well absorbed in the small intestine, 
because of its more alkaline pH and large surface area. 
However, nicotine is poorly absorbed from the stomach, 
because of its acidic environment resulting in greater ion-
ized nicotine. Unlike when it is swallowed, nicotine’s bio-
availability is greater through the lung or through the oral 
mucosa because nicotine reaches systemic circulation 
before passing through the liver (first-pass metabolism). 
Earlier studies that examined a wide range of animal 
species have shown that nicotine alone can lead to self-
administration in preference to an inert control substance 
(Henningfield and Goldberg 1983; USDHHS 1988; Swed-
berg et al. 1990; Rose and Corrigall 1997; Royal College of 
Physicians of London 2000). Humans have also demon-
strated a preference for nicotine over a control substance 
in studies examining intravenous administration (Hen-
ningfield and Goldberg 1983; Harvey et al. 2004), nasal 
administration (Perkins et al. 1996a), and use of medicinal 
gum (Hughes et al. 1990a). Furthermore, if levels of nico-
tine in the body are altered, smokers tend to compensate 
or titrate their dose by (1) smoking more if the levels of 
nicotine are reduced or blocked by a nicotinic receptor 
antagonist or (2) smoking less if exogenous nicotine or 
higher levels of nicotine are administered (USDHHS 1988; 
NCI 1996, 2001). Titration of the level of nicotine in the 
body during smoking involves adjusting smoking behav-
iors by changing the (1) number of puffs on a cigarette, 
(2) duration of the puffs, (3) interpuff intervals, and/or (4) 
number of cigarettes smoked (Griffiths et al. 1982). For ex-
ample, researchers observed this compensatory smoking 
behavior in smokers who had either switched from ciga-
rettes with a high machine-determined yield of nicotine 
to cigarettes with a low yield (Scherer 1999; NCI 2001) or 
reduced the number of cigarettes smoked (Fagerström 
and Hughes 2002; Hecht et al. 2004). The resulting levels 
of cotinine and other biochemical indicators of exposure 
to tobacco were proportionately lower than expected, con-
sidering the reduction in the nicotine yield of the cigarette 
or the number of cigarettes smoked. 
Researchers have observed that ingredients besides 
nicotine in tobacco or tobacco smoke (e.g., nornicotine 
and acetaldehyde) have either synergistic effects with nic-
otine or reinforcing effects of their own. Several pharma-
cologically active metabolites of nicotine were observed in 
the central nervous system (CNS) after acute administra-
tion of nicotine (Crooks and Dwoskin 1997). Nornicotine 
is both a metabolite of nicotine and a minor tobacco alka-
loid. According to a review by Crooks and Dwoskin (1997), 
S(-)-nornicotine evokes concentration-dependent and 
calcium-ion (Ca2+)-dependent increases in endogenous 
release of dopamine from rat striatal slices and from 
mouse striatal synaptosomes. At low nornicotine concen-
trations, nicotinic receptor antagonists, such as mecamyl-
amine and [3H]-dihydro-β-erythroidine (DHβE), inhibit 
dopamine release evoked by S(-)-nornicotine. At high 
nornicotine doses, this inhibition is not observed, thereby 
indicating that at high doses, nonselective mechanisms 
may be associated with the release of dopamine. In addi-
tion, S(-)-nornicotine, R(+)-nornicotine, and nicotine 
appear to activate the neural mechanisms responsible 
for behavioral sensitization. For example, administra-
tion of S(-)-nornicotine desensitized nicotine receptors, 
but at a potency 12-fold lower than that of nicotine. 
S(-)-nornicotine also showed cross-desensitization with 
nicotine; that is, receptors desensitized by nicotine were 
also desensitized by S(-)-nornicotine. This result suggests 
the involvement of common subtypes of nicotinic recep-
tors (Dwoskin et al. 2001). 
Researchers have observed similar behavioral effects 
from nicotine and nornicotine. In one study examining 
acute or chronic (repeated) administration of S(-)-nico-
tine, R(+)-nornicotine, and S(-)-nornicotine on locomo-
tor activity, the effects of both nornicotine enantiomers 
were qualitatively different from that of the S(-)-nico-
tine enantiomer after acute administration (Dwoskin 
et al. 1999a). Unlike S(-)-nicotine, neither nornicotine 
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enantiomer produced hyperactivity following acute injec-
tion with the doses used in the study. However, long-term 
administration of a nornicotine enantiomer, specifically 
S(-)-nornicotine, showed patterns of effects similar to 
those of nicotine. Furthermore, long-term pretreatment 
with either nornicotine enantiomer produced cross- 
sensitization to the locomotor stimulant effects after a 
nicotine challenge. 
Studies in rats show that (-)-nornicotine substi-
tutes for (-)-nicotine in a drug-discrimination paradigm 
(Goldberg et al. 1989) and partially substitutes for (+)- 
amphetamine as a discriminative stimulus, although it 
is less potent than (-)-nicotine (Bardo et al. 1997). In a 
study of self-administration by rats (Bardo et al. 1999), 
S(-)-nicotine and RS(±)-nornicotine produced a number 
of responses on a lever to obtain these drugs that was 
higher than the number on a lever to obtain an inactive or 
saline infusion used as a control. Furthermore, response 
decreased when saline was substituted for nornicotine, 
confirming that the animals were responding for nor-
nicotine. Response increased when nornicotine was again 
available. In another study, pretreatment with (±)-nor-
nicotine produced a dose-dependent decrease in nicotine 
self-administration (Green et al. 2000). 
These results indicate that nornicotine functions 
as a positive reinforcer but has less potency than that of 
nicotine. Researchers have speculated that this reduced 
effect may be attributable to (1) the longer half-life of nor-
nicotine; (2) the use of RS(±)-nornicotine rather than the 
pure S(-)-nornicotine, which is considered more potent in 
evoking dopamine release in the brain; or (3) the reduced 
potency of nornicotine in the release of dopamine (Bardo 
et al. 1999). Because nornicotine is present only as a 
minor metabolite, it is unclear whether it would have any 
significant pharmacologic effect in smokers. 
Less data are available on cotinine, which is a major 
metabolite of nicotine (Benowitz and Jacob 1994). Studies 
suggest that cotinine is available in the CNS and stimu-
lates nicotinic receptors to evoke the release of dopamine 
in a calcium-dependent manner from superfused rat stria-
tal slices but that it is much less potent than nicotine or 
S(-)-nornicotine (Dwoskin et al. 1999b). (In superfusion, 
artificial central spinal fluid is poured over thin slices of 
brain tissue to maintain function and enable in vitro stud-
ies.) Other studies indicated that cotinine has a low affinity 
for nicotinic receptors (Abood et al. 1981, 1985) and may 
be associated with increased serotonin (5HT) levels (De 
Clercq and Truhaut 1963; Yamamoto and Domino 1965; 
Essman 1973; Rosencrans and Chance 1977; Fuxe et al. 
1979; Risner et al. 1985; Goldberg et al. 1989; Takada et al. 
1989; Erenmemisoglu and Tekol 1994). Studies in animals 
and humans have shown that cotinine is psychoactive and 
behaviorally active (Hatsukami et al. 1997, 1998a), but 
most studies showed this effect only with high cotinine 
doses. In human clinical studies, cotinine demonstrates 
effects opposite those of nicotine, indicating that cotinine 
may function as a nicotine antagonist (Keenan et al. 1994; 
Hatsukami et al. 1998a,b). 
Acetaldehyde, a constituent in tobacco smoke that 
results from burning sugars and other materials in the 
tobacco leaf, may play a role in increasing the reinforc-
ing effects of nicotine (DeNoble and Mele 1983). In a later 
study, acetaldehyde enhanced the acquisition of nicotine 
self-administration among adolescent rats but not among 
adult rats (Belluzzi et al. 2005). The authors point out 
that adolescence may be a time of particular sensitivity 
to the effects of nicotine. This observation is supported by 
the fact that even a limited exposure to nicotine during 
adolescence may lead to symptoms of dependence (Kandel 
and Chen 2000; DiFranza et al. 2002b). In animals, nico-
tine treatment during adolescence leads to neurochemical 
changes in the brain that differ from those observed in 
adults (Adriani et al. 2002; Slotkin 2002). Furthermore, 
studies show an increased sensitivity to the rewarding 
effects of nicotine in adolescent compared with adult 
rodents (Adriani et al. 2002; Levin et al. 2003; Belluzzi et 
al. 2004). Further research is needed to understand the 
mechanism(s) by which acetaldehyde enhances the rein-
forcing effects and other effects of nicotine.
Fowler and colleagues (2003) point out that com-
pared with nonsmokers and former smokers, current 
smokers had lower levels of MAOA, which preferentially 
oxidizes norepinephrine and serotonin, and of MAOB, 
which preferentially oxidizes phenethylamine. Both forms 
of MAO also oxidize dopamine, tyramine, and octopamine. 
Because former smokers showed normal MAO levels, the 
low levels in smokers appear to result from the pharmaco-
logic effects of tobacco use, rather than from an inherent 
characteristic of smokers. Low levels of MAO may contrib-
ute to the reinforcing effects of tobacco use, because of 
the resulting higher levels of catecholamines. Nicotine 
does not appear to be responsible for this effect. Rather, 
the responsible constituents appear to be extracts (2,3,6- 
dimethyl-benzoquinone and 2-naphthylamine) from flue-
cured tobacco leaves (Khalil et al. 2000; Hauptmann and 
Shih 2001). Animal studies with rats and mice have also 
shown that cigarette smoke and solutions of cigarette 
smoke (Yu and Boulton 1987; Carr and Basham 1991), as 
well as cigarette tobacco extract (Yu and Boulton 1987), 
inhibit MAO activity in the brain. The MAO inhibition in 
smokers is partial, with reductions at about 30 and 40 
percent for MAOA and MAOB, respectively (Fowler et al. 
2003). The reduction in MAOB levels does not appear to be 
rapidly reversible, as demonstrated by a study that showed 
no difference in MAOB levels when smokers were scanned 
by positron emission tomography (PET) at 10 minutes or 
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11 hours after smoking a cigarette (Fowler et al. 2000). 
One study found that the intensity of the withdrawal 
symptoms was inversely related to platelet MAO activ-
ity (Rose et al. 2001a); that is, smokers with low platelet 
activity at baseline experienced the most severe with-
drawal symptoms. 
In summary, nicotine is the most potent constitu-
ent associated with the reinforcing effects of tobacco. 
However, researchers have identified other constituents 
in tobacco and tobacco smoke that may be reinforc-
ing or facilitate reinforcing effects of tobacco. Nicotine 
metabolites have also been identified as potential rein-
forcers or enhancers of the reinforcing effects of nicotine. 
Researchers have observed that in addition to nicotine and 
other constituents of tobacco and tobacco smoke, sensory 
aspects of nicotine and environmental stimuli also have a 
significant role in maintaining smoking behavior (Rose et 
al. 1993; Shahan et al. 1999; Caggiula et al. 2001, 2002b; 
Perkins et al. 2001d) (for details, see “Learning and Condi-
tioning” later in this chapter).
Pharmacokinetics
Nicotine addiction depends on the amount of nico-
tine delivered and the way in which it is delivered, which 
can either enhance or reduce its potential for abuse: the 
faster the delivery, rate of absorption, and attainment of 
high concentrations of nicotine, the greater is the poten-
tial for addiction (Henningfield and Keenan 1993; deWit 
and Zacny 1995; Stitzer and de Wit 1998). 
Nicotine can be readily absorbed in the lung, oral 
mucosa, and nose, and through the skin. Table 4.4 shows 
(1) the bioavailability and amount of nicotine absorbed 
per unit dose of products containing nicotine and (2) the 
time to reach maximum blood concentrations of nicotine 
(Tmax). Figure 4.1 shows the concentrations of nicotine 
in venous blood and the peak concentrations across the 
products containing nicotine. The mean peak concentra-
tions of nicotine are higher with use of tobacco products 
than with use of nicotine replacement products, and ciga-
rette smoking produced both the highest peak concentra-
tion and most rapid rate of nicotine absorption. Venous 
concentrations of nicotine from smoking are lower than 
arterial concentrations. Ratios of arterial concentrations 
to venous concentrations ranged from 2.3 to 10 across 
studies (Henningfield et al. 1993; Gourlay and Benowitz 
1997; Rose et al. 1999). What accounts for the variabil-
ity in arterial to venous nicotine concentration ratios 
observed across studies is unclear but may be a function 
of the study procedures and cigarette brands that were 
tested. In one study, lower-than-expected arterial nicotine 
concentrations were observed. The low concentration was 
attributed to the distribution of nicotine into the lungs 
and the slow release of nicotine into arterial circulation 
(Rose et al. 1999). The greater reinforcing efficacy of 
rapid delivery of nicotine was therefore thought to be due 
to both direct effects on the CNS and to stimulation of 
nicotinic receptors in the lung. These results would also 
suggest that neuronal nicotinic receptors associated with 
reinforcing effects of nicotine may be sensitive to low con-
centrations of nicotine. Clearly, more studies are needed 
to resolve the issues related to arterial concentrations of 
nicotine and consequent physiological effects. 
Oral use of smokeless tobacco products results in 
high venous concentrations of nicotine equal to those for 
use of cigarettes. Although the Tmax for delivery of nico-
tine in nasal spray appears to be less (faster) than that for 
Table 4.4 Bioavailability and amount of nicotine absorbed per unit dose and time to maximum venous blood 
concentration of nicotine by product
Product Bioavailability per dose Time to maximum concentration
Cigarette 1–2 mg Within 5 minutes
Nicotine gum (2 mg, 4 mg) 1 mg, 2 mg 30 minutes
Nicotine inhaler 2 mg/cartridge 20–30 minutes
Nicotine nasal spray 0.5 mg 10 minutes
Nicotine patch 15–22 mg (during 16–24 hours) 4–9 hours
Smokeless tobacco 3.6–4.5 mg 20–30 minutes
Source: Data are from Benowitz 1988; Fant et al. 1999a; Fagerström 2000; Medical Economics Company 2000. Table is adapted from 
Stratton et al. 2001 with permission from the National Academies Press, © 2001, National Academy of Sciences.
Note: mg = milligrams.
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Figure 4.1 Venous blood concentrations of nicotine over time for various nicotine delivery systems
Source: Adapted from Fant et al. 1999b with permission from Elsevier, © 1999.
Note: mg = milligrams; ng/mL = nanograms per milliliter; data table for above data found at 
end of chapter.
smokeless tobacco products, the addiction potential may 
be higher for smokeless tobacco than for nicotine nasal 
spray, because the rate of nicotine absorption for smoke-
less tobacco is faster. Within 10 minutes after adminis-
tration of a smokeless tobacco product, a nicotine boost 
of 10 nanograms per milliliter can be achieved (Holm et 
al. 1992) compared with two to three times longer after 
administration of nasal spray. However, the rise of arterial 
concentrations from nicotine nasal spray compared with 
smokeless tobacco is unknown. A further complication 
is that the rate and amount of nicotine absorption vary 
across smokeless tobacco products (Figure 4.2). This vari-
ability results from the processing and pH of the smoke-
less tobacco product. Cigarettes also vary in nicotine 
content. The tobacco plant, the curing process, and the 
additives can determine the pH of the tobacco and tobacco 
smoke (see Chapter 3, “Chemistry and Toxicology of Ciga-
rette Smoke and Biomarkers of Exposure and Harm”). 
Nonetheless, although the pharmacokinetics of 
some smokeless tobacco products may overlap with those 
of medicinal nicotine products, medicinal products tend 
to have a slower rate and a lower amount of nicotine 
absorption than do the most popular brands of conven-
tional smokeless tobacco products (Kotlyar et al. 2007). 
Among the medicinal nicotine products, nicotine nasal 
spray has the fastest rate of nicotine absorption, followed 
by nicotine gum, the nicotine lozenge, and the nico- 
tine patch. 
Together, these results demonstrate that the nico-
tine pharmacokinetics associated with cigarette smoking 
is likely to lead to high potential for addiction, whereas 
medicinal nicotine products have relatively minimal 
potential for addiction. For example, the extent of liking, 
and therefore the addiction potential for these products, 
are related to the speed of nicotine delivery (Henningfield 
and Keenan 1993). Nicotine delivered through cigarette 
smoking and intravenously shows the greatest dose-re-
lated liking for the drug, and nicotine delivered transder-
mally is associated with the least liking (Henningfield and 
Keenan 1993; Stratton et al. 2001). 
The pharmacokinetic profile of a drug can determine 
the user’s pattern of drug delivery. Cigarette smoking 
results in rapidly rising arterial concentrations of nicotine 
that reach the brain in about 10 to 19 seconds (Benowitz 
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Figure 4.2 Mean plasma nicotine concentrations after administration of each of four smokeless tobacco products 
or mint snuff
Source: Adapted from Fant et al. 1999a with permission from BMJ Publishing Group Ltd., © 1999. 
Note: ng/mL = nanograms per milliliter; data table for above data found at end of chapter.
1990). The peak levels decline quickly as nicotine is taken 
up by peripheral tissues, followed by an elimination of 
nicotine from the body (Benowitz et al. 1988). This profile 
enables the smoker to finely control the nicotine dose to 
obtain the desired effect and enables frequent doses. These 
characteristics facilitate the addiction potential of ciga-
rettes (Benowitz 1999). In contrast, oral nicotine products 
such as smokeless tobacco result in a more gradual rate 
of nicotine absorption and the nicotine levels are more 
sustained, resulting in a reduced ability of the smoker to 
manipulate the nicotine dose and less frequent dosing. 
The nicotine patch is the extreme example of slow absorp-
tion and once-a-day dosing, which results in a minimal 
potential for addiction.
Nicotine metabolism may also play a role in the rein-
forcing effects of nicotine. Researchers have hypothesized 
that the rate of nicotine metabolism should be related to 
smoking behaviors and that faster elimination of nico-
tine is associated with increased smoking and nicotine 
dependence (Benowitz 1999). Although surprisingly few 
published studies have tested this hypothesis, the research 
evidence has given some support to it (see “Genetics” later 
in this chapter). However, the evidence is modest. The rate 
of nicotine metabolism accounts for less than 16 percent 
of variation in the number of cigarettes smoked per day 
(Benowitz et al. 2003; Johnstone et al. 2006), and there is 
no significant variance in the FTND (Benowitz et al. 2003; 
Johnstone et al. 2006; Kandel et al. 2007) or in scoring 
on the Horn-Russell Scale (Johnstone et al. 2006). Kan-
del and colleagues (2007) found no significant association 
between the rate of metabolism and the number of ciga-
rettes per day or nicotine dependence as measured by 
the FTND in a sample of young (18 through 26 years of 
age), less dependent, light smokers (average of 12 ciga-
rettes per day). Possible reasons for the apparent discon-
nect between rate of metabolism and nicotine dependence 
include the following: (1) The questionnaire measures of 
adult nicotine dependence used may not be the most sen-
sitive measures of the rate of metabolism (Benowitz et al. 
2003; Johnstone et al. 2006). (2) The rate of metabolism 
may be related to nicotine dependence only during the 
transition from experimentation to “addicted” smoking 
(Benowitz et al. 2003). (3) The rate of metabolism is not 
an important determinant of smoking behavior in young 
smokers because of a low level of smoking (Kandel et 
al. 2007).
One of the reasons metabolism per se may not be 
directly related to measures of nicotine dependence is 
that the pharmacokinetics of nicotine metabolism are one 
step removed from the pharmacodynamics of nicotine, 
that is, from the impact (1) on neurotransmitters in the 
reward pathway, (2) on central effects, as measured by 
electroencephalography and cerebral blood flow, and (3) 
on peripheral effects such as cardiovascular responses. 
Both central and peripheral effects contribute to subjec-
tive reactions to nicotine and the subsequent likelihood 
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of continued smoking. (For discussion of the pharmaco-
dynamics of nicotine in the brain, see “Pathophysiology of 
Nicotine Addiction” later in this chapter.)
The factors contributing to the high addiction 
potential of tobacco products are undoubtedly multiple 
and have complex interrelationships, making it a chal-
lenge to parse their relative contributions. In addition, 
smoking results in rapid delivery of nicotine by cigarette 
smoke and in exposure to chemicals other than nicotine 
that have central and sensory effects, including taste and 
draw resistance, as well as stimuli associated with smok-
ing (Scherer 1999; Caggiula et al. 2002a; Rose 2006). 
Relatively few studies have been conducted outside the 
tobacco industry to determine how features of the ciga-
rette are engineered to increase its addictive potential. 
However, tobacco industry documents suggest that more 
than nicotine dosing and pharmacokinetics are important 
in determining the overall addiction potential of modern 
cigarettes (Slade et al. 1995; Hurt and Robertson 1998; 
Wayne et al. 2004). (For description of design features that 
can enhance nicotine delivery and absorption rate, see 
Chapter 3, “Chemistry and Toxicology of Cigarette Smoke 
and Biomarkers of Exposure and Harm.”) 
Components of Nicotine Addiction
What are the effects of nicotine, and how does 
it cause addiction? The factors that may contribute to 
addictive behaviors include (1) neuroadaptations that 
occur with the persistent use of nicotine (e.g., tolerance), 
(2) withdrawal symptoms experienced when intake of 
the drug is stopped, and (3) the effects of nicotine that 
reinforce dependence. The primary reinforcing effects 
can entail the rewarding (psychoactive or psychostimu-
lant) effects of nicotine (positive reinforcement) and/or 
the	alleviation	of	aversive	or	negative	states	or	stimuli—
for example, relief from withdrawal symptoms (negative 
reinforcement). Nicotine may also enhance the reinforc-
ing values of other reinforcers or stimuli, which may also 
contribute to its reinforcing effects. 
Strong learning processes also contribute to addic-
tive behaviors. These learning processes include condi-
tioning in which stimuli associated with drug use evoke 
responses that are similar to the effects from the drug or 
similar to withdrawal symptoms or that may modulate 
drug effects. One hypothesis is that incentive sensitiza-
tion can occur, in which some of the conditioned stimuli 
(CSs) are given priority in the allocation of attention and 
become a strong source of motivation to seek the drug 
(Robinson and Berridge 2001). Incentive sensitization 
consists of neuroadaptations from repeated use of a drug 
that render brain-reward systems hypersensitive (sensi-
tized) to drug-associated stimuli. Also, nicotine’s ability 
to be a secondary reinforcer of CSs to other reinforcers 
strengthens its addictive effects. Nicotine tolerance, with-
drawal, and reinforcement in humans are examined in the 
next section, which is followed by a section on learning 
and conditioning in nicotine addiction.
Physiological Mechanisms and 
Indicators: Nicotine Tolerance, 
Withdrawal, and Reinforcement
Chronic Tolerance
Tolerance is a reduced responsiveness to a drug as a 
function of earlier exposure to that drug. This reduction 
in responsiveness is a consequence of drug use (Kalant et 
al. 1971). Therefore, tolerance should be distinguished 
from innate differences in drug responses that may 
relate to an initial risk of dependence, such as responses 
attributable to genetic or other constitutional factors (see 
“Genetics” later in this chapter). Sensitization, the oppo-
site of tolerance, is an enhanced responsiveness to nico-
tine as a function of earlier exposure to the drug (Kalant 
et al. 1971). Sensitization is not addressed here, because 
it has not been clearly demonstrated in clinical studies. 
However, animal research suggests that sensitization 
occurs in response to locomotor activity and other physi-
cal and behavioral effects of exposure to nicotine (Le Foll 
et al. 2003; Samaha et al. 2005).
Tolerance and sensitization can be characterized on 
the basis of the time course of the adaptation involved. 
Acute tolerance develops within minutes after the initial 
exposure of the day (e.g., first few cigarettes) and is gener-
ally lost with overnight abstinence from smoking (Perkins 
et al. 1995). Acute tolerance may help to explain patterns 
of smoking during the course of a day (Balfour et al. 2000), 
but researchers think it is less important than chronic 
tolerance for an understanding of dependence (Di Chiara 
2000). Chronic tolerance develops over weeks, months, 
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or years (Kalant et al. 1971). Tolerance can also be dis-
tinguished on the basis of mechanisms. Pharmacokinetic 
tolerance is a reduced response to a drug because of an 
increase in drug clearance or metabolism that results in a 
smaller concentration of the drug in the body for a given 
administered dose. This type of tolerance is not discussed 
here, because clinical studies showed no evidence of a 
pharmacokinetic tolerance to nicotine in humans (Beno-
witz and Jacob 1993). However, innate differences in nico-
tine metabolism are well known (see “Genetics” later in 
this chapter). Pharmacodynamic tolerance is a reduced 
response to a given concentration of a drug in the body 
that results from changes in tissue sensitivity. The follow-
ing discussion focuses on the association between chronic 
pharmacodynamic tolerance to nicotine and dependence 
on nicotine. 
Chronic Tolerance to Nicotine
Chronic tolerance to nicotine or to most drugs is dif-
ficult to examine in clinical studies for practical and ethical 
reasons. The time required for the onset of chronic toler-
ance generally precludes longitudinal studies of changes 
in tolerance. Thus, the study of chronic tolerance usu-
ally requires cross-sectional comparisons between groups 
that differ in past histories of smoking, which can require 
administering nicotine to nonsmokers. Such comparisons 
may also introduce potential bias due to self-selection of 
drug history and because smoking history may covary with 
many other important differences that affect responses to 
nicotine, such as history of other drug use and psychiatric 
history (Hughes et al. 2000; Richter et al. 2002). 
Despite methodologic limitations, studies have 
clearly shown a chronic tolerance for many self-reported 
responses to nicotine, such as a subjective mood. For 
example, smokers show fewer responses than do non-
smokers to the same amount of nicotine, as evidenced by 
measures of subjective stimulation that may be viewed as 
pleasurable, such as arousal, vigor, and a subjective expe-
rience often referred to as “head rush” or “buzz,” as well as 
some experiences that may be viewed as aversive, includ-
ing tension and nausea (Perkins et al. 2001b). However, 
chronic tolerance is less apparent for many other effects 
of nicotine, including cardiovascular responses (Perkins 
et al. 2001b). Chronic tolerance is virtually absent for 
simple psychomotor effects such as finger-tapping speed 
and Stroop task performance (Perkins et al. 2001b). This 
research is reviewed in detail elsewhere (Perkins 2002).
Association of Nicotine Tolerance with 
Dependence in Adults
Chronic tolerance to some effects of nicotine devel-
ops after long-term smoking. However, tolerance appears 
to be a nonsensitive marker for dependence among those 
with any history of extensive smoking (Perkins 2002). Per-
kins hypothesized that if a close association exists between 
tolerance and the level of dependence, then (1) more 
dependent smokers would show tolerance greater than 
that of less dependent smokers, (2) tolerance to nico-
tine before smoking cessation would predict the success 
of a subsequent attempt to stop smoking, and (3) toler-
ance would decrease with a longer duration of abstinence 
after cessation, indicating loss of dependence. However, 
the limited evidence suggests no such links between toler-
ance and dependence (Perkins 2002). 
First, some research (Shiffman et al. 1992; Perkins 
et al. 2001b) shows little or no difference in tolerance to 
most effects of nicotine between dependent smokers and 
a subset of smokers who do not meet dependence crite-
ria—for	example,	smokers	of	up	to	five	cigarettes	per	day	
who do not experience withdrawal symptoms and who 
often go for long periods without smoking (Shiffman et 
al. 1992). Second, the magnitude of tolerance to nico-
tine before smoking cessation does not predict the sever-
ity of withdrawal or the duration of abstinence after an 
attempt to stop smoking, although a measure of nicotine 
reinforcement predicts both (Perkins et al. 2002a). Third, 
longitudinal studies show no change in chronic tolerance 
within one week or one month of smoking cessation and 
no difference in tolerance between former smokers who 
stopped smoking for 1 to 4 years or 6 to 19 years (Perkins 
et al. 2001c).
The conclusion that tolerance among smokers is not 
a good index of dependence warrants additional research 
(Perkins 2002). Most of these studies compared responses 
at low doses of nicotine to avoid aversive effects in groups 
with histories of limited smoking. Even so, tolerance to 
higher doses of nicotine may be associated with indices 
of dependence. Moreover, the acute effects of nicotine 
that explain its reinforcing quality are still not under-
stood fully, so chronic tolerance to responses that were 
not assessed in this earlier research may be tied closely to 
dependence. In addition, chronic tolerance may be more 
critical during the onset of dependence in the adolescent 
years than it is in adults (Kandel and Chen 2000), because 
tolerance to the aversive effects of nicotine must occur for 
adolescents to escalate from one to two cigarettes per day 
to one pack per day (see “Epidemiology of Tobacco Use 
and Nicotine Dependence in Adults” later in this chapter). 
However, chronic tolerance may no longer be important 
after the onset of dependence. 
Withdrawal
In tobacco-dependent smokers, a reliable conse-
quence of abstaining from smoking for more than a few 
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hours is the onset of distress indicated by self-reported 
behavioral, cognitive, and physiological symptoms and by 
clinical signs (APA 2000; Shiffman et al. 2004b; Hughes 
2007). The subjective symptoms of withdrawal are mani-
fested by affective disturbance, including irritability and 
anger, anxiety, and a depressed mood. The behavioral 
symptoms include restlessness, sleep disturbance, and an 
increased appetite, typically assessed by self-reports. Cog-
nitive disturbances usually center on difficulty concen-
trating (Shiffman et al. 2004b; Hughes 2007). Researchers 
believe	 these	 symptoms—known	 collectively	 as	 with-
drawal—are	major	factors	that	impair	the	ability	to	remain	 
abstinent from smoking (Patten and Martin 1996; see 
“Trajectory of Recovery or Relapse” later in this chapter). 
The management of withdrawal and craving symptoms 
(e.g., the urge to smoke) is a primary treatment strategy to 
maintain smoking cessation. Withdrawal symptoms typi-
cally emerge within a few hours after the last cigarette is 
smoked, peak within a few days to one week, and return to 
precessation baseline levels after two to four weeks (Shiff-
man et al. 2004b). However, individual variability in the 
time course of withdrawal may be substantial and clini-
cally significant (see “Trajectory of Recovery or Relapse” 
later in this chapter).
Individual withdrawal symptoms are often viewed as 
different manifestations of the same underlying process. 
One approach suggests that symptoms should be tightly 
linked in terms of pattern, intensity, time course, rela-
tionship to relapse, and neurobiologic factors. Another-
approach suggests that symptoms should be assessed 
individually instead of by aggregating symptom scores 
into one total score (Shiffman et al. 2004b) (see “Patho-
physiology of Nicotine Addiction” and “Trajectory of 
Recovery or Relapse” later in this chapter). 
Unlike nicotine tolerance, the severity of withdrawal 
is more strongly related to some of the indices of nicotine 
dependence (such as cessation). For example, although 
nicotine-dependent and nonnicotine-dependent smokers 
generally do not differ in tolerance to nicotine, nicotine-
dependent smokers are more likely to experience more 
severe withdrawal during initial abstinence (Shiffman 
1989b). The observation that withdrawal but not toler-
ance is associated with dependence has also been noted 
for other drugs of abuse, especially alcohol (Schuckit et al. 
1999; Hasin et al. 2000; O’Neill and Sher 2000).
Individual Differences in Withdrawal
Individual differences in the severity and pattern of 
withdrawal are topics of major clinical interest (see “Tra-
jectory of Recovery or Relapse” later in this chapter). A 
history of major depression may exacerbate withdrawal 
after smoking cessation (Pomerleau et al. 2004) and may 
increase the risk of relapse in women but perhaps not in 
men (Hall et al. 1998). The role of a major depressive dis-
order in relapse has been inconsistent and may be related 
to how depression is defined (see “Trajectory of Recovery 
or Relapse” later in this chapter), and few other character-
istics have been associated with differences in withdrawal 
for men and women. For example, even though women 
generally have more difficulty than do men in maintain-
ing abstinence from smoking, the severity of withdrawal 
in men and women does not appear to differ (Benowitz 
and Hatsukami 1998). However, withdrawal severity may 
be moderated by the phase of the menstrual cycle in 
women, with more severe withdrawal and depressed mood 
among women who stop smoking during the luteal phase 
than among those who stop during the follicular phase 
(Allen et al. 1996; Perkins et al. 2000). Other than studies 
of the effects of medication to relieve withdrawal symp-
toms, few researchers have examined other factors that 
acutely modify withdrawal. 
Reinforcement
In behavioral psychology, a stimulus  is considered 
reinforcing if it increases a response or behavior resulting 
in obtaining that stimulus. Thus, a drug is reinforcing if it 
is self-administered more than an inert substance used for 
comparison (e.g., placebo). “Reward,” on the other hand, 
is a less specific term defined as an index of subjective 
hedonic effects of substance use (Everitt and Robbins 
2005), and it is typically assessed after drug intake by 
ratings such as “liking” and “good effects.” Ratings of 
drug reward may help to explain reinforcement, but they 
should be kept distinct from measures of reinforcement, 
which are inherently behavioral. 
After a drug is established to be reinforcing, 
research can then focus on the neurobiologic or behavioral 
underpinnings of the reinforcing effects. (For discussion 
of research on the neurobiology of nicotine reinforce-
ment, see “Pathophysiology of Nicotine Addiction” later in 
this chapter.) Behavioral or subjective effects of nicotine 
that may be reinforcing have not been definitively iden-
tified. Methodologic issues complicate the study of what 
makes nicotine either positively or negatively reinforc-
ing. Pleasurable effects indicate positive reinforcement, 
whereas reductions in negative effects, such as relief 
from withdrawal, indicate negative reinforcement. These 
distinctions are important because exploration of posi-
tively reinforcing effects may be critical to understanding 
why adolescents begin to smoke cigarettes (i.e., onset of 
addiction) and why persons relapse after an attempt to 
stop smoking. Negatively reinforcing effects may be spe-
cific to relief from acute withdrawal and thus relevant 
only to relapse and not to the initiation of smoking or the 
Nicotine Addiction: Past and Present  119
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease
onset of addiction. Some research in nonsmokers links 
acute self-administration of nicotine with pleasurable 
subjective responses of increased vigor and arousal, sug-
gesting that positive reinforcement occurs with initial 
experience with nicotine (Perkins et al. 2001a). Similar 
research should focus on whether initial nicotine rein-
forcement is linked to relief from preexisting aversive 
symptoms, such as depressive symptoms. 
Other effects of nicotine may also reinforce its use, 
but their links with self-administration have not been 
clearly established. These effects include modulating 
negative affect (e.g., reducing fatigue, anxiety, or sadness) 
(Kassel et al. 2003), enhancing attention and concentra-
tion during cognitively demanding tasks (Heishman et al. 
1994), and perhaps preventing hunger and maintaining a 
lower body weight (Perkins 1993). Evidence suggests that 
these effects are observed largely in abstinent smokers ex-
periencing withdrawal and are thus examples of negative 
rather than positive reinforcement. 
Finally, animal research indicates that nicotine may 
have a secondary reinforcing function, aside from the 
direct (primary) reinforcing effects noted here. These 
studies, conducted mostly by Caggiula, Donny, and col-
leagues (e.g., Chaudhri et al. 2006), show that nicotine 
can enhance the reinforcing value of other reinforcers 
not associated with nicotine intake. Primary reinforcing 
effects require rapid administration of nicotine and are 
contingent on a response, whereas other reinforcement-
enhancing effects can occur regardless of the speed of nic-
otine delivery or the contingency of response. Although 
recent work suggests the occurrence of reinforcement- 
enhancing effects of nicotine (Barr et al. 2008), the clini-
cal research is insufficient to warrant extensive discus-
sion of how this influence promotes nicotine dependence. 
However, this influence may help to explain why smok-
ing appears to acutely increase consumption of other 
reinforcers, such as alcohol (Mitchell et al. 1995), and 
it may facilitate understanding of the difficulties involved 
in smoking cessation. If nicotine has reinforcement- 
enhancing effects, then smoking cessation removes these 
effects, leading to a lessening of reinforcement from many 
other reinforcers and not just the loss of reinforcement 
from smoking. 
Smoking Frequency and Tobacco Addiction
The most common index of reinforcement in 
research on tobacco or nicotine addiction is the number 
of cigarettes smoked per day (smoking frequency). That 
is, drugs that are highly reinforcing will tend to be self-
administered to a greater extent.  Typically, the number of 
cigarettes smoked per day is assessed by self-report. Bio-
chemical measures of the amount of smoking exposure 
include blood, salivary, and urinary levels of cotinine, the 
main metabolite of nicotine. Smoking frequency is related 
to a variety of dependence measures including scores on 
scales of nicotine dependence such as the widely used 
FTND (Hughes et al. 2004a). Higher frequency of smok-
ing was found to predict a more severe withdrawal and a 
faster relapse after an attempt to stop smoking (Ockene 
et al. 2000), which are both important clinical indices of 
addiction. Higher frequency of smoking is also associated 
with early lapses after smoking cessation, such as smoking 
on the first day of cessation or within the first two weeks, 
which are each strongly associated with an increased risk 
of relapse (Kenford et al. 1994). Other indices of smoking 
reinforcement or persistence are related to a high level 
of addiction. These indices include a longer duration of 
smoking, young age at smoking initiation, no previous 
attempt to stop smoking, and a shorter duration of absti-
nence during previous attempts to stop smoking (Ockene 
et al. 2000) (see “Trajectory of Recovery or Relapse” later 
in this chapter).
Acute Measures of Reinforcement
Reinforcement is often assessed in basic research 
studies by analyzing regular, or extent of, smoking behav-
ior over a period of time. This is usually determined by 
the number of cigarettes smoked per day but occasionally 
by microtopographic measures of puffing behaviors, blood 
nicotine levels, or the percentage of carbon monoxide in 
expired air (Lee et al. 2003), a biochemical index of acute 
smoking exposure. Smoking behavior in such short-term 
studies has been sensitive to a variety of manipulations of 
nicotine exposure, demonstrating the reinforcing effects 
of nicotine. For example, the intensity of acute smoking 
behavior increases when the nicotine yield of the cigarette 
is lowered, which is a compensation to maintain nicotine 
intake (Zacny and Stitzer 1988). The increase in plasma 
concentrations of nicotine from smoking is greater after 
pretreatment with mecamylamine, a nicotine recep-
tor antagonist. The increase is probably a result of more 
intense puffing in an attempt to overcome the blockade of 
nicotine receptors (Rose et al. 2001b).  Factors have been 
observed to moderate the reinforcing effects of tobacco. 
Some studies have shown increased smoking reinforce-
ment after pretreatment with alcohol (Nil et al. 1984; 
Mitchell et al. 1995) or with stimulant drugs such as 
d-amphetamine (Tidey et al. 2000), methylphenidate 
(Rush et al. 2005), or cocaine (Roll et al. 1997), but not 
with other stimulants such as caffeine (Nil et al. 1984; 
Lane and Rose 1995). The increase in smoking reinforce-
ment from acute pretreatment with drugs may help to 
explain the association between a history of drug use and 
nicotine dependence (Richter et al. 2002).
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Several other procedures provide sensitive and 
acute measures of smoking or nicotine reinforcement. 
These procedures include performance on a task (operant 
responding) on various schedules of reinforcement for 
puffs on a cigarette and the choice of nicotine or nonnico-
tine cigarettes. Instances of working for puffs on a ciga-
rette and choosing nicotine over nonnicotine cigarettes 
increase with smoking abstinence (Perkins et al. 1994, 
1996b). The operant response to obtain puffs on a ciga-
rette increases when the required number of responses per 
reinforcer is changed and access to alternative reinforcers 
is reduced, showing regulation of smoking intake (John-
son	 and	 Bickel	 2003).	 A	 slightly	 different	 procedure—
responding for puffs on a progressive-ratio schedule by 
gradually increasing the response requirements after 
each	earned	puff—may	also	provide	a	 sensitive	measure	
of the reinforcing value of smoking (Perkins et al. 2002b). 
However, few findings have related this measure to nico- 
tine dependence.
Separation of Nicotine Reinforcement from 
Smoking Reinforcement
Nicotine dependence generally involves the intake 
of nicotine by tobacco use, especially cigarette smoking. 
Therefore, the contribution of the many nonnicotine 
aspects of tobacco associated with smoking cigarettes 
should be distinguished from the influence of nicotine 
per se. The self-administration of cigarette smoke is not 
the same as the self-administration of nicotine. Among 
many differences between nicotine delivery through 
smoking and delivery in other forms, the smoke stimuli 
that typically accompany nicotine from cigarette smoking 
may acquire conditioned reinforcing effects that maintain 
smoking behavior (Caggiula et al. 2001) (see “Learning 
and Conditioning” in the next section). 
Nevertheless, some of the manipulations that alter 
smoking behavior also alter the self-administration of 
novel nicotine formulations. Nicotine alone, isolated from 
tobacco smoke, is reinforcing in humans (Perkins et al. 
1996a; Harvey et al. 2004). The choice of nicotine nasal 
spray instead of a placebo nasal spray increases with smok-
ing abstinence (Perkins et al. 1996b) and subsequently 
predicts a more severe withdrawal and a faster relapse 
during an attempt to stop smoking without medication 
(Perkins et al. 2002a). Blocking the effects of nicotine with 
mecamylamine pretreatment increases the intravenous 
self-administration of nicotine (Rose et al. 2003a). Also, 
under the same conditions of assessment, the amount 
of nicotine spray used voluntarily is correlated with the 
amount of voluntary smoking (Perkins et al. 1997). This 
finding indicates a generalizability between nicotine rein-
forcement through smoking and reinforcement through 
at least one novel form of nicotine delivery.
Individual Differences in Nicotine 
Reinforcement
Individual differences in nicotine reinforcement 
may provide direction for the study of individual differ-
ences in nicotine addiction and in approaches to treat-
ing addiction. In some studies, the reinforcing effects 
of nicotine tend to be less in women than in men, but 
the reinforcing effects of nonnicotine stimuli related to 
tobacco smoke (e.g., “cues”) tend to be greater in women 
than in men (Perkins et al. 2001d, 2002b). In light of the 
generally greater difficulty most women have with smok-
ing cessation, this observation suggests that the influence 
of nonnicotine stimuli can be important to the persistence 
of smoking behavior (i.e., dependence) (Caggiula et al. 
2001; Rose 2006). Other characteristics that may be asso-
ciated with greater reinforcement from smoking or from 
nicotine include comorbid psychiatric disorders (Lasser 
et al. 2000), a history of alcohol dependence (Keenan 
et al. 1990; Hughes et al. 2000), and perhaps other drug 
dependence (Richter et al. 2002), as well as other subgroups 
associated with a high prevalence of smoking and low rates 
of cessation. Similarly, smokers who are not obese may 
find the nicotine in cigarettes more reinforcing than do 
obese smokers (Blendy et al. 2005). 
Learning and Conditioning
Nicotine and Secondary Reinforcement
Perhaps as powerful as the direct effects of smok-
ing and nicotine on neural functioning are the associative 
processes that develop with repeated tobacco use (Cag-
giula et al. 2002a; Hyman 2005). The classic conditioning 
paradigm provides an important conceptual and theo-
retical framework for consideration of the powerful asso-
ciative learning processes that, according to Bevins and 
Palmatier (2004), develop in a specific manner. Smoking 
serves as the unconditioned stimulus (US), and the sub-
jective and physiological effects of smoking and exposure 
to nicotine serve as unconditioned responses. Exterocep-
tive (environmental) and interoceptive (internal) stimuli 
that occur repeatedly in temporal proximity to smoking 
become CSs. CSs include smoking paraphernalia (e.g., an 
ashtray), sensory aspects of smoking (e.g., cigarette smell 
or taste), and/or situational cues (e.g., smoking in the car 
while driving to work). The acquired response evoked by 
CSs becomes a conditioned response. With longer-term 
smoking, conditioned responses include urges to smoke. 
Repeated pairings of these CSs with cigarette smoking 
result in the CSs alone (before smoking) triggering urges 
to smoke (to want and to seek a cigarette) (Niaura 2000; 
Berridge and Robinson 2003). 
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Nicotine as a Conditioned Stimulus
Bevins and Palmatier (2004) have extended the asso-
ciative learning model of nicotine dependence by hypoth-
esizing that nicotine also has important actions as a CS of 
smoking behavior (the conditioned response) (Figure 4.3). 
The traditional role of nicotine has been limited to serving 
as a US. As a CS, nicotine acquires new or additional affec-
tive properties through being paired repeatedly with other 
stimuli such as coffee. In other words, nicotine enhances 
the salience of these and numerous other stimuli, which 
strengthens the associative bond and increases smok- 
ing behavior. 
Nicotine as a Modifier of Associative 
Processes
In addition to serving as a CS, nicotine modifies 
associative processes in conditioned and unconditioned 
manners (Bevins and Palmatier 2004). As a conditioned 
modulator (Figure 4.3), the interoceptive cuing of 
nicotine serves as a contextual stimulus that “sets the 
occasion” for an association between a discrete CS in the 
environment and smoking (Bevins and Palmatier 2004). 
The CS-US association is conditioned on the drug state 
(context). Examples include smoking while drinking alco-
hol to relax and smoking during a break at work to cope 
with distress. As an unconditioned modulator, nicotine 
may enhance the salience of other stimuli that have incen-
tive values to the person (Bevins and Palmatier 2004). For 
example, as depicted in connector “a” (solid line) of Fig-
ure 4.3, nicotine enhances the incentive or reward value of 
alcohol, which has its own significant reward value. This 
“incentive amplification” is unconditioned because the 
effects of nicotine do not depend on a contingent asso-
ciation between smoking and the motivational stimulus. 
“Incentive amplification” by nicotine is not limited to 
other drug reinforcers. Nicotine also enhances the rein-
forcing effects of nondrug reinforcers, such as light stimu-
lus (Palmatier et al. 2007).
Positive Reinforcement and Learning
The positive reinforcing action of nicotine is attrib-
utable in large part to its influence on the brain regions 
associated with reward processes (e.g., the mesolimbic 
dopaminergic system) (Balfour 2004). In a review of posi-
tive-reinforcement theory as applied to nicotine addiction, 
Glautier (2004) suggests several mechanisms underly-
ing positive-reinforcement processes. Besides exerting a 
direct reinforcing action through its effects on core brain-
reward centers, nicotine may enhance the reinforcing 
efficacy of smoking-related cues as a result of priming the 
smoker to selectively attend to those stimuli. In addition, 
nicotine acquires indirect reinforcing actions through its 
Figure 4.3 Associative learning processes in nicotine addiction 
Source: Adapted from Bevins and Palmatier 2004 with permission from Sage Publications Inc. Journals, © 2004.
Note: Connections 1, 2, and 3 reflect the role of the unconditioned stimuli (USs), conditioned stimuli (CSs), and occasion setter, 
respectively. Solid lines “a” and “b” refer to nicotine’s ability to amplify incentive salience. Dashed lines (“a*” through “d*”) denote 
potentially interesting feedback functions in which conditioned associations may be strengthened.
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effect on other behaviors. According to Hogarth and Duka 
(2006), considerable evidence suggests that nicotine- 
conditioned effects are mediated by a smoker’s expecta-
tions of the effects of nicotine coupled with an appetitive 
emotional response that reflects the positive value of nico-
tine to the smoker (e.g., pleasure or relaxation).
Although clearly influential, positive reinforcement 
is not a likely primary motivational influence on persis-
tence in smoking (Baker et al. 2004), except possibly in 
the case of occasional smoking (Shiffman and Paty 2006). 
Unlike expectations of negative reinforcement, such as 
smoking to relieve stress, expectations of positive rein-
forcement do not predict the likelihood of a relapse after 
smoking cessation. This finding indicates that positive-
reinforcement processes may have less motivational sig-
nificance for relapse than do negative-reinforcement 
processes (Wetter et al. 1994). Relapse is less likely to 
occur during positive-affect states than during negative-
affect states (Shiffman et al. 1996c) (see “Trajectory of 
Recovery or Relapse” later in this chapter).
Negative Reinforcement and Learning
Negative reinforcement refers to processes by which 
smoking or nicotine reduces aversive states, such as pain, 
craving, difficulty concentrating, and the negative-affect 
states generally associated with nicotine withdrawal. Nico-
tine addiction is maintained in part because persons learn 
during the early stages of smoking that tobacco use allows 
them to escape aversive states associated with smoking 
abstinence or because they learn later that it helps them to 
avoid these aversive states (Eissenberg 2004). These states 
include irritability and an anxious or depressed mood. 
With continued use of cigarettes by smokers over time, 
the associative link between tobacco use and the relief 
of withdrawal-associated aversive states is strengthened. 
Tiffany and colleagues (2004) hypothesize that a crucial 
phase in the development of nicotine addiction may be 
the transition from experimental smoking to smoking to 
reduce the experience of negative states. 
Baker and colleagues (2004) extend the conceptu-
alization of this negative-reinforcement model of tobacco 
dependence by focusing on the role of negative affect. 
Within this reformulation of negative reinforcement, neg-
ative affect is the core symptom of the nicotine withdrawal 
syndrome that drives a person to smoke to relieve aversive 
states. Traditional negative-reinforcement models have 
emphasized the role of environmental cues, such as inter-
personal conflict, but not internal cues, such as physiolog-
ical symptoms that signal impending withdrawal-related 
states of negative affect. With repeated pairings of nico-
tine withdrawal and smoking to relieve withdrawal, per-
sons addicted to nicotine may learn over time to detect 
internal cues at a level that is not in the immediate aware-
ness of the smoker, especially cues associated with nega-
tive-affect states, regardless of whether they are related to 
withdrawal (Baker et al. 2004). Nicotine operates on both 
aversive withdrawal states and distress associated with 
external stressors, according to Baker and colleagues 
(2004). However, nicotine may be less effective in reduc-
ing negative affect associated with distress from external 
stressors. Consistent with this view, cigarette smoking 
has not been found to attenuate experimentally induced 
negative affect in the laboratory setting (Conklin and 
Perkins 2005). Studies of smoking in real-world settings 
have found little or no association between subjective 
negative affect and smoking behavior (Piasecki 2006). 
Baker and colleagues (2004) further hypothesize that 
smokers acquire a “motivational-processing sequence in 
which interoceptive signals of negative affect engage drug 
self-administration response sequences and may induce 
awareness of the desire or urge to use a drug without 
awareness of the affective origins or setting events for the 
desire” (p. 47). 
The finding that negative-reinforcement processes 
may not be consciously accessible (Baker et al. 2004) 
could contribute to the difficulty smokers experience in 
trying to stop smoking. When negative affect or external 
stressors become sufficiently strong, the person becomes 
aware of them, and the negative affect leads to biases in 
information processing. One example is attentional bias 
for negative affect cues that trigger smoking (Baker et al. 
2004). Although it is provocative, Baker and colleagues’ 
model of negative reinforcement should be viewed as pro- 
visional and requiring validation. Related individual dif-
ferences, such as the inability to tolerate distress, may 
influence learning and conditioning processes (Brown et 
al. 2005). Using momentary ecological assessment, Shiff-
man and Waters (2004) found that rapid increases in 
negative affect exert especially strong influence in precipi-
tating lapses to smoking (see “Trajectory of Recovery or 
Relapse” later in this chapter for a more detailed discus-
sion of smoking relapse). 
Environmental Context
Animal studies confirm the powerful role that envi-
ronmental stimuli play in nicotine self-administration. 
When environmental stimuli are paired with nicotine self-
administration, the extinguished drug-seeking behavior 
is reinstated (Le Foll and Goldberg 2005). The important 
role of environmental context in nicotine addiction is 
observed in its effect on relapse. (For more description, 
see “Trajectory of Recovery or Relapse” later in this chap-
ter.) Studies of smokers consistently report an association 
among exposure to smoking cues, craving, and positive 
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and negative affective states, which could be construed 
as emotional cues followed by return to smoking after an 
attempt to stop (Shiffman 1982; Marlatt and Gordon 
1985). These studies, however, rely on subjectively recalled 
events that may be prone to several types of memory bias. 
Using methods of ecological momentary assessment in 
an electronic diary, Shiffman and colleagues (1996c) con-
firmed that lapses in smoking abstinence were strongly 
associated with being in situations in which smoking was 
permitted, cigarettes were available, and other persons 
were smoking.
Clinical studies have used a cue-exposure paradigm 
to explore the association of smoking cues with craving 
and physiological and behavioral responses. These studies 
are premised on the assumption that they yield insights 
into how environmental and internal stimuli play a role in 
provoking smoking and relapse (Niaura et al. 1988; Cag-
giula et al. 2001; Chiamulera 2005). Stimuli are presented 
in a variety of modes, including photographic and video, 
auditory, in vivo (presence of cigarette paraphernalia or 
smoking by another person), and the use of imagery (e.g., 
request to imagine specific situations). In a meta-analytic 
review, Carter and Tiffany (1999) found that exposure to 
smoking cues increased craving most reliably, followed 
in order by sweat gland activity and heart rate changes. 
Sweating and changes in heart rate probably reflect an 
increased arousal of the sympathetic nervous system. 
Other researchers have noted cue effects on an increase 
in reaction time (Sayette and Hufford 1994), cognitive 
interference on the Stroop test (Munafò et al. 2003), and 
similar paradigms used to assess attentional interfer-
ence (Mogg and Bradley 2002). Imaging studies of cue 
responses also suggest that neural activity is greatest in 
brain areas involved in emotion and reward, including the 
prefrontal cortex, limbic lobe (anterior cingulate, poste-
rior hippocampus, and right posterior amygdala), medial 
thalamus, and midbrain structures (ventral tegmentum) 
(Due et al. 2002; McClernon and Gilbert 2004; David et 
al. 2005). 
Exposure to smoking cues among smokers also 
decreases the prepulse inhibition of the acoustic startle 
reflex, an effect associated with an increase in dopaminer-
gic activity in the ventral tegmental brain region (Hutchi-
son et al. 1999b). The effects of smoking cues on neural 
responses and craving are also moderated by factors such 
as the perceived availability of cigarettes. After cue expo-
sure, craving increased more when there is an expectation 
of the opportunity to smoke (perceived availability) than 
when there is perceived unavailability (Carter and Tiffany 
1999). Exposure to a cigarette cue under the condition 
of perceived availability is associated with an increase in 
activation of the ventromedial prefrontal cortex and a 
decrease in activation of the dorsolateral prefrontal cortex 
compared with exposure to a neutral cue (Wilson et al. 
2004). This pattern of neural activation with correspond-
ing increases in craving can be seen as setting the stage for 
behaviors that culminate in smoking.
Responses to cues in laboratory experiments are 
associated with responses to smoking cessation treat-
ments. For example, acute increases in heart rate assessed 
among smokers in response to a cue exposure at the end 
of a treatment protocol were related to a later relapse to 
smoking (Niaura et al. 1989). An acute deceleration in 
heart rate assessed when smokers observed a cigarette 
being lit during the cue-exposure procedure also predicted 
relapse. Heart rate deceleration in this context may reflect 
a greater attention paid to the stimulus (e.g., a lit ciga-
rette). Subsequently, Waters and colleagues (2004) found 
that a cue-provoked craving before treatment predicted 
relapse, but only among those who were treated with an 
active nicotine patch instead of a placebo patch, suggest-
ing inconsistent results or uncertainty in the link between 
cue-provoked craving in the laboratory and relapse. 
If cue-provoked responses assessed in the laboratory 
are associated with smoking relapse, then treatments that 
decrease or blunt these responses may increase the likeli-
hood of successful smoking cessation. A review by Conklin 
and Tiffany (2002) suggests that conventional extinction-
type treatments, such as exposure to smoking-related 
cues unaccompanied by the reinforcing effects of nicotine 
or exposure with response-prevention treatments, are 
ineffective in helping persons to stop smoking. This find-
ing may relate to the possibility that stimulus-response 
pairing, if sufficiently strong, cannot be forgotten or 
unlearned (LaBar and LeDoux 2001; Conklin and Tif-
fany 2002; Niaura 2002). In addition, the large number of 
potential cues likely serves to maintain smoking behav-
ior or the state-dependent learning processes. How-
ever, methods such as use of denicotinized cigarettes or 
antagonists (e.g., mecamylamine) show significant effects 
on reducing the rewarding value of smoking cues and 
have the potential to enhance smoking cessation (Rose 
and Behm 2004; Rose 2006). Other cognitive or behav-
ioral methods based in modern learning theory may also 
show more promise in suppressing the stimulus-response 
bond. Pharmacologic treatments show some promise in 
decreasing cue reactivity. Compared with a placebo gum, 
nicotine polacrilex gum diminished the craving response 
to smoking cues more rapidly (Shiffman et al. 2003). In 
a study using the same cue-exposure paradigm, a more 
recent formulation of a rapid-release nicotine gum 
reduced craving more than did conventional nicotine 
polacrilex gum (Niaura et al. 2005). Nicotine polacri-
lex gum is an effective smoking cessation aid (Silagy et 
al. 2004). Its efficacy may be associated with its ability to 
diminish a cue-provoked craving. 
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Other rapid-release formulations of nicotine 
replacement therapy (NRT), including gum and nasal 
spray, may similarly help persons to stop smoking, in part 
because these formulations decrease the craving response 
to cues. In contrast, although slower-releasing NRT for-
mulations (e.g., a nicotine patch) appear to lower absolute 
levels of craving, these formulations do not blunt cue-
provoked craving (Tiffany et al. 2000; Waters et al. 2004). 
One study has suggested that treatment with bupropion 
blunts cue-provoked craving, but the study did not con-
trol for abstinence status (Brody et al. 2004a). Other non-
nicotine compounds (e.g., naltrexone and olanzapine) also 
may blunt cue-provoked craving (Hutchison et al. 1999a, 
2004). This finding suggests that the cue-exposure para-
digm may be a useful screening tool for testing pharmaco-
logic aids to smoking cessation; however, further studies 
need to be conducted to better understand why some med-
ications affect cue-induced cravings and others do not.
Summary and Future Directions
Long-term exposure to nicotine produces biologic 
adaptations leading to reduced sensitivity to some of the 
effects of nicotine (tolerance) and symptoms of distress 
soon after cessation of drug use (withdrawal). Toler-
ance of nicotine in adolescent smokers may be related to 
onset of drug dependence, even though tolerance in adult 
smokers does not appear to be related to different indices 
of nicotine addiction. Withdrawal symptoms, especially 
self-reported cravings and negative affect, are related to 
some indices of addiction. A narrower focus on the indi-
vidual withdrawal symptoms most strongly related to 
relapse, such as negative affect (e.g., depressed mood), 
may increase understanding of the underlying mecha-
nisms associated with the maintenance of nicotine addic-
tion and requires further study. 
Positive reinforcement from nicotine may play 
a more significant role in the initiation of smoking, 
and negative reinforcement, particularly relief from 
withdrawal, is an important contributor to the persistence 
of smoking and relapse. Measures of nicotine’s reinforc-
ing	 effects,	 especially	 the	most	 common	measure—self- 
reported	number	of	cigarettes	smoked	per	day—are	con-
sistently related to other indices of addiction, including 
the risk of relapse. However, other objective measures of 
nicotine’s reinforcing effects, especially those reflecting 
persistence in smoking behavior, may provide even stron-
ger markers of addiction for predicting clinical outcomes 
and for testing the efficacy of new treatments or tobacco 
products. Such measures may also be useful as endophe-
notypes of dependence for future research into the eti-
ology of addiction, including the influence of a person’s 
genetic composition. Therefore, the development of these 
validated markers and measures for nicotine and smoking 
reinforcement is critical for future research examining 
the etiology and treatments for nicotine addiction and for 
tobacco product testing.
Nicotine addiction results not only from the phar-
macodynamic effects of nicotine but also from associative 
learning and conditioning. Nicotine serves not only as a 
US, but can also serve as a CS and a modifier of associative 
processes. Motivational influences on persistent smok-
ing are more likely tied to negative reinforcement than to 
positive reinforcement. 
Interoceptive (internal) cues of negative affect have 
been linked to craving and relapse, whereas positive affec-
tive states are less likely to lead to relapse. Exteroceptive 
(environmental) cues also play an important role in elicit-
ing craving and relapse. Reactivity to both internal and 
environmental cues may provide another measure of nico-
tine addiction. Factors such as age, gender, and psychiat-
ric comorbid history are important to consider in future 
research, because they have or may have an important role 
in moderating responses to nicotine (see “Epidemiology of 
Tobacco Use and Nicotine Dependence in Adults” later in 
this chapter). Because of the importance of learning in the 
development and maintenance of nicotine addiction, this 
is an area that requires more extensive research.
Pathophysiology of Nicotine Addiction
Because nicotine is one of the primary constituents 
responsible for tobacco addiction, research to promote 
an understanding of the neurobiology of tobacco addic- 
tion focuses on the mechanisms mediating nicotine 
addiction. As noted previously, dependence on nicotine 
is characterized by both the persistence of a drug-taking 
behavior and the emergence of withdrawal symptoms on 
abrupt cessation of nicotine administration (Wikler 1973; 
Levine 1974; Stewart et al. 1984; Ludwig 1986; O’Brien et 
al. 1990; Hughes and Hatsukami 1992; Koob et al. 1993; 
Markou et al. 1993, 1998; APA 1994; Kenny and Markou 
2001). Therefore, both the neurosubstrates (brain struc-
tures, pathways, and systems) mediating the reinforc-
ing effects of acute administration of nicotine and those 
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mediating the nicotine withdrawal syndrome are rel-
evant to drug dependence. The physiological systems that 
develop adaptations to repeated nicotine administration 
and lead to the emergence of withdrawal signs on cessa-
tion of nicotine administration are likely to intersect with 
systems that mediate the acute effects of nicotine (Markou 
et al. 1998; Kenny and Markou 2001). That is, drug depen-
dence develops as a neurobiologic adaptation to chronic 
drug exposure. 
Accordingly, this section first reviews the systems 
and pathways mediating the reinforcing effects of nico-
tine and then discusses the neuroadaptations that occur 
because of chronic nicotine exposure. These neurobio-
logic adaptations mediate the tolerance to and effects of 
withdrawal from nicotine that are interlinked in most 
theoretical conceptualizations. Researchers have hypoth-
esized that the sensitization to the locomotor-activating 
effects of drugs, including effects observed after repeated 
nicotine administrations, reflect a progressive augmenta-
tion in the motivation to self-administer the drug (Robin-
son and Berridge 1993). (The locomotor-activating effects 
consist of progressively increased locomotor responses to 
repeated drug-challenge injections.) However, no direct 
evidence suggests that sensitization to the locomotor-
activating effects of nicotine reflects any aspect of depen-
dence on nicotine. Therefore, sensitization is not covered 
in this section. If sensitization to the reinforcing effects of 
nicotine develops, it will most likely be relevant to early 
phases of tobacco use involving the acquisition of tobacco 
smoking as a continuing behavior. 
The final discussion focuses on the comorbidity 
of nicotine dependence and psychiatric disorders in the 
context of shared substrates that mediate nicotine depen-
dence and depression-like aspects of psychiatric disorders 
(Markou et al. 1998; Markou and Kenny 2002; Paterson 
and Markou 2007).
Nicotinic Acetylcholine Receptors
Nicotine, an alkaloid in concentrations of approxi-
mately 1 to 3 percent in tobacco (Browne 1990), is an 
agonist at the nicotinic acetylcholine receptors (nAChRs) 
expressed both in the peripheral nervous system and the 
CNS (Henningfield et al. 1996; Vidal 1996; Holladay et 
al. 1997; Paterson and Norberg 2000). Similar to other 
ligand-gated ion channels, neuronal nAChRs are com-
posed of five membrane-spanning subunits that combine 
to form a functional receptor (Lindstrom et al. 1996; 
Role and Berg 1996; Albuquerque et al. 1997; Lèna and 
Changeux 1998, 1999; Dani 2000; Gotti et al. 2006). Neu-
ronal nAChR subunits are arranged in different combina-
tions to form nAChRs with distinct pharmacologic and 
kinetic properties. The neuronal α subunit exists in nine 
isoforms (α2 through α10), whereas the neuronal β sub-
unit exists in three isoforms (β2, β3, and β4) (Arneric et 
al. 1995; Wonnacott 1997; Elgoyhen et al. 2001). Study 
of oocyte expression systems injected with pairwise com-
binations of different neuronal α and β subunits indicate 
that these subunits combine with a stoichiometry of 
2α:3β to produce a functional neuronal nicotinic hetero-
oligomeric receptor (Deneris et al. 1991; Conroy and Berg 
1995; Colquhoun and Patrick 1997). In contrast, α7, α8, 
and α9 subunits form homo-oligomeric complexes com-
posed of five α subunits and no β subunits (Chen et al. 
1998). Only the α7 pentamer is expressed in the CNS.
Neuronal nAChRs in rats are divided broadly into 
three classes: (1) those with a high-affinity binding site for 
racemic	 nicotine—the	 nAChRs	 containing	 α4, of which 
the α4β2 combination is the most abundant (Flores et al. 
1992; Picciotto et al. 1995); (2) those with a high affinity 
for the radioiodine [125I]α-bungarotoxin that correspond 
to the homomeric α7 nAChRs (Clarke 1992); and (3) 
those	with	a	high	affinity	for	neuronal	bungarotoxin—the	
α3-containing nAChRs (Schulz et al. 1991). The precise 
combinations of nAChR subunits that constitute active 
brain nAChRs in vivo have been primarily inferred from 
their pharmacologic profile (Sershen et al. 1997; Kaiser et 
al. 1998; Luo et al. 1998; Sharples et al. 2000). However, 
advances have identified nAChR subunits expressed by 
individual neurons in specific brain regions (Lèna et al. 
1999; Sheffield et al. 2000).
The predominant role of nAChRs in the brain is 
the modulation of neurotransmitter release, because 
nAChRs are situated primarily on presynaptic terminals 
(Wonnacott 1997). Nevertheless, nAChRs are also found 
at somatodendritic, axonal, and postsynaptic sites (Sar-
gent 1993). As a result of actions at the nAChR sites, 
nicotine stimulates the release of most neurotransmitters 
throughout the brain (Araujo et al. 1988; Toide and Arima 
1989; McGehee and Role 1995; Gray et al. 1996; Role and 
Berg 1996; Wilkie et al. 1996; Albuquerque et al. 1997; 
Alkondon et al. 1997; Kenny et al. 2000; Grady et al. 2001). 
Therefore, as discussed in the next section, various trans-
mitter systems are likely to be involved in the rewarding 
effects of nicotine and in the adaptations that occur in 
response to chronic exposure to nicotine, which give rise 
to dependence and withdrawal responses.
Neurosubstrates of Nicotine 
Reinforcement
The mesocorticolimbic brain system in the mid-
brain of mammals is composed of interconnected brain 
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structures. This system has been shown to be critically 
involved in the effects of drugs of abuse (Koob 2008). 
Among the main components of this system are the 
dopaminergic neurons originating in the ventral teg-
mental area (VTA) and projecting to the nucleus 
accumbens and the frontal cortex. The activity of these 
VTA dopamine neurons is regulated by the release of the 
excitatory neurotransmitter glutamate from neuronal 
projections originating from several sites, including the 
nucleus accumbens and the frontal cortex. Other inputs 
that also regulate activity of the mesolimbic system are 
(1) γ-aminobutyric acid (GABA) inhibitory interneurons 
located within the VTA and the nucleus accumbens and (2) 
cholinergic projections from brainstem nuclei to the VTA. 
These cholinergic projections release the endogenous 
neurotransmitter acetylcholine, which acts on excitatory 
nAChRs located on glutamate and GABA neuronal termi-
nals in the VTA (Figure 4.4). Extensive investigations over 
decades have conclusively demonstrated a critical role of 
the mesocorticolimbic system and its connections in sev-
eral behavioral and affective responses to drugs of abuse. 
Dopamine and Nicotinic Acetylcholine Receptors
As with other drugs of abuse, it has been demon-
strated that the mesolimbic dopaminergic system and 
nAChRs within that system are critically involved in the 
reinforcing properties of nicotine (Watkins et al. 2000; 
Picciotto and Corrigall 2002; Balfour 2004). Acute admin-
istration of nicotine increased the firing rate of dopaminer-
gic neurons in the VTA (Grenhoff et al. 1986; Pidoplichko 
et al. 1997) and elevated dialysate levels of dopamine in 
the shell of the nucleus accumbens (Imperato et al. 1986; 
Damsma et al. 1989; Mifsud et al. 1989; Benwell and Bal-
four 1992; Pontieri et al. 1996; Nisell et al. 1997; Carboni 
et al. 2000). These effects of nicotine may occur through 
excitatory actions at nAChRs on the mesolimbic dopami-
nergic neurons in both the VTA and the nucleus accum-
bens and at nAChRs located on local neuronal circuitry 
within these brain regions (McGehee and Role 1996; Nisell 
et al. 1997; Teng et al. 1997). The nAChRs in the VTA play a 
more important role than those in the nucleus accumbens 
in the effects of nicotine on the release of dopamine from 
the nucleus accumbens (Nisell et al. 1994a,b, 1997). 
Several findings support the conclusion that nAChRs 
located within the VTA are involved in nicotine reinforce-
ment. Intravenous nicotine self-administration is a proce-
dure that allows the assessment of the reinforcing effects 
of nicotine by measuring the number of infusions a rat 
chooses to receive intravenously through an indwelling 
permanent catheter by pressing a lever during one-hour 
daily sessions in a testing chamber. Each of four factors 
decreased intravenous nicotine self-administration in rats 
(Picciotto and Corrigall 2002). The factors were (1) injec-
tions of the competitive nAChR antagonist DHβE into the 
VTA (Williams and Robinson 1984) but not the nucleus 
accumbens (Corrigall et al. 1994), (2) development of 
lesions of the mesolimbic dopaminergic projections from 
the VTA to the nucleus accumbens (Corrigall et al. 1992), 
(3) development of cholinergic lesions of the brainstem 
pedunculopontine tegmental nucleus that project to the 
VTA (Lança et al. 2000), and (4) systemic administration 
of dopamine receptor antagonists (Corrigall and Coen 
1991b). Studies suggest an involvement of the nAChR 
subtypes containing a4β2 in both the nicotine-induced 
release of dopamine and nicotine reinforcement (Picciotto 
et al. 1998; Schilström et al. 1998b; Watkins et al. 1999; 
Grillner and Svensson 2000; Sharples et al. 2000). In addi-
tion, mutant mice with hypersensitive α4 nAChRs show a 
50-fold increase in sensitivity to the reinforcing effects of 
nicotine measured by a place-preference procedure (Tap-
per et al. 2004). A place-preference procedure assesses the 
rewarding effects of a drug by measuring the preference a 
rat exhibits for a compartment previously associated with 
the effects of a drug instead of a compartment associated 
with an injection of saline. The place-preference finding 
by Tapper and colleagues (2004) further indicates a criti-
cal role of α4 nAChRs in nicotine reinforcement. The α7 
homomeric receptors may be involved in the reinforc-
ing effects of nicotine. Methyllycaconitine, an antagonist 
with limited selectivity for the α7 nAChR, decreased the 
intravenous nicotine self-administration procedure in 
rats (Markou and Paterson 2001), although another study 
with rats showed no effects of this antagonist on nicotine- 
induced hyperactivity or nicotine self-administration 
(Grottick et al. 2000). Finally, both the α4β2 and α7 sub-
types are implicated in the effects of nicotine on mem-
ory (Levin et al. 1999; Bancroft and Levin 2000) and the 
anxiolytic effects of nicotine (Gordon 1999; Cheeta et al. 
2001), which also contribute to persistent tobacco use 
(USDHHS 1988).
Glutamate
Other mechanisms by which nicotine may elevate 
striatal dopamine levels include increases in excitatory 
glutamatergic inputs from the frontal cortex to the 
nucleus accumbens and/or excitatory glutamatergic 
inputs to VTA dopaminergic neurons projecting to the 
striatum. Nicotine increases the release of glutamate by 
agonist actions at excitatory presynaptic nAChRs on glu-
tamatergic terminals in various brain sites, including the 
VTA (Fu et al. 2000; Grillner and Svensson 2000; Mans-
velder and McGehee 2000), nucleus accumbens (Reid 
et al. 2000), prefrontal cortex (Gioanni et al. 1999), and 
hippocampus (Gray et al. 1996). In the VTA, nicotine acts 
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Figure 4.4 Neural pathways for γ-aminobutyric acid, glutamate, dopamine, and excitatory neurotransmitters
Source: Markou 2006. Reprinted with permission from Wiley-Blackwell, © 2006.
Note: The circular symbol with the reverse arrow attached to it depicts a neuron. The circle is the cell body, and the reverse arrow is 
the terminal that releases neurotransmitter(s) out of its open site into the synapse at the indicated projection brain site. The minus 
sign (-) indicates inhibitory input of the neurotransmitter, and the plus sign (+) indicates excitatory input of the neurotransmitter. 
Some neurons are interneurons projecting within a particular brain site, and other neurons project from one brain site to another 
distant brain site. GABA = γ-aminobutyric acid; nAChR = nicotinic acetylcholine receptor; mGluR2/3 = metabotropic glutamate 2/3 
receptor; VTA = ventral tegmental area.
at presynaptic α7 nAChRs located on glutamate neurons 
(neurons that release glutamate as the primary neu-
rotransmitter). Activation of these α7 nAChRs on gluta-
mate neurons (Mansvelder and McGehee 2000) increases 
the release of glutamate in the VTA. This activity, in turn, 
stimulates the release of dopamine in the nucleus accum-
bens (Nisell et al. 1994a,b; Schilström et al. 1998a,b; Fu 
et al. 2000; Mansvelder and McGehee 2000). That is, this 
increased release of glutamate acts at metabotropic and 
ionotropic glutamate receptors located on postsynaptic 
dopamine neurons (neurons that have dopamine as the 
primary neurotransmitter). Activation of these glutamate 
receptors leads to excitation of the dopamine neurons that 
results in increased release of dopamine in terminal brain 
sites where these neurons project, such as the nucleus 
accumbens, the amygdala, and the frontal cortex. 
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Ionotropic antagonists of N-methyl-d-aspartate 
receptors blocked (prevented) tolerance to the locomo-
tor depressant effects of acute nicotine administration 
(Shoaib and Stolerman 1992; Shoaib et al. 1994) and 
blocked sensitization to the locomotor stimulant effects 
of chronic nicotine administration (Shoaib and Stoler-
man 1992). Most relevant to addiction is the finding that 
blockade of the postsynaptic metabotropic glutamate 
receptor subtype 5 (mGluR5) with 2-methyl-6-(phenyl- 
ethynyl)pyridine (MPEP) decreased intravenous nicotine 
self-administration in rats and mice (Paterson et al. 2003) 
and decreased the motivation to self-administer nicotine 
(Paterson and Markou 2005). These effects are likely me-
diated by decreasing the nicotine-stimulated release of 
dopamine in the mesolimbic system. At doses that blocked 
nicotine self-administration, MPEP had no effect on 
response for food (Paterson et al. 2003). The progressive-
ratio schedule of reinforcement, which gradually increases 
the response requirements after each earned reward, 
allows the assessment of the motivation for reinforcers, 
such as nicotine or food, by evaluating the maximal num-
ber of responses emitted by the rat (i.e., breaking point) to 
receive a single intravenous infusion of nicotine or a single 
food reward. In this schedule, MPEP had a greater effect on 
motivation for nicotine than on motivation for food, even 
when the magnitudes of reinforcer value were equated to 
support equal breaking points for nicotine and food un-
der baseline conditions (Paterson and Markou 2005). This 
selectivity of the MPEP effects for nicotine reinforcement 
versus food reinforcement suggests that MPEP selectively 
blocks the reinforcing effects of nicotine without affecting 
motor performance or food reinforcement. Furthermore, 
evidence suggests a potential role of ionotropic glutamate 
receptors in the effects of nicotine. Animals that self- 
administered nicotine chronically exhibited an increase in 
ionotropic glutamate receptor subunits in brain regions, 
such as the VTA and the frontal cortex, that are implicated 
in the reinforcing effects of nicotine (Wang et al. 2007).
γ-Aminobutyric Acid
GABA is the major inhibitory transmitter in the 
brain and is another transmitter system critically involved 
in the reinforcing effects of acute nicotine administra-
tion. Several factors inhibit the release of mesolimbic 
dopamine, including inhibitory GABA transmission on 
ascending afferents to dopaminergic VTA neurons from 
the pedunculopontine tegmental nucleus (Walaas and 
Fonnum 1980; Yim and Mogenson 1980), descending 
GABA-ergic inputs from the ventral pallidum and the 
nucleus accumbens, GABA interneurons within the VTA, 
and medium spiny GABA neurons in the nucleus accum-
bens (Walaas and Fonnum 1979; Heimer and Alheid 1991; 
Churchill et al. 1992; Dewey et al. 1992; Kalivas et al 1992; 
Klitenick et al. 1992; Sugita et al. 1992; Engberg et al. 
1993). As suggested by this neuroanatomy and extensive 
electrophysiological studies, interactions between the 
GABA, dopaminergic, and glutamatergic systems in the 
VTA are complex (Mansvelder and McGehee 2000; Mans-
velder et al. 2002). Glutamate afferents to the VTA excite 
dopamine neurons, and GABA-ergic afferents to the VTA 
inhibit dopamine neurons. Excitatory nAChRs are located 
on both glutamate and GABA-ergic neurons. The nAChRs 
on GABA neurons desensitize quickly to chronic adminis-
tration of nicotine, but the nAChRs on glutamate neurons 
require higher doses of nicotine for desensitization. This 
delicate balance leads to a nicotine-induced increase in 
the release of dopamine in the nucleus accumbens, the 
terminal area of VTA neurons (Schilström et al. 1998b; 
Mansvelder and McGehee 2000). Similar transmitter 
interactions may also occur in other brain sites.
Increased GABA-ergic transmission abolishes 
both the nicotine-induced increases in dopamine in the 
nucleus accumbens and the reinforcing effects of nico-
tine (Dewey et al. 1999; Brebner et al. 2002). Systemic 
injections of γ-vinyl GABA (vigabatrin) increased GABA 
levels and decreased nicotine self-administration in rats 
(Paterson and Markou 2002). Vigabatrin is an irrevers-
ible inhibitor of GABA transaminase, the primary enzyme 
involved in GABA metabolism (Jung et al. 1977; Lippert 
et al. 1977). Systemic injections of vigabatrin also abol-
ished the expression and acquisition of nicotine-induced 
conditioned place preference (Dewey et al. 1998). The 
administration of vigabatrin also lowered nicotine- 
induced increases in dopamine in the nucleus accum-
bens in both untreated rats and those receiving long-term 
treatment with nicotine in a dose- and time-dependent 
manner measured by in vivo microdialysis. In addition, 
vigabatrin abolished nicotine-induced increases in stria-
tal dopamine in primates, as determined by PET scan 
(Brebner et al. 2002). 
The use of receptor-selective agonists in animals 
suggests the involvement of GABAB receptors in the 
reinforcing effects of nicotine. Systemic injections or 
microinjections of baclofen or CGP44532 [(3-amino- 
2[S]-hydroxypropyl)-methylphosphinic	acid]—two	GABAB 
receptor	agonists—into	the	nucleus	accumbens	shell,	the	
VTA, or the pedunculopontine tegmental nucleus that 
sends cholinergic, GABA-ergic, and glutamatergic projec-
tions to the VTA decreased the reinforcing effects of nico-
tine (Shoaib et al. 1998; Corrigall et al. 2000, 2001; Fattore 
et al. 2002; Paterson et al. 2004). However, injections 
into the caudate-putamen did not have these effects. The 
decreases in nicotine self-administration persisted even 
after administration of CGP44532 for 14 days, indicating 
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little tolerance to this effect of the GABAB receptor agonist 
with this duration of treatment (Paterson et al. 2005b); 
that is, the reduction in nicotine self-administration 
persisted over time. The issue of tolerance is important 
because long-term administration of drug therapies is 
necessary to achieve smoking cessation. However, in stud-
ies of rats, vigabatrin and GABAB receptor agonists also 
decreased response for food, although at doses higher than 
the threshold doses for inducing decreases in nicotine 
self-administration (Paterson and Markou 2002; Paterson 
et al. 2004, 2005b). These effects on response for food may 
reflect nonspecific effects on performance by GABA-ergic 
compounds or specific effects on food intake. The possibil-
ity of effects on food intake is intriguing, because weight 
gain associated with abstinence from smoking is often a 
concern for smokers, especially women, who want to stop 
smoking cigarettes.
Thus, increased GABA transmission through the 
activation of GABAB receptors blocks the reinforcing 
effects of nicotine. However, a clinical study shows that 
one dose of baclofen had no effect on either the number 
of cigarettes smoked or the craving for nicotine (Cousins 
et al. 2001). Nevertheless, other clinical studies show that 
long-term administration of baclofen reduced abuse of 
cocaine and alcohol, as well as cue-induced brain activa-
tion (Ling et al. 1998; Addolorato et al. 2000, 2002a,b). 
Therefore, long-term treatment with these GABA-ergic 
drugs may first be required to reduce tobacco smoking.
Opioid, Endocannabinoid, and Serotonin Systems
The data on the possible role of opioid systems in 
the rewarding effects of nicotine remain inconclusive. 
Nicotine did not induce a conditioned place preference 
in µ-opioid receptor *NULL-mutant mice, but it did so 
in wild-type animals (Berrendero et al. 2002). Similarly, 
nicotine induced a conditioned place preference in wild-
type but not in preproenkephalin *NULL-mutant mice. 
A nicotine-induced elevation in dopamine overflow in 
the nucleus accumbens was absent in *NULL mutants 
(Berrendero et al. 2005). However, systemic or intra-VTA 
administration of the opiate receptor antagonist naltrex-
one or the opiate receptor agonist d-Ala2,N-Me-Phe4-Gly-
ol-enkephalin, respectively, had limited or no effects on 
nicotine self-administration in rats (Corrigall and Coen 
1991a; Corrigall et al. 2000). 
In humans, acute and short-term nicotine adminis-
tration leads to the release of β-endorphins, endogenous 
opioid peptides that have reinforcing effects (Davenport 
et al. 1990; Boyadjieva and Sarkar 1997). Furthermore, in 
humans, the acute administration of naltrexone decreased 
the reinforcing value of nicotine in a procedure involving 
choice between puffs on nicotinized versus denicotinized 
cigarettes (i.e., compared with placebo, naltrexone signifi-
cantly reduced the number of nicotine cigarette choices) 
(Rukstalis et al. 2005). This result is consistent with a pre-
vious finding that acute administration of naltrexone sig-
nificantly decreased the total number of choice cigarettes 
smoked (e.g., subjects were given a choice to smoke four 
cigarettes in a two-hour period of time) (Epstein and King 
2004). However, a randomized, double-blind trial of nal-
trexone for smoking cessation found only a nonsignificant 
trend toward increased cessation rates, and the effect dis-
appeared at 12 months after cessation (Covey et al. 1999). 
Other clinical trials examining the effects of naltrexone 
versus placebo in smokers who were assigned nicotine 
patches to aid cessation have also observed no significant 
effects of naltrexone on improving treatment outcomes 
(King et al. 2006; O’Malley et al. 2006). Thus, the possible 
involvement of the opiate system in the reinforcing effects 
of nicotine remains at best unclear, and the use of opi-
ate antagonists as treatments for dependence on tobacco 
smoking appears unwarranted. A Cochrane review in 2001 
concluded that opioid antagonists failed to significantly 
increase long-term abstinence from smoking on the 
basis that the limited evidence was insufficient to support 
a conclusive finding on whether naltrexone is an aid to 
smoking cessation (David et al. 2006). Although one study 
suggested an effect of gender, women benefited more than 
men from treatment with naltrexone (King et al. 2006).
The evidence is much stronger for the role of 
serotonin in the reinforcing effects of nicotine. Acute 
administration of nicotine elevated extracellular serotonin 
in the nucleus accumbens (Schiffer et al. 2001) and the 
VTA (Singer et al. 2004). Serotonin was also implicated 
in a neurochemical sensitization to nicotine, which some 
researchers hypothesize to be relevant to aspects of nico-
tine dependence. The administration of the serotonin 
(5HT2) receptor agonist (±)-2,5-dimethoxy-4-iodoam-
phetamine (Olausson et al. 2001) or the 5HT2C receptor 
agonist (S)-2-(chloro-5-fluoro-indol-1-yl)-1-methylethyl-
amine fumarate (Di Matteo et al. 2004) blocked the in-
creased overflow of serotonin observed after a nicotine 
challenge in nicotine-treated rats. In addition, nicotine 
increased serotonin overflow in cortical areas (Toth et al. 
1992; Ribeiro et al. 1993; Summers and Giacobini 1995; 
Singer et al. 2004) and in the dorsal hippocampus (Singer 
et al. 2004). In contrast, Balfour and Ridley (2000) found a 
decrease in the serotonin overflow after acute administra-
tion of nicotine. However, Singer and colleagues (2004) 
used anesthetized rats, and Balfour and Ridley (2000) 
used in vivo microdialysis in conscious rats. In addition, 
administration of nicotine for at least 20 days was asso-
ciated with decreased serotonin levels in the dorsal hip-
pocampus (Benwell and Balfour 1979; Balfour and Ridley 
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2000). However, nicotine administration for 14 days was 
associated with increased serotonin levels (Takada et al. 
1995). Nicotine infusion into the ventromedial nuclei 
or the lateral hypothalamic area increased the release of 
serotonin in this area (Yang et al. 1999; Ramos et al. 2004). 
Together, the findings suggest that acute administration 
of nicotine increases serotonin levels but that long-term 
administration leads to decreases in serotonin levels that 
may mediate the affective aspects of nicotine dependence 
and withdrawal (Harrison et al. 2001).
Studies provide conflicting evidence on the role 
of cannabinoid subtype 1 (CB1) receptors in modulating 
the reinforcing effects of nicotine. CB1 knockout mice 
(i.e., mice genetically engineered to lack CB1 receptors) 
self-administered nicotine (Cossu et al. 2001) but did not 
exhibit conditioned place preference to nicotine (Castañe 
et al. 2002). Furthermore, the CB1 receptor antagonist 
rimonabant (SR141716) decreased nicotine seeking and 
self-administration of nicotine induced by the presenta-
tion of conditioned cues and also attenuated a nicotine-
induced release of dopamine in the nucleus accumbens 
shell (Cohen et al. 2002, 2005; De Vries et al. 2005). Thus, 
the data from experimental studies of rodents on the role 
of the cannabinoid system are inconclusive and so are 
the clinical data (Le Foll and Goldberg 2005). However, 
an analysis of data pooled from three clinical trials of 
rimonabant compared with a placebo showed modest suc-
cess at the end of treatment (Cinciripini et al. 2006).
Norepinephrine
Data also suggest a role of norepinephrine in the 
effects of nicotine. Acute nicotine administration increases 
extracellular norepinephrine in the nucleus accumbens, 
the hippocampus, and the cortex in rats (Brazell et al. 
1991; Mitchell et al. 1993; Summers and Giacobini 1995; 
Benwell and Balfour 1997; Schiffer et al. 2001). Nicotine-
evoked hippocampal release of norepinephrine in vivo was 
attenuated by α-bungarotoxin but was unaffected by either 
of the nAChR antagonists mecamylamine or DHβE, im-
plicating α7 nAChRs, rather than α4β2 nAChRs associated 
with the release of norepinephrine in this region of the 
brain (Fu et al. 1999). However, norepinephrine release 
from hippocampal synaptosomes in rats was sensitive to 
mecamylamine, DHβE, and methyllycaconitine suggest-
ing that the release of norepinephrine may not be specific 
to α7 nAChRs (Clarke and Reuben 1996). Additional stud-
ies suggest the role of norepinephrine in nicotine’s effects. 
Intravenous self-administration of nicotine increased 
norepinephrine concentrations in the amygdala and the 
hypothalamic paraventricular nucleus (Fu et al. 2001, 
2003). In vitro studies indicated that nicotine increased 
release of norepinephrine in (1) prefrontal cortex slices of 
rats (Rao et al. 2003) and (2) locus coeruleus neurons of 
fetal rats grown in cultures (Gallardo and Leslie 1998). 
Consistent with these neurochemical findings, 
short-term or long-term administration of reboxetine, 
the selective noradrenaline reuptake inhibitor, decreased 
nicotine self-administration in rats (Rauhut et al. 2002). 
However, reboxetine also decreased sucrose-maintained 
response, although to a lesser degree than nicotine-
maintained response. Reboxetine acts as a noncompetitive 
nAChR antagonist, in addition to blocking noradrenaline 
reuptake (Miller et al. 2002). Thus, it is not conclusive that 
the effects of reboxetine on nicotine self-administration 
are attributable to its effects on noradrenaline reuptake 
rather than to its actions as an nAChR antagonist. 
Bupropion, a smoking cessation aid, also inhibits 
reuptake of norepinephrine, as well as dopamine (Ferris et 
al. 1983). Administration of bupropion increased extracel-
lular concentrations of dopamine and epinephrine in the 
nucleus accumbens, hypothalamus, and prefrontal cortex 
(Nomikos et al. 1989, 1992; Li et al. 2002). Furthermore, 
electrophysiological studies indicated that bupropion 
decreased the firing rates of dopamine neurons in the 
nucleus accumbens and noradrenergic neurons in the 
locus coeruleus but had no effect on firing of serotonin 
dorsal raphe neurons (neurons located in the dorsal raphe 
firing) (Cooper et al. 1994). 
Despite the demonstrated effects of bupropion on 
neurotransmitter and receptor systems that appear to 
mediate the effects of nicotine, bupropion had inconsis-
tent effects on nicotine self-administration in rats. Some 
studies showed a decrease in nicotine self-administration 
in fixed-ratio schedules of reinforcement but had no effects 
in a progressive-ratio schedule (Glick et al. 2002; Bruijn-
zeel and Markou 2003). In contrast, another study (Shoaib 
et al. 2003) indicated that repeated daily administration 
of bupropion increased nicotine self-administration in a 
fixed-ratio schedule, but the results were not significant 
(Shoaib et al. 2003). Finally, Rauhut and coworkers (2003) 
showed that low doses of bupropion increased and high 
doses of bupropion decreased nicotine self-administration 
and response for sucrose. 
In summary, these findings suggest a strong 
effect of nicotine on transmission of norepinephrine, but 
bupropion, which inhibits the reuptake of both dopamine 
and norepinephrine, has inconsistent effects on nicotine 
self-administration in rodents. Thus, other properties of 
bupropion, such as relief from withdrawal symptoms, may 
contribute to its efficacy as an aid to smoking cessation. 
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Neurosubstrates of Nicotine 
Dependence and Withdrawal
Nicotine Withdrawal Syndrome in Rodents
Smoking cessation leads to an aversive withdrawal 
syndrome lasting one to four weeks after cessation (Shiff-
man et al. 2004b). As noted previously, this withdrawal 
syndrome has affective, behavioral, somatic, and cognitive 
components (see “Physiological Mechanisms and Indica-
tors: Nicotine Tolerance, Withdrawal, and Reinforcement” 
earlier in this chapter). The nicotine withdrawal syndrome 
is considered an important motivational factor that con-
tributes to the perpetuation of nicotine dependence and 
continuing behaviors related to tobacco smoking (Mar-
kou et al. 1998; Kenny and Markou 2001). Withdrawal 
signs are often opposite to the acute effects of the drug 
(e.g., improved concentration versus poor concentration), 
probably reflecting the finding that the development of 
nicotine dependence leads to changes in brain function to 
counteract the acute effects of nicotine (e.g., increase in 
receptor number). 
One of the first and most widely used measures 
developed to investigate the neurobiology of the nicotine 
withdrawal syndrome and nicotine dependence is the fre-
quency of somatic signs reliably observed in rats, but less 
reliably observed in mice (Malin et al. 1992; Epping-Jordan 
et al. 1998; Hildebrand et al. 1999; Isola et al. 1999; Car-
boni et al. 2000; Malin 2001; Semenova and Markou 2003; 
Salas et al. 2004). The most prominent somatic signs in 
rats are abdominal constrictions (writhes), gasps, ptosis, 
facial fasciculation, and eyeblinks. These somatic signs are 
both centrally and peripherally mediated (Hildebrand et 
al. 1999; Carboni et al. 2000; Watkins et al. 2000; Malin 
2001; Cryan et al. 2003). 
The somatic components of nicotine withdrawal 
are unpleasant. However, avoidance of the negative 
affect and depression-like components of withdrawal may 
play a more important role in the maintenance of nicotine 
dependence than do the somatic aspects of withdrawal 
(Hughes 1992; Kenny and Markou 2001). In rodents, a 
valid and reliable measure of the affective and motiva-
tional aspects of drug withdrawal is the elevation of brain-
reward thresholds observed after cessation of long-term 
administration of nicotine (Epping-Jordan et al. 1998; 
Harrison et al. 2001; Cryan et al. 2003; Semenova and 
Markou 2003). Elevations of reward thresholds are an 
operational measure of “diminished interest or pleasure” 
in rewarding stimuli (i.e., anhedonia), which is a symptom 
of nicotine withdrawal and a core symptom of depression 
(APA 1994). Similar threshold elevations are observed 
during withdrawal from all major drugs of abuse in rodents 
(Kokkinidis et al. 1980; Markou and Koob 1991; Schul-
teis et al. 1994, 1995; Paterson et al. 2000; Spielewoy and 
Markou 2003). Several dissociations have been identified 
between the threshold elevations and the somatic signs of 
nicotine withdrawal, and these observations are similar to 
those in clinical studies (see “Physiological Mechanisms 
and Indicators: Nicotine Tolerance, Withdrawal, and Rein-
forcement” earlier in this chapter). These findings suggest 
that the various aspects of withdrawal are mediated by 
different substrates (Epping-Jordan et al. 1998; Watkins 
et al. 2000; Harrison et al. 2001; Semenova and Markou 
2003). Other rodent models that may be relevant to the 
disruption of behavioral performance in humans involve 
(1) disruptions induced by termination of administration 
of nicotine on behavioral responses maintained by food 
(Carroll et al. 1989); (2) increases in the acoustic startle 
response in rats (Helton et al. 1993); and (3) decreases 
in prepulse inhibition (i.e., decrease in the adaptation 
response to a stronger stimuli after presentation of a prior 
weaker stimuli) in mice (Semenova et al. 2003). 
Important study data indicate that rats with thresh-
old elevations reflecting a reward deficit associated with 
nicotine withdrawal can become conditioned to previously 
neutral environmental stimuli (Kenny and Markou 2005) 
(see “Learning and Conditioning” earlier in this chapter). 
Nicotine-dependent rats were presented with a light and 
tone CS and received injections of the nicotinic recep-
tor antagonist DHβE for four consecutive days before an 
assessment of brain-reward thresholds. This procedure led 
to elevations of brain-reward thresholds in the nicotine-
dependent rats. When the rats were presented with just the 
light and tone CS on the test day, thresholds were again 
elevated, reflecting a conditioned state of negative affect. 
This type of conditioned affective response may lead to a 
relapse to tobacco smoking to alleviate this conditioned 
state of negative affect. This finding may partly explain the 
relapse observed months or even years after a person last 
smoked a cigarette. 
Subsequent data suggest that the experience of 
nicotine withdrawal in male adolescent rats may dif-
fer from that in adult rats. At the time of this review, no 
females have been tested. The evidence for this hypothesis 
is threefold. First, male adolescent rats displayed fewer 
somatic signs of nicotine withdrawal than did adult males. 
Second, although male adolescent rats displayed a con-
ditioned place aversion produced by nicotine withdrawal, 
it was less robust than that seen in adult males. Third, 
adolescent male rats did not display the decreases in 
brain-reward function seen in adult rats experiencing 
withdrawal (O’Dell et al. 2006, 2007).
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Neurochemical Correlates of Nicotine Withdrawal
Several experimental approaches are used to inves-
tigate the neuronal substrates of nicotine dependence and 
withdrawal. In vivo microdialysis studies provide infor-
mation about the neurochemical changes occurring in 
specific brain sites with nicotine dependence. The precipi-
tation of nicotine withdrawal in nicotine-treated rats, but 
not in controls, with administration of drugs that probe 
various transmitter systems and receptors suggests that 
chronic exposure to nicotine induces adaptations in spe-
cific transmitter systems and receptors. The combination 
of the in vivo microdialysis technique with the precipi-
tated nicotine withdrawal technique indicates that the 
circuits mediating the acute effects of nicotine develop 
adaptations with nicotine dependence that lead to the 
withdrawal syndrome (Figure 4.4 depicts the brain struc-
tures and their interconnections forming circuits dis-
cussed in this chapter). 
During nicotine withdrawal precipitated by systemic 
or intra-VTA administration of the nAChR antagonist 
mecamylamine in nicotine-treated rats, dialysate levels 
of dopamine were decreased in the nucleus accumbens 
(Fung et al. 1996; Hildebrand et al. 1998; Carboni et al. 
2000) and in the central nucleus of the amygdala (Pana-
gis et al. 2000). These mecamylamine injections into the 
VTA also produced, in a dose-dependent manner, most of 
the somatic signs of nicotine withdrawal (Hildebrand et al. 
1999). This finding suggests the involvement of nAChRs in 
the VTA in the expression of the somatic signs of nicotine 
withdrawal. Most important, similar decreases in levels of 
dopamine in the nucleus accumbens were observed in rats 
allowed to self-administer nicotine for 25 days, beginning 
24 to 48 hours after the last session for self-administration 
of nicotine (Rahman et al. 2004). Decreases in dopamine 
levels in the nucleus accumbens are also associated with 
withdrawal from other drugs of abuse, such as ethanol, 
morphine, cocaine, and amphetamine (Rossetti et al. 
1992). In contrast, the increases in dialysate dopamine 
levels observed in the frontal cortex (Hildebrand et al. 
1998; Carboni et al. 2000) were similar to those observed 
during withdrawal from other drugs of abuse (Imperato 
et al. 1986). Thus, it appears that common substrates are 
involved in the mediation of the withdrawal signs associ-
ated with different drugs of abuse that involve alterations 
in dopamine transmission in the nucleus accumbens and 
the frontal cortex. 
The smoking cessation aid bupropion, an atypi-
cal antidepressant, acts at least partly by inhibiting the 
neuronal uptake of dopamine, which thereby increases 
dopamine transmission (Nomikos et al. 1992). Bupro-
pion reverses both the threshold elevations and the 
somatic signs associated with nicotine withdrawal (Cryan 
et al. 2003) in rats, although its effects on nicotine self- 
administration are inconsistent (Glick et al. 2002; Bruijn-
zeel and Markou 2003; Shoaib et al. 2003). Taken together, 
the above data strongly suggest that a decrease in meso-
limbic dopaminergic transmission mediates aspects of 
nicotine withdrawal. 
Another transmitter system that may be involved in 
nicotine dependence and withdrawal is the norepineph-
rine system. However, to date, the role of this system in 
nicotine dependence has not been investigated as exten-
sively as that of the dopamine system. Acute administra-
tion of nicotine elevates extracellular noradrenaline levels 
in the nucleus accumbens (Schiffer et al. 2001), hippo-
campus (Brazell et al. 1991; Mitchell et al. 1993; Benwell 
and Balfour 1997), cortex (Summers and Giacobini 1995), 
amygdala, and hypothalamic paraventricular nucleus (Fu 
et al. 2001). These findings indicate that nicotine with-
drawal may be characterized by a decrease in noradrener-
gic transmission. This hypothesis is supported by evidence 
for the beneficial effects on smoking cessation of nortrip-
tyline, a norepinephrine reuptake inhibitor (Hughes et al. 
2004b) and the ameliorative effects of the α2-adrenoceptor 
agonist clonidine on nicotine withdrawal in double-blind, 
placebo-controlled studies (Covey and Glassman 1991). 
Other neurotransmitter systems such as sero-
tonin, endocannabinoid, or opioid may also be involved 
in withdrawal, but research on these systems is limited. 
A few studies suggest the involvement of the opioid sys-
tem. For example, naloxone precipitates somatic signs of 
withdrawal in nicotine-dependent rats (Malin et al. 1993; 
Watkins et al. 1999). Some studies also demonstrate the 
involvement of the serotonin system (see “Antidepressant 
and Antipsychotic Drugs and Nicotine Withdrawal” later 
in this chapter).
Receptors and Behavioral Signs of Nicotine 
Withdrawal
Studies document that administration of a variety 
of nAChR antagonists induces behavioral signs of with-
drawal in addition to the neurochemical effects of with-
drawal in nicotine-treated rats. Systemic or intra-VTA 
administration of mecamylamine or systemic or intra-
ventricular administration of chlorisondamine induced 
somatic signs and/or elevation of reward threshold in 
nicotine-dependent rats only (Hildebrand et al. 1999; Wat-
kins et al. 2000). Administration of the nAChR antagonist 
DHβE, which is selective for high-affinity nAChRs con-
taining α4 (Harvey and Luetje 1996), induced threshold 
elevations (Epping-Jordan et al. 1998; Bruijnzeel and Mar-
kou 2004) but did not induce increases in somatic signs in 
nicotine-dependent rats (Epping-Jordan et al. 1998). This 
finding demonstrates that the threshold elevations are not 
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due to nonspecific performance effects of the antagonists. 
Together, these results illustrate the involvement of 
nAChRs in the VTA in both the somatic and affective 
aspects of withdrawal. 
In addition, work in knockout mice demonstrates a 
critical role of β4 but not β2 nAChRs in the somatic signs 
of withdrawal (Salas et al. 2004; Jackson et al. 2008). β2 
nAChRs are critical for the reinforcing effects of nico-
tine (Picciotto and Corrigall 2002) and for the affective 
signs of nicotine withdrawal, as reflected in anxiety-like 
behavior and conditioned place aversion (Jackson et al. 
2008). The α7 homomeric nAChRs may be involved in the 
reinforcing effects of nicotine (Markou and Paterson 
2001) and perhaps only in some somatic aspects but not 
in the affective aspects of nicotine withdrawal (Markou 
and Paterson 2001; Jackson et al. 2008). Specifically, 
administration of the α7 nAChR antagonist methyl-
lycaconitine did not precipitate either the typical 
somatic signs of nicotine withdrawal or the reward deficits 
reflected in threshold elevations in nicotine-dependent 
rats (Markou and Paterson 2001). However, in α7 knock-
out mice, no hyperalgesia was present during nicotine 
withdrawal, an effect seen in wild-type mice during nic-
otine withdrawal (Jackson et al. 2008). However, these 
α7 knockout mice showed normal levels of somatic and 
affective signs of nicotine withdrawal. Thus, the role of α7 
nAChRs may be limited to some somatic signs, including 
hyperalgesia, of nicotine withdrawal. Finally, α4 nAChRs 
have been shown to be involved in the reinforcing effects 
of nicotine (Tapper et al. 2004). Their role in nicotine 
withdrawal has not been clearly delineated, but it may 
influence both affective and somatic withdrawal effects 
(Salas et al. 2004; Gonzales et al. 2006; Jorenby et al. 2006; 
Jackson et al. 2008). Overall, the observation that nAChR 
antagonists precipitate the behavioral and neurochemical 
signs of withdrawal in nicotine-dependent rats, but not 
in controls, suggests that chronic exposure to nicotine 
induces a compensatory reduction in endogenous cholin-
ergic tone that leads to the nicotine withdrawal syndrome.
Because glutamate stimulates dopamine release 
(Schilström et al. 1998a; Mansvelder and McGehee 2000), 
decreased glutamate transmission may mediate nico-
tine withdrawal. Systemic or intra-VTA administration 
of the mGluR subtype 2/3 (mGluR2/3) agonist LY314582 
led to withdrawal-like threshold elevations in nicotine- 
dependent rats but not in control rats (Kenny et al. 2003). 
These mGluR2/3 receptors are found primarily presyn-
aptically (i.e., on the transmitting neuron at the synap-
tic terminal that extends to the synapse, and the released 
transmitters target the postsynaptic neuron), where they 
inhibit glutamate transmission (Cartmell and Schoepp 
2000; Kenny and Markou 2004). The increased sensitivity 
of nicotine-dependent rats to an agonist at the pre-
synaptic inhibitory mGluR2/3 suggests that nicotine 
dependence is characterized by increased inhibition of glu-
tamate transmission through these receptors, resulting in 
decreases in the release of glutamate when nicotine is no 
longer present to stimulate glutamate release. Consistent 
with this hypothesis, the mGluR2/3 antagonist LY341495 
reversed the threshold elevations observed in rats that 
had spontaneous nicotine withdrawal (Kenny et al. 2003). 
Similarly, activity decreased in postsynaptic α-amino-3-
hydroxy-5-methyl-4-isoxazole proprionic/kainate recep-
tors, although no adaptations in mGluR5 receptors were 
observed in nicotine-dependent rats (Kenny et al. 2003). 
This result was somewhat surprising considering the 
important role found for this receptor in the reinforc-
ing effects of nicotine (Paterson et al. 2003; Paterson and 
Markou 2005). Taken together, all of the above findings 
indicate that decreased glutamate transmission result-
ing from adaptations in presynaptic and postsynaptic 
receptors may contribute to the affective aspects of nico- 
tine withdrawal. 
These data on the lack of adaptations in mGluR5 
activity highlight the finding that not all systems involved 
in the reinforcing effects of nicotine develop changes with 
long-term exposure to nicotine. This notion is also sup-
ported by data demonstrating that there are no changes 
in GABA transmission, GABAB receptor activity, or α7 
nAChR activity in nicotine-dependent rats, despite the 
important role of the GABAB receptor and possibly the α7 
nAChR in the reinforcing effects of nicotine (Markou and 
Paterson 2001; Paterson and Markou 2002; Paterson et al. 
2004, 2005a,b). 
Molecular Mechanisms
Activated nAChRs are permeable to both sodium 
ions and Ca2+, which lead to activation of the neurons 
and thus the release of many transmitters (Wonnacott 
et al. 2005). The widespread brain activation induced by 
acute or long-term administration of nicotine is shown by 
the expression of C-FOS in areas such as the amygdala, 
bed nucleus of the stria terminalis, lateral septum, hypo-
thalamic nuclei, striatum, parts of the cortex, superior 
colliculus, optic tract, interpeduncular nucleus, supra-
mammillary nucleus, periaqueductal gray matter, nucleus 
of the solitary tract, and locus coeruleus (Merlo Pich et 
al. 1999). C-FOS–related antigens are C-FOS proteins 
that heterodimerize with C-JUN proteins to produce com-
plexes of activator protein-1 and transcriptionally regulate 
large numbers of genes related to plasticity (Dobranzki et 
al. 1991; Merlo Pich et al. 1997).
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Another protein researchers have studied exten-
sively is the cyclic adenosine monophosphate–response 
element binding protein (CREB), because it is part of 
the signaling cascade for several receptors, including 
nAChRs (Nestler 2001). Acute treatment with nicotine 
had no effect on levels of total CREB or phosphorylated 
CREB (p-CREB). However, 18 hours after withdrawal 
from long-term administration of nicotine, total concen-
trations of CREB and p-CREB decreased in the shell but 
not in the core of the nucleus accumbens (Pluzarev and 
Pandey 2004) and in the medial and basolateral amygdala 
but not in the central amygdala (Pandey et al. 2001). The 
high Ca2+ permeability of nAChRs also leads to the stimu-
lation of additional intracellular messenger systems such 
as calmodulin-dependent protein kinases, including Ca2+ 
calmodulin-dependent protein kinase II (CaMKII), which 
is the most abundant kinase in the brain (Schulman and 
Hanson 1993). Acute administration of nicotine in mice 
induced increases in CaMKII expression in the spinal cord 
that was involved in the antinociceptive effects of nicotine 
(Damaj 2000).
These are a few examples of the molecular changes 
observed after acute or long-term administration of 
nicotine and on withdrawal from long-term administra-
tion. These molecular changes demonstrate that nicotine 
induces changes in molecular mechanisms involved in 
long-term plasticity. Such molecular effects are likely to 
mediate several aspects of dependence on nicotine. 
Clinical Imaging Studies
Clinical imaging studies have confirmed findings 
from basic research in rodents and have provided addi-
tional critical information about brain sites and processes 
involved in tobacco addiction in humans that cannot 
readily be investigated in animals (e.g., hedonic responses 
and craving). Some of the effects of nicotine in various 
regions of the brain have also been described elsewhere 
(see “Learning and Conditioning” earlier in this chap-
ter). Similar to other drugs of abuse, nicotine decreases 
global glucose metabolism in the brain, as determined 
by PET with [18F]fluorodeoxyglucose (Stapleton et al. 
2003). Long-term exposure to tobacco smoke also inhibits 
MAOA and MAOB activity (Volkow et al. 1999). Congruent 
with the suggested role of mesolimbic dopamine in the 
rewarding effects of nicotine in rodents, PET studies with 
[11C]raclopride indicate that cigarette smoking increased 
dopamine levels in the striatum of smokers (Brody et 
al. 2004b) and that the hedonic response of the smoker 
to cigarette smoking was proportional to the dopamine 
released in the striatum (Barrett et al. 2004). Other areas 
activated by nicotine or smoking are the prefrontal 
cortex, ventral putamen, anterior cingulated cortex, supe-
rior parietal cortex, and thalamus (Kumari et al. 2003; Rose 
et al. 2003b; Brody et al. 2004b; Fallon et al. 2004; Jacob-
sen et al. 2004; Brody 2006). Smoking-associated images 
during inductions of craving that often lead to smoking 
increased the functional magnetic resonance imaging sig-
nal in reward circuits such as the right posterior amyg-
dala, posterior hippocampus, VTA, and medial thalamus 
(Due et al. 2002). As mentioned previously, long-term 
administration of bupropion attenuated cue-induced crav-
ing and led to blunted activation of the perigenual and 
ventral anterior cingulate cortex (Brody et al. 2004a). 
Functional magnetic resonance imaging was used 
in an interesting comparison of the effects of nicotine on 
the brains of patients with schizophrenia and the brains 
of control participants. Nicotine-induced activation of 
the anterior cingulate cortex and bilateral thalamus was 
greater in patients with schizophrenia than in control par-
ticipants during performance of a cognitive task (Jacob-
sen et al. 2004). This finding suggests that nicotine may 
improve cognitive performance in patients with schizo-
phrenia by enhancing the thalamocortical functional con-
nectivity (Jacobsen et al. 2004) (see “Schizophrenia and 
Nicotine Dependence” later in this chapter). Relevant 
to the high prevalence of smoking among patients with 
depression, smokers showed cortical responses suggesting 
vulnerability to depression in a study that used tryptophan 
depletion to increase the depressed mood in smokers (Per-
gadia et al. 2004).
Psychiatric Comorbidity
Antidepressant and Antipsychotic Drugs and 
Nicotine Withdrawal
Another experimental approach used to identify sys-
tems that mediate nicotine withdrawal and dependence 
is a study of pharmacologic manipulations that reverse 
spontaneous nicotine withdrawal. Inferences can be made 
regarding the underlying abnormality associated with 
withdrawal through the mechanisms associated with the 
pharmacotherapy. On the basis of the phenomenological 
similarities among depression, the depression-like aspects 
of nicotine withdrawal, and the negative symptoms of 
schizophrenia, researchers hypothesize that overlapping 
neurobiologic substrates may mediate these depressive 
symptoms and that antidepressant and atypical antipsy-
chotic treatments would alleviate the depression-like 
aspects of nicotine withdrawal (Markou et al. 1998; 
Markou and Kenny 2002). 
Such common substrates mediating nicotine depen- 
dence and psychiatric disorders may explain the high 
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prevalence of tobacco smoking among psychiatric popula-
tions. Compared with the percentage of smokers in the 
general population (20 to 30 percent), a higher percentage 
of mentally ill patients were smokers (26 to 88 percent, 
depending on the mental illness) (Lasser et al. 2000), 
particularly those with schizophrenia, depression, or 
addiction to alcohol or other drugs (Hughes et al. 1986; 
Glassman et al. 1990; Breslau 1995). For illustrative pur-
poses, substrates that mediate depression, schizophrenia, 
and nicotine dependence are described in the follow- 
ing sections.
Depression and Nicotine Dependence
Although the estimates vary across age, popula-
tion, and criteria for tobacco dependence, most estimates 
suggest that the incidence of major depressive disorder 
among smokers is approximately two to three times that 
among nonsmokers (Hughes et al. 1986; Glassman et al. 
1988, 1990; Kandel et al. 2001; Fergusson et al. 2003). A 
history of major depression increased the risk for progres-
sion to daily smoking and nicotine dependence, and a his-
tory of daily smoking and nicotine dependence increased 
the risk for major depression (Breslau et al. 1993b, 1998). 
A depressed mood is one of the symptoms of tobacco 
withdrawal syndrome experienced by a significant propor-
tion of persons who attempt to stop smoking (West et al. 
1984; Hughes and Hatsukami 1992; APA 1994). Therefore, 
tobacco smoking may be self-medication for either the 
depression that preceded the drug use or the smoking-
induced depression (Pomerleau et al. 1978; Waal-Manning 
and de Hamel 1978; Hughes et al. 1986; Glassman 1993; 
Markou et al. 1998). 
In particular, 5HT and the 5HT1A receptors appear 
to be critically involved in the mode of action of several 
antidepressant drugs used clinically (Markou et al. 1998) 
and may play a role in nicotine withdrawal (Kenny and 
Markou 2001). Systemic administration of 5HT1A recep-
tor agonists, such as 8-hydroxy-2-dipropylaminotetralin 
(8-OH-DPAT), exacerbated the increased startle response 
observed during nicotine withdrawal, whereas 5HT1A 
receptor antagonists (e.g., WAY-100635) alleviated this 
increased response (Rasmussen et al. 1997, 2000). In addi-
tion, the responsiveness of dorsal raphe nucleus neurons 
to 8-OH-DPAT increased during nicotine withdrawal (Ras-
mussen and Czachura 1997). Thus, nicotine withdrawal 
may increase the inhibitory influence of somatodendritic 
5HT1A autoreceptors in the raphe nuclei, and thereby 
decrease the release of serotonin in the forebrain and lim-
bic brain sites (Benwell and Balfour 1979, 1982; Ridley 
and Balfour 1997). This conclusion is supported by the 
observation that a serotonergic antidepressant treatment 
involving the coadministration of the selective serotonin 
reuptake inhibitor fluoxetine and the 5HT1A receptor 
antagonist p-MPPI [4-(2ʹ-methoxy-phenyl)-1-[2ʹ-(n-2ʹʹ-
pyridinyl)-p-iodobenzamido]ethyl-piperazine] rapidly 
reversed the elevation in thresholds of brain-stimulation 
reward observed in rats with nicotine withdrawal, but the 
treatment did not block the somatic signs of withdrawal 
(Harrison et al. 2001). Consistent with this finding, the 
5HT1A receptor partial agonist buspirone has shown lim-
ited efficacy in smoking cessation trials and may reduce 
the severity of withdrawal in persons attempting to stop 
smoking (West et al. 1991; Hilleman et al. 1992, 1994; 
Schneider et al. 1996). In conclusion, like depressions not 
induced by drugs, the depression-like aspects of nicotine 
withdrawal may be at least partly mediated by a decrease 
in monoaminergic transmission. 
Consistent with the hypothesis that shared sub-
strates mediate nicotine dependence and depression, 
clinical trials indicate that two of the antidepressant drug 
treatments are efficacious aids for smoking cessation. 
The atypical antidepressant bupropion, which primarily 
inhibits the reuptake of dopamine, was more effective than 
a placebo in clinical trials to achieve smoking cessation 
(Fiore et al. 2008), and bupropion has been approved for 
this use by the U.S. Food and Drug Administration (FDA). 
Preclinical research suggests that bupropion reverses 
both the depression-like and somatic aspects of nicotine 
withdrawal (Cryan et al. 2003), although its effects on the 
rewarding effects of nicotine are inconsistent (Bruijnzeel 
and Markou 2003). In addition, the tricyclic antidepres-
sant nortriptyline, which primarily inhibits the reuptake 
of norepinephrine, is recommended by WHO and the 
U.S. Public Health Service (Fiore et al. 2008) as a smok-
ing cessation aid. In conclusion, similar monoaminergic 
mechanisms appear to be involved in both depression and 
nicotine dependence. 
Schizophrenia and Nicotine Dependence
More than 80 to 90 percent of patients with schizo-
phrenia smoke compared with 20 to 30 percent of the 
general population (Masterson and O’Shea 1984; Goff et 
al. 1992; de Leon et al. 1995; Hughes 1996; Diwan et al. 
1998). Persons with schizophrenia are commonly heavy 
smokers (>1.5 packs of cigarettes per day); smoke high-tar 
cigarettes, which are also high in nicotine content; and 
extract more nicotine from cigarettes than do smok-
ers without schizophrenia (Masterson and O’Shea 1984; 
Hughes et al. 1986; Olincy et al. 1997). 
The mesolimbic dopamine system and its effer-
ent and afferent connections to other brain sites and 
systems, particularly dopamine-glutamate interactions, 
are strongly implicated in both the reinforcing effects of 
nicotine and schizophrenia (Snyder 1976; Carlsson 1977). 
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Abnormalities in these systems may render patients with 
schizophrenia more susceptible to the rewarding effects 
of nicotine (Chambers et al. 2001). Such patients may 
use nicotine to counteract the cognitive and/or depres-
sion-like aspects of schizophrenia that are not effectively 
treated with most antipsychotic drugs (Markou and Kenny 
2002). Nicotine administration through tobacco smok-
ing ameliorated visuospatial cognitive deficits of patients 
with schizophrenia (George et al. 2002) that involve the 
prefrontal cortex (Funahashi and Kubota 1994; Goldman-
Rakic 1995; Callicott et al. 1998; Kikuchi-Yorioka and 
Sawaguchi 2000; Manoach et al. 2000).
Two forms of sensory-gating deficits (the inability 
to ignore or filter out irrelevant sensory information) 
that patients with schizophrenia exhibit may be influ-
enced by actions on α7 or other nAChRs (Freedman et al. 
1997; Adler et al. 1998). The two deficits are (1) auditory 
P50 gating, a form of sensory blocking, and (2) prepulse 
inhibition of the startle response. Thus, smoking may be 
a form of self-medication to compensate for these gating 
deficits. In support of this hypothesis, one study found 
that acute nicotine treatment reversed disruptions in pre-
pulse inhibition induced in mice by the administration 
of the N-methyl-d-aspartate receptor antagonist phency-
clidine, which mimics human psychosis (Spielewoy and 
Markou 2003).
Nicotine administration may be a form of self-
medication for the depression-like negative symptoms of 
schizophrenia. The atypical antipsychotic drug clozapine 
treats the negative symptoms of schizophrenia most effec-
tively and has decreased tobacco smoking in some persons 
without any encouragement to reduce smoking (George 
et al. 1995). In addition, long-term pretreatment with clo-
zapine attenuated the severity of the nicotine withdrawal 
syndrome in rats (Semenova and Markou 2003).
Summary and Future Directions
The VTA region of the brain and the dopamine neu-
rotransmitter are primarily responsible for the positive 
reinforcing aspects of nicotine addiction. An increase in 
dopamine levels is mediated by nicotine directly stimulat-
ing nAChRs, primarily α4β2 and α7 homomeric nAChRs 
in the VTA. Nicotine stimulates nAChRs on glutamater-
gic terminals that release glutamate, an excitatory neu-
rotransmitter, which results in increased dopamine release 
in the nucleus accumbens and the frontal cortex. Nicotine 
also excites nAChRs on GABA-releasing terminals. Thus, 
levels of GABA, an inhibitory neurotransmitter, are also 
increased by nicotine. However, the interplay between 
the quick desensitization of nAChRs on the GABA neu-
ron and the higher doses of nicotine required to desensi-
tize nAChRs on the glutamate neuron results in a greater 
increase in dopamine levels. A critical role may also be 
played by nicotine-induced increases in norepinephrine 
transmission, although the role of this transmitter sys-
tem in nicotine dependence has not been investigated as 
extensively as that of the dopamine, glutamate, and GABA 
systems. The role of endocannabinoids, serotonin, and 
endogenous opiates in nicotine addiction is less certain. 
The neurophysiology associated with withdrawal 
symptoms may be based on the type of symptoms experi-
enced (e.g., somatic versus affective). The nAChRs appear 
to be involved in both the somatic and affective compo-
nents of nicotine withdrawal. Animal studies suggest that 
β4 plays an important role in the somatic symptoms of 
withdrawal, whereas β2 seems to play a role in the affec-
tive symptoms of withdrawal. The neuronal subunit α7 
may be involved only in some of the somatic (e.g., hyperal-
gesia) aspects of withdrawal. The role of α4 is unclear, but 
it may influence both affective and somatic withdrawal 
effects. Decreased mesolimbic dopaminergic transmis-
sion seems to mediate various aspects of the withdrawal 
syndrome. Noradrenergic and serotonergic systems 
may also play a role in withdrawal. Decreased glutamate 
transmission appears to mediate the affective aspects of 
withdrawal, but GABA transmission does not appear to 
change with withdrawal. Although not discussed in this 
section, some studies also suggest that a dysregulation 
in the hypothalamic-pituitary axis occurs subsequent to 
withdrawal (al’Absi et al. 2004), and this dysregulation 
has been associated with relapse to smoking (al’Absi et al. 
2005). In future research, the involvement of specific neu-
roreceptors and neurotransmitters relevant to the various 
aspects of addiction needs to be differentiated (see “Physi-
ological Mechanisms and Indicators: Nicotine Tolerance, 
Withdrawal, and Reinforcement” earlier in this chapter).
Finally, understanding the pathophysiology of 
depression and schizophrenia, other psychiatric illnesses, 
and substance abuse disorders, as well as the effects of 
medications used to treat these disorders in smokers, may 
enhance understanding of the pathophysiology of nicotine 
addiction. Because of the high amount of overlap between 
prevalence of nicotine dependence and comorbid psychi-
atric disorders, the similar monoamines affected by these 
disorders, and the use of similar treatment medications, 
it is possible that common substrates mediate nicotine 
dependence and depression or schizophrenia, as well as 
other psychiatric disorders and can provide insight into 
effective treatments. 
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Genetics
There is strong evidence for a genetic influence on 
smoking behavior. Since the last Surgeon General’s report 
on nicotine addiction (USDHHS 1988), knowledge has 
significantly increased in this area. For example, estimates 
of heritability have been determined for various pheno-
types of smoking behavior. Studies of molecular genetic 
association and linkage studies were conducted to identify 
loci that influence these phenotypes. Furthermore, phar-
macogenetic studies of smoking cessation were under-
taken to increase understanding of interactions between 
genes and treatments. This research offers the possibility 
of interventions for smoking cessation that are tailored to 
individual genotypes. 
Heritability of Smoking Behavior
Smoking behavior and nicotine addiction have gen-
erated far less research in behavioral genetics than have 
other addictive behaviors such as alcoholism. This is 
despite evidence from animal studies suggesting that key 
factors—such	as	the	number	and	distribution	of	nicotinic	
receptors	and	the	development	of	nicotine	tolerance—are	
under a strong genetic influence (Stitzel et al. 2000). The 
evidence that does exist from studies of twins, adoption, 
and separated twins, however, has consistently suggested 
a strong genetic component in smoking behavior (Gilbert 
and Gilbert 1995). Behavioral genetics studies enable the 
contribution of genetic influences, environmental influ-
ence shared by persons such as twins or biologic relatives 
(shared environmental influences), and environmental 
influences unique to an individual (unique environmen-
tal influences) to be distinguished. The heritability coef-
ficient itself reflects the genetic contribution. According 
to this evidence, inherited factors account for 28 to 85 
percent of the observed variation in current smoking 
behavior in the population from which the data were drawn 
(Gilbert and Gilbert 1995). Researchers have suggested that 
the evidence for a genetic influence on smoking behavior 
is stronger than that for a genetic influence on alcohol-
ism (Heath et al. 1995). Moreover, these studies have also 
indicated that these genetic factors relate to two aspects of 
smoking behavior: initiation and persistence.
Smoking Initiation
By comparing concordance rates for being a current 
or former smoker versus a lifetime nonsmoker, research-
ers can estimate the genetic contribution to smok-
ing initiation. Such comparisons suggest that genetic 
contributions to smoking initiation are substantial. For 
example, one study (Heath et al. 1995) reports heritability 
coefficients for smoking initiation of 0.44 in women and 
0.51 in men in a sample of Swedish adults born between 
1926 and 1958. This study also reports a strong influence 
of shared environmental factors on both smoking ini-
tiation and persistence, with little evidence of a role for 
unique environmental influences. Many additional stud-
ies have confirmed the heritability of smoking initiation, 
as well as smoking persistence and nicotine dependence 
(True et al. 1997; Kendler et al. 1999). Although the overall 
conclusion is robust, the specific heritability coefficients 
reported by individual studies are highly variable, ranging 
from less than 0.30 to more than 0.80 (Sullivan and Kend-
ler 1999). This finding may be attributable to differences 
in the definitions of smoking initiation across studies. For 
example, current and former smokers are combined into 
a single “ever smoking” category in some studies, but not 
in others, and some studies require a threshold of expo-
sure (e.g., 100 cigarettes smoked) and others do not have 
this requirement. Lack of critical attention to definition of 
phenotype may lead to inconsistencies across studies and 
to misleading conclusions.
The role of shared environmental influences on 
initiation of smoking and persistence in smoking is also 
inconsistent across populations, and some studies report 
minimal shared environmental influences (Heath et al. 
1993). Differences in heritability coefficients by gender 
are generally not reported or are minimal, although one 
study (Hamilton et al. 2006) that tested differences by 
gender in the magnitude of genetic and environmental 
effects in a large cohort of twins indicated significantly 
higher heritability for smoking initiation in males than 
in females but no significant differences for smoking per-
sistence. In that study, heritability for smoking initiation 
was defined as having smoked 100 or more cigarettes over 
their lifetime. In contrast, however, one meta-analysis (Li 
et al. 2003) reported higher heritability for smoking initia-
tion in females than in males and higher heritability for 
smoking persistence in males than in females. Together, 
the evidence supports the importance of both genetic and 
shared environmental factors on smoking initiation. How-
ever, the relative importance of these factors is highly vari-
able across populations. For example, one study reports 
different heritability coefficients for smoking behaviors in 
African Americans compared with White Americans (True 
et al. 1997). Nevertheless, evidence from non-Western 
cultures (Niu et al. 2000) suggests that the genetic 
influence on smoking behavior remains an important risk 
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factor even in populations with much higher prevalence of 
smoking (e.g., in China). Reported heritability coefficients 
may vary with environmental factors such as the preva-
lence of smoking. For example, some of the highest heri-
tability coefficients for smoking initiation are reported in 
studies on the population of twins during the Vietnam era, 
in which the participants were members of the U.S. Army 
at a time when smoking prevalence in the military was 
very high (True et al. 1997). This natural experiment, in 
which environmental variation in smoking initiation was 
minimized, may account for the high heritability coeffi-
cients in this study.
Smoking Persistence and Nicotine Dependence
Understanding smoking initiation is important to 
elucidate the etiology of nicotine addiction. However, 
smoking persistence is responsible for the adverse health 
consequences of smoking. The evidence for a genetic 
influence on smoking persistence (i.e., studies comparing 
current smokers with former smokers) is also strong. Sev-
eral studies reported heritability coefficients of more than 
0.50 for smoking persistence (Heath and Martin 1993) 
and nicotine dependence (Broms et al. 2007) in both 
men and women, and some studies (Sullivan and Kendler 
1999; Vink et al. 2004) reported heritabilities of more than 
0.70 for nicotine dependence. Studies of multiple indices 
of nicotine dependence (Lessov et al. 2004) indicate that 
salient behavioral indices are similar for women and men, 
with measures such as time to the first cigarette in the 
morning and the number of cigarettes smoked per day 
that may represent the most highly heritable symptoms 
of nicotine dependence for both women and men. Inter-
preting these results is complicated because genetic fac-
tors that influence smoking initiation may also influence 
smoking persistence and subsequent dependence. Some 
data (True et al. 1999) also suggest a common genetic 
vulnerability to nicotine and alcohol dependence in men. 
The balance of evidence suggests that the risk of smoking 
initiation is influenced by both genetic and environmental 
factors (True et al. 1997). However, the risk of smoking 
persistence is more strongly a function of genetic factors 
and some of the genetic influences on smoking behavior 
contribute to a risk for both smoking initiation and per-
sistence (Kendler et al. 1999). Few studies have directly 
assessed the heritability of smoking cessation. However, 
one research study (Xian et al. 2003, 2005) indicated a 
heritability of 0.54 for failed smoking cessation, and an-
other (Broms et al. 2006) suggests that genetic factors are 
related to the number of cigarettes smoked per day and to 
smoking cessation but are largely independent of smok-
ing initiation. Another study (Pergadia et al. 2006) has 
reported genetic influences specific to nicotine with-
drawal, which may contribute both to smoking persis-
tence and smoking cessation. However, because evidence 
from studies of twins and of adoption strongly indicates 
a genetic component in other aspects of smoking behav-
ior, smoking cessation may also be strongly influenced by 
genetic factors.
Molecular Genetic Research on 
Smoking Behavior
Consistent evidence for the heritability of smok-
ing behaviors led to molecular genetic studies designed 
to elucidate the specific genetic factors and biologic 
mechanisms involved in nicotine addiction. Two general 
scientific approaches to address this question include 
genetic linkage analysis and candidate gene studies. In 
linkage analysis, genetic variants or markers throughout 
the genome are tested within families (e.g., sibling pairs) 
and examined to identify markers that cosegregate with 
the trait of interest (e.g., nicotine dependence). This is a 
hypothesis-generating approach and does not require a 
priori knowledge about the biologic pathways involved. 
In contrast, studies of candidate genes, which are based 
on associations, use case-control methods to compare 
the prevalence of variants of candidate genes in two 
unrelated	groups—for	example,	persons	who	are	dependent	
on nicotine and those who are not dependent on nicotine. 
Although case-control studies have greater statistical 
power and are less costly than linkage analysis, such stud-
ies are not designed to identify novel genetic loci. 
Cigarette smoking and nicotine dependence are 
complex traits arising from the interplay of multiple 
genetic and environmental influences. As mentioned previ-
ously (see “Definition of Nicotine Addiction” earlier in this 
chapter), definition of phenotype is a critical factor in genetic 
studies.	Many	genes	are	 likely	 involved	 in	smoking—for	 
example, genes that influence the positive rewarding 
effects of nicotine, those that contribute to withdrawal 
symptoms and the negative reinforcing effects of nicotine 
(Pomerleau 1995), and those that determine general sus-
ceptibility to addiction (Nestler 2000). Interacting effects 
such as personality and environment are likely to also 
play an important role (Heath et al. 1995). Issues such as 
population heterogeneity (e.g., age, gender, and ethnic-
ity) and bias (false positives results) introduced by ethnic 
admixture in study populations may also have a substan-
tial impact on the outcome of association-based studies 
and may contribute to problems in replicating results 
(Munafò and Flint 2004).
Nicotine Addiction: Past and Present  139
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease




Representative genetic linkage studies of smoking 
behavior phenotypes up to mid-2005 are shown in Table 
4.5, although several of these report data from the same 
study samples (e.g., Collaborative Studies on the Genet-
ics of Alcoholism and the Framingham Heart Study). 
Despite the success of linkage approaches in unraveling the 
genetic antecedents of disease (Menzel 2002), these initial 
findings about smoking behavior have not been consis-
tent. Potential explanations include lack of refinement in 
phenotype definition and the relatively small sample sizes 
in some studies of smoking behavior. Subsequent studies 
have taken into account the complexity and heterogeneity 
of the nicotine dependence phenotype by using alternate 
measures, such as heavy smoking, severity of withdrawal, 
and history of smoking cessation (Li et al. 2006; Swan et 
al. 2006). These data suggest that different genetic loci 
are linked to different measures and support a multidi-
mensional concept of the nicotine dependence phenotype 
(Swan et al. 2006). 
In addition to linkage studies, investigations using 
an approach of genomewide association can also reveal 
promising novel candidate genes for nicotine depen-
dence (Bierut et al. 2007). With advancements in geno-
typing technology, phenotype definition, and analytic 
approaches, both case-control studies and linkage analysis 
will likely identify an increasing number of associations 
with novel variants important in nicotine dependence 
(Li 2006). Examples include NTRK2 (Beuten et al. 2007), 
GABARAP (Lou et al. 2007), CHRNA5 (Saccone et al. 
2007), and ANKK1 (Gelernter et al. 2006).
Table 4.5 Continued
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Candidate Gene Studies
A variety of plausible candidate genes have been 
examined for associations with smoking behavior. Most 
of these studies have focused on genetic variations in 
relevant neurotransmitter pathways, nicotine-metabo-
lizing enzymes, or nAChRs. Genetic variants of relevant 
neurotransmitter pathways may have more generalized 
influences on addictive behaviors. Genes for nicotine- 
metabolizing enzymes and nAChRs may be specific for 
effects on nicotine dependence.
Nicotine Metabolism
To date, more than 20 published studies of candidate 
genes have investigated genes involved in the nicotine 
metabolism pathway (Table 4.6). Most of these studies in-
vestigated CYP2A6, for which researchers have identified 
functional genetic variants (Xu et al. 2002). Variants asso-
ciated with *NULL activity (e.g., *2/*4) or reduced activity 
(*9/*12) are associated with reduced levels of the CYP2A6 
enzyme and slower rates of nicotine metabolism, result-
ing in higher plasma nicotine levels from a given dose 
of nicotine (Malaiyandi et al. 2006). Thus, persons who 
carry these low activity alleles tend to have a lower risk of 
becoming smokers and, if they smoke, have slower rates 
of nicotine metabolism and tend toward reduced ciga-
rette consumption compared with persons with a wild-
type genotype (e.g., *1/*1). Furthermore, evidence from a 
meta-analysis that compared current versus former smok-
ers suggests that the CYP2A6 alleles for reduced activity 
may increase the likelihood of smoking cessation (Munafò 
et al. 2004). However, the results are not consistent within 
or across all studies (Table 4.6). These inconsistencies may 
be attributable to relatively small sample sizes in some 
studies and differences in definition of phenotype and eth-
nic ancestry and genetic background. 
Some studies investigated other cytochrome genes 
(CYP2D6 and CYP2E1), but evidence for a significant 
and reproducible role of these variants has not emerged, 
perhaps because the role of these enzymes in nicotine 
metabolism is limited.
Neuronal Nicotinic Receptors 
Researchers have examined several genes for nAChR 
subunits to discover associations with smoking status 
(Table 4.7). The genes CHRNA4, CHRNA7, and CHRNB2 
code for the α4, α7, and β2 subunits, respectively. How-
ever, because the functional relevance of variation in 
these genes is not known, these studies have explored 
associations of single nucleotide polymorphisms (SNPs) 
of unknown functional significance. To date, there is no 
evidence for associations of SNPs in the CHRNB2 gene 
with smoking behavior. However, two studies provide 
evidence for the role of CHRNA4 in nicotine dependence 
(Feng et al. 2004; Li et al. 2005). A small study of smok-
ers with schizophrenia indicated that the CHRNA7 gene 
may be associated with smoking status. The relevance 
of this finding in the general population of smokers is 
unknown. However, studies have reported that these 
nAChR subtypes play a role in reinforcing the effects of 
nicotine and possibly withdrawal (see “Pathophysiology 
of Nicotine Addiction” earlier in this chapter). Moreover, 
because of the history of failure to replicate initial sig-
nificant findings, these single studies require replication 
before the evidence can be considered to be confirmed. 
Recently, genomewide scans have revealed an asso-
ciation of novel genes, such as NRXN1 and NRXN3, with 
nicotine dependence (Bierut et al. 2007). In addition, 
genomewide association and candidate gene studies have 
identified associations of smoking behavior and nico-
tine dependence with SNPs in the CHRNA5/CHRNA3/
CHRNB4 gene cluster and in CHRNB3, which code for the 
nicotinic receptor subunits α5, α3, β4 and β3, respectively 
(Saccone et al. 2007; Berrettini et al. 2008; Bierut et al. 
2008; Grucza et al. 2008; Sherva et al. 2008; Stevens et al. 
2008; Thorgeirsson et al. 2008; Weiss et al. 2008; Caporaso 
et al. 2009; Chen et al. 2009). 
Dopaminergic and Serotonergic 
Neurotransmitter and Receptor Systems
A large number of candidate gene studies have 
investigated genes involved in the dopamine pathway, 
and most have investigated the gene for the dopamine 
receptor D2 (DRD2) (Table 4.8). Most studies of the DRD2 
*TAQ1A polymorphism have reported an association with 
smoking behavior, typically smoking status, but a sub-
stantial number have shown no association. Moreover, the 
functional significance of the *TAQ1A polymorphism re-
mains unclear, although there is some reported evidence 
for an association with the density of D2 receptors in the 
brain. One study investigated the functional DRD2-141C 
*INS/*DEL polymorphism and reported a significant 
association with smoking status (Yoshida et al. 2001). A 
modest number of studies have investigated other genes 
for dopamine receptors (DRD1, DRD4, and DRD5), DAT, 
and genes involved in dopamine synthesis and metabo-
lism, including tyrosine hydroxylase (an enzyme that con-
verts amino acid l-tyrosine to dihydroxyphenylalanine, a 
precursor of dopamine), DβH (an enzyme that converts 




Table 4.6 Studies of candidate genes for nicotine metabolism and smoking behavior
  Population   
  
Study
(country) Study group Controls
Dominant 
ancestry Gene
Cholerton et al. 1996 
(United Kingdom)
100 current smokers 104 lifetime nonsmokers NR CYP2D6
Boustead et al. 1997 
(United Kingdom)
100 current smokers None NR CYP2D6




80 alcohol- and tobacco-
dependent smokers
184 nonnicotine-dependent and 
former smokers
European CYP2A6
London et al. 1999 
(United States)
299 current or former 
smokers
161 lifetime nonsmokers NR CYP2A6
Gu et al. 2000 
(United Kingdom)
142 current smokers 501 former smokers 
389 lifetime nonsmokers
European CYP2A6
Rao et al. 2000 
(Canada)
292 current smokers NA European CYP2A6
Saarikoski et al. 2000 
(Finland)
85 current smokers 236 variable smokers 
264 lifetime nonsmokers
European CYP2A6
Tiihonen et al. 2000 
(Finland)
285 current smokers 680 former smokers or lifetime 
nonsmokers
European CYP2A6
Loriot et al. 2001 
(United States)
65 current smokers 142 former smokers European CYP2A6
Schulz et al. 2001 
(Germany)
130 current smokers 108 former smokers 
109 lifetime nonsmokers
European CYP2A6
Tan et al. 2001 
(China)
380 persons who ever 
smoked
246 lifetime nonsmokers East Asian CYP2A6
Zhang et al. 2001 
(Japan)
96 current smokers 141 nonsmokers East Asian CYP2A6
Ando et al. 2003 
(Japan)
57 current smokers 44 former smokers 
139 lifetime nonsmokers
East Asian CYP2A6
Howard et al. 2003 
(Canada)





Minematsu et al. 2003 
(Japan)
92 current smokers  
111 former smokers
123 nonsmokers East Asian CYP2A6
Fujieda et al. 2004 
(Japan)
1,705 smokers NA East Asian CYP2A6




NA East Asian CYP2A6
O’Loughlin et al. 2004 
(Canada)
228 adolescents who 
inhaled
NA European CYP2A6
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(country) Polymorphism Primary phenotype Main findings
Cholerton et al. 1996 
(United Kingdom)
*3, *4A, *5 Smoking status No association with smoking status
Boustead et al. 1997 
(United Kingdom)
*3, *4A, *5 Cigarettes/day 
Nicotine dependence
Association with nicotine dependence
Pianezza et al. 1998 
(Canada)
*1, *2, *3 Nicotine dependence Association with nicotine dependence (dependent 
vs. nondependent smokers) and amount smoked
London et al. 1999 
(United States)
*1, *2, *3 Smoking status 
Cigarettes/day
Marginal association with smoking status (lifetime 
nonsmokers vs. current and former smokers)
Gu et al. 2000 
(United Kingdom)




Association with smoking status (former vs. 
current smokers and lifetime nonsmokers)
Rao et al. 2000 
(Canada)
*1, *2, *4, 
duplication
Cigarettes/day Association with cigarettes/day
Saarikoski et al. 2000 
(Finland)
*1, *2, *3, *4B, 
*4C, *5, *10, *16
Smoking status Association with smoking status (heavy vs. 
variable smokers and lifetime nonsmokers)
Tiihonen et al. 2000 
(Finland)




No association with smoking status or cigarettes/
day
Loriot et al. 2001 
(United States)
*1, *2, *4 Cigarettes/day No association with cigarettes/day
Schulz et al. 2001 
(Germany)
*1, *2, *3 Smoking status  
Cigarettes/day
No association with smoking status or cigarettes/
day
Tan et al. 2001 
(China)
*1, *4 Smoking status  
Pack-yearsa
No association with smoking status or pack-years
Zhang et al. 2001 
(Japan)
*1, *DEL Smoking status  
Cigarettes/day
No association with smoking status or cigarettes/
day
Ando et al. 2003 
(Japan)
*1A, *1B, *4C Smoking status  
Cigarettes/day
No association with smoking status or cigarettes/
day
Howard et al. 2003 
(Canada)
*1C, *1D Nicotine dependence 
Cotinine levels/cigarette 
Cigarettes/day
Association with nicotine dependence in those of 
East Asian ancestry and cotinine concentrations/
cigarette in those of African ancestry
Minematsu et al. 2003 
(Japan)
*1, *3, *DEL Smoking status 
Pack-years
Association with pack-years among current and 
former smokers
Fujieda et al. 2004 
(Japan)
*1A, *1B, *4, *7, 
*9, *10, *11
Cigarettes/day Association with cigarettes/day
Iwahashi et al. 2004 
(Japan)
*1A, *1B, *4C Smoking status Association with smoking status
O’Loughlin et al. 2004 
(Canada) 
*1, *2, *4, *9, *12 Nicotine dependence 
Cigarettes/day
Association with increased risk of acquisition of 
nicotine dependence, but reduced cigarettes/day 




  Population   
  
Study
(country) Study group Controls
Dominant 
ancestry Gene
Schoedel et al. 2004 
(Canada)
375 current smokers 224 nonsmokers European CYP2A6
Vasconcelos et al. 2005 
(Brazil)
144 current smokers 
61 former smokers
207 nonsmokers Mixed CYP2A6
Note: NA = not applicable; NR = data not reported.
aPack-years = the number of years of smoking multiplied by the number of packs of cigarettes smoked per day.
Table 4.7 Studies of candidate genes for neuronal nicotine receptors and smoking behavior
   Population      
Study
(country) Study group Controls
Dominant 
ancestry Gene
Silverman et al. 2000 
(United States)
317 high- and 238 low-nicotine 
dependent smokers
317 nonsmokers European CHRNB2
Lueders et al. 2002 
(United States)
184 current smokers 132 former smokers  
427 lifetime nonsmokers
European CHRNB2
De Luca et al. 2004 
(Canada)
108 current smokers  
with schizophrenia
69 current nonsmokers  
with schizophrenia
European CHRNA7
Feng et al. 2004 
(China) 
577 male smokers from  
206 families
Family-based design East Asian CHRNA4
Li et al. 2005 
(United States)
1,568 smokers from  
602 families




Of the published studies of candidate genes involved 
in the serotonin pathway, eight investigated 5HTT, and 
three investigated TPH, which is involved in serotonin 
synthesis (Table 4.9). All but one study of the functional 
5HTTLPR polymorphism found an association with smok-
ing behavior. Three additional studies investigated the 
MAOA gene, which is involved in metabolism of both 
dopamine and serotonin and in norepinephrine path-
ways. Two of the three studies reported an association 
with smoking behavior that included both smoking sta-
tus and cigarette consumption. Other studies of candidate 
genes are summarized in Table 4.10. Research is notably 
lacking on genes involved in glutamatergic and GABA-
ergic mechanisms, despite basic research indicating the 
neurobiologic effects of nicotine on these systems. One 
study (Beuten et al. 2005) reports a significant association 
between a haplotype of SNPs in the GABAB2 gene and nic-
otine dependence.
In summary, a few candidate genes appear to be 
associated with smoking behavior. Meta-analysis is a 
potentially powerful tool for assessing population-wide 
effects of candidate genes on complex behavioral phe-
notypes, such as smoking, although such meta-analysis 
requires that the phenotypes examined across studies 
are similar. It may also provide evidence for unrevealed 
diversity, such as heterogeneity in apparently similar 
populations (Munafò and Flint 2004). Despite the large 
number of studies reporting on the association between 
specific candidate genes and smoking behavior, one meta-
analysis (Munafò et al. 2004) highlights the lack of depth 
of the research compared with the breadth that exists. 
The conclusion is that the “…evidence for a contribu-
tion of specific genes to smoking behavior remains mod-
est” (p. 583). In this analysis, 5HTT and CYP2A6 were the 
only candidate genes for which there was evidence of an 
association with smoking behavior. Studies published 
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(country) Polymorphism Primary phenotype Main findings
Schoedel et al. 2004 
(Canada)
*1A, *1B, *2, *4, *5, *6, 
*7, *8, *9, *10, *12
Smoking status  
Cigarettes/day
Association with smoking status and 
cigarettes/day
Vasconcelos et al. 2005  
(Brazil)
*1A, *1B, *2, *4, *9 Smoking status Association with smoking status (current and 
former smokers vs. nonsmokers) among those 
of European and mixed ancestry
Study
(country) Polymorphism Primary phenotype Main findings
Silverman et al. 2000 
(United States)
Multiple Smoking status  
Nicotine dependence
No association with smoking status or 
nicotine dependence
Lueders et al. 2002 
(United States)
Haplotype Smoking status  
Nicotine dependence
No association with smoking status or 
nicotine dependence
De Luca et al. 2004 
(Canada)
D15S1360 Smoking status Association with smoking status (current 
smokers vs. nonsmokers)
Feng et al. 2004 
(China) 
Haplotype Nicotine dependence Association with nicotine dependence




Nicotine dependence Association of CHRNA4 gene with nicotine 
dependence 
No association with CHRNB2 gene
more recently strongly indicate that SNPs in the CHRNA5/
A3/B4 gene cluster are associated with smoking behavior 
and nicotine dependence (Berrettini et al. 2008; Bierut et 
al. 2008; Grucza et al. 2008; Sherva et al. 2008; Stevens 
et al. 2008; Thorgeirsson et al. 2008; Weiss et al. 2008; 
Caporaso et al. 2009; Chen et al. 2009; Saccone et al. 2009). 
Nonetheless, the relatively small effects and evidence for 
substantial heterogeneity between studies suggest that 
extreme care is necessary in the design of case-control 
studies of genetic association.
Pharmacogenetic Approaches
The basic premise of the pharmacogenetic approach 
is that inherited differences in drug metabolism and drug 
targets have important influence on the toxic effects and 
the efficacy of treatment (Evans and Relling 1999; Poolsup 
et al. 2000). Advantages of a pharmacogenetic approach to 
the study of smoking cessation treatments include (1) use 
of more refined phenotypes for genetic analyses, which is 
facilitated by prospective assessment of withdrawal symp-
toms, side effects of treatment, and measures of the level 
of reward from nicotine; (2) use of various treatment con-
ditions to aid smoking cessation; and (3) use of experi-
mental designs that control the dosing and timing of the 
therapy (Lerman and Niaura 2002; Munafò et al. 2005b; 
Caporaso et al. 2009).
Nicotine Replacement Therapy
To date, two pharmacogenetic trials of NRT have 
been conducted. One placebo-controlled trial using the 
nicotine patch by a large group of general practice phy-
sicians in the United Kingdom (Johnstone et al. 2004b; 
Yudkin et al. 2004) focused on variations in the dopa-
mine pathway, including the DβH and DRD2 genes. The 
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Table 4.8 Studies of candidate genes for dopamine and smoking behavior
   Population      
Study
(country) Study group Controls
Dominant
ancestry Gene
Noble et al. 1994 
(United States)
57 current smokers 115 former smokers  
182 lifetime nonsmokers
European DRD2
Comings et al. 1996 
(United States)
312 current smokers 714 lifetime nonsmokers European DRD2
Comings et al. 1997 
(United States)
371 current smokers 126 lifetime nonsmokers European DRD1 
DRD2
Lerman et al. 1997 
(United States)
315 current smokers 232 lifetime nonsmokers European TH
Shields et al. 1998 
(United States)
283 current smokers 192 lifetime nonsmokers European and 
African
DRD4
Singleton et al. 1998 
(United Kingdom)
104 current smokers 117 lifetime nonsmokers NR DRD2
Spitz et al. 1998 
(United States)
46 current smokers 67 former smokers  
13 lifetime nonsmokers
European DRD2
Lerman et al. 1999 
(United States)




Sabol et al. 1999 
(United States)
283 current smokers 231 former smokers  
593 lifetime nonsmokers
European DAT




60 nonnicotine-dependent or 
light smokers
NR DRD2
Bierut et al. 2000 
(United States)
388 habitual smokers 
566 nonhabitual smokers
Family-based study European DRD2
Costa-Mallen et al. 2000 
(United States)
152 newly diagnosed 
Parkinson’s disease patients
231 with no history of 
Parkinson’s or other 
neurodegenerative disease
European DRD2
Jorm et al. 2000 
(Australia)
198 current smokers 211 former smokers  
452 lifetime nonsmokers
European DAT
McKinney et al. 2000 
(United Kingdom)
225 current smokers No controls European DβH 
MAOA 
COMT
Wu et al. 2000 
(United States)





Sullivan et al. 2001 
(United States)
595 current smokers 338 lifetime nonsmokers European DRD5
Yoshida et al. 2001 
(Japan)
77 current smokers 57 former smokers  
198 lifetime nonsmokers
East Asian DRD2
David et al. 2002 
(United Kingdom)
266 current smokers 270 former smokers  
265 lifetime nonsmokers
NR COMT
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(country) Polymorphism Primary phenotype Main findings
Noble et al. 1994 
(United States)
*TAQ1A Smoking status Association with smoking status (current and former 
smokers vs. lifetime nonsmokers)
Comings et al. 1996 
(United States)
*TAQ1A Smoking status Association with smoking status




Smoking status  
Packs/day
Association of DRD1 and DRD2 genes with smoking status 
and packs/day
Lerman et al. 1997 
(United States)
VNTR Smoking status No association with smoking status
Shields et al. 1998 
(United States)
VNTR Smoking status  
Cigarettes/day
Association with smoking status in participants of African 
ancestry
Singleton et al. 1998 
(United Kingdom)
*TAQ1A Smoking status  
Nicotine dependence
No association with smoking status or nicotine dependence




Smoking status  
Age at smoking 
initiation
No association with smoking status
Association of both polymorphisms with age at smoking 
initiation 




Smoking status Association of DAT and DRD2 genes with smoking status in 
participants of European ancestry
Sabol et al. 1999 
(United States)
VNTR Smoking status Association with smoking status (current vs. former 
smokers)




Smoking status Association of FOK1 polymorphism with smoking status 
(nicotine-dependent vs. nonnicotine-dependent or light 
smokers)




Smoking status No association with smoking status





Smoking status No association with smoking status
Jorm et al. 2000 
(Australia)
VNTR Smoking status No association with smoking status





Cigarettes/day Association of DβH and MAOA genes with cigarettes/day




Smoking status  
Cigarettes/day
Association of both polymorphisms with smoking status 
(current vs. former smokers and lifetime nonsmokers) and 
cigarettes/day
Sullivan et al. 2001 
(United States)
Haplotype Smoking status  
Nicotine dependence
No association with smoking status 
Association with nicotine dependence, although marginal




Smoking status Association of TAQ1A polymorphism only with smoking 
status (current vs. former smokers and lifetime 
nonsmokers)








   Population      
Study
(country) Study group Controls
Dominant
ancestry Gene
Hamajima et al. 2002 
(Japan)
226 current smokers 133 former smokers  
434 lifetime nonsmokers
East Asian DRD2
Johnstone et al. 2002 
(United Kingdom)
1,524 current smokers NA European DβH 
MAOA
Qi et al. 2002 
(China)
174 current smokers 152 former smokers and 
lifetime nonsmokers
East Asian DRD2
Vandenbergh et al. 2002 
(United States)




Ito et al. 2003 
(Japan)
147 current smokers 99 former smokers 
258 lifetime nonsmokers
East Asian MAOA 
MAOB
Lee et al. 2003 
(South Korea)
94 current smokers 93 lifetime nonsmokers East Asian DRD2







Audrain-McGovern et al. 
2004a 
(United States)
292 adolescents who ever 
smoked
NA European DRD2 
DAT
Johnstone et al. 2004b 
(United Kingdom)
732 current smokers 243 lifetime nonsmokers European DRD2
Ling et al. 2004 
(China)
668 current smokers Family-based study East Asian DAT
Luciano et al. 2004 
(Australia)
769 current smokers and 
nonsmokers
Family-based study European DRD4







Colilla et al. 2005 
(United States)
277 female current smokers 505 female former smokers European and 
African
COMT
Costa-Mallen et al. 2005 
(United States)
232 persons who ever 
smoked
158 lifetime nonsmokers European DRD2 
MAOB
Elovainio et al. 2005 
(Finland)
37 current smokers 113 nonsmokers European DRD4
Freire et al. 2006 
(Brazil)
220 alcoholic and 
nonalcoholic smokers
112 nonsmokers European DRD2 
DβH
Laucht et al. 2005 
(Germany)
184 adolescents who ever 
smoked
119 adolescent lifetime 
nonsmokers
European DRD4
Zetteler et al. 2005 
(United Kingdom)
141 current smokers NA European DβH
Note: NA = not applicable; NR = data not reported.
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Smoking status Association of TAQ1A polymorphism only with smoking 
status in men (current vs. former smokers and lifetime 
nonsmokers)




Cigarettes/day No association with cigarettes/day






Association of *TAQ1A polymorphism only with cigarette 
use 
No association with smoking status
Vandenbergh et al. 
2002 
(United States)
VNTR Smoking status Association with smoking status (lifetime nonsmokers vs. 
former and current smokers)






Association of MAOA gene with smoking status among 
women and nicotine dependence among men
Lee et al. 2003 
(South Korea)
*TAQ1A Smoking status Association with smoking status 
Evidence of heterosis in women
Anney et al. 2004 
(Australia)









Association of DRD2 gene with smoking progression in 
those exposed to nicotine
Johnstone et al. 2004b 
(United Kingdom)
*TAQ1A Smoking status 
Cigarettes/day
No association with smoking status or cigarettes/day
Ling et al. 2004 
(China)
*RS27072 Nicotine dependence 
Age at smoking 
initiation
No association with nicotine dependence 
Association with age at smoking initiation among nicotine-
dependent smokers only
Luciano et al. 2004 
(Australia)
VNTR Smoking status 
Cigarettes/day
No association with smoking status or cigarettes/day
Olsson et al. 2004 
(Australia)
VNTR Nicotine dependence Association with nicotine dependence




Smoking status Association with smoking status





Smoking status No association with smoking status, although there was 
interactive effect between DRD2 and MAOB genes in men
Elovainio et al. 2005 
(Finland)
VNTR Smoking status Association with smoking status




Smoking status Association of DRD2 gene with smoking status 
Marginal association of DβH gene with smoking status
Laucht et al. 2005 
(Germany)
VNTR Smoking status 
Daily smoking
Association with smoking status and daily smoking in men
Zetteler et al. 2005 
(United Kingdom)




Table 4.9 Studies of candidate genes for serotonin and smoking behavior
   Population   
Study
(country) Study group Controls Dominant ancestry Gene
Lerman et al. 1998 
(United States)
268 current smokers 230 lifetime nonsmokers European and 
African
5HTT
Ishikawa et al. 1999 
(Japan)
202 current smokers 103 former smokers 
82 lifetime nonsmokers
East Asian 5HTT
Hu et al. 2000 
(United States)
177 current smokers 124 former smokers 
458 lifetime nonsmokers
European 5HTT
Lerman et al. 2000 
(United States)
185 current smokers None European and 
African
5HTT
McKinney et al. 2000 
(United Kingdom)
225 current smokers None European MAOA
Lerman et al. 2001 
(United States)
249 current smokers 202 lifetime nonsmokers European TPH
Johnstone et al. 2002 
(United Kingdom)
1,524 current smokers None European MAOA
Ito et al. 2003 
(Japan)
147 current smokers 99 former smokers 
258 lifetime nonsmokers
East Asian MAOA 
MAOB
Mizuno et al. 2004 
(Japan)
233 current smokers 135 former smokers 
667 lifetime nonsmokers
East Asian TPH
Brody et al. 2005 
(United States)
110 current smokers  
100 former smokers
275 lifetime nonsmokers European and 
African
5HTT
Gerra et al. 2005 
(Italy)
107 adolescents who ever 
smoked
103 adolescent lifetime 
nonsmokers
European 5HTT
Kremer et al. 2005 
(Israel)
244 persons who ever 
smoked
486 lifetime nonsmokers Other 5HTT
Munafò et al. 2005a 
(United Kingdom)
141 current smokers None European 5HTT
Reuter and Hennig 2005 
(Germany)
108 current smokers 144 nonsmokers European TPH
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Lerman et al. 1998 
(United States)
LPR Smoking status No association with smoking status
Ishikawa et al. 1999 
(Japan)
LPR Smoking status Association with smoking status (current vs. former smokers 
and lifetime nonsmokers)
Hu et al. 2000 
(United States)
LPR Smoking status Association with smoking status (current vs. former smokers 
and lifetime nonsmokers) among participants with high levels 
of neuroticism
Lerman et al. 2000 
(United States)
LPR Nicotine dependence Association of neuroticism with nicotine dependence among 
those with short allele
McKinney et al. 2000 
(United Kingdom)
C1460T Cigarettes/day Association with cigarettes/day
Lerman et al. 2001 
(United States)
A779C Smoking status 
Nicotine dependence
No association with smoking status or nicotine dependence 
Association with age at smoking initiation
Johnstone et al. 2002 
(United Kingdom)
C1460T Cigarettes/day No association with cigarettes/day






Association of MAOA gene with smoking status among women 
and with nicotine dependence among men
Mizuno et al. 2004 
(Japan)
C218A Smoking status No association with smoking status
Brody et al. 2005 
(United States)
LPR Smoking status 
Nicotine dependence
No association with smoking status or nicotine dependence
Gerra et al. 2005 
(Italy)
LPR Smoking status Association with smoking status






Association with smoking status (persons who ever smoked vs. 
lifetime nonsmokers) 
No association with nicotine dependence
Munafò et al. 2005a 
(United Kingdom)
LPR Nicotine dependence Association with nicotine dependence
Reuter and Hennig 
2005 
(Germany)
A779C Smoking status 
Nicotine dependence
Association with nicotine dependence (nonsmokers scored as 
having zero nicotine dependence)
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Table 4.10 Other studies of candidate genes for smoking behavior
   Population      
Study 
(country) Study group Controls
Dominant 
ancestry Gene
Garciá-Closas et al. 1997 
(United States)
315 current smokers None European CYP1A1 
GSTM1 *NULL
Comings et al. 2001 
(United States)
12 current smokers 
326 nicotine-dependent 
smokers 
59 former smokers 
120 lifetime nonsmokers 
399 nondependent controls
European CCK
Hamajima et al. 2001 
(Japan)
126 current smokers 837 nonsmokers East Asian IL-1β
Pitha et al. 2002 
(Czech Republic)
75 current and former 
smokers
60 lifetime nonsmokers European CD14
Uno et al. 2002 
(Japan)
124 current smokers 131 former smokers 
690 lifetime nonsmokers
East Asian IL-1β
Füst et al. 2004 
(Hungary)
171 persons who ever 
smoked
140 lifetime nonsmokers European TNF2 
C4A 
C4B
Smits et al. 2004 
(The Netherlands)
20,938 persons, including 
current and former 
smokers and lifetime 
nonsmokers





Beuten et al. 2005 
(United States)
990 current smokers 
286 nonsmokers
Family-based study European and 
African
GABAB2
Liu et al. 2005 
(Japan)
213 current smokers 71 former smokers 
55 lifetime nonsmokers
East Asian Various
Ma et al. 2005 
(United States)
1,568 current smokers 
469 nonsmokers
Family-based study European and 
African
DDC
Takimoto et al. 2005 
(Japan)
109 current smokers 162 nonsmokers East Asian CCK 
CCKAR
Note: NA = not applicable.
aPack-years = the number of years of smoking multiplied by the number of packs of cigarettes smoked per day.
dopamine pathway is widely considered to be central in 
the development of nicotine dependence (see “Patho-
physiology of Nicotine Addiction” earlier in this chapter). 
Releasing dopamine after nicotine administration acti-
vates postsynaptic dopamine receptors, including the D2 
receptor, whereas DβH is involved in the synthesis of nor-
adrenalin from dopamine (Koob and Le Moal 2001). 
The *TAQ1A (C32806T) allele of the DRD2 gene is 
associated with reduced numbers of dopamine D2 recep- 
tors in the corpus striatum (Thompson et al. 1997), 
but the functional significance of this variant remains 
unclear. The *1368A allele of the DβH gene is associated 
with smoking status (McKinney et al. 2000), although this 
polymorphism is not considered functional. The nicotine 
patch was significantly more effective for smoking cessa-
tion than was a placebo for carriers of the *A1 allele of 
the DRD2 gene but not among those who were homozy-
gous for the more common *A2 allele (Johnstone et al. 
2004b). The difference in the effects of treatment in the 
genotype groups was significant after the first week of 
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Garciá-Closas et al. 
1997 
(United States)
*MSP1 Pack-yearsa No association with pack-years
Comings et al. 2001 
(United States)
C-45T Smoking status 
Nicotine 
dependence
Association with smoking status (current vs. former 
smokers vs. lifetime nonsmokers) and nicotine dependence 
(nicotine-dependent smokers vs. nondependent controls)
Hamajima et al. 2001 
(Japan)
C-31T Smoking status No association with smoking status
Pitha et al. 2002 
(Czech Republic)
C-159T Smoking status Association with smoking status (current and former 
smokers vs. lifetime nonsmokers)
Uno et al. 2002 
(Japan)
C-31T Smoking status No association with smoking status







Association of TNF2 gene with smoking status (persons 
who ever smoked vs. lifetime nonsmokers)







Smoking status No association with smoking status




Association with nicotine dependence
Liu et al. 2005 
(Japan)
Various Smoking status Association of OGG1, 5HTT, EPHX1, ESR1, and CYP17A1 
genes with smoking status




Association with nicotine dependence





Smoking status Association of CCK gene with smoking status
treatment but not at the end of 12 weeks of treatment. 
The nicotine patch was highly effective among smokers 
with both the DRD2 *A1 allele and the DβH *A allele, but 
it was less effective for smokers with other genotypes. This 
genetic association with treatment response was signifi-
cant at both 1 and 12 weeks of treatment, which suggests 
that the short-term efficacy of the nicotine patch may be 
modulated by DRD2 and DβH genes. Longer follow-up in 
this analysis supported the association of the DRD2 vari-
ant with abstinence from smoking at 6- and 12-month 
follow-ups, although this effect was observed only among 
women and the results for the DβH gene were not 
reported (Yudkin et al. 2004).
The second pharmacogenetic trial of NRT was an 
open-label trial of the nicotine patch versus nicotine 
nasal spray. This trial examined the role of the gene for 
the µ-opioid receptor (OPRM1) (Lerman et al. 2004). 
The opioid receptor is the primary site of action for the 
rewarding effects of the endogenous opioid peptide 
β-endorphin (Zadina et al. 1997), which is released in 
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response to nicotine (Davenport et al. 1990; Boyadjieva 
and Sarkar 1997). Exon 1 of the human OPRM1 gene 
includes a common A118G (ASN40ASP) missense SNP. 
The *ASP40 variant has been associated with reduced 
messenger RNA (mRNA) and lower protein levels for the 
receptor (Zhang et al. 2005). Smokers carrying the OPRM1 
*ASP40 variant were significantly more likely than those 
who were homozygous for the *ASN40 variant to be 
abstinent from smoking at the end of the treatment phase 
(Lerman et al. 2004). The differential treatment response 
among smokers was most pronounced for the nicotine 
patch, modest and nonsignificant for nicotine nasal spray, 
and nonsignificant for a placebo, in the bupropion clinical 
trial described in the next section. A longitudinal analy-
sis in the nicotine patch group revealed a dose-response 
effect of the nicotine patch. The effect of the genotype in 
the *ASP40 group was greatest during the nicotine patch 
treatment of 21 milligrams (mg), but the effect was reduced 
as the treatment was tapered and disappeared after discon-
tinuation. In addition, smokers who carried the *ASP40 
variant gained less weight during the treatment period and 
reported greater reductions in symptoms of negative 
mood than did those who were not carriers of the variant. 
These findings suggest that smokers carrying the *ASP40 
variant may be candidates for maintenance therapy with 
the 21-mg nicotine patch.
Additional investigations provided evidence for an 
association of the COMT VAL158 MET polymorphism with 
prospective smoking cessation in an NRT open-label trial. 
Female smokers treated with either the nicotine patch or 
nicotine nasal spray who carried the low-activity allele, 
which is associated with a slower degradation of dopa-
mine, were significantly more likely than were those who 
did not carry this allele to stop smoking independent of 
the treatment. These findings are consistent with those 
reported in a retrospective comparison of female current 
versus female former smokers in a case-control study 
(Table 4.8) (Colilla et al. 2005).
Bupropion
The first pharmacogenetic analysis of treatment 
for tobacco dependence was conducted as part of a pla-
cebo-controlled clinical trial of bupropion for smoking 
cessation (Lerman et al. 2002) that focused on CYP2B6. 
Smokers who carried the CYP2B6 variant, which, to some 
extent, is associated with slower nicotine metabolism, 
reported greater increases in craving for cigarettes after 
the target date for smoking cessation and had significantly 
higher rates of relapse to smoking than did those with-
out the variant. These effects were modified by a signifi-
cant interaction among gender, genotype, and treatment, 
which suggests that bupropion attenuated the effects of 
genotype among female smokers.
A second report from this clinical trial (Lerman 
et al. 2006) examined two SNPs that may influence the 
expression of the DRD2 receptor. These SNPs included an 
insertion/deletion variant in the promoter region of the 
DRD2 gene (DRD2 -141C *INS/*DEL). The transcrip-
tional efficiency of the more common *-141C INS C allele 
is greater than that of the variant with the *-141C DEL C 
allele (Arinami et al. 1997), and a functional synonymous 
SNP in the DRD2 (C957T) gene decreases mRNA stabil-
ity and protein synthesis (Duan et al. 2003). At the end of 
the treatment phase, a statistically significant interaction 
between the DRD2 -141C *INS/*DEL genotype and the 
treatment indicated a more favorable response to bupro-
pion among smokers homozygous for the *INS C allele 
than that for smokers carrying a *DEL C allele.
One study investigated whether the *TAQ1A poly-
morphism in the DRD2 gene is associated with smoking 
cessation outcomes after treatment with a combination of 
bupropion and behavioral counseling in smokers enrolled 
in an open-label randomized trial of effectiveness (Swan et 
al. 2005). Compared with women who were homozygous 
for the *A2 allele, women with at least one *A1 allele were 
significantly more likely to stop taking bupropion because 
of side effects from the medication and at 12 months 
were somewhat more likely to report smoking. However, 
relapse to smoking by 12 months after treatment was not 
statistically significant and constituted only a trend. Sig-
nificant associations or trends were not observed in men.
In addition, another study reported data on 239 
smokers who were offered bupropion in a group of general 
practice physicians in the United Kingdom (Johnstone 
et al. 2004a). Only 54 of these smokers made an active 
attempt to stop smoking. Allele frequencies for polymor-
phisms in the DRD2, DAT, DβH, and MAOA genes were 
reported. However, the sample size was insufficient for 
formal analysis of the effects of these polymorphisms on 
smoking cessation.
Varenicline
Varenicline, a partial agonist at the α4β2 nAChR, 
was approved by FDA as a treatment for smoking cessa-
tion in 2006 (USFDA 2006). Several large trials provide 
evidence that varenicline was more effective than bupro-
pion or placebo as an aid to smoking cessation (Gonza-
les et al. 2006; Jorenby et al. 2006; Tonstad et al. 2006). 
Because of the efficacy and relative target selectivity (e.g., 
targeting a specific receptor subtype) of this compound, 
pharmacogenetic studies of varenicline are warranted. 
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Summary and Future Directions
Research on genetic influences on smoking behav-
ior has yielded important insights about the biobehavioral 
basis of nicotine dependence. There is strong and consis-
tent evidence from studies of twins that smoking initia-
tion and nicotine dependence are influenced by heritable 
factors. Support for the role of functional genetic varia-
tion in nicotine-metabolizing enzymes (e.g., CYP2A6) and 
genetic variation in nAChR subunit genes (e.g., CHRNA5) 
is largely consistent, although the extent of their con-
tribution to nicotine dependence is unclear. Additional 
but inconsistent evidence supports the roles of genetic 
variants in the dopamine pathways. Although the phar-
macogenetic approach to smoking cessation holds early 
promise, larger studies in more diverse populations are 
required (Lerman et al. 2007). Designs for case-control 
studies of genetic association are limited, partly by the 
use of crude measures of smoking behavior phenotypes. 
This finding supports the importance of future studies 
to explore associations of candidate genes with endophe-
notypes, which are intermediate phenotypes of smoking 
behavior. Some phenotypes are biologically more proxi-
mal to their genetic antecedents than are complex 
behavioral phenotypes, because biologic proximity affords 
a more homogeneous phenotype and a stronger genetic 
signal. Endophenotypes that may be relevant to nicotine 
dependence encompass acoustic startle response, includ-
ing prepulse inhibition and affective modulation of the 
acoustic startle (Hutchison et al. 2000); measures of the 
reinforcing value of nicotine in a paradigm of behavioral 
choice (Blendy et al. 2005; Ray et al. 2006); various para-
digms of craving related to reactivity to cues (Tiffany et 
al. 2000); measures of attentional bias, such as the modi-
fied Stroop task (Munafò et al. 2003) and the dot-probe 
task (Waters et al. 2003a); and patterns of withdrawal after 
smoking cessation (David et al. 2003). The list of candidate 
endophenotypes is growing rapidly, and these may offer 
powerful measures for genetic analysis, although the role 
of these putative endophenotypes remains speculative in 
some cases. 
Also deserving of attention is the study of the inter-
action between genetic variants, nicotine dependence, 
and disorders comorbid with nicotine dependence (e.g., 
depression and anxiety). Two studies suggest that smok-
ing behaviors and nicotine dependence are influenced 
by an interaction between the 5HTT gene and anxiety-
related traits (Hu et al. 2000; Lerman et al. 2000). In 
one study, however, this association was not replicated 
(Munafò et al. 2005a). A better understanding of genetic 
influences on nicotine dependence in different psychiatric 
populations would be valuable for the development of tar-
geted medications.
Pharmacogenetic investigations of smoking cessa-
tion treatments have provided promising initial evidence 
that genetic variations in drug targets, such as the dopa-
mine system or nAChRs, may predict responses to treat-
ments. Only a few such studies have been conducted, and 
these have focused on the two FDA-approved approaches 
for smoking cessation pharmacotherapy: bupropion and 
NRT. Several additional pharmacotherapies have been 
tested for efficacy in smoking cessation (Lerman et al. 
2005). Although the overall effects of alternate pharma-
cotherapies, such as fluoxetine and naltrexone, have been 
modest, it is possible that subgroups of smokers who 
benefit from such treatments can be identified by geno-
type. Although pharmacogenetic research on smoking 
cessation treatments is in the early stages, this research 
may ultimately be used to tailor pharmacotherapies to 
smokers most likely to benefit, thereby improving the 
efficacy. Emerging health policy and ethical issues related 
to genetically tailored smoking cessation treatments are 
important to consider (Shields et al. 2004), as are barriers 
to and facilitators of the integration of genetic tests into 
smoking cessation in clinical practice (Shields et al. 2004; 
Munafò et al. 2005b).
Recent studies have begun to provide compelling 
support for association of some common genetic variants 
with smoking behavior and related disease phenotypes, 
such as SNPs within the CHRNA5/A3/B4 gene clus-
ter (Amos et al. 2008; Hung et al. 2008; Liu et al. 2008; 
Thorgeirsson 2009); however, the effect sizes described in 
these studies are very small, and it has been suggested that 
efforts may need to be directed elsewhere if the genetic 
architecture of complex traits is to be fully elucidated 
(Goldstein 2009; Hardy and Singleton 2009; Hirschhorn 
2009). In particular, the hypothesis that common pheno-
types, such as nicotine dependence, will be explained by 
common genetic variants has been questioned because 
the  effect sizes observed to date suggest an unrealistically 
large number of alleles to explain the known heritability 
of a given phenotype (Goldstein 2009).
A complementary approach may be to seek out 
less common genetic variations that may have a more 
profound effect on phenotypes of interest. For example, 
recent studies have identified a possible role for copy 
number variants and de novo mutations in the etiology 
of psychiatric phenotypes such as schizophrenia (Xu et al. 
2008) and autism (Sebat et al. 2007). Although no stud-
ies have yet investigated the role of copy number variants 
in smoking behavior, such studies are likely to emerge in 
the near future. As our understanding of the functional 
biology of genetic variation continues to develop, so too 
will the technologies and methods available to dissect the 




Prevalence and Trajectory Toward Nicotine Dependence
Genes appear to predispose persons to smoking 
initiation and persistence and possibly are related to the 
extent of difficulty a person has in smoking cessation. 
Genetic transmission may include inheritance of poly-
morphisms of specific genes that affect responses of the 
body and the brain to nicotine. These responses include 
the rate of metabolism of nicotine, receptor sensitivity to 
nicotine and to certain neurotransmitters, and the levels 
of neurotransmitters available at neural synapses. These 
individual differences in response to nicotine are likely to 
affect the trajectory toward the development of nicotine 
dependence. Characterization of differences in trajecto-
ries has primarily focused on the adolescent population, 
because most smokers begin smoking cigarettes during 
this period of life. The next section describes the preva-
lence of adolescent smoking to increase understanding of 
the scope for potential development of dependence, dif-
ferences in trajectory patterns toward dependence, and 
determinants for developing nicotine addiction. Epide-
miologic, laboratory, and clinical studies are described to 
elucidate the emerging science in this area.
Epidemiology of Adolescent 
Smoking
A large body of epidemiologic literature has exam-
ined the prevalence of smoking, its initiation in adoles-
cence, and the progression among adolescents from 
experimentation to regular use of cigarettes. This lit-
erature includes research on national samples in both 
school-based studies (University of Michigan 2007) and 
household studies (Substance Abuse and Mental Health 
Services Administration 2004). However, compared with 
an extensive amount of literature that examines adoles-
cent smoking, work on adolescent nicotine dependence is 
more recent, so there are fewer empirical studies on early 
antecedents of nicotine addiction than on the anteced-
ents of adolescent smoking (Colby et al. 2000a). Thus, in 
reviewing existing data, it is important to separate ciga-
rette smoking and nicotine addiction as distinct outcomes 
(Hughes 2001). In addition, because most studies have 
focused on adolescent cigarette smoking rather than other 
forms of tobacco use, this review is restricted to studies of 
cigarette smoking.
Subsequent data suggest that approximately one 
in five high school students report “current” smoking, 
defined as any smoking in the past month (CDC 2008b). 
Smoking prevalence increases with age throughout 
adolescence. For example, data from the Monitoring the 
Future study (Johnston et al. 2007) show that current 
smoking is reported by 8.7 percent of 8th graders, 14.5 
percent of 10th graders, and 21.0 percent of 12th grad-
ers. In addition to age, the prevalence of adolescent smok-
ing varies with race and ethnicity. The highest rates were 
reported by American Indian and Alaska Natives, followed 
by non-Hispanic Whites, Hispanics, African Americans, 
and Asians (National Institute on Drug Abuse 2003). Few 
characteristics of adolescent smoking differed by gender, 
but adolescents with less-educated parents, lower aspira-
tions for higher education, and rural residence are more 
likely to smoke cigarettes (Johnston et al. 2007). Finally, 
some adolescents smoke at high levels of frequency and 
quantity. For example, daily smoking is reported by 4.0 
percent of 8th graders, 7.6 percent of 10th graders, and 
12.2 percent of 12th graders; and 1.5 percent of 8th grad-
ers, 3.3 percent of 10th graders, and 5.9 percent of 12th 
graders smoke one-half pack or more of cigarettes per day 
(Johnston et al. 2007).
Measuring Nicotine Dependence in 
Adolescents
Colby and colleagues (2000b) summarized the lit-
erature on methods of measuring adolescent nicotine 
dependence. These researchers note that the two major 
approaches to measurement were formal diagnostic mea-
sures, such as interviews based on the DSM-IV criteria (APA 
1994) and brief self-report measures that were most often 
modifications of the FTQ (Fagerström 1978). A brief self-
report measure, Hooked on Nicotine Checklist (HONC), 
has been developed and used in longitudinal studies of the 
early acquisition of nicotine dependence (DiFranza et al. 
2002a; O’Loughlin et al. 2003). This measure defines the 
onset of nicotine dependence as the point of experienc-
ing loss of autonomy over tobacco use (DiFranza et al. 
2002a). Although multiple measures have proved useful 
in predicting aspects of smoking behavior, as previously 
noted in this chapter, there is no gold standard for assess-
ing nicotine dependence, either in adolescents or adults 
(Colby et al. 2000a,b; O’Loughlin et al. 2002).
The complexity of assessing adolescent nicotine 
dependence is evident from the modest correlation found 
between two of the most common methods for measur-
ing	dependence—DSM-based diagnoses and FTQ-derived 
self-report	 measures—and	 the	 fact	 that	 these	 mea-
sures do not identify the same adolescents as nicotine 
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dependent (Kandel et al. 2005). This finding has also 
been reported for adult smokers (Moolchan et al. 2002). 
Kandel and colleagues (2005) found a low agreement 
between DSM-based and FTQ-derived measures, except 
with high cigarette consumption (≥16 cigarettes per day). 
The DSM-based measure identified a higher prevalence 
of adolescent dependence because smokers met diagnos-
tic criteria at much lower quantities of cigarettes than 
with the FTQ-derived measure (e.g., 60 versus 19 percent 
among those adolescent smokers smoking two to five ciga-
rettes per day). Furthermore, for adolescent smokers who 
smoked a low number of cigarettes per day (e.g., 2.5 ciga-
rettes), increasing depressive symptoms were associated 
with higher risk for DSM-diagnosed dependence (Kandel 
et al. 2005). This association between DSM diagnoses of 
tobacco dependence and depression has also been reported 
in adults (Breslau and Johnson 2000) (see “Epidemiol-
ogy of Tobacco Use and Nicotine Dependence in Adults” 
later in this chapter). These findings led the investigators 
to believe that the DSM criteria identify a psychological 
component or behavioral symptoms common to both 
dependence and depression, which are not found in the 
FTQ-derived measure. Finally, Kandel and colleagues 
(2005) examined ethnic differences in dependence and 
found that non-Hispanic Whites had higher prevalence 
of dependence than other racial or ethnic groups, but 
this difference was accounted for by higher prevalence of 
smoking among this population. Once adjustment was 
made for differences in prevalence of smoking, differences 
by ethnicity were attenuated or eliminated. Thus, exten-
siveness of smoking must be considered when measuring 
dependence in youth.
Prevalence of Symptoms and Diagnoses in 
Adolescence
Studies suggest that adolescents report symptoms 
of dependence even at low levels of cigarette consump-
tion (Colby et al. 2000a,b; Hughes 2001; DiFranza et al. 
2002b; Panday et al. 2007). The difference in sensitivity 
to nicotine in adolescents and adults is also reported in 
animal models (Slotkin 2002; Adriani et al. 2003; Torres 
et al. 2008). For example, Levin and colleagues (2003) 
found that when rats were first exposed to nicotine in 
adolescence, they self-administered more nicotine than 
did rats exposed in adulthood. These differences in self-
administration by age at first exposure persisted into 
adulthood. Similarly, Beluzzi and colleagues (2004) found 
that a single nicotine injection during early adolescence 
was sufficient to establish conditioned place preference in 
rats, whereas such injections in late adolescence or adult-
hood were not sufficient. Thus, paradigms for both self-
administration and conditioned place preference in rats 
suggest that adolescence may be a developmental stage of 
particular vulnerability to the effects of tobacco exposure. 
Furthermore, a study by Torres and colleagues (2008), 
using a conditioned place preference paradigm, showed 
that adolescent rats not only found lower doses more rein-
forcing but also found higher doses less aversive compared 
with adult rats. If so, adolescents may be particularly vul-
nerable to developing tobacco dependence. DiFranza and 
colleagues (2002b) concluded that, on average, the onset 
of an initial symptom of tobacco dependence occurred 
when adolescents smoked only two cigarettes once a week. 
Even adolescents who smoked only once or twice in their 
lives reported an average of 1.3 symptoms on the HONC 
(1.0 for males and 1.4 for females) (O’Loughlin et al. 
2003). As a cautionary note, the interpretation of the 
results relies on whether the HONC reflects valid symp-
toms of dependence.
Kandel and Chen (2000) examined a proxy measure 
of DSM diagnosis of nicotine dependence in data from 
the National Household Survey on Drug Abuse (now the 
National Survey on Drug Use & Health). They reported 
that, compared with adults, adolescents met the criteria 
for dependence at lower levels of cigarette consumption. 
Some researchers have suggested that these age dif-
ferences reflect a greater sensitivity to nicotine among 
adolescents than among adults (Kandel and Chen 2000). 
However, researchers have also noted that these age dif-
ferences can reflect cohort effects (Breslau et al. 2001; 
Hughes 2001). That is, given the national reductions in 
smoking prevalence are accompanied by greater social 
proscriptions against smoking, smoking among more 
recent (younger) cohorts may represent more “hard core” 
smoking with greater levels of dependence (Breslau et 
al. 2001), although other researchers have questioned 
whether a “hardening of smokers” has actually occurred 
(O’Connor et al. 2006).
Reported prevalence of nicotine dependence among 
current adolescent smokers varies depending on whether 
heavy or light smokers are considered. In one study, 19.4 
percent of adolescents who smoked weekly were consid-
ered to be dependent on the basis of an analog measure 
from the ICD criteria (O’Loughlin et al. 2003). Even less-
than-weekly tobacco use may result in progression toward 
nicotine dependence. A later study found that the most 
susceptible youth lose autonomy over tobacco within one 
or two days of first inhaling from a cigarette. The appear-
ance of tobacco withdrawal symptoms and failed attempts 
to stop smoking can precede daily smoking dependence, 
as defined by ICD-10, and typically appears before con-
sumption reaches two cigarettes per day (DiFranza et al. 
2007). One study using data from the National Survey 
on Drug Use & Health reports a 28-percent prevalence 
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of last-year nicotine dependence (based on symptoms 
approximating DSM-IV dependence criteria) among ado-
lescents aged 12 through 17 years who smoked during 
the last month, which was only slightly lower than the 
prevalence for adults (e.g., 30 to 32 percent among those 
aged 18 through 49 years) (Kandel and Chen 2000). The 
majority of adolescent daily smokers meet criteria for 
nicotine dependence. For example, Kandel and colleagues 
(2005) found that 87 percent of adolescent daily smokers 
met DSM criteria and 63 percent met the modified FTQ 
criteria (score >3). Similarly, O’Loughlin and colleagues 
(2003) found that 65.9 percent of seventh graders who 
smoked daily met ICD criteria.
There has also been interest in whether adolescents 
experience withdrawal symptoms on the discontinuation 
of smoking, either as part of an attempt to stop smoking 
or during periods when they cannot smoke. Colby and col-
leagues (2000a) summarized six retrospective studies in 
which adolescent smokers recalled their experiences dur-
ing periods of nonsmoking. Most adolescents reported at 
least one symptom of withdrawal. Craving was the most 
commonly reported symptom upon abstinence. Fernando 
and colleagues (2006) analyzed data from the National 
Youth Tobacco Survey and reported that 63 percent of 
adolescents who smoked five or fewer cigarettes per day 
reported at least one withdrawal symptom. Hanson and 
colleagues (2003) examined the effects of the nicotine 
patch on adolescent-reported withdrawal symptoms. 
Compared with the placebo group, the nicotine patch 
group had lower scores for withdrawal symptoms.
Killen and colleagues (2001) recruited adolescents 
from alternative high schools and from a homeless shelter 
who smoked at least 10 cigarettes per day. There were two 
assessment sessions. Participants were randomly assigned 
to the nicotine patch or the placebo patch for the second 
assessment. The researchers found a decrease in heart rate 
across sessions only for the placebo condition. However, 
they found significant increases in self-reported with-
drawal symptoms for both the nicotine patch and the 
placebo patch conditions. The most intense withdrawal 
symptoms were craving and anxiety, which were not re-
lieved by the nicotine patch. Finally, some adolescents who 
believed they had worn a nicotine patch had expectancy 
effects; they reported less craving and frustration and a 
greater ability to concentrate. Together, these results sug-
gest that adolescent smokers experience withdrawal symp-
toms but that expectancy effects also influence findings. 
Prokhorov and colleagues (2005) suggest caution about 
interpreting nonspecific symptoms such as irritability, 
depression, insomnia, and trouble concentrating, which 
can have multiple causes besides tobacco withdrawal.
Some animal data suggest that adolescents experi-
ence a dampened withdrawal response compared with that 
in adults (O’Dell et al. 2004, 2006). O’Dell and colleagues 
(2004) precipitated withdrawal with mecamylamine in 
rats receiving long-term administration of nicotine versus 
saline and found mecamylamine-induced withdrawal in 
adult rats but not in adolescent rats. These findings in ani-
mal studies, combined with limited clinical data, indicate 
the need for further studies of differences in withdrawal 
symptoms by age.
Trajectories of Smoking from Adolescence to 
Adulthood
Cigarette smoking shows age-related trends with 
typical initiation of smoking occurring in early adoles-
cence. Retrospective data from the 1999 National Survey 
on Drug Use & Health (Kopstein 2001) suggest that the 
average age at first use of cigarettes is 15.4 years and the 
average age at initiation of daily smoking is 18 years. Data 
from both retrospective and longitudinal studies suggest 
that smoking prevalence or incidence of daily smoking 
in adolescents increases over time, peaks in young adult-
hood, and then declines (Chen and Kandel 1995; Bre-
slau et al. 2001). However, these data are limited in that 
they describe a single “average” trajectory of age-related 
changes in smoking behavior, which obscures substantial 
heterogeneity among smokers. For example, there is vari-
ation in age at smoking initiation (Breslau et al. 1993a; 
Chassin et al. 2000) in the time it takes to progress to daily 
smoking, and in the time to develop dependence symp-
toms (DiFranza et al. 2002b).
Advances in mixture modeling (Nagin 1999; Muthén 
and Muthén 2000) have enabled longitudinal studies 
to identify multiple age-related trajectories of smoking 
behavior. Some of these studies conducted follow-up on 
participants through adolescence (Colder et al. 2001; 
Audrain-McGovern et al. 2004b; Abroms et al. 2005). Wills 
and colleagues (2004) performed cluster analysis rather 
than mixture modeling. These studies have all identified 
multiple trajectory groups, which typically include a group 
with early-onset (7th grade) regular smoking (smoking 
at least a few times a week); a group with experimental 
smoking (smoking occasionally each year); nonsmokers; 
and a group with intermediate- (regular smoking in 9th 
grade) and late-onset (regular smoking in 10th grade) 
regular smoking. These studies do not assess tobacco 
dependence, and even the late-onset groups were younger 
than age 18 years. Karp and colleagues (2005) studied only 
adolescents who had started to smoke. Most of their par-
ticipants remained at low levels of smoking, but there was 
heterogeneity in the speed at which the others escalated 
their cigarette use, and youth across all rates of escalation 
were more likely to show symptoms of nicotine depen-
dence than those individuals who maintained low levels 
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of cigarette use. Soldz and Cui (2002) conducted follow-
up on participants through 12th grade. They identified 
the following groups: nonsmokers, experimental smok-
ers, smokers with early or late escalation of smoking, and 
stable continuing smokers. Their findings are noteworthy 
for identifying a group who stopped smoking, which was 
absent in other studies.
Several studies had follow-up from adolescence to 
adulthood. White and colleagues (2002b) recruited 374 
adolescents in New Jersey through random telephone 
sampling. The participants were interviewed five times 
from age 12 years to age 30 or 31 years. The investigators 
identified three trajectory groups: (1) nonsmokers and 
experimental smokers; (2) occasional smokers and smok-
ers whose smoking peaked at 18 years of age and then 
declined; and (3) heavy smokers and regular smokers. Pre-
dictor variables distinguished between nonsmoking and 
smoking trajectories but could not predict heavy smoking 
among smokers. Predictor variables were disinhibition 
items from the Zuckerman Sensation Seeking Scale, low 
school grades, and use of other drugs. Chassin and col-
leagues (2000) recruited 8,556 adolescents in 6th through 
12th grades in a midwestern county school system and 
surveyed them annually in 1980 through 1983. Addi-
tional follow-ups were conducted in 1987 and 1993 and 
identified a greater number of groups reflecting smoking 
trajectory. The groups included nonsmokers, experimen-
tal smokers, persons with early smoking initiation who 
became stable smokers, persons with late smoking ini-
tiation who became stable smokers, and persons who 
stopped smoking. On average, persons with early smok-
ing initiation who became stable smokers were smoking 
daily by 15 years of age and averaged more than one-half 
pack of cigarettes per day by 18 years of age. In contrast, 
persons with late smoking initiation who became stable 
smokers averaged weekly smoking at age 18 years but less 
than one-half pack per day. Thus, the stable group with 
early initiation was also at particular risk for heavy smok-
ing. This group was characterized by (1) a high frequency 
of parental smoking, perhaps reflecting both genetic and 
environmental risk factors; (2) less parental support; 
and (3) greater attitudinal tolerance for deviant behavior 
(“deviance proneness”).
Orlando and colleagues (2004) identified similar 
groups: nonsmokers; triers (never exceeding one or two 
cigarettes per year, increasing slightly in early adoles-
cence, then decreasing to very low levels in young adult-
hood); late-onset increasers (started at a low smoking rate, 
but increased smoking steadily with the sharpest increase 
occurring between 18 and 23 years); decreasers (smoked 
a few times per month at age 13 years but decreased to 
once or twice a year by age 23 years); and early increas-
ers (started out at low level of smoking at age 12 years 
but rose sharply to weekly smoking by age 14 years with 
continuing increases in smoking). These researchers also 
identified a group of heavy smokers throughout the age 
range of 13 through 23 years. The studies by Chassin and 
associates (2000) and Orlando and colleagues (2004) both 
found that the group with late initiation seemed to be pro-
tected in adolescence by family factors, including (across 
the two studies) less familial smoking, more parental sup-
port, intact families, and higher levels of parental educa-
tion. However, Orlando and colleagues (2004) found that 
the trajectory groups of the stable heavy smokers, the 
persons with early initiation who increased cigarette con-
sumption, and those with late initiation who increased 
cigarette consumption all converged to a similar point 
of heavy smoking by 23 years of age. Thus, these stud-
ies identify a group of persons with early initiation and 
sharply escalating cigarette consumption who are at high 
risk for heavy smoking. However, late initiation of smok-
ing does not necessarily imply protection against heavy 
smoking. Divergence among these groups may occur at 
ages older than 23 years, which were not represented in 
the study by Orlando and colleagues (2004).
Several studies focused on African Americans. Juon 
and colleagues (2002) conducted follow-up on inner-city 
participants who had low socioeconomic status (SES) and 
divided them into nonsmokers, former smokers, smok-
ers with late initiation (after age 18 years), and smokers 
with early initiation. The group with early initiation was 
more aggressive in childhood, more likely to have lax pa-
rental supervision, and had more drug problems. White 
and colleagues (2004) modeled trajectories of the number 
of cigarettes smoked each day. They identified nonsmok-
ers, light smokers, and heavy smokers and found that 
African Americans started smoking later and had lower 
cigarette consumption than did White participants. Simi-
larly, Blitstein and colleagues (2003) found that progres-
sion of smoking was more likely to be slow among African 
Americans. Finally, Brook and colleagues (2006) modeled 
trajectories for African American and Puerto Rican adoles-
cents from age 14 to 26 years and identified the following 
groups: nonsmokers, persons whose smoking peaked at 18 
years of age and then declined, smokers with late initia-
tion, and smokers with early initiation. Although there are 
few studies, these findings suggest that the age at smoking 
initiation and the speed of progression in cigarette con-
sumption may differ by ethnicity. This hypothesis should 
be considered in describing smoking trajectories from 
adolescence to adulthood.
Another important consideration is that none of 
these longitudinal studies spanning adolescence and 
adulthood directly assessed nicotine dependence. There-
fore, the extent to which predictors of early progression 
to heavy smoking are predictors of nicotine dependence 
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is unknown. However, Storr and colleagues (2004) per-
formed a latent class analysis of nicotine dependence 
symptoms by using data from the National Survey on Drug 
Use & Health. The findings indicated that early smoking 
initiation leads to a higher probability of experiencing 
nicotine dependence features within two years of smoking 
onset compared with those smokers who initiated smok-
ing after age 20 years. 
Determinants of Nicotine Addiction
Researchers have described the progression of ciga-
rette smoking as a process of multiple stages, including 
precontemplation, contemplation or preparation, initial 
trying, experimental or irregular smoking, and established 
daily smoking (Mayhew et al. 2000). Researchers have also 
suggested that movement across these stages is deter-
mined by different factors (Flay et al. 1983). For example, 
social factors such as peer modeling and opportunities to 
experiment may have a greater influence on initial experi-
mentation with smoking, whereas factors such as genetic 
risk, negative affect, and propensity to develop tolerance 
to nicotine have been hypothesized to play a greater role 
in determining movement across later stages of smoking 
(Flay et al. 1983). However, the empirical evidence for 
such stage-specific predictors is weak. Mayhew and col-
leagues (2000) reviewed this literature and found that few 
studies tested for stage-specific predictors. Rather, most 
studies aggregated data across stages, predicting any pro-
gression in smoking or predicting broad categories such 
as “regular” smoking, which ranges from smoking a sin-
gle cigarette a month to daily heavy smoking. Moreover, 
much of the research on adolescent smoking initiation is 
motivated by an interest in smoking prevention. There-
fore, many studies focus on the initiation of smoking or 
experimental smoking. Few studies have examined predic-
tors of nicotine dependence or daily heavy smoking. For 
these reasons, little is known about stage-specific predic-
tors of nicotine dependence.
Some studies have used genetically informed 
designs to examine the extent to which adolescent 
tobacco dependence is related to additive genetic influ-
ences, shared environmental influences that make siblings 
more alike, and unshared environmental influences that 
make siblings different (Boomsma et al. 2002). From the 
extensive literature on the genetics of adolescent smok-
ing, several studies are selected for review, because they 
focus on heavy smoking or nicotine dependence in ado-
lescence. McGue and colleagues (2000) report that 44 
percent of the variance in nicotine dependence among 
17-year-old twins was associated with additive genetic 
influence. However, shared environment also played an 
important role, accounting for 37 percent of the variance 
in nicotine dependence. Similarly, a study that focused on 
high frequency of smoking rather than nicotine depen-
dence reports that both additive genetic and shared envi-
ronmental influences were important (Rende et al. 2005). 
One study reported differences by gender in heritability 
for “problem” tobacco use (Rhee et al. 2003). Heritability 
was a stronger influence, and shared environmental fac-
tors were a weaker influence for female than for male ado-
lescents. Thus, studies of behavioral genetics in relation 
to adolescent heavy smoking or nicotine dependence sug-
gest the importance of both genetic and environmental 
influences, although in an adult study population, tobacco 
dependence seems to be more strongly influenced by 
genetics (see “Genetics” earlier in this chapter). 
Researchers have also associated maternal smoking 
during pregnancy with the later development of tobacco 
dependence in offspring. Buka and colleagues (2003) 
examined a sample (aged 17 to 39 years) from the Provi-
dence (Rhode Island) cohort of the National Collaborative 
Perinatal Project. They found an elevated risk for tobacco 
dependence when the mother smoked more than one 
pack of cigarettes per day during pregnancy. However, the 
investigators note that these results could also be 
explained by genetic influences. Moreover, because post-
natal maternal smoking was not considered, social envi-
ronmental mechanisms of intergenerational transmission 
of nicotine dependence (e.g., role modeling) could also 
influence findings. For example, Cornelius and colleagues 
(2005) found that the relationship between prenatal expo- 
sure and adolescent smoking was not significant after 
adjustment for factors such as the mother’s current smok-
ing and the smoking of friends.
Studies have also associated child and adolescent 
psychopathology with nicotine dependence and heavy 
smoking. Using data from the Yale Longitudinal High-Risk 
Study, Dierker and colleagues (2001) found a significant 
association of nicotine dependence with anxiety disorder, 
affective disorder, conduct disorder, oppositional defiant 
disorder, substance dependence, and parental substance 
dependence. The investigators reported that affective 
disorders and drug use disorders remained unique pre-
dictors of nicotine dependence after adjustment for con-
founding comorbidities. These relationships were found 
only for nicotine dependence and not for distinguishing 
between nonsmoking and experimentation or between 
regular smoking and a combined group of earlier stages 
of smoking progression. Clark and Cornelius (2004) also 
examined adolescents with or without parental substance 
use disorder. They found that substance use disorders 
and daily smoking in parents, as well as conduct disorder, 
oppositional defiant disorder, and attention-deficit/hyper-
activity disorder in offspring predicted progression to daily 
smoking. However, these researchers found no significant 
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relationship between anxiety or depressive disorders in 
adolescents and progression to daily smoking.
In a longitudinal study of a large sample of ado-
lescents recruited from high schools, Rohde and col-
leagues (2004) report a finding similar to that of Clark and 
Cornelius (2004). Externalizing disorders (e.g., attention- 
deficit/hyperactivity disorder, disruptive behavior dis-
orders, and alcohol and drug use disorders) are more 
strongly and consistently associated with smoking ciga-
rettes than are internalizing disorders (e.g., mood and 
anxiety disorders). In a multivariate analysis that included 
familial psychopathology, familial smoking, and composite 
variables of internalizing and externalizing disorders, only 
the externalizing disorders predicted both progression to 
daily smoking and to nicotine dependence among daily 
smokers. Thus, these studies show a consistent support 
for externalizing disorders, but less consistent support for 
internalizing disorders, as predictors of frequent smoking 
or nicotine dependence. The inconsistent effects of inter-
nalizing disorders may reflect variation in study samples 
and methods and, particularly, differences in the choice 
of which variables are statistically controlled in models of 
multiple predictors. Inconsistent results may also reflect 
the presence of moderating variables. For example, Patton 
and colleagues (1998) found that depression and anxiety 
were significant predictors of transition to daily smoking 
only when there were high levels of peer smoking.
Finally, Lloyd-Richardson and colleagues (2002) 
used	data	from	a	cross-sectional	study—the	National	Lon-
gitudinal	Study	of	Adolescent	Health—to	compare	adoles-
cents who were at different smoking stages. The smoking 
stages compared were persons who never smoked; experi-
mental smokers, who tried a cigarette but had not smoked 
in the past 30 days and had never smoked daily; intermit-
tent smokers, who reported some smoking but no daily 
smoking in the past 30 days; and regular smokers, who 
smoked daily for the past 30 days. The investigators exam-
ined whether predictor variables had different effects at 
different smoking stages. For example, a variable might be 
particularly important at early stages of smoking and thus 
would differentiate persons who never smoked from those 
who experimented with smoking but would not signifi-
cantly differentiate among the other groups. The results 
showed some stage specificity of predictors. Peer smok-
ing and low level of school connectedness more strongly 
differentiated between regular smokers and persons who 
never smoked, experimental smokers, and intermittent 
smokers than differentiated among persons who never 
smoked, experimental smokers, and intermittent smokers. 
Thus, according to the investigators, peer smoking and 
low school connectedness were more influential in later 
stages of smoking than in early stages. Alcohol use showed 
the opposite pattern and so was thought to be more influ-
ential in the early stages of smoking. However, there was 
also evidence that predictors were not stage specific. For 
example, depression, delinquency, parental smoking, and 
family connectedness significantly differentiated among 
all the smoking groups, and thus these variables were not 
found to be stage-specific predictors.
Summary and Future Directions
The literature on adolescent nicotine addiction is 
relatively recent and less extensive than that resulting 
from the years of research that has been conducted on 
adolescent smoking. Some data suggest that compared 
with adults, adolescents display nicotine addiction at lower 
levels of cigarette consumption and so may be particularly 
vulnerable to addiction when exposed to tobacco. To both 
replicate and explain this phenomenon, there is a critical 
need for systematic assessment of how adolescents dif-
fer	in	their	experience	of	different	aspects	of	addiction— 
development of tolerance, withdrawal, reinforcing 
effects,	 associative	 learning—which	 makes	 this	 popula-
tion more vulnerable to addiction compared with adults. 
The developing brain may be especially susceptible and 
receptive to acute or repeated doses of nicotine (Adriani 
et al. 2003; Schochet et al. 2005) and potentially other 
tobacco-related constituents and to associative learn- 
ing processes. 
Multiple trajectories of smoking from adolescence to 
adulthood have been identified, with one subgroup show-
ing early initiation and a steep escalation of smoking asso-
ciated with familial smoking and lack of parental support 
and with risk for chronic heavy smoking in adulthood. 
Further studies are needed to identify the genetic and 
environmental contributions to such trajectories, as well 
as the endophenotypes underlying the genetic contribu-
tions. Epidemiologic studies are particularly useful in 
providing an understanding of the critical environmen-
tal influences that may interact with specific genes to 
enhance the risk for developing nicotine dependence. 
Another risk factor for nicotine addiction may be the 
diagnosis or symptoms of externalizing disorders. Previ-
ous research has been focused on the common neurosub-
strates associated with nicotine addiction and depression 
(see “Psychiatric Comorbidity” earlier in this chapter). 
However, a better understanding of the relationship and 
the neurophysiology that links smoking to externalizing 
disorders is needed. In summary, future research needs to 
focus on the complex interactions among genes, environ-
ment, social and neurodevelopmental phases, and their 
influence on the trajectory toward nicotine dependence. 
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Epidemiology of Tobacco Use and Nicotine Dependence in Adults
Prevalence of Cigarette Smoking 
and Nicotine Dependence
According to one study, the prevalence of current 
smoking among adults (aged ≥18 years), as assessed by the 
National Health Interview Survey, was approximately 19.8 
percent, or 43.4 million U.S. adults (CDC 2008a). Accord-
ing to the survey, 77.8 percent of current smokers smoked 
every day and 22.2 percent smoked on some days. (Cur-
rent smokers are defined as those who smoked ≥100 times 
during their lifetime and who are smoking every day or on 
some days.) This high prevalence of daily smokers indi-
cates the highly addictive nature of cigarettes. More men 
(22.3 percent) than women (17.4 percent) reported cur-
rent smoking. For the racial and ethnic groups, the lowest 
prevalence of smoking was among Asians (9.6 percent), 
and the highest prevalence was among American Indi-
ans and Alaska Natives (36.4 percent). Across educational 
levels and SES, the highest prevalence of smoking was 
among	persons	with	low	levels	of	education—44.0	percent	
of those with a General Educational Development diploma 
and 33.3 percent of those with 9 to 11 years of education, 
versus	 6.2	 percent	 of	 those	with	 graduate	 degrees—and	
persons	with	 the	 lowest	 levels	 of	 income—28.8	 percent	
of adults living below the poverty level and 20.3 percent 
of those living at or above the poverty level. The preva-
lence of smoking was lowest among persons aged 65 years 
or older (10.2 percent) and highest among those aged 18 
through 24 years (23.9 percent).
In adults, the diagnosis of nicotine dependence or 
addiction in population surveys has largely been based on 
DSM 3rd ed. (rev) (DSM-III-R), DSM-IV (APA 1987, 1994, 
2000), and ICD-10 (WHO 1992) diagnostic criteria. The 
adult survey instruments used to make the diagnosis have 
included the National Institute of Mental Health Diag-
nostic Interview Survey and the Composite International 
Diagnostic Interview-Substance Abuse Module (Colby et 
al. 2000b). Researchers also have used data from other 
population surveys, such as the National Survey on Drug 
Use & Health to assess symptoms of tobacco depen-
dence. That survey includes terms or phrases such as (1) 
“reported daily use of the product for two weeks or lon-
ger,” (2) “have tried to cut down on smoking,” (3) “unable 
to cut down or quit or experienced difficulty quitting,” (4) 
“felt a need for more tobacco for the same effect,” (5) “felt 
dependent,” or (6) “felt sick or experienced withdrawal 
symptoms when stopping smoking.” Results have been 
reported on the percentage of smokers who indicated one 
or more of these symptoms of dependence or experienced 
at least one of the withdrawal symptoms, psychoactive 
effects (e.g., “it relaxes or calms me”), or difficulty with 
smoking cessation, as a sign of potential tobacco depen-
dence (CDC 1994, 1995a,b). Researchers have also used 
the presence of a specified number of these symptoms as 
a proxy measure for DSM-IV criteria for nicotine depen-
dence (Kandel et al. 1997). 
The prevalence of nicotine dependence based on 
these measures in population- or community-based 
samples from studies conducted in the United States are 
shown in Table 4.11. The variability in the prevalence of 
nicotine dependence can be mostly attributed to the char-
acteristics of the population surveyed and the diagnostic 
tools used. The lifetime prevalence of DSM-III-R diagno-
sis of nicotine dependence in the general U.S. population 
ranges from 20 to 24 percent, and past-year prevalence of 
DSM-IV diagnosis of nicotine dependence is 9 to 13 per-
cent. By virtually any measure, the prevalence of lifetime 
nicotine dependence is higher for cigarette smoking than 
for any other category of substance abuse (Anthony et al. 
1994; Giovino et al. 1995). The results from Table 4.11 also 
illustrate that almost one-third of persons who have ever 
tried smoking cigarettes became dependent on nicotine. 
Examination of self-reports of specific symptoms 
by adult daily or dependent smokers (Table 4.12) shows 
that in the majority of studies that assessed these symp-
toms, the least frequently reported symptoms include 
tolerance, withdrawal, and giving up activities as a result 
of tobacco use. The most frequently reported symptoms 
include efforts to reduce smoking and the inability to 
reduce smoking; feeling dependent; using more ciga-
rettes than intended; and perhaps, continuing to smoke 
cigarettes despite experiencing problems. Therefore, 
the symptoms of nicotine dependence most likely to be 
reported among adults tend to be behavioral or a loss 
of control over smoking, and the least reported items 
appear to be physiological (e.g., symptoms of tolerance 
and withdrawal). In a study by Kandel and Chen (2000), 
a higher proportion of adolescents reported experiencing 
symptoms of tolerance (22.2 percent) and/or physical and 
psychological problems (27.0 percent) resulting from to-
bacco use, compared with the proportion of adults aged 
18 through 49 years (14.4 and 20.3 percent, respectively) 
and adults aged 50 years or older (9.9 and 11.0 percent, 
respectively). These results may reflect either the cohort 
effect or the effect described previously as higher sensi-
tivity in adolescents than that in adults to the effects 
of nicotine on physiological symptoms of dependence. 
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Table 4.11 Lifetime and current prevalence of nicotine dependence in population studies in the United States
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Note: CIDI = World Health Organization’s Composite International Diagnostic Interview ; CIDI-SAM = CIDI Substance Abuse Module; 
DSM-III = Diagnostic and Statistical Manual of Mental Disorders, 3rd ed.; DSM-III-R = DSM, 3rd ed. (rev); DSM-IV = DSM, 4th ed.; 
FTND = Fagerström Test for Nicotine Dependence; FTQ = Fagerström Tolerance Questionnaire; ICD-10 = International 
Classification of Diseases, Tenth Revision; NESARC = National Epidemiology Survey on Alcohol and Related Conditions; 
NHSDA = National Survey on Drug Use & Health; NIAAA = National Institute on Alcohol Abuse and Alcoholism; 
NIMH-DIS = National Institute of Mental Health Diagnostic Interview Schedule.
aNIMH-DIS included ever smoking daily for ≥1 month plus DSM-III-R criteria for dependence with ≥3 of the following symptoms 
persisting for ≥1 month: greater use than intended; unsuccessful efforts to control use; important activities given up; continued use 
despite social, psychological, or health problems; tolerance; withdrawal symptoms; and use to avoid withdrawal symptoms. Excluded 
2 symptoms listed in the general DSM-III-R criteria for psychoactive substance use disorders: (1) great deal of time spent in activities 
necessary to acquire substance or recover from effects and (2) frequent intoxication or withdrawal symptoms when expected to fulfill 
major role obligations.
bCIDI criteria included daily smoking for ≥1 month plus DSM-III-R criteria for dependence with ≥3 of criteria with symptoms 
persisting for ≥1 month.
cData on persons who ever smoked estimated from synthesis with NHSDA data.
dDSM-IV criteria for dependence with ≥3 of the following symptoms within a 12-month period: tolerance; withdrawal; using larger 
amounts or longer than intended (assessed as needed or if smoker felt dependent on nicotine); unsuccessful efforts to cut down; 
negative social, occupational, and physical consequences; and persistent physical and psychological problems. Excluded spending 
significant amount of time to obtain substance; instead, quantity (smoking ≥2 packs daily in past 30 days) was examined in relation to 
dependence.
eNIAAA used DSM-IV criteria modified as follows: use of nicotine to relieve or avoid withdrawal as operationalized by using the 
following four symptom items: (1) use of nicotine on awakening, (2) use of nicotine after situation in which use was restricted, (3) 
use of nicotine to avoid nicotine withdrawal symptoms, and (4) waking up in middle of the night to use tobacco. “Giving up activities 
in favor of nicotine use” was assessed as (1) giving up or cutting down on important activities, such as associating with friends or 
relatives or attending social activities, because tobacco use was not permitted at activity and (2) giving up or cutting down on activities 
that were of interest or that gave pleasure because tobacco use was not permitted. The “great deal of time spent using tobacco” 
criterion was assessed by single symptom item, chain-smoking. The “using tobacco more than intended” criterion was operationalized 
as having a period when tobacco was used more than intended. Nicotine dependence was assessed for any tobacco product, including 
cigarettes, cigars, pipes, chewing tobacco, and snuff.
However, on the basis of animal studies, withdrawal 
symptoms would be presumed to be fewer in adolescents 
than in adults (O’Dell et al. 2004, 2006), yet more ado-
lescents are endorsing physical problems than do adults. 
As pointed out previously, factors other than withdrawal 
may be associated with higher endorsement of withdrawal 
symptoms among adolescents.  Another possibility is that 
questions on physical dependence, particularly on toler-
ance, are not asked in a manner that is understood by or 
relevant to adult smokers. 
The symptoms most frequently reported by adults 
appear to be less specific to the diagnosis of nicotine 
dependence. For example, Breslau and colleagues (1994) 
observed that (1) 88.6 percent of dependent smokers 
reported the symptom of dependence described as “smok-
ing more than intended” (p. 747) and (2) 93.6 percent 
reported “unsuccessful attempts to quit” (p. 747). How-
ever, these items were also reported by a substantial per-
centage of nondependent smokers (47.9 and 25.2 percent, 
respectively) who smoked daily for a month or more 
during their lifetime but never met criteria for nicotine 
dependence. However, 87 percent of dependent smokers 
as opposed to only 12 percent of nondependent smokers 
reported one or more of the three physiological indicators 
of dependence (tolerance, withdrawal symptoms, and/or 
cigarette use to avoid withdrawal symptoms). 
With regard to the onset of nicotine dependence 
relative to daily smoking, one study of data from the 
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Figure 4.5 Cumulative incidence curves of daily smoking and nicotine dependence in the National Comorbidity 
Survey
Source: Breslau et al. 2001. Reprinted with permission from American Medical Association, © 2001.
Note: Participants included 4,144 daily cigarette smokers and 2,136 smokers who were nicotine dependent.
National Comorbidity Survey showed that the highest 
rates of becoming nicotine dependent, as defined by DSM-
III-R, occurred in the first 16 years from the year after 
progression to daily smoking, whereas in the subsequent 
10 years the progression to nicotine dependence declined 
and continued at a slower rate (Figure 4.5) (Breslau et al. 
2001). Thus, nicotine dependence generally followed daily 
smoking, although 5.4 percent of nicotine dependence 
began before or in the same year as progression to daily 
smoking. In most cases, the onset of nicotine dependence 
occurred one or more years after the initiation of daily 
smoking. These results appear somewhat contrary to 
results described in “Prevalence of Symptoms and Diag-
noses in Adolescence” earlier in this chapter, which indi-
cates that dependence symptoms may occur even earlier 
in a person’s history of smoking. The discrepancies in 
results may be a function of how nicotine dependence was 
diagnosed or defined, that is, whether one was examining 
symptoms or a diagnosis of dependence or cohort effects.
Prevalence by Dose, Duration, and 
Subpopulations
The results from Table 4.11 also show that the more 
a person smokes, the greater is the likelihood of a diag-
nosis of nicotine dependence (CDC 1995b). Kandel and 
Chen (2000) observed a linear dose-response relationship 
between the number of cigarettes smoked in the past 
month and the percentage of smokers with nicotine de-
pendence in the last year. This finding was based on 
self-reporting of symptoms approximating DSM-IV cri-
teria for dependence and was confirmed in other studies 
(Kawakami et al. 1998). The percentage of male and fe-
male smokers with a diagnosis of dependence rose sharply 
and significantly as the amount of smoking increased 
from less than one cigarette per day, to one to five ciga-
rettes per day, and to one-half pack per day. Thereafter, 
the increase in the percentage of smokers with a diagno-
sis of dependence tended to rise minimally; however, at 
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Table 4.12 Prevalence of selected symptoms of nicotine dependence reported in selected studies
numbers higher than one and one-half packs of cigarettes 
per day, females showed a higher prevalence of depen-
dence than did males. The duration of cigarette smoking 
has also been related to the prevalence of nicotine depen-
dence (Kandel and Chen 2000). 
Kandel and Chen (2000) also found that among 
persons who smoked in the last month, the prevalence 
of nicotine dependence in middle-aged adults was similar 
to that in adolescents. After adjustment for the quantity 
of cigarettes smoked, the prevalence of dependence was 
generally higher among adolescents than among adults, 
particularly at lower levels of cigarette consumption. 
Several reasons that may account for this finding (i.e., 
cohort effects) have been discussed previously (see “Prev-
alence of Cigarette Smoking and Nicotine Dependence” 
earlier in this chapter). The lowest rates of nicotine 
dependence were in adults aged 50 years or older; this 
finding was attributed to lower sensitivity to increased 
quantity of nicotine intake. The investigators also found 
that the prevalence of nicotine dependence was higher 
among females than among males, even after adjustment 
for the number of cigarettes smoked. However, this dif-
ference was observed only among persons 18 through 
49 years of age. The prevalence of dependence was also 
higher among Whites than among Blacks, and this differ-
ence was particularly evident at the lower levels of ciga-
rette consumption. 
Other studies have found no differences by gender 
in the prevalence of nicotine dependence (Breslau et al. 
1991; Anthony et al. 1994) but have confirmed differ-
ences by race when DSM criteria were used to diagnose 
nicotine dependence (Breslau et al. 1994, 2001). However, 
when time to the first cigarette was used as an indicator of 
dependence, more Blacks than Whites reported smoking 
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within 10 minutes of awakening even though Blacks had 
lower or similar levels of cigarette consumption (Royce et 
al. 1993). In another study, Blacks also reported shorter 
time to the first cigarette than did Whites (Ahijevych and 
Gillespie 1997). Differences in nicotine metabolism and 
blood concentrations of cotinine may contribute to dif-
ferences in the prevalence of dependence among Blacks 
and Whites (Benowitz et al. 1999). Among smokers who 
ever smoked daily, nonnicotine-dependent Blacks were 
2.5 times more likely to persist in smoking than were 
nondependent Whites (Breslau et al. 2001). These find-
ings suggest a weakness in diagnostic systems categorized 
by differences in ethnic and racial groups, differences in 
sensitivity to nicotine across groups, or differences in 
sociocultural factors (e.g., extent of cigarette promotion 
or smoking restrictions) that contribute to persistence in 
smoking across groups. 
Nicotine Dependence and 
Psychiatric Comorbidity
As described in the previous sections, studies have 
found a strong association between nicotine dependence 
and comorbid disorders that warrants further discus-
sion. It is estimated that nearly one-half of all cigarettes 
sold in the United States (44 percent) are consumed by 
people with mental illnesses or substance abuse disor-
ders. In addition, the prevalence of tobacco use among 
those with either addictions and/or mental illness is 
between 38 to 98 percent, as opposed to 19.8 percent 
for the general population (Schroeder 2009). Breslau 
and colleagues (1991) have conducted several stud-
ies. One earlier population-based study in Michigan 
observed that young adults with a diagnosis of nicotine 
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dependence reported higher prevalence of alcohol and 
drug dependence and major depression and anxiety disor-
ders than did persons who had never experienced nicotine 
dependence (Breslau et al. 1991). The relationships 
between each disorder and nicotine dependence were 
observed even when adjustments were made for confound-
ing comorbidities. These findings are similar to those 
observed for adolescent smokers described earlier (Dier-
ker et al. 2001) (see “Determinants of Nicotine Addiction” 
earlier in this chapter). However, the results were contrary 
to other findings among adolescents (Clark and Cornelius 
2004; Rohde et al. 2004). Other population-based research 
and clinical studies have also pointed to the strong rela-
tionship between daily smokers or nicotine-dependent 
smokers (as opposed to lifetime nonsmokers or non- 
dependent smokers) and substance use disorders, anxi-
ety disorders, and depression, with higher prevalence of 
comorbid psychiatric disorders among nicotine-depen-
dent smokers and higher prevalence of nicotine-depen-
dent smokers among persons with comorbid disorders. 
For example, in a U.S. population-based survey, Grant and 
colleagues (2004) observed that the prevalence of alcohol 
use disorders, current mood disorders, or current anxi-
ety disorders among adult respondents with diagnoses of 
nicotine dependence during the past year ranged from 21 
to 23 percent compared with 9 to 11 percent in the gen-
eral population. Conversely, other studies have shown the 
percentage of persons with nicotine dependence among 
respondents with these comorbid disorders ranging from 
25 to 35 percent and as high as 52 percent among respon-
dents with drug use disorders compared with 12.8 percent 
in the general population (Glassman et al. 1990; Breslau 
et al. 1994, 2004b; Lasser et al. 2000; Degenhardt and Hall 
2001; Kandel et al. 2001; Isensee et al. 2003; Schmitz et al. 
2003; Grant et al. 2004; John et al. 2004).
Furthermore, studies have shown that the more 
severe the nicotine dependence, the more likely was the 
association with comorbid disorders. For example, John 
and colleagues (2004) found that the greater the number 
of nicotine-dependent symptoms or nicotine withdrawal 
symptoms and the higher the total FTND scores, the 
higher the odds ratios for psychiatric disorders. Nonethe-
less, even nonnicotine-dependent smokers, compared with 
nonsmokers, had significantly higher prevalence of alco-
hol and drug dependencies, but not of major depression 
or anxiety disorders (Breslau et al. 1991, 1994, 1996). This 
result suggests that smoking may either physiologically 
or perhaps more critically, socially, lower the threshold 
for substance abuse disorders. Conversely, the greater 
the number of psychiatric disorders experienced by the 
individual, the higher the prevalence or odds of smoking, 
particularly daily or heavy smoking (Lasser et al. 2000; 
Breslau et al. 2004b) and of diagnosis of nicotine depen-
dence (Breslau et al. 2004b; John et al. 2004). 
The relationship of major depression or anxiety 
disorders with nicotine dependence is complex and not 
extensively explored. Breslau and colleagues (1993b) 
examined the relationship between depression and nico-
tine dependence in a prospective investigation of 14 
months. The investigators found that major depressive 
disorder increases the risk of progression to nicotine 
dependence and more severe levels of dependence. These 
results were confirmed in a subsequent analysis of cross-
sectional data from the National Comorbidity Survey in 
which preexisting major depressive disorders, several 
anxiety disorders (e.g., phobias, generalized anxiety dis-
orders, and posttraumatic stress disorders), and substance 
use disorders had resulted in an increased risk for pro-
gression to daily smoking or onset of nicotine dependence 
among daily smokers (Breslau et al. 2004b). Of the anxiety 
disorders assessed, neither preexisting agoraphobia nor 
panic disorder predicted a subsequent progression to daily 
smoking, and panic disorder did not increase the relative 
risk of transition to nicotine dependence. Similar findings 
had also been observed in earlier epidemiologic cross-
sectional studies of adults (Breslau and Klein 1999) and 
in longitudinal studies with follow-up of adolescents into 
young adulthood (Johnson et al. 2000; Isensee et al. 2003). 
Conversely, Breslau and colleagues (1993b) also 
observed that a history of nicotine dependence increased 
the risk for a subsequent first incident or recurrence of 
major depressive disorder. Daily smoking or nicotine 
dependence increased the risk of a subsequent onset of 
drug use, anxiety disorders, major depression, or dysthy-
mia both in epidemiologic studies (Breslau et al. 1998, 
2004a; Breslau and Klein 1999) and in population-based 
longitudinal studies (Kendler et al. 1993; Isensee et al. 
2003). In a population-based longitudinal cohort study, 
adolescents who smoked one or more packs of cigarettes 
per day had higher odds of the onset of anxiety disorders 
(e.g., generalized anxiety disorders, panic disorder, and 
agoraphobia) in adulthood than did adolescents who 
smoked less than one pack a day (Johnson et al. 2000). 
Analysis of cross-sectional data from the National 
Comorbidity Survey found no differences between nicotine- 
dependent and nondependent daily smokers in the likeli-
hood of a subsequent first onset of a psychiatric disorder 
(Breslau et al. 2004a). Therefore, daily smoking appears to 
be just as important a risk factor as a diagnosis of nicotine 
dependence. This finding may reflect the limitations of the 
criteria for a diagnosis of nicotine dependence.
This bidirectional finding in relation to cigarette 
smoking and some of the mood and substance use dis-
orders can be considered either causal or a reflection of 
an underlying factor that is common to the predisposi-
tion to both disorders. For example, psychiatric disorders 
may lead to self-medication with nicotine, which targets 
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the neurosystems that have mood-altering effects, or 
long-term exposure to nicotine may alter neurobiologic 
substrates, leading to the development of psychiatric 
comorbidities. Another possibility is that psychiatric dis-
order and nicotine addiction share genetic or environ-
mental vulnerabilities or risk factors. 
Few studies have been directed toward providing 
evidence for whether these factors are responsible for 
the relationships between smoking and psychiatric disor-
ders. Support for self-medication of psychiatric disorders 
would come from three findings that show (1) smokers 
with psychiatric disorders have rates of smoking cessation 
lower than those for smokers who do not have these dis-
orders; (2) remission of disorders is less likely to predict 
progression to daily smoking, because there is no need 
for self-medication, but preexisting active disorders are 
associated with increased risk for smoking and/or nico-
tine dependence; and (3) prevalence of smoking is higher 
among persons with remission of disorders than among 
those who continue to experience psychiatric symptoms 
because smoking reduced the psychiatric symptoms.
To date, the data show that the impact of psychi-
atric disorders on smoking cessation is equivocal (see 
“Trajectory of Recovery or Relapse” later in this chapter). 
However, these studies are limited to the disorders of ma-
jor depression and alcohol abuse or dependence. Major 
depressive disorder is the only psychiatric disorder to 
meet the first two characteristics associating cigarette 
smoking with self-medication (findings 1 and 2) (Romans 
et al. 1993; Breslau et al. 2004a) (see “Trajectory of Recov-
ery or Relapse” later in this chapter). 
If the development of psychiatric disorders were 
caused by the effects of cigarette smoking or nicotine 
exposure, then findings to support this hypothesis would 
show that (1) a longer and higher exposure increases a 
smoker’s odds of developing a psychiatric disorder; (2) 
longer abstinence from smoking leads to reduced risk for 
psychiatric disorder, unless the effects are irreversible; 
and (3) current but not former smoking is associated with 
higher risk for psychiatric disorder. The only disorders 
that appear to meet these characteristics are panic disor-
ders and agoraphobia (Breslau and Klein 1999; Johnson et 
al. 2000; Isensee et al. 2003; Breslau et al. 2004a). 
Support for common factors, hereditary or acquired, 
would be based on findings that show (1) both current and 
former daily smoking increase the risk for psychiatric 
disorders, (2) both active disorders and disorders in 
remission or only disorders in remission predict daily 
smoking or a progression to nicotine dependence, and (3) 
familial or genetic vulnerability is shared across nicotine 
dependence or smoking and psychiatric disorders. The 
greatest support for shared common factors is for sub-
stance abuse disorders and smoking. 
Remission of substance abuse disorders has been 
a predictor of daily smoking and progression to nicotine 
dependence (Breslau et al. 2004b). Results of studies on 
families and twins support a shared familial and genetic 
vulnerability across substance use disorders (Bierut et al. 
1998; Merikangas et al. 1998; Tsuang et al. 1998). The data 
on common factors for major depressive disorders and 
smoking are conflicting, showing both support (Breslau et 
al. 1994; Kendler and Gardner 2001; Johnson et al. 2004) 
and lack of support (Dierker et al. 2002; McCaffery et al. 
2003). Researchers have attributed inconsistency in these 
results to differences in levels of cigarette consumption, 
definitions of depression, study methods, and analytic 
approaches (Johnson et al. 2004). The use of antidepres-
sant treatments for both depression and smoking cessa-
tion, regardless of a history of depression, would support 
the concept of shared substrates that mediate nicotine 
dependence and depression (see “Pathophysiology of Nico-
tine Addiction” earlier in this chapter).
As a caveat, the strong relationship between nicotine 
dependence and some psychiatric disorders may be a func-
tion of the method used to diagnose nicotine dependence. 
For example, in another study conducted by Breslau and 
Johnson (2000), nicotine dependence, as defined by the 
FTND score, was not related to major depression. These 
researchers attributed the strong relationship between the 
DSM-III-R definition of nicotine dependence and major 
depression to the numerous behavioral symptoms associ-
ated with the diagnosis of nicotine dependence.
Summary and Future Directions
The effects of dose, age, race, and gender may be 
related to the prevalence of nicotine dependence. The 
number of cigarettes smoked per day and the duration 
of smoking are positively related to the percentage with 
diagnosis of nicotine dependence. Prevalence of nicotine 
dependence among adolescent smokers may be higher 
than that among adult smokers, particularly for those 
who smoke fewer cigarettes per day. Conflicting study 
results suggest that prevalence of nicotine dependence, 
as defined by DSM criteria, is higher among Whites than 
among Blacks but that prevalence is lower in Whites when 
time to the first cigarette of the day is the criterion for 
dependence. It is unclear whether the prevalence of nico-
tine dependence differs by gender. These results suggest 
the need for further research to explore reasons for the 
inconsistent findings across subgroups of smokers. A sig-
nificant association also exists between psychiatric dis-
orders and smoking, but the nature of this association is 
unclear. Depending on the disorder, the relationship may 
be causal; for example, smoking may increase the odds of 
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panic disorder and major depressive disorder and may lead 
to self-medication with tobacco use. On the other hand, 
this association may result from common underlying fac-
tors that involve fundamental psychological or physiologi-
cal processes, such as intolerance to states of negative 
affect or neurotransmitter dysfunction in a common path-
way, which lead to nicotine dependence, substance abuse, 
and possibly depression. To date, understanding the causal 
relationships has relied predominantly on cross-sectional 
data sets. Prospective studies have been limited and have 
examined only a few psychiatric disorders, but this type 
of study is necessary to lend stronger evidence for any 
bidirectional causality or for common underlying causes 
of cigarette smoking and nicotine dependence with spe-
cific psychiatric disorders. A clearer understanding of 
these relationships will result in a deeper understanding 
of the pathophysiology of nicotine addiction. Moreover, 
the studies of adults are limited in that the focus has 
been primarily on internalizing rather than externalizing 
disorders. In studies of adolescents, externalizing disor-
ders may play an even greater role than do internalizing 
disorders in the development of nicotine addiction (see 
“Determinants of Nicotine Addiction” earlier in this chap-
ter). Therefore, studies encompassing a broader range of 
diagnoses are warranted. 
Trajectory of Recovery or Relapse
Studying recovery from smoking can provide valu-
able information on the nature of tobacco addiction and 
the factors affecting it. Every year about 45 percent of daily 
smokers in the United States stop smoking for 24 hours, 
but only 5 percent or less achieve long-lasting abstinence 
(CDC 2002, 2004). Thus, relapse is the principal limiting 
factor in the transition from smoking to nonsmoking sta-
tus. This finding underscores the need to understand the 
nature of relapse and the factors affecting it.
Relapse: Definitions and 
Limitations of the Literature
Integration of information about relapse is difficult 
because definitions of critical events differ among stud-
ies. For instance, it seems useful to distinguish a lapse 
from a relapse. A lapse refers to an occurrence of smoking 
or tobacco use that takes place after an attempt to stop 
smoking but is not part of an ongoing pattern of con-
sistent use (Brandon et al. 1986). Relapse refers to the 
point after an attempt to stop smoking when tobacco use 
becomes ongoing and persistent (Brandon et al. 1986). 
Although standards have been offered for defining 
“relapse” (Hughes et al. 2003), many reported results are 
based on idiosyncratic standards. In addition, there is no 
formally accepted definition of a “lapse.” For instance, 
some studies define a lapse as only the first use of tobacco 
after an attempt to stop smoking, and other studies use 
broader definitions. Because of this diversity, this review 
reports results according to the definitions used by the 
investigators in each study. In addition, some investiga-
tors distinguish between relapse and failure of smoking 
cessation, with relapse occurring only after a period of 
abstinence (e.g., after 48 hours) (Hughes et al. 2003). 
Again, few studies make such a distinction. Therefore, to 
render the bulk of the evidence comparable, this review 
uses the concept of return to smoking after a cessation 
attempt as an index of vulnerability to relapse, regardless 
of the duration of abstinence. In general, no distinction is 
made between cessation failure and relapse. Finally, some 
of the reviewed studies predict the likelihood of relapse 
while others predict relapse latency. In this review, either 
prediction is taken to reflect a higher level of vulnerability 
to relapse.
Natural History of Relapse
Prevalence
Two key characteristics of relapse are its high prev-
alence and its rapidity. Past reviews have consistently 
reported that persons who decide to stop smoking on 
their own and those who receive placebos in clinical trials 
achieve 6- to 12-month abstinence rates of only 3 to 5 per-
cent (Cohen et al. 1989; Hughes et al. 2004c). Thus, within 
one year of an attempt to stop smoking, about 95 per-
cent of persons who try to stop without a pharmacologic 
aid continue to smoke or resume smoking. Reviews of 
efficacious treatments reveal that 20 to 25 percent of those 
who tried to stop smoking succeeded for six months (Fiore 
et al. 2008). This finding means that about 75 percent of 
persons who try to stop smoking by using evidence-based 
treatments return to smoking within six months. The risk 
of relapse, however, does not end 6 to 12 months after 
the attempt at smoking cessation. Findings in studies of 
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long-term outcome suggest that relapse ultimately claims 
30 to 40 percent of smokers who stop smoking for one 
year (Eisinger 1971; Gilpin et al. 1997; Krall et al. 2002). 
For instance, Yudkin and colleagues (2003) found that 
about one-half of the smokers who had stopped smoking 
for one year relapse to smoking within the subsequent 
seven years. However, roughly 50 percent of those who 
have ever smoked eventually become long-term former 
smokers (Husten 2005) because many make repeated 
attempts to stop smoking until they are successful.
Rapidity
Most smokers who ultimately relapse resume smok-
ing early after their attempt to stop. This pattern of early 
lapsing has been reported in persons receiving treatment 
(Kenford et al. 1994), as well as in those who decide on 
their own to stop smoking and in smokers who receive 
placebos (Hughes et al. 2004c). For example, Kenford and 
colleagues (1994) found that 80 to 90 percent of those 
who were smoking at six months after trying to stop had 
resumed smoking in the first two weeks of the attempt 
to stop. Other studies report similarly high rates of early 
lapsing in populations of treated and untreated smokers 
(Garvey et al. 1992; Gulliver et al. 1995; Westman et al. 
1997; Hughes et al. 2004a). Women who stop smoking 
during pregnancy, however, tend not to relapse early in 
the attempt to stop, but rather tend to relapse after deliv-
ery, which is often weeks or months after initial cessation 
(Fingerhut et al. 1990; USDHHS 1990; Floyd et al. 1993; 
Stotts et al. 2000; Colman and Joyce 2003). 
Lapse-Relapse Relationship
The odds of an eventual relapse are especially high 
among those who lapse or engage in initially isolated 
smoking episodes after the cessation date. Data suggest 
that lapsing is the single best predictor of an ultimate 
relapse (Brandon et al. 1990; Hughes et al. 1992; Kenford 
et al. 1994; Nides et al. 1995). Moreover, the risk of an 
ultimate relapse appears to increase with the number of 
lapse events (Wileyto et al. 2004). Nevertheless, even mul-
tiple lapses do not inevitably lead to a relapse (Nides et 
al. 1995). This finding attests to the wide variation in the 
course of both relapse and successful cessation in a popu-
lation of smokers attempting to stop smoking.
The pattern of a return to regular smoking varies 
considerably across individuals and typically occurs over 
days and weeks rather than hours. On average, smok-
ers have a second lapse three or four days after the first 
lapse (Shiffman et al. 1996b). Almost one-half of smokers 
have the second lapse within 24 hours of the first lapse 
(Brandon et al. 1990). On average, the latency between the 
first lapse to a relapse is three to five weeks (Brandon et 
al. 1990; Shiffman et al. 1996a,b; Gwaltney et al. 2005a), 
which suggests that there is time after an initial lapse to 
engage in additional treatment to prevent progression to 
full relapse.
Risk Factors
To promote more precise thinking about the time 
courses and interactive and cumulative effects of different 
types of influences on relapse, several reviews recommend 
an organizational framework for categorizing forces that 
influence a relapse (Shiffman et al. 1986; Shiffman 1989a; 
Piasecki et al. 2002). In general, such recommendations 
have proposed three factors as important influences on 
relapse: person factors, emergent processes, and situa-
tional instigators. Person factors are stable characteristics 
that preexist the attempt to stop smoking and endure (e.g., 
gender and history of or proneness to depression). Emer-
gent processes are dynamic factors that unfold over time 
and emerge sometime during the postcessation period. 
Such processes tend not to be bound to context. For 
example, although these processes may arise in response 
to an episodic event such as stress, they can persist for 
days or weeks. Withdrawal is an example of a dynamic 
variable that arises gradually in response to falling 
blood concentrations of nicotine (Hughes et al. 1990b; 
Piasecki et al. 2003a). Although situational factors may 
affect withdrawal symptoms (McCarthy et al. 2006), the 
symptoms persist well beyond the situational influences 
and are not wholly explained by them. Situational instiga-
tors are factors such as cues, contexts, or events that give 
rise to short-lived (phasic) reactions lasting from seconds 
to hours. Such reactions might comprise affective reac-
tions to a stressor, such as an argument, or to exposure to 
smoking cues, such as seeing someone smoke. 
Thus, this organizational scheme reflects the insti-
gator of the process, such as a contextual cue, as well as 
the time course of vulnerability associated with relapse. 
Such categorization is complex, because the distinction 
among the time courses of influences is somewhat arbi-
trary and various influences may interact (Piasecki et al. 
2002; Gwaltney et al. 2005b). These influences are not 
mutually exclusive or independent, which adds to the 
complexity of this organizational method. For example, 
person factors may affect situational reactions or emer-
gent patterns of symptoms. The categorization scheme 
described here is only one approach to conceptualizing 
the causes of relapse. This approach has, however, allowed 
researchers to identify factors that consistently predict 
relapse and is consistent with a greater body of research 
and theory showing that person factors, phasic reactions, 




Cognitive and Attitudinal Influences
There is evidence that relatively stable attitudinal 
variables affect the vulnerability to relapse of smokers. For 
example, precessation assessments of expectations that 
smoking will alleviate distress (e.g., negative moods and 
stress) predict the subsequent likelihood of a relapse (Wet-
ter et al. 1994; Brandon et al. 1999). In addition, multiple 
studies conclude that baseline measures of confidence 
in the ability to stop smoking can also predict outcomes 
(Condiotte and Lichtenstein 1981; Baer et al. 1986; Shiff-
man et al. 2000). Other findings indicate that confidence 
before attempts to stop smoking and positive expectations 
may interact to predict risk of relapse to smoking. Smok-
ers with low confidence and high expectations for smoking 
reinforcement are especially likely to relapse (Shadel and 
Mermelstein 1993; Dijkstra and Brosschot 2003). Finally, 
high levels of motivation, based on health concerns (Nides 
et al. 1995; Dijkstra and Brosschot 2003) or other reasons 
(Turner and Mermelstein 2004), may foster cessation and 
protect against relapse. However, motivation tends to be 
less effective than other factors, such as level of tobacco 
dependence or self-efficacy, that is, self-confidence in the 
ability to stop smoking cigarettes (Hyland et al. 2004; Uni-
versity of Michigan 2006).
Other cognitive variables are less consistently 
related to lapse and relapse. For instance, expectations 
about the negative effects of smoking (e.g., risk of disease) 
appear to predict the motivation or intention to stop 
smoking but not the likelihood of a relapse (Wetter et al. 
1994; Brandon et al. 1999). Also, one study found that a 
strong commitment to continuing abstinence from smok-
ing was related to reduced rates of relapse, but this find-
ing was obtained in a population that comprised persons 
who abused opiates and alcohol in addition to smokers, 
and this condition made the relevance to smoking per se 
unclear (Hall et al. 1990).
Finally, cognitive dimensions such as expectations 
or motivation are sometimes hard to classify. For example, 
motivational structures and attitudes may affect behavior 
over many years (Etter et al. 2003b; Beltman and Volet 
2007). However, motivational phenomena change over 
time and can be affected by contextual factors (Beltman 
and Volet 2007; McCaul et al. 2007; Sanderson et al. 2008; 
Weiss-Gerlach et al. 2008). Therefore, cognitive and 
motivational factors are discussed both as person factors 
and emergent processes, with the distinction reflecting 
the time course of their emergence.
Other data show that the attentional salience of 
smoking cues also predicts vulnerability to relapse. 
Using the Stroop paradigm, researchers presented 
smoking-related and neutral words to 158 volunteers for a 
smoking cessation program (Waters et al. 2003b). Results 
show that if words related to smoking attracted the atten-
tion of smokers, an early relapse was more likely within a 
three-month follow-up interval. In theory, the attention-
grabbing properties of words related to smoking reflect 
the motivational potency of smoking that could then 
account for the greater likelihood of a relapse.
Tobacco Dependence
Measures of tobacco dependence predict the likeli-
hood that a smoker will achieve long-term abstinence 
from tobacco use. For instance, self-report measures of 
dependence tend to predict cessation and relapse (Bre-
slau and Johnson 2000; Piper et al. 2004; Shiffman et 
al. 2004a). However, the various self-report measures 
of dependence often do not show good agreement with 
one another (Breslau and Johnson 2000; Moolchan et al. 
2002). This finding is consistent with emerging evidence 
that nicotine dependence is multifactorial (Hudmon et 
al. 2003; Piper et al. 2004; Shiffman et al. 2004b). More 
recent evidence suggests that some dependence factors 
are more predictive of dependence than are others. In par-
ticular, self-report measures of tobacco dependence that 
assess heavy automatic smoking that is not discriminated 
on time or context are most consistently associated with 
heightened risk of relapse (Transdisciplinary Tobacco Use 
Research Center 2007; Piper et al. 2008). This finding is 
consistent with the observation that objective measures 
of a high rate of smoking, such as expired carbon monox-
ide levels and serum concentrations of cotinine, are often 
related to the likelihood of a relapse (Nørregaard et al. 
1993; Faue et al. 1997; Kenford et al. 2002). Even in 
the best circumstances, however, measures of tobacco 
dependence account for only modest amounts of varia-
tion in risk of relapse. This finding is consistent with the 
notion that relapse is a function of multiple person fac-
tors, emerging processes, and contextual factors. 
In addition to dependence, the sensitivity of a 
smoker to a nicotine reinforcement predicts a shorter 
latency to relapse (Perkins et al. 2002a). In contrast, for-
mal laboratory measures of tolerance to the effects of nic-
otine do not appear to be significantly related to relapse 
(Perkins et al. 2002a).
Demographic and Lifestyle Variables
Studies have related numerous variables of demo-
graphic factors and lifestyle to vulnerability to relapse. For 
example, researchers have related an increased likelihood 
of relapse to younger age (Nides et al. 1995; Ockene et 
al. 2000; Hyland et al. 2004), a low SES or a low level of 
education (Nides et al. 1995; Ockene et al. 2000; Wetter 
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et al. 2005b), being unmarried (Nides et al. 1995; Ockene 
et al. 2000), higher levels of tonic stress, and more stress-
ors or the perception of a higher stress level (Swan et al. 
1988; Wewers 1988; Cohen and Lichtenstein 1990; McKee 
et al. 2003). Of these factors, low SES and low educational 
status appear to be especially strong and consistent pre-
dictors of ability to abstain from smoking on a continu-
ing basis (Mullen 2004; Wetter et al. 2005a; Fernández et 
al. 2006; Lee and Kahende 2007; Letourneau et al. 2007). 
In addition, some data from clinical trials and population 
samples indicate that women may be less likely than men 
to maintain abstinence from tobacco use (Hubert et al. 
1987; Bjornson et al. 1995; Community Intervention Trial 
for Smoking Cessation 1995; Wetter et al. 1999; Smith et 
al. 2003; Hyland et al. 2004). However, such relationships 
are not consistently found across different data sets. For 
instance, as noted above, numerous data sets reveal that 
females are more likely to relapse to tobacco use than are 
males. However, a substantial number of studies fail to find 
such a relationship (Gritz et al. 1998; Killen et al. 2002; 
Westmaas and Langsam 2005; Velicer et al. 2007; Walsh 
et al. 2007). Besides the issue of consistency, additional 
topics deserve greater research attention. These topics 
include exploration of how the various person factors 
“work together” to affect the success or failure of smok-
ing cessation. In addition, it is important to determine 
whether the different person factors are associated with 
different sorts of relapse mechanisms or processes; that is, 
regardless of the likelihood of relapse in different smoker 
groups, it is important to determine whether relapse pro-
cesses “unfold” differently in such groups. 
Research suggests that men and women may differ 
in sensitivity to environmental events. There is evidence, 
for instance, that environmental or conditioned cues 
related to use of nicotine, such as seeing information 
about nicotine dose, seeing others smoking, or receiving 
cues previously paired with nicotine, tend to elicit stron-
ger motivational response to use the drug in women than 
in men (Pomerleau et al. 2005; Perkins et al. 2006; Lev-
enthal et al. 2007; Walsh et al. 2007). These data agree 
with animal research data showing that nicotine-paired 
environmental cues are more effective in eliciting self-
administration of nicotine in female rats than in male rats 
(Chaudhri et al. 2005). Complementary data suggest that 
men are more likely to be responsive to actual nicotine 
dose and other pharmacologic properties than are women 
(Perkins et al. 2006). If men are indeed more sensitive to 
nicotine’s pharmacologic properties than are women, this 
could explain why men who use NRT sometimes achieve 
higher levels of success with smoking cessation than do 
women who use NRT (Wetter et al. 1999; Perkins 2001; 
Cepeda-Benito et al. 2004) and why this finding did not 
hold for use of psychosocial interventions (Velicer et 
al. 2007).
Other studies show additional differences by gender. 
Data from study of a community-based population sam-
ple suggest that financial stressors may be more likely to 
inhibit smoking cessation in women than in men and that 
negative health events are more likely to prompt cessation 
in men (McKee et al. 2003). Other research shows that 
male smokers tend to be more reactive to relatively minor 
stressful events (i.e., hassles) than are women (Wetter et 
al. 1999; Delfino et al. 2001; Todd 2004). Although there is 
mounting evidence of differences by gender in reaction to 
nicotine or environmental cues (Perkins et al. 1999), and 
in motivation to use tobacco or nicotine, these differences 
have not been definitively linked with either relapse or dif-
ferences by gender in relapse. Even less is known about 
the relationship of factors such as low SES or educational 
attainment to likelihood of smoking cessation (Wetter et 
al. 2005a).
One innovative approach to unraveling the complex 
interrelationships among the multiple person factors and 
relapse is to conduct classification or decision-tree analy-
ses. These analyses have been used to determine whether 
categories of person factors (e.g., male versus female) 
comprise smoker subgroups that can be distinguished 
on the basis of their risk profiles for cessation failure. 
One example of this approach generated six subgroups of 
women smokers (Swan et al. 2004). For some subgroups, 
cessation failure appeared to be related to educational 
attainment and the number of previous attempts to stop 
smoking; for others, failure was more strongly related to 
body mass index and family history of depression (Swan et 
al. 2004). In contrast, male smokers comprised subgroups 
more highly distinguished by variables related to nicotine 
dependence, such as FTND score (Heatherton et al. 1991) 
and the number of years of smoking. In addition, male 
subgroups were distinguished on the basis of previous 
NRT and a history of depression. This type of classification 
or decision-tree analysis is useful because it has the poten-
tial to reveal factors that are highly predictive of cessation 
outcome in a subgroup of smokers, even if a factor is not 
important over an entire sample (Swan et al. 1997, 1999). 
Further research is needed to assess the replicability of 
such findings. 
Psychiatric and Affective Dimensions
Some researchers have reported that the vulner-
ability to failure of smoking cessation or relapse to smok-
ing is positively related to a history of depression, alcohol 
intake, a tendency toward negative affect, and an intoler-
ance of psychological distress. As with most other indi-
vidual differences, these relationships are either small in 
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magnitude, inconsistent, or both. For example, both stud-
ies of population samples and clinical trials indicate that 
a history of depression or depressive symptoms predicts a 
greater likelihood of a relapse or a failure to stop smok-
ing (Anda et al. 1990; Romans et al. 1993; Ferguson et al. 
2003; Smith et al. 2003; Japuntich et al. 2007). However, 
one meta-analysis of data from 15 clinical trials failed to 
find such an effect (Hitsman et al. 2003). Studies in this 
meta-analysis generally excluded participants who were 
currently depressed or taking antidepressant medication. 
One hypothesis is that if depression is correlated 
with vulnerability to relapse, the correlation may be 
attributable to the presence of two specific subpopulations 
of persons who have depression. Hitsman and colleagues 
(2003) observed that several studies have found a relation-
ship between recurrent (multiple episode) depression and 
heightened risk of failure to stop smoking (Glassman et 
al. 1993; Covey et al. 1999; Brown et al. 2001). Haas and 
colleagues (2004) also found that a high rate of failure to 
stop smoking was associated with a history of multiple, 
but not single, episodes of depression. There also is evi-
dence that current depression is more strongly associated 
with relapse than is past depression (Niaura et al. 2001; 
Japuntich et al. 2007; Turner et al. 2008). These results sug-
gest that associations between depression and relapse may 
be attributable to subpopulations with depression, that is, 
those who are either currently depressed or who are prone 
to recurrent depression. These types of depression may be 
linked to risk of relapse because both were associated with 
recurrent or chronic negative mood (Niaura et al. 2001; 
Haas et al. 2004; Japuntich et al. 2007), and negative mood 
has repeatedly been linked with increased likelihood of 
relapse to smoking among persons with depression 
(Kahler et al 2002; Leventhal et al. 2008). However, it is 
possible that the heightened risk of relapse presented by 
current or recurrent depression is caused by other factors, 
such as poor coping skills or low self-efficacy.
There is also mixed evidence as to whether a history 
of alcohol abuse or dependence increases vulnerability to 
relapse to smoking. Some studies show an elevated risk of 
relapse (Hughes 1993; Breslau et al. 1996), but in others 
risk is not elevated (Covey et al. 1993; Hurt et al. 1995). 
Perhaps the best characterization of the evidence is the 
finding that active abuse of or dependence on alcohol con-
stitutes a risk factor for relapse to smoking (Hurt et al. 
1994; Kalman et al. 2001, 2002). However, there may be 
little or no risk if problems with alcohol are in remission 
(Hughes and Callas 2003). Evidence also shows that an 
active consumption of alcohol enhances the risk of relapse 
to smoking (Krall et al. 2002; McKee et al. 2003). Thus, 
the risk of relapse posed by alcohol use is not attribut-
able to alcohol being a marker for a trait-like vulnerabil-
ity to relapse but rather is attributable to the immediate 
(situational) effects of intoxication. However, there is 
modest evidence that another syndrome of disinhibition, 
attention-deficit/hyperactivity disorder, is associated with 
elevated risk of relapse to smoking (Humfleet et al. 2005).
An additional affective dimension that has been 
studied and may contribute to a heightened risk for 
relapse is the ability of a person to tolerate distress or to 
persist in a distressing task. Hence, several studies have 
associated measures of distress tolerance among smok-
ers with the likelihood of or latency to relapse. In these 
studies, smokers with low vulnerability to relapse showed 
a greater persistence in tasks such as breathholding and 
mental arithmetic than did smokers with high vulnerabil-
ity to relapse (Hajek et al. 1987; Brown et al. 2002). This 
finding provides evidence that characteristics such as an 
inability or unwillingness to tolerate distress is linked to 
a vulnerability to relapse. An inability to tolerate negative 
affect may be especially related to early relapse to smoking 
(Zvolensky et al. 2004; Brown et al. 2008).
In summary, the person factors that yield the stron-
gest or most consistent prediction of relapse are measures 
of tobacco dependence and cognitive and attitudinal vari-
ables such as expectation of smoking reinforcement. In 
addition, measures of low SES and low educational attain-
ment are also fairly consistently related to risk of relapse. 
Other relatively stable person factors are more modestly 
or inconsistently related to smoking relapse. Predictors 
of relapse vary from study to study, probably reflecting 
differences in the populations studied, different mixes 
of predictors included in the studies, and diverse meth-
ods and measures of the same target constructs. In addi-
tion, much of the variation in vulnerability to relapse is 
no doubt caused by other factors not measured in most 
studies—for	 example,	 exposure	 to	 episodic	 events	 and	
reactions to smoking cessation (Shiffman et al. 1996a,c; 
Kenford et al. 2002; Gwaltney et al. 2005a,b; McCarthy et 
al. 2006). Also, other variables may account for apparent 
direct associations between person factors and relapse. 
For instance, persons who drink heavily may be especially 
likely to socialize with other smokers, and an exposure to 
smokers may cause heightened risk of relapse.
Emergent Processes
Emergent processes are reflected in rapid changes 
in symptoms or behaviors that occur within several days 
before a lapse or relapse. Researchers have typically stud-
ied emergent processes across two temporal windows: one 
that begins at the time of smoking cessation and there-
fore captures initial responses to the event and a second 
that starts close in time to a lapse in cessation and cap-
tures changes in behaviors or symptoms leading up to 
the event. Both types of analyses provide evidence that 
Nicotine Addiction: Past and Present  175
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease
emergent processes set the stage for smoking lapses and 
relapses. In general, emergent processes do not depend 
on	the	sort	of	 treatment	or	cessation	strategy	used—for	 
example, they occur in smokers receiving active or pla-
cebo pharmacotherapy.
Tobacco Withdrawal and Affective Symptoms
Perhaps the strongest evidence that emergent pro-
cesses affect vulnerability to relapse comes from research 
on the tobacco withdrawal syndrome. Until recently, 
major reviews concluded there was little evidence that 
withdrawal symptoms were consistently related to the 
likelihood of a relapse (Hughes et al. 1990b; Patten and 
Martin 1996). However, in the decade ending in 2004, 
research has shed light on the nature of withdrawal, as 
well as its relationship to a relapse (Hughes 2007). First, 
in many smokers, perhaps most of those attempting to 
stop smoking, withdrawal symptoms are persistent and 
often remain elevated for months after an attempt to stop 
smoking (Gilbert et al. 1998, 2002; Piasecki et al. 1998, 
2000). Second, withdrawal results (1) in great heteroge-
neity of symptoms, both in and across smokers, and (2) in 
volatile changes in affect and craving (see Figure 4.6 for 
craving pattern) (Piasecki et al. 2003a; McCarthy et al. 
2006). Third, withdrawal results in vulnerability to more 
severe symptoms in reaction to environmental events 
than those that occur before smoking cessation (Figure 
4.7) (McCarthy et al. 2006). In addition, research shows 
that some of these symptomatic effects of tobacco with-
drawal are associated with an increased vulnerability to 
relapse. In general, smokers are more likely to relapse 
if withdrawal symptoms after smoking cessation are 
severe, increase in severity over time, or are highly vari-
able (Piasecki et al. 1998, 2000, 2003b; McCarthy et al. 
2006). Research also shows that withdrawal symptoms 
indicate vulnerability to relapse, as the result of either 
immediate increases in symptoms in response to absti-
nence from smoking or emergent changes in symptoms 
that occur across the days preceding a lapse in smoking 
cessation (Figure 4.8) (Piasecki et al. 2003b; McCarthy et 
al. 2006). 
Withdrawal measures tap a variety of symptoms, but 
research suggests that self-reported craving and negative 
affect are the symptoms most predictive of relapse (West 
et al. 1989; Killen et al. 1991; Swan et al. 1996; Killen 
and Fortmann 1997; Piasecki et al. 1998; McCarthy et al. 
Figure 4.6 Individual estimated slopes in craving ratings over three weeks prequit, from just before to just after 
midnight on the quit date, and over three weeks postquit
Source: McCarthy et al. 2006.
Note: The synthesized trajectories are based on multiple daily ratings made in real time with electronic diaries. The heavy black 
line represents the mean trend in craving ratings across all individuals. All other lines represent the slopes or trajectories of craving 
ratings for individual smokers and show how variable withdrawal symptoms can be across smokers across time. 
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2006). Other elements of the withdrawal syndrome, such 
as sleep disturbances or weight gain, are less consistent 
indices of a vulnerability to relapse (Wetter et al. 1995; 
Borrelli et al. 2001).
One piece of evidence that supports the role of 
withdrawal in precipitating relapse is research show-
ing that withdrawal suppression appears to mediate the 
effects of pharmacologic treatments for smoking cessation 
(McCarthy et al. 2006; Shiffman et al. 2006). Statistical 
tests suggest that nicotine replacement and bupropion 
treatments reduce relapse risk to the extent that they sup-
press withdrawal symptoms. These studies suggest only 
partial mediation, however, consistent with the notion 
that other factors also influence relapse.
Although it is clear that emergent trends can set the 
stage for lapses and relapses to smoking, much remains to 
be learned about these associations. The time course by 
which emergent symptoms anticipate lapses, for example, 
needs more focused examination, because a gradual emer-
gence of symptoms would permit the delivery of preven-
tive interventions. Several studies show that craving and 
exacerbation of withdrawal symptoms precede lapses by 
several days (Piasecki et al. 2003b; McCarthy et al. 2006; 
Allen et al. 2008). However, as noted earlier in this sec-
tion, other research shows that lapse-provoking increases 
in negative affect unfold within hours rather than days 
(Figure 4.9) (Shiffman and Waters 2004).
Cognitive and Attitudinal Influences
Emergent cognitive and attitudinal processes may 
also enhance vulnerability to relapse. For instance, one 
study used real-time data recording to show that low 
Figure 4.7 Reactions for the three-week period before the quit date and the three-week period after the quit date
Source: McCarthy et al. 2006.
Note: Data are from 70 smokers making a quit attempt. The y-axis depicts the magnitude of the average standardized coefficient 
derived from multivariate, multilevel models. Episodic event coefficients were estimated separately in the prequit and postquit 
periods. The beta weights shown reflect the degree of symptom change (in overall withdrawal, hunger, craving, and negative affect) 
associated with the presence versus absence of an episodic event. (A) Symptom coefficients associated with smoking in the past 
15 minutes in models of overall withdrawal. (B) Symptom coefficients associated with recent exposure to smoking behavior. 
(C) Symptom coefficients associated with exposure to recent stressful events. (D) Symptom coefficients associated with recent 
strong urges and temptations. Results suggest greater symptomatic reactivity to events after quitting than before quitting.
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abstinence and self-efficacy estimates, along with high 
expectations of smoking reinforcement, predicted a lapse 
to smoking that occurred on the following day (Gwaltney 
et al. 2005a). These effects were independent of scores 
for these measures on the day of smoking cessation, 
suggesting that the effects reflect emergent processes and 
not trait differences. Other research shows that persons 
who lapse to smoking appear to experience a marked dip 
in motivation during the week leading up to a lapse (He-
deker and Mermelstein 1996). 
Timing and Motivational Significance of 
Emergent Processes 
As previously noted, both symptomatic and attitudi-
nal changes emerge across the period after smoking cessa-
tion and predict a relapse. Such changes may occur in the 
first few hours after cessation or in the hours or days just 
before a lapse to smoking (Figures 4.8 and 4.9) (Hedeker 
and Mermelstein 1996; Gwaltney et al. 2005a). Emergent 
symptoms may occur at any time during the postcessa-
tion period. However, research shows that symptoms that 
occur early in this period (e.g., in the first 24 hours) may 
Figure 4.8 Withdrawal severity and lapse behavior among smokers who abstained for the first five days of a quit 
attempt
Source: Piasecki et al. 2003b.
Note: Matched abstainers (MAs; n = 152) had never smoked during the follow-up period. Transient lapsers (TLs; n = 124) had lapsed 
but did not immediately resume regular smoking. Protracted lapsers (PLs; n = 28) had immediately returned to regular smoking 
upon lapsing. The figure shows predicted withdrawal severity growth functions for these three groups over several periods: baseline 
(prequit: prior to day 0 in the first panel), the first five days of the quit attempt, the five days preceding and following the lapse dates 
of the lapsers (TL and PL participants); and last five days of the quit attempt (when TL and PL participants were smoking and MA 
participants were abstinent). Each lapsed participant was paired with an MA to produce temporal equivalence across the prelapse and 
postlapse windows. To compare the symptoms of lapsers with those of nonlapsers, the investigators randomly matched each lapser 
with a person who did not lapse, then compared the predicted symptom trajectories of these individuals over the same postquit 
periods of time defined by when a lapse actually occurred.
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be more tightly linked to outcomes than are later symp-
toms. For instance, in the Killen and Fortmann (1997) 
research, 2,600 smokers were entered into three studies 
through population-based recruitment. Across all three 
studies, craving ratings gathered early in the attempt to 
stop smoking (e.g., 24 hours postcessation) predicted 
relapses across the first year after cessation. Smokers 
with ratings in the highest quartile for craving were twice 
as likely to relapse as were smokers in the lowest quar-
tile (31 versus 16 percent, respectively, averaged across 
all three studies). This research agrees with a wealth of 
other evidence that appearance of symptoms early in the 
attempt to stop smoking is negatively related to an ability 
to remain abstinent and to avoid a relapse (Killen et al. 
1991; Doherty et al. 1995; McCarthy et al. 2006). 
These data supported a large amount of evidence 
showing that various types of self-reports become mark-
edly more predictive of ultimate outcomes as soon as 
persons have some experience in the attempt to stop 
smoking (Kenford et al. 2002; Gwaltney et al. 2005a). This 
evidence suggests that even though smokers have experi-
ence with abstinence from smoking and have memories of 
previous attempts to stop smoking, many are still unpre-
pared for the forces unleashed by abstinence, which ulti-
mately lead to a relapse. 
Situational Instigators
A large body of research shows that lapses and 
relapse are associated with a limited set of contextual or 
situational features. Studies that use remote data collec-
tion techniques, in which data are gathered long after 
the lapse or relapse occurred, show that the contexts of 
lapses are characterized by features such as negative 
affect, urges to smoke, alcohol consumption, and cues to 
smoke (O’Connell and Martin 1987; Brandon et al. 1990). 
Figure 4.9 Negative affect in the days and hours preceding the first lapse for smokers who attributed their first 
lapse to a stressor or bad mood (stress trigger) or to some other type of event (other trigger)
Source: Adapted from Shiffman and Waters 2004 with permission.
Note: Stress trigger, n = 29; other trigger, n = 61. These data suggest that increasing negative affect is a risk factor for lapsing for some 
smokers. Error bars show one standard error. 
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Research using real-time data acquisition shows that 
situations in which lapses occur (lapse situations) can be 
distinguished from temptations, that is, instances in 
which smoking did not actually occur, and from random 
occasions on the basis of the negative moods that occur in 
relation to lapses (Shiffman et al. 1996c). Negative moods 
are significantly more likely to co-occur with lapses than 
with temptations without smoking or to occur alone at 
randomly determined times. These negative moods tend 
to be strongly associated with reports of interpersonal 
stress such as arguments.
Shiffman and colleagues (1996c) also found that 
lapse situations can be distinguished from temptation 
situations and random occasions in that lapses are more 
likely to be accompanied by alcohol intake and strong 
urges to smoke that occur later in the day. Considerable 
additional evidence demonstrates that alcohol intake sets 
the stage for lapses (Borland 1990; Brandon et al. 1990). 
Also, both lapses and temptation situations tend to co-
occur in the presence of other persons who are smoking. 
Thus, the availability of cigarettes and the modeling of 
smoking are associated with an increased desire to smoke. 
However, such cues do not reliably distinguish between 
the desire to smoke and the occurrence of smoking. 
Finally, the smoker is not a passive party in the progres-
sion to relapse. The data show that the execution of a cop-
ing response is more characteristic of temptation than of 
lapse occasions, suggesting that coping detoxifies tempta-
tion situations (Shiffman et al. 1996c). 
Attesting to the powerful influence of contextual 
factors, recent research shows that smoking policies or 
the numbers of smokers in the person’s environment reli-
ably predict likelihood of relapse or success in cessation 
(Letourneau et al. 2007). For instance, risk of relapse or 
rapidity of relapse is heightened by the number of smokers 
in a person’s social network, whether the person’s part-
ner smokes (Mullen 2004; Letourneau et al. 2007; Macy 
et al. 2007; Solomon et al. 2007), and whether there are 
smoking restrictions at the person’s place of work or at 
home (Gilpin et al. 1999; Lee and Kahende 2007; Macy et 
al. 2007). However, some data suggest that bans in social 
contexts or restaurants may not be related to the success 
of cessation (Albers et al. 2007).
In general, research on situational indicators sug-
gests that temptations to smoke and smoking lapses are 
contingent on internal symptoms of withdrawal (e.g., 
urges to smoke), alcohol use, and environmental signals 
of smoking, including the availability of cigarettes and the 
status of smoking restrictions. These findings are consis-
tent with theories that drug availability and distress both 
constitute potent prods to motivation for drug use (Niaura 
et al. 1988; Skjei and Markou 2003; Baker et al. 2004). 
Integration Across Relapse Influences
Person factors, situational cues, and emergent pro-
cesses all influence risk of relapse. Moreover, research sug-
gests that relapse risk reflects an interaction among these 
types of influences (Shiffman 1989a; Piasecki et al. 2002). 
For example, the intensity of the urge to smoke during 
temptation events predicts the likelihood of a lapse (Shiff-
man et al. 1997). However, this relationship depends on 
the level of urges to smoke reported on the day of smok-
ing cessation. Thus, situational ratings are related to trait 
characteristics, such as tobacco dependence or emergent 
trends (e.g., withdrawal) that affect ratings for the urge to 
smoke on the day of smoking cessation. The relationship 
between the type of lapse situation and an emergent nega-
tive affect are shown in Figure 4.9. Data also show that 
the intensity of the urge to smoke during temptation epi-
sodes grows in the days leading up to a lapse (Shiffman et 
al. 1997). These data provide further evidence for the role 
of emergent processes in affecting situational reactions 
that, in turn, are related to lapse events. Finally, this same 
research shows that the level of the urge to smoke 
reported by persons on awakening predicted the likelihood 
of a lapse later on the same day. For some reason, urges 
to smoke in the morning, as opposed to urges reported at 
other times, tended to provide the most powerful predic-
tions of lapses. In sum, research on the urge to smoke 
shows that the likelihood of a lapse reflects the interaction 
of trait factors, emergent processes, and situational cues.
Other data suggest interactive influences on the 
likelihood of a lapse. For example, Gwaltney and col-
leagues (2005b) found that persons who have low levels 
of trait-like self-efficacy at baseline show marked declines 
in self-efficacy in situations that produce strong urges or 
negative affect. Hence, trait measures capture a person’s 
vulnerability to succumb to situational challenges. A chief 
goal of future research is to elucidate how various types 
of influences on relapse interact to produce a relapse in a 
particular person at a particular time. 
Transition from Lapse to Relapse  
or Recovery
Exploration of the factors that transform lapses into 
relapses is vital, because initial incidents of tobacco use 
routinely usher in a return to regular smoking (Baer et 
al. 1989; Garvey et al. 1992; Kenford et al. 1994). Study of 
the factors that influence the lapse-relapse progression is 
also important, because it seems that factors affecting this 
progression differ from factors that affect the occurrence 
of the lapse itself. For instance, Wileyto and colleagues 
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(2005) found that the likelihood of lapse in a smoker was 
relatively unaffected by his or her dependence level (FTND 
score) or symptoms of depression. However, both of these 
factors were associated with greater difficulty in recover-
ing	from	a	lapse—that	is,	reestablishing	abstinence	for	at	
least 24 hours. 
Researchers have found that the probability or the 
latency of a relapse after a lapse can be predicted by nico-
tine dependence (Shiffman et al. 1996b, 1997) and by fea-
tures of the lapse situation, such as the failure to make 
a coping response, feelings of hopelessness, and stronger 
urges to smoke during the lapse (Shiffman et al. 1996b). 
In addition, postlapse declines in self-efficacy of absti-
nence indicate a greater likelihood of or a faster progres-
sion to a relapse (Gwaltney et al. 2005b). Thus, it appears 
that individual capitulation in the cessation attempt and 
high levels of nicotine dependence foster the progression 
to a relapse. 
Lapses appear to play a causal role in precipitat-
ing a relapse. This finding is indicated by the report that 
smokers randomly assigned to experimental lapse events 
resume smoking more rapidly than do smokers not 
assigned to such lapse experiences (Chornock et al. 1992). 
Summary and Future Directions
The data suggest that factors contributing to a 
relapse are multidimensional and involve many processes 
associated with addiction, including personal traits, past 
experiences with nicotine, associative learning and condi-
tioning, and the manifestation of withdrawal symptoms. 
Development of treatments to prevent lapses (occasional 
smoking) is important, because these events so frequently 
lead to a relapse. In addition, this review suggests that 
treatments should target specific phenomena that may 
motivate lapses and relapses: (1) increases in withdrawal 
symptoms, especially urges to smoke and negative affect 
that occur in the first 48 hours of smoking cessation (Fig-
ures 4.6 and 4.8); (2) emergent increases or spikes in nega-
tive affect and urges that occur at any point after smoking 
cessation (Figures 4.8 and 4.9); (3) the drop in self- 
confidence or the increase in urges engendered by a lapse; 
(4) urges that occur shortly after awakening that may 
or may not reflect conditioned withdrawal effect (Figure 
4.6); (5) a trait-like intolerance of distress; (6) increased 
urges to smoke and withdrawal symptoms prompted by 
smoking-related cues or stressful events (Figure 4.7); and 
(7) alcohol consumption and its effects on cognitive and 
motivational processes. Although relapse has also been 
associated with relatively stable demographic factors such 
as SES and educational status, it is unclear why these 
factors are associated with failure of smoking cessation 
and which treatment strategies could be used to counter 
them. Future research should be focused on further refin-
ing types for relapse and recovery, understanding genetic 
and neurobiologic underpinnings, and developing effec-
tive treatments for these types. 
Evidence Summary
The 1988 Surgeon General’s Report, The Health 
Consequences of Nicotine Addiction, concluded that 
“nicotine is the drug in tobacco that causes addiction” 
(USDHHS 1988, p. 9). Studies show that animals self-
administer or prefer nicotine over saline and that many 
people smoke to regulate blood concentrations of nico-
tine. For example, if smokers are given cigarettes with 
lower nicotine yields than their usual brands, they tend 
to smoke more intensely or to cover the filter ventilation 
holes to increase their nicotine intake. The VTA region of 
the brain and the mesocorticolimbic dopamine neurons 
originating in this brain site are primarily responsible for 
the positive reinforcing aspects of nicotine. An increase 
in levels of dopamine is mediated by nicotine directly 
stimulating nAChRs, primarily α7 homomeric and α4β2-
containing nAChRs within the VTA, thus increasing activ-
ity of VTA neurons projecting to the nucleus accumbens 
and the frontal cortex. Nicotine stimulates α7 nAChRs on 
glutamatergic terminals that release glutamate, an excit-
atory neurotransmitter, which results in increased release 
of dopamine in the nucleus accumbens, amygdala, and 
frontal cortex. Nicotine also excites nAChRs on GABA-
releasing terminals. Thus, levels of GABA, an inhibitory 
neurotransmitter, are also increased by nicotine. However, 
the interplay between the quick desensitization of nAChRs 
on the GABA neuron and the higher doses of nicotine re-
quired to desensitize nAChRs on the glutamate neuron 
result in a greater increase in dopamine levels. 
The neurophysiology associated with withdrawal 
symptoms may be based on the type of symptoms 
experienced (e.g., somatic versus affective). It appears that 
nAChRs differ in their involvement in both the somatic 
and affective components of nicotine withdrawal and 
dependence. As seen in animal studies, β4 nAChRs play an 
important role in the somatic signs of withdrawal, whereas 
β2 nAChRs play an important role in the affective, but not 
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somatic, aspects of withdrawal. The role of α4 nAChRs is 
unclear, but these receptors may play a role in both the 
affective and somatic withdrawal effects of nicotine addic-
tion. The α7 nAChRs appear to be involved only in some of 
the somatic signs of nicotine withdrawal. 
The amount and speed of nicotine delivery also plays 
a critical role in the potential for abuse of tobacco prod-
ucts. The speed and amount of nicotine delivered to the 
brain depend on the amount of nicotine in the product, 
the alkalinity of the product, and the route of adminis-
tration. Nicotine, 3-(1-methyl-2-pyrrolidinyl)pyridine, is a 
volatile alkaloid in the tobacco plant, and its absorption 
and renal secretion is highly dependent on pH. Products 
with higher alkalinity are associated with greater amounts 
of nicotine in the nonionized or free base state, which can 
vaporize more easily into the gas phase, can be deposited 
directly on the lung tissues, and crosses cell membranes 
more rapidly than ionized nicotine. Tobacco products 
can contain constituents such as ammonia to increase 
the conversion of nicotine to the nonionized or free base 
state. Physical design features such as filter-tip ventila-
tion also increase the free base fraction of nicotine (see 
Chapter 3, “Chemistry and Toxicology of Cigarette Smoke 
and Biomarkers of Exposure and Harm”). The fastest rate 
of nicotine delivery is through smoking cigarettes. Nico-
tine, when inhaled, enters the lungs, which present a large 
surface area of small airways and alveoli, undergoes dis-
solution in pulmonary fluid at a high pH, is transported 
to the heart, and then immediately passes to the brain. 
This rapid and bolus delivery of nicotine through ciga-
rettes leads to greater control over the amount of nicotine 
delivered to the brain and results in higher abuse potential 
than do other tobacco- or nicotine-containing products. 
Nicotine in the tobacco product and its kinetic 
profile are not the only factors that might contribute to 
a tobacco product’s potential for addiction. Other con-
stituents may also serve as reinforcers or may enhance 
blood levels of nicotine or its effects. For example, animal 
studies have shown that nornicotine, a secondary tobacco 
alkaloid, functions as a reinforcer, but at less potency than 
nicotine. The effect of nornicotine in humans is unclear. 
Acetaldehyde, another constituent in tobacco smoke, 
which results from burning sugars and other materials in 
the tobacco leaf, may play a role in increasing the rein-
forcing effects of nicotine. In animal studies, acetaldehyde 
enhanced the acquisition of nicotine self-administration 
among adolescent rats but not adult rats. Extracts from 
flue-cured tobacco that appear to inhibit MAO activity 
in the brain may be another contributory factor to the 
reinforcing effects of cigarettes. Increased MAO inhibi-
tion results in increased levels of catecholamines. Current 
smokers have lower levels of MAO than do nonsmokers or 
former smokers. 
Tobacco product design and ingredients contrib-
ute to the risk of addiction by reducing noxious effects 
such as the unpleasant taste of nicotine and unpleasant 
sensory effects (see Chapter 2, “The Changing Cigarette”). 
Such designs include ventilation to cool the smoke and 
ingredients such as menthol and chocolate that make 
nicotine inhalation more pleasant. Other nonnicotine fac-
tors can also contribute to addiction potential. These fac-
tors include the associative learning processes (internal 
and environmental cues linked with nicotine administra-
tion) that develop with repeated tobacco use. This associa-
tive learning can be as powerful as the direct effects of 
nicotine. For example, presenting smokers with sensory 
aspects of smoking without nicotine has resulted in a 
decrease in craving for cigarettes, a decreased subset of 
withdrawal symptoms, and short-term reinforcing efficacy 
similar to that of cigarettes containing nicotine (see Chap-
ter 3, “Chemistry and Toxicology of Cigarette Smoke and 
Biomarkers of Exposure and Harm”).
Typically, smoking initiation occurs during ado-
lescence. Research shows that adolescent smokers 
report some symptoms of dependence even at low levels 
of cigarette consumption, and animal studies show that 
sensitivity to nicotine in adolescents differs from that 
in adults. For example, results from the paradigms of 
self-administration and conditioned place preference in 
rats demonstrate that adolescence may be at a stage of 
development with higher sensitivity to nicotine exposure 
than that in adults. Using mixture modeling, longitudinal 
studies have identified multiple age-related trajectories 
of smoking behavior. These trajectories typically include 
smokers with early initiation of smoking and steep accel-
eration of smoking, persons who engage in experimental 
or light smoking, smokers with late initiation and acceler-
ated progression of smoking, persons who stopped smok-
ing, and those who never smoked. The group with early 
initiation and steeply escalating and persistent smoking 
has been associated with familial smoking, which reflects 
genetic and/or environmental risk factors, less parental 
support, and a risk for chronic heavy smoking in adult-
hood. Ethnic differences have also been observed for the 
age at initiation of smoking and the speed of progression 
in smoking. These studies showed that African Americans 
were more likely to have slower progression of smok-
ing and a lower number of cigarettes smoked than do 
Whites. Studies that have looked at predictors for devel-
oping nicotine addiction or heavy smoking suggest the 
importance of both genes and environmental influences. 
Parental smoking, parental substance abuse disorders, 
and externalizing disorders (attention-deficit/hyperactiv-
ity, disruptive behavior, and alcohol and drug abuse) have 




Initiation and persistence of smoking and nicotine 
dependence show strong heritability. Most coefficients of 
reported heritability range from less than 0.3 to more than 
0.8 and vary on the basis of the smoking behavior phe-
notype examined and the social or environmental factors 
such as prevalence of smoking. The balance of evidence 
suggests that the risk of smoking initiation is influenced 
by both genetic and environmental factors, whereas the 
risk of smoking persistence may have a stronger genetic 
component. Although some genetic influences on smok-
ing initiation and persistence are common, there are also 
separate and unique genetic influences for initiation and 
for persistence. Studies also suggest that the ability to stop 
smoking is under a strong genetic influence, and some 
consider this phenotype to be the key behavioral pheno-
type for nicotine dependence. Molecular genetic studies 
have been conducted to examine the specific genetic fac-
tors and biologic mechanisms involved in nicotine addic-
tion. Most of the candidate gene studies have focused on 
genetic variation in nAChRs, relevant neurotransmitter 
pathways, or genes for nicotine-metabolizing enzymes. 
Candidate gene studies are association-based studies 
comparing prevalence of candidate gene variants in two 
unrelated	 groups—for	 example,	 nicotine-dependent	 ver-
sus nondependent persons. Examples of candidate gene 
variants that have been examined include nAChR sub-
units, such as CHRNA4 and CHRNA5; dopamine receptors 
D2 and D4 (DRD2 and DRD4) and dopamine transporter 
(DAT) genes; tryptophan hydroxylase, which is associ-
ated with serotonin biosynthesis; serotonin transporter 
5HTTLPR, which is associated with genes that code for 
serotonin reuptake; MAOA and DβH genes, which affect 
norepinephrine pathways; genes in the endogenous opioid 
pathway (e.g., OPRM1); and genes involved in the metabo-
lism of nicotine (e.g., CYP2A6).
To date, the only candidate genes with consistent 
evidence of an association with smoking behavior or nico-
tine dependence are CYP2A6 and 5HTT and SNPs in the 
CHRNA5/A3/B4 gene cluster. More research has been con-
ducted on the effects of CYP2A6. Variants of P-450 CYP2A6 
associated with *NULL or reduced activity are associated 
with reduced levels of the CYP2A6 enzyme and slower 
rates of nicotine metabolism, leading to higher plasma 
levels of nicotine for a given dose of nicotine. Persons 
who carry these variants with *NULL or reduced activity 
tend to have lower risk for becoming smokers, reduced 
cigarette consumption, and possibly higher likelihood 
of successful smoking cessation than that for persons 
with wild-type genotypes and higher rates of nicotine 
metabolism. Research in this area will be greatly enhanced 
when there is agreement in the field on phenotypes for 
smoking initiation, trajectory toward nicotine depen-
dence, and nicotine dependence. One area of research that 
has provided promising initial evidence is the pharmaco-
genetics of treatment to aid in smoking cessation, which 
included examining genetic variations in drug-metabo-
lizing enzymes and variations in drug targets to predict 
responses to treatment. It is important to recognize that 
although genes may play an important role in the various 
aspects of smoking behavior, the risk for smoking exists in 
persons without the gene variants, and it is predominantly 
exposure, rather than the host, that leads to smoking- 
related illnesses.
Studying recovery from smoking can provide valu-
able information on the nature of tobacco addiction and 
the factors that affect it. Relapse to smoking occurs at 
a high rate, and most smokers who ultimately relapse 
resume smoking early after the attempt to stop smoking. 
The risk for relapse is particularly high among those who 
lapse or engage in a single episode of smoking after their 
first day of cessation. The pattern of return to smoking 
varies across individuals. However, on average, a second 
lapse occurs within 24 hours of the first lapse, and lapse 
to relapse occurs three to five weeks after the cessation 
attempt. Several multidimensional factors may be associ-
ated with relapse. These factors include the expectations 
that the effects from smoking will be rewarding, confi-
dence in the ability to stop smoking, educational status, 
and degree of tobacco dependence. Situational indicators 
suggest that temptations to smoke and smoking lapse and 
relapse are associated with alcohol use and environmental 
signals such as the sight of others smoking and the avail-
ability of cigarettes. 
Evidence supports the relationship of tobacco with-
drawal syndrome with vulnerability to relapse. Studies 
show three important findings for many smokers: (1) 
withdrawal symptoms are persistent and often severe for 
several months after an attempt to stop smoking, (2) the 
heterogeneity in withdrawal symptoms is great, and (3) 
features such as the severity, variability, and the course 
of withdrawal symptoms confer increased risk for relapse. 
Craving and negative affect are the withdrawal symptoms 
most predictive of relapse, including urges to smoke 
that are experienced immediately after awakening in the 
morning. Research suggests complex interrelationships 
within and across the different types of influences. Future 
research is needed to elucidate these interactions. 
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Conclusions
1. Nicotine is the key chemical compound that causes 
and sustains the powerful addicting effects of com-
mercial tobacco products.
2. The powerful addicting effects of commercial 
tobacco products are mediated by diverse actions of 
nicotine at multiple types of nicotinic receptors in the 
brain.
3. Evidence is suggestive that there may be psychoso-
cial, biologic, and genetic determinants associated 
with different trajectories observed among popula-
tion subgroups as they move from experimentation to 
heavy smoking.
4. Inherited genetic variation in genes such as CYP2A6 
contributes to the differing patterns of smoking 
behavior and smoking cessation. 
5. Evidence is consistent that individual differences in 
smoking histories and severity of withdrawal symp-
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4 mg) Nicoderm Nicotrol
-10 2.5 2.5    3.0      
0 3.0 2.0 1.0 2.5 0 1.5
10 15.5 12.0 6.5 6.0      
20 13.0 14.5 5.0 9.0      
30 12.9 14.5 4.5 10.0 3 2.0
40 8.5 14.4 3.0 9.8      
50 7.9 12.5 2.8 9.0      
60 7.4 12.7 2.4 8.5 8 4.2
70 6.9 12.5 2.2 9.0      
80 6.5 12.0 2.1 8.9      
90 6.1 11.8 2.0 8.5 10 5.0
100 6.0 11.4 1.9 7.5      
110 5.7 11.0 1.8 6.5      
120 5.1 10.8 1.7 6.0 12 6.2
Data table for Figure 4.2 Mean plasma nicotine concentrations after administration of each of four smokeless tobacco 
products or mint snuff
Time Copenhagen Skoal Wintergreen
Skoal Long Cut 
Cherry Skoal Bandits Mint “Snuff”
0 6.34 4.22 4.29 6.52 4.88
1 5.65 3.47 4.15 5.15 4.05
2 8.20 3.63 4.31 4.54 4.17
3 9.54 5.18 4.95 4.91 4.54
4 10.77 6.44 4.28 4.71 4.23
6 16.29 8.50 7.26 5.63 3.99
8 15.68 9.89 9.46 6.87 4.10
10 17.54 12.11 9.75 6.65 4.07
15 18.60 14.42 11.51 6.95 4.02
20 21.52 16.77 14.45 8.57 4.03
25 22.33 15.65 15.68 7.96 4.40
30 22.45 17.10 16.16 9.31 3.85
35 23.93 16.64 17.32 8.97 3.66
40 22.43 15.86 16.04 9.07 3.77
45 20.65 14.78 14.99 8.56 3.61
60 17.58 13.20 12.48 7.57 4.00
75 15.48 11.72 11.41 7.08 3.48
90 13.70 10.71 10.61 6.43 3.67
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≥1 pack/day (N = 1,010) 91.2 84.3    23.9 79.2 33.3               
Breslau et al. 
1994
Random sample  
Health maintenance 
organization 
Aged 21–30 years (N = 1,200)
All smokersa (N = 394)       60.4 27.4    30.5 68.8 44.4 26.6  6.6   
Breslau et al. 
1994
Random sample  
Health maintenance 
organization 
Aged 21–30 years (N = 1,200)
Dependentb (N = 202)       93.6 45.5    58.9 88.6 72.3 49.0 12.9   
Breslau et al. 
1994
Random sample  
Health maintenance 
organization 
Aged 21–30 years (N = 1,200)
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Kawakami et al. 
1999d
Current male smokers
Volunteers (N = 58)       64.2    55.2 67.2 84.5 65.5 60.3 10.3   
Kawakami et al. 
1999d
Current male smokers
Smoking cessation patients  
(N = 151)       65.5    54.7 73.0 73.0 56.1 63.5 17.6   
Kawakami et al. 
1999d
Current male smokers
Health Risk Assessment survey 
sample (N = 194)       59.3    36.1 58.2 67.5 42.8 49.0  8.2   
Storr et al. 2004 NHSDA
1995–1998
Recently initiated       21.7 16.0       17.9 4.7–5.3     4.9 20.1
Table 4.12 Continued
Note: NA = data not available; NHSDA = National Survey on Drug Use & Health.
aSmoked daily for ≥1 month in their lifetime.
bDiagnostic and Statistical Manual of Mental Disorders, 3rd ed. (rev) (DSM-III-R) criteria for nicotine dependence.
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Introduction
The 2004 Surgeon General’s report, The Health 
Consequences of Smoking: A Report of the Surgeon Gen-
eral (U.S. Department of Health and Human Services 
[USDHHS] 2004), concluded that the evidence is suffi-
cient to infer a causal relationship between smoking and 
cancers of the lung, larynx, oral cavity, pharynx, esopha-
gus, pancreas, bladder, kidney, cervix, and stomach, and 
acute myeloid leukemia. In addition, the report found that 
evidence suggests a causal relationship between smoking 
and colorectal and liver cancers. This chapter examines 
the mechanisms by which cigarette smoking induces 
cancer. Literature citations for this section’s discussion 
appear in subsequent sections of this chapter, as appropri-
ate. A schematic overview of the pertinent mechanisms 
discussed in this chapter is presented in Figure 5.1. The 
figure depicts the major established pathways of cancer 
causation by cigarette smoking: (1) the exposure to car-
cinogens (cancer-causing substances), (2) the formation 
of covalent bonds between the carcinogens and DNA (DNA 
adduct formation), and (3) the resulting accumulation 
of permanent somatic mutations in critical genes (genes 
appear in italics). Somatic mutations lead to clonal out-
growth and, through accumulation of additional muta-
tions, to development of cancer. 
Each puff of each cigarette contains a mixture of 
thousands of compounds, including more than 60 well- 
established carcinogens. The carcinogens in cigarette 
smoke belong to multiple chemical classes, including 
polycyclic aromatic hydrocarbons (PAHs), N-nitrosamines, 
aromatic amines, aldehydes, volatile organic hydrocar-
bons, and metals. In addition to these well-established car-
cinogens, others have been less thoroughly investigated. 
These include alkylated PAHs, oxidants, free radicals, and 
ethylating agents. Considerable evidence indicates that 
in human cancers caused by cigarette smoking, PAHs, 
N-nitrosamines, aromatic amines, and certain volatile 
organic agents play a major role. Extensive data in the 
literature demonstrate the uptake of these carcinogens 
by smokers. The data confirm the expected presence of 
metabolites of these substances in the urine of smokers at 
higher levels than those in nonsmokers.
Most carcinogens in cigarette smoke require a 
metabolic activation process, generally catalyzed by cyto-
chrome P-450 enzymes (P-450s), to convert the carcino-
gens to forms that can covalently bind to DNA and form 
DNA adducts. P-450s 1A1 and 1B1, which are inducible 
by cigarette smoke through interactions with the aryl 
hydrocarbon receptor, are particularly important in the 
metabolic activation of PAHs. The inducibility of these 
P-450s may be a critical aspect of cancer susceptibility in 
smokers. P-450s 1A2, 2A6, 2A13, and 2E1 are also 
important in the activation of cigarette smoke carcino-
gens. Competing with the activation process is metabolic 
detoxification, which excretes carcinogen metabolites in 
generally harmless forms and is catalyzed by a variety of 
enzymes, including glutathione-S-transferases (GSTs), 
uridine-5’-disphosphate-glucuronosyltransferases (UGTs), 
epoxide hydrolases, and sulfatases. The balance between 
metabolic activation and detoxification of carcinogens 
varies among persons and likely affects cancer susceptibil-
ity. Persons with a higher activation and lower detoxifica-
tion capacity are at the highest risk for smoking-related 
cancers. This finding is supported by considerable evi-
dence from molecular epidemiologic studies of the poly-
morphisms (variants) in these enzymes.
The metabolic activation of carcinogens results 
in the formation of DNA adducts, which are absolutely 
central to the carcinogenic process. However, some car-
cinogens can directly form DNA adducts without meta-
bolic activation. Since the mid-1980s, extensive studies 
have examined the presence of DNA adducts in human 
tissues. Studies that used nonspecific methods, such as 
32P-postlabeling and immunoassays, to measure adducts 
concluded that adduct levels in the lung and in other tis-
sues are higher in smokers than in nonsmokers. Some 
epidemiologic data link higher adduct levels with a higher 
probability of developing cancer.
There are ample cellular repair systems that can 
remove DNA adducts and maintain a normal DNA struc-
ture. These systems include direct repair of DNA bases by 
alkyltransferases, the excision of DNA damage by base and 
nucleotide excision repair, mismatch repair, and double-
strand break repair. If repair enzymes are overwhelmed 
by DNA damage or for other reasons cannot function 
efficiently, DNA adducts may persist and increase the 
likelihood of developing somatic mutations. Inherited 
polymorphic variants in some DNA repair enzymes are 
also associated with decreased DNA repair activity and a 
potentially higher probability of developing cancer.
Persistent DNA adducts can cause miscoding (e.g., 
insertion of the wrong base) during replication of DNA 
when DNA polymerase enzymes process the adducts 
incorrectly. Considerable specificity exists in the relation-
ship between specific DNA adducts caused by carcinogens 
in cigarette smoke and the types of observed somatic 
mutations; for example, an O6-methylguanine adduct 
causes G→A transitions. These types of mutations are 
frequently observed in the KRAS oncogene in lung 
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cancer and in the TP53 gene in a variety of cancers 
induced by cigarette smoke. The KRAS and TP53 muta-
tions observed in lung cancer in smokers appear to reflect 
DNA damage caused by metabolically activated PAHs. How-
ever, a number of other carcinogens or toxicants, such as 
N-nitrosamines and aldehydes, as well as oxidative dam-
age, are also likely to be involved. Animal studies have 
firmly established the cancer-causing role of mutations in 
these genes.
Gene mutations can cause the loss of normal func-
tions in control of cellular growth, ultimately resulting 
in cellular proliferation and cancer. Studies have strongly 
linked chromosome damage in cells throughout the 
aerodigestive tract to exposure to cigarette smoke. The 
protective process of programmed cell death (apoptosis) 
can counterbalance these mutational events by removing 
cells with DNA damage. The balance between mechanisms 
leading to apoptosis and those suppressing apoptosis has 
a major impact on tumor growth. In addition, research-
ers have observed numerous cytogenetic changes in 
lung cancer. 
The central track of Figure 5.1 that proceeds through 
genetic damage is clearly established as a major pathway 
by which carcinogens in cigarette smoke can cause cancer. 
However, the top and bottom tracks of Figure 5.1 indicate 
that other pathways also contribute to carcinogenesis. 
Nicotine and tobacco-specific nitrosamines bind to nico-
tinic receptors and other cellular receptors. This binding 
then leads to the activation of protein kinase B (AKT, also 
known as PKB), protein kinase A (PKA), and other key 
biologic pathways for cytogenetic changes. Cigarette 
smoke activates EGFR and COX-2, both known to be 
important in cell proliferation and transformation. Fur-
thermore, the occurrence of cocarcinogens and tumor 
promoters in cigarette smoke is well established. Although 
these compounds are not carcinogenic, they clearly 
enhance the carcinogenicity of cigarette smoke carcino-
gens through mechanisms that usually lead to stimula-
tion of cell proliferation. The reversibility of cancer risk 
after smoking cessation supports the role of tumor pro-
moters and other epigenetic factors in tobacco carcino-
genesis. However, the specifics of these effects have not 
been fully elucidated. An important epigenetic pathway is 
the enzymatic hypermethylation of promoter regions of 
genes, which can result in gene silencing. If this occurs 
in tumor-suppressor genes, the result can be unregulated 
cellular proliferation.
Figure 5.1 Link between cigarette smoking and cancer through carcinogens in tobacco smoke
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Carcinogens in Cigarette Smoke
Carcinogens in cigarette smoke that were evalu-
ated by the International Agency for Research on Cancer 
(IARC 2004) are listed in Table 5.1. All are carcinogenic 
in laboratory animals, and 15 are rated as carcinogenic in 
humans (group 1 carcinogens). Similar evaluations have 
been published by the USDHHS (2005). The total exposure 
of smokers to these compounds is approximately 1.4 to 2.2 
milligrams (mg) per cigarette (Table 5.1). This estimate 
is based on machine measurements and may underesti-
mate actual exposure. Some of the strongest of these car-
cinogens are PAHs, N-nitrosamines, and aromatic amines, 
which occur in the lowest amounts, and some of the 
weaker carcinogens, such as acetaldehyde and isoprene, 
occur in the highest amounts. Thus, a simple addition of 
the amounts of carcinogenic agents could be misleading. 
For other carcinogens in cigarette smoke that IARC has 
not evaluated (e.g., broad spectra of PAHs and aromatic 
amines), data on frequency of occurrence, levels, and car-
cinogenic activities are incomplete (IARC 1986). 
PAHs are incomplete combustion products first 
identified as carcinogenic constituents of coal tar (Phil-
lips 1983). These products occur as mixtures in tar, soot, 
broiled foods, automobile engine exhaust, and other 
materials generated by incomplete combustion (IARC 
1983). Generally, PAHs are carcinogens that act locally. 
Some PAHs, such as benzo[a]pyrene (B[a]P), have power-
ful carcinogenic activity. Studies have typically evaluated 
PAH carcinogenicity by application to mouse skin, but 
PAHs also induce tumors of the lung, trachea, and mam-
mary gland, depending on the route of administration and 
the animal model used (Dipple et al. 1984). 
Heterocyclic compounds include analogs of PAHs 
containing nitrogen, as well as simpler compounds such 
as furan, which is a liver carcinogen. N-nitrosamines are 
a large class of carcinogens with demonstrated activity in 
at least 30 animal species (Preussmann and Stewart 1984). 
They are potent and systemic carcinogens that affect dif-
ferent tissues depending on their structure. Two of the 
most important N-nitrosamines in cigarette smoke are the 
tobacco-specific 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) and N’-nitrosonornicotine (NNN) 
(Hecht and Hoffmann 1988). NNK caused lung tumors 
in all species tested, and activity in rats was particularly 
high. Studies using animal models have demonstrated 
that NNK also induces tumors of the pancreas, nasal cav-
ity, and liver. In addition, NNN produces esophageal and 
nasal tumors in rats and respiratory tract tumors in mice 
and hamsters (Hecht 1998). 
Aromatic amines in cigarette smoke are combustion 
products that include the well-known human bladder car-
cinogens 2-naphthylamine and 4-aminobiphenyl (4-ABP), 
which were first characterized as human carcinogens 
attributable to industrial exposures in the dye industry 
(Luch 2005). Heterocyclic aromatic amines are also com-
bustion products and are best known for their occurrence 
in broiled foods (Sugimura 1995), but they also occur in 
cigarette smoke.
Aldehydes such as formaldehyde and acetaldehyde 
occur widely in the human environment and are endo-
genous metabolites found in human blood (IARC 1995c, 
1999; Gao et al. 2002). The phenolic compounds cat-
echol and caffeic acid are common dietary constituents. 
High doses of catechol cause glandular stomach tumors 
when administered in the diet. Catechol can also act as a 
cocarcinogen, enhancing the activity of carcinogens such 
as B[a]P (IARC 1999). Dietary caffeic acid caused renal 
cell tumors in female mice (IARC 1993). The volatile 
hydrocarbons include 1,3-butadiene, a powerful multior-
gan carcinogen in mice that was shown to have weaker 
activity in rats, and benzene, a known human leukemogen 
(IARC 1982, 1999). 1,3-butadiene and benzene are argu-
ably the two most prevalent potent carcinogens in ciga-
rette smoke, on the basis of toxicologic criteria (Fowles 
and Dybing 2003).
Other carcinogenic organic compounds in cigarette 
smoke include the human carcinogens vinyl chloride in 
low amounts and ethylene oxide in substantial quantities 
(IARC 1979). Ethylene oxide is associated with malignan-
cies of the lymphatic and hematopoietic systems in both 
humans and laboratory animals (IARC 1994). Diverse met-
als such as the human carcinogen cadmium are also pres-
ent in cigarette smoke, as is the radioisotope polonium 
210, which is carcinogenic to humans. 
Cigarette smoke also contains oxidants such as 
nitric oxide (about 600 micrograms [µg] per cigarette) 
and related species (Hecht 1999). Free radicals have been 
detected by electron spin resonance and spin trapping 
(Hecht 1999). Researchers postulate that the major spe-
cies of free radicals are a quinone-hydroquinone complex. 
Other compounds may also be involved in the oxidative 
damage produced by cigarette smoke. In addition, several 
studies demonstrate the presence in cigarette smoke of an 
uncharacterized ethylating agent, which ethylates both 
DNA and hemoglobin (Hb) (Carmella et al. 2002a; Singh 
et al. 2005). 
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Table 5.1 IARC evaluations of carcinogens in mainstream cigarette smoke
     
IARC evaluations of evidence of 
carcinogenicity in humans   
Carcinogena
Quantity 
(per cigarette) In animals In humans IARC groupb
IARC Monographc 
(volume, year)
Polycyclic aromatic hydrocarbons               
Benz[a]anthracene 20–70 ng Sufficient    2A 32, 1983; S7, 1987
Benzo[b]fluoranthene 4–22 ng Sufficient    2B 32, 1983; S7, 1987
Benzo[j]fluoranthene 6–21 ng Sufficient    2B 32, 1983; S7, 1987
Benzo[k]fluoranthene 6–12 ng Sufficient    2B 32, 1983; S7, 1987
Benzo[a]pyrene 8.5–17.6 ng Sufficient Limited 1 32, 1983; S7, 1987; 
92, in press
Dibenz[a,h]anthracene 4 ng Sufficient    2A 32, 1983; S7, 1987
Dibenzo[a,i]pyrene 1.7–3.2 ng Sufficient    2B 32, 1983; S7, 1987
Dibenzo[a,e]pyrene Present Sufficient    2B 32, 1983; S7, 1987
Indeno[1,2,3-cd]pyrene 4–20 ng Sufficient    2B 32, 1983; S7, 1987
5-methylchrysene ND–0.6 ng Sufficient    2B 32, 1983; S7, 1987
Heterocyclic compounds               
Furan 20–40 µg Sufficient    2B 63, 1995a
Dibenz[a,h]acridine ND–0.1 ng Sufficient    2B 32, 1983; S7, 1987
Dibenz[a,j]acridine ND–10 ng Sufficient    2B 32, 1983; S7, 1987
Dibenzo[c,g]carbazole ND–0.7 ng Sufficient    2B 32, 1983; S7, 1987
Benzo[b]furan Present Sufficient    2B 63, 1995a
N-nitrosamines               
N-nitrosodimethylamine 0.1–180 ng Sufficient    2A 17, 1978; S7, 1987
N-nitrosoethylmethylamine ND–13 ng Sufficient    2B 17, 1978; S7, 1987
N-nitrosodiethylamine ND–25 ng Sufficient    2A 17, 1978; S7, 1987
N-nitrosopyrrolidine 1.5–110 ng Sufficient    2B 17, 1978; S7, 1987
N-nitrosopiperidine ND–9 ng Sufficient    2B 17, 1978; S7, 1987
N-nitrosodiethanolamine ND–36 ng Sufficient    2B 17, 1978; 77, 2000




110–133 ng Sufficient Limited 1 37, 1985; S7, 
1987; 89, in press
Aromatic amines               
2-toluidine 30–200 ng Sufficient Limited 2A S7, 1987; 77, 2000
2,6-dimethylaniline 4–50 ng Sufficient    2B 57, 1993
2-naphthylamine 1–22 ng Sufficient Sufficient 1 4, 1974; S7, 1987
4-aminobiphenyl 2–5 ng Sufficient Sufficient 1 1, 1972; S7, 1987
Heterocyclic aromatic amines                 
2-amino-9H-pyrido[2,3-b]indole 25–260 ng Sufficient    2B 40, 1986; S7, 1987
2-amino-3-methyl-9H-pyrido[2,3-b]indole 2–37 ng Sufficient    2B 40, 1986; S7, 1987
2-amino-3-methylimidazo[4,5-f]quinoline 0.3 ng Sufficient    2A S7, 1987; 56, 1993
3-amino-1,4-dimethyl-5H-pyrido   
[4,3-b]indole
0.3–0.5 ng Sufficient    2B 31, 1983; S7, 1987
3-amino-1-methyl-5H-pyrido[4,3-b]indole 0.8–1.1 ng Sufficient    2B 31, 1983; S7, 1987
2-amino-6-methylpyrido[1,2-a:3’, 
2’-d]imidazole
0.37–0.89 ng Sufficient    2B 40, 1986; S7, 1987
2-aminodipyrido[1,2-a:3’,2’-d]imidazole 0.25–0.88 ng Sufficient    2B 40, 1986; S7, 1987
2-amino-1-methyl-6-phenylimidazo 
[4,5-b]pyridine
11–23 ng Sufficient    2B 56, 1993
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Table 5.1 Continued
     
IARC evaluations of evidence of 
carcinogenicity in humans   
Carcinogena
Quantity 
(per cigarette) In animals In humans IARC groupb
IARC Monographc 
(volume, year)
Aldehydes               
Formaldehyde 10.3–25 µg Sufficient Sufficient 1 S7, 1987; 62, 1995b
Acetaldehyde 770–864 µg Sufficient 2B S7, 1987; 71, 1999
Phenolic compounds               
Catechol 59–81 µg Sufficient    2B S7, 1987; 71, 1999
Caffeic acid <3 µg Sufficient    2B 56, 1993
Volatile hydrocarbons               
1,3-butadiene 20–40 µg Sufficient Limited 2A S7, 1987; 71, 1999
Isoprene 450–1,000 µg Sufficient    2B 60, 1994; 71, 1999
Benzene 12–50 µg Sufficient Sufficient 1 29, 1982; S7, 1987
Nitrohydrocarbons               
Nitromethane 0.5–0.6 µg Sufficient    2B 77, 2000
2-nitropropane 0.7–1.2 ng Sufficient    2B S7, 1987; 71, 1999
Nitrobenzene 25 µg Sufficient    2B 65, 1996
Miscellaneous organic compounds                 
Acetamide 38–56 µg Sufficient    2B S7, 1987; 71, 1999
Acrylamide Present Sufficient    2A S7, 1987; 60, 1994
Acrylonitrile 3–15 µg Sufficient    2B S7, 1987; 71, 1999
Vinyl chloride 11–15 ng Sufficient Sufficient 1 19, 1979; S7, 1987
1,1-dimethylhydrazine Present Sufficient    2B 4, 1974; 71, 1999
Ethylene oxide 7 µg Sufficient Limited 1 60, 1994; S7, 1987
Propylene oxide 0–100 ng Sufficient    2B 60, 1994; S7, 1987
Urethane 20–38 ng Sufficient    2B 7, 1974; S7, 1987
Metals and inorganic compounds               
Arsenic 40–120 ng Sufficient Sufficient 1 84, 2004
Beryllium 0.5 ng Sufficient Sufficient 1 S7, 1987; 58, 1993
Nickel ND–600 ng Sufficient Sufficient 1 S7, 1987; 49, 1990
Chromium (hexavalent) 4–70 ng Sufficient Sufficient 1 S7, 1987; 49, 1990
Cadmium 41–62 ng Sufficient Sufficient 1 S7, 1987; 58, 1993
Cobalt 0.13–0.20 ng Sufficient    2B 52, 1991
Lead (inorganic) 34–85 ng Sufficient Limited 2A 23, 1980; S7, 1987; 
 87, in press
Hydrazine 24–43 ng Sufficient    2B S7, 1987; 71, 1999
Radioisotope polonium-210 0.03–1.0 
picocurie
Sufficient    1 78, 2001
Source: Adapted from Hoffmann et al. 2001 and International Agency for Research on Cancer 2004 with permission from American 
Chemical Society, © 2001 and International Agency for Research on Cancer, © 2004.
Note: IARC = International Agency for Research on Cancer; ND = not detected; ng = nanograms; S7 = Supplement 7; 
µg = micrograms.
aVirtually all these compounds are known carcinogens in experimental animals, and IARC found sufficient evidence for 
carcinogenicity in animals for all the compounds.
bUsing data on cancer in humans and, in some cases, other data, IARC established classifications for compounds as group 1 
(carcinogenic to humans), group 2A (probably carcinogenic to humans), and group 2B (possibly carcinogenic to humans).
cIf more than two IARC evaluations were performed, only the two most recent monographs are listed.
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In summary, cigarette smoke contains diverse car- 
cinogens. PAH, N-nitrosamines, aromatic amines, 1,3- 
butadiene, benzene, aldehydes, and ethylene oxide are 
probably the most important carcinogens because of their 
carcinogenic potency and levels in cigarette smoke. 
Biomarkers of Carcinogens  
in Smokers
Measurements of carcinogens or their metabolites 
in urine, blood, and breath can provide convenient and 
reliable quantitative information on human exposure to 
carcinogens. The information provided by these measure-
ments, which are biomarkers of exposure, is critical to 
objective evaluation of carcinogen doses in smokers.
Urinary Biomarkers
Urinary biomarkers are the most widely applied 
biomarkers of carcinogen exposure in smokers (Hecht 
2002b). Urine is relatively simple to obtain in large quan-
tities, and obtaining study participants’ consent and speci-
mens for testing is almost never a difficulty. Carcinogens 
in cigarette smoke and/or their metabolites are frequently 
present in substantial quantities in urine. Therefore, reli-
able quantitation is generally feasible. This section pro-
vides an overview of some of the urinary biomarkers most 
commonly used to estimate carcinogen doses in smokers. 
The chemical structures of all compounds discussed in 
this section are illustrated in Figure 5.2. 
Polycyclic Aromatic Hydrocarbons
Phenanthrene metabolites. Phenanthrene is the 
simplest PAH with a bay region (the region of a molecule 
between positions 4 and 5), a feature closely associated 
with the carcinogenic activity of PAHs (Figure 5.2). Phen-
anthrene, however, is inactive as a carcinogen (LaVoie 
and Rice 1988). Concentrations of phenanthrene in main-
stream smoke range from 85 to 620 nanograms (ng) 
per cigarette (IARC 1986). Studies have quantified the 
phenanthrene metabolites phenanthrols, phenanthrene 
dihydrodiols, and r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tet-
rahydrophenanthrene (trans, anti-PheT) in human urine 
(Hecht 2002b). Levels of phenanthrols in human urine 
differed between smokers and nonsmokers in some stud-
ies but not in others (reviewed in Carmella et al. 2004a). 
There are sources of phenanthrene exposure other than 
cigarette smoke, and all people have phenanthrene 
metabolites in their urine. This finding is well documented 
in environmental and occupational settings with high 
exposures to PAH (Grimmer et al. 1993, 1997; Angerer et 
al. 1997). One metabolite of phenanthrene, trans, anti-
PheT, results from the diol epoxide metabolic activation 
pathway common to many carcinogenic PAHs. This me-
tabolite is a promising new biomarker for PAH uptake and 
metabolic activation and can be readily quantified by gas 
chromatography (GC)-negative ion chemical ionization–
mass spectrometry (MS) (Hecht et al. 2003). Levels of 
trans, anti-PheT are higher in smokers than in nonsmok-
ers (Hecht et al. 2003).
1-hydroxypyrene. Pyrene is a noncarcinogenic 
component in all PAH mixtures; levels in mainstream 
cigarette smoke were 50 to 270 ng per cigarette (IARC 
1986). The major metabolite of pyrene is 1-hydroxypyrene 
(1-HOP) glucuronide, which can be measured in urine 
(Jongeneelen et al. 1985). To quantify 1-HOP in urine, 
enzymatic hydrolysis is used to release 1-HOP, which is 
then enriched by reverse-phase chromatography and quan-
tified by high-performance liquid chromatography (HPLC) 
with fluorescence detection. Studies have described varia-
tions of this method (Carmella et al. 2004b). Hundreds of 
studies of occupational and environmental PAH exposure 
have measured 1-HOP as a surrogate marker for total PAH 
exposure. In reviews of the data on the effects of smok-
ing (Jongeneelen 1994, 2001; Van Rooij et al. 1994; Levin 
1995; Heudorf and Angerer 2001; Hecht 2002b), most of 
the studies noted that 1-HOP levels in the urine of smok-
ers were about twice as high as those in the urine of non-
smokers, although some studies have reported greater 
differences. Levels of 1-HOP may be influenced by genetic 
polymorphisms in carcinogen-metabolizing enzymes 
(Alexandrie et al. 2000; Nerurkar et al. 2000; Nan et al. 
2001; van Delft et al. 2001).
Other metabolites of polycyclic aromatic hy-
drocarbons. Studies examining urine biomarkers have 
measured phenolic metabolites of naphthalene and a 
variety of PAHs, which show promise as urinary biomark-
ers of PAH uptake from cigarette smoke (Hecht 2002b; 
Smith et al. 2002a,b; Serdar et al. 2003). Studies have 
quantified B[a]P metabolites in urine, but the levels are 
generally low, limiting their routine application in large 
studies (Hecht 2002b). 
Aromatic Amines and Heterocyclic  
Aromatic Amines
Researchers have quantified aromatic amines, but 
not their metabolites, in human urine. In one study, levels 
of 2-toluidine excreted by smokers were 6.3 ± 3.7 (stan-
dard deviation [SD]) µg/24 hours and levels excreted by 
nonsmokers were 4.1 ± 3.2 (SD) µg/24 hours. The differ-
ence was not significant (El-Bayoumy et al. 1986). Another 
investigation reported urine levels of 2-toluidine that were 
higher in smokers than in nonsmokers (Riffelmann et al. 
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Note: 1-HOP = 1-hydroxypyrene; DHBMA = dihydroxybutylmercapturic acid; iso-NNAC = 4-(methylnitrosamino)-4-(3-pyridyl)butyric 
acid; MHBMA = monohydroxybutenylmercapturic acid; NAB = N’-nitrosoanabasine; NATB = N’-nitrosoanatabine; 
NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NNAL-N-Gluc = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol-N-glucuronide; 
NNAL-O-Gluc = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol-O-glucuronide; NNN = N’-nitrosonornicotine; NNN-N-Gluc = N’-nitro-
sonornicotine-N-glucuronide; NPRO = N-nitrosoproline; NSAR = N-nitrososarcosine; NTCA = N-nitrosothiazolidine 4-carboxylic acid; 
S-PMA = S-phenylmercapturic acid; trans, anti-PheT = r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene; tt-MA = trans,trans-
muconic acid.
Figure 5.2 Chemical structures of biomarkers of carcinogen exposure
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1995). There appear to be significant sources of human 
uptake of 2-toluidine in addition to cigarette smoke. 
Although these sources are not fully characterized, diet 
is one likely source. Amounts of 4-ABP excreted by smok-
ers (78.6 ± 85.2 [SD] ng/24 hours) were similar to those 
excreted by nonsmokers (68.1 ± 91.5 ng/24 hours), and 
amounts of 2-naphthylamine excreted by smokers (84.5 
± 102.7 ng/24 hours) were similar to those excreted by 
nonsmokers (120.8 ± 279.2 ng/24 hours) (Grimmer et al. 
2000). In another study, Hb adducts appeared to be better 
biomarkers of exposure to aromatic amines from tobacco 
smoke than were urinary levels of metabolites (Skipper 
and Tannenbaum 1990). 
Researchers have measured urinary biomarkers of 
heterocyclic aromatic amines mainly in studies of dietary 
exposure. Little information is available on the contribu-
tions of cigarette smoke to urinary levels of heterocyclic 
aromatic amines (Hecht 2002b).
N-Nitrosamines
4-(methylnitrosamino)-1-(3-pyridyl)-1-bu-
tanol and its glucuronides. In rodents and humans, 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
and its glucuronides are quantitatively significant 
metabolites of NNK (Hecht 1998). Both NNAL and NNK 
are pulmonary carcinogens with particularly strong activ-
ity in rats; NNAL also induces pancreatic tumors (Hecht 
1998). Glucuronidation of NNAL at the pyridine nitrogen 
gives NNAL-N-glucuronide, and conjugation at the carbi-
nol oxygen yields NNAL-O-glucuronide. Both NNAL-N-
glucuronide and NNAL-O-glucuronide exist as a mixture 
of two diastereomers, and each diastereomer is a mixture 
of E- and Z-rotamers (Upadhyaya et al. 2001). The NNAL-
N-glucuronide and NNAL-O-glucuronide isomers are 
collectively referred to as NNAL glucuronides. (R)-NNAL-
O-glucuronide does not induce tumors in mice (Upad-
hyaya et al. 1999). The (S) isomer has not been tested, 
but glucuronidation generally deactivates a carcinogenic 
metabolite in any event.
NNAL and NNAL glucuronides can be readily deter-
mined in urine by using GC with nitrosamine-selective 
detection (Carmella et al. 1993, 1995; Hecht et al. 1999) 
and by MS methods (Carmella et al. 1993, 1999; Parsons et 
al. 1998; Lackmann et al. 1999; Hecht et al. 2001; Byrd and 
Ogden 2003). Typical levels are about 1 nanomole (nmol) 
of NNAL in 24 hours and 2.2 nmol of NNAL glucuronides 
in 24 hours, with no detection of unchanged NNK. NNAL 
and NNAL glucuronides are absolutely specific to expo-
sure to tobacco and have not been detected in the urine 
of nontobacco users unless they were exposed to second-
hand smoke. Because NNAL is not present in cigarette 
smoke, the origin of NNAL and NNAL glucuronides found 
in urine is the metabolism of NNK. Most investigations 
demonstrate a correlation between NNAL plus NNAL gluc-
uronides and cotinine in urine. This finding indicates that 
NNAL and NNAL glucuronides are a biomarker of uptake 
of the lung carcinogen NNK and that cotinine is a bio-
marker of nicotine uptake. Ratios of NNAL glucuronides 
to NNAL vary at least 10-fold in smokers. This ratio could 
be a potential indicator of cancer risk, because NNAL 
glucuronides are detoxification products, whereas NNAL 
is carcinogenic (Carmella et al. 1995; Richie et al. 1997). 
In human urine, (S)-NNAL-O-glucuronide is the pre-
dominant diastereomer of NNAL-O-glucuronide, and the 
level of (S)-NNAL is slightly higher than that of (R)-NNAL 
(Carmella et al. 1999). (S)-NNAL is the more tumorigenic 
enantiomer of NNAL in the A/J mouse lung (Upadhyaya 
et al. 1999). NNAL and NNAL glucuronides are released 
slowly from the human body only after smoking cessa-
tion. This finding has been linked to a particularly strong 
retention of (S)-NNAL, possibly at a receptor site (Hecht et 
al. 1999; Zimmerman et al. 2004). Recent studies indicate 
that levels of NNAL plus NNAL-glucuronides are not only 
biomarkers of NNK exposure but also are biomarkers of 
risk for lung cancer in smokers (Church et al. 2009; Yuan 
et al. 2009) 
N’-nitrosonornicotine, N’-nitrosoanatabine, 
N’-nitrosoanabasine, and their pyridine-N-glucuro-
nides. Researchers developed a method to analyze NNN, 
N’-nitrosoanatabine (NATB), N’-nitrosoanabasine (NAB), 
and their pyridine N-glucuronides (e.g., NNN-N-glucuro-
nide) in human urine. NATB and NAB are tobacco-specific 
nitrosamines that like NNN and NNK are formed by the 
nitrosation of tobacco alkaloids (Hecht and Hoffmann 
1988). Studies show that NATB is not carcinogenic but 
that NAB is a weak esophageal carcinogen in rats (Hecht 
1998). Mean levels of total NNN, NATB, and NAB in the 
urine of 14 smokers were 0.18 ± 0.22 SD, 0.19 ± 0.20, and 
0.040 ± 0.039 picomoles/mg of creatinine, respectively. 
These compounds have not been detected in the urine of 
nonsmokers with no exposure to secondhand smoke.
Nitrosamino acids. Researchers have used the 
N-nitrosoproline (NPRO) test to compare endogenous 
nitrosation in smokers and nonsmokers (Bartsch et al. 
1989). The results of clinical studies indicate that the 
frequency of endogenous formation of NPRO is higher 
in smokers than in nonsmokers and that it may be 
enhanced by thiocyanate catalysis (Bartsch et al. 1989; 
Tsuda and Kurashima 1991; Tricker 1997). However, 
some population-based studies document similar levels of 
NPRO in smokers and nonsmokers, because this precur-
sor biomarker for nitrosamine formation is primarily from 
dietary sources (Tricker 1997).
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The major nitrosamino acids present in human 
urine are N-nitrososarcosine, N-nitrosothiazolidine 
4-carboxylic acid (NTCA), and trans- and cis-isomers of 
N-nitroso-2-methylthiazolidine 4-carboxylic acid (NMTCA) 
(Bartsch et al. 1989; Tsuda and Kurashima 1991). NTCA 
and NMTCA are formed by reactions of formaldehyde or 
acetaldehyde with cysteine, followed by nitrosation. Some 
studies demonstrate increased levels of urinary NTCA 
and NMTCA in smokers (Tsuda and Kurashima 1991). 
Although some studies show a correlation between 
total nitrosamino acids and urinary nicotine plus cotinine 
among smokers (Malaveille et al. 1989), other studies 
show mixed results (Tricker 1997). Collectively, the avail-
able data support the concept that nitrosamines can be 
formed endogenously in smokers under some conditions.
Studies suggest that 4-(methylnitrosamino)-4-(3-
pyridyl)butyric acid is a potential monitor of endogenous 
nitrosation of nicotine (Djordjevic et al. 1991). However, 
researchers could not find any evidence for its formation 
after oral administration of nicotine or cotinine to persons 
abstaining from smoking (Tricker et al. 1993).
1,3-butadiene. The major urinary metabolites 
of 1,3-butadiene are monohydroxybutenyl-mercapturic 
acids (MHBMAs) and dihydroxybutyl-mercapturic acid 
(DHBMA). Levels of MHBMA were 86.4 ± 14.0 (SD) µg/24 
hours in smokers and 12.5 ± 1.0 µg/24 hours in nonsmok-
ers—a significant difference (Urban et al. 2003). Cor-
responding levels of DHBMA were 644 ± 90 (SD) µg/24 
hours in smokers and 459 ± 72 µg/24 hours in nonsmok-
ers, which were not significantly different (Urban et al. 
2003). DHBMA does not appear to be specific to exposure 
to 1,3-butadiene and is probably not a useful biomarker. 
Hb adducts have also proven useful as markers of long-
term exposure to 1,3-butadiene. The long half-lives of 
these adducts result in an average measurement that is 
more time weighted than that for some other metabolites 
(e.g., urinary meta-bolites) (Swenberg et al. 2001; Boysen 
et al. 2007). 
Benzene. One path of benzene metabolism pro-
ceeds by ring oxidation, ultimately by ring cleavage to 
trans,trans-muconaldehyde, and finally to trans,trans-
muconic acid (tt-MA), a metabolite widely used as a bio-
marker of benzene uptake (Scherer et al. 1998). Most 
studies have found significantly elevated levels of tt-MA 
in the urine of smokers (Scherer et al. 1998; Cocco et 
al. 2003; Lee et al. 2005). Levels of tt-MA were 1.4 to 4.8 
times higher in smokers than in nonsmokers, and the 
additional amount of tt-MA excreted by smokers ranged 
from 0.022 to 0.20 mg/gram of creatinine (Scherer et al. 
1998). However, sorbic acid, a food constituent that can be 
transformed metabolically into tt-MA, can contribute to 
urinary levels of tt-MA and thereby decrease its specificity 
as a biomarker for benzene uptake (Scherer et al. 1998; 
Pezzagno et al. 1999). 
S-phenylmercapturic acid (S-PMA) is formed by 
the metabolism of the glutathione conjugate of benzene 
oxide and has the potential to be specific for benzene 
uptake (Stommel et al. 1989; van Sittert et al. 1993; 
Boogaard and van Sittert 1995, 1996; Qu et al. 2000). 
In one study, S-PMA levels were significantly higher in 
smokers (1.71 micromoles [μmol]/mole of creatinine) 
than those in nonsmokers (0.94 μmol/mole of creatinine), 
whereas tt-MA levels were not significantly different 
(Boogaard and van Sittert 1996). Researchers believe that 
S-PMA and tt-MA are the most sensitive biomarkers for 
low levels of exposure to benzene (Qu et al. 2000, 2003). 
Phenol, hydroquinone, catechol, and 1,2,4-tri- 
hydroxybenzene are also urinary metabolites of benzene. 
Studies relating urinary levels of these metabolites to 
occupational exposure to benzene have mixed results, 
because background levels of the metabolites are high 
(Inoue et al. 1988, 1989; Ong et al. 1995, 1996; Qu et al. 
2000). Urinary catechol levels did not differ significantly 
between smokers and nonsmokers (Carmella et al. 1982), 
and diet has been shown to be a major source of urinary 
catechol (Carmella et al. 1982).
Products of oxidative damage. The presence of 
free radicals and oxidants in cigarette smoke can lead to 
oxidative DNA damage and the subsequent formation of 
products such as 8-oxodeoxyguanosine, thymine glycol, 
thymidine glycol, and 5-hydroxymethyluracil. Repair of 
these modified DNA constituents ultimately leads to their 
excretion in urine. Researchers have frequently quantified 
8-oxodeoxyguanosine in urine of smokers and nonsmok-
ers (Loft and Poulsen 1998; Prieme et al. 1998; Renner 
et al. 2000). Cigarette smoking usually results in levels of 
8-oxodeoxyguanosine in urine that modestly increase to 
16 to 50 percent higher than those in nonsmokers, but 
studies have also reported negative results (Nia et al. 2001; 
Harman et al. 2003; Mukherjee et al. 2004). Smoking ces-
sation caused a 21-percent decrease in the excretion of 
8-oxodeoxyguanosine (Prieme et al. 1998). Longitudinal 
studies have not shown convincing increases in urinary 
8-oxodeoxyguanosine that were attributable to smoking, 
and a complex pattern of factors may affect background 
levels of this biomarker in urine (Kasai et al. 2001; Pilger 
et al. 2001; Mukherjee et al. 2004). Studies on the effects 
of smoking on urinary levels of 5-hydroxymethyluracil 
or 5-hydroxymethyldeoxyuridine have obtained mixed 
results (Pourcelot et al. 1999; Harman et al. 2003). One 
study showed a correlation between smoking and urinary 
excretion of 3,N4-ethenodeoxycytidine, which may result 
from endogenous lipid peroxidation (Chen et al. 2004a). 
Studies have also detected 1,N6-ethenodeoxyadenosine in 
human urine, but no differences were observed between 
levels in smokers and those in nonsmokers (Hillestrøm 
et al. 2004). 
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Products of alkylating agents. The reaction of 
alkylating agents with DNA forms alkyladenines, alkylgua-
nines, and other products (Singer and Grunberger 1983). 
Alkylation at the 3-position of deoxyadenosine or at the 
7-position of deoxyguanosine results in products with 
an unstable glycosidic bond. These products are readily 
removed from DNA, either spontaneously or by glycosyl-
ases, which results in the urinary excretion of 3-alkylade-
nines and 7-alkylguanines. Studies have more extensively 
investigated 3-alkyladenines as biomarkers of exposure to 
alkylating agents, because researchers expected the back-
ground levels of 3-alkyladenines in urine to be lower than 
those of 7-alkylguanines. However, substantial amounts 
of 3-methyladenine occur in the diet (Prevost et al. 1993; 
Fay et al. 1997). Nevertheless, two controlled studies dem-
onstrated an increase in the urinary excretion of 3-meth-
yladenine among smokers (Kopplin et al. 1995; Prevost 
and Shuker 1996). Another study found lower background 
levels of 3-ethyladenine than those of 3-methyladenine 
(Prevost et al. 1993). Two studies demonstrated convinc-
ing increases in urinary levels of 3-ethyladenine in smok-
ers, indicating the presence in cigarette smoke of an 
unidentified ethylating agent (Kopplin et al. 1995; Prevost 
and Shuker 1996). There was no effect from smoking on 
urinary levels of 3-(2-hydroxyethyl)adenine (Prevost and 
Shuker 1996). A population-based study found higher 
levels of both 3-methyladenine and 7-methylguanine in 
smokers than in nonsmokers, and a second study found 
no difference in the 3-methyladenine levels (Shuker et al. 
1991; Stillwell et al. 1991).
Metals. Studies of urinary cadmium have most 
consistently demonstrated differences between smok-
ers and nonsmokers. Large studies in Germany and the 
United States showed increases in urinary cadmium lev-
els with age and smoking (IARC 2004). These results were 
consistent with those of other studies. 
Breath and Blood Biomarkers
Benzene, 1,3-butadiene, and a variety of volatile 
organic compounds including xylenes, styrene, isoprene, 
2,5-dimethylfuran, ethane, and octane were measured in 
expired air; levels were generally higher in smokers than 
in nonsmokers (Gordon et al. 2002; Perbellini et al. 2003; 
IARC 2004). Levels of benzene and 1,3-butadiene in the 
breath of smokers were 360 and 522 µg/cubic meter (m3), 
respectively (Gordon et al. 2002). In another study, mean 
benzene levels ranged from 58.1 to 81.3 µg/m3, depending 
on the cigarette brand (IARC 2004). 
Studies have quantified volatile organic compounds, 
including benzene and styrene, in the blood of smokers; 
levels were generally higher than those in the blood of 
nonsmokers. Benzene levels in blood were significantly 
associated with the number of cigarettes smoked (IARC 
2004). Cadmium levels were also higher in the blood of 
smokers. Measurements of NNAL in blood demonstrated a 
mean level of 42 femtomoles/milliliter of plasma in smok-
ers; NNAL was not detected in nonsmokers (Carmella et 
al. 2005). Cigarette smoke induces oxidative damage as 
determined by elevated blood protein carbonyls (Reznick 
et al. 1992) and blood protein-bound glutathione (Muscat 
et al. 2004). F2-isoprostane levels, which are biomarkers 
of oxidative damage, were higher in the plasma of smok-
ers than in the plasma of nonsmokers and decreased with 
vitamin C treatments (Morrow et al. 1995; Dietrich et al. 
2002). Hb adducts and DNA adducts in white blood cells 
are discussed in the next section.
Summary
Quantitative analysis of carcinogens or their metab-
olites in urine, breath, and blood provides a convenient and 
reliable method of comparing carcinogen exposure among 
smokers and between smokers and nonsmokers. The most 
extensive measurements have been made in urine. Uri-
nary biomarkers of several major types of carcinogens 
in cigarette smoke are reliable indicators of exposure. 
These biomarkers include trans, anti-PheT and 1-HOP 
for PAH; total NNAL (NNAL plus NNAL glucuronides) for 
NNK; MHBMA for 1,3-butadiene; and tt-MA and S-PMA 
for benzene. The measurements provide good estimates 
of minimum doses of relevant carcinogens in smokers and 
allow comparisons with those in nonsmokers. The total 
carcinogen dose is generally difficult to calculate because 
the extent of conversion of a given carcinogen to the mea-
sured metabolite is usually unknown and can vary widely 
among individuals. Nevertheless, the results of these stud-
ies are illuminating. They show, for example, that levels 
of metabolites of benzene (about 1,100 nmol/24 hours of 
tt-MA and 8 nmol/24 hours of S-PMA) and 1,3-butadiene 
(about 340 nmol/24 hours of MHBMA) exceed levels of 
other biomarkers (e.g., about 3 nmol/24 hours of NNAL 
plus NNAL glucuronides and 2 nmol/24 hours of 1-HOP). 
These results are consistent with the levels of benzene and 
1,3-butadiene in cigarette smoke, which were higher than 
those of NNK and PAH. 
However, metabolites of benzene and a metabolite 
of 1,3-butadiene (DHBMA) are also found in nonsmokers 
in considerable quantities. Comparisons of smokers and 
nonsmokers demonstrate that total NNAL is the most 
discriminatory carcinogen biomarker because the only 
source of the parent carcinogen NNK is tobacco products. 
Total NNAL is not detected in nonsmokers unless they 
have been exposed to secondhand tobacco smoke. There-
fore, this biomarker is particularly useful for compar-
ing carcinogen uptake in smokers who, for example, use 
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different tobacco products, because the measurements are 
not confounded by other exposures such as diet, occupa-
tion, or the general environment. 
Metabolic Activation and 
Detoxification of Carcinogens
Most of the carcinogens listed in Table 5.1 require 
metabolic activation to become intermediate agents, gen-
erally electrophiles, which react with nucleophilic sites in 
DNA to form DNA adducts. All PAHs, heterocyclic com-
pounds, N-nitrosamines, aromatic amines, and heterocy-
clic aromatic amines in cigarette smoke require metabolic 
activation. Other compounds in Table 5.1 that require 
metabolic activation are 1,3-butadiene, isoprene, benzene, 
nitromethane, 2-nitropropane, nitrobenzene, acrylamide, 
vinyl chloride, and urethane. Detoxification reactions in 
most cases compete with metabolic activation and also 
affect the disposition of compounds that do not require 
metabolic activation, such as ethylene oxide.
An overview of the metabolism of six carcinogens 
in tobacco smoke that are implicated in the forma-
tion of DNA adducts identified in human tissues is pre-
sented in Figure 5.3. The six carcinogens are B[a]P, NNK, 
N-nitrosodimethylamine (NDMA), NNN, ethylene oxide, 
and 4-ABP. 
The major metabolic activation pathway of B[a]P 
that results in DNA adducts identified in human tissues 
is the conversion to the highly mutagenic B[a]P-7,8-
diol-9,10-epoxides (BPDEs). The formation of BPDE 
occurs in three steps: the metabolism of B[a]P to B[a]
P-7,8-epoxide; hydration of B[a]P-7,8-epoxide to give the 
dihydrodiol B[a]P-7,8-diol; and further epoxidation to 
produce BPDE. One of the four enantiomers is strongly 
carcinogenic and reacts with DNA to form adducts at N2 
of deoxyguanosine (BPDE-N2-deoxyguanosine) (Cooper et 
al. 1983; IARC 1983; Thakker et al. 1985). This adduct was 
also observed in animals treated with B[a]P. 
Two other proposed metabolic activation pathways 
of B[a]P exist, but the evidence for their involvement in 
DNA adduct formation in laboratory animals and humans 
is not as strong as that for BPDE. One pathway involves 
the conversion of B[a]P-7,8-diol to the corresponding cat-
echol metabolite catalyzed by dihydrodiol dehydrogenase. 
The catechol can undergo redox cycling to produce a qui-
none reactive with DNA, and the redox cycling process can 
produce oxidative damage to DNA (Penning et al. 1999; Yu 
et al. 2002). Another metabolic activation process occurs 
when one electron oxidation of B[a]P produces unstable 
depurinating DNA adducts that can lead to apurinic sites 
and miscoding (Casale et al. 2001). A common mechanism 
of metabolic activation for a number of PAHs is the forma-
tion of diol epoxides in which the epoxide ring is in the bay 
region of the PAH molecule, similar to that in BPDE (Con-
ney 1982; Thakker et al. 1985; Baird and Ralston 1997). 
Competing with B[a]P metabolic activation processes are 
detoxification pathways leading to (1) phenols through 
direct hydroxylation or rearrangement of initially formed 
epoxides, (2) dihydrodiols through hydration of epoxides 
catalyzed by epoxide hydrolase, and (3) formation of gluta-
thione, glucuronide, and sulfate conjugates. Researchers 
have also observed the formation of quinone metabolites 
from initial hydroxylation at the 6-position, followed by 
further oxidation (Cooper et al. 1983).
Metabolic activation of NDMA occurs by α-hydro-
xylation and leads to an unstable α-hydroxymethyl metab-
olite. This compound spontaneously loses formaldehyde 
and forms methanediazohydroxide, the same intermedi-
ate agent produced in the α-methylene hydroxylation of 
NNK. Researchers also observed the consequent forma-
tion of methyl DNA adducts such as 7-methylguanine, 
O6-methylguanine, and O4-methylthymidine. Denitrosa-
tion produces nitrite and methylamine and is a detoxifica-
tion pathway (Preussmann and Stewart 1984; Hecht and 
Samet 2007). The metabolism of NNK and NDMA forms 
aldehydes, whose roles in carcinogenesis are unclear, but 
studies show that formaldehyde reacts with DNA and pro-
tein to form cross-links and other products (Chaw et al. 
1980; Beland et al. 1984; Hecht and Samet 2007). 
α-hydroxylation of NNN adjacent to the pyridine 
ring produces the same intermediate agent formed by 
methyl hydroxylation of NNK, which leads to pyridyloxo-
butyl (POB)-DNA adducts (Hecht 1998). α-hydroxylation 
distal from the pyridine ring also produces a reactive 
diazohydroxide, but its reactions with DNA have not been 
fully characterized. The acetate esters of the α-hydroxy-
NNN metabolites are mutagenic (Hecht 1998; Hecht and 
Samet 2007). β-hydroxylation of NNN, a minor pathway, 
and pyridine-N-oxidation are detoxification reactions. 
NNN is also detoxified by denitrosation and oxidation to 
produce norcotinine, and by glucuronidation of the pyri-
dine ring (Hecht 1998; Stepanov and Hecht 2005; Hecht 
and Samet 2007). 
Ethylene oxide reacts directly with DNA to form 
7-(2-hydroxyethyl)guanine and other adducts (IARC 1994; 
Hecht and Samet 2007). Competing detoxification path-
ways involve glutathione conjugation and excretion of 
mercapturic acids (IARC 1994). 
4-ABP is metabolically activated by N-hydroxylation 
(Kadlubar and Beland 1985; Hecht and Samet 2007). 
Conjugation of the resulting hydroxylamine with acetate 
or other groups, such as sulfate, ultimately produces 
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mainly at C-8 of guanine. Other aromatic amines, as well 
as heterocyclic aromatic amines, are predominantly acti-
vated metabolically in similar ways. Acetylation of 4-ABP 
can be a detoxification pathway if it is not followed by 
N-hydroxylation. Ring hydroxylation and conjugation of 
the phenols result in detoxification.
Two other important carcinogens from cigarette 
smoke that require metabolic activation are benzene and 
1,3-butadiene. DNA adducts of these compounds have not 
been detected in human samples. However, there is con-
siderable information on their conversion to intermediate 
agents that react with DNA. 
Benzene is metabolized to benzene epoxide, which 
is in equilibrium with its 7-member ring tautomer oxepin 
(Scherer et al. 2001; Hecht and Samet 2007). Researchers 
have observed the reaction of benzene epoxide with DNA 
to produce 7-phenylguanine. Further metabolism of ben-
zene epoxide-oxepin can occur in a variety of ways. One 
way is nonenzymatic rearrangement to phenol, which 
can be further hydroxylated to hydroquinone, catechol, 
and 1,2,4-trihydroxybenzene. These metabolites can then 
be conjugated as glucuronides or sulfates. Hydroquinone 
can be further oxidized to benzoquinone, which can bind 
to DNA, or hydration catalyzed by epoxide hydrolase can 
produce benzene dihydrodiol, which can then be con-
verted to catechol or tt-MA. Another possibility involves 
conjugation with glutathione that ultimately produces 
S-PMA. Other pathways of benzene metabolism result in 
the formation of biphenyl and benzene dioxetane, which 
can also lead to tt-MA (Scherer et al. 2001; Hecht and 
Samet 2007). Studies have detected nitrobenzene, nitro-
biphenyl, and nitrophenol isomers in the bone marrow 
of mice treated with benzene; these isomers presumably 
formed from reactions of benzene with endogenously 
generated nitric oxide (Chen et al. 2004b; Hecht and 
Samet 2007). 
1,3-butadiene is metabolically activated by epoxida-
tion to give a monoepoxide that can be further metabo-
lized to a diepoxide and a dihydrodiol epoxide (van Sittert 
et al. 2000; Hecht and Samet 2007), which all form DNA 
adducts. The dihydrodiol epoxide also produces cross-links 
in DNA and may be the most important of these interme-
diate agents (Park and Tretyakova 2004; Hecht and Samet 
2007). The epoxides can be hydrated to dihydrodiols and 
conjugated by reactions with glutathione. 1,3-butadiene 
metabolism can also lead to epoxidation and forma-
tion of N-terminal Hb adducts, providing a longer-term, 
“time-weighted” measurement of exposure (Swenberg et 
al. 2001).
Although details remain to be determined, the 
major pathways of metabolic activation and detoxification 
of some of the principal carcinogens in cigarette smoke 
are well established. Reactive intermediate agents that 
are critical in forming DNA adducts include diol epoxides 
of PAH, diazonium ions generated by α-hydroxylation 
of nitrosamines, nitrenium ions formed from esters of 
N-hydroxylated aromatic amines, and epoxides such as 
ethylene oxide. Glutathione and glucuronide conjugation 
play major roles in the detoxification of carcinogens in 
cigarette smoke. 
Enzymology of Carcinogen 
Metabolism
Introduction
A number of enzyme families are important in 
both the activation and detoxification of carcinogens in 
cigarette smoke, including P-450s, GSTs, UGTs, N-acetyl-
transferases (NATs), epoxide hydrolases, and sulfotrans-
ferases. The importance of each enzyme to the activation 
or detoxification of a particular carcinogen depends on 
characteristics of both the carcinogen (size, polarity, and 
lipophilicity) and the enzyme (structure, tissue distribu-
tion, and regulation of expression). The large number of 
carcinogens in cigarette smoke and the wide variety of 
enzymes involved in metabolizing these carcinogens pre-
clude a comprehensive discussion of current understand-
ing of the contribution of each enzyme to every pathway. 
Therefore, the goals of this presentation are to introduce 
the families of enzymes involved and to highlight some 
of the activation and detoxification reactions for specific 
enzymes and carcinogens.
Cytochrome P-450 Enzymes
P-450s, encoded by CYP genes, are microsomal 
enzymes that catalyze the oxidation of myriad chemicals, 
including many of the carcinogens in cigarette smoke. 
Sequencing the human genome has identified 57 CYP 
genes, about 15 of which are considered important in 
the metabolism of xenobiotics (Nelson 2003; Guengerich 
2004). Among the P-450s encoded by these genes, a rea-
sonable argument can be made for the role of six (1A1, 
1B1, 1A2, 2A6, 2A13, and 2E1) as important catalysts for 
the metabolic activation of carcinogens in cigarette smoke. 
PAHs are metabolized by P-450s 1A1 and 1B1 (Shimada and 
Fujii-Kuriyama 2004), aromatic amines by P-450 1A2 
(Kim and Guengerich 2005), and N-nitrosamines by 
P-450s 2A6, 2A13, and 2E1 (Yoo et al. 1988; Guengerich 
et al. 1991; Yamazaki et al. 1992; Jalas et al. 2005; Wong 
et al. 2005a). P-450 2E1 also catalyzes the epoxidation of 
benzene and 1,3-butadiene (Guengerich et al. 1991; Bolt 
et al. 2003). 
Surgeon General’s Report
238 Chapter 5
P-450s 1A1 and 1B1 are expressed in a wide range 
of extrahepatic tissues and catalyze both the activation 
and detoxification reactions of PAH metabolism (Shimada 
and Fujii-Kuriyama 2004). In addition, both enzymes are 
inducible by the PAHs in cigarette smoke (Nebert et 
al. 2004). Induction of these two enzymes is generally 
mediated by the aryl hydrocarbon receptor, but differ-
ences may exist in the mode of induction for each enzyme. 
Historically, researchers believed that P-450 1A1 was the 
predominant P-450 catalyst for the metabolism of PAHs, 
particularly in the lung. However, the discovery of P-450 
1B1 (Sutter et al. 1994) clarified the equal or more pre-
dominant role P-450 1B1 may play in the activation of 
PAHs compared with that of P-450 1A1 (Shimada et al. 
1996). Studies show that P-450 1B1, which is heterolo-
gously expressed, activates the proximate carcinogen of 
many PAHs and that in several cases, P-450 1B1 was more 
efficient than P-450 1A1 (Shimada et al. 1996). For exam-
ple, (+)-B[a]P-7,8-diol was activated to a genotoxic species 
to a greater extent by P-450 1B1 than by P-450 1A1 (Shi-
mada et al. 1996). In addition, the ratio of the maximum 
velocity (Vmax) of an enzyme-catalyzed reaction to the 
concentration of a substrate that leads to half-maximal 
velocity (Km) for the formation of B[a]P-7,8-diol was 3.5-
fold greater for P-450 1B1 than for P-450 1A1 (Shimada 
et al. 1999). (The Vmax to Km ratio measures an enzyme’s 
efficiency.) In contrast, P-450 1A1 was a better catalyst of 
B[a]P 3-hydroxylation, which is a detoxification pathway 
(Shimada et al. 1997). Taken together, these data indicate 
that P-450 1B1 activity, but not P-450 1A1 activity, may 
contribute to individual susceptibility to B[a]P-induced 
carcinogenesis. However, cigarette smoke has many dif-
ferent PAH carcinogens, and either P-450 1B1 or 1A1 
individually or together may be important in their meta-
bolic activation.
As noted previously (see “Cytochrome P-450 
Enzymes” earlier in this chapter), both P-450 1A1 and 1B1 
are inducible by PAHs. Studies have reported that levels 
of messenger RNA (mRNA) and protein of both P-450s 
were higher in the lungs of smokers than in the lungs of 
lifetime nonsmokers (Willey et al. 1997; Kim et al. 2004a; 
Port et al. 2004). The levels of P-450 1A1 and 1B1 proteins 
were correlated in lung microsomes from all participants 
who smoked. However, the absolute amount of P-450 1A1 
in each person was, on average, more than 10-fold greater 
than the amount of P-450 1B1 (Kim et al. 2004a). Despite 
the ability of P-450 1B1 to more efficiently mediate the 
activation of some PAHs, the higher P-450 1A1 levels may 
result in each enzyme contributing similarly to the total 
metabolism of PAHs. An equally important factor in deter-
mining the role of these P-450s in the activation of PAHs 
in cigarette smoke is the variability in the induction of 
P-450s across individuals. Researchers do not know 
whether the responsible mechanism is common to both 
P-450s 1A1 and 1B1.
Studies have characterized P-450 1A2 as the best 
catalyst for aromatic amine N-oxidation, which is the first 
step in the activation of these bladder carcinogens (Butler 
et al. 1989; Landi et al. 1999; Kim and Guengerich 2005). 
P-450 1A2 is both constitutively expressed and inducible 
in the liver. The induction of P-450 1A2 is mediated by the 
aryl hydrocarbon receptor, and hepatic levels vary more 
than 60-fold from person to person (Nebert et al. 2004). 
Cigarette smoking induces the levels of this enzyme in the 
liver. Researchers have also reported that P-450s 1A1 and 
1B1 metabolically activate a number of aromatic amines, 
including 4-ABP, and may play a role in extrahepatic 
metabolism (Shimada et al. 1996).
Although hepatic P-450 2A6 catalyzes the metabolic 
activation of NNK (Yamazaki et al. 1992; Jalas et al. 2005), 
P-450 2A6 is not a particularly efficient catalyst. The extra-
hepatic P-450 2A13 might be a more important catalyst of 
the activation of this carcinogen (Jalas et al. 2005). P-450 
2A13 is expressed in the lung (Su et al. 2000) and catalyzes 
the α-hydroxylation of NNK significantly more efficiently 
than does P-450 2A6. P-450 2A13 is an excellent catalyst 
of NNK α-hydroxylation, with a low Km and a high Vmax. 
P-450 2A13 is the sole catalyst of NNK α-hydroxylation in 
human fetal nasal tissue and is considered equally impor-
tant in the lung (Wong et al. 2005b). P-450 2E1 has also 
catalyzed the activation of both NNN and NNK (Yamazaki 
et al. 1992). However, the catalytic efficiencies of these 
reactions are poor (Hecht 1998; Jalas et al. 2005). Studies 
have identified P-450 2E1 as the best catalyst of NDMA 
metabolism (Yoo et al. 1988; Guengerich et al. 1991) and 
as an excellent catalyst of the epoxidation and activation of 
benzene and 1,3-butadiene (Guengerich et al. 1991; Bolt 
et al. 2003).
Epoxide Hydrolases
Several carcinogens of tobacco smoke, including 
PAH, 1,3-butadiene, and benzene, are metabolized to 
epoxides. These epoxide metabolites are substrates for 
MEH (also known as EPHX1), an enzyme that catalyzes 
their hydrolysis (Wood et al. 1976; Snyder et al. 1993; 
Krause and Elfarra 1997; Fretland and Omiecinski 2000). 
In mammals, at least five epoxide hydrolases were identi-
fied. However, four of these predominantly or exclusively 
catalyze the hydrolysis of endogenous substrates (Fretland 
and Omiecinski 2000). The fifth, MEH, plays a role in both 
the detoxification and activation of xenobiotics. Specifi-
cally, MEH is involved in the formation of the reactive diol 
epoxide metabolites of PAHs, and its activity is therefore 
critical to the carcinogenicity of these compounds (Con-
ney 1982). For example, MEH catalyzes the hydrolysis of 
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B[a]P-7,8-epoxide to B[a]P-7,8-diol, which is then oxi-
dized to the ultimate carcinogen BPDE (Levin et al. 1976; 
Gautier et al. 1996). The importance of this enzyme to 
PAH carcinogenicity is supported by the observation that 
MEH-null mice are highly resistant to carcinogenesis 
induced by 7,12-dimethylbenz[a]anthracene (Miyata et 
al. 1999).
In contrast to its role in the activation of PAHs, 
MEH detoxifies the epoxides of 1,3-butadiene (Krause 
and Elfarra 1997; Wickliffe et al. 2003). Studies have 
reported that several polymorphisms in MEH result in an 
increased sensitivity to the genotoxic effects of 1,3-buta-
diene (Abdel-Rahman et al. 2003, 2005). Benzene oxide is 
also a substrate for MEH (Snyder et al. 1993). However, 
male mice deficient in MEH are not susceptible to toxic 
effects induced by benzene (Bauer et al. 2003). The role of 
benzene oxide in carcinogenesis is unclear.
Glutathione-S-Transferases
Another mechanism that may detoxify carcinogenic 
epoxides is conjugation with glutathione. This reaction 
can be catalyzed by cytosolic GSTs (Sheehan et al. 2001; 
Hayes et al. 2005), which are dimeric. Seven classes (alpha, 
mu, pi, sigma, theta, omega, and zeta) exist in mammalian 
species (Sheehan et al. 2001), and at least 16 GST sub-
units exist in humans. However, only four homodimeric 
enzymes to date have been characterized as catalysts of 
glutathione conjugation of tobacco smoke carcinogens 
(Cheng et al. 1995; Norppa et al. 1995; Wiencke et al. 1995; 
Jernstrom et al. 1996; Sundberg et al. 1998, 2002; Landi 
2000; Verdina et al. 2001; Fustinoni et al. 2002; Sørensen 
et al. 2004a; Hayes et al. 2005). These enzymes are mem-
bers of four GST classes: alpha (GSTA1-1), mu (GSTM1-1), 
pi (GSTP1-1), and theta (GSTT1-1). The protein levels of 
each GST vary significantly from person to person, as well 
as across tissues within an individual (Rowe et al. 1997; 
Sherratt et al. 1997; Mulder et al. 1999). Researchers have 
identified several polymorphisms in the genes encoding 
these subunits (Hayes et al. 2005). Of particular note with 
regard to cancer risk in smokers are the *NULL alleles 
for GSTM1 and GSTT1, which have decreased detoxifica-
tion capacity and elevated DNA damage. GSTA1, GSTM1, 
and GSTT1 are expressed in the liver of persons who are 
not homozygous for either null phenotype; little GSTP1 is 
present in the liver (Rowe et al. 1997; Sherratt et al. 1997; 
Mulder et al. 1999). In contrast, the lung expresses higher 
levels of GSTP1 than those expressed by the other three 
subunits (Rowe et al. 1997; Sherratt et al. 1997). 
GSTA1-1, GSTM1-1, and GSTP1-1 each catalyze the 
glutathione conjugation of a number of PAH diol epox-
ides (Jernstrom et al. 1996; Sundberg et al. 1998, 2002). 
However, the efficiencies and stereoselectivity of each of 
these enzymes vary with the diol epoxide substrate. For 
example, GSTM1-1 is a more efficient catalyst of gluta- 
thione conjugation of (+)-anti-BPDE than is either 
GSTA1-1 or GSTP1-1 (Sundberg et al. 1997). The GSTA1-1 
and GSTP1-1 enzymes have overall Kcat/Km values for 
catalytic rate or turnover number that are about 3-fold 
lower than the value for GSTM1-1, but GSTM1-1 is almost 
30-fold better as a catalyst for the conjugation of (-)-anti-
BPDE (Sundberg et al. 1997). The contribution of each GST 
enzyme to the detoxification of PAH diol epoxides var-
ies with the substrate and across different tissues on the 
basis of their expression levels. In lung tissue from smok-
ers, levels of (+)-anti-BPDE–DNA adducts were depen-
dent on the GSTM1 genotype (Alexandrov et al. 2002). 
Persons with the GSTM1 null genotype had significantly 
higher adduct levels than did those with the GST wild-type 
genotype. These data support the importance of GSTM1-1 
activity in BPDE detoxification in the lung, but they do 
not exclude a role for GSTA1-1 and GSTP1-1 in the detoxi-
fication of this or other PAHs.
GSTM1-1 and GSTT1-1 enzymes play a key role in 
the conjugation of two 1,3-butadiene epoxide metabolites: 
3,4-epoxybutene (EB) and diepoxybutane (DEB) (Norppa 
et al. 1995; Wiencke et al. 1995; Thier et al. 1996; Ber-
nardini et al. 1998; Landi 2000; Fustinoni et al. 2002; 
Schlade-Bartusiak et al. 2004). The direct measurement 
of either GSTM1-1 or GSTT1-1 activity with these epoxide 
substrates has not been reported. However, several stud-
ies of sister chromatid exchange (SCE) in human lympho-
cyte cultures from persons with the GSTT1 null genotype 
support the role of GSTT1-1 in the detoxification of DEB 
(Norppa et al. 1995; Wiencke et al. 1995; Bernardini et 
al. 1998; Landi 2000; Schlade-Bartusiak et al. 2004). In 
conflict with these data, one study reports the increased 
mutagenicity of DEB in Salmonella typhimurium TA1535 
expressing GSTT1-1, suggesting that the conjugation of 
this diepoxide is an activation pathway (Thier et al. 1996). 
The role of both GSTM1-1 and GSTT1-1 in the detoxifica-
tion of EB is supported by a higher induction of SCE by 
EB in lymphocyte cultures from persons with either the 
GSTM1-1 or the GSTT1-1 null genotype (Uusküla et al. 
1995; Bernardini et al. 1998). Although GSTs play a role 
in the metabolism of 1,3-butadiene, it remains unclear 
whether polymorphisms in GSTs modulate the carcino-
genic effects of 1,3-butadiene in humans (Fustinoni et 
al. 2002).
One major excreted metabolite of benzene is 
S-PMA, which is formed from the glutathione conjugate of 
benzene oxide (Snyder and Hedli 1996). This glutathione 
conjugate may be generated both enzymatically and non-
enzymatically, and it is not clear which pathway predomi-
nates. However, a number of studies on benzene exposure 
and toxicity have suggested a role for either GSTM1-1 or 
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GSTT1-1 in the conjugation of benzene oxide (Hsieh et 
al. 1999; Verdina et al. 2001; Wan et al. 2002; Kim et al. 
2004b). Researchers have not directly measured which 
enzyme is the better catalyst of glutathione conjugation 
of benzene oxide. The in vivo role of GSTT1-1 in benzene 
oxide detoxification is supported by a report that S-PMA 
levels excreted by persons exposed to benzene who carried 
the wild-type GSTT1* allele were higher than those of per-
sons homozygous for the GSTT1* NULL allele (Sørensen 
et al. 2004b). 
Ethylene oxide is also detoxified by glutathione 
conjugation (Brown et al. 1996). Although studies have 
not directly evaluated the role of specific human GSTs, 
evidence supports the role of GSTT1-1 as a catalyst of 
this reaction (Hallier et al. 1993; Fennell et al. 2000). On 
exposure to ethylene oxide, lymphocytes from persons 
with the GSTT1-1* NULL allele had higher levels of SCE 
than did those from persons with the wild-type allele (Hall-
ier et al. 1993). In addition, levels of 2-hydroxyethylvaline 
Hb adducts were higher in smokers than in nonsmok-
ers, because of exposure to ethylene and ethylene oxide 
in cigarette smoke, and were higher in smokers with the 
GSTT1* NULL allele than in those with the wild-type allele 
(Fennell et al. 2000).
Uridine-5’-Diphosphate-Glucuronosyltransferases
Conjugation with glucuronic acid is an important 
metabolic pathway for a number of carcinogens in tobacco 
smoke (Bock 1991; Hecht 2002a; Nagar and Remmel 2006). 
(Conjugation is the addition of a polar moiety to a metab-
olite to facilitate excretion.) The microsomal enzymes, 
UGTs, catalyze these conjugation reactions. Researchers 
have identified 18 human UGTs that are members of two 
families (UGT1 and UGT2) (Tukey and Strassburg 2000; 
Burchell 2003; Nagar and Remmel 2006). The UGT1A pro-
teins are encoded by a single gene cluster, and expression 
of the nine members of this subfamily occurs through exon 
sharing. Exon 1 is unique for each UGT1A, whereas exon 2 
to exon 5 are shared by all UGT1As (Tukey and Strassburg 
2000). Thus, all UGT1A proteins are identical in the 245 
amino acids of the carboxyl terminus encoded by exon 2 
to exon 5 (Tukey and Strassburg 2000; Finel et al. 2005). 
In contrast, proteins from the UGT2 family are all unique 
gene products (Riedy et al. 2000; Tukey and Strassburg 
2000). The expression of UGTs is tissue specific, and there 
are large differences in expression among tissues (Gregory 
et al. 2000, 2004; Tukey and Strassburg 2000; Wells et al. 
2004). For example, UGTs 1A1, 1A3, 1A4, 1A6, and 1A9 are 
highly expressed in the liver; UGTs 1A7, 1A8, and 1A10 
are mainly expressed in extrahepatic tissues (Tukey and 
Strassburg 2000; Gregory et al. 2004; Wells et al. 2004).
Aromatic amines and their N-hydroxy metabolites 
are glucuronidated to facilitate excretion (Bock 1991; 
Tukey and Strassburg 2000; Zenser et al. 2002). Glucuron-
idation is a detoxification reaction. Therefore, variations in 
the expression and catalytic efficiency of the enzymes that 
catalyze this reaction may influence the carcinogenicity of 
particular aromatic amines. In general, researchers have 
suggested that members of the UGT1A family contribute 
to the glucuronidation of these carcinogens (Orzechowski 
et al. 1994; Green and Tephly 1998; Tukey and Strassburg 
2000; Zenser et al. 2002). However, UGT2B7 also catalyzes 
their glucuronidation (Zenser et al. 2002). In most cases, 
data support UGT1A9 as the best catalyst. For the tobacco 
smoke carcinogen 4-ABP, the relative catalytic efficiency 
of N-glucuronidation is UGT1A9>UGT1A4>UGT1A7>UGT
2B7>UGT1A6, but the catalytic efficiency of all these pro-
teins is approximately equal to that of UGT1A1 (Zenser et 
al. 2002). 
The phenol and diol metabolites of PAHs are pri-
marily eliminated as glucuronide conjugates. Researchers 
have studied the role of specific UGTs in the metabolism 
of B[a]P (Bock 1991; Guillemette et al. 2000; Fang et al. 
2002; Dellinger et al. 2006). Studies with UGT1A-deficient 
rats have implicated UGT1A enzymes in the detoxification 
of B[a]P (Wells et al. 2004). The glucuronidation of B[a]P- 
7,8-diol and 3-hydroxy-, 7-hydroxy-, and 9-hydroxy-B[a]P 
by heterologously expressed human UGTs has been char-
acterized for a number of UGT1A and UGT2B enzymes 
(Fang et al. 2002; Dellinger et al. 2006). Among the phe-
nols, UGT1A10 was the most efficient UGT1A catalyst of 
glucuronidation. UGTs 2B7, 2B15, and 2B17 all catalyzed 
conjugation of the three B[a]P phenols. However, the Km 
of the reaction for UGT2B enzymes was 2- to 250-fold 
higher than that for UGT1A10 (Dellinger et al. 2006). For 
the carcinogenic (-)-B[a]P-7,8-diol, UGT1A10 was a bet-
ter catalyst of glucuronidation than was UGT1A9, and 
UGT2B7 did not catalyze detectable levels of glucuronida-
tion (Fang et al. 2002), but UGT2B7 did catalyze the gluc-
uronidation of (+)-B[a]P-7,8-diol. 
In smokers, glucuronidation also plays an impor-
tant role in the excretion of the NNK metabolite NNAL 
(Carmella et al. 2002b; Hecht 2002a). Both O-linked and 
N-linked NNAL glucuronide conjugates are formed (Car-
mella et al. 2002b). In addition, the direct detoxifica-
tion of the hydroxymethyl metabolite of NNK occurs by 
glucuronidation in rats (Murphy et al. 1995). However, 
the contribution of this pathway to NNK detoxification 
in smokers has not been identified. In vitro studies with 
fibroblasts both from UGT1A-deficient and control rats 
have confirmed a role for UGT1A enzymes in the protec-
tion of these cells from NNK-induced micronuclei forma-
tion (Kim and Wells 1996). Human UGT1A9, UGT2B7, 
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and UGT2B17 catalyze NNAL-O-glucuronidation, with 
UGT2B17 being the most active, and UGT1A4 catalyzes 
NNAL-N-glucuronidation (Ren et al. 2000; Wiener et al. 
2004b; Lazarus et al. 2005). The rate of NNAL O- and 
N-glucuronidation by human liver microsomes varies sig-
nificantly among persons; researchers have suggested that 
polymorphisms in UGT2B7 and UGT1A4 contribute to this 
variability (Wiener et al. 2004a).
Glucuronidation may also contribute to the de-
toxification of benzene (Bock 1991). In hepatocytes from 
rats treated with 3-methylcholanthrene to induce UGTs, 
phenol glucuronidation increases compared with sulfa-
tion. Glucuronide conjugates are more stable than the 
corresponding sulfates, and researchers have suggested 
the glucuronidation of phenol as a detoxification pathway 
(Bock 1991). However, to date, the role of glucuronidation 
in benzene-induced carcinogenesis has not been charac-
terized and is poorly understood.
N-Acetyltransferases
NATs are cytosolic enzymes that catalyze the trans-
fer of the acetyl group from acetylcoenzyme A to an 
acceptor molecule (Hein et al. 2000b). This transfer 
occurs through an enzyme intermediate in which cysteine 
68 is acetylated and then deacetylated during the course 
of the reaction. Humans express two unique enzymes, 
NAT1 and NAT2, which catalyze both N- and O-acetylation 
reactions. Researchers have recognized the polymorphic 
nature of NAT2 for more than 40 years and, more recently, 
have identified more than 35 alleles (Hein et al. 2000b; 
Hein 2002). NAT1 is less well studied but is also poly-
morphic, and more than 25 alleles have been identified 
(Hein 2002; University of Louisville School of Medicine 
2006). Researchers suggest that polymorphisms in both 
NAT1 and NAT2 influence the activation and detoxifica-
tion of carcinogenic aromatic amines in tobacco smoke 
(Hein 2002).
The N-acetylation of aromatic amines, such as 
4-ABP, is a detoxification reaction (Hein 2002). In con-
trast, O-acetylation of the N-hydroxy metabolites of 
arylamines generated by P-450 (e.g., N-hydroxy-4-ABP) is 
an activation reaction leading to DNA adduct formation 
(Hein et al. 1993, 1995; Hein 2002). NAT1 and NAT2 both 
catalyze each of these reactions (Hein et al. 1993). How-
ever, NAT2 is generally considered the more important 
catalyst of detoxification, and NAT1 is the more impor-
tant catalyst of activation (Badawi et al. 1995; Hein 2002). 
This assumption is based on differences in the catalytic 
efficiency of the enzymes and their tissue distribution in 
humans as well as on studies with animal models (Hein et 
al. 1993; Hein 2002). 
Studies with recombinant human NAT1 and NAT2 
have described differences in the N-acetylation of 4-ABP. 
The apparent affinity of 4-ABP for NAT2 is significantly 
greater than that for NAT1, and ratios of NAT1 activity to 
NAT2 activity and clearance calculations support a greater 
role for NAT2 than for NAT1 in the N-acetylation of aryl-
amines (Hein et al. 1993). The characterization of NAT1 
as the key catalyst of the O-acetylation (i.e., activation) 
of aromatic amines is more speculative and is primarily 
driven by the tissue distribution of NAT1 (see the discus-
sion below). No data in the literature report differences 
between the efficiencies of NAT1- and NAT2-catalyzed 
O-acetylation of aromatic amines. However, more recent 
studies that engineered S. typhimurium strains to over-
express either NAT1 or NAT2 reported that NAT1, but not 
NAT2, catalyzed the genotoxic activation of N-hydroxy-
4-ABP (Oda 2004). These data provide support for NAT1 
as an important catalyst in the activation of this aro- 
matic amine. 
The organ and tissue distribution of NAT1 and NAT2 
differ markedly (Dupret and Rodrigues-Lima 2005). The 
NAT2 protein is mainly expressed in the gut and liver; the 
NAT1 protein is expressed in the liver and a number of 
other tissues, including the colon and bladder. Research-
ers believe that aromatic amines in tobacco smoke con-
tribute to smoking-related bladder cancer. Therefore, the 
potential activation of these compounds in the bladder is 
important in understanding the etiology of bladder can-
cer. Researchers have detected NAT1 activity, but not NAT2 
activity, in samples of bladder tissue from smokers (Bad-
wawi et al. 1995). In addition, DNA adduct levels measured 
by 32P-postlabeling correlated with NAT1 activity. These 
data are thus consistent with a role for NAT1 in the activa-
tion of arylamines in tobacco smoke.
Epidemiologic studies that demonstrate a modest 
increase in risk of bladder cancer in persons phenotypi-
cally and genotypically identified as having slow acetyla-
tion catalyzed by NAT2 further support the role of NAT2 
in the detoxification of aromatic amines (Green et al. 
2000; Hein et al. 2000a; Gu et al. 2005) (see “Molecular 
Epidemiology of Polymorphisms in Carcinogen-Metabo-
lizing Genes” later in this chapter). A number of the NAT2 
variant alleles identified in persons with slow acetyla-
tion were expressed heterologously and demonstrated a 
decrease in activity for both the N-acetylation of 4-ABP and 
O-acetylation of N-hydroxy-4-ABP, primarily because of 
the instability of the variant enzymes (Hein et al. 1995; 
Zhu et al. 2002). Both activation and detoxification would 
be diminished in persons expressing variant NAT2 activity, 
but NAT1 activity would be maintained. Studies that have 
characterized NAT1 proteins from a number of variants of 
this gene have also reported a decrease in enzyme activity 
(Fretland et al. 2002). 
Surgeon General’s Report
242 Chapter 5
DNA Adducts and Biomarkers
Introduction
Although formation of carcinogen-DNA adducts is 
a well-characterized phenomenon in laboratory animals, 
there were no reports of analyses of DNA adducts in smok-
ers before the mid-1980s. In the past 20 years, a large 
body of literature on DNA adducts in human tissues has 
emerged with the development of sensitive methods such 
as HPLC fluorescence, GC–MS, liquid chromatography 
(LC)–MS, electrochemical detection, 32P-postlabeling, 
and immunoassay. Researchers have applied all of these 
methods to analyze DNA adducts, producing data on these 
biomarkers in molecular epidemiologic studies of can-
cer susceptibility. Thus, a discussion of DNA adducts in 
human tissues also includes biomarkers of DNA adduct 
formation in smokers. 
Characterized Adducts in the Human Lung
Available data on characterized DNA adducts in 
human lung tissue, the tissue most extensively inves-
tigated to date, are summarized in Table 5.2. The small 
number of studies reflects several difficulties in this 
research. First, DNA from human lung tissue is difficult to 
obtain. The amounts of DNA available from routine proce-
dures, such as bronchoscopy, are generally too small for 
analysis of specific DNA adducts. Second, the levels of DNA 
adducts are generally low: between 1 in 10 million and 1 
in 100 million normal DNA bases. Analyzing such small 
amounts of material is challenging. Nevertheless, meth-
ods such as those listed previously and in Table 5.2 were 
successfully applied. However, because of the limitations 
noted, the number of participants in most of the studies 
is small.
The major DNA adduct of B[a]P observed in labora-
tory animals is BPDE-N2-deoxyguanosine. Acid hydrolysis 
of DNA containing this adduct releases B[a]P-7,8,9,10-
tetraol, which can be analyzed by HPLC with fluorescence 
detection (Rojas et al. 1998). Other BPDE-derived DNA 
adducts may be hydrolyzed simultaneously. This assay 
has been applied to lung tissue obtained during surgery 
(Alexandrov et al. 2002; Boysen and Hecht 2003). Com-
pared with nonsmokers, smokers with the GSTM1 null 
genotype displayed higher levels of BPDE-DNA adducts 
in lung tissue, although this finding is based on a small 
number of cases (Rojas et al. 1998, 2004). BPDE-DNA 
adducts were detectable in 40 percent of the smokers with 
whole lung analyses (Boysen and Hecht 2003) and in all 
samples with analyses of bronchial epithelial cells (Rojas 
et al. 2004). When the adduct localization in genes was 
determined by in vitro studies, one target was seen to be 
at mutational hot spots in the P53 tumor-suppressor gene 
and the KRAS oncogene in cells (Tang et al. 1999; Feng et 
al. 2002).
Several studies have quantified 7-methyldeoxygua-
nosine in human lung tissue. The source of this adduct in 
smokers could be NDMA, NNK, or perhaps other methyl-
ating agents. Studies have reported mixed results: some 
show higher adduct levels in smokers than in nonsmok-
ers (Hecht and Tricker 1999; Lewis et al. 2004). One study 
examined O6-methyldeoxyguanosine in human lung tis-
sue but was too small to draw conclusions about the effect 
of smoking (Wilson et al. 1989). 
Three small studies provided evidence for ethyl DNA 
adducts in human lung tissue (Wilson et al. 1989; Blömeke 
et al. 1996; Godschalk et al. 2002). Levels of both O6-ethyl- 
deoxyguanosine and O4-ethylthymidine were higher in 
smokers than in nonsmokers. Although one source of 
these adducts could be N-nitrosodiethylamine, its level in 
cigarette smoke is low. As discussed previously, cigarette 
smoke contains a direct-acting, but chemically uncharac-
terized, ethylating agent that may be responsible for the 
presence of these adducts (see “Carcinogens in Cigarette 
Smoke” earlier in this chapter).
NNK and NNN are metabolically activated to inter-
mediate agents that pyridyloxobutylate DNA. The result-
ing POB-DNA adducts can be hydrolyzed with acid to 
yield 4-hydroxy-1-(3-pyridyl)-1-butanone, which can be 
detected by GC–MS. Application of this method demon-
strated higher levels of POB-DNA adducts in lung tissue 
of smokers than in that of nonsmokers in a small study 
(Foiles et al. 1991). One study detected 7-(2-hydroxyethyl)
deoxyguanosine in human lung tissue (Zhao et al. 1999), 
and ethylene oxide is the likely source of this adduct. Stud-
ies have detected 4-ABP–DNA adducts in human lungs but 
show no clear effect of smoking on adduct levels (Wilson 
et al. 1989; Lin et al. 1994).
Researchers have quantified 1,N6-ethenodeoxy-
adenosine and 3,N4-ethenodeoxycytidine in human lungs 
by 32P-postlabeling (Godschalk et al. 2002). These adducts 
may result from lipid peroxidation or from metabolic acti-
vation of vinyl chloride or ethyl carbamate. No differences 
were reported between smokers and nonsmokers. Studies 
of the oxidative-damage product 8-oxodeoxyguanosine in 
the human lung obtained mixed results regarding a rela-
tionship between detection of this product and smoking 
status (Asami et al. 1997; Lee et al. 1999a). 
In summary, data on the quantitation of specific 
DNA adducts in the human lung are limited. However, 
some studies document clear evidence for elevated lev-
els of adducts resulting from exposure to specific car-
cinogens such as B[a]P, NNK, or NNN. Several methods 
used in these studies—HPLC fluorescence, GC–MS, 
LC–MS, and 32P-postlabeling with modifications for specific 
adducts—have the potential for application to molecular 
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Table 5.2 DNA adducts in human lung tissue
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epidemiologic studies that relate specific DNA adduct lev-
els to tobacco exposure and cancer risk.
Uncharacterized Adducts in Human Lung Tissue
Studies have extensively applied two main nonspe-
cific methods—32P-postlabeling and immunoassay—to 
analyze DNA adducts in human lung tissue, as well as in 
other tissues. Researchers have discussed the advantages 
and disadvantages of these methods (Kriek et al. 1998; 
Wild and Pisani 1998; Poirier et al. 2000; Phillips 2002). 
Major advantages include high sensitivity for analyzing 
small amounts of DNA, simplicity of analysis, and no need 
for extremely expensive equipment. Disadvantages include 
a lack of chemical specificity, particularly in 32P-postlabel-
ing analyses, and difficulty in quantitation. Studies have 
extensively reviewed the application of these methods to 
tissues obtained from smokers (Phillips 2002; Wiencke 
2002; IARC 2004). 
The output of assays using 32P-postlabeling is 
often a “diagonal radioactive zone” (DRZ), which con-
sists of uncharacterized radioactive components referred 
to in the literature as hydrophobic or aromatic DNA 
adducts. In most cases, little if any evidence supports the 
true chemical characteristics of these adducts. Neverthe-
less, the intensity of the DRZ is consistently elevated in 
samples from smokers. Immunoassays have used various 
methods of detection, including the fluorescent staining 
of tissue specimens that allows for the location of adducts. 
Cross-reactivity is a common problem of immunoassays. 
For example, antibodies raised against protein conjugates 
of B[a]P–DNA adducts cross-react with adducts generated 
from other PAHs.
Many studies using 32P-postlabeling methods 
examined DNA adduct levels in the peripheral lung, bron-
chial epithelium, or cells obtained by bronchial lavage of 
smokers. Most of the studies found that adduct levels were 
higher in smokers compared with nonsmokers (Győrffy 
et al. 2004; IARC 2004). Investigations that attempted 
to draw quantitative relationships between the extent 
of smoking and adduct levels had inconsistent results 
(IARC 2004). 
Adducts in Other Tissues
Numerous studies have evaluated DNA adduct 
formation in fetuses and in various tissues and fluids of 
smokers, including samples from the larynx, oral and 
nasal mucosa, bladder, cervix, breast, pancreas, stomach, 
placenta, and cardiovascular system, and samples of spu-
tum, sperm, and blood cells. Researchers have compre-
hensively reviewed these studies (Phillips 2002; Weincke 
2002; IARC 2004), most of which used 32P-postlabeling 
and immunoassay techniques.
Levels of 7-alkyl-deoxyguanosines determined by 
32P-postlabeling in laryngeal DNA were higher in 
smokers than in nonsmokers (Szyfter et al. 1996), and they 
correlated with the DRZ in these samples. Studies used 
immunoassay also to detect 4-ABP–DNA adducts in laryn-
geal tissue (Flamini et al. 1998). Other studies examined 
the DRZ by 32P-postlabeling (IARC 2004).
Researchers have detected 1,N2-propanodeoxy-
guanosine (PdG) adducts derived from acrolein and cro-
tonaldehyde in the DNA of gingival tissue of smokers and 
nonsmokers; adduct levels were higher in smokers (Nath 
et al. 1998). Adducts detected by 32P-postlabeling in oral 
and nasal tissue were also higher in smokers than in non-
smokers. Use of immunoassay techniques revealed that 
levels of BPDE-DNA, 4-ABP–DNA, and malondialdehyde-
DNA adducts in human oral mucosal cells of smokers were 
higher than those for nonsmokers (IARC 2004).
Using 32P-postlabeling, researchers found 4-ABP–
DNA (C-8 deoxyguanosine) adducts in exfoliated uro-
thelial cells and bladder biopsy samples (IARC 2004). In 
studies using antibodies to 4-ABP–DNA, levels detected 
in biopsy specimens from the bladder of smokers were 
higher than those for nonsmokers (IARC 2004). Studies 
using 32P-postlabeling of bladder DNA from smokers and 
nonsmokers yielded mixed results; some studies showed 
higher adduct levels in smokers (IARC 2004). 
Using GC–MS, Melikian and colleagues (1999) docu-
mented that BPDE-DNA adducts were higher in cervical 
epithelial cells of smokers than in those of nonsmokers. An 
immunohistochemical analysis using antibodies to BPDE-
DNA adduct in human cervical cells also showed higher 
adduct levels in smokers than in nonsmokers (Mancini 
et al. 1999). 32P-postlabeling consistently showed higher 
adduct levels in cervical tissues of smokers than in those 
of nonsmokers (IARC 2004). 
The 32P-postlabeling of DNA from breast tissue 
yields the characteristic DRZ from smokers. Researchers 
also investigated adduct levels by using antibodies against 
BPDE-DNA; results were generally mixed with respect to 
smoking status (IARC 2004). Studies that used 32P-post-
labeling to measure adduct levels in pancreatic and stom-
ach tissues reported a correlation with smoking status 
(IARC 2004). 
Some studies indicate the presence of smoking-
related DNA adducts in human placenta, but the overall 
relationship of placental DNA adducts to smoking is weak 
(IARC 2004). Analyses of sperm DNA also reported mixed 
results with respect to smoking status (IARC 2004).
Many studies have examined DNA adducts in blood 
cells (IARC 2004). The common use of blood cells in these 
studies is obviously related to the ease of clinically obtain-
ing these samples. From this viewpoint, blood cell DNA 
is advantageous for biomarker studies. A disadvantage of 
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using blood cells is that adduct levels in blood cells are 
not necessarily directly related to levels of DNA adducts in 
the tissues in which smoking-related cancers occur. The 
collective results of the studies are somewhat inconsistent 
with respect to the effects of smoking on levels of DNA 
adducts. This inconsistency probably results in part from 
competing sources of adduct formation such as diet, occu-
pation, and the general environment. Another factor is the 
lifetime of the blood cells investigated; longer-lived cells 
appear to provide more consistent results with respect to 
smoking (IARC 2004). Studies comparing levels of blood 
cell–DNA adducts in smokers with or without cancer had 
mixed results (IARC 2004). 
A meta-analysis of the relationship of DNA adduct 
levels in smokers to cancer, determined by 32P-postlabel-
ing, used data from case-control studies of lung cancer 
(five studies), oral cancer (one study), and bladder cancer 
(one study). Six studies measured adducts in white blood 
cells, and one study used normal lung tissue. Among cur-
rent smokers, adduct levels for case patients were signifi-
cantly higher than those for control participants (Veglia 
et al. 2003).
Protein Adducts as Surrogates for DNA Adducts
Researchers have proposed that levels of carcino-
gen-Hb adducts and carcinogen-albumin adducts be used 
as surrogates for the measurements of DNA adducts dis-
cussed in the preceding section (Osterman-Golkar et al. 
1976; Ehrenberg and Osterman-Golkar 1980). Although 
these proteins are not considered targets for carcinogen-
esis, all carcinogens that react with DNA are also thought 
to react with protein to some extent. Advantages of Hb 
adducts as surrogates include the ready availability of 
Hb in blood and the long lifetime of the erythrocyte in 
humans (approximately 120 days), which provides an 
opportunity for adducts to accumulate. Other research-
ers have comprehensively reviewed studies on protein 
adducts in smokers (Phillips 2002; IARC 2004).
The Hb adducts of aromatic amines have emerged 
as highly informative carcinogen biomarkers. Levels of 
these adducts are consistently higher in smokers than in 
nonsmokers, particularly for 3-ABP–Hb and 4-ABP–Hb 
adducts. Adduct levels decrease with smoking cessa-
tion and are related to the number of cigarettes smoked 
(Maclure et al. 1990; Skipper and Tannenbaum 1990; 
Castelao et al. 2001). Adducts that form with the amino ter-
minal valine of Hb are also informative. Important examples 
include adducts derived from ethylene oxide, butadiene, 
acrylonitrile, and acrylamide (Bergmark 1997; Fennell 
et al. 2000; Swenberg et al. 2001). Ethylated N-terminal 
valine of Hb is also higher in smokers than in nonsmokers 
(Carmella et al. 2002a). 
Summary
Overwhelming evidence indicates that DNA adduct 
levels are higher in most tissues of smokers than in cor-
responding tissues of nonsmokers. This observation pro-
vides bedrock support for the major pathway of cancer 
induction in smokers that proceeds through DNA adduct 
formation and genetic damage. DNA adducts studied can 
generally be divided into two classes: nonspecific adducts, 
which are detected by 32P-postlabeling and immunoassay, 
and specific adducts, which are detected by structure-
specific methods. Studies of nonspecific DNA adducts are 
far more common than studies of specific DNA adducts, 
which are still scarce and are limited mainly to human 
lung tissue. Strong evidence exists for the presence of 
a variety of specific adducts in the human lung, and in 
several cases, adduct levels are higher in smokers than 
in nonsmokers. Measuring levels of Hb adducts by MS 
provides a simple and perhaps more practical approach 
for assessing carcinogen exposure of the cell. In several 
instances, levels of specific adducts are substantially 
higher in smokers than in nonsmokers. Collectively, the 
results of these biomarker studies demonstrate the poten-
tial for genetic damage in smokers from the persistence 
of DNA adducts. The propagation of this genetic damage 
during clonal outgrowth is consistent with the accumu-
lation of multiple genetic changes observed in lung can- 
cer progression. 




Genetic polymorphisms may play a role in tobacco-
related neoplasms. Researchers have established cigarette 
smoking as a major cause of lung cancer: more than 85 
percent of lung cancers are attributable to smoking (Ries 
et al. 2004). However, not all smokers develop lung cancer, 
and lung cancer can arise in lifetime nonsmokers. This 
variation in disease has stimulated interest in molecular 
epidemiologic investigations of genetic polymorphisms, 
including carcinogen-metabolizing enzymes that may 
lead to variations in susceptibility to the carcinogens in 
tobacco smoke (Table 5.3). Considerable data exist on 
genetic polymorphisms in cancers other than lung can-
cer, but the discussion here focuses only on lung cancer 




Studies have identified polymorphisms in phase I 
and II enzymes. Phase I enzymes, such as P-450s, gen-
erally add an oxygen atom to a carcinogen, and phase II 
enzymes, such as GSTs or UGTs, modify the carcinogen by 
making it highly water soluble for more facile excretion. 
These enzymes are involved in the activation and detoxi-
fication of carcinogens and may be associated with a dif-
ferential ability to process carcinogens. Researchers have 
hypothesized that the accumulation of active carcinogen 
metabolites and hence increased DNA adduct formation 
add to lung cancer risk. Studies of cases with autopsy of 
cancer-free lung tissue indicate that polymorphisms in 
CYP1A1 and GSTM1 genes may be associated with higher 
DNA adduct levels, suggesting that variations in meta-
bolic pathways can play a role in individual response to 
carcinogen exposure (Kato et al. 1995). Numerous studies 
have extended this line of analysis to investigate whether 
this differential ability to metabolize carcinogens leads to 
differential lung cancer risk. Overall, data from the study 
of these polymorphisms have generated inconsistent 
results. These inconsistencies may be explained in part by 
the combination of a small sample size and variable fre-
quencies of the polymorphic alleles within different ethnic 
populations. A summary of some of the specific gene poly-
morphisms investigated is provided in Table 5.3. A recent 
review summarizes the effects of genetic polymorphisms 
on lung cancer (Schwartz et al. 2007), and specific exam-
ples are discussed here.
CYP1A1 Gene
Researchers hypothesize that interindividual varia-
tions in the ability to activate carcinogens such as PAH 
through the CYP1A1 gene may lead to differential carci-
nogenic effects. Studies describe at least two variant poly-
morphisms in the CYP1A1 gene. The first is a T3801C base 
change in intron 6, which results in a new MSPI restric-
tion site (Kawajiri et al. 1990). (A restriction site is a site in 
the gene that is cleaved by a specific restriction enzyme.) 
The second polymorphism is an A2455G base change in 
exon 7, which results in an Ile to Val amino acid change 
(Hayashi et al. 1991). Although these polymorphisms ap-
pear to be linked, study results are inconsistent, and wide 
disparities exist among populations. 
Studies of Japanese and Chinese populations 
associate both of the CYP1A1 variant polymorphisms with 
an increase in lung cancer risk. Nakachi and colleagues 
(1991) were the first to report an association of the *MSPI 
polymorphism with lung cancer risk. For patients with 
lung cancer, the frequency of harboring the homozygous 
Table 5.3 Selected gene polymorphisms evaluated by molecular epidemiology investigations for relationship to 
lung cancer through variation in susceptibility to carcinogens in tobacco smoke
Metabolic genes Nucleotide change Amino acid change Enzymatic activity
CYP1A1 T→C (MSPI) NA Increased
CYP1A1 A→G Ile462Val Increased
CYP2E1 T→A (DRAI) NA Increased
CYP2E1 G→C (RSAI) NA Increased
CYP2A13 C→T Arg257Cys Decreased
GSTM1 Deletion NA None
GSTP1 A→G Ile105Val Decreased
GSTT1 Deletion NA None
NAT2 T→C Ile114Thr Decreased
NAT2 C→T Lys161Lys Decreased
NAT2 A→G Lys268Arg Decreased
NAT2 G→A Arg197Gln Decreased
NAT2 C→T Tyr94Tyr Decreased
NAT2 G→A Gly286Glu Decreased
MEH T→C Tyr113His Decreased
MEH A→G His139Arg Increased
Note: NA = not applicable.
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variant genotype was more than two times higher than 
that for control participants. Among patients with squa-
mous cell carcinoma (SCC), the homozygous variant 
genotype was associated with an increased risk of develop-
ing lung cancer, especially in those with a lower cumula-
tive dose of cigarette smoke. At low levels of exposure to 
cigarette smoke, the odds ratio (OR) for developing lung 
cancer among persons with the homozygous variant gen-
otype was 7.31 (95 percent confidence interval [CI], 2.13–
25.12). This increased risk was persistent, but of a lesser 
magnitude, at higher levels of exposure to cigarette smoke 
(Nakachi et al. 1991). Okada and colleagues (1994) 
reported similar findings. 
Studies have also associated the ILE462VAL poly-
morphism of CYP1A1 with lung cancer risk in Japanese 
and Chinese populations. Again, the homozygous variant 
*VAL/*VAL genotype was associated with lung cancer at 
lower cumulative doses of cigarette smoke (Nakachi et al. 
1993; Yang et al. 2004; Ng et al. 2005). One explanation 
posited for this relationship with the dose level in smok-
ers has been that the relevant enzyme is saturated at high 
doses but not at low doses of cigarette smoke (Vineis et 
al. 1997). The effects of genetic variability and differential 
enzymatic activity are more apparent at low doses, when 
saturation has not been reached. 
Results have been inconsistent outside Asian popu-
lations. Individual studies often lack statistical power to 
detect an association (Shields and Harris 2000). Also, 
CYP1A1 polymorphisms are common in Asian populations 
(30 percent of the population) (Nakachi et al. 1993), but 
are far less common among Europeans and North Ameri-
cans (<10 percent of the population) (Warren and Shields 
1997). A study of African Americans and Mexican Ameri-
cans showed a twofold increase in the risk of lung cancer 
among light smokers with the *MSPI variant genotype 
(Ishibe et al. 1997). However, a Brazilian study showed 
an increase in risk with the *ILE/*VAL polymorphism but 
not with the MSPI polymorphism (Hamada et al. 1995). A 
more recent study suggested that in Latinos, the *MSPI 
variant genotype was associated with an overall inverse 
OR of 0.51 (95 percent CI, 0.32–0.81), which reflected the 
inverse interaction with smoking (Wrensch et al. 2005). 
Reports from Finland, Norway, and Sweden show a lack of 
association between either of the CYP1A1 polymorphisms 
and lung cancer risk (Tefre et al. 1991; Hirvonen et al. 
1992; Alexandrie et al. 2004). A meta-analysis provides 
little support for this association (Houlston 2000).
Because of the small sample sizes in these studies, 
Vineis and colleagues (2003) conducted an analysis of 
pooled data from the International Collaborative Study 
on Genetic Susceptibility to Environmental Carcinogens, 
which included raw data from 22 case-control studies 
totaling 2,451 cases and 3,358 controls. This data set thus 
comprised approximately one-half of the case-control 
studies published at that time. Researchers found an 
association in Whites between the CYP1A1 homozygous 
*MSPI variant and lung cancer risk after adjustment 
of values for age and gender (OR = 2.36; 95 percent CI, 
1.16–4.81). The association held for both SCC and adeno-
carcinomas (Vineis et al. 2003). However, this association 
failed to reach statistical significance among Asians in 
this analysis. Moreover, studies such as the research con-
ducted by Nakachi and colleagues (1991, 1993) discussed 
previously in this section were not included, making the 
Asian data difficult to interpret.
CYP2E1 Gene
The CYP2E1 gene is involved in the metabolic 
activation of NDMA, as well as several other tobacco 
smoke carcinogens. Le Marchand and colleagues (1998) 
performed a population-based, case-control study with 
341 lung cancer cases and 456 controls. These researchers 
found that CYP2E1 polymorphisms were associated with a 
decrease in risk of lung adenocarcinoma. A Chinese study 
(Wang et al. 2003c) confirmed this finding. However, the 
presence of at least one variant CYP1A1 *MSPI allele was 
associated with an increased risk of SCC, both alone (2.4-
fold increase in risk) and in combination with GSTM1 de-
letion (3.1-fold increase in risk) (Le Marchand et al. 1998). 
These researchers suggest that the associations between 
CYP1A1 and CYP2E1 polymorphisms and subsets of lung 
cancer indicate a specificity of PAHs to induce SCC and of 
nitrosamines to induce adenocarcinomas. 
CYP2A13 Gene
The CYP2A13 gene is expressed primarily in the 
respiratory tract and participates in the metabolic activa-
tion of N-nitrosamines such as NNK. Researchers have 
identified a polymorphism in CYP2A13 in which a C→T 
transition leads to an Arg→Cys substitution at position 
257. The variant 257CYS protein, the product of this gene, 
has one-half to one-third the capacity of the 257ARG pro-
tein to activate NNK (Su et al. 2000; Zhang et al. 2002). In 
a study of 724 lung cancer patients and 791 control par-
ticipants, Wang and colleagues (2003a) demonstrated that 
the variant CYP2A13 genotype (*C/*T or *T/*T) was asso-
ciated with a reduced risk for lung cancer, particularly for 
adenocarcinomas (OR = 0.41; 95 percent CI, 0.23–0.71). 
The reduction in risk did not reach statistical significance 
for SCC or other histologies of lung cancer. The reduced 
risk for adenocarcinomas was apparent only in smokers, 
and in light smokers rather than in heavy smokers (Wang 
et al. 2003a). This finding again indicates that genetic 
polymorphisms may play a greater role when the carcino-




Study reports have noted large variations in enzy-
matic activity for several GSTs. About 50 percent of the 
White population is homozygous for a deletion in the 
GSTM1 gene that leads to null expression (Seidegard et 
al. 1988). The GSTM1 enzyme is important in detoxify-
ing carcinogens, and numerous studies have investigated 
the possible association of the GSTM1 null genotype with 
lung cancer risk. 
Some studies have found an association between 
the GSTM1 null mutation and lung cancer across many 
populations. In a Japanese population, the GSTM1 null 
genotype was positively correlated with SCC of the lung 
but not with adenocarcinomas (Kihara et al. 1993). A sim-
ilar analysis in a Finnish population also correlated the 
GSTM1 null genotype with SCC (Hirvonen et al. 1993). 
Analyses of Scottish (Zhong et al. 1991), Norwegian 
(Ryberg et al. 1997), and Turkish populations (Pinarbasi et 
al. 2003) had similar findings. A U.S. study also suggested 
that the GSTM1 null genotype was associated with a mod-
est elevation in lung cancer risk, which increased among 
heavy smokers (Nazar-Stewart et al. 2003). However, some 
studies have not shown a significant association between 
the GSTM1 null genotype and lung cancer risk for SCC 
or overall for lung cancer (London et al. 1995; Rebbeck 
1997). A meta-analysis of data from 12 case-control stud-
ies comprising 1,593 cases and 2,135 controls showed a 
moderate increase in the risk of lung cancer across all 
histologies with the GSTM1 null genotype (OR = 1.41; 95 
percent CI, 1.23–1.61) (McWilliams et al. 1995). A more 
recent meta-analysis of 43 studies including more than 
18,000 persons showed a smaller but statistically signifi-
cant OR of 1.17 (95 percent CI, 1.07–1.27) (Benhamou et 
al. 2002). 
Kihara and colleagues (1994) analyzed data on 178 
Japanese patients with lung cancer and 201 healthy con-
trol participants and found that the GSTM1 null genotype 
was associated with an overall increase in lung cancer risk 
(OR = 1.87; 95 percent CI, 1.21–2.87). The strongest asso-
ciation was for SCC (OR = 2.13; 95 percent CI, 1.11–4.07). 
With stratification by the amount of smoking, the propor-
tion of GSTM1 null genotype increased progressively in 
the SCC group from 50 percent in light smokers to 72 
percent in heavy smokers (Kihara et al. 1994). One study 
suggested that higher intakes of cruciferous vegetables 
reduced lung cancer risk among persons with the GSTM1 
genotype (highest versus lowest tertile for amount of 
smoking; OR = 0.61; 95 percent CI, 0.39–0.95) but not 
among persons with the GSTM1 null genotype (highest 
versus lowest tertile; OR = 1.15; 95 percent CI, 0.78–1.68) 
(Wang et al. 2004b). However, several other studies have 
shown a greater protective effect in persons with the 
GSTM1 null genotype who consumed cruciferous vegeta-
bles (London et al. 2000; Spitz et al. 2000). One hypoth-
esis is that these participants were less able to eliminate 
protective isothiocyanates by conjugation with glutathi-
one. In a case-control study, Cheng and colleagues (1999) 
analyzed data from 162 patients with SCC of the head and 
neck and 315 healthy control participants. They found 
that 53.1 percent of the case patients and 42.9 percent of 
the control participants were null for GSTM1 (p <0.05), 
whereas 32.7 percent of case patients and 17.5 percent of 
control participants were null for GSTT1 (p <0.001).
Thus, the effect of GSTM1 alone may not be dra-
matic. However, it appears to be magnified by gene- 
environment and gene-diet interactions, and the effects 
were significantly greater as exposure to cigarette smoke 
increased. In addition, the high frequency of GSTM1 poly-
morphisms observed across all ethnicities may contribute 
to the importance of this variant as a risk factor for devel-
oping lung cancer (Brennan et al. 2005). 
CYP1A1 and GSTM1 in Combination
Studies of the effect of combined CYP1A1 and GSTM1 
variant genotypes hypothesized that increased PAH activa-
tion and decreased PAH detoxification in tobacco smokers 
might lead to an increase in lung cancer risk. Numerous 
studies have explored this association. Perhaps the stud-
ies with the strongest support for this association come 
from Japan, although they are generally limited by small 
sample sizes. 
Combination of the CYP1A1 variant genotype and 
the GSTM1 null genotype enhanced the risk of smoking-
related lung cancers in a Japanese population. Hayashi 
and colleagues (1992) demonstrated this finding with the 
*ILE/*VAL polymorphism. These investigators found an 
increased frequency of the homozygous *VAL/*VAL gen-
otype combined with the GSTM1 null genotype in lung 
cancer patients compared with control participants (8.5 
percent versus 2.2 percent, respectively). Nakachi and 
colleagues (1991) reported similar results with both the 
*MSPI and *ILE/*VAL polymorphisms and the GSTM1 
null genotype. The case-control study found that for light 
smokers, either of the two CYP1A1 susceptible genotypes 
combined synergistically with the deficient GSTM1 geno-
type to create a high risk for lung cancer (OR = 16; 95 
percent CI, 3.76–68.02 for *MSPI, and OR = 41; 95 percent 
CI, 8.68–193.61 for *ILE/*VAL). Eighty-seven percent 
of the light smokers who developed lung cancer had at 
least one of the three homozygous variant genotypes. The 
investigators suggested that particularly when the ciga-
rette dose is low, CYP1A1 and GSTM1 may be an impor-
tant determinant of susceptibility to lung cancer (Nakachi 
et al. 1991). 
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Kihara and colleagues (1994) also demonstrated a 
synergistic effect. Persons with these variant genotypes 
in both CYP1A1 and GSTM1 had a much higher risk of 
lung cancer than did those with the variant CYP1A1 and 
wild-type GSTM1 (OR = 21.9; 95 percent CI, 4.68–112.7 
versus OR = 3.2; 95 percent CI, 0.37–24.0). Studies in 
Scandinavian populations (Alexandrie et al. 1994; Anttila 
et al. 1994), as well as U.S. populations (García-Closas et 
al. 1997), support an increase in the risk of lung cancer 
with the combination of variant CYP1A1 and GSTM1 gen-
otypes. Using data from the International Collaborative 
Study on Genetic Susceptibility to Environmental Car-
cinogens database, Vineis and colleagues (2004) found a 
statistically significant effect of the *MSPI variant on lung 
cancer risk in Whites (OR = 2.6; 95 percent CI, 1.2–5.7) 
with evidence for an interaction between the MSPI and 
GSTM1 null genotypes (OR = 2.8; 95 percent CI, 0.9–8.4).
GSTP1 Gene
Studies have reported polymorphisms in the GSTP1 
gene family of phase II enzymes with high expression in 
the lung. One GSTP1 polymorphism includes an A→G 
base change that leads to an isoleucine→valine substi-
tution, which results in lower enzymatic activity toward 
1-chloro-2,4-dinitrobenzene (Watson et al. 1998) but 
higher activity toward PAH diol epoxides (Sundberg et al. 
1998). Several studies showed no statistically significant 
association between GSTP1 polymorphisms and lung can-
cer risk (Harris et al. 1998; Katoh et al. 1999; To-Figueras 
et al. 1999; Nazar-Stewart et al. 2003). However, in the 
study with the largest sample size of 1,042 cases and 1,161 
controls, the GSTP1 homozygous variant genotype was 
associated with a higher lung cancer risk at any level of 
exposure to smoke than was the wild-type genotype (Miller 
et al. 2003). 
The combination of the GSTM1 null genotype and 
the GSTP1 *G/*G genotype may increase lung cancer 
risk (Ryberg et al. 1997; Kihara et al. 1999; Perera et al. 
2002). In a study of 1,694 cases and 1,694 controls, double 
variants in GSTM1 and GSTP1, as well as in GSTP1 and 
TP53, were associated with an increase in lung cancer 
risk among persons aged 55 years or younger (adjusted 
OR [AOR] = 4.03; 95 percent CI, 1.47–11.1 for the M1-
P1 double variant, and AOR = 5.10; 95 percent CI, 1.42–
18.30 for the P1-P53 double variant) (Miller et al. 2002). 
Another study included 350 persons younger than age 50 
years with a diagnosis of lung cancer who were identified 
from the metropolitan Detroit Surveillance, Epidemiol-
ogy, and End Results program. The study compared these 
patients with 410 control participants matched by age, 
race, and gender. The results indicated that African Amer-
icans carrying at least one *G allele at the GSTP1 locus 
were 2.9 times more likely to develop lung cancer than 
were African Americans without a *G allele (95 percent 
CI, 1.29–6.20). African Americans with either one or two 
genotypes that carry risk at the GSTM1 and GSTP1 loci 
were at higher risk of developing lung cancer than were 
African Americans who had fully functional GSTM1 and 
GSTP1 genes (OR = 2.8; 95 percent CI, 1.1–7.2 for GSTM1, 
and OR = 4.0; 95 percent CI, 1.3–12.2 for GSTP1). No sig-
nificant single-gene associations were observed between 
GSTM1, GSTT1, or GSTP1 and early-onset lung cancer in 
Whites (Cote et al. 2005). 
GSTT1 Gene
Previous results have not supported an association 
of the GSTT1 gene with lung cancer risk (To-Figueras et 
al. 1997; Malats et al. 2000; Stücker et al. 2002; Ruano-
Ravina et al. 2003; Wang et al. 2003b). In a study of Chi-
nese living in Hong Kong, the GSTT1 null genotype was 
associated with a higher risk of lung cancer than was the 
functional GSTT1 genotype (AOR = 1.69; 95 percent CI, 
1.12–2.56) only in nonsmokers (Chan-Yeung et al. 2004). 
A study from Denmark also suggested that the GSTT1 null 
genotype is associated with a higher risk of lung cancer 
(Sørensen et al. 2004a). 
NAT2 Gene
Several widely studied polymorphisms for the NAT2 
gene are associated with decreased activity or reduced 
stability of the enzyme. Phenotypically, these polymor-
phisms result in slow or fast acetylation. Study results on 
the association of the NAT2 gene with lung cancer risk 
are conflicting. Most studies report no overall increase 
in risk with the genotype for either slow or fast acetyla-
tion (Philip et al. 1988; Martinez et al. 1995; Bouchardy 
et al. 1998; Saarikoski et al. 2000). However, a few studies 
report an increase in risk with the genotype for either slow 
acetylation (Oyama et al. 1997; Seow et al. 1999) or fast 
acetylation (Cascorbi et al. 1996). In the largest study, of 
1,115 lung cancer patients and 1,250 control participants, 
no association between the NAT2 genotype and lung can-
cer risk was observed. However, the study noted a signifi-
cant interaction with smoking. Among nonsmokers, the 
genotype for rapid acetylation decreased lung cancer risk 
more than did the genotype for slow acetylation. This 
relationship was reversed among smokers, and persons with 
the genotype for rapid acetylation had a higher risk. The 
authors hypothesized that for nonsmokers, the NAT2 pro-
tein may provide a means for N-acetylation, thereby detoxi- 
fying aromatic amines and protecting a person against 
cancer. However, cigarette smoke markedly induces CYP 
oxidation and could increase the production of reactive 
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intermediate agents in smokers. In this setting, NAT2 may 
instead O-acetylate these metabolites and thereby produce 
more reactive metabolites, thus augmenting the cancer 
risk (Zhou et al. 2002b). A study from Denmark confirmed 
the associations of the NAT2 gene with smoking status 
(Sørensen et al. 2005). However, a study from Taiwan 
suggested that the NAT2 genotype for fast acetylation is 
associated with an increased risk of lung cancer among 
women who were lifetime nonsmokers (Chiou et al. 2005). 
The NAT2 protein plays an important role in the bio-
activation and detoxification of the aromatic amines asso-
ciated with bladder cancer induced by cigarette smoke. In 
the phenotypic studies, persons with slow acetylation had 
increased risk of bladder cancer, particularly when they 
had occupational exposure to arylamines or were cigarette 
smokers (Green et al. 2000; Johns and Houlston 2000). In 
the genotype analysis, more than 20 independent studies, 
many with small sample size have assessed the association 
of NAT2 polymorphisms with the risk of bladder cancer. A 
meta-analysis of published case-control studies conducted 
in the general population (22 studies, 2,496 cases, and 
3,340 controls) examined the relationship of acetylation 
status (phenotype and genotype) to bladder cancer risk. 
Persons with slow acetylation had a 40-percent increase in 
risk compared with risk for persons with rapid acetylation 
(OR = 1.4; 95 percent CI, 1.2–1.6) (Marcus et al. 2000b). 
However, studies conducted in Asia generated a summary 
OR of 2.1 (95 percent CI, 1.2–3.8), studies in Europe gen-
erated a summary OR of 1.4 (95 percent CI, 1.2–1.6), and 
studies in the United States generated a summary OR of 
0.9 (95 percent CI, 0.7–1.3). 
In addition, a case series meta-analysis of data from 
a case series of 16 studies of bladder cancer, conducted in 
the general population and involving 1,999 cases, showed 
a weak interaction between smoking status and NAT2 slow 
acetylation (OR = 1.3; 95 percent CI, 1.0–1.6). The interac-
tion was stronger when analyses were restricted to studies 
conducted in Europe (OR = 1.5; 95 percent CI, 1.1–1.9) 
(Marcus et al. 2000a). In a pooled analysis of data from 
1,530 cases and 731 controls from four case-control stud-
ies plus two case series conducted in Whites in European 
countries, a significant association was reported between 
NAT2 slow acetylation and bladder cancer (OR = 1.42; 95 
percent CI, 1.14–1.77) (Vineis et al. 2001). The risk of can-
cer was elevated in smokers and in persons with occupa-
tional exposure to cigarette smoke, and the highest risk 
was for persons with slow acetylation (Vineis et al. 2001).
In a hospital-based, case-control study of 201 men 
in northern Italy and a case-control study with 507 White 
patients with bladder cancer in the United States, findings 
also suggested that the NAT2 genotype for slow acetyla-
tion was associated with an increased risk of bladder can-
cer, especially with the joint effects of cigarette smoking 
and occupational exposure to aromatic amines (Hung et 
al. 2004; Gu et al. 2005). In a case-control study of blad-
der cancer in females, exclusive use of permanent hair 
dye was associated with a 2.9-fold increased risk of blad-
der cancer among persons with the NAT2 genotype and 
slow acetylation but not in those with the NAT2 genotype 
and rapid acetylation (Gago-Dominguez et al. 2003). All 
of these results confirmed that the genotype for NAT2 
slow acetylation is a risk factor for bladder cancer through 
interaction with smoking or occupational exposure. How-
ever, several studies that included populations of Chinese 
(Ma et al. 2004), northern Indians (Mittal et al. 2004), and 
Poles (Jaskula-Sztul et al. 2001) reported no association 
between the NAT2 genotype and bladder cancer risk.
Microsomal Epoxide Hydrolase
Like NAT2, MEH can act as both an activator and a 
detoxifier of carcinogens. As a detoxifier, MEH catalyzes the 
hydrolysis of highly reactive epoxide intermediate agents 
to less reactive dihydrodiols that are excretable. As an 
activator, MEH is involved in further metabolism of PAH 
epoxides. Several identified polymorphisms include a T→C 
base change in exon 3 leading to a tyrosine→histidine 
substitution at residue 113, which is associated with a 
decrease in enzymatic activity, and an A→G base change 
in exon 4, leading to a histidine→arginine substitution 
at residue 139, which leads to an increase in enzymatic 
activity (Hassett et al. 1994). Several reports of studies 
have noted an increased risk of lung cancer among persons 
carrying polymorphisms associated with an increase in 
enzymatic activity. A study of Mexican Americans and Afri-
can Americans found a greater risk of lung cancer among 
young Mexican Americans with the exon 4 polymorphism, 
but not among those with the exon 3 polymorphism. No 
association was observed among African Americans (Wu 
et al. 2001). The homozygous variant genotype at exon 4 
confers increased enzymatic activity and was again asso-
ciated with an increase in lung cancer risk in a study in 
Texas (Cajas-Salazar et al. 2003). A study from Austria sug-
gested an association between the exon 3 polymorphism 
of the MEH gene and a significantly decreased risk of lung 
cancer (Gsur et al. 2003). The combination of exon 3 and 
exon 4 polymorphisms that conferred high enzymatic 
activity also significantly increased the risk (Cajas-Salazar 
et al. 2003; Park et al. 2005). In a Chinese population in 
Taiwan, high MEH activity, defined by the corresponding 
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combination of exon 3 and exon 4 polymorphisms, was 
associated with an increased risk for SCC (Lin et al. 2000). 
In a French population, high MEH activity was similarly 
associated with lung cancer risk (Benhamou et al. 1998). 
A study of 974 White patients with lung cancer and 
1,142 control participants found no relationship between 
MEH polymorphisms and lung cancer risk overall. How-
ever, evidence of gene-environment interactions was 
observed. Low-activity MEH genotypes were a risk factor 
for lung cancer among nonsmokers (OR = 1.89; 95 percent 
CI, 1.08–3.28) but were protective among heavy smokers 
(OR = 0.65; 95 percent CI, 0.42–1.00) (Zhou et al. 2001b). 
This effect was stronger in SCC than in adenocarcinoma. 
The researchers hypothesized that this difference may be 
explained by the dual actions of MEH. In nonsmokers, 
the presence of low MEH activity may lead to a decreased 
ability to detoxify environmental pollutants, thus increas-
ing lung cancer risk. In smokers, MEH may participate in 
activating the PAHs in cigarette smoke. Therefore, low 
activity is protective for heavy smokers. Similar results 
were reported in a Slovak study (Habalová et al. 2004).
In a meta-analysis of data from seven published 
studies that included 2,078 case patients with lung can-
cer and 3,081 control participants, investigators found 
no consistent overall association for either the exon 3 or 
exon 4 polymorphisms with lung cancer risk (Lee et al. 
2002c). However, in an analysis of pooled data from eight 
studies (four published and four unpublished at that time) 
with 986 case patients and 1,633 control participants, 
researchers observed a significant decrease in lung cancer 
risk (OR = 0.70; 95 percent CI, 0.51–0.96) for the exon 3 
*HIS/*HIS genotype. The protective effect of the exon 3 
polymorphism seems stronger for adenocarcinomas of the 
lung than for other histologic types. Researchers found no 
overall association between MEH activity and lung cancer 
risk and no consistent modification of the carcinogenic 
effect of smoking according to the MEH polymorphism. 
However, the risk of lung cancer decreased among lifetime 
nonsmokers with high MEH activity and among heavy 
smokers with the exon 3 *HIS/*HIS genotype (Lee et 
al. 2002c).
Genes in the Pathway for Metabolism  
of Reactive Oxygen Species
Studies have identified an alanine→valine substi-
tution at codon 16 of manganese superoxide dismutase 
(SOD), which may be associated with a less efficient 
enzyme transport into mitochondria. The *VAL/*VAL gen-
otype is associated with risk of lung cancer higher than 
that for the wild-type genotype (AOR = 1.67; 95 percent 
CI, 1.27–2.20) (Wang et al. 2001a). Other studies also asso-
ciate the heterozygous variant genotype with an increased 
risk of lung cancer (AOR = 1.34; 95 percent CI, 1.05–1.70) 
(Wang et al. 2001a, 2004c). Studies have identified a G→A 
polymorphism in the promoter region of myeloperoxidase 
(MPO) that decreases *A allele transcription. A study of 
bronchoalveolar lavage fluid and cells from 106 White 
smokers who had lung cancer showed an association of 
the variant genotypes with reduced MPO activity in the 
fluid and reduced levels of smoking-related DNA adducts 
in bronchoalveolar cells (Van Schooten et al. 2004). The 
association was stronger in persons having two variant 
alleles (homozygous variants) than it was in persons 
having one normal and one variant allele (heterozyg- 
ous variants).
Findings on lung cancer risk are conflicting. Most 
studies performed since 1999 suggested that the variant 
MPO genotypes are associated with a decreased risk of 
lung cancer (Le Marchand et al. 2000; Dally et al. 2002; 
Feyler et al. 2002; Kantarci et al. 2002; Lu et al. 2002; 
Schabath et al. 2002). In contrast, two studies found no 
association between either the heterozygous or homo-
zygous variant genotypes and lung cancer risk (Xu et al. 
2002; Chevrier et al. 2003). Another study suggested that 
the MPO-G463A polymorphism associated with a novel 
estrogen-receptor-binding site modifies the association 
between the SOD ALA16VAL polymorphism and risk of 
non-small-cell lung cancer (NSCLC) differently by gender. 
For women carrying MPO variant genotypes, the AOR of 
the SOD polymorphism (*VAL/*VAL versus *ALA/*ALA) 
was 3.26 (95 percent CI, 1.55–6.83). No associations were 
found in men or women who carried the MPO *G/*G wild-
type genotype (Liu et al. 2004). 
Summary
Studies to date suggest a role for genetic polymor-
phisms in the risk of lung and bladder cancer in smokers 
and support a possible association between specific genes 
and smoking status. Investigations continue on the role 
of multiple genetic variants that occur simultaneously 
and the interactions between metabolic gene variants and 
other kinds of heritable variations, such as DNA repair, 




DNA Repair and Conversion of Adducts to Mutations
Repair of DNA Adducts
Introduction
Tobacco products and smoke contain many chemi-
cals that can damage DNA. Multiple repair pathways 
protect a human cell against the mutagenic and carcino-
genic activities of these DNA-damaging agents. Pathways 
involved in the repair of tobacco-related DNA damage 
include direct base repair by alkyltransferases, excision of 
DNA damage by base excision repair (BER), or nucleotide 
excision repair (NER), mismatch repair (MMR), and dou-
ble-strand break repair (DSBR). The inadequate removal 
of DNA damage results in increased rates of mutagenesis 




O6-alkylguanine adducts are repaired by the repair 
protein O6-alkylguanine–DNA alkyltransferase (AGT) in 
a reaction involving transfer of the methyl group from 
the O6 position of guanine to a cysteinyl residue on the 
protein (Pegg 2000). This transfer reaction results in an 
error-proof repair as it regenerates an unmodified gua-
nine residue in DNA. However, the repair protein is inacti-
vated as the alkylated protein undergoes a conformational 
change (Daniels et al. 2000) and is degraded (Srivenugo-
pal et al. 1996; Xu-Welliver and Pegg 2002). As a conse-
quence of this repair mechanism, the constitutive levels 
of AGT determine the initial repair capacity of a cell by 
this mechanism. Overall capacity of the O6-alkylguanine 
repair is determined by the rate of protein synthesis and 
the amount of alkylation at the O6 position of guanine. 
Substrate Specificity
Mammalian AGT specifically repairs O6-alkylgua-
nine adducts, and it repairs the larger O6-alkylguanine 
residues more readily than does the bacterial protein. In 
rodents, AGT repairs O6-methylguanine, O6-butylguanine, 
and O6-[4-oxo-4-(3-pyridyl)butyl]guanine at comparable 
rates, whereas human AGT repairs the bulky adducts more 
slowly (Mijal et al. 2004). This ability of the rodent protein 
to accommodate such large structural differences likely 
results from the additional amino acid residue (Gly166) 
in the binding pocket of the rodent proteins (Loktionova 
and Pegg 2002). Therefore, the steric constraints of an 
active AGT site determine whether it can efficiently repair 
a bulky O6-alkylguanine adduct such as those more com-
monly resulting from exposure to smoke.
Protecting Against Mutagenicity of Tobacco 
Carcinogens
Tobacco smoke contains a number of alkylating 
agents, such as tobacco-specific nitrosamines, which are 
capable of forming O6-alkylguanine adducts (Wang et al. 
1997; Hecht 1998). AGT protects against the mutagenic 
and carcinogenic properties of alkylating agents.
In vitro studies. Increased expression of AGT pro-
tects against the mutagenic effects of O6-alkylguanine 
(Ellison et al. 1989) and alkylating agents (Kaina et al. 
1991; Wu et al. 1992; Ferrezuelo et al. 1998a,b). Consis-
tently, alkylating agents are more toxic and mutagenic 
when coadministered with AGT inactivators such as 
O6-benzylguanine or related compounds (Dolan et al. 
1990, 1991; Bronstein et al. 1992). The mutagenic activ-
ity of O6-methylguanine or O6-[4-oxo-4-(3-pyridyl)bu-
tyl]guanine is enhanced when cells are pretreated with 
O6-benzylguanine (Pauly et al. 1995, 2002). This finding 
indicated that AGT is important in protecting against 
the mutagenic activity of these adducts derived from 
tobacco constituents.
In vivo studies. AGT is depleted in tissues from 
NNK-treated rats, and AGT levels are depleted in Clara 
cells (Belinsky et al. 1988). NNK also reduces AGT levels 
in the lungs and liver of A/J mice (Peterson et al. 2001). 
Although the liver function recovers to control values 
within 96 hours after exposure, AGT activity remains 
depressed in the lung. Consistently, O6-methylguanine is 
efficiently repaired in the liver of NNK-treated mice, but 
it persists for at least two weeks in lung DNA (Peterson 
and Hecht 1991; Peterson et al. 2001). Notably, levels of 
O6-methylguanine in lung DNA are highly correlated with 
pulmonary tumorigenic activity in A/J mice (Peterson 
and Hecht 1991; Peterson et al. 2001). These observations 
strongly suggest that the inefficient repair of O6-meth-
ylguanine, presumably by AGT, is linked to the tumori-
genic activity of NNK. This conclusion is supported by the 
observation from another study that high AGT levels pro-
tect against NNK-induced lung tumorigenesis and that 
NNK is a less potent lung carcinogen in transgenic mice 
containing the human AGT transgene (Liu et al. 1999).
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Base Excision Repair
Overview
BER is a major pathway for the repair of small DNA 
damage, primarily to alkylated and oxidized DNA bases, as 
well as the repair of apurinic/apyrimidinic (AP) sites and 
single-stranded breaks (Fortini et al. 2003; Fromme et al. 
2004). BER is initiated by a recognition of the damaged 
DNA by specific DNA glycosylases. Studies have charac-
terized 12 human glycosylases (Table 5.4) (Christmann et 
al. 2003; Fortini et al. 2003). Each enzyme has different 
but sometimes overlapping substrate specificities that are 
subgrouped into type I and type II glycosylases, depending 
on their mode of action (Christmann et al. 2003). Type 
I glycosylases catalyze the cleavage of the N-glycosidic 
bond, leaving an AP site. Type II glycosylases remove 
the damaged base in a similar manner. They contain 3’- 
endonuclease activity that cleaves the AP site, which gen-
erates a single-strand break with a 3’-terminal deoxyribose 
phosphate. Spontaneous hydrolysis of a glycosidic bond 
can also directly generate AP sites. AP sites are substrates 
for DNA AP endonuclease, which cuts the phosphodiester 
Table 5.4 Human DNA glycosylases
Study Glycosylase Specificity Subgroup
Chakravarti et al. 1991 
O’Connor and Laval 1991 
Samson et al. 1991
Alkylpurine DNA glycosylase  
or methylpurine DNA  
glycosylase 




Hendrich and Bird 1998 
Hendrich et al. 1999
Methyl-CpG binding endonuclease 1 U or T opposite G, preferentially in 
CpG sites
Type I
Slupska et al. 1996, 1999 
Fortini et al. 2003
Adenine DNA glycosylase A opposite 8-oxoguanine Type I
Hazra et al. 2002a,b Nei-like DNA glycosylase 1 Formamidopyrimidines, oxidized 
pyrimidines, 8-oxo guanine opposite C, 
G, or T
Type II
Hazra et al. 2002a,b Nei-like DNA glycosylase 2 5-hydroxyuracil, 5-hydroxy cytosine Type II
Takao et al. 2002 Nei-like DNA glycosylase 3 Fragmented and oxidized pyrimidines NR
Aspinwall et al. 1997  
Hilbert et al. 1997  
Miyabe et al. 2002  
Fortini et al. 2003
Thymine glycol DNA glycosylase 1 Ring-saturated, oxidized, and 
fragmented pyrimidines
Type II
Bjørås et al. 1997  
Radicella et al. 1997 
Rosenquist et al. 1997  
Fortini et al. 2003
8-oxoguanine DNA glycosylase 1 8-oxoguanine opposite C, T, or G Type II
Hazra et al. 1998 8-oxoguanine DNA glycosylase 2 8-oxoguanine opposite A or G NR
Haushalter et al. 1999  
Nilsen et al. 2001
Mismatch-specific uracil DNA 
glycosylase 1
Uracil opposite G Type I
Neddermann and Jiricny 
1993, 1994  
Neddermann et al. 1996
Thymidine DNA glycosylase Uracil, T, or ethenoC opposite G;  
T opposite G, C, or T
Type I
Olsen et al. 1989 
Muller and Caradonna 1991  
Fortini et al. 2003
Uracil DNA glycosylase Uracil Type I
Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003. 
Note: NR = data not reported.
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bond and causes the formation of a strand break with a 
5’-terminal deoxyribose phosphate (Barzilay et al. 1995). 
Once the phosphodiester bond is cleaved, BER can 
proceed through two pathways: short-patch or long-patch 
(Figure 5.4). The balance of the two pathways can depend 
on tissue type (Sancar et al. 2004). In general, short-patch 
BER dominates when BER is initiated by glycosylases. 
Long-patch BER is the preferred pathway when BER is 
initiated with the formation of AP sites through spontane-
ous hydrolysis or oxidative base loss (Sancar et al. 2004). 
In short-patch BER, DNA polymerase β (polβ) 
inserts a new nucleotide at the lesion site and catalyzes 
the release of 5’-terminal deoxyribose phosphates by 
β-elimination (Matsumoto and Kim 1995; Sobol et al. 
1996; Prasad et al. 1998). This step is followed by ligation 
of the remaining break by the ligase III x-ray repair cross-
complementation group 1 (XRCC1) complex (Kubota et 
al. 1996). 
Long-patch BER occurs in oxidized or reduced AP 
sites, 3’-unsaturated aldehydes, or 3’-phosphates, because 
these modifications are resistant to β-elimination by polβ. 
Therefore, this damage is further processed by long-patch 
repair dependent on the proliferating cell nuclear antigen 
(PCNA) after the insertion of a nucleotide at the lesion 
site by polβ (Christmann et al. 2003; Fortini et al. 2003). 
This mechanism displaces the damaged strand, which is 
followed by DNA synthesis of an oligonucleotide (up to 
10 nucleotides) by pold or pole in concert with PCNA and 
replication factor C (Stucki et al. 1998). The flap endo-
nuclease 1 (FEN1) recognizes and cleaves off the damaged 
oligonucleotide flap structure (Klungland and Lindahl 
1997). Ligase I catalyzes the final ligation step (Prasad et 
al. 1996; Srivastava et al. 1998).
Substrate Specificity
Tobacco smoke is rich in reactive oxygen species 
that can oxidize DNA bases. BER is an important pathway 
for the repair of oxidized DNA bases, such as 8-oxogua-
nine and oxidized pyrimidines, and for the repair of single-
strand breaks. Tobacco smoke contains N-nitrosamines 
capable of generating small alkylguanine damage that is 
repaired by this pathway. The small chemical alterations 
frequently miscode if they are not repaired by BER. There-
fore, this pathway is particularly important in preventing 
mutagenesis.
Protecting Against Mutagenicity and 
Carcinogenicity of Tobacco Carcinogens
Single-gene knockouts of glycosylases in mice 
are well tolerated, with only modest increases in rates 
of spontaneous mutagenesis (Fortini et al. 2003). This 
observation likely results from an overlapping specificity 
of the various glycosylases and repair pathways. However, 
mutagenicity of methyl methanesulfonate (MMS) in lym-
phocytes from alkylpurine-DNA-N-glycosylase–null mice 
was three to four times higher than that in lymphocytes 
from wild-type control mice (Elder et al. 1998). Most of 
the mutations were AT→TA transversions. In addition, 
8-oxoguanine DNA glycosylase 1 (OGG1) knockout mice 
that are aging eventually develop lung cancer (Sakumi 
et al. 2003). However, in another study, knockout of pro-
teins involved in the steps after removal of the base caused 
the knockout mice to die at a very young age (Fortini et 
al. 2003).
Imbalances in the proteins involved in this pathway 
could have negative consequences. Chinese hamster ovary 
cells that overexpress alkylpurine DNA glycosylase are 
more sensitive to both the toxic and mutagenic effects of 
MMS and have higher numbers of mutations at AT base 
pairs than do normal Chinese hamster ovary cells (Cal-
léja et al. 1999). This result suggests that an enhanced 
repair of 3-methyladenine leads to an accumulation of 
unprocessed AP sites that are also mutagenic. Findings 
in another study indicate that imbalances and/or poly-
morphisms in the proteins involved in BER may cause an 
increase in cancer susceptibility (Fortini et al. 2003).
Nucleotide Excision Repair
Overview
NER repairs a wide class of helix-distorting lesions 
that interfere with base pairing, blocking transcription 
and normal replication (Petit and Sancar 1999; Sancar et 
al. 2004). NER is the primary repair mechanism for bulky 
DNA damage caused by chemicals or ultraviolet (UV) 
radiation or as a result of protein-DNA cross-links (Sancar 
et al. 2004). Two NER pathways exist (Figure 5.5): global 
genomic NER (GGR), which surveys the whole genome 
for DNA damage, and transcription-coupled repair (TCR), 
which primarily repairs damage that interferes with tran-
scription. Both pathways involve recognition of DNA dam-
age and excision of the damaged DNA, followed by the 
synthesis and ligation of new DNA.
Global genomic nucleotide excision repair. 
Researchers think that GGR is largely transcription inde-
pendent, occurring throughout the genome because no 
gene or strand preference for this repair pathway exists 
(Hanawalt et al. 2003). Proteins involved in this pathway 
are presented in Table 5.5. The initial step involves recog-
nition of DNA damage (Figure 5.5). The complex of repair 
factors in the xeroderma pigmentosum group C (XPC) 
and the homologous recombinational repair group 23B 
(HR23B) can directly recognize some DNA damage (Hey 
et al. 2002). However, in some cases, DNA-binding pro-
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Figure 5.4 Mechanism of base excision repair
Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003.
Note: 5’dRP = 5’-deoxyribose phosphate; AP = apurinic/apyrimidinic; dRPase = DNA deoxyribophosphodiesterase; 
FEN1 = flap endonuclease 1; Lig = ligase; OH = hydroxide; P = phosphate; PCNA = proliferating cell nuclear antigen; 
pol = polymerase; RF-C = replication factor C; XRCC1 = x-ray repair cross-complementation group 1. 
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Figure 5.5 Mechanism of nucleotide excision repair: (A) global genomic repair; (B) transcription-coupled repair
Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003. 
Note: CSA = Cockayne syndrome complementation group A; CSB = Cockayne syndrome complementation group B; DDB = DNA 
binding protein; ERCC1 = excision repair cross-complementation group 1; HR23B = homologous recombinational repair group 23B; 
mRNA = messenger RNA; PCNA = proliferating cell nuclear antigen; pol = polymerase; RNAPII = RNA polymerase II; RPA = replica-
tion protein A; TFIIH = transcription initiation factor IIH; TFIIS = transcription initiation factor IIS; XP = xeroderma pigmentosum 
(groups A–G).
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tein is required to enhance the DNA distortion before the 
recruitment of XPC-HR23B (Tan and Chu 2002; Hanawalt 
et al. 2003). Repair factors XPA and replication protein 
A are then recruited to the complex to verify that the 
alteration in the DNA structure results from a lesion, as 
opposed to a natural variation in DNA structure (Hanawalt 
et al. 2003). 
The DNA is then unwound at the site of the lesion. 
This step occurs on recruitment of the basal transcrip-
tion initiation factor IIH (TFIIH) multiprotein complex 
(Christmann et al. 2003). This complex is likely involved 
in a further verification of damage and detection of the 
damaged strand. The helicase subunits of TFIIH, XPB, and 
XPD then unwind the DNA around the lesion. 
Once the DNA has unwound, the lesion is excised 
at defined sites on either side of the damage (Evans et al. 
1997). The 3’-incision is catalyzed by XPG (Habraken et al. 
1994; O’Donovan et al. 1994), and the 5’-incision is cata-
lyzed by the excision repair cross-complementation group 
1 (ERCC1) XPF complex (Sijbers et al. 1996). The result-
ing DNA gap is filled in by the PCNA-dependent polymer-
ases: pold and pole (Aboussekhra et al. 1995; Araújo et al. 
2000). The final ligation is performed by DNA ligase I and 
associated proteins (Aboussekhra et al. 1995; Mu et al. 
1995; Araújo et al. 2000). Findings from in vivo studies 
suggest that the NER machinery is assembled in a step-
wise manner from the individual components at the lesion 
site. After the repair of a DNA lesion, the entire complex is 
believed by researchers to disassemble (Houtsmuller et al. 
1999; Hoeijmakers 2001).
GGR appears to be inducible in humans (Hanawalt 
et al. 2003). The proteins that recognize DNA damage in 
GGR are maintained at low levels under normal physio-
logical conditions. However, as a result of genomic stress, 
the efficiency of GGR is increased through the activation 
of the P53 tumor-suppressor gene (Hanawalt et al. 2003). 
Consequently, the levels of XPC and XPE increase. Repair 
of PAH adducts depends on the presence of the P53 pro-
tein (Hanawalt et al. 2003). These adducts are not repaired 
in human fibroblasts that lack a functional P53 protein or 
other gene product (Lloyd and Hanawalt 2000, 2002; Wani 
et al. 2000).
Transcription-coupled repair. TCR occurs when 
DNA damage blocks elongating RNA polymerases (Tor-
naletti and Hanawalt 1999). The transcription-coupled, 
repair-specific factors belong to two Cockayne syndrome 
Table 5.5 Factors involved in nucleotide excision repair activity in humans
Factor Proteins Factor activity Role in repair
XPA XPA DNA binding Damage recognition
RPA P70 XPA binding Damage recognition
RPA P34 DNA binding NR
RPA P11 NR NR
TFIIH XPB DNA-dependent ATPase Formation of preincision complexes
TFIIH XPD Helicase NR
TFIIH P62 GTP NR
TFIIH P52 NR NR
TFIIH P44 CAK NR
TFIIH CDK7 NR NR
TFIIH CYCH NR NR
TFIIH P34 NR NR
XPC XPC DNA binding Molecular matchmaker
XPC HR23B NR Stabilization of preincision complex 1
XPG XPG NR 3’ incision
XPF XPF NR 5’ incision 
XPF ERCC1 NR NR
Source: Adapted from Petit and Sancar 1999 with permission from Elsevier, © 1999.
Note: ATPase = adenosine triphosphatase; CAK = cyclin-dependent kinase-activating kinase; CDK7 = cyclin-dependent kinase 7;  
CYCH = cytochrome c-type biogenesis protein; ERCC1 = excision repair cross-complementation group 1; GTP = guanosine 
triphosphate; HR23B = homologous recombinational repair group 23; NR = data not reported; RPA = replication protein A; 
TFIIH = transcription initiation factor IIH; XP = xeroderma pigmentosum (groups A–G).
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complementation groups (A and B) and are involved in 
the displacement of the stalled polymerase (Christmann 
et al. 2003). At this point, TFIIH is recruited to the lesion, 
and the subsequent steps in TCR proceed in a manner 
apparently similar to the steps for GGR. Because of the 
mechanism of DNA damage recognition, TCR is specific 
to a DNA strand. 
Substrate Specificity
The substrate specificity of NER ranges from small 
to large distortions in DNA structure. The bulky DNA 
damage generated by PAHs and aromatic amines in 
tobacco smoke is repaired primarily by NER (Friedberg 
2001). The finding that human NER repairs 8-oxoguanine 
in vitro more efficiently than thymine dimers or thymine 
glycol (Reardon et al. 1997) suggests that this pathway 
may be important for the repair of this mutagenic adduct. 
In addition, human NER repairs O6-methylguanine and 
N6-methyladenine, as well as A:G and G:G mismatches 
(Huang et al. 1994).
Protecting Against Mutagenicity and 
Carcinogenicity of Tobacco Carcinogens
Consistent with the primary role of NER in the 
repair of bulky DNA damage from PAHs and aromatic 
amines, cells deficient in NER are more susceptible to the 
mutagenic and toxic effects of PAHs (Quan et al. 1994, 
1995; Lloyd and Hanawalt 2000, 2002; Wani et al. 2000).
Mismatch Repair
Overview
MMR corrects replication errors (base-base or 
insertion-deletion mismatches) resulting from DNA poly-
merase errors. This repair pathway is also involved in 
the repair of alkylation DNA damage, such as repair of 
O6-methylguanine (Duckett et al. 1996), cisplatin-derived 
1,2-intrastrand cross-links (Duckett et al. 1996), and 
adducts derived from B[a]P (Wu et al. 1999), 2-aminofluo-
rene, and N-acetyl-2-aminofluorene (Li et al. 1996). This 
pathway can also repair 8-oxoguanine (Colussi et al. 2002).
An overview of MMR is displayed in Figure 5.6. Rec-
ognition of DNA damage occurs primarily by the mutSα 
complex (Christmann et al. 2003). This complex is com-
posed of the mutS homologous proteins MSH2 (Fishel 
et al. 1993; Leach et al. 1993) and MSH6 (Palombo et al. 
1995). Once the heterodimer is bound to the mismatch, 
it undergoes an adenosine-triphosphate (ATP)-dependent 
conformational change (Stojic et al. 2004). This com-
plex is involved in determining which strand is the newly 
synthesized DNA (Christmann et al. 2003). A second het-
erodimer (mutLα) composed of mutL homologs MLH1 
and PMS2 then binds to the mutSα-DNA complex in an-
other ATP-dependent step (Nicolaides et al. 1994; Papado-
poulos et al. 1994; Li and Modrich 1995; Stojic et al. 2004). 
Exonuclease I then excises the DNA strand containing the 
mispaired base (Genschel et al. 2002), followed by the 
resynthesis of new DNA by pold (Longley et al. 1997).
MSH2 can also complex with MSH3 to form mutSβ 
(Acharya et al. 1996; Palombo et al. 1996). The substrate 
specificity of this alternate complex is different from that 
of mutSα (Christmann et al. 2003). The mutSα complex 
recognizes base-base mismatches, as well as insertion-
deletion mismatches (Umar et al. 1994), whereas mutSβ 
binds only to insertion-deletion mismatches (Palombo et 
al. 1996; Genschel et al. 1998). 
Figure 5.6 Mechanism of mismatch repair
Source: Adapted from Christmann et al. 2003 with permission 
from Elsevier, © 2003.
Note: For two steps dependent on adenosine triphosphatase 
(ATPase), see text. C = cytosine; G = guanine; HMLH1 = human 
mutL homolog 1 protein; HMSH2 = human mutS homolog 2 
protein; HMSH6 = human mutS homolog 6 protein; 
HPMS2 = human postmeiotic segregation increased 2 protein; 
SSB = single-stranded DNA binding protein; T = thymine.
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Protecting Against Mutagenicity and 
Carcinogenicity of Tobacco Carcinogens
Persistent adducts that escape repair by AGT, BER, 
or NER may be processed by MMR. Because MMR occurs 
after DNA replication (Stojic et al. 2004), this is the last 
opportunity for DNA damage repair before cell division. 
Consequently, a defective MMR results in an increase 
in mutagenesis (Schofield and Hsieh 2003). The overall 
effect of a defective MMR is the likelihood that cells with 
persistent DNA damage survive with a miscoded DNA. 
This combination results in a higher cancer risk.
The role of MMR in the toxicity and mutagenicity 
of alkylating agents is well documented for methylating 
agents (Karran 2001; Stojic et al. 2004). Cells lacking 
functional MMR are more resistant to the toxic effects of 
methylating agents (Koi et al. 1994; Risinger et al. 1995; 
Umar et al. 1997; de Wind et al. 1999; Karran 2001; Sto-
jic et al. 2004). However, these cells are sensitive to the 
mutagenic effects of these compounds (Umar et al. 1997; 
Zhu et al. 1998). These effects are linked to the ineffective 
MMR of O6-methylguanine. As a result, a defective MMR is 
associated with increases in mutagenesis and carcinogen-
esis mediated by O6-methylguanine (Hickman and Sam-
son 1999; Pauly and Moschel 2001). Similar effects were 
reported for ethylating agents (Claij et al. 2003).
Double-Strand Break Repair
Overview
Two pathways exist for DSBRs: homologous recom-
bination and nonhomologous end-joining. Homologous 
recombination occurs during DNA replication in the S 
and G2 phases, whereas nonhomologous end-joining 
occurs during G0 and G1 phases. Homologous recombina-
tion uses the sister chromatid as the template for aligning 
the breaks in the proper orientation and is consequently 
error free (Hoeijmakers 2001). However, nonhomologous 
end-joining does not require sequence homology between 
the two breaks to ligate them and is therefore prone to 
errors (Hoeijmakers 2001).
Homologous Recombination
The meiotic recombination 11 (MRE11)-RAD50-
NBS1 protein complex initiates DSBR by catalyzing the 
degradation of the DNA in the 5’ to 3’ direction, generating 
3’ single-stranded DNA (Figure 5.7). This single-stranded 
DNA is protected from degradation by a heptameric ring 
complex of RAD52 proteins (Stasiak et al. 2000). Replica-
tion factor A facilitates the assembly of a RAD51 nucleo-
protein filament, which consists of RAD51B, RAD51C, and 
RAD51D, as well as XRCC2 and XRCC3 (Christmann et al. 
2003). RAD51 is able to exchange the single strand with 
the same sequence from the sister chromatid DNA. This 
double-stranded copy is then used as a template to cor-
rectly repair with DNA synthesis machinery. The resulting 
Holliday structures are subsequently resolved to generate 
the repaired DNA (Constantinou et al. 2001). 
Nonhomologous End-Joining
Nonhomologous end-joining merely links the ends 
of a DSB together in the absence of a template (Figure 
5.8). The break is initially recognized by a heterodimer 
consisting of the proteins KU70 (Reeves and Sthoeger 
1989) and KU80 (Jeggo et al. 1992). This binding protects 
the DNA from digestion and associates it with the protein 
kinase catalytic subunit DNA-PKcs, which is dependent on 
DNA. This complex, in turn, activates XRCC4-ligase IV, 
which connects the broken DNA pieces together once the 
MRE11-RAD50-NBS1 complex has processed the break 
(Maser et al. 1997; Nelms et al. 1998). Researchers think 
that FEN1 and Artemis also play a role in the processing 
of DSBs (Christmann et al. 2003). 
Protecting Against Mutagenicity and 
Carcinogenicity of Tobacco Carcinogens
Scientists think that DSBs trigger large chromo-
somal aberrations such as chromosomal breaks and 
exchanges (Pfeiffer et al. 2000). Studies link an increase in 
chromosomal aberrations to tobacco exposure (DeMarini 
2004). These aberrations are more common in pulmonary 
lung tumors from smokers than in those from nonsmok-
ers (Sanchez-Cespedes et al. 2001). DSBs are also impor-
tant in triggering cell death (Rich et al. 2000; Lips and 
Kaina 2001).
Molecular Epidemiology  
of DNA Repair
Studies support the substantial interindividual vari-
ations in DNA repair capacity (DRC). Researchers hypoth-
esize that common variants in the genes that regulate 
these protein expressions may modulate repair and influ-
ence susceptibility to tobacco carcinogenesis. Two com-
plementary approaches to studying DNA repair as a risk 
factor for tobacco carcinogenesis are applying functional 
assays and genotyping variants in gene pathways for DNA 
repair. Table 5.6 summarizes some relevant genes and 




Figure 5.7 Proposed mechanism of homologous recombination
Source: Adapted from Christmann et al. 2003 with permission from Elsevier, © 2003.
Note: MRE11 = meiotic recombination 11; RAD = S. cerevisiae DNA damage recognition and repair protein; RPA = replication 
protein A; XRCC2/XRCC3 = x-ray repair cross-complementation groups 2 and 3.
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Functional Assays of DNA Damage and  
Repair to Tobacco Carcinogens
Berwick and Vineis (2000) extensively reviewed the 
types of functional assays. The review included assays that 
use a chemical or physical mutagen challenge such as 
mutagen sensitivity, single-cell microgel electrophoresis 
(comet assay), and assays of induced adducts and unsched-
uled DNA synthesis. The review also included the host-cell 
reactivation (HCR) assay, which measures cellular ability 
to remove adducts from plasmids transfected into lym-
phocyte cultures in vitro by the expression of damaged 
reporter genes. 
Host-Cell Reactivation Assay
The HCR assay measures the expression level of 
damaged reporter genes, which are involved in reacti-
vation of the host cell. The assay uses undamaged host 
lymphocytes, is fast, and objectively measures intrinsic 
cellular repair (Athas et al. 1991). In the assay, lympho-
cytes are transfected with a damaged, nonreplicating 
recombinant plasmid harboring a chloramphenicol acet-
yltransferase (CAT) reporter gene (PCMVCAT). To study 
tobacco-related cancers, the mutagen challenge is B[a]P 
(Gelboin 1980). Experimental conditions produce at least 
one BPDE-DNA adduct per plasmid, completely block-
ing transcription of the PCMVCAT gene without induc-
ing conformational changes in the DNA. This finding is 
important because conformational change of the plasmid 
could reduce the transfection rate. Because even a single 
unrepaired DNA adduct can effectively block PCMVCAT 
transcription (Koch et al. 1993), any measurable PCMV-
CAT activity reflects the ability of the transfected cells to 
remove BPDE-induced adducts from the plasmids (Athas 
et al. 1991).
Both lymphocytes and skin fibroblasts from patients 
with basal cell carcinoma, but not with XP, were found 
to have lower excision repair rates than those from per-
sons without cancer (Wei et al. 1993). Consequently, the 
repair capacity of lymphocytes may reflect the overall 
repair capacity of a person. Spitz and colleagues (2003) 
showed that case patients with lung cancer had a sig-
nificantly lower DRC than did control participants and 
that case patients aged 63 years or younger and lifetime 
nonsmokers had a lower DRC than that of matched con-
trol participants. DRC appears to be highest among case 
patients and control participants who were current smok-
ers than among those who were former smokers and 
lifetime nonsmokers. Heavy smokers among both case 
patients and control participants tended to have more pro-
ficient DRC than did light smokers. This finding indicated 
that cigarette smoking may stimulate DRC in response 
to the DNA damage caused by carcinogens in tobacco. 
Such an adaptation would be consistent with a baseline 
DRC that can be mobilized on an increased demand for 
repair (Eller et al. 1997; Cheng et al. 1998). This adapta-
tion of DRC to smoking, if it exists, appears to be long 
term rather than transient, because the effect was still 
present in former smokers but was not stronger in those 
who had smoked in the 24 hours before the blood sample 
was drawn (Wei et al. 2000). The finding that long-term 
heavy smokers with lung cancer had an efficient DRC may 
also indicate that heavy exposure overwhelms even rela-
tively resistant phenotypes.
Luciferase Host-Cell Reactivation Assay
Researchers have modified the HCR assay by 
replacing CAT with luciferase (LUC). The cell-extraction 
procedure is far more simplified for the LUC assay. A lumi-
nometer measures LUC optical density, and the laboratory 
Figure 5.8 Proposed mechanism of nonhomologous 
end-joining
Source: Adapted from Christmann et al. 2003 with permission 
from Elsevier, © 2003.
Note: FEN1 = flap endonuclease 1; MRE11 = meiotic 
recombination 11; PKcs = protein kinase catalytic subunit; 
XRCC4 = x-ray repair cross-complementation group 4.
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Table 5.6 Select candidate genes and polymorphisms implicated in repair of tobacco-induced DNA damage
Gene Nucleotide position Nucleotide change Amino acid change Allele frequency
Alkyltransferases            
AGT, MGMT       Ile143Val 0.05–0.2
Base excision repair            
MBD4 13390 T/C Ser342Pro 0.05
MBD4 13402 G/A Glu346Lys 0.07
TDG 27090 G/A Gly199Ser 0.09
MUTYH 18556 G/C Gly335His 0.44
OGG1 18069 C/G Ser326Cys 0.25
APEX1 11865 T/G Glu148Asp 0.25
XRCC1 32584 C/T Arg194Trp 0.08
XRCC1 33746 G/A Arg280His 0.05
XRCC1 34432 G/A Arg399Gln 0.31
ADPRT 75787 T/C Val761Ala 0.38
ADPRT 77525 C/T Pro882Leu 0.20
POLD1 24569 G/A Arg19His 0.12
POLD1 27479 A/G His119Arg 0.16
POLD1 27715 A/G Ser173Asn 0.06
Nucleotide excision repair            
XPC 30197 C/T Ala499Val 0.24
XPC 42635 A/C Lys939Gln 0.38
XPD 16232 G/A Asp312Asn 0.40
XPD 28572 A/C Lys751Gln 0.33
XPF 34637 T/C Ser662Pro 0.06
RAD23B 48769 C/T Ala249Val 0.18
CCNH 23563 C/T Val270Ala 0.10
XPG 39583 G/C His1104Asp 0.32
LIG1 29008 A/C Ala170Ala 0.39
LIG1 61130 C/T Asp802Asp 0.21
LIG1 62525 C/G Ala814Ala 0.30
Double-strand break repair            
Homologous recombination            
RAD51 692 (cDNA) G/T Ala143Ser 0.33
XRCC3 26044 T/C Thr241Met 0.22
RAD52 45137 C/A Ser346Ter 0.05
RAD54L 1222 (cDNA) G/C Arg374Ser 0.11
BRCA2 27113 T/G His372Asn 0.23
BRCA2 93268 G/A Ile3412Val 0.05
RAD50 3374 (cDNA) G/T Arg1111Ile 0.25
NBS1 137331 C/G Gln185Glu 0.46
Nonhomologous end-joining            
KU70 336 (cDNA) G/A Glu107Lys 0.06
KU70 454 (cDNA) T/C Val146Ala 0.11
KU70 1825 (cDNA) T/C Leu603Pro 0.10
KU80 1487 (cDNA) C/T Pro485Leu 0.14
LIG4 8 (cDNA) C/T Ala3Val 0.07
LIG4 27 (cDNA) C/T Thr9Ile 0.14
XRCC4 21965 G/T Ala247Ser 0.08
Note: cDNA = complementary DNA.
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procedures are shorter. The results for the DRC phenotype 
from the independent CAT and LUC assays in parallel are 
highly correlated, with a correlation coefficient of 0.65 
(p <0.0001) (Qiao et al. 2002a). This finding suggests that 
these two assays are comparable. 
8-Oxoguanine DNA Glycosylase Activity Assay
The OGG test is another functional repair assay that 
measures the specific activity of the enzyme 8-oxoguanine 
DNA N-glycosylase in protein extracts prepared from 
peripheral blood mononuclear cells (Paz-Elizur et al. 
2003). The OGG1 enzyme removes 8-oxoguanine from 
DNA and leaves behind an abasic site that is rapidly cleaved 
by the AP lyase of OGG1. OGG activity (in units per µg of 
protein extract) is the amount of fragment cleaved by 1 µg 
of extract in one hour under standard reaction condi-
tions (Paz-Elizur et al. 2003). In a pilot case-control study 
of NSCLC, the mean value of OGG activity in the case 
patients was significantly lower than that in the control 
participants and was independent of tumor histology, 
gender, and smoking status (Paz-Elizur et al. 2003). In 
addition, OGG activity in protein extracts from peripheral 
blood mononuclear cells correlated well with that from 
lung tissue in the same patients (p = 0.003).
Mutagen Sensitivity Assays
Researchers use cytogenetic assays extensively to 
measure human exposure and response to genotoxic 
agents. These assays are based on the unproven hypoth-
esis that the extent of genetic damage in the lymphocytes 
may reflect critical events in carcinogenesis in the affected 
tissues. The assays can only indirectly indicate DRC from 
the cellular damage that remains after mutagenic expo-
sure and recovery and therefore probably reflect nonspe-
cific impairment of the DNA repair machinery (Berwick 
and Vineis 2000).
Hsu and colleagues (1989) developed the in vitro 
mutagen challenge assay to demonstrate interindividual 
differences in susceptibility to carcinogenic agents. This 
assay counts the frequency of bleomycin-induced breaks 
in short-term lymphocyte cultures, as a measure of cancer 
susceptibility. Bleomycin is a clastogenic agent that mim-
ics the effects of radiation by generating free oxygen radi-
cals capable of producing DNA single-strand breaks and 
DSBs after forming a complex with DNA, ferrous ions, and 
oxygen that releases oxygen radicals (Burger et al. 1981). 
Most of the breaks are repaired by BER. Repair is rapid, 
with a half-life of only a few minutes (López-Larraza et 
al. 1990). 
Mutagen sensitivity is an independent risk factor for 
lung cancer that has a dose-response relationship with the 
number of induced chromosomal breaks (Spitz et al. 1995, 
2003; Strom et al. 1995; Wu et al. 1995, 1998a; Zheng et 
al. 2003). The risks associated with mutagen sensitivity, 
stratified by smoking status, are elevated in all smoking 
strata but are highest in current smokers and in the heavi-
est smokers. For studying tobacco-related cancers, a more 
appropriate mutagen to trigger DNA damage is BPDE; 
BPDE-induced sensitivity is a risk factor for lung cancer 
(Wei et al. 1996; Wu et al. 1998a,b).
Comet Assay
The comet assay (single-cell microgel electrophore-
sis) is applicable to any cell line or tissue from which a 
single-cell suspension can be obtained (Ross et al. 1995). 
Singh and associates (1988) have described the methods in 
detail. For this assay, a cell culture is mixed with agarose 
gel and attached to a microscope slide. The cells are lysed 
by submerging the slides in freshly prepared lysis buffer 
to remove all cellular proteins. To allow for DNA denatur-
ation, unwinding, and expression of the alkali-labile sites, 
the slides are then placed in an alkali buffer (pH = 12.0). 
To separate the damaged DNA from the intact nuclei, a 
constant electric current is applied, and the slides are neu-
tralized, fixed, and stored in the dark at room temperature 
until ready for analysis. During electrophoresis, dam-
aged DNA migrates from the nucleus toward the anode 
as a result of the constant electric current, which forms 
the typical “comet” cell. A predetermined number of cells 
are manually selected, and comet cells are automatically 
quantified with appropriate imaging software.
Case patients with lung and bladder cancer had 
significantly higher levels of induced DNA damage af-
ter exposure to both BPDE and g-radiation, which were 
assessed by the mean “tail moment” in lymphocytes. (The 
tail moment is the product of lymphocyte tail length and 
the fraction of the total DNA in the tail.) Higher levels of 
DNA damage were positively associated with increased 
risk of bladder and lung cancer (Schabath et al. 2003; Wu 
et al. 2005). Schmezer and colleagues (2001) showed that 
case patients with lung cancer were significantly more 
sensitive to bleomycin and had a reduced DRC (68 percent 
in case patients and 81 percent in control participants 
[p <0.001]). Rajee-Behbahani and colleagues (2001) 
reported a similar DRC finding of 67 percent in 160 case 
patients with lung cancer and 79.3 percent in 180 con-
trol participants. When the data from the cases and con-
trols were considered together, only 18 percent of the case 
patients were below the median level of sensitivity to bleo-
mycin for all control participants, and 82 percent were in 
the hypersensitive range. 
Mohrenweiser and Jones (1998) have pointed out 
several lines of evidence documenting that differences 
in DRC reflect genetic differences. DRC in lymphocyte 
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subpopulations from an individual exhibited similar 
repair capacities. Furthermore, intraindividual variations 
in repair capacity among subpopulations of lymphocytes 
are significantly smaller than are interindividual varia-
tions (Crompton and Ozsahin 1997). The phenotype of 
reduced repair capacity in the NER pathway is indepen-
dent of the phenotype for DSBR (Wu et al. 1998a).
Researchers have performed extensive resequenc-
ing of DNA repair genes to identify variations that may be 
associated with a reduced function of their encoded pro-
teins rather than an absence of function. Such polymor-
phisms could explain interindividual differences in DRC 
(Spitz et al. 2001; Qiao et al. 2002b; Wu et al. 2003). 
Although the variant alleles are likely to be associated 
with only a modest cancer risk, because they exist at a 
polymorphic frequency, the attributable risks can become 
substantial. As Berwick and Vineis (2000) noted, stud-
ies that compare genetic polymorphisms with results of 
functional assays will likely be the most valuable type of 
investigations to clarify the role of a defect in DRC with 
the development of cancer. 
Polymorphisms in O6-Alkylguanine–DNA 
Alkyltransferase
The ability of a cell to withstand alkyl damage is 
related to the number of AGT molecules in the cell and 
the rate of de novo synthesis of AGT. AGT levels differed 
among persons, and protein levels in the liver, colon, and 
peripheral blood varied 4-, 10-, and 20-fold, respectively 
(Myrnes et al. 1983; Strauss et al. 1989; Povey et al. 2000). 
Environmental and genetic factors, but not age, affect 
expression levels of AGT (Margison et al. 2003). AGT lev-
els are higher in normal lung, colorectal, and placental 
tissues from smokers than in those from nonsmokers, 
although these findings are controversial (Slupphaug et 
al. 1992; Drin et al. 1994; Povey et al. 2000). Exposure 
to AGT inhibitory aldehydes, such as formaldehyde from 
occupational exposure, can deplete AGT activity (Hayes et 
al. 1997). Expression of AGT is higher in NSCLC tumor tis-
sues from smokers than in those from nonsmokers (Mat-
tern et al. 1998). However, small-scale studies examining 
AGT activity in peripheral lymphocytes have not observed 
significant differences between smokers and nonsmokers 
(Vähäkangas et al. 1991; Oesch and Klein 1992; Hall et al. 
1993) or between case patients with cancer and control 
participants (Boffetta et al. 2002). It is not clear how well 
AGT activity in lymphocytes predicts levels in lung tissue.
The AGT gene contains multiple polymorphisms in 
the 5’ upstream region, which comprises the promoter 
and enhancer regions, as well as exon 1 (Egyházi et al. 
2002; Krzesniak et al. 2004). These genetic variations 
may account for some of the interindividual variations in 
expression levels. Eight allelic variants in this region occur 
at a frequency of at least 0.01. One-half of these variants 
have a prevalence of 0.1 to 0.6, and this finding suggests 
a contribution to the variability in AGT expression within 
populations (Krzesniak et al. 2004). The prevalence of the 
best-studied enhancer polymorphism, C1099T, is 0.09 
to 0.12 and is associated with an increase in promoter- 
enhancer activity in the LUC assay (Krzesniak et al. 2004). 
However, heterozygotes for this enhancer polymorphism 
do not appear to be at a markedly lower risk of developing 
lung cancer (OR = 0.82; 95 percent CI, 0.41–1.67) (Krz-
esniak et al. 2004). None of the other enhancer-promoter 
polymorphisms have been examined for their relationship 
with AGT or cancer risk.
Mutations at or near the cysteine acceptor site can 
affect AGT activity (Crone et al. 1994). Two polymorphisms 
have been identified in this region of the protein: codon 
143 *ILE/*VAL and codon 160 *GLY/*ARG. The variant 
isoform codon 160 *GLY/*ARG has exhibited activity to 
repair bulky alkylated DNA adducts that is significantly 
less than that of the GLY wild-type phenotype (Edara et al. 
1996; Mijal et al. 2004). The estimated prevalence of the 
143 variant is 0.07 in Whites, 0.03 in African Americans 
(Kaur et al. 2000), and as high as 0.24 in Swedish popu-
lations (Ma et al. 2003). The codon 160 variant allele is 
likely a mutant, because it was found at a frequency less 
than 0.01 (Kaur et al. 2000). These researchers reported a 
marginally significant increase in the risk of lung cancer 
associated with the codon 143 *ILE/*VAL genotype (OR = 
2.1; 95 percent CI, 1.01–4.7), and no interaction of geno-
type and smoking dose was seen. More recently, Cohet and 
colleagues (2004) reported an OR of 2.05 (95 percent CI, 
1.03–4.07) for lung cancer among lifetime carriers of the 
codon 143 and 160 variant alleles who were nonsmokers. 
The authors suggested that the strongest risk was associ-
ated with exposure to secondhand tobacco smoke.
Polymorphisms in the Pathway  
for Repair of Base Excision
Cross-Complementation  
Group 1 for Excision Repair
The XRCC1 gene encodes a protein that functions 
in BER and involves the excision of the damaged region, 
followed by repair synthesis that uses the opposite strand 
as the template. The XRCC1 protein forms scaffolding 
with DNA ligase III, polβ, and poly (adenosine diphos-
phate–ribose) polymerase (PARP) to rejoin DNA strand 
breaks and repair gaps left during BER. Of the estimated 
17 variants, 1 is a polymorphism at the XRCC1 28152 site 
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(G→A transition) of codon 399 in exon 10 that results in a 
nonconservative amino acid substitution of arginine 
for glutamine. Goode and colleagues (2002) extensively 
reviewed the conflicting results for lung cancer studies. 
For example, Divine and colleagues (2001) reported a 
more than twofold risk for lung adenocarcinoma associ-
ated with the *GLN/*GLN genotype. Zhou and colleagues 
(2003) found an association that was largely restricted to 
nonsmokers and light smokers. Some studies failed to find 
any association between the *GLN/*GLN genotype and 
lung cancer risk (Butkiewicz et al. 2001; Ratnasinghe et 
al. 2001; Popanda et al. 2004; Zhang et al. 2005b). How-
ever, Matullo and colleagues (2001a) did find an associa-
tion for bladder cancer. David-Beabes and London (2001) 
reported a decreased risk of lung cancer for both African 
American and White patients. Other studies also report 
conflicting findings regarding an increased risk associated 
with the exon 10 *ARG/*ARG genotype (Lee et al. 2001; 
Stern et al. 2001).
Another polymorphism at the XRCC1 26304 site 
(C→T transversion) of codon 194 in exon 6 results in a 
nonconservative amino acid substitution of arginine. Most 
studies suggest a reduced risk of cancer associated with 
the 399*ARG variant allele (Goode et al. 2002). Studies 
of lung, bladder, head and neck, and gastric cancers all 
showed inverse associations with the variant allele; some 
studies included evidence of an interaction with smoking 
(Sturgis et al. 1999; David-Beabes and London 2001; Rat-
nasinghe et al. 2001; Stern et al. 2001). Two studies noted 
no association for esophageal and lung cancers (Butkie-
wicz et al. 2001; Lee et al. 2001).
A few earlier studies evaluated the functional sig-
nificance of these polymorphisms. Lunn and colleagues 
(1999) noted that persons with the 399*GLN allele were 
at a significantly higher risk (OR = 2.4) for exhibiting 
detectable aflatoxin B1 adducts and a higher frequency 
of the glycophorin A variant than were carriers of the 
399*ARG/*ARG allele. This study also reported a dose-
response relationship between smoking status and pres-
ence of the polymorphism for detecting the adducts and 
the glycophorin A variant (Lunn et al. 1999). However, 
no significant effects were noted for other XRCC1 poly-
morphisms. Duell and colleagues (2000) found elevated 
SCE frequencies and polyphenol DNA adducts with 
399*GLN/*GLN homozygous genotypes. Abdel-Rahman 
and El-Zein (2000) noted that persons carrying the 
*GLN allele had significantly higher numbers of SCEs in 
response to NNK treatment than did *ARG/*ARG geno-
type carriers. No differences were detected in persons with 
the codon 194 genotype. 
Matullo and colleagues (2001b) found higher DNA 
adduct levels among lifetime nonsmokers who were 
healthy and were homozygous for the 399*GLN allele 
than among those with the wild-type genotype (15.6 ver-
sus 6.78, p = 0.007). Wang and colleagues (2003a) showed 
that persons with the variant 194*TRP allele had fewer 
bleomycin- and BPDE-induced breaks per cell than did 
those with the wild-type genotype. The XRCC1 codon 399 
is within the BRCT domain (amino acids 301 to 402) that 
interacts with PARP and is in many proteins with activity 
involving response to DNA damage and cell-cycle check-
points. This region also has homology with yeast RAD4 
repair-related genes. Because the role of XRCC1 in BER 
brings together DNA polβ, DNA ligase III, and PARP at the 
site of DNA damage, repair activity of the exon 10 vari-
ant may be altered. The codon 194 polymorphism is in 
the linker region of the XRCC1 N-terminal domain sepa-
rating the helix 3 and polβ involved in binding a single- 
nucleotide gap DNA substrate (Marintchev et al. 1999). 
Therefore, this polymorphism is less likely to cause a sig-
nificant change in repair function. 
OGG1 Gene
The product of the OGG1 gene catalyzes the excision 
of a modified base, 8-oxoguanine, which may be formed by 
exposure to reactive oxygen species. The reduced ability to 
excise 8-oxoguanine may lead to an accumulation of oxi-
dation-induced mutations. Studies have identified several 
polymorphisms at the OGG1 locus. The most frequently 
studied polymorphism is a common C→G transversion in 
exon 7 that results in an amino acid alteration at codon 
326 (Ser→Cys). The HOGG1 protein encoded by the wild-
type 326*SER allele exhibited substantially higher DNA 
repair activity than did the 326*CYS variant in an in vitro 
Escherichia coli complementation activity assay (Kohno 
et al. 1998). 
Researchers have observed fairly consistent 
increased risks of OGG1 polymorphisms (Goode et al. 
2002). The largest study was a U.S.-population-based, 
multiethnic study of lung cancer that identified a sig-
nificantly increased risk associated with the *CYS/*CYS 
genotype (*CYS/*CYS versus *SER/*SER; OR = 2.1; 95 
percent CI, 1.2–3.7) (Le Marchand et al. 2002). A small, 
hospital-based study of lung cancer in Japan supported 
these results (Sugimura et al. 1999). Findings in a third 
study of lung cancer that also suggested an increased risk 
had similar findings for comparison of the two homozy-
gote groups (OR = 2.2; 95 percent CI, 0.4–11.8) (Wikman 
et al. 2000). Analyses of esophageal cancer also showed an 
increased risk associated with the *CYS/*CYS genotype 
(OR = 1.9; 95 percent CI, 1.3–2.6) (Xing et al. 2001). How-




Polymorphisms in the Pathway for  
Nucleotide Excision Repair
Xeroderma Pigmentosum A
XPA is an essential DNA-binding protein in the 
NER pathway that aids in correctly positioning the repair 
machinery around the damaged areas and in maintaining 
contact with core repair factors during the repair process. 
XPA interacts with other proteins, such as replication 
protein A, TFIIH, and XRCC1/XPF (Volker et al. 2001). 
Studies have identified an A→G transversion variant 
in the 5’ noncoding region (Butkiewicz et al. 2000). 
Researchers investigating this polymorphism in lung can-
cer reported similar results in two studies. Wu and col-
leagues (2003) reported that the presence of one or two 
copies of the *G allele instead of the *A allele was associ-
ated with a reduced lung cancer risk for all ethnic groups. 
Furthermore, control participants with one or two copies 
of the *G allele demonstrated more efficient DRC, as mea-
sured by the HCR assay, than did control participants with 
the homozygous A genotype. In a study in Korea, Park and 
colleagues (2002) reported that the *G/*G genotype was 
also associated with a significantly decreased lung cancer 
risk when the combined *A/*A and *A/*G genotype was 
used as the reference group. Butkiewicz and colleagues 
(2004) reported similarly increased risks that had border-
line statistical significance for the *A/*A genotype in all 
participants and for SCC and adenocarcinomas. For heavy 
smokers, the risk estimate was 2.52 (95 percent CI, 1.2–
5.4). Popanda and colleagues (2004) reported a nonsignifi-
cant risk of 1.53 for the *A/*A genotype compared with the 
*G/*G genotype. Thus, all studies confirm the protective 
effect of the *G/*G genotype and the enhanced risk for the 
*A/*A genotype. 
Xeroderma Pigmentosum C
XPC is the step-limiting factor in NER. Researchers 
have found two single nucleotide polymorphisms (SNPs) 
in the coding region. ALA499VAL is a single *C/*T nucleo-
tide polymorphism that codes for an amino acid substitu-
tion (Ala/Val) at codon 499. Another SNP, LYS939GLN, is 
a single *A/*C nucleotide polymorphism that codes for an 
amino acid substitution (Lys/Gln) at codon 939. This vari-
ant allele is associated with an increased risk of bladder 
cancer (Sanyal et al. 2004). There is also a bi-allelic poly 
AT insertion/deletion polymorphism (PAT) in intron 9 of 
XPC. The *PAT allele has been associated with risk of head 
and neck cancer (Shen et al. 2001).
Cross-Complementation Group 1  
for Excision Repair 
The XRCC1 gene codes for a 5’ incision subunit of 
the NER complex (Mohrenweiser et al. 1989). The XRCC1 
and XPF proteins form a stable complex in vivo and in 
vitro (de Laat et al. 1999). Although studies have reported 
no defect in the human XRCC1 gene, cells from XRCC1-
deficient mice have an increase in genomic instability and 
a repair-deficient phenotype (Melton et al. 1998). Five 
known polymorphisms of the XRCC1 gene do not cause an 
amino acid change and are validated in the SNP500Can-
cer Database of the National Cancer Institute. How-
ever, researchers think that a polymorphism with A→C 
transversion at nucleotide 8092 in the 3’ untranslated 
region affects mRNA stability (Shen et al. 1998). Studies 
have implicated the XRCC1 polymorphism in the risk of 
adult-onset glioma (Chen et al. 2000) but not in head and 
neck cancer (Sturgis et al. 2002). Zhou and colleagues 
(2005) found no overall effect on lung cancer risk, but 
they did find a lower lung cancer risk in heavy smokers 
and a significantly higher risk in lifetime nonsmokers 
(OR = 2.11; 95 percent CI, 1.03–4.31). 
Xeroderma Pigmentosum  
Complementation Group D
XPD (XRCC2) is one of the seven genetic comple-
mentation groups that encode for proteins in the NER 
pathway. The XPD protein has a role in both NER and 
basal transcription. XPD functions as an evolutionary 
conserved ATP-dependent helicase within the multisub-
unit transcription repair factor complex TFIIH. Of the 
three polymorphisms identified in XPD, two are in exons 
and the third is silent. The G→A transition in exon 10 at 
codon 312 results in an amino acid change (Asp→Asn). 
The transition A→C at codon 751 in exon 23 produces a 
Lys→Gln change. The amino acid substitution Lys751Gln 
in exon 23 does not reside in a known helicase/adenos-
ine triphosphatase domain, but it is an amino acid resi-
due identical in human, mouse, hamster, and fish XPD. 
This finding suggests a functional relevance for such 
a highly evolutionary conserved sequence (Shen et al. 
1998). Goode and colleagues (2002) extensively reviewed 
numerous reports from case-control studies of lung 
cancer that have conflicting results. The largest study 
included 1,092 lung cancer case patients and 1,240 con-
trol participants who were spouses or friends (Zhou et al. 
2002a). The overall AOR was 1.47 (95 percent CI, 1.1–2.0) 
for the ASP312ASN polymorphism (*ASN/*ASN versus 
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*ASP/*ASP), but there was no association for the LYS-
751GLN polymorphism (*GLN/*GLN versus *LYS/*LYS). 
Analyses of the interactions between genes and smoking 
revealed that the adjusted ORs for each of the two polymor-
phisms decreased significantly as pack-years1 increased. 
The interaction between the ASP312ASN polymorphism 
and smoking status was stronger than that between the 
LYS751GLN polymorphism and smoking. The researchers 
concluded that cumulative cigarette smoking modified 
the association between XPD polymorphisms and lung 
cancer risk. Spitz and colleagues (2001) reported AORs 
for the variant LYS751GLN and ASP312ASN genotypes 
of 1.36 and 1.51, respectively, although neither estimate 
was statistically significant. For persons homozygous for 
the variant genotype at either locus, the AOR was 1.84 (95 
percent CI, 1.11–3.04; p = 0.018 for trend).
A recent review and meta-analysis of nine interna-
tional case-control studies that included 2,886 lung can-
cer cases and 3,085 controls for codon 312 (LYS751GLN) 
and 3,374 lung cancer cases and 3,880 controls for codon 
751 (ASP312ASN) did not demonstrate significant associa-
tions with either variant genotype (Benhamou and Sarasin 
2005). However, for U.S. studies alone, both variants were 
associated with a significantly increased risk for lung can-
cer (ORs = 1.43 and 1.25, respectively). Hu and colleagues 
(2004) conducted another meta-analysis. The combined 
case-control studies reported a 21-percent higher risk 
for the 751*C/*C genotype (OR = 1.21; 95 percent CI, 
1.02–1.43) and a 27-percent higher risk for the 
XPD 312*A/*A genotype (OR = 1.27; 95 percent CI, 
1.04–1.56) among cases than among controls. Among 
studies of persons of Asian versus White descent, only 
the studies of Whites found a significantly higher risk for 
the XPD 751*C/*C genotype (OR = 1.23; 95 percent CI, 
1.03–1.47). For the XPD 312*A/*A genotype, the risk 
among Whites compared with other races had border-
line statistical significance (OR = 1.22; 95 percent CI, 
0.99–1.49) among cases compared with controls. TFIIH 
transcriptional activity may be tolerant to amino acid 
changes in the XPD protein, and mutations may destroy 
or alter the repair function without affecting transcrip-
tional activity. As Lunn and colleagues (2000) suggested, 
the effects of the *LYS allele may differ in different repair 
pathways, as assessed by different repair assays. The over-
all effect of conservative mutations in XPD may be subtle, 
because they do not alter XPB and XPD helicase activity, 
and multiple alterations might be needed before any effect 
is noted. 
XPF/ERCC1 Gene Complex
ERCC1 forms a complex with XPF when it makes a 
dual incision at the single-strand to double-strand transi-
tion at the 5’ end of the damaged DNA strand (Shen et 
al. 1998). This complex is required to repair interstrand 
cross-links. A T→C transition at codon 662 results in a 
serine→proline substitution. Fan and colleagues (1999) 
reported six SNPs, five in coding regions. Three of the 
SNPs resulted in nonconserved amino acid differences. 
XPG/ERCC5 Gene Complex
This complex shows homology with yeast RAD2 
and carries out incision at the 3’ end of the lesion in 
the DNA strand (Harada et al. 1995; Hyytinen et al. 
1999). Only two of the seven validated SNPs appear 
with significant frequency. In one polymorphism, a 
single nucleotide substitution (G→C) causes an amino 
acid change (His1104Asp) at codon 1104. In the other 
polymorphism, a C→G substitution produces an amino 
acid change from cysteine to serine at codon 529. San-
yal and colleagues (2004) showed that the variant *C/*C 
genotype was significantly less frequent in cases of blad-
der cancer than in controls. Jeon and colleagues (2003) 
reported similar findings for 310 lung cancer cases, in 
which the frequency of the variant genotype was less than 
that for the other two genotypes combined (AOR = 0.54; 
95 percent CI, 0.37–0.80). This protective effect was at-
tenuated in heavy smokers. Jeon and colleagues (2003) 
pointed out that because this SNP is in the C-terminus, it 
might alter binding to other proteins in the incision com-
plex, thereby affecting DRC. 
RAD23B Gene
The RAD23B gene is an evolutionary, well-conserved 
gene with 10 exons. The protein complexes with XPC to 
bind to different types of lesions and recruit the necessary 
factors for NER. Of the six validated SNPs, four are seen 
with considerable frequency. One of the most frequently 
observed polymorphisms is a substitution (C→T) result-
ing in an amino acid change at codon 249 (Ala249Val). 
Genotype-Phenotype Correlations
Amino acid differences, especially at conserved sites 
in these enzymes, could result in changes in repair profi-
ciency. The next logical step is the challenging task of eval-
uating the functional relevance of these polymorphisms. A 
variety of factors that modulate the path from genotype to 
1Pack-years = the number of years of smoking multiplied by the number of packs of cigarettes smoked per day.
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phenotype include protein-protein interaction, posttrans-
lational modification, gene silencing, epigenetic regula-
tion, and environmental factors. Furthermore, proteins 
involved in DNA repair pathways are often multifunc-
tional, resulting in a variety of phenotypes. 
Both of the common genotypes *LYS/*LYS 751 and 
312 *ASP/*ASP XPD were associated with a DRC more 
efficient than that for heterozygotes and with a signifi-
cantly higher DRC than that for the homozygote mutants 
(Spitz et al. 2001). These results were confirmed in a differ-
ent study population with a different mutagen challenge: a 
UV exposure of 800 joules per square meter that like BPDE 
invoked NER (Qiao et al. 2002b). Additional validation 
came from a correlative study that used the comet assay to 
assess DNA damage and repair (Schabath et al. 2003). These 
data are consistent with some of the published small-scale 
studies of these types of genotype-phenotype correlations. 
Hou and colleagues (2002) noted a significant increase 
in DNA adduct levels, as measured by 32P-postlabeling, 
with an increased number of variant alleles in exon 10 
(p = 0.02) and exon 23 (p = 0.001). In addition, persons 
with the combined exon 10 *A/*A and exon 23 *C/*C 
genotype showed significantly higher levels of adducts 
than those for persons carrying any of the other geno-
types (p = 0.02). Lunn and colleagues (2000) reported that 
possessing the common XPD genotype, *LYS/*LYS 751, 
was associated with an increased risk of suboptimal DRC, 
which was reflected in the number of x-ray–induced lym-
phocyte chromatid aberrations. No association with the 
*ASN312 allele was found.
However, Møller and colleagues (1998) reported no 
relationship between the LYS751GLN polymorphism and 
DRC, as measured by HCR or comet assay in 80 partici-
pants, including 20 healthy persons. Another study with a 
small sample of 76 healthy persons found no association 
between either SCE frequencies or the presence of DNA 
adducts by LYS751GLN genotype (Duell et al. 2000). 
For a complex disease such as cancer, multiple 
genes—each with a small effect—probably act indepen-
dently or interact with other genes to influence the dis-
ease phenotype. Although these data suggest that the 
polymorphisms have a functional relevance, biochemical 
and biologic characterizations of the variants are needed 
to validate these findings. 
Polymorphisms in the Pathway for  
Double-Strand Break Repair 
The XRCC3 gene encodes a protein that acts in 
the pathway for DSB/homologous recombination repair 
(DSB/REC repair) and repairs chromosomal damage such 
as breaks, translocations, and deletions. XRCC3 is a pro-
tein related to RAD51, which is a critical component of 
DSB/REC. Shen and colleagues (1998) identified a C→T 
substitution in exon 7 at position 18067 of XRCC3, a poly-
morphism that results in a threonine→methionine amino 
acid substitution at codon 241. David-Beabes and col-
leagues (2001) found no significant association between 
the XRCC3241 polymorphism and lung cancer. This find-
ing was consistent with a smaller study of NSCLC that 
also found no association after adjustments for age and 
smoking (Butkiewicz et al. 2001). Wang and colleagues 
(2003c) reported an elevated but not statistically signifi-
cant risk of lung cancer associated with polymorphisms 
of the XRCC3 *T allele in African Americans and Mexican 
Americans, which was evident largely in heavy smokers. 
Other studies have associated this XRCC3 polymorphism 
with an increased risk for melanoma skin cancer (Winsey 
et al. 2000) and bladder carcinoma (Matullo et al. 2001a). 
The THR241MET genetic variant may also contribute to 
increases in DNA adducts and bladder cancer risk (Stern 
et al. 2002). 
Summary
The association between common variants in DNA 
repair genes and the risk for tobacco-induced cancers is 
the focus of considerable interest, but the results to date 
are inconsistent. Complementary functional studies are 
likely to be valuable in addressing these inconsistencies. 
Molecular epidemiologists now have better access to high-
throughput genotyping platforms and an enhanced ability 
to focus on analyses based on pathways. Haplotype analy-
ses also increase the power to detect relevant associations. 
In addition, computational algorithms such as PolyPhen 
and Scale-Invariant Feature Transform correlate with risk 
estimates, and new analytic tools are being developed. 
Conversion of DNA Adducts  
to Mutations
DNA replication plays a major role in inducing point 
mutations—substitutions of one base pair for another and 
small mutations due to insertion or deletion of bases. DNA 
adducts per se are not mutations and can be removed by 
various DNA repair mechanisms in cells (Friedberg et al. 
1995). When repair is not completed before a replication 
complex encounters the DNA adducts or other lesions, 
various events are induced, which are sensed by cell-cycle 
checkpoint mechanisms that halt cell-cycle progression 
(Sancar et al. 2004). When the lesion is a strand break, 
replication causes a DSB that is repaired by homologous 
recombination or by the erroneous nonhomologous end-
joining mechanism. When the lesion is an interstrand 
Cancer  269
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease
cross-link, the stall of a replication complex triggers the 
unhooking of the cross-link by endonucleolytic inci-
sions on both sides of the cross-link in one strand. When 
the lesion is a modified base or the loss of a base, a DNA 
polymerase often inserts a nucleotide, either correctly or 
incorrectly, opposite the lesion and extends the DNA 
strand beyond the site. The modification of a template nu-
cleotide generally impairs its ability to serve as a template 
in efficiency and fidelity. Therefore, DNA synthesis slows 
down or is blocked at the site of the adducted template. 
Translesion DNA synthesis occurs when a DNA 
polymerase succeeds in DNA synthesis over the modified 
template. The synthesis reaction sometimes results in the 
insertion of an incorrect nucleotide opposite a lesion. This 
insertion leads to base-substitution mutations, the skip-
ping of the lesion nucleotide template, or the realignment 
of a growing primer strand on the template strand at the 
adducted region, which produces frameshift mutations. 
This step results in the introduction of mutations, and 
the subsequent replication of the mutated strand estab-
lishes the mutation in the genome. This section describes 
the mechanism of mutation induction by translesion 
DNA synthesis.
Molecular Analysis of Conversion to Mutations
The strategy for studying the conversion of adducts 
to mutations is to incorporate a chemically characterized 
DNA adduct or lesion into a specific sequence (Basu and 
Essigmann 1988). A DNA adduct can be incorporated into 
an oligonucleotide sequence by total chemical synthesis. 
However, a modified oligonucleotide may be prepared by 
direct reaction with a mutagen, followed by HPLC and/or 
gel electrophoresis purification. The modified oligonucle-
otide is then used as a substrate for in vitro and in vivo 
studies of translesion DNA synthesis, repair, and struc-
ture. This experimental approach generally demonstrates 
a clear relationship between cause and effect. The advan-
tage of this approach is the ability to analyze in detail 
events in translesion synthesis such as (1) quantification 
of the effects of blocking DNA synthesis, (2) miscoding fre-
quency, and (3) miscoding specificity. 
In vitro studies of translesion synthesis that use 
purified DNA polymerases complement the in vivo studies. 
As described in the following section, cells have various 
types of DNA polymerases and some of them are responsible 
for translesion synthesis. Therefore, the characterization 
of in vitro translesion synthesis could help to identify the 
polymerase responsible for translesion synthesis in cells. 
In vitro studies can be divided into two phases: insertion 
and extension steps. The insertion step determines which 
nucleotide is most efficiently inserted opposite a lesion by 
a given polymerase. The extension step determines which 
nucleotide terminus is most efficiently extended opposite 
a lesion. These experiments characterize the efficiency 
and fidelity of translesion synthesis by a given polymerase. 
The results of the in vitro experiments may be reflected 
in translesion synthesis in cells if the polymerase is 
involved in the synthesis. The involvement of a candidate 
polymerase is examined by studying translesion synthesis 
in a host cell lacking the polymerase of interest. Finally, 
the involvement is confirmed by a complementation 
experiment in mutant cells that express the exogenous 
gene for the polymerase of interest. Thus, translesion syn-
thesis across a given DNA lesion is studied in detail. One 
limitation of this site-specific experiment is the inability 
to study the effects on chromosomal aberrations. In addi-
tion, the results may not apply to other sequence contexts. 
Nevertheless, this approach has provided a tremendous 
amount of information on the mechanism of DNA adduct 
conversion to mutations. 
Translesion Synthesis in Mammalian Cells
DNA polymerases are key players in mutation induc-
tion. They introduce mutations during replication and 
determine the types of mutations generated. Great prog-
ress has been made in DNA polymerase studies in the last 
several years. Many novel DNA polymerases were discov-
ered in prokaryotes and eukaryotes (Hübscher et al. 2002). 
These DNA polymerases play important roles in various 
aspects of DNA metabolism. The Y family polymerases 
(Ohmori et al. 2001) include eukaryotic polh, polk, and 
polτ, as well as REV1 and E. coli polIV and polV. In addi-
tion, polz is a member of the B family. Researchers think 
these Y family polymerases are specialized for translesion 
synthesis (Prakash and Prakash 2002). These discoveries 
have led to the general idea that these polymerases are 
responsible for overcoming the blocking effects of DNA 
adducts and constitute an important mechanism for tol-
erating unrepaired DNA lesions. 
The role of the polh polymerase is most clearly 
understood. This polymerase is coded by the XPV gene, 
which is defective in persons with XP variant cells (John-
son et al. 1999; Masutani et al. 1999). Although these cells 
possess NER capability, they carry a predisposition to skin 
cancer on exposure to sunlight. The discovery that polh 
is able to bypass the cis-syn thymine-thymine dimer effi-
ciently and accurately (Masutani et al. 1999) indicates that 
this polymerase plays a very important role in protection 
from the deleterious effects of unrepaired UV photoprod-
ucts. In its absence, the unrepaired lesions are bypassed by 
one or more other polymerases in an error-prone manner 
leading to skin cancer (Gibbs et al. 1998, 2000). X-ray crys-
tallographic studies reveal that Y family polymerases have 
loose catalytic pockets enabling them to accommodate 
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Table 5.7 Translesion-specialized DNA polymerases (pol) and activities on various DNA lesions
DNA adduct polh polk polz polh + polz poli + polz pold + polz REV1 + polz
cis-syn TT + (a) – (b) – (c)    – (c)      
(6-4) TT – (a) – (b) – (c) + (d) + (c)      
Abasic site + (a) + (b) – (c) + (e) + (c) + (f) + (f)
Acetylaminofluorene  
C8-dG adduct
+ (a) + (b)               
Cisplatin intrastrand  
dG-dG adduct
+ (a) – (b)               
1,N6- 
ethenodeoxyadenosine
+ (g) + (g)               
8-oxodeoxyguanosine + (h) + (i)               
(+) BPDE-N2-dG + (j) + (i)               
(–) BPDE-N2-dG    + (i)               
Note: (a) Masutani et al. 2000; (b) Ohashi et al. 2000; (c) Johnson et al. 2000; (d) Johnson et al. 2001b; (e) Yuan et al. 2000;  
(f) Haracska et al. 2001; (g) Levine et al. 2001; (h) Haracska et al. 2000; (i) Zhang et al. 2000a; (j) Zhang et al. 2000b. 
BPDE-N2-dG = trans-anti-benzo[a]pyrene-N2-deoxyguanosine; dG = deoxyguanosine; TT = thymine-thymine dimer.
Figure 5.9 Model of mechanism for mammalian translesion synthesis
Note: Replicative polymerase d encounters DNA lesion (open circle) in template, progression of DNA synthesis is blocked, and d 
temporarily disengages. Y family polymerases (h, k, i, and REV1) are recruited to the sites, and 1 or more polymerases catalyze the 
insertion of a nucleotide opposite a lesion and the extension from the newly generated terminus. With some DNA lesions, the Y family 
polymerases can insert a nucleotide (N), but further extension is inhibited. Then, the second translesion polymerase, z, catalyzes the 
extension step. After translesion synthesis, d resumes replication.
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unusual base pairs (Trincao et al. 2001). This structural 
feature could explain the low fidelity of DNA synthesis on 
a normal DNA template. 
In vitro experiments on translesion synthesis using 
purified polymerases reveal that each polymerase cata-
lyzes bypass synthesis across various lesions with a differ-
ent efficiency and fidelity (Table 5.7). The current model 
of the mechanism for mammalian translesion synthesis 
is illustrated in Figure 5.9. When a replicative DNA poly-
merase is inhibited by a lesion, translesion synthesis can 
be completed by the action of one polymerase or by the 
cooperation of two polymerases (Prakash and Prakash 
2002). Among these polymerases, polz is unique because it 
has low ability to insert a nucleotide opposite a lesion but 
is efficient at extending from unmatched terminal pairs 
(Johnson et al. 2000). Therefore, researchers think that 
this polymerase plays a role mainly in extending from a 
terminus opposite a lesion where another polymerase has 
inserted a nucleotide and the further extension is blocked. 
Factors in Outcome of Translesion Synthesis
Many studies reveal that the efficiency and fidelity 
of translesion synthesis depend on the host (Moriya et al. 
1994, 1996). Some DNA adducts miscode in one host (hu-
man cells) but not in another (E. coli), and the reverse also 
occurs (Moriya et al. 1994; Pandya and Moriya 1996). This 
finding underscores the importance of evaluating transle-
sion events in the appropriate host: human cells. The dis-
crepancy most likely reflects the difference in the activity 
of the translesion polymerases involved.
Sequence context also plays an important role in 
determining the outcome of translesion synthesis. Gen-
erally, a DNA adduct in iterated sequences, such as 
monotonous repeats (e.g., GGGGG) and dinucleotide re-
peats (e.g., GCGCGC), tends to cause frameshift mutations 
because these sequences misalign easily (Benamira et al. 
1992). However, the same adduct induces base-substitu-
tion mutations in a different sequence context (Moriya et 
Table 5.8 Mutational specificity of selected DNA adducts derived from tobacco smoke
Study DNA adduct Mutation specificity
Loechler et al. 1984
Dosanjh et al. 1991
Pauly and Moschel 2001
O6-methyldeoxyguanosine G→A
Pauly et al. 2002 O6-[4-oxo-4-(3-pyridyl)butyl]-deoxyguanosine G→A
Dosanjh et al. 1991
Pauly and Moschel 2001
O4-methylthymidine T→C
Wood et al. 1990
Moriya 1993
8-oxodeoxyguanosine G→T
Kanuri et al. 2002
Yang et al. 2002
1,N2-propanodeoxyguanosine from acrolein G→T
Moriya et al. 1994 3,N4-ethenodeoxycytidine C→A, T
Pandya and Moriya 1996 1,N6-ethenodeoxyadenosine A→G, T
Lawrence et al. 1990
Cabral Neto et al. 1994
Gibbs and Lawrence 1995
Apurinic/apyrimidinic sites AP→T, A, G
Moriya et al. 1996
Page et al. 1998
Benzo[a]pyrene-7,8-diol-9,10-epoxide-N2-deoxyguanosine G→T, A, C
Page et al. 1999 Benzo[a]pyrene-7,8-diol-9,10-epoxide-N6-deoxyadenosine A→T
Verghis et al. 1997 4-aminobiphenyl-C8-deoxyguanosine G→C
Surgeon General’s Report
272 Chapter 5
al. 1994). Sequence context influences base-substitution 
events (Moriya et al. 1996; Page et al. 1998) and trans-
lesion efficiency (Latham et al. 1993) (see “Benzo[a]
pyrene-7,8-Diol-9,10-Epoxide-N2-Deoxyguanosine stereo-
isomers” later in this chapter).
Thus, translesion events are determined by the 
interplay between a DNA adduct, its sequence environ-
ment, and the DNA polymerase involved. This finding 
underscores the importance of conducting experiments 
with use of a proper sequence context and host. 
Conversion of Cigarette-Smoke-Induced  
DNA Adducts to Mutations
Conversion of DNA adducts induced by cigarette 
smoke to mutations is summarized in Table 5.8. The dis-
cussion that follows provides additional details.
O6-Pyridyloxobutyl-Deoxyguanosine
O6-POB-deoxyguanosine is formed by a pyridyloxo-
butylating metabolite of the tobacco-specific N-nitrosa-
mines NNK and NNN and is removed by AGT. Therefore, 
in the presence of this repair enzyme, the adduct induced 
only a moderate miscoding frequency. The resulting 
mutations were G→A transitions. In the absence of AGT, 
the miscoding frequency markedly increased to more than 
90 percent (Pauly et al. 2002). The results were similar in 
E. coli and human cells. These results indicate that the 
frequency of miscoding for this adduct is high. The DNA 
polymerase involved almost exclusively inserts deoxythy-
midine monophosphate opposite the adduct, leading to 
G→A transitions. Thus, repair by the alkyltransferase is 
extremely critical to the avoidance of mutation induction 
by this adduct. The biologic characteristics of this adduct 
are similar to those of O6-methyldeoxyguanosine (Pauly 
and Moschel 2001). The DNA polymerase that catalyzes 
the translesion synthesis and the bypass efficiency of this 
synthesis remain to be determined. 
O6-Methyldeoxyguanosine  
and O4-Methylthymidine
The O6-methyldeoxyguanosine and O4-methyl-
thymidine adducts induce mutations by stable pairing 
to thymidine (Dosanjh et al. 1993) and deoxyguanosine 
(Toorchen and Topal 1983), respectively. Accordingly, 
their miscoding potentials are high (Dosanjh et al. 1991; 
Pauly and Moschel 2001) and are similar to those of O6-
POB-deoxyguanosine. MMR acts on base pairs containing 
O6-methyldeoxyguanosine after replication (Branch et al. 
1993) and leads to cell death as a result of a futile MMR. 
Therefore, MMR mutants are more resistant to methyl-
ating agents (Branch et al. 1993) and are more prone to 
mutation after exposure to these agents (Pauly and Mos-
chel 2001).
8-Oxodeoxyguanosine
8-oxodeoxyguanosine is a representative adduct 
formed by oxidative damage to DNA, and researchers have 
extensively studied its mutagenic properties and repair 
mechanisms (Grollman and Moriya 1993). The miscod-
ing property of this adduct derives from its propensity to 
assume a syn conformation and to pair easily with deoxy-
adenosine (anti), which leads to G→T transversions. To 
avoid this mutation induction, cells have developed an 
elaborate postreplication BER mechanism that specifi-
cally removes misinserted deoxyadenosine by the action 
of the DNA glycosylase, adenine-DNA-glycosylase (Parker 
and Eshleman 2003). Subsequently, when deoxycytidine 
monophosphat) is inserted opposite the adduct, 8-oxo-
deoxyguanosine is removed by another BER initiated by 
OGG1, and a G:C pair is restored. 
This adduct is also formed in the nucleotide pool. 
When 8-oxodeoxyguanosine-triphosphate is inserted 
opposite a deoxyadenosine template, the misinsertion 
leads to an A→C transition. To avoid this event, the cellu-
lar enzyme MTH1 converts 8-oxodeoxyguanosine triphos-
phate to 8-oxodeoxyguanosine monophosphate, which is 
no longer a substrate for DNA synthesis. Thus, cells have 
developed several layers of defense mechanisms against 
8-oxodeoxyguanosine. Therefore, the apparent frequency 
of mutation induction by this adduct is low in normal 
cells. However, when MYH is inactivated, the frequency 
of G→T transversions increases drastically (Moriya and 
Grollman 1993; Hashimoto and Moriya, unpublished data) 
and mutations in this gene lead to a high incidence of 
spontaneous human colon cancer (Al-Tassan et al. 2002). 
1,N2-Propanodeoxyguanosine
Various unsaturated α,β-aldehydes, such as acrolein 
and crotonaldehyde, produce the DNA adduct PdG. Ac-
rolein produces two positional isomers: 8-(g-) and 6-(α-) 
xy hydroxyl PdG. When positioned in double-stranded 
DNA, the α adduct is more genotoxic than the g adduct. 
The α adduct has significantly more blocking effects, and 
the g adduct, but not the α adduct, miscodes with G→T 
transversions at a frequency of approximately 10 percent 
(Yang et al. 2002). Most of the miscoding events were 
induced by polh (Yang et al. 2003). Structural studies 
reveal that the exocyclic ring of the g adduct, but not the 
α adduct, opens in a manner similar to that of the malo-
ndialdehyde-induced deoxyguanosine adduct (Mao et al. 
1999) when paired to deoxycytidine (de los Santos et al. 
2001). This finding may account for the weaker blocking 
effect and the lack of miscoding, because the ring-opened 
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g adduct pairs nicely to deoxycytidine with the Watson-
Crick type of (anti-anti) conformation. When the g 
adduct is inserted in single-stranded DNA and replicates 
in mammalian cells, the resulting structure miscodes by 
inducing G→T transversions (Kanuri et al. 2002). In addi-
tion, the ring-opened deoxyguanosine adduct forms inter-
strand G-G cross-links in the sequence 5’CpG (Kozekov et 
al. 2003), which may also contribute to the genotoxicity 
of acrolein. 
Exocyclic Etheno Adducts
Although the etheno adduct 1,N6-ethenodeoxy-
adenosine miscodes efficiently in simian kidney cells, it 
does not miscode in E. coli (Pandya and Moriya 1996). This 
finding emphasizes the importance of the host. The find-
ing is probably attributable to the difference in the fidelity 
of the DNA polymerase involved in translesion synthesis. 
The etheno adduct 3,N4-ethenodeoxycytidine miscodes 
efficiently in both hosts (Moriya et al. 1994).
Apurinic/Apyrimidinic Sites
AP sites are generated by the cleavage of a glyco-
sidic bond between a base and a sugar in DNA for various 
reasons such as (1) the action of a DNA glycosylase and 
(2) modifications to a base that destabilize the glycosidic 
bond. These sites do not convey any coding information. 
Deoxyadenosine is often inserted opposite these sites in 
E. coli (Lawrence et al. 1990), which is known as “the A 
rule” (Strauss 1991). However, this rule does not appear 
to be applicable in mammalian cells: various bases are 
inserted opposite these sites in those cells (Cabral Neto et 
al. 1994; Gibbs and Lawrence 1995).
Benzo[a]pyrene-7,8-Diol-9,10-Epoxide-N2-
Deoxyguanosine Stereoisomers
Studies have extensively characterized the geno-
toxicity of different stereoisomers of BPDE-N2-deoxy-
guanosine (Moriya et al. 1996; Fernandes et al. 1998). 
A prominent feature is that both the surrounding DNA 
sequence and the host markedly influence miscoding fre-
quency (Moriya et al. 1996; Fernandes et al. 1998; Page et 
al. 1998) and miscoding specificity (Kozack et al. 2000). 
The major adduct, (+)-BPDE-N2-deoxyguanosine, induces 
mainly G→T and G→A transversions in 5’-TGC and 
5’-AGA sequence contexts, respectively, which research-
ers hypothesize is attributable to differences in adduct 
conformations in different sequence contexts (Kozack et 
al. 2000). The deoxyadenosine adduct (BPDE-N6-deoxy-
adenosine) also miscodes with A→T transversions (Page 
et al. 1999).
4-Aminobiphenyl-C8-Deoxyguanosine
The adduct 4-ABP-C8-deoxyguanosine barely mis-
codes in E. coli by inducing G→C transversions (Verghis 
et al. 1997). Because researchers observed G→T, G→A, 
and G→C mutations in an experiment that used a ran-
domly modified single-strand DNA (Verghis et al. 1997), 
the possibilities of the effects from the sequence context 
and the involvement of other deoxyguanosine adducts, 
such as those at N2, remain to be explored. Furthermore, 
it appears that a 4-ABP-deoxyadenosine adduct induces 
A→T transversions (Lasko et al. 1988; Hatcher and Swam-
inathan 1995). 
Assessment of Genotoxicity of DNA Adducts
Genotoxic properties of a DNA lesion can be char-
acterized by using chemically defined substrates. The 
genotoxicity of a DNA lesion is determined by factors 
such as the efficiency and fidelity of translesion synthesis 
and repair. For point mutations, however, the “genotoxic 
potency” of a DNA adduct can be determined by assessing 
the bypass efficiency and the miscoding potency. Accord-
ing to this formula, a DNA lesion that is easily bypassed 
with a high frequency of miscoding events is defined as 
a highly genotoxic DNA adduct. Furthermore, when the 
genotoxicity of a DNA lesion is assessed, the information 
on its abundance in the genome, which reflects the bal-
ance between formation and removal, should also be con-
sidered. Therefore, conceptually, the total genotoxicity of 
a DNA adduct could be estimated by determining its geno-
toxic potency and its abundance in DNA. 
According to these criteria, the genotoxicity of the 
8-oxodeoxyguanosine adduct, which is a unique case, 
would be high because it exists in high levels in genomic 
DNA and is easily bypassed by a DNA polymerase with a 
high miscoding frequency. However, the apparent geno-
toxicity is low because of the postreplication repair that 
is catalyzed by MYH. Therefore, when the postreplication 
repair is inactivated, this adduct can become a significant 
genotoxic adduct (Al-Tassan et al. 2002).
Data for the genotoxic effects of DNA lesions derived 
from tobacco smoke are scarce, and a systematic study 
is needed. Together with information on the abundance 
of each lesion, the genotoxicity of tobacco-related DNA 
adducts might be ranked by using site-specific modified 
plasmids, introducing them with the use of host cells, and 
subsequently recovering them for sequence analysis. 
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Gene Mutations in Tobacco-Induced Cancer
Chromosome Instability and Loss
Lung Cancer
The detection of numerous cytogenetic changes 
provided the first link to the molecular pathogenesis of 
lung cancer. Mapping chromosomal sites for rearrange-
ment, breakpoints, and losses revealed both common 
and distinct changes in both SCLC and NSCLC. In SCLC, 
breakpoints are commonly seen in chromosomes 1, 3, 5, 
and 17, although researchers have observed losses of the 
short arm (p) of chromosomes 3 and 17 and of the long 
arm (q) of chromosome 5 (Balsara and Testa 2002). Sub-
sequent studies using comparative genomic hybridization 
showed that deletions on chromosomes 3p, 4q, 5q, 10q, 
13q, and 17p were common in SCLC (Petersen et al. 1997). 
In NSCLC, multiple numeric and structural changes were 
seen across many chromosomes. The most frequent sites 
(60 to 80 percent) for chromosome loss were found on 
chromosomes 3p, 6q, 8p, 9p, 9q, 17p, 18q, 19p, 21q, and 
22q (Balsara and Testa 2002). Some of the most common 
sites for chromosome loss included 3p, 9p, 13q, and 17p. 
These sites were also detected in nonmalignant bron-
chial epithelium of current and former smokers and were 
absent in lifetime nonsmokers (Mao et al. 1997; Witsuba et 
al. 1997). These findings strongly link tobacco exposure to 
the development of chromosome damage throughout the 
aerodigestive tract.
Identification of Tumor-Suppressor Genes
The commonality for specific regions in the genome 
to lose alleles suggested the presence of tumor-suppres-
sor genes within these loci. The RB gene was the first 
tumor-suppressor gene linked to lung cancer (Harbour et 
al. 1988). A loss of function of this gene through either 
deletion or point mutation occurs in 90 percent of SCLCs, 
whereas few NSCLCs harbor changes in this tumor- 
suppressor gene (Table 5.9) (Shimizu et al. 1994). The 
most frequently inactivated tumor-suppressor gene in 
lung cancer is TP53. TP53 mutations are found in 70 
percent of SCLCs, 65 percent of SCCs, and 33 percent of 
adenocarcinomas (Greenblatt et al. 1994). (For discus-
sion of specific mutations and their potential relation-
ship to carcinogens in cigarette smoke, see “Relationship 
of TP53 Mutations to Smoking and Carcinogens” later in 
this chapter.)
A frequent deletion within chromosome 3p14 led 
to the identification of the FHIT gene (Zabarovsky et 
al. 2002). The most common fragile site of the human 
genome FRA3B maps in the FHIT gene and may contribute 
to the susceptibility of this locus to gene rearrangement 
induced by carcinogens in cigarette smoke. Researchers 
have observed a loss of the FHIT protein in 50 percent of 
lung cancers, but somatic mutations are uncommon in 
the FHIT gene. The epigenetic inactivation by methyla-
tion of the 5’CpG island located in the promoter region 
of FHIT represents another mechanism for inactivating 
this gene in lung cancer (see “Gene Promoter Hypermeth-
ylation in Cancer Induced by Tobacco Smoke” later in 
this chapter).
The importance of the inactivation of tumor-
suppressor genes FHIT, RB, and TP53 in lung cancer is 
evident from their functions. The binding of hypophos-
phorylated RB to cyclin-dependent kinase (CDK) 4 or 6 
blocks transit of the RB protein through the G1/S bound-
ary of the cell cycle. Inactivating mutations result in the 
loss of a functional hypophosphorylated protein associ-
ated with a shortening of the G1 phase of the cell cycle 
and the enhancement of cell proliferation, a hallmark of 
the cancer cell (Nevins 1992). The TP53 gene is central to 
several critical processes needed to control the response 
of the cell to exogenous stress from exposure to ciga-
rette smoke. This gene functions as a transcription factor 
within several pathways and as a sensor of DNA damage 
(Robles et al. 2002). Thus, the TP53 gene has an important 
role in cell-cycle checkpoints, DNA repair, apoptosis, and 
senescence. A loss of TP53 function is also an early event 
Table 5.9 Frequency of mutation or deletion of 
tumor-suppressor genes in lung cancer









RB 13q14 90 15
TP53 17p13 70 50
CHFR 12q24 ND 6
MYO18B 22q12 ND 13
PTEN 10q23 9 17
LKB1/STK11 19p13 ND 35
Note: ND = not determined.
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in the genesis of SCC that occurs in bronchial dysplasia 
(Sozzi et al. 1992; Bennett et al. 1993). Studies have also 
detected TP53 mutations in peripheral lung tissue from 
patients with lung cancer, a finding that supports a role 
for this gene in the early development of adenocarcinomas 
(Hussain et al. 2001). The FHIT gene induces apoptosis 
mediated by CASPASE-8 and independent of mitochon-
drial mediators and inhibits cell growth through interac-
tions with the SRC protein kinase (Pekarsky et al. 2004; 
Roz et al. 2004). A loss of function of the FHIT, RB, and 
TP53, genes leads to the immortalization of bronchial 
epithelial cells, a key step in neoplastic transformation 
(Reddel et al. 1988) (see “Signal Transduction” later in 
this chapter). 
Tumor-Suppressor Genes  
Inactivated in Lung Cancer
The search for tumor-suppressor genes inactivated 
through the two-hit mechanism of the loss of one allele 
and the mutation of the remaining allele has not recently 
identified any genes with a frequency of inactivation 
approaching that seen for the RB and TP53 genes. The 
discussion that follows describes the involvement of sev-
eral genes and their functions in subsets of lung cancer 
(Table 5.9). The mitotic checkpoint gene CHFR, which 
functions in early prophase to regulate chromosome 
condensation, was mutated in 3 of 53 lung carcino-
mas (Mariatos et al. 2003). Studies found three somatic 
mutations in the proapoptotic gene CASPASE-8 in 2 of 30 
lung tumors (Hosomi et al. 2003). MYO18B is a candidate 
tumor-suppressor gene at chromosome 22q12. Of 46 pri-
mary NSCLCs, 6 contained somatic mutations within this 
gene. Restoring MYO18B function in cell lines inhibited 
anchorage-independent growth, thus supporting its func-
tion as a tumor-suppressor gene in lung cancer (Nishioka 
et al. 2002).
The PTEN gene is located on chromosome 10. Its 
gene product is phosphatidylinositol 3’-phosphatase, a 
protein tyrosine phosphatase that uses the phosphoinosit-
ide second messenger, phosphatidylinositol 3,4,5-triphos-
phate (PIP3), as a physiological substrate (Maehama et al. 
2001). Researchers have identified point mutations of the 
PTEN gene in cell lines from 3 of 35 SCLCs and 3 of 18 
NSCLCs; there were two homozygous deletions in primary 
SCLCs (Forgacs et al. 1998). Mutations that impair PTEN 
function result in a marked increase in PIP3 levels and in 
the constitutive activation of AKT survival, thus signaling 
pathways that in turn promote hyperplasia and tumor for-
mation. Thus, although it is not common in lung cancer, 
a PTEN mutation or deletion profoundly affects an impor-
tant signaling pathway in the cell. 
Two additional genes with poorly characterized 
functions and localized to chromosome 3p are altered 
in lung cancer through deletion or mutation. A specific 
ATG→AGG mutation in codon 50 of the ARP gene was 
seen in 8 of 20 lung cancers. In addition, researchers 
observed either exon deletion or intron insertion in the 
DLC1 gene in 11 of 30 NSCLCs (Zabarovsky et al. 2002). 
Frequent deletion involving the short arm of chromosome 
19 occurs in lung adenocarcinomas (Sanchez-Cespedes 
et al. 2001). One gene mapped to this chromosome 
region is STK11, in which germline mutations are causal 
for Peutz-Jeghers syndrome. This syndrome is character-
ized by a series of anomalies and increased risk for gas-
trointestinal and extraintestinal malignancies (Giardiello 
et al. 1987). Inactivating mutations and/or deletion of the 
LKB1/STK11 protein were described in about one-third of 
primary adenocarcinomas (Sanchez-Cespedes et al. 2002; 
Ji et al. 2007), and these abnormalities were closely asso-
ciated with mutation of the KRAS oncogene in the same 
tumors (Ji et al. 2007; Matsumoto et al. 2007). The STK11 
gene may function as a growth-inhibiting gene that is 
activated through phosphorylation by the ATM gene, 
which senses DNA damage (Sapkota et al. 2002), and acts 
through pathways dependent or independent of the P53 
protein to suppress invasion and metastasis (Karuman et 
al. 2001; Upadhyay et al. 2006; Ji et al. 2007). In addition 
to inactivating by mutation, epigenetic silencing by pro-
moter hypermethylation has emerged as a major mecha-
nism for inactivating many genes in lung cancer, some of 
which are described here (e.g., MYO18B). (For a detailed 
discussion, see “Gene Promoter Hypermethylation in 
Cancer Induced by Tobacco Smoke” later in this chapter.)
Activation of Oncogenes in Lung Cancer
Oncogenes encode proteins that influence cell 
cycling and promote cancer. They are usually “gain-of-
function” mutations of normal genes. Researchers see 
KRAS gene mutations in approximately 30 to 40 percent 
of adenocarcinomas but rarely in SCCs, SCLCs, or lung 
tumors from nonsmokers (Slebos et al. 1990; Westra et 
al. 1996; Ahrendt et al. 2003). Mutations are localized to 
codons 12, 13, and 61. More than 85 percent occur within 
codon 12. Nearly 70 percent of the mutations are G→T 
transversions within codon 12 that change a glycine 
codon (GGT) to valine (GTT) or cysteine (TGT). Mouse 
lung tumors induced by B[a]P and other PAHs show exclu-
sively G→T transversions in codon 12 of the Kras gene. 
These findings support the hypothesis that activation of 
this oncogene in lung tumors results from DNA damage 
leading to base mispairing of these deoxyguanosines. In 
vitro studies have demonstrated that DNA adducts formed 
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from the metabolism of B[a]P, NNK, and reactive oxygen 
species can all lead to G→T transversions (Table 5.8) (You 
et al. 1989; Belinsky et al. 1992). Thus, the activation of 
carcinogens in tobacco smoke and the pulmonary inflam-
mation that ensues from exposure to particulate matter 
together can lead to activation of the KRAS oncogene. 
Studies detected KRAS gene mutations in 39 percent 
of atypical alveolar hyperplasia, a putative precursor to 
adenocarcinoma (Slebos et al. 1996). A similarity in the 
percentage of precursor lesions and tumors containing 
KRAS mutations supports the importance of this gene in 
tumor progression in a subset of adenocarcinomas. 
The sequence of events leading to activation of the 
RAS signal transduction pathway is well characterized 
(Lechner and Fugaro 2000). When the RAS protein is 
activated through mutations in codon 12, 13, or 61, it 
binds irreversibly to guanosine triphosphate (GTP) in 
the cell, which initiates a cascade of protein activations, 
beginning with v-raf-murine leukemia viral oncogene 1 
(RAF-1), that transmits a signal from the cell membrane 
to the nuclear transcription machinery. Ultimately, these 
signals culminate in the activation of transcription factors 
including MYC, FOS, and JUN, which in turn influence 
many cellular activities such as transcription, translation, 
cytoskeletal organization, and cell-cell interactions. This 
signal remains active until GTPase (guanosine triphos-
phatase) dephosphorylates GTP to guanosine diphosphate. 
Thus, a RAS oncogene mutation leads to the disruption of 
many cellular pathways and provides a strong oncogenic 
signal for neoplastic transformation (see “Signal Trans-
duction” later in this chapter).
The MYC family of genes (C-MYC, N-MYC, and 
L-MYC) plays a prominent role in the growth of the 
developing and mature adult lung. Extensive studies have 
evaluated the expression and amplification of these genes 
in NSCLC and SCLC (Jänne and Johnson 2000). Most 
lung cancers express one or more of the MYC family of 
genes, whereas gene amplification is seen in a minority 
of primary tumors (Table 5.10). Gene rearrangements 
involving different exons are associated with amplifica-
tion detected in cell lines but are uncommon in primary 
tumors (Kinzler et al. 1986; Mäkelä et al. 1991; Sekido 
et al. 1992). Mechanisms responsible for the increased 
expression of the MYC genes in the absence of gene am-
plification are not well understood. Increased expression 
could occur through increased activity in the RAS signal-
ing pathway through either KRAS oncogene mutations or 
effects on the activity of genes in this pathway, such as the 
activity of mitogen-activated protein kinase (MAPK) (Jull 
et al. 2001).
Increased gene expression is common in lung can-
cer but often is not associated with gene amplification. 
Two genes studied extensively are EGFR and NEU (HER-2/
NEU [ERBB2]). EGFR is the receptor for the epidermal 
Table 5.10 Frequency of gene amplification and increased expression of genes in lung cancer
      Frequency (%)
Gene Tumor histology Amplification Expression
C-MYC Small-cell lung cancer 5 25
N-MYC Small-cell lung cancer 7 3
L-MYC Small-cell lung cancer 12 33
EGFR Small-cell lung cancer 0 0
HER-2/NEU Small-cell lung cancer <1 0–7
C-MYC Non-small-cell lung cancer 8 33
N-MYC Non-small-cell lung cancer 0 ND
L- MYC Non-small-cell lung cancer 3 ND
EGFR Non-small-cell lung cancer 9–25 34–62
HER-2/NEU Non-small-cell lung cancer 2–4 23–58
Note: ND = not determined.
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growth factor and the HER-2/NEU protein, and the bind-
ing of these growth factors to this receptor is associated 
with increased DNA synthesis, cell proliferation, and dif-
ferentiation. An increased expression of the EGFR gene 
was not seen in SCLCs but occurred in 34 to 62 percent 
of NSCLCs (Hirsch et al. 2003b; Suzuki et al. 2005). In 
addition, an increased expression of this gene was more 
common in SCC than in adenocarcinoma—82 versus 44 
percent (Hirsch et al. 2003b). In contrast, gene amplifica-
tion was detected in 9 to 25 percent of tumors (Hirsch 
et al. 2003b; Suzuki et al. 2005). Expression of the HER- 
2/NEU gene was seen in 23 to 58 percent of NSCLCs and 
in 0 to 7 percent of SCLCs (Shi et al. 1992; Junker et al. 
2005; Pelosi et al. 2005). Similar to EGFR, HER-2/NEU 
was more commonly expressed in SCC than in adenocar-
cinoma, and gene amplification was rare in all tumors 
(<5 percent).
Observation of EGFR expression in 34 to 62 percent 
of NSCLCs led to the development of small molecule 
inhibitors of the tyrosine kinase domain of the wild-type 
EGFR protein (Fukuoka et al. 2003; Herbst and Bunn 2003; 
Lynch et al. 2004; Amann et al. 2005; Baselga and Arteaga 
2005). The clinical response of approximately 10 percent 
of European patients and 30 percent of patients from 
Japan to treatment with the EGFR inhibitors gefitinib or 
erlotinib led to a search for the mechanism responsible 
(Kris et al. 2003; Pérez-Soler et al. 2004). The outcome of 
these studies was the identification of somatic mutations 
in the tyrosine kinase domain of the EGFR gene in most 
patients who had demonstrated a clinical response to the 
drugs (Lynch et al. 2004; Amann et al. 2005). In addition, 
recent studies suggest that the EGFR copy number and 
KRAS mutation may also be involved in determining a 
response to gefitinib and erlotinib. Subsequent studies 
have sequenced the EGFR gene in thousands of NSCLCs 
from patients in Asia, Europe, and the United States. These 
studies found that most mutations were due to either a 
deletion involving exon 19 or a missense mutation in exon 
21. In addition, mutations were two to three times more 
likely in women than in men and three to five times more 
likely in nonsmokers than in current or former smok-
ers (Johnson and Jänne 2005). Finally, the prevalence of 
mutations was 10 percent in tumors of patients from 
Europe and the United States compared with 30 percent 
in tumors from persons of Asian background residing in 
Japan and Taiwan. 
The BRAF gene encodes a RAS-regulated kinase that 
can mediate cell growth. BRAF mutations were found in 
5 of 179 NSCLCs and are almost exclusively confined to 
adenocarcinomas (Brose et al. 2002; Naoki et al. 2002). 
Although the mutation is relatively uncommon in lung 
cancer, its location in either exon 11 or exon 15 altered the 
phosphorylation of BRAF by AKT (Guan et al. 2000). The 
disruption of AKT-induced BRAF inhibition could contrib-
ute to malignant transformation. 
Oncogene Activation, Tumor-Suppressor Gene 
Inactivation, and Lung Cancer Survival
Researchers have studied the prognostic impact of 
commonly altered genes in lung cancer. The effect of an 
activated KRAS oncogene on survival was assessed in 69 
patients, including 48 with stage I adenocarcinoma that 
was completely resected (Slebos et al. 1990). Twelve of 19 
patients with a KRAS mutation died within the follow-
up period (median, 47 months) compared with 22 of 50 
patients with a tumor negative for the KRAS oncogene. 
This significant difference in survival was observed even 
though patients with a KRAS mutation had a less advanced 
disease than those with no mutation. All seven patients 
with stage III disease were negative for mutations. Rosell 
and colleagues (1993) conducted a similar study of largely 
stage I resected adenocarcinomas that again revealed a 
reduced survival rate independent of lymph node status 
for patients whose tumor contained a mutated KRAS 
gene. In contrast, a larger study of 127 adenocarcinomas 
found no difference in survival by KRAS mutation status 
(Keohavong et al. 1996). Overall, data are conflicting with 
respect to KRAS mutations as prognostic factors and fur-
ther research is needed (Aviel-Ronen et al. 2006).
Studies have examined the effect of TP53 gene 
mutations on prognosis in both early- and late-stage lung 
cancers. After four years of follow-up, the hazard ratio for 
106 patients with stage I resected NSCLC with a TP53 
mutation was 2.8 for death, compared with patients who 
had a wild-type gene (Ahrendt et al. 2003). Four years 
after surgery, 78 percent of patients with no TP53 muta-
tion and 52 percent with a TP53 mutation were alive. A 
previous study by Tomizawa and colleagues (1999) found 
a similar survival benefit for patients with stage I NSCLC 
and no TP53 mutations, which also confer a poor clinical 
outcome for those with advanced NSCLC. Independent of 
chemotherapy or supportive care, median survival dura-
tion for patients with stage III or IV NSCLC with or with-
out a TP53 mutation was 17 versus 39 weeks, respectively 
(Murakami et al. 2000). Recently, a study of 420 patients 
with primary head and neck cancer (Poeta et al. 2007) 
showed that disruptive TP53 mutations in tumor DNA are 
associated with reduced survival after surgical treatment 
of SCC of the head and neck (hazard ratio, 1.7; 95 percent 
CI, 1.2–2.4; p = 0.003). 
Together, it is apparent that the inactivation of the 
TP53 tumor-suppressor gene and the activation of the 
KRAS oncogene in NSCLCs and other tumors are cor-
related with exposure to cigarette smoke and contribute 
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to a phenotype that reduces survival in both early and 
advanced stages of the disease.
Relationship of TP53 Mutations  
to Smoking and Carcinogens
TP53 Mutations in Smoking-Associated  
Lung Cancers
TP53 gene mutations are found in approximately 40 
percent of human lung cancers; TP53 is the most com-
monly mutated tumor-suppressor gene in lung cancer 
(see “Identification of Tumor-Suppressor Genes” earlier in 
this chapter). These mutations are generally more com-
mon in smokers than in nonsmokers (Greenblatt et al. 
1994; Hernandez-Boussard and Hainaut 1998; Pfeifer et 
al. 2002). One study shows that the relative risk of having 
a TP53 mutation in lung cancer was up to 13 times higher 
in lifetime heavy smokers than in lifetime nonsmokers 
(Le Calvez et al. 2005). G→T transversions are commonly 
observed in smoking-associated lung cancers (Greenblatt 
et al. 1994; Hainaut and Hollstein 2000; Hainaut and 
Pfeifer 2001). The frequency of G→T transversions in lung 
cancers from smokers is higher than that for lung cancers 
and most other cancers in nonsmokers (Greenblatt et al. 
1994; Husgafvel-Pursiainen and Kannio 1996; Hernandez-
Boussard and Hainaut 1998; Bennett et al. 1999; Hainaut 
and Pfeifer 2001). Mutational patterns for lung cancers 
from smokers and nonsmokers are shown in Figure 5.10. 
The difference between 28.9 percent G→T transversion 
mutations in “designated smokers” (i.e., smoking status 
Figure 5.10 Patterns of TP53 gene mutations and percentage of G→T transversion mutations in human lung 
cancers
Source: Data are from the R9 version (July 2004) of the International Agency for Research on Cancer TP53 mutation database (IARC 
2006).
Note: Cell lines and metastatic cancers were excluded, as well as cancers with defined exposures other than tobacco (e.g., asbestos, 
radon, mustard gas, and air pollution) (see database Web site for specifications of exposure data). Nonsmokers included a series of 21 
mutations (Le Calvez et al. 2005) not included in the database, in addition to 165 database entries. Data from Gao et al. 1997 were 
excluded (see Hainaut and Pfeifer 2001 for detailed selection criteria). N = total number of mutations. 
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indicated in literature) and 13.4 percent G→T mutations 
in nonsmokers has high statistical significance (p <0.001, 
χ2 test). The frequency of G→T transversions is higher in 
lung cancer tumors than in other tumors, except for liver 
cancers associated with geographic areas with evidence 
of food contamination from aflatoxins (Greenblatt et 
al. 1994). 
In most internal cancers not strongly linked to 
smoking, such as breast, brain, and colorectal, the fre-
quency of G→T mutations is 8 to 10 percent (Figure 
5.10). Nonsmokers have a higher percentage of G→A tran-
sitions (42.5 percent) than do smokers (27.9 percent), a 
difference that is also statistically significant. Figure 5.10 
includes categories of both designated smokers and “all 
lung cancer cases minus nonsmokers.” This category 
is based on the knowledge that, overall, 90 percent of 
these lung cancers occur in smokers (Proctor 2001). The 
proportion of G→T transversions, as well as the overall 
mutation pattern for all persons with lung cancers, 
except nonsmokers, is similar to observations of research-
ers for designated smokers (Figure 5.10). The difference 
in G→T transversions in smokers versus nonsmokers 
may be attributable to bias in the database used, which 
pools data from studies that differ in aims, size, and meth-
ods for ascertaining smoking status. However, in a more 
recent study of a series of 21 mutations that was designed 
to address this possibility, TP53 gene mutations were 
found in 27.5 percent of current smokers, 15.8 percent of 
former smokers, and 4.8 percent of lifetime nonsmokers 
(Le Calvez et al. 2005). These observations suggest that 
the difference in G→T transversions in smokers versus 
nonsmokers may be larger than that indicated in the data-
base, perhaps due to the misclassification in the database 
of long-term former smokers as nonsmokers. 
To address the issue of whether the major histologic 
types of lung cancer show differences in TP53 mutational 
patterns, researchers analyzed the IARC TP53 mutation 
database separately for these tumors (Figure 5.11). The fre-
quencies of G→T transversions in the TP53 database were 
31.4 percent in adenocarcinomas, 27.1 percent in SCCs, 
27.5 percent in SCLCs, and 34.7 percent in large-cell car-
cinomas. Furthermore, the global mutation patterns were 
similar in the two main histologic types: adenocarcinoma 
and SCC. Thus, the different types of lung cancer in smok-
ers all show an excess of G→T transversions compared 
with cancers unrelated to exposure to tobacco smoke. 
TP53 mutations do not occur at random along the 
coding sequence. They are typically clustered at mutation 
“hot spots,” which are within the DNA binding domain 
of the TP53 protein and span codons 120 to 300. Figure 
5.12 shows the concordance of codon distribution of G→T 
transversions (upper panel) along the TP53 gene in lung 
cancer with the distribution of adducts in this gene in 
bronchial epithelial cells treated with BPDE. Hot spots 
of G→T mutations in cancers of the brain, breast, and 
colon differ from those in lung cancers (Pfeifer et al. 2002). 
The codons containing mutation hot spots are important 
because they may allow determination of which carcino-
gen caused the mutation. However, hot spot codons may 
exist solely as a consequence of phenotypic selection in 
tumors. To address this issue, studies have compared the 
mutational events in different types of cancers at a num-
ber of common hot spot codons. The major lung cancer 
mutation hot spots at codons 158, 245, 248, and 273 are 
commonly G→T transversions in lung cancer but are 
generally other mutation types (almost exclusively G→A) 
in other internal tumors not associated with smoking 
(Pfeifer et al. 2002). 
G→T  Transversions in Lung Cancer
The major product of the diol epoxide BPDE reac-
tion with DNA is BPDE-N2-deoxyguanosine, which 
induces mainly G→T transversions, depending on the 
sequence context, after a DNA polymerase carries out 
error-prone translesion synthesis past this adduct (Eisen-
stadt et al. 1982; Chen et al. 1990; Ruggeri et al. 1993; 
Yoon et al. 2001) (see “Conversion of DNA Adducts to 
Mutations” earlier in this chapter). Using the UvrABC 
incision method in combination with a ligation-mediated 
polymerase chain reaction (LMPCR), scientists mapped 
the distribution of BPDE and other PAH diol epoxide 
adducts at the nucleotide level along exons of the TP53 
gene in normal human bronchial epithelial cells treated 
with diol epoxide (Denissenko et al. 1996; Smith et al. 
2000). Frequent adduct formation occurred at gua-
nine positions in codons 156, 157, 158, 245, 248, and 
273. These positions of preferential formation of PAH 
adducts are major mutational hot spots in human lung 
cancers (Figure 5.12). The only exception is codon 156, 
where G→T substitution commonly results in a pheno-
typically silent mutation and is therefore not selected dur- 
ing tumorigenesis. 
Researchers analyzed the distribution of BPDE-N2-
deoxyguanosine within TP53 exons by using stable isotope 
labeling LC-electrospray ionization tandem MS (Tretya-
kova et al. 2002; Matter et al. 2004). In this approach, 
specific guanine nucleobases within TP53 gene sequences 
were labeled with 15N so the BPDE adducts originating 
from these positions could be distinguished from the 
lesions formed at other sites. Researchers observed an 
excellent agreement with the data from the UvrABC-
LMPCR method (Denissenko et al. 1996). All four dia-
stereomers of BPDE-N2-deoxyguanosine were formed 
preferentially at the frequently mutated TP53 codons 157, 
158, 245, 248, and 273. The contributions of individual 
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diastereomers to the total adducts at a given site varied 
but were highest (70.8 to 92.9 percent) for (+)-trans-
BPDE-N2-deoxyguanosine (Matter et al. 2004). 
A mechanistic basis for the selectivity of forma-
tion of diol epoxide–DNA adducts in the TP53 gene is the 
enhancement of adduct formation by 5-methylcytosine 
bases present at CpG dinucleotide sequences (Denissenko 
et al. 1997; Chen et al. 1998; Weisenberger and Romano 
1999; Tretyakova et al. 2002; Matter et al. 2004). All CpG 
sequences in TP53 coding exon 5 through exon 9 were 
completely methylated in all of the tissues examined, 
including the lung (Tornaletti and Pfeifer 1995). In the 
TP53 gene of lung cancers, the five major G→T muta-
tional hot spots at codons 157, 158, 245, 248, and 273 
(Figure 5.12) consisted of methylated CpGs (Yoon et al. 
2001). Methylation at CpG sites may increase the binding 
of planar carcinogenic compounds at the intercalation step 
through the hydrophobic effect of the methyl group that 
can stabilize intercalated adduct conformations (Zhang 
et al. 2005a). However, the precise mechanism by which 
cytosine methylation at CpG sites enhances carcinogen 
binding and mutagenesis still needs to be determined. In 
contrast, the presence of 5’-neighboring 5-methylcytosine 
inhibited formation of guanine adducts by NNK metabo-
lites (Rajesh et al. 2005). 
Studies show that the preferential formation of 
BPDE adducts at methylated CpG sites is reflected in 
the strongly enhanced mutagenesis at CpG sequences 
after cells were treated with BPDE. This finding was dem-
onstrated with three different mutated reporter genes, 
Figure 5.11 Patterns of TP53 gene mutations and percentage of G→T transversion mutations in different histologic 
types of lung cancer
Source: Data are from the R9 version (July 2004) of the International Agency for Research on Cancer TP53 mutation database (IARC 
2006).
Note: Cancers were classified according to International Classification of Diseases, Tenth Revision (ICD-10), World Health Organiza-
tion 1994. The data set excluded lung cancers from nonsmokers. Cell lines and cancers metastatic to the lung were excluded, as well 
as all cancers with defined exposures other than tobacco (e.g., asbestos, radon, mustard gas, and air pollution). ADC = adenocarcino-
ma (ICD C34-8140/3); LCC = large-cell carcinoma (ICD C34-8012/3); N = total number of mutations; SCC = squamous cell carcinoma 
(ICD C34-8070/3); SCLC = small-cell lung carcinoma (ICD C34-8041/3).
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including two chromosomal genes with methylated CpG 
sequences (Yoon et al. 2001).
Methylated CpG sites are preferentially modified 
by several carcinogens, including aromatic amines and 
aflatoxins (Chen et al. 1998). However, the exact range of 
compounds that target methylated CpGs is not known. 
In one study, researchers did not observe a preferential 
mutagenesis at methylated CpGs by the aromatic amine 
4-ABP (Besaratinia et al. 2002). G→T transversions 
resulting from 8-oxodeoxyguanosine are not specifi-
cally targeted to methylated CpG sequences (Lee et al. 
2002a). A more recent study demonstrated that the DNA 
adduction profile of acrolein in the P53 gene was similar 
to that of BPDE and other PAH diol epoxides, indicating 
that this α,β-unsaturated aldehyde reacts at methylated 
CpG sites and, because of its high concentration in ciga-
rette smoke compared with that of PAHs, could contrib-
ute to the TP53 mutations observed in lung tumors from 
smokers (Feng et al. 2006).
Hussain and colleagues (2001) have shown that 
exposing bronchial epithelial cells to BPDE produces G→T 
transversions in the TP53 gene at lung cancer hot spot 
codons 157, 248, and 249. Nontumorous lung tissues from 
smokers with lung cancer carried a high TP53 mutational 
Figure 5.12 Concordance between codon distribution of G→T transversions along TP53 gene in lung cancers (top) 















































Source: Adduct data were quantitated from Denissenko et al. 1996 and Smith et al. 2000. 
Note: Distribution of G→T mutations is shown along the TP53 coding sequence, and “hot spot” codons for major mutations are indi-
cated. Mutation data from the International Agency for Research on Cancer TP53 mutation database were used. Cell lines and cancers 
metastatic to the lung were excluded, as well as all cancers with defined exposures other than tobacco (e.g., asbestos, radon, mustard 
gas, and air pollution). Length of bars indicates relative adduct frequency at major hot spots for adducts. For adducts of BPDE, the 
strongest binding site has a value of 1. Sites with values less than 0.2 are not shown. Numbers correspond to TP53 codon numbers.
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Figure 5.13 Patterns of TP53 gene mutations and percentage of G→T transversions in smoking-associated cancers 
other than lung cancer
Source: Data are from R9 version (July 2004) of International Agency for Research on Cancer TP53 mutation database 
(IARC 2006). 
Note: Oral cancers include cancers of oropharynx, hypopharynx, gum, palate, floor of mouth, and tongue. Cases with defined  
exposures other than tobacco (e.g., asbestos, radon, mustard gas, and air pollution) were excluded. ADC = adenocarcinoma; 
N = total number of mutations; SCC = squamous cell carcinoma.
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load at these codons, even when another TP53 mutation 
was present in the tumor itself. DeMarini and colleagues 
(2001) studied TP53 and KRAS mutations in lung tumors 
from Chinese women who were nonsmokers and whose 
tumors were associated with exposure to smoky coal 
containing high levels of PAHs and probably other com-
pounds such as acrolein. The tumors showed a high per-
centage of mutations that were G→T transversions in 
the KRAS oncogene (86 percent) or the TP53 gene (76 
percent). In the TP53 gene, the mutations clustered at 
the CpG-rich codons 153 through 158 and at codons 249 
and 273. 
The site specificity of mutagenesis by PAH diol epox-
ides implies that targeted adduct formation, in addition to 
phenotypic selection, is responsible for shaping the TP53 
mutational spectrum in lung tumors. According to the 
IARC TP53 mutation database, more than 80 percent of 
G→T transversions in lung cancers are targeted to gua-
nines on the nontranscribed DNA strand. This observation 
suggests that a preferential repair of DNA lesions occurs 
on the transcribed strand. DNA repair experiments ana-
lyzing BPDE adducts in the TP53 gene showed that the 
nontranscribed strand is repaired more slowly than is the 
transcribed strand (Denissenko et al. 1998). These find-
ings support the proposal that both the initial DNA adduct 
levels and a bias in repair of DNA strands may contribute 
to the mutational spectrum of the human TP53 gene in 
lung cancer. 
TP53 Gene Mutations in Other  
Smoking-Associated Cancers
Of four cancer types analyzed, only SCC of the lar-
ynx showed a strong similarity with lung cancers. Preva-
lence of G→T transversions was high (25.9 percent), and 
many occurred at PAH-target codons 157 and 245. A gra-
dient in the upper respiratory tract reflects the prevalence 
of TP53 G→T transversions in cancers of smokers. This 
prevalence ranges from low in the oral cavity, to interme-
diate in the larynx, and high in various histologic types of 
lung cancers. The gradient may reflect the existence of an 
underlying, parallel gradient in the extent of exposure of 
respiratory tract cells to carcinogens in tobacco smoke. 
In oral cancers, studies show that the TP53 mutation load 
is proportional to the extent of smoking, with an almost 
fourfold increase in the prevalence of mutations among 
heavy smokers compared with nonsmokers (Brennan et 
al. 1995). In one study of oral and esophageal SCC, how-
ever, the frequency of G→T transversions is only slightly 
higher (16.5 and 19.6 percent, respectively) than those in 
cancers not strongly related to exposure to tobacco smoke 
(e.g., breast, colorectal, and brain cancers). The patterns 
of mutations in both oral and esophageal SCC are similar, 
perhaps reflecting the importance of common risk factors, 
such as the combined use of tobacco and alcohol, infec-
tions by human papilloma virus (Gillison and Shah 2003), 
and various lifestyle behaviors such as tobacco chewing 
or consuming scalding hot beverages, as well as similar 
histology in oral and esophageal tissues. In contrast, the 
mutation pattern is different in esophageal adenocarcino-
mas, with a high prevalence of G→T transversions at CpG 
sites (Figure 5.13) and a type of mutation that could be 
associated with the overproduction of reactive nitrogen 
species due to inflammation (Ambs et al. 1999). 
For bladder cancer, the mutation pattern shows an 
unusually high prevalence of G→A transitions at non-CpG 
sites. These mutations are not distributed at random, and 
bladder-specific mutation hot spots can be seen at codons 
280 and 285, according to the IARC TP53 database. Both 
codons occur within the same primary sequence context 
(5’AGAG), which raises the possibility that this sequence 
may be a preferential target site for a carcinogen involved 
in bladder carcinogenesis. However, aromatic amines, 
a potent class of bladder carcinogens in tobacco smoke, 
produce mainly G→T mutations (Besaratinia et al. 2002). 
Limitations to the Study of TP53 Mutations  
and Smoking-Induced Cancer
Although the study of mutations in the TP53 gene 
provides potentially useful leads for understanding mech-
anisms of tobacco carcinogenesis, this approach also has 
limitations. As already mentioned, various carcinogen-
DNA adducts can produce G→T transversions and even 
similar spectra of mutations. In addition, most of this 
research is not population based, and the studies may 
be biased with respect to the stage of lung cancer repre-
sented. Finally, lack of a mutation in the TP53 gene does 
not necessarily mean that the tumor is not related to 




Loss of Mechanisms for Growth Control
Signal Transduction
Introduction
Normally, cell signaling is very tightly regulated and 
begins with the transduction of the signal through a mem-
brane receptor. The signal is conveyed through a series of 
intracellular proteins, and the result is the regulation of 
cellular processes including proliferation and apoptosis. 
In lung cancer cells, the processes governing these events 
are frequently deregulated by DNA-damaging mutations 
induced by cigarette smoke or other alterations in the 
molecules of numerous signaling pathways. The balance 
between mechanisms leading to apoptosis (proapoptotic) 
and those suppressing apoptosis (antiapoptotic) or sup-
pressing increased proliferation will have a major impact 
on lung tumor growth. Identifying and targeting signaling 
pathways that lead to therapeutic resistance could help to 
neutralize a patient’s resistance to standard therapies. 
Apoptosis
Apoptosis was first described in 1972 (Kerr et al. 
1972). The term “apoptosis” is from the Greek word for 
“falling off.” Apoptosis is a natural process that consists of 
a well-orchestrated cascade of distinct biologic and histo-
logic events (Kerr et al. 1972). These events are critical for 
eliminating injured or genomically unstable cells while 
minimizing damage to surrounding normal cells (Martin 
2002). The induction of apoptosis prevents the malignant 
growth of cancer cells (Rich et al. 2000). The deregulation 
of the mechanisms governing apoptosis is a distinctive 
characteristic of most cancer cells (Hanahan and Wein-
berg 2000).
Apoptosis is characterized by morphologic features 
including membrane blebbing, cell shrinking, and chro-
mosomal condensation. Apoptosis is generally believed 
to occur through two “effector” mechanisms: extrinsic 
(death receptor mediated) and intrinsic (mitochondrial 
mediated) (Hengartner 2000). The extrinsic pathway is 
regulated by binding a “death receptor molecule” to the 
cancer cell’s membrane receptor (i.e., death receptor). 
The intrinsic pathway is mediated by rendering the mito-
chondrial membrane permeable, a phenomenon directly 
influenced by the ratio of the interaction of proapoptotic 
and antiapoptotic proteins. In general, researchers believe 
that the inactivation of apoptosis through the intrinsic 
pathway is the primary mechanism through which DNA-
damaging agents from tobacco smoke act to enhance 
the survival of lung cancer cells, which is the focus of 
this section. 
Key Apoptotic Regulators
One or more pathways may lead to apoptosis. Stress 
signals stimulate a pathway that activates proteins to 
respond to DNA damage. These proteins subsequently 
phosphorylate, activate, and stabilize the P53 protein. The 
activated P53 protein drives the transcription of genes 
associated with cell-cycle arrest, DNA repair, and apop-
tosis. These genes include the BCL-2 family of proteins, 
which consists of both proapoptotic and antiapoptotic 
members. The BCL-2 family of proteins interacts with the 
outer mitochondrial membrane to regulate the release of 
cytochrome c, which results in the activation of aspartyl 
and cysteine proteases (caspases) (Igney and Krammer 
2002). The caspases are crucial executioners of apoptosis 
(Meier et al. 2000; Reed 2000). Once stimulated, the cas-
pases activate endonucleases that subsequently cleave the 
DNA of the targeted cell into nucleosome-sized fragments, 
which is a common characteristic of apoptosis. 
A multitude of signaling molecules mediate the 
mechanisms that govern apoptosis. An imbalance in pro-
apoptotic and antiapoptotic signaling events contributes 
to the development and progression of lung cancer. The 
mechanisms for the deregulation of apoptosis can be 
categorized into (1) the decrease of signaling associated 
directly with the induction of apoptosis and (2) the 
increase of signaling leading to the suppression of apop-
tosis. This decrease may include mutations induced by 
cigarette smoke or other smoke-related mechanisms that 
activate oncogenes or inactivate tumor-suppressor pro-
teins or other proapoptotic proteins. The increase may 
include mutations induced by cigarette smoke, certain 
kinases, other antiapoptotic proteins or transcription 
factors, or overexpression or constitutive activation of 
growth factors. The end result of this deregulation usually 
includes a profound resistance to apoptosis. 
Regulation of  Tumor Suppressors and 
Proapoptotic Proteins
Decrease of important proapoptotic proteins of the 
BCL-2 family and tumor suppressors such as the P53 and 
RB proteins is a characteristic in many types of cancers, 
including lung cancer. This decrease provides lung cancer 
cells with a strong ability to resist apoptosis, which leads 
to a distinct advantage for cell survival (Figure 5.14).
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BCL-2 Family Proteins
In normal cells, stresses initiate apoptosis through 
the mitochrondrial or intrinsic pathway, and the BCL-2 
family proteins are important mediators of the apoptotic 
response. These proteins are characterized by the pres-
ence of one to four conserved BCL-2 homology (BH) 
domains. The BCL-2 family can be divided into antiapop-
totic members: BCL-2, BCL-XL, and myeloid cell leuke-
mia-1. The proapoptotic BCL-2 proteins are subdivided 
into two groups: the multidomain BAX subfamily (BAK, 
BAX, and BOK) and the BH3-only proteins (BAD, BID, 
and BIM) (Korsmeyer 1995; Hale et al. 1996; Adams and 
Cory 1998; Huang and Strasser 2000; Cory et al. 2003). 
The BCL-2 family of proteins appears to directly influ-
ence the permeability of the mitochondrial membrane to 
regulate apoptosis. 
The interaction of BAX with the mitochrondrial 
membrane causes the release of cytochrome c into the 
cytosol, where it binds to apoptotic-releasing factor 1. 
The binding of cytochrome c and apoptotic-releasing fac-
tor 1 results in the activation of cysteine-aspartic acid 
protease-9 (CASPASE-9), which is required to form the 
“apoptosome” complex that initiates apoptosis. The apop-
totic response is critically dependent on the ratio of the 
expression of proapoptotic and antiapoptotic BCL-2 mem-
bers (Zha et al. 1997; Korsmeyer 1999; Kroemer 1999; 
Reed 1999; Huang and Strasser 2000; Lutz 2000; Cheng 
et al. 2001; Ruvolo et al. 2001). A lack of BAX (Zhang et al. 
2000a; Schmitt and Lowe 2002) or an increase of BCL-2 
or BCL-XL (Schott et al. 1995; Walczak et al. 2000; Chipuk 
et al. 2001) suppresses apoptosis, whereas a decrease of 
BCL-XL or BCL-2 enhances apoptosis (Hayward et al. 
2003). Dimers containing BAX and BCL-2 inactivate BAX 
and therefore inhibit apoptosis. In addition, phosphoryla-
tion of the BAD protein results in its inactivation, because 
only the nonphosphorylated form of BAD can antagonize 
the antiapoptotic BCL-2 or BCL-XL at the mitochondrial 
membrane (Hermeking 2003). 
Nicotine suppresses the death of lung cancer cells 
by phosphorylation mediated by the extracellular signal-
regulated kinase (ERK) of BCL-2 (Heusch and Maneckjee 
1998; Mai et al. 2003). Conversely, NNK inactivates BAD 
through β-adrenergic receptors and protein kinase C 
(PKC), which promotes survival of NSCLC cells (Lahn et 
al. 2004; Jin et al. 2005). Nicotine also stimulates cell sur-
vival through the phosphorylation and inhibition of BAD 
activated by β-adrenergic-receptor–mediated AKT-, PKA-, 
and/or ERK-dependent pathways (Jin et al. 2004a). These 
studies show that BCL-2 family members are critical effec-
tors of signaling pathways that promote cancer cell sur-
vival in response to components of cigarette smoke—in 
these cases, through direct receptor binding rather than 
DNA damage.
P53 Protein
The P53 pathway is clearly involved in cellular life 
or death. The P53 tumor-suppressor protein can induce 
the expression of BAX and additional proapoptotic mem-
bers of the BCL-2 family (Miyashita and Reed 1995; Yin et 
al. 1997; Oda et al. 2000a,b; Nakano and Vousden 2001). 
In addition to having direct effects on BCL-2 family pro-
teins, the P53 protein also increases activity of the APAF1 
gene (Robles et al. 2001), which as indicated earlier, is 
a member of the apoptosome complex and is critical for 
the activation of CASPASE-9 to initiate apoptosis (Soen-
gas et al. 1999) (see “BCL-2 Family Proteins” earlier in 
this chapter). Although it is primarily a nuclear protein, 
P53 may function outside the nucleus by translocating 
to the mitochondria, where it interacts directly with an-
tiapoptotic proteins such as BCL-2 and BCL-XL to induce 
apoptosis (Mihara et al. 2003). The aberrant inactivation 
of P53 leads to a deregulation of cell-cycle control and a 
suppression of many crucial proapoptotic pathways (Ford 
Figure 5.14 Tobacco-associated suppression of 
proapoptotic proteins and tumor-
suppressor proteins
Note: Tobacco-associated suppression of proapoptotic proteins 
and tumor-suppressor proteins increases cell proliferation and 
resistance to apoptosis. Two major signaling pathways that are 
downregulated by DNA-damaging tobacco agents are the TP53 
protein and the proapoptotic family of BCL-2 proteins. 
APAF1 = apoptotic-releasing factor 1; BAX = BCL-2 associated 
X protein; CASPASE-9 = cysteine-aspartic acid protease-9.
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and Hanawalt 1995; Wang et al. 1995a,b; Offer et al. 1999; 
Vogelstein et al. 2000; Zhou et al. 2001a). The loss of P53 
function markedly decreases the sensitivity of lung cancer 
cells to apoptosis induced by exposure to tobacco smoke 
or other stresses (Lowe et al. 1994).
Retinoblastoma Protein
Inactivation of the RB protein results in the release 
and activation of the transcription factor E2F (Flemington 
et al. 1993; Helin et al. 1993). Some E2F family members 
induce expression of the genes important in apoptosis, 
such as the P14ARF gene (DeGregori et al. 1997; Bates et 
al. 1998). The P14ARF protein is a negative regulator of 
murine double minute 2 (MDM2), a P53 binding protein. 
The inhibition of MDM2 leads to elevated P53 levels and 
apoptosis. The E2F protein can also activate proapoptotic 
BCL-2 family members and caspases (Nahle et al. 2002; 
Hershko and Ginsberg 2004). 
Regulation of Antiapoptotic Proteins and Effects
Studies document that many genes and signaling 
proteins are overexpressed or display gain-of-function 
mutations in lung cancers. These include the EGFR 
gene, signal transduction and activator of transcription, 
PKC, RAS/MAPK, phosphatidylinositol-3 kinase (PI-3K)/
AKT, PTEN, nuclear factor-kappa B (NF-kB), and COX 
(Figure 5.15). 
Figure 5.15 Protein-signaling pathways deregulated in lung cancer
Note: Many protein-signaling pathways deregulated in lung cancer represent a dense interactive network with a range of 
potential survival-enhancing effects. Tobacco- or cigarette smoke-associated activation of antiapoptotic proteins provides lung cancer 
cells with a distinct growth advantage. Major protein survival-signaling pathways activated by tobacco carcinogens are illustrated. 
KRAS and P53 are boxed to emphasize that KRAS and TP53 are the most commonly mutated genes. Mutationally activated KRAS is 
locked in its active form, resistant to the inactivating effects of GTPase-activating proteins, and cannot hydrolyze guanosine triphos-
phate to guanosine diphosphate. Similarly, mutated P53 cannot carry out many of its normal protective functions with respect to cell 
cycle control and apoptosis. AKT = protein kinase B; AP-1 = activator protein-1; BAD = BCL-associated death protein; BAX = BCL-2 
associated X protein; CASPASE-9 = cysteine-aspartic acid protease-9; ERK = extracellular signal-regulated kinase; IkKα = I kappa-B  
kinase alpha; MDM2 = murine double minute 2 protein; MEK = mitogen-activated protein kinase kinase; NF-kB = nuclear factor- 
kappa beta; PI-3K = phosphatidylinositol 3-kinase; PKC = protein kinase C signaling pathway; PTEN = phosphatase and tensin  
homolog; RAF = v-raf murine leukemia viral oncogene; RSK2 = P90 ribosomal protein S6 kinase; STAT3 = signal transducer and 
activator of transcription 3. 
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Epidermal Growth Factor Receptor
Exposure of oral cells to cigarette smoke caused 
an increase in EGFR tyrosine kinase activity (Moraitis et 
al. 2005). Signaling through EGFR can lead to survival 
signals that suppress dependent (downstream) apoptotic 
pathways or stimulate cell proliferation. Some evidence 
suggests that EGFR signaling can influence the levels and 
activities of antiapoptotic BCL-2 family members (Kari et 
al. 2003). The EGFR gene is overexpressed and thus con-
stitutively activated in lung cancer cells (Sridhar et al. 
2003) and bronchial preneoplastic lesions (Rusch et al. 
1995; Kurie et al. 1996; Piyathilake et al. 2002). In addi-
tion, a truncated form of the EGFR protein (EGFRvIII) is 
constitutively active in NSCLC cells (Okamoto et al. 2003). 
The expression of this mutant form of EGFR is associ-
ated with an increase in cell transformation and with the 
constitutive activation of important downstream signal-
ing pathways for survival, including the PI-3K/AKT path-
way (Antonyak et al. 1998; Moscatello et al. 1998; Tang et 
al. 2000). 
RAS/Mitogen-Activated Protein Kinase
Activation of the RAS pathway sends a strong anti-
apoptotic signal, and the constitutive activation of RAS 
can transform normal cells. Oncogenic RAS protein has a 
primary role in the development of lung cancer (Johnson 
et al. 2001a). RAS activates several pathways, including 
RAF/mitogen-activated protein kinase kinase (MEK)/ERK, 
PKC, PI-3K/AKT, and NF-kB (Kauffmann-Zeh et al. 1997; 
Kennedy et al. 1997; Peeper et al. 1997; Baldwin 2001). 
These pathways are commonly deregulated by RAS in lung 
cancers (Adjei 2001a,b). RAF/MEK/ERK pathway activa-
tion can lead to changes in downstream gene expression 
through the activation of activator protein-1 (AP-1). AP-1 
is a well-characterized transcription factor composed of 
homodimers and/or heterodimers of the JUN and FOS 
gene families (Angel and Karin 1991). AP-1 regulates the 
transcription of various genes. Many stimuli, including 
tumor promoters, mediate AP-1 binding to the DNA of 
genes that govern cellular processes such as inflamma-
tion, proliferation, and apoptosis (Angel and Karin 1991). 
Phosphatidylinositol-3 Kinase, 
Phosphatidylinositol 3’-Phosphatase,  
and Protein Kinase B
PI-3K consists of a family of heterodimeric com-
plexes, each composed of a p110 catalytic subunit and 
a regulatory subunit that exists primarily as a p85 form 
(Tolias et al. 1995; Vanhaesebroeck et al. 1997; Wymann 
and Pirola 1998). This family of proteins is involved in 
the regulation of proliferation, viability, adhesion, and 
motility migration in numerous cell types (Carpenter and 
Cantley 1996; Khwaja 1999; Rameh and Cantley 1999; 
Blume-Jensen and Hunter 2001; Roymans and Slegers 
2001). Cell survival and oncogenic transformation require 
PI-3K activation (Datta et al. 1999; Stambolic et al. 1999). 
PI-3K–dependent kinases include 3-phosphoinositide–
dependent protein kinase-1 (PDK1) and AKT (PKB). The 
PI-3K pathway can also be activated by the EGFR protein 
and by an activated RAS protein (Rodriguez-Viciana et 
al. 1997). One of the first steps in PI-3K signaling is the 
activation of PDK1, which phosphorylates and activates 
AKT (Coffer et al. 1998; Belham et al. 1999). AKT phos-
phorylates and inactivates several proapoptotic proteins, 
including BAD and CASPASE-9. Other targets of AKT 
important in the regulation of apoptosis include glycogen-
synthase-kinase-3 (Pap and Cooper 1998), the Forkhead 
transcription factor FKHRL1 (Brunet et al. 1999), and the 
mammalian target of rapamycin/p70S6 kinase (McCor-
mick 2004). Furthermore, AKT inactivates P53 by phos-
phorylating MDM2, which increases the ability of MDM2 
to bind to and promote P53 degradation (Ogawara et al. 
2002). AKT also suppresses apoptosis by activating NF-kB 
through AKT phosphorylation of I kappa-B kinase alpha 
(Ozes et al. 1999; Romashkova and Makarov 1999).
Most NSCLC cells display an increase in PI-3K 
activity that results in highly active AKT and other down-
stream mediators (Moore et al. 1998; Brognard et al. 
2001). AKT is important in the survival of lung cancer 
cells and is constitutively activated in most NSCLC cell 
lines to promote the survival of NSCLC cells under stress-
ful conditions (Brognard et al. 2001). Studies have also 
found AKT expression in SCLC tumor samples (Lee et al. 
2002b; Mukohara et al. 2003), SCLC cell lines (Moore et 
al. 1998), SCLC tumors (Blackhall et al. 2003), mouse 
tumors induced by tobacco carcinogens (West et al. 2003), 
and human bronchial dysplastic lesions (Tsao et al. 2003). 
(For additional details on AKT activation by components 
of cigarette smoke through receptor interactions, see 
“Activation of Cytoplasmic Kinase by Tobacco Smoke” 
later in this chapter.)
Nuclear Factor-Kappa B
NF-kB is a rapidly induced transcription factor 
responsive to stress that functions to intensify the tran-
scription of a variety of genes, including those encoding 
cytokines, growth factors, and acute response proteins 
(Baldwin 1996). Nicotinic activation of nicotinic acetylcho-
line receptors (nAChRs) stimulates NF-kB activity down-
stream of ERK and AKT, which promotes tumor growth 
and angiogenesis through the vascular endothelial growth 
factor (VEGF) in vivo (Heeschen et al. 2001, 2002). More-
over, NF-kB activation by exposure to cigarette smoke in 
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lung cancer cells induces the expression of COX-2 (Anto 
et al. 2002; Shishodia and Aggarwal 2004). Recent results 
suggest that nicotine, but not NNK, activates NF-kB– 
dependent survival of lung cancer cells in addition to their 
proliferation. These studies illustrate that the activation 
of NF-kB by nicotine or by cigarette smoke in its entirety 
through receptor binding can promote tumorigenesis in 
the lung through many mechanisms, including increased 
levels of VEGF and COX-2.
Cyclooxygenase
COX-1 and COX-2 were shown to catalyze synthe-
sis of prostaglandins from arachidonic acid. Research-
ers observed that COX-1 was constitutively expressed in 
most tissues, whereas COX-2 was inducible and found at 
elevated levels in various cancers (Koki et al. 2002; Dan-
nenberg and Subbaramaiah 2003; Dubinett et al. 2003). In 
lung cancers, researchers have found COX-2 expression at 
most stages of tumor progression (Hida et al. 1998; Huang 
et al. 1998; Wolff et al. 1998; Hosomi et al. 2000; Ander-
son et al. 2002; Fang et al. 2003). Others reported high 
levels of COX-2 in NSCLC and premalignant lesions, but 
COX-2 expression is less consistent in SCLC (Wolff et al. 
1998; Hosomi et al. 2000). Studies show that NNK induces 
a high expression of COX-2 in rats (El-Bayoumy et al. 
1999). Levels of COX-2 mRNA are about four times higher 
in the oral mucosa of smokers than in that of lifetime non-
smokers (Moraitis et al. 2005). Researchers believe that 
at least one role of COX-2 in cancer is associated with 
cell resistance to apoptosis and an increase in metastatic 
potential (Gupta and Dubois 2001). The supporting evi-
dence shows that COX-2 overexpression coincides with an 
increased BCL-2 expression (Tsujii and DuBois 1995) and an 
increased stabilization of the antiapoptotic protein sur-
vivin (Li et al. 1998a; Krysan et al. 2004). Lung cancer 
cells that were induced to express COX-2 demonstrated 
an increase in survival time (Lin et al. 2001b), and COX-2 
inhibitors stimulated apoptosis in lung carcinoma cells 
(Hida et al. 2000; Yao et al. 2000; Chang and Weng 2001). 
Summary
Apoptosis is commonly suppressed in lung cancer, 
which correlates with increases in cancer cell survival 
and proliferation. Deregulation of the many pathways for 
growth control (Figure 5.15) in lung cancer is attributable 
partly to interactions of carcinogens in cigarette smoke 
with the KRAS oncogene, the P53 tumor-suppressor 
gene, and other genes. These pathways represent a dense 
interactive network with a range of potential effects on 
cell survival. Mechanisms associated with cigarette smoke 
that increase resistance to apoptosis include activation of 
antiapoptotic proteins and/or suppression of proapoptotic 
and tumor-suppressor proteins. 
Cigarette Smoke and Activation of 
Cell-Surface Receptors in Cancer
Airway Epithelial Cells
Nicotinic Acetylcholine Receptors
Neuronal nAChRs are large membrane-associated 
proteins that are the first line of contact between cells and 
components of cigarette smoke such as nicotine and NNK. 
These proteins were originally described as receptors for 
acetylcholine (ACh). Their function in the brain has been 
studied in detail because of their ability to mediate the 
addictive effects of nicotine. Each receptor is made up of 
five subunits arranged in a barrel-like structure, creating 
a pore that allows calcium to enter the cell in response 
to ligand binding. Nine alpha subunits (α2 through α10) 
and three beta subunits (β2 through β4) combine with 
each other to form heteropentamers (combinations of α2 
through α6 with β2 through β4) or homopentamers (α7 
through α10). Each nAChR consists of 5 subunits, and 
researchers have identified at least 12 subunits; thus, 
many functional nAChRs exist. Different ligands, includ-
ing nicotine, NNK, and ACh, have varying affinities for 
different nAChRs. Despite this complexity, the primary 
receptors that mediate the addictive effects of nicotine 
are α4β2 nAChRs, whereas α7 nAChRs are high-affinity 
receptors for NNK (Lindstrom 1997, 2003). Moreover, the 
discovery that mutations in the α4 nAChR subunit lower 
the threshold for addiction raises the possibility that 
genetic variations in these receptors could increase sus-
ceptibility to nicotine dependence and exposure to car-
cinogens through smoking (Tapper et al. 2004). 
Although nAChRs were originally thought to be lim-
ited to neuronal cells, studies have identified functional 
nAChRs in tissues outside the nervous system. This find-
ing raises the possibility that these receptors may mediate 
some of the systemic effects of smoking. In lung tissues, 
researchers have discovered nAChRs in human bronchial 
epithelial cells, vascular endothelial cells, pulmonary neu-
roendocrine cells, neuroepithelial bodies, NSCLC cells, 
and SCLC cells (Tarroni et al. 1992; Maneckjee and Minna 
1994; Macklin et al. 1998; Maus et al. 1998; Schuller and 
Orloff 1998; Wang et al. 2001b; Fu et al. 2003; Schuller et 
al. 2003; Song et al. 2003a,b; Tsurutani et al. 2005). 
The stimulation of nAChRs by components of ciga-
rette smoke has biologic effects on cells that are important 
for the initiation, progression, and maintenance of cancer. 
Cancer  289
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease
The activation of nAChRs in lung epithelial cells by nico-
tine or NNK promotes the survival and proliferation of 
human mesothelioma and lung cancer cells (Maneckjee 
and Minna 1994; Schuller and Orloff 1998; West et al. 
2002; Schuller et al. 2003; Trombino et al. 2004; Tsurutani 
et al. 2005). In normal cells, nicotine can stimulate prop-
erties consistent with cell transformation and the early 
stages of cancer formation, such as increased cell prolif-
eration, decreased cellular dependence on the extracellu-
lar matrix for survival, and decreased contact inhibition, 
which is the natural process of arresting cell growth when 
two or more cells come in contact with each other (West 
et al. 2003). Furthermore, nicotine stimulation of endo-
thelial nAChRs promotes angiogenesis, another property 
of cancer (Heeschen et al. 2001, 2002; Zhu et al. 2003). 
Thus, the induced activation of nAChRs in lung tissues 
by components of cigarette smoke can promote processes 
required for development of cancer.
In addition to stimulating nAChRs directly, compo-
nents of cigarette smoke can indirectly stimulate nAChRs 
by promoting the growth of tobacco-related cancers that 
express and secrete ACh, the endogenous ligand for these 
receptors. SCLC and NSCLC cells synthesize, transport, 
and release ACh in vitro, which stimulates proliferation of 
cancer cells through the autocrine activation of nAChRs 
(Song et al. 2003a; Proskocil et al. 2004). This finding 
suggests that there are many mechanisms for activation 
of nAChRs in lung cancer and further emphasizes the 
importance of these receptors in the biology of tobacco- 
related cancer.
ß-Adrenergic Receptors
The β-adrenergic receptors are neuronal recep-
tors that may play a role in mediating effects of cigarette 
smoke related to signal transduction. NNK is structur-
ally similar to epinephrine, the endogenous ligand for 
the β-adrenergic receptor, suggesting that in addition to 
binding nAChRs, NNK may bind to these receptors. Once 
bound to β-adrenergic receptors, NNK can stimulate the 
release of arachidonic acid (Schuller et al. 1999; Weddle 
et al. 2001). The enzyme COX-2 converts arachidonic acid 
to prostaglandin E2, which mediates inflammation and 
promotes cell survival and proliferation in cancer. This 
finding is important because cell lines from human lung 
cancer overexpress the β-adrenergic receptor (Schuller et 
al. 2001), and several studies suggest that the presence or 
expression of arachidonic acid is a risk factor for pulmo-
nary adenocarcinomas (Alavanja et al. 1993, 2001). Thus, 
these studies indicate that the β-adrenergic receptor may 
be an important mediator of signal transduction pathways 
associated with exposure to cigarette smoke.
Other Receptors
The ERBB family is another group of EGFRs that 
indirectly mediate signal transduction associated with cig-
arette smoke. The four types of ERBB receptors are EGFR 
(HER-1), HER-2, HER-3, and HER-4. These receptors act 
in pairs to stimulate downstream signaling pathways that 
mediate the survival and proliferation of both normal 
cells and cancer cells. Ligands that bind to ERBB family 
members include the epidermal growth factor TGFα and 
amphiregulin. In addition, receptors can be activated in 
the absence of a ligand through overexpression of the 
receptors themselves. Both of these mechanisms play 
a role in activation of these receptors mediated by ciga- 
rette smoke. 
The hypothesis that ERBB receptors mediate the 
effects of cigarette smoke on airway epithelial cells 
emerged from correlative clinical data and mechanisms 
defined in vitro. Clinical data include many reports of 
EGFR and HER-2 overexpression in lung cancer (Hen-
dler and Ozanne 1984; Cerny et al. 1986; Veale et al. 1987; 
Hirsch et al. 2003a; Tan et al. 2003). In addition, some 
studies have shown that EGFR overexpression and activa-
tion in human lung cancers correlate with shorter sur-
vival times, suggesting that they play an important role in 
development of cancer (Kern et al. 1990; Kanematsu et al. 
2003; Selvaggi et al. 2004). 
Clinical data also support the hypothesis that ERBB 
expression and activation change with exposure to ciga-
rette smoke or its components. Studies have demon-
strated the overexpression of EGFR and ERBB3 in the 
bronchial epithelium of smokers (Yoneda 1994; O’Donnell 
et al. 2004). Results of mechanistic in vitro studies, such 
as the demonstration that NNK-induced transformation 
of lung epithelial cells is associated with an increase in 
EGFR expression, support these observations (Lonardo 
et al. 2002). Moreover, exposure to nicotine alone can 
increase the expression of EGFR in cervical cancer cell 
lines (Mathur et al. 2000). Studies also demonstrate that 
exposure to tobacco smoke increases the activity of EGFR, 
and metabolites of B[a]P induce activation of EGFR and 
downstream signaling pathways that promote prolifera-
tion (Burdick et al. 2003; Moraitis et al. 2005). These stud-
ies support the idea that components of cigarette smoke 
modulate the expression and activation of the ERBB fam-
ily of receptors. 
In addition to increasing the expression of ERBB 
family members, components of tobacco smoke stimu-
late cells to produce ligands that activate the receptors. In 
clinical specimens, studies have described the coexpres-
sion of EGFR and its ligand TGFα in human NSCLC. In 
one study, both EGFR and TGFα were expressed in 38 
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percent of the cases of NSCLC examined (Rusch et al. 
1993). In a second study, 72 percent of SCCs and 34 
percent of adenocarcinomas expressed both EGFR and 
TGFα (Hsieh et al. 2000). This finding may be clinically 
important because a retrospective analysis showed that the 
coexpression of EGFR and TGFα is an indicator of a 
poor prognosis (Tateishi et al. 1990). These studies sug-
gest that the stimulation of ERBB ligands induced by 
cigarette smoke may be an important mechanism of sig- 
nal transduction.
Consistent with the clinical data, in vitro studies 
show that condensate from cigarette smoke stimulates 
the release of amphiregulin and TGFα from the cell mem-
brane, which leads to the autocrine activation of EGFR 
and cell proliferation (Richter et al. 2002; Lemjabbar et al. 
2003; Moraitis et al. 2005). Several studies demonstrate 
that cigarette smoke condensate activates matrix metal-
loproteinases (MMPs), which are enzymes on the extracel-
lular surface of cells that cleave these ligands from the 
extracellular matrix. Support for these in vitro observa-
tions comes from the demonstration that MMP activity is 
higher in lung tissues from smokers than in those from 
nonsmokers (Kang et al. 2003; Kangavari et al. 2004). 
In addition to stimulating downstream kinases, 
EGFR activation by cigarette smoke may provide a mecha-
nistic link to the increased inflammation characteristic 
of smokers by increasing COX-2 activity (see “Activation 
of Cytoplasmic Kinase by Tobacco Smoke” later in this 
chapter). In vitro data suggest that autocrine activation 
of EGFR, by the expression of the TGFα and AREG genes 
induced by tobacco smoke, stimulates COX-2 expression 
(Moraitis et al. 2005). Cigarette smoke also increases 
COX-2 expression by lung fibroblasts in vitro, and B[a]P 
increases COX-2 expression by oral epithelial cells (Kelley 
et al. 1997; Martey et al. 2004). Thus, many in vitro stud-
ies demonstrate that EGFR activation by components of 
cigarette smoke can contribute to inflammation through 
the increased expression and activation of COX-2.
Clinical data support the validity of these in vitro 
observations. For example, studies document increased 
levels of COX-2 in the oral mucosa of smokers (Moraitis 
et al. 2005) and in urothelial tissues from smokers with 
bladder cancer (Badawi et al. 2002). Moreover, COX-2 is 
expressed only in neoplastic epithelial cells, not in nor-
mal bronchial epithelial cells (Hastürk et al. 2002). COX-2 
overexpression in lung cancer is associated with tumor 
angiogenesis and survival and proliferation of tumor cells 
(Riedl et al. 2004) and with a poor prognosis in NSCLC 
(Achiwa et al. 1999; Yuan et al. 2005). Thus, the stimu-
lation of EGFR that leads to COX-2 activity by exposure 
to cigarette smoke is another mechanism mediated by a 
growth factor receptor to promote cell survival and prolif-
eration in carcinogenesis. 
Activation of Cytoplasmic Kinase  
by Tobacco Smoke
Activation of cell-surface receptors by components 
of tobacco smoke stimulates downstream kinases that 
mediate cancer cell survival, proliferation, and resistance 
to chemotherapy. The best-described kinases activated 
by smoking are AKT, ERK, PKC, and PKA. All of these 
kinases can be activated by cigarette smoke components 
through nAChRs, but ERBB family members also mediate 
AKT and ERK activation by cigarette smoke components. 
In addition, β-adrenergic receptor activation by cigarette 
smoke components can activate PKA and PKC. Thus, 
these proteins can be activated by tobacco smoke compo-
nents through multiple receptor-mediated mechanisms, 
suggesting that the proteins are important mediators of 
smoking-induced signal transduction. 
Protein Kinase B
The serine/threonine kinase AKT may be the critical 
effector of signaling induced by cigarette smoke, because 
AKT is stimulated in response to the activation of nAChRs, 
β-adrenergic receptors, and the ERBB family of receptors. 
Moreover, AKT controls many cellular processes that 
promote cell survival, proliferation, and the resistance of 
cancer cells to chemotherapy. Clinical data also suggest 
that AKT activation indicates a poor prognosis in many 
tobacco-related cancers. Thus, activation of this kinase 
by components of tobacco smoke can affect many cellular 
processes important for the initiation, growth, and pro-
gression of tumors. 
AKT might be important for the initiation as well as 
the maintenance of tobacco-related cancers. Nicotine and 
NNK cause rapid AKT activation through different nAChRs 
(West et al. 2003; Tsurutani et al. 2005). B[a]P metabo-
lites activate AKT in breast epithelial cells, although the 
cellular receptor responsible for the effect has not been 
identified (Burdick et al. 2003). Furthermore, nicotine-
induced AKT activation in normal human bronchial cells 
or in small airway epithelial cells promotes cell survival, 
proliferation, and anchorage-independent growth, all 
of which are properties of transformed cells (West et al. 
2003). These studies are important because they suggest 
that AKT activation by tobacco smoke components may 
precede the formation of DNA mutations that cause can-
cer. Thus, AKT activation could serve as a biochemical 
gatekeeper for lung carcinogenesis by promoting the sur-
vival of cells that would normally die from DNA damage.
In addition to promoting AKT-dependent growth 
and survival of normal epithelial cells, tobacco smoke 
components have similar effects on cells throughout the 
phenotypic spectrum of transformation. In a mouse model 
of NNK-induced lung tumorigenesis, an increase in AKT 
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activation was associated with an increase in the progres-
sion of NNK-induced lung lesions (West et al. 2004b). In 
human lung cancer cells, nicotine or NNK activated the 
AKT pathway and stimulated AKT-dependent prolifera-
tion through nAChRs (Tsurutani et al. 2005). Moreover, 
these researchers showed that nicotinic activation of AKT 
increased survival of lung cancer cells after treatment with 
chemotherapeutic agents or radiation (Tsurutani et al. 
2005). The fact that tobacco smoke components activate 
AKT and promote the survival of cancer cells is important, 
and it is supported by the finding that cancer patients who 
continue to smoke during chemotherapy have a worse 
prognosis than those who stop smoking (Johnston-Early 
et al. 1980; Browman et al. 1993; Videtic et al. 2003). 
Clinical data and preclinical models support the 
hypothesis that AKT activation is an early event in carci-
nogenesis. AKT is activated in preneoplastic lung lesions 
induced by exposure to NNK (West et al. 2004a) and in dys-
plastic lung lesions from smokers (Massion et al. 2004). In 
addition, AKT activation is associated with poor survival 
in patients with tobacco-related cancers, including lung 
cancer and pancreatic cancer (David et al. 2004; Hirami 
et al. 2004; Yamamoto et al. 2004; Tsurutani et al. 2005). 
Together, these clinical studies support the idea that AKT 
plays an important role in the formation and maintenance 
of tobacco-related cancers.
Extracellular Signal-Regulated Kinases
In addition to AKT, ERK may play an important role 
in smoking-related cancers because it can be activated 
in response to components of tobacco smoke through 
both nAChR and ERBB receptors. In normal cells, ERK 
is activated in response to many extracellular signals and 
stimulates cell proliferation. In SCLC and pulmonary neu-
roendocrine cells, NNK-induced activation of nAChR leads 
to the activation of RAF-1 and its downstream effector ERK 
(Jull et al. 2001; Schuller et al. 2003). In addition, B[a]P 
metabolites activate ERK (Burdick et al. 2003), and nico-
tine activates ERK and promotes cell survival (Heusch and 
Maneckjee 1998). Thus, like AKT, ERK can be activated as 
an acute response to tobacco smoke components. Because 
ERK and AKT can promote cell survival and proliferation, 
early activation of both kinases may contribute to the ini-
tiation, promotion, and progression of cancer. 
Researchers have also described ERK activation 
in tobacco-related cancers, thus validating the mecha-
nisms defined in vitro. ERK activation is associated with 
poor survival in SCLC, which occurs almost exclusively 
in smokers (Blackhall et al. 2003). The overexpression of 
C-MYC, an oncogene activated by ERK, has been described 
in lung cancer and promotes proliferation as well as 
resistance to cell death (Zajac-Kaye 2001). Thus, tobacco 
smoke components stimulate ERK, which promotes cell 
proliferation and contributes to the poor prognosis of 
lung cancer patients with this biochemical alteration.
Protein Kinase C
The PKC kinases also mediate cellular responses 
to exposure to tobacco smoke. Several isoforms of PKC 
can promote cell survival, most notably PKCα. Nico-
tine- and NNK-induced activation of PKCα through the 
β-adrenergic receptor promotes the survival of lung 
cancer cells (Schuller et al. 2003). In addition, nicotinic 
activation of nAChRs activates PKC in human bronchial 
epithelial cells, as well as in lung cancer cells (Maneck-
jee and Minna 1994; Carlisle et al. 2004). In SCLC, NNK- 
induced activation of nAChRs causes PKC activation 
associated with cell proliferation (Jull et al. 2001). 
Another PKC isoform, PKCd, seems to act atypically in 
NSCLC cells. Activation of PKCd in NSCLC promotes cell 
survival and resistance to chemotherapeutic agents (Clark 
et al. 2003), and nicotine can prevent chemotherapy from 
inhibiting PKC (Heusch and Maneckjee 1998). Like AKT, 
nicotinic activation of PKC has ramifications for smok-
ers by contributing to chemotherapeutic resistance. This 
finding is consistent with the finding that patients with 
lung cancer who continue to smoke during chemotherapy 
have a worse prognosis than those who stop smoking. 
A clinical study also demonstrates the importance 
of PKC in tobacco-related cancers. Lahn and colleagues 
(2004) found that PKCα is overexpressed in a subset of 
NSCLC. Collectively, the results suggest that the activa-
tion of prosurvival PKC isoforms by cigarette smoke is an 
important mechanism of cell proliferation mediated by 
nAChRs and β-adrenergic receptors in carcinogenesis. 
Protein Kinase A
Another cytoplasmic kinase activated by compo-
nents of tobacco smoke is PKA. Under normal physi-
ological conditions, PKA is stimulated through the 
production of cyclic adenosine monophosphate by activated 
G protein–coupled receptors. Nicotinic activation of PKA 
occurs through both nAChRs and β-adrenergic receptors 
(Dajas-Bailador et al. 2002; Jin et al. 2004a). The primary 
effect of nAChR-mediated PKA activation was an increase 
in cell proliferation. Nicotinic activation of PKA through 
β-adrenergic receptors, however, promoted cell survival. 
Although the data on PKA are limited, they suggest that 
PKA might be an important mediator of signal transduc-
tion, mediating cell survival and proliferation in response 
to activation by nAChRs and β-adrenergic receptors.
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Downstream Targets of Signaling Cascades 
Mediated by Tobacco Smoke
Activation of cell-surface receptors induced by com-
ponents of tobacco smoke and the subsequent activation 
of cytoplasmic kinases stimulate other proteins that dic-
tate cellular responses, such as cell survival and prolifera-
tion. Although activated kinases have many downstream 
targets, the two most studied are the transcription fac-
tor NF-kB and proteins in the BCL-2 family. Activation 
of these proteins by tobacco smoke components through 
signaling cascades promotes processes involved in initia-
tion, progression, and maintenance of cancers (see “Sig-
nal Transduction” earlier in this chapter).
Gene Promoter Hypermethylation 
in Cancer Induced by  Tobacco 
Smoke
Alternative to Mutation
Gene promoter hypermethylation is an epigenetic 
change of a gene involving extensive methylation at the 5’ 
position of C in CpG islands within the promoter region 
and often extending into exon 1 of regulatory genes (Jones 
and Baylin 2002; Herman and Baylin 2003). “Epigenetic” 
refers to alteration in gene expression resulting from 
changes other than DNA sequence. The end result of this 
process can be loss of gene transcription and therefore the 
silencing of gene function. 
Inactivation of the P16 Gene in Lung Cancer
One region on chromosome 9p contains the 
CDKN2A (P16) tumor-suppressor gene (Kamb et al. 1994; 
Merlo et al. 1994). Mutations within the P16 coding 
sequence are uncommon in lung cancer (Kamb et al. 
1994). In contrast, this gene is inactivated by hypermeth-
ylation at prevalences up to 60 percent and 70 percent in 
adenocarcinomas and SCC of the lung, respectively (Merlo 
et al. 1995; Belinsky et al. 1998; Kim et al. 2001; Zöchbaur-
Müller et al. 2001; Divine et al. 2005). This discovery of 
inactivation of a tumor-suppressor gene by hypermeth-
ylation in lung cancer and identification of such inacti-
vation of the P16 gene launched an area of research to 
uncover other genes inactivated by this mechanism. The 
targeting of P16 for inactivation is likely attributable to 
the critical function of this gene in the cell, which is to 
inhibit CDKs that bind cyclin D1 and phosphorylate the 
RB gene product (Lukas et al. 1995; Weinberg 1995). 
This regulation is lost if either the P16 or the RB gene is 
inactivated. The reciprocal relationship between RB 
alterations in SCLC and P16 alterations in NSCLC sup-
ports the premise that dysfunction within the RB pathway 
is a major target in research on the genesis of lung cancer 
(Swafford et al. 1997).
Critical Pathways Inactivated in Non-Small-Cell 
and Small-Cell Lung Cancer
More than 50 genes are inactivated by gene pro-
moter hypermethylation in lung cancer, and new genes 
are still being identified through genomewide screening 
approaches (Suzuki et al. 2002; Palmisano et al. 2003). 
The pathways and genes involved are summarized in 
Table 5.11. 
Of particular importance is the DNA repair gene 
AGT, which protects cells from the carcinogenic effects 
of alkylating agents by removing adducts from the O6 
position of deoxyguanosine (see “Repair of DNA Adducts” 
earlier in this chapter). Failure to repair this DNA adduct 
could lead to mutations in genes such as KRAS and TP53. 
AGT is inactivated by gene promoter methylation in 24 to 
48 percent of adenocarcinomas (Esteller et al. 1999; Zöch-
baur-Müller et al. 2001; Pulling et al. 2003). SCLC studies 
conducted for methylation of this gene are limited. Stud-
ies have reported an association between AGT promoter 
hypermethylation and a G→A transition mutation at CpG 
sites within the TP53 gene in NSCLC (Wolf et al. 2001). 
In contrast, no association was found between AGT gene 
methylation and a transition mutation in codon 12 of the 
KRAS gene from adenocarcinomas (Pulling et al. 2003). 
The RAS superfamily of GTP-binding proteins 
plays an important role in signal transduction pathways 
that control cell proliferation, differentiation, and death 
(Campbell et al. 1998; Downward 2001) (see “Activation 
of Oncogenes in Lung Cancer” earlier in this chapter). 
Researchers identified a new family of genes that encode 
RAS-binding proteins. One of these genes, RASSF1A, is 
located at chromosome 3p21 and inactivated in 30 per-
cent of NSCLCs and in 100 percent of SCLCs (Dammann 
et al. 2000; Burbee et al. 2001). Attempts to determine 
the function of this gene are continuing (Agathanggelou 
et al. 2003). RASSF1A protein forms a heterodimer with 
NORE1A, which allows it to bind with the proapoptotic 
protein MST1 (Khokhlatchev et al. 2002). Binding RAS 
to this complex may mediate RAS-dependent apopto-
sis. NORE1A is also silenced by methylation in NSCLC 
but not in SCLC (Hesson et al. 2003). Therefore, silenc-
ing either RASSF1A or NORE1A could effectively block 
apoptosis mediated by RAS activation. Two other RASSF 
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family members appear to be involved in lung cancer 
development. Studies show that RASSF2 binds directly to 
the KRAS gene in a GTP-dependent manner and appears 
to promote both cell-cycle arrest and apoptosis through 
this interaction (Vos et al. 2003). The expression of this 
gene is markedly reduced in some lung cancer cell lines, 
thus suggesting silencing by gene promoter hypermethyl-
ation. There is support for this mechanism of inactivation 
in studies on colon cancer that document hypermethyl-
ation of this gene in 70 percent of tumors (Hesson et al. 
2005). A third member of this gene family, RASSF4, shares 
25 percent homology with RASSF1A and 40 percent with 
RASSF2 and is methylated in approximately 20 percent of 
NSCLCs and SCLCs (Eckfeld et al. 2004). Thus, the loss 
of function among members of the RASSF gene family is 
important to the development of lung cancer.
Gene Silencing in Lung Cancer
The most extensively studied gene with respect to 
timing of methylation in NSCLC is P16. Examination of 
biopsy specimens from premalignant lesions obtained 
from people without SCLC or from different airways or 
at different bronchial generations revealed a progressive 
increase in the prevalence of P16 methylation as the dis-
ease developed. The frequency of P16 methylation was 
17 percent in basal cell hyperplasia, and the frequency 
increased incrementally over the histologic stages to 60 
percent in SCCs (Belinsky et al. 1998). Further studies 
examined bronchial epithelial cells obtained by bronchos-
copy from cancer-free smokers and found that inactiva-
tion of the P16 gene is likely one of the earliest events in 
lung cancer (Belinsky et al. 2002). Researchers detected 
P16 methylation in specimens from 25 of 137 biopsy pro-
cedures (18 percent) classified as histologically normal, 
metaplasia, or mild dysplasia. In contrast, no P16 meth-
ylation was found in biopsy specimens obtained from life-
time nonsmokers. Researchers used an animal model to 
determine the timing of P16 methylation in adenocarci-
nomas. In rats, 94 percent of adenocarcinomas induced 
by NNK were hypermethylated at the P16 promoter; this 
change was frequently detected in precursor lesions to the 
tumors: adenomas and hyperplastic lesions (Belinsky et 
al. 1998).
Inactivation of the AGT gene appears to be a later 
event in lung cancer than is the inactivation of P16. Only 
3 of 40 biopsy specimens (8 percent) from heavy smokers 
with histologies including normal, hyperplasia, metapla-
sia, and dysplasia showed methylation of the AGT gene 
(Pulling et al. 2003). In addition, the prevalence of AGT 
methylation increased between stage I adenocarcinoma 
and stages II to IV. Finally, of the 137 bronchial biopsy 
specimens studied, 3 percent of the DAPK gene and none 
of the RASSF1A genes showed methylation, which sug-
gests that the silencing of these genes likely occurs after 
P16 inactivation in SCC (Pulling et al. 2003). In con-
trast, the inactivation of DAPK by methylation in alveolar 
hyperplasias in a murine model of lung adenocarcinomas 
suggests a role for this gene in the early development of 
adenocarcinomas (Pulling et al. 2004). 
Gene Promoter Hypermethylation, Prognosis,  
and Clinical Risk Factors
Numerous studies have evaluated relationships 
between gene promoter methylation and established clini-
cal risk factors such as smoking dose and tumor stage. 
In addition, researchers have examined in detail the effect 
of gene-specific methylation on the survival of patients 
Table 5.11 Pathways altered through gene silencing 
by promoter methylation







Cell cycle P16 26–70 0
Cell cycle PAX5a 64–74 ND
Cell cycle PAX5ß 52–61 ND
Cell cycle CHFR 10–19 ND
DNA repair AGT 27–47 0–19
Apoptosis DAPK 24–48 33
Apoptosis CASPASE-8 0 35–52
Apoptosis FAS ND 40
Apoptosis TRAIL-R1 ND 40




RAS signaling RASSF4 20 20
RAS signaling NORE1A 24 0
Invasion E-CADHERIN 16–19 ND
Invasion H-CADHERIN 43 ND
Invasion TIMP3 19–24 ND
Invasion LAMA3 27–58 65
Invasion LAMB3 20–32 77
Invasion LAMC2 13–32 58
Invasion MYO18B 31 45
Source: Belinsky 2004. Reprinted with permission from 
Macmillan Publishers Ltd., © 2004. 
Note: ND = not determined.
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with a diagnosis of early-stage lung cancer. Results from 
investigations of the most commonly studied genes in 
lung cancer are highlighted here.
P16 methylation was significantly associated with 
pack-years of smoking and with an independent risk factor 
that predicts a shorter survival for patients who had resec-
tion of a stage I adenocarcinoma (Kim et al. 2001). Several 
other studies also support P16 methylation as a prognostic 
factor for survival of patients who had resection of a stage 
I adenocarcinoma (Suzuki et al. 2002; Wang et al. 2004a). 
In contrast, RASSF1A methylation in stage III NSCLC was 
a stronger predictor of poor survival than was P16 meth-
ylation (Wang et al. 2004a). These two genes may differ 
in that the silencing of P16 is an early event involved in 
initiation of tumorigenesis, whereas RASSF1A methyla-
tion is a later event more likely involved in progression 
of tumorigenesis. Thus, the methylation of RASSF1A may 
lead to a more aggressive tumor phenotype. This hypoth-
esis is supported by the more frequent involvement of 
RASSF1A methylation in tumors with a vascular invasion, 
pleural involvement, and a poorly differentiated histol-
ogy (Tomizawa et al. 2002). Persons who started smoking 
before 19 years of age were 4.2 times more likely to have 
methylation of the RASSF1A gene than were those who 
started smoking after 19 years of age (Kim et al. 2003). 
This research also suggests that for patients with stage I 
or stage II NSCLC at diagnosis, methylation of this gene is 
associated with a poorer prognosis (Kim et al. 2003).
Other Tobacco-Related Cancers
In addition to the studies on lung cancer described 
here, other studies have shown association of cigarette 
smoking with gene promoter hypermethylation in other 
tobacco-related cancers, such as the head and neck and 
bladder. Aberrant promoter methylation is common in 
head and neck cancer and has been detected by using 
saliva samples (Rosas et al. 2001). Promoter methylation 
of the P16, DAPK, E-CADHERIN, and RASSF1A genes was 
associated with smoking and commonly found in head 
and neck cancer (Hasegawa et al. 2002). P16 promoter 
hypermethylation and the loss of P16 protein expression 
were detected in head and neck SCC; loss of expression 
correlated significantly with a history of alcohol con-
sumption or tobacco use (Ai et al. 2003). The prevalence 
of P15 methylation in the healthy epithelium of patients 
with head and neck SCC who had long-term smoking 
and drinking behaviors was significantly higher than that 
in nonsmokers (Wong et al. 2003). Another study sug-
gested that P15 gene methylation could be induced by 
chronic smoking and drinking and could play a role in 
the early stages of head and neck SCC (Chang et al. 2004). 
Cigarette smoking was also associated with an increased 
risk of promoter methylation of the P16 gene in bladder 
cancer (Marsit et al. 2006).
Molecular Epidemiology of  
Cell-Cycle Control and Tobacco-
Induced Cancer
Introduction
Cell-cycle checkpoints delay cell-cycle progression, 
thereby affording adequate time for DNA repair to occur. 
Such checkpoint signaling also activates pathways lead-
ing to apoptosis if the damage cannot be repaired. The 
introduction of new techniques of profiling gene expres-
sion has enabled researchers to comprehensively evaluate 
activity of proteins in regulating the cell cycle (Singhal 
et al. 2003). A hallmark of the neoplastic cell is the abil-
ity to disrupt the tightly regulated cell-cycle control and 
enable the cell to bypass checkpoints, especially at the 
G1/S and G2/M boundaries (Hanahan and Weinberg 2000). 
Persons with defects in cell-cycle checkpoints (acquired or 
inherited) could therefore exhibit chromosome damage, 
genomic instability, and increased susceptibility to 
tobacco carcinogenesis. 
In vitro studies show an association between expo-
sure to tobacco carcinogens and the disruption of cell-
cycle control (Khan et al. 1999). Furthermore, Jin and 
colleagues (2004b) provide data showing that NNK pro-
motes cell survival and proliferation through phosphory-
lation of the proteins BCL-2 and C-MYC. Studies implicate 
tobacco carcinogens in genetic alterations in the P16-RB 
and P14ARF-P53 pathways, mainly through the forma-
tion of DNA adducts. Variations in cell-cycle checkpoints 
might also be attributed to functional polymorphisms 
in cell-cycle control genes. The SNP500Cancer Database 
reports that 27 genes related to the cell cycle are polymor-
phic, and these include genes that control checkpoints for 
both the G1/S and G2 phases of the cell cycle. However, 
only a few genes, including CCND1, TP53, P21, and P73, 
have been studied in tobacco-related cancers.
CCND1 Gene
The CCND1 gene, together with CDK4, P16, and 
the tumor-suppressor gene RB, comprise a linked system 
governing the passage of the cell through the cell cycle 
(Betticher et al. 1997). A common finding in a variety of 
cancers is the amplification or overexpression of CCND1, 
which contributes to tumor initiation, progression, 
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and outcome, such as death. A G→A polymorphism at 
codon 242 in the conserved splice donor region of exon 
4 increases alternate splicing (Betticher et al. 1995). 
The alternate transcript appears to encode for a protein- 
missing sequence involved in protein turnover, and there-
fore, the encoded protein may have a longer half-life. This 
extended half-life, in turn, would facilitate passage of dam-
aged cells through the checkpoint for the G1/S phase and 
promote proliferation rather than apoptosis. Researchers 
have studied the association between the CCND1 genotype 
and cancer risk in several tobacco-related cancers. Qiul-
ing and colleagues (2003) reported that the CCND1 *A/*A 
genotype was associated with a significantly increased 
risk of lung cancer (OR = 1.87; 95 percent CI, 1.01–3.45) 
compared with that for the *G/*G genotype. The risk was 
even higher in young persons and men. A similar finding 
was reported in cancer of the head and neck (Zheng et 
al. 2001). These investigators demonstrated that carriers 
of the *A/*A genotype, on average, had diagnoses of can-
cer 3.5 years earlier than did carriers of the*G/*G geno-
type. Wang and colleagues (2002) reported that the *A/*A 
genotype was associated with a significantly higher risk 
of transitional cell carcinoma of the bladder than that for 
the *A/*G plus *G/*G genotypes (OR = 1.76; 95 percent 
CI, 1.09–2.84). However, neither Cortessis and colleagues 
(2003) nor Yu and colleagues (2003) reported significant 
associations with either bladder cancer or esophageal SCC, 
respectively. Spitz and colleagues (2005) demonstrated an 
increased risk for lung cancer associated with this poly-
morphism. The risk estimate was 1.35 (95 percent CI, 
1.05–1.73) for the *A/*A and *A/*G genotypes compared 
with the *G/*G genotypes.
P21 Protein
Cell-cycle inhibitor protein P21 (WAF1/CIP1) acts as 
a checkpoint regulator for the G1/S and G2/M phases. Mar-
wick and colleagues (2002) showed a significant increase 
in P21 mRNA expression in alveolar epithelial cells after 
exposure to condensate from cigarette smoke and con-
cluded that oxidative stress induced by cigarette smoke 
modulates the expression of P21. 
Three studies of lung cancer have examined the 
association of cancer risk with a polymorphism of P21 at 
codon 31 (SER31ARG), but the findings were inconsistent. 
Själander and colleagues (1996) reported an increased fre-
quency of the variant allele (*ARG) among patients with 
lung cancer (p <0.004). Two other studies failed to repli-
cate this finding (Shih et al. 2000; Su et al. 2003). How-
ever, Chen and colleagues (2002) reported that the variant 
allele (*ARG) was associated with increased risk of blad-
der cancer.
TP53 Gene
Studies have reported 14 polymorphisms in the 
TP53 gene, 3 of which have been widely studied: a G→C 
polymorphism at codon 72 (proline/arginine), a 16bp 
insertion in intron 3, and a G→A transition in intron 6. 
Polymorphisms in codons 21, 36, and 213 are silent. The 
polymorphism in codon 47 involves a rare allele with a fre-
quency less than 5 percent. The codon 72 polymorphism 
on exon 4 produces variant proteins with an arginine 
(CGC) or proline (CCC) at the site. Thomas and colleagues 
(1999) reported differences between the two variants in 
their ability to interact with basic elements of the tran-
scriptional machinery and to induce apoptosis. Weston 
and colleagues (1992) reported an increased frequency 
of the proline allele in lung adenocarcinoma, which was 
consistent with findings in a Japanese study of lung cancer 
(Kawajiri et al. 1993). Jin and colleagues (1995) reported 
significantly higher risks for the *PRO/*PRO genotype 
among patients with lung cancer who were younger than 
55 years of age and among patients reporting fewer than 
30 pack-years of smoking. In a study of NSCLC, Nelson 
and coworkers (2005) found that mutation on the *PRO 
allele was associated with a significantly worse outcome 
than that for patients with no mutation or with mutation 
on the *ARG allele.
Mutations in intron sequences may initiate aberrant 
pre-mRNA splicing that results in a defective protein (Hil-
lebrandt et al. 1997) or that may influence mutations in 
the coding region. Either result would increase the likeli-
hood of a deleterious phenotype (Malkinson and You 1994). 
Biroš and colleagues (2001) reported a higher percentage 
of the intron 6 variant allele in patients with lung cancer 
than in control participants. However, Birgander and col-
leagues (1995) found no association of the allele with lung 
cancer. Several studies estimated the pairwise haplotype 
frequencies for the polymorphisms in exon 4 and introns 
3 and 6. The researchers proposed that the P53 haplotypes 
were associated with a higher risk for lung cancer (Birgan-
der et al. 1995; Biroš et al. 2001). In one study of 635 pairs 
of lung cancer patients and control participants, variant 
alleles of TP53 exon 4, introns 3 and 6, and their variant 
haplotypes were associated with an increased risk of lung 
cancer (Wu et al. 2002). In a meta-analysis of TP53 poly-
morphisms and lung cancer risk that included data from 
16 case-control studies, Matakidou and colleagues (2003) 
concluded that persons with the P53 exon 4 *PRO/*PRO 
genotype had a 1.18-fold increase in lung cancer risk 
(OR = 1.18; 95 percent CI, 0.99–1.41). Other researchers 
have observed a similar association with polymorphisms 
of P53 introns 3 and 6. However, evidence of these associa-
tions has not been consistent (Wang et al. 1999; Mabrouk 




The P73 gene activates the promoters of several 
genes that are responsive to the TP53 gene and participate 
in cell-cycle control, DNA repair, and apoptosis and inhibit 
cell growth in a P53-like manner by inducing apoptosis or 
cell-cycle arrest in the G1 phase (Nomoto et al. 1998; Cai 
et al. 2000). Loss of heterozygosity at the P73 locus is rela-
tively common. Studies have identified an estimated 17 
polymorphisms. Two common SNPs at positions 4 (G→A) 
and 14 (C→T) in the uncoding region of exon 2 of the 
P73 gene are in complete linkage disequilibrium and may 
affect P73 function by altering the efficiency of translation 
initiation (Kaghad et al. 1997).
Studies have reported the role of the P73 
G4C14→A4T14 polymorphism in the risk of smoking-
related cancer (Ryan et al. 2001; Hamajima et al. 2002; 
Hiraki et al. 2003; Huang et al. 2003). In NSCLC, the most 
significant effect observed was among male smokers 
(OR = 1.87; 95 percent CI, 1.25–2.80) with SCLC, suggest-
ing that this P73 polymorphism may have an impact on 
the repair of tobacco-associated DNA damage. A study of 
1,054 patients with lung cancer and 1,139 control partici-
pants found a dose-response relationship between the fre-
quency of heterozygous or homozygous variant alleles and 
risk of lung cancer (trend test, p <0.001). ORs were 1.32 
(95 percent CI, 1.10–1.59) for the frequency of heterozy-
gous alleles and 1.54 (95 percent CI, 1.05–2.26) for the 
frequency of homozygous alleles (Li et al. 2004b). The risk 
of lung cancer was more pronounced in persons younger 
than 50 years of age, men, light smokers, and patients with 
SCLC. The variant genotypes were also associated with an 
increased risk for SCCs of the head and neck that was sta-
tistically significant (OR = 1.33) and an even higher risk 
among current smokers (OR = 1.77) (Li et al. 2004a). 
Other Aspects
Carcinogenic Effects of  Whole 
Mixture and Fractions of  
Tobacco Smoke
Researchers have conducted inhalation studies of 
cigarette smoke in hamsters, rats, mice, rabbits, dogs, and 
nonhuman primates. The model systems used in these 
studies had various problems, including the inability of 
any study to accurately duplicate human smoking behav-
iors. Nevertheless, comprehensive reviews of these studies 
have found a large amount of useful information (IARC 
1986, 2004; Coggins 1998; Witschi 2000). Researchers 
observed the most consistent results on cancer induction 
in Syrian golden hamsters; whole cigarette smoke and its 
particulate phase induced malignant tumors and other 
lesions in the larynx. Tumors were not induced by the gas 
phase of cigarette smoke. 
Findings of studies that induced malignant tumors 
by inhalation of cigarette smoke and its particulate phase 
are consistent with those in the substantial amount of 
literature demonstrating that condensate from cigarette 
smoke, which lacks volatile constituents of the gas phase, 
causes benign and malignant tumors when applied to 
mouse skin and rabbit ears or instilled in rat lungs by 
intrapulmonary administration (Hoffmann et al. 1978; 
IARC 1986, 2004). Collectively, these results clearly show 
that major carcinogenic fractions of cigarette smoke 
reside in the particulate phase.
Extensive fractionation studies were conducted 
with cigarette smoke condensate (Hoffmann et al. 1978). 
Bioassays of the resulting fractions applied to the skin of 
mice demonstrated that the neutral portion of the con-
densate has carcinogenic activity and the acidic portion 
has tumor-promoting and cocarcinogenic activity. The 
recombined neutral and acidic portions accounted for 
about 80 percent of the carcinogenic activity of the con-
densate. Subfractionation of the neutral portion revealed 
that certain PAHs were the major tumor initiators in this 
fraction. However, these PAHs alone, in the levels at which 
they occur, were insufficient to induce tumors. Moreover, 
when these PAHs were added to the condensate, the tumor 
yield was higher than with the condensate alone. These 
results indicate that the combination of PAHs acting as 
tumor initiators, together with cocarcinogens in the con-
densate, accounted for the tumorigenicity of the conden-
sate on mouse skin. Researchers identified catechol and 
alkyl catechols as major cocarcinogens in the condensate, 
and the weakly acidic portion of the condensate demon-
strated tumor-promoting activity (Van Duuren and Gold-
schmidt 1976; Hecht et al. 1981). Other cocarcinogens in 
cigarette smoke include undecane, pyrene, fluoranthene, 
and B[a]P (Van Duuren and Goldschmidt 1976). The 
identity of tumor promoters in cigarette smoke is largely 
unknown, although simple phenols may contribute 
weakly (Hecht et al. 1975). Researchers have also observed 
tumor-promoting activity of cigarette smoke in inhalation 
experiments with hamsters (IARC 1986). PAH-enriched 
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fractions of cigarette smoke condensate instilled in the rat 
lung also resulted in tumor formation (IARC 1986).
These results clearly demonstrate the carcinogenic, 
tumor-promoting, and cocarcinogenic activity of the par-
ticulate phase of cigarette smoke. However, some data 
indicate that constituents of the gas phase also contribute 
to tumor induction. Early studies in Snell’s mice dem-
onstrated an increase in pulmonary adenocarcinomas in 
animals exposed to the gas phase alone (IARC 2004). In an 
exposure model using 89 percent sidestream smoke and 11 
percent mainstream smoke, increased multiplicity of lung 
adenomas was consistently observed in A/J mice exposed 
to the smoke for five months, followed by a four-month 
resting period. Tumor response in this model was clearly 
attributable to the gas phase, because filtration had no 
effect on multiplicity of lung adenomas (Witschi 2000; 
IARC 2004). The results of these studies indicate that a 
volatile carcinogen in cigarette smoke—possibly 1,3-bu-
tadiene—produced a tumorigenic response in the A/J 
mouse lung.
Two other studies not included in the reviews previ-
ously cited here demonstrate convincingly that cigarette 
smoke administered to rats or mice by whole-body expo-
sure for extended periods induces benign and malignant 
tumors of the respiratory tract (Mauderly et al. 2004; 
Hutt et al. 2005). When male and female F-344 rats were 
exposed to smoke from 1R3 research cigarettes or to clean 
air for six hours per day, five days per week for up to 30 
months, the exposure significantly increased the inci-
dence of nonneoplastic and neoplastic proliferative lung 
lesions in females. The combined incidence of bronchoal-
veolar adenomas and carcinomas was 14 percent in the 
high-exposure group (250 mg of particulates per m3 of 
air), 6 percent in the low-exposure group (100 mg/m3), 
and none in the controls. Mutations in codon 12 of the 
KRAS gene occurred in 4 of 23 tumors. Both males and 
females had significant increases in neoplasia of the nasal 
cavity (Mauderly et al. 2004). Female B6C3F1 mice were 
exposed to smoke for 6 hours per day, 5 days per week, 
for 925 days (250 mg/m3) or were sham exposed. The 
incidence of lung adenoma (28 percent) and lung adeno-
carcinoma (20 percent) in the mice exposed to smoke 
were significant (Hutt et al. 2005). 
Synergistic Interactions in  
Tobacco Carcinogenesis
Alcohol
There is persuasive epidemiologic evidence that 
alcohol consumption and smoking synergistically increase 
the risk for cancers of the oral cavity, pharynx, larynx, and 
esophagus (IARC 2004). No single mechanism clearly 
explains these observations, but several have been pro-
posed and there is reasonable support for some. The most 
consistent body of evidence relates to the effects of alcohol 
on the distribution of carcinogenic nitrosamines. Swann 
and colleagues (1984) demonstrated that alcohol could 
inhibit the hepatic metabolism and clearance of NDMA, 
a carcinogen in tobacco smoke. This inhibition occurs 
because ethanol competitively inhibits hepatic cyto-
chrome P-450 2E1, the main hepatic enzyme responsible 
for metabolism of NDMA. Consequently, more NDMA 
reaches extrahepatic tissues where it can be metabolically 
activated and has the potential to cause cancer. Ander-
son and coworkers (1992, 1996) demonstrated that coad-
ministration of ethanol and NDMA to A/J mice resulted 
in an incidence of lung tumors higher than that in mice 
treated with NDMA alone and that this increase was a con-
sequence of inhibition of hepatic metabolism and not of 
tumor promotion. Furthermore, administration of etha-
nol to patas monkeys before they received NDMA resulted 
in a 14.6-fold increase in O6-methylguanine in esophageal 
DNA and other extrahepatic tissues (Anderson et al. 1996). 
Another potential mechanism also involves the 
effects of ethanol on P-450 2E1, but as an inducer of this 
enzyme. Chronic ethanol consumption is known to induce 
production of hepatic P-450 2E1, and researchers hypothe-
sized that this induction could lead to increased metabolic 
activation of carcinogens in tobacco smoke (McCoy et al. 
1979). Some N-nitrosamines in tobacco smoke—NDMA, 
N-nitrosodiethylamine, and N-nitrosopyrrolidine—are all 
substrates for P-450 2E1. McCoy and colleagues (1981) 
demonstrated that chronic ethanol consumption in ham-
sters increased the metabolism of N-nitrosopyrrolidine 
in hepatic and target tissue (e.g., trachea), as well as the 
carcinogenicity of this nitrosamine, which increases the 
occurrence of tumors in the nasal cavity and trachea. The 
carcinogenicity of N-nitrosodiethylamine in the rat esoph-
agus was also increased by simultaneous administration 
of ethanol (Gibel 1967). Overall, however, the effects of 
ethanol consumption on N-nitrosamine carcinogen-
esis have been mixed, and they appear to depend on the 
N-nitrosamine studied and the protocol used. For exam-
ple, long-term ethanol consumption had no effect on the 
carcinogenicity of NNN in the hamster and only modest or 
no effect in the rat (McCoy et al. 1981; Trushin et al. 1984). 
Other mechanisms for the enhancing effect of 
alcohol consumption on tobacco carcinogenesis have been 
discussed (Pöschl and Seitz 2004). Persons who abuse 
alcohol generally have nutritional deficiencies, which 
could exacerbate the effects of smoking. They commonly 
have folate deficiency that could contribute to an inhibi-
tion of transmethylation, which is important in gene reg-
ulation. Zinc deficiency is known to result in enhanced 
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carcinogenesis in the rat esophagus (Fong et al. 2001). 
Reduced serum and hepatic levels of vitamin A in persons 
with long-term alcohol abuse may affect carcinogenesis. 
Alcohol could also act as a solvent, increasing absorption 
of tobacco carcinogens (Squier et al. 1986).
Asbestos
Smoking and exposure to asbestos interact synergis-
tically to increase the risk for lung cancer (IARC 2004). 
The mechanism for this synergy is unknown. Research-
ers have investigated a number of possibilities, however, 
and these have been summarized (Nelson and Kelsey 
2002). It has been proposed that asbestos fibers serve as a 
vehicle to deliver tobacco carcinogens to the cell nucleus. 
Surfactant phospholipids may help to solubilize carcino-
genic PAH, increasing their concentrations in the lung 
epithelium. Studies have also demonstrated that asbestos 
fibers can induce chromosomal aberrations and extensive 
deletions, potentially adding to the DNA damage produced 
by carcinogens in tobacco smoke. Furthermore, asbestos 
may cause oxidative damage that could be related to in-
flammation and cell death related to pulmonary fibrosis 
associated with exposure to asbestos. It seems likely that 
asbestos fibers could cause proliferation that may increase 
the probability of mutations attributable to DNA damage 
by tobacco smoke carcinogens.
Carcinogens as Causes of  
Specific Cancers
Data from carcinogenicity studies, product analyses, 
and findings from studies using biochemistry and molecu-
lar biology support a significant role for certain carcino-
gens in tobacco-induced cancer (Table 5.12). 
Considerable evidence favors PAHs and NNK as 
major factors in development of lung cancer. PAHs are 
strong carcinogens acting locally; thus, fractions of 
tobacco smoke enriched in these compounds are carcino-
genic (Hoffmann et al. 1978; Deutsch-Wenzel et al. 1983; 
IARC 1983) (see “Carcinogens in Cigarette Smoke” ear-
lier in this chapter). Researchers have detected PAH-DNA 
adducts in human lungs, and the spectrum of mutations 
in the TP53 gene isolated from lung tumors was similar to 
the pattern of DNA damage produced in vitro by PAH diol 
epoxide metabolites and in cell cultures by B[a]P (Pfeifer 
et al. 2002; Phillips 2002; Boysen and Hecht 2003; Liu et 
al. 2005) (see “DNA Adducts and Biomarkers” earlier in 
this chapter).
NNK is a strong systemic carcinogen in lungs of 
rodents that induces lung tumors independent of the 
route of administration (Hecht 1998). NNK was found to 
be particularly potent in the rat. Significant incidence of 
lung tumors was induced by total doses as low as 6 mg/
kilogram (kg) of body weight or by 1.8 mg/kg as part of 
a dose-response trend. These doses are comparable to an 
estimated NNK dose of 1.1 mg/kg in persons who have 
smoked for 40 years (Hecht 1998). DNA adducts derived 
from NNK or from the related tobacco-specific nitro-
samine, NNN, are present in lung tissue from smokers, 
and metabolites of NNK are found in the urine of smok-
ers (Hecht 2002b). Epidemiologic data indicate that a 
systemic carcinogen causes lung cancer in cigar smokers 
who do not inhale the smoke; this finding is consistent 
with the tumorigenic properties of NNK (Boffetta et al. 
1999; Shapiro et al. 2000). 
The changing histology of lung cancer is also con-
sistent with the role of NNK: adenocarcinoma has now 
overtaken SCC as the most common lung cancer type. 
This nitrosamine in tobacco smoke produces primarily 
adenocarcinomas in rodents. However, this outcome has 
also been attributed to differing inhalation patterns of 
current cigarette smokers (Travis et al. 1995; Hecht 1998). 
As nitrate concentrations in tobacco increased from 1959 
to 1997, NNK concentrations in mainstream smoke 
increased and those of B[a]P decreased. Researchers 
attributed these changes to tobacco blends with higher 
levels of air-cured tobacco, the use of reconstituted 
tobacco, and other factors (Hoffmann et al. 2001). Other 
compounds that could be involved in lung cancer include 
1,3-butadiene, isoprene, ethylene oxide, ethyl carbamate, 
aldehydes, benzene, metals, and oxidants, but the collec-
tive evidence for each of these substances is not as strong 
as the evidence for PAHs and NNK (Hecht 1999). 
The particulate phase of cigarette smoke causes 
tumors of the larynx in hamsters, which could be attrib-
uted to PAHs (IARC 1986). TP53 gene mutations identified 
in tumors of the human larynx support a role for PAHs 
in the development of this cancer (Pfeifer et al. 2002). 
N-nitrosamines, as well as acetaldehyde and formalde-
hyde, induce nasal tumors in rodents and are likely can-
didates for causing nasal tumors associated with smoking 
(Preussmann and Stewart 1984; IARC 1995c, 1999). On 
the basis of animal studies, PAH, NNK, and NNN are the 
most likely causes of oral cancer in smokers (Hoffmann 
and Hecht 1990). N-nitrosamines are the most effective 
esophageal carcinogens known. NNN causes tumors of 
the esophagus in rats and is the most prevalent N-nitrosa-
mine carcinogen in cigarette smoke (Hecht and Hoffmann 
1989; Lijinsky 1992). 
NNK and several other N-nitrosamines and furan 
in cigarette smoke are effective hepatocarcinogens in rats 
(Preussmann and Stewart 1984; IARC 1995b). NNK and 
its major metabolite NNAL are the only known pancreatic 
carcinogens in tobacco products. Biochemical data from 
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Table 5.12 Carcinogens and tobacco-induced cancers
Study Cancer type Likely carcinogen involvementa
Hoffmann and Hecht 1990
Hecht et al. 1994
Törnqvist and Ehrenberg 1994
Hecht 1999
Hoffmann et al. 2001
Pfeifer et al. 2002
Lung PAHs, NNK (major), 1,3-butadiene, isoprene, ethylene oxide, 
ethyl carbamate, aldehydes, benzene, metals
IARC 1986
Hoffmann et al. 2001
Pfeifer et al. 2002
Larynx PAHs
Preussmann and Stewart 1984
IARC 1995c, 1999
Hecht 1998
Nasal NNK, NNN, other nitrosamines, aldehydes
Hecht et al. 1986
Hoffmann et al. 1987, 1995, 2001
Hecht and Hoffmann 1988, 1989
Hoffmann and Hecht 1990
Hecht 1998
Vainio and Weiderpass 2003
Oral cavity PAHs, NNK, NNN
Hecht and Hoffmann 1989
Lijinsky 1992
Hecht 1998
Hoffmann et al. 2001
Esophagus NNN, other nitrosamines
Preussmann and Stewart 1984
IARC 1995a
Hecht 1998
Liver NNK, other nitrosamines, furan
Rivenson et al. 1988
Hecht 1998
Hoffmann et al. 2001
Prokopczyk et al. 2002
Pancreas NNK, NNAL
Melikian et al. 1999




Hoffmann and Hecht 1990
Skipper and Tannenbaum 1990
Skipper et al. 1994
Landi et al. 1996
Probst-Hensch et al. 2000
Hoffmann et al. 2001
Bladder 4-aminobiphenyl, other aromatic amines
IARC 1982 Leukemia Benzene
Source: Adapted from Hecht 2003 with permission.
Note: IARC = International Agency for Research on Cancer; NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; 
NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; PAHs = polycyclic aromatic hydrocarbons.




studies of human tissue provide some support for the 
role of these carcinogens in smoking-related pancreatic 
cancer, although the studies did not detect DNA adducts 
(Rivenson et al. 1988; Prokopczyk et al. 2002, 2005). Bio-
chemical studies demonstrate that both NNK and PAHs 
can reach the cervix in humans and are metabolically 
activated in these tissues (Melikian et al. 1999; Prokopc-
zyk et al. 2001). Researchers have detected DNA adducts 
derived from B[a]P and other hydrophobic compounds in 
cervical tissue from smokers (Melikian et al. 1999; Phillips 
2002). Therefore, in combination with the human papil-
loma virus, these compounds may contribute to develop-
ment of cervical cancer in smokers (IARC 1995a). 4-ABP 
and 2-naphthylamine are known human bladder carcino-
gens, and considerable data from human studies support 
the role of aromatic amines as the major cause of bladder 
cancer in smokers (IARC 1974; Skipper and Tannenbaum 
1990; Skipper et al. 1994; Landi et al. 1996; Probst-Hensch 
et al. 2000; Castelao et al. 2001). The most probable cause 
of leukemia in smokers is exposure to benzene, which 
occurs in large quantities in cigarette smoke and is a 
known cause of acute myelogenous leukemia in humans 
(IARC 1982).
Cigarette smoke causes oxidative damage probably 
because it contains free radicals, such as nitric oxide, and 
contains mixtures of hydroquinones, semiquinones, and 
quinones that can induce reduction and oxidation (redox 
cycling) (Pryor et al. 1998; Hecht 1999). Smokers have 
lower levels of ascorbic acid in plasma and, sometimes, 
higher levels of oxidized DNA bases in white blood cells 
than do nonsmokers. However, the role of oxidative dam-
age as a cause of specific tobacco-induced cancers remains 
unclear (Hecht 1999). 
Tobacco Carcinogens, Immune 
System, and Cancer
Cigarette smoke alters a range of immunologi-
cal functions including innate and adaptive immune 
responses (Sopori 2002). These effects, acting as tumor- 
promoting or cocarcinogenic stimuli, could affect 
tobacco-related carcinogenesis. Cigarette smoking 
increases the number of alveolar macrophages in the 
lung, possibly leading to higher levels of oxygen radicals 
and MPO activity, which are hypothesized to be impor-
tant in tumor promotion. Investigators examined the 
effects of smoking on the function of natural killer (NK) 
cells—a lymphoid cell type involved in surveillance of 
tumor growth (Lu et al. 2007). They obtained strong evi-
dence that suppression of NK cell activation was related 
to increased lung metastases in mice exposed to cigarette 
smoke. Other studies demonstrated that nicotine is 
immunosuppressive and thus might be responsible for 
some of the effects of cigarette smoke (Sopori 2002).
Epidemiology of Family History  
and Lung Cancer
Studies of familial aggregation of lung cancer pro-
vide indirect evidence supporting the possibility of an 
inherited component to tobacco carcinogenesis. A num-
ber of published studies showed that significantly more 
lung cancers were reported in first-degree relatives of pro-
bands with lung cancer than were reported in first-degree 
relatives of healthy control participants. Assuming that 
the family structure does not differ between cases and 
controls, this pattern could be explained by shared genes 
among the family members, shared smoking patterns, or 
a combination of both factors. By incorporating smoking 
histories of the probands and the first-degree relatives 
into a study of familial aggregation, researchers can begin 
to assess the level of familial risk of cancer while adjusting 
for tobacco use. However, few studies of familial aggrega-
tion incorporate history of involuntary exposure of fam-
ily members to tobacco smoke. Estimates of the overall 
proportion of patients with lung cancer who have fam-
ily history of lung cancer in a first-degree relative range 
from 6 (Li and Hemminki 2004) to 16 percent (Sellers et 
al. 1992).
Forty years ago, Tokuhata and Lilienfeld (1963) 
observed that the number of deaths from lung cancer 
was higher among relatives of lung cancer case patients 
than it was among relatives of control participants. These 
researchers also reported a fourfold excess of lung cancer 
mortality in nonsmoking relatives of 270 lung cancer pro-
bands. The effect among relatives who smoked was less 
pronounced (twofold). These findings suggest that the 
risk was not solely attributable to shared smoking patterns 
in the relatives. Other studies have since demonstrated a 
familial component of risk for lung cancer. The ORs asso-
ciated with family history ranged from 1.3 to 7.2 (Ooi et al. 
1986; Samet et al. 1986; Wu et al. 1988, 1996; Osann 1991; 
Shaw et al. 1991; Schwartz et al. 1996; Mayne et al. 1999). 
For example, in a comparison of 336 lung cancer pro-
bands with relatives of control spouses, Ooi and colleagues 
(1986) reported an association between a family history 
of lung cancer and a threefold excess risk (OR = 3.09; 95 
percent CI, 1.9–5.0). Shaw and associates (1991) found an 
OR of 2.8 (95 percent CI, 1.2–6.6) for risk of lung cancer 
among two or more relatives of case patients. Brownson 
and colleagues (1997) reported a trend for increasing risk 
associated with the number of first-degree relatives with 
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lung cancer. The risk was more than twofold for persons 
with five affected family members. 
One approach that evaluates familial aggregation 
while controlling for the impact of smoking focused on 
lifetime nonsmokers. Wu and colleagues (2004) evalu-
ated 216 lung cancer probands who were female non-
smokers and reported that family history of lung cancer 
was associated with a 5.7-fold (OR = 5.7; 95 percent CI, 
1.9–16.9) increase in lung cancer risk. Wu and colleagues 
(1988) noted, after adjustment for exposure to second-
hand smoke, a 30-percent increase in risk that was not 
statistically significant for history of cancers of the 
respiratory tract. This association was especially evident 
in mothers and sisters. The risk was also slightly elevated 
for lung cancer (OR = 1.3; 95 percent CI, 1.0–1.6). Mayne 
and colleagues (1999) also focused on familial risk in a 
population-based, case-control study of 437 lifetime 
nonsmokers and former smokers who had lung cancer 
and 437 matched control participants. The investigators 
observed increased risk of cancers of the aerodigestive 
tract among parents of case patients (OR = 2.78; 95 percent 
CI, 1.30–5.95) and increased risk of lung cancer among 
siblings and offspring of case patients (OR = 4.14; 95 per-
cent CI, 0.88–19.46; p = 0.07). They also reported approxi-
mately twofold increases in risk of breast cancer among 
mothers (OR = 2.52; 95 percent CI, 1.21–5.24) and sisters 
(OR = 2.07; 95 percent CI, 0.99–4.31) of lung cancer 
patients who were nonsmokers. On the other hand, 
Kreuzer and colleagues (2002) reported no evidence of 
familial risk in 234 lung cancer probands who were 
female nonsmokers.
Other investigators have reported familial aggrega-
tion of lung cancer among relatives of case patients who 
were nonsmokers with early-onset of lung cancer (at 
≤60 years of age). Schwartz and colleagues (1996) noted 
that family members of these case patients (aged 40 to 59 
years) had a sixfold increase in risk of lung cancer after 
adjustments for the age, gender, and race of each relative. 
In a subsequent study involving 118 population-based pro-
bands, Schwartz and colleagues (1999) also showed that 
family members of case patients younger than 40 years of 
age who had lung cancer were at increased risk for other 
cancers. Kreuzer and colleagues (1998) concluded that 
lung cancer in a first-degree relative was associated with a 
2.6-fold increase in risk of lung cancer among young case 
patients younger than 46 years of age. Elevated risk was 
not detected in older case patients. A study in Germany of 
945 lung cancer cases and 983 controls reported increased 
risk of lung cancer among first-degree relatives (RR = 1.7; 
95 percent CI, 1.1–2.5) and a 4.75-fold increase in risk 
among relatives of probands younger than 50 years of age 
who had a diagnosis of lung cancer (Bromen et al. 2000). 
Radzikowska and colleagues (2001) also noted stronger 
evidence from a study in Poland for aggregation of cancers 
among 757 patients with lung cancer who were younger 
than 50 years of age. 
On the other hand, Etzel and colleagues (2003) 
observed the familial aggregation of lung cancer and 
smoking-related cancers in late-onset lung cancers in 
persons older than 55 years of age, but not in early-onset 
lung cancers. An advantage of this study was the ability to 
adjust for the smoking status of the relatives. The study 
noted an excess of cancer among relatives of probands 
who were current smokers but not among relatives of life-
time nonsmokers. More recently, Li and Hemminki (2004) 
evaluated familial risks by using data from the Swedish 
Family Cancer Database and demonstrated that the his-
tologic type of lung cancer in relatives was generally ran-
dom. These researchers also estimated that 25 percent of 
familial lung cancers were diagnosed before 50 years of 
age, which represented about 1.6 percent of all lung can-
cers before 68 years of age. 
However, a cohort study of lung cancer mortality 
among male twins showed no role for genetic predisposi-
tion (Braun et al. 1994). Li and colleagues (1998b) used 
a parametric likelihood approach and adjustment for 
shared covariates to study familial association in the age at 
onset that they hypothesized to be attributable to genetic 
factors. The analysis indicated that a history of smoking, 
exposure to secondhand smoke, and chronic obstructive 
airway disease were all associated with lung cancer risk. 
After adjustments were made for these factors, there was 
little evidence of familial aggregation.
In a recent series with high-risk multiplex fami-
lies, Bailey-Wilson and colleagues (2004) mapped a major 
susceptibility locus of lung cancer through a genome-
wide linkage analysis to chromosome 6q23–25 near the 
PARKIN gene, which carries predisposition for a signifi-
cantly increased hereditary risk of lung cancer. A study 
of this locus also indicated presence of gene-environment 
interaction, and even light smoking by carriers of this 
gene significantly increased the risk for lung cancer com-
pared with that among heavy smokers. Carriers who did 
not smoke had much lower risk, comparable to risk for 
noncarriers. This finding indicated existence of a sensi-
tive group of persons for whom any amount of smoking 
is deleterious.
Studies have also presented evidence of Mendelian 
inheritance in lung cancer. Sellers and colleagues (1990) 
found that the pattern of occurrence of lung cancer was 
compatible with the Mendelian codominant inheritance 
of a rare and major autosomal gene. However, a similar 
study of families with lung cancer probands who did not 
smoke revealed no evidence for a major gene model and 
reported that an environmental model best explained 
the segregation pattern in the data (Yang et al. 1997). 
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Gauderman and Morrison (2000) determined that when 
the same data were analyzed but missing data for smok-
ing behaviors were produced from modeling techniques, a 
single autosomal dominant locus provided a slightly bet-
ter fit than the codominant model suggested by Sellers 
and colleagues (1990). In addition to possible etiologic 
heterogeneity, the inconsistency of these findings may 
be partly due to the insufficient power for the statistical 
analysis of limited sample sizes. A reanalysis by Yang and 
colleagues (1999) found evidence of a major gene with the 
Mendelian codominant model in the families of probands 
of nonsmokers younger than 60 years of age. This analysis 
rejected both the codominant and environmental models 
and suggested that multiple genetic and/or environmen-
tal factors contribute to the age at onset of lung cancer. 
Therefore, researchers need more complex genetic models 
for the distribution of age at onset.
Xu and colleagues (2005) completed a segrega-
tion analysis on 14,378 persons from 1,561 case families 
with aggregation of lung cancer. In their modeling, these 
researchers adjusted for the effects of smoking, gender, 
and age. This work provided evidence for a model involv-
ing multiple gene loci and interactions that contribute to 
the age at onset of lung cancer. 
One caveat that applies to all of these studies is 
the validity of data on family history, an issue indirectly 
addressed in an evaluation of family histories of can-
cer in participants in the Prostate, Lung, Colorectal and 
Ovarian Cancer Screening Trial (Pinsky et al. 2003). The 
data showed that in the ratios of reported-to-expected 
rates of cancer in family members, there were impor-
tant differences in rates of reporting family history of 
cancer according to the gender, race, ethnicity, and age 
of the respondents. These differences were mostly due to 
underreporting with respect to these covariates. Zio-
gas and Anton-Culver (2003) found that family histories 
of cancer reported by probands were more accurate for 
first-degree relatives and that probands referred through 
clinics had lower false-positive rates for reporting of fam-
ily history than did population-based probands. Bondy 
and colleagues (1994) evaluated the accuracy of cancer 
diagnosis reported by probands among family members 
by comparing reported cancer information with docu-
mentation available through medical records and death 
certificates. The study noted high levels of accuracy for 
cancers of first-degree relatives, as evidenced by agreement 
between reporting by probands and information in 
records. Thus, these findings of familial aggregation sug-
gest a role for the inherited susceptibility of lung cancer 
beyond that associated with familial clustering of smoking 
behaviors, taking into account family size and structure.
 A genomewide association study in 2008 identified 
a region of strong linkage disequilibrium on the long arm 
of chromosome 15 as a susceptibility locus for lung can-
cer (Amos et al. 2008). Studies replicating this association 
have focused attention on the most likely candidate genes 
in this region, CHRNA3 and CHRNA5, which encode sub-
units of the nAChR (Hung et al. 2008). Le Marchand and 
colleagues (2008) found that carriers of the lung-cancer-
associated variants in these genes extract more nicotine 
and are thus exposed to a higher internal dose of carci-
nogenic nicotine-derived nitrosamines. SNPs in the same 
region have also been associated with nicotine dependence 
and smoking intensity (Caporaso et al. 2009). 
Evidence Summary
Although cigarette smoke contains diverse carcino-
gens, PAH, N-nitrosamines, aromatic amines, 1,3-butadi-
ene, benzene, aldehydes, and ethylene oxide are among 
the most important carcinogens because of their carcino-
genic potency and levels in cigarette smoke. Moreover, the 
major pathways of metabolic activation and detoxification 
of some of the principal carcinogens in cigarette smoke are 
well established. Reactive intermediate agents critical in 
forming DNA adducts include diol epoxides of PAH, diazo-
nium ions generated by α-hydroxylation of nitrosamines, 
nitrenium ions formed from esters of N-hydroxylated aro-
matic amines, and epoxides such as ethylene oxide. Glu-
tathione and glucuronide conjugation play major roles in 
detoxification of carcinogens in cigarette smoke.
Familial predisposition and genetic polymorphisms 
may play a role in tobacco-related neoplasms. Research-
ers have established cigarette smoking as a major cause 
of lung cancer; more than 85 percent of lung cancers are 
attributable to smoking. However, not all smokers develop 
lung cancer, and lung cancer can arise in lifetime non-
smokers. This variation in disease has stimulated inter-
est in molecular epidemiology of genetic polymorphisms, 
including genes that regulate the cell cycle and genes 
for carcinogen-metabolizing enzymes that may lead to 
variations in susceptibility to the carcinogens in tobacco 
smoke. Studies to date suggest a role for these genetic 
polymorphisms in the risk of lung and bladder cancer in 
smokers, and they support the possibility of interactions 
between genes and smoking status. 
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Quantitative analysis of carcinogens or their metab-
olites in urine, breath, and blood provides a convenient 
and reliable method of comparing exposure to carcino-
gens among smokers and between smokers and non-
smokers. Urinary biomarkers of several major types of 
carcinogens in cigarette smoke are reliable indicators of 
exposure, and the measurements provide good estimates 
of minimum doses of relevant carcinogens in smokers 
and allow comparisons with nonsmokers. The total car-
cinogen dose is generally difficult to calculate because the 
extent of conversion of a given carcinogen to the measured 
metabolite is usually unknown. However, relative carcino-
gen levels in cigarettes generally correlate with metabolite 
levels in urine. Comparisons of smokers and nonsmokers 
demonstrate that total NNAL is the most discriminatory 
biomarker in that tobacco products are the only source of 
the parent carcinogen NNK.
Evidence is overwhelming that DNA adduct levels 
are higher in most tissues of smokers than in correspond-
ing tissues of nonsmokers. This observation provides 
bedrock support for the major pathway of cancer induc-
tion in smokers that proceeds through formation of DNA 
adducts and genetic damage. Studies of specific adducts 
are still scarce and are limited mainly to human lung tis-
sue. Strong evidence supports the presence of a variety of 
specific adducts in the human lung, and in several studies, 
adduct levels are higher in smokers than in nonsmokers. 
Collectively, the results of these biomarker studies clearly 
demonstrate the potential for genetic damage in smokers 
from the persistence of DNA adducts. 
Adducts lead to mutations that drive the process 
of tumor formation and progression through additional 
genetic alterations. Chromosomal losses are more com-
mon in tumors from smokers. Furthermore, inactivating 
mutations of the TP53 tumor-suppressor gene and activat-
ing mutations of the KRAS oncogene in NSCLCs and other 
tumors are correlated with exposure to cigarette smoke, 
and they contribute to a phenotype that reduces survival 
time in both early and advanced stages of the disease. Dif-
ferent types of lung cancer in smokers all show an excess 
of G→T transversions compared with cancers that are not 
related to exposure to tobacco smoke. The site specificity 
of mutagenesis by PAH diol epoxides implies that targeted 
adduct formation, in addition to phenotypic selection, is 
responsible for shaping the TP53 mutational spectrum 
in lung tumors. Propagation of these genetic alterations 
during clonal outgrowth is consistent with accumulation 
of multiple genetic changes observed in progression of 
lung cancer.
Gene promoter hypermethylation is an epigenetic 
change involving extensive methylation at the 5-position 
of C in CpG islands within the promoter region and often 
extending into exon 1 of regulatory genes. The end result 
of this process can be loss of gene transcription and there-
fore the silencing of gene function. Promoter methylation 
of several genes including P16 occurs early in tumor for-
mation. P16 methylation was significantly associated with 
pack-years of smoking and was an independent risk fac-
tor for shorter survival in patients with early resectable 
adenocarcinomas. Other genes such as RASSF1A may be 
more frequently methylated in various tumor types from 
smokers. Methylation of genes, such as AGT promoter 
hypermethylation, may increase G→A transition muta-
tions at CpG sites within the TP53 gene in NSCLC.
The activation of nAChRs in lung epithelial cells 
by nicotine or NNK promotes survival and proliferation 
of cancer cells and also leads to increased angiogenesis. 
Activation of cell-surface receptors induced by components 
of tobacco smoke and subsequent activation of cytoplas-
mic kinases stimulate other proteins that dictate cellular 
responses, such as cell survival and proliferation. Although 
activated kinases have many downstream targets, the two 
most studied are the transcription factor NF-kB and pro-
teins in the BCL-2 family. Activation of key intracellular 
proteins by tobacco smoke components through signaling 
cascades promotes processes that are important for initia-
tion, progression, and maintenance of cancer. Apoptosis, 
the normal mechanism of endogenous cell elimination, is 
also commonly suppressed in lung cancer by these com-
ponents. Thus, key genetic and epigenetic events that lead 
to cancer causation, as well as critical cellular pathways 
that further growth and development of transformed cells, 
are directly targeted by components of cigarette smoke 





1. The doses of cigarette smoke carcinogens resulting 
from inhalation of tobacco smoke are reflected in lev-
els of these carcinogens or their metabolites in the 
urine of smokers. Certain biomarkers are associated 
with exposure to specific cigarette smoke carcinogens, 
such as urinary metabolites of the tobacco-specific 
nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1- 
butanone and hemoglobin adducts of aro- 
matic amines. 
2. The metabolic activation of cigarette smoke carcino-
gens by cytochrome P-450 enzymes has a direct effect 
on the formation of DNA adducts.
3. There is consistent evidence that a combination of 
polymorphisms in the CYP1A1 and GSTM1 genes 
leads to higher DNA adduct levels in smokers and 
higher relative risks for lung cancer than in those 
smokers without this genetic profile.
4. Carcinogen exposure and resulting DNA damage 
observed in smokers results directly in the numerous 
cytogenetic changes present in lung cancer.
5. Smoking increases the frequency of DNA adducts of 
cigarette smoke carcinogens such as benzo[a]pyrene 
and tobacco-specific nitrosamines in the lung and 
other organs.
6. Exposure to cigarette smoke carcinogens leads to 
DNA damage and subsequent mutations in TP53 and 
KRAS in lung cancer. 
7. There is consistent evidence that smoking leads to the 
presence of promoter methylation of key tumor sup-
pressor genes such as P16 in lung cancer and other 
smoking-caused cancers.  
8. There is consistent evidence that smoke constituents 
such as nicotine and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone can activate signal transduction 
pathways directly through receptor-mediated events, 
allowing the survival of damaged epithelial cells that 
would normally die. 
9. There is consistent evidence for an inherited sus-
ceptibility of lung cancer with some less common 
genotypes unrelated to a familial clustering of smok- 
ing behaviors. 
10.  Smoking cessation remains the only proven strategy 
for reducing the pathogenic processes leading to can-
cer in that the specific contribution of many tobacco 
carcinogens, alone or in combination, to the develop-
ment of cancer has not been identified.
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Table 5.2 DNA adducts in human lung tissue
Study Carcinogen DNA base Adduct structuresa
Type of 
evidenceb
Rojas et al. 1998, 2004
Boysen and Hecht 2003
Benzo[a]pyrene dG 1
Wilson et al. 1989
Mustonen et al. 1993 
Kato et al. 1995
Blömeke et al. 1996
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Kato et al. 1995
Blömeke et al. 1996
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Foiles et al. 1991 NNK
N’-nitrosonornicotine
dG, T, dC 1
Eide et al. 1999 Ethylene oxide dG 7—HOCH2CH2 2
Wilson et al. 1989





Study Carcinogen DNA base Adduct structuresa
Type of 
evidenceb








Asami et al. 1997
Lee et al. 1999a
Oxidants dG 8—oxo 3
Note: dC = deoxycytidine; dG = deoxyguanosine; NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; T = thymidine.
aAdduct structures show position of attachment to the base (e.g., N2-, O6-, or 7- of dG) and the organic moiety derived from the car-
cinogen.
b1 = detection of a released adducted moiety by a specific method; 2 = detection of a nucleoside or base by a relatively nonspecific 
method (e.g., 32P-postlabeling or immunoassay); 3 = detection of a nucleoside or base by a specific method (e.g., mass spectrometry, 
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Introduction
This chapter reviews the epidemiology of smoking-
induced cardiovascular disease (CVD) and the mecha-
nisms by which tobacco smoke is thought to cause CVD. 
The discussion includes use of biomarkers to diagnose 
smoking-induced CVD and treatment implications of 
the pathophysiology of the disease. The link between 
secondhand smoke and CVD has been reviewed in the 2006 
report of the Surgeon General, The Health Consequences 
of Involuntary Exposure to Tobacco Smoke (U.S. Depart-
ment of Health and Human Services [USDHHS] 2006), so 
discussion of secondhand smoke in this report is limited.
Tobacco Use and Cardiovascular Disease
Cigarette smoking is a major cause of CVD, and 
past reports of the Surgeon General extensively reviewed 
the relevant evidence (U.S. Department of Health, Edu-
cation, and Welfare [USDHEW] 1971, 1979; USDHHS 
1983, 2001, 2004). Cigarette smoking has been respon-
sible for approximately 140,000 premature deaths annu-
ally from CVD (USDHHS 2004). More than 1 in 10 deaths 
worldwide from CVD in 2000 were attributed to smoking 
(Ezzati et al. 2005). In the United States, smoking 
accounted for 33 percent of all deaths from CVD and 20 
percent of deaths from ischemic heart disease in persons 
older than 35 years of age (Centers for Disease Control and 
Prevention 2008). Cigarette smoking also influences other 
cardiovascular risk factors, such as glucose intolerance 
and low serum levels of high-density lipoprotein cholester-
ol (HDLc). However, studies have reported that smoking 
increases the risk of CVD beyond the effects of smoking on 
other risk factors. In other words, the risk attributable to 
smoking persisted even when adjustments were made for 
differences between persons who smoke and nonsmokers 
in levels of these other risk factors (Friedman et al. 1979; 
USDHHS 1983, 2001, 2004; Shaper et al. 1985; Criqui et 
al. 1987; Ragland and Brand 1988; Shaten et al. 1991; Nea-
ton and Wentworth 1992; Freund et al. 1993; Cremer et 
al. 1997; Gartside et al. 1998; Wannamethee et al. 1998; 
Jacobs et al. 1999a). For example, in one study, the effect 
of cigarette smoking on the risk of coronary heart disease 
(CHD) was evident even among persons with low serum 
levels of cholesterol (Blanco-Cedres et al. 2002).
Beyond its status as an independent risk factor, 
smoking appears to have a multiplicative interaction with 
the other major risk factors for CHD—high serum levels 
of lipids, untreated hypertension, and diabetes mellitus 
(USDHHS 1983). For instance, if the presence of smoking 
alone doubles the level of risk, the simultaneous presence 
of another major risk factor is estimated to quadruple the 
risk (2 × 2). The presence of two other risk factors with 
smoking results in approximately eight times the risk (2 × 
2 × 2) of persons with no risk factors. Cigarette smoking 
also is a cause of peripheral arterial disease (PAD), aor-
tic aneurysm, CHD, and cerebrovascular disease, but the 
relative risk (RR) of disease varies with the vascular bed 
(USDHEW 1971, 1979; USDHHS 1983, 2001, 2004). The 
highest RRs are observed for diseases of peripheral arter-
ies in the lower extremities, and the lowest are for stroke; 
RRs are intermediate for CHD and aortic aneurysm.
The general mechanisms by which smoking results 
in cardiovascular events include development of athero-
sclerotic changes with narrowing of the vascular lumen 
and induction of a hypercoagulable state, which create 
risk of acute thrombosis (USDHHS 1983, 2004). The rapid 
decline in risk of a recurrent myocardial infarction (MI) 
after smoking cessation (USDHHS 1990) supports the role 
of smoking in thrombosis. In addition, abundant evidence 
demonstrates that smoking contributes to development 
of atherosclerotic plaque (Strong and Richards 1976; 
Auerbach and Garfinkel 1980; Solberg and Strong 1983; 
USDHHS 1983, 2004).
Estimation of Risk
The risk of CHD from cigarette smoking can be 
described in terms of RR and excess risk (Thun et al. 
1997). The RR is the ratio of CHD rates for populations 
of smokers to rates for lifetime nonsmokers. Excess risk 
is the difference between the rates of disease for smokers 
and nonsmokers. 
These two estimates of risk can lead to conflicting 
impressions of the changes in smoking-related CHD risks 
with advancing age. The RRs and excess death rates for 
CHD are shown by age group in data from Cancer Preven-
tion Study II (CPS-II) (Thun et al. 1997), sponsored by the 
American Cancer Society (see Figure 6.1 for data on men). 
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The RRs were highest at younger ages (35 to 54 years) and 
declined steeply with advancing age. This finding leaves 
the false impression that the disease burden of CHD from 
smoking declined with age or was low among older smok-
ers. However, excess CHD death rates for smokers by age 
group presented different evidence. The high RR for CHD 
at younger ages can be explained in part because mortal-
ity rates are low for death from CHD at those ages and 
because coronary events in young people occur primarily 
among smokers. Even though RR declined with increas-
ing age, because the absolute rate of deaths from CHD 
increased markedly, the magnitude of the CHD burden 
produced by smoking increased with advancing age.
The age at onset of substantial excess risk differs 
by disease. For smokers, age-specific excess death rates 
attributable to CHD, lung cancer, cerebrovascular disease, 
and chronic obstructive pulmonary disease (COPD) are 
illustrated by data from CPS-II (Figure 6.2 shows data for 
men) (Thun et al. 1997). For persons younger than age 45 
years, CHD was the dominant cause of increased mortality 
attributable to cigarette smoking. Excess rates for death 
from lung cancer increased steeply after age 50 years, and 
excess death rates from COPD were largely confined to 
the seventh and eighth decades of life. Late in life, excess 
deaths from COPD matched and those from lung cancer 
exceeded the excess death rates attributable to CHD. The 
RR for death from a cerebrovascular disease among smok-
ers was substantially elevated among younger smokers 
(RR = 4 to 5; data not shown). However, the absolute rate 
of stroke at these younger ages was low, and this finding 
resulted in a low excess mortality rate. At older ages, the 
death rate from stroke in the general population increased 
and the RR among smokers declined, thus moderating the 
excess death rate attributable to smoking.
Coronary Heart Disease
Cigarettes Smoked per Day
Studies showed increased risk of having CHD at all 
levels of cigarette smoking, and increased risks were evi-
dent even for persons who smoked fewer than five ciga-
rettes per day (Rosengren et al. 1992; Prescott et al. 2002; 
Bjartveit and Tverdal 2005). Prospective mortality studies 
conducted in the 1960s and 1970s showed a clear increase 
in CHD mortality with an increase in the number of ciga-
rettes smoked per day, regardless of the actual number 
Figure 6.1 Relative risk and excess death rate for coronary heart disease among men, by age group
Source: Burns 2003. Adapted from Thun et al. 1997 with permission from Elsevier, © 2003.
Note: Data are from the American Cancer Society’s Cancer Prevention Study II; data table for above data found at end of chapter.
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(Doll and Peto 1976; USDHHS 1983). Other studies sug-
gested that risk increased up to at least 40 cigarettes per 
day (Miettinen et al. 1976; Willett et al. 1987). However, 
more recent data appeared to show an increase in CHD 
risk with more cigarettes smoked per day only up to about 
25 cigarettes; the risk increased relatively little even with 
further increases in cigarette consumption (Neaton and 
Wentworth 1992; Rosengren et al. 1992; Thun et al. 1997). 
Law and Wald (2003), who conducted a meta- 
analysis of five large studies of smoking and CHD, dem-
onstrated a nonlinear dose-response relationship between 
the number of cigarettes smoked per day and the RR of 
disease (Figure 6.3). The researchers suggested that the 
effect of cigarette smoking on risk of CHD may have a low 
threshold and that the dose-response characteristics of 
the risk relationship are less steep at higher doses. This 
hypothesis was used to explain the seeming anomaly of a 
high RR of CHD associated with relatively low exposure to 
secondhand smoke. By using serum levels of cotin-
ine (a metabolite of nicotine) as biomarkers of expo-
sure, Whincup and colleagues (2004) explored the dose 
response relationship between exposure to cigarette 
smoke and CHD in persons involuntarily exposed to 
cigarette smoke. More than 2,000 men who said they 
did not smoke had blood levels of cotinine measured in 
1978–1980 and then had follow-up for 20 years. Nico-
tine exposure was examined by quartiles of blood coti-
nine as follows: less than or equal to 0.7 nanograms per 
milliliter (ng/mL), 0 to 1.4, 1.5 to 2.7, and 2.8 to 14.0. 
Hazard ratios for CHD, which included deaths and non- 
fatal MIs, were significantly increased at all upper quar-
tiles (hazard ratios, 1.43 to 1.57) compared with the lowest 
exposure quartile, after adjustment for established CHD 
risk factors. Hazard ratios were also higher at the first 
and second five-year follow-ups (3.73 to 10.58 and 1.95 
to 2.48, respectively) than those at later follow-ups. The 
Figure 6.2 Age-specific excess death rates among male smokers for coronary heart disease, lung cancer, chronic 
obstructive pulmonary disease (COPD), and cerebrovascular disease
Source: Burns 2003. Adapted from Thun et al. 1997 with permission from Elsevier, © 2003.
Note: Data are from the American Cancer Society’s Cancer Prevention Study II; data table for above data found at end of chapter.
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Figure 6.3 Dose-response relationship between number of cigarettes smoked per day and relative risk of ischemic 
heart disease
Source: Law and Wald 2003. Reprinted with permission from Elsevier, © 2003.
Note: The dose-response relationship between exposure to tobacco smoke and ischemic heart disease events is compartmentalized into 
separate associations attributable to confounding (difference between smokers and nonsmokers in blood pressure, body weight, blood 
lipids, and diet), cause and effect maximal at low dose, and cause and effect with linear dosimetry.
substantial cardiovascular risk attributable to involuntary 
exposure to cigarette smoke (USDHHS 2006) and the 
practice in most CVD studies of not excluding from the 
control group persons who had secondhand smoke expo-
sure have resulted in underestimation, in many research 
reports, of the effects of active smoking compared with no 
exposure to cigarette smoke. 
The data on secondhand smoke and CHD risk indi-
cate that the dose-response relationship between exposure 
to smoke and cardiovascular effects is nonlinear. Another 
consideration is that the number of cigarettes smoked 
per day may not provide a linear measure of exposure to 
tobacco smoke. When carboxyhemoglobin or serum coti-
nine levels were used as measures of the smoke taken in, 
persons who smoked more cigarettes per day had higher 
levels of these biologic substances (Benowitz 1996). Even 
so, the carboxyhemoglobin and cotinine levels were sub-
stantially lower than those predicted by linear extrapola-
tion from data on persons who reported smoking 1 to 20 
cigarettes per day (Law et al. 1997). Among smokers of 40 
or more cigarettes per day, the levels of these biomark-
ers were 35 percent lower than those predicted by linear 
extrapolation from data on persons who reported smoking 
fewer than 20 cigarettes per day.
At the same reported number of cigarettes per day, 
cotinine levels varied substantially (Benowitz 1996). 
Smokers titrate cigarette smoke to achieve a consistent 
intake of nicotine by altering the number of cigarettes 
smoked per day or by changing the puffing pattern—
that is, by taking deeper, faster, more, or longer puffs 
(National Cancer Institute [NCI] 2001). When these smoking 
behaviors fail to restore the level of nicotine intake, as they 
may with cigarettes that have very low machine-measured 
yields, smokers may increase the number of cigarettes per 
day to maintain the same level of nicotine intake.
These observations suggest that the number of cig-
arettes smoked per day may have become a less precise 
measure of exposure to tobacco smoke with the introduc-
tion of cigarettes with low machine-measured yields of 
tar and nicotine. This diminished precision of cigarettes 
smoked per day as a measure of exposure may account 
for some of the discordance between studies that define 
increased risk by an increase of more than one pack per 
day in the number of cigarettes smoked. By using serum 
cotinine as an indicator of nicotine intake and exposure 
to tobacco smoke in the population demonstrates a linear 
increase for 10 to 15 cigarettes per day. However, as use 
exceeds 10 to 15 cigarettes per day, a progressively smaller 
increment in serum cotinine for each increment in the 
number of cigarettes smoked per day is observed (Carabal-
lo et al. 1998; O’Connor et al. 2006). This flattening of the 
relationship between exposure and cigarettes smoked per 
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day was similar to flattening of the relationship between 
the RR of CHD and the number of cigarettes smoked per 
day. Thus, researchers should be cautious about defin-
ing the absence of a continuing increase in risk among 
smokers of more than 20 cigarettes per day as evidence 
that increases in actual exposure are not accompanied by 
increases in risk. 
Duration of Smoking
Researchers have not always demonstrated a sig-
nificant relationship between duration of cigarette smok-
ing and CHD risk when adjustment was made for other 
risk factors and the number of cigarettes smoked per day 
(Kuller et al. 1991; Tverdal 1999). Variation in the number 
of cigarettes smoked per day and in the products smoked 
during the lifetime of a smoker is often substantial, but 
this variable is not well captured in epidemiologic studies. 
Age is colinear with duration of smoking, because 
the two variables grow in tandem after a person starts to 
smoke and the RRs for smoking and CHD decline with 
advancing age. Furthermore, most smokers begin to 
smoke during adolescence, which promotes the colinear-
ity. These realities make it difficult to estimate the inde-
pendent contributions of age and duration of smoking 
to risk of CHD in multivariate models. However, the two 
studies of the American Cancer Society are a good source 
of data, because each study consists of more than 1 mil-
lion men and women (Burns et al. 1997; Thun et al. 1997). 
Analyses of these data stratified by age and the number 
of cigarettes smoked per day showed steady increases in 
CHD mortality rates with increasing duration of smoking 
for persons younger than age 70 years. Using data from 
CPS-I, investigators calculated the risk of developing CHD 
by age and duration of smoking (see Table 6.1 for data on 
White men) (Burns et al. 1997). For almost all age groups 
younger than age 70 years, RRs increased with increas-
ing duration of smoking. Data from CPS-II on men (Thun 
et al. 1997) also demonstrated a pattern of increasing RR 
with age-specific mortality due to CHD and increasing 
duration of smoking for each level of cigarettes smoked 
per day (Table 6.2). Even though data in these analyses 
were not adjusted for potential differences in other car-
diovascular risk factors, the findings presented a convinc-
ing picture of increasing risk of CHD with longer duration 
of smoking.
Smoking Cessation
The risks of MI and death from CHD are lower 
among former smokers than among continuing smokers 
in many studies, including those with data adjusted for 
levels of other risk factors (Gordon et al. 1974; Åberg et 
al. 1983; USDHHS 1990; Kuller et al. 1991; Frost et al. 
1996). The risk fell rapidly, decreasing about one-half in 
one year (Lightwood and Glantz 1997). Risks appear to 
remain slightly elevated for more than a decade after per-
sons stopped smoking, but in some studies this increased 
risk was not statistically significant (Dagenais et al. 1990; 
Omenn et al. 1990; Kawachi et al. 1993a, 1994; Jacobs et 
al. 1999a; Qiao et al. 2000). Among smokers who had MI or 
angiographically documented CHD, persons who stopped 
smoking had a substantially lower rate of reinfarction than 
did those who continued to smoke. Reduction in risk was 
evident within the first year after MI. Risk continued to 
be lower among former smokers than among continuing 
Table 6.1 Rate ratios for coronary heart disease among White men, by age and duration of cigarette smokinga
   Duration of smoking (years)
Age (years) 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59
40–44 1.95 2.47 4.23 NR NR NR NR NR
45–49 1.79 2.5 2.66 2.64 4.39 NR NR NR
50–54 2.06 2.25 2.22 2.74 2.82 3.4 NR NR
55–59 1.71 1.66 2.13 2.03 2.43 2.99 2.17 NR
60–64 1.83 1.44 1.86 1.75 1.92 2.12 2.45 4.06
65–69 1.34 1.56 1.52 1.61 1.49 1.6 2.09 2.25
70–74 1.17 1.14 1.23 1.08 1.55 1.26 1.53 1.78
75–79 1.09 1.2 1.31 1.12 1.55 1.46 0.94 1.36
Source: Adapted from Burns et al. 1997.
Note: NR = data not reported: data table for above data found at end of chapter.
aFrom Cancer Prevention Study I, American Cancer Society.
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smokers for prolonged periods after the first MI (Daly et al. 
1983; Omenn et al. 1990). Studies also demonstrated rapid 
reduction in risk after persons stopped smoking among 
populations at high risk for CHD (Ockene et al. 1990) and 
among women (Kawachi et al. 1993a, 1994). 
Patients with angiographically documented CHD 
who stopped smoking at the diagnosis of CHD (Vlietstra et 
al. 1986) or before diagnosis (Hermanson et al. 1988) had 
lower death rates from MI or CHD than did continuing 
smokers. In addition, the benefit of stopping smoking did 
not decline with advancing age.
In the 16-year follow-up of the Multiple Risk Factor 
Intervention Trial Research Group (1990, 1996), mortality 
from CHD was 11.4 percent lower in the “special interven-
tion” group than in the “usual care” group. This result 
may illustrate the benefit of stopping smoking, because 
one of the interventions targeted smoking cessation. A 
trial of advice to civil servants in London, England, to stop 
smoking demonstrated an 18-percent reduction in mortal-
ity from CHD in the intervention group versus the control 
group after 10 years of follow-up (Rose et al. 1982). Suskin 
and colleagues (2001) reported that in addition to benefits 
for CHD, stopping smoking also reduces morbidity and 
mortality in patients with left ventricular dysfunction. In 
this study, the benefits of stopping smoking on mortality 
and recurrent congestive heart failure requiring hospital-
ization were similar to the benefits from treatments with 
angiotensin-converting-enzyme (ACE) inhibiting drugs, 
b-blockers, or spironolactone, which are mainstays for 
the treatment of heart failure.
Women
Women have lower absolute rates of CHD than do 
men. However, cigarette smoking has been associated 
with higher RR of MI (Njølstad et al. 1996) and higher 
CHD mortality (Kawachi et al. 1994; Thun et al. 1997) 
among women than among men. The absolute increase in 
risk of CHD from smoking is similar for men and women 
(USDHHS 1983, 2001).
A prospective evaluation of fatal and nonfatal CVD 
events among women in the Nurses’ Health Study (Willett 
et al. 1987) found that smoking was an independent cause 
of CVD. Age-adjusted risks of disease increased progres-
sively with more cigarettes smoked per day up to 45 or 
more per day. Even when the combined risks of fatal CHD 
and nonfatal MI were adjusted for levels of other risk fac-
tors, risks increased with increasing numbers of cigarettes 
per day.
Researchers have demonstrated a rapid decline in 
excess risk of CHD in women after they stopped smok-
ing cigarettes. Even so, 10 to 14 years of nonsmoking are 
required before risks approach those of lifetime nonsmok-
ers (Kawachi et al. 1993a, 1994). 
Table 6.2 Death rates and rate ratios for death from coronary heart disease among men, by age and duration of 
smoking by number of cigarettes smoked per daya






















1–19 50–59 241.1 276 277.9 NR 2.7 3.1 3.2 NR
1–19 60–69 340.6 560.3 643.5 866.5 1.1 1.8 2.1 2.8
20 50–59 213.9 272.6 493.4 956.4 2.4 3.1 5.6 NR
20 60–69 299.9 509 729.5 1,088.9 1 1.6 2.4 3.5
21–39 50–59 195.8 237.4 367.2 NR 2.2 2.7 4.2 NR
21–39 60–69 232.2 350.8 607.2 1,113.4 NR 1.1 2 3.6
40 50–59 144.9 281.6 321.4 664.5 1.6 3.2 3.7 NR
40 60–69 470.8 458.3 607.6 988.3 1.5 1.5 2 3.2
Source: Adapted from Thun et al. 1997.
Note: NR = data not reported; data table for above data found at end of chapter.
aFrom Cancer Prevention Study II, American Cancer Society (CPS-II).
bCPS-II data, Appendix Table 10, Thun et al. 1997.
cCPS-II data, Appendix Table 12, Thun et al. 1997.
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Race and Ethnicity
In 2004, heart disease mortality was higher among 
African Americans than among Whites (National Heart, 
Lung, and Blood Institute [NHLBI] 2007). From 1999 
through 2004, the prevalence of acute MI was higher for 
African Americans than for Whites aged 35 through 54 
years; however, for ages 55 years and older, the prevalence 
of acute MI was higher among Whites (NHLBI 2007).
The INTERHEART study is a case-control investiga-
tion of acute MI in 52 countries in Africa, Asia, Australia, 
the Middle East Crescent, and North and South Ameri-
ca (Teo et al. 2006). The odds ratio (OR) for acute MI in 
smokers was 2.95 for this large multiethnic population 
compared with lifetime nonsmokers. In addition, the risk 
of MI was higher among persons who smoked bidis than 
among nonsmokers in countries where use of this form of 
tobacco is common.
Researchers also identified cigarette smoking as 
a significant risk factor for CHD among Hispanic popu-
lations (Mendelson et al. 1998) and Asian populations 
(Kiyohara et al. 1990; Miyake et al. 2000; Lam et al. 2002).
Sudden Death
Most sudden death is due to CVD. In many epidemi-
ologic studies, RRs for sudden cardiac death were higher 
than RRs for CHD or MI among persons who smoked. The 
RRs for sudden death among current smokers, compared 
with lifetime nonsmokers, often exceeded 3.0 (USDHEW 
1971, 1979; Dawber 1980; Kannel and Thomas 1982; 
USDHHS 1983; Wannamethee et al. 1995; Sexton et al. 
1997). In multivariate analyses of the combined data from 
the Framingham Heart Study and the Albany Study, which 
examined sudden cardiac death in men aged 45 through 
64 years, cigarette smoking was the risk factor with the 
highest statistical significance (Kannel et al. 1975). In a 
study of data from the 1986 National Mortality Followback 
Survey among persons with no history of CHD, cigarette 
smoking was the only modifiable risk factor associated 
with sudden coronary death and it was one factor associ-
ated with increased risk of sudden coronary death among 
persons with known CHD (Escobedo and Zack 1996; Esc-
obedo and Caspersen 1997). Cigarette smoking was also 
associated with risk of sudden cardiac death in the 18-year 
follow-up of the Honolulu Heart Program (Kagan et al. 
1989) and the 28-year follow-up of the Framingham Heart 
Study (Cupples et al. 1992).
Peters and colleagues (1995) found an associa-
tion between smoking cessation and reduction in death 
from cardiac arrhythmia for patients with left ventricular 
dysfunction after MI. Finally, the risk of recurrent cardiac 
arrest among smokers surviving out-of-hospital cardiac 
arrest was lower among persons who then stopped smok-
ing than among those who continued to smoke (Hall-
strom et al. 1986). 
Stroke
After adjustment of data for other risk factors, 
cigarette smokers have higher risk of stroke and higher 
mortality from cerebrovascular disease than do lifetime 
nonsmokers, and a dose-response relationship is evident 
(USDHHS 1983, 2001, 2004; Neaton et al. 1984; Colditz 
et al. 1988; Wolf et al. 1988; Kannel and Higgins 1990; 
Kuller et al. 1991; Freund et al. 1993; Hames et al. 1993; 
Håheim et al. 1996; Tanne et al. 1998; Jacobs et al. 1999a; 
Sharrett et al. 1999; Djoussé et al. 2002). In addition, in 
the 20-year follow-up of a prospective study of mortal-
ity that controlled for other cardiovascular risk factors, 
cigarette smoking increased the risk of death from stroke 
and mortality rates grew the number of cigarettes smoked 
increased (Hart et al. 1999). 
In a meta-analysis of data from 32 studies, the over-
all RR for stroke associated with cigarette smoking was 
1.5 (95 percent confidence interval [CI], 1.4–1.6) (Shin-
ton and Beevers 1989). The RRs varied with the stroke 
subtypes: 1.9 for cerebral infarction, 0.7 for cerebral 
hemorrhage, and 2.9 for subarachnoid hemorrhage. The 
researchers reported a dose-response relationship 
between the number of cigarettes smoked per day and the 
RR. The data suggested a sustained higher risk of stroke 
among former smokers younger than age 75 years than 
the risk for nonsmokers in the same age group. For all 
ages combined, RR for former smokers was 1.2.
During the 26-year follow-up of the cohort in the 
Framingham Heart Study, cigarette smoking was a sig-
nificant risk factor for stroke (Wolf et al. 1988). The risk 
declined, however, among smokers who had stopped 
smoking for two years and was similar to that of lifetime 
nonsmokers after five years of abstinence from smok-
ing. In the 12-year follow-up of the Nurses’ Health Study 
(Kawachi et al. 1993b), RR for stroke among current 
smokers was 2.58 compared with nonsmokers, but it was 
1.34 among former smokers compared with nonsmok-
ers. Once those who stopped smoking had abstained for 
two to four years, their risk for stroke could not be dis-
tinguished from that of lifetime nonsmokers. In addition, 
the pattern of decline in total risk for stroke after stopping 





Mortality studies consistently demonstrated higher 
risk of death from abdominal aortic aneurysm among cig-
arette smokers than among nonsmokers (Hammond and 
Horn 1958; Weir and Dunn 1970; USDHHS 1983, 2004; 
Strachan 1991; Nilsson et al. 2001). In addition, the risk 
rose with an increasing number of cigarettes smoked per 
day (Kahn 1966; Hammond and Garfinkel 1969; Burns et 
al. 1997; Blanchard et al. 2000; Vardulaki et al. 2000). 
Studies have demonstrated an association of ciga-
rette smoking with prevalence of aortic aneurysm or aor-
tic dilation, as determined by ultrasonography in cohorts 
of men and women, even after adjustment for a large 
number of known risk factors (Alcorn et al. 1996; Lee et 
al. 1997; Wilmink et al. 1999; Jamrozik et al. 2000; Led-
erle et al. 2001). The U.S. Preventive Services Task Force 
(2005) recommended a one-time screening by ultrasonog-
raphy for abdominal aortic aneurysm among men aged 65 
to 75 years who had ever smoked. Cigarette smoking has 
been associated with increased growth of abdominal aortic 
aneurysms (Brady et al. 2004). This finding suggests that 
more frequent monitoring of smokers for this condition 
is necessary. With increasing duration of abstinence from 
smoking, the risk of developing an abdominal aneurysm 
appears to slowly decline (Wilmink et al. 1999). 
Peripheral Arterial Disease
Cigarette smoking and diabetes are well established 
as the major risk factors for PAD, and a strong dose- 
response relationship for smoking was observed even after 
adjustment for other CVD risk factors (Weiss 1972; Kan-
nel and Shurtleff 1973; USDHHS 1983; Wilt et al. 1996; 
Price et al. 1999; Meijer et al. 2000; Ness et al. 2000). 
Data from the Framingham Heart Study demonstrated 
increased risk of PAD among both young and older male 
and female cigarette smokers after adjustment for other 
cardiovascular risk factors. In addition, this risk increased 
with the increase in the number of cigarettes smoked per 
day, and this result was statistically significant (Freund 
et al. 1993). The Framingham Offspring Study reported a 
similar finding (Murabito et al. 2002). Finally, researchers 
have observed a significantly higher rate of late arterial 
occlusion in patients who continued to smoke after 
peripheral vascular surgery than in those who stopped 
smoking (Wray et al. 1971; Ameli et al. 1989; Wiseman et 
al. 1989). Among smokers with claudication, progression 
to critical limb ischemia is reduced in those who stopped 
smoking (Jonason and Bergström 1987).
Pipes, Cigars, and  
Low-Tar Cigarettes
“Low-tar” or “light” cigarettes were designed to 
produce low machine-measured yields of tar and nicotine 
(NCI 2001). Design characteristics of low-tar cigarettes 
include increased ventilation and more rapid cigarette 
burn rate. By changing the way they smoke or the number 
of cigarettes smoked, persons who smoke these products 
can obtain as much nicotine as from “regular” or “full- 
flavored” cigarettes, thereby satisfying their addiction 
(USDHEW 1979; NCI 2001). Comprehensive reviews of 
this issue concluded that use of low-tar cigarettes has not 
resulted in meaningful reduction in the risk of CVD (NCI 
2001; Stratton et al. 2001; Scientific Advisory Committee 
on Tobacco Product Regulation 2002; USDHHS 2004).
Compared with persons who smoke cigarettes, 
smokers who exclusively smoke pipes or cigars have lower 
risk for many smoking-related diseases (NCI 1998). Smoke 
from pipes and cigars contains the same toxic substances 
as cigarette smoke, but those who use a pipe or cigar usu-
ally smoke at lower intensity; observation indicates that 
they tend not to inhale the smoke, thus reducing their 
exposure to its toxic substances (USDHEW 1979; NCI 
1998; Shanks et al. 1998). Most current cigar users are 
young males who often smoke less than one cigar daily 
(NCI 1998); no data on risk for this population are avail-
able. For older adults who regularly use cigars, particular-
ly those who smoke more than one cigar per day or inhale 
the smoke, risk of CHD is modestly higher than that for 
nonsmokers (NCI 1998; Iribarren et al. 1999; Jacobs et al. 
1999b; Baker et al. 2000). Studies have reported similar 
increases in risks for CHD and cerebrovascular disease for 
persons who smoke a pipe exclusively (Henley et al. 2004).
Summary
Cigarette smoking and involuntary exposure to 
cigarette smoke are major causes of CHD, stroke, aortic 
aneurysm, and PAD. The risk is seen both as an increased 
risk of acute thrombosis of narrowed vessels and as an 
increased degree of atherosclerosis in the blood vessels 
involved. The cardiovascular risks attributable to cigarette 
smoking increase with the number of cigarettes smoked 
and with the duration of smoking. However, risk is sub-
stantially increased even by exposure to low levels of cig-
arette smoke as with exposure to secondhand smoke or 
smoking a few cigarettes per day. Risks are not reduced 
by smoking cigarettes with lower machine-measured 
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yields of tar and nicotine. Smokers of only pipes or 
cigars seem to have lower risks of CVD than do cigarette 
smokers. However, cigarette smokers who switch to pipes 
or cigars often inhale the tobacco smoke and may not 
experience the lower CVD risk of persons who primarily 
smoke a pipe or cigar. Stopping cigarette smoking and 
eliminating exposure to secondhand smoke rapidly and 
substantially reduce risks of various CVDs.
Secondhand Tobacco Smoke and Cardiovascular Disease
The 2006 Surgeon General’s report on involun-
tary exposure to tobacco smoke (USDHHS 2006) and 
Barnoya and Glantz (2005) extensively reviewed risks of 
CVD among nonsmokers exposed to secondhand tobacco 
smoke. They found a causal relationship among both men 
and women between exposure to secondhand smoke and 
increased risks of CHD morbidity and mortality. Pooled 
RRs from meta-analyses indicated a 25- to 30-percent in-
crease in risk of CHD from exposure to secondhand smoke. 
The study by Whincup and associates (2004), which was 
based on blood levels of cotinine in men, suggested a 
50- to 60-percent increase in risk of CHD from exposure 
to secondhand smoke. The risk of acute MI appeared to 
decline rapidly after cessation of exposure to secondhand 
smoke, as evidenced by a decline in hospital admissions 
for MI after smoke-free laws were put in place (Dinno and 
Glantz 2007; Lightwood and Glantz 2009; Meyers et al. 
2009). As for stroke, the evidence was insufficient to infer 
a causal relationship between increased risk of CHD mor-
bidity and mortality and exposure to secondhand smoke. 
Studies of the effects of secondhand smoke on subclini-
cal vascular disease, particularly thickening of the walls 
of the carotid arteries, also suggest a causal relationship 
between exposure to secondhand smoke and atheroscle-
rosis. As mentioned previously, the substantial CVD risk 
associated with involuntary exposure to cigarette smoke 
indicates that the risks estimated in most studies of active 
smoking are biased downward because the control groups 
generally included large numbers of persons with expo-
sure to secondhand smoke. 
Pathophysiology
This section on pathophysiology focuses primarily 
on mechanisms by which cigarette smoking may increase 
risk of CVD.
Cigarette Smoke Constituents and 
Cardiovascular Disease
Three constituents of cigarette smoke have received 
the greatest attention as potential contributors to CVD: 
nicotine, carbon monoxide (CO), and oxidant gases. Some 
research also investigated the contributions of polycyclic 
aromatic hydrocarbons (PAHs), particulate matter, and 
other constituents of tobacco smoke to the pathophysi-
ology of CVD including atherogenesis (Brook et al. 2004; 
Vermylen et al. 2005; Bhatnagar 2006). 
Nicotine, which is absorbed rapidly from cigarette 
smoke, was found in arterial blood levels of 40 to 100 ng/
mL after each cigarette was smoked (Henningfield et al. 
1993). The typical dose of nicotine systematically absorbed 
from each cigarette is 1 to 2 milligrams (mg). Although 
plasma nicotine levels peaked sharply after each cigarette, 
trough values also rose during the first six to eight hours 
of regular smoking during the day (Benowitz et al. 1982a). 
This accumulation pattern was consistent with an elimi-
nation half-life for nicotine of two hours (Benowitz et al. 
1982a). In persons who smoke regularly, venous plasma 
levels of nicotine reached a plateau in early afternoon and 
remained at that level until bedtime (Figure 6.4). Signifi-
cant levels of nicotine were in the smoker’s venous blood 
even on waking in the morning. Thus, these findings 
indicate that the regular smoker is exposed to significant 
levels of nicotine 24 hours per day. 
Nicotine is a sympathomimetic drug that releases 
catecholamines both locally from neurons and systemi-
cally from the adrenal gland. In studies of the pharmaco-
dynamics of nicotine, the intensity of its maximal effect 
was greater with more rapid delivery (Porchet et al. 1987). 
Pharmacodynamic studies also indicated that although 
tolerance to the effects of nicotine developed rapidly, tol-
erance was incomplete (Porchet et al. 1987). In one study, 
a constant intravenous infusion of nicotine increased the 
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heart rate even though nicotine levels in the blood were 
relatively low. As the infusion continued, the heart rate 
reached a plateau despite a progressive rise in blood levels 
of nicotine (Benowitz et al. 1982a). The same phenome-
non was observed in comparisons of acceleration of heart 
rate with level of blood nicotine during regular cigarette 
smoking throughout the day (Benowitz et al. 1984). 
In another study, heart rate measured by ambulatory 
monitoring was higher throughout the day when persons 
were smoking than when they were not smoking (Benow-
itz et al. 1984). The extent of elevation was independent of 
the blood level of nicotine absorbed from the cigarettes. 
The researchers concluded that the elevated heart rate 
reflected persistent stimulation of the sympathetic 
Figure 6.4 Plasma nicotine and carboxyhemoglobin concentrations throughout a day of cigarette smoking
Source: Benowitz 2003. Adapted from Benowitz et al. 1982b with permission from Elsevier, © 2003.
Note: Mean (± standard error of measurement) blood nicotine and carboxyhemoglobin concentrations in cigarette smokers. 
Participants smoked cigarettes every half-hour from 8:30 a.m. to 11:00 p.m., for a total of 30 cigarettes per day. ng/mL = nanograms 
per milliliter.
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nervous system, a possible contributing factor to CVD. 
Nicotine may also contribute to endothelial dysfunc-
tion, lipid abnormalities, and insulin resistance (Beno 
witz 2003). 
CO is a major constituent of cigarette smoke. In 
regular smokers, carboxyhemoglobin levels average 
about 5 percent, compared with 10 percent or higher 
in heavy smokers (Benowitz et al. 1982b). These values 
compare with levels of 0.5 to 2 percent in nonsmokers, 
depending on exposure to automobile exhaust. Like nico-
tine levels, elevated carboxyhemoglobin levels persist for 
24 hours a day in smokers (Figure 6.4).
CO exposure can aggravate ischemia and worsen 
symptoms in persons with vascular disease, although it is 
not clear that CO contributes directly to atherosclerosis 
(Benowitz 2003). CO binds avidly to hemoglobin, reduc-
ing the amount of hemoglobin available to carry oxygen 
and impeding release of oxygen by hemoglobin. In some 
studies, inhalation of CO at levels comparable to those in 
cigarette smokers reduced exercise tolerance in patients 
with angina pectoris, intermittent claudication, or COPD 
(Calverley et al. 1981; Allred et al. 1989). Another study 
reported that CO exposure in persons with obstructive 
coronary disease resulted in a greater degree of exercise-
induced ventricular dysfunction and an increase in the 
number and complexity of ventricular arrhythmias dur-
ing exercise (Sheps et al. 1990). Inhaling CO reduced the 
threshold for ventricular fibrillation in animals (DeBias et 
al. 1976).
Long-term CO exposure in smokers resulted in 
greater red blood cell mass and reduced the oxygen- 
carrying capacity of red blood cells, resulting in relative 
hypoxemia (Benowitz 2003). In response to hypoxemia, 
red blood cell masses increased to maintain the amount of 
oxygen needed by organs in the body. The increase in red 
blood cell mass increased blood viscosity and may contrib-
ute to hypercoagulation in smokers. 
Cigarette smoke delivers a high level of oxidizing 
chemicals to smokers, including oxides of nitrogen and 
many free radicals from both the gas and tar phases of 
cigarette smoke (Church and Pryor 1985). Exposure to 
oxidant chemicals in smoke was associated with depletion 
of endogenous levels of antioxidants, manifested as lower 
blood levels of vitamin C in smokers than in nonsmok-
ers (Lykkesfeldt et al. 2000). Cigarette smoking also was 
reported to increase levels of lipid peroxidation products 
in the plasma and urine of smokers (Morrow et al. 1995). 
Study results also indicated that oxidant stress contrib-
utes to several potential mechanisms of CVD, including 
inflammation, endothelial dysfunction, lipid abnormali-
ties such as oxidation of low-density lipoprotein (LDL), 
and platelet activation (Burke and FitzGerald 2003).
Acrolein, a reactive aldehyde produced by endog-
enous lipid peroxidation, is present at high levels in cig-
arette smoke. Acrolein binds covalently to form protein 
adducts, and acrolein-induced modification of proteins 
has been implicated in atherogenesis. Acrolein modifies 
apolipoprotein A-I (APO A-I), the major protein in HDL 
(Shao et al. 2005). HDL protects against atherosclerosis. 
Acrolein-protein adducts co-localize with APO A-I in mac-
rophages in the intima of human atheromatous blood ves-
sels (Szadkowski and Myers 2008). 
Acrolein also oxidized thioredoxins 1 and 2 in endo- 
thelial cells. Thioredoxins are prominent antioxidant 
proteins that regulate the oxidation-reduction balance 
critical for normal cell function. These results suggest 
that oxidation of thioredoxins can result in dysfunction 
and death of endothelial cells, contributing to athero-
sclerosis. In addition, acrolein induces production of the 
enzyme cyclooxygenase-2 (COX-2) in human endothelial 
cells in vitro (Park et al. 2007). This finding is relevant 
because COX-2 is expressed in atherosclerotic lesions and 
may participate in atherogenesis. Acrolein may contribute 
to thrombogenicity in smokers by inhibiting antithrom-
bin activity (Gugliucci 2007). Finally, acrolein induces 
hypercontraction in isolated human arteries and could 
contribute to smoking-induced coronary vasospasm 
(Conklin et al. 2006).
Cigarette smoke contains a number of metals, in-
cluding aluminum, cadmium, copper, lead, mercury, 
nickel, and zinc. Metals in cigarette smoke catalyze the 
oxidation of cellular proteins (Bernhard et al. 2005). This 
reaction may lead to structural damage, endothelial dys-
function, and detachment of endothelial cells from the 
walls of blood vessels. Mixtures of metals and oxidants 
may be particularly damaging to endothelial cells. Cadmi-
um levels are higher in serum of smokers, and cadmium 
accumulates in the aortic walls of smokers (Abu-Hayyeh 
et al. 2001). Epidemiologic evidence indicates an associa-
tion between serum levels of cadmium and lead and CVD, 
including hypertension and MI (Abu-Hayyeh et al. 2001). 
PAHs found in the tar fraction of cigarette smoke 
reportedly accelerated atherosclerosis in experimen-
tal animals. Weekly injections of benzo[a]pyrene and 
7,12-dimethylbenz[a]anthracene, at doses below those 
that produce tumors, increased development of athero-
sclerotic plaque in the aortas of cockerels (Penn and Sny-
der 1988). Similarly, inhaled butadiene, a component of 
the vapor phase of cigarette smoke, increased the amount 
of atherosclerotic plaque in the same animal model (Penn 
and Snyder 1996). The researchers speculated that one 
mechanism of atherogenesis is a mutation, followed by 
hyperproliferation of smooth muscle or other cells that 
may contribute to growth of atherosclerotic plaque.
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Studies of the cardiovascular effects of smoke-
less tobacco may be informative for understanding the 
pathophysiology of smoking-induced CVD. Oral and nasal 
smokeless tobacco products have been used for centuries 
around the world (International Agency for Research on 
Cancer [IARC] 2007). Traditional smokeless tobacco prod-
ucts vary widely among countries; however, similar to 
Sweden, forms of oral snuff are the most common types 
of products used in the United States (Substance Abuse 
and Mental Health Services Administration 2009). These 
products contain a large array of chemicals, including nic-
otine, nitrosamines, nitrosamine acids, PAHs, aldehydes, 
and metals (IARC 2007). A recent systematic review 
reported that studies from both the United States and 
Sweden showed an increased risk of death from MI and 
stroke related to the frequency and duration of use of 
smokeless tobacco products (Boffetta and Straif 2009). 
This review relied heavily (85–89 percent of the weight) 
on results of a large U.S. cohort study conducted in 
two waves between 1959–1971 and 1982–1988 and may 
Figure 6.5 Overview of mechanisms by which cigarette smoking causes an acute cardiovascular event
Source: Benowitz 2003. Reprinted with permission from Elsevier, © 2003.
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not represent risk associated with products currently 
marketed in the United States and Europe. As in ciga-
rettes, nicotine is the principal alkaloid in smokeless 
tobacco products, and the concentrations of nicotine (mg/
gram [g] tobacco) are similar between cigarettes and the 
types of oral snuff sold in the United States (Djordjevic 
and Doran 2009). An analysis comparing the effects of 
using oral snuff with those of smoking cigarettes pro-
vided insights into the role of nicotine versus the effects 
of other toxins from tobacco smoke on CVD and car-
diovascular risk factors (Benowitz et al. 1988, 1989). In 
addition clinical trials of nicotine patches in patients with 
known CVD have not shown that transdermal nicotine 
increased cardiovascular risk (Working Group for the 
Study of Transdermal Nicotine in Patients with Coronary 
Artery Disease 1994; Joseph et al. 1996). In the study 
of 3,094 middle-aged smokers with chronic obstruc-
tive lung disease, the U.S. Lung Health Study found no 
evidence of increased cardiovascular risk in subjects who 
quit smoking by using nicotine gum versus those who 
quit without use of nicotine gum (Murray et al. 1996). 
These studies and related  evidence suggest that chemi-
cals other than nicotine may contribute to the elevated 
risk of death from MI and stroke. In the INTERHEART 
study, the OR of acute MI was 2.23 among those who 
used only smokeless tobacco compared with those who 
used no tobacco. The OR was comparable to that of cur-
rent cigarette smokers (OR = 2.95) compared with those 
who used no tobacco (Teo et al. 2006). In addition, the 
risk of acute MI among smokers who also used smokeless 
tobacco was the highest risk related to tobacco use (OR = 
4.09), suggesting that some of the toxicants involved in 
the elevated cardiovascular risk could be contained in both 
tobacco smoke and smokeless products. Smokeless 
tobacco products have been found to have significant 
amounts of numerous other toxicants and carcinogens, 
particularly tobacco-specific nitrosamines as well as 
volatile aldehydes and PAHs (Stepanov et al. 2008). Addi-
tional research on these and other toxicants in smokeless 
tobacco, such as heavy metals like cadmium, is needed to 
understand the observed cardiovascular risks among users 
of smokeless tobacco products.
Mechanisms
Cigarette smoking produces acute myocardial isch-
emia by adversely affecting the balance of demand for 
myocardial oxygen and nutrients with myocardial blood 
supply (Figure 6.5). The increase in demand for oxygen 
in the myocardium is a consequence of nicotine stimu-
lation of the sympathetic nervous system and the heart. 
Cigarette smoking acutely increases levels of plasma 
norepinephrine and epinephrine and enhanced 24-hour 
urinary excretion of these catecholamines (review by 
Benowitz and Gourlay 1997). Regular smoking increases 
the heart rate both in the short term (up to 20 beats per 
minute) and throughout the day (average increase, 7 beats 
per minute), as measured during ambulatory monitoring. 
Nicotine also increases heart rate, blood pressure, and 
myocardial contractility. These hemodynamic changes 
result in increases in myocardial work that in turn require 
increased myocardial blood flow.
In healthy persons, cigarette smoking increases cor-
onary blood flow in response to increases in myocardial 
work. In smokers, the response in coronary blood flow to 
increased myocardial demand was impaired (i.e., reduced 
coronary vasodilatory reserve) (Czernin and Waldherr 
2003). Cigarette smoking played a direct role by constrict-
ing coronary arteries through nicotine-mediated action 
on a-adrenergic receptors and by induction of endothelial 
dysfunction by nicotine and oxidizing chemicals (Nicod 
et al. 1984; Puranik and Celermajer 2003). In addition, 
oxidant chemicals contribute to platelet activation and 
thrombogenesis (Burke and FitzGerald 2003). 
Exposure to CO may also contribute to the adverse 
hemodynamic effects of cigarette smoking. By producing 
functional anemia, CO increases the need for coro-
nary blood flow, especially during physical exertion. An 
in-adequate vasodilatory flow reserve produced by ciga-
rette smoking, in the face of need for increased coronary 
blood flow mediated by carbon dioxide, could contribute 
to myocardial ischemia with exercise in smokers.
In addition to the mechanisms described in Fig-
ure 6.5, cigarette smoking has effects on inflammation, 
insulin sensitivity, and lipid abnormalities that most likely 




Blood Pressure and Heart Rate
In 1907, Erich Hesse published “The Influence of 
Smoking on the Circulation,” which documents his obser-
vations on the effects of smoking on heart rate and blood 
pressure (Hesse 1907). In most study participants, both 
heart rate and blood pressure increased immediately after 
smoking. Hesse observed a greater response in blood pres-
sure after smoking in persons who smoked than in non-
smokers. Speculating that the increases in blood pressure 
and heart rate reflected stimulation of the heart or ner-
vous system, he instituted a rule prohibiting patients with 
a “heart weakness” from smoking, to avoid unnecessary 
strain and stress for the heart muscle. Many investigators 
confirmed Hesse’s observations on the hemodynamic 
effects of cigarette smoking (Deanfield et al. 1986; Czernin 
et al. 1995; Barutcu et al. 2004). 
The positive chronotropic, inotropic, and blood 
pressure effects of smoking are explained by nicotine-
induced activation of the sympathetic nervous system 
(review by Benowitz 2003). Nicotine promotes the release 
of epinephrine and norepinephrine from the adrenal 
medulla and terminal nerve endings, resulting in 
increased heart rate and greater contractility through 
stimulation of myocardial b1 receptors. Peripheral vas-
cular resistance increases through a-receptor mediated 
vasoconstriction that in turn increases blood pressure. 
Coronary b2 and a2 receptors are also stimulated: stimu-
lation of b2 receptors promoted vasodilation, and stimula-
tion of a2 receptors promoted vasoconstriction (Cryer et 
al. 1976; Benowitz 2003). 
Cryer and colleagues (1976) elucidated the mecha-
nisms behind observed hemodynamic changes during 
smoking. They observed more than a 150-percent increase 
in plasma epinephrine levels (from 44 to 113 picograms 
[pg]/mL) at 10 minutes after participants started to smoke 
a cigarette. Norepinephrine values increased to a smaller 
degree (from 227 to 315 pg/mL) at 12.5 minutes after the 
start of smoking. These increases were associated with 
significant increases in heart rate and blood pressure. 
Pretreatment with a-receptor blockers and b-receptor 
blockers had little effect on the increase in plasma levels of 
catecholamines, but increases in blood pressure and heart 
rate were eliminated. This study confirmed that smoking-
induced increases in blood pressure and heart rate are 
attributable to adrenergic mechanisms. 
The hemodynamic effects of cigarette smoking 
are mediated primarily by nicotine, although oxidizing 
chemicals in tobacco smoke also affect vascular function. 
Intravenous nicotine, nicotine nasal spray, and nicotine 
chewing gum all increased the heart rate up to 10 to 15 
beats per minute and raised systolic blood pressure by up to 
5 to 10 millimeters of mercury (mm Hg), responses similar 
to the effects of cigarette smoking (Gourlay and Benowitz 
1997). Nicotine increased cardiac output by increasing 
both heart rate and myocardial contractility. Different vas-
cular beds express different types and ratios of adrenergic 
receptors. Therefore, not all vascular responses to nico-
tine or tobacco smoke are the same. For example, nicotine 
constricts some vascular beds, such as the skin, and cuta-
neous vasoconstriction explains the reduced temperature 
of the fingertip observed with administration of nicotine 
(Benowitz et al. 1982a). Conversely, nicotine appears to 
dilate other vascular beds, such as skeletal muscle (Diana 
et al. 1990). Vasodilation of skeletal muscle may partly 
result from the increase in cardiac output, although the 
release of epinephrine from nerve terminals may also 
contribute. The net result of increases in heart rate, blood 
pressure, and myocardial contractility is an increase 
in myocardial work, followed by increased myocardial 
blood flow. 
Coronary Blood Flow
An important hemodynamic consequence of ciga-
rette smoking is its effect on blood flow in the coronary 
arteries. Cigarette smoking acutely increased coronary 
blood flow by up to 40 percent, apparently a response to 
the increase in myocardial work (review by Czernin and 
Waldherr 2003). 
In anesthetized dogs, coronary blood flow showed 
a biphasic response to nicotine. Initially, researchers 
hypothesized that increases in coronary blood flow—
in the large coronary vessels as well as the smaller 
vessels—resulted from an increase in myocardial meta-
bolic demand. 
Cigarette smoking impairs the response of coro-
nary blood flow to an increase in myocardial demand for 
oxygen; that is, it reduces the coronary vasodilatory flow 
reserve. Thus, the increase in coronary blood flow based 
on the level of myocardial work is less than would be 
expected in the absence of exposure to tobacco smoke. 
Considerable evidence indicates that cigarette smok-
ing causes dysfunction of the coronary arterial endothe-
lium (see “Endothelial Injury or Dysfunction” later in 
this chapter). 
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Cigarette smoking may also be associated with 
coronary vasoconstriction. Although cigarette smoking 
increases coronary blood flow in a person who does not 
have CHD, it may decrease coronary blood flow in the 
presence of coronary disease. Regan and colleagues (1960) 
measured coronary sinus blood flow in seven male volun-
teers with documented CHD before and after they smoked 
two cigarettes during a period of about 25 minutes; car-
diac work increased by about 30 percent during smoking. 
Even so, in response to smoking, coronary blood flow fell 
in three patients, did not change in three patients, and 
increased in one patient. Similar paradoxical responses 
were observed after long-term smokers were exposed to 
cold by testing with cold pressors (Campisi et al. 1998). 
In the testing, the hand is immersed in ice water for one 
to two minutes. This painful procedure evokes a mixed 
adrenergic response involving coronary receptors a1 and 
a2 (vasoconstriction), b2 (vasodilation), and myocardial 
b1 (indirect coronary vasodilation). Endothelial a2 recep-
tors that promote indirect coronary vasodilation may also 
be involved. In healthy volunteers, cold-induced increases 
of about 30 percent in the product of heart rate and blood 
pressure were associated with appropriate and similar 
increases in blood flow. In contrast, smokers showed no 
measurable increases in blood flow in response to the 
cold. Campisi and colleagues (1998) ascribed this observa-
tion to coronary endothelial dysfunction. 
Kaufmann and colleagues (2000) provided addi-
tional evidence for the association between smoking and 
endothelial dysfunction. Using quantitative positron emis-
sion tomography, they found that coronary microvascular 
function was abnormal in smokers but could be restored 
by infusion of vitamin C. Earlier, Zeiher and colleagues 
(1995) used quantitative coronary angiography to mea-
sure the effects of long-term smoking on the diameter of 
the coronary artery at study entry, during flow-mediated 
coronary vasodilation, and after intracoronary administra-
tion of nitroglycerin. The study population consisted of 
patients with or without mild disease of the left anterior 
descending coronary artery and no other cardiac prob-
lems. Flow-mediated vasodilation was markedly blunted 
in long-term smokers. In a study of smokers with CHD, 
cigarette smoking increased coronary vascular resistance, 
an effect that can be blocked by a-adrenergic blockers. 
This finding indicates that the mechanism of increased 
coronary artery resistance is at least partly due to stimula-
tion of the sympathetic nervous system by nicotine. 
Intracoronary measurements by Doppler ultraso-
nography demonstrated that cigarette smoking constricts 
epicardial arteries and increases total coronary vascular 
resistance. This result indicates that impairment of coro-
nary blood flow by cigarette smoking results from con-
striction of both epicardial and resistance blood vessels. 
In one study, after pretreatment with calcium-channel-
blocking agents or nitroglycerin, cigarette smoking 
increased coronary blood flow in patients with CHD who 
had manifested no increase after cigarette smoking alone 
(Winniford et al. 1987). This finding that coronary vaso-
dilator drugs, which block chemically mediated vasocon-
striction, permit the usual increase in coronary blood flow 
in response to increased myocardial work supports the 
hypothesis that cigarette smoking directly produces coro-
nary vasoconstriction. In another study, chewing 4 mg of 
nicotine gum by healthy nonsmokers blunted the increase 
in coronary blood flow that occurs with increased heart 
rate produced by cardiac pacing (Kaijser and Berglund 
1985). This result confirmed that even low doses of nico-
tine can directly constrict coronary arteries in humans.
Another study found that nicotine worsened myo-
cardial dysfunction in “regionally stunned” ischemic 
myocardium of anesthetized dogs (Przyklenk 1994). In 
a placebo-controlled experiment, transient ischemia was 
induced in dogs by clamping the left anterior descending 
coronary artery for 15 minutes. Segmental shortening 
of the myocardium recovered to only 29 percent of the 
preischemic baseline values in dogs pretreated with nico-
tine, compared with 54 percent in saline-treated control 
dogs. The doses of nicotine administered to the animals 
did not alter heart rate, blood pressure, or blood flow or 
cause myocyte necrosis. 
In patients with vasospastic angina, cigarette smok-
ing is associated with increased occurrence of the condi-
tion and a poorer response to medication compared with 
the response in nonsmokers (Caralis et al. 1992). The 
researchers observed that cigarette smoking during coro-
nary angiography (cardiac catheterization) produced an 
acute coronary vasospasm.
Schelbert and colleagues (1979) extensively stud-
ied the relationship of coronary vasomotion, endothelial 
function, and myocardial blood flow to potential revers-
ibility of coronary vasomotor abnormalities. They adopted 
a noninvasive approach by measuring blood flow with 
positron emission tomography using 13N ammonia: (1) 
at rest during testing with cold pressors to probe endo-
thelium-dependent coronary vasomotion and (2) during 
dipyridamole-induced hyperemia to assess endothelium-
independent coronary vasomotion. Using this protocol, 
Czernin and associates (1995) investigated the effects of 
short- and long-term smoking on myocardial blood flow 
and flow reserve in smokers. The investigators sought to 
determine whether abnormalities in coronary vasomo-
tion in response to cold could be reversed in response to 
l-arginine infusion (Campisi et al. 1998, 1999). The find-
ings indicated that short-term and long-term smokers 
had normal coronary vasodilatory capacity. Short-term 
smoking, however, reduced flow reserve in both short- and 
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long-term smokers. Also, exposure of long-term smokers 
to cold resulted in abnormal blood flow. The smoking-
associated abnormalities in vasomotion were restored by 
intravenous l-arginine, and this result further implicates 
the endothelium as the target of toxic substances con-
tained in cigarette smoke. Campisi and colleagues (1999) 
quantified myocardial blood flow during exposure to cold 
while l-arginine, the substrate of ENOS, was infused 
intravenously for 45 minutes at a dose of 30 g as 10 per-
cent arginine hydrochloride. This infusion produced sig-
nificant improvement in responses of myocardial blood 
flow to cold. In addition to active smoking, exposure to 
secondhand smoke for 30 minutes abruptly reduces cor-
onary blood flow velocity in nonsmokers, as assessed by 
echocardiography (Otsuka et al. 2001).
Summary
Cigarette smoking impairs the vascular endothelial 
function and activates the sympathetic nervous system. 
These effects can result in inappropriate reduction in or 
failure to increase coronary blood flow in response to 
increases in myocardial demand. Together with long-term 
atherosclerotic damage from smoking, these effects con-
tribute to ischemic cardiac events. Coronary endothelial 
dysfunction clearly increases the risk for cardiovascular 
events. The smoking-induced alterations in vasomotor 
function appear to be substantially reversible, which 
underscores the importance of smoking cessation pro-
grams and policies to promote a smoke-free environment.
Smoking and the Endothelium
Endothelial Injury or Dysfunction
Endothelial injury and dysfunction are thought to 
contribute to the initiation of atherogenesis and to have a 
major role in acute cardiovascular events. Cigarette smok-
ing produces endothelial injury and dysfunction in both 
peripheral and coronary arteries. Other cardiovascular 
risk factors such as hypercholesterolemia, diabetes, and 
hypertension also produce endothelial dysfunction.
The healthy endothelium is a diaphanous film of tis-
sue that invests the luminal surface of all blood and lym-
phatic vessels. In larger-conduit vessels, the endothelium 
forms a monolayer between the circulating blood and the 
vessel wall. The tissue capillaries, which are the small-
est conduits for blood and lymphatic flow, are composed 
exclusively of endothelial cells. Because of the ubiquity 
of endothelial cells, the surface area of the endothelium 
in a human weighing 70 kilograms (kg) is 1,000 to 4,000 
square meters—equivalent to two to four tennis courts—
with a weight of approximately 1 kg (Wolinsky 1980). The 
endothelium produces a variety of paracrine factors that 
regulate vascular homeostasis, including proteins, lip-
ids, and small molecules that (1) can relax or activate the 
underlying vascular smooth muscle, (2) regulate the inter-
action of the vessel wall with circulating blood elements, 
and (3) modulate vessel structure (Aird 2005). In healthy 
persons, the endothelium primarily exerts a vasodila-
tor influence that reduces vascular resistance and main-
tains blood flow. The endothelium maintains the blood’s 
fluidity by elaborating anticoagulant substances and 
generally resists adherence of platelets and infiltration of 
immune cells. 
Regeneration of Endothelium
With aging, the normal functioning of the endo-
thelium requires replacement of apoptotic or injured 
cells. Normally, the turnover of endothelial cells is low, 
on the order of 0.1 percent of the cells undergoing 
mitosis at any time (Wright 1972). The rate of endothelial 
turnover increases, however, in areas of disturbed flow 
(bends, branches, or bifurcations of blood vessels). The 
length of chromosome telomeres documents that endo-
thelial aging occurs more rapidly in these areas (Chang 
and Harley 1995). Furthermore, the accelerated aging in 
these areas may lead to focal senescence, which is demon-
strated by impaired endothelium-dependent vasodilation 
(McLenachan et al. 1990). 
Persons who smoke may have impaired ability to 
regenerate the endothelium. The endothelial monolayer is 
regenerated in part from circulating endothelial progeni-
tor cells derived from bone marrow, and the supply of these 
cells may be a key determinant of endothelial health. The 
number of circulating endothelial progenitor cells, which 
is estimated by ex vivo colony counts or by analysis using 
fluorescence-activated cell sorting, is directly associated 
with the ability of the endothelium to induce vasodila-
tion (Hibbert et al. 2003; Hill et al. 2003). Smokers have 
reduced numbers of circulating endothelial progenitor 
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cells and impaired endothelium-dependent vasodilation 
(Vasa et al. 2001, Hill et al. 2003). In addition, smoking 
cessation was associated with a rebound in the number 
of circulating endothelial progenitor cells and improve-
ment in endothelium-dependent vasodilation (Moreno et 
al. 1998; Kondo et al. 2004). 
Endothelial Dysfunctions
A variety of endothelial dysfunctions may contribute 
to disorders of vessel tone and structure that precede clin-
ical vascular disease. Cardiovascular risk factors such as 
hypercholesterolemia, hypertension, diabetes, and use of 
tobacco cause endothelial aberrations long before clinical 
vascular disease becomes evident. Endothelial dysfunc-
tion is the first step in vascular disease, because it leads to 
vascular inflammation, cell proliferation, and thrombosis, 
which contribute to progression of vascular disease.
Endothelial generation of adhesion molecules 
increases in smokers, as evidenced by higher plasma 
levels of soluble adhesion molecules (Blann et al. 1997, 
1998). These molecules include soluble forms of the vas-
cular cell adhesion molecule (sVCAM) and the intercel-
lular adhesion molecule (sICAM). The soluble adhesion 
molecules, which are shed from the endothelium, reflect 
the increased endothelial production of these adhesion 
molecules in the context of vascular inflammation. Endo-
thelial adhesion molecules are required for adherence to 
blood leukocytes and their infiltration into the vessel wall 
(Gimbrone 1995). The increased elaboration of adhe-
sion molecules is an endothelial dysfunction that pro-
motes leukocyte infiltration, vascular inflammation, and 
progression of atherosclerosis. Studies have associated 
elevated levels of either sVCAM or sICAM with increased 
risk of cardiovascular events (Blankenberg et al. 2001).
Smoking also impairs the ability of the endothe-
lium to resist thrombosis. Compared with nonsmokers, 
smokers have higher levels of von Willebrand factor pro-
tein (MacCallum 2005) and tissue factor (Matetzky et al. 
2000; Sambola et al. 2003), which may be generated by 
the endothelium. Tissue factor activates the coagulation 
cascade, and von Willebrand factor protein mediates 
adherence of platelets to the vessel wall (MacCallum 
2005). Furthermore, study findings indicate that smoking 
impairs capacity to lyse the thrombus that is formed. Plas-
ma levels of tissue plasminogen activator (tPA), a throm-
bolytic protein produced by the endothelium, are reduced 
in smokers (Newby et al. 2001). In contrast, smoking 
increases levels of plasminogen activator inhibitor-1 
(PAI-1) (Simpson et al. 1997). By interfering with the 
function of tPA, PAI-1 reduces thrombolytic capacity 
(MacCallum 2005). Imbalance in thrombolytic capacity 
attributable to higher PAI-1 values or reduction in tPA 
levels is associated with occurrence of adverse cardiovas-
cular events. 
The healthy endothelium elaborates vasodilator 
substances such as nitric oxide (NO), prostacyclin, atrial 
natriuretic peptide, endothelium-derived hyperpolariz-
ing factor, and adrenomedullin (Chen and Burnett 1998; 
Busse and Fleming 2003; Brain and Grant 2004). In 
doing so, the healthy endothelium increases the diameter 
of the blood vessels and reduces resistance to blood flow. 
When the endothelium becomes diseased, synthesis and 
bioactivity of the vasodilators are reduced, and the balance 
tips in favor of endothelium-derived vasoconstrictors such 
as endothelin and thromboxane (Vanhoutte et al. 2005). 
This derangement in endothelial function has clinical 
consequences. Because vasodilator function is impaired, 
coronary vascular resistance increases, and ischemia can 
result. Furthermore, endothelial vasodilator dysfunction 
in the coronary arteries of humans is associated with 
reversible myocardial perfusion defects, which are 
associated with other vascular abnormalities (Hasdai et al. 
1997b). These abnormalities include expression of adhe-
sion molecules, adherence and infiltration of leukocytes, 
and proliferation of smooth muscle cells. 
Most of the endothelium-derived vasodilators also 
oppose key processes involved in atherogenesis (cell adhe-
sion, proliferation, and inflammation) (Cooke and Dzau 
1997a,b). Thus, by reducing the generation or bioactiv-
ity of endothelial vasodilators, exposure to tobacco can 
accelerate atherosclerosis. This mechanistic explanation 
for tobacco-related CVD is supported by the finding that 
dysfunction of endothelial vasodilators is an independent 
predictor of vascular events (Schächinger et al. 2000; 
Suwaidi et al. 2000; Gokce et al. 2003). The role of these 
mechanisms involving NO is vascular protection, which is 
impaired by exposure to tobacco.
Nitric Oxide and Vascular 
Homeostasis
NO induces vasodilation by stimulating soluble gua-
nylate cyclase to produce cyclic guanosine monophos-
phate (Ignarro et al. 1984). NO, which has a short half-life, 
avidly interacts with sulfhydryl-containing proteins, heme 
proteins, and oxygen-derived free radicals. By virtue of its 
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ability to nitrosylate proteins, NO may change their activ-
ity or behavior (Hess et al. 2005). The significant increase 
in vascular resistance induced in animals and humans 
exposed to pharmacologic antagonists of ENOS reflects 
the physiological importance of this endothelium-derived 
vasodilator (Rees et al. 1989; Vallance et al. 1989). 
Endothelium-derived NO also inhibits adherence 
of platelets and leukocytes to the vessel wall (Kubes et 
al. 1991; Tsao et al. 1994). This effect is mediated partly 
by activation of cyclic guanosine monophosphate and 
phosphorylation of intracellular signaling proteins such 
as vasodilator-stimulated phosphoprotein (Smolenski et 
al. 1998). In addition, NO suppresses expression of adhe-
sion molecules and chemokines that regulate endothelial 
interactions with circulating blood elements (Tsao et al. 
1996, 1997). These observations suggest that NO is an 
endogenous antiatherogenic molecule. Impairment of 
ENOS contributes to the pathologic alterations in vas-
cular reactivity and structure observed in atherosclerosis 
(Cooke and Dzau 1997a,b). The pharmacologic inhibi-
tion or genetic deficiency of ENOS inhibits endothelium- 
dependent vasodilation, impairs blood flow in tissues, and 
raises blood pressure (Huang et al. 1995; Kielstein et al. 
2004). Furthermore, NO deficiency promotes adherence 
to and intimal accumulation of mononuclear cells and 
accelerates formation of lesions in animal models of 
atherosclerosis (Kuhlencordt et al. 2001). In contrast, 
enhancing production of NO in the vessel wall slows or 
even reverses atherogenesis and restenosis (Cooke et al. 
1992; von der Leyen et al. 1995; Candipan et al. 1996). 
NO is a survival factor for endothelial cells, and it induces 
apoptosis of macrophages and proliferation of vascular 
smooth muscle cells (Wang et al. 1999).
Certain polymorphisms of the ENOS gene predict 
development of CHD (Ichihara et al. 1998; Tsukada et al. 
1998; Yoshimura et al. 1998). The ENOS gene GLU298ASP 
polymorphism is more prevalent in patients with vari-
ant angina, essential hypertension, and acute MI (Hibi 
et al. 1998; Miyamoto et al. 1998; Shimasaki et al. 1998; 
Yoshimura et al. 1998). Intriguingly, this polymorphism is 
associated with greater sensitivity to the effects of smok-
ing on endothelial vasodilator function. Young men who 
are carriers of the ENOS *ASP298 allele have increased 
susceptibility to smoking-associated reduction in endo-
thelial function (Leeson et al. 2002). Similarly, a qua-
druple repeat of a sequence of 27 base pairs in *intron 4 
of the ENOS gene (allele *a) is associated with increased 
risk of CHD and acute MI (Ichihara et al. 1998). Smokers 
who are homozygous for the ENOS allele *a are at risk for 
more severe CHD than are those who are not homozygous 
(Wang et al. 1996). 
Endothelium-Dependent 
Vasodilation
The effect of exposure to tobacco on endothelium-
dependent vasodilation in humans was assessed by observ-
ing its effect on flow-mediated vasodilation. As blood flow 
through a vessel is increased, the vessel relaxes. In animal 
models, this flow-mediated vasodilation was abolished 
by removing the endothelium (Pohl et al. 1986). When 
a pharmacologic antagonist of ENOS was used, flow- 
mediated vasodilation in the rabbit iliac artery depended 
on the endothelial release of NO (Cooke et al. 1991). Cel-
ermajer and colleagues (1992) used duplex ultrasonogra-
phy to record flow-mediated vasodilation of the brachial 
artery in response to hyperemic vasodilation of the fore-
arm. The investigators induced vasodilation by using 
a blood pressure cuff inflated to suprasystolic pressures 
to transiently occlude blood flow in the forearm. Joan-
nides and colleagues (1995) extended this finding by 
showing that flow-mediated vasodilation of the brachial 
artery could be abolished by pharmacologic antagonism 
of ENOS. Subsequently, numerous studies used this 
approach to document impairment of flow-mediated, 
endothelium-dependent vasodilation in smokers and in 
persons exposed to secondhand smoke (Celermajer et al. 
1993, 1996; Barua et al. 2001). Researchers also observed 
that tobacco use impaired endothelium-dependent vaso-
dilation in the coronary microcirculation. Intracoronary 
infusion of acetylcholine induced vasodilation that was 
partly attributable to release of NO, and this response was 
blunted in persons who smoked (Kugiyama et al. 1996). 
Impairment of Endothelium-
Dependent Vasodilation
Many factors contribute to the ability of tobacco to 
impair endothelial function. Tobacco use adversely affects 
the ENOS pathway. Exposure of cultured endothelial cells 
derived from human coronary arteries or umbilical veins 
to sera from smokers reduced expression and activity of 
ENOS (Barua et al. 2001, 2003). The researchers attrib-
uted this effect partly to the oxygen-derived free radicals 
in tobacco smoke. In addition, the half-life of NO was 
markedly shortened by oxidative stress (Rubanyi and Van-
houtte 1986). 
Superoxide anion reacts avidly with NO to form a 
peroxynitrite (ONOO−) anion, which itself is a highly 
reactive free radical (Beckman and Koppenol 1996). Oth-
er sources of free radicals that may inactivate NO and 
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impair endothelial vasodilator function include activated 
leukocytes, xanthine oxidase, the mitochondrial electron-
transport chain, and uncoupling of ENOS itself (Heitzer 
et al. 2000; Barua et al. 2003; Kayyali et al. 2003; Sydow 
and Münzel 2003; Guthikonda et al. 2003). Investigators 
postulated that this uncoupling occurs when amounts of 
the NOS cofactor tetrahydrobiopterin or the NO precursor 
l-arginine are insufficient. These conditions involve trans-
fer of electrons from ENOS to oxygen and thus formation 
of a superoxide anion. 
Oxidative stress also impairs the NOS pathway by 
increasing accumulation of asymmetric dimethylarginine 
(ADMA), an endogenous competitive inhibitor of ENOS 
produced by all cells during degradation of methylated 
nuclear proteins (Vallance et al. 1992; Tran et al. 2003). 
Most of the ADMA produced is degraded by the enzyme 
dimethylarginine dimethylaminohydrolase. Oxidative 
stress impairs the activity of this enzyme and leads to 
accumulation of ADMA and suppression of ENOS 
(Cooke 2004). 
Blood levels of antioxidant vitamins are lower than 
normal in smokers, reflecting endogenous consumption 
of these vitamins in response to ongoing oxidant stress 
(Lykkesfeldt et al. 2000). Administration of vitamin C 
reverses the impairment of endothelium-mediated 
vasodilation in smokers, a finding consistent with an 
oxidant mechanism of endothelial dysfunction (Heitzer et 
al. 1996). 
Nicotine itself may injure endothelial cells. Stud-
ies showed that in levels similar to those found in the 
blood of cigarette smokers, nicotine altered structural and 
functional characteristics of cultured vascular smooth 
muscle and endothelial cells (Csonka et al. 1985; Thyberg 
1986). In one study, oral nicotine administered to rats to 
achieve blood levels comparable to those in human smok-
ers produced myointimal thickening of the aorta after an 
experimental injury (denudation of the endothelium with 
a balloon catheter) (Krupski et al. 1987). The excessive 
myointimal thickening in nicotine-treated animals is con-
sistent with persistent injury to endothelial cells. Stud-
ies reported increased numbers of circulating endothelial 
cells in the venous blood, reflecting endothelial injury, 
and decreased platelet aggregate ratios, reflecting platelet 
aggregation in persons who had never smoked but who, 
for experimental purposes, smoked cigarettes contain-
ing tobacco (Davis et al. 1985). These results were not 
observed in nonsmokers who smoked cigarettes that did 
not contain tobacco. These findings further support a role 
for nicotine in injury to endothelial cells.
Nicotine may influence endothelial function in 
other ways. In studies of cultured endothelial cells, nico-
tine enhanced release of the basic fibroblast growth factor 
and inhibited production of transforming growth factor 
b1 (Villablanca 1998; Cucina et al. 1999). Nicotine also 
increased DNA synthesis, mitogenic activity, and endo-
thelial proliferation. Nicotine has been shown to induce 
endothelial dysfunction (Chalon et al. 2000; Sarabi and 
Lind 2000; Neunteufl et al. 2002).
Pathologic Angiogenesis
Another endothelial function influenced by exposure 
to tobacco is development of new blood vessels (angiogen-
esis). Angiogenesis requires activation of endothelial cells 
by an angiogenic cytokine, followed by endothelial cell 
proliferation and migration and the formation of tubes. 
Exposure to secondhand smoke promotes tumor angio-
genesis and growth (Zhu et al. 2003). Human lung cancer 
cells implanted in a subcutaneous or orthotopic location 
grew more rapidly in mice when they were exposed to sec-
ondhand tobacco smoke. Furthermore, these mice had 
higher plasma levels of vascular endothelial growth factor, 
and capillary density in their tumor nodules was greater 
than that in control mice. Mecamylamine, an antagonist 
of the nicotinic acetylcholine receptor (nAChR), abol-
ished the effects of exposure to secondhand smoke. These 
observations indicate that secondhand smoke increases 
tumor angiogenesis and growth, at least partly through a 
nicotine-mediated mechanism. 
Researchers observed the effect of nicotine in pro-
moting pathologic angiogenesis in numerous murine 
models of tobacco-related diseases, including lung can-
cer, atherosclerosis, and retinopathy (Heeschen et al. 
2001, 2002; Natori et al. 2003; Shin et al. 2004; Suñer 
et al. 2004). Tumor angiogenesis was required for tumor 
growth, and correspondingly, promotion of tumor 
angiogenesis accelerated tumor growth (Folkman 2003). 
Conversely, antiangiogenic agents inhibit progression 
of cancer and are now approved as treatment for some 
advanced human malignant diseases (Jain 2005). The 
effect of nicotine on promotion of tumor angiogenesis 
may be attributable to a direct effect on endothelial cells. 
In clinically relevant levels, nicotine promoted endothe-
liaprocesses that may be involved in tumor angiogenesis. 
At these doses, nicotine promoted survival, proliferation, 
and migration of endothelial cells (Heeschen et al. 2001, 
2002). Nicotine also induced elaboration and release of 
angiogenic factors, including NO, prostacyclin, vascular 
endothelial growth factor, and fibroblast growth factor 
(Carty et al. 1996; Heeschen et al. 2001a; Lane et al. 2005). 
These effects of nicotine were mediated by nAChRs on the 
endothelium (Heeschen et al. 2002). Conversely, phar-
macologic inhibition or genetic deficiency of endothelial 
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nAChRs reduced angiogenic response to nicotine. A vari-
ety of human lung cancer cells synthesized acetylcholine 
or expressed nAChRs. Nicotine increased growth of these 
cells in vitro, but this effect was inhibited by antagonists 
of the nAChRs (Schuller 2002).
The importance of pathologic angiogenesis in 
growth of tumors is well known. Less widely recognized, 
however, is the role of neovascularization in progression 
of atherosclerotic plaque. Large atherosclerotic plaques 
in human coronary arteries are well vascularized by 
microvessels originating from the vasa vasorum (Barger 
et al. 1984). In mice with hypercholesterolemia, growth 
of atheroma can be inhibited by antiangiogenic agents, 
and in the same murine models, nicotine promoted neo-
vascularization of plaque and its progression in the aorta 
(Heeschen et al. 2001; Moulton et al. 2003). The effect of 
nicotine in increasing neovascularization and progression 
of plaque may partially explain increased risk of athero-
sclerotic disease in persons who smoke. 
Similarly, in a model of age-related macular degen-
eration in mice, nicotine stimulated retinal neovascular-
ization (Suñer et al. 2004). This effect was antagonized 
by hexamethonium, another antagonist of nAChRs. In a 
clinical study, the most virulent form of age-related macu-
lopathy is associated with retinal neovascularization that 
contributes to visual deterioration, and tobacco smokers 
are at greater risk of age-related macular degeneration 
than are nonsmokers (Christen et al. 1996; Seddon et al. 
1996). Thus, a variety of tobacco-related diseases are char-
acterized by pathologic neovascularization, an effect that 
may be promoted by nicotine.
Notwithstanding nicotine’s effect as a promoter of 
neovascularization, long-term exposure to tobacco may 
impair therapeutic angiogenesis. In a murine model 
of hindlimb ischemia, short-term exposure to nicotine 
paradoxically increased capillary density and improved 
regional blood flow in the ischemic hindlimb (Heeschen et 
al. 2001, 2003). However, long-term exposure to nicotine 
for 16 weeks (about one-third of the life span of a mouse) 
before induction of ischemia obliterated angiogenic 
response to nicotine (Konishi et al. 2010). 
The relevance of animal models for research on 
nicotine and angiogenesis to human smokers is not clear. 
It is important to differentiate studies that show effects 
of pure nicotine from those in which the exposure is to 
tobacco smoke. In mice, effects of nicotine on angiogen-
esis depended on release of NO, but the net effect of smok-
ing in humans seems to be impaired release of NO. Also, 
most studies on angiogenesis involve short-term admin-
istration of nicotine, although tolerance to the effects of 
nicotine may develop with long-term use. 
Inhibition of ACE normalized impaired bradykinin- 
mediated, endothelium-dependent venodilation in smok-
ers (Chalon et al. 1999). Furthermore, coronary vasomotor 
responses to acetylcholine in patients with CHD 
improved in response to the ACE inhibitor quinapril to 
a much greater extent in smokers than in nonsmokers 
(Schlaifer et al. 1999). ACE inhibitors have an antioxidant 
activity, which could contribute to the clinical benefit 
in smokers.
Summary
The endothelium, a delicate monolayer of cells that 
invests all blood vessels, is a major regulator of vascular 
reactivity and structure. Healthy endothelium maintains 
vascular homeostasis by promoting fluidity of the blood, 
vasodilation, and relaxation of the underlying vascu-
lar smooth muscle. Endothelial dysfunction regularly 
accompanies and promotes vascular disease. Endothelial 
vasodilator dysfunction is an independent risk factor for 
major adverse cardiovascular events and mortality. Active 
smoking and involuntary exposure to cigarette smoke 
injure endothelial cells and impair endothelial vasodila-
tion. Thus, each type of exposure to tobacco or tobacco 
smoke contributes to the development of CVD.
Thrombogenic Effects
This section on thrombogenic effects reviews the 
state of knowledge of mechanisms by which smoking 
or secondhand smoke exposure may predispose a per-
son to thrombosis, a pathologic reaction that commonly 
results in smoking-related MI or stroke. Smoking-mediat-
ed thrombosis appears to be a major factor in the patho-
genesis of acute cardiovascular events. 
Epidemiologic evidence indicates that cigarette 
smoking increases risk of acute MI and sudden death 
more than it increases risk of angina pectoris. Researchers 
hypothesize that risk of acute MI and sudden death is 
mediated by thrombosis, whereas angina is mediated 
primarily by hemodynamic factors. Successful revas-
cularization in patients with MI after treatment with 
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thrombolysis is more likely in smokers than in non-
smokers (Bowers et al. 1996). At the time of MI, smokers 
are younger and have fewer cardiac risk factors and less 
severe underlying coronary disease than do nonsmokers 
(Metz and Waters 2003). Enhanced thrombosis superim-
posed on less severely stenotic arteries best explains these 
observations. In men who died suddenly, a history of ciga-
rette smoking was significantly more likely when patho-
logic examination showed acute thrombosis (75 percent of 
cases) than when the finding was plaque with no throm-
bosis (41 percent) (Burke et al. 1997). Conversely, stable 
plaque with no thrombosis was the more common finding 
in nonsmokers. 
Thrombosis occurs when fibrinogen is converted 
to fibrin, a process involving interaction of platelets, 
blood-borne proteins, endothelial cells, and subendo-
thelial vascular tissue. An endogenous antithrombotic 
mechanism involves these same components. Imbalance 
in these pathways results in predisposition to thrombosis. 
Virchow’s triad, first described in 1856 and modified by 
Aschoff in 1924, provides a framework for risk factors for 
thrombosis that is still valid. These authorities described 
the cardinal risk factors as “alterations in blood coagula-
tion,” “alterations in blood flow,” and “alterations in the 
blood vessel wall.” 
Alterations in Blood
Blood contains platelets, red blood cells, and leuko-
cytes suspended in plasma. Plasma in turn contains a va-
riety of coagulation proteins and lipids that also contrib-
ute to the clotting process. Smokers tend to develop MI 
at a lower burden of atheroma than do nonsmokers. This 
finding suggests a greater role for formed elements of 
blood or for cardiac electrical instability in cardiovascular 
events in smokers.
Platelets
Platelets, although only a minor component of the 
solid phase of blood, are critical to the coagulation process 
and are important mediators of the impact of smoking on 
cardiovascular outcomes (Figure 6.6). 
Turnover and Activation
Studies have reported that sudden cardiac death 
is 2.5 times higher in smokers than in nonsmokers 
(Kannel et al. 1984; Goldenberg et al. 2003). Research 
findings broadly implicated activation of platelets and 
subsequent focal ischemia in sudden cardiac death among 
smokers. The turnover of platelets is accelerated in ciga-
rette smokers (Fuster et al. 1981). Researchers related the 
number of newly formed reticulated platelets, rather than 
absolute platelet count, to incidence of thrombotic events 
(Rinder et al. 1998). 
Urinary excretion of thromboxane metabolites 
(TxMs), such as 2,3-dinor thromboxane B2 (TxB2) and 
11-dehydro TxB2, which are markers of platelet activation 
in vivo, increases in smokers in a dose-dependent manner 
(Murray et al. 1985). Studies demonstrated increases in 
levels of urinary TxM among smokers who were monozy-
gotic twins but divergent for smoking behaviors (Lassila 
et al. 1988). These increases were also observed in young 
Swedish army recruits who smoked but had no apparent 
vascular disease (Wennmalm et al. 1991). Studies also 
showed that mainstream and sidestream smoke directly 
promoted platelet activation and enhanced activation 
induced by shear stress (Rubenstein et al. 2004). 
Elevated levels of TxM observed in persons who 
smoke decreased substantially within days of smoking 
cessation, although they did not reach the levels found in 
nonsmokers (Rangemark et al. 1993; Saareks et al. 2001). 
In an ex vivo study, platelets from smokers showed greater 
aggregation than those from nonsmokers (Takajo et al. 
2001). A decline in platelet aggregation during 14 days of 
abstinence from smoking was reversed rapidly after smok-
ing was resumed (Morita et al. 2005). Ex vivo aggregabil-
ity, however, is a crude index of in vivo platelet activation 
and aggregation. Some studies reported diminished ex 
vivo aggregability in smokers. This finding suggests that 
partial activation in vivo resulted in the harvest of a less 
responsive subset of platelets for study ex vivo. Increased 
levels of urinary TxMs in smokers may be attributable to 
activation of both platelets and macrophages. Low-dose 
aspirin, which inhibits COX activity in platelets, substan-
tially depressed the increment of TxM in smokers, lead-
ing investigators to hypothesize that TxM was principally 
derived from the activity of platelet COX-1 rather than 
macrophage COX-2 (Nowak et al. 1987; McAdam et 
al. 2005). 
Generation of Nitric Oxide 
Platelets constitutively express ENOS. Although 
platelet-derived NO is a modest inhibitor of platelet acti-
vation in vitro, it may be critical to inhibit recruitment 
of platelets to a growing thrombus (Freedman et al. 
1997). Aggregating platelets obtained from patients with 
acute coronary syndromes produced less NO than did 
those from patients with stable angina (Freedman et al. 
1998). Such findings must be interpreted with caution, 
however, because results reflect in vivo platelet activity 
(see “Turnover and Activation” earlier in this chapter). 
In one study, levels of platelet-derived NO were lower in 
smokers than in nonsmokers (Takajo et al. 2001). This 
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finding was associated with lower levels of intraplatelet-
reduced glutathione—a marker of oxidative stress and 
increased platelet aggregation. In another study, both the 
platelet-derived release of NO and the glutathione levels 
recovered in a time-dependent manner after smoking ces-
sation, but they rapidly decreased again when smoking was 
resumed (Morita et al. 2005). Abstinence from smoking 
was also associated with decreased agonist-induced platelet 
aggregation ex vivo. Furthermore, levels of intraplatelet 
nitrotyrosine and urinary 8-hydroxy-2’-deoxyguanosine, 
which are markers of oxidative stress, were also depressed 
after smoking cessation. One study showed that supple-
mentation with vitamin C restored NO levels and platelet 
aggregation in current smokers to levels observed in non-
smokers (Takajo et al. 2001). Another study demonstrated 
that the normal morning increase in platelet sensitivity 
to NO ex vivo was lost in smokers, leaving platelets poten-
tially more susceptible to activation during early morning 
hours, when MIs are most common (Sawada et al. 2002). 
In yet another study, platelets from smokers were less 
Figure 6.6 Potential sites of actions and mechanisms of effects of smoking on platelets
Note: Smoking decreases NO-mediated inhibition of platelet activation and increases platelet activation through oxidative stress and 
other mechanisms. NO = nitric oxide.
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sensitive to administration of nitroglycerin, a documented 
NO donor (Haramaki et al. 2001). 
Oxidative Stress and Platelet Function
Cigarette smoke has been shown to be an abundant 
source of free radicals (Church and Pryor 1985). Levels 
of isoprostanes—quantitative indices of in vivo oxidative 
stress—are higher in smokers than in nonsmokers (Reilly 
et al. 1996; Chehne et al. 2001; Dietrich et al. 2002), and 
they decrease with smoking cessation (Reilly et al. 1996; 
Praticò et al. 1997). In addition to serving as biomarkers of 
oxidative stress, isoprostanes may serve as secondary mes-
sengers that exert biologic effects, at least in vitro. 
Studies demonstrated elevated production of iso-
prostanes and decreased levels of reduced glutathione in 
the platelets of smokers (Takajo et al. 2001). Intraplatelet 
levels of nitrotyrosine, which is a marker of modification 
of proteins induced by oxidative stress, decreased with 
smoking abstinence but increased rapidly when smoking 
was resumed, together with return of increased sensitivity 
to agonist-induced platelet aggregation ex vivo (Morita et 
al. 2005). In another study, products from activated plate-
lets induced oxidative stress in vascular smooth muscle 
cells, which is associated with increased expression of tis-
sue factor, a highly thrombogenic protein (Görlach et al. 
2000). Other investigators showed that administration of 
antioxidants to persons with diabetes, just as to smokers, 
decreased production of isoprostane and urinary TxM 
(Davì et al. 1999) and decreased platelet aggregation ex 
vivo (Salonen et al. 1991). 
Isoprostanes and Platelet Function
In one study, platelets oxidized ex vivo demonstrated 
increased aggregation induced by shear stress, an effect 
that is only partly inhibited by administration of aspirin 
(Chung et al. 2002). In another study, oxidation of plate-
let membranes was associated with reduced expression of 
glycoprotein Ib, a receptor for the von Willebrand factor 
that is critical to platelet activation and aggregation under 
conditions of shear stress (Escolar and White 2000). The 
researchers postulated that decreased expression of gly-
coprotein Ib indicates a highly reactive status of platelets. 
Some evidence indicates that isoprostanes may act 
as platelet and vascular agonists through ligation of the 
thromboxane A2 receptor (TP) (Audoly et al. 2000). To 
date, no molecular evidence exists for a distinct isopros-
tane receptor (Praticò et al. 1996). One study reported that 
infusion of isoprostanes elevated blood pressure and acti-
vated platelets—effects that are lost in mice lacking TP. 
Binding of isoprostane iPF2a-III to TP promoted change 
in platelet shape and facilitated response to other proag-
gregatory stimuli (Praticò et al. 1996). In another study, 
however, isoprostane alone did not induce platelet activa-
tion and partially blocked the proaggregatory effects of TP 
agonists and high-dose collagen (Cranshaw et al. 2001). 
Also, isoprostane iPF2a-III was reported to decrease the 
antiplatelet activity of NO (Minuz et al. 1998). Some 
researchers speculated that this isoprostane has a role in 
the resistance to low-dose aspirin observed in patients 
with CVD (Csiszar et al. 2002). It is not known, however, 
how these effects, which are demonstrable in vitro, relate 
to endogenous levels of isoprostanes attained locally in 
vivo under conditions of oxidative stress.
Summary
Thus, platelets from smokers demonstrate a dose-
dependent increase in activity and adhesiveness that rap-
idly decreases with smoking abstinence. Findings suggest 
that the inhibitory NO pathway is impaired and respon-
siveness to other agonists is increased at least partially 
through the mediation of TP. 
Red Blood Cells
Hematocrit in Adults
Smoking is associated with an increase in hemato-
crit or red blood cell mass attributable to increased lev-
els of CO and carboxyhemoglobin. Hematocrit decreases 
with smoking cessation, but increased blood viscosity and 
deformability of red blood cells may persist (Haustein et 
al. 2004). Increases in hematocrit and blood viscosity are 
associated with increasing risk of CVD. It is unclear, how-
ever, whether these risk factors are independent of smok-
ing and other conventional risk factors, particularly in 
women (Lowe et al. 1997; Irace et al. 2003; Woodward et 
al. 2003). When data are adjusted for smoking, hyperten-
sion, and high cholesterol, viscosity remains a significant 
risk factor for stroke and for PAD but not for ischemic 
heart disease. This finding suggests that the effect of high 
viscosity may be an independent risk factor for stroke or 
PAD (Lee et al. 1996; Lowe et al. 1997). 
Hematocrit in Neonates
Researchers showed that the effects of smoking on 
hematocrit were transmitted to the fetus during preg-
nancy. Some studies reported a dose-dependent increase 
in hemoglobin levels in infants of mothers who smoked 
(al-Alawi and Jenkins 2000; Habek et al. 2002). Further-
more, infants born to mothers who smoked more than 20 
cigarettes per day had higher rates of fetal hypoxia, poly-
cythemia, and neurological complications than did infants 





In one study, persons who smoked had higher num-
bers of circulating polymorphonuclear leukocytes than 
did nonsmokers (Sela et al. 2002). In other research, 
neutrophils from smokers had higher levels of myeloper-
oxidase (Bridges et al. 1985) and increased expression of 
integrins CD11b, CD15, and CD63, which are markers 
of leukocyte activation (Gustafsson et al. 2000). Further-
more, when stimulated, these leukocytes released super-
oxide at a faster rate than did leukocytes from nonsmokers 
(Sela et al. 2002), which further increased local oxidative 
stress. Studies documented a greater variety of circulating 
cellular adhesion molecules, including ICAM-1, VCAM, 
P-selectin, and E-selectin, in smokers than in nonsmokers 
(Mazzone et al. 2001; Bermudez et al. 2002). An increase 
in these cellular adhesion molecules (monocytes) may 
facilitate recruitment of inflammatory cells to sites of vas-
cular injury (Figure 6.7). 
Monocytes
Monocytes from smokers demonstrated increased 
expression of the integrins CD11b and CD18, which aug-
ment adhesiveness of monocytes to endothelial cells, at 
least in vitro (Weber et al. 1996). This process is thought 
to be mediated by activation of protein kinase C (Kalra 
et al. 1994) and is attenuated by supplementation with 
vitamin C (Weber et al. 1996). In one study, isoprostane 
iPF2a-III inhibited adhesion of monocytes to cultured der-
mal cells or renal endothelial cells in rats but paradoxi-
cally increased adhesion of monocytes to human endo-
thelial cells in the umbilical vein (Leitinger et al. 2001; 
Kumar et al. 2005). Adhesion of monocytes to endothelial 
cells may increase their access into the subendothelium, 
where they differentiate into macrophages and promote 
atherogenesis (Ross 1999). Differentiation of monocytes 
into macrophages depends on production of intracellular 
reactive oxygen species induced by nicotinamide adenine 
dinucleotide phosphate, but no evidence exists for a role 
of cigarette smoking in this differentiation (Barbieri et 
al. 2003). 
Summary
In summary, smoking induced changes in the 
numbers and activity of polymorphonuclear leukocytes 
and monocytes. In addition, it promoted expression of 
chemoattractant and adhesion molecules and integrins, 
which would be expected to increase recruitment of 
activated leukocytes to areas of oxidative stress, including 
sites of platelet deposition after vascular injury. 
Circulating Proteins
In addition to its effects on the cellular elements 
of blood, smoking alters the proteins involved in the 
coagulation pathway by changing procoagulant factors in 
Figure 6.7 Potential sites of effects of smoking on thrombosis through oxidative stress and other mechanisms
Note: 1. Increased numbers and activation of polymorphonuclear leukocytes; increased production of superoxide radicals; and 
increased expression of integrins and adhesion molecules on leukocytes and endothelial cells. 2. Increased oxidation of LDL 
cholesterol; oxidized LDL cholesterol taken up more easily into macrophages to produce foam cells; and increased adhesiveness of 
monocytes to endothelial cells. 3. Increased levels of fibrinogen; increased nitration of tyrosine residues on fibrinogen, rendering it 
more thrombogenic; impaired activity of plasmin; and decreased thrombolysis. LDL = low-density lipoprotein.
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the circulation and anticoagulation factors derived from 
the endothelium. 
Fibrinogen
Study findings indicate that circulating levels of 
fibrinogen increase in smokers and decrease with smok-
ing cessation (Thomas et al. 1995; Hunter et al. 2001; Tuut 
and Hense 2001). Also, research suggests that elevated 
fibrinogen values are an independent risk factor for CHD 
(Paramo et al. 2004) and deep-vein thrombosis (Vayá et al. 
2002). For CVD, the predictive effect was reportedly simi-
lar and additive to traditional cardiovascular risk factors 
(Woodward et al. 1998). The effect of fibrinogen on CVD is 
partly attributable to smoking and seems to be mediated 
through alterations in rates of synthesis by the liver. Use 
of snuff is not associated with increased fibrinogen levels 
(Eliasson et al. 1995).
Nitration of tyrosine residues, a marker of 
NO-dependent damage, is increased in smokers (Petru-
zzelli et al. 1997). Presence of these residues depends 
strictly on availability of nitrogen dioxide radicals that 
are in turn derived from ONOO− (Kirsch et al. 2002). 
Tyrosine nitration modifies a variety of proteins, including 
fibrinogen (Petruzzelli et al. 1997; Pignatelli et al. 2001). 
Nitrogenated fibrinogen is more reactive and thrombo-
genic than is native fibrinogen (Gole et al. 2000), a fact 
that seems attributable to accelerated formation of clots 
without modification in plasmin-induced thrombolysis 
(Vadseth et al. 2004). The antioxidants glutathione and 
vitamin C protect against formation of nitrogenated 
fibrinogen by interfering with interaction of nitrate radi-
cals with tyrosine (Kirsch and de Groot 2000; Kirsch et al. 
2001). ONOO− is likely to derive from interaction of NO 
from cigarette smoke with superoxide radicals from pul-
monary macrophages (Deliconstantinos et al. 1994). In 
studies of both animal models and human volunteers, 
even brief exposure to tobacco smoke induced prolonged 
production (>30 minutes) of ONOO−, apparently from 
pulmonary macrophages (Deliconstantinos et al. 1994). 
Plasmin
Circulating plasminogen is activated to plasmin by 
fibrin, thrombin, and tPA. Plasminogen has fibrinolytic 
and collagenase activities. In vitro studies showed that 
levels of ONOO− increased in smokers and that ONOO− 
induced nitration of plasminogen in a concentration- 
dependent manner and reduced proteolytic activ-
ity of plasmin (Nowak et al. 2004). This effect is partially 
reduced by glutathione. 
C-Reactive Protein
Chronic, low-level inflammation—reflected by 
elevated levels of C-reactive protein (CRP) and other bio-
markers—is an important risk factor for atherosclerosis 
(Koenig et al. 1999). Investigators reported that levels of 
CRP, which likely contributes to both oxidative stress and 
mitogenic and fibrogenic characteristics of atheroscle-
rotic plaque, are higher in smokers than in nonsmokers 
in a dose-dependent manner (Bakhru and Erlinger 2005). 
This increase persisted even after adjustment for diabetes, 
lipid profile, and CVD, as well as age, gender, and race. 
More important, five years after smoking cessation, CRP 
levels were decreased to levels similar to those in lifetime 
nonsmokers. This finding suggests vascular healing. The 
timeframe is consistent with that observed in the multi-
national monitoring of trends and determinants of CVD 
(MONICA) (Dobson et al. 1991) and in the Northwick Park 
Heart studies (Meade et al. 1987). In those studies, cardio-
vascular risk was reduced at two to five years after a person 
stopped smoking. 
Oxidized Low-Density Lipoprotein 
Cholesterol
In vitro research on oxidative modification of LDL 
cholesterol (LDLc) by extracts from cigarette smoke 
showed a significant increase in atherogenicity (Chisolm 
and Steinberg 2000). In one study, LDL isolated after par-
ticipants smoked six or seven cigarettes was more suscep-
tible to ex vivo oxidation than was LDL isolated after 24 
hours of abstinence from smoking (Harats et al. 1989). In 
another study, oxidizability of LDL ex vivo decreased with 
smoking cessation (Sasaki et al. 1997). Oxidized LDLc, 
but not native LDL, interacted with scavenger recep-
tors on lipid-laden lung cells (foam cells) and was readily 
incorporated into atherosclerotic plaque. Findings in oth-
er studies suggest that oxidized LDL prompts migration 
and degranulation of neutrophils (Sedgwick et al. 2003) 
and increases expression of the Toll-like receptor, a trans-
membrane protein in macrophages, thus promoting their 
activation (Xu et al. 2001). 
Clinical studies produced conflicting data on the 
ability of cigarette smoke to oxidize LDLc and on the role 
of cigarette smoke in the process in vivo. Findings in sev-
eral studies (Scheffler et al. 1992; Mahfouz et al. 1995; 
Kagota et al. 1996; Gouaźe et al. 1998; Yamaguchi et al. 
2005), but not all studies (Princen et al. 1992; Siekmeier 
et al. 1996; Marangon et al. 1997; van den Berkmortel et al. 
2000), suggest that smoking increases oxidation of LDLc. 
Studies of an animal model suggest a similar oxidative 
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effect (Yamaguchi et al. 2002, 2004). In one study, modi-
fication of LDLc by cigarette smoke was diminished in a 
dose-dependent manner by administration of fluvastatin 
(Yamaguchi et al. 2002; Franzoni et al. 2003). Fluvastatin 
is a potent scavenger of the peroxyl radical. A similar 
clinical study showed no decrease in oxidized LDL with 
administration of atorvastatin, despite improvement in 
endothelial function (Beckman et al. 2004). It is unclear 
whether failure to demonstrate an association between 
improved endothelial function and oxidative stress in 
the study of atorvastatin reflects a true independence of 
these effects, a distinction from fluvastatin, or limitations 
attributable to the small sample size. 
Thus, cigarette smoking may induce changes in 
both coagulation and fibrinolytic pathways to promote a 
prothrombotic state. In addition to its effects on inflam-
matory cells, smoking promotes production of inflamma-
tory markers and acute-phase reactants. 
Alterations in Blood Vessels
Nitric Oxide
Cigarette smoking has injurious effects on the vas-
cular endothelium (see “Smoking and the Endothelium” 
earlier in this chapter). Abnormalities in the release of 
chemical mediators occur as a consequence of endothelial 
dysfunction and are likely to contribute to the prothrom-
botic condition of smokers. Examples include decreases in 
NO-mediated inhibition of interactions between platelets 
and the blood vessel wall, in platelet-induced NO, and in 
inhibition of platelet activation (see “Platelets” earlier in 
this chapter). Blood vessel tone is more sensitive to low 
NO levels than is platelet function (Loscalzo 2001). The 
importance of NO deficiency mediated by oxidative stress 
in thrombosis is suggested by familial childhood stroke 
resulting from deficiency in glutathione peroxidase. This 
condition decreases NO levels in association with both in-
creased expression of P-selectin in platelets and platelet 
aggregation and activation (Kenet et al. 1999). 
Prostacyclin Production
In vitro studies showed impaired production of 
prostacyclin by vascular cells exposed to cigarette smoke 
extracts. In vivo studies, however, showed increased bio-
synthesis of prostacyclin that is presumed to be reactive to 
accelerated interactions of platelets and neutrophils with 
vessel walls in smokers (Murray et al. 1990; Lassila and 
Laustiola 1992). Consistent with this concept, levels of 
markers of platelet and leukocyte activation were greater 
in smokers than in nonsmokers. Thus, the augmented 
biosynthesis of prostacyclin is likely to reflect a compen-
satory reaction by the vascular endothelium. 
von Willebrand Factor
Studies reported higher circulating levels of von 
Willebrand factor in smokers than in nonsmokers (Blann 
and McCollum 1993; Smith et al. 1993), and findings 
indicated that these levels may precede clinically overt 
atherosclerosis (Prisco et al. 1999). The von Willebrand 
factor is essential for initial adhesion of activated plate-
lets to the vessel wall and for expansion of thrombi. It is 
unclear to what degree high levels of von Willebrand fac-
tor might contribute to the increased thrombosis and ath-
erogenesis observed in smokers. 
Tissue Factor
Tissue factor is a prothrombotic protein made by 
numerous cells in the blood vessel wall, predominantly 
macrophages but also vascular smooth muscle and endo-
thelial cells. Tissue factor is released when the endothe-
lium is injured and can start the clotting cascade. Studies 
assessing the effects of smoking on tissue factor yielded 
mixed results (Barua et al. 2002; Sambola et al. 2003). The 
immunoreactivity of tissue factor was higher in specimens 
of plaque obtained during endarterectomy from smokers 
than in those from nonsmokers (Matetzky et al. 2000). In 
mice with APO E deficiency that were fed high-cholesterol 
diets, exposure to cigarette smoke resulted in higher lev-
els of tissue factor and VCAM-1 and higher macrophage 
counts in atherosclerotic plaques than in those of unex-
posed mice (Lykkesfeldt et al. 2000). Aspirin treatment 
of cigarette smokers and of mice exposed to smoke was 
associated with lower levels of tissue factor in plaque. This 
finding indicates that aspirin may have a protective role 
for smokers.
Tissue Plasminogen Activator
Vascular endothelial cells and other tissues secrete 
tPA. This protein has a central role in fibrinolysis, which 
limits expansion of clots during thrombosis and eventu-
ally dissolves the clot during thrombolysis. Evidence from 
the Physicians’ Health Study indicates that high levels 
of tPA are an independent risk factor for stroke and sug-
gests that activation of the endogenous fibrinolytic system 
occurs years before arterial vessels become occluded (Rid-
ker et al. 1994). PAI-1, which is also secreted by vascular 
endothelial cells, opposes the actions of tPA. 
Data on the effects of smoking on tPA and PAI-
1 are conflicting (Blann et al. 2000; Enderle et al. 2000; 
Matetzky et al. 2000; Newby et al. 2001). Using an in vitro 
model, researchers showed that serum from smokers 
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impaired tPA production by human umbilical vein endo-
thelial cells but that PAI-1 production was unchanged 
(Barua et al. 2002). In an in vivo model, bradykinin (Newby 
et al. 1999; Pretorius et al. 2002) and substance P (Newby 
et al. 1999; Pretorius et al. 2002) stimulated the produc-
tion of tPA, which had decreased in smokers, but there 
was no effect on the release of methacholine-induced tPA. 
Vitamin C failed to ameliorate this decrease (Pellegrini et 
al. 2004). Studies showed that levels of PAI-1 may decrease 
after smoking cessation (Simpson et al. 1997). 
Thus, the evidence suggests that smoking 
decreases the production of tPA and perhaps also increas-
es the amount of PAI-1 produced. These changes would 
be expected to impair fibrinolytic activity. Alternatively, 
a population-based study demonstrated increased lev-
els of fibrinogen, but fibrinolytic activity in smokers did 
not differ from that in nonsmokers (Eliasson et al. 1995). 
Another study suggested that differences between smok-
ers and nonsmokers in thrombolysis may be evident only 
in older adults (Ikarugi et al. 2003). 
Summary
A variety of abnormalities can be observed in 
endothelial cell function among smokers compared with 
nonsmokers. These abnormalities affect the ability of the 
endothelium to modulate vascular tone, platelet func-
tion, thrombogenesis, and thrombolysis. Administra-
tion of antioxidants mitigates some but not all of these 
abnormalities. The relative importance of these abnormal-
ities and their interactions in clinical settings remains to 
be elucidated. 
Exposure to Secondhand  
Tobacco Smoke
In one study, levels of fibrinogen and coagulation 
factor VII were higher in nonsmoking adolescent offspring 
of smokers than in nonsmoking adolescent offspring of 
nonsmokers (Stavroulakis et al. 2000). This finding is in 
keeping with a prothrombotic state in smokers. In addi-
tion, levels of PAI-1 were lower in nonsmoking offspring of 
smokers. This result suggests decreased fibrinolysis, but 
there was no difference in tPA levels. Levels of thrombo-
modulin, which is produced by the vascular endothelium 
and has anticoagulant effects, were higher in nonsmoking 
offspring of smokers, but levels of von Willebrand factor 
were unchanged. Another study demonstrated that TxM 
levels increased in one exposure to secondhand smoke; 
after six hours of exposure, levels approached those 
observed in smokers (Schmid et al. 1996). In other 
research, exposure to secondhand smoke decreased sensi-
tivity of platelets to the inhibitory effects of prostacyclin in 
vitro (Burghuber et al. 1986). 
Thus, many of the effects from active smoking can 
be observed in persons involuntarily exposed to cigarette 
smoke. The magnitude of the effect of secondhand smoke 
is relatively large considering the low systemic exposure 
to tobacco smoke for nonsmokers compared with that for 
active smokers and supports the finding of high cardiovas-
cular risk at low levels of exposure to smoke. 
Nicotine and Thrombosis
Nicotine replacement therapy (NRT) does not seem 
to increase the acute risk of thrombosis, even in patients 
with established cardiac disease (Joseph et al. 1996). 
However, investigators have not fully studied cardiovascu-
lar effects of extended administration of nicotine, which 
might be used as an adjunct for persons trying to stop 
smoking (Stratton et al. 2001). The high urinary excretion 
of TxM in smokers declines rapidly after smoking cessa-
tion. In one study, this decline did not occur in smokers 
who were using NRT, suggesting that nicotine may be 
contributing to platelet activation (Saareks et al. 2001). 
However, other studies in which smokers switched to nic-
otine patches found a decline in eicosanoid excretion and 
that long-term use of smokeless tobacco, which results 
in nicotine exposure similar to that of cigarette smokers, 
does not increase urinary excretion of TxM (Wennmalm 
et al. 1991; Benowitz et al. 1993). These findings suggest 
that nicotine per se does not activate platelets. When nico-
tine or cotinine was added to the platelet-rich plasma of 
nonsmokers, platelet-dependent formation of thrombin 
increased (Hioki et al. 2001). The magnitude of the effect 
was similar to that observed in smokers, even though the 
basal nicotine levels in smokers were higher than those 
in nonsmokers. When cultured endothelial cells from the 
human brain were exposed to nicotine, tPA levels were 
unchanged (Zidovetzki et al. 1999). Rather, PAI-1 mes-
senger RNA and protein expression increased, favoring 
a prothrombotic state. Alternatively, when transdermal 
nicotine was administered to nonsmokers, the release 
of tPA induced by substance P was greater than that in 
nonsmokers who had received placebo patches (Pellegrini 
et al. 2001). This finding suggests a more favorable effect 
in vivo. 
A study of cardiovascular biomarkers indicates that 
smokeless tobacco produced neither the inflammatory 
reaction found in smokers nor endothelial dysfunc-
tion, activation of platelets, or evidence of oxidant stress 
(Axelsson et al. 2001). Leukocyte counts; levels of CRP, 
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fibrinogen, and antioxidant vitamins; and lipid profiles 
were similar in users of smokeless tobacco and in persons 
who did not use tobacco. 
Summary
Multiple factors produced in the blood and released 
from the vasculature determine the likelihood of a clini-
cally significant thrombosis. Cigarette smoke and com-
ponents of the smoke stimulate formation or activity 
of factors that favor the development of thrombosis. It 
remains to be seen whether biomarkers of individual 
cardiovascular risk among smokers will emerge and 
which genetic variants might particularly influence these 
risks in smokers. The implications of the hypercoagulable 
state are observed both in the epidemiology of active and 
involuntary smoking-related cardiovascular events and in 
the rapid rate of decline in the major component of excess 
risk for those events after smoking cessation. A hyperco-
agulable state can result in acute MI in persons who have 
less severe underlying coronary disease, so smokers who 
stop smoking have a better prognosis than do nonsmok-
ers after MI. A more gradual decline of residual risk may 
reflect resolution of smoking-induced vascular injury, 
which in turn stimulates platelet activation. 
Inflammation
Studies demonstrate that cigarette smoking results 
in a chronic inflammatory state, evidenced by increased 
counts of circulating leukocytes, CRP, and acute-phase 
reactants such as fibrinogen (Tracy et al. 1997; Jensen et 
al. 1998; Tuut and Hense 2001). Cigarette smoking also 
activates monocytes and enhances recruitment and adhe-
sion of leukocytes to blood vessel walls, an integral step 
in vascular inflammation (Lehr et al. 1994). Research 
indicates that inflammation contributes to atherogenesis, 
because high leukocyte counts and high levels of CRP and 
fibrinogen are all powerful predictors of future cardiovas-
cular events (Libby et al. 2002).
However, the mechanisms by which cigarette smok-
ing promotes inflammation are not completely elucidated. 
As discussed previously, oxidant stress appears to be a crit-
ical factor; oxidized LDL is a proinflammatory stimulus 
(see “Cigarette Smoke Constituents and Cardiovascular 
Disease” earlier in this chapter). Studies also show that 
the products of lipid peroxidation are proinflammatory, 
acting in part on the receptor for platelet-activating factor 
(PAF). In hamsters, the antioxidant vitamin C prevented 
adhesion of leukocytes to the endothelium and leukocyte-
platelet aggregation (Lehr et al. 1994). In the same animal 
model, adhesion of leukocytes and formation of leukocyte-
platelet aggregates were mediated by PAF-like agonists 
(Lehr et al. 1997). This PAF-like factor was derived from 
oxidative modification of phospholipids and was distinct 
from biosynthetic PAF. Treatment with vitamin C inhibited 
generation of PAF-like lipids. In contrast, oral l-arginine 
but not vitamin C reversed the effect of sera from smok-
ers by promoting monocyte-endothelial cell adhesion, 
which is associated with higher levels of ICAM (Newby et 
al. 2001). The study findings suggest that smoking-related 
impairment of NO release is an important determinant of 
increased adhesion of monocytes to endothelial cells.
Nicotine may contribute to inflammation by acting 
as a chemotactic agent for migration of neutrophils (Nicod 
et al. 1984). One study indicates that nicotine enhanced 
leukocyte-endothelium interactions, resulting in greater 
leukocyte rolling and adhesion in the cerebral microcir-
culation of mice (Nitenberg et al. 1993). Nicotine report-
edly acts on human monocyte-derived dendritic cells to 
stimulate an inflammatory response (Nowak et al. 1987). 
Dendritic cells, which were detected in the walls of arter-
ies and in atherosclerotic lesions, present antigens and are 
thus required for the start of adaptive immunity. Studies 
showed that nicotine is a potent inducer of expression of 
a variety of co-stimulatory molecules and that it increases 
secretion of the proinflammatory cytokine interleukin-12 
in cultured dendritic cells (Aicher et al. 2003). Nicotine 
augmented the capacity of dendritic cells to stimulate 
proliferation of T cells and cytokines. Finally, intravenous 
injection of nicotine increased the movement of dendritic 
cells into atherosclerotic lesions in vivo in mice deficient 
in APO E. This line of research suggests that nicotine 
could contribute to adaptive immunity, which may have 
a role in atherogenesis. However, switching from smoking 
to transdermal nicotine resulted in a significant decline 
in the leukocyte count (Benowitz et al. 1993). In addition, 
use of smokeless tobacco did not produce higher leuko-
cyte counts or higher CRP levels than are seen in persons 
who do not use tobacco. These observations suggest that 
nicotine is not the main determinant of the inflammatory 
response in smokers. 
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Smoking and Diabetes
Cigarette smoking is widely known to increase the 
risks of CVD. Even so, this knowledge does not appear to 
influence smoking behaviors among patients with diabe-
tes, who bear a higher risk of cardiovascular morbidity and 
mortality than those who do not have diabetes (Haffner et 
al. 1998). Surveys found that smoking patterns were simi-
lar in patients with diabetes and comparable populations 
without that disorder (Ford et al. 1994; Gill et al. 1996). 
Numerous experimental studies demonstrated 
that smoking had negative effects on the metabolism of 
glucose and lipids in persons with or without diabetes. 
Investigators reported that cigarette smoking in patients 
with diabetes was associated with deterioration of meta-
bolic control (Madsbad et al. 1980; Bott et al. 1994) and 
increased risk of microvascular and macrovascular com-
plications and death (Chase et al. 1991; Morrish et al. 
1991). Furthermore, cigarette smoking increases risk of 
type 2 diabetes in the general population (Will et al. 2001). 
This risk may be mediated through direct metabolic 
effects alone or in combination with a metabolically unfa-
vorable lifestyle. 
Risk
In several prospective studies, cigarette smoking 
was associated with increased risk of type 2 diabetes in 
both men and women (Willi et al. 2007). Generally, these 
prospective studies were large and population based. Most 
of the information was collected by mailing participants 
a questionnaire, which in some cases, was supplemented 
with information from medical records. Most of these 
studies included follow-up of more than 10 years. Results 
were generally presented after adjustments for possible 
covariates. 
In the Health Professionals Follow-Up Study, the 
RR of developing diabetes among men who smoked 25 
or more cigarettes per day was 1.94 (95 percent CI, 1.25–
3.03) when nonsmokers were the reference group (Rimm 
et al. 1995). In a smaller British study, the risk of diabetes 
was 50 percent higher among smokers, but this finding 
was not independent of other risk factors, such as obe-
sity and low levels of physical activity (Perry et al. 1995). 
Another British study demonstrated that RR for diabetes 
in men who smoked was approximately 1.7, after adjust-
ments for the effects of age, body mass index, physical 
activity, alcohol intake, social class, undiagnosed CHD, 
and treatment for hypertension (Wannamethee et al. 
2001). Mean follow-up was almost 17 years. The increased 
risk of diabetes was lower 5 years after smoking cessation, 
and the risk normalized 20 years later. A Japanese study 
found similar results and also reported a positive correla-
tion between use of tobacco products and risk of diabetes 
(Uchimoto et al. 1999).
Almost identical results were presented in the Physi-
cians’ Health Study (Manson et al. 2000). During 12 years 
(255,830 person-years1) of follow-up, the risk of diabetes 
in men who smoked more than 20 cigarettes per day was 
70 percent higher than that in nonsmokers, after adjust-
ment for multiple variables. The results also showed 
a significant positive association between the risk of 
developing diabetes and higher consumption of cigarettes 
(Manson et al. 2000). In addition, the Insulin Resistance 
Atherosclerosis Study monitored a cohort of 906 study 
participants for five years with equal representation of 
African Americans, Hispanics, and Whites (Foy et al. 
2005). For all persons studied, current smoking was asso-
ciated with development of diabetes: the adjusted OR was 
2.66 (95 percent CI, 1.49–4.77). Among participants who 
had normal glucose tolerance at baseline, the OR was 5.27 
(95 percent CI, 2.11–13.16).
At least three other studies of men confirmed the 
main results of these prospective studies (Feskens and 
Kromhout 1989; Kawakami et al. 1997; Ko et al. 2001). 
There have been fewer studies with women, but two major 
prospective surveys yielded similar results. In the Nurses’ 
Health Study (114,247 women; 1,277,589 person-years 
of follow-up), RR for diabetes in heavy smokers was 1.42, 
after adjustments for other risk factors (Rimm et al. 1993). 
In an analysis of data from the Nurses’ Health Study 
after 16 years of follow-up, Hu and colleagues (2001) 
showed that the strongest predictors of diabetes were 
being overweight or obese. In addition, poor diet, smok-
ing, abstinence from alcohol, and low levels of physi-
cal activity were all independently associated with the 
risk of developing diabetes. Adjusted RR for developing 
diabetes was approximately 1.4 for smokers compared 
with nonsmokers.
Data from CPS-I, a prospective cohort study con-
ducted between 1959 and 1972, were used to analyze the 
correlation between tobacco use and risk of diabetes in 
both men and women (Will et al. 2001). In comparison 
1Person-year = the sum of the number of years that each member of a population has been smoking.
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with the risk of developing diabetes for nonsmokers, the 
risks were higher for men who smoked more than one 
pack of cigarettes per day (RR = 1.19) or two packs per 
day (RR = 1.45). Risks were also higher for women who 
smoked more than one pack per day (RR = 1.21) or two 
packs per day (RR = 1.74). After smoking cessation, the 
risk returned to normal after 5 years for women and after 
10 years for men (Will et al. 2001).
Only a few studies, all from the 1970s or 1980s, failed 
to demonstrate a positive association between smoking 
and diabetes, likely due to inadequate study design or lack 
of power in the study to test this hypothesis (Medalie et al. 
1975; Keen et al. 1982; Wilson et al. 1986).
It is generally accepted that risk increases more for 
type 2 diabetes than for type 1, because type 1 diabetes is 
relatively rare among the age groups in the studies. Risk 
for type 2 diabetes is also consistent with the adverse met-
abolic effects of smoking (see “Insulin Resistance” later in 
this chapter). Type 1 diabetes is insulin deficiency caused 
by autoimmune destruction of pancreatic beta cells; 
in type 2 diabetes, insulin resistance is combined with 
impaired secretion of insulin (Reaven 1988; Kahn 2001).
Metabolic Control
Some studies examined the effects of cigarette 
smoking on the body’s requirement for insulin and meta-
bolic control in patients with diabetes. In a cross-sectional 
study, Madsbad and colleagues (1980) investigated the 
relationship between insulin doses and related variables 
in patients treated with injections of insulin. Insulin 
doses and serum levels of triglycerides were significantly 
higher in the 114 persons who smoked than in the 163 
who did not smoke, and these values increased in a dose-
dependent manner in relation to the number of cigarettes 
smoked. Hemoglobin A1c (HbA1c)—a marker of long-term 
glucose elevation—was not measured in this study, but 
blood and urine levels of glucose did not differ between 
the two groups. This finding suggests that in patients who 
smoke, a larger insulin dose is needed to achieve meta-
bolic control similar to that in patients who do not smoke.
In a cross-sectional study of 192 patients with type 
1 diabetes, smoking was more common in those with 
higher HbA1c values (Lundman et al. 1990). Other dif-
ferences between the smokers and nonsmokers were in 
attitudes toward diabetes, psychological well-being, and 
similar factors. 
In a relatively large prospective study that exam-
ined the effects of intensified insulin treatment and 
of an educational program, smoking was the most 
consistent determinant of HbA1c levels in relatively young 
articipants treated with insulin (Bott et al. 1994). The 
investigators performed a three-year follow-up on 697 
patients with diabetes who had no debilitating late com-
plications. HbA1c levels were higher throughout the study 
in smokers but eventually improved to levels similar to 
those in nonsmokers, presumably because of the educa-
tional program.
Insulin Resistance
The metabolic effects of smoking have been gener-
ally studied in persons who did not have diabetes. Insulin 
sensitivity was usually determined by using the euglyce-
mic hyperinsulinemic clamp technique (DeFronzo et al. 
1979). This technique or a slightly modified version of it 
is considered to be the gold standard in metabolic studies. 
In 1993, Attvall and colleagues showed that short-
term smoking caused impaired insulin sensitivity in 
healthy young men. Separately, two cross-sectional stud-
ies of men compared uptake of insulin-mediated glucose 
(insulin sensitivity) in smokers and nonsmokers (Fac-
chini et al. 1992; Eliasson et al. 1997a). Insulin sensitivity 
was significantly lower (by 10 to 40 percent) in smokers. 
The degree of insulin resistance was positively correlated 
with tobacco use, and in long-term users of nicotine gum, 
with serum cotinine values (Eliasson et al. 1994, 1996). 
Because cotinine is a metabolite of nicotine, serum and 
urine levels of cotinine reflect the amount of nicotine use. 
Insulin resistance in smokers normalized eight weeks 
after smoking cessation, despite a weight gain of 2.7 kg 
(Eliasson et al. 1997a). 
Smokers in these two cross-sectional studies had 
signs of insulin-resistance syndrome, such as signifi- 
cantly high serum levels of free fatty acids (FFAs) and 
triglycerides and low levels of HDLc (Facchini et al. 1992; 
Eliasson et al. 1997b). In the study by Eliasson and col-
leagues (1997b), smokers had a high proportion of ath-
erogenic small and dense LDL particles, high fibrinogen 
levels, and high PAI-1 activity compared with those of 
nonsmokers. PAI-1 activity among long-term users of 
nicotine gum was similar, but effects on lipids were not 
as pronounced as those in smokers (Eliasson et al. 1996). 
One aspect of insulin-resistance syndrome that 
attracted attention was postprandial hypertriglyceridemia, 
a phenomenon associated with CVD and insulin resistance 
(Patsch et al. 1992; Jeppesen et al. 1995). This phenom-
enon is also observed in smokers (Axelsen et al. 1995; Eli-
asson et al. 1997b), but its cause is unknown. One possible 
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explanation is the inability of smokers to adequately clear 
triglyceride-rich chylomicrons and their remnants from 
the body (Mero et al. 1997). 
Other studies that did not use exact measurements 
of insulin sensitivity reported changes in glucose metabo-
lism in smokers compared with nonsmokers. Compared 
with nonsmokers, smokers were hyperinsulinemic and 
relatively glucose intolerant (Eliasson et al. 1991; Zava-
roni et al. 1994; Frati et al. 1996; Ronnemaa et al. 1996). 
A large cross-sectional study showed that after adjust-
ments for confounding factors, smoking behaviors were 
clearly correlated with HbA1c values in persons who did 
not have diabetes (Sargeant et al. 2001), but researchers 
have debated the importance of HbA1c in persons who do 
not have diabetes. Even so, these findings add support to 
the hypothesis that use of tobacco exerts adverse effects on 
glucose homeostasis.
Results in a few studies did not support these find-
ings. Godsland and Walton (1992) found no differences in 
insulin sensitivity between women smokers and nonsmok-
ers, but this result may be attributable to lower levels of 
tobacco use. In addition, the results were from analysis of 
data obtained to test a different hypothesis. In a study of 
metabolic changes in patients with or without hyperten-
sion, no differences in insulin sensitivity between smokers 
and nonsmokers were detected (Nilsson et al. 1995). How-
ever, the study design likely did not enable discrimination 
between metabolic changes caused by hypertension and 
those caused by smoking.
In patients with type 1 diabetes, Helve and colleagues 
(1986) examined cross-sectional and short-term effects of 
smoking on insulin sensitivity. Despite elevated levels of 
circulating epinephrine, cortisol, growth hormone, and 
glucagon after smoking, no effect of smoking on insulin 
sensitivity was observed. The investigators concluded that 
fluctuations in blood glucose and metabolic control dis-
guised the influence of smoking in these patients with dia-
betes. In a study of 28 smokers and 12 nonsmokers with 
type 2 diabetes, the researchers measured insulin sensi-
tivity by using euglycemic clamps (Targher et al. 1997). 
Smokers had higher insulin resistance and glucose intol-
erance than did nonsmokers. The researchers concluded 
that smoking markedly and in a dose-dependent manner 
aggravated insulin resistance observed in patients with 
type 2 diabetes (Targher et al. 1997). 
Axelsson and colleagues (2001) reported that nico-
tine administered intravenously to nonsmokers caused a 
marked reduction (about 30 percent) in insulin sensitivity 
in those with type 2 diabetes but not in healthy control 
participants. These results suggest that nicotine and pos-
sibly tobacco use or other environmental factors may have 
particularly adverse effects in persons susceptible to dia-
betes but not in those who are healthy (insulin sensitive). 
Microvascular Complications
Microvascular complications in diabetes (retinopa-
thy, nephropathy, and neuropathy) are linked to metabolic 
control in both type 1 and type 2 disease (New England 
Journal of Medicine 1993; Lancet 1998). The mechanisms 
for development of microvascular complications are not 
fully understood, although several pathogenetic pathways 
have been suggested (Brownlee et al. 1984; Tomlinson 
1999; Cai and Boulton 2002). Hyperglycemia has a central 
role as a trigger for subsequent events, such as conversion 
of glucose to sorbitol by aldose reductase; nonenzymatic 
glycosylation of proteins and receptors in susceptible tis-
sues; increased exposure to oxidative stress; and activation 
of protein kinase C and mitogen-activated protein kinases. 
Researchers have suggested that these pathogenetic path-
ways lead to the disturbances in morphology and function 
found in diabetic nephropathy, retinopathy, and neuropa-
thy (Brownlee et al. 1984; Tomlinson 1999; Cai and Boul-
ton 2002).
Nephropathy
Some studies showed that smoking increased risk of 
microvascular complications in diabetes. Several studies 
of patients with type 1 diabetes reported negative effects 
of tobacco use on albuminuria and renal function. Chase 
and colleagues (1991), for example, showed that the albu-
min excretion rate was 2.8 times higher in smokers than 
in nonsmokers, after statistical corrections for glycemic 
control, duration of diabetes, age, gender, and blood pres-
sure. In addition, albuminuria progressed at a more rapid 
rate in smokers than in nonsmokers.
Smoking promoted progression of renal disease 
in persons with type 2 diabetes (Biesenbach et al. 1997; 
Chuahirun and Wesson 2002; Chuahirun et al. 2003). Bie-
senbach and colleagues (1997) studied only 36 patients, 
but follow-up lasted 13 years. At study entry, smokers and 
nonsmokers had similar clinical and laboratory character-
istics, but progression of nephropathy and development 
of atherosclerotic disease progressed more rapidly in the 
smokers than in the nonsmokers. Multiple regression 
analysis showed that only tobacco use and blood pres-
sure levels were independently associated with impair-
ment in renal function. This finding underscored the 
roles of smoking and vascular disease in susceptibility to 
renal disease (Biesenbach et al. 1997). In two prospective 
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studies by Chuahirun and colleagues (2002, 2003), the 
effects of cigarette smoking on acceleration of nephropa-
thy in patients with type 2 diabetes were confirmed even in 
those who had optimal therapy for hypertension. Research 
presented further evidence of functional and structural 
changes in the glomeruli of patients with type 2 diabetes 
who smoke (Baggio et al. 2002). In a study of 96 patients 
who had biopsy of the kidney, electron and light micros-
copy demonstrated significant changes in glomeruli and 
basal membranes that corresponded to impaired glomeru-
lar filtration rates in the smokers.
Retinopathy
Generally, investigators have not considered smok-
ing to be a substantial risk factor for diabetic retinopathy 
(Porta and Bandello 2002). Findings in fairly large stud-
ies with mixed populations showed no strong support for 
such an association, except in older adults with certain 
conditions (Walker et al. 1985; Moss et al. 1991). At least 
two studies of patients with type 1 diabetes, however, sug-
gest that smoking does predispose these patients to reti-
nopathy (Mulhauser et al. 1986, 1996). In addition, Chase 
and colleagues (1991) showed that retinopathy was more 
common in patients with type 1 diabetes who smoked than 
in those who did not smoke, but after adjustments for 
covariates, differences were not statistically significant. 
The study also reported accelerated progression of reti-
nopathy in patients who smoked. Thus, smoking may 
be a risk factor for diabetic retinopathy, but only in cer- 
tain subgroups.
Neuropathy
The role of tobacco in the development of diabetic 
neuropathy is relatively difficult to examine because of 
methodologic problems and the frequent prevalence of 
confounding factors (Westerman et al. 1992). Diabetic 
neuropathy usually develops during a long period, and it 
may affect different sensory, motor, and autonomic nerve 
fibers in varying degrees in individuals. This variation 
makes it difficult to standardize study methods. One case-
control study reported that risk of neuropathy was three 
times higher in patients with type 1 diabetes who smoked 
than in those who did not smoke (Mitchell et al. 1990). 
Smoking was not related to neuropathy in patients with 
type 2 diabetes. In a study of young patients treated with 
insulin, independent risk factors for progression of distal 
sensory neuropathy, apart from poor glycemic control, 
were cigarette smoking, greater height, and female gender 
(Christen et al. 1999). Other studies in patients with type 
1 diabetes confirmed the roles of glycemic control and 
smoking behaviors in development of clinical neuropathy 
(Maser et al. 1989; Reichard 1992). 
Macrovascular Complications
The multiple effects of smoking on the vascular and 
hemostatic systems and on inflammation are reviewed 
elsewhere in this chapter (see “Hemodynamic Effects,” 
“Smoking and the Endothelium,” “Nicotine and Throm-
bosis,” and “Inflammation” earlier in this chapter). Dia-
betes patients are particularly susceptible to some effects 
of smoking, because their risk of cardiovascular morbidity 
and mortality is elevated (Jarrett et al. 1982; Manson et al. 
1991; Morrish et al. 1991).
In a study cohort in London, England, in the pro-
spective Multinational Study of Vascular Disease in Diabe-
tes, sponsored by the World Health Organization, smokers 
with type 1 or type 2 diabetes had significantly increased 
risk of CHD, but not stroke, during the eight-year follow-
up (Morrish et al. 1991). In the Diabetes Control and Com-
plications Trial (New England Journal of Medicine 1993), 
designed to study the role of intensive insulin treatment 
and optimized glycemic control in type 1 diabetes, smok-
ing was not a significant risk factor for macrovascular 
complications. Because the participants were relatively 
young, this trial was not optimally designed to study the 
role of tobacco use. Other studies with slightly older par-
ticipants who had type 1 diabetes reported that smoking 
increased risk of CHD (Moy et al. 1990; Sinha et al. 1997).
Among patients with type 2 diabetes in the United 
Kingdom Prospective Diabetes Study, cigarette smoking 
was a significant and independent risk factor for CHD 
(Turner et al. 1998), stroke (Kothari et al. 2002), and 
PAD (Adler et al. 2002). Also, an analysis of data from 
the Nurses’ Health Study demonstrated that for women 
with type 2 diabetes, a dose-effect relationship existed 
between smoking behaviors and mortality (Al-Delaimy et 
al. 2001). Compared with nonsmokers, risk of mortality 
from all causes was 1.64 for women who smoked 15 to 34 
cigarettes per day and 2.19 for women who smoked more 
than 34 cigarettes per day. Ten years after smoking cessa-
tion, risk of mortality had normalized. Researchers pub-
lished similar data on smoking and CHD risk in the same 
cohort (Al-Delaimy et al. 2002).
A relatively large prospective study that analyzed 
the effects of smoking cessation on cardiovascular risk in 
persons with diabetes compared mortality risk for former 
smokers with that for lifetime nonsmokers (Chaturvedi et 
al. 1997). Compared with mortality risk for lifetime non-
smokers, risk of death from all causes was approximately 
50 percent higher for patients who had stopped smoking 
during the past one to nine years and 25 percent higher 
for those who had not smoked for more than nine years. 
Smoking cessation reduced mortality risk among per-
sons with diabetes, but risks remained high several years 
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after smoking cessation and were highly dependent on the 
duration of smoking. 
Pathophysiological Mechanisms
Having diabetes, even for nonsmokers, is associ- 
ated with long-term exposure to oxidative stress, 
impaired endothelial function, and dyslipidemia (Brown-
lee et al. 1984; Turner et al. 1998; Dogra et al. 2001; Cai 
and Boulton 2002; Komatsu et al. 2002). The causes of 
type 2 diabetes are still not fully understood, although 
the main metabolic aberrations are well characterized. 
Research showed that type 2 diabetes is caused by insu-
lin resistance in combination with relative impairment of 
insulin secretion (Reaven 1988; Kahn 2001). Published 
studies have not demonstrated a significant impairment 
in insulin secretion among cigarette smokers (Epifano et 
al. 1992; Facchini et al. 1992; Persson et al. 2000), but 
several studies documented a negative effect of smoking 
on insulin sensitivity (Facchini et al. 1992; Eliasson et 
al. 1997a,b). 
Cigarette smoking and intake of nicotine increase 
the circulating levels of insulin-antagonistic hormones 
(i.e., catecholamines, cortisol, and growth hormone) 
(Kershbaum and Bellet 1966; Cryer et al. 1976; Wilkins 
et al. 1982; Kirschbaum et al. 1992). Smoking also acti-
vates the sympathetic nervous system (Niedermaier et al. 
1993; Lucini et al. 1996). Nicotine likely impairs insulin 
sensitivity directly or indirectly through these and possi-
bly other mechanisms. An additional negative factor for 
insulin-mediated glucose uptake is high circulating levels 
of FFAs, secondary to increased lipolysis (Bergman and 
Ader 2000). Research has shown that smoking acutely ele-
vates circulating FFA levels (Kershbaum and Bellet 1966).
Researchers have proposed, but not fully elucidated, 
the potential role of endothelial dysfunction or inflam-
mation in development of insulin resistance and type 
2 diabetes. 
Summary
Many clinical and experimental studies have found 
significant associations between cigarette smoking and 
development of diabetes, impaired glycemic control, and 
diabetic complications (microvascular and macrovascu-
lar). A different lifestyle of smokers, in contrast to that 
maintained by nonsmokers, may also contribute to these 
effects. Most of the reviewed studies, however, either 
attempted to statistically adjust for confounding factors 
or were designed to examine short-term effects of tobacco 
and nicotine.
The development of type 2 diabetes is another harm-
ful consequence of cigarette smoking, one that adds to the 
heightened risks of CVD. In diabetes care, smoking cessa-
tion is crucial to facilitating glycemic control and limiting 
development of complications.
Lipid Abnormalities
Cigarette smoking is associated with an atherogenic 
lipid profile likely to contribute to risk of CVD. 
Epidemiologic Observations
Several observations are central to the relationship 
between cigarette smoking and lipids. Compared with 
nonsmokers, smokers have higher levels of triglycerides 
associated with very-low-density lipoprotein (VLDL), 
total triglycerides, and APO B, in addition to modest in-
creases in LDLc and lower levels of plasma HDLc and APO 
A-I (Billimoria et al. 1975; Criqui et al. 1980; Wilson et 
al. 1983; Craig et al. 1989; Muscat et al. 1991; Freeman 
and Packard 1995; Villablanca et al. 2000). These findings 
are robust and are reported in numerous survey studies. 
Researchers observed a dose-response relationship 
between the number of cigarettes smoked per day and 
plasma lipid levels (Muscat et al. 1991). In contrast, plas-
ma lipid and lipoprotein levels in former smokers typically 
are similar to those in nonsmokers. 
The ratio of LDLc to HDLc, which is used as a mea-
sure of atherogenic risk, is higher in smokers than in 
nonsmokers. Cigarette smoking is thought to raise the 
LDLc to HDLc ratio by 15 to 20 percent. Increased lev-
els of plasma triglycerides are associated with lower HDLc 
levels, but reduction in HDLc from cigarette smoking per-
sists even after corrections for levels of total triglycerides. 
Early epidemiologic studies, such as the Lipid Research 
Clinics Program Prevalence Study and the Framingham 
Heart Study (Criqui et al. 1980; Muscat et al. 1991; Free-
man and Packard 1995), emphasized lower HDLc values as 
the primary effect of cigarette smoking. 
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Researchers have estimated, however, that these 
effects of cigarette smoking on plasma lipids and lipopro-
teins account for only 10 percent of the observed 70 per-
cent increase in risk of vascular disease associated with 
cigarette smoking (Craig et al. 1989). In the Edinburgh 
Artery Study, for example, adjusting for known CHD risk 
factors reduced the RR of CHD in heavy smokers from 
3.94 to 2.72 and the RR in moderate smokers from 2.72 to 
1.70 (Price et al. 1999). However, cigarette smoking still 
accounted for 75 percent of the risk of developing PAD, 
after adjustment for other known risk factors, such as 
hyperlipidemia and type 2 diabetes (Lu and Creager 2004). 
Other researchers reported similar findings (Cullen et al. 
1998). Cigarette smoking thus appears to have atherogen-
ic effects that are not explained by traditional CHD risk 
factors, including abnormal levels of blood lipids.
Analyses of mechanisms related to lipid and lipopro-
tein metabolism may be required for understanding the 
atherogenicity of cigarette smoking. Such mechanisms 
include lipid oxidation; changes in composition of lipo-
proteins; alterations in plasma- and lipoprotein-associated 
lipid transfer enzymes; changes in metabolism of fatty 
acids; effects on levels of postprandial lipids; and chang-
es in cholesterol fluxes, particularly reverse cholesterol 
transport (RCT). The following discussion reviews the 
effects of cigarette smoking on these potential underly- 
ing mechanisms.
Lipoprotein Composition and 
Apolipoprotein Levels
Cigarette smoking clearly reduces APO A-I and the 
ratio of A-I to A-II (Mero et al. 1998). APO A-I is a major 
component of HDL particles. The reduction in A-I levels 
observed in smokers is similar to, although perhaps some-
what lower than, the reduction in HDLc levels seen in this 
population. For example, Mero and colleagues (1998) doc-
umented that levels of plasma APO A-I were 4 to 6 percent 
lower and HDLc values were 6 to 9 percent lower in mod-
erate-to-heavy smokers. The effects of cigarette smoking 
on APO B and other APOs are also well documented (Bil-
limoria et al. 1975; Craig et al. 1989; Muscat et al. 1991; 
Villablanca et al. 2000).
Researchers have associated abnormalities in dif-
ferent subfractions of HDL with different risks of CHD. 
Cigarette smoking reduced different HDL subfractions in 
different studies (Billimoria et al. 1975; Craig et al. 1989; 
Muscat et al. 1991). Even so, the true atherogenicity of dif-
ferent HDL subfractions remains controversial. The role 
of altered HDL subfractions in arterial disease associated 
with cigarette smoking requires further study. 
Plasma- and Lipoprotein-
Associated Lipid Transfer Enzymes
Several enzymes in plasma—either free or associ-
ated with lipoproteins—are involved in transport and 
use of lipids. Lipoprotein lipase (LPL) activity is involved 
in clearance of total triglycerides from triglyceride-rich 
lipoproteins (TGRLs), particularly the chylomicra formed 
in persons after a meal containing fat. Cigarette smoking 
reportedly reduced plasma LPL activity after a mixed meal 
(Freeman et al. 1998). Reduced LPL activity may contrib-
ute to the reduced clearance of TGRLs reported for total 
triglycerides, APO B, and retinyl-ester components of 
TGRLs (Mero et al. 1998). In another study, the cholesterol 
ester transfer protein (CETP) received considerable atten-
tion as a therapeutic target for raising HDLc levels (Brous-
seau et al. 2004; Ruggeri 2005). CETP mediates transfer 
of cholesterol esters between HDL and other lipoproteins 
(VLDL and LDL). However, controversy exists as to wheth-
er CETP activity is beneficial or deleterious to the process 
of RCT. Moreover, the proatherogenic or antiatherogenic 
consequences of changing HDLc by the CETP mechanism 
remain uncertain (Ruggeri 2005). Studies have reported 
both increases and decreases in plasma CETP activity in 
smokers (Dullaart et al. 1994; Zaratin et al. 2004). 
Some studies measured other enzymes in smokers. 
For example, cigarette smoking did not appear to mark-
edly alter lecithin cholesterol acyltransferase activity 
(McCall et al. 1994).
Oxidized Lipoproteins
Many investigators hypothesized that oxidized LDL 
is highly atherogenic (Dullaart et al. 1994; Zaratin et al. 
2004), and studies reported increased oxidative damage 
to LDL in smokers (Ambrose and Barua 2004). However, 
attribution of a precise atherogenic contribution from 
oxidative damage to LDL remains speculative. The inad-
equacy of the metrics of pro-oxidative and antioxidative 
status in vivo needs to be resolved before the role of oxida-
tive damage to LDL can be adequately evaluated.
Postprandial Lipid Changes
Traditionally, plasma lipid and lipoprotein mea-
surements used to evaluate CHD risks have, for largely 
technical reasons, been performed in the fasting (posta-
bsorptive) state. Plasma levels of metabolites are more 
easily characterized in steady-state conditions than in a 
nonsteady state. From a pathophysiological perspective, 
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however, events in the postprandial state may be critical 
in atherogenesis (Zilversmit 1979). Some studies explored 
effects of cigarette smoking on postprandial lipid metabo-
lism (Mero et al. 1998). For example, total triglycerides 
increased to higher levels after a mixed meal in smokers 
than in nonsmokers. These researchers observed increases 
in plasma APO B level and reductions in levels of APO A-I, 
lipoprotein A-I, HDLc, and LDL-APO B after a meal. Other 
investigators postulated that the mechanisms underlying 
altered postprandial lipid changes in smokers include 
lower LPL activity (Freeman et al. 1998), but higher 
endogenous production of VLDL-total triglycerides by the 
liver has not been excluded. The postprandial effects of 
cigarette smoking in particular and their role in athero-
genesis in general are not completely understood.
Metabolism of Free Fatty Acids
Changes in FFAs (nonesterified fatty acids) are 
attributed to an increase in adipocyte lipolysis, and they 
represent the most well-characterized mechanistic action 
of cigarette smoking in the context of alterations in lipids 
and lipoproteins. Many studies reported higher plasma lev-
els of FFAs in smokers than in nonsmokers (Kershbaum et 
al. 1963; Bizzi et al. 1972; Walsh et al. 1977; Hellerstein et 
al. 1994; Neese et al. 1994). 
Using stable (nonradioactive) isotopes to measure 
FFA kinetics, researchers demonstrated that cigarette 
smoking immediately and markedly increased influx of 
FFAs into the bloodstream and thereby raised plasma 
levels of FFA (Hellerstein et al. 1994; Neese et al. 1994). 
Plasma FFAs are primarily derived from adipose tissue 
by lipolytic breakdown of stored triglycerides. Catechol-
amines stimulate hormone-sensitive lipase activity in 
adipose tissue and oppose various antilipolytic actions of 
insulin. Increases in FFA levels and flux induced by smok-
ing were temporally correlated with increases in plasma 
epinephrine levels (Watts 1960; Bizzi et al. 1972; Arcavi et 
al. 1994; Hellerstein et al. 1994; Neese et al. 1994). These 
increases are prevented by b-adrenergic blockers. Nico-
tine increases the adrenal medullary release of epineph-
rine in persons with nontolerance of nicotine (Arcavi et 
al. 1994). Therefore, the model implicated as the cause of 
increases in plasma FFA levels induced by cigarette smok-
ing seems clear: cigarette smoking→nicotine→increased 
plasma epinephrine→increased lipolysis in adipose 
tissue→increased release of FFAs into plasma→increased 
plasma levels of FFA. 
The fate of FFAs released into the bloodstream in 
response to cigarette smoking is also relevant. Cigarette 
smoking increases expenditure of energy through the 
activity of nicotine and catecholamines (Ilebekk et al. 
1975; Perkins et al. 1989; Hellerstein et al. 1994; Neese et 
al. 1994). However, most of the FFAs released in response 
to cigarette smoking are not oxidized but taken up and 
reesterified to triglycerides in tissues, particularly the 
liver. This conclusion was partly based on kinetic studies 
that compared the rates at which plasma FFA appeared 
with whole-body rates of fat oxidation (Hellerstein et al. 
1994; Neese et al. 1994). These studies demonstrated that 
the rate of FFA influx into plasma in response to ciga-
rette smoking greatly exceeded changes in whole-body 
fat oxidation. 
Accordingly, the catabolic effects of cigarette smok-
ing on total adipose triglycerides do not directly promote 
oxidation of body fat (weight loss); instead, the primary 
result is overproduction of VLDL-total triglycerides 
(Hellerstein et al. 1994; Neese et al. 1994). This “futile 
cycle,” a substrate cycle in which adipose triglycerides 
are converted to hepatic VLDL triglycerides, is modestly 
wasteful of energy. It accounts for about 5 percent of the 
thermogenic effects of long-term cigarette smoking—for 
example, fewer than 10 kilocalories (kcal)/day if cigarette 
smoking increases total energy expenditure by 200 kcal/
day. This cycle, however, may be the central driving force 
behind the atherogenic dyslipidemia associated with ciga-
rette smoking. Overproduction of VLDL-total triglycerides 
typically results in elevated plasma levels of VLDL-total 
triglycerides and APO B, as well as increased numbers of 
LDL particles (Sniderman et al. 2001). Furthermore, high 
VLDL-total triglycerides contribute to lowering of HDLc 
through CETP-mediated transfer of cholesterol-ester from 
HDL to VLDL particles (Brousseau et al. 2004; Ruggeri et 
al. 2005). Influx of FFAs into the liver for reesterification 
and secretion of total triglycerides is most likely a major 
reason for the low HDLc levels observed in smokers, but 
perhaps it does not represent the entire effect of smoking 
on HDLc (Criqui et al. 1980; Muscat et al. 1991; Freeman 
and Packard 1995). 
If nicotine-stimulated release of catecholamine is 
responsible for the hypertriglyceridemia and low HDLc 
levels observed in smokers, NRT as an adjunct to smok-
ing cessation should logically prevent improvements in 
plasma lipids and lipoproteins after smoking cessation. 
Moffatt and colleagues (2000) reported that nicotine-
patch therapy prevented the normalization of HDLc lev-
els observed with smoking cessation in the absence of the 
nicotine patch. The patch also prevented weight gain after 
smoking cessation (Allen et al. 2005), a finding consis-
tent with the hypothesis that shared catecholamines are 
the basis for two important effects of cigarette smoking: 
weight reduction and dyslipidemia. Other studies, how-
ever, did not confirm that use of the nicotine patch as an 
agent for smoking cessation prevents improvements in 
HDL levels (Allen et al. 1994). In addition, lipid profiles 
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are similar in persons who use smokeless tobacco and in 
those who do not use any form of tobacco. To the extent 
that dyslipidemia contributes to vascular disease associ-
ated with cigarette smoking, it is important to determine 
the full range of effects of NRT on lipid and lipopro- 
tein metabolism.
Reverse Cholesterol Transport
RCT refers to the pathway by which cholesterol is 
mobilized from tissues, carried through the blood, and 
excreted from the body. HDL and its associated membrane 
receptors (e.g., SR-B1, ABC-A1, and ABC-G1), plasma 
enzymes (e.g., CETP and phospholipid transfer protein), 
APOs (e.g., APO A-I), and hepatobiliary enzymes (e.g., cho-
lesterol 7a-hydroxylase) constitute a system that mediates 
the complex process of RCT through pathways that are 
increasingly well characterized in molecular terms (Neese 
et al. 1994; Tall 1998). RCT is generally accepted as the 
leading explanation for the cardioprotective activity of 
HDL, although other actions of HDL (e.g., antioxidative 
and anti-inflammatory) may also be involved.
Flux through the RCT pathway and, thus, antiath-
erogenic activity cannot be predicted simply from plasma 
levels of HDL or APO A-I (Tall 1998). Thus, changes in lev-
els of HDLc, VLDL-total triglycerides, and other lipopro-
teins may not fully capture the effects of cigarette smoking 
on pro-atherogenic or antiatherogenic fluxes such as RCT. 
Until more recently, however, there were no viable tech-
niques for measuring RCT fluxes. Therefore, this question 
could be addressed only indirectly—for example, through 
changes in lipid transfer proteins in plasma that may 
influence the efficiency of RCT. Studies reported decreas-
es in activity of CETP and phospholipid transfer protein 
in smokers after they had smoked a cigarette (Zaratin et 
al. 2004). 
Reduced capacity for remodeling HDL particles in 
the vascular compartment could alter these fluxes in a 
manner not reflected by HDLc levels. This possibility will 
remain speculative, however, until RCT fluxes are mea-
sured in humans. The ability to directly measure effects of 
cigarette smoking on the cardioprotective process of RCT 
could provide a major tool for advancing understanding 
of the role of lipids in causing vascular disease associated 
with cigarette smoking.
Effects of Smoking Cessation
Research on smoking cessation largely confirmed 
the associations observed in smokers (Gordon et al. 1975; 
Rabkin 1984; Stamford et al. 1986; Critchley and Capewell 
2004). Many studies documented the return of normal 
levels of plasma lipids and lipoproteins after cessation of 
cigarette smoking.
Therapeutic Implications of 
Pathogenic Mechanisms
If stimulation of lipolysis underlies the atherogenic 
dyslipidemia associated with cigarette smoking, inhibi-
tion of lipolysis might be an effective therapeutic strat-
egy to improve blood lipid profiles in smokers or persons 
receiving NRT. This strategy is an attractive approach in 
one sense because inhibition of lipolysis does not block 
the thermogenic actions of nicotine. The cycle of lipoly-
sis and reesterification accounts for less than 5 percent 
of the increase in energy expenditure observed in ciga-
rette smokers (Hellerstein et al. 1994; Neese et al. 1994). 
Another consideration is that if FFAs released by lipolysis 
are involved in the insulin resistance reportedly associat-
ed with cigarette smoking (Facchini et al. 1992), lipolysis 
inhibitors may have an additional therapeutic use. 
Niacin, a hypolipidemic agent, is thought to act 
at least partly by inhibiting total triglyceride lipolysis in 
adipose tissue (Meyers et al. 2004). The use of niacin in 
smokers who are at high risk for CHD has not been fully 
investigated. The side effects of niacin, including cutane-
ous flushing and worsening of insulin resistance in some 
persons, perhaps from effects on pancreatic islet function, 
may discourage its clinical use. The impact of niacin and 
its analogs on lipolysis is complex. They induce a rebound 
overshoot of lipolysis after initial inhibition, but niacin 
does reduce production of VLDL-total triglycerides (Wang 
et al. 2001). 
Other strategies for use of lipolysis inhibitors to 
prevent CHD related to cigarette smoking may require 
development of specific antilipolytic agents that are well 
tolerated. One possibility is the thiazolidinedione class 
of insulin-sensitizing drugs. In one study, such drugs 
reduced lipolysis in adipose tissue, perhaps by activating 
glyceroneogenesis and thereby promoting intra-adipocyt-
ic reesterification of FFAs (Chen et al. 2005). No studies 
are known to have tested the efficacy of thiazolidinediones 
in smokers to determine effects on lipid abnormalities or 
sensitivity to insulin. However, recent research indicates 
that rosiglitazone (a thiazolidinedione) increases CHD 
risk, although pioglitazone, another drug in the same 
class, does not increase this risk (Lincoff et al. 2007; Nis-
sen and Wolski 2007). Thus, it is unclear whether the 
possible benefits of this class of drugs in smokers will 
be pursued.
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Summary
Effects of cigarette smoking on standard mea-
sures of blood lipids and lipoproteins are well character-
ized. The most important effects are to lower levels of 
HDLc and increase levels of total triglycerides. The meta-
bolic mechanisms underlying these changes are known 
to some extent, particularly the catecholamine-mediated 
increase in adipocyte lipolysis, changes in plasma levels 
of FFAs, and reesterification of FFAs by the liver. How-
ever, the predicted effect from changes in standard lipid 
risk factors for vascular disease associated with cigarette 
smoking appears to be modest. Future research will reveal 
whether this estimation of a modest effect is a true esti-
mate of the pathogenic importance of smoking-induced 
changes in blood lipid levels or an inability to measure the 
full effects of cigarette smoking on atherogenesis. 
Cardiovascular Biomarkers
Biomarkers of smoking-related CVD risk are useful 
for stratifying individual risk and, perhaps, for assessing 
product risk. Biomarkers for CVD risk can be divided into 
three categories: (1) constituents of cigarette smoke that 
contribute to CVD, (2) physiological changes involving 
potential mechanisms of CVD, and (3) chemical biomark-
ers of cardiovascular dysfunction and disease (Table 6.3). 
Studies showed that cigarette smoking altered many of the 
CVD biomarkers, as evidenced by comparisons of smokers 
with nonsmokers and former smokers. However, fewer 
studies prospectively examined reversal of such changes 
after smoking cessation. More important, to date, there 
are no data on how changes in smoking-related biomark-
ers predict risk of disease. 
Three constituents of cigarette smoke received the 
greatest attention as potential contributors to CVD: CO 
measured as exhaled CO or as blood carboxyhemoglobin, 
nicotine, and oxidant chemicals (Benowitz 2003). These 
constituents are used as general biomarkers of exposure 
to tobacco or tobacco smoke. Apparently, no direct mea-
sures of levels of oxidizing chemicals in the body have 
been developed, but numerous measures of the biologic 
consequences of exposure to oxidizing chemicals exist. 
Exposure to particulate matter in cigarette smoke is like-
ly to contribute to CVD in smokers (Brook et al. 2004; 
Vermylen et al. 2005; Bhatnagar 2006), but no direct bio-
markers of particulate exposure are available. Particulate 
matter appears to affect oxidative stress, coagulability, and 
inflammation, for which biomarkers are available. A lesser 
body of research suggests that PAHs and other constitu-
ents of tobacco smoke may also contribute to atherogen-
esis (Penn and Snyder 1988, 1996). Urine levels of PAH 
metabolites can also be measured in smokers; 1-hydroxy-
pyrene is most widely used for this purpose. 
Cigarette smoke exposes the smoker to high levels 
of potentially oxidizing chemicals (Burke and FitzGerald 
2003). In one study, cigarette smoking increased levels of 
lipid peroxidation products, such as F2-isoprostanes, in 
the plasma and urine (Nowak et al. 1987). Other markers 
of oxidative stress in smokers included higher plasma lev-
els of oxidized LDL and oxidized fibrinogen, higher urine 
levels of substances reactive with thiobarbituric acid, and 
reduced plasma levels of antioxidant vitamins such as E, 
C, and beta-carotene. 
The hemodynamic effects of cigarette smoking can 
be observed while a person smokes a cigarette. These 
effects include elevation in heart rate, blood pressure, 
and cardiac output. Coronary blood flow, as assessed by 
coronary perfusion studies, may increase or decrease with 
smoking, depending on underlying atherosclerosis and 
endothelial function (Czernin and Waldherr 2003). 
Researchers have proposed numerous biomarkers 
for measuring endothelial dysfunction, and many of these 
biomarkers are affected by cigarette smoking. The func-
tional assessment most widely used is flow-mediated arte-
rial vasodilation (Puranik and Celermajer 2003), a test that 
measures the diameter of the brachial artery in response 
to changes in forearm blood flow. The brachial artery is 
imaged by using Doppler ultrasonography before and 
after release of a blood pressure cuff that is inflated over 
the forearm to occlude arterial blood flow. With release of 
the cuff, the increase in blood flow triggers an increase 
in the diameter of the brachial artery that is mediated by 
release of NO and prostacyclin by endothelial cells. Many 
researchers demonstrated impairment of flow-mediated 
dilation in populations of active smokers and persons 
exposed involuntarily to cigarette smoke, but estimates of 
impairment in persons with no exposure to smoke over-
lapped considerably with those for the other two groups. 
Other potential markers of endothelial dysfunction that 
can be measured in the blood include ADMA, von Will-
ebrand factor, tPA, E-selectin, and P-selectin. Prostacyclin 
metabolites can be measured in the urine (Cooke 2000). 
Selectins are adhesion molecules released by both endo-
thelial cells and platelets (Ley 2003). 
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Markers of the hypercoagulable state include 
increased urine levels of thromboxane A2 metabolites. 
Thromboxane A2 is released when platelets aggregate in 
vivo, and its metabolites in urine are a useful noninvasive 
measure of the point of activation (Nowak et al. 1987). 
Other relevant biomarkers of a hypercoagulable state 
include fibrinogen, red blood cell mass, blood viscosity, 
tPA, PAI-1, homocysteine, and P-selectin (Benowitz 2003).
Biomarkers used to assess an inflammatory state 
include total leukocyte and neutrophil counts and levels 
of CRP, fibrinogen, and interleukin-6 (Pearson et al. 2003). 
In addition, the counts of several cell-surface adhesion 
molecules increased in inflammatory states. These mol-
ecules included ICAM, sVCAM-1, and monocyte chemoat-
tractant protein-1.
Another study found several markers to be useful for 
assessing insulin resistance (Eliasson 2003). For example, 
in persons with insulin resistance, levels of plasma glu-
cose were likely to be elevated in fasting status and two 
hours after eating. HbA1c levels, which reflect plasma glu-
cose levels throughout the day, were elevated in persons 
in a hyperglycemic state. The ratio of insulin to glucose 
after glucose loading was useful as an index of insulin 
sensitivity. The most definitive investigations were glu-
cose-clamping studies, in which insulin levels were mea-
sured when the glucose level was constant or vice versa. 
Numerous standard markers of lipids may be altered 
in cigarette smokers. These markers include HDLc, LDLc, 
the ratio of total cholesterol to HDL, and serum triglycer-
ide levels. 
Nuclear coronary perfusion studies with or without 
physical exercise are among several functional studies for 
diagnosing cardiovascular dysfunction or disease. They 
indicate that cigarette smoking reduces cardiac perfusion 
in patients with coronary disease (Czernin and Waldherr 
2003). Reserve in endothelial function can be assessed 
by studying flow-mediated dilation (see “Endothelium-
Dependent Vasodilation” earlier in this chapter). Find-
ings in another study indicate that vascular disease can 
be assessed by measuring intima-media thickness of the 
carotid and femoral arteries by ultrasonography, which 
provides a direct measure of early atherosclerotic changes 
in blood vessels (de Groot et al. 2004). 
Numerous cardiovascular biomarkers that might be 
used to assess the effects of cigarette smoking and invol-
untary smoking and that are expected to increase the risk 
of CVD are discussed here. Many biomarkers, however, 
do not reflect causal pathways related to development of 
CVD. Instead, they reflect the pathophysiological effects 
of the constituents of cigarette smoke. In addition, many 
biomarkers are influenced by processes and risk factors 
that are independent of cigarette smoking. Many of the 
same abnormalities produced by smoking are also pro-
duced by diabetes, hypercholesterolemia, and hyper-
tension. Thus, it is unclear which biomarkers are most 
specific to cigarette smoking. It is also unclear which bio-
markers best predict the risk of CVD attributable to ciga-
rette smoke. Also, a given biomarker profile can indicate 
any of several marked differences in a person’s susceptibil-
ity to CVD. 
The potential exists to develop improved biomarkers 
for CVD by using advances in high-throughput genom-
ics and by examining the relationships of gene polymor-
phisms or alterations in protein expression or activity to 
smoking-induced disease (Zhang et al. 2001). Emerging 
genomic and proteomic technologies may cast light on 
the signaling pathways activated by smoking and the con-
stituents of tobacco smoke that culminate in cardiovascu-
lar dysfunction. Such approaches may also contribute to 
an understanding of individual differences in susceptibil-
ity to the cardiovascular complications of smoking. 
Numerous studies of clinical genetics examined dif-
ferences in susceptibility to smoking-induced CVD as a 
function of different genetic variants (Wang et al. 2003). 
Such studies, combined with genomic and proteomic 
approaches, may provide mechanistic information on 
pathogenesis and, in combination with other biomark-
ers, may result in better predictions of cardiovascular risk 
in smokers.
Smoking Cessation and Cardiovascular Disease
Smoking cessation reduces the risk of cardiovascular 
morbidity and mortality for smokers with or without CVD 
(USDHHS 1990). Smoking directly accelerates atherogen-
esis, causes acute cardiovascular events, and contributes 
to and acts synergistically with other risk factors, such 
as hyperlipidemia and diabetes (see “Smoking and Diabe-
tes” earlier in this chapter). Although cigarette smoking 
does not cause hypertension, smoking is associated with 
higher blood pressure in persons with hypertension and 
enhances the likelihood of complications, including pro-
gression of renal disease in patients with hypertension 
(Green et al. 1986; Mann et al. 1991; McNagny et al. 1997; 
Regalado et al. 2000). One study demonstrated that ciga-
rette smoking was a substantial contributor to morbidity 
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and mortality in patients with left ventricular dysfunction 
(Suskin et al. 2001). In such patients, the benefit of reduc-
ing the likelihood of death by smoking cessation is equal 
to or greater than the benefit of therapy with inhibitors of 
ACE, b-blockers, or spironolactone. Smoking cessation is 
particularly important in patients with diabetes. For these 
patients, smoking markedly increases cardiovascular risks, 
including the risk that diabetic nephropathy will progress. 
Smoking also increases insulin resistance and increases 
the difficulty of controlling diabetes. For these and other 
reasons, smoking cessation in patients with CVD is an 
essential therapeutic intervention. 
The 1990 Surgeon General’s report on smoking ces-
sation (USDHHS 1990) outlines the evidence that stop-
ping smoking helps to prevent CVD, and subsequent 
research has reinforced this concept (Hasdai et al. 1997a; 
van Domburg et al. 2000; Wilson et al. 2000). Estimates 
in case-control and cohort studies indicate that most risk 
reduction for mortality occurred in the first one to three 
years after smoking cessation, and approximately one-
half of the risk of smokers for a nonfatal MI was elimi-
nated in the first year after cessation. It takes about three 
to five years of abstinence from smoking for most of the 
excess CVD risk to be gone (USDHHS 1990; Lightwood 
and Glantz 1997). 
Smoking cessation after MI reduces the risk of car-
diovascular morbidity and mortality by 36 to 50 percent 
(USDHHS 1990; Kumanan et al. 2000; Wilson et al. 2000; 
Rea et al. 2002; Critchley and Capewell 2003). Smoking 
cessation is highly cost-effective (Krumholz et al. 1993; 
Lightwood 2003) and is recommended in professional 
guidelines for prevention of recurrent cardiovascular 
events in persons with known CVD (Smith et al. 2001). 
Evidence supports the central roles of smoking cessation 
and eliminating exposure to secondhand smoke in pre-
venting development and progression of CVD (USDHHS 
1990, 2006; Benowitz and Gourlay 1997; Hasdai et al. 
1997a; van Domburg et al. 2000; Wilson et al. 2000; Gold-
enberg et al. 2003).
Methods
Tobacco use and dependence are determined by 
complex physiological and psychological factors. Use of 
nicotine causes tolerance, physical dependence, and a 
withdrawal syndrome when smoking is stopped (USDHHS 
1988). Use of tobacco is a learned behavior that becomes 
part of the daily routine of a smoker and is often used to 
cope with stress, anxiety, anger, and depression (USDHHS 
1988; Rigotti 2002). 
Interventions to achieve smoking cessation tar-
get both the physiological and psychological factors that 
contribute to tobacco use. Evidence from randomized 
controlled clinical trials of cessation methods has been 
summarized in meta-analyses conducted independently 
by two groups—the U.S. Public Health Service (PHS) 
and the Cochrane Database of Systematic Reviews (the 
Cochrane Library). These reviews document the efficacy of 
both psychosocial counseling and pharmacologic agents 
for cessation (Fiore et al. 2000, 2008). Combination of 
the two methods is the most effective strategy. Interven-
tions in psychosocial counseling range from brief coun-
seling by the physician to intensive, cognitive-behavioral 
counseling interventions during several weeks. There is a 
dose-response relationship between behavioral treatment 
and smoking cessation; that is, the efficacy of counsel-
ing interventions increases with increased intensity and 
duration of the program (Fiore et al. 2000, 2008; USDHHS 
2000). The U.S. Food and Drug Administration (FDA) 
has approved pharmacotherapy for tobacco dependence. 
The pharmacotherapy includes five types of NRT (gum, 
transdermal patch, nasal spray, vapor inhaler, and loz-
enge), sustained-release bupropion, and varenicline. PHS 
designated these medications as first-line therapies for 
smoking cessation in Treating Tobacco Use and Depen-
dence: Clinical Practice Guidelines (Fiore et al. 2000). Two 
other drugs—nortriptyline and clonidine—were effica-
cious in randomized controlled trials and were shown to be 
effective in the Cochrane review and in meta-analyses con-
ducted for development of the PHS guidelines (Fiore et 
al. 2000, 2008; Gourlay et al. 2004; Hughes et al. 2004b). 
These drugs have not been approved by FDA for use in 
smoking cessation, and in the PHS report, they are desig-
nated as second-line interventions. There is no evidence to 
support use of alternative therapies such as acupuncture 
and hypnosis for smoking cessation (Abbot et al. 1998; 
Fiore et al. 2000, 2008; White et al. 2002).
Interventions
Multiple randomized controlled clinical trials dem-
onstrated the benefits of counseling patients with CVD 
on smoking cessation (Table 6.4) (Thomson and Rigotti 
2003). In contrast, relatively few clinical trials tested the 
safety or efficacy of pharmacotherapy for treating smokers 
with CVD (Table 6.5). Researchers raised concerns about 
the safety of NRT and sustained-release bupropion in 
patients with CVD, because both agents can have sym-
pathomimetic activity and can theoretically increase 
myocardial work, and NRT might also reduce the myocar-
dial oxygen supply through coronary vasoconstriction by 
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Taylor et al. 
1990
Acute MI
I vs. C: 86 vs. 87
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3.5 hours for baseline 
and postdischarge 
counseling
TC: 1, 2, 3 weeks, 
then every 
month x 4 
CV for relapse after 
smoking cessation
12 months
I vs. C: 61 vs. 32
1.9 (1.3, 2.8)
p <0.001
Ockene et al. 
1992
Coronary angiogram
I vs. C: 135 vs. 132
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Massachusetts
Health educator  
30 minutes
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Note: CAD = coronary artery disease; CI = confidence interval; CV = clinic visit; FV = validated by family; I vs. C = intervention versus 
control; MI = myocardial infarction; OR = odds ratio; RR = relative risk; SR = self-reported; TC = telephone call.
Cardiovascular Diseases  397
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease








RR or OR 
(95% CI), 
p value
Adverse events  
(I vs. C)
Transdermal 
nicotine                  
Working Group 















14 mg could be 
increased to 











in episodes of 
angina or change 
in blood pressure, 
heart rate, or 
EKG readings






I vs. C: 288 vs. 287
10 Veterans Affairs 
medical centers
United States
21 mg x 6 weeks
14 mg x 2 weeks
7 mg x 2 weeks
Behavioral 
counseling
15 minutes at 
study entry
10 minutes at 
1 and 6 weeks
14 weeks
I vs. C: 21 
vs. 9
6 months
I vs. C: 14 
vs. 11
12 months















Tzivoni et al. 
1998
Stable outpatients 
with CAD in 
smoking cessation 
program
I vs. C: 52 vs. 54
2 centers
Israel
21 mg (>20 
cigarettes/day) 













in EKG changes, 
exercise testing, 




release                  




I vs. C: 313 vs. 313














Monthly x 12 
CV: brief 
counseling at 3, 
6, and 12 months
12 months






















RR or OR 
(95% CI), 
p value
Adverse events  
(I vs. C)
Rigotti et al. 
2006
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I vs. C: 124 vs. 124









40 minutes in 
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I vs. C: 37 
vs. 27
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No difference in 
CVD mortality 
(0% vs. 2%) or 
in CVD events at 
12 weeks (16% 
vs. 14%, IRR 1.22 
[0.61–2.48]) or 
1 year (26% vs. 
18%, IRR 1.56 
[0.88, 2.82])
Note: BID = twice a day; CAD = coronary artery disease; CI = confidence interval; CV = clinic visit; CVD = cardiovascular disease; 
EKG = electrocardiogram; I vs. C = intervention versus control; IRR = incidence rate ratio; mg = milligrams; MI = myocardial 
infarction; NS = not significant; OR = odds ratio; RR = relative risk; TC = telephone call.
aAbstinence measured by point prevalence (no smoking in previous seven days) unless otherwise noted.
bp value calculated with c2 test. 
Counseling
Several randomized controlled clinical trials demon-
strated the efficacy of counseling for patients hospitalized 
with CVD (Table 6.4). The evidence for efficacy is strongest 
for patients who had acute MI (Pozen et al. 1977; Taylor et 
al. 1990; Ockene et al. 1992; DeBusk et al. 1994; Dornelas 
et al. 2000). In one study, an intensive, nurse-managed 
intervention to achieve smoking cessation for 173 smok-
ers hospitalized with an acute MI doubled the cessation 
rates at one year (61 versus 32 percent, p <0.001) (Taylor et 
al. 1990). At the bedside, the nurse delivered a 30-minute 
cognitive-behavioral counseling session focused on self-
efficacy and prevention of relapse. Additional counseling 
was delivered by telephone at one, two, and three weeks 
after discharge and then every month for four months. 
A second study of the same patients expanded the nurse-
delivered counseling model to target multiple cardiac risk 
factors (DeBusk et al. 1994). This study also reported rates 
of smoking abstinence higher than those in the first study 
(Taylor et al. 1990). A third trial assigned 100 consecu-
tive smokers admitted with MI to either minimal care or 
bedside counseling with seven follow-up telephone calls 
(Dornelas et al. 2000). Smoking cessation rates at one year 
were higher in the intervention group than in the mini-
mal care group (55 versus 34 percent, p <0.05). A more re-
cent study of 240 smokers admitted to the hospital for MI, 
unstable angina, or cardiac bypass surgery demonstrated 
that counseling by cardiac nurses untrained in counsel-
ing and then follow-up counseling during the next five 
months reduced smoking rates at one year (50 versus 37 
percent, absolute risk reduction, 13 percentage points [95 
percent CI, 0 to 26 percentage points]) (Quist-Paulsen and 
Gallefoss 2003). 
Other studies that lacked the same intensity of fol-
low-up after hospital discharge produced less impressive 
results. One study examined a multicomponent behav-
ioral smoking intervention delivered to 267 patients hav-
ing coronary angiography (Ockene et al. 1992). Compared 
with patients who did not receive the intervention, those 
with angiography had higher rates of validated smoking 
abstinence at 6 months (45 versus 34 percent) and 12 
months (35 versus 28 percent), but these differences were 
not statistically significant. Two randomized trials (Rigotti 
et al. 1994; Hajek et al. 2002) and one partially randomized 
trial (Bolman et al. 2002) examined the effects of inpatient 
counseling with minimal follow-up in cardiac patients. 
These studies showed no improvement in abstinence rates 
with the counseling intervention versus usual care. 
The most successful counseling interventions 
for cardiac inpatients include high-intensity baseline 
counseling with sustained contacts after discharge for 
prevention of relapse. However, even with the most suc-
cessful counseling interventions, at least 40 percent of 
smokers who have cardiac disease resume smoking within 
one year. Guidelines for smoking cessation recommend 
addition of pharmacotherapy to counseling (Fiore et 
al. 2000, 2008). Pharmacotherapy has the potential to 
improve smoking cessation rates in smokers with CVD 
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(see “Nicotine Replacement Therapy” and “Bupropion” 
later in this chapter).
Nicotine Replacement Therapy
NRT helps smokers stop smoking and also reduces 
nicotine withdrawal symptoms, which begin a few hours 
after the last cigarette is smoked and can last up to four 
weeks (Hughes et al. 1992). The typical withdrawal syn-
drome is characterized by agitation, anxiety, depressed 
mood, difficulty concentrating, increased appetite, insom-
nia, irritability, restlessness, and an intense craving to 
smoke. Most smokers who stop smoking relapse to smok-
ing within the first week, when withdrawal symptoms 
are strongest. 
In multiple clinical trials, all the NRT products 
approximately doubled rates of smoking abstinence com-
pared with rates for participants receiving a placebo (Fiore 
et al. 2000; Silagy et al. 2004). Meta-analyses conducted 
for PHS demonstrated ORs of 1.9 (95 percent CI, 1.7–2.2) 
for the nicotine patch and 1.5 (95 percent CI, 1.3–1.8) for 
nicotine gum. Meta-analyses from the Cochrane Library 
found similar results; ORs were 1.74 (95 percent CI, 
1.57–1.93) for the patch and 1.66 (95 percent CI, 1.52–
1.81) for the gum (Silagy et al. 2004). For smokers with 
greater dependence on nicotine, the 4-mg dose of nicotine 
gum was more effective than the 2-mg dose. Maximum 
effectiveness depended on correct chewing techniques. 
Similar ORs were reported after meta-analyses of data on 
the nicotine inhaler and nicotine nasal spray (Fiore et al. 
2000). Only one study compared the efficacy of four forms 
of NRT (patch, gum, inhaler, and nasal spray); they dem-
onstrated similar efficacy rates after 12 weeks of follow-up 
(Hajek et al. 1999).
Nicotine directly affects the cardiovascular system by 
multiple mechanisms (see “Cigarette Smoke Constituents 
and Cardiovascular Disease” earlier in this chapter). The 
various effects lead to increased heart rate, blood pressure, 
and myocardial contractility, and reduced coronary blood 
flow. Nicotine may also contribute to insulin resistance 
and development of a more atherogenic lipid profile. The 
nicotine dose in NRT products is usually lower than the 
dose from smoking, but there have been concerns about 
the safety of NRT in patients with CVD. Case reports in 
the medical literature described atrial fibrillation, MI, and 
stroke in patients receiving NRT (Joseph and Fu 2003). It 
is difficult to assess the cardiovascular risk from NRT on 
the basis of these reports, because of the inability to con-
trol for individual risk factors for these events, especially 
that these persons were smokers (Benowitz and Gourlay 
1997; Joseph and Fu 2003). 
To date, three randomized controlled trials of trans-
dermal use of nicotine have been conducted in patients 
with stable CVD. The first study enrolled 156 patients 
with CHD and randomly assigned them to receive either 
14-mg nicotine patches or a placebo for five weeks (Work-
ing Group for the Study of Transdermal Nicotine in 
Patients with Coronary Artery Disease 1994). The dose 
was increased to 21 mg if smoking persisted. Smoking 
abstinence was achieved at five weeks by 36 percent in the 
patch group and 22 percent in the placebo group (p <0.05). 
Patients recorded all episodes of angina, palpitations, and 
other cardiac symptoms in daily diaries and had a 12-lead 
electrocardiogram at three time points. The nicotine 
patch did not affect the frequency of angina, arrhythmias, 
or depression of the ST segment (isoelectric period) on 
electrocardiograms during the five weeks of treatment, 
even in patients who smoked intermittently. 
A second randomized trial of transdermal nicotine 
included 584 outpatients with CVD from 10 Veterans 
Affairs hospitals (Joseph et al. 1996). The participants were 
randomly assigned to receive 21-mg patches or a placebo 
for 10 weeks. Primary cardiovascular endpoints during 14 
weeks of follow-up included MI, cardiac arrest, death, and 
hospital admission for angina, dysrhythmia, or congestive 
heart failure. The two groups did not differ in the propor-
tion of patients who reached at least one cardiovascular 
endpoint (5.4 versus 7.9 percent, p = 0.23). Concomitant 
use of the nicotine patch and smoking was not associated 
with an increase in adverse events. Although use of the 
patch was safe in this population, no improvement was 
observed in rates of short-term or long-term smoking 
abstinence in comparisons with the placebo group (Joseph 
et al. 1996; Joseph and Antonuccio 1999).
A third trial tested use of the nicotine patch in 106 
smokers with CHD (Tzivoni et al. 1998). Patients were 
randomly assigned to receive nicotine patches or placebo 
patches for two weeks. All patients had ambulatory elec-
trocardiogram monitoring and exercise testing at study 
entry, after the first application of the patch, and at two 
weeks. No difference was observed at any of the three time 
points, between the patch and placebo groups, in resting 
heart rate, blood pressure, the number or duration of isch-
emic episodes, frequency of arrhythmias, exercise dura-
tion, or time to 1-mm depression of the ST segment on an 
electrocardiogram. In a randomized study of 234 patients 
with both cardiovascular and respiratory diseases, no 
increase in adverse events was observed in patients 
assigned to the nicotine patch or the placebo (Campbell 
et al. 1996).
In a case-control study, Kimmel and colleagues 
(2001) found no increased risk of a first MI with use of the 
nicotine patch in persons who stopped smoking or those 
who continued to smoke. Using a computerized database 
for general practice in the United Kingdom, Hubbard and 
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colleagues (2005) studied the relative incidence of MI and 
stroke in four two-week periods before and after the first 
prescription for NRT. They found a progressive increase in 
risk in the 56 days after the first NRT prescription but no 
evidence of increased cardiovascular events or mortality 
in the 56 days after the NRT prescription.
Meine and colleagues (2005) addressed the safety 
of transdermal nicotine in the setting of acute CHD. 
These investigators analyzed data in the Duke Univer-
sity Cardiovascular Databank for 9,991 smokers who 
had cardiac catheterization after hospital admission for 
unstable angina or non-ST-segment MI. This retrospective 
observational study compared outcomes of patients who 
did or did not receive transdermal nicotine during hospi-
talization. The study identified 194 patients who had been 
treated with transdermal nicotine during the hospital 
stay. The investigators used a “propensity score analysis” 
to compare patients receiving transdermal nicotine with 
matched patients from the database who did not receive 
the medication. Because patients were not randomly 
assigned to receive transdermal nicotine, selection bias 
could have confounded these results. In an attempt to 
reduce this bias, patients who did or did not receive trans-
dermal nicotine were matched on demographic charac-
teristics, diagnosis, cardiac risk factors, and mean cardiac 
ejection fraction. Rates of cardiac outcomes in the two 
groups were compared. No differences in 7-day, 30-day, or 
one-year mortality rates were observed. Patients receiving 
transdermal nicotine were not more likely to have coro-
nary artery bypass grafting or percutaneous transluminal 
coronary angioplasty during hospitalization. It was not 
possible to control for the dose of medication received, 
the amount of smoking before hospital admission, or 
relapse to smoking after hospitalization. These results 
provide some evidence that NRT was safe in the setting of 
acute CVD, but randomized controlled trials are needed to 
establish the safety of NRT in patients who have unstable 
cardiac disease.
Other studies examined markers of exposure to 
tobacco smoke related to cardiovascular risk as surro-
gate endpoints for cardiovascular events in clinical trials. 
There was no evidence that NRT raised blood pressure in 
any of the efficacy trials, but these trials typically excluded 
patients with poor control of hypertension. In one small 
trial of 30 smokers with or without hypertension, NRT 
increased mean arterial pressure in smokers with normal 
blood pressure but not in smokers who had hypertension 
(Tanus-Santos et al. 2001).
To date, two studies have tested the effect of NRT 
on coronary circulation in smokers with CHD. One study 
examined the size of defects in myocardial perfusion in 36 
patients with baseline CHD who were treated with nicotine 
patches (Mahmarian et al. 1997). Participants continued 
to smoke but at reduced levels. The researchers concluded 
that use of the patch, even with concomitant smoking and 
higher plasma levels of nicotine, resulted in reduction of 
exercise-induced ischemia in a comparison with baseline 
values. This finding suggested that components of tobacco 
smoke other than nicotine are responsible for impaired 
coronary blood flow. The second study investigated the 
effect of nicotine gum on coronary perfusion in former 
cigarette smokers having angiography (Nitenberg and 
Antony 1999). The findings demonstrated that the gum 
did not reduce the surface area of normal or diseased seg-
ments of the coronary artery. Other studies of the effects of 
smoking cessation on lipids and thrombosis reported 
improvements in these markers, even among smokers 
using NRT (Allen et al. 1994; Lúdvíksdóttir et al. 1999; 
Eliasson et al. 2001; Haustein et al. 2002).
In summary, despite anecdotal reports of cardiovas-
cular events attributable to use of NRT, data from multiple 
clinical trials of smokers with or without CVD show no 
evidence for increased cardiovascular risk when NRT 
is used to treat tobacco dependence. However, the safe-
ty of NRT has not been tested in a more acute setting, 
such as during hospitalization for a cardiovascular event. 
Observational data suggest that use of the nicotine patch 
in patients with unstable cardiac disease is probably 
safe (Meine et al. 2005), but randomized trials are need-
ed to confirm these findings. Current PHS guidelines 
recommend that NRT be used with caution in smokers 
with unstable angina, MI in the past two weeks, or serious 
arrhythmia (Fiore et al. 2000).
Bupropion
Bupropion is an aminoketone approved by FDA in 
1989 for treatment of depression and in 1997 for smoking 
cessation. The drug is included in national guidelines as 
first-line therapy for smoking cessation (Fiore et al. 2000, 
2008). Its mechanism of action is not fully understood, but 
researchers think it acts by inhibiting neuronal uptake of 
norepinephrine and dopamine. Bupropion may also block 
activity of nAChRs. The mechanism of action for smoking 
cessation appears to be unrelated to the antidepressant 
effects of bupropion. A preparation of the drug for sus-
tained release provides a better safety profile and more 
convenient dosing than does the immediate-release form. 
Evidence from several randomized controlled tri-
als shows that bupropion doubled the smoking cessation 
rates obtained with a placebo. Meta-analyses of data on 
bupropion for smoking cessation conducted by PHS and 
the Cochrane Library yielded ORs of 2.1 (95 percent CI, 
1.5–3.0) and 2.06 (95 percent CI, 1.77–2.40), respectively 
(Fiore et al. 2000; Hughes et al. 2004b). One trial com-
pared use of bupropion, a nicotine patch, bupropion plus 
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a patch, and a placebo among 893 participants (Jorenby 
et al. 1999). Smoking abstinence rates at one year were 
15.6 percent in the placebo group, 16.4 percent in the 
nicotine-patch group, 30.3 percent in the bupropion 
group (p <0.0001 versus the placebo group), and 35.5 
percent in the bupropion-plus-patch group (p <0.0001 
versus the placebo group; p = 0.06 versus the bupropion- 
alone group). 
The major risk of bupropion is that it lowers a 
person’s seizure threshold. The risk of seizure from the 
sustained-release formulation is 0.1 percent, which is no 
different from that for other antidepressants (Hughes et 
al. 1999; Rigotti 2002). No seizures were reported in any of 
the clinical trials that tested sustained-release bupropion 
for smoking cessation.
As with NRT, early case reports of serious cardio-
vascular events with sustained-release bupropion raised 
questions about the safety of this agent in patients with 
CVD. These reports, which were mostly in Canada and 
England, included cardiac deaths, chest pain, MI, and 
myocarditis (Joseph and Fu 2003). Assessment of the con-
tribution of bupropion to these events is difficult because 
evaluation of other cardiac risk factors in these patients was 
not possible.
To date, none of the efficacy trials of bupropion for 
smoking cessation has reported a significant increase 
in cardiovascular events. Two randomized controlled 
trials enrolled only smokers with CVD. The first trial 
enrolled 629 outpatients with stable CVD—that is, MI or an 
interventional cardiac procedure more than three months 
earlier and stable angina pectoris, PAD, or congestive 
heart failure (Tonstad et al. 2003). Patients were randomly 
assigned to receive bupropion or a placebo for seven weeks. 
This study found no differences in the number of deaths 
in the two groups—two in the bupropion group and two 
in the placebo group. Overall, 38 participants (6 percent) 
reported a single adverse cardiovascular event—24 in the 
bupropion group and 14 in the placebo group. The most 
common cardiovascular events were angina pectoris, 
hypertension, and palpitations; 13 events occurred in the 
bupropion group versus 8 events in the placebo group. 
No statistical tests were performed on the rates of adverse 
events. Patients who took bupropion were more likely to 
have stopped smoking at one year than were patients who 
took the placebo (27 versus 12 percent, p <0.001).
A second trial enrolled 248 smokers hospitalized 
with acute CVD, including acute MI, unstable angina, 
or other cardiovascular conditions (Rigotti et al. 2006). 
Patients were randomly assigned to receive sustained- 
release bupropion or a placebo for 12 weeks, and all 
patients received intensive counseling during hospital-
ization and follow-up. At the one-year follow-up, the dif-
ference between death rates in the bupropion group (no 
deaths) and in the placebo group (two deaths) was not 
statistically significant. During the 12 weeks of drug treat-
ment, the difference between the number of cardiovascular 
events in the bupropion group (20 events) and the placebo 
group (17 events) was also not significant. Cardiovascular 
events included death, nonfatal MI, unstable angina, con-
gestive heart failure, stroke, and coronary revasculariza-
tion procedure. At the one-year follow-up, the number of 
cardiovascular events in the bupropion group (32 events, 
26 percent) exceeded the number in the placebo group 
(22 events, 18 percent), but this difference was not signifi-
cant. In addition, at one year, the difference between the 
smoking abstinence rates for the bupropion group (25 
percent) versus the placebo group (21 percent) was not 
significant. However, the results after 12 weeks of drug 
treatment suggested that bupropion had short-term effi-
cacy (37 versus 27 percent, p = 0.08). 
In summary, sustained-release bupropion is effective 
and safe for treating smokers with stable CVD. The drug 
appears to be less efficacious in smokers hospitalized with 
acute CVD than in other groups of patients. Bupropion is 
the only medication for treating tobacco dependence that 
has been tested in patients with acute CVD, and it appears 
to be safe for those with either stable or acute disease. 
Other Pharmacotherapy
Varenicline, a partial agonist of the a4b2 nAChR, 
has been marketed for the treatment of tobacco depen-
dence but its use in smokers with CVD has not yet been 
studied (Coe et al. 2005). The drug produces approximate-
ly 50 percent of the receptor stimulation provided by nico-
tine, but it blocks the effects of any nicotine taken in from 
cigarette smoking. Clinical trials have found it superior 
to bupropion in promoting smoking cessation, and pro-
longed administration has been shown to reduce relapse 
in smokers who had been abstinent 12 weeks after initial 
therapy (Gonzalez et al. 2006; Jorenby et al. 2006; Tonstad 
et al. 2006). Two other medications have been demonstrat-
ed to be effective for smoking cessation: nortriptyline, a 
tricyclic antidepressant, and clonidine, a central a-agonist 
antihypertension agent. However, neither drug has been 
approved by FDA for smoking cessation. Both agents have 
potential cardiovascular side effects, and the safety profile 
of these drugs should be considered carefully before use in 
smokers with CVD. 
Meta-analyses of data on use of clonidine for treat-
ing smokers resulted in ORs for smoking abstinence of 
2.1 (95 percent CI, 1.4–3.2) (Fiore et al. 2000) and 1.89 
(95 percent CI, 1.30–2.74) (Gourlay et al. 2004). To date, 
no safety data for patients with CVD are available. How-
ever, clonidine is known to cause orthostatic hypotension, 
rebound hypertension from abrupt cessation of the drug, 
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and rarely, atrioventricular nodal blockade. Nortriptyline 
is also effective in promoting smoking cessation; meta-
analyses yielded ORs of 3.2 (95 percent CI, 1.8–5.7) (Fiore 
et al. 2000) and 2.79 (95 percent CI, 1.70–4.59) (Hughes 
et al. 2004b). Nortriptyline was designated a second-line 
drug for smoking cessation in PHS clinical guidelines 
because of a smaller evidence base of support and greater 
side effects than those of other medications for smoking 
cessation. In general, tricyclic antidepressants are avoided 
in patients with CVD because of concerns about increased 
risks for arrhythmias and depression of myocardial con-
tractility (Joseph and Fu 2003).
Although the focus of the preceding section (“Meth-
ods”) was on clinical interventions to reduce smoking, it 
is important to recognize that policy-based interventions, 
such as smoke-free environments and community and 
statewide tobacco control programs, are also important 
elements in a strategy to improve cardiovascular health. 
For example, smoke-free workplaces are a highly cost- 
effective approach to promoting smoking cessation with 
an impact on cardiovascular health (Ong and Glantz 2004). 
Decreases in admissions to hospitals have been observed 
after smoke-free laws have gone into effect (Dinno and 
Glantz 2007). The California Tobacco Control Program 
substantially accelerated the decline in the heart disease 
death rate in the state (Fichtenberg and Glantz 2000).
It should be noted that although long-term smok-
ing quit rates after various interventions in cardiovascular 
patients may appear to be low (most less than 30 percent), 
smoking cessation therapy has an important impact on 
CVD, and the cost per life saved is lower than that of many 
other therapeutic interventions for CHD that are consid-
ered to be the standard (such as treatment of hypertension 
and hyperlipidemia) (Lightwood 2003).
Summary
Smoking cessation is a key element in both primary 
and secondary prevention of CVD. Guidelines from PHS 
recommend counseling, NRT, sustained-release bupro-
pion, and varenicline as first-line treatments to achieve 
smoking cessation. Studies show that NRT and bupropion 
are effective in patients with CVD, although not all trials 
demonstrated efficacy. Several studies have demonstrated 
the safety of NRT in patients with stable CVD, but ran-
domized trials are needed to establish the safety of this 
treatment for patients hospitalized with acute disease. 
Bupropion appears to be safe in patients with stable or 
unstable CVD, but it is less effective in patients with acute 
disease. Varenicline is a partial agonist of the a4b2 nAChR 
that is effective in treating tobacco dependence, but it has 
not yet been studied in smokers with CVD. The develop-
ment of more effective pharmacotherapies to aid smok-
ing cessation that are safe in persons with CVD is a high 
research priority.
Methods to Reduce Exposure
Evidence-based interventions for treating smok-
ers include behavioral and pharmacological treatments, 
which significantly increase rates for long-term absti-
nence from smoking. Even so, absolute rates of abstinence 
are modest; they range from 8 to 25 percent, depending 
on the study population and the treatment. In addition, 
only a small proportion of smokers are interested in treat-
ment at any given time. Interest in smoking cessation and 
success in achieving long-term abstinence are greater 
among patients with CVD than in the general population 
of smokers (Thomson and Rigotti 2003). Nevertheless, 
abstinence rates remain disappointingly low, particu-
larly in light of the important health benefits for this 
population when they do stop smoking (USDHHS 1990; 
Burns 2003). 
Suboptimal treatment outcomes prompted inter-
est in testing interventions that might decrease the risk 
of smoking among those who continue to use tobacco. 
These strategies are often termed “harm reduction” inter-
ventions, although data are limited as to whether harm is 
really lessened with reduced exposure to tobacco. To date, 
the effect of methods for reducing exposure on risk factors 
for CVD and on development of CVD has been evaluated 
in a limited number of clinical trials, prospective cohort 
studies, and epidemiologic studies.
Endpoints with respect to CVD that have been mea-
sured in studies of reduced exposure include measures of 
exposure to tobacco constituents (e.g., nicotine and CO); 
biomarkers of inflammation (e.g., CRP, leukocyte counts, 
and fibrinogen); thrombosis (e.g., fibrinogen and PAI-1); 
lipid abnormalities (e.g., levels of total cholesterol, HDLc, 
LDLc, triglycerides, APOs A-I and B, and HDLc to LDLc 
ratio); oxidative stress that reflects and may contribute 
to cardiovascular risk (e.g., F2-isoprostanes); and clinical 
outcomes (blood pressure, heart rate, angina, exercise tol-
erance, MI, other adverse events, and death) (Table 6.3). 
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Reduced Smoking
Important methodologic considerations in evalu-
ating studies of reduced smoking include the extent and 
duration of smoking reduction, use of nicotine replace-
ment products, doses, and timing of endpoint measure-
ments (Table 6.6). In addition, some studies report 
outcome data on the basis of intention to treat all par-
ticipants, regardless of whether treatment was success-
ful. Others report only on subgroups who achieve specific 
goals for smoking reduction.
Eliasson and colleagues (2001) tested the effect of 
nicotine nasal spray on achieving smoking reduction and 
abstinence among 58 healthy adult smokers in an open- 
label cohort study. The primary goal for the first eight weeks 
of the study was to reduce daily smoking by 50 percent; 
participants were asked to stop smoking after eight weeks. 
Cardiovascular risk factors were evaluated at baseline, at 
eight weeks, and after eight weeks of abstinence. The 33 
study participants provided data at all three time points. 
After participants completed eight weeks of smoking 
reduction, mean cigarette use decreased by 50.2 percent, 
expired CO dropped 17 percent, and plasma thiocyanate 
decreased by 20.1 percent. Significant improvements 
included fibrinogen levels (from 2.9 g/liter [L] to 2.65 
g/L, p = 0.011); hemoglobin values (from 13.8 to 13.3 
g/L, p <0.001); leukocyte counts (from 7.0 to 6.2 x 109/L, 
p = 0.005); and HDLc to LDLc ratio (from 0.33 to 0.37, 
p <0.005). Eight weeks of abstinence from smoking was 
associated with further improvements in hemoglobin lev-
els, leukocyte counts, and HDL and LDL levels, and sig-
nificant reduction in PAI-1 activity. These researchers did 
not observe improvements in HDLc and LDLc levels with 
reduction in smoking. 
Hurt and colleagues (2000) conducted a small, open-
label cohort study to test the effect of a nicotine inhaler 
on biomarkers of exposure to cigarette smoke among 23 
heavy smokers. Levels of blood thiocyanate, several urine 
carcinogens, and expired CO were measured at study entry 
and at 4, 8, 12, and 24 weeks. Despite an average reduction 
among participants from 40 or more to 10 cigarettes per 
day, expired CO decreased only from 30.4 to 26.0 parts per 
million (ppm), reflecting compensatory smoking or mis-
reporting of reduction in smoking. This change was not 
statistically significant.
In the U.S. Lung Health Study, 5,887 male and 
female smokers were randomly assigned to one of three 
groups: intervention for smoking cessation, including 
nicotine gum, plus bronchodilator therapy; intervention 
plus a placebo; or usual care (Hughes et al. 2004a). Among 
3,923 participants in the intervention at the one-year 
follow-up, 1,722 continued to smoke daily. Reduction in 
the number of cigarettes smoked was not an objective of 
the intervention, but 16 percent of those who continued 
to smoke daily smoked 1 to 24 percent fewer cigarettes 
than at baseline; another 27 percent reduced smoking by 
25 to 49 percent; 19 percent, by 50 to 74 percent; and 11 
percent, by 75 to 99 percent. The mean reduction in ciga-
rettes smoked was 29 percent (from 32 to 22 cigarettes 
per day), and the mean reduction in CO levels was 24 per-
cent (from 34 to 26 ppm). Thus, more than 80 percent of 
those who did not stop smoking achieved some level of 
reduction. However, the reduction in CO was not as large 
as the reduction in cigarettes per day. This finding again 
suggests compensatory smoking.
Hatsukami and colleagues (2005) examined the 
effect of smoking reduction on cardiovascular risk fac-
tors among 151 cigarette smokers interested in stopping 
smoking but not in reducing their smoking. Nicotine 
patches and gum were used to assist with reduction of 
smoking. The cardiovascular risk factors (CO and choles-
terol levels, leukocyte counts, blood pressure, and heart 
rate) were measured for 12 weeks after study entry. Bio-
markers did not change among persons who continued to 
smoke ad libitum, but the 61 persons who reduced smok-
ing achieved significant improvements. Smokers who 
reduced the self-reported number of cigarettes smoked per 
day by 40 percent or more had significantly reduced leu-
kocyte counts (from 7.39 to 6.98 x 109/L, p <0.001); high-
er HDLc levels (from 50.3 to 52.8 mg per deciliter [dL], 
p <0.0167); improved HDL to LDL ratios (from 0.47 to 
0.49, p <0.0167); lower APO B levels (from 103.7 to 103.0 
mg/dL, p <0.0167); lower systolic blood pressure (from 
123.0 to 120.3 mm Hg, p <0.0167); and lower heart rate 
(from 75.7 to 70.2 beats per minute, p <0.001). Although 
some of these changes were statistically significant, they 
are modest, and the clinical importance is undetermined. 
Levels of triglycerides, total cholesterol, APO A-I, and 
diastolic blood pressure did not change, and LDLc levels 
increased from 122.1 to 124.4 mg/dL (p <0.0167). 
To date, only one randomized controlled trial of an 
intervention for smoking reduction among persons with 
known CVD has been conducted (Joseph et al. 2005). Treat-
ment included behavioral counseling and NRT with patch-
es and gum. The goal of this study of 152 participants was 
at least a 50-percent reduction in cigarettes smoked per 
day; usual care was the standard for comparison. At study 
entry, participants smoked an average of 27.4 cigarettes 
per day. At six months, the intervention group had reduced 
cigarette use by 39 percent, versus a decline of 25 percent 
in the usual care group, but this difference was not statis-
tically significant. Biomarkers for carcinogenesis and CVD 
were measured, as were clinical outcomes. No significant 
differences between the treatment groups were observed 
for levels of CO, fibrinogen, F2-isoprostanes, or CRP, or 
for leukocyte counts. The groups did not differ in clinical 
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outcomes, including body weight, distance completed in 
a six-minute walking test, the proportion of participants 
completing that test, the prevalence and frequency of 
angina, the need for urgent cardiac care, and other serious 
adverse events. Because no significant differences between 
treatment groups were observed and because both groups 
achieved significant reductions in cigarette use from base-
line, results for the entire cohort at six months were com-
pared with the baseline data. There were no significant 
differences in biomarkers of cardiovascular risk, including 
leukocyte counts and levels of F2-isoprostanes or CRP, but 
CO had decreased by 6.0 ppm (p = 0.007). 
Godtfredsen and colleagues (2003) conducted a pro-
spective cohort study in Denmark to examine changes 
in the incidence of MI after spontaneous reductions in 
cigarette use. This study included 10,956 men and 8,467 
women who provided detailed information on smoking 
behavior during two examinations. Mortality registers and 
hospital registers were searched for an incident of hospital 
admission or a death attributable to MI. A sample consist-
ing of pooled data from three population studies yielded 
643 participants who were heavy smokers at study entry 
and were evaluated for the effects of reduced smoking. 
These persons reported unassisted reductions in 
tobacco use by at least 50 percent and were compared 
Table 6.6 Smoking reduction and cardiovascular disease endpoints: biomarkers and clinical outcomes
               Reduction from baseline
Study Design n Follow-up NRT CPD Nicotine CO (ppm)




23 24 weeks Inhaler ≥40 to 10** -a NS











643c Mean 13.8 
years
NA ≥50%d Significant 13.2 vs. 8.7***









61 12 weeks Patch and 
gum
24.16 to 6.93*; 
>40%
-f 19.9 to 
6.77***
Joseph et al.h 
2005
RCT 152 6 months Patch and 
gum
27.7 to 16.8* NS NS
Note: APO A-I = apolipoprotein A-I; APO B = apolipoprotein B; BP = blood pressure; CCSC = Canadian Cardiovascular Society 
classification; CO (ppm) = carbon monoxide (parts per million); CPD = cigarettes/day; Fibr = fibrinogen concentrations; 
g/L = grams per liter; Hb = hemoglobin; HDL = high-density lipoprotein; hs-CRP = high-sensitivity C-reactive protein; 
LDL = low-density lipoprotein; mg/dL = milligrams per deciliter; MI = myocardial infarction; n =  number in sample (or study)  
population; NA = not applicable; NRT = nicotine replacement therapy; NS = not significant; PAI-1 = plasminogen activator 
inhibitor-1; Plts = platelets; RCT = reverse cholesterol transport; SAEs = serious adverse events; Trigly = triglycerides; 
WBC = white blood cells.
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with 1,379 persons who reported abstinence from smok-
ing. Outcomes were adjusted for baseline cardiovascu-
lar risk factors. Smoking cessation was associated with 
a hazard ratio for MI of 0.71 (95 percent CI, 0.59–0.85), 
but smoking reduction was not associated with a statis-
tically significant reduction in risk of MI (hazard ratio, 
1.15 [95 percent CI, 0.94–1.40]). A subgroup analysis 
demonstrated significant reductions in levels of expired 
CO among persons who reduced cigarette smoking. The 
investigators concluded that the results were consis-
tent with a short-term thrombogenic effect of tobacco 
exposure rather than with a cumulative effect of exposure. 
They speculated that an approximate 50-percent reduc-
tion (from 20 g to 10 g of tobacco smoked per day) was 
not sufficient to improve cardiovascular risk. These epi-
demiologic data make an important contribution because 
they are population based and come from a large cohort 
of smokers who reduced their smoking during a period 
longer than the usual timeframe for clinical trials. 
In summary, these studies show that a significant 
reduction in cigarette use, even to levels as low as 10 ciga-
rettes per day, results in reduction of exposure to CO from 
tobacco smoke that is smaller than expected. This find-
ing most likely reflects compensatory smoking. Some but 
   Reduction from baseline




(mg/dL) HDL (mg/dL) Other biomarkers Clinical outcomes
Hurt et al. 
2000
- - - - - - -




7.0 to 6.2** 2.9 to 
2.6*





- - - -e NS - Systolic BP NS
Diastolic BP 80.7 
vs. 78.8***
Risk of MI NS
Hughes et al. 
2004a










50.27 to 52.82* Trigly NS
APO A-I NS
APO B 103.74 to 
103.0*
Systolic BP 122.97 
to 122.29*
Diastolic BP NS
Heart rate 75.7 to 
70.18***
Joseph et al.h 
2005







cardiac or other 
SAEs NS
aThiocyanate concentrations increased from 189 to 198 micromoles/L (p <0.05).
bHDL to LDL ratio increased from 0.33 to 0.37, p <0.005. 
cTotal cohort = 19,423.
d22.2 grams tobacco per day in continued heavy smokers versus 10.5 grams per day in reducers (p <0.001).
eTotal cholesterol NS.
fAnatabine decreased from 4.69 to 3.02 nanograms per milligram of creatinine (statistically significant).
gHDL to LDL ratio increased from 0.47 to 0.49, p <0.0167.
hReduction in CPD reported for smoking reduction intervention group, significance tests reported for smoking reduction versus 
control group. 
*p <0.05, **p <0.01, ***p <0.001.
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not all studies showed reduced exposure to nicotine, as 
well as improvements in values for hemoglobin, leukocyte 
counts, and fibrinogen and cholesterol levels. However, 
the improvements in values are relatively minor compared 
with those observed with abstinence from smoking. Many 
of these improvements occurred in study participants who 
were using NRT (see “Nicotine Replacement Therapy” 
below). None of the studies showed improvements in clin-
ical outcomes of heart disease, consistent with evidence 
presented earlier that low levels of smoke exposure trig-
ger many of the adverse cardiovascular effects of smoke 
(see “Exposure to Secondhand Tobacco Smoke” earlier in 
this chapter). 
Nicotine Replacement Therapy
In addition to providing data on smoking reduction, 
the Lung Health Study of 3,094 persons offered a unique 
opportunity to examine the natural history and safety of 
prolonged use of nicotine gum among thousands of peo-
ple during a five-year follow-up (Murray et al. 1996). Per-
sistent smoking, but not use of nicotine gum, predicted 
fatal and nonfatal cardiovascular events and elevation of 
diastolic blood pressure. 
In general, trials of smoking cessation and smoking 
reduction showed improvements in lipid profiles, even 
with NRT. Eliasson and colleagues (2001) observed that 
use of nicotine nasal spray for smoking reduction or ces-
sation yielded significant improvements in HDLc to LDLc 
ratios at 9 weeks, with further improvements if smok-
ers abstained from smoking for 17 weeks (see “Reduced 
Smoking” earlier in this chapter). In addition, significant 
improvements in fibrinogen levels and leukocyte counts 
were observed. A clinical trial of smoking cessation also 
reported significant decreases in hemoglobin values, leu-
kocyte counts, and total and LDLc concentrations (Lúd-
víksdóttir et al. 1999). In addition, HDLc to LDLc ratios 
improved among participants who abstained from smok-
ing after three months of treatment with a nicotine nasal 
spray. Allen and colleagues (1994) also observed signifi-
cantly increased HDLc levels in participants treated with 
the nicotine patch. 
Investigators have noted improvements in markers 
of thrombogenesis among persons who abstained from 
smoking and were using medicinal nicotine. In one study, 
plasma fibrinogen levels were reduced among 164 men 
using a combination of a nicotine patch and gum for 12 
weeks to stop smoking (Haustein et al. 2002). In another 
study, use of transdermal nicotine appeared to activate 
platelet aggregation less than smoking did (Benowitz et 
al. 1993). 
Mahmarian and colleagues (1997) used single pho-
ton emission computed tomography to measure the com-
bined effects of smoking and use of nicotine patches on 
myocardial perfusion. In 36 patients with known CHD who 
were treated with nicotine patches, the amount of heart 
muscle deprived of normal blood flow (size of perfusion 
defects) decreased despite increased serum nicotine lev-
els. The baseline size of defects and changes in CO levels, 
but not in nicotine levels, predicted the size of perfusion 
defects. The researchers concluded that the reduction in 
the size of defects resulted from reduction in smoking that 
was facilitated by NRT and from decreased exposure to CO. 
They also concluded that nicotine patches were safe to use 
in smokers with heart disease. 
Nitenberg and Antony (1999) used angiography to 
examine short-term effects of use of nicotine gum on per-
fusion of the coronary arteries in former cigarette smok-
ers at study entry, after a test with immersion of the hand 
in cold water (cold pressor test) before and after adminis-
tration of the gum. The gum did not augment the result 
of the cold pressor test, which constricted normal and 
diseased segments of the coronary artery, reducing their 
cross-sectional area, and it did not reduce the surface area 
of the arterial segments at rest or under conditions of 
sympathetic stimulation. 
These results suggest that reduction of exposure to 
tobacco smoke through use of NRT or with abstinence 
from smoking is associated with improvements in bio-
markers of cardiovascular risk. 
Summary
Epidemiologic studies demonstrate a strong dose-
response relationship between the number of cigarettes 
smoked per day and cardiovascular risk. The relationship 
is not linear, however, and even low levels of exposure to 
tobacco, such as a few cigarettes per day, occasional smok-
ing, or exposure to secondhand tobacco smoke are suffi-
cient to substantially increase risk of cardiac events. Some 
interventions have accomplished significant reductions in 
the number of cigarettes smoked per day, but the reduc-
tions in levels of biomarkers of exposure and biomarkers of 
cardiovascular risk factors are not proportional, probably 
because of compensatory smoking by study participants 
and the nonlinear dose-response relationship. The limited 
data on clinical outcome do not confirm reduction in car-
diovascular events due to reduced smoking. Other meth-
ods for reducing exposure, including NRT with abstinence 
from smoking, are associated with more improvement in 
risk factors for CVD than is smoking reduction with or 
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without pharmacologic support. Accordingly, these meth-
ods hold more potential for reducing risk. 
Implications
These findings suggest that to lower cardiac risk, 
interventions would have to reduce exposure to tobacco 
smoke to extremely low levels or eliminate the exposure. 
Studies of smoking reduction to date suggest that goals 
would be difficult to accomplish. Reducing exposure by 
reducing smoking, therefore, appears to have limited 
promise for improving cardiac risk unless this method 
contributes to eventual smoking cessation (Hughes 2000). 
Because smoking cessation is associated with marked 
improvements in the risk of MI, sudden death, and stroke, 
it should be stressed as the goal for interventions deal-
ing with dependence on tobacco. The safety and efficacy of 
long-term NRT use to reduce cardiovascular risk by main-
taining smoking cessation have not been established. 
Evidence Summary
Exposure to tobacco smoke is associated with accel-
erated atherosclerosis and an increased risk of acute MI, 
stroke, PAD, aortic aneurysm, and sudden death. Smok-
ing appears to have both causal relationships and mul-
tiplicative interactions with other major risk factors for 
CHD, including hyperlipidemia, hypertension, and diabe- 
tes mellitus. 
The cardiovascular risk attributable to cigarette 
smoking increases sharply at low levels of cigarette con-
sumption and with exposure to secondhand smoke. The 
risk then tends to plateau at higher levels of smoking. This 
finding indicates a low threshold for effect and a nonlinear 
dose-response relationship. Some of the nonlinearity of 
the relationship between the number of cigarettes smoked 
per day and CVD risk may be due to impreciseness of this 
measure of actual exposure to smoke. However, the data 
on risk associated with exposure to secondhand smoke 
indicate a true nonlinear relationship between exposure 
and CVD risk. Cardiovascular risk is not reduced by smok-
ing cigarettes of lower machine-delivered yields of nico-
tine or tar. 
The constituents of tobacco smoke believed to be 
responsible for cardiovascular disease include oxidiz-
ing chemicals, nicotine, CO, and particulate matter. 
Oxidizing chemicals, including oxides of nitrogen and 
many free radicals, increase lipid peroxidation and con-
tribute to several potential mechanisms of CVD, including 
inflammation, endothelial dysfunction, oxidation of LDL, 
and platelet activation. 
Nicotine is a sympathomimetic drug that increases 
heart rate and cardiac contractility, transiently increasing 
blood pressure and constricting coronary arteries. Nico-
tine may also contribute to endothelial dysfunction, insu-
lin resistance, and lipid abnormalities. However, interna-
tional epidemiologic evidence and data from clinical trials 
of nicotine patches suggest that chemicals other than nic-
otine contribute to an elevated risk of death from MI and 
stroke. CO reduces the delivery of oxygen to the heart and 
other tissues and can aggravate angina pectoris or PAD 
and can lower the threshold for arrhythmias in the pres-
ence of CHD. Exposure to particulates is associated with 
oxidant stress and cardiovascular autonomic disturbances 
that potentially contribute to acute cardiovascular events. 
Cigarette smoking causes acute cardiovascular 
events such as MI and sudden death by adversely affect-
ing the balance of myocardial demand for oxygen and 
nutrients and coronary blood flow. Smoking results in 
increased myocardial work, reduced coronary blood flow, 
and enhanced thrombogenesis. Enhancement of throm-
bogenesis appears to be particularly important in that 
smokers with acute MI have less severe underlying cor-
onary artery disease than do nonsmokers with MI, but 
smokers have a greater burden of thrombus.
Several potential mechanisms appear to contribute 
to the effects of smoking in accelerating atherosclerosis. 
These mechanisms include inflammation, endothelial 
dysfunction, impaired insulin sensitivity, and lipid abnor-
malities. Cigarette smoking is a risk factor for diabetes 
and aggravates insulin resistance in persons with diabetes. 
The mechanism appears to involve both the effects of oxi-
dizing chemicals in the smoke and the sympathomimetic 




1. There is a nonlinear dose response between expo-
sure to tobacco smoke and cardiovascular risk, with 
a sharp increase at low levels of exposure (including 
exposures from secondhand smoke or infrequent 
cigarette smoking) and a shallower dose-response 
relationship as the number of cigarettes smoked per 
day increases.
2. Cigarette smoking leads to endothelial injury 
and dysfunction in both coronary and peripheral 
arteries. There is consistent evidence that oxidizing 
chemicals and nicotine are responsible for endothe- 
lial dysfunction.
3. Tobacco smoke exposure leads to an increased risk 
of thrombosis, a major factor in the pathogenesis of 
smoking-induced cardiovascular events.
4. Cigarette smoking produces a chronic inflamma-
tory state that contributes to the atherogenic disease 
processes and elevates levels of biomarkers of inflam-
mation, known powerful predictors of cardiovascu- 
lar events.
5. Cigarette smoking produces an atherogenic lipid pro-
file, primarily due to an increase in triglycerides and a 
decrease in high-density lipoprotein cholesterol.
6. Smoking cessation reduces the risk of cardiovascular 
morbidity and mortality for smokers with or without 
coronary heart disease.
7. The use of nicotine or other medications to facilitate 
smoking cessation in people with known cardiovas-
cular disease produces far less risk than the risk of 
continued smoking.
8. The evidence to date does not establish that a reduc-
tion of cigarette consumption (that is, smoking fewer 
cigarettes per day) reduces the risks of cardiovascu-
lar disease.
9. Cigarette smoking produces insulin resistance and 
chronic inflammation, which can accelerate macro-
vascular and microvascular complications, including 
nephropathy.
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Data table for Figure 6.1 Relative risk and excess death rate for coronary heart disease among men, by age group
Age group (years) Relative Risk Excess Death Rate
35-39 3.3  20.5








   80+ 1.4 825.7
Data table for Figure 6.2 age-specific excess death rates among male smokers for coronary heart disease, lung can-
cer, chronic obstructive pulmonary disease (COPD), and cerebrovascular disease
Age group (years) Lung Cancer Coronary Heart Disease
Cerebro-Vascular 
Disease COPD
35-39      1.4   20.5   11.9   
40-44    18.7   70.7     0.2   
45-49    35.5 119.8   16.3     3.2
50-54   109.9 156.6   19.0   11.1
55-59   200.8 204.1   29.0   19.9
60-64   349.5 317.3   49.8   40.3
64-69   560.1 366.7   81.4 140.5
70-74   874.1 473.2 108.2 234.5
75-79 1066.3 439.6 252.8 522.0
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Introduction
The respiratory system extends from the nose and 
upper airway to the alveolar surface of the lungs, where 
gas exchange occurs. Inhaled tobacco smoke moves from 
the mouth through the upper airway, ultimately reach-
ing the alveoli. As the smoke moves more deeply into the 
respiratory tract, more soluble gases are adsorbed and 
particles are deposited in the airways and alveoli. The sub-
stantial doses of carcinogens and toxins delivered to these 
sites place smokers at risk for malignant and nonmalig-
nant diseases involving all components of the respiratory 
tract including the mouth.
Consider, for example, the lungs of a 60-year-old 
person with a 40-pack-year1 smoking history starting at 
age 20 years. By age 60 years, this person will have inhaled 
the smoke from approximately 290,000 cigarettes and will 
bear a substantial risk for chronic obstructive pulmonary 
disease (COPD) and lung cancer. The dose of inhaled toxic 
particles and gases received from each of these cigarettes 
varies depending on the nature of the tobacco, the volume 
and number of puffs of smoke drawn from the cigarette, 
the amount of air drawn in through ventilation holes as 
the smoke is inhaled, and local characteristics within the 
lung that determine the diffusion of toxic gases and the 
deposition of particles. Because of this repetitive and sus-
tained injurious stimulus, the repair and remodel process 
that heals the damaged lung tissue takes place at the same 
time the lung’s defenses continue to deal with this unre-
lenting inhalation injury.
This chapter addresses the mechanisms by which 
tobacco smoke causes diseases other than cancer in the 
lower respiratory tract: the trachea, bronchi, and lungs. 
Beginning with the first Surgeon General’s report in 
1964 (U.S. Department of Health, Education, and Welfare 
[USDHEW] 1964), cigarette smoking has been caus-
ally linked to multiple diseases and to other adverse 
effects on the respiratory system (Table 7.1). In addition 
to causing lung cancer and COPD, smoking increases the 
risk of death from pneumonia and causes chronic bron-
chitis (U.S. Department of Health and Human Services 
[USDHHS] 2004). Typically, the lungs of smokers show 
evidence of diffuse changes affecting the lining of the air-
ways, the epithelium, and the structure of the bronchi-
oles, which are the smaller air-conducting tubes.
Previous reports of the Surgeon General have also 
addressed the effects of smoking on the respiratory tract. 
In discussing the plausibility of associations of cigarette 
smoke with chronic bronchitis and emphysema, the 1964 
report gave full consideration to the nature of tobacco 
smoke and its effects on the respiratory tract (USDHEW 
1964). That report concluded that cigarette smoking “…
is the most important of the causes of chronic bronchitis 
in the United States…” (p. 302) and that “a relationship 
exists between pulmonary emphysema and cigarette 
smoking, but it has not been established that the relation-
ship is causal” (p. 302). The 1984 report, which focused 
on COPD, covered mechanisms by which smoking affects 
the lung’s structure and function and the deposition and 
toxicity of cigarette smoke in the lung (USDHHS 1984). 
The report concluded that “cigarette smoking is the 
major cause of chronic obstructive lung disease in the 
United States…” (p. vii). The mechanisms of lung inju-
ry were considered further in the 1990, 2004, and 2006 
reports (USDHHS 1990, 2004, 2006). 
The principal nonmalignant respiratory diseases 
caused by cigarette smoking—COPD, emphysema, chron-
ic bronchitis, and asthma—are defined in Table 7.2. The 
definitions indicate that chronic bronchitis is a specific set 
of symptoms, whereas emphysema refers to a particular 
pattern of lung damage. COPD comprises a clinical syn-
drome characterized by limitation in airflow; persons with 
COPD often have chronic bronchitis as well, and their 
lungs typically display emphysema. Other nonmalignant 
respiratory diseases that have been linked to smoking 
include asthma and idiopathic pulmonary fibrosis 
(USDHHS 2004), but the evidence has not reached a level 
of certainty sufficient to warrant a conclusion of cause 
and effect.
The nonmalignant respiratory diseases caused by 
smoking contribute substantially to the burden of mor-
bidity and mortality attributable to smoking in the United 
States (Table 7.1). In 2005, the Centers for Disease Con-
trol and Prevention (CDC) estimated that an average of 
123,836 deaths per year could be attributed to lung cancer 
caused by smoking for the period 1997–2001 (CDC 2005). 
CDC estimated an additional 90,582 deaths from COPD 
and 10,872 from pneumonia and influenza annually. 
Great advances have been made in our understand-
ing of how smoking causes these diseases. Research has 
been facilitated by methods that directly assess changes 
in the lungs. Methods for obtaining biologic mate-
rial from human lungs include bronchoalveolar lavage 
(BAL), a technique that allows recovery of cellular and 
1Pack-years = the number of years of smoking multiplied by the number of packs of cigarettes smoked per day.
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noncellular components of the epithelial surface of the lower 
respiratory tract (Cantrell et al. 1973; Hunninghake et 
al. 1979; Reynolds 1987). BAL is of value in the study of 
immune and inflammatory mechanisms in the lower air-
ways, because most of the cells recovered are believed to be 
derived from both air spaces and lung interstitium. Lung 
tissue obtained by biopsy or autopsy procedures can be 
used for cellular, protein, and nucleic acid assays. Exhaled 
breath condensate provides information about the com-
position of epithelial lining fluid (ELF) that can be used 
to detect inflammation and redox disturbance (Paredi et 
al. 2002). Blood samples may be used to assess systemic 
inflammatory responses, and blood cells serve as a source 
of nucleic acids.
Table 7.1 Causal conclusions on smoking and diseases of the respiratory tract other than lung cancer: the 2004 
and 2006 reports of the Surgeon General
Active Smoking
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Source: U.S. Department of Health and Human Services 2004, 2006.
Characteristics of Tobacco Smoke
Tobacco smoke, which comprises an aerosol (a mix-
ture of solid and liquid particles) and gases, has thousands 
of chemical components, including many well-charac-
terized toxins and carcinogens (International Agency for 
Research on Cancer [IARC] 2004). Many of these compo-
nents are in the gas phase, and others are components of 
the particles. Nicotine, for example, is bound to particles in 
mainstream smoke. The chemical components in tobacco 
smoke were covered comprehensively in IARC Monograph 
83 (IARC 2004) and described in previous reports of the 
Surgeon General. Numerous components of the smoke 
have the potential to injure the airways and alveoli. 
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Table 7.2 Definitions for principal nonmalignant respiratory diseases caused by cigarette smoking
Chronic obstructive 
pulmonary disease (COPD)
A preventable and treatable disease characterized by airflow limitation that is not fully reversible. 
The limitation is usually progressive and is associated with an abnormal inflammatory response 
of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD 
affects the lungs, it also produces significant systemic consequences.  
Emphysema Permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by 
destruction of their walls and without obvious fibrosis. In patients with COPD, either condition 
may be present. However, the relative contribution of each to the disease process is often difficult 
to discern.  
Chronic bronchitis Chronic productive cough for 3 months in each of 2 successive years in a patient in whom other 
causes of productive chronic cough have been excluded. 
Asthma A chronic inflammatory disease of the airways in which many cell types play a role—in particular, 
mast cells, eosinophils, and T lymphocytes. In susceptible persons, the inflammation causes 
recurrent episodes of wheezing, breathlessness, chest tightness, and cough, particularly at night 
and/or in the early morning. These symptoms are usually associated with widespread and variable 
airflow obstruction that is at least partly reversible either spontaneously or with treatment. The 
inflammation also causes an associated increase in airway responsiveness to a variety of stimuli. 
Source: American Thoracic Society 2000 and American Thoracic Society/European Respiratory Society Task Force 2005.
Components of tobacco smoke with the potential 
to injure the lungs through a variety of mechanisms are 
listed in Table 7.3. Some components adversely affect host 
defenses; others act through specific or nonspecific mech-
anisms. Notably, cigarette smoking has very strong oxi-
dant potential in that both the gas and tar phases contain 
high concentrations of free radicals (Repine et al. 1997). 
Many of the components of cigarette smoke are the targets 
of regulations because of their toxic effects: these include 
nitrogen dioxide, carbon monoxide, and various metals. 
For information on the toxic effects of components, see 
reports of the U.S. Environmental Protection Agency 
(EPA) and other agencies (USEPA 1993, 2000; USDHHS 
2000) and standard resources in toxicology (Gardner et al. 
2000; Klaassen 2001). 
Assessment of toxic effects of cigarette smoke in the 
respiratory tract requires consideration of the complexity 
of the mixture inhaled and the possibility of synergistic 
interactions among its many components. Although it 
is little studied, the possibility of numerous interactions 
has great plausibility because of the myriad components 
of cigarette smoke and the interlocking pathways of 
lung injury.
Table 7.3 Selected components of cigarette smoke 
and potential mechanisms of injury
Component Mechanism
Acrolein Cilia toxic; impairs lung defenses
Formaldehyde Cilia toxic; irritant
Nitrogen oxides Oxidant activity
Cadmium Oxidative injury; promotion of 
emphysema
Hydrogen cyanide Oxidative metabolism of cells 
affected
Dosimetry of  Tobacco Smoke  
in the Respiratory System
To protect the lungs from injury, the respiratory 
tract has an elegant set of mechanisms for handling the 
particles and gases in inhaled air (Figure 7.1). These 
defenses include physical barriers, reflexes and the cough 
response, the sorptive capacity of the epithelial lining, 
the mucociliary apparatus, alveolar macrophages, and 
immune responses of the lung (Schulz et al. 2000). These 
defenses are critical because of the substantial volume of 
air inhaled daily: about 10,000 liters per day are inhaled 
by an adult. Even harmful substances present at low 
concentrations may eventually achieve a toxic dose after 
sustained exposure. In addition, high-level exposures, 
particularly when sustained, may overwhelm the lung’s 
defenses, and some agents have the potential to reduce the 
efficacy of these defenses. Cigarette smoke, for example, 
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Source: Cook 2000. Reprinted with permission from Elsevier Health, © 2000.
contains components that impair mucociliary clearance 
(Table 7.3).
The size of particles in the smoke inhaled directly 
from a cigarette (mainstream smoke) has been studied 
in a variety of systems. These studies indicate that the 
mass median aerodynamic diameter of particles is 0.3 to 
0.4 micrometers (μm) (Martonen 1992; Bernstein 2004). 
Particles of this size penetrate to and are deposited in the 
deep lung. 
The handling of particles by the lung’s defense 
mechanisms depends on their size (Figure 7.2). Large par-
ticles (e.g., many pollens and road dust) are removed in 
the upper airway, largely by impaction (USDHHS 1984). 
Small particles, with a mean aerodynamic diameter less 
than about 2.5 μm, reach the lungs, where they deposit 
in airways and alveoli by impaction, sedimentation, or dif-
fusion. About 60 percent of the particles inhaled in main-
stream smoke are deposited. Although these particles are 
subject to handling by the mucociliary apparatus and 
alveolar macrophages, removal is not complete because 
of their very high numbers in the lungs of long-term 
smokers, which show evidence of a substantial burden of 
retained particles. Similarly, evidence shows that smokers 
clear these particles at a reduced rate (Cohen et al. 1979; 
USDHHS 1984; Kreyling and Scheuch 2000). 
The removal of gases in the respiratory tract is 
accomplished through sorption by the liquid that lines 
the epithelial layer (Kreyling and Scheuch 2000). Both the 
site and the efficacy of removal of gases depend on the sol-
ubility of the gas. Highly soluble gases are removed high 
in the respiratory tract, but insoluble gases (e.g., carbon 
monoxide) may reach the alveoli and diffuse across the 
alveolar-capillary membrane. These dosimetric consider-
ations indicate a high potential for lung injury in active 
smokers, who inhale a rich mixture of gases and particles 
that penetrates throughout the lungs, with deposit of par-
ticles and sorption of gases in the two anatomic sites most 
critical to respiration, the airways and alveoli.
Major Pulmonary Diseases Caused 
by Smoking
This section provides a brief overview of the prin-
cipal diseases of the lung that are caused by smoking. A 
brief description of pathophysiology and pathogenesis is 
provided as background for the more comprehensive dis-
cussions of mechanisms. These topics are covered in great 
detail elsewhere (Mason et al. 2005) and were addressed in 
the 1984 and 2004 Surgeon General’s reports (USDHHS 
1984, 2004).
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Figure 7.2 Fractional deposition of inhaled particles in the human respiratory tract
Source: Oberdörster et al. 2005. Reprinted with permission from Environmental Health Perspectives, © 2005. Figure based on data 
from the International Commission on Radiological Protection 1994. Drawing courtesy of Dr. Jack R. Harkema, Michigan State 
University. 
Note: µm = micrometers.
Chronic Bronchitis
The symptom complex of chronic bronchitis has 
been investigated for decades. In the 1950s, the British 
Medical Research Council suggested that a diagnosis of 
chronic bronchitis was warranted when the symptoms of 
chronic cough and production of sputum were present on 
most days of the month for at least three months in two 
consecutive years without any other explanation (BMJ 
1965). This proposal is reflected in the current definition 
of chronic bronchitis (Table 7.2). Earlier, Reid (1960) had 
used the size of the mucous gland layer as a predictor for 
the postmortem diagnosis of this condition but did not 
implicate the inflammatory process in the pathogenesis 
of either enlargement of the gland or the production of 
excess mucus. Subsequent studies of lung tissue surgical-
ly removed from cancer patients (Figure 7.3) have shown 
that the symptoms of chronic bronchitis are associated 
with an inflammatory response involving the mucosal 
surface, submucosal glands, and gland ducts, particularly 
in the small bronchi that are 2 to 4 millimeters (mm) in 
diameter (Mullen et al. 1985; Saetta et al. 1997). In addi-
tion, longitudinal studies of chronic bronchitis in persons 
with normal lung function have clarified that its pres-
ence does not predict future progression to more severe 
obstructive lung disease (Fletcher et al. 1976; Saetta et 
al. 1997). Presence of chronic bronchitis in persons who 
already have limited airflow, however, is predictive of a 
more rapid decline in lung function and a higher risk of 
hospitalization than are seen with a similar limitation of 
airflow but no chronic bronchitis (Saetta et al. 1997). 
The inflammatory immune cells that infiltrate 
the epithelium, subepithelium, and glandular tissue in 
chronic bronchitis include the polymorphonuclear neu-
trophils (PMNs), macrophages, CD8-positive (CD8+) and 
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CD4-positive (CD4+) T lymphocytes, and B cells that are 
part of the adaptive inflammatory immune process (Di 
Stefano et al. 1996; O’Shaughnessy et al. 1997; Saetta 
et al. 1997). This chronic inflammation, consisting of 
enlargement of the mucous glands and remodeling of the 
walls of both large and small bronchi reflects a deregu-
lated healing process in tissue persistently damaged by 
the inhalation of tobacco smoke (Hogg 2004). The conse-
quences of this process include both the development of a 
chronic cough and the accumulation of excess mucus in 
the airway’s lumen. However, this inflammatory process 
has little influence on airflow limitation unless it extends 
to the small conducting airways that account for much of 
the increase in airway resistance in COPD. 
Studies reported from the laboratory of Snider and 
associates in Israel (Breuer et al. 1993) were the first to 
show that elastase from PMNs was an important agent for 
the secretion of mucus by epithelial goblet cells. Later, 
Nadel (2001) and other investigators (Takeyama et al. 
1999, 2000, 2001a,b; Burgel et al. 2000; Lee et al. 2000; 
Kohri et al. 2002) extended these observations by link-
ing the PMN-induced production of mucin to stimula-
tion of EGFR. They showed that PMN elastase triggered 
the cleavage of membrane-tethered transforming growth 
factor alpha (TGFα), allowing it to attach to the external 
binding site of EGFR. This step is followed by phosphory-
lation of the intracellular component of this receptor and 
stimulation of downstream signaling pathways that acti-
vate the expression of the MUC5AC gene and lead to the 
production of mucus (Takeyama et al. 1999). This type of 
experiment established that EGFR and its ligands provide 
a regulatory axis for the production of mucin that involves 
several membrane-bound ligands of EGFR, such as TGFα 
and heparin-binding EGF. Nadel (2001) has also shown 
that reactive oxygen species (ROS) can bypass the extra-
cellular sphere of influence of this regulatory axis. Other 
studies have shown that ROS can directly activate EGFR’s 
intracellular domain (Burgel et al. 2000; Takeyama et al. 
2000; Kohri et al. 2002).
Figure 7.3 Comparison of normal bronchial gland (A) with enlarged bronchial glands (B and C) from a patient with 
chronic bronchitis
Source: Hogg 2004. Reprinted with permission from Elsevier, © 2004.
Note: (A) Histology of bronchus with epithelial lining that extends from lumen into gland duct and gland. (B) Enlarged glands from a 
patient with chronic bronchitis. (C) One of these glands at higher magnification showing inflammatory cells (arrow and arrowhead). 
Several studies of human lungs showed that the symptoms of chronic bronchitis were associated with an inflammatory response 
involving the mucosal surface, submucosal glands, and gland ducts, particularly in the smaller bronchi 2–4 millimeters in diameter.
Pulmonary Diseases  443
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease
More recent work in transgenic mice has found that 
overexpression of epithelial sodium ion channels resulted 
in excess reabsorption of epithelial sodium and volume 
depletion of periciliary fluid (Mall et al. 2004). The deple-
tion of the periciliary fluid layer interferes with the fre-
quency of ciliary beats and results in decreased clearance 
and adherence of mucus to the airway surface. Results of 
this study showed that depletion of the periciliary fluid 
in animals is associated with the accumulation of mucus 
in the lumen of both large and small airways, leading to 
greater susceptibility to infection of the lower respiratory 
tract and early death. 
Chronic Obstructive Pulmonary Disease
The hallmark of COPD is chronic airflow obstruction 
demonstrated with spirometry and the accompanying 
dyspnea and limitation of activity. Maximum expiratory 
flow is determined by the product of the resistance to flow 
in the small conducting airways (centimeters of water 
[H2O] per liter per second) and the elastic recoil of the 
lung parenchyma that drives expiratory flow (liters per 
centimeter of H2O). The product of these two variables, 
the time constant, characterizes the rapidity with which 
the lung fills and empties during respiration. Surprisingly, 
the time constant of the lung remains stable over a wide 
range of breathing frequencies in healthy lungs, but if dis-
ease increases either the compliance as in emphysema or 
the resistance as in obstruction of small airways, the time 
required to empty the lung is prolonged (Otis et al. 1956). 
The presence of a fixed limitation in airflow can be diag-
nosed by using a spirometer to measure the volume of air 
that can be forcibly expired from the lungs in one second 
(forced expiratory volume [FEV1]) and then determin-
ing its ratio to forced vital capacity (FEV1/FVC) after the 
administration of a bronchodilator. 
The classic cohort study of the natural history of 
chronic bronchitis and emphysema performed by Fletch-
er and colleagues (Lancet 1965; Fletcher 1976) used this 
type of measurement to test the hypothesis of a sequence 
beginning with tobacco smoking and then moving to 
symptoms of chronic bronchitis or recurrent chest infec-
tions and, finally, chronic limitation of airflow. The natu-
ral history of the decline in FEV developed by Fletcher and 
colleagues (1976) to summarize findings of a six-year lon-
gitudinal study of men working in West London is illus-
trated in Figure 7.4. Subsequent studies have confirmed 
these findings (USDHHS 1984). The horizontal lines 
added to the Fletcher diagram indicate the boundaries of 
the five-stage classification of the severity of COPD by the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD). The measurements used were FEV1 and FEV1/
FVC (Pauwels et al. 2001; GOLD 2006). According to this 
classification, GOLD stage 0 defines persons with a normal 
FEV1 and FEV1/FVC who have symptoms attributable to 
significant exposure to tobacco smoke as being at risk for 
developing COPD. Those with mild, moderate, severe, or 
very severe COPD are placed in GOLD stages 1 through 4, 
respectively (Takeyama 2001b). 
Fletcher and colleagues (1976) observed that only 
15 to 25 percent of the smokers in the study developed air-
flow limitation, and they showed that smoking cessation 
slowed the rate of decline in FEV1 in those who stopped 
smoking permanently. In subsequent studies of various 
populations, only a minority of smokers developed COPD. 
This repeated finding indicates a role for genetic factors 
that may determine susceptibility to cigarette smoke. 
These investigators rejected the hypothesis of a pathoge-
netic continuum from smoking to obstructive bronchitis. 
Most persons who developed airflow limitation during the 
study had no evidence of chronic bronchitis, a finding that 
was not consistent with the hypothesis of a continuum 
from smoking to bronchitis to obstruction. Subsequent 
studies have confirmed that the presence of chronic bron-
chitis in persons with normal lung function (GOLD stage 
0) does not predict progression of disease (Vestbo and 
Lange 2002). Using data from the Copenhagen City Heart 
Study, however, Vestbo and colleagues (1996) found that 
the symptoms of chronic bronchitis were associated with 
an accelerated decline in FEV1. 
Acute exacerbations, a concern in treatment of 
COPD, are attributed to viral infections (Monto et al. 
1975; Smith et al. 1980; Seemungal et al. 2001), bacte-
rial infections, and occupational and environmental air 
pollution; an important residual of cases had no obvi-
ous cause (Pauwels et al. 2001; Rabe et al. 2007). Some 
unexplained exacerbations of COPD might be attribut-
able to latent viral infection, because such infections can 
deregulate the expression of adhesion proteins that might 
initiate this response (Gonzáles et al. 1996; Keicho et al. 
1997). Although Fletcher and colleagues (1976) found 
that these exacerbations had no effect on the rate of 
decline of FEV1 in the working men in West London, the 
U.S. Lung Health Study showed that such exacerbations 
were associated with a more rapid decline in persons with 
mild disease who continued to smoke (Kanner et al. 2001). 
Subsequently, other investigators found that frequent 
exacerbations in patients with more severe COPD, espe-
cially those resulting from a higher bacterial load, were 
associated with more accelerated decline in FEV1 (Donald-
son et al. 2002; Wilkinson et al. 2003). Collectively, these 
data suggest that when lung defenses become compro-
mised in the later stages of COPD, chronic infection might 
play a role in the pathogenesis of the airflow limitation. 
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Obstruction of Small Airways
Although spirometric measurement of FEV1 and 
the FEV1/FVC provides a reliable method for diagnosing 
airflow limitation and classifying its severity, spirom-
etry cannot distinguish the contributions of either the 
obstruction of small airways or emphysematous destruc-
tion to the airflow limitation in COPD. Direct measure-
ments of pressures and flows within the lung have shown 
that the small bronchi and bronchioles (<2 mm in diam-
eter) are the major sites of airway obstruction in COPD 
(Hogg et al. 1968; van Brabandt et al. 1983; Yanai et al. 
1992). This obstruction is related to an inflammatory pro-
cess that thickens the airway wall, fills the lumen with 
exudates containing mucus, and narrows the airway by 
depositing connective tissue in the airway wall (Figure 7.5). 
McLean (1956) and Leopold and Gough (1957) recognized 
that an inflammatory process was present in the small 
bronchi and bronchioles of lungs affected by centrilobular 
emphysema. Leopold and Gough (1957) hypothesized that 
centrilobular emphysema resulted from an extension of 
this process from the small conducting airways into the 
respiratory bronchioles. Later, Matsuba and Thurlbeck 
(1972) demonstrated an excess deposition of connective 
tissue in the adventitia of the small conducting airways in 
advanced emphysema and suggested that peribronchiolar 
fibrosis narrowed the airway lumen. In addition, cross-
sectional studies of the pathology of COPD have shown 
that the peripheral inflammatory immune process found 
in the lungs of all smokers is amplified in severe (GOLD 
stage 3) and very severe (GOLD stage 4) COPD (Fletcher 
et al. 1976; Hogg et al. 2004). More recent evidence indi-
cates that at these levels of disease severity, these changes 
are associated with an increase in the adaptive immune 
response. These findings may reflect the response to an 
antigenic stimulus from a limited number of antigens that 
might be microbial or possibly from autoantigens that 
develop within the damaged lung tissue (Agustí et al. 
2003; Voelkel and Taraseviciene-Stewart 2005). 
Figure 7.4 Natural history of decline in forced expiratory volume with aging measured in a group of working men 
in West London over about six years
Source: Hogg 2004. Reprinted with permission from Elsevier, © 2004.
Note: Adapted from Fletcher et al. 1976. Horizontal lines have been added to their diagram to indicate the boundaries of the 
classification of severity of chronic obstructive pulmonary disease by the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD).
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Figure 7.5 Nature of an obstruction in the small conducting airways (<2 millimeters in diameter)
Source: Hogg 2004. Reprinted with permission from Elsevier, © 2004.
Note: A normal airway (A) is compared with another airway (B) in which the lumen is partially filled with a bland mucous plug 
containing a few epithelial cells. (C) An airway in which the wall contains an active inflammatory process that partially fills the lumen 
with inflammatory exudates containing mucus. (D) Airway narrowed by collagen deposition in the peribronchiolar space.
Emphysema
Emphysema was first described by René Laënnec in 
1834 on the basis of observations made on the cut sur-
face of postmortem human lungs that had been air-dried 
in inflation (Laënnec 1834), but the concept that emphy-
sematous destruction produced airflow limitation by 
decreasing the elastic recoil forces required to drive air 
out of the lung was not fully developed until 1967 (Mead et 
al. 1967). The earliest concept regarding the pathogenesis 
of emphysema postulated that overinflation compressed 
the lung capillaries, leading to atrophy of lung tissue; this 
concept was mentioned in major textbooks of pathology 
as late as 1940 (McCallum 1940). As mentioned previ-
ously (see “Obstruction of Small Airways” earlier in this 
chapter), McLean (1956) and Leopold and Gough (1957) 
were the first to implicate the inflammatory response in 
the pathogenesis of alveolar destruction in their early 
descriptions of centrilobular emphysema, but skepticism 
about this association persisted because of the possibil-
ity that preterminal bronchopneumonia may have been 
responsible for the inflammation observed in the postmor-
tem studies. The subsequent demonstration that emphy- 
sema could be produced experimentally by depositing 
the enzyme papain in the lung (Gross et al. 1964), com-
bined with observational studies showing the association 
between emphysema and deficiency of α1-antitrypsin 
(AAT) (Laurell and Eriksson 1963), led naturally to the 
hypothesis that the pathogenesis of emphysema was 
based on a functional proteolytic imbalance within the 
Surgeon General’s Report
446 Chapter 7
inflammatory response induced by tobacco smoke (Gadek et 
al. 1979). 
Currently, emphysema is defined as “abnormal, per-
manent enlargement of air spaces distal to the terminal 
bronchiole, accompanied by the destruction of their walls, 
and without obvious fibrosis” (Snider et al. 1985, p. 183). 
The condition can now be diagnosed and quantified dur-
ing life by several techniques. Postmortem examinations 
have provided indirect information on the prevalence of 
emphysema (Thurlbeck 1963; Ryder et al. 1971). 
An important study from the United Kingdom 
(Ryder et al. 1971) found emphysema in 62 percent (219) 
of 353 consecutive postmortem examinations. On average, 
when present, the condition occupied 12.6 percent (range, 
0.5 to 95 percent) of total lung volume. Smoking history 
was established in 179 of the 353 patients, and emphy-
sema was present in 75 percent (80) of the 106 smokers. 
The mean proportion of total lung volume occupied by 
emphysema in smokers was 10.8 percent (range, 0 to 90 
percent). Emphysema was also present in 28 percent (21) 
of 73 nonsmokers, but the mean proportion of the lung 
taken up by emphysema in nonsmokers was only 1.7 per-
cent (range, 0 to 40 percent). In addition, the nonsmokers 
lived longer than the smokers (aged 64.8 versus 60.2 years; 
p <0.05) and emphysema appeared at a later age (Ryder 
et al. 1971).
A laboratory study of more than 400 lungs removed 
from patients being treated for lung cancer (Hogg 2004) 
confirmed that a small proportion of smokers had emphy-
sema and that the proportion with emphysema increases 
with the number of pack-years of smoking. However, the 
dose-response relationship plateaus at 50 to 100 pack-
years, and about 40 percent of smokers are affected (Fig-
ure 7.6). Although imaging by computed tomography 
(CT) has now confirmed that emphysema can be found in 
persons with a normal FEV1, population-based studies of 
its prevalence, as detected by CT, have not been attempted. 
Centrilobular and Panacinar Forms of Emphysema
Pathologically, emphysema is characterized by its 
location as centrilobular or panlobular; the radiographic 
correlates are centriacinar emphysema and panacinar 
emphysema, respectively (Friedlander et al. 2007). Centri-
lobular emphysema is characteristic of smokers, whereas 
panacinar emphysema is found with AAT deficiency. In 
general, persons with a predominance of centrilobular 
emphysema have physiological abnormalities consistent 
with abnormal function of small airways, whereas panlob-
ular emphysema is associated with high lung compliance. 
A substantial portion of people with emphysema have 
both types.
Figure 7.6 Dose-response relationship between level of smoking and the percentage of 408 patients in the  
St. Paul’s Lung Study with morphologic evidence of significant emphysema in their lungsa 
Source: Hogg 2004. Reprinted with permission from Elsevier, © 2004.
aThe relationship plateaued with about 40 percent of the heavy smokers having emphysema.
bPack-years = the number of years of smoking multiplied by the number of packs of cigarettes smoked per day.
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A postmortem bronchogram from a patient with 
lesions of centrilobular emphysema visible at a micro-
scopic low power is shown in Figure 7.7. The nature of 
these lesions is shown to better advantage in Figure 7.8. 
Several normal terminal bronchioles within a second-
ary lung lobule (A) and the histology of a normal acinus 
beyond a single terminal bronchiole (B) can be compared 
with a line drawing from Leopold and Gough’s (1957) 
original description of centrilobular emphysema (C) and 
a postmortem radiograph showing the destruction of the 
respiratory bronchioles (D). These centrilobular lesions 
affect the upper regions of the lung more commonly than 
the lower regions (Figure 7.9) and are also larger and 
more numerous in the upper lung (Gadek et al. 1979). 
Heppleston and Leopold (1961) used the term “focal 
emphysema” to describe a less severe form of centri-
lobular emphysema, but Dunnill (1982) argued that this 
distinction was not helpful and that the two conditions 
probably had a similar origin, with focal emphysema being 
more widely distributed and less severe than the classic 
centrilobular form. Dunnill also preferred the term “cen-
triacinar” to “centrilobular.” “Centriacinar” seems more 
suitable in that each secondary lobule contains several 
acini (Figure 7.8A) and not all are involved in emphyse-
matous destruction.
Wyatt and colleagues (1962) provided the first 
detailed account of the panacinar form of emphysema, 
in which more uniform destruction of the entire acinus 
takes place. Thurlbeck (1963) showed that it can be diffi-
cult to distinguish normal lung from lung with mild forms 
of panacinar emphysema, unless fully inflated specimens 
are carefully examined under a dissecting microscope. In 
contrast to centrilobular emphysema, the panacinar form 
tends to be more severe in the lower lobes than in the 
upper lobes (Figure 7.9), but this difference is substan-
tial only in severe disease (Thurlbeck 1963). Panacinar 
emphysema is commonly associated with AAT deficiency 
but is also found in cases with no identified genetic abnor-
mality (Thurlbeck 1963).
Other Forms of Emphysema
“Distal acinar,” “mantle,” and “paraseptal” emphy-
sema describe lesions in the periphery of the lobule. 
These types of lesions are found along the lobular septa, 
particularly in the subpleural region (Hogg and Senior 
2002). They also occur in isolation and have been asso-
ciated with spontaneous pneumothorax in young adults 
(Ohata and Suzuki 1980) and bullous lung disease in older 
adults, whose lung function improved after the removal of 
large cysts (Morgan 1995). Less frequent forms of emphy-
sema include the unilateral form (McLeod syndrome) that 
occurs as a complication of severe childhood infection by 
rubella or adenovirus; the congenital lobar form, a devel-
opmental abnormality in newborns; and paracicatricial 
emphysema, which forms around scars and lacks any spe-
cial distribution within the acinus or lobule (Thurlbeck 
1963; Dunnill 1982).
Pulmonary Hypertension
The invasive nature of right-heart catheterization 
in older adults with comorbid disease has made it diffi-
cult to study the prevalence of pulmonary hypertension in 
patients with COPD. In one six-year study of 131 patients 
(Kessler et al. 2001), COPD ranged from moderate (GOLD 
stage 2) to very severe (GOLD stage 4). At baseline, none 
of the patients had pulmonary hypertension, but after six 
years, it was present in 25 percent of the patients at rest 
and in more than 50 percent during exercise. These data 
suggest that the prevalence of pulmonary hypertension 
increases steadily with progression of COPD, appearing 
first during exercise and later at rest. 
Figure 7.7 Postmortem bronchogram performed on 
the lungs of a person with centrilobular 
emphysema
Source: Hogg 2007. Reprinted with permission from Informa 
Healthcare, © 2007.
Note: The lesions hang from the distal airways like “Christmas 
tree balls” (arrow). 
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When pulmonary hypertension is absent at rest, but 
present during exercise, some of the increase in pulmo-
nary vascular pressures can be attributed to the mechani-
cal events associated with dynamic hyperinflation of the 
lung in persons with airflow limitation (Horsfield et al. 
1968; Jezek et al. 1973; Weitzenblum et al. 1981; Wright 
et al. 1983a). When the time required to exhale becomes 
longer than the time between breaths, lung volume tends 
to increase, first as the breathing rate increases during 
exercise and later as it does so at rest. This increase in 
lung volume increases intrathoracic pressure, an increase 
that is transmitted to all the vessels within the thorax. As 
a result, both pulmonary artery and left atrial pressures 
are higher than atmospheric pressure but not higher than 
intrathoracic pressure. Treatment with oxygen at this 
stage of the disease lowers both pulmonary artery and 
left atrial pressure by slowing the breathing rate, thereby 
relieving the dynamic hyperinflation and lowering in-
trathoracic pressure. However, when lung emptying is 
more severely prolonged and alveolar pressure rises above 
intrathoracic pressure, there is a true increase in pulmo-
nary artery pressure (Weitzenblum et al. 1981). Hypoxic 
vasoconstriction of the muscular pulmonary arteries and 
emphysematous destruction of the pulmonary vascular 
bed are more likely to contribute to pulmonary hyper-
tension in severe (GOLD stage 3) and very severe (GOLD 
stage 4) COPD. At these more advanced stages, affected 
persons commonly experience chronic hypoxia and exten-
sive destruction of the pulmonary capillary bed. 
Studies of the microvessels of the lung in mild 
(GOLD stage 1) and moderate (GOLD stage 2) COPD show 
consistent changes in the intima. In more severe (GOLD 
Figure 7.8 Details of centrilobular emphysema lesions
Source: Hogg 2004. Reprinted with permission from Elsevier, © 2004. 
Note: (A) Several normal terminal bronchioles within a secondary lung lobule defined by its surrounding connective tissue septa 
(solid arrow) are shown for comparison with (B) the histology of a normal acinus beyond a single terminal bronchiole. (C) Line 
drawing from Leopold and Gough’s original (1957) description of centrilobular emphysema showing the destruction of the respiratory 
bronchioles, and (D) a postmortem radiograph of the dilatation and destruction of the respiratory bronchioles. AD = alveolar duct; 
CLE = centrilobular emphysema; RB = respiratory bronchioles; TB = terminal bronchioles.
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stage 3) and very severe (GOLD stage 4) COPD, the vessel 
wall is commonly altered by fibroelastic thickening—the 
proliferation of smooth muscle and extension of the mus-
cle into small vessels that do not normally contain muscle. 
However, the contribution of smooth muscle to thickness 
of the vessel wall is also reported to be greater in smok-
ers with normal lung function than in nonsmokers and 
still greater in smokers whose lung function is impaired 
(Horsfield et al. 1968). In patients who have very severe 
emphysema, the overall wall thicknesses of vessels with 
external diameters of 100 to 200 µm correlate with both 
the rise in pulmonary arterial pressure during exercise 
and the difference between the pulmonary artery pres-
sures measured during rest and during exercise (Hale et 
al. 1984; Kubo et al. 2000). The increase in muscle in the 
pulmonary arteries, which is variable, probably depends 
on the severity of the COPD. A greater amount of muscle 
has been observed in the pulmonary vessels of smokers 
than in those of nonsmokers (Horsfield et al. 1968), but 
in mild COPD, little if any increase in muscle has been 
observed (Weitzenblum et al. 1981; Haniuda et al. 2003). 
Muscular medial thickening (Barberà et al. 2003), as 
opposed to overall wall thickening (Hale et al. 1984; Kubo 
et al. 2000), does not appear to be related to the severity of 
the pulmonary hypertension or the vascular response to 
oxygen in patients with COPD (Wright et al. 1992). 
Reports from Barberà and associates (2003) from 
Spain indicate that this vascular remodeling process is 
also associated with, and possibly preceded by, an inflam-
matory process in which the vessels become infiltrated 
with a population of cells similar to those found around 
the small airways. The precise meaning of this finding and 
its role in the pathogenesis of the peripheral lung lesions 
observed in COPD is under investigation. 
Figure 7.9 Cut surface of lungs removed from two patients with different forms of emphysema before receiving  
a lung transplant
Source: From Dr. Joel Cooper in Hogg 2004. Reprinted with permission from Elsevier, © 2004. 
Note: (A) The lung on the left is affected by centrilobular emphysema, which affected the upper lobe more severely than the lower 
lobe. (B) The lung on the right is from a patient who had α1-antitrypsin deficiency, which involved the lower lobe to a greater degree 
than the upper lobe.
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Smoking and Respiratory Defense Mechanisms
of tobacco smoke interferes with these defenses, result-
ing in both increased production of mucus and decreased 
effectiveness of the clearance process in the airway’s 
lumen (Hogg 2008). Impairment of these defenses 
increases the potential for infection (Knowles and Bouch-
er 2002; Drannik et al. 2004). Tobacco smoke also disrupts 
the tight junctions that form the epithelial barrier (Jones 
et al. 1980; Hulbert et al. 1981) and initiates the infiltra-
tion of the damaged tissue by a variety of inflammatory 
The innate defense system of the lung includes 
the apparatus for producing and clearing mucus, the 
epithelial cell barrier, and infiltrating inflammatory 
immune cells (Figure 7.10) (Abbas et al. 2000c; Knowles 
and Boucher 2002). The pulmonary epithelium plays a 
critical role in the host defense by recognizing insults 
and initiating innate responses (Greene and McElvaney 
2005; Martin and Frevert 2005; Mayer and Dalpke 2007; 
Sabroe et al. 2007; Torrelles et al. 2008). The inhalation 
Figure 7.10 Innate and adaptive immune system of the lung, including the mucous production and clearance 
apparatus, the epithelial barrier, and the inflammatory immune response
Source: Hogg 2007.  Reprinted with permission from Informa Healthcare, © 2007.
Note: Chronic stimulation of this system by the tobacco-smoking habit results in both increased production and decreased clearance 
of mucus from the airway’s lumen, disruption of the tight junctions that form the epithelial barrier and infiltration of the damaged 
tissue by polymorphonuclear and mononuclear phagocytes as well as natural killer cells and CD4+ and CD8+ T cells, and B-cell 
lymphocytes. The adaptive immune response requires antigen presentation primarily by dendritic cells and the organization of 
the lymphocytes into follicles with germinal centers. This type of response is rarely found in healthy nonsmokers but has been 
documented in about 5 percent of peripheral lung units of smokers with normal lung function, increasing to about 20 to 30 percent 
of airways in the later stages of chronic obstructive pulmonary disease. The source of antigen that drives this sharp increase in the 
adaptive immune response is unknown and may be related to either the colonization or infection of the lower airways by a variety 
of microbes in the later disease stages or to autoantigens that develop in the damaged tissue. DCs = dendritic cells; GC = germinal 
center; NK = natural killer.
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immune cells, including polymorphonuclear and mono-
nuclear phagocytes, natural killer cells, CD4+ and CD8+ T 
cells, and B lymphocytes (Nagaishi 1972; Niewoehner et al. 
1974; Bosken et al. 1992; Richmond et al. 1993; Di Stefano 
et al. 1996; O’Shaughnessy et al. 1997; Ekberg-Jansson et 
al. 2001; Retamales et al. 2001; Cosio et al. 2002; Aoshiba 
et al. 2004; Hogg et al. 2004; Buzatu et al. 2005). The lym-
phocytes become organized into lymphoid follicles with 
germinal centers to mount an effective adaptive immune 
response. Lymphoid collections with these character-
istics have been demonstrated in about 5 percent of the 
smaller airways of smokers (Hogg et al. 2004), and their 
frequency increases to about 20 to 30 percent of airways in 
the later stages of COPD (Nagaishi 1972; Richmond et al. 
1993; Hogg et al. 2004). The source of antigen that drives 
this sharp increase in the adaptive immune response is 
unknown and may be related to either the colonization 
or infection of the lower airways by a variety of microbes 
in the later stages of the disease or to autoantigens that 
develop in the damaged tissue. This inflammatory immune 
process persists after cessation of smoking (Wright et al. 
1983b; Rutgers et al. 2000). Smoking cessation slows the 
rate of decline in lung function and delays death (Fletcher 
et al. 1976; Anthonisen et al. 2005). 
This section of the chapter briefly reviews both the 
inflammatory immune process in relation to the repair 
and remodeling of the tissue damaged by tobacco smoke 
and discusses the roles of these processes in the pathogen-
esis of the lesions that define COPD. This section of the 
chapter briefly reviews the inflammatory immune process 
in relation to the repair and remodeling of the tissue dam-
aged by tobacco smoke and discusses its contribution to 
the pathogenesis of the lesions that define COPD. Both of 
these aspects of the pathogenesis of COPD are the focus of 
substantial research at present.
Infiltration of Innate  
Inflammatory Immune Cells
The epithelial cells covering the lung surface and 
the alveolar macrophages protecting that surface are key 
in defending the lung against inhaled gases and particles. 
Both of these cell types produce a broad array of proin-
flammatory chemokines and cytokines. When these sig-
naling molecules are stimulated by tobacco smoke, they 
can be measured in induced sputum (Traves et al. 2002), 
in BAL fluid from patients with COPD (Morrison et al. 
1998b), and in supernates of cultured cells exposed to 
particles and gases under controlled in vitro conditions 
(Becker et al.1996; Quay et al. 1998; Mukae et al. 2000; 
Fujii et al. 2001, 2002; van Eeden et al. 2001). More than 
50 types of chemokine ligands (L) in four families were 
identified by the position of the cysteine residue; they were 
designated as CC, CXC, C, and CX3C (Proudfoot 2002; 
Lukacs et al. 2005). These ligands interact with more than 
20 chemokine receptors (R) to direct leukocyte traffic in 
the inflammatory immune response. Many chemokines, 
such as interleukin-8 (IL-8, or CXCL8), interact with more 
than one receptor (CXCR1 and CXCR2) to control the 
infiltration of PMN into damaged lung tissue (Keatings et 
al. 1996; Yamamoto et al. 1997). IL-8 is markedly increased 
in the sputum of patients with COPD (Keatings et al. 1996; 
Yamamoto et al. 1997) and can readily be measured in the 
supernates of cultured human bronchial epithelial cells 
(HBECs) as they take up toxic particles (Fujii et al. 2001, 
2002). CXCL1 is also secreted by airway epithelial cells and 
alveolar macrophages and activates PMNs, monocytes, 
basophils, and T lymphocytes through CXCR2 (Proudfoot 
2002; Lukacs et al. 2005). The migration of T lymphocytes 
is controlled by the chemokine receptor CXCR3 that is 
expressed in human peripheral airways (Saetta et al. 2002) 
and interacts with other chemokines, including CXCL9, 
CXCL10, and CXCL11 (Clark-Lewis et al. 2003). Increas-
ingly, evidence indicates that safe and effective inhibitors 
of proinflammatory chemokines and cytokines may ben-
efit persons who have COPD (Proudfoot 2002; Lukacs et 
al. 2005). 
In studies involving the coculture of alveolar macro-
phages and HBECs, paracrine stimulation between these 
cell types enhances their production of chemokines and 
cytokines capable of controlling the recruitment and acti-
vation of leukocytes (TNFα, IL-1β, IL-8, and macrophage 
inflammatory protein 1α), enhancing phagocytosis (inter-
feron-gamma), stimulating natural killer cell and T-cell 
function (IL-12), and initiating the repair process (gran-
ulocyte-macrophage colony-stimulating factor) (Mukae 
et al. 2001; Goto et al. 2004). Furthermore, instillation 
of the supernatants from alveolar macrophages and/or 
HBECs challenged with particles in vitro produces a sys-
temic response similar to that achieved by instilling the 
same number of particles directly into the lungs of ani-
mals (Goto et al. 2004). The magnitude of the systemic 
response correlates with the number of particles phago-
cytosed by the macrophages (Mukae et al. 2001). More 
limited studies of living persons indicate that cytokines 
produced in the lungs (TNFα, IL-1β, and IL-6) enter the 
blood after smoke inhalation during natural forest fires 
and stimulate the liver to produce acute phase proteins 
and the bone marrow to increase production of leukocytes 
and release them into the circulation (Tan et al. 2000; van 
Eeden and Hogg 2000). Other studies in humans have 
shown a relationship among the count of circulating leu-
kocytes, decline in lung function, and risk for early death 
from COPD (Chan-Yeung et al. 1988; Weiss et al. 1995). 
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These and other reports indicate that the inhalation of 
toxic particles and gases causes a local innate inflamma-
tory immune response in the lung, initiating an adaptive 
immune response. 
Adaptive Immune Response
The transition from the innate response to the more 
sophisticated adaptive immune response takes place in 
lymphoid follicles with germinal centers (Figure 7.10), 
found either in regional lymph nodes or in lymphoid 
collections within lung tissue (Figure 7.11). Those in 
the lung tissue are similar to those in the lymphoid 
collections observed in tonsils and adenoids in the 
nasopharynx and to Peyer’s patches in the small bowel and 
the appendix of the large bowel (Nagaishi 1972; Pabst and 
Gehrke 1990; Richmond et al. 1993; Hogg et al. 2004). All 
of these structures are part of the mucosal immune sys-
tem and differ from true lymph nodes in having no cap-
sule and not receiving afferent lymphatic vessels (Nagaishi 
1972; Hogg et al. 2004). The epithelium that covers the 
follicles in lung tissue contains specialized M cells (Fig-
ure 7.11) that transport antigens from the lumen to the 
lamina propria but do not function as antigen-presenting 
cells. Dendritic cells located in the epithelium and lam-
ina propria pick up the antigen, which either penetrates 
the epithelial barrier or is transported by the M cells, and 
Figure 7.11 Lymphoid collections within lung tissue
Source: Adapted from Hogg et al. 2007 with permission from Massachusetts Medical Society, © 2007.
Note: (A) Collection of bronchial lymphoid tissue with a lymphoid follicle containing a germinal center (GC) surrounded by a rim of 
darker-staining lymphocytes extending to the epithelium of both the small airway and alveolar surface (Movat’s stain, x6). (B) Follicle 
in which GC stains strongly for B cells (x6). (C) Serial section of the same airway stained for CD4-positive T cells, which are scattered 
around the edge of the follicle and in the airway wall (x6.5). (D) Diagram of immune process triggered by antigens.
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carry it to either the mucosal lymphatic collections or the 
regional lymph nodes (Buzatu et al. 2005). Lymphocytes 
enter these collections from the blood by attaching to spe-
cialized high endothelial cells lining the microvessels that 
supply mucosal lymphoid follicles (Abbas et al. 2000a,b). 
The B cells concentrate in germinal centers rich in B 
lymphocytes, and the CD4+ and CD8+ T cells concentrate 
at the edge of the follicles and in the spaces between them 
(Hogg et al. 2004). This separation and concentration of 
B and T lymphocytes (Figure 7.11) greatly increases the 
opportunity for the migrating dendritic cells to present 
antigen to immature T and B lymphocytes as they make 
their way through the lymphoid collections to the effer-
ent lymph. The T and B cells activated by the presented 
antigen migrate to the outer edge (dark zone) surround-
ing the germinal center (Figure 7.11) and enrich this zone 
with CD4+ helper T cells and B and T lymphocytes that 
have recognized similar antigens. This aggregation greatly 
increases the opportunity for CD4+ helper T cells, B cells, 
and T cells that have recognized the same antigen to inter-
act to initiate an adaptive response. 
The primary stimulus for production of antibod-
ies is provided by the interaction between CD4+ helper 
T-cell receptors and the major histocompatibility complex 
class II antigen complex on the B cell (Abbas et al. 2000b). 
Secondary costimulatory signals delivered by interactions 
between B-7 on the dendritic cell and its ligand CD28 
on the B cell and between CD40 on CD4+ helper T cells 
and its ligand on B cells stimulate clonal proliferation 
of the B cell and the production of antibodies (Abbas et 
al. 2000a,b). 
The rich diversity of antigen receptors expressed 
on mature T and B lymphocytes is made possible by a 
somatic recombination of a limited number of gene seg-
ments encoded in spatially segregated regions of the germ 
line. The specificity of the antibodies produced is further 
enhanced by an affinity maturation process that depends 
on the presentation of the antigen to maturing B cells by a 
network of follicular dendritic cells in the germinal center 
(Abbas et al. 2000b). The B cells expressing high-affinity 
antibody to the antigen presented to them bind tightly 
to it and receive signals that allow them to survive and 
develop into either memory cells or antibody-producing 
plasma cells (Figure 7.11). Those B cells producing low-
affinity antibody fail to make this tight connection and are 
removed through apoptosis (Abbas et al. 2000b). 
The antigens that drive the production of antibod-
ies in the lungs of cigarette smokers in either the early or 
late stages of COPD are poorly understood. The marked 
increase in the adaptive immune response that occurs in 
the later stages of the disease has been attributed to anti-
gens introduced by colonization and infection of the lung 
with microorganisms (Sethi et al. 2002; Hogg et al. 2004; 
Murphy et al. 2005) and to autoantigens arising from 
within damaged lung tissue (Agustí et al. 2003; Voelkel 
and Taraseviciene-Stewart 2005). 
The persistent innate and adaptive immune inflam-
matory response described here is present in the lungs 
of all long-term smokers and appears to be amplified in 
those smokers who develop severe COPD (Figure 7.12) 
(Keatings et al.1996; Retamales et al. 2001; Hogg et al. 
2004). Hogg and colleagues (2004), who examined predic-
tors of FEV1 obtained from quantitative analysis of lung 
specimens, measured inflammation, as well as the amount 
of tissue remodeling of airway walls. The various tissue 
indicators were compared across strata of GOLD stages 
for COPD. The extent of the immune response increased 
from the least to the most severe stage, although the total 
accumulated volume of cells increased only for B cells and 
CD8+ cells. In a multivariate analysis, these investigators 
found that the index of the remodeling of the wall tissue 
of small airways had the strongest association with the 
level of FEV1, greater than the association with infiltra-
tion of the tissue by inflammatory cells (Hogg et al. 2004). 
Ongoing research should provide greater insight into the 
roles of innate and adaptive immune responses (Curtis et 
al. 2007).
Tissue Remodeling
Tissue remodeling in general is an intrinsic property 
of the wound-healing process most carefully studied in 
tissue damaged by an isolated injury (Clark 1996; Kumar 
et al. 2005). Observations of changes in small airways in 
lungs that represent the full range of COPD severity indi-
cate the importance of a repair or remodeling process that 
thickens small airway walls (Hogg 2004). This type of inju-
ry initiates an acute inflammatory response lasting about 
three days (Figure 7.13). The increase in microvascular 
permeability that is part of this inflammatory process 
allows large molecules, such as fibrinogen, to leak from 
the vessels and initiate the formation of primitive granu-
lation tissue. This tissue is subsequently organized by the 
processes of angiogenesis and fibrogenesis, which lead to 
the formation of a mature scar (Kumar et al. 2005). Stud-
ies of the details of these processes in the lungs of smokers 
have been reported (Hogg 2004).
Angiogenesis is the formation of new blood vessels 
within the granulation tissue by both budding from ex-
isting vessels at the edge of the wound and deposition of 
angioblasts derived from bone marrow, such as endothe-
lial progenitor cells (EPCs) in the provisional matrix (Rafii 
et al. 2002; Reyes et al. 2002; Hill et al. 2003; Kubo and Ali-
talo 2003). Studies by Conway and associates (2001) and 
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Kumar and colleagues (2005) laid a foundation for under-
standing the process of angiogenesis. Vascular endothelial 
growth factor (VEGF) and one of its receptors (VEGFR-2) 
enhance vascular permeability, encourage the prolifera-
tion of EPCs in the bone marrow and at the injury site, 
and control differentiation of EPCs in the granulation tis-
sue as they form the fragile endothelial tubes. These early 
vascular structures are stabilized by the interaction of 
angiopoietin 1 with tyrosine kinase receptors on endothe-
lial cells. Platelet-derived growth factor and TGFβ control 
the recruitment of smooth muscle to their outer surface 
and enhance production of the extracellular matrix that 
stabilizes these newly formed vessels. The migration 
of endothelial cells formed from EPCs is controlled by 
integrins, especially αvβ3 and matricellular proteins. 
These integrins, which participate in angiogenesis, 
include tenascin-C and thrombospondin, a secreted acidic 
protein rich in cysteine (Conway et al. 2001; Kumar et 
al. 2005). 
The fibrogenic process is initiated by the activation of 
resting interstitial fibroblasts that migrate into the primi-
tive granulation tissue (Kumar et al. 2005). These resting 
fibroblasts have a stellate shape with octopus-like projec-
tions that form a network connecting the epithelial to the 
endothelial boundaries of the interstitial compartment 
(Walker et al. 1995; Behzad et al. 1996; Burns et al. 2003). 
The fibroblasts’ projections send small, short extensions 
through tiny preformed holes in both the endothelial and 
epithelial basement membranes. The investigators also 
used three-dimensional reconstructions of serial electron 
micrographs of the interstitial space of the alveolar wall 
to demonstrate that the migrating inflammatory immune 
cells use both the preformed holes in the basement mem-
brane and the surface of the fibroblast to navigate through 
the interstitial space. They found (Figure 7.14) that by 
seeking corners where three endothelial cells meet, the 
migrating inflammatory cells exit the microvessels in the 
alveolar wall without disrupting the tight junctions. After 
exiting, the migrating cells come into contact with the 
endothelial basement membrane and follow its surface 
until they contact one of the preformed holes that nor-
mally accommodate a fibroblast extension; the cells then 
crawl through the holes to enter the interstitial space. 
There, they contact the surface of a fibroblast that guides 
their movement through the interstitial compartment to 
bring them to the preformed holes in the epithelial base-
ment membrane, where they exit. The cells then seek the 
junctions between alveolar type 1 and 2 epithelial cells to 
reach the alveolar surface (Walker et al. 1995; Burns et 
al. 2003). Pathways that are similar but not as well stud-
ied are used by migrating inflammatory cells to move 
Figure 7.12 Persistent innate and adaptive immune inflammatory response in alveolar tissue
Source: Data from Table 3 in Retamales et al. 2001. 
Note: Adaptive immune inflammatory response is present in the lungs of long-term smokers with normal lung function, 
is amplified in smokers who develop severe chronic obstructive pulmonary disease, and persists many years after smoking cessation. 
CD4+ = CD4-positive T cells; CD8+ = CD8-positive T cells; Mac = macrophages; PMN = polymorphonuclear neutrophils.
aPack-years = the number of years of smoking multiplied by the number of packs of cigarettes smoked per day.
*p <0.05.
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from the bronchial microvasculature to the conducting 
airways’ surface. 
Activation of the resting fibroblasts at the edge of 
a wound starts their migration into the primitive granu-
lation tissue to initiate fibrogenesis (Cross and Mustoe 
2003; Werner and Grose 2003). This process begins with 
differentiation of the fibroblasts into proto-myofibroblasts 
that contain bundles of microfilaments termed stress 
fibers and these proto-myofibroblasts then mature into 
myofibroblasts containing both stress fibers and α-SM 
actin (Kumar et al. 2005). The myofibroblasts generate 
contractile force within the granulation tissue in response 
to agonists such as endothelin; the increase in force they 
generate correlates with the level of expression of α-SM 
actin (Tomasek et al. 2002; Cross and Mustoe 2003; 
Kumar et al. 2005). Together with the reorganization of 
the extracellular matrix secreted by these cells, the forces 
generated by the myofibroblast reduce the size of the dam-
aged tissue. Other reports indicate presence in the lung of 
myofibroblast precursors with a mesenchymal stem cell 
phenotype that has potential for differentiation along dif-
ferent pathways and for direction of specific types of tissue 
repair (Sabatini et al. 2005). 
The inflammatory immune cells infiltrating the 
damaged tissue disappear within a few days of an uncom-
plicated single wound (Figure 7.13) but persist in the 
face of the relentless tissue damage caused by sustained 
smoking (Kumar et al. 2005). This persistent infiltra-
tion of inflammatory cells is associated with deregula-
tion of the process of repair and remodeling that leads 
to the formation of a healthy scar. In a healthy scar, the 
balance between cellular and matrix synthesis and degra-
dation controls the deposition of collagen that forms the 
scar (fibrosis). Synthesis is regulated by a wide variety of 
cytokines and growth factors, and degradation is con-
trolled by the secretion and activation of proteolytic 
enzymes, including both matrix metalloproteinases 
(MMPs) and serine proteases. These processes are dereg-
ulated by the persistent injury that occurs in numerous 
chronic diseases, including diseases of the joint tissues 
such as rheumatoid arthritis, of the liver (hepatic cirrho-
sis), and of the lungs (pulmonary fibrosis). Deregulated 
healing may also underlie the pathogenesis of the lesions 
that develop in the lungs of smokers with COPD. 
The more specific aspects of lung remodeling are 
a focus of research. Lung remodeling is central in the 
Figure 7.13 Remodeling process after a single clean surgical wound
 
  
Source: Kumar et al. 2005. Adapted from Clark 1996 with permission from Springer Science and Business Media, © 1996. 
Note: A clean surgical wound initiates an acute inflammatory response that lasts for about 3 days and is associated with an increase 
in microvascular permeability that allows large molecules such as fibrinogen to leak from the vessels and participate in the formation 
of primitive granulation tissue. This tissue is subsequently organized by the processes of angiogenesis and fibrogenesis leading to 
the formation of a mature scar. A major difference between this process and that observed in the lung tissue of tobacco smokers is 
persistent stimulation of the tissue by tobacco smoke as it heals, resulting in a persistent inflammatory immune response. 
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process that leads to airway fibrosis and narrowing in 
small airway obstruction, emphysema, and pulmonary 
hypertension (Postma and Timens 2006). Both the innate 
and adaptive immune responses are involved in these pro-
cesses (Hogg 2008). Inflammation caused by smoking is 
central in driving these processes, but the heterogeneity 
of phenotypes among persons with COPD remains unex-
plained (Kim et al. 2008).
Summary
The healing of wounds inflicted by stimuli that per-
sist as the healing takes place provides a model to study 
the pathogenesis of a wide variety of chronic inflamma-
tory lesions. This model provides useful insights into the 
pathogenesis of the lesions found in the lungs of long-
term smokers because the damage to lung tissue induced 
by the smoking habit must heal in the presence of a 
chronic stimulus. As a result, the normal tissue remod-
eling process essential to repair lung tissue damaged by 
inhaled smoke takes place in the presence of a chronic im-
mune inflammatory process. Evidence is growing that this 
chronic process deregulates the normal healing process in 
which the deposition of collagen to form a mature scar 
is determined by a combination of both deposition and 
degradation of collagen. Deregulation of the chemokines, 
cytokines, and growth factors that determine collagen 
Figure 7.14 Diagram based on three-dimensional reconstructions of serial electron micrographs illustrating how 
inflammatory immune cells navigate through interstitial space of alveolar wall
Source: Walker et al. 2005. Reprinted with permission from Elsevier, © 2005.
Note: Migrating inflammatory cells exit the microvessels in the alveolar wall without disrupting the tight junctions by seeking corners 
where 3 endothelial cells meet (arrows). They contact the endothelial basement membrane and follow it to preformed holes that allow 
them to enter the interstitial space and contact the surface of a fibroblast. They use the fibroblast surface to guide their movement 
across the interstitial compartment to the epithelial basement membrane where they find similar preformed holes and enter the 
epithelial compartment. They exit this compartment between the type 1 and type 2 alveolar epithelial cells. AL = alveolar airspace;  
CL = capillary lumen; En = endothelium; F = fibroblast; I = interstitial space; P = pericytes; T1 = type 1; T2 = type 2.
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deposition and the MMPs and serine proteases that con-
trol its degradation could account for both the thickening 
of the airway walls and the emphysematous destruction of 
the peripheral lung in COPD. An important feature of this 
hypothesis is that the application of what is known about 
the healing of chronic wounds to the pathogenesis of the 
pulmonary problems associated with smoking tobacco 
might lead to a better understanding of pathogenesis and 
new and better insights into targets for the development 
of new treatments for COPD. 
Oxidative Stress
Rahman and MacNee (1998) elucidated the mech-
anisms by which oxidative stress is considered to play a 
central role in the lung injury caused by inhaling tobacco 
smoke. The lungs are directly exposed to the oxygen in 
inhaled air, and because the respiratory tract has direct 
contact with the environment through the large vol-
ume of inhaled air, it is subject to oxidative injury from 
inhaled oxidants generated exogenously. These exogenous 
oxidants come from cigarette smoke, ozone, nitrogen 
oxides, sulfur oxides, and other airborne pollutants. 
Endogenous oxidants are also generated from phagocytes 
and other lung cells. Consequently, the lungs have evolved 
an efficient antioxidant system to protect the airways and 
alveoli against both exogenous and endogenous oxidants. 
The lungs are protected against oxidative challenges by 
well-developed enzymatic and nonenzymatic antioxidant 
systems. If the balance between oxidant and antioxidant 
shifts unfavorably because of either an excess of oxidants 
or a depletion of antioxidants, oxidative stress occurs. Oxi-
dative stress not only produces direct injurious effects in 
the lungs but also activates molecular mechanisms that 
initiate lung inflammation.
Generation of Reactive  
Oxygen Species
Oxygen, which constitutes 21 percent of the air 
inhaled, is a key element in the oxidation of organic com-
pounds, the process by which mammalian cells produce 
the energy needed to sustain life (Davies 1995). One-ninth 
of all inhaled oxygen undergoes tetravalent reduction to 
produce H2O in a reaction catalyzed by cytochrome oxi-
dase in the mitochondrial electron-transport chain. Oxy-
gen is also reduced in a nonenzymatic pathway in four 
reductions of single electrons:
O2 + 4H
+ + 4e– → 2H2O (Davies 1995) (1)
The terminal electron acceptor in the respira-
tory chain is cytochrome oxidase, which must donate its 
reducing equivalents to oxygen to sustain electron trans-
port for the production of adenosine triphosphate. The 
sequential tetravalent reduction of oxygen by the mito-
chondrial electron-transport chain is the process of aero-
bic energy production, but it can lead to the production of 
ROS (Davies 1995). 
Free radicals are molecules with at least one 
unpaired electron (Davies 1995). The superoxide anion 
(O2•
–), the hydroxyl radical (•OH), and nitric oxide (NO) 
are examples of free radicals, whereas hydrogen peroxide 
(H2O2) is not a free radical, because all of its electrons are 
paired. Together, the free radicals are termed ROS. The 
addition of one electron to oxygen produces O2•
–; adding 
a second electron leads to formation of H2O2, and a third 
electron results in the formation of •OH (Figure 7.15). 
Addition of a fourth electron to oxygen results in its full 
reduction to H2O. 
The mitochondria are a major intracellular locus 
for the generation of O2•
– (Davies 1995). A further source 
for generating O2•
– is the reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase enzymatic sys-
tem (Davies 1995; Conner and Grisham 1996). O2•
– is also 
generated by other mechanisms, including xanthine, sul-
fite, and aldehyde oxidases and metabolism of arachidonic 
acid. This anion, which is relatively unstable, has a half-
life of milliseconds. Because of its charge, O2•
– does not 
cross cell membranes easily, but it will react with proteins 
that contain transition metal groups, such as heme moi-
eties or clusters of iron sulfur. These reactions may result 
in damage to amino acids or loss of protein or enzyme 
function. The majority of O2•
– generated in vivo under-
goes reactions that are nonenzymatic or are catalyzed by 
superoxide dismutase (SOD) and produce H2O2.
H2O2 is also produced directly by several oxidase 
enzymes, including xanthine oxidase, monoamine oxi-
dase, and amino acid oxidase (Davies 1995):
O2•
– + O2•
– + 2H+ → H2O2 + O2   (2)
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H2O2 can undergo oxidation by eosinophil-specific 
peroxidase (EPO) and neutrophil-specific myeloperoxi-
dase (MPO), a reaction that uses halides (X–) as a cosub-
strate to form hypohalous acids (HOX), which are potent 
oxidants, and other reactive halogenating species:
H2O2 + X
– + H+ → HOX + H2O  (3)
where X = bromide and chloride (Davies 1995).
In a series of reactions catalyzed by transition metal 
irons, O2•
– and H2O2 react in vivo to produce •OH (Hal-
liwell and Gutteridge 1990). One such reaction is the 
iron-catalyzed Haber-Weiss reaction in which the ferric 
ion (Fe3+) is reduced to the ferrous ion (Fe2+). The Fenton 
reaction follows, as Fe2+ catalyzes the transformation of 
H2O2 into •OH:
O2•
– + Fe3+ → Fe2+ + O2
H2O2 + Fe
2+ → Fe3+ + OH– + •OH  (4)
•OH can also be formed in vivo by reactions involv-
ing MPO and EPO (Halliwell and Gutteridge 1990). In 
conditions with physiological concentrations of halides, 
MPO produces hypochlorous acid and EPO produces 
hypobromous acid. Hypochlorous acid can generate •OH 
after reacting with O2•
–: 
O2•
– + HOX → •OH + X+ + O2   (5)
•OH is the most reactive of all the radicals produced, 
reacting immediately with organic molecules at its site of 
production (Halliwell and Gutteridge 1995).
NO, which is produced endogenously throughout 
the human body, has a variety of roles. NO is produced 
from its amino acid substrate l-arginine by the reaction 
of NO synthases (NOSs) (Figure 7.16). Several forms of 
NOS have been characterized (Lowenstein and Snyder 
1992) and are classified as either constitutive or inducible 
(Nathan and Xie 1994; Wink et al. 1996). The constitu-
tive forms (NOS I and III) are cytosolic and were originally 
described and cloned from neuronal and endothelial cells, 
respectively (Nathan and Xie 1994). They are dependent 
on calcium and calmodulin and release relatively small 
amounts of NO for short periods in response to receptor 
and physical stimulation. The inducible form of NOS (NOS 
II) is independent of the calcium ion, and it generates NO 
in large amounts for long periods (Wink et al. 1996). NO 
contains an odd number of electrons and is therefore a 
radical and highly reactive in nature. 
Figure 7.15 Formation of reactive oxygen species
Source: Bowler et al. 2004. Reprinted with permission from Taylor & Francis Group, © 2004. http://www.informaworld.com.
Note: Sequential reduction of oxygen by the addition of electrons (e–) results in the formation of reactive oxygen species: superoxide 
anion (O2•
–), hydrogen peroxide (H2O2), and the hydroxyl radical (•OH). O2•
– can combine with nitric oxide (NO) to form 
peroxynitrite (ONOO–). O2•
– and the hydroxide radical OH– can initiate lipid peroxidation to form lipid peroxides (ROO•) that 
propagate free radical chain reactions. R and R   represent lipid substituent groups. H+ is a cationic hydrogen, and 2H+ represents 
2 cationic hydrogens.
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The reaction of NO with O2 results in the formation 
of nitrite (NO2
–) (Beckman and Koppenol 1996). Physi-
ological concentrations of NO and O2 may be too low for 
this reaction, but this result may have little importance in 
vivo. NO2
– is also a substrate for MPO and EPO, which cat-
alyze peroxidase-mediated oxidation and chlorination of 
biologic targets (Weiss et al. 1986). Peroxidase-catalyzed 
oxidation of NO2
– results in the formation of a nitrogen 
dioxide radical (NO2•). NO2
– is a major end product of NO 
that does not accumulate in vivo, because it is rapidly oxi-
dized to nitrate (NO3
–) (Wink et al. 1996). NO also reacts 
rapidly with free radicals to form reactive nitrogen species 
(RNS) (Parks et al. 1981; Singh and Evans 1997). One such 
reaction is that of NO with O2•
– to form the potent oxidant 
peroxynitrite (ONOO–). ONOO– is relatively stable, but it 
can be protonated to yield peroxynitrous acid (ONOOH), 
which then rapidly decomposes to NO3
– (Conner and 
Grisham 1996). ONOOH is highly reactive, unstable, and 
capable of both oxidizing and nitrating reactions. The 
amino acid tyrosine is particularly susceptible to nitration 
with the formation of free or protein-associated 3-nitroty-
rosine, which has been used as a marker for the genera-
tion of RNS in vivo (Ramezanian et al. 1996; van der Vliet 
et al. 1999).
NO also reacts with compounds containing thiol 
groups, resulting in the formation of S-nitrosothiols 
(SNOs). This reaction is considered to be the mechanism 
by which NO groups are transported and targeted to spe-
cific effector sites acting as signaling molecules (Patel 
et al. 1999). SNOs such as S-nitroso-l-glutathione may 
inhibit enzymes that respond to oxidative stress, such 
as glutathione peroxidase (GPX), glutathione reductase 
(GRX), glutathione-S-transferase (GST), and glutamate 
cysteine ligase (GCL) (Clark and Debnam 1988; Becker et 
al. 1995; Han et al. 1996). 
Antioxidants in Lungs
Although ROS and RNS have physiological func-
tions, they also have the potential to cause tissue injury. 
The balance between these physiological functions and 
the potential to cause injury or damage is determined 
by their relative rates of formation and removal (Gutter-
idge 1994). Normally, ROS and RNS are removed rapidly, 
before they produce cellular dysfunction and eventually 
cell death. An antioxidant is defined as a substrate that, 
when present at lower concentrations than those of an 
oxidizable substrate, significantly delays or inhibits oxi-
dation of that substrate. Antioxidants can be classified 
as either enzymatic or nonenzymatic (Figure 7.17). The 
enzyme antioxidants include SOD and catalase (Kinnula 
and Crapo 2003), the glutathione (GSH) redox system 
(Rahman and MacNee 2000), and the thioredoxin system 
(Arnér and Holmgren 2000).
Enzyme Antioxidants
The SOD family of enzymes is made up of ubiqui-
tous antioxidant enzymes that catalyze the dismutation 
of O2•
– into H2O2 and oxygen. Three SOD enzymes have 
been identified in mammals: manganese SOD (MNSOD), 
Figure 7.16 Synthesis of nitric oxide (NO) and related products
Note: FAD = flavin adenine dinucleotide; FMN = flavin mononucleotide; H4B = tetrahydrobiopterin; H2O = water; 




copper zinc SOD (CUZNSOD), and extracellular SOD 
(ECSOD) (McCord and Fridovich 1970; Marklund 1984; 
Oury et al. 1996). All three enzymes are expressed widely 
in human lungs (Kinnula and Crapo 2003). CUZNSOD, 
the major intracellular SOD, is present in both the cytosol 
and the nucleus of lysosomes (Slot et al. 1986) of human 
lungs. It is highly expressed in bronchial epithelium and is 
the most abundant SOD in the lungs (Lakari et al. 1998). 
MNSOD, which is localized in the mitochondria, is highly 
expressed in alveolar macrophages and type II alveolar 
epithelial cells in human lungs (Lakari et al. 1998, 2000).
ECSOD, the major extracellular SOD, is localized 
to the extracellular matrix and is particularly abundant 
in the blood vessels of the lungs, but it has also been 
found in bronchial and alveolar epithelium and in alveolar 
macrophages (Kinnula and Crapo 2003). CUZNSOD and 
MNSOD are generally considered to be the major scaven-
gers of O2•
–. ECSOD is present at relatively high concentra-
tions in the lungs, and its localization to the extracellular 
matrix suggests that it may provide an important pro-
tective mechanism in the lung matrix. Marklund (1984) 
showed that concentrations of ECSOD in the lungs were 2 
to 10 times higher than those in other solid organs. SODs 
can also be induced by cytokines and oxidants (Kinnula 
and Crapo 2003).
Catalase is a tetrameric hemoprotein that undergoes 
oxidation and reduction at its active site in the presence 
of H2O2 (Chance et al. 1979). Accordingly, it has reduc-
tive activity for small molecules, such as H2O2 and methyl 
or ethyl hydroperoxide (Pietarinen et al. 1995; Carter et 
al. 2004). Catalase does not metabolize the peroxides with 
larger molecules, such as hydroperoxide products of lip-
id peroxidation. It is expressed intracellularly, mainly in 
alveolar macrophages and neutrophils. 
The most important and abundant intracellular 
thiol antioxidant, GSH, has a critical function in main-
taining the redox status within cells, and it is involved in 
the detoxification of compounds by conjugation reactions 
through GST (Meister and Anderson 1983). The enzymes 
associated with reduced GSH metabolism include GPXs, 
GCL, and GSH synthase. 
The GSH peroxidases are a selenium-containing 
family of enzymes that play a central role in reducing 
H2O2, but they can also reduce lipid peroxides. There 
are five GPX gene products, one of which (GPX3) can be 
detected in the ELF of the human lung (Comhair et al. 
2001). GPX requires GSH to serve as an electron donor. 
The oxidized GSH that results from this reaction (oxidized 
glutathione [GSSG]) is subsequently reduced back to GSH 
by GRX, a reaction generated by NADPH from the hexose 
monophosphate shunt as an electron donor (Meister and 
Anderson 1983; Deneke and Fanburg 1989).
In healthy nonstressed cells, the intracellular ratio 
of GSH to GSSG is high, which ensures the availability 
Figure 7.17 Oxidant and antioxidant systems in the lungs
Note: Cu+ = copper ion; Fe2+ = iron ion; H2O2 = hydrogen peroxide; O2•
– = superoxide anion; •OH = hydroxyl radical.
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of GSH and thereby promotes active reduction of H2O2 
through the GSH system (Doelman and Bast 1990; Bast et 
al. 1991). GSH can also function as a water-soluble anti-
oxidant interacting directly with reactive oxygen interme-
diates in nonenzymatic catalyzed reactions. Scavenging of 
O2•
– by GSH leads to the formation of thiol radicals (GS•) 
and H2O2. Thus, a substance that is generally thought of 
as an antioxidant may possess pro-oxidant activity under 
certain conditions.
GSH is synthesized by GCL and GS (Slot et al. 1986; 
Soini et al. 2001). The rate-limiting enzyme in GSH syn-
thesis is GCL, which therefore plays a fundamental role in 
the regulation of GSH homeostasis in the lungs. GCL is 
a heterodimer with two subunits: a catalytic active heavy 
subunit and a light subunit that regulates the affinity of 
the heavy subunit for substrates and inhibitors. Both sub-
units of GCL are localized in the cytosol of cells and are 
particularly expressed in human bronchial epithelium and 
to a lesser extent in alveolar macrophages.
The fluid lining the alveolar epithelium has par-
ticularly high GSH levels. Cantin and colleagues (1987) 
estimated GSH levels in ELF specimens obtained by BAL. 
Total GSH levels in ELF, including reduced GSH and oxi-
dized GSSG, were 140 times higher than those in plasma. 
Most of the GSH was present in the reduced form. GSH 
levels were higher for smokers than for nonsmokers. 
The thioredoxin (TRX) system consists of the thio-
redoxin proteins TRX-1 and TRX-2; thioredoxin-like pro-
teins (e.g., TLX-1 and 2; SPTRX-1 and 2); thioredoxin 
reductases (e.g., TRXR-1 and 2); peroxiredoxins (PRXs, 
thioredoxin peroxidases); and glutaredoxins (Rhee et al. 
1999; Holmgren 2000; Powis et al. 2000; Gromer et al. 
2004). These enzymes are important in reducing protein 
disulfides and may have additional antioxidant proper-
ties. They protect cells against high oxygen tensions and 
participate in the proliferation and survival of cells. TRX 
and TRXR are expressed in bronchial and alveolar epithe-
lium and macrophages (Tiitto et al. 2003). Human lung 
expresses PRXs in bronchial epithelium, alveolar epithe-
lium, and macrophages (Kinnula et al. 2002).
Nonenzymatic Antioxidants
Nonenzymatic antioxidant compounds may act 
directly with oxidizing agents and are therefore said to be 
“scavengers.” Vitamin E (α-tocopherol) is a membrane-
bound antioxidant that terminates the chain reaction 
of lipid peroxidases by scavenging lipid peroxyl radicals 
(LOO•) (Bast et al. 1991; van Acker et al. 1993; Davies 
1995), thus producing the vitamin E radical, which is 
much less reactive than LOO•. At high concentrations, 
however, the radical form of vitamin E may be pro-oxidant 
(Bast et al. 1991). Vitamin C can also directly scavenge 
O2•
– and •OH to form a semidehydroascorbate free radical 
subsequently reduced by GSH (McCay 1985). Vitamin C is 
not considered a major antioxidant because it also has per-
oxide properties. Whether the pro-oxidant or antioxidant 
properties of vitamin C predominate in a particular tissue 
is determined by the available iron stores; iron overload 
favors excess generation of oxidants (Rowley and Halliwell 
1983; Bast et al. 1991).
Other nonenzymatic antioxidants include beta- 
carotene, which scavenges O2•
– and peroxyl radicals, and 
uric acid, which scavenges •OH, O2•
–, and peroxyl radi-
cals. In addition, glucose can scavenge •OH, bilirubin 
scavenges LOO•, taurine quenches hypochlorous acid, 
albumin binds transition metals, and cysteine and cyste-
amine donate sulfhydryl groups (Bast et al. 1991).
Mucin is a glycoprotein with a core rich in serine 
and threonine to which sulfhydryls are attached. The 
antioxidant properties of mucus are derived from the 
abundance of sulfhydryl moieties in its structure (Gum 
1992), which actively scavenge oxidants such as •OH 
(Cross et al. 1984, 1997). Alveolar ELF contains high 
concentrations of GSH (100-fold higher than in plasma), 
90 percent of which is in the reduced form (Cantin et al. 
1987). ELF also contains catalase, SOD, and GPX (Can-
tin and Crystal 1985). Other antioxidants in ELF include 
ceruloplasmin, transferrin, ascorbate, vitamin E, ferritin, 
albumin, and small molecules such as bilirubin (Heffner 
and Repine 1989).
The GSTs and multidrug-resistance proteins (MRPs) 
are a group of detoxifying enzymes that require intra- 
cellular GSH for catalytic activity. Researchers have 
identified three mammalian GST families (cytosolic, 
mitochondrial, and microsomal) (Hayes et al. 2005) and 
nine related MRPs (Kruh and Belinsky 2003). Both of 
these classes of detoxification enzymes are expressed in 
healthy lungs, predominantly in the airways (Anttila et 
al. 1993). They function to protect cells against oxidant-
generating compounds, drugs, and other end products of 
oxidative metabolism.
γ-glutamyltranspeptidase (γGT), an enzyme in plas-
ma membrane is expressed in lung epithelial cells and 
induced by oxidative stress (Kugelman et al. 1994). GSH 
is not freely diffusible into cells because it must first be 
broken down into its amino acids. γGT breaks down the 
γ-glutamyl bond of GSH. Heme oxygenase-1 is a stress 
response protein with important functions in cell protec-
tion and homeostasis; this enzyme can also be induced by 
oxidants and cytokines (Choi and Alam 1996).
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Oxidants and Cigarette Smoke
Cigarette smoke is a complex mixture of more than 
4,700 chemical compounds, including free radicals and 
other oxidants at high concentrations (Church and Pryor 
1985; Pryor and Stone 1993). Among the reported conse-
quences of oxidants in cigarette smoke are direct damage 
to lipids, nucleic acids, and proteins; depletion of antioxi-
dants; and enhancement of the respiratory burst in phago-
cytic cells (Bowler et al. 2004; MacNee 2005a). Inactivation 
of proteases and enhancement of molecular mechanisms 
involved in the expression of proinflammatory mediator 
genes are other oxidant-induced effects.
Cigarette smoke is often separated into two phases 
(tar and gas), which both contain free radicals. The gas 
phase is less stable and contains approximately 1015 
radicals per puff; and the more stable tar phase has been 
estimated to contain more than 1017 free radicals per 
gram (Zang et al. 1995). Short-lived oxidants, such as 
O2•
– and NO, are predominantly found in the gas phase 
(Pryor and Stone 1993). NO and O2•
– immediately react 
to form the highly reactive ONOO− molecule. NO is pres-
ent in cigarette smoke at concentrations of 500 to 1,000 
parts per million. Free radicals in the tar phase of cigarette 
smoke, such as the long-lived semiquinone radical (Q•–), 
are organic and can react with O2•
– to form •OH and H2O2 
(Nakayama et al. 1989). Q•– is an example of a radical in 
the tar phase of cigarette smoke that can reduce oxygen 
to produce superoxide, the •OH, and H2O2. The aque-
ous phase of cigarette smoke condensate may undergo 
redox recycling for a considerable time in ELF of smokers 
(Nakayama et al. 1989; Zang et al. 1995). The tar phase of 
cigarette smoke is also an effective metal chelator and can 
bind iron to produce tar-semiquinone + tar-Fe2+, which 
can generate H2O2 continuously.
Quinone (Q), hydroquinone (QH2), and Q•
– in 
the tar phase are present in equilibrium (Pryor and 
Stone 1993):
Q + QH2 → 2H
+ + Q•–   (6)
Aqueous extracts of cigarette tar contain Q•–. This 
radical can reduce oxygen to form O2•
–, which may dis-
mutate to form H2O2:
Q•– + O2  →  Q + O2•–    (7)
2 O2•
– + 2H+  →  O2 + H2O2   (8)
In addition, cigarette tar and lung ELF contain 
metal ions such as iron. In these circumstances, the Fen-
ton reaction results in the production of •OH. Cigarette 
smokers deposit up to 20 mg of tar per day (≤1 gram per 
day) in their lungs per cigarette smoked. 
Cell-Derived Oxidants
In smokers, inflammation is a characteristic feature 
of the lungs and other organs (Saetta et al. 2002; Bowler et 
al. 2004; Di Stefano et al. 2004). This inflammation gener-
ates additional oxidants that contribute to oxidative stress. 
Alveolar macrophages obtained by BAL from the lungs of 
smokers are more activated than those obtained from the 
lungs of nonsmokers (Schaberg et al. 1992). One conse-
quence of this activation is the release of higher levels 
of ROS, such as O2•
– and H2O2, thereby further increas-
ing the oxidative burden produced directly by inhaling 
cigarette smoke. Exposure to cigarette smoke in vitro has 
also been shown to increase the oxidative metabolism of 
alveolar macrophages (Hoidal et al. 1981). Subpopulations 
of higher-density alveolar macrophages, which are more 
common in the lungs of smokers, may be responsible for 
the increased production of O2•
– that occurs in the mac-
rophages of smokers (Schaberg et al. 1995).
Lung epithelial cells are another source of ROS. 
Type II alveolar epithelial cells have been shown to release 
both H2O2 and O2•
– in quantities similar to the amounts 
released by alveolar macrophages (Rochelle et al. 1998). 
ROS released from type II cells are able, in the presence 
of MPO, to inactivate AAT in vitro (Wallaert et al. 1993).
ROS can also be generated intracellularly from sev-
eral sources, such as mitochondrial respiration, which is 
the largest source of free radicals. In the mitochondria, 
electrons leak from the electron-transport chain onto 
oxygen to form O2•
– (Halliwell and Gutteridge 1990). A 
further significant cytosolic source of superoxide is the 
enzyme xanthine dehydrogenase, which has been shown 
to be present at higher levels in cell-free BAL fluid in 
patients with COPD than in that of healthy persons, in 
association with increased production of superoxide and 
uric acid (Pinamonti et al. 1996). A substantial amount of 
superoxide is also produced by membrane oxidases, such 
as cytochrome P-450 and the NADPH oxidase system. In 
addition, NO is generated from arginine by the action of 
NOS. Depending on the relative amounts of ROS and RNS, 
particularly superoxide and NO, which are almost always 
produced simultaneously at sites of inflammation, these 
species can react together to produce the powerful oxidant 
ONOO− (Beckman and Koppenol 1996). The generation of 
ONOO− is thought to prolong the action of NO and to be 
responsible for most of the adverse effects of excess gen-
eration of NO.
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Assessment of Oxidative Stress
Oxidative stress can be measured by direct measure-
ments of the oxidative burden, indirectly as the responses 
to oxidative stress, and by examining the effects of oxida-
tive stress on target molecules (Table 7.4). Assessments of 
the oxidative burden in the air spaces can be derived by 
measuring H2O2 in BAL fluid or in exhaled breath conden-
sate (Dekhuijzen et al. 1996; Nowak et al. 1998). Air space 
leukocytes obtained by BAL can be assessed ex vivo for 
the ability to produce ROS. Spin trapping, a technique in 
which a radical reacts with a more stable molecule, can be 
used to measure oxidants in biologic systems; spin trap-
ping has shown increased ROS in the BAL fluid from pa-
tients with COPD (Pinamonti et al. 1998). NO is produced 
in the lungs by the catalytic activity of NOS as a marker 
of inflammation and indirectly as a marker of oxidative 
stress, and it can be measured in exhaled breath. Among 
the indirect measures for assessing oxidative stress is an 
examination of the increased activity of the hemoxygenase 
system, which is reflected in the carbon monoxide levels 
in exhaled breath. Assessment of the effects of oxidative 
stress on target molecules may include measuring the 
reaction of ROS with lipids, proteins, or nucleic acids to 
form markers of oxidative stress. For example, ROS at-
tack proteins to form protein carbonyls, ONOO− reacts 
with tyrosine to form nitrotyrosine, and ROS react with 
lipids to liberate ethane and isoprostane and with DNA to 
form base-paired adducts (e.g., 7-hydroxy-8-oxo-2’-deoxy-
guanosine) or with GSH to produce oxidized GSH. These 
markers can be measured in blood, breath condensate, 
BAL fluid, and lung tissue as an indicator of the effects of 
free radicals on target molecules.
Evidence of Smoking-Induced 
Oxidative Stress
In Vitro Studies
Studies have examined the consequences of acute 
(short-term) exposure to cigarette smoke for a wide range 
of cells (Table 7.5). Many studies have focused on oxida-
tive stress and have shown an increase in markers of such 
stress after exposure to whole cigarette smoke or con-
densate of cigarette smoke. The cell types studied have 
included alveolar macrophages, type II alveolar epithelial 
cell lines consisting largely of A549 cells, and neutrophils. 
For exposure to cigarette smoke, most of the studies have 
used cigarette smoke extract (CSE) as the exposure agent; 
a smaller number have used cigarette smoke. The con-
centrations of CSE and the duration of exposure have dif-
fered among studies, and concentrations of CSE from that 
produced by one cigarette per milliliter to that produced 
by four cigarettes per milliliter. The exposure times have 
varied between 1 second and 24 hours. All of the studies 
have shown that acute exposure to cigarette smoke causes 
increased oxidative stress.
Exposure of plasma to cigarette smoke in vitro 
depletes antioxidants, including vitamin C, ubiniquol-10, 
α-tocopherol, cryptoxanthin, retinol, and beta-carotene 
and leads to lipid peroxidation (Eiserich et al. 1995; Han-
delman et al. 1996; Scott et al. 2005). In vivo, smokers 
are well documented to have lower serum levels of vita-
min C and beta-carotene and perhaps α-tocopherol than 
do nonsmokers (Tribble et al. 1993; Faruque et al. 1995; 
Adams et al. 1997; Lykkesfeldt et al. 1997; Motoyama et 
al. 1997; Munro et al. 1997; Alberg 2002; Northrop-Clewes 
and Thurnham 2007). This relationship between smoking 
status and reduced vitamin C levels may be dose related 
(Tribble et al. 1993; Faruque et al. 1995; Marangon et al. 
1998). The hypothesis was that reduced levels of vitamin C 
in smokers are due to the activation of leukocytes and sub-
sequent generation of ROS (Winklhofer-Roob et al. 1997).
Table 7.4 Measurements of oxidative stress
Direct measurements of oxidative burden
Hydrogen peroxide in breath condensate or BAL fluid
Reactive oxygen species in BAL fluid and peripheral blood 
leukocytes 
Nitric oxide in exhaled breath
Responses to oxidative stress
Carbon monoxide in breath, reflecting hemoxygenase 
activity
Antioxidants, antioxidant enzymes in blood, sputum, BAL 
fluid, and lung tissue
Effects of oxidative stress on target molecules
Oxidized proteins (e.g., carbonyl residues and oxidized and 
nitrated proteins)
Lipid peroxidation products (e.g., F2-isoprostanes and  
4-hydroxy-2-nonenal)
DNA oxidation products (e.g., 8-hydroxy-2’-deoxyguanosine)
Hydrocarbons in breath condensate, sputum, BAL fluid, 
blood, urine, and lung tissue
Note: BAL = bronchoalveolar lavage. 
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GSSG, the oxidized form of GSH, is released from 
endothelial cells after 30 minutes of exposure to ciga-
rette smoke (Noronha-Dutra et al. 1993). Although 
intracellular GSH decreased within 3 hours of exposure 
to cigarette smoke (Bridgeman et al. 1991; Li et al. 1994; 
Carnevali et al. 2003), GSH and GCL increased 24 hours 
after exposure. This finding suggests a protective cellu-
lar mechanism against the oxidative stress induced by 
cigarette smoke (Rahman et al. 1996b). Immediately after 
exposure to six puffs of cigarette smoke, H2O2 and super-
oxide molecules were detected in the membranes of epi-
thelial cells in the tracheal explant model (Hobson et al. 
1991), but this consequence of exposure was prevented by 
antioxidants. Twenty-four hours after exposure to CSE, NO 
was released from endothelial cells (Tuder et al. 2000). In 
contrast, inducible NOS (INOS) expression and release of 
nitrate from epithelial cells exposed to CSE were decreased 
(Hoyt et al. 2003). Exposure to cigarette smoke was also 











measurement Effect of smoking
Kharitonov 
et al. 1995
17 smokers 8 hours 1 5 and 15 
minutes
Exhaled air: ENO decreased after 5 minutes  
(65 ± 6.3 to 44 ± 6.4 ppb); returned to control 











Unknown 1 60 minutes Blood: TEAC decreased; TBARS increased
Chambers 
et al. 1998
24 smokers 1 hour 1 1  and 10 
minutes





12 hours 2 60 minutes BAL fluid: leukocyte superoxide anions 
increased; TBARS showed no significant 
change; TEAC increased; glutathione showed 
no significant change; oxidized glutathione 
showed no significant change; neutrophils 
increased





10 nonsmokers  




12 smokers 12 hours 2 15 hours Breath condensate: 8-isoprostane increased 
after 15 minutes; no significant change after 
5 hours




4 hours 2 30 and 90 
minutes
Breath condensate: nitrate + nitrite increased 
after 30 minutes; no significant change after 
90 minutes; nitrite, peroxynitrite, and ENO 
showed no significant change
Tsuchiya et 
al. 2002
20 smokers 6 hours 1 5 and 60 
minutes
Blood: nitrate, nitrite, ascorbic acid, cysteine, 
methionine, and uric acid decreased after  
5 minutes; no significant change after  
30 minutes
Source: Adapted from van der Vaart et al. 2004 with permission from BMJ Publishing Group Ltd., © 2004.
Note: BAL = bronchoalveolar lavage; ENO = exhaled nitric oxide; ppb = parts per billion; TBARS = thiobarbituric acid reactive 
substances; TEAC = trolox equivalent antioxidant capacity.
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shown to activate the pentose phosphate pathway, which 
is a source of NADPH for the enzyme GRX in endothe-
lial cells (Noronha-Dutra et al. 1993). The activities of the 
main enzymes in the GSH redox cycle have been shown to 
be decreased by the acute exposure of alveolar epithelial 
cells to cigarette smoke (Rahman et al. 1996a). Cigarette 
smoke causes depletion of intracellular GSH in cultured 
airway epithelial cells and transient decreases in GPX 
and glucose-6-phosphate activities (Rahman et al. 1998). 
Exposure to cigarette smoke also causes an increase in the 
expression of GPX (Rahman and MacNee 1999). In vitro 
studies also suggest that after initial GSH depletion, GSH 
levels increased, apparently due to GCL induction (Rah-
man et al. 1996a). Exposure of neutrophils and alveolar 
macrophages to cigarette smoke produces morphologic 
changes in the cells that result in cell blebbing, which 
indicates oxidant-induced damage (Lannan et al. 1994).
Animal Studies
Several studies have assessed the short-term effects 
of the inhalation of cigarette smoke on markers of oxida-
tive stress in lung tissue, BAL fluid, and blood in animals 
(Table 7.6). These studies have found increased levels of 
oxidative stress after such exposure.
GSH, the major thiol antioxidant in the lungs, rap-
idly and immediately decreases in the lung tissue of rats 
and other laboratory animals after exposure to cigarette 
smoke (Cotgreave et al. 1987; Bilimoria and Ecobichon 
1992; Ishizaki et al. 1996; Li et al. 1996). GSH levels 
may return to normal by two to six hours after exposure 
to smoke (Cotgreave et al. 1987; Bilimoria and Ecobi-
chon 1992) or may remain at levels higher than baseline 
(Ishizaki et al. 1996). GSSG levels increased 1 hour after 
exposure to smoke in animal models and decreased at 
6 hours after acute exposure, returning to normal levels 
after 24 hours (Li et al. 1996). Acute exposure to cigarette 
smoke in rats did not produce any change in the amount 
of cysteine in the lungs; cysteine is an essential amino 
acid for the synthesis of GSH (Cotgreave et al. 1987). 
Other markers of oxidative stress, including 4-hydroxy-2- 
nonenal (4-HNE) and 8-hydroxy-2’-deoxyguanosine 
(8-OH-dG), were elevated in lung tissue after acute expo-
sure to cigarette smoke (Ishizaki et al. 1996; Aoshiba et 
al. 2003a). Furthermore, INOS messenger RNA (mRNA) 
and endothelial NOS are increased after acute exposure to 
cigarette smoke (Wright et al. 1999).
ELF is the initial target for oxidative stress, and 
extracellular GSH levels obtained by BAL in rats were 
reduced immediately (Cotgreave et al. 1987) and remained 
at reduced levels six hours after smoke inhalation (Li et al. 
1996). Twenty-four hours after acute exposure to cigarette 
smoke, GSH concentrations return to baseline values (Li 
et al. 1996). Evidence indicates that short-term cigarette 
smoking depletes intracellular GSH concentrations (Cot-
greave et al. 1987) and increases levels of GSSG (Cavarra 
et al. 2001b) and 8-OH-dG (Aoshiba et al. 2003a) that are 
associated with decreased antioxidant capacity in BAL 
fluid (Cavarra et al. 2001b). Evidence of systemic oxida-
tive stress has been shown in animal models after acute 
exposure to cigarette smoke, as shown by a decrease in 
antioxidants (Uotila 1982; Ishizaki et al. 1996). This find-
ing is associated with an increase in products of lipid per-
oxidation such as 8-epi-prostaglandin2α in blood (Cavarra 
et al. 2001b).
Consequences of Smoke-Induced 
Oxidative Stress
Epithelial Injury
Among the first injurious effects of cigarette smoke 
on the lungs is an increase in epithelial permeability, 
which has been demonstrated in animal models (Li et al. 
1994). In the lung tissue of rats, increased epithelial per-
meability is associated with a decrease in GSH levels and 
an increase in GSSG levels. Depletion of GSH in the lungs 
increased epithelial permeability both in vivo and in vitro 
with use of cultured epithelial monolayers (Li et al. 1994).
Inflammatory Responses
Oxidative stress has been shown to enhance gene 
expression of proinflammatory mediators through the 
redox-sensitive transcription factors nuclear factor-kappa 
B (NF-kB) and activator protein-1 (AP-1). Animal stud-
ies have shown enhanced NF-kB nuclear binding after 
exposure to cigarette smoke, which was associated with 
increased gene expression and protein release of proinflam-
matory cytokines (Nishikawa et al. 1999). Furthermore, 
the molecular mechanisms associated with enhanced 
inflammatory responses after exposure to cigarette smoke 
are thought to involve an increase in histone acetylation 
and decreased histone deacetylase (HDAC) activity, result-
ing in enhanced histone acetylation, unwinding of chro-
matin, and hence, enhanced gene expression (Marwick et 
al. 2004). These effects have been demonstrated in animal 
models of exposure to cigarette smoke.
Susceptible Animal Models
The role of oxidative stress in the development of 
lung disease induced by cigarette smoke has been demon-
strated in animal models: increasing oxidative stress has 
led to higher frequency of emphysema induced by ciga-
rette smoke. NRF-2 is a controlling transcription factor 
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Table 7.6 Studies of oxidative stress in animals exposed to smoke





























Experiment 1a—Blood: MUG 
increased after 20 hours







8 1 hour 0 hours Nose only BAL fluid: intracellular GSH 
decreased; free GSH decreased; 
extracellular GSH decreased
Blood: GSH showed no significant 
change; cysteine increased















NR 0, 3, and 6 
hours
Nose only Lung homogenate: GSH 
decreased at 0 hours in rats 
but only at high exposures in 
guinea pigs; levels returned to 
preexposure within 3 hours






7 2 hours 24 hours Nose only Lung homogenate CNOS mRNA 
and protein showed no significant 
change; INOS mRNA increased, 
protein showed no significant 
change; ENOS mRNA increased, 
















BAL fluid at 0 hours: trolox 
equivalent antioxidant capacity 
decreased, levels returned to  
preexposure within 20 minutes;
glutathione disulfide increased;
ascorbic acid decreased; protein 
thiols decreased; neither 
total glutathione nor vitamin 
E showed any significant 
change; 8-epi-PGF2α increased; 
prevented in a subgroup of case/
controls by pretreatment with 
N-acetylcysteine  
Plasma: 8-epi-PGF2α increased 
at 0, 20, and 60 minutes; total 
cell count, alveolar macrophages, 
polymorphonuclear neutrophils, 
and lymphocytes showed no 
significant change; human 
secretory leukoprotease inhibitor 
inactivated
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Lung tissue: 8-oxo-dG and 4-HNE 
increased after 1 hour in bronchial 
epithelial cells and type II alveolar 
cells; cellularity increased after 
1–16 hours  
BAL fluid: 8-oxo-dG levels 
increased after 1 hour; no 
significant change after 24 hours
Source: Adapted from van der Vaart et al. 2004 with permission from BMJ Publishing Group Ltd., © 2004.
Note: 4-HNE = 4-hydroxy-2-nonenal; 8-epi-PGF2α = 8-epi-prostaglandin F2α; 8-oxo-dG = 7-hydroxy-8-hydroxy-2’-deoxyguanosine; 
BAL = bronchoalveolar lavage; CNOS = constitutive nitric oxide synthase; ENOS = endothelial nitric oxide synthese; GSH = reduced 
glutathione; INOS = inducible nitric oxide synthase; mRNA = messenger RNA; MUG = methylumbelliferyl glucuronide; NR = data not 
reported.
aLungs were isolated, ventilated with cigarette smoke, and perfused with 4-MUG.
bIsolated lungs were simultaneously ventilated with cigarette smoke and perfused with MUG.
for the expression of antioxidant genes. In NRF-2 knock-
out mice, exposure to smoke produced more evidence of 
oxidative stress in the lungs, which was associated with 
an increased inflammatory response and enhanced devel-
opment of emphysema compared with those in wild-type 
mice (Foronjy et al. 2006). Furthermore, a transgenic ani-
mal that overexpressed SOD showed diminished smoke-
induced emphysema. These findings suggest a role for 
oxidative stress in the development of emphysema (Ran-
gasamy et al. 2004).
Antioxidants have been shown to reduce the effects 
of oxidative stress after exposure to cigarette smoke. The 
thiol antioxidants nacystelyn and N-acetylcysteine have 
each been used to reduce the inflammatory responses after 
exposure to cigarette smoke and also the injurious effects, 
principally emphysema (Antonicelli et al. 2004; Rubio et 
al. 2004). After exposure to cigarette smoke, recombinant 
SOD has been shown to reduce the inflammatory response 
in several ways: by decreasing the inflammatory response 
in the lungs, reducing the influx of neutrophils, decreas-
ing IL-8 gene expression and release, and decreasing 
NF-kB activation (Nishikawa et al. 1999).
Human Studies
Several studies have shown evidence of both 
local and systemic oxidative stress in humans after acute 
exposure to cigarette smoke (Table 7.7). Some studies 
were undertaken in long-term smokers with normal lung 
function, and some have been performed in smokers who 
were instructed to refrain from smoking before the acute 
exposure at intervals between 7 and 24 hours. Reports 
of other studies have not provided information on 
abstention, and in some studies, the participants were not 
instructed to refrain from smoking.
Local Oxidative Stress in Lungs
The acute effects of cigarette smoking on oxidative 
stress have been assessed with markers in exhaled air, 
BAL fluid, and blood. Most of these studies have shown an 
immediate increase in oxidative stress after acute expo-
sure, but some have shown no effect (Table 7.7). Five stud-
ies have described the effects of acute exposure to cigarette 
smoke on markers of oxidative stress in breath condensate 
or exhaled air. In breath condensate, the lipid peroxida-
tion product 8-isoprostane increased 15 minutes after 
acute exposure (Montuschi et al. 2000). In addition, lipid 
peroxides have been shown to increase in exhaled breath 
30 minutes after exposure to smoke (Guatura et al. 2000). 
Furthermore, exhaled NO has been shown to increase 1 
and 10 minutes after acute exposure to smoke (Chambers 
et al. 1998), but in another study it decreased 5 minutes 
after exposure (Kharitonov et al. 1995). The inconsistency 
between these studies probably relates to differences in 
the measurements of exhaled NO and among the groups 
studied. High levels of exhaled NO have not been observed 
at time points after exposure (15, 30, and 90 minutes) 
(Kharitonov et al. 1995; Balint et al. 2001). Nitrate, an end 




Table 7.7 In vitro studies of oxidative stress











measurement Effect of smoke exposure
Powell and 
Green 1971
Rabbit AMs CSE NR NR NR G3PD activity in AMs decreased, effect 
prevented by cysteine; G6PD and LDH 







CS 1, 3, and 5 
puffs
NR NR Intracellular GSH decreased, not 









40 minutes Hydrogen peroxide and O2  
– increased 
along epithelial cell membranes, 
prevented by SOD
3 and 6 puffs: cell separation, focal 




Rat PMNs CSE 1 20 
minutes
20 minutes Radical oxidant scavenger production 
from PMNs decreased, prevented by 
SOD; oxygen consumption from PMNs 
increased
Noronha-
Dutra et al. 
1993
HUVEC CSE 0.5 30 
minutes
30 minutes Pentose phosphate pathway activated; 
GSSG release increased
Li et al. 
1994
A549 cell line CSE 1 1–6 hours 1, 4, 6, and 24 
hours
Epithelial permeability increased 
at 1 hour, prevented by GSH, no 
significant change 24 hours after 
wash; intracellular GSH decreased, no 
significant change 24 hours after wash
Rahman et 
al. 1996b
A549 cell line CSE 1 puff/3 mL 4, 16, or 
28 hours
0 hours Intracellular CSE GSH increased after 
24 hours; GSSG no significant change; 
γGCS activity increased; γGCS-HS 
mRNA increased






CSE 0, 0.006, 
0.024
Overnight Directly after O2  
– production showed no significant 
change; HSP 70 increased; membrane 
pseudopodes decreased; submembrane 
vacuoles increased; surfactant 
prevented CSE effects 









CSE 0.1 24 hours 24 hours VEGF decreased protein and mRNA in 
all cells except A549 cell line;
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Table 7.7 Continued











measurement Effect of smoke exposure







4 and 24 
hours
24 hours Nitrate decreased at 4 and 24 hours in 
all cell types; INOS-positive LA-4 cells 
decreased at 24 hours; INOS mRNA 
decreased; ENOS and NNOS mRNA 
showed no change in LA-4 cells; ENOS 




RPMEC CSE 20 µg/mL 4 and 24 
hours
4 and 24 hours XO activity increased at 4 and 24 






CSE 0.05–0.1 24 hours 24 hours Necrosis increased, no apoptosis;a
GSH inhibits necrosis and apoptosis  
(Jurkat cells); GSH/GSSG decreased 
intracellularly; inhibition CASPASE-3 
activation (Jurkat cells)
Source: Adapted from van der Vaart et al. 2004 with permission from BMJ Publishing Group Ltd., © 2004.
Note: A549 = human lung adenocarcinoma epithelial cell line; AMs = alveolar macrophages; CS = cigarette smokers;  
CSE = cigarette smoke extract; G3PD = glyceraldehyde 3-phosphate dehydrogenase; G6PD = glucose 6-phosphate dehydrogenase; 
γGCS = gamma-glutamylcysteine synthetase; γGCS-HS = gamma-glutamylcysteine synthetase heavy subunit; GSH = reduced 
glutathione; GSSG = oxidized glutathione; HBEC = human bronchial epithelial cells; Hep G2 = human hepatocellular carcinoma cell 
line; HSP 70 = heat shock protein 70; HUVEC = human umbilical vein endothelial cells; INOS = inducible nitric oxide synthase; 
LA-4 = mouse lung epithelial cell line; LDH = lactate dehydrogenase; mL = milliliter; µg = microgram; mRNA = messenger RNA; 
NNOS = neuronal nitric oxide synthase; NR = data not reported; O2•
– = superoxide anion; PMN = polymorphonuclear neutrophil; 
RPMEC = rat pulmonary microvascular endothelial cells; SOD = superoxide dismutase; U937 = human leukemic monocyte 
lymphoma cell line; VEGF = vascular endothelial growth factor; XO = xanthine oxidase.
aLight microscopy, TUNEL (terminal dUTP nick-end labeling) assay, electron microscopy.
but nitrite and nitrotyrosine, which are also products 
of NO metabolism, did not increase (Balint et al. 2001). 
In humans, all the oxidative markers of oxidative stress 
increase within the first hour after acute exposure, and 
most markers return to normal within 90 minutes (van 
der Vaart et al. 2004). 
Only one study has investigated the effects of smok-
ing on markers of oxidative stress in ELF or BAL fluid. 
In this study, release of O2•
– by air space leukocytes 
increased after exposure to smoke (Morrison et al. 1999). 
In addition, systemic antioxidant capacity decreased, as 
measured by the Trolox Equivalent Antioxidant Capacity 
(Rahman et al. 1996a; Morrison et al. 1999). Surprisingly, 
however, the antioxidant capacity in BAL fluid increased 
after exposure to smoke, possibly because all of the par-
ticipants were long-term smokers and already had a high 
antioxidant capacity in BAL fluid. After smoking, no differ-
ences were observed in levels of reduced or oxidized GSH 
in leukocytes or in thiobarbituric acid reactive substances 
(TBARS), as evidenced by measuring lipid peroxidation in 
BAL fluid or in ELF. 
Systemic Oxidative Stress
After just one cigarette has been smoked, nitrite, 
nitrate, and cysteine decrease in peripheral blood (Tsuchi-
ya et al. 2002). In a study by Hockertz and colleagues 
(1994), no differences were observed in the production 
of reactive oxygen intermediates from circulating neu-
trophils after exposure to smoke, but an earlier study 
gave conflicting findings (Drost et al. 1992). In contrast 
to levels in BAL fluid, TBARS in plasma increased after 
exposure to smoke and antioxidant capacity was decreased 
when measured within one hour after smoking (Rahman 
et al. 1996a; Tsuchiya et al. 2002). However, in smokers, 
levels of the lipid peroxidation product F2-isoprostane 
did not change in plasma after exposure to smoke (Mor-
row et al. 1995), possibly because all participants were 
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long-term smokers who had already developed high 
F2-isoprostane levels.
Epithelial Injury 
Increased epithelial permeability, which can be 
measured by 99mTc-DTPA lung clearance (Morrison et al. 
1998a), has been shown to increase in cigarette smokers 
one hour after exposure to smoke (Morrison et al. 1999). 
Another study (Gil et al. 1995), however, showed no dif-
ference in epithelial permeability 15 minutes after expo-
sure to cigarette smoke in long-term smokers. Epithelial 
permeability, measured by radiolabeled urea, decreased 
after acute exposure to cigarette smoke (Ward et al. 2000), 
but no differences could be detected when measurements 
were made by positron emission tomography scanning 
with use of radiolabeled transferrin (Kaplan et al.1992). 
Inflammatory Responses 
The numbers of neutrophils in the blood and BAL 
fluid from long-term smokers are higher than in those 
from nonsmokers (Hunninghake and Crystal 1983; Kus-
chner et al. 1996; van Eeden and Hogg 2000). Findings on 
the effect of short-term cigarette smoking on the number 
of neutrophils in BAL fluid have been inconsistent. Some 
studies reported an increase (Morrison et al. 1999), and 
others reported no change (Janoff et al. 1983b). Exposure 
to smoke has not been shown to change the number of 
monocytes or the total number of leukocytes in BAL fluid 
(Janoff et al. 1983b). However, counts of peripheral blood 
granulocytes increase after acute exposure to cigarette 
smoke (Winkel and Statland 1981; Abboud et al. 1986; 
Hockertz et al. 1994), and counts of peripheral blood 
eosinophils decrease after such exposure (Winkel and 
Statland 1981). Acute exposure to cigarette smoke has 
also been shown to reduce the number of B cells (Hock-
ertz et al. 1994) and the total number of lymphocytes in 
peripheral blood (Winkel and Statland 1981). In contrast, 
the number of CDB-positive cells and the ratio of CD4+ to 
CD8+ cells are not affected by acute exposure to cigarette 
smoke (Hockertz et al. 1994). In capillary blood, the total 
number of basophils decreased 10 minutes after the smok-
ing of two cigarettes (Walter and Nancy 1980), and the 
number of degranulated basophils increased (Walter and 
Walter 1982).
Neutrophil kinetics in the lungs have been examined 
after exposure to cigarette smoke by using an assessment 
of the first pass of radiolabeled neutrophils through the 
pulmonary circulation. Retention of neutrophils in the 
lungs increased after acute exposure to cigarette smoke 
(MacNee et al. 1989). This increased retention was not due 
to an alteration of pulmonary hemodynamics (Skwarski 
et al. 1993) but resulted from decreased deformability of 
leukocytes (Drost et al. 1993) and/or the increased expres-
sion of the adhesion molecule l-selectin in blood neutro-
phils after acute exposure to cigarette smoke (Patiar et al. 
2002).
After acute exposure to cigarette smoke, changes in 
GSH have been studied in human, animal, and in vitro 
models. The ratio of GSH to GSSG, which reflects oxida-
tive stress, has been shown to decrease after acute expo-
sure in both animal and in vitro studies but not in a single 
human study (Morrison et al. 1999). This discrepancy may 
be explained by differences in species and dose of smoke 
and differences between human BAL fluid and animal 
lung homogenate. 
Exposure to cigarette smoke has been shown to 
damage fatty acids in cell membranes and thereby re-
sult in increased products of lipid peroxidation both in 
humans, as seen in exhaled air and plasma (Rahman et al. 
1996a; Montuschi et al. 2000), and in animals, as seen in 
BAL fluid and lung tissue (Ishizaki et al. 1996; Aoshiba et 
al. 2003a).
Summary
The time courses of the changes in markers of oxi-
dative stress after exposure to smoke have been studied in 
humans and in animal models. In humans, all the oxida-
tive markers of oxidative stress increase within the first 
hour after acute exposure, and most markers return to 
normal quickly. In animal models, markers of oxidative 
stress generally increase during the first 6 hours after 
exposure to cigarette smoke and return to normal by 24 
hours. These findings have been demonstrated in lung tis-
sue, BAL fluid, and blood. In studies with in vitro models, 
only a few time points have been examined. Initial deple-
tion of GSH after acute exposure to cigarette smoke is fol-
lowed in most cases by an increase in GSH 24 hours later. 
This finding suggests a protective mechanism against oxi-
dative stress from smoke that may reflect the increase in 
GSH seen in long-term cigarette smokers. 
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Oxidative Stress in Chronic Obstructive Pulmonary Disease
There is considerable evidence, largely indirect, for 
increased oxidative stress in the lungs of COPD patients. 
As explained previously, oxidative stress can be measured 
in several ways, including direct measurements of oxi-
dant burden, indirect measures using response to oxida-
tive stress, and measurements of the effects of oxidative 
stress on target molecules (see “Assessment of Oxidative 
Stress” earlier in this chapter). Spin trapping, a technique 
by which a radical reacts with a more stable molecule, can 
be used to measure oxidants in biologic systems. The tech-
nique of spin trapping has been applied to measure BAL 
fluid in patients with COPD and has shown increased ROS 
(Pinamonti et al. 1998).
Numerous studies have shown that markers of oxi-
dative stress are increased in the lungs of COPD patients 
compared not only with those in healthy persons but also 
with those in smokers having a similar smoking history 
who have not developed COPD (MacNee 2000). Patients 
with COPD have higher levels of H2O2 in exhaled breath 
condensate, a direct measurement of air space oxidative 
burden, than do former smokers with COPD or nonsmok-
ers (Dekhuijzen et al. 1996; Nowak et al. 1998). Elevat-
ed levels of H2O2 in the exhaled breath of smokers are 
thought to derive partly from increased release of O2•
– by 
alveolar macrophages (Hoidal et al. 1981).
NO has been used as a marker of airway inflam-
mation and indirectly as a measure of oxidative stress. 
Increased NO in exhaled breath has been seen in some 
studies of patients with COPD, but the levels are not as 
high as those reported in asthma (Maziak et al. 1998; Del-
en et al. 2000). Other studies have found either normal or 
even lower-than-normal levels of exhaled NO in patients 
with stable COPD compared with those in healthy persons 
(Clini et al. 1998; Rutgers et al. 1999). Smoking directly 
increases exhaled NO levels, however, thereby limiting 
the usefulness of this marker in COPD. The rapid reac-
tion of NO with O2•
–, described previously, or with thiols 
may alter NO levels in breath (see “Generation of Reactive 
Oxygen Species” earlier in this chapter). Nitrosothiol lev-
els have been shown to be higher in breath condensate in 
smokers and in COPD patients than those in nonsmokers 
(Corradi et al. 2001). ONOO−, formed by the reaction of 
NO with O2•
–, can cause nitration of tyrosine to produce 
nitrotyrosine (Petruzzelli et al. 1997). Nitrotyrosine levels 
are elevated in sputum leukocytes of patients with COPD, 
and they are correlated negatively with FEV1 (Ichinose et 
al. 2000).
Exhaled carbon monoxide, as a measure of the 
response of heme oxygenase to oxidative stress, has been 
shown to be elevated in exhaled breath in persons with 
COPD compared with that in persons without COPD 
(Montuschi et al. 2001). Carbon monoxide is also present 
in cigarette smoke, however, which limits its usefulness as 
a marker of oxidative stress in persons who smoke. 
Lipid peroxidation products such as TBARS or 
malondialdehyde are elevated in sputum from COPD 
patients, and the levels correlate negatively with FEV1 
(Nowak et al. 1999; Tsukagoshi et al. 2000; Corradi et al. 
2003). Urinary levels of 8-isoprostane, another lipid per-
oxidation product, are also higher in persons with COPD 
(Praticò et al. 1998). Levels of 8-isoprostane in breath 
condensate are also higher in persons with COPD than 
in healthy persons and smokers who have not developed 
the disease, and they correlate with the degree of airway 
obstruction (Paredi et al. 2000a). Isoprostanes may also 
reflect systemic effects caused by ROS (Morrow et al. 
1995). Plasma levels of free F2-isoprostanes are higher in 
smokers than in nonsmokers and are decreased after ces-
sation of smoking. 
Lipid peroxides can interact with enzymatic or 
nonenzymatic antioxidants and can decompose by react-
ing with metal ions or iron-containing proteins, thereby 
forming hydrocarbon gases and unsaturated aldehydes. 
Hydrocarbons are thus by-products of fatty acid peroxi-
dation (Paredi et al. 2000b). COPD patients have higher 
levels of exhaled ethane in breath than do persons in the 
control group, and these levels correlate negatively with 
lung function (Habib et al. 1995; Paredi et al. 2000b).
There is evidence that concentrations of these mark-
ers of oxidative stress are also increased in the lung tissue 
of COPD patients. The lipid peroxidation product 4-HNE 
reacts quickly with extracellular proteins to form adducts, 
which have been shown to be present at higher concentra-
tions in airway epithelial and endothelial cells in the lungs 
of COPD patients than in those of smokers with a simi-
lar smoking history who have not developed the disease 
(Rahman et al. 2002). Other markers of oxidative stress, 
such as 8-OH-dG and 4-HNE, have been shown to have 
increased expression associated with emphysematous 
lesions in the lungs (Tuder et al. 2003c).
Pathogenesis of Chronic 
Obstructive Pulmonary Disease
Many studies have shown higher levels of biomark-
ers of oxidative stress in COPD patients than in healthy 
smokers. Furthermore, several studies show relationships 
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between markers of oxidative stress and the degree of 
airflow limitation in COPD (Repine et al. 1997; MacNee 
2000). However, the presence of oxidative stress and its 
relationship to airflow limitation may be an epiphenom-
enon because oxidative stress occurs in any inflammatory 
response. Cohort studies have not shown that the pres-
ence of enhanced oxidative stress relates to the decline in 
FEV1 or to the progression of COPD.
Protease-Antiprotease Imbalance
In COPD, the protease burden in the lungs is 
increased because of the influx and activation of inflam-
matory leukocytes that release proteases. It has been pro-
posed that a relative “deficiency” of antiproteases such as 
AAT, because of their inactivation by oxidants, creates a 
protease-antiprotease imbalance in the lungs. This hypoth- 
esis forms the basis of the protease-antiprotease theory 
of the pathogenesis of emphysema (Janoff et al. 1983a; 
Stockley 2001). Inactivation of AAT by oxidants occurs at 
a critical methionine residue in its active site and can be 
produced by oxidants from cigarette smoke or oxidants 
released from inflammatory leukocytes, resulting in a 
marked reduction in the inhibitory capacity of AAT in vitro 
(Bieth 1985; Evans and Pryor 1992). In vivo study of the 
acute effects of cigarette smoke on the functional activ-
ity of AAT show a transient but nonsignificant fall in the 
antiprotease activity of BAL fluid one hour after cigarette 
smoking (Abboud et al. 1985). In addition, in vitro expo-
sure of lung epithelial cells to proteases leads to increased 
release of ROS, suggesting that proteases increase oxida-
tive stress (Aoshiba et al. 2001b).
Hypersecretion of Mucus
Oxidant-generating systems such as xanthine and 
xanthine oxidase have been shown to cause the secretion 
of mucus from airway epithelial cells (Adler et al. 1990; 
Wright et al. 1996). Oxidants are also involved in the sig-
naling pathways for EGF, which has an important role in 
the production of mucus (Nadel 2001). In addition, H2O2 
and superoxide have been shown to cause a significant 
impairment of ciliary function after short-term exposure 
at low concentrations (Feldman et al. 1994). These effects 
may have important implications in the pathogenesis 
of COPD.
Lung Inflammation
Oxidative stress is present wherever inflammation 
exists. It may also be a mechanism for enhancing the air 
space inflammation that is characteristic of COPD (Pau-
wels et al. 2001). Oxidative stress can result in the release 
of chemotactic factors, such as IL-8, from airway epithe-
lial cells (Gilmour et al. 2003), and epithelial cells from 
COPD patients have been shown to release more IL-8 than 
those of smokers or healthy persons (Profita et al. 2003). 
Lipid peroxidation products such as 8-isoprostane can also 
act as signaling molecules and cause the release of inflam-
matory mediators such as IL-8 from lung cells (Scholz et 
al. 2003). The lipid peroxidation product 4-HNE can cause 
increased production of TGFβ (Leonarduzzi et al. 1997) 
and increased expression of the gene encoding for the anti- 
oxidant enzyme γ-glutamylcysteine synthetase (Arsalane 
et al. 1997). 
An enhanced inflammatory response in the lungs 
is characteristic of COPD (Di Stefano et al. 2004; Hogg 
2004). Oxidative stress may have a fundamental role in 
enhancing inflammation through the increased pro-
duction of redox-sensitive transcription factors, such as 
NF-kB and AP-1, and also by activation of the extracellu-
lar signal-regulated kinase, C-JUN N-terminal kinase, and 
p38 mitogen-activated protein kinase pathways (Rahman 
and MacNee 1998; MacNee and Rahman 2001). Cigarette 
smoke has been shown to activate all of these signaling 
mechanisms.
Genes for many inflammatory mediators are regu-
lated by NF-kB, which is present in the cytosol in an 
inactive form linked to its inhibitory protein IkB. Many 
stimuli, including oxidants, result in activation of IkB 
kinase, producing phosphorylation and cleaving of IkB 
from NF-kB. The release of NF-kB is a critical event in the 
inflammatory response and is redox sensitive (Janssen-
Heininger et al. 1999; MacNee 2000). Studies both in mac-
rophage cell lines and in alveolar and bronchial epithelial 
cells show that oxidants cause the release of inflammatory 
mediators (e.g., IL-8, IL-1, and NO) and that these events 
are associated with increased expression of the genes for 
these inflammatory mediators and with increased nuclear 
binding and activation of NF-kB (Jiménez et al. 2000; Par-
mentier et al. 2000). The linking of NF-kB to its consen-
sus site in the nucleus leads to enhanced transcription of 
proinflammatory genes and hence inflammation, which 
induces more oxidative stress, creating a vicious circle 
as enhanced inflammation and increased oxidative stress 
perpetuate each other.
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Nuclear binding of NF-kB is increased in the airway 
macrophages and airway epithelial cells of COPD patients 
(Di Stefano et al. 2002). In a guinea pig model, exposure to 
cigarette smoke led to influx of neutrophils into the lungs 
and increased IL-8 gene expression, protein release, and 
NF-kB activation (Nishikawa et al. 1999). These increases 
and the neutrophil influx were reduced by pretreatment 
with superoxide dismutase, suggesting a role for oxidant 
stress. NF-kB is activated and translocated to the nucle-
us to a greater extent in lung tissue in smokers and in 
patients with COPD than in healthy persons (Szulakowski 
et al. 2006), and NF-kB activation in lung tissue has been 
shown to correlate with FEV1 (Crowther et al. 1999).
A study of gene expression in rat epithelium after 
exposure to cigarette smoke showed that smoke causes 
rapid induction of antioxidant stress-response genes and 
drug-metabolizing enzymes, such as heme oxygenase 
and quinone oxidoreductase, all of which had decreased 
expression after long-term exposure to cigarettes (Gebel 
et al. 2004). The protein kinase C signaling pathway is 
also sensitive to tobacco smoke and increases its activity 
by twofold to threefold when stimulated by 5-percent CSE 
(Wyatt et al. 1999).
A further event controlling gene transcription that 
may be affected by oxidative stress and may enhance lung 
inflammation is chromatin remodeling. Under normal 
circumstances, DNA is wound tightly around a core of 
histone residues. This configuration prevents access for 
transcription factors to the transcriptional machinery and 
also reduces access of RNA polymerase to DNA, thereby 
resulting in transcriptional repression and gene silenc-
ing (Rahman and MacNee 1998; MacNee 2001). Histone 
acetyltransferases (HATs) cause the acetylation of his-
tone residues, resulting in a change in their charge and 
unwinding of DNA and allowing access for transcription 
factors such as NF-kB and RNA polymerase to the tran-
scriptional machinery, thereby enhancing gene expres-
sion. This process is reversed by HDACs, enzymes that 
deacetylate histone residues, resulting in the rewinding 
of DNA and gene silencing. The exact role of oxidative 
stress in modifying HAT and HDAC activity is unknown, 
but it appears that oxidative stress can result in increased 
HAT activity and decreased HDAC activity (Gilmour et al. 
2003), which would enhance gene transcription.
Oxidative stress results in HAT activity in epithelial 
cells (Tomita et al. 2003). Histone acetylation can be shown 
to occur after the exposure of epithelial cells to cigarette 
smoke and is prevented by the antioxidant therapy N-ace-
tylcysteine, indicating that the process is redox sensitive 
(Anderson et al. 2004). Furthermore, in animal models, 
exposure to cigarette smoke results in increased acety-
lated histone in the lung and decreased HDAC activity, 
and both of these events would enhance gene expression 
(Marwick et al. 2002). In addition, HDAC activity in alve-
olar macrophages obtained from cigarette smokers has 
been shown to be decreased, which would also enhance 
gene expression (Ito et al. 2001). This event may be due 
to nitration of HDAC2 by ONOO− (Ito et al. 2001, 2004a). 
More recent studies have suggested that acetylate histone 
residues, such as H4, are present to a greater extent in 
lung tissue in smokers and in COPD patients who smoke. 
These increases in H4 are associated with a decrease in 
HDAC2 in COPD patients who smoke and in patients with 
severe COPD (Ito et al. 2005; Szulakowski et al. 2006). A 
correlation has also been shown between decreased HDAC 
activity in lung tissue and FEV1 in patients with COPD.
Apoptosis
There are two types of cell death: apoptosis, which 
is organized and noninflammatory, and necrosis, which 
is unorganized, destructive, and proinflammatory. One 
hypothesis is that loss of alveolar endothelial cells by apop-
tosis may be an initial event in the development of emphy-
sema (Tuder et al. 2003b). Apoptosis has been shown to 
occur to a greater extent in endothelial cells in emphyse-
matous lungs than in lungs of nonsmokers (Kasahara et 
al. 2001).
Airway lymphocytes (Majo et al. 2001) and stimu-
lated peripheral blood leukocytes (Hodge et al. 2003) from 
patients with COPD also show increased apoptosis. The 
process of endothelial apoptosis is thought to be under 
the influence of VEGFR-2 receptors. Decrease of VEGFR-2 
has been shown to produce emphysema in animals, and 
reduced expression of VEGFR-2 is evident in emphyse-
matous human lungs (Kasahara et al. 2001). Studies have 
also shown that the apoptosis and emphysema induced 
by VEGF inhibition in animal models is associated with 
increased markers of oxidative stress and is prevented by 
antioxidants, suggesting that oxidative stress is involved 
in this process (Tuder et al. 2003c).
Systemic Involvement
Although COPD predominantly affects the lungs, it 
has important systemic consequences, including cachexia 
and skeletal muscle function (Wouters et al. 2002; Lan-
gen et al. 2003). Increasing evidence suggests that similar 
mechanisms involving oxidative stress and inflammation 
in the lungs may also be responsible for many of the sys-
temic effects of COPD (Langen et al. 2003).
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Peripheral blood neutrophils from COPD patients 
have been shown to release more ROS than such neu-
trophils from unaffected persons (Rahman et al. 1996a). 
Products of lipid peroxidation are also increased in plas-
ma in smokers and patients with COPD (Rahman et al. 
1996a). In addition, increased levels of nitrotyrosine have 
been shown to occur in the plasma of COPD patients (Ichi-
nose et al. 2000).
Patients with COPD often display weight loss, which 
correlates inversely with the occurrence of exacerbations 
and is seen as an independent indicator of outcome (Gray-
Donald et al. 1996; Landbo et al. 1999). In addition, loss 
of fat-free mass results in peripheral muscle dysfunction, 
decreased exercise capacity, and reduced health status 
(Palange et al. 1995; Baarends et al. 1997; Engelen et al. 
2000b). Several factors influence the loss of weight and 
fat-free mass in COPD patients, including malnutrition, 
imbalance in overall protein turnover and the hormones 
involved in this process, tissue hypoxia, and pulmonary 
inflammation (Jenkins and Ross 1996; Engelen et al. 
2000b; Eid et al. 2001; Wouters et al. 2002).
Oxidative stress may also have a role in the cachexia 
and loss of fat-free mass that occurs in COPD. Skeletal 
muscle is exposed continuously to changes in the redox 
environment that occur during exercise. Several stud-
ies have shown evidence of increased oxidative stress in 
patients with COPD both locally and systemically, partic-
ularly during exercise (Couillard et al. 2002, 2003; Lan-
gen et al. 2003). Presence of lipid peroxidation products 
in the serum, accompanied by an increase in the ratio of 
oxidized to reduced GSH, occur during exercise in COPD 
patients to a greater extent than in healthy persons (Sas-
tre et al. 1992; Viña et al. 1996; Heunks and Dekhuijzen 
2000). Skeletal muscle cells adapt to oxidative stress by 
increasing production of antioxidant enzymes such as 
SOD, catalase, and GPX (Franco et al. 1999). Study find-
ings also showed evidence of disturbed redox homeosta-
sis in COPD associated with emphysema. GSH levels in 
skeletal muscle were lower in COPD patients with emphy-
sema than in those who did not have emphysema and were 
associated with reduced concentrations of glutamate, an 
important substrate in the synthesis of glutamine and 
GSH (Engelen et al. 2000a). Other studies demonstrate 
a decrease in GPX activity, elevated GRX activity, and 
increased lipid peroxidation, which indicate oxidative 
damage in the skeletal muscle of experimental hamsters 
with emphysema (Mattson et al. 2002). These results sug-
gest that GSH metabolism is impaired in COPD.
Increased ROS production in skeletal muscle during 
exercise may result from stimulation of the mitochondrial 
electron-transport chain by TNFα (Li et al. 1999), which 
is known to be elevated in the circulation of patients with 
COPD who lose weight (Di Francia et al. 1994). Leuko-
cytes infiltrating skeletal muscles in COPD patients may 
be another source of ROS (Adams et al. 2002). In addition, 
exercise increases the activity of xanthine and xanthine 
oxidase, a further source of ROS (Andrade et al. 1998). 
ROS also contribute to oxidative stress in muscles, and 
inducible NO expression has been shown to increase in 
skeletal muscle in response to inflammatory cytokines and 
activation of NF-kB (Adams et al. 2002). Oxidative stress 
may directly compromise muscle function by decreasing 
contractility and by increasing the susceptibility of mus-
cle to oxidants (Barclay and Hansel 1991; Andrade et al. 
1998). ROS may also oxidize proteins in the contractile 
apparatus, such as sulfhydryl residues in the contractile 
proteins, which may impair muscle function (MacFarlane 
and Miller 1992). In addition to impairing muscle func-
tion, resulting in muscle fatigue, oxidative stress may 
induce muscle atrophy. Atrophy is the result of an imbal- 
ance in muscle protein metabolism, which has been 
described in studies showing that oxidative stress induced 
inhibition of muscle-specific protein expression (Buck and 
Chojkier 1996; Langen et al. 2004). Furthermore, oxida-
tive stress may result in apoptosis of muscle cells, which 
has been described in skeletal muscle cells, and may con-
tribute to muscle atrophy (Stangel et al. 1996).
Summary
Considerable evidence now exists for both local and 
systemic oxidative stress in COPD patients. Increasing evi-
dence suggests that oxidative stress is involved in many of 
the pathogenic processes involved in COPD, as well as in 
systemic phenomena such as skeletal muscle dysfunction. 
Cigarette smoke provides an extraordinarily strong dose of 
free radicals to the lung, initiating processes of oxidative 
injury that involve multiple cell types and the entire lung. 
Local inflammation results and markers of inflammation 
are higher, both in smokers and in persons with COPD, 
than are those in nonsmokers. Oxidative stress unfavor-
ably tips the protease-antiprotease balance toward prote-
ase, leading to tissue damage and COPD.
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AAT deficiency is a long-established genetic risk fac-
tor for COPD and a model for the determination of sus-
ceptibility to cigarette smoking by causing COPD through 
a genetic mutation. However, only a minority of patients 
with COPD (1 to 2 percent) inherit the severe AAT defi-
ciency that places them at highly increased risk of COPD 
(Lieberman et al. 1986). Consequently, only a small pro-
portion of COPD cases are thought to be attributable 
to this gene-environment interaction (Lieberman et 
al. 1986).
The AAT protein is encoded by the SERPINA1 gene 
on chromosome 14q32.1. Approximately 100 protease 
inhibitor (PI) alleles have been identified, some resulting 
in decreased serum levels of AAT (American Journal of 
Respiratory and Critical Care Medicine 2003). The *M 
allele accounts for more than 95 percent of the PI alleles 
in U.S. populations and is associated with normal serum 
levels of AAT (Brantly et al. 1988). The *S allele, which 
leads to mildly reduced AAT levels, and the *Z allele, which 
leads to severely reduced AAT levels, occur at frequencies 
above 1 percent in U.S. populations. A smaller percentage 
of people inherit *NULL alleles, which lead to the absence 
of any AAT production through a heterogeneous set of 
mutational mechanisms. Persons with two *Z alleles or 
one *Z and one *NULL allele are commonly referred to 
as having the PI *Z phenotype, because their serum sam-
ples cannot be distinguished by the isoelectric focusing 
technique commonly used to assess PI type (Ogushi et al. 
1987). Persons with PI *Z alleles have approximately 15 
percent of normal serum AAT levels, and this quantitative 
reduction in circulating AAT is the primary determinant 
of increased risk for emphysema. In addition, molecule by 
molecule, the Z protein is a slightly less effective serine PI 
than is the M protein.
Immunologic assay of the AAT level in serum is a 
common test for AAT deficiency, but confirmation of the 
diagnosis of AAT deficiency requires determination of PI 
type, which is typically performed by isoelectric focusing 
of serum in specialized laboratories. Molecular genotyp-
ing by polymerase chain reaction can distinguish the com-
mon PI alleles (*M, *S, and *Z) with use of DNA from a 
variety of cellular sources (von Ahsen et al. 2000; Stockley 
and Campbell 2001). However, high-throughput complete 
sequencing tests for rare PI alleles are not yet widely avail-
able, so rare alleles that produce severe AAT deficiency 
(e.g., *NULL alleles) can be misclassified as normal if 
comprehensive molecular tests are not used.
AAT is one of the serpin protease inhibitors (ser-
pins), an important family of PIs. The association between 
inherited AAT deficiency and pulmonary emphysema was 
critical for the development of the protease-antiprotease 
hypothesis on the pathogenesis of emphysema (Janoff 
1985; Niewoehner 1988; Churg and Wright 2005). AAT 
is the major serum PI of neutrophil elastase, which is 
encoded by the ELA2 gene. Neutrophil elastase is a potent 
elastase considered to be involved in the elastin degrada-
tion that leads to emphysema (Travis and Salvesen 1983). 
Although AAT demonstrates some inhibitory activity 
against a range of proteases, it is an extremely effective 
inhibitor of neutrophil elastase (Beatty et al. 1980). The 
functional specificity of AAT is determined by a methio-
nine at amino acid position 358 of the AAT protein, which 
is the PI residue at the active inhibitory site (Mahadeva 
and Lomas 1998). The *Z allele encodes a single base sub-
stitution that replaces glutamic acid at amino acid posi-
tion 342 in the M protein with lysine, thus eliminating a 
critical salt bridge in the AAT protein. The low serum AAT 
levels in PI *Z alleles occur because the Z protein polym-
erizes within the endoplasmic reticulum of hepatocytes, 
the primary site of AAT synthesis, preventing release of 
the protein. 
The prevalence of AAT deficiency is particularly high 
in populations of Northern European descent. Molecular 
haplotype analysis of polymorphic loci adjacent to the 
AAT *Z allele suggests a single mutational origin for the 
majority of *Z alleles in modern populations, an ancestral 
mutation that likely occurred in Northern Europe (Byth 
et al. 1994). Hutchison (1998), who reviewed the Euro-
pean screening studies for AAT deficiency, found that the 
highest frequencies of the *Z allele were in northwestern 
Europe. Although screening studies have typically found 
low frequencies of the *Z allele in populations of African 
and Asian descent (Kellermann and Walter 1970), the 
review of the worldwide screening literature in control 
cohorts, prepared by de Serres (2002), suggested that 
there could be significant numbers of PI *Z carriers in 
almost every region of the world. These estimates were 
based on calculations assuming Hardy-Weinberg equilib-
rium and accurate AAT typing in these control popula-
tions, but it remains to be determined how significantly 
these estimates were affected by PI typing errors, new 





Although increased risk for the development of 
COPD among persons with the PI *Z allele has been well 
established, the magnitude of this risk and the natural his-
tory of the entire population with the PI *Z allele remain 
unclear. This population in the United States is estimated 
at 80,000 to 100,000. Among persons known to have the 
PI *Z allele, early-onset COPD is often observed clinically. 
Classic emphysema with the greatest severity in the low-
er lobes has been described among adults with the PI *Z 
allele and COPD, but diffuse or upper lobe emphysema can 
also be observed in this population (Parr et al. 2004). 
Several early studies of large numbers of persons 
with the PI *Z allele demonstrated that PI *Z-type persons 
who smoked cigarettes tended to develop more severe 
COPD at an earlier age than did PI *Z-type persons who 
were nonsmokers (Larsson 1978; Tobin et al. 1983; Janus 
et al. 1985). More recently, Seersholm and colleagues 
(1994) demonstrated significantly higher mortality rates 
in smokers with PI *Z than in nonsmokers with PI *Z. 
Silverman and colleagues (1992) demonstrated an inter-
action between PI type and cigarette smoking, by compar-
ing the patterns of phenotypic expression in smokers by 
the percentage with specific predicted FEV1 values and the 
patterns in participants with the PI *M, PI *M/*Z, or PI *Z 
allele, in the St. Louis Alpha-1-Antitrypsin Study.
The St. Louis Alpha-1-Antitrypsin Study also dem-
onstrated the importance of ascertainment bias in limiting 
insight into the natural history of AAT deficiency. If most 
persons with the PI *Z allele are identified because they 
already have COPD, it would appear that most persons with 
this genotype will develop COPD. Among 52 persons with 
this allele, Silverman and colleagues (1989) confirmed the 
expected result that persons with the PI *Z allele who were 
tested for AAT deficiency because they already had COPD 
(index persons) all had significantly reduced FEV1 values. 
However, marked variability in development of airflow 
obstruction was demonstrated in nonindex persons with 
the PI *Z allele whose genotype was ascertained, not 
because of existing COPD, but by genotyping in family 
studies or because they had liver disease. In Denmark, 
Seersholm and colleagues (1995) confirmed differences 
between lung function in index and nonindex persons 
with the PI *Z allele that were independent of age and 
smoking history.
The PI *Z type is a major risk factor for COPD, and 
cigarette smoking increases the risk for COPD in per-
sons with the PI *Z allele (Silverman et al. 1989). Even 
so, some smokers with PI *Z maintain normal pulmonary 
function into older ages, whereas some nonsmokers with 
PI *Z develop COPD at an early age (Black and Kueppers 
1978). For example, among 18 lifetime nonsmokers with 
the PI *Z allele, the investigators found significant vari-
ability in lung function and respiratory symptoms, despite 
the absence of a history of smoking or other significant 
environmental exposures.
In a study of 205 nonsmokers with the PI *Z allele in 
Sweden, Piitulainen and colleagues (1998) observed that 
using a kerosene heater and working in agriculture were 
associated with lower lung function. Among 128 persons 
with PI *Z, Mayer and associates (2000) found that high 
exposure to mineral dust was associated with increased 
cough symptoms and reduced FEV1.
Because less than 10 percent of the estimated total 
of persons with the PI *Z genotype in the United States 
have been identified (American Journal of Respiratory 
and Critical Care Medicine 2003), the natural history of 
COPD in persons with the PI *Z allele remains uncertain. 
In addition to cigarette smoking, other environmental 
factors and genetic modifiers likely influence the devel-
opment of COPD among persons with PI *Z. Largely in 
response to the underdiagnosis of persons with PI *Z, 
the American Thoracic Society and European Respiratory 
Society Task Force (American Journal of Respiratory and 
Critical Care Medicine 2003) recommended testing for 
AAT deficiency in all adults with COPD, emphysema, or 
asthma with chronic airflow obstruction.
Familial Aggregation of Phenotypes 
Related to Chronic Obstructive 
Pulmonary Disease
Pulmonary Function in the General Population
Several types of studies have suggested that genetic 
factors influence variation in spirometric measurements 
in the general population. Studies of twins who were not 
selected for lung disease have found greater correlations in 
the measure of lung function between monozygotic twins, 
who share all of their genetic variation, than between 
dizygotic twins, who share approximately one-half of their 
genetic variation. Comparison of correlations between 
monozygotic and dizygotic twins allows for estimating 
the heritability of lung function, the percentage of total 
phenotypic variation in lung function that is related to 
genetic factors. For example, in a study of 127 monozy-
gotic and 141 dizygotic twin pairs by the National Heart, 
Lung, and Blood Institute (NHLBI), the estimated heri-
tability for FEV1 values, after adjustment for age, height, 
weight, and smoking was 74 percent (Hubert et al. 1982). 
Redline and colleagues (1987) also observed significantly 
higher correlations for FEV1 between monozygotic twins 
than between dizygotic twins. Tishler and associates 
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(2002) studied 352 adult twin pairs and found evidence 
suggesting a relationship between history of cigarette 
smoking and unidentified potential susceptibility genes. 
Studies in nuclear families have also supported a 
role for genetic determinants of pulmonary function in 
the general population; both path analysis and variance 
component analysis have been used. Lewitter and col-
leagues (1984), who used path analysis in a study of 404 
nuclear families, estimated that 41 to 47 percent of varia-
tion in FEV1 values was related to genetic factors. Using 
variance component analysis in a study of 439 persons 
from 108 families, Astemborski and associates (1985) 
estimated that after adjustment for age, gender, race, and 
smoking history, 28 percent of the variation in FEV1 and 
24 percent of the variation in FEV1/FVC were related to 
genetic determinants. More recently, Palmer and col-
leagues (2001) performed variance component modeling 
of spirometric phenotypes in the Busselton Health Study 
and estimated the heritability of FEV1 as 39 percent. 
Although these studies in the general population provide 
compelling evidence that genetic factors influence varia-
tion in level of pulmonary function, they do not necessar-
ily provide insight into the role of genetic factors in the 
development of COPD.
Airflow Obstruction
Studies assessing the role of familial aggregation 
of phenotypes in the occurrence of airflow obstruction in 
relatives of patients with COPD have supported a role for 
genetic factors in the development of COPD. In an early 
study, Larson and colleagues (1970) reported higher rates 
of airflow obstruction in first-degree relatives of COPD 
patients than in the control group. Later, Kueppers and 
associates (1977), who studied 114 persons with COPD, 
compared the spirometric values in siblings with those in 
a matched control group and found that the siblings had 
significantly lower FEV1 values after adjustment for smok-
ing history.
In the Boston Early-Onset COPD Study, Silverman 
and colleagues (1998) focused on persons with severe, 
early-onset COPD without AAT deficiency. Among non-
smokers who were first-degree relatives of these probands 
with early-onset COPD, FEV1 and FEV1/FVC values were 
similar to those in nonsmokers in the control group. 
Using generalized estimating equations to adjust for age 
and pack-years of smoking, the investigators found, how-
ever, that current or former smokers among first-degree 
relatives of the probands with early-onset COPD had sig-
nificantly higher risk for reduced FEV1 values than did 
smokers in the control group. In Great Britain, McClos-
key and associates (2001) compared the rates of airflow 
obstruction in 173 siblings of probands who had severe 
COPD with those for a population-based control cohort. 
As was found in the Boston Early-Onset COPD Study, 
nonsmokers who were siblings of COPD patients had 
risk of airflow obstruction similar to that for nonsmok-
ers in the control group. In contrast, current or former 
smokers who were siblings of probands with COPD had 
a significantly higher risk of airflow obstruction than did 
smokers from the general population. The significant 
familial aggregation of phenotypes for airflow obstruc-
tion in COPD families, which persists after adjustment for 
intensity of cigarette smoking, strongly suggests genetic 
influences on susceptibility to developing chronic air- 
flow obstruction. 
Chronic Bronchitis
Familial aggregation of chronic cough and produc-
tion of phlegm (chronic bronchitis) has also been dem-
onstrated. In a sample of 9,226 persons from the general 
population, Higgins and Keller (1975) found significantly 
higher rates of chronic bronchitis in offspring when at 
least one parent had chronic bronchitis than if neither 
parent had the disorder, but there was no adjustment for 
cigarette smoking. Speizer and colleagues (1976), using 
National Health Interview Survey data and adjusting for 
cigarette smoking, demonstrated significantly higher 
rates of bronchitis or emphysema among offspring when 
at least one parent had bronchitis or emphysema. Tager 
and associates (1978) also adjusted for history of cigarette 
smoking in their analysis and found that rates of chronic 
bronchitis or airflow obstruction in first-degree relatives 
of probands with chronic bronchitis or airflow obstruc-
tion were significantly higher than those in first-degree 
relatives of the control group. Finally, in the Boston Early- 
Onset COPD Study, Silverman and colleagues (1998) 
found significantly higher risk of chronic bronchi-
tis among smokers who were first-degree relatives of 
probands with early-onset COPD than among control 
smokers. This analysis was adjusted for the intensity of 
cigarette smoking. 
Linkage Analysis of Phenotypes 
Related to Chronic Obstructive 
Pulmonary Disease
Several studies of genetic linkage across the 
human genome were perfomed in families from the 
general population who were not selected because of the 
presence of particular respiratory disease (Table 7.8). The 
purpose was to examine the relationship between spiro-
metric values and genetic determinants of pulmonary 
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function. These genetic determinants may predispose 
family members to COPD, or they may only contribute 
to variation in pulmonary function within the normal 
range. Joost and colleagues (2002) analyzed linkage to 
quantitative spirometric measurements made before use 
of a bronchodilator in 1,578 persons from 330 pedigrees 
in the Framingham Heart Study. The largest linkage sig-
nal, which did not reach the criteria for genomewide sig-
nificance, was on chromosome 6q for prebronchodilator 
FEV1. The score of the logarithm of the odds (LOD) ratio, 
or likelihood ratio, was 2.4. In a subset of this study popu-
lation, flanking short tandem repeat (STR) markers were 
Table 7.8 Genomewide linkage analysis studies in general-population samples and in families with chronic 
obstructive pulmonary disease (COPD) 
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1,578 persons   
330 pedigrees
FEV1 •	 	 4p:	1.6
•	 	 6q:	2.4
  
Malhotra et al. 
2003
Extended Utah 
Centre d’Etude du 
Polymorphisme 
Humain pedigrees
264 persons   
26 pedigrees
FEV1/FVC •	 	 2q:	2.0 Parametric limit of 
detection score without 
heterogeneity showed 
most significant linkage 
evidence on 2q
Wilk et al. 
2003a
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Note: FEF25–75 = forced expiratory flow between 25 and 75 percent of FVC; FEV1 = forced expiratory volume in 1 second;  
FVC = forced vital capacity.
aLimit of detection scores >1.5 are presented.
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genotyped to increase the information available for link-
age analysis, and significant linkage of FEV1 to chromo-
some 6q was identified with a maximum LOD score of 5.0 
(Wilk et al. 2003b).
Wilk and colleagues (2003a) performed genome-
wide linkage analysis with prebronchodilator spirometric 
phenotypes in 2,178 participants in the NHLBI Family 
Heart Study, a population that partially overlapped that 
with the pedigrees from the Framingham Heart Study 
used by Joost and colleagues (2002). Even so, the linkage 
results differed substantially from those in the Framing-
ham Heart Study. The most impressive signals suggested 
linkage of FEV1 to chromosome 3q and FEV1/FVC to chro-
mosome 4p. 
Finally, Malhotra and associates (2003) performed 
genomewide linkage analysis of quantitative prebroncho-
dilator spirometric measurements in extended pedigrees. 
The findings suggested linkage of FEV1/FVC values to 
chromosome 2q and to chromosome 5q but no linkage for 
either FEV1 or FVC. 
Chronic Obstructive Pulmonary 
Disease in Families
The Boston Early-Onset COPD Study includes 
extended pedigrees obtained through persons with severe 
early-onset COPD but without AAT deficiency. Genome-
wide linkage analysis has been performed with 585 mem-
bers of 72 pedigrees involving early-onset COPD (Table 
7.8). Initially, qualitative phenotypes of airflow obstruc-
tion and chronic bronchitis were analyzed, and no statisti-
cally significant or even suggestive regions of linkage were 
identified (Silverman et al. 2002a). Although limiting the 
sample to smokers only and genotyping of flanking STR 
markers identified several linkage regions of potential 
interest, linkage analysis of quantitative spirometric phe-
notypes provided more compelling evidence for linkage, 
especially with use of postbronchodilator spirometric 
values (Silverman et al. 2002b; Palmer et al. 2003). Find-
ings suggested linkage of the postbronchodilator values 
of FEV1 to chromosomes 8p (LOD = 3.30) and 1p (LOD 
= 2.24). Postbronchodilator FEV1/FVC was also linked to 
multiple regions, most significantly to markers on chro-
mosomes 2q (LOD = 4.42) and 1p (LOD = 2.52).
Genotyping additional STR markers and repeating 
linkage analysis of quantitative spirometric phenotypes 
provided stable-to-increased evidence for linkage on chro-
mosomes 2q, 12p, and 19q (Celedón et al. 2004; DeMeo et 
al. 2004). Stratified linkage analysis of samples only from 
smokers also provided stable-to-increased evidence for 
linkage to these genomic regions. Findings suggested that 
genetic determinants in those regions confer increased 
risk for COPD because of a relationship between history of 
cigarette smoking and unidentified potential susceptibil-
ity genes. 
Overall, the linkage results of quantitative spiromet-
ric measurements in the persons with pedigrees from the 
Boston Early-Onset COPD Study (Hersh et al. 2005) and 
samples from the general population have demonstrated 
only modest concordance. The most impressive linkage 
signals in the study have been obtained with postbroncho-
dilator spirometric measures, which have not been used in 
the linkage studies of the general population. The Boston 
Early-Onset COPD Study demonstrated linkage of FEV1/
FVC to chromosome 2q. The suggestive linkages of FEV1/
FVC to chromosome 1p in the NHLBI Family Heart Study 
and the Boston Early-Onset COPD Study indicate a region 
that may influence spirometric measurements in both the 
general population and persons with COPD. One explana-
tion for inconsistent linkage results in studies of COPD 
families and studies of pedigrees in the general population 
is that different genetic determinants could influence nor-
mal variation in spirometry and COPD. In addition, the 
lack of concordance among results from linkage studies in 
the general population could relate to genetic heteroge-
neity among study populations, false-positive evidence for 
linkage in some regions, or inadequate power of the study 
to replicate linkage signals.
Genetic Association with Chronic 
Obstructive Pulmonary Disease
A large number of studies to determine associations 
have assessed genetic variants in candidate genes hypoth-
esized to be involved in the development of COPD. These 
were primarily case-control studies of patients with COPD 
and control groups. Candidate gene loci significantly 
associated with COPD in at least two studies are listed in 
Table 7.9. In addition to the PI *M/*Z genotype of AAT, 
which has been variably associated with COPD (Hersh et 
al. 2004), replicated associations have been demonstrated 
for genes of α1-antichymotrypsin (SERPINA3) (Poller et 
al. 1993; Sandford et al. 1998; Benetazzo et al. 1999; Ishii 
et al. 2000a), GSTM1 (GSTM1) (Baranova et al. 1997; Har-
rison et al. 1997; Yim et al. 2000; He et al. 2004), GSTP1 
(GSTP1) (Ishii et al. 1999; Yim et al. 2002; He et al. 2004), 
vitamin D binding protein (GC) (Kauffmann et al. 1983; 
Horne et al. 1990; Schellenberg et al. 1998; Ishii et al. 
2001; Sandford et al. 2001; Kasuga et al. 2003; Ito et al. 
2004b), TGFβ1 (TGFß1) (Celedón et al. 2004; Wu et al. 
2004), TNF (TNF) (Huang et al. 1997; Higham et al. 2000; 
Ishii et al. 2000b; Patuzzo et al. 2000; Sakao et al. 2001; 
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Table 7.9 Replicated candidate gene associations in chronic obstructive pulmonary disease (COPD)
Study Sample size Genetic variants studied
α1-antitrypsin PI  
*M/*Z heterozygotes      




Celedon et al. 2004 585 persons in 72 pedigrees
304 cases vs. 441 controls
5 SNPs (including same exonic SNP)




Smith and Harrison 1997 68 COPD cases
94 emphysema cases vs. 203 blood donor controls
Exon 3 nonsynonymous SNP (slow) and Exon 
4 nonsynonymous SNP (fast)
Takeyabu et al. 2000 79 emphysema cases vs. 58 smoking controls and 
114 healthy controls
Exon 3 and 4 SNPs
Yim et al. 2000 83 cases vs. 76 smoking controls Exon 3 and 4 SNPs
Yoshikawa et al. 2000 40 COPD cases and 140 controls among poison-gas 
workers
Exon 3 and 4 SNPs
Sandford et al. 2001 283 COPD persons with rapid FEV1 decline vs. 308 
COPD persons with slow FEV1 decline in the U.S. 
Lung Health Study
Exon 3 and 4 SNPs
Hersh et al. 2005 949 persons in 127 pedigrees with early-onset COPD
304 cases vs. 441 smoking controls
8 SNPs including Exon 3 and 4 SNPs
TNFα      
Huang et al. 1997 42 cases vs. 42 smoking controls and 99 blood donor 
controls
1 promoter SNP at -308
Higham et al. 2000 86 cases vs. 63 smoking controls and 199 blood 
donor controls
-308 SNP
Ishii et al. 2000b 53 cases vs. 65 smoking controls -308 SNP
Patuzzo et al. 2000 66 cases vs. 98 healthy controls and 45 cases of 
nonobstructive pulmonary disease
-308 SNP
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Hersh et al. 2004 Presence or absence of COPD




No overall consensus 
on risk for lung disease 
in persons with 
PI *M/*Z alleles
TGFß1         
Celedon et al. 2004 Families with early-onset COPD: qualitative 
and quantitative airflow obstruction 
phenotypesa
Case/control: presence/absence of COPD
3 significant SNPs at p <0.05 (1 
promoter and 2 in the 3’ genomic 
region)
3 significant SNPs at p <0.05 (2 
promoter SNPs and 1 exonic SNP)
1 promoter SNP 
replicated in both  
study populations
Wu et al. 2004 Presence/absence of COPD p ≤0.01 vs. both control groups Exonic SNP replicated 
in both case-control 
studies but not in 
family-based study
EPHX1         
Smith and Harrison 
1997
Presence/absence of COPD or emphysema Significant associations of exon 3 
SNP with emphysema group and 
of exon 4 SNP with COPD group
Several negative studies 
had small samples
Takeyabu et al. 2000 Presence/absence of emphysema No significant association   
Yim et al. 2000 Presence/absence of COPD No significant association   
Yoshikawa et al. 2000 Presence/absence of COPD No significant association   
Sandford et al. 2001 Rapid vs. slow FEV1 decline in persons with 
COPD
Significant association of exons 3 
and 4 SNP haplotypes with rapid 
FEV1 decline
  
Hersh et al. 2005 Families with early-onset COPD: 
quantitative and qualitative airflow 
obstruction phenotypesa
Case/control: presence/absence of COPD
Significant association of exon 4 
SNP only in case-control sample
  
TNFα         
Huang et al. 1997 Presence/absence of COPD with chronic 
bronchitis
Significant association vs. both 
control groups (p <0.001)
Several studies with 
significant associations, 
but many negative 
studies; many studies 
had small sample sizes
Higham et al. 2000 Presence/absence of COPD No significant association   
Ishii et al. 2000b Presence/absence of COPD No significant association   




Study Sample size Genetic variants studied
Sakao et al. 2001 106 cases vs. 110 smoking controls and 129 blood 
donor controls
-308 SNP
Sandford et al. 2001 283 cases with rapid vs. 304 cases with slow FEV1 
decline `U.S. Lung Health Study
-308 SNP
Kucukaycan et al. 2002 169 cases vs. 358 blood donor controls 4 SNPs including -308 and +489
Ferrarotti et al. 2003 63 cases vs. 86 smoking controls -308 SNP
Hersh et al. 2005 949 members of 127 pedigrees with early-onset 
COPD and 304 cases vs. 441 smoking controls
5 SNPs including -308 and +489
GSTM1      
Baranova et al. 1997 87 cases of severe chronic bronchitis vs. 102 cases 
of moderate chronic bronchitis vs. 172 smoking 
controls
Null variant
Harrison et al. 1997 111 lung cancer patients with emphysema vs. 57 
without emphysema
Null variant (homozygous null vs. all others)
Yim et al. 2000 83 cases vs. 76 smoking controls Null variant
He et al. 2004 544 persons with COPD and low FEV1 vs. 554  with 
high FEV1  U.S. Lung Health Study
Null variant
Hersh et al. 2005 Families with early-onset COPD: 949 persons in 127 
pedigrees
Case/control: 304 cases vs. 441 smoking controls
Null variant
GSTP1      
Ishii et al. 1999 53 cases vs. 50 healthy controls 1 nonsynonymous SNP (ILE105VAL)
Yim et al. 2002 89 cases vs. 94 smoking controls 1 nonsynonymous SNP (ILE105VAL)
He et al. 2004 544 persons with COPD and low FEV1 vs. 554 with 
high FEV1 
U.S. Lung Health Study
1 nonsynonymous SNP (ILE105VAL)
Hersh et al. 2005 949 members of 127 pedigrees with early-onset 
COPD and 304 cases vs. 441 smoking controls
2 nonsynonymous SNPs (ILE105VAL and 
ALA114VAL)
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Study Phenotype Results/p value for association Comments
Sakao et al. 2001 Presence/absence of COPD Significant differences in allele 
frequencies in COPD cases vs. both 
control groups  
(p <0.01)
  
Sandford et al. 2001 Rapid vs. slow FEV1 decline in persons with 
COPD
No significant association   
Kucukaycan et al. 2002 Presence/absence of COPD Significant association with +489 
variant only
  
Ferrarotti et al. 2003 Presence/absence of COPD with reduced 
Dl,co
No significant association   
Hersh et al. 2005 Families with early-onset COPD: 
quantitative and qualitative airflow 
obstruction phenotypesa
Case/control: presence/absence of COPD
Significant associations with 
qualitative and quantitative airflow 
obstruction phenotypes with SNP 
-308 in COPD pedigrees only
  
GSTM1         
Baranova et al. 1997 Presence/absence of COPD Higher null/null frequency in 
both cases of moderate and severe 
chronic bronchitis and severe 
chronic bronchitis vs. controls (p 
<0.001)
  
Harrison et al. 1997 Presence/absence of emphysema in resected 
lung tissue
Significantly increased frequency 
of homozygosity for null variant in 
persons with emphysema (p <0.05)
Only homozygosity 
for null variant was 
typically assessed
Yim et al. 2000 Presence/absence of COPD No significant association   
He et al. 2004 High vs. low FEV1 in persons with COPD No significant association   
Hersh et al. 2005 Families with early-onset COPD: qualitative 
and quantitative airflow obstruction 
phenotypesa
Case/control: presence/absence of COPD
No significant association   
GSTP1         
Ishii et al. 1999 Presence/absence of COPD Homozygous 105ILE more 
common in COPD cases
Several studies with 
significant associations, 
but different alleles, 
are associated at 
amino acid 105 SNP in 
different studies
Yim et al. 2002 Presence/absence of COPD No significant association   
He et al. 2004 High vs. low FEV1 in persons with COPD Homozygous 105VAL gene more 
common in low FEV1 group
Hersh et al. 2005 Families with early-onset COPD: qualitative 
and quantitative airflow obstruction 
phenotypesa
Case/control: presence/absence of COPD
Borderline higher frequency of 





Study Sample size Genetic variants studied
SFTPB      
Guo et al. 2001 97 cases vs. 82 smoking controls 4 SNPs, 1 promoter, and 3 intragenic indels
Seifart et al. 2002 118 cases vs. 118 matched controls and 110 
population-based controls
SP-B INTRON 4 indels
Hersh et al. 2005 949 members of 127 pedigrees with early-onset 
COPD and 304 cases vs. 441 smoking controls
1 nonsynonymous SNP (THR131IL3) and 1 
short tandem repeat
α1-antichymotrypsin      
Poller et al. 1993 100 COPD cases vs. 100 controls 2 nonsynonymous SNPs: PRO229ALA and 
LEU55PRO
Sandford et al. 1998 168 COPD cases vs. 61 controls PRO229ALA and LEU55PRO
Benetazzo et al. 1999 66 COPD cases vs. 45 controls with nonobstructive 
pulmonary disease and 98 healthy volunteers
4 coding SNPs (THR15ALA, LEU55PRO, 
PRO229ALA, and MET389VAL) and 1 indel 
(1258DELAA)
Ishii et al. 2000a 53 COPD cases vs. 65 controls 2 coding SNPs in protein (PRO229ALA and 
LEU55PRO) and 1 coding SNP in signal 
peptide (ALA15THR)
Hersh et al. 2005 949 members of 127 pedigrees with early-onset 
COPD and 304 cases vs. 441 smoking controls
ALA15THR, LEU55PRO, and PRO229ALA 
polymorphisms
Vitamin D binding protein 
(group-specific component 
[GC])      
Kauffmann et al. 1983 43 lifetime nonsmokers with low FEV1 vs. 45 heavy 
smokers with high FEV1
GC*1S/F and GC*2 alleles
Horne et al. 1990 104 COPD cases vs. 413 controls GC phenotype by isoelectric focusing 
Schellenberg et al. 1998 75 COPD cases vs. 64 smoking controls SNPs THR420LYS (GC*2) and ASP416GLU 
(GC*1S)
Ishii et al. 2001 63 COPD cases vs. 82 controls GC*1F/*1S and GC*2 alleles
Sandford et al. 2001 283 persons with COPD with rapid FEV1 decline vs. 
308 persons with COPD with slow FEV1 decline
THR420LYS and ASP416GLU polymorphisms
Kasuga et al. 2003 537 persons with COPD with high FEV1 vs. 533 with 
low FEV1 
U.S. Lung Health Study
GC* haplotypes
Table 7.9 Continued
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Study Phenotype Results/p value for association Comments
SFTPB         
Guo et al. 2001 Presence/absence of COPD Significant association with SNP at 
+1580 (p <0.05)
  
Seifart et al. 2002 Presence/absence of COPD and COPD 
severity
INTRON 4 variants significantly 
associated 
(p <0.05) with respiratory failure 
subgroup
  
Hersh et al. 2005 Families with early-onset COPD: 
quantitative and qualitative airflow 
obstruction phenotypesa
Case/control: presence/absence of COPD
Significant SNP association 
with moderate-to-severe airflow 
obstruction (p <0.05)
Significant SNP association only 
with gene-x-smoking interaction 
term (p <0.01)
  
α1-antichymotrypsin         
Poller et al. 1993 Presence/absence of COPD Significant SNP association (p 
<0.05) with PRO229ALA
No studies replicated 
associations of the same 
genetic variants
Sandford et al. 1998 Presence/absence of COPD No significant association   
Benetazzo et al. 1999 Presence/absence of COPD No significant association   
Ishii et al. 2000a Presence/absence of COPD Significant SNP association with  
ALA15THR only
  
Hersh et al. 2005 Families with early-onset COPD: 
quantitative and qualitative airflow 
obstruction phenotypesa
Case/control: presence/absence of COPD
No significant association   





Kauffmann et al. 1983 Presence/absence of COPD No significant association   
Horne et al. 1990 Presence/absence of COPD Significant association with 
inferred GC* allele (p <0.01)
  
Schellenberg et al. 1998 Presence/absence of COPD Significant protection against 
COPD with GC*2/GC*2 genotype
  
Ishii et al. 2001 Presence/absence of COPD Significantly increased frequency 
of GC*1F allele in COPD cases
  
Sandford et al. 2001 Rapid vs. slow FEV1 decline in COPD cases No significant association   
Kasuga et al. 2003 High vs. low FEV1 among COPD cases No significant association   
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Study Sample size Genetic variants studied
Ito et al. 2004b 103 COPD cases vs. 88 smoking controls GC*1S/*1F and GC*2
Hersh et al. 2005 949 members of 127 pedigrees with early-onset 
COPD and 304 cases vs. 441 smoking controls
THR420LYS and ASP416GLU
Note: Dl,co = diffusing capacity of the lung for carbon monoxide; FEV1 = forced expiratory volume in 1 second; FVC = forced vital 
capacity; indel = DNA mutation; PI = protease inhibitor; SNP = single nucleotide polymorphism; SP-B = surfactant protein B.
aIn families with early-onset COPD, quantitative spirometric phenotypes included FEV1/FVC before and after use of a bronchodilator; 
qualitative phenotypes included mild-to-severe airflow obstruction (FEV1 <80% predicted with FEV1/FVC <90% predicted) and 
moderate-to-severe airflow obstruction (FEV1 <60% predicted with FEV1/FVC <90% predicted).
Table 7.9 Continued
Sandford et al. 2001; Küçükaycan et al. 2002; Ferrarotti et 
al. 2003), surfactant protein B (SFTPB) (Guo et al. 2001; 
Seifart et al. 2002; Hersh et al. 2005), and microsomal 
epoxide hydrolase (EPHX1) (Smith and Harrison 1997; 
Takeyabu et al. 2000; Yim et al. 2000; Yoshikawa et al. 
2000; Sandford et al. 2001). Although at least two stud-
ies support an association of a genetic variant with COPD 
in these candidate genes, every case also has at least one 
negative study.
Several factors could contribute to the inconsistent 
results from case-control studies of genetic association 
with COPD. Genetic heterogeneity in different popula-
tions could contribute to difficulty in replicating associa-
tions between studies, and false-positive or false-negative 
results could contribute to inconsistent replication. A 
potentially important factor is that case-control studies 
of association are susceptible to supporting associations 
based only on population stratification; that is, they reflect 
differences between populations rather than true associa-
tions (Freedman et al. 2004). Population stratification can 
result from incomplete matching between cases and con-
trols, which might include failure to account for differ-
ences in ethnicity and geographic origin that may affect 
the results. In addition, most published studies on genetic 
associations of COPD have not focused on genomic 
regions linked to COPD-related phenotypes, regions in 
which association studies may be more fruitful. 
As of 2008, only one study, a linkage analysis of family-
based genetic association for COPD, has been reported (Celedón 
et al. 2004). The design of the study is typically not vulnerable to 
effects of population stratification. The study focused on genet-
ic variants in TGFß1, a gene that is located within the region of 
linkage to FEV1 on chromosome 19q in the Boston Early-On-
set COPD Study and that was associated with COPD in another 
case-control study of genetic association (Wu et al. 2004). Five 
TGFß1 single nucleotide polymorphisms (SNPs) were geno-
typed in families in the Boston Early-Onset COPD Study. Fam-
ily-based association analysis showed that one SNP in the pro-
moter region of TGFß1 (RS2241712) and two SNPs in the 3’ 
untranslated region of TGFß1 (RS2241718 and RS6957) 
were significantly associated with FEV1 (p <0.05). Among 
304 case patients with severe COPD from the National 
Emphysema Treatment Trial and 441 smokers in the control 
group from the Normative Aging Study, two SNPs in the pro-
moter region of TGFß1 (RS2241712 and RS1800469) and one 
SNP in exon 1 of TGFß1 (RS1982073) were significantly as-
sociated with COPD (p ≤0.02) (Celedón et al. 2004). Additional 
research to replicate the genetic associations in TGFß1 and 
identify the functional variants in or near TGFß1 is required. 
A variety of candidate genes have been examined 
in genetic association studies focused on COPD, but no 
genetic loci other than the SERPINA1 gene for severe AAT 
deficiency proved to be significant risk factors for COPD. 
Mouse Models of Genetics for 
Chronic Obstructive Pulmonary 
Disease
Although rodent models have provided important in-
sights into the potential biochemical mechanisms of COPD, 
there has been no publication of research using quantitive trait 
locus mapping to identify susceptibility loci through experi-
mental crosses of relatively susceptible and relatively nonsus-
ceptible strains. Significant differences between murine strains 
in susceptibility to the development of smoking-induced 
COPD have been demonstrated (Guerassimov et al. 2004), and 
use of these strain-specific differences to perform quantita-
tive trait locus mapping may provide unique opportunities to 
uncover genetic determinants of COPD (Shapiro et 
al. 2004).
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Study Phenotype Results/p value for association Comments
Ito et al. 2004b Presence/absence of COPD Significantly increased frequency 
of  
GC*1F allele in COPD cases
  
Hersh et al. 2005 Families with early-onset COPD: 
quantitative and qualitative airflow 
obstruction phenotypesa
Case/control: presence/absence of COPD
No significant association   
Summary
Severe AAT deficiency is a proven genetic risk fac-
tor for COPD. Although considerable insight into the 
pathogenesis of COPD has been provided by studies of AAT 
deficiency, fundamental questions about the natural his-
tory of this deficiency remain unanswered.
Only a small percentage of patients with COPD 
inherit severe AAT deficiency, and additional genetic fac-
tors likely influence the development of the disorder. 
Further efforts in linkage analysis, association studies, 
and research on animal models may lead to identification 
of such factors. To achieve a complete understanding of 
COPD pathophysiology, characterization of the interac-
tions among genetic determinants, cigarette smoking, 
and possibly other environmental factors is required. 
Identification of genetic factors influencing the develop-
ment of COPD unrelated to AAT deficiency could eluci-
date the biochemical mechanisms causing COPD, allow 
identification of more susceptible persons, and lead to new 




The information on pathogenesis of emphysema dis-
cussed here was obtained from original research articles, 
most published since the early 1990s. These articles were 
found by consulting reviews of the literature (Pardo and 
Selman 1999; Mahadeva and Shapiro 2002; Barnes et al. 
2003; Tuder et al. 2003a; Barnes 2004b; MacNee 2005b) 
and by searching the Internet with use of a variety of 
terms relevant to the pathogenesis of emphysema. The 
review includes citations through June 2005. 
In reviewing the literature, special attention was 
paid to reports that distinguished between “emphysema” 
and the all-encompassing term “chronic obstructive pul-
monary disease.” In recent years this distinction has been 
made by using chest CT and microscopy of lung tissue. 
Introduction
One long-accepted definition of emphysema is “a 
condition of the lung characterized by abnormal, perma-
nent enlargement of air spaces distal to the terminal bron-
chiole, accompanied by destruction of their walls, and 
without obvious fibrosis” (Snider et al. 1985, p. 183). This 
definition emphasizes the loss of alveolar tissue. However, 
in emphysema induced by tobacco smoke, the lung tissue 
exhibits active synthesis of extracellular matrix (Lang et 
al. 1994; Wright and Churg 1995; Vlahovic et al. 1999), 
apoptosis, and proliferation of alveolar cells (Calabrese et 
al. 2005). Accordingly, emphysematous lung tissue should 
be viewed as undergoing remodeling rather than simply 
resulting from a destructive process. 
The current model of the pathogenesis of emphy-
sema, which involves diverse processes of varying impor-
tance, is summarized in Figure 7.18. In this pathogenetic 
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scheme, accumulation of inflammatory cells in the periph- 
eral tissues of smokers’ lungs appears to be pivotal (Fin-
kelstein et al. 1995; Abboud et al. 1998), and proteases 
from inflammatory cells have multiple potential roles in 
causing injury. 
Inflammatory cells linked to the development of 
emphysema include neutrophils, macrophages, and lym-
phocytes. How inflammatory cells are first recruited and 
activated in response to smoking remains incompletely 
understood, but the inflammatory process, once initiat-
ed, can persist for years after smoking has stopped. Thus, 
emphysematous tissues from transplant surgery and sur-
gery to reduce lung volume show large numbers of inflam-
matory cells, even among persons who stopped smoking 
long before the surgery (Retamales et al. 2001; Shapiro 
2001). In addition, some evidence from serial chest CT 
examinations indicates that emphysema also progresses 
after the cessation of smoking (Soejima et al. 2000). Prod-
ucts of neutrophils and macrophages can degrade extra-
cellular matrix, inactivate PIs, and convert proenzymes to 
their active matrix-degrading form. 
The role of lymphocytes in emphysema has been a 
topic of research over the past decade (Finkelstein et al. 
1995; Cosio et al. 2002; Boschetto et al. 2003), and find-
ings indicate that T-cell factors can induce macrophages 
to express proteases (Grumelli et al. 2004). ROS, both in 
cigarette smoke and released by inflammatory cells or epi-
thelial cells, impinge on protease-antiprotease balance in 
the lungs in multiple ways, including inactivation of AAT, 
increased expression of chemokines such as IL-8, activa-
tion of MMPs, and induction of the transcription of NF-kB, 
leading to increased expression of MMPs (MacNee 2005b). 
Three discoveries in the 1960s linked elastases to 
emphysema: (1) association between early-age onset of 
Figure 7.18 Pathogenesis of smoking-induced pulmonary emphysema
Note: Three pathways for pathogenesis are shown. The circles indicate steps in which proteases are or may be involved. (1) Smoke 
components recruit inflammatory cells to the lower respiratory system via factors released from alveolar macrophages and structural 
cells of the lungs. Recruited cells, macrophages, and structural cells release proteases and reactive oxygen species that degrade the 
extracellular matrix of the respiratory tissues. (2) Smoke components directly affect viability of lung cells, leading to liberation of 
proteases that can degrade lung matrix. (3) Smoke components may disrupt the function of protease inhibitors such as α1-antitrypsin, 
facilitating the activity of proteases. AAT = α1-antitrypsin; PMNs = polymorphonuclear neutrophils.
Pulmonary Diseases  489
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease
emphysema and deficiency of AAT (Eriksson 1965); (2) 
production of emphysema in experimental animals by 
putting elastolytic proteases, such as papain, directly 
into the lung (Gross et al. 1965); and (3) demonstration 
that neutrophils contain and release a potent elastolytic 
enzyme (Janoff and Scherer 1968). Together, these dis-
coveries led to formulation of the “elastase-antielastase” 
hypothesis for the pathogenesis of emphysema. This 
hypothesis posits development of emphysema in response 
to unchecked intrapulmonary activity of neutrophil elas-
tase due to an excess of inflammatory cells, a deficiency 
of intrapulmonary elastase inhibition, or a combination 
of increased elastolytic burden and decreased elastase 
inhibitory capacity. This hypothesis remains tenable, but 
it does not incorporate more recent data indicating that 
(1) MMPs, including collagenases from inflammatory 
cells and lung structural cells (Table 7.10) (Foronjy and 
D’Armiento 2001), are associated with emphysema and (2) 
the destruction of alveolar walls in emphysema may begin 
with death of alveolar cells rather than with degradation 
of the alveolar extracellular matrix (Kasahara et al. 2001; 
Aoshiba et al. 2003b; Tuder et al. 2003b). 
Proteases
Data from Human Studies
Several types of data link proteases to the causa-
tion of emphysema in humans: (1) assays of proteolytic 
Table 7.10 Matrix metalloproteinases in emphysema
Study
Emphysema 
detection Test samples Observations Comments








No increase in expression 
of macrophage elastase 
(MMP-12)




BAL fluid •	 Increased	collagenase	activity
•	 Increased	gelatinase	B	(MMP-9)
MMPs probably neutrophil 
derived  
Ohnishi et al. 
1998




No increase in expression 
of macrophage elastase 
(MMP-12)








MMPs in BAL fluid from 
inflammatory cells; no 
increase in gelatinase B 
(MMP-9) in AM culture 
media in emphysema 
Segura-Valdez 
et al. 2000
Histology Lung tissue from 






MMPs expressed by both 
inflammatory cells and 
structural cells of lung
Imai et al. 2001 Histology Lung tissue from 
lung transplantation 
and  LVRS
•	 Increased	collagenase	1	(MMP-1) Collagenase expressed by 
type II cells; no increase in 






Cellular DNA •	 Increased	gelatinase	B	(MMP-9)	
polymorphism in smokers with 
emphysema
Polymorphism also 
associated with increased 
incidence of coronary 
atherosclerosis
Source: Adapted from Hogg and Senior 2002 with permission from BMJ Publishing Group Ltd., © 2002.
Note: AM = alveolar macrophage; BAL = bronchoalveolar lavage; LVRS = lung volume reduction surgery; MMP = matrix 
metalloproteinase; mRNA = messenger RNA; MT = membrane type. 
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activity and protease content in BAL fluid; (2) measure-
ments of protease proteins, proteolytic activities, and pro-
tease mRNAs associated with alveolar macrophages from 
emphysematous lung; (3) immunostains of proteases in 
emphysematous tissue; and (4) determinations of prote-
ase mRNAs in lung tissue. The association between AAT 
deficiency and emphysema is perhaps the strongest evi-
dence (American Journal of Respiratory and Critical Care 
Medicine 2003).
Bronchoalveolar Lavage
The BAL technique samples cells and mediators 
from the lower respiratory tract, but in COPD the volumes 
of lavage recovered are often low (Linden et al. 1993; Soler 
et al. 1999), and the presence of emphysema adversely 
influences the recovery of BAL fluid (Löfdahl et al. 2005). 
In one study of patients with COPD who were scored for 
emphysema by chest CT, patients with high scores had 
recoveries of fluid less than one-half the volume for those 
with low scores. 
Numerous studies have examined proteases in BAL 
fluid. In studies with evaluation for emphysema, it appears 
that protease levels were higher in some persons with 
emphysema than they were in control groups (Muley et 
al. 1994; Yoshioka et al. 1995; Betsuyaku et al. 1995, 1996, 
1999, 2002, 2003; Finlay et al. 1997a,b; Abboud et al. 1998; 
Takeyabu et al. 1998). The proteases included elastase, 
both free and in complex with AAT; MMP-1, -8, -9, -12, and 
-14; and cysteine proteases. However, interpretation of 
these data is limited by three considerations: (1) although 
emphysema is documented by CT, quantification of the 
emphysema is not reported in most studies; (2) studies do 
not always explicitly state whether persons with emphy-
sema are current smokers; and (3) some control groups 
included nonsmokers and smokers. Regardless of these 
problems, the presence of emphysema is associated with 
no more than modest, approximately twofold, increases in 
proteases.
Numerous factors are known to regulate MMPs, a 
class of proteases increasingly implicated in emphysema, 
but few studies have assessed the expression of MMP regu-
latory factors in the context of emphysema. In one study, 
levels of the extracellular MMP inducer, basigin, a trans-
membrane protein that stimulates production of several 
MMPs, were much higher in BAL fluid from current and 
former smokers than from those who never smoked (Bet-
suyaku et al. 2003). Among smokers, however, levels did 
not differ for persons with or without emphysema.
Alveolar Macrophages
Alveolar macrophages appear to have a central 
role in orchestrating inflammation in COPD through 
production of cytokines, chemokines, and ROS, in addi-
tion to being a source of proteases and PIs (Barnes 2004a; 
Shapiro 2005). However, few studies have focused on 
macrophages from lungs with documented emphysema 
(Muley et al. 1994; Betsuyaku et al. 1995; Finlay et al. 
1997b), and in these studies the measurements have been 
from macrophages that have been in culture, making 
the relevance of the findings to the in vivo state unclear. 
Despite these caveats, studies of emphysema suggest an 
increase in alveolar macrophage mRNA for MMP-1 (col-
lagenase 1) and MMP-9 (gelatinase B) (Finlay et al. 1997a; 
Betsuyaku et al. 1999). Regardless of the presence of 
emphysema, however, alveolar macrophages from smok-
ers express more MMP-9, an elastolytic protease, than 
do those from nonsmokers (Russell et al. 2002a). MMPs 
appear to account for most of the elastolytic activity 
released from alveolar macrophages of persons with COPD 
(Russell et al. 2002b). MMP-12, a protease strongly impli-
cated in smoke-induced emphysema in mice (Hautamaki 
et al. 1997), was more recently found to be increased in 
macrophages of persons with COPD (Molet et al. 2005). 
The role of current smoking is not clear in this observa-
tion, however, and diagnosis of emphysema was not docu-
mented in the study.
Promising techniques are becoming available for 
analysis of the products of alveolar macrophages in asso-
ciation with smoking, COPD, and emphysema (Koike et 
al. 2002; Wu et al. 2005). Considering that most of the 
macrophages within the lungs are associated with tissue, 
analysis of alveolar macrophages harvested by BAL may 
not represent all the phenotypes of macrophages in the 
lung. Laser-capture microdissection of pulmonary mac-
rophages from histological lung sections is a method for 
procuring macrophages within the tissue, as well as in 
alveolar spaces (Fuke et al. 2004), and future use of this 
approach is expected to provide much more data on mac-
rophage proteases in the context of emphysema. 
Studies of Lung Tissue
Immunohistochemistry. Studies of emphysema-
tous lung tissue support the hypothesis that proteases are 
involved in the pathogenic process. With use of antibody 
to human elastin, several types of abnormalities of elastic 
fiber were found in the lungs of persons with emphysema, 
including fragmented elastic fibers in AAT deficiency and 
poorly formed elastic fibers and clumps of elastin in smok-
ers with centriacinar emphysema (Fukuda et al. 1989). 
The clumps appear to be from synthesis of new aberrant 
elastin, resembling changes observed in experimental 
elastase-induced emphysema (Kuhn et al. 1976). In lungs 
confirmed to have emphysema, alveolar macrophages, 
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interstitial cells, and epithelial cells express immunore-
active MMP-1 and MMP-2 (gelatinase A) (Segura-Valdez 
et al. 2000). Structural cells in emphysematous lungs 
express MMP-1 (Imai et al. 2001) and MMP-14 (mem-
brane-type 1 MMP [MT1-MMP]) (Ohnishi et al. 1998).
Gene profiling. Gene profiling of emphysematous 
lung tissue has found only limited changes in proteases 
and PIs in comparisons with control lung tissue (Golpon 
et al. 2004; Ning et al. 2004; Spira et al. 2004). However, 
these data represent small numbers of lungs, and esti-
mates of emphysema by chest CT or morphometry of fixed 
lung have not been uniformly provided. Also, the tissue 
analyzed has not always been limited to alveolar parenchy-
ma. Gene profiling does not quantify neutrophil proteases 
and circulating PIs produced at sites other than the lungs.
Direct effects of cigarette smoke. Cigarette 
smoke has long been thought to induce protease expres-
sion in the lungs indirectly through cytokines (Churg 
et al. 2002, 2004), but smoke may act directly on struc-
tural cells of the lungs to induce protease expression. 
In response to exposure to smoke, human small airway 
epithelial cells (Mercer et al. 2004) and human lung fibro-
blasts (Kim et al. 2004) in culture increased expression of 
MMP-1 without a concomitant increase in the expression 
of tissue inhibitor of metalloproteinase (TIMP)-1. In some 
studies, cytokines enhanced the direct effects of smoke 
(Mercer et al. 2004). 
Biomarkers of Protease Involvement in 
Emphysema
As noted previously, elastic fibers in emphysematous 
lung tissue show disruptions and fenestrations of the elas-
tin (Fukuda et al. 1989; Finlay et al. 1996) that suggest 
degradative events (see “Studies of Lung Tissue” earlier 
in this chapter). Elastin-derived peptides (desmosines) 
in plasma, serum, and BAL fluid are markers of elastin 
breakdown. A number of desmosine assays have been 
devised, and a highly sensitive, precise assay method (Ma 
et al. 2003) has been applied in studies of AAT supplemen-
tation therapy (Stolk et al. 2005). Increased urinary des-
mosines have been reported in smokers (Stone et al. 1995) 
and in persons who had rapid declines in FEV1 (Gottlieb et 
al. 1996), but the presence of emphysema was not deter-
mined. Similarly, levels of elastin-derived peptides found 
in BAL fluid from current smokers were higher than those 
from former smokers and lifetime nonsmokers, regard-
less of associated mild COPD or emphysema (Betsuyaku et 
al. 1996). 
Therapy to Control Proteases
The most direct antiprotease therapy for control 
of emphysema is supplementation with AAT for patients 
with severe AAT deficiency (American Journal of Respi-
ratory and Critical Care Medicine 2003). Usually given 
intravenously once a week, this therapy appears to slow 
the rate of decline in FEV1, reduce the number of lung 
infections, enhance survival, and reduce lung inflamma-
tion as measured by sputum markers, although the opti-
mal dose is still under study (Stoller and Aboussouan 2004; 
Stolk et al. 2005). In patients with moderate-to-advanced 
emphysema who are not AAT deficient, oral all-trans reti-
noic acid lowered plasma levels of MMP-9 and release of 
MMP-9 from alveolar macrophages without affecting lev-
els of TIMP-1, so the balance of protease activity appeared 
to shift toward protease inhibition (Mao et al. 2003). 
Whether these effects translate into a therapeutic benefit 
for emphysema is uncertain.
Data from Animal Models
By incorporating measurements and experimental 
designs that are not possible in human studies, animal 
models have improved understanding of the role of prote-
ases in emphysema and are useful in evaluating agents for 
antiprotease therapy in patients with emphysema (Hele 
2002; Voelkel 2004). 
Most recent models of emphysema have used mice. 
These animals provide the convenience of genetic manip-
ulation, and findings indicate that humans and mice may 
have shared susceptibility factors for exposure to smoke 
(Shapiro et al. 2004). Emphysema can be induced in nor-
mal mice with cigarette smoke (Hautamaki et al. 1997) 
but significant differences in susceptibility exist among 
strains (Cavarra et al. 2001a; Guerassimov et al. 2004). 
By genetic manipulation, emphysema can be induced in 
resistant strains. For example, mice deficient in Nrf2, a 
transcription factor for antioxidant and detoxifying genes, 
develop emphysema in response to smoke, even though 
their ICR strain is normally resistant to the effect of smoke 
(Rangasamy et al. 2004). Overexpression of certain pro-
teins in the lung (e.g., IL-13) can lead to emphysema with-
out exposure to an exogenous factor (Table 7.11) (Zheng 
et al. 2000). However, deleting the expression of certain 
proteins, such as surfactant protein D (Wert et al. 2000) 
and TIMP-3 (Leco et al. 2001), in the lungs can also lead to 
the development of emphysema. Inflammation is a com-
mon feature of these and other models, but inflammation 
does not appear to be required in all models. Emphysema 
induced by an MMP-1 transgene (D’Armiento et al. 1992) 
or by severe caloric restriction (Massaro and Massaro 
2004) occurs without overt inflammation.
Although enlarged terminal air spaces are the 
hallmark of emphysema, it is important to distinguish 
between enlargement attributable to faulty alveolar forma-
tion during development and that occurring after normal 
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lung development. Thus, models of enlargement in which 
alveolar development is abnormal, such as in MT1-MMP 
deficiency (Atkinson et al. 2005), may not be relevant to 
human emphysema associated with smoking, in which 
the presumption is that the lung was previously normal. 
Despite strong evidence implicating elastases in 
the pathogenesis of emphysema, research findings begin-
ning in 1992 (D’Armiento et al. 1992) indicate that col-
lagenolytic enzymes that do not degrade elastin may also 
be involved in the pathogenesis of emphysema. The key 
discovery was the finding of emphysema in mice engi-
neered to harbor a transgene consisting of a haptoglobin 
promoter linked to the human MMP-1 (interstitial colla-
genase) gene. These mice show expression of the Mmp-1 
gene in lung tissue, enlarged air spaces, bullous lesions, 
and reduced collagen fibers in alveolar walls and pleura. 
Depending on the level of transgene expression, the lung 
lesions can start either soon after birth or later, indicating 
that the emphysema is clearly postdevelopmental (Foron-
jy et al. 2003). Apart from demonstrating that collagenase 
activity could lead to emphysema, results with these mice 
also suggest two conclusions: (1) lung inflammation was 
minimal, indicating that proteases causing emphysema 
could come from structural cells of the lungs; and (2) the 
elastic fibers in the lung showed minimal inflammation, 
indicating that emphysema can occur without obvious 
disruption and resynthesis of elastic fibers. 
Models of Emphysema Involving Cigarette Smoke
Model systems for exposing mice to cigarette smoke 
to produce emphysema vary in the cigarettes used, the 
manner in which cigarette smoke is delivered, and assess-
ment of the dose of smoke actually reaching the animals. 
Standard research cigarettes are commonly used, and the 
exposure is produced by directing smoke from a single 
cigarette to the nose of a mouse restrained in a single-
body compartment or by exposing groups of mice that are 
free to move in a chamber in which cigarette smoke is put 
into the atmosphere. The intensity of exposure to smoke, 
if monitored, is typically indexed by the level of carboxy-
hemoglobin in the blood (Wright and Churg 1995). The 
smoking regimens usually require nearly daily exposures 
for months to achieve emphysema. 
As noted previously, strains of mice can exhibit 
extremely different susceptibility to the development of 
emphysema from smoke inhalation (see “Susceptible Ani-
mal Models” earlier in this chapter). These differences in 
susceptibility are matched by differences in the accumula-
tion of lymphocytes and neutrophils in the lung tissue. 
Higher numbers of these cell types in the tissue is associ-
ated with emphysema.
For four decades, elastases have been foremost in 
pathogenetic schemes linking proteases to the pathogen-
esis of emphysema, and in recent years, the importance 
of elastases has been supported in studies involving mice 
Table 7.11 Mouse models of overexpression of a protein leading to emphysema
Study Mediator Promoter Lung pathology Mechanism




Haptoglobulin Disruption of alveolar 
walls and coalescence of 
alveolar spaces
Degradation of collagen by 
collagenase
Wang et al. 2000 Interferon-gamma CC10-rtTA Emphysema with alveolar 
enlargement, enhanced 
lung volumes, and 
enhanced pulmonary 
compliance
Increased macrophages and 
neutrophils in BAL fluid; 
decreased secretory leukocyte 
proteinase inhibitor; increased 
MMP-9 and -12 and cathepsins  
B, D, H, L, and S
Zheng et al. 2000 Interleukin-13 CC10-rtTA Emphysema with 
enhanced lung volumes 
and compliance, 
mucus metaplasia, and 
inflammation
Increased MMP-2, -9, -12, -13, 
and -14 and cathepsins B, H, K, 
L, and S; treatment with MMP or 
cysteine proteinase antagonists 
significantly decreased 
emphysema and inflammation 
but not mucus
Source: Adapted from Mahadeva and Shapiro 2002 with permission from BMJ Publishing Group Ltd., © 2002. 
Note: BAL = bronchoalveolar lavage; CC10-rtTA = clara cell 10-kDa protein promoter-reversible tetracycline transactivator; 
MMP = matrix metalloproteinase.
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with deficiencies of macrophage elastase (Hautamaki et al. 
1997) or neutrophil elastase (Shapiro et al. 2003). Mice 
with no macrophage elastase have virtually complete pro-
tection from smoke-induced emphysema; mice without 
neutrophil elastase have approximately 70 percent protec-
tion. The finding that a “knockout” of either of these elas-
tolytic enzymes is protective indicates interplay between 
these enzymes in the pathogenesis of emphysema. The 
evidence suggests that neutrophil elastase is the principal 
culprit in matrix degradation and that macrophage elas-
tase acts, at least partly, as a proinflammatory agent by 
facilitating release of TNFα (Churg et al. 2004) and as a 
shield for neutrophil elastase by the capacity to cleave AAT. 
Although overexpression of collagenase, as described 
above, has been associated with emphysema, studies 
have performed only limited assessment of collagenase 
expression in response to smoke. In guinea pigs exposed 
to smoke, collagenase mRNA and protein were found in 
alveolar macrophages and structural cells of the lungs 
coincident with decreased lung collagen and enlarged air 
spaces (Selman et al. 1996). 
Antiprotease Therapy for Experimental Smoke-
Induced Emphysema
As noted previously, studies of gene disruption have 
shown that inactivating the genes for MMP-12 (Hauta-
maki et al. 1997) or neutrophil elastase (Shapiro et al. 
2003) provides major protection against the development 
of emphysema from cigarette smoke (see “Alveolar Mac-
rophages” earlier in this chapter). Similarly, PIs against 
MMPs or neutrophil elastase have proved effective in mice, 
in limiting the enlargement of air spaces associated with 
exposure to cigarette smoke (Table 7.12). Various routes 
of administration have been tried; ilomastat, a broad- 
spectrum MMP inhibitor, produced highly significant pro-
tection when inhaled (Pemberton et al. 2005). These stud-
ies consistently show that compounds protecting against 
emphysema also produce a concurrent reduction of the 
typical inflammatory response to exposure to smoke. 
Accordingly, PIs should be regarded as anti-inflammatory 
agents, as well as antiproteases. 
Apoptosis
In contrast to findings in the lungs of nonsmokers, 
apoptotic epithelial cells are identifiable in the lungs of 
smokers (Segura-Valdez et al. 2000; Kasahara et al. 2001; 
Calabrese et al. 2005), and they are found in isolated 
alveolar macrophages subjected to cigarette smoke in 
vitro (Aoshiba et al. 2001a). The apoptotic cell types include 
alveolar macrophages and lung structural cells. Apoptosis, 
proteases, and emphysema were linked when emphysema 
developed within six hours after the protease CASPASE-3 
was instilled into the lungs of mice (Aoshiba et al. 2003b). 
Apoptosis and emphysema have also been produced by 
intrapulmonary instillation of VEGF receptor block-
ers (Kasahara et al. 2000) and by producing a temporary 
reduction in lung VEGF by intratracheal administration of 
an adeno-associated CRE recombinase virus to mice that 
have a floxed VEGF (Tang et al. 2004). The mechanisms 
by which apoptosis leads to emphysema are still not well 
Table 7.12 Effects of protease inhibitors in experimental smoke-induced emphysema
Study Animal Drug/route/frequency Smoking protocol Protection against emphysemaa 

























Note: AAT = α1-antitrypsin.
aGraded by air space enlargement in comparison of animals exposed to tobacco smoke with unexposed animals. 
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understood. In the CASPASE-3 study (Aoshiba et al. 
2003b), elastase activity was found in BAL fluid, and 
induction of apoptosis of alveolar type II cells in culture 
resulted in liberation of elastin peptides from an elastin 
substrate culture medium. Accordingly, in this model, 
apoptosis appears to induce emphysema by causing pro-
teolytic degradation of extracellular matrix. 
Summary
Since its inception about 40 years ago, the prote-
ase-antiprotease hypothesis of emphysema pathogenesis 
has gained increasing support from studies in persons 
with emphysema and from those using animal models 
of emphysema. The high risk of emphysema among per-
sons with AAT deficiency, particularly current smokers, 
continues to be compelling evidence for the linking of 
smoking and neutrophil elastase to emphysema. However, 
other proteases, particularly certain MMPs, appear to be 
involved in emphysema. Success in protecting mice from 
smoke-induced emphysema through genetic manipula-
tions of proteases or by treatment with PIs has reinforced 
the protease-antiprotease hypothesis. For many years, the 
hypothesis specifically focused on elastase-antielastase 
imbalance and inflammatory cells infiltrating the lung as 
the source of proteases. These ideas have been modified 
in recent years to encompass discoveries that collageno-
lytic activity may produce emphysema and that structural 
cells of the lungs may contribute to the protease burden 
of the lung. Despite great progress, much more needs 
to be known about the proteolytic mechanisms involved 
in the pathogenesis of emphysema, such as the role of 
immune cells in protease regulation in emphysema 
and the effects of proteases on structural cells of the 
lungs. New techniques for analyzing biologic materials, 
combined with the capacity to document and quan-
tify emphysema noninvasively, offer promise for better 
understanding of the role of proteases in emphysema in 
the years ahead. 
Summary
COPD is a rising cause of morbidity and mortality 
in the United States and elsewhere. Smoking has long 
been causally linked to COPD, and decades of clinical and 
experimental research have provided insights into the 
mechanisms underlying this causal linkage. The extensive 
evidence reviewed in this chapter highlights the critical 
role of oxidative injury, driven by the high level of ROS in 
cigarette smoke. COPD is the only disease caused by ciga-
rette smoking that is associated with genetic mutations 
leading to AAT deficiency. This genetic association led to 
the protease-antiprotease hypothesis on the pathogenesis 
of emphysema that is now well supported by work in ani-
mal models. The ROS in cigarette smoke and secondarily 
released by epithelial and inflammatory cells can unfavor-
ably tip the protease-antiprotease scale in multiple ways. 
Although these mechanisms are now well characterized, 
the factors leading to COPD in the minority of affected 
smokers are not completely understood.
Evidence Summary
This chapter addresses mechanisms of lung injury 
by tobacco smoke that lead to development of COPD and 
considers the role of genetic factors, including specific 
genes, in increasing risk for COPD. The chapter acknowl-
edges that COPD is a broad phenotypic designation with 
underlying damage and structural changes in the lung’s 
airways and alveoli. This section systematically evaluates 
the evidence related to genetic susceptibility and to the 
two major mechanisms of injury considered: oxidative 
stress and protease-antiprotease imbalance.
Oxidative Stress
Cigarette smoke contains massive quantities of free 
radicals in its gas and tar phases; concentrations of free 
radicals are 1015 per puff and 1017 per gram, respectively. 
The approximately 200 or more puffs inhaled daily by a 
typical smoker of one pack per day would lead to a sus-
tained high-level daily dose of free radicals. The chemical 
pathways by which these free radicals produce damaging 
ROS have been well characterized, as have the chemical 
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reactions by which ROS damage target molecules, includ-
ing lipids, proteins, and DNA. The plausibility of oxidative 
stress as a mechanism of disease production is well docu-
mented and further affirmed through biomarker studies.
In various experimental systems, oxidative stress 
from exposure to cigarette smoke causes damage to com-
ponents of the lung: the epithelium, the airways, and 
the alveoli. In humans, smoking is followed by a rise in 
markers of systemic oxidative stress and of oxidative stress 
affecting the lungs more specifically. The time course of 
the response to oxidative stress from smoking has also 
been characterized, showing a rise in markers after expo-
sure to tobacco smoke. There is also substantial evidence 
for increased levels of oxidative stress markers in the lungs 
of persons with COPD. This large body of experimental and 
observational evidence is consistent in demonstrating that 
ROS can damage the lung and that evidence of oxidative 
stress is strongly linked with COPD. Oxidative stress is one 
of several mechanisms contributing to the development of 
COPD. However, the available evidence has not addressed 
whether oxidative stress is a necessary mechanism or suf-
ficient by itself to cause COPD.
Genetic Susceptibility to  
Cigarette Smoke
All smokers do not develop COPD, indicating that 
smoking alone is not sufficient to cause COPD. A variety 
of lines of evidence support a role for genetic factors in 
determining susceptibility to cigarette smoke. Familial 
aggregation of phenotypes for lung function and for COPD 
has been repeatedly demonstrated. In addition, there is 
strong clinical and epidemiologic evidence on genetically 
inherited AAT deficiency and risk for emphysema. This 
chapter offers the conclusion that protease-antiprotease 
imbalance is involved in the development of emphysema 
and sufficient by itself to produce it.
The general observation that smoking alone does 
not lead universally to COPD, and the specific observa-
tion that genotypes associated with severe AAT deficiency 
lead to emphysema, imply a role for genetic factors in the 
pathogenesis of emphysema. To date, however, genetic 
loci other than SERPINA1 have not been linked to risk 
for COPD. 
Protease-Antiprotease Imbalance
Emphysema is a prominent and highly prevalent 
component of the COPD phenotype. The potential role of 
a protease-antiprotease balance shifted toward unchecked 
proteolytic activity was first identified with the finding of 
enhanced risk for emphysema in persons with AAT and the 
supporting experimental demonstration that emphysema 
could be produced experimentally by proteolytic enzymes. 
These enzymes damage the elastin in the lung, which is 
essential to maintaining the lung’s elasticity and ventila-
tory function. Thus, it is directly plausible that this mech-
anism has a role in producing emphysema. 
Three lines of evidence support a role for protease-
antiprotease imbalance in causing emphysema. First, in 
experimental models and in smokers, a shift of protease-
antiprotease balance in a destructive direction has been 
repeatedly demonstrated, as has corresponding injury to 
elastin fibers. Second, in animal models, instillation of 
proteolytic enzymes can produce emphysema, as does 
exposure to cigarette smoke. Genetically engineered mice 
with deficient macrophage or neutrophil elastase are pro-
tected from smoke-induced emphysema. Third, persons 
with homozygous AAT deficiency who smoke develop 
emphysema at a young age.
This substantial consistent and complementary 
evidence supports a causal role for protease-antiprotease 
imbalance in the pathogenesis of emphysema, a criti-
cal element of the COPD phenotype. This mechanism 
is also substantially plausible because of the impor-
tance of elastin in determining ventilator function. The 
evidence further indicates that protease-antiprotease 
imbalance is sufficient to produce emphysema in smokers. 
Human evidence comes from the long-described and well- 
documented occurrence of early-onset emphysema in 
smokers with low levels of AAT consequent to mutations 
of SERPINA1. Findings in animal models confirm the suf-




1. Oxidative stress from exposure to tobacco smoke has 
a role in the pathogenetic process leading to chronic 
obstructive pulmonary disease.
2. Protease-antiprotease imbalance has a role in the 
pathogenesis of emphysema.
3. Inherited genetic variation in genes such as SERPI-
NA3 is involved in the pathogenesis of tobacco-caused 
chronic obstructive pulmonary disease.
4. Smoking cessation remains the only proven strategy 
for reducing the pathogenetic processes leading to 
chronic obstructive pulmonary disease.
Implications
Two major mechanisms underlying the causation of 
COPD by cigarette smoking have been identified: oxidative 
stress (injury) and protease-antiprotease imbalance. These 
mechanisms are triggered by the inhalation of combus-
tion products directly into the lungs of smokers. Although 
the lung has defense mechanisms that function to check 
injury by inhaled agents, these defenses are overwhelmed 
by the sustained inhalation of cigarette smoke. Doses of 
inhaled smoke that could be tolerated without resulting in 
oxidative injury and protease-antiprotease imbalance have 
not been identified. Smoking cessation remains the only 
way to check and halt these processes.
COPD is the only disease caused by smoking that 
is strongly associated with a specific genetic disorder, 
namely, AAT deficiency. The occurrence of COPD in young 
smokers should trigger testing for AAT deficiency, but 
such screening is not recommended for the general popu-
lation. Studies in progress are expected to extend under-
standing of the genetic basis of COPD.
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Introduction
Health professionals have long considered expo-
sure to tobacco smoke harmful to reproduction, affecting 
aspects from fertility and pregnancy outcome to fetal and 
child development. Tobacco smoke contains thousands 
of compounds, some of which are known to have toxic 
effects on reproductive health, such as carbon monoxide 
(CO), nicotine, and metals. Along with more than four 
million births in the United States annually, 10 to 20 per-
cent of pregnancies end in miscarriage or stillbirth before 
delivery, and another 10 percent of couples who want to 
conceive a child experience infertility or reduced fertil-
ity. In 2007, 17.4 percent of all women and approximately 
19 percent of women of reproductive age (18 through 44 
years) smoked cigarettes (Centers for Disease Control and 
Prevention [CDC] 2008). Smoking rates among women of 
reproductive age vary by other factors such as education, 
race, and geographic area, ranging from about 10 percent 
in Utah to nearly 30 percent in Kentucky and West Virginia 
(CDC 2005). From 2002 to 2005, 17.3 percent of pregnant 
women reported smoking cigarettes in the past month 
(NSDUH Report 2007). CDC’s Pregnancy Risk Assessment 
Monitoring System is an ongoing, population-based sur-
veillance system designed to identify and monitor selected 
self-reported maternal behaviors and experiences that 
occur before, during, and after pregnancy among women 
who deliver a live infant. In 2002, the prevalence of smok-
ing in the three months before pregnancy ranged from 
13.6 percent (Utah) to 37.0 percent (West Virginia); in the 
last three months of pregnancy, from 6.8 percent (Utah) 
to 25.3 percent (West Virginia); and after pregnancy, from 
9.0 percent (Utah) to 33.7 percent (West Virginia) (Wil-
liams et al. 2006). Prevalence of smoking is generally 
higher among men. In 2003, 24.1 percent reported smok-
ing and prevalence was higher among younger men than 
among older men. This chapter examines reproductive 
and developmental outcomes, although the term “repro-
ductive” may be used generally to describe both, in rela-
tion to smoking.
The reproductive endpoints include aspects 
affecting a person’s ability to conceive a child, such as 
menstrual cycle function, semen quality, fertility, and 
menopause, in addition to complications of pregnancy, 
such as miscarriage, ectopic pregnancy, and preterm 
delivery. Developmental endpoints that affect child 
health status include birth weight, congenital anoma-
lies, and perinatal and infant deaths—especially sudden 
infant deaths and sudden unexplained infant deaths 
which have been associated with exposure to second-
hand smoke—and they extend into childhood with neu-
robehavioral endpoints and puberty. Previous Surgeon 
General’s reports have examined epidemiologic data for 
most of these endpoints. This chapter cites conclusions 
from those earlier reports, examines in more detail 
endpoints for which the evidence was not sufficient to 
establish causality, and provides an updated review of the 
epidemiologic literature for these endpoints. Other sec-
tions explore the possible biologic basis for an effect of 
smoking on reproduction and development from the 
pathophysiological levels to the cellular and genetic levels. 
When studying the reproductive effects of smoking 
in humans, there are several exposure issues to bear in 
mind. Most studies have examined the effects of active 
smoking on fertility or pregnancy. For the past decade, 
interest has also increased in the effects of secondhand 
exposure to tobacco smoke, so these studies are men-
tioned when available (U.S. Department of Health and 
Human Services [USDHHS] 2006). Because smoking rates 
have declined, persons who are involuntarily exposed to 
tobacco smoke probably now outnumber active smok-
ers. Thus, many nonsmokers are exposed to some of the 
same toxins to which smokers are exposed. The problem 
of involuntary exposure may be particularly pervasive 
for women who stop smoking during pregnancy. They 
may live with partners or family members who continue 
to smoke, so the potential still exists for exposure to 
tobacco smoke in the household. Such an exposure may 
also occur in the workplace. However, local, state, and fed-
eral laws against smoking in the workplace have led to 
a decline in this type of exposure. The critical exposure 
periods may be very specific for certain pregnancy out-
comes or congenital anomalies, but most epidemiologic 
studies do not seek such detailed information about 
exposure to tobacco smoke. For endpoints of child devel-
opment, postnatal exposure to tobacco smoke may also 
be important but difficult to separate from prenatal expo-
sure, because the two are correlated. 
Current smoking may be assessed for reproductive 
endpoints such as fertility, but this timing may not reflect 
exposure during the critical period when fertility began 
if the woman has stopped smoking as a result of ongo-
ing fertility problems. Fertility may also be affected by her 
partner’s smoking, either directly or indirectly as exposure 
to secondhand smoke. Research shows the long-lasting 
effects of prenatal exposures on later health, even in adult-
hood. Thus, age at puberty, fertility, or even maintenance 
of a pregnancy may be affected by in utero exposure to 
tobacco smoke, but this relationship is rarely studied. For 
age at menopause, patterns of exposure to tobacco smoke 
over a lifetime may be important. 
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Reproductive Endpoints
Menstrual Function, Menarche, and Menopause
Menstrual Cycling
The effects of exogenous exposures on menstrual 
function have become the focus of much research. Stud-
ies of these effects are hindered because cyclic patterns of 
menstruation vary and do not have one well-defined health 
endpoint. For example, some menstrual disturbances such 
as irregularity do not have standard definitions, and oth-
ers, such as dysmenorrhea (painful menstruation), may 
be subjective. However, menstrual morbidity has a signifi-
cant impact on women’s health and economics (e.g., phy-
sician visits and time lost from work) (Harlow and Ephross 
1995). Furthermore, menstrual cycle patterns are a useful 
marker of ovarian function and reproductive health and 
may affect risks of chronic disease. The 2004 Surgeon 
General’s report on the health consequences of smoking 
did not examine menstrual function or menopause, but 
the 2001 report on women and smoking reached sugges-
tive conclusions that are expanded upon here (USDHHS 
2001, 2004).
Beginning in the 1960s, numerous studies have 
examined menstrual function in relation to smoking, 
but most were focused on dysmenorrhea or other self-
reported symptoms. As summarized in the 2001 Surgeon 
General’s report on women and smoking (USDHHS 2001), 
the prevalence of dysmenorrhea was increased with cur-
rent smoking, with intermediate effects among former 
smokers (Brown et al. 1988; Parazzini et al. 1994; Harlow 
and Park 1996; Mishra et al. 2000), but not in all studies 
(Andersch and Milsom 1982). A Chinese study of exposure 
to secondhand smoke in nonsmoking women reported an 
adjusted risk for dysmenorrhea that increased with higher 
exposure levels (Chen et al. 2000). In examining multi-
ple endpoints or symptoms, a community survey in Los 
Angeles, California, revealed that the prevalence of phy-
sician-attended menstrual disorders (e.g., dysmenorrhea 
and oligomenorrhea) was higher among heavy smokers 
(≥15 cigarettes per day) than among nonsmokers (Sloss 
and Frerichs 1983). A postal survey in England found that 
compared with nonsmokers, smokers more frequently 
reported six of seven aspects of “abnormal” menstruation, 
including frequent, short, or irregular periods and pro-
longed and heavy bleeding (Brown et al. 1988). 
Similarly, other worldwide studies have reported 
higher risks of multiple symptoms, including premen-
strual tension, heavy periods, severe pain, and frequent 
and irregular periods among smokers, especially heavy 
smokers (Kritz-Silverstein et al. 1999; Mishra et al. 2000). 
Additional studies reported increased risks of short and/or 
irregular cycles among smokers, with some dose-response 
relationships observed (Kato et al. 1999; Rowland et al. 
2002). Using prospective menstrual diaries to improve 
ascertainment, Hornsby and colleagues (1998) found more 
reporting of dysmenorrhea, an increased daily amount of 
bleeding, and a shorter duration of bleeding among smok-
ers. The findings suggested that heavy smokers (>10 ciga-
rettes per day) had irregularity or greater variability in 
cycle length than did nonsmokers. However, the study had 
limited power to examine higher smoking levels, and the 
study sample was selective in that the participants’ moth-
ers had participated in a clinical trial of diethylstilbestrol 
while pregnant with them.
Other studies have assessed menstrual cycle param-
eters by measuring hormone levels to define lengths of 
phases in the cycle. A small study noted cycles of heavy 
smokers that were, on average, 1.6 days shorter than cycles 
of nonsmokers, and the mean follicular phase was shorter 
by 1.4 days (Zumoff et al. 1990). A study based on dia-
ries and daily measurement of urinary levels of hormone 
metabolites reported that heavy smoking (≥20 cigarettes 
per day) was also associated with menstrual cycle lengths 
that were shorter by 2.6 days and more variable than those 
of nonsmokers (Windham et al. 1999b). The shortening of 
the cycle occurred primarily during the follicular phase. 
The findings also suggested an increased risk of a short 
luteal phase (<11 days) and anovulation, but the confi-
dence intervals (CIs) for these endpoints were wide and 
not significant. The mean duration of bleeding in smok-
ers was not different. Another study, based on diaries of 
workers in the semiconductor industry, as well as levels 
of hormone metabolites, found little difference in cycle 
length among smokers compared with nonsmokers (Liu 
et al. 2004a). However, this finding was modified by age: 
shorter follicular phases were associated with smoking 
only among women older than 35 years of age. The data 
also revealed a nonsignificant increase in risk of anovu-
lation among smokers. Dose-response relationships were 
not examined (Liu et al. 2004b).
Alterations in menstrual cycle function may have 
several ramifications, including a burden on the health 
care system. Dysmenorrhea may lead to a loss of work 
productivity. Women with variable cycle lengths may 
have difficulty trying to conceive, because the timing of 
ovulation is less predictable. Anovulation has an obvious 
relevance for time to conception or fertility. Cycles that 
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are shortened during the follicular phase might indicate 
abnormal folliculogenesis and ovum maturation. A short 
luteal phase may indicate a progesterone response that is 
inadequate for implantation and maintenance of the tro-
phoblast. Studies have implicated a luteal phase defect as 
a cause of infertility as well as a cause of recurrent spon-
taneous abortion (SAB) (Regan et al. 1990; Tulppala et al. 
1991). These effects are consistent with evidence for asso-
ciation of smoking with decreased fertility (see “Fertility” 
later in this chapter). Women with short menstrual cycles 
may also be at a higher risk of breast cancer (Kelsey et 
al. 1993).
Reproductive Life Span—Menarche  
to Menopause
Smoking may also affect the duration of menstrual 
cycling (reproductive life span). The 2001 Surgeon Gener-
al’s report on women and smoking summarized numerous 
studies that consistently found a younger age at natural 
menopause among women who smoked than that for 
nonsmokers (USDHHS 2001). The studies also concluded 
that smokers may have more menopausal symptoms. In 
an earlier meta-analysis, the difference in the mean age 
at natural menopause ranged from 0.8 to 1.7 years (Midg-
ette and Baron 1990). This same meta-analysis showed 
a prevalence ratio for being postmenopausal that was 
nearly doubled among current smokers versus lifetime 
nonsmokers, with dose-response trends by the number of 
cigarettes smoked. Later studies confirmed these findings 
(Cooper et al. 1999; Harlow and Signorello 2000; Meschia 
et al. 2000; Brett and Cooper 2003). One study reported 
a decrease in mean age at natural menopause with cur-
rent active smoking but did not find an association among 
former smokers or with exposure to secondhand smoke 
(Cooper et al. 1999). However, two studies that were more 
briefly described found an earlier age at menopause with 
exposure to secondhand tobacco smoke (Everson et al. 
1986; Tajtakova et al. 1990). In a population-based study 
in the United States, smoking was weakly associated with 
transition to menopausal status and strongly associated 
with postmenopausal status (Brett and Cooper 2003). This 
finding led the authors to suggest that the menopausal 
transition period may be shortened in smokers. 
On the other end of the spectrum, some studies have 
examined age at menarche (start of menstrual periods) in 
relation to parental smoking. On the basis of data from a 
longitudinal birth cohort study, daughters whose mothers 
had smoked heavily during pregnancy had an earlier mean 
age at menarche by several months (Windham et al. 2004). 
This effect was greater among non-Whites than among 
Whites. Two studies from Poland reported a younger 
age at menarche for daughters of smoking mothers than 
that for daughters of nonsmoking mothers (Kolasa 1997; 
Kolasa et al. 1998). A retrospective study of teachers found 
a slightly higher risk of early menarche among women 
who reported that during their childhoods, their par-
ents had smoked at home (Reynolds et al. 2004). These 
later studies primarily examined exposure to secondhand 
smoke, and the timing with respect to puberty was not 
established. However, mothers who smoked postnatally, 
especially before smoking was socially prohibited, may 
have smoked during pregnancy as well. Windham and col-
leagues (2004) showed that girls with high prenatal and 
childhood exposure to secondhand smoke had the earliest 
mean age at menarche. One study examined the effects of 
parental smoking on puberty in both boys and girls and 
reported earlier pubertal milestones in boys whose moth-
ers had smoked during pregnancy, but not in girls. How-
ever, the study had such small numbers that the power 
to examine age at menarche was insufficient (Fried et al. 
2001). 
Changes that affect the reproductive life span can 
have an impact on other aspects of a woman’s health. 
Shorter cycles may lead to a more rapid depletion of 
oocytes, shortening the reproductive life span and leading 
to earlier menopause (Whelan et al. 1990; Bromberger et 
al. 1997). Early menopause is associated with other hor-
mone-related health problems such as osteoporosis and 
cardiovascular disease (Harlow and Ephross 1995; Sow-
ers and La Pietra 1995; Cooper and Sandler 1998). Early 
menarche or puberty may lead to psychosocial problems, 
adolescent pregnancy and attendant risks, other adverse 
reproductive outcomes, and breast cancer (Hardy et al. 
1978; Liestol 1980; MacMahon et al. 1982a; Martin et al. 
1983; Sandler et al. 1984; Wilson et al. 1994; Ge et al. 
1996; He and Karlberg 2001).
Fertility
Fertility is an endpoint that is difficult to compare 
across studies, because no standard definition exists. 
Fecundity refers to the biologic ability to conceive, given 
unprotected intercourse, and depends on the reproductive 
capacity of both sexual partners. The clinical definition of 
infertility in the United States usually connotes lack of con-
ception after one year of unprotected intercourse during 
the fertile phase. However, couples who delay childbearing 
may seek treatment before one year, which further com-
plicates studies. Subfertility refers to any form of reduced 
fertility in couples trying to conceive, and one way to study 
it is by measuring time to conception or pregnancy. One 
commentary indicated that about 20 percent of couples 
experience subfertility, defined as the inability to conceive 
within six months (Gnoth et al. 2005). About 50 percent 
of these couples conceive in the next six months, leaving 
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10 percent of couples that match the clinical definition of 
infertility. Another 50 percent will likely conceive sponta-
neously in the next three years, leaving 5 percent infertile. 
Smoking affects fertility in men and women, as well as the 
success of in vitro fertilization (IVF).
Fertility in Females
Numerous studies have found associations of smok-
ing with reduced fertility. The 2001 Surgeon General’s 
report concluded that “women who smoke have increased 
risks for conception delay and for both primary and sec-
ondary infertility” (USDHHS 2001, p. 14). The 2004 Sur-
geon General’s report also reviewed the literature and 
concluded that “the evidence is sufficient to infer a causal 
relationship between smoking and reduced fertility in 
women” (USDHHS 2004, p. 7). Other reviews have found 
consistent decrements in fertility associated with smoking, 
as well as evidence for dose-response trends. In a meta-
analysis of data from 12 studies, the odds ratio (OR) was 
1.6 (95 percent CI, 1.3–1.9) for infertility among smokers 
(Augood et al. 1998). Furthermore, meta-analyses of data 
on IVF treatment indicated a reduction in fecundity (con-
ception rate per cycle) among women smokers ranging 
from 0.57 (95 percent CI, 0.42–0.78) to 0.66 (95 percent 
CI, 0.49–0.88) (Hughes and Brennan 1996; Augood et al. 
1998). In a later qualitative review of 22 studies, all but 3 
of the studies indicated a detrimental effect of smoking on 
female fecundity (Wilks and Hay 2004). The Practice Com-
mittee of the American Society for Reproductive Medicine 
(PCASRM) also issued a statement strongly supporting 
evidence for an association between smoking and infertil-
ity, estimating that 13 percent of infertility may be attrib-
utable to smoking (PCASRM 2004).
Several studies also examined the effects of expo-
sure to secondhand tobacco smoke on fertility, but these 
effects may be difficult to separate from the direct effects 
of smoking on the partner’s fecundity. Researchers have 
reviewed these studies and found suggestive but incon-
sistent results (National Cancer Institute [NCI] 1999; 
USDHHS 2001, 2006), so there are insufficient data to 
reach conclusions. A study published since two of those 
reviews examined the effects of exposure to mainstream 
and sidestream smoke on IVF outcomes. The research-
ers found that implantation and pregnancy rates were 
reduced by about one-half from both types of exposure to 
tobacco smoke among smokers compared with nonsmok-
ers (Neal et al. 2005). The investigators noted that the 
association of exposure to sidestream smoke may reflect 
some direct effect of smoking on the male partners. How-
ever, they claimed that this could not explain the entire 
effect in that they observed no difference in implantation 
and pregnancy rates by the partner’s smoking level. 
Intriguingly, some studies have also examined the 
effects of in utero exposure to maternal smoking on later 
fertility or fecundability. One study found a significantly 
reduced likelihood of conception in smokers versus non-
smokers (fecundability ratio [FR]) of 0.5 (Weinberg et al. 
1989); another study found a slightly reduced FR of 0.9 
(Wilcox et al. 1989); and a third study found a slightly 
increased FR of 1.1 but also observed no effect of active 
smoking among the women (Schwingl 1992). In the 
range of these studies, a Danish study reported FRs for in 
utero exposure to cigarette smoking of 0.70 among adult 
nonsmokers and 0.53 among smokers, as well as 0.67 for 
female smokers with no in utero exposure, all compared 
with that for nonsmokers who had no in utero exposure 
(Jensen et al. 1998b). This study also found a similarly 
decreased fecundability in males exposed to smoking 
in utero.
Effects on Semen Quality and Male Fertility
For decades, epidemiologic studies have investi-
gated the effects of cigarette smoking on semen quality, 
because of its relationship to male fertility (Campana et al. 
1996; Eggert-Kruse et al. 1996; Bonde et al. 1998; Chia et 
al. 2000), although this relationship is not always predic-
tive (Polansky and Lamb 1988; Guzick et al. 2001). Semen 
quality is measured by seminal plasma constituents and 
sperm cell characteristics such as ejaculate volume, sperm 
count, sperm motility, and sperm morphology. The World 
Health Organization (WHO) Laboratory Manual for the 
Examination of Human Semen and Sperm-Cervical Mu-
cus Interaction (WHO 1980, 1987, 1992, 1999b) provides 
reference values for many semen parameters associated 
with fertility. A number of epidemiologic studies of smok-
ing effects have used WHO reference values to categorize 
participants by their fertility status. Reproductive hor-
mones are important determinants of normal sperm pro-
duction and male sexual function and have thus also been 
studied in relation to exposure to cigarette smoking (see 
“Endocrine System” later in this chapter).
The 2004 Surgeon General’s report reviewed the 
published epidemiologic literature evaluating semen 
quality and fertility and concluded that “the evidence is 
inadequate to infer the presence or absence of a causal 
relationship between active smoking and sperm quality” 
(USDHHS 2004, p. 28). However, “the evidence suggests 
that smokers may have decreased semen volume and 
sperm number and increased abnormal [morphologic] 
forms, although any clinical relevance of these findings 
is not clear” (USDHHS 2004, p. 534). A stronger causal 
statement could not be made at that time because of vari-
ability in published findings across studies. Reviews on 
this topic (Mattison 1982; Stillman et al. 1986; Little and 
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Vainio 1994; Vine 1996; Marinelli et al. 2004; PCASRM 
2004) and one meta-analysis of data from 20 studies cover-
ing 1966–1992 (Vine et al. 1994) attribute this variation in 
the findings across studies to weaknesses in study designs. 
These weaknesses include a failure to adjust for potential 
confounders, small sample sizes, inadequate exposure 
assessments, and the use of fertility clinic populations. 
Subsequent to the 2004 Surgeon General’s report 
(USDHHS 2004), the PCASRM review (2004), and the 
review by Marinelli and colleagues (2004), some publica-
tions have strengthened the evidence for decrements in 
adult semen quality and fertility associated with exposure 
to tobacco smoke either prenatally or in adulthood (Table 
8.1). Both studies in Table 8.1 that evaluated adult semen 
quality after in utero exposure found decrements in sperm 
concentration (Storgaard et al. 2003; Jensen et al. 2004). 
Studies conducted in clinical settings using assisted 
reproductive technology with extremely sensitive mea-
sures of fertilization and very early pregnancy loss also 
reported adverse effects from paternal smoking. Some 
studies had low power for detecting effects, but one of the 
largest studies, which was based on a retrospective review 
of records, did not find independent effects of cigarette 
smoking. However, the researchers reported a reduction 
in seminal volume, sperm concentration, and the percent-
age of motile sperm in men who smoked and consumed 
alcohol, behaviors that tend to be correlated (Martini et 
al. 2004). Another study based on a retrospective review 
of medical records for exposure assessments could not 
include more than 46 percent of the medical records ini-
tially reviewed, because of insufficient data, particularly 
data related to smoking (Ozgur et al. 2005). Although the 
study found no significant differences in sperm density, 
normal sperm tail morphology decreased or abnormal 
forms increased. 
Spermatogenesis in the adult testes depends on a 
hormonal milieu that is temporally and compartmentally 
specific (e.g., seminiferous tubule, interstitial space, and 
epididymis). Thus, factors likely to be responsible for the 
decrements seen in semen quality and male fertility are 
constituents of cigarette smoke that influence the nor-
mal development and adult function of the hypothalamus 
and pituitary gland or that influence the differentiation, 
development, and adult function of Leydig and/or Sertoli 
cells that secrete hormones (see “Endocrine System” later 
in this chapter). Support for the contribution of smoking 
effects on hormonal factors to male fertility is still evolv-
ing (Meikle et al. 1989; Michnovicz et al. 1989; Sofikitis 
et al. 1995; Chapin et al. 2004). Other potential mecha-
nisms of smoking for male infertility include effects on 
the sperm plasma membrane (Belcheva et al. 2004) and 
tobacco-related damage to DNA and/or chromosomes in 
gametes (PCASRM 2004) (see “Genetic Damage to Sperm” 
later in this chapter). Studies have associated in utero 
exposure to polycyclic aromatic hydrocarbons (PAHs) in 
tobacco smoke with adverse effects on male fertility and 
on testes (see “Polycyclic Aromatic Hydrocarbons” later in 
this chapter). Additional targeted research in human pop-
ulations with use of molecular laboratory tools will help to 
elucidate the mechanisms underlying these observations.
Study designs have not addressed the timing of 
exposures in relation to sperm cell maturation in the 
testes, the formation and secretion of fluids contributed 
by accessory organs outside the testes, and events dur-
ing fertilization. This information is critical to unravel-
ing mechanisms of the toxic effects of tobacco smoke, 
determining whether these exposures result in long-term 
risks to male reproductive health, and documenting the 
benefits of smoking cessation. For example, if spermato-
gonial stem cells prove to be the cells most sensitive to 
exposure to tobacco smoke, then long-term consequences 
might be observed even after smoking cessation. However, 
if mechanisms of toxic effects relate primarily to effects 
on epididymal sperm or to direct effects on mature sperm 
in the ejaculate from seminal plasma constituents, then 
smoking cessation could result in immediate benefits.
Pregnancy Complications
This section addresses a variety of complications 
that may occur during pregnancy. These complications 
primarily represent difficulties the pregnant mother may 
experience trying to maintain a healthy pregnancy, but 
there also may be wide-ranging effects on the health of 
the fetus or the offspring. In general, these conditions 
may be influenced by maternal age, reproductive history, 
and medical history or conditions affecting the maternal 
endocrine or immune systems, uterine structure, and 
cardiovascular system, among others. Exogenous expo-
sures may also play a role in causing or exacerbating these 
conditions. This section briefly presents the etiology of 
these complications and puts potential smoking-induced 
mechanisms into context. (For details on the mechanisms 
of these complications, see “Pathophysiological and Cel-
lular and Molecular Mechanisms of Smoking” later in 
this chapter.) 
Spontaneous Abortion
SAB is typically defined as the involuntary termi-
nation of an intrauterine pregnancy before 20 weeks 
of gestation. Studies have reported recognized SABs in 
approximately 12 percent of pregnancies, and most occur 
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Table 8.1 Association of adult cigarette smoking and in utero exposure to cigarette smoke with semen parameters 
and fertility in adultsa
Study Population
Study 
period Definition of smoking Findings
Effects from 
adult smoking
           
Chia et al. 2000 240 fertile and 218 
infertile men from 
obstetric and andrology 
clinic populations
NR Self-reported number 
of cigarettes/day and 
smoking history
•  Smoking predictive of risk of infertility
Trummer et al. 
2002
260 smokers, 70 
former smokers, and 
258 nonsmokers 






•  NS difference in density, motility, and mor-
phology
Gaspari et al. 
2003
69 current smokers, 22 
former smokers, and 
88 lifetime nonsmokers 
from infertility clinic 
population, 75 with 
1-year follow-up for 
fertility
2001 Self-reported number 
of cigarettes/day and 
smoking history
•  PAH-DNA adducts in sperm associated with 
infertility but not cigarette smoking 
•  PAH-DNA adducts associated directly with 
abnormal forms of sperm and inversely with 
asthenospermia
Künzle et al. 
2003
655 smokers and 
1,131 nonsmokers 






•  Lower sperm density, total motile cells, and 
citrate concentration
•  Fewer morphologically normal cells
•  Higher pH
•  No significant difference in volume, vitality, 
and fructose concentration
Loft et al. 2003 225 women with first 
pregnancy, 74 male 






•  Likelihood of pregnancy in a menstrual 
cycle inversely associated with 8-oxo-dG 
concentrations, but levels not associated 
with smoking status
Zitzmann et al. 
2003





nonsmoker or smoker 
(≥5 cigarettes/day for 
2 years)
•  Paternal smoking predictive of fertilization 
in IVF but not in ICSI
•  Paternal smoking predictive of clinical preg-
nancy in ICSI and IVF
•  Increased progressive motility and decreased 
normal forms of sperm among smokers
Chen et al. 
2004
22 smokers, 57 former 
smokers, and 227 
nonsmokers from 
infertility clinic 
population in study of 






smoker, or lifetime 
nonsmoker
•  NS differences in concentration, motility, 
and morphology of sperm
Jurasovic et al. 
2004




NR Self-reported number 
of cigarettes/day
•  Decreased blood prolactin
•  Positive correlation with blood cadmium
•  NS differences in concentration, motility, 
and morphology of sperm
Martini et al. 
2004
3,430 nonsmokers, 
422 light smokers, and 
124 heavy smokers 





review of records 
for cigarettes/day: 0, 
1–20, >20
•  NS differences in concentration, motility, 
and morphology of sperm across categories 
of smoking independent of alcohol intake
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Study OR, RR, or % (95% CI or p value) Comments
Effects from  
adult smoking
     
Chia et al. 2000 Infertility in smokers compared with nonsmokers = 2.96  
(1.98–4.42)
None
Trummer et al. 
2002
NR None
Gaspari et al. 
2003
Smokers = 1.58 
Nonsmokers = 1.62 in relative staining intensity (NS) 
PAH-DNA adducts associated with abnormal head (r = 0.3), 
abnormal neck (r = -0.2), and abnormal physiological forms  
(r = -0.2)
None
Künzle et al. 2003 Decreased density by 15.3%, p = 0.0001
Decreased total motile cells by 16.6%, p = 0.002
Decreased normal forms by 10.6%, p = 0.0007
Decreased citrate concentration by 22.4%, p = 0.007
Correlation of alcohol intake 
and smoking (p = 0.002) after removing 
heavy drinkers because moderate alcohol 
intake has not been associated with 
infertility; no adjustment
Loft et al. 2003 Correlation of smoking and 8-oxo-dG 
concentrations
Spearman correlation 0.02 (NS)
Adequate semen count required to 
extract enough DNA for bioassay because 
variance by smoking may bias findings
Zitzmann et al. 
2003
ICSI pregnancy failures in partners of male smokers compared 
with partners of nonsmokers 
2.95 (1.32–6.59)
IVF pregnancy failures in partners of male smokers compared 
with partners of nonsmokers
2.65 (1.33–5.30)
None
Chen et al. 2004 NS 20% decrease in sperm density in current smokers compared 
with lifetime nonsmokers
Small number of smokers
Jurasovic et al. 
2004
Decreased blood prolactin (p = 0.02) 
Correlations with blood: Cadmium, +0.80 (p <0.001),
Selenium, -0.26 (p <0.01), Selenium-glutathione, 
peroxidase, -0.30 (p <0.001)
None
Martini et al. 
2004
Significantly decreased density by 11%, decreased total motile 
sperm 10%, decreased rapid sperm by 14% for men who smoked 
>1 cigarette and drank ≤52 grams of ethanol/day compared with 
no smoking or drinking




before 12 weeks of gestation (Regan et al. 1989). However, 
very early pregnancy loss may go unrecognized and/or 
unreported. An estimated 30 to 45 percent of conceptions 
actually end in pregnancy loss (Wilcox et al. 1988; Eske-
nazi et al. 1995). Studies of tissue from SABs suggest that 
50 to 80 percent of losses have an abnormal karyotype, 
depending on the mother’s age and the gestational age at 
the time of the loss; a higher proportion of abnormalities 
is found in losses at earlier gestational ages (Kajii et al. 
1980; Hogge et al. 2003; Philipp et al. 2003). In addition 
to fetal abnormalities, other factors that likely contribute 
to SAB include maternal anatomical abnormalities of the 
uterus, immunologic disturbances, thrombotic disorders, 
and endocrine abnormalities (Christianson 1979; Cramer 
and Wise 2000; Regan and Rai 2000). Infections may also 
play a role, but data are limited and inconsistent (Cramer 
and Wise 2000; McDonald and Chambers 2000; Matovina 
et al. 2004). 
Several studies have demonstrated a moderate 
association between smoking and SAB (DiFranza and Lew 
1995). The 2004 Surgeon General’s report on the health 
consequences of smoking found the evidence suggestive 
but not sufficient to infer a causal relationship between 
smoking and SAB (USDHHS 2004). However, numerous 
studies are available since the handful reviewed at that 
time (Table 8.2), and most show positive associations. 
These results represent both retrospective and prospec-
tive study designs from a number of different countries, 
with adjustment for various confounders. One study 
found an association with amount smoked before preg-
nancy (Nielsen et al. 2006), and another reported an 
association among former smokers (Mishra et al. 2000), 
but others did not observe these associations (Chatenoud 
et al. 1998; Wisborg et al. 2003). The later study had a 
very low SAB rate of approximately 1 percent, so many 
SABs were likely missed, particularly early in pregnancy. 
Two studies used a measurement of cotinine to verify 
exposure to tobacco smoke and found relatively high risks 
of SAB (Ness et al. 1999; George et al. 2006). Estimates of 
the increase in risk of SAB from smoking are 30 to 100 
percent, some in a dose-response pattern (Kline et al. 
1977; Chatenoud et al. 1998; USDHHS 2004; George et al. 
2006; Nielsen et al. 2006). In a meta-analysis of data from 
13 studies, the pooled ORs for SAB in smokers were 1.24 
(95 percent CI, 1.19–1.30) for cohort studies and 1.32 (95 
percent CI, 1.18–1.48) for case-control studies (DiFranza 
and Lew 1995). In one study, the association with smoking 




period Definition of smoking Findings
Ozgur et al. 
2005
116 heavy smokers, 
82 light smokers, and 





review of records 
for cigarettes/day: 0, 
1–19, ≥20
•  Increased rapidly motile cells among smokers 
of ≥20 compared with 1–19 cigarettes/day
•  Increased coiled-tail defects among smokers
•  NS difference in density and total motile cells 
in nonsmokers compared with heavy smokers
Effects during 




           
Storgaard et al. 
2003






Maternal recall of 
smoking during 
pregnancy: 0, 1–10, 
11–20, >20 cigarettes/
day
•  In utero exposure to >10 cigarettes/day 
associated with lower sperm density (48%), 
lower inhibin B, and higher follicle-stimu-
lating hormone
•  No dose-response relationship or signifi-
cant change in other semen parameters or 
hormones
Jensen et al. 
2004
1,770 military inductees 
from Denmark, Estonia, 




Maternal recall of 
maternal and paternal 
smoking during 
pregnancy: yes, no
•  Lower sperm concentration and total sperm 
count among those exposed to smoking
•  NS difference in sperm motility, 
morphology, or testis size
Note: 8-oxo-dG = 7-hydroxy-8-oxo-2’-deoxyguanosine; CI = confidence interval; ICSI = intracytoplasmic sperm injection; 
IVF = in vitro fertilization; NR = not reported; NS = not statistically significant; OR = odds ratio; PAH = polycyclic aromatic 
hydrocarbon; RR = rate ratio.
aNot included in the 2004 Surgeon General’s report on the health consequences of smoking.
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et al. 1995), but another study did not find a differential 
effect by chromosomal abnormality (George et al. 2006).
In examining exposure to secondhand smoke, 
the 2006 Surgeon General’s report on the health conse-
quences of involuntary exposure to tobacco smoke con-
cluded that the evidence was “inadequate to infer the 
presence or absence of a causal relationship” with SAB, 
on the basis of a few studies with inconsistent results 
(USDHHS 2006, p. 13). Since then, two studies have found 
an association with secondhand smoke on the order of 60 
to 80 percent, one with a biomarker of cotinine (George 
et al. 2006) and one that examined very early fetal loss 
(Venners et al. 2004). Another study did not find an asso-
ciation in examining only paternal smoking (Chatenoud 
et al. 1998), and one found an effect of exposure to second-
hand smoke at either home or work only among women 
who also consumed alcohol or high amounts of caffeine 
(Windham et al. 1999c). 
Proposed mechanisms for an effect from tobacco 
smoke include fetal hypoxia from exposure to CO, vaso-
constrictive and antimetabolic effects resulting in placen-
tal insufficiency and the subsequent death of the embryo 
or fetus (PCASRM 2004), and direct toxic effects of con-
stituents of cigarette smoke. 
Ectopic Pregnancy
Ectopic pregnancy occurs when a fertilized egg is 
implanted outside the uterus, usually within the fallopian 
tube. It is estimated to occur in 1 to 2 percent of pregnan-
cies (Chow et al. 1987; Goldner et al. 1993; Van Den Eeden 
et al. 2005) and accounts for approximately 6 percent of 
pregnancy-related deaths in the United States (Berg et al. 
2003; Chang et al. 2003). Factors associated with ectopic 
pregnancy include a history of sexually transmitted dis-
eases and pelvic inflammatory disease, increased number 
of sexual partners, maternal age, history of SAB, history 
of surgical procedures affecting the fallopian tubes, previ-
ous use of an intrauterine device, and vaginal douching 
(Kendrick et al. 1997; Pisarska et al. 1998; Bouyer et al. 
2003). Affected women are at increased risk of infertility 
and recurrent ectopic pregnancy in subsequent pregnan-
cies (Chow et al. 1987; Coste et al. 1991; Washington and 
Katz 1993; Skjeldestad et al. 1998), as would be expected 
among women with tubal damage.
The 2004 Surgeon General’s report found the 
evidence suggestive but not sufficient to infer a causal 
relationship between smoking and ectopic pregnancy 
(USDHHS 2004). A number of studies have associated 
Study OR, RR, or % (95% CI or p value) Comments
Ozgur et al.  
2005
Decreased rapidly motile cells by 30% at ≥20 compared with 
1–19 cigarettes/day (p <0.05)
Decreased normal tail morphology by 18% for smokers of ≥20 
cigarettes/day compared with nonsmokers (p <0.05)
Retrospective review of records with no 
exposure validation measures; missing 
data on more than 46% of records
Effects during 
adulthood of in 
utero exposure to 
cigarette smoke
     
Storgaard et al. 
2003
Decreased sperm concentration by 48%
(-69 to -11%) at exposure of >10 cigarettes/day
None
Jensen et al.  
2004
Decreased sperm concentration by 20.1%
(6.8–33.5%) 





Table 8.2 Association between maternal smoking and spontaneous abortion (SAB), 1998–2006
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smoking with ectopic pregnancy, and in a meta-analysis 
of data from nine studies, the OR from pooled data on 
ectopic pregnancy from smoking was 1.77 (95 percent CI, 
1.31–2.22) (Castles et al. 1999). In addition, two other 
studies also reported significant associations between 
smoking and ectopic pregnancy (Bouyer et al. 2003; Karaer 
et al. 2006). Both found evidence of a dose-response rela-
tionship, even after adjustment for important potential 
confounders, such as a history of sexually transmitted dis-
eases and infertility. In one study, the magnitude of the 
association of ectopic pregnancy and smoking was similar 
to that seen with infectious causes (Bouyer et al. 2003). 
In addition, plausible mechanisms for a relationship 
between smoking and ectopic pregnancy exist. The ovi-
duct plays a critical role in the pickup and transport of the 
oocyte, and failure of this function can result in ectopic 
pregnancy. Both in vivo and in vitro studies showed that 
smoking impairs mammalian oviduct function (Talbot and 
Riveles 2005).
Preeclampsia
Preeclampsia is a syndrome of reduced organ perfu-
sion attributable to vasospasm and endothelial activation 
with an onset after 20 weeks of gestation that is marked by 
proteinuria, hypertension, and dysfunction of the endothe-
lial cells lining the uterus (National High Blood Pressure 
Education Program 2000; Sibai et al. 2005). The disease 
can be mild or severe. When accompanied by seizures 
that cannot be attributed to other causes, the diagnosis is 
established as eclampsia by exclusion. Preeclampsia affects 
approximately 2 to 8 percent of pregnancies (American 
Journal of Obstetrics and Gynecology 1988; Duley 2003; 
Zhang et al. 2003; Villar et al. 2004), and the incidence 
is highest in nulliparous women. The reported incidence 
varies widely, likely because of variation in population 
characteristics such as parity, race and/or ethnicity, and 
environmental factors (Zhang et al. 1997), as well as het-
erogeneity in classification systems (American Journal of 
Obstetrics and Gynecology 1988; Villar et al. 2004). Pre-
eclampsia is a leading cause of pregnancy-related mortal-
ity in the United States (Berg et al. 2003). Morbidity and 
mortality are particularly high with early-onset disease 
(<33 weeks of gestation) (Sibai 2003; von Dadelszen et al. 
2003). Preeclampsia is also associated with fetal growth 
restriction, placental abruption, and perinatal death (Sibai 
et al. 2005). 
Risk factors for preeclampsia include preexist-
ing medical conditions, multifetal gestation, an elevated 
body mass index (BMI), and older maternal age (Sibai et 
al. 2005). Immunologic factors have also been implicated 
(Zhang et al. 1997; Dekker and Robillard 2003; Einarsson 
et al. 2003), as have infectious and/or inflammatory 
conditions (Sibai et al. 2005). Evidence from epidemio-
logic and physiological studies has led to several hypoth-
eses on the cause of preeclampsia. First, preeclampsia 
seems to be characterized by poor formation of the 
placenta (placentation) with a shallow invasion of the 
decidua and myometrium by trophoblast cells, resulting in 
an incomplete transformation of maternal spiral arteries 
that then retain their muscular characteristics (Brosens 
et al. 1972; Naicker et al. 2003). This process leads to pla-
cental ischemia and reperfusion and results in increased 
oxidative stress and vascular disease. Poor placentation in 
preeclamptic pregnancies could be the result of maternal-
fetal immune maladaptation (Sibai et al. 2005). Research-
ers think that the clinical manifestations of preeclampsia 
result from the release of placental factors in response to 
ischemic conditions, resulting in the endothelial dysfunc-
tion of maternal circulation (Roberts and Redman 1993). 
Endothelial dysfunction is characterized by a disruption 
in regulatory functions of vasomotor tone through coagu-
lation, by platelet activity, and by fibrinolysis in the vascu-
lar endothelium (Roberts et al. 1989, 1991). It is unclear 
which placental factors may be involved, but one hypoth-
esis is that an imbalance between proangiogenic and anti-
angiogenic factors may contribute. Animal and human 
studies support the hypothesis that angiogenic proteins 
may play a role in the etiology of preeclampsia (Maynard 
et al. 2003; Levine et al. 2004).
Smoking is inversely associated with preeclampsia; 
the pooled risk reduction is 32 percent (Conde-Agudelo et 
al. 1999). The 2004 Surgeon General’s report found the 
evidence sufficient to infer a causal relationship between 
smoking and a reduced risk of preeclampsia (USDHHS 
2004). Whether a dose-response relationship exists is 
unclear because study results are conflicting (Marcoux et 
al. 1989; Klonoff-Cohen et al. 1993; Zhang et al. 1999). 
Investigators have proposed three mechanisms through 
which smoking could reduce the risk of preeclampsia 
(Maynard et al. 2003; Fisher 2004): 
1. exposure to thiocyanate, which has a hypotensive 
effect (Andrews 1973); 
2. inhibition of thromboxane A2 production, a potent 
vasoconstrictor and platelet aggregation stimulator, 
or increase in levels of prostacyclin, a vasodilator and 
platelet aggregation inhibitor (Ylikorkala et al. 1985; 
Davis et al. 1987; Marcoux et al. 1989), both of which 
would improve the ratio of thromboxane A2 to prosta-
cyclin (Lindqvist and Maršál 1999); and 
3. stimulation of proangiogenic factors, such as vas-
cular endothelial growth factor (VEGF), and/or 
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reduction in antiangiogenic factors, such as soluble 
VEGF receptor Flt-1 (sFlt-1) (Maynard et al. 2003; 
Fisher 2004; Jeyabalan et al. 2008). 
Placenta Previa
Placenta previa is the complete or partial obstruc-
tion of the cervical os by the placenta that affects approxi-
mately 0.4 percent of all births (Comeau et al. 1983; Iyasu 
et al. 1993; Faiz and Ananth 2003). Placenta previa has 
been associated with maternal and infant complications, 
such as preterm delivery, a hemorrhage that requires a 
blood transfusion, maternal death, and fetal or neonatal 
death (Salihu et al. 2003; Creasy et al. 2004). Neonatal 
mortality in pregnancies complicated by placenta previa 
may be up to three times higher than that in the gen-
eral obstetric population (Salihu et al. 2003). The cause 
of placenta previa is unknown. However, risk factors with 
plausible etiologic mechanisms include advanced mater-
nal age, multiparity, multifetal gestation, and a history of 
a cesarean section or a previous abortion (Ananth et al. 
2003; Faiz and Ananth 2003; Creasy et al. 2004). 
Epidemiologic studies have consistently reported 
an increased risk of placenta previa among smokers, and 
many studies show a dose-response relationship (Meyer et 
al. 1976; Zhang and Fried 1992; Monica and Lilja 1995). 
The estimated relative risks (RRs) from smoking are 1.3 to 
3.0 (Castles et al. 1999; Andres and Day 2000; Cnattingius 
2004). The 2004 Surgeon General’s report found the evi-
dence sufficient to infer a causal relationship between 
smoking and placenta previa (USDHHS 2004). A mecha-
nism commonly proposed to explain this association is the 
chronic hypoxemia and ischemia that result from smok-
ing, with compensatory placental enlargement. However, 
not all studies have shown a clinically significant increase 
in placental size in smokers (Zhang et al. 1999; Larsen et 
al. 2002). 
Placental Abruption
Placental abruption, the premature separation of 
the placenta from the uterine wall, affects 0.5 to 2 per-
cent of pregnancies (Rasmussen et al. 1996a; Ananth et 
al. 2001, 2005; Kyrklund-Blomberg et al. 2001). However, 
reported perinatal mortality in affected women is 8 to 12 
percent (Raymond and Mills 1993; Ananth and Wilcox 
2001; Kyrklund-Blomberg et al. 2001). Abruption may 
account for up to 14 percent of perinatal deaths (Rasmus-
sen et al. 1996b; Ananth and Wilcox 2001). Ananth and 
Wilcox (2001) estimated that the perinatal mortality rate 
associated with abruption was 119 per 1,000 births com-
pared with 8.2 per 1,000 among all births. Abruption can 
also result in neonatal asphyxia (Heinonen and Saarikoski 
2001), preterm delivery, and maternal disseminated intra-
vascular coagulation if thromboplastic material is released 
into the mother’s circulatory system (Hladky et al. 2002). 
It is likely that the etiology of placental abruption 
is multifactorial (Misra and Ananth 1999). Potential risk 
factors include advanced maternal age (35 years or older), 
high parity, previous abruption, a history of infertility, 
preterm premature rupture of membranes (PPROM), 
small for gestational age (SGA), infant congenital mal-
formations, multifetal pregnancy, hypertensive disorders, 
polyhydramnios, thrombophilia, diabetes, trauma, sud-
den uterine decompression, previous cesarean section, 
and uterine infections (Abdella et al. 1984; Williams et 
al. 1991; Raymond and Mills 1993; Ananth et al. 1996a,b; 
Kramer et al. 1997; Rasmussen et al. 1999; Cunningham 
et al. 2001; Kyrklund-Blomberg et al. 2001). Underlying 
causes of abruption could include vessel fragility, vascular 
malformations, uterine scarring from previous cesarean 
section, and placentation abnormalities (Dommisse and 
Tiltman 1992; Rasmussen et al. 1999; Hladky et al. 2002). 
In addition, failure of the maternal spiral arteries to trans-
form into low-resistance dilated vessels could predispose 
the mother to ischemia and vessel rupture (Eskes 1997). 
In one study, a high percentage of placentas from women 
with severe abruption showed an absence of trophoblastic 
transformation, and not all cases were attributable to pre-
eclampsia (Dommisse and Tiltman 1992). 
Studies have consistently associated smoking with 
an increased risk of placental abruption. Relative risks 
range from 1.4 to 1.9 (Raymond and Mills 1993; Ananth 
et al. 1999; Castles et al. 1999; Andres and Day 2000). 
The 2004 Surgeon General’s report found the evidence 
sufficient to infer a causal relationship (USDHHS 2004). 
In addition, study findings support a dose-response rela-
tionship (Ananth et al. 1999). Raymond and Mills (1993) 
found a 20-percent increase in the risk of abruption for 
every 10 cigarettes the mother smoked per day. Etio-
logic mechanisms proposed by researchers to explain this 
relationship include smoking-related degenerative and/or 
inflammatory changes in the placenta (Cnattingius 2004); 
decreased vitamin C (ascorbic acid) levels in smokers 
(Faruque et al. 1995), leading to impaired collagen syn-
thesis (Cnattingius 2004); microinfarcts; and atheroma-
tous changes in placental vessels (Naeye 1979; Andres 
and Day 2000) (see “Placenta” and “Maternal and Fetal 
Cardiovascular System” later in this chapter). Analyses 
of consecutive pregnancies indicate that abruption risk is 
decreased when women stop smoking between pregnan-
cies, suggesting that effects of smoking are transient and 





Delivery at less than 37 completed weeks of gestation 
(preterm delivery) is a leading cause of neonatal mortality 
and morbidity in developed countries and is often divided 
into categories of moderate preterm (32 to 36 weeks) and 
very preterm (<32 weeks) delivery. Preterm delivery com-
plicated 12.3 percent of pregnancies in the United States 
in 2003 (Hamilton et al. 2004). Rates of preterm delivery 
in the United States and other industrialized countries 
have been increasing in the past decade and are partially 
attributable to an increase in the frequency of multiple 
births (Hamilton et al. 2004).
The underlying causes of preterm delivery are com-
plex and multifactorial. Contributing factors include 
multigestational pregnancy, preeclampsia, placental 
abruption, placenta previa, intrauterine infections, uter-
ine overdistension, and abnormal uterine anatomy, in 
addition to disorders of the cervix, endocrine system, and 
placenta. Other risk factors include race (e.g., African 
Americans have higher risk), low socioeconomic status 
(SES), underlying maternal medical conditions, genito-
urinary infections, poor maternal weight gain or nutri-
tion, young or advanced maternal age, short maternal 
stature, and fetal abnormalities (Haram et al. 2003; Iams 
2003). Approximately 25 percent of preterm deliveries 
are medically indicated and are attributable to conditions 
affecting the mother and/or the fetus, and the remaining 
75 percent are spontaneous (Meis et al. 1995; Iams 2003). 
A substantial body of evidence indicates that intrauter-
ine bacterial infections are associated with preterm labor 
and delivery, especially at earlier gestational ages (Cassell 
et al. 1993; Kimberlin and Andrews 1998; Andrews et al. 
2000; Goldenberg and Culhane 2003). Most intrauterine 
infections are believed to result from ascending infection, 
resulting from changes in vaginal/cervical flora, including 
bacterial vaginosis, or from the introduction of pathologic 
organisms. If these organisms ascend to the intrauter-
ine cavity, they can cause an inflammatory reaction. The 
infection may progress to involve the chorion and/or 
amnion, fetal vessels, or the amniotic cavity, and even 
the fetus (review by Gonçalves et al. 2002; Romero et al. 
2002). Systemic maternal infection or maternal infections 
remote from the genitourinary tract have also been asso-
ciated with preterm labor and delivery, but the risk of pre-
term labor and delivery attributable to these conditions is 
thought to be low (Romero et al. 2002). One mechanism 
proposed to explain the onset of preterm labor attribut-
able to intrauterine infection is that bacterial invasion of 
the choriodecidual space results in the release of endotox-
ins and exotoxins, which, in turn, stimulate the produc-
tion of cytokines such as TNFα, interleukin-6 (IL-6), IL-8, 
IL-1α, IL-1β, and granulocyte colony-stimulating factor. 
One hypothesis is that cytokines, endoxins, and exotoxins 
stimulate the release of prostaglandins and initiate neu-
trophil activation, which results in the release of metal-
loproteases. This process results in stimulation of uterine 
contractions by prostaglandins, rupture of chorioamniotic 
membranes, and softening of the cervix by metallopro-
teinases (review by Goldenberg et al. 2000).
Researchers have consistently associated smoking 
with preterm delivery, and smoking likely increases the 
risk of both very preterm and moderate preterm births 
(Kyrklund-Blomberg and Cnattingius 1998; Ancel et al. 
1999; Cnattingius et al. 1999; Gardosi and Francis 2000). 
The 2004 Surgeon General’s report found that the evi-
dence was sufficient to infer a causal relationship between 
smoking and preterm delivery (USDHHS 2004). Smoking 
appears to increase the risk of both medically indicated 
and spontaneous preterm delivery (Kyrklund-Blomberg 
and Cnattingius 1998). However, estimates of the mag-
nitude of the association vary among studies. In a meta-
analysis of pooled data from 20 prospective studies, the 
estimate for any maternal smoking versus none was 1.27 
(95 percent CI, 1.21–1.33), and the ORs were 1.25, 1.38, 
and 1.31 for light, moderate, and heavy maternal smok-
ing, respectively (Shah and Bracken 2000), suggesting a 
truncated dose-response relationship.
Exposure to secondhand smoke is also associated 
with preterm delivery in several studies. The 2006 Sur-
geon General’s report concluded that the evidence was 
suggestive but not sufficient to infer a causal relation-
ship (USDHHS 2006). A study by Kharrazi and colleagues 
(2004) included measurement of cotinine and found that 
nonsmokers with higher levels had earlier delivery than 
did those with no measurable exposure to secondhand 
smoke. The risk increased about 30 percent with each log 
increase in cotinine (adjusted OR [AOR] = 1.29 [95 per-
cent CI, 0.97–1.72]). 
Parity may modify the association between preterm 
delivery and smoking. As previously stated, the incidence 
of preeclampsia is highest among nulliparous women (see 
“Preeclampsia” earlier in this chapter). Because smoking 
protects against preeclampsia and preeclampsia can result 
in preterm delivery, the adverse effects of smoking on risk 
of preterm delivery may be masked in nulliparous women 
(Burguet et al. 2004). 
Mechanisms through which smoking may contrib-
ute to preterm delivery are unknown. Researchers have 
proposed that smoking could increase risk of intrauterine 
infections (review by Cnattingius 2004). Smokers have 
a twofold-to-threefold increase in risk for bacterial vagi-
nosis, which is a risk factor for preterm delivery (Morris 
et al. 2001). Researchers have hypothesized that smok-
ing increases this risk through its effects on vaginal flora 
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or through depletion of Langerhans cells, resulting in 
local immunosuppression (Smart et al. 2004). Alterations 
in the cervical cytokine profile have been associated with 
increased risk of preterm delivery; women with a high 
anti-inflammatory and low proinflammatory profile are at 
highest risk (Simhan and Krohn 2009). Cigarette smoking 
has been associated with increased cervical anti-inflam-
matory cytokines in early pregnancy, which could make 
women who smoke more vulnerable to reproductive tract 
infections and subsequent preterm delivery (Simhan et al. 
2005). Smoking can also reduce zinc levels, which could 
increase susceptibility to vaginal infections (Edman et al. 
1986; Sikorski et al. 1990; Shubert et al. 1992). Immu-
nosuppressive effects of smoking could also increase the 
risk of upper genital infections, known to be associated 
with preterm labor and PPROM. Neonates born to smok-
ers have been noted to have a decrease in all leukocytes, 
indicating possible fetal immune dysregulation (Pachlo-
pnik Schmid et al. 2007). Pathways other than those 
involving infections have also been proposed. For example, 
investigators have suggested that smoking during preg-
nancy increases contractile sensitivity and activity of the 
myometrium, with exposure to oxytocin by upregulating 
expression of messenger RNA (mRNA) for oxytocin recep-
tor (Egawa et al. 2003). Compared with unexposed preg-
nant rats, those with exposure to cigarette smoke were 
found to have higher contractile sensitivity and activity in 
response to oxytocin (Egawa et al. 2003).
Finally, findings have also suggested that smok-
ing may disrupt the integrity of type III collagen, lead-
ing to weakening and rupture of the membranes and an 
increased risk of medical indications for preterm deliv-
ery, such as placental abruption and intrauterine growth 
restriction (IUGR) (Cnattingius 2004). 
Preterm Premature Rupture of Membranes 
PPROM is defined as the rupture of amniotic mem-
branes before the onset of labor and before 37 completed 
weeks of gestation. PPROM occurs in up to 4.5 percent 
of deliveries and in approximately 40 percent of preterm 
births (Mercer et al. 2000). Pregnancies complicated by 
PPROM have higher rates of neonatal morbidity than 
do pregnancies complicated by idiopathic preterm labor 
(Arias and Tomich 1982). 
Factors that researchers have associated with 
PPROM include (1) nutritional deficiencies in vitamin C 
(Hadley et al. 1990; Casanueva et al. 1993), copper (Artal 
et al. 1979; Kiilholma et al. 1984), and zinc (Sikorski et 
al. 1990; Scholl et al. 1993); (2) vaginal bleeding (Harger 
et al. 1990; Ekwo et al. 1992); (3) multifetal pregnancies 
(Mercer et al. 1993); (4) a history of preterm delivery or 
PPROM in a previous pregnancy (Naeye 1982; Harger et al. 
1990; Ekwo et al. 1992; Mercer et al. 2000); (5) obstetric 
complications involving uterine overdistension (French 
and McGregor 1996); and (6) bacterial vaginosis (Kurki et 
al. 1992; Mercer et al. 2000) and intra-amniotic infections 
(Naeye and Peters 1980; Ekwo et al. 1993; Heffner et al. 
1993). However, it can be difficult to determine whether 
an intra-amniotic infection precedes or follows the rup-
ture of membranes. A review by Lee and Silver (2001) dis-
cusses in detail the risk factors for PPROM.
Researchers suggest that structural deficiencies in 
the architecture of the amniotic membrane could increase 
the risk of PPROM (Shubert et al. 1992; Lee and Silver 
2001). Studies of spontaneously ruptured membranes 
demonstrate that membranes are thinner and collagen 
content is lower near the site of rupture. Moreover, these 
alterations appear to be focal rather than generalized 
(Skinner et al. 1981; Kanayama et al. 1985; French and 
McGregor 1996). The tensile strength of tissue depends 
on the collagens, especially types I and III. The amni-
otic membranes of women with PPROM have decreased 
amounts of type III, type V, and total collagen (Skinner 
et al. 1981; Kanayama et al. 1985; al-Zaid et al. 1988). In 
addition, Athayde and colleagues (1998) found that women 
with PPROM had higher amniotic fluid levels of metallo-
proteinases that degrade collagen types IV and V than did 
women with term labor. These researchers also suggested 
that infection could be an additional trigger if the host 
responds to an infection by activating matrix-degrading 
enzymes (Athayde et al. 1998). 
Many studies have associated smoking with an 
increased risk of PPROM (Lee and Silver 2001). The 2004 
Surgeon General’s report found sufficient evidence to 
infer a causal relationship between smoking and PPROM 
(USDHHS 2004). Researchers have hypothesized that 
smoking increases the risk of PPROM through several 
pathways. The effects of smoking on the immune system 
could increase the risk of genital tract infection or disrupt 
the cytokine system (French and McGregor 1996). Smok-
ing could increase the inflammatory response and reduce 
the availability of nutrients such as vitamin C or decrease 
the uptake of nutrients by the placenta (French and 
McGregor 1996; Lykkesfeldt et al. 1996, 2000) (see “Other 
Molecular Mechanisms” later in this chapter). 
Developmental Endpoints
This section on developmental effects summarizes 
the epidemiologic evidence for prenatal effects of mater-
nal smoking on the infant and child, including endpoints 
such as birth weight, perinatal or infant mortality, birth 
defects, and neurobehavioral. The discussion also briefly 
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notes the evidence for effects from exposure to second-
hand smoke on these outcomes. Studies have examined 
the effects of smoking on child growth, but this topic is 
not addressed in this report. Studying childhood health 
in relation to prenatal smoking is complicated by the pos-
sibility of exposure to secondhand smoke subsequent to 
birth, as well as other intervening factors between birth 
and some later outcomes that are difficult to assess.
Fetal Size and Growth
The first and the most widely studied effect of mater-
nal smoking is the influence on fetal growth. Fetal growth 
cannot be directly assessed, so birth weight is used as a 
surrogate. However, birth weight reflects not only growth 
but also gestational age, as well as genetic potential, which 
is not commonly assessed. To account for gestational age, 
studies may examine IUGR, which is usually assessed from 
the distribution of birth weight by gestational week, in a 
standard population. The common definition of SGA is 
less than the 10th percentile of weight for the age. Another 
parameter that is examined includes low birth weight 
(LBW) (<2,500 grams [g]), sometimes among term births 
only (≥37 weeks).
The first Surgeon General’s report on smoking and 
health in 1964 noted an association of maternal smok-
ing with LBW (U.S. Department of Health, Education, 
and Welfare 1964). The 2001 Surgeon General’s report 
on women and smoking concluded that “infants born to 
women who smoke during pregnancy have a lower aver-
age birth weight and are more likely to be SGA than are 
infants born to women who do not smoke” (USDHHS 
2004, p. 15). Furthermore, the 2004 Surgeon General’s 
report concluded that “the evidence is sufficient to infer a 
causal relationship between maternal active smoking and 
fetal growth restriction and low birth weight” (USDHHS 
2004, p. 28). These conclusions are based on a multitude 
of studies with consistent evidence of a dose-response 
relationship, confirmed by more recent studies using a 
biomarker of exposure to tobacco smoke.
Infants of smokers typically weigh 150 to 200 g 
less than infants of nonsmokers and are twice as likely 
(ORs = 1.5 to 2.5) to be LBW or SGA. Maternal smoking 
appears to have the strongest effect on birth weight through 
growth retardation and, to a lesser extent, through a short-
ened gestation (Ananth and Platt 2004; USDHHS 2004). 
On the basis of a maternal smoking rate of about 12 per-
cent during pregnancy, the etiologic fraction (EF) for LBW 
from smoking was calculated as 6.4 percent for all births 
and 10.9 percent for single births (Magee et al. 2004). The 
EF for LBW from smoking among births at full term was 
slightly higher at 13.4 percent or 16.7 percent for single 
births, which comprise most births. The authors also 
reported that 60 percent of the effect of smoking on LBW 
in the overall population was among light smokers. 
Because of the established effects of maternal active 
smoking, many studies have also examined fetal growth in 
relation to exposure of the mother to secondhand smoke. 
Several reviews concluded that exposure to secondhand 
smoke is associated with adverse effects on infant growth 
or an increased risk of LBW and SGA (NCI 1999; WHO 
1999a; USDHHS 2001; British Medical Association 2004). 
Moreover, the 2006 Surgeon General’s report concludes 
that “the evidence is sufficient to infer a causal relation-
ship between exposure to secondhand smoke and a small 
reduction in birth weight” (USDHHS 2006, p. 13). The 
highest quality studies indicate birth weight decrements 
of 15 to 100 g and an OR for LBW or SGA of 1.1 to 1.7 
from exposure to secondhand smoke (NCI 1999). A meta-
analysis of pooled data conducted through 1995 calculated 
a mean weight decrement of 28 g (95 percent CI, 16–40) 
among infants of mothers who did not smoke but were 
exposed to secondhand smoke and ORs of 1.2 for IUGR and 
1.4 for LBW (Windham et al. 1999a). One study based on 
a sensitive assay for cotinine showed a birth weight decre-
ment of 27.2 g (95 percent CI, 0.6–53.7) per unit change 
in log cotinine, which represented a decrement of about 
100 g between the highest and lowest cotinine quintiles 
(Kharrazi et al. 2004). 
Several studies have shown that the effects of expo-
sure to tobacco smoke, primarily active but also involun-
tary exposure, appear to be stronger among older mothers 
(Wen et al. 1990; Wisborg et al. 1996; Haug et al. 2000; 
Windham et al. 2000; Salihu et al. 2005). Risk may also 
vary by racial and ethnic groups, and some studies (Main-
ous and Hueston 1994; USDHHS 1998; Windham et al. 
2000) noted stronger effects among non-Whites or Blacks. 
Some of these variations may be a result of differences in 
nicotine metabolism among racial groups or differences 
in smoking and exposure patterns. Smoking may cause 
reduced birth weight or fetal growth due to fetal hypoxia 
resulting from exposure to CO, other effects on fetal 
nutrition, or the action of PAHs (see “Tobacco Smoke Tox-
icants and the Reproductive System” and “Other Molecu-
lar Mechanisms” later in this chapter). 
Perinatal and Infant Mortality
The definition of perinatal mortality may vary 
slightly across studies, but it commonly includes still-
birth at more than 28 weeks of gestation and early neo-
natal deaths (first 7 days of life). Infant mortality includes 
death of a live-born child in the first year of life and can 
be divided into the neonatal (first month) and postneo-
natal (1 month to 1 year) periods. Neonatal mortality is 
more related to prenatal conditions. Previous reports of 
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the Surgeon General have reviewed the data for an effect 
of smoking on mortality. The 2001 report concluded, “the 
risk for perinatal mortality—both stillbirth and neonatal 
deaths—and the risk for sudden infant death syndrome 
(SIDS) are increased among the offspring of women who 
smoke during pregnancy” (USDHHS 2001, p. 15). The 
2004 Surgeon General’s report also concluded, “the evi-
dence is sufficient to infer a causal relationship between 
sudden infant death syndrome and maternal smoking dur-
ing and after pregnancy” (USDHHS 2004, p. 7). However, 
the report noted the difficulty of separating prenatal from 
postnatal effects of maternal smoking.
Many studies have found a slightly increased risk 
of approximately 20 to 30 percent for stillbirth or neona-
tal mortality associated with smoking (USDHHS 2004). 
A meta-analysis of pooled data from 23 cohort studies of 
perinatal mortality calculated a RR of 1.26 (95 percent CI, 
1.19–1.34) (DiFranza and Lew 1995). In one study, the 
risk was higher for postneonatal death (AOR = 1.6; 95 per-
cent CI, 1.41–1.85) than for neonatal death (AOR = 1.2; 
95 percent CI, 1.05–1.30), which was primarily attribut-
able to two causes: respiratory disease and SIDS (Malloy et 
al. 1988). A study in India (Gupta and Subramoney 2006) 
reports an adjusted risk for stillbirth three times higher 
for mothers who use smokeless tobacco than for those 
who do not use smokeless tobacco. Some evidence for a 
dose-response relationship was shown for frequency of 
use. Two previous studies from India had also reported an 
increased risk of stillbirth or perinatal death with use of 
smokeless tobacco (primarily chewing tobacco) (Krishna 
1978; Shah et al. 2000). These investigations lend further 
support to the literature on the adverse effects of tobacco 
use, which may be related to heavy metals or nicotine, 
because CO from tobacco smoke would not be present (see 
“Tobacco Smoke Toxicants and the Reproductive System” 
later in this chapter).
Studies of SIDS and maternal smoking that con-
trolled for other factors showed ORs of 1.8 to 3.1. Several 
of those studies also report a dose-response relationship 
(NCI 1999; USDHHS 2004). A meta-analysis compar-
ing women who did or did not smoke during pregnancy, 
regardless of smoking status after delivery, calculated a 
pooled OR of 2.98 (95 percent CI, 2.51–3.54) (DiFranza 
and Lew 1995). Some studies have attempted to separate 
the effects of prenatal exposure from those of postnatal 
exposure. In one study, the risk of SIDS was increased in 
infants with only postpartum exposure to tobacco smoke 
but was even greater with both prenatal and postnatal 
exposures (Schoendorf and Kiely 1992). A large study 
in which participants were asked detailed questions on 
exposure to tobacco smoke found similar risks for mater-
nal or paternal smoking, but the risks increased with more 
smokers in the household (Klonoff-Cohen et al. 1995). 
In addition, some studies that attempted to examine the 
independent effects of paternal smoking observed elevated 
risks of SIDS (Mitchell et al. 1993; Blair et al. 1996). Rates 
of SIDS have decreased over time with strong public 
education campaigns to place infants in the supine posi-
tion while they sleep. Subsequent studies found that the 
risk attributable to maternal smoking has concomitantly 
increased and smoking may now be the greatest pre-
ventable cause of SIDS (Chong et al. 2004; Anderson et 
al. 2005).
Birth weight is one of the strongest predictors of 
infant survival. However, the effects of reduced growth 
versus shortened gestation are important to consider in 
determining etiology. Both reduced growth and shortened 
gestation appear to be related to infant mortality and SIDS 
(McCormick 1985; Oyen et al. 1995; Paneth 1995; Ananth 
and Platt 2004). The longer the gestation for a given birth 
weight, the lower is the mortality (McCormick 1985; Wil-
cox and Skjærven 1992). The increased risk of mortality 
associated with LBW appears to continue beyond infancy 
into childhood (Samuelson et al. 1998; Xu et al. 1998). 
Furthermore, studies suggest an association of mater-
nal smoking with a higher mortality rate that continues 
beyond infancy. This effect was greater after adjustment 
for birth weight (Hofvendahl 1995). Infants who experi-
ence symmetrical growth retardation (in weight, length, 
and head circumference) associated with maternal smok-
ing may be less likely to exhibit later “catch-up” growth 
and appear to be more likely to have cognitive deficits 
and difficulties in school (McCormick 1985). Thus, other 
effects associated with maternal smoking, such as peri-
natal mortality, may be mediated through reduced fetal 
growth and, to some extent, through a shortened gesta-
tion period (Ananth and Platt 2004). Some studies have 
found higher risks of infant mortality associated with 
smoking among mothers who are 35 years of age or older 
or of certain racial groups (Cnattingius et al. 1988; Li and 
Daling 1991). Studies have also found an increased risk of 
SIDS with placental abnormalities (Li and Wi 1999), thus 
suggesting another mechanism by which smoking may 
lead to SIDS. 
Birth Defects 
The 2004 Surgeon General’s report summarized 
epidemiologic studies published between 1974 and 1998 
on the relationship between maternal smoking during 
pregnancy and the risk for congenital malformations 
(USDHHS 2004). The report concluded that “the evidence 
is inadequate to infer the presence or absence of a causal 
relationship between maternal smoking and congenital 
malformations in general” (USDHHS 2004, p. 28). For oral 
clefts, however, several studies reported increased risks, 
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and the evidence was considered to be suggestive, but not 
sufficient, to infer a causal relationship with smoking.
Since the 2004 Surgeon General’s report, additional 
studies have examined possible associations of maternal 
smoking with major birth malformations. The evidence 
in support of an association between smoking and an 
increased risk for oral clefts has become stronger (Table 
8.3). A meta-analysis of data from studies published 
between 1974 and 2001 focused on 9 studies that exam-
ined total orofacial clefts and 15 that examined cleft lip 
with or without cleft palate and cleft palate alone. The 
study found an association between maternal smoking 
and a 34-percent increase in the risk of cleft lip with or 
without cleft palate and a 22-percent increase in the risk 
of cleft palate alone (Little et al. 2004a). More recently, 
similar findings were also observed by Honein and col-
leagues (2007). Other studies provide evidence of a dose-
response relationship for maternal smoking and the risk 
for cleft lip with or without cleft palate (Wyszynski and 
Wu 2002; Little et al. 2004b; Honein et al. 2007) and 
for cleft palate alone (Little et al. 2004b). A recent study 
assessing maternal tobacco exposure by cotinine levels in 
mid-pregnancy serum samples found an OR of 2 for cleft 
lip with or without cleft palate (Shaw et al. 2009).
Studies on interactions between genes and smoking 
and between vitamin use and smoking contribute to an 
understanding of the etiology of oral clefts (van Rooij et al. 
2002; Jugessur et al. 2003; Shi et al. 2007) (see “Fetal Tis-
sue and Organogenesis” and “Smoking and Maternal and 
Neonatal Genetic Polymorphisms” later in this chapter). 
One study reported an increase in the risk for cleft lip with 
or without cleft palate that was strongest among offspring 
whose mothers had smoked but had not consumed mul-
tivitamins during the periconceptive period (Shaw et al. 
2002). Results did not suggest an interaction for isolated 
cleft palate. Study findings also supported an increased 
risk of clefting with paternal smoking or involuntary 
exposure to tobacco smoke (Savitz et al. 1991; Zhang et al. 
1992; Shaw et al. 1996). Whether paternal smoking acts 
through exposure of the mother to secondhand smoke or 
directly on male gametes is not clear.
A number of studies have also investigated mater-
nal smoking in relation to cardiovascular malformations. 
A review of data from 13 studies published between 1971 
and 1999 found mixed results. Twelve of the studies pro-
vided results for cardiovascular malformations combined 
and seven studies for specific subgroups of cardiovascular 
defects examined separately (Källén 2002a). Combining 
all cardiovascular malformations represents a heteroge-
neous group but examining subgroups resulted in low 
power for several studies. The conflicting results probably 
reflect differences in research methods, including case 
ascertainment, classification, control of confounding, and 
sample size of the case group. Other studies have reported 
associations of maternal smoking with cardiovascular 
malformations (Table 8.4), including conotruncal defects, 
atrial septal defects, and atrioventricular septal defects 
(Torfs and Christianson 1999); l-transposition of the great 
arteries (Steinberger et al. 2002; Kuehl and Loffredo 2003); 
and conotruncal defects among offspring whose mothers 
did not use vitamins (Shaw et al. 2002). Steinberger and 
colleagues (2002) found an association between paternal 
smoking and single-ventricle defects. These more recent 
exploratory studies present methodologic issues similar 
to those noted in the meta-analysis by Källén (2002a). In 
addition, Malik and colleagues (2008) found an associa-
tion between periconceptual smoking and septal heart 
defects. There is a need for further research with large, 
population-based studies that incorporate standardized 
methods for case ascertainment and classification to 
determine whether a relationship exists between maternal 
smoking and the risk of cardiovascular malformations.
Studies of other birth defects have found an asso-
ciation between maternal smoking and an increased risk 
for clubfoot (Honein et al. 2000; Skelly et al. 2002), cra-
niosynostosis (Källén 1999; Carmichael et al. 2008), and 
gastroschisis (Werler et al. 2003), but not for spina bifida 
(Table 8.5) (Shaw et al. 2002; van Rooij et al. 2002). Stud-
ies report mixed results for maternal smoking and limb 
deficiency defects (Hwang et al. 1998; Shaw et al. 2002; 
Carmichael et al. 2004), Down syndrome (Chen et al. 
1999; Yang et al. 1999), and for cryptorchidism and hypo-
spadias (Akre et al. 1999; Källén 2002b; Pierik et al. 2004). 
Maternal smoking may interfere with normal 
organ development in offspring in several ways, includ-
ing through fetal hypoxia, alterations in essential nutri-
ents, teratogenic effects, and DNA damage. Those effects 
may be related to exposure to tobacco smoke components 
such as CO, nicotine, cadmium, and PAHs (Chernoff 1973; 
Mochizuki et al. 1984; Lammer et al. 2004; Munger et al. 
2004; Ziaei et al. 2005). In addition, certain populations 
with genetic polymorphisms may be more susceptible to 
damage attributable to exposure to tobacco smoke because 
of alterations in metabolic pathways (see “Fetal Tissue and 
Organogenesis” and “Smoking and Maternal and Neonatal 
Genetic Polymorphisms” later in this chapter). 
Neurodevelopment
Maternal smoking and exposure to secondhand 
tobacco smoke during pregnancy affect infant health sta-
tus at birth as described earlier and are hypothesized to 
affect physical and mental development in infancy and 
early childhood as well. Studies have reported evidence 
of lower weights and shorter heights into the preschool 
period (Fox et al. 1990), in addition to correlations of 
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maternal smoking with microcephaly and hydrocephaly, 
particularly among female infants (Honein et al. 2001). 
Reviews have also examined the links between maternal 
smoking and mental development in offspring (Hardy 
and Mellits 1972; Lassen and Oei 1998). Earlier Surgeon 
General’s reports examined this topic and reported pos-
sible effects. However, at the time of the 2004 Surgeon 
General’s report, the evidence was considered “inadequate 
to infer the presence or absence of a causal relationship 
between maternal smoking and physical growth and neu-
rocognitive development of children” (USDHHS 2004, p. 
601), and this conclusion was echoed in the examination 
of secondhand smoke (USDHHS 2006). Some key stud-
ies, as well as others published since those included in the 
prior reports of the Surgeon General (e.g., 2004 and later), 
are summarized below. 
Researchers have suggested that prenatal exposure 
to smoking poses a unique risk for neurologic develop-
ment and intellectual abilities attributable to impairments 
of the central nervous system (Olds et al. 1994). Drews and 
colleagues (1996) studied a sample of 221 children aged 
10 years and reported that those with mental retardation 
were more likely than control participants with no men-
tal retardation to have mothers who had smoked during 
pregnancy. Moreover, the rates of retardation increased 
with the number of cigarettes mothers smoked. McCart-
ney and colleagues (1994) speculated that intrauterine 
exposure to nicotine specifically affects the physiology of 
outer hair cells in the ear that underlies language ability 
and leads to poorer performance scores among offspring 
on assessments that rely heavily on verbal abilities.
Investigators have found it difficult to document 
a consistent impact of maternal smoking on cognitive 
development in infants and young children, because many 
factors affect cognitive development. For example, in a 
study of two- and four-year-old children of mothers who 
smoked compared with children in the same age groups 
whose mothers did not smoke, Baghurst and colleagues 
(1992) reported small but significant group differences on 
the Bayley Scales of Infant Development (BSID) and the 
McCarthy Scales of Children’s Abilities (MSCA). However, 
group differences were not significant after controlling 
for SES, maternal intelligence quotient, and quality of 
the home learning environment. Sexton and colleagues 
(1990) also reported better scores among three-year-olds 
whose mothers had stopped smoking during pregnancy 
compared with children whose mothers had smoked 
more than 10 cigarettes a day during pregnancy. Group 
differences in performance on the Minnesota Child 
Development Inventory and the MSCA were small, but dif-
ferences remained significant after adjustment for birth 
weight, SES, and certain maternal and child character-
istics. Trasti and colleagues (1999) reported lower scores 
on the Wechsler Preschool and Primary Scale of Intelli-
gence-Revised for a sample of 369 children aged five years 
whose mothers had smoked during pregnancy compared 
with children of mothers who did not smoke. However, 
significant group differences were not found after adjust-
ment for maternal education level. These researchers also 
reported no differences on the BSID in a sample of 376 
children from the same population at 13 months of age by 
mothers’ smoking status. 
Batstra and colleagues (2003) reported poorer per-
formance on mathematics and spelling achievement tests 
among a group of 1,186 children aged 5 through 11 years 
whose mothers smoked, and differences remained after 
adjustment for SES and for prenatal and perinatal compli-
cations. A Danish study found effects of prenatal smoking 
during the third trimester on adult intelligence even after 
adjustment for sociodemographic variables (Mortensen 
et al. 2005). In contrast to other studies, Eskenazi and 
Trupin (1995) reported slightly higher but nonsignificant 
scores on the Peabody Picture Vocabulary Test and the 
Raven Progressive Matrices Test for five-year-old children 
whose mothers had smoked during pregnancy compared 
with those for children of mothers who had not smoked, 
even after adjustment for parental education, SES, age, 
race, and preschool attendance. Some significant decre-
ments in performance on these same measures and signif-
icant differences in the maternal-rated activity levels were 
attributable to exposure to secondhand tobacco smoke 
during childhood. Other studies show cognitive deficits 
with prenatal exposure to secondhand smoke that are 
exacerbated by conditions of material hardship (Rauh et 
al. 2004). After adjustment, decrements in cognitive and 
academic abilities were reported with increasing cotinine 
levels within the range indicating exposure to secondhand 
smoke during childhood (Yolton et al. 2005).
Despite these inconsistent findings on general 
assessments of children’s cognition and intelligence, 
findings more consistently show an association between 
maternal smoking and children’s lower performance on 
assessments of verbal skills in general, as well as on spe-
cific language and auditory tests. For example, a sample 
of 110 children aged 6 to 11 years whose mothers had 
smoked during pregnancy performed more poorly on 
tasks tapping phonologic processing skills that are known 
to be related to both language and reading abilities 
(McCartney et al. 1994). Follow-up studies of the same 
cohort reported that maternal smoking and maternal 
involuntary exposure to tobacco smoke negatively affected 
the performance of children aged 9 and 12 years on stan-
dardized assessments of language and reading, as well 
as on assessments of general intelligence skills (Fried et 
al. 1997). Butler and Goldstein (1973) studied a sample 
of more than 9,000 children aged 7 and 11 years whose 
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Table 8.3 Association between maternal smoking and orofacial clefts (OFCs), 1999–2009a
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Table 8.4 Association between maternal smoking and cardiovascular malformations, by phenotype,  
1999–2008
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Table 8.5 Association between maternal smoking and noncardiovascular congenital malformations, by type of 
malformation, 1998–2008
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mothers had smoked during pregnancy. These children 
were three to five months behind children of nonsmok-
ing mothers in reading, mathematics, and general cogni-
tive abilities. In more than 5,000 youth aged 6 through 
16 years from the Third National Health and Nutrition 
Examination Survey, deficits in reading and mathematics 
scores were associated with higher current exposure to 
secondhand smoke (Yolton et al. 2005).
Researchers have used various types of tests that 
measure both cognitive and behavioral aspects of develop-
ment to study the relationship between possible language 
impairments and maternal smoking. Data from studies 
using evoked brain responses indicate that infants born to 
mothers who smoked approximately one pack of cigarettes 
per day showed atypical patterns of brain organization, 
which reflected poorer speech discrimination than that of 
infants born to mothers who did not smoke. Compared 
with infants of smokers, the unexposed infants exhibited 
more common forms of brain lateralization for speech 
and showed evidence of better discrimination of conso-
nant and vowel syllables (Molfese et al. 2004). This find-
ing parallels findings in studies that reported long-term 
impacts on language and cognitive domains in children 
whose mothers smoked (Makin et al. 1991; McCartney et 
al. 1994). These results indicate that prenatal exposure 
to smoking in otherwise healthy infants can be linked to 
significant changes in brain physiology associated with 
basic perceptual skills. These effects may be long term, 
with impacts noted in later school performance. A study 
of gravid mice exposed to tobacco smoke supports these 
findings. The study revealed that the offspring had a 
developmental delay in neonatal reflexes and notable 
behavioral deficits in adulthood, including impaired 
learning and memory abilities (Li and Wang 2004). CO 
in tobacco smoke induces fetal hypoxia and may con-
tribute to these effects (see “Carbon Monoxide” later in 
this chapter).
Table 8.5 Continued
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Pathophysiological and Cellular and Molecular  
Mechanisms of Smoking
This section explores various mechanisms by which 
smoking may affect reproductive and developmental out-
comes at the pathophysiological and cellular levels.
Endocrine System
One mechanism by which smoking may contribute 
to various reproductive outcomes is alterations in hor-
mone function. Researchers have suggested that smoking 
has antiestrogenic effects (Baron et al. 1990). However, 
there is also evidence of effects on hormones other than 
estrogen, which may vary by gender and the stage of life.
Premenopausal Women 
Hormone function has been difficult to study in 
non-clinic-based populations, because of the cyclic 
nature of hormone excretion and day-to-day variations in 
premenopausal women. During regular menstrual cycles, 
the hormone dynamics are predictable in a pattern that 
reflects the integrity of the hypothalamic-pituitary-gonadal 
(HPG) axis. Excretion of the follicle-stimulating hormone 
(FSH) from the pituitary gland is critical for ovarian folli-
cle recruitment, development, and maturation (van Sant-
brink et al. 1995). The synthesis and excretion of estrogen 
by the follicles reflect ovarian activity that then modulates 
the release of gonadotropins from the pituitary through a 
negative-feedback loop. After ovulation has occurred, the 
follicle undergoes luteinization, and the corpus luteum 
excretes progesterone and some estrogen to prepare the 
uterine lining for implantation. In the absence of concep-
tion, estrogen and progesterone levels decline, followed 
by menstruation. Should fertilization occur, the steroid 
levels continue to rise along with levels of other hor-
mones, such as human chorionic gonadotropin (hCG), to 




Smoking has been considered potentially antiestro-
genic (Baron et al. 1990), primarily because of the nature 
of its association with hormonally related diseases such as 
reproductive cancers. However, the 2001 Surgeon Gen- 
eral’s report on women and smoking concluded that cir- 
culting levels of the major endogenous estrogens are not 
altered among smokers (USDHHS 2001). Some studies 
were hampered by a lack of biosampling points, small 
numbers of participants, or the inclusion of postmeno-
pausal or potentially perimenopausal women. Details on 
15 studies of premenopausal women are provided in Table 
8.6. Most of these studies excluded women who were tak-
ing hormones or who were known to have menstrual prob-
lems. Nevertheless, the studies represent a variety of ages 
and did not always adjust for factors such as age and obe-
sity. Two studies (MacMahon et al. 1982b; Westhoff et al. 
1996) reported levels of urinary excretion of estrone, estra-
diol, and/or estriol in the luteal phase among smokers that 
were lower than those among nonsmokers, suggesting 
reduced estrogen production. However, several other 
studies did not observe significant differences in serum 
levels of estradiol by smoking status among premeno-
pausal women (Longcope and Johnston 1988; Key et al. 
1991; Berta et al. 1992). The study by Michnovicz and col-
leagues (1986) is often cited for the discovery that smoking 
induced the 2-hydroxylation of estrone to relatively inac-
tive metabolites and decreased estriol excretion. A later, 
much larger study, however, did not find differences in the 
circulating levels of the 2α- or 16α-hydroxy metabolites in 
nulliparous smokers versus nonsmokers after adjustment 
for age, ethnicity, and length of menstrual cycle (Jern-
ström et al. 2003). Zumoff and colleagues (1990) measured 
serum at multiple points during the cycle and found that 
estradiol was actually increased among heavy smokers in 
the follicular phase, particularly early, at baseline. A study 
with only a single serum sample obtained in the early fol-
licular phase (Lucero et al. 2001) found that current smok-
ers had higher baseline estradiol levels than did former 
olifetime nonsmokers, but this finding was not significant 
after adjustment. Examination of dose by pack-years1 did 
not indicate a dose-response pattern, but this analy-
sis may have been diluted by including former smokers 
with smokers if the effects do not persist after smok- 
ing cessation. 
Among women who had IVF, smokers had higher 
baseline levels of 17-β-estradiol than did nonsmokers 
(Weigert et al. 1999). A later study examined hormonal 
dynamics by daily measurement of urinary levels of 
estrone and progesterone metabolites throughout the 
cycle, in relation to smoking level that was verified by 
cotinine bioassay (Windham et al. 2005). This analysis 
showed that heavy smokers had elevated baseline (e.g., 
early follicular phase) levels of the steroid metabolites, a 
finding consistent with results in other studies (Longcope 
and Johnston 1988; Zumoff et al. 1990; Key et al. 1996; 
Lucero et al. 2001). A study of Chinese nonsmokers exam-
ined the effects of secondhand smoke on urinary levels of 
hormone metabolites and found an association with lower 
mean levels of estrone conjugates only for nonconceptive 
cycles (Chen et al. 2005). 
Some of the disease patterns observed with smok-
ing may reflect changes in androgen or progesterone lev-
els, rather than estrogen levels, or changes in the ratio of 
androgens to estrogens. Some studies have reported that 
smoking increases adrenal activity and have found eleva-
tions in adrenal androgens among postmenopausal smok-
ers (Friedman et al. 1987; Khaw et al. 1988; Longcope and 
Johnston 1988; Key et al. 1991). Researchers have found 
elevated serum testosterone levels in female smokers that 
were positively correlated with estradiol levels in men-
strual cycling women who had IVF (pre-hCG treatment) 
(Barbieri et al. 2005). Elevated testosterone levels in 
female smokers were also positively correlated with obe-
sity (Longcope and Johnston 1988; Sowers et al. 2001). 
Zumoff and colleagues (1990) reported elevated serum 
levels of progesterone among heavy smokers during the 
early follicular phase, a time when most progesterone is 
from the adrenal cortex. This finding is again consistent 
with the urine metabolite results reported by Windham 
and colleagues (2005) (Table 8.6). However, Zumoff and 
colleagues (1990) observed little difference in progester-
one levels in the luteal phase. Windham and colleagues 
(2005) observed dampened progesterone metabolites in 
the luteal phase with heavy smoking. Berta and colleagues 
(1992) found that regular smokers had lower plasma lev-
els of progesterone in a single sample per day during the 
mid-luteal phase. However, the small study by Westhoff 
and colleagues (1996) did not find these differences in 
examining data on all smokers without considering the 
amount smoked. In addition, the study on exposure to sec-
ondhand smoke did not report reductions in progesterone 
metabolite levels with exposure (Chen et al. 2005). 
In vitro experiments support the effects on proges-
terone by showing that granulosa and tumor cells treated 
with alkaloids found in cigarette smoke or with an aque-
ous extract of cigarette smoke showed a dose-dependent 
inhibition of progesterone production (Bódis et al. 1997; 
Gocze et al. 1999; Gocze and Freeman 2000; Miceli et al. 
2005). In contrast, estradiol production was little affected 
or was slightly stimulated. Cell growth and DNA content 
1Pack-years = the number of years of smoking multiplied by the number of packs of cigarettes smoked per day.
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also decreased with treatment, leading the authors to 
suggest that smoking directly inhibits cellular proges-
terone synthesis through less specific cytotoxic effects on 
progesterone-producing cells (Gocze and Freeman 2000). 
Other proposed mechanisms include modulations in the 
prostaglandin system (Miceli et al. 2005) or inhibition of 
aromatase enzymes. 
Some studies examined gonadotropin FSH levels 
by smoking status (Table 8.6). Three studies that mea-
sured a single serum FSH level in the first few days of the 
cycle found higher levels associated with smoking (Cra-
mer et al. 1994; Cooper et al. 1995; Lucero et al. 2001). 
Another study with a similar finding of higher FSH in 
smokers did not include the time during the menstrual 
cycle when the single serum sample was obtained (Backer 
et al. 1999). In addition to the limitation of single serum 
samples, these studies tended to include some perimeno-
pausal or postmenopausal older women even though FSH 
levels naturally rise during and after menopause. Another 
study measured daily urinary levels of FSH metabolites in 
women of reproductive age. These findings also showed 
mean FSH levels among moderate-to-heavy smokers (≥10 
cigarettes per day) that were higher than those among 
nonsmokers during the luteal-follicular phase transition 
between cycles (Windham et al. 2005).
Serum levels of FSH increase with age, and research-
ers think this increase reflects the diminishing supply of 
oocyte- and gonadotropin-responsive follicles that leads to 
the release of the HPG axis from ovarian control (Mar-
cus et al. 1993; Cramer et al. 1994; Westhoff et al. 1996). 
The FSH level is thus considered a marker of ovarian 
reserve or competence, and as such, it may also be useful for 
identifying agents with toxic effects on the ovaries (Scott 
et al. 1989; Scott and Hofmann 1995). As progesterone 
modulates FSH in the endocrine feedback loop, the lower 
levels of luteal phase progesterone metabolites observed 
in some studies are consistent with the decreased entrain-
ment of FSH, which would lead to the observed elevations. 
The increase in FSH may accelerate the recruitment and 
development of follicles, moving ovulation earlier, and 
perhaps leading to inadequate follicle development fol-
lowed by inadequate function of the corpus luteum. Pro-
gesterone controls the endometrial response and is critical 
for early maintenance of pregnancy. Studies have impli-
cated a luteal phase deficiency as a cause of infertility and 
fetal loss (Pittaway et al. 1983; Tulppala et al. 1991). Earlier 
ovulation would also be consistent with the shortening of 
the menstrual cycle or of the follicular phase observed 
in smokers (see “Menstrual Function, Menopause, and 
Menarche” earlier in this chapter). The pattern of higher 
FSH levels, shorter cycles, and thus more frequent ovu-
lation in smokers is also consistent with the observation 
that smokers tend to experience earlier menopause (see 
“Menstrual Function, Menopause, and Menarche” earlier 
in this chapter). 
Pregnant Women
The 2001 Surgeon General’s report noted that 
smoking more clearly affects estrogen levels during preg-
nancy than when a woman is not pregnant (USDHHS 
2001). Several studies show that smokers have lower cir-
culating levels of estriol and estradiol than do nonsmokers 
(USDHHS 2001), confirmed for estriol measured multiple 
times throughout pregnancy (Kaijser et al. 2000). Fur-
thermore, the study found a positive correlation of estriol 
and birth weight. This study’s results support the hypoth-
esis of Michnovicz and colleagues (1986) that smokers 
and nonsmokers may metabolize estrogens differently, 
with acceleration of the 2-hydroxylation versus the 
16α-hydroxylation pathway in smokers. In addition, some 
studies show an increase in 2-hydroxylation and 4-hydrox-
ylation activity in placental tissues of smokers (Chao et al. 
1981; Juchau et al. 1982). In a later study using placen-
tal microsomes, smokers had increased placental forma-
tion of 4-hydroxyestradiol, 7α-hydroxyestradiol, and most 
markedly, 15α-hydroxyestradiol, but little or no difference 
in the overall rate of placental estradiol metabolism or in 
the formation of the estrone, 2α-hydroxyestradiol, and 
other metabolites (Zhu et al. 2002). A study of progester-
one in placental tissue samples revealed that levels among 
smokers were lower than those among nonsmokers 
(Piasek et al. 2001), a finding consistent with the data for 
nonpregnant women. 
Using stored serum samples, Kandel and Udry 
(1999) found that the cotinine levels were positively cor-
related with the testosterone levels, especially in samples 
obtained during the second trimester of pregnancy. In 
turn, maternal testosterone levels were correlated with 
those in adult daughters. An animal study also showed 
that nicotine infusion resulted in increased plasma testos-
terone in ovine fetuses. This study also associated mater-
nal exposure to nicotine with increased testosterone levels 
in 30-day-old (adolescent) female offspring of rats but not 
in male offspring (Smith et al. 2003). Changes in hormone 
patterns during pregnancy may therefore affect both preg-
nancy outcome and the endocrine profile of the offspring, 
thus relating to possible effects on neurobehavioral end-
points, puberty, or later reproductive status, including 
semen quality.
Men
Numerous studies have also examined hormone 
levels in men in relation to smoking (Table 8.7). Some 
studies examined the acute effects of smoking cigarettes 
in a standardized protocol, and others studied baseline 
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hormone levels in smokers compared with those in non-
smokers. The results from studies spanning many years 
are inconsistent. These studies also vary in consider-
ing obesity, which may be important because increased 
weight is associated with the peripheral conversion of an-
drogens to estrogens. Also, studies generally report total 
circulating levels of hormones but vary in reports of free 
or bioavailable levels. 
The most consistent finding is an increase of andro-
stenedione in smokers in three studies (Barrett-Connor 
and Khaw 1987; Dai et al. 1988; Field et al. 1994). Testos-
terone levels also increased with smoking in many studies, 
but some studies found decreases or no differences (Table 
8.7). The study by Sofikitis and colleagues (1995) is note-
worthy for demonstrating differences between apparent 
endocrine versus paracrine levels of testosterone related 
to effects from smoking. Animal studies show that prena-
tal exposure to nicotine is related to decreased testoster-
one levels in adult male rats (Segarra and Strand 1989) 
Table 8.6 Continued
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and that cotinine, but not nicotine, inhibits testosterone 
synthesis in testes of neonatal rats (Sarasin et al. 2003). 
Four studies that measured estradiol or estrone had 
inconsistent results. However, results from one of the 
studies showing an association with smoking were not 
adjusted for BMI or weight, although adjustment was 
made for age. The findings for the gonadotropins, FSH 
and luteinizing hormone (LH), tend to show no effect of 
smoking. 
In 1990, one study (Barrett-Connor 1990) suggested 
that the ratio of androgen to estrogen is critical in deter-
mining the gender-specific risk of some hormone-related 
diseases and that smoking may alter this ratio. Nicotine or 
its metabolites may influence endocrine profiles directly 
and indirectly. PAHs also act on the cytochrome P-450 
systems involved in the metabolism of endogenous 




Table 8.7 Association between smoking and reproductive hormones in healthy men
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The mammalian oviduct transports gametes to the 
fertilization site and provides a suitable environment for 
fertilization and development before implantation. Factors 
that impair oviductal physiology can lead to reproductive 
problems, such as fertilization failure, ectopic pregnancy, 
and failure of implantation. Numerous epidemiologic 
studies have correlated maternal smoking with reproduc-
tive problems that can originate in the oviduct, including 
increased infertility and ectopic pregnancy (Stillman et al. 
1986; Buck et al. 1997) (see “Review of Epidemiologic Lit-
erature on Smoking” earlier in this chapter). 
The mammalian oviduct has three anatomic 
regions: (1) the infundibulum, which picks up the oocyte 
cumulus complex after it is ovulated from the ovary; (2) 
the ampulla, where fertilization occurs; and (3) the isth-
mus, which conducts sperm to the ampulla and provides a 
site for preimplantation development. Proper functioning 
of each region is necessary for normal reproduction.
The oviduct is an in vivo target of cigarette smoke 
and its components. Contraction of both the human ovi-
duct (Neri and Eckerling 1969) and the rabbit oviduct 
(Ruckebusch 1975) is altered by exposure to tobacco 
smoke. Inhalation of mainstream or sidestream smoke 
at doses that produce serum cotinine levels within the 
range of those found in active smokers and persons 
involuntarily exposed to tobacco smoke caused blebbing 
of the oviductal epithelium and decreased the ratio of cili-
ated to secretory cells in hamsters (Magers et al. 1995). In 
another study of hamsters, in which the oviduct was 
directly observed before, during, and after inhalation 
of tobacco smoke at doses equivalent to those received 
by humans, both mainstream and sidestream smoke 
decreased ampullary smooth muscle contractions and 
slowed embryo transport through the oviduct (DiCarlan-
tonio and Talbot 1999). Nicotine altered the motility of 
oviducts of rhesus monkeys (Neri and Marcus 1972), 
decreased oviductal blood flow (Mitchell and Hammer 
1985), decreased sodium and potassium levels in oviductal 
epithelial cells of mice (Jin et al. 1998), and increased lac-
tate dehydrogenase levels in oviductal epithelium of rats 
(Rice and Yoshinaga 1980). 
In vitro studies using oviductal explants have been 
valuable in characterizing the effects of cigarette smoke 
on various biologic processes, including ciliary beat fre-
quency, oocyte pickup rate, and smooth muscle contrac-
tion (Huang et al. 1997; Riveles et al. 2003). Solutions of 
particulate matter, whole mainstream smoke, and 
mainstream and sidestream smoke in the gas phase in-
hibited ciliary beat frequency, oocyte pickup rate, and 
smooth muscle contraction in a dose-dependent man-
ner in hamsters (Knoll and Talbot 1998). Although this 
inhibition was originally reported for unfiltered (2R1) 
research cigarettes, a similar inhibition was subsequently 
shown for filter-tipped (1R4F) research cigarettes, unfil-
tered and filter-tipped commercial cigarettes, and “harm- 
reduction” cigarettes that are lower in carcinogens than 
are traditional brands (Riveles 2004). The data on harm-
reduction cigarettes are important in demonstrating that 
these cigarettes still contain toxicants that can adversely 
affect diverse biologic processes. Exposure to sidestream 
whole smoke, in contrast to mainstream smoke, stimu-
lated ciliary beat frequency (Knoll and Talbot 1998). The 
oocyte pickup rate was inhibited even in samples in which 
beat frequency was stimulated, which shows that pickup 
depends on factors other than ciliary beating. Adhesion 
between the extracellular matrix of the oocyte cumulus 
complex and the tips of the cilia is an additional factor 
essential for pickup (Talbot et al. 1999; Lam et al. 2000). 
If adhesion is too strong or too weak, oocyte pickup can 
fail (Lam et al. 2000). Exposure to both mainstream and 
sidestream smoke increases adhesion (Gieseke and Tal-
bot 2003), which could account for decreased pickup 
rates even when cilia beat at normal or accelerated rates. 
Exposure to tobacco smoke adversely affects other adhe-
sive processes involving cells, asbestos, and bacteria (Can-
tral et al. 1995; Churg et al. 1998; El Ahmer et al. 1999).
Therefore, in vitro studies demonstrate that 
exposure to tobacco smoke adversely affects oviductal 
structure and functioning and that nicotine can impair 
oviductal physiology. Together with in vitro data, in vivo 
studies demonstrate that maternal smoking adversely 




Formation of the placenta in the uterus (placenta-
tion) is a complex process that is not fully understood. 
Fetal stem cells (cytotrophoblasts) form a polarized epithe-
lium attached to a basement membrane that surrounds a 
stromal core containing the placental vasculature and 
forming chorionic villi. These villi are surrounded by 
a multinucleate syncytial covering. Floating villi are 
attached only to the fetal side of the placenta. In con-
trast, anchoring villi are formed when cytotrophoblastic 
cells detach from the basement membrane, penetrate the 
uterine wall, and invade maternal arteries and veins. 
Cytotrophoblasts travel deeply into uterine arterioles, 
replace the maternal endothelial lining, and disrupt the 
smooth muscle wall. This physiological transformation 
converts the maternal vasculature from a high-resistance, 
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low-capacitance system to a low-resistance, high-capaci-
tance system that allows for increased blood flow to the 
fetus. Blood from the spiral arteries then enters the inter-
villous space where an exchange of substances between the 
mother and the fetus occurs (Khong 2004). As the placenta 
develops, the villous system also undergoes remodeling. 
The terminal villi elongate, and there is a large increase in 
the peripheral villi capillary volume (Mayhew 2002; Torry 
et al. 2004). In addition, the thickness of the collective lay-
ers of the villi that separate maternal and fetal circulatory 
systems (villous membrane) decreases, enhancing the 
exchange of nutrients and metabolic products between 
the mother and fetus (Mayhew 1998). Interference with 
the development and remodeling of the placental vascu-
lature likely contributes to adverse pregnancy outcomes. 
Effects of Smoking 
Studies have examined the effects of maternal smok-
ing on the placenta, but the results are often conflicting. 
Real or apparent inconsistencies among studies may 
reflect differences in laboratory techniques and terminol-
ogy. However, many studies appear to fall into one of three 
general areas of research: (1) cytotrophoblastic invasion 
of the uterus and subsequent transformation of uterine 
blood vessels; (2) development of the fetal capillary and 
villous system, particularly with respect to whether the 
placenta can compensate for maternal hypoxia by increas-
ing the supply of oxygen (O2) and nutrients to the fetus; 
and (3) transportation of nutrients across the placenta 
(see “Amino Acids” later in this chapter).
As previously stated, cytotrophoblastic cells in nor-
mal pregnancy invade the uterine arterioles and trans-
form them into a high-capacitance system that allows for 
an increase in blood flow to the fetus. Incomplete trans-
formation of the spiral arteries results in a high vascular 
resistance in the placenta and a decrease in blood flow to 
the intervillous space. Studies have described a dimin-
ished physiological transformation in placentas from 
women with preeclampsia (Brosens et al. 1972; Naicker 
et al. 2003), SAB (Khong et al. 1987), IUGR (Khong et al. 
1986), PPROM (Kim et al. 2002), preterm labor (Kim et al. 
2003), preterm birth (Kim et al. 2003), or placental abrup-
tion (Dommisse and Tiltman 1992).
Physiological transformation appears to be dis-
turbed in women who smoke cigarettes during pregnancy. 
In vitro studies have shown that formation of cytotropho-
blastic cell columns, which is necessary for the invasion 
of the uterine wall, is disrupted, perhaps from the effects 
of exposure to nicotine (Genbacev et al. 1995). Among 
women who smoke, there also appears to be a reduc-
tion in the number of cytotrophoblastic stem cells in the 
floating villi and a reduction in the number of anchoring 
villi that successfully invade the uterine wall, which may 
reflect a premature depletion of cytotrophoblastic stem 
cells (Genbacev et al. 1995). The interference by smok-
ing in cytotrophoblastic invasion of the uterine wall could 
lead to increased risk of adverse pregnancy outcomes.
Paradoxically, maternal smoking is protective 
against preeclampsia, which is also characterized by an 
incomplete transformation of the spiral arteries. As pre-
viously noted, an imbalance between proangiogenic and 
antiangiogenic placental factors may contribute to mani-
festations of preeclampsia, and smoking may exert its 
protective effects by affecting this imbalance (Genbacev et 
al. 2003; Maynard et al. 2003) (see “Pregnancy Compli-
cations” earlier in this chapter). In a normal pregnancy, 
the placenta releases proangiogenic factors, VEGF, and the 
placental growth factor (PlGF). Placental soluble FMS-like 
sFlt-1, which is elevated in preeclampsia, is an antagonist 
of both VEGF and PlGF. An elevated sFlt-1 level is asso-
ciated with lower levels of VEGF and PlGF and leads to 
endothelial dysfunction. Maternal smoking appears to 
increase the placental expression of VEGF-A (Zhou et al. 
2002), a major regulator of cytotrophoblastic differentia-
tion along the invasive pathway that is decreased in the 
preeclamptic placenta. In contrast, studies have found 
decreased levels of sFlt-1 in the plasma of smokers (Belgore 
et al. 2000), but not in pregnant smokers (Kämäräinen et 
al. 2009). The 2004 Surgeon General’s report on the health 
consequences of smoking noted that “the decreased risk of 
preeclampsia among smokers compared with nonsmok-
ers does not outweigh the adverse outcomes that can 
result from prenatal smoking” (USDHHS 2004, p. 576). 
Additional research is needed to confirm or refute the 
notion that the effects on VEGF-A and/or sFlt-1 explain 
the reduced risk of preeclampsia in smokers. 
Findings on the effects of maternal smoking on the 
development of the villous capillary system are incon-
sistent. The fetus of a smoker develops under conditions 
of reduced partial pressure of O2, because hemoglobin 
has an affinity for CO from cigarette smoke that greatly 
exceeds its affinity for O2. Thus, the expectation is to see 
compensatory responses in the placenta similar to those 
observed with other hypoxic conditions. Such compensa-
tory responses to hypoxia could include increased volume 
density, branching, and dilation of the fetal capillary sys-
tem; increased density and proliferation of the cytotro-
phoblasts; thinning of the villous membrane (Kingdom 
and Kaufmann 1997; Mayhew 1998; Bush et al. 2000); 
and increased maternal and fetal hematocrits. Studies 
have documented increases in both the maternal and fetal 
hematocrits among smokers (Bodnar et al. 2004), which 
should lead to increased delivery of O2 to the fetus. 
In addition, several studies have found that the 
placentas of smokers are heavier or larger than those in 
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nonsmokers (Naeye 1978; van der Veen and Fox 1982; 
Howe et al. 1995; Williams et al. 1997), which suggests an 
expansion of the peripheral villous tree. However, other 
researchers have found no increase or only a small 
increase in placental size and/or weight in smokers (Spira 
et al. 1975; Picone et al. 1982; Demir et al. 1994; Sanyal et 
al. 1994; Williams et al. 1997; Zhang et al. 1999; Larsen et 
al. 2002). In many of these studies, the ratio of placental 
to fetal weight was higher in smokers than in nonsmok-
ers even when the placental weight did not increase. This 
increase in the ratio of placental to fetal weight could 
result from a compensatory response to hypoxia, but this 
explanation has not been established. Studies of morphol-
ogy have described increase (Pfarrer et al. 1999), decrease 
(Asmussen 1980; Burton et al. 1989; Teasdale and Ghis-
laine 1989; Bush et al. 2000; Larsen et al. 2002), and no 
appreciable difference (van der Velde et al. 1983; May-
hew 1996) in dimensions of the villous capillary system 
of smokers.
In contrast, studies have consistently shown that 
maternal smoking is associated with a thickening of the 
villous membrane, which would decrease the ability of 
nutrients to diffuse through the placenta (Burton et al. 
1989; Jauniaux and Burton 1992; Demir et al. 1994; Bush 
et al. 2000; Larsen et al. 2002). This increased thickness 
was attributed to the increased thickness of the tropho-
blastic component (Jauniaux and Burton 1992; Bush et 
al. 2000) and to a thickening of the basement membrane 
(Asmussen 1980; Demir et al. 1994). The thickening of 
the villous membrane is opposite from an expected com-
pensatory thinning in response to a hypoxic environ-
ment and could contribute to fetal growth restriction. 
Researchers have hypothesized that direct toxic effects of 
maternal smoking on the placenta are responsible for the 
thickening of the villous membrane, perhaps due to the 
accumulation of cadmium that is associated with a reduc-
tion in fetal capillary volume (Burton et al. 1989; Bush et 
al. 2000).
Studies have also explored other effects of maternal 
smoking on the cellular and noncellular composition of 
the villous system. Researchers have described changes 
in placental morphology of smokers, including cytotro-
phoblastic hyperplasia, focal syncytial necrosis, the loss 
or distortion of syncytial microvilli, decreased vasculosyn- 
cytial membranes, decreased syncytial pinocytotic vesi-
cles, the degeneration of cytoplasmic organelles, increased 
syncytial knots and decreased syncytial buds, and 
increased collagen levels in the villous stroma (van 
der Veen and Fox 1982; van der Velde et al. 1983, 1985; 
Demir et al. 1994). Evidence of increases in syncytial 
knots and necrotic areas suggests an increase in syncytial 
damage among smokers (Demir et al. 1994). However, 
these effects are not consistent in all studies (Teasdale and 
Ghislaine 1989; Ashfaq et al. 2003). Researchers have found 
it difficult to clearly connect these findings with adverse 
pregnancy outcomes, because the observed changes are 
not pathognomonic for any particular disorder. However, 
these cellular and molecular abnormalities of the villous 
system could lead to an impaired exchange of metabolic 
products, O2, and nutrients between the mother and fetus.
Maternal and Fetal  
Cardiovascular Systems
Smoking acutely increases the heart rate and blood 
pressure of smokers, particularly after a period of absti-
nence from smoking (e.g., first cigarette of the day). This 
finding has led to the suggestion that changes in blood 
flow may be a mechanism for the lower birth weight 
observed in infants of smokers. Numerous studies have 
investigated the effect of cigarette smoke on the cardio-
vascular system of pregnant women or their fetuses. The 
studies can be broadly divided into those that examined 
differences in basal cardiovascular parameters between 
nonsmokers and smokers after an interval of abstinence 
and those that examined the acute cardiovascular effects 
immediately after the pregnant women had each smoked 
one or two cigarettes. A body of work investigating the 
relationships of smoking with maternal blood pressure 
and preeclampsia is not presented here, as preeclampsia 
is described above. 
Seven studies investigated the basal cardiovascu-
lar state of mothers who smoked and their fetuses com-
pared with those in a control group of mothers who did 
not smoke and their fetuses (Table 8.8). Four studies used 
a radioisotope to study blood flow through the placenta 
(Table 8.9). In 28 studies, the acute maternal and fetal 
cardiovascular effects of maternal smoking were exam-
ined, and some of these studies also reported baseline dif-
ferences (Table 8.10). The participants in these 39 studies 
had healthy singleton pregnancies unless otherwise noted. 
Most of the percentage differences in the parameters were 
calculated for this Surgeon General’s report from data and 
graphs in the original articles, but the statistically signifi-
cant data are those of the original investigators. 
Basal Function 
Maternal Heart Rate and Blood Pressure 
During Smoking Abstinence
One prospective study of 203 smokers and 292 non-
smokers at 18, 24, 28, and 34 weeks of gestation found no 
differences in maternal heart rate during abstinence from 
smoking (Table 8.8) (Newnham et al. 1990). Two smaller 
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Table 8.8 Basal maternal and fetal cardiovascular effects of smoking 




144 nonsmokers, 82 smokers
Gestational age >20 weeks  
Healthy and high-risk pregnancies 
Lifetime nonsmokers vs. smokers
Unadjusted data
Maternal heart rate: no data collected; Maternal blood pressure: 
diastolic blood pressure at first prenatal clinic visit during 
abstinence 9% lower (p <0.05) in smokers than in nonsmokers; 
systolic blood pressure higher in smokers than in nonsmokers but 
no significant data or actual numbers given
Phelan 1980 478 women
350 nonsmokers, 128 smokers
Gestational age 32–40 weeks
All high-risk pregnancies
Repeated NST between 32 and 40 weeks’ 
gestation
NST: smokers had higher rate of nonreactive NST (21% vs. 13%, 
p <0.005), but nonreactive NST in nonsmokers stayed nonreactive 
on subsequent NST; usually, nonreactive NST in a smoker may or 




19 nonsmokers, 5 smokers
Gestational age 20–38 weeks
Fetal heart rate: no difference in second or early third trimester; 
heart rate 9% higher in smokers than in nonsmokers (p <0.01) 
in late pregnancy; Fetal blood flow: aorta—significant increase in 
blood flow (30–50% depending on gestational age) in smokers vs. 
nonsmokers (no p value given)
Newnham et al. 
1990
495 women
292 nonsmokers, 203 smokers
Gestational age 18–34 weeks
Study conducted at 18, 24, 28, and 34 
weeks’ gestation
     
Maternal heart rate: no difference between smokers and 
nonsmokers during abstinence; Maternal blood pressure: no 
difference between smokers and nonsmokers; Fetal heart rate: 
no difference between smokers and nonsmokers; Blood flow: no 
difference in umbilical artery or uteroplacental S/D ratio between 
smokers and nonsmokers
Matkin et al. 
1999
5,369 women
2,478 smokers, 2,891 nonsmokers
Gestational age 20–40 weeks
Maternal blood pressure: in general, lower mean diastolic blood 
pressure and higher mean systolic blood pressure in smokers; no 
significant differences between nonsmokers and any of smokers’ 
groups (p >0.05); no dose-response relationship demonstrable 
between smoking levels and blood pressure 
Lees et al. 2001 5,121 women
4,821 nonsmokers, 800 smokers
Gestational age 23 weeks
Uterine artery: at pulsatile index of >1.45 (>95% for cohort), 
likelihood ratio for severe adverse outcome was 5 for nonsmokers 
and 10 for smokers; odds ratio for severe adverse outcome for 
smokers, after adjustment for pulsatile index, was 2.18 (95% 




69 nonsmokers, 74 smokers
28 smokers <10 cigarettes/day
45 smokers >10 cigarettes/day
Median gestational age 34–35 weeks
Abstinence 20 minutes–4 hours before 
study
Blood flow: uterine arteries—no difference in S/D ratio or  
RI values in smokers vs. nonsmokers; umbilical arteries— 
median S/D ratio 13% greater and median RI value 5% greater 
in smokers than in nonsmokers (p <0.05); Fetal middle cerebral 
artery: no difference in S/D ratio or RI values between smokers and 
nonsmokers
Note: Sonographic technology (ultrasound/Doppler) was used to determine maternal heart rate and blood pressure and for fetal 
monitoring. Prospective studies were conducted during variable periods of abstinence (no smoking before or during protocol). Most 
percentages were calculated for this Surgeon General’s report from data in the study articles or estimated from graphs in the articles. 
NST = nonstress test; RI = resistance index; S/D = systolic/diastolic.
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studies also found no differences in the maternal heart 
rate in smokers and nonsmokers at baseline (Table 8.10) 
(Bruner and Forouzan 1991; Kimya et al. 1998). Many 
other studies that investigated maternal blood pressure 
or fetal heart rate did not report data on maternal heart 
rate, possibly indicating that they did not find a difference 
between smokers and nonsmokers. 
The first study that prospectively evaluated mater-
nal blood pressure during abstinence from smoking found 
a significantly lower diastolic blood pressure among 
smokers than among nonsmokers (MacGillivray et al. 
1969). Three later studies have not replicated these results 
(Newnham et al. 1990; Kimya et al. 1998; Matkin et al. 
1999). The largest study, of more than 5,000 participants, 
also found that smokers tended to have a lower mean 
diastolic blood pressure of 1 to 3 millimeters of mercury, 
but this difference was not statistically significant and is 
unlikely to be clinically significant (Table 8.8) (Matkin et 
al. 1999). The study by Newnham and colleagues (1990) 
was larger than that by MacGillivray and colleagues 
(1969) and of a similar design, but no significant differ-
ences in maternal diastolic or systolic blood pressure were 
observed. Two investigations found that the systolic blood 
pressure of smokers was higher than that of nonsmokers 
(MacGillivray et al. 1969; Matkin et al. 1999). However, 
MacGillivray and colleagues (1969) did not report signifi-
cance data, and Matkin and colleagues (1999) found the 
difference to be nonsignificant. 
Sufficient clinical data indicate that there is no clin-
ically significant difference in the mean maternal heart 
rate or blood pressure in healthy pregnant nonsmokers 
and smokers during abstinence from smoking. Further 
study of the blood pressure distribution, especially in 
the tails of the statistical distribution, may be warranted, 
because the percentage of women with blood pressure at 
or near the hypertensive range is most important clini-
cally, and this group is at a higher risk of adverse preg-
nancy outcomes (Lees et al. 2001).
Fetal Heart Rate
Four studies provide data on fetal heart rate collected 
from smokers during periods of abstinence and com-
pared with data from nonsmokers (Eldridge et al. 1986; 
Table 8.9 Maternal and fetal cardiovascular effects: radioisotope studies of placental intervillous blood flow (IBF) 
conducted before and after smoking




Gestational age 35–40 weeks
Xenon133 IBF: overall mean decrease in IBF of 21% (p <0.05) resolved 





11 women with hypertension
(9 nonsmokers, 2 smokers) 
Gestational age 34–40 weeks
Maternal heart rate: mean increase of 15% in both groups  
(p >0.001); Maternal blood pressure: increase of 6% (p <0.001) in 
healthy women and 2.5% (p <0.05) in women with hypertension;
Xenon133 IBF: baseline IBF 19% lower in women with hypertension; 
smoking resulted in mean 21% (p <0.05) decrease in IBF in healthy 
women, and a 28% (p <0.05) increase in IBF in women with 
hypertension; no change in myometrial blood flow in either group
Rauramo et al. 
1983a
7 women
1 smoker, 6 nonsmokers
Gestational age 37–38 weeks
Xenon133 IBF: decrease in mean IBF of 20% in 7 measurements 
(p <0.001), with a concomitant 54% fall in mean differential indices 
and 45% fall in interval indices; in 5 measurements, an increase in 
mean IBF, differential indices, and interval indices (24%, p not  
significant; 37%, p <0.001; and 45%, p <0.01, respectively); 
relationship between change in IBF and smoking was not clearly 
stated, but it appears that rise in IBF occurred after fall in IBF; IBF 
returned to baseline within 20 minutes
Philipp et al. 
1984
40 women
20 smokers, 20 nonsmokers
Gestational age 32–38 weeks  
Smokers studied after smoking  
2 cigarettes and compared with 
nonsmokers 
Uteroplacental blood flow measured by indium113 labeled transferrin: 
significant difference in distribution of scan types (p <0.005); normal 
flow in 15% of smokers vs. 55% of nonsmokers; intermediate flow in 
65% of smokers vs. 30% of nonsmokers; and abnormal flow in 20% of 
smokers vs. 15% of nonsmokers
aSame group of investigators.
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Table 8.10 Acute maternal and fetal cardiovascular effects of smoking
Study Design/population Outcome and comments  
Gennser et al. 
1975a
12 smokers
Gestational age 33–39 weeks
Maternal heart rate: median increase of 29% (p <0.01) and 
correlated with nicotine plasma level; Fetal heart rate: no 
consistent change
Nylund et al. 1979 12 smokers
Gestational age 39–45 weeks
Hospitalization, high-risk pregnancies  
Data graphically displayed
Maternal heart rate: mean increase of 27% (p <0.001); Maternal 
blood pressure: mean increase in systolic blood pressure of 12% 
(p <0.05) and in diastolic blood pressure of 14% (p <0.05); Fetal 
heart rate: mean increase of 15% (p <0.001)




Gestational age 34 weeks
Maternal heart rate: mean increase of 35% during smoking and 
25% after smoking (p <0.01); Maternal blood pressure: mean 
increase in systolic blood pressure and diastolic blood pressure 
of 7% and 13%, respectively, during smoking (p <0.01); return 
to baseline by 20 minutes after smoking; Fetal heart rate: mean 
increase of 17% (p <0.01); return to baseline by 30 minutes after 
smoking
Barrett et al. 1981 26 smokers
Gestational age 31–44 weeks
All high-risk pregnancies  
1 hour abstinence before testing
NST: none developed a nonreactive NST after smoking; Fetal heart 
rate: slight transient increase in 7 smokers, no change in 
18 smokers, and decrease in 1 smoker
Kariniemi et al. 
1982a
N = 8: 1 smoker, 7 nonsmokers
Gestational age 37–41 weeks
Maternal heart rate: mean increase of 17% (p <0.001); Maternal 
blood pressure: mean systolic blood pressure increase of 11% 
(p <0.001) and mean diastolic blood pressure increase of 20% 
(p <0.001); fetal heart rate and variability data not given in 
relationship to smoking
Forss et al. 1983a 8 women
3 smokers, 5 nonsmokers
Gestational age 22–26 weeks
Data provided only graphically
Maternal heart rate: increased (p <0.001); Maternal blood pressure: 
increased (p <0.01); Fetal heart rate and variability: heart rate 
increased (p <0.01); no change in short-term variability, decreased 
long-term variability
Jouppila et al. 
1983
19 smokers
Gestational age 29–39 weeks
Maternal heart rate: 13% increase (p >0.05); Fetal heart rate: 4% 
increase (p >0.05); Fetal blood flow: aorta—no change in diameter, 
1% decrease in blood flow (p not significant); umbilical vein—no 
change in diameter, 10% increase in blood flow (p not significant) 
Lehtovirta et al. 
1983a
8 women 
1 smoker, 7 nonsmokers
Gestational age 37–40 weeks
Data provided only graphically
Maternal heart rate: increased (p <0.001); Maternal blood pressure: 
increased (p <0.001); Fetal heart rate and variability: no significant 
increase in heart rate but significant decreases in short- and long-
term variability




Gestational age 37–40 weeks
Studied on 2 days, smoking on 1 day 
and no smoking on 1 day
Order of smoking randomized
Fetal heart rate: increase of 2% with smoking (p not significant); 
Fetal heart rate variability: decrease of 63% in number of 
accelerations lasting ≥40 minutes (p <0.01)
Kariniemi et al. 
1984a
8 women
Smoking status not given
Gestational age 27–32 weeks
Maternal heart rate: 24% increase (p <0.001); Maternal blood 
pressure: 9% increase in systolic blood pressure (p <0.01), 15% 
increase in diastolic blood pressure (p <0.001); Fetal heart rate and 
variability: 11% increase in heart rate (p <0.001), decrease in both 
DI and II of 24% (p <0.001)
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Table 8.10  Continued
Study Design/population Outcome and comments  
Pijpers et al. 1984 14 smokers
Gestational age 34–38 weeks
All abstained for 24 hours
7 smoked cigarette and were studied 
before, during, and after smoking, and 
7 abstained
Both studied at similar time points
Maternal heart rate: 11% increase for smokers (p <0.05) compared 
with women who abstained; Maternal blood pressure: 5% and 10% 
increase in systolic and diastolic blood pressure, respectively 
(p <0.05), with no change in women who abstained; Fetal heart 
rate: 4.5% increase (p <0.05) compared with women who abstained; 
Fetal blood flow: aorta—no significant change in velocity or in 




Gestational age 34–40 weeks
Fetal heart rate: 14% increase (p <0.01), returned to baseline by 
20 minutes after smoking; Fetal heart rate variability: significant 
decrease in short-term variability of fetal heart rate but no 




Gestational age 33–37 weeks
Maternal heart rate: median increase of 42% (p <0.01); Fetal 
heart rate: median increase of 14% (p <0.01); Fetal blood flow: 
aorta—11.6% increase in median diastolic diameter (p <0.01); 
13.8% increase in median pulsatile index (p <0.01); significant 




Gestational age 31–40 weeks
Maternal heart rate: median increase of 29% (p <0.01); Maternal 
blood pressure: median increase in systolic and diastolic blood 
pressure of 14% and 12.5%, respectively (p <0.01); Fetal heart rate: 
median increase of 13% (p <0.01); Fetal blood flow: aorta—5% 
increase in median diameter, 15% increased peak, 20% increased 
mean blood velocity, and 30% increased flow (p <0.01); umbilical 
vein—9% increase in median diameter, 38.5% increase in flow 




Gestational age 33–40 weeks
Fetal heart rate: 15% increase (p <0.05), return to baseline by 
30 minutes after smoking; Fetal blood flow: aorta—5 minutes 
after smoking, pulsatile index decreased by 9%, and least diastolic 






Gestational age 24–39 weeks 
Abstinence 2–12 hours
Maternal heart rate: 15% median increase (p <0.05); Maternal 
blood pressure: 8.7% median increase in systolic blood pressure 
(p <0.05), and no increase in diastolic blood pressure; Fetal heart 
rate: 4.3% median increase (p <0.05); Blood flow: no change in 
fetal cardiac output
Lindblad et al. 
1988a
24 smokers
Gestational age 33–36 weeks
Maternal heart rate: 16% increase (p <0.01); Maternal blood 
pressure: no significant increase in systolic blood pressure; 
11% increase in diastolic blood pressure (p <0.01); Fetal heart rate: 
14% increase (p <0.001); Fetal blood flow: aorta—11% increase in 
flow (p <0.01); umbilical vein—20% increase in flow (p <0.01)
Morrow et al. 
1988
15 smokers
Gestational age 36–41 weeks
Maternal heart rate: 30% increase (p <0.0001); Maternal blood 
pressure: slight increase in systolic blood pressure (p not 
significant), and 14% increase in diastolic blood pressure 
(p = 0.0002); Fetal heart rate: 7% increase (p = 0.001); Blood flow: 
uterine artery—increase in S/D ratio (p = 0.08, powered [80%] to 
detect 17% change in S/D ratio); umbilical artery—26% increase in 
S/D ratio (p = 0.0001)
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24 nonsmokers, 23 smokers
Gestational age 26–34.5 weeks  
Smokers studied before and after 
smoking and compared with control 
nonsmokers
Maternal heart rate and fetal heart rate: no significant difference at 
baseline between nonsmokers and smokers; no significant change 
after smoking; Uterine artery and umbilical artery blood flow: no 
significant difference at baseline between nonsmokers and smokers; 
no difference after smoking in flow velocity waveform or S/D ratio
Graca et al. 1991 51 women
Gestational age 34–38 weeks
Fetal heart rate: increase of >10 beats per minute in most fetuses 
after maternal smoking (estimated to be increase of approximately 
6–8%) and decreased short-term variability
Castro et al. 1993 19 smokers
Mean gestational age 28 weeks 
+1 week
Maternal heart rate: 27% increase (p < 0.001); Maternal blood 
pressure: 8% increase in systolic and 19% increase in diastolic 
blood pressure (p <0.001); Uterine artery blood flow: baseline S/D 
ratio >90% in 13 subjects; significant decrease in S/D ratio (15%) 
and resistance index (12%)
Oncken et al. 
1996
9 smokers
Gestational age 24–36 weeks
Percentages estimated from graphs
No p value or statement of significance 
given
Maternal heart rate: 17% increase; Maternal blood pressure: 4% 
increase in mean arterial pressure; Fetal heart rate: 2% increase; 
Blood flow: umbilical artery—8% decrease in resistance index; 
uterine artery—1% decrease in resistance index
Huisman et al. 
1997
5 smokers
Gestational age 8–16 weeks (studied 
weekly)
All twin pregnancies
Maternal heart rate: 12% increase (p <0.005); Maternal blood 
pressure: no significant change; Fetal heart rate: no significant 
change; Umbilical artery blood flow: 13% increase in pulsatile 
index (p <0.01)  
Oncken et al. 
1997
15 smokers
Gestational age 24–34 weeks
Overnight abstinence, then studied 
every 2 hours during 8 hours of ad lib 
smoking
Maternal heart rate: significant increase 2 hours after baseline 
(p <0.001); Maternal blood pressure: approximately 6% mean 
increase in systolic blood pressure at 2 hours after baseline 
(p <0.001); Fetal heart rate: 0.7% increase (p not significant); Fetal 
heart rate reactivity: nonsignificant change: 1 loss of reactivity at 
4 hours, 2 gained reactivity, and 12 had no change in reactivity; 
Blood flow: fetal MCA—2.4% decrease in resistance index at 
4 hours (p = 0.02); umbilical artery—3% increase in resistance 
index at 2 hours (significance not stated); uterine artery—
nonsignificant fluctuation (decrease and increase) in mean 
resistance index over 8 hours
Kimya et al. 1998 43 women
22 smokers, 21 nonsmokers
Gestational age 20–40 weeks
Smokers studied before and after 
smoking and compared with control 
nonsmokers
Maternal heart rate: no difference at baseline between smokers and 
nonsmokers, 23% increase (p <0.01) after smoking; Maternal blood 
pressure: no difference at baseline, systolic and diastolic blood 
pressure increased by 11% and 23%, respectively, after smoking 
(p <0.05); Blood flow: uterine artery—at baseline, smokers had 
12% lower S/D ratio, 19% lower pulsatile index, and 19% lower 
resistance index compared with those of smokers (p <0.001); after 
smoking—no significant change in S/D ratio, pulsatile index, or 
resistance index; umbilical artery—no difference in pulsatile index 
or resistance index for nonsmokers vs. smokers at baseline and 
after smoking; S/D ratio was 13% lower in nonsmokers, with no 
change in S/D ratio after smoking
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Study Design/population Outcome and comments  
Coppens et al. 
2001
26 women
13 smokers, 13 nonsmokers
>10 cigarettes/day
Mean gestational age 37–38 weeks 
Smokers studied before and after 
smoking and compared with control 
nonsmokers
Fetal heart rate: no difference between smokers and nonsmokers at 
baseline or after smoking; Fetal heart rate variability: at baseline, 
percentage of time in high variability was 31% lower in smokers 
than in nonsmokers (p <0.05); similar differences remained after 
smoking; Blood flow: umbilical artery—at baseline, no difference 
in pulsatile index between nonsmokers and smokers; pulsatile 
index increased by 76% after smoking (p <0.05)
Oncken et al. 
2002
15 smokers
Gestational age 29–36 weeks
Smoked 1 cigarette/hour for  
8 hours
Studied at baseline and at 4 hours, just 
before 4th cigarette
Fetal heart rate: baseline vs. 4 hours—no change (p = 0.17);  
Fetal heart rate variability: nonstress test—20% were nonreactive 
at baseline, and 73% were nonreactive at 4 hours (p = 0.013); 
nonreactive tests at baseline were also nonreactive at 4 hours; all 
fetuses demonstrated fetal breathing movements indicating fetal 
well-being
Ates et al. 2004 67 smokers
Gestational age 32–40 weeks
Maternal heart rate: 6% increase (p <0.001); Maternal blood 
pressure: no significant increase (p = 0.2); Fetal heart rate:  
no significant increase; Fetal heart rate variability: 7% decrease in 
variability (p = 0.08) and 19% decrease in number of accelerations 
(p = 0.035); Blood flow: umbilical artery and fetal MCA—no 
significant change in resistance index, pulsatile index, S/D ratio, or 
maximum and minimum velocity
Note: Maternal heart rate and blood pressure measurements and fetal monitoring used sonographic technology (ultrasound/
Doppler). Prospective studies were conducted before and after smoking. Unless noted otherwise in description of study design, the 
following applies to all studies: overnight (>8 hours) smoking abstinence before smoking study cigarette. All were healthy singleton 
pregnancies, and percentage changes are for means. Most percentages were calculated for this Surgeon General’s report from numeric 
data in article or estimated from graphs. DI = differential index or indices; II = interval index or indices; MCA = middle cerebral 
artery; S/D = systolic/diastolic.
aSame group of investigators.
Newnham et al. 1990; Bruner and Forouzan 1991; Cop-
pens et al. 2001). These studies found no differences 
except for the small study by Eldridge and colleagues 
(1986). This study compared 19 nonsmokers with 5 smok-
ers and found no difference in fetal heart rate during the 
second or early third trimester, but it did find a significant 
9-percent elevation among smokers late in the pregnancy.
Acute Effects of Smoking 
Maternal Heart Rate
Twenty-one studies provide data on the immediate 
effect of smoking one or two cigarettes on maternal heart 
rate (Table 8.10). The general design of these studies is 
similar. Healthy active smokers with singleton births in 
the latter half of pregnancy abstained from smoking over-
night and were then studied before and after smoking one 
or two cigarettes. The different designs of the studies are 
noted in Table 8.10. All but two of the studies (Jouppila et 
al. 1983; Bruner and Forouzan 1991) found a statistically 
significant transient increase in maternal heart rate imme-
diately after smoking. The largest study, with 67 pregnant 
smokers, found a significant increase of 6 percent in ma-
ternal heart rate (Ates et al. 2004), and one smaller study, 
with 17 pregnant smokers, found a significant 42-percent 
increase in maternal heart rate immediately after smoking 
(Sindberg Eriksen and Gennser 1984). Other increases in 
maternal heart rate ranged from 10 to 30 percent, which 
were similar to the nonsignificant effect in the study con-
ducted by Jouppila and colleagues (1983). 
Sufficient clinical data establish that smoking a 
cigarette after a period of abstinence transiently elevates 
maternal heart rate, although the magnitude of the 
increase varies. This finding holds true even when stud-
ies involving nonsmokers are excluded. Only one study 
(Oncken et al. 1997), however, addressed the effect of ad 
lib smoking throughout the day on maternal heart rate. 
Oncken and colleagues (1997) found a maximal increase of 
11 beats per minute in maternal heart rate two hours after 
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baseline—an increase of approximately 13 percent—with 
ad lib smoking. The clinical significance of a transiently 
elevated maternal heart rate during pregnancy 
is unknown. 
Maternal Blood Pressure
Of the 16 studies that examined the acute effects 
of smoking on maternal blood pressure (Table 8.10), all 
but 2 (Huisman et al. 1997; Ates et al. 2004) reported a 
transient but significant elevation in the mean or median 
diastolic or systolic blood pressure or in the mean arterial 
pressure. The largest increases, ranging from 10 to 23 per-
cent, were observed for diastolic blood pressure, but most 
studies found an increase of less than 15 percent. The larg-
est study, with 67 participants, found a small but nonsig-
nificant increase in diastolic blood pressure after smoking 
(Ates et al. 2004). In general, the acute effect of smoking 
on maternal systolic blood pressure was less than the 
effect on diastolic blood pressure. Three studies reported 
no significant increase in systolic blood pressure, and the 
largest study found a small but nonsignificant (p = 0.2) 
increase (Table 8.10) (Ates et al. 2004). In the remaining 
10 studies, transient increases ranged from 5 to 14 per-
cent. These data indicate that smoking after abstinence 
transiently increases diastolic blood pressure and, to a 
lesser extent, systolic blood pressure. Because one large 
study (Ates et al. 2004) found a nonsignificant effect of 
smoking on maternal blood pressure, additional large 
studies may be needed. 
The release of catecholamine may mediate the eleva-
tions in maternal heart rate and blood pressure reported 
in these studies. In a study of pregnant women, smoking 
was associated with an acute rise in plasma levels of nor-
epinephrine, epinephrine, and dopamine and an associ-
ated acute rise in maternal heart rate and blood pressure 
(Quigley et al. 1979).
Fetal Heart Rate
Twenty-five studies (Table 8.10) collected data on 
fetal heart rate before and after mothers smoked one or 
two cigarettes. Ten studies, including the largest study 
(Ates et al. 2004) and two studies with a control group 
of nonsmokers (Bruner and Forouzan 1991; Coppens et 
al. 2001), found no effect of smoking on fetal heart rate. 
Five studies reported that smoking after abstinence was 
associated with a 2- to 8-percent transient increase in 
fetal heart rate, and eight studies reported an increase 
of 11 to 17 percent in fetal heart rate. The studies that 
found mean elevations in the fetal heart rate above 10 
percent were conducted between 1979 and 1988. The 
five studies published after 1996 reported no statistically 
significant difference. 
Variability in Fetal Heart Rate 
Healthy fetal heart rate is variable, and there are 
short- and long-term patterns to this variability. The 
“differential index” is an alternative term for short-term 
variability, and the “interval index” is an alternative term 
for long-term variability. Healthy fetal heart rate also has 
episodes of accelerations. Researchers use the variability 
in fetal heart rate and the presence of episodes of accel-
erations to measure fetal well-being. This variability and 
acceleration are measured in the noninvasive nonstress 
test (NST). A reactive NST is a sign of fetal well-being, and 
a nonreactive NST is a sign of fetal distress. The NST is 
routinely used in the third trimester of pregnancy and 
during labor to monitor high-risk pregnancies and to 
assess low-risk pregnancies if concerns develop. Healthy 
fetuses have transient periods of decreased variability and 
accelerations, which would appear as a transiently nonre-
active NST. 
Data on fetal heart rate reactivity and accelerations 
and the NST are presented in Tables 8.8 and 8.10. A large 
cohort of mothers with high-risk pregnancies among 
smokers and nonsmokers was studied repeatedly over 
the course of the pregnancies (Table 8.8) (Phelan 1980). 
Although smokers had a high rate of nonreactive NSTs, 
many were reactive at a subsequent visit. A nonreactive 
NST in a pregnant smoker should generally be repeated 
to rule out a false nonreactive result. There are no reports 
on the prevalence of nontransient, abnormal NSTs among 
healthy smokers versus healthy nonsmokers. 
Nine studies investigated variability in fetal heart 
rate before and after maternal smoking (Table 8.10). All 
but two studies (Oncken et al. 1997; Coppens et al. 2001) 
found that either maternal smoking transiently decreased 
short- and long-term variability or the NST became non-
reactive. Three of the studies with positive findings were 
conducted with a control group of nonsmokers by the 
same team of investigators (Forss et al. 1983; Lehtovirta 
et al. 1983; Kariniemi et al. 1984). One investigator did 
not find a loss of reactivity from smoking one cigarette but 
did find a large increase in nonreactive NSTs with addi-
tional smoking (Oncken et al. 2002). The two largest stud-
ies (Graca et al. 1991; Ates et al. 2004) found a significant 
decrease in variability of fetal heart rate and an accelerated 
increase after smoking.
These data indicate that maternal smoking tran-
siently decreases variability of fetal heart rate. However, 
the clinical significance of these transient decreases in the 
heart rate of fetuses of smokers is not clear. Generally, the 
nontransient changes in these parameters are the clini-
cally important changes. 
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Blood Flow in Uterus, Placenta, and Fetus
Table 8.9 presents data on blood flow in the uterus 
and placenta from studies that used a radioisotope, which 
is considered the “gold standard” because it directly 
measures flow. The development of fetal sonographic 
technology has replaced radioisotope studies, because 
radioisotopes measure only maternal blood flow and 
expose the mother and fetus to radiation. Sonography is 
noninvasive and can be used to assess blood flow in both 
the fetus and the mother. Table 8.10 presents data from 
ultrasound and Doppler sonography on vessel diameter 
and blood velocity. These data are then used to calculate 
blood flow, which is difficult to measure, because the 
sonographer must visually mark the diameter of a ves-
sel. Flow is proportional to the fourth power of the vessel 
radius, so even very small changes in the measurement of 
the diameter have a large effect on the calculation. Fur-
thermore, all of the studies are unblinded. Sonographic 
technology advanced greatly between 1978 and 2004, 
which may partly explain the variations in the results from 
more than 25 years of publications, as is discussed here. 
The most commonly used surrogate measures of 
blood flow are the ratio of systolic to diastolic blood flow 
velocity (S/D ratio), pulsatile index, and resistance index 
(RI). The S/D ratio is defined as the ratio of the time- 
averaged maximal systolic and diastolic blood flow 
velocities. The pulsatile index is defined as the difference 
between peak velocity and the lowest diastolic velocity, 
divided by the mean velocity during the heart cycle. The 
RI is defined as the difference between the maximal sys-
tolic and diastolic flow velocities, divided by the systolic 
flow velocity.
Independent of studies of smoking, researchers have 
used the S/D ratio, pulsatile index, and RI measures to 
monitor high-risk pregnancies and to predict outcomes 
(Maulik et al. 1990; Alatas et al. 1996; Fong et al. 1999; 
Özeren et al. 1999; Coleman et al. 2000; Gudmundsson et 
al. 2003; Axt-Fliedner et al. 2005; Li et al. 2005). In low-
risk pregnancies, these measures of blood flow are not sen-
sitive to or specific predictors of adverse outcomes such 
as preeclampsia or IUGR (Kurmanavichius et al. 1990; 
Irion et al. 1998; Albaiges et al. 2000; Harrington et al. 
2004; Schwarze et al. 2005), except when the measures are 
markedly abnormal (Becker et al. 2002; Papageorghiou et 
al. 2005).
Four radioisotope studies of placental intervillous 
blood flow (IBF) have been performed (Table 8.9). Histori-
cally, these four studies have provided the initial data for 
the hypothesis that decreased maternal blood flow through 
the placenta caused fetal growth retardation. Three stud-
ies by the same group of investigators used xenon133 to 
determine the acute effect of smoking on IBF among 
nonsmokers (Lehtovirta and Forss 1978, 1980; Rauramo 
et al. 1983). The results of the three studies are contradic-
tory. Smoking resulted in either an acute increase or a 
decrease in IBF, depending on the patient and the study. 
The fourth radioisotope study used indium113-labeled 
transferrin to compare smokers immediately after smok-
ing with nonsmokers (Philipp et al. 1984). This study 
found a significant difference in the distribution of nor-
mal and abnormal blood flow between the two groups, 
and a smaller proportion of scans were normal among 
the smokers.
Of four studies conducted during abstinence from 
smoking, two found no difference in blood flow param-
eters of uterine arteries between nonsmokers and smok-
ers (Table 8.8) (Newnham et al. 1990; Albuquerque et 
al. 2004); the latter did find a difference in blood flow in 
umbilical arteries, but the larger Newnham study did not. 
The very small study by Eldridge and colleagues (1986) 
found an increase in aortic blood flow. The most impor-
tant study found an association between the risk of a 
severe adverse pregnancy outcome and a pulsatile index 
for the uterine artery that doubled among smokers (Lees 
et al. 2001).
Sixteen studies used Doppler sonography to 
examine blood flow parameters in maternal smokers 
and their fetuses before and after smoking or in smokers 
after smoking compared with nonsmokers and their 
fetuses (Table 8.10). Four studies by the same group of 
investigators found that smoking dramatically increased 
four parameters (blood flow, velocity, diameter, and pulsa-
tile index) (Sindberg Eriksen et al. 1984; Sindberg Eriksen 
and Marsal 1984, 1987; Lindblad et al. 1988). One study 
found an acute 76-percent increase in the pulsatile index 
of the umbilical artery after maternal smoking (Coppens 
et al. 2001). Six studies found no effect on blood flow, 
velocity, diameter, S/D ratio, pulsatile index, and RI in the 
uteroplacental or fetal blood vessels (Jouppila et al. 1983; 
Pijpers et al. 1984; Sorensen and Borlum 1987; Bruner 
and Forouzan 1991; Kimya et al. 1998; Ates et al. 2004). 
However, Oncken and colleagues (1997) found a negli-
gible change, and four studies found either increases or 
decreases in the S/D ratio and the pulsatile index (Table 
8.10) (Morrow et al. 1988; Castro et al. 1993; Oncken et al. 
1996; Huisman et al. 1997).
In summary, differences between blood flow in 
smokers during abstinence and that in nonsmokers do 
not appear to be significant. However, the study by Lees 
and colleagues (2001) raises concerns because it indicates 
that with an elevated pulsatile index in the uterine artery, 
maternal cigarette smoking doubles the risk of a severe, 
adverse pregnancy outcome. The data on the acute effects 
of smoking on maternal and fetal blood flow are more 
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contradictory, and no generalizations can be made at 
this time.
Fetal Tissue and Organogenesis 
Timing and Critical Periods
The embryonic period includes the first eight 
weeks after fertilization and constitutes a significant 
period in human development. During this time, all 
major internal and external structures start to develop, 
involving many complex interactions that must occur in 
an orderly sequence. The embryonic period is a time of 
rapid differentiation, and the developing organs are partic-
ularly susceptible to the effects of exogenous agents. The 
stage of embryonic development determines the embryo’s 
susceptibility to unfavorable environmental factors. The 
embryo is most easily disturbed during the organogenesis 
period, from day 15 to day 60 after conception. In addition, 
each system or organ of an embryo has a critical period 
when its development may be altered. The effects of some 
environmental toxins on the developing embryo and fetus 
can be direct and lethal or subtle with delayed but serious 
consequences. Thus, multiple factors are involved in iden-
tifying and evaluating the effects of exposure to tobacco 
smoke on the developing baby. 
Evidence on Effects of Smoking
Some epidemiologic studies report an association 
between maternal smoking and various congenital mal-
formations. In this area of research, the associations with 
smoking most frequently examined and published relate 
to nonsyndromic orofacial clefting, congenital heart dis-
ease, malformations of the lower extremities such as club-
foot or limb deficiency defects, hypospadias, gastroschisis, 
and craniosynostosis (see “Birth Defects” earlier in this 
chapter). Data supporting a causal association between 
nonsyndromic orofacial clefting and maternal smoking 
have strengthened, but few studies have addressed pos-
sible pathogenetic mechanisms. 
Traditionally, investigators have used animal models 
and postmortem tissues to detect the effects on organo-
genesis of exposure to tobacco smoke by conducting gross 
morphologic, soft tissue, and skeletal examinations. Early 
studies of this type involving exposure to mainstream cig-
arette smoke provide little data supporting an effect on 
organogenesis. Of seven studies, four did not find any 
effects (Wagner et al. 1972; Reznik and Marquard 1980; 
Peterson et al. 1981; Bassi et al. 1984), and three men-
tioned limited findings but lacked sufficient details for a 
full evaluation (Schoeneck 1941; Tachi and Aoyama 1983; 
Amankwah et al. 1985). 
A subsequent set of experiments exposed pregnant 
Wistar rats to sidestream cigarette smoke, and the pups 
were then examined for gross morphologic changes (Table 
8.11). Researchers observed a dose-dependent reduction 
in birth weight (p <0.001) but no increase in macroscopi-
cally visible gross anomalies (Nelson et al. 1999a). Ossifi-
cation was delayed throughout the skeleton in all exposed 
groups regardless of the dose. The second part of the 
experiment studied the histopathologic changes in tissues 
such as the lung, liver, stomach, kidney, and intestines 
(Nelson et al. 1999b). The lung tissues of pups of dams 
exposed to smoke showed increased apoptosis, mesen-
chymal changes, and hyperplasia of bronchial muscles. 
Researchers found abnormal hematopoiesis, prolifera-
tion of bile ducts in the liver, and delayed maturation 
of the glomeruli, gastric epithelia, and intestinal villi. 
Another study exposed Sprague-Dawley rats to main-
stream tobacco smoke by nose-only inhalation (Car-
mines et al. 2003). Males were exposed four weeks before 
and during mating, and females were exposed two weeks 
before and during mating and through gestational day 
20. Exposure to tobacco smoke was confirmed by bio-
marker evaluation. Researchers evaluated external and 
internal abnormal macroscopic findings, histopathology 
of the placenta and fetal tissue, and skeletal radiograms. 
They concluded that exposure to tobacco smoke was not 
associated with any congenital malformations in the off-
spring. However, numerous abnormalities were described, 
including hypoplasia of the internal genital structures in 
the exposed adult male rats and decreased ossification in 
the fetuses of the exposed dams. 
Epidemiologic studies show that offspring of 
maternal smokers have abnormal lung function and 
associated higher incidences of lower respiratory disor-
ders. The identification of nicotinic acetylcholine recep-
tors in fetal lung suggests a mechanism that may underlie 
the observed postnatal pulmonary abnormalities. This 
hypothesis was tested in monkeys to determine whether 
maternal exposure to nicotine would produce changes in 
lung function or morphology in newborn monkeys similar 
to the changes observed in human infants (Sekhon et al. 
2001). Pregnant rhesus monkeys were infused with either 
nicotine comparable to heavy smoking in humans (1.5 
milligrams per kilogram per day [mg/kg/day], n = 7) or 
saline (n = 7) timed to days 26 through 160 of gestation. 
The fetuses were delivered by cesarean section and on the 
next day had pulmonary function testing. They were then 
sacrificed, and their lungs were weighed and fixed. There 
was a significant decrease in fetal lung weight (16 percent) 
and fixed lung volume (14 percent) after in utero exposure 
to nicotine. All lung function tests (e.g., peak tidal expi-
ratory volume, mean mid-expiratory volume, and forced 
expiratory volume at peak expiratory flows) were also 
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Table 8.11 Animal and in vitro studies on association between maternal smoking and congenital abnormalities with 








Pregnant Wistar rats were 
exposed to sidestream 
cigarette smoke (13 mg of 
tar, 0.9 mg of nicotine)
Pups examined
Histopathologic changes 
in tissues such as lung, 




exposure to cigarette 
smoke
• Lung tissues showed 
increased apoptosis, 
mesenchymal changes, 




proliferation of bile 
ducts in liver
• Delayed maturation 
of glomeruli, gastric 




Pregnant Wistar rats were 
exposed to sidestream 
cigarette smoke (13 mg of 






exposure to cigarette 
smoke
• Dose-dependent 
reduction of birth 
weight was observed  
(p <0.001)
• No macroscopically 
visible gross anomaly 
was observed
• Delay in ossification 
in entire skeleton was 
observed in all exposed, 
regardless of dose
Subrama-




exposed to sidestream 
cigarette smoke and 
unexposed control group
2 weeks after exposure, 
females inseminated by 
unexposed males
Exposure continued during 
mating and pregnancy
Pups from the exposed 
group continued to be 
exposed to cigarette smoke 
until examination
Lung surfactant proteins 
SP-A and SP-B in 
bronchoalveolar lavage 
fluids, preparations from 
postnatal days 1, 3, 7, 14, 
21, and 35 from sham- 
and smoke-exposed pups
Determine whether 
perinatal exposure to 
sidestream cigarette 
smoke decreases 
amount of surfactant in 
developing rat pups
• Smoke-exposed pups 
showed reduced level 
of SP-A on day 1 and a 
higher level of SP-A and 
phospholipids on day 21
• Perinatal exposure to 
sidestream smoke can 
have deleterious effects 
on the developing lung
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27 Spanish-type female 
goats and 28 Western 
ewes were given Nicotiana 
glauca during pregnancy
Concentration of anabasine 
in the dried plants was 
0.175–0.23% vs. 2.4% in 
extracts
Treatment groups divided 
into 6 subgroups and fed 
dried plant by gavage or 
anabasine-rich extract by 
capsule on days 32 and 41 
of gestation
Low initial dose (5–8 mg/
kg) titrated until clinical 
signs of toxicity (maximum 
18 mg/kg)
Intrauterine growth, 
presence or absence of 
CP, facial asymmetry, and 
skeletal contractures in 
newborn goats and sheep
Compare incidence 
of plant-induced CP 
formation between sheep 
and goat treatment 
groups
Determine differences 
in sensitivity of study 
animals exposed to same 
toxicants in similar doses 
and manner
Determine other 
variables that might 
explain cause of CP 
formation
• Fetuses from both  





• 21 of 45 (47%) 
newborn goats exposed 
during the early part 
of pregnancy (32–41 
gestational days) had 
CP; only 1 of 45 
(2.2%) had skeletal 
contractures
• 1 of 35 (2.9%) lambs 
had CP, and 6 of 35 
(17%) had contractures
• Goat model is more 
efficient and reliable for 
studying CP deformities
• Tobacco plant and 
its extract is a well-
established cause 
of congenital cleft 
formation
• Exact mechanism 
is undetermined, 
but neuromuscular 




Pregnant rhesus monkeys 
received subcutaneous 
infusion of nicotine  
(1.5 mg/kg per day  
(n = 7) or saline (n = 7) on 
gestational days 26–160
After delivery by cesarean 
section, fetuses had 
pulmonary function testing 
on next day
Pulmonary function 
before and after exposure 
to nicotine
Lung weight and 
morphology
Interaction of nicotine 
with nicotinic 
acetylcholine receptor 




mechanics observed in 
human infants whose 
mothers smoked during 
pregnancy
• Lung weight and fixed 
lung volume were 
significantly decreased 
in exposed monkeys 
(16% and 14%, 
respectively)
• Fixed lung volume 
and lung volume 
normalized to body 
weight decreased (14%, 
p = 0.001; 11%,  
p = 0.006, respectively)
• All lung function 
test results were 
significantly lower 
in newborns exposed 













effects of smoke from 
1R4F reference cigarette 
examined
Sprague-Dawley rats 
exposed for 2 hours/day, 
7 days/week, by nose-
only inhalation at target 
mainstream smoke levels 
of 150, 300, and 600 mg/m3 
of total particulate matter 
Males exposed 4 weeks 
before and during mating 
and females for 2 weeks 
before and during mating 
and through gestational 
day 20
Sham controls: filtered 
air to simulate nose-only 
exposure, and cage controls 
maintained untreated




evaluation of placenta and 
fetal tissue 
External and internal 
malformations
Macroscopic and 
microscopic findings and 
changes determined by 
skeletal radiograms
Parental exposure to 
tobacco smoke may 
cause congenital 
malformations
• Exposure duration was 
limited
• Number of study and 
control subjects was 
inadequate
• Morphologic and 
dysmorphic evaluations 
were not thorough
• Adult male rats showed 
hypoplasia of the 
internal male genital 
structures
• Fetuses from dams 
exposed to tobacco 
smoke showed 
decreased ossification




54 sudden and unexplained 
fetal and infant deaths 
(13 stillbirths, 7 neonatal 





Sections of brainstem 





analysis of arcuate nucleus
Decrease in size of 
the arcuate nucleus of 
brainstem was expected 
in group exposed to 
smoke
• Mothers of 18 of 34 
infants with hypoplasia 
in >20% of arcuate 




• EN2 is a candidate gene 
thought to regulate 
development of arcuate 
nucleus
• Cigarette smoke may 
directly affect this gene, 
resulting in brainstem 
abnormalities
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Proposed mechanism or 
hypothesis Findings
de la Chica 
et al. 2005
Prospective study
25 control mothers and 
25 mothers who smoked 
(≥10 cigarettes/day for ≥10 
years)
Amniocytes obtained by 













has a genotoxic effect 
on amniotic cells, 
expressed as increased 
chromosomal instability
Analyze whether any 
chromosomal regions 
are especially affected by 
tobacco
• Smoking as defined 
and during pregnancy 




• Band 11q23, known 
to be involved in 
leukemogenesis, seems 
especially sensitive to 
genotoxic compounds 
contained in tobacco
Ejaz et al. 
2005
Chicken embryo model
In vivo examination of 
neonatal development
Effects examined of 
different preparations of 
nicotine and solutions of 
whole mainstream smoke 
on embryonic movements 
during neonatal 
development
Activity level before and 
after exposure to nicotine 
was measured
Kinematic analysis Evaluate effects of 
nicotine and solutions 
of whole mainstream 
smoke on embryonic 
movements
• Low doses of nicotine 
induced hyperactivity, 
and higher doses 
induced hypoactivity
• Significant (p <0.01) 
decrease in movements 
with application of 10 
mg of nicotine and 
different preparations 













of 42 stillborn babies
In 30 of 42, no cause 
of death was identified 
(sudden intrauterine 
unexplained death)
In 12 of 42, causes of death 
were known (intrauterine 
explained death)
15 sudden intrauterine 
unexplained deaths and 
1 intrauterine explained 




Brainstems studied by 
immunohistochemistry 
to assay expression of 
EN2 gene, somatostatin, 




Morphologic changes of 
brainstem expected in 
the smoke-exposed group
• Brainstem sections 
from 13 stillbirths with 
no definite cause of 
death but with known 
exposure to tobacco 
smoke showed varying 
degrees of hypoplasia 
of arcuate nucleus 
and abnormal staining 
pattern with antibodies 
applied
• Exposure in utero to 
maternal smoking 
may strongly 
interfere with brain 
biologic parameters, 
including decrease in 
noradrenergic activity 
in brainstem
Note: CP = cleft palate; mg = milligrams; mg/kg = milligrams per kilogram; mg/m3 = milligrams per cubic meter.
significantly lower in the newborns exposed to nicotine, 
demonstrating that prenatal exposure to nicotine com-
promises lung growth and pulmonary function. Although 
there was no histopathologic description of the examined 
lungs, researchers have described changes in lung mor-
phology in humans (DiFranza et al. 2004), as well as in 
rats (Nelson et al. 1999b). Another experiment exposed 
female Sprague-Dawley rats aged 12 weeks to tobacco 
smoke and then mated them to unexposed males. Post-
natal measurements of the pups’ lung surfactant levels of 
protein (SP-A and SP-B) in bronchoalveolar lavage fluids 
showed a reduced level of SP-A on day 1 and a higher level 
of SP-A and phospholipid on day 21 among pups exposed 
to smoke (Subramaniam et al. 1999). 
One study examined the induction of cleft palate 
by Nicotiana glauca (wild-tree tobacco) or anabasine-
rich extracts during the first trimester of pregnancy and 
compared Spanish-type goats with crossbred Western-
type sheep (Panter et al. 2000). Bilateral cleft palate was 
induced in 100 percent of the embryonic and fetal goats 
by gavage of the pregnant mothers with anabasine-rich 
extracts. Eleven percent of the newborn goats showed 
extracranial abnormalities, mainly contractures of the 
metacarpal joints, in addition to bilateral cleft palate. Most 
of these contractures resolved spontaneously within four 
to six weeks after delivery. In contrast, only two lambs 
from ewes exposed to both substances had cleft palate. 
However, all lambs exposed to both substances had con-
tractures, which indicated differential susceptibility of 
the species. The researchers postulated that an alkaloid-
induced reduction in fetal movement during the period of 
normal palate closure caused the cleft palate and the mul-
tiple flexion contractures. This postulation is supported by 
a later study that used the chick embryo model to conduct 
an in vivo examination of the effects of different prepa-
rations of solutions of nicotine and of mainstream whole 
smoke on embryonic movements during neonatal devel-
opment (Ejaz et al. 2005). In this experiment, low doses 
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of nicotine induced hyperactivity and high doses induced 
hypoactivity. Accordingly, there was a significant (p <0.01) 
decrease in movements after applying 10 mg of nicotine 
and different preparations of whole mainstream smoke 
solutions. The decrease in embryonic movements was 
dose dependent and did not resolve by the end of the 
experiment. The researchers concluded that nicotine 
could alter embryonic movements that are important dur-
ing embryogenesis for the differentiation and maturation 
of the body systems. 
In a clinical study, researchers collected amnio-
cytes from routine amniocenteses of 25 control women 
and 25 women who smoked (≥10 cigarettes per day for 
≥10 years). Amniocytes of the smokers showed increased 
chromosomal instability; breakpoints involving band 
11q23, which is commonly implicated in hematopoietic 
malignancies, was the chromosomal region most affected 
(de la Chica et al. 2005). Another study examined autopsy 
specimens from 42 stillborn infants (Lavezzi et al. 2005). 
Researchers studied the brainstem tissue by immunohis-
tochemistry to evaluate the expression of the EN2 gene, 
somatostatin, and the tyrosine hydroxylase enzyme. 
Brainstem sections from stillborn infants whose mothers 
had smoked during pregnancy showed hypoplasia of the 
arcuate nucleus and an abnormal staining pattern with 
the antibodies applied. Thus, in utero exposure to mater-
nal smoking may strongly interfere with brain biologic 
parameters of brain development, including a decrease 
in the noradrenergic activity in the brainstem, resulting 
in pulmonary hypodevelopment and even an apparently 
unexplained sudden death of the fetus (Lavezzi et al. 2005).
Researchers have identified an increasing number 
of polymorphisms of genes encoding drug- and/or toxin-
metabolizing enzymes, transporters, and receptors. Some 
of these genetic factors have a major impact on drug sen-
sitivity, adverse reactions, or variations of responses to 
environmental toxins. As a result, many investigators have 
studied polymorphisms of certain candidate genes to elu-
cidate the pathogenesis of the effects of maternal smoking 
on the developing embryo and fetus (see “Smoking and 
Maternal and Neonatal Genetic Polymorphisms” later in 
this chapter). 
Investigators have proposed other mechanisms for 
the adverse effects of smoking on organogenesis, particu-
larly orofacial clefting. CO contributes to fetal hypoxia, 
which investigators have associated with an increased risk 
for cleft lip and cleft palate in susceptible strains of mice 
(Millicovsky and Johnston 1981; Bronsky et al. 1986; Bai-
ley et al. 1995). Impaired uteroplacental circulation may 
result in a reduced supply of essential nutrients for embry-
onic tissues (van Rooij et al. 2001). Studies have associated 
poor intake of vitamin B6 and multivitamins with a risk of 
oral clefts (Botto et al. 2004; Munger et al. 2004). Other 
possible mechanisms include (1) reductions in serum 
folate levels mediated by maternal smoking (McDonald et 
al. 2002; Mannino et al. 2003; Ortega et al. 2004), (2) expo-
sure to cadmium that is present in increased amounts in 
the placentas of smokers (Ronco et al. 2005) and is associ-
ated with teratogenic effects in certain rats (Ferm 1971; 
Chernoff 1973), and (3) DNA damage by PAHs (Lammer 
et al. 2004; Perera et al. 2004). Further work is needed to 
elucidate the extent to which these or other mechanisms 
involving the complex mixture of chemicals in cigarette 
smoke account for the increased risk of oral clefts. 
Immune System
Cigarette smoking is associated with an increased 
risk for many types of infectious diseases including pneu-
mococcal pneumonia, Legionnaires’ disease, meningo-
coccal disease, influenza, the common cold, and infection 
with Helicobacter pylori (Arcavi and Benowitz 2004). In 
addition, studies have associated smoking with seroposi-
tivity for human immunodeficiency virus (HIV) and an 
increase in the transmission of HIV from infected mothers 
to their offspring (Boulos et al. 1990; Royce and Winkel-
stein 1990; Burns et al. 1991, 1994). 
The mechanisms through which smoking increases 
the risk of infection are not well defined and are likely 
complex, involving both innate and adaptive immune 
responses. Compared with nonsmokers, smokers appear 
to have a leukocytosis (Corre et al. 1971; Friedman et al. 
1973; Yeung and Buncio 1984; Hughes et al. 1985; Calori 
et al. 1996; Jensen et al. 1998a) and elevations in levels of 
all major blood cell types (Corre et al. 1971). This leukocy-
tosis could be a result of nicotine-induced increases in the 
release of catecholamine (Friedman et al. 1973). However, 
the consequences of an increased white blood cell count 
are unclear. It appears that there are increases in both 
CD4+ (an HIV-helper white blood cell) and CD8+ (an HIV-
suppressor white blood cell) T-cell populations in smok-
ers, although heavy smokers may have reduced CD4+ cell 
counts, and effects may vary by race (Sopori 2002; Arcavi 
and Benowitz 2004). A decline in CD4+ cell counts could 
contribute to a decrease in B-cell proliferation and immu-
noglobulin (Ig) synthesis, which would increase the risk of 
infection (Arcavi and Benowitz 2004). However, in a study 
of pregnant smokers compared with pregnant nonsmok-
ers, a decline in CD4+ count was not described (Luppi et 
al. 2007). 
In general, smoking appears to have immunosup-
pressive effects. For example, lymphocytes in smokers 
appear to have a decreased response to T-cell mitogens 
(Sopori 2002), and polymorphonuclear leukocytes show 
decreases in chemotaxis and migration (Noble and Penny 
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1975; Corberand et al. 1979), which do not appear to be 
attributable to exposure to nicotine (Sasagawa et al. 1985). 
Study findings suggest that smokers have reduced titers of 
antibodies to the influenza virus and low serum levels of 
all Ig classes except IgE (Gerrard et al. 1980; Sopori 2002). 
In addition, smoking may increase levels of autoantibod-
ies, perhaps contributing to some autoimmune disorders 
(Mathews et al. 1973; Másdóttir et al. 2000; Sopori 2002). 
Smoking may also affect the balance of function between 
helper T-cell subsets 1 and 2 (Th1 and Th2), because 
researchers have observed increases in Th2- and/or Th1-
related cytokines in smokers (Tsunoda et al. 2003; Cozen 
et al. 2004). In vitro experiments suggest that nicotine 
impairs the immunostimulatory activity of dendritic cells 
(antigen-presenting cells) and adversely affects the differ-
entiation of monocytes into dendritic cells (Nouri-Shirazi 
and Guinet 2003; Guinet et al. 2004). Finally, studies have 
also associated smoking with low counts and reduced 
cytotoxic activity of natural killer cells, which are impor-
tant components of innate immunity (Tollerud et al. 1989; 
Zeidel et al. 2002). Potential mechanisms through which 
exposure to tobacco or nicotine might result in an altered 
immune function include the induction of glucocorticoid 
hypersecretion and the increased release of catechol-
amines, which both inhibit the immune response or the 
activation of the autonomic nervous system (Sopori and 
Kozak 1998; Borovikova et al. 2000; Sopori 2002). Activa-
tion of the parasympathetic arm of the autonomic nervous 
system attenuates the systemic inflammatory response.
Studies suggest that smoking also induces systemic 
chronic inflammatory effects, which is possibly a conse-
quence of increased oxidative stress (Cross et al. 1999; 
Hecht 1999; van der Vaart et al. 2005). As described earlier 
in this section, smokers have a leukocytosis compared with 
white blood cell counts in nonsmokers, and studies have 
associated smoking with elevated levels of C-reactive pro-
tein (Tracy et al. 1997; Wong et al. 2001; Bermudez et al. 
2002). However, findings in studies of cytokine profiles in 
blood are not consistent (van der Vaart et al. 2005). Some 
studies suggest that smoking suppresses the production of 
proinflammatory cytokines such as IL-1, IL-6, and TNFα, 
which are important components of the immune response 
to intracellular pathogens such as viruses and fungi 
(Sopori and Kozak 1998; Ouyang et al. 2000). However, 
other studies have shown an enhanced production of IL-6 
and TNFα, as well as other cytokines including IL-1β 
(Zeidel et al. 2002; van der Vaart et al. 2005).
Smoking could contribute to an increased risk of 
adverse pregnancy outcomes by its effects on the immune 
system through an increased risk of maternal infection, 
an alteration of the inflammatory response, or both. For 
example, studies have consistently associated smoking 
with a twofold-to-threefold increase in risk for bacterial 
vaginosis (Morris et al. 2001), which is a risk factor for 
preterm delivery. Researchers have hypothesized that 
smoking increases this risk through its effects on vagi-
nal flora or through the depletion of Langerhans cells, 
resulting in local immunosuppression (Smart et al. 
2004). Smoking can also reduce zinc levels, which could 
increase susceptibility to vaginal infections (Edman et al. 
1986; Sikorski et al. 1990; Shubert et al. 1992). Cigarette 
smoking has been associated with increased cervical anti-
inflammatory cytokines in early pregnancy, which could 
make women who smoke more vulnerable to reproductive 
tract infections and subsequent preterm delivery (Simhan 
et al. 2005, 2009). Finally, the immunosuppressive effects 
of smoking could contribute to protective effects against 
preeclampsia, because preeclampsia appears to involve 
an exaggerated or inappropriate immune response. More 
research is needed to fully define these potential relation-
ships and pathways. 




CO is formed as a by-product of combustion and 
is thus present in tobacco smoke. It is a potent and even 
lethal toxin whose primary target organ is the brain. The 
fetus is more susceptible to the toxic effects of CO than 
is the mother. Symptomatic exposures to CO that the 
mother will fully recover from may end in permanent 
neurologic damage to the fetus or even fetal death (e.g., 
stillbirth) (Norman and Halton 1990; Koren et al. 1991). 
The fetal effects of CO are well studied (Koren et al. 1991; 
Penney 1996). 
CO is the toxin found in the highest concentration 
in cigarette smoke. The dose per cigarette is 10 to 20 times 
the dose of nicotine (Hoffman et al. 1997). Furthermore, 
CO is not found in unsmoked tobacco products. The toxic 
effects of CO result predominantly from its binding to 
hemoglobin (Longo 1976, 1977). Each molecule of hemo-
globin can carry four molecules of O2 (Hsia 1998). The 
binding and unbinding of O2 to hemoglobin depends on 
the local level of O2. High levels of O2 facilitate binding to 
hemoglobin, and low levels (hypoxia) facilitate the release 
of O2 from hemoglobin. The O2 binds to hemoglobin as 
blood passes through the O2-rich lungs and is delivered 
to tissues as blood traverses the capillary beds. When one 
molecule of O2 is released from hemoglobin, a conforma-
tional change in hemoglobin facilitates the release of fur-
ther O2 molecules. 
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Hypoxia, Fetal Growth, and  
Other Abnormalities
CO binds to hemoglobin with an affinity more than 
200 times that of O2 (Sauter 1994). Once CO binds to one 
of the four binding sites of hemoglobin, the hemoglobin 
is altered so greater tissue hypoxia is required before O2 
will be released from the other binding sites (Hsia 1998). 
In addition, CO prevents the conformational change in 
hemoglobin that occurs with O2 unbinding. The release 
of one O2 molecule does not facilitate the release of sub-
sequent O2 molecules when hemoglobin also binds CO.
The binding of CO to hemoglobin is tenacious, with 
a half-life of five to six hours. Fetal hemoglobin binds CO 
more tightly than does adult hemoglobin, and the fetus 
has higher levels of carboxyhemoglobin than those of the 
mother; the average ratio of fetal to maternal carboxyhe-
moglobin is 1.8 (Cole et al. 1972; Longo 1977; Bureau et 
al. 1982). It takes approximately seven hours for CO to 
equilibrate between the mother and the fetus (Bureau 
et al. 1982). The net effect of the CO and hemoglobin 
interaction is chronic hypoxia in fetal tissue (Longo 1977) 
or, more accurately, chronic cellular hypoxia that per-
sists during periods of maternal abstinence from smok-
ing, such as during sleep. Simply put, CO from cigarette 
smoke deprives the fetus of O2, which is essential for the 
aerobic metabolism that produces adenosine triphosphate 
(ATP). ATP stores chemical energy that is ubiquitously 
used to drive all manner of chemical reactions in the body. 
This chronic yet mild O2 deprivation in the fetus is likely a 
major underlying mechanism of smoking-associated fetal 
growth retardation (Longo 1976, 1977). 
Data from both clinical and animal studies indi-
cate that CO is probably the foremost toxin responsible 
for the LBW associated with maternal smoking (Garvey 
and Longo 1978; Lynch and Bruce 1989; Penney 1996; 
England et al. 2003). A well-designed study found a 
decrease in birth weight that was almost five times greater 
for infants of smokers than for infants of snuff users, 
even after adjustment for variables (England et al. 2003). 
The mean adjusted decrease in birth weight was 39 g for 
infants of snuff users and 190 g for infants of smokers 
compared with infants of nonsmokers. Because CO is the 
main toxin in cigarette smoke but not in snuff, this differ-
ence in birth weight implicates CO as the likely hazard. 
Even mild, long-term exposure to CO in animals resulted 
in fetal growth retardation; maternal carboxyhemoglobin 
levels were 4 to 9 percent (Garvey and Longo 1978; Pen-
ney 1996). The carboxyhemoglobin levels associated with 
smoking are 5 to 10 percent.
Studies have found central nervous system abnor-
malities in fetuses and pups of pregnant rats with long-
term exposure to CO (Storm and Fechter 1985a,b; Storm 
et al. 1986; Fechter 1987; Carratù et al. 1993a,b; Packiana-
than et al. 1993). Behavioral studies of prenatally exposed 
animals have revealed persistent postnatal effects associ-
ated with CO exposure that produced maternal carboxy-
hemoglobin levels of 6 to 16 percent. These levels were 
not associated with small litter size or altered duration of 
gestation but with LBW (Fechter and Annau 1976, 1980, 
1997; Abbatiello and Mohrmann 1979; Mactutus and Fech-
ter 1984, 1985; Singh 1986; Fechter 1987). CO-induced 
hypoxia appears related to other congenital anomalies 
including cleft lip and cleft palate in susceptible strains of 
mice (Millicovsky and Johnston 1981; Bronsky et al. 1986; 
Bailey et al. 1995). Subsequent epidemiologic studies of 
birth defects in relation to CO levels from air pollution 
early in gestation found associations between higher CO 
levels and various cardiac defects, but the findings were 
not consistent (Ritz et al. 2002; Gilboa et al. 2005).
Blood Hyperviscosity
Carboxyhemoglobin results in functional anemia in 
both the mother and fetus that stimulates production of 
red blood cells and elevates maternal and fetal hemato-
crits (Meberg et al. 1979; Bureau et al. 1983; Bili et al. 
1996). As the hematocrit increases, the viscosity of the 
blood increases. At birth, the healthy newborn hematocrit 
is normally 44 to 64 percent, which is well above adult val-
ues. Because of the increased viscosity, healthy newborns 
are at risk for stroke if the hematocrit is above 65 percent. 
The hematocrit can be lowered with partial-exchange 
transfusions. Compared with newborns of nonsmokers, 
newborns of smokers have higher hematocrits that there-
fore increase the risk of stroke and a need for exchange 
transfusion (D’Souza et al. 1978; Buchan 1983). Elevated 
maternal hematocrits and a consequently higher blood 
viscosity in the mother may also be risk factors for subop-
timal placental perfusion (Bureau et al. 1983; Knottnerus 
et al 1990).
Preeclampsia
Data indicate that CO functions as a gaseous local-
ized messenger (Ryter et al. 2004). CO appears to activate 
guanylate cyclase and modulate the mitogen-activated 
protein kinase signaling pathway (Ryter et al. 2004). 
Heme oxygenases (HO-1, HO-2, and HO-3) degrade 
heme into ferrous ion, CO, and biliverdin, which all have 
important physiological functions at low concentrations 
but are toxic in high concentrations (Ryter et al. 2004). 
CO appears to have localized functions similar to those 
of nitric oxide (NO), a gas that affects vascular tone and 
platelet aggregation (Ryter et al. 2004). CO also appears 
to have cytoprotective effects against oxidative stress by 
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reducing inflammation and suppressing apoptosis (Ryter 
et al. 2004; Tsuchihashi et al. 2004). 
Researchers think it is likely that the CO from cig-
arette smoke is responsible for the reduced risk of pre-
eclampsia associated with smoking. The basis for this 
rationale is that users of snuff, which does not contain 
CO, have an increased risk of preeclampsia (England et 
al. 2003). The pathophysiology of preeclampsia remains 
to be elucidated, but the transformation of the spiral 
arterioles, which supply blood to the placenta, into low-
resistance high-flow vessels appears to be incomplete (see 
“Preeclampsia” and “Placenta” earlier in this chapter). 
Spiral arteries may still be responsive to vasoconstrictive 
stimuli. Episodic constriction resulting in reduced blood 
flow to the placenta can cause hypoxia-reperfusion injury, 
which elicits endothelial damage and an inflammatory 
response. A hypoxic uterine environment appears to be a 
normal stimulus for the transformation of spiral arterioles 
during pregnancy (Lyall 2003). CO via carboxyhemoglo-
bin can augment this tissue hypoxia and may stimulate 
the normal transformation of spiral arterioles. Addition-
ally, CO functions similarly to NO as a vasorelaxant and 
may counteract the effects of circulating vasoconstrictive 
agents on preeclamptic spiral arterioles. Both hypoxic 
environment and vasorelaxation may help to prevent 
hypoxia-reperfusion injury and the consequential inflam-
mation and endothelial damage, thereby reducing the risk 
of preeclampsia (Bainbridge et al. 2005). 
Independent of preventing hypoxia-reperfusion 
injury, CO may function similarly to NO in maintain-
ing normal endothelial function and preventing platelet 
aggregation. Also, research in the area of tissue transplan-
tation has found that exogenous CO significantly reduces 
the inflammatory environment in allograft rejections 
(Tsuchihashi et al. 2004). Researchers postulate that CO 
may have a similar role in the heightened inflammatory 
environment of the preeclamptic placenta. Although some 
evidence supports this model of CO and preeclampsia, the 
data are not extensive (Barber et al. 2001; McLaughlin et 
al. 2001). Investigators do not know how important CO is 
as a local messenger during pregnancy or how exogenous 
CO supplements endogenous CO.
Summary
CO is the toxin in cigarette smoke that is found in 
the highest concentrations. The major effect of CO is to 
deprive the fetus of O2 by binding to hemoglobin. The 
binding of CO to hemoglobin also results in functional 
anemia that eventually produces a rise in the hematocrit. 
Elevated hematocrit in the mother may adversely affect 
blood flow in the placenta, leading to placental problems 
and potentially to fetal growth retardation. CO appears 
to prevent preeclampsia by augmenting uterine hypoxia 
and, thus, development of arterioles or other local effects 
similar to those of NO. However, this possibly beneficial 
role for CO is far outweighed by its hypoxic effects involv- 
ing hemoglobin.
Nicotine
Nicotine, the principal alkaloid in tobacco, is a 
major contributor to the addictive properties of smoking. 
The diverse pharmacologic and toxicologic properties of 
nicotine are discussed in Chapter 4, “Nicotine Addiction: 
Past and Present,” and are only briefly touched on here. 
Nicotine has both short- and long-term effects and is 
likely causally related to several of the endpoints discussed 
in this chapter. The Office of Environmental Health Haz-
ard Assessment of the California Environmental Protec-
tion Agency (Cal/EPA) lists nicotine as a developmental 
toxicant. Nicotine is known to cross the placenta and con-
centrate in the fetus at levels slightly higher than those 
in the mother. Nicotine may decrease placental perfusion, 
leading to hypoxia of the fetus and acidosis.
As noted earlier in this chapter, nicotine may be 
involved in the development of various congenital anoma-
lies or neurobehavioral problems. Experimental studies 
of rhesus monkeys exposed to nicotine in utero showed 
decreases in fetal lung weight, volume, and function (Sek-
hon et al. 2001) similar to those observed in offspring of 
maternal smokers (see “Fetal Tissue and Organogenesis” 
earlier in this chapter). Thus, nicotine may be the key 
constituent of tobacco smoke to impair fetal lung devel-
opment and lead to altered lung function and perhaps 
increased respiratory illness. In an experiment with chick 
embryos, low doses of nicotine induced hyperactivity and 
higher doses induced hypoactivity (Ejaz et al. 2005). The 
researchers concluded that nicotine could alter embryonic 
movements that are important during embryogenesis for 
the differentiation and maturation of the embryo’s organ 
systems. McCartney and colleagues (1994) speculated that 
intrauterine exposure to nicotine specifically affects the 
outer hair cells in the ear, which influence language abil-
ity, leading to poorer performance scores on assessments 
that rely heavily on verbal abilities.
Nicotine may also interfere with pregnancy by affect-
ing oviduct function, which may lead to ectopic pregnancy 
or problems with fertilization and implantation, or by 
affecting transport of essential nutrients, which could 
affect fetal growth (see earlier sections). For example, 
nicotine altered oviduct motility in rhesus monkeys 
(Neri and Marcus 1972), decreased oviductal blood flow 
in rats (Mitchell and Hammer 1985), and decreased 
sodium and potassium concentrations in oviductal epithe-
lial cells of mice (Jin et al. 1998). In vitro studies report 
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that nicotine, CO, and cyanide impair amino acid uptake 
in placental microvilli (Rowell and Sastry 1978; Horst 
and Sastry 1988; Sastry 1991). In addition, nicotine may 
impair amino acid transport (Fisher et al. 1984). Studies 
show reduced levels of several amino acids in fetal plasma, 
umbilical plasma, and placental villi in maternal smokers 
compared with those in nonsmokers (Jauniaux et al. 1999, 
2001), and nicotine inhibits in vitro transport of arginine 
in human placentas (Pastrakuljic et al. 2000) (see “Amino 
Acids” later in this chapter). The reports of associations 
of smokeless tobacco use with several adverse pregnancy 
outcomes, such as LBW, preterm delivery, stillbirth, and 
placental morphologic changes (Agrawal et al. 1983; 
Gupta and Sreevidya 2004; Gupta and Subramoney 2006), 
suggest that a component of tobacco smoke in addition to 
CO, perhaps nicotine, contributes to these toxic effects. 
Nicotine appears to be one of the components of 
tobacco smoke that has endocrine-disrupting effects, 
which, in turn, may affect several other reproductive and 
developmental endpoints. In vitro experiments show that 
treatment of cells with alkaloids found in tobacco smoke 
(namely, nicotine, cotinine, anabasine, or a combination of 
these substances) or with an aqueous extract of cigarette 
smoke resulted in a dose-dependent inhibition of proges-
terone production (Bódis et al. 1997; Gocze et al. 1999; 
Gocze and Freeman 2000; Miceli et al. 2005), whereas 
estradiol production showed little effect or was slightly 
stimulated. These findings support the effects of smoking 
on progesterone observed in epidemiologic studies. Cell 
growth and DNA content also decreased with treatment, 
leading the authors to suggest that smoking directly 
inhibits cellular progesterone synthesis through less spe-
cific cytotoxic effects on progesterone-producing cells 
(Gocze and Freeman 2000). Other scientists concluded 
that nicotine and M-nicotine, the methylated metabolite, 
can induce a type of luteal insufficiency by inhibiting pro-
gesterone release, probably through modulations in the 
prostaglandin system (Miceli et al. 2005) or inhibition of 
aromatase enzymes.
In animal models, nicotine acts on the HPG axis to 
increase secretion of adrenocorticotropic hormone from 
the pituitary gland, which then stimulates production of 
adrenocortical hormone (Matta et al. 1998). This finding 
is consistent with hormone profiles observed in clinical 
studies (see “Endocrine System” earlier in this chapter). 
Studies have also reported that nicotine acts directly 
on steroidogenesis by inhibiting various hydroxylases 
involved in their metabolism and on aromatases involved 
in converting androgens to estrogens (Barbieri et al. 
1986a,b, 1987). Animal studies show that prenatal expo-
sure to nicotine is related to decreased testosterone levels 
in adult male rats (Segarra and Strand 1989). They also 
report that cotinine, but not nicotine, inhibits testos-
terone synthesis in testes of neonatal rats (Sarasin et al. 
2003). A small study of administration of nicotine to men 
and women by a transdermal patch found that the patch 
significantly lengthened the interpulse interval of pulsa-
tile LH secretion in male nonsmokers but not in female 
nonsmokers or in smokers (Funabashi et al. 2005).
Metals
Presence in Tobacco Smoke
The particulate component of tobacco smoke con-
tains metals. Their presence depends on the origin of the 
tobacco, the formulation of the cigarette product, and the 
method of smoking; detection depends on the method 
and sensitivity of the analysis. Analyses have quantified 
cadmium (<1.2 to 90.3 nanograms [ng] per cigarette), 
lead (0 to 41.4 ng/microgram [µg]), and mercury (<0.25 
to 4.3 ng/µg) in mainstream smoke (Houlgate 2003). 
Nickel and chromium were not detectable (limit of detec-
tion = 1.8 and 1.7 ng per cigarette, respectively), although 
other studies have identified these metals in tobacco 
smoke (Smith et al. 1997; Torjussen et al. 2003). Arsenic 
was detectable but not quantifiable (limit of quantitation 
= 2.7 ng per cigarette). Studies have also detected addi-
tional metals such as zinc (U.S. Environmental Protec-
tion Agency [USEPA] 1992) and beryllium (Smith et al. 
1997) in cigarette smoke. In sidestream smoke, there are 
estimated amounts only for cadmium, nickel, and zinc 
(National Research Council 1986). Very few animal toxi-
cology studies of metals, which are reviewed here, used 
inhalation exposure. Clinical data are available on the bio-
availability of cadmium and nickel from cigarette smoke, 
but researchers have studied only cadmium in connec-
tion with smoking-induced toxic effects on reproduction 
and development. 
Exposure of reproductive organs to metals from cig-
arette smoke depends on (1) the uptake from the lung to 
the circulation, (2) the presence of transporters at blood-
tissue barriers, and (3) the regulation of uptake and egress 
at the cellular level. In the fetus and the testes, there 
are physical barriers to blood flow (the placenta and the 
blood-testes barrier) and highly selective metal transport 
mechanisms (Hidiroglou and Knipfel 1984; Sylvester and 
Griswold 1994; Ballatori 2002; Asano et al. 2004; Gruper 
et al. 2005). 
General Mechanisms
Metals reaching the cells and reproductive organs of 
the fetus can act through several common mechanisms. 
Transition metals, which can assume more than one 
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valence state, can influence electron-exchange reactions 
and oxidative stress within cells. Metals can also sub-
stitute for the appropriate trace element at sites where 
nutritionally essential trace elements are important, such 
as active sites of enzymes, sites for regulatory elements 
of transcription factors, and metal-binding sites in recep-
tor complexes or ion channels. Metals can also displace 
essential trace elements at storage sites, such as the bone 
matrix or heme molecules. Most mechanisms are posited 
for metals in the ionic form. Various compounds that 
incorporate metals may take metals from cigarette smoke 
before reaching the circulatory system and reproductive 
organs. However, the relevance of the various biologic 
actions of metals in smoking-related reproductive disease 
awaits further research. Current assessments must rely 
on parallels between smoking-related and metal-induced 
adverse reproductive effects.
Reproductive Effects of Specific Metals
The toxic effects of the heavy metals lead, mercury, 
and cadmium on reproduction and development are well 
known and widely reviewed in both clinical and animal 
studies (Clarkson et al. 1985; Andrews et al. 1994; Goyer 
and Clarkson 2001). The toxicity of mercury and lead 
is highly dependent on whether the metal is organic or 
inorganic. The most sensitive endpoint for lead and methyl 
mercury is the neurobehavior of children (Mendola et 
al. 2002). In addition, male and female reproductive ef-
fects from metal toxicity are well documented, including 
effects on fertility, menstrual cycle function, and adverse 
pregnancy outcomes (Ward et al. 1987; Golub 2005b; 
Hoyer 2005; Sokol 2005). At low levels of exposure that 
are potentially relevant to cigarette smoke, studies have 
not demonstrated effects on fertility in women but have 
associated infertility with paternal occupational exposure 
to lead (Sallmén et al. 2000). Literature reviews have indi-
cated associations between prenatal exposure to lead and 
SAB, preterm delivery, and reduced birth weight (Andrews 
et al. 1994; Antilla and Sallmén 1995; Borja-Aburto et al. 
1999). One study associated exposure to lead with delayed 
puberty (Selevan et al. 2003), but exposure to mercury had 
little effect on the timing of puberty (Denham et al. 2005).
An extensive number of studies on exposure to lead 
in male animals all report abnormalities in spermatogen-
esis and production of reproductive hormones. Studies of 
men report an inverse relationship between levels of lead 
in blood and levels in sperm, in addition to adverse preg-
nancy outcomes in their partners (Anttila and Sallmén 
1995; Lin et al. 1998; Sokol 2005). The use of mercury in 
dental amalgams has led to studies of dentists and dental 
assistants, but evidence for reproductive effects in either 
males or females is limited. One study found decreased 
fertility in female dental assistants with greater exposure 
to lead (Rowland et al. 1994). Sperm production is affected 
in animal models with exposure to some mercury doses. 
Finally, experimental studies of exposure to mercury in 
birds and fish demonstrate hormonal effects relevant to 
endocrine disruption (Golub 2005b). 
Researchers have investigated cadmium as the agent 
in cigarette smoke responsible for LBW in newborns of 
smokers. Studies document that cadmium accumulation 
in the blood and placentas of pregnant smokers correlated 
with LBW (Kuhnert et al. 1982, 1987a). Other studies 
associated placental cadmium, but not blood cadmium, 
with LBW of newborns of smokers (Ward et al. 1987; 
Sikorski et al. 1988). Studies have reported inconsistent 
associations between exposure to cadmium and birth 
weight in newborns of women exposed to cigarette smoke 
in the workplace or by environmental contamination 
(Huel et al. 1981, 1984; Bonithon-Kopp et al. 1986; Berlin 
et al. 1992; Loiacono et al. 1992; Fréry et al. 1993; Nishijo 
et al. 2002). LBW was a significant finding in some studies 
that administered cadmium, usually as cadmium chloride, 
to rats and mice by injection, inhalation, or orally in food 
and drinking water (Cal/EPA 1996). Many of these studies 
found delayed ossification, another indicator of develop-
mental delay. At higher doses, fetal viability was affected. 
One proposed mechanism of the effect of cadmium 
on birth weight is interference with the placental trans-
fer of the essential trace elements zinc and copper (Sowa 
et al. 1982; Steibert et al. 1984; Sasser et al. 1985; Sowa 
and Steibert 1985; Kuhnert et al. 1987a; Chmielnicka and 
Sowa 1996). Researchers hypothesize that cadmium also 
interferes with progesterone production in the placenta 
(Jolibois et al. 1999a,b; Piasek et al. 2001; Kawai et al. 2002; 
Henson and Chedrese 2004). Studies have found that cad-
mium acts as an estrogenic agent. Initially, in vitro stud-
ies demonstrated that cadmium binds to a specific site 
on the estrogen receptor and mimics estradiol-induced 
gene transcription (Garcia-Morales et al. 1994; Choe et al. 
2003; Johnson et al. 2003b). Other studies found that the 
effects of in vivo administration of cadmium on the uterus 
and mammary glands could be blocked by antiestrogenic 
agents (Johnson et al. 2003b). Animal studies show that 
cadmium accumulates in ovaries, that there is a loss of 
ovarian follicles, and that steroid production declines 
(Hoyer 2005). Elevated levels of cadmium in the follicu-
lar fluid of smokers (Zenzes et al. 1995) were not associ-
ated with impaired fertility (Drbohlav et al. 1998; Younglai 
et al. 2002). Studies have also associated smoking with 
elevated cadmium levels in seminal fluid. At least one 
study noted a negative correlation with cadmium levels 
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and semen quality, but another found no correlation (Saa-
ranen et al. 1989; Chia et al. 1994). Animal studies have 
shown some negative effects on spermatogenesis. 
Chromium, nickel, and zinc are essential human 
dietary nutrients (Institute of Medicine 2000). They are 
present in tobacco and have been studied for their toxic 
effects on reproduction and development (Keen 1996; 
Golub 2005a). Almost all information on toxicity comes 
from laboratory animal studies, and very little is known 
about exposure through inhalation. Exposure to chro-
mium (as Cr+6) produced embryo and fetal loss, growth 
restrictions, and malformations when administered in 
drinking water to mice at a minimum dose of 60 mg/kg per 
day (Trivedi et al. 1989; Junaid et al. 1995, 1996). Studies 
show that chromium is a testicular and ovarian toxicant 
that also affects fertility when administered in drinking 
water to rodents (Saxena et al. 1990; Zahid et al. 1990; 
Murthy et al. 1991, 1996; Bataineh et al. 1997). Nickel 
is teratogenic in mice and rats when it is injected (Lu et 
al. 1979; Mas et al. 1985). When nickel was administered 
over a long period in drinking water, perinatal mortality 
was a common finding (Smith et al. 1993). Studies have 
also demonstrated the testicular toxicity of nickel that was 
injected intraperitoneally or administered orally to 
rodents, but ovarian toxicity and male fertility were not 
studied (Kakela et al. 1999; Doreswamy et al. 2004). Long-
term studies that administered zinc to male and female 
rodents found no effects on fertility (Ogden et al. 2002; 
Johnson et al. 2003a).
Growing evidence suggests adverse effects on 
human pregnancy outcomes (e.g., stillbirth, SAB, and 
LBW) from exposure to arsenic in drinking water (Hopen-
hayn-Rich et al. 2000; Ahmad et al. 2001; Hopenhayn et 
al. 2003; Yang et al. 2003). Animal studies demonstrate 
toxic effects on ovaries and testicles from arsenic in drink-
ing water (Chattopadhyay et al. 1999, 2001; Pant et al. 
2001), and earlier literature discusses arsenic teratogen-
esis (Golub et al. 1998). These studies support further 
efforts to assess the bioavailability of arsenic from ciga-
rette smoke.
Most of these metals, such as lead, cadmium, mer-
cury and mercury compounds, nickel carbonyl, and inor-
ganic oxides of arsenic, are listed as “known by the state to 
cause reproductive toxicity” under California’s Proposition 
65 program, affecting a variety of endpoints. (Information 
supporting the listings can be found at the agency’s web 
site [http://www.oehha.ca.gov].) Thus, some or all of these 
compounds may contribute to the adverse effects of smok-




PAHs are ubiquitous products of the partial com-
bustion of carbon-containing materials, and they appear 
as important components of environmental pollution. 
Although some sources are natural, the predominant 
sources of PAHs found in the air are usually anthropo-
genic. Examples include vehicle exhausts, products from 
industrial processes, and emissions from fossil fuel power 
plants (International Agency for Research on Cancer 
[IARC] 1983), as well as tobacco smoke (IARC 1986, 2004; 
USEPA 1992). The usual definition of a PAH specifies 
hydrocarbons with no heteroatom substitutents or ring 
members that include at least two or, according to some 
authors, three concatenated aromatic (usually benzene-
like) rings. The two-ring members of the class, primar-
ily naphthalenes, are included within the definition used 
in EPA’s identification of “polycyclic organic material” as 
a hazardous air pollutant. These two-ring members are 
abundant in tobacco smoke and show some chemical and 
toxicologic differences from other PAHs. This discussion 
primarily addresses the effects of PAHs with three or more 
rings, while also noting some specific effects of naphtha-
lenes. The five-ring compound benzo[a]pyrene (B[a]P) is 
one of the most extensively studied PAHs. In addition to 
carcinogenesis, studies have reported direct fetotoxic and 
teratogenic effects associated with PAHs, as well as adverse 
effects on reproduction. Other notable effects include 
immunotoxicity, endocrine effects, and toxic effects on the 
lungs. Key studies are summarized in Table 8.12, and the 
results are discussed in detail here.
The toxic effects and dose-response relationships 
described for specific PAHs are primarily based on experi-
ments on toxic effects in animals, which are the focus of 
this summary. Several corresponding effects in humans 
result from exposure to pollutant mixtures containing 
PAHs, such as diesel exhaust. Human exposure to PAHs 
generally involves mixtures that are ill defined and poorly 
quantified, so it is difficult to separate the effects of PAHs 
from those of other components of the mixtures. 
Most of the toxic endpoints described for PAHs 
appear to result from the generation of reactive inter-
mediate agents by metabolism, followed by reactions of 
these intermediates (e.g., as B[a]P 7,8,9,10-dihydrodiol) 
with the cellular components, particularly DNA, in both 
adult and fetal tissues (Kleihues et al. 1980; Bolognesi et 
al. 1985; Shugart and Matsunami 1985). Unless repaired, 
the adducts that are produced give rise to mutations that 
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Table 8.12 Reproductive and developmental effects of polycyclic aromatic hydrocarbons (PAHs),  
by endpoint
Study Design: animal model or population Endpoint






PAH treatment (80 mg/kg) of juvenile mice (4–6 weeks old):
C57BL/6N (AHH inducible) and DBA/2N (AHH noninducible)
Toxic effects to 
reproductive system 
in adults
Shum et al. 
1979
C57BL/6 (AHH responsive) or AKR (nonresponsive) mice 
exposed to B[a]P (50–300 mg/kg intraperitoneally) at day 7, 10, 




Mice exposed prenatally to B[a]P (10, 40, or 160 mg/kg per day) on days 7–16 
of gestation
Fertility study
Beginning at 7 weeks of age, each F1 male was placed with 10 untreated 
females for 25 days
Beginning at 6 weeks of age, each F1 female was cohabitated continuously 
with an untreated male for 6 months
Fertility index = females pregnant/females exposed to males x 100
Birth weight 
Adult reproductive 





Mice (AHH responsive or nonresponsive) exposed to B[a]P (100 mg/kg 
intraperitoneally)





1982; Urso and 
Johnson 1988; 
Urso et al. 1992









lymphocyte response of 
cultured lymphocytes, 
measures of T-cell 
function
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Study Findings Comments
Krarup 1969 • Oocyte destruction and ovarian tumorigenesis A typical effect reported early, 





• Number of primordial oocytes severely depleted in ovaries 
of mice exposed to carcinogenic PAHs (B[a]P, 3-methyl-
cholanthrene, 7,12-dimethylbenz[a]anthracene, but not 
by a noncarcinogenic PAH or an AHH inducer (pyrene, 
β-naphthoflavone)
• PAHs eventually resulted in complete destruction of oocytes in 
both strains, but effect is faster in AHH inducible strain
Destruction of oocytes is related to 
inducibility of AHH; researchers 
assumed in this case that activation 
of the enzyme led to generation of 
more reactive metabolites, which 
caused greater oocyte destruction: 
this is supported by the inactivity 
of β-naphthoflavone, an AHH 
inducer not metabolized to reactive 
intermediates; however, other AH 
receptor actions may also be involved
Shum et al. 
1979
• In utero toxicity and teratogenicity: stillbirths, resorptions, 
malformations increased in exposed mice
• Effects approximately 2–3 times as severe in C57BL/6 mice, 
which are responsive to AHH induction at all exposure times




• Pup weights significantly reduced compared with those for 
controls at all doses (p <0.01) at 20 and 42 days; decreasing 
trend in pup weight with dose at day 4
• Exposed mice of both sexes as adults showed loss of fertility in 
controlled breeding studies with untreated partners
• Mice given B[a]P at 40 or 160 mg/kg per day essentially infertile  
(p <0.01) with histologic abnormalities of gonads
• Testes of males exposed to B[a]P at 40 mg/kg showed severe 
atrophy and aspermic seminiferous tubules
• Ovaries of exposed females hypoplastic or atrophied with few 
follicles or corpora lutea
• Mean litter size reduced (p <0.01) with treatment of females but 





• 30% oocyte destruction of primordial oocytes Effect was not linked to AHH 
induction in this experiment
Urso and 
Gengozian 
1982; Urso and 
Johnson 1988; 
Urso et al. 1992
• Increases in Lyt2 cells in fetal liver
• Often profound immunosuppression in neonatal offspring and 
later in life; postnatal thymic and splenic suppression 
• Approximately 50% reduction in plaque-forming cells in sheep 
erythrocyte assay in 1-week-old offspring after mid- or late-
gestational treatment with 150 µg of B[a]P
• Changes in maternal immune system, which may affect 
maintenance of pregnancy: thymic suppression, including 










B6C3F1 mice exposed to B[a]P (maternal dose of 50, 100,  
or 150 mg/kg/day) on days 13–17 of gestation
Developmental immunotoxicity
Offspring examined for T-cell and 






BALB/c mice exposed to B[a]P in utero: single dose of  
150 mg/kg of B[a]P on days 11–13 of gestation
Developmental immunotoxicity
Nicol et al. 
1995 
Exposure to B[a]P in utero
Normal mice and mice deficient in the P53 tumor suppressor gene
Teratogenicity
Perera et al. 
1998
Epidemiologic exposure to PAHs by ambient air pollution in 
Poland
70 newborns from Krakow (industrialized) and 90 from Limanowa 
(rural but coal used for home heating) 
PAH-DNA adducts in leukocytes and plasma cotinine measured in 
umbilical cord blood
Birth weight and developmental delay
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• Severe depletion of T cells in both thymus and liver
• Changes in proportions of surface antigens (CD4, CD8, and 
heat stable) in isolated thymocytes
• Reduction in total cellularity of thymus and liver
Researchers suggested that these 
changes indicated impaired maturation 
in surviving thymocytes consistent with 
long-term immunosuppression seen in 
mice exposed to B[a]P in utero
Lummus  and 
Henningsen 
1995
• Numbers of T cells in fetal liver severely reduced compared 
with those for untreated controls; severe atrophy of fetal 
thymus
• Neonates showed decreased overall thymic cells and 
increases in some splenic cells
• 6-week-old juvenile mice showed recovery of total T cells to 
control levels in spleen and thymus but depletion of thymic 
cells bearing fetal liver T-cell antigen
Changes in relative proportions of 
different types of T cells, distinguished 
by various surface antigens, result 
in disturbance of immune system 
development; some apparently B[a]
P-resistant cell types repopulate depleted 
lymphoid organs, but overall function 
of the immune system is changed and 
remains depressed
Nicol et al. 1995 • Malformations and increased rate of fetal death
• Embryotoxicity and teratogenicity 2- to 4-fold higher in  
P53-deficient mice than in controls
The P53 gene, which is important in 
regulation of DNA repair and apoptosis, 
has a significant embryo-protective effect 
in the B[a]P-exposed fetus
Perera et al. 
1998
• In newborns with high (>median) versus low (≤median) 
levels of PAH-DNA adducts:
– Mean birth weight reduced by 147 g (p <0.05)
– Birth length reduced by 1.1 cm (p <0.02)
– Head circumference reduced by 0.9 cm (p <0.001)
• Cotinine also significantly and inversely associated with low 





Study Design: animal model or population Endpoint
Dejmek et al. 2000 Epidemiologic exposure to PAHs and PM 
by ambient pollution in Czech Republic
3,349 births in Teplice and 1,505 in 
Prachatice between April 1994 and March 
1998
Continuous measurement of PAH, PM10, 
and PM2.5
AOR for IUGR correlated monthly with 
PAH and PM pollution levels
Birth weight and developmental delay
Matikainen et al. 2001 Young mice, oocytes, and human 
ovarian tissue explants exposed to 
7,12-dimethylbenz[a]anthracene
Toxic effects to reproductive system 
in adults
Note: AH = aryl hydrocarbon; AHH = aryl hydrocarbon hydroxylase; AOR = adjusted odds ratio; B[a]P = benzo[a]pyrene; 
CI = confidence interval; cm = centimeters; g = grams; IUGR = intrauterine growth retardation, where birth weight is <10th 
percentile by gender and gestational week; mg/kg = milligrams per kilogram; ng = nanograms; ORs = odds ratios; PM = particulate 
material; PM10 = particulate matter in which particles are ≤10 micrometers; PM2.5 = particulate matter in which particles are ≤2.5 
micrometers; µg = micrograms.
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• AORs for IUGR show significant increases with levels of PAH 
at both locations early in pregnancy during first month of 
gestation; AOR for medium exposure = 1.63 (95% CI = 0.87–
3.06) and for high exposure, 2.39) (95% CI = 1.01–5.65)
• In Prachatice, relationship was more noticeable (AOR 2.44 [95% 
CI, 0.6–9.83]) in subset closer to pollutant source
• Pollution in Teplice high in both PM and PAH, but in Prachatice, 
high in PAH and generally lower in PM
• IUGR was observed in 9.6% of pregnancies in Teplice and 8.2% in 
Prachatice
Because the ratio of PM and PAH varied 
between locations and with time, the 
continuous model was able to show that 
the risk of IUGR increased with level of 
PAH exposure, rather than with PM, and 




• Oocyte destruction and ovarian failure; mechanism involves 
enhancement of apoptosis
Effect is dependent on the BAX promoter 
gene and the AH receptor
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are then followed by cytotoxicity and/or cancer and pos-
sibly teratogenicity (Wells and Winn 1996). Both phase 
I (activation) enzymes and phase II (detoxification and 
conjugation) enzymes are important in the metabolism 
and toxicity of PAHs, and both are inducible by PAHs. The 
structural genes determining the stability and activity 
of the enzymes and the regulatory genes controlling the 
expression of the enzymes, show polymorphisms in both 
humans and animals. One of these enzymes is aryl hydro-
carbon hydroxylase (AHH), which is influenced by induc-
tion of cytochrome P-450 activity. Animals are described 
as genetically “responsive” when AHH activity is induced 
by exposure to PAHs and to other activators of the AH 
receptor. There are also important changes in the levels 
and types of enzymes expressed at different developmental 
stages, particularly during the latter part of fetal devel-
opment and the immediate postnatal period (Cresteil et 
al. 1986). Researchers have used the resulting variations 
in metabolic capabilities of the fetus and young animal to 
investigate the mechanisms of and differential susceptibil-
ity to PAH toxicity.
Toxic Effects on Reproduction
Investigators have known for some time that 
exposure of the adult female rodent to PAHs damages 
the resting ovarian follicle complexes, leading to oocyte 
destruction (Krarup 1969; Mattison and Thorgeirsson 
1979; Mattison and Nightingale 1982) (Table 8.12). Stud-
ies have revealed similar effects in women, primarily as 
premature reproductive senescence (menopause), after 
exposure to mixed pollutants. As noted previously, pre-
mature senescence is associated with smoking (Jick et 
al. 1977; USDHHS 1980) (see “Menstrual Function, Men-
arche, and Menopause” earlier in this chapter).
Mattison and Nightingale (1982) reported a 30-per-
cent destruction of primordial oocytes in adult mice 
exposed to a single dose of B[a]P. After comparing suscep-
tibility to this effect in different strains of mice that were 
responsive or unresponsive to inducers of cytochrome 
P-450 enzymes, these researchers suggested that the 
determining factor for oocyte destruction involves the 
ratio of phase II (detoxifying) to phase I (activating) 
enzyme activities. Later investigations have shown the 
involvement of mechanisms that control apoptosis in 
oocyte destruction (e.g., Matikainen et al. 2001). The 
researchers described three sets of studies using treat-
ment with 7,12-dimethylbenz[a]anthracene in young 
mice, isolated oocytes, or xenografts of human ovary 
tissue. They found that both a functional AH receptor 
and a functional BAX promoter gene were necessary for 
oocyte destruction in mice. Moreover, this apoptosis con-
trol system was induced in oocytes by the activation of 
the aryl-hydrocarbon-responsive AH receptor. This find-
ing provides an alternative direct route for triggering the 
cytotoxic response to PAHs, which is in contrast to the 
earlier proposal involving reactive PAH metabolites.
Toxic Effects on Development
Teratogenicity. Many fetotoxins, including PAHs, 
produce a spectrum of effects: anatomic and functional 
teratogenesis; prenatal, perinatal, and postnatal mortality; 
growth retardation; and developmental delay. To observe 
the combination of these outcomes in a particular experi-
ment may depend on dose level and timing, the test spe-
cies used, and other experimental conditions. The most 
commonly observed effects of PAHs in animal studies are 
growth retardation and fetal mortality, but a few experi-
ments have demonstrated anatomic teratogenic effects. 
The number of surviving offspring is reduced in these 
experiments, so it appears that the dose range over 
which surviving, but malformed, offspring are produced 
is narrow. 
Intraperitoneal B[a]P given to mice at day 7 or 10 
of gestation causes toxic effects in utero (e.g., a reduc-
tion in the number of surviving offspring) and teratoge-
nicity (Table 8.12) (Shum et al. 1979). The severity of the 
effect was correlated with the ability of the fetus and the 
maternal systems to metabolize B[a]P. A greater impact 
on prenatal and postnatal mortality was noted in C57BL/6 
mice, which are responsive to induction of AHH, than 
in unresponsive AKR inbred mice. This finding suggests 
a role for reactive intermediate agents of PAHs. Malfor-
mations observed only in the responsive mice included 
clubfoot, hemangioendothelioma, cleft palate, and other 
anomalies of the skeleton and soft tissues. 
Nicol and colleagues (1995) also observed malfor-
mations and an increased rate of fetal death after in utero 
exposure to B[a]P. The embryotoxicity and teratogenicity 
were twofold-to-fourfold higher in mice deficient in the 
P53 tumor-suppressor gene than in the controls with the 
normal P53 gene. The P53 gene, which is important in the 
regulation of DNA repair and apoptosis, thus has a signifi-
cant embryoprotective effect in the fetus exposed to B[a]P, 
which is also characteristic in relation to other DNA-
damaging teratogens such as phenytoin (Nicol et al. 1995; 
Wells and Winn 1996).
Prenatal impacts on adult reproductive func-
tion. Animal studies have demonstrated similar but more 
drastic reproductive effects in both males and females 
exposed to PAHs in utero rather than as adults. As adults, 
offspring exposed to B[a]P in utero showed a loss of fertil-
ity in controlled breeding studies with untreated partners 
(Table 8.12). High doses of B[a]P resulted in complete 
infertility and histologic abnormalities of the gonads 
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(Mackenzie and Angevine 1981). Although most obser-
vations of reduced fertility in adults focused on females, 
this experiment also showed a clear reduction in fertility 
among the treated F1 males. Examination of the testes 
showed severely atrophied and essentially aspermic semi-
niferous tubules. The ovaries of females were hypoplastic 
and had very few follicles or corpora lutea. Most of the ani-
mals exposed to the high doses had no identifiable ovaries 
or only remnants of ovarian tissue. 
Kristensen and colleagues (1995) also reported 
reductions in fertility among female NMRI mice after 
exposure in utero to 10 mg of B[a]P/kg per day given 
orally. Watanabe (2005) reported decreases in the number 
of spermatozoa and Sertoli cells in the testes of adult rats 
exposed in utero to diesel exhaust.
Investigations of the mechanism of oocyte depletion 
have emphasized the importance of the AH receptor and 
BAX activation in the induction of apoptotic destruction 
of oocytes and in the natural process that reduces the ini-
tial fetal complement of primordial oocytes early in their 
development to the lower levels that characterize the adult 
female. These findings do not necessarily exclude a sepa-
rate role for cytotoxic effects from DNA damage by reac-
tive PAH metabolites in the destruction of germ cells. The 
mechanisms involved in the induction of impaired sperm 
quality and male infertility after adult or fetal exposure to 
PAHs are less extensively studied. Therefore, it is unclear 
whether other factors and/or mechanisms apply.
Effects on birth weight and developmental 
delay. Clinical studies of exposure to PAH-containing 
mixtures of pollutants in utero have reported reductions 
in birth weight, apparently attributable to both premature 
birth and IUGR, as well as variations in other size mea-
sures, such as length and head circumference at birth. 
More recent studies have used correlations with PAH- 
derived DNA adducts and the differential impact of pol-
lution sources with high versus low PAH levels to more 
clearly establish the role of PAHs on LBW.
Perera and colleagues (1998) studied developmen-
tal effects of fetal exposure to PAHs through ambient pol-
lution from burning coal in Poland (Table 8.12). Plasma 
cotinine and PAH-DNA adducts in leukocytes were mea-
sured in umbilical cord blood as dosimeters of cigarette 
smoke and transplacental PAH, respectively. Newborns 
whose levels of PAH-DNA adducts were above the median 
(3.85 per 108 nucleotides) had a significantly decreased 
birth weight, length, and head circumference. Cotinine 
was also significantly and inversely associated with birth 
weight and length. Similarly, Dejmek and colleagues 
(2000) studied birth outcomes in relation to air pollu-
tion in two towns in the Czech Republic, one industrial-
ized (Teplice) and one rural (Prachatice) (Table 8.12). The 
authors defined IUGR as a birth weight below the 10th 
percentile by gender and gestational week. In Teplice, 
IUGR was observed in 9.6 percent of pregnancies, while at 
Prachatice, 8.2 percent were affected. There was a signifi-
cant association of IUGR with exposure to air pollution, 
particularly to PAHs rather than to particulate matter 
(Table 8.12). The association between PAH exposure and 
IUGR was only significant during the first month of gesta-
tion. The AOR was 1.63 (95 percent CI, 0.87–3.06) for a 
medium exposure and 2.39 (95 percent CI, 1.01–5.65) for 
a high exposure. Researchers interpreted these findings as 
indications that the induction of IUGR by a PAH exposure 
resulted from an early developmental effect. 
Despite the exposures to mixed pollutants, these 
studies provide specific correlations of impacts on birth 
weight and development with PAH exposure either 
through a determination of specific DNA adducts or on 
the basis of differential exposures to PAHs and other pol-
lutants. Extensive evidence from other studies shows an 
impact of air pollution on birth weight and other preg-
nancy outcomes (Šrám et al. 2005), supporting the plausi-
bility of a causal relationship between LBW and exposure 
to PAHs, in spite of the difficulties in assigning causality to 
specific compounds within mixtures. 
Animal studies also show developmental delay and 
LBW after in utero exposure to pure PAHs, thus strength-
ening the epidemiologic data. MacKenzie and Angevine 
(1981) reported statistically significant reductions in 
weights of exposed pups compared with those of controls 
for all in utero doses of B[a]P, as well as evidence of a 
progressive dose response. Similarly, Bui and colleagues 
(1986) observed reductions in fetal weight in a mechanis-
tic study that compared the effects of B[a]P with those 
of methadone, another known fetotoxicant. These au-
thors also observed reductions in uterine weight among 
the pregnant dams, which suggest that B[a]P treatment 
affects both the fetus and the maternal system. 
Developmental Immunotoxicity
PAH exposures have a variety of effects on the 
immune system. Extensive literature describes the 
effects of exposure to pollutant mixtures containing PAHs 
in adult humans. Researchers have demonstrated interest 
in performing studies on the initiation and exacerbation 
of asthma and other allergic respiratory conditions from 
exposure to diesel exhaust, often in combination with 
other allergens (Riedl and Diaz-Sanchez 2005). Findings 
suggest that these exposures can potentiate allergic reac-
tions to antigens such as pollen. Exposure early in life may 
result in a shift in T-cell activity patterns toward a more 
atopic profile. Studies have also linked these effects to 
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exposures to other pollutant mixtures that contain PAHs, 
including tobacco smoke (NCI 1999). Literature reviews 
also describe mechanistic studies of similar processes in 
animals. As noted earlier, the presence of PAHs in these 
pollutant mixtures raises the likelihood that these sub-
stances are among the causative agents. However, it is not 
generally possible to separate the PAH effects from those 
of other components in the mixture. Synergistic inter-
actions among these components may also be a signifi- 
cant factor. 
In contrast to the stimulatory or adjuvant effects at 
comparatively low exposure levels, higher doses of PAHs 
in humans have immunosuppressive effects (Karakaya 
et al. 2004). Similar findings and investigations of the 
mechanisms involved have been extensively described in 
adult animals (Table 8.12). The primary effects noted after 
fetal and neonatal exposures involved immunosuppres-
sion, which is often profound and persistent (Urso and Gen-
gozian 1982; Urso and Johnson 1988; Urso et al. 1992), and 
includes both selective and overall reductions in various 
cellular components of the immune system, particularly 
T cells (Holladay and Smith 1994; Lummus and Hen-
ningsen 1995). Holladay and Luster (1996) have reviewed 
the effects of B[a]P on T-cell development and the long-
term consequences on the development of the immune 
system. Although development of the immune system 
begins in utero, important structural and functional 
changes occur after birth. In view of this continuing 
development, enhanced sensitivity to exposures to 
immunotoxicants both during gestation and infancy is to 
be expected.
Toxic Effects of Naphthalene
Studies have not widely reported or characterized 
naphthalene as a cause of toxic effects on reproduction 
and fetotoxic or teratogenic effects. However, Plasterer 
and colleagues (1985) did report a slight reduction in the 
number of pups per litter, as well as toxic effects in the 
mother after high oral doses of naphthalene, that is, the 
lethal dose for 50 percent of the population (LD50). How-
ever, the reports of preferential toxic effects in the neonate 
or infant described here are examples of toxic effects on 
postnatal development.
Researchers have reported hemolysis in infants 
exposed to very high doses of naphthalene (Siegel and Wa-
son 1986). This effect appears to be caused by the metabo-
lites (1- and 2-naphthol and 1- and 2-naphthoquinones) 
that produce methemoglobinemia. Also, naphthalene 
damaged both ciliated and Clara cells of the bronchiolar 
epithelium in mice (Plopper 1992a,b; Van Winkle et al. 
1995). Neonatal mice were more sensitive to this damage 
than were adult mice (Fanucchi et al. 1997). Although the 
experiment involved intraperitoneal dosing, the effects 
appear to depend on the metabolism of naphthalene in the 
target tissues and are therefore probably independent of 
the route of administration. 
Endocrine Disruption
Many investigators have reported that PAHs disrupt 
reproductive and developmental events and other physi-
ological processes under endocrine control. Some of these 
effects appear to reflect direct action on hormones and 
their receptors as opposed to the cytotoxic action of reac-
tive metabolites noted earlier. The nuclear AH receptor is 
responsible for regulating several cytochrome P-450 iso-
enzymes and triggering their induction in the presence 
of various xenobiotics, including PAHs, chlorinated diox-
ins, and coplanar polychlorinated biphenyls. This receptor 
also appears to have a range of other functions, includ-
ing the modulation and proliferation of cell growth. The 
role of this receptor in the regulation of apoptosis, which 
includes the BAX gene product, has already been noted 
in the context of oocyte loss and may be involved in other 
processes in which apoptosis occurs. 
The AH receptor also appears to interact with and 
in some cases control the expression of other nuclear 
receptors. B[a]P reduces the expression of receptors for 
the epidermal growth factor and the in vitro secretion of 
chorionic gonadotropin by human placental cells (Zhang 
et al. 1995). PAHs reportedly have antiestrogenic effects. 
Chaloupka and colleagues (1992) used MCF-7 human 
breast cancer cells to investigate in vitro the inhibition 
by 3-methylcholanthrene (a synthetic PAH) of estradiol-
stimulated cell growth. Subsequently, Navas and Segner 
(2000) described antiestrogenic effects of various PAHs on 
synthesis of vitellogenin in cultured hepatocytes of rain-
bow trout by 17-β-estradiol. In both systems, the binding 
of the PAH to the AH receptor appears to be the event that 
triggers a range of cellular responses, including a reduced 
expression of the estrogen receptor. 
Other Compounds
Tobacco smoke contains thousands of compounds, 
some of which have also been identified as known or sus-
pected reproductive toxicants, in addition to the com-
pounds already described here in detail. Examples include 
toluene, carbon disulfide, dichlorodiphenyltrichloroeth-
ane, styrene, benzene, and vinyl chloride. 
Other compounds that are less well studied may also 
influence reproductive outcomes. As noted earlier in this 
chapter (see “Tubal Function”), cigarette smoke impairs 
oviductal functioning (Knoll and Talbot 1998) and inhibits 
the growth of the chick chorioallantoic membrane (CAM) 
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(Melkonian et al. 2000, 2002). To identify which chemicals 
in tobacco smoke are responsible for these toxic effects, 
solutions of mainstream smoke were fractionated and the 
eluates were screened for inhibitory activity in the CAM 
and oviductal assays. The CAM assay measures CAM and 
embryonic growth, and the oviductal assays measure cili-
ary beat frequency, oocyte pickup rate, and rate of smooth 
muscle contraction. The chemicals in each eluate that 
retained 80 percent or more of the inhibitory activity were 
identified by gas chromatography and mass spectrom-
etry. This approach identified pyridine, pyrazine, phenol, 
indole, and quinoline derivatives as the major groups of 
inhibitory compounds (Ji et al. 2002; Melkonian et al. 
2003; Riveles et al. 2003, 2004, 2005). Members of each 
group were highly effective in both the CAM and oviductal 
assays that measure diverse biologic processes. In every 
group, some chemicals were inhibitory at nanodoses and 
picomolar doses, and indole was inhibitory in the oviductal 
assays at femtomolar doses. In general, methyl and ethyl 
substitutions increased the toxicity of these compounds. 
Some of the inhibitory chemicals (e.g., 3-ethylpyridine 
and pyrazine) are on the Flavor and Extract Manufactur-
er’s Association’s Generally Recognized as Safe list and the 
“Everything” Added to Food in the United States list from 
the U.S. Food and Drug Administration (FDA); some are 
added to cigarettes to enhance flavor.
Other Molecular Mechanisms
In addition to the molecular mechanisms of specific 
toxins outlined here, researchers have conducted gen-
eral investigations of smoking in relation to pathways for 
molecular mechanisms.
Genetic Damage to Sperm
Concern exists that exposures to toxins such as 
those in cigarette smoke may cause damage to sperm 
DNA that could be transmitted to offspring (Chapin et al. 
2004). This important question of male-mediated toxic 
effects on development can now be addressed directly 
through use of tools of molecular genetics that detect 
and measure chromosomal changes and DNA damage 
in ejaculated sperm cells (Perreault et al. 2003). Studies 
have reported significant increases in sperm DNA and 
chromatin damage, including oxidative DNA damage, in 
smokers compared with nonsmokers from both infertility 
clinic and nonclinic populations (Fraga et al. 1996; Shen 
et al. 1997); strand breaks (Sun et al. 1997; Potts et al. 
1999); native DNA stainability (Sofikitis et al. 1995; Spanò 
et al. 1998); denaturation of labile sites (Potts et al. 1999); 
DNA adducts (Zenzes et al. 1999a,b; Horak et al. 2003); 
and apoptosis (Belcheva et al. 2004). Only a few studies 
did not find statistically significant differences related to 
exposure to cigarette smoke. One of these studies focused 
on DNA strand breaks (Sergerie et al. 2000) and another 
on oxidative DNA damage (Loft et al. 2003). Both studies 
were conducted in nonclinical populations.
Researchers have determined a statistically signifi-
cant trend across published studies (p <0.001) for sperm 
aneuploidy associated with smoking (Robbins et al. 2005). 
Sperm carrying aberrant chromosomes are capable of 
fertilizing eggs that result in aneuploid offspring. For 
example, the father contributes the extra Y chromosome 
in 100 percent of XYY offspring, the extra chromosome 
in approximately 30 to 50 percent of XXY offspring with 
Klinefelter syndrome, and in up to an estimated 80 per-
cent of the offspring with missing X in Turner’s syndrome 
(Hassold 1998; Martínez-Pasarell et al. 1999). In addition 
to congenital anomalies, damage to genetic material could 
affect sperm quality and could be manifested as infertility 




Deficiencies of micronutrients may contribute 
to adverse pregnancy outcomes, and smoking could act 
through this relationship. As previously mentioned, a 
decrease in the amount of collagen III likely leads to a 
weakening of the tensile strength of amniotic membranes, 
which could increase the risk of PPROM. Vitamin C is 
required for collagen formation in amnion epithelial cells, 
and studies have noted reduced vitamin C in women with 
PPROM (Wideman et al. 1964; Casanueva et al. 1993). 
Studies consistently show that plasma vitamin C lev-
els are lower in smokers than in nonsmokers, a finding 
that appears to be attributable to a lower intake as well as 
increased utilization in the body (Preston 1991; Lykkes-
feldt et al. 2000; Cogswell et al. 2003). Vitamin C levels in 
the amniotic fluid of smokers are also lower than those 
in nonsmokers (Barrett et al. 1991). Vitamin C is impor-
tant for normal immune functioning. Deficiencies of vita-
min C are associated with impaired immunocompetence, 
reduced counts of polymorphonuclear leukocytes, phago-
cytosis, and depressed cell-mediated immunity (Long and 
Santos 1999). A vitamin C deficiency in smokers could 
contribute to adverse pregnancy outcomes by impairing 
maternal immune responses to genital tract infections. 
Data on other antioxidant levels in smokers are conflict-
ing (Cogswell et al. 2003).
Zinc deficiency may also play a causal role in PPROM 
and other adverse outcomes. Zinc is necessary for DNA 
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synthesis, transcription, and translation, as well as cell 
division and cell growth (Fisher 1975; Vallee and Falchuk 
1993; Prasad 1996). Low zinc levels result in impaired 
immune function (Fraker and King 2004), increased sus-
ceptibility to infectious diseases (Fischer Walker and Black 
2004), and cell death (Fraker 2005). Researchers have 
found reduced serum and amniotic fluid levels of zinc 
in pregnant women with PPROM (Anderson 1979; Kiil-
holma et al. 1984). A prospective study of pregnant women 
associated a low zinc intake with a threefold increase in 
PPROM (Scholl et al. 1993). Some data suggest that smok-
ers are more likely to experience a zinc deficiency than 
are nonsmokers (Cogswell et al. 2003). Levels of mater-
nal dietary zinc, plasma zinc, and zinc in red blood cells 
are similar in smokers and nonsmokers close to the time 
of delivery. However, shortly after delivery, zinc levels in 
cord blood and polymorphonuclear cells, which may be 
a more sensitive indicator of zinc depletion, were lower 
in smokers than in nonsmokers (Simmer and Thompson 
1985; Kuhnert et al. 1987b). Cadmium, which accumu-
lates in the placenta and binds to zinc, may contribute to 
a local zinc deficiency in smokers (Kuhnert et al. 1987a,b, 
1988a,b; Preston 1991).
Amino Acids
In addition to a supply of nutrients delivered to the 
fetus through the uteroplacental circulation, fetal growth 
depends on nutrient transport across the syncytiotropho-
blast. Because the placenta is impermeable to most pro-
teins, almost all of the fetal proteins are synthesized by 
the fetus from amino acids supplied by the mother. Amino 
acids from the mother’s blood are taken up by the active 
transport of placental trophoblasts and then diffused into 
the umbilical venous blood. There is accumulating evi-
dence that abnormalities in amino acid transport across 
the placenta can contribute to impaired fetal growth (Pas-
trakuljic et al. 1999). In addition, many studies suggest 
that maternal smoking adversely affects this transport, 
and this effect may be one mechanism by which smoking 
restricts fetal growth. Levels of several amino acids in fetal 
plasma, umbilical plasma, and placental villi are lower in 
smokers than in nonsmokers (Jauniaux et al. 1999, 2001) 
(see “Carbon Monoxide” and “Nicotine” earlier in this 
chapter). Additional research is needed to determine more 
precisely how the results of the in vivo and in vitro stud-
ies may be related to adverse pregnancy outcomes among 
maternal smokers.
Nitric Oxide Activity
Researchers have also studied the effects of smok-
ing on NO activity. Endothelial NO is a potent vasodilator 
synthesized by NO synthase in vascular endothelial cells 
(ENOS) (Moncada and Higgs 1993). NO regulates blood 
pressure by its effects on vascular resistance. Evidence 
suggests that a decrease in the release of basal NO may pre-
dispose a person to hypertension, vasospasm, and throm-
bosis, whereas elevated levels may be associated with shock 
(Moncada and Higgs 1993; Änggård 1994; Cooke and Dzau 
1997; Oemar et al. 1998). In pregnancy, NO is also present 
in placental villi and is believed to play an important role 
in the vasodilatory response of the maternal, uteropla-
cental, and fetoplacental circulatory systems (Myatt et al. 
1991, 1992; Poston et al. 1995). Reductions of NO activity 
in placental villi from pregnancies with preeclampsia and 
IUGR suggest a role for NO in pregnancy complications 
(Sooranna et al. 1995). In vitro research indicates that the 
mRNA and the protein expression of ENOS are decreased 
in endothelial cells from preeclamptic pregnancies (Wang 
et al. 2004).
Studies have associated maternal smoking with a 
dose-dependent decrease in endothelial-dependent vessel 
dilation (Lekakis et al. 1998; Poredoš et al. 1999) and with 
an inhibition of ENOS activity, depending on the ENOS 
genotype (Wang et al. 2000b). Researchers have reported 
that endothelial cells from the umbilical cords of infants 
born to smokers had a 40-percent reduction in ENOS 
activity and a 32-percent reduction in ENOS levels com-
pared with those in cells from infants born to nonsmok-
ers. Furthermore, the ENOS activity level was associated 
with the number of cigarettes smoked per day (Andersen 
et al. 2004). The effects of maternal smoking on ENOS 
activity could lead to lower NO levels, resulting in a loss of 
dilatory capacity and contributing to IUGR.
Smoking and Maternal and 
Neonatal Genetic Polymorphisms
Investigators have reported differences in the 
human metabolism of toxic constituents in tobacco 
smoke (Benowitz et al. 1999; Lee et al. 2000; Yang et al. 
2001). These metabolic differences may reflect a differen-
tial induction of toxins and drug-metabolizing enzymes, 
such as phase I cytochrome P-450; phase II glutathione-
S-transferase (GST); NAT1 and 2; placental alkaline phos-
pholipase; lysyl oxidase; the platelet-activating factor 
acetylhydrolase; TGFα; TGFβ3; and microsomal epoxide 
hydrolase. Genetic polymorphisms that alter the expres-
sion of these enzymes are in the pathway of development 
of disease such as lung cancer. These polymorphisms 
also appear to modify the relationship between prenatal 
exposure to tobacco smoke and birth outcomes. Studies of 
prenatal exposure to fetotoxins present in tobacco smoke 
(e.g., PAHs, AH, and benzene) have linked these toxins 
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to adverse pregnancy outcomes through the inducibil-
ity of phase I enzymes such as CYP1A1 (Huel et al. 1993; 
Lagueux et al. 1999; Dejmek et al. 2000; Wang et al. 
2000a), which can vary by host genotype.
Birth Defects
Initial investigations of the mechanisms of mater-
nal or neonatal metabolism of tobacco smoke toxins and 
adverse birth outcomes were conducted in studies of birth 
defects. Several studies examined the potential interaction 
of maternal exposure to tobacco smoke and maternal and/
or neonatal genotypes in association with orofacial cleft in 
newborns (Table 8.13). The genetic polymorphisms that 
code for the expression of tissue damage, inflammatory 
response, and immune mediator enzymes and that were 
examined in those studies include TGFα and TGFß3, 
MSX1, and EPHX1, as well as gene variants of both phase 
I activation and phase II detoxification enzymes CYP1A1, 
GSTM1, GSTT1, NAT1, and NAT2. Prenatal exposure to 
tobacco smoke was measured by self-reports of maternal 
active smoking, maternal exposure to secondhand smoke, 
and paternal active smoking. Most of these studies exam-
ined the TGFα genotype in neonates. In one study, geno-
typing was performed in both neonates and parents. 
A case-control study of infants with a TGFα *TAQ1 
genotype that contained a rare allele and whose moth-
ers had smoked during pregnancy found a significantly 
elevated risk for cleft palate in offspring (Table 8.13) 
(Hwang et al. 1995). In a large, population-based, case-
control study conducted by the California Birth Defects 
Monitoring Program registry, the risks of cleft palate and 
cleft lip with or without cleft palate were significantly 
elevated among White infants with TGFα *rare geno-
types (*A2) whose mothers were heavy smokers (Shaw et 
al. 1996). However, three subsequent case-control stud-
ies (Christensen et al. 1999; Romitti et al. 1999; Beaty et 
al. 2001) that failed to replicate these findings had fewer 
cases and one study had used a lower cutpoint for smoking 
than that used by Shaw and colleagues (1996). None of the 
five studies cited above presented regression models with 
terms for estimating maternal smoking levels and the 
TGFα genotype interactions. Zeiger and colleagues (2005) 
conducted a meta-analysis of data from these five stud-
ies and found a marginally significant interaction between 
maternal smoking and infant TGFα *allele genotypes 
(*A2) in relation to cleft palate (OR = 1.95 [95 percent CI, 
1.22–3.10]). There was no evidence of an interaction in 
relation to cleft lip and cleft palate (OR = 0.86 [95 percent 
CI, 0.53–1.40]).
Romitti and colleagues (1999) also examined the 
TGFß3 genotype and maternal smoking in relation to 
the risk of cleft palate or cleft lip and cleft palate (Table 
8.13). These researchers found a significantly elevated risk 
for the conditions among infants who were homozygous 
for the common *1 allele at the X5.1 or 5’UTR.1 site and 
whose mothers had smoked 10 or more cigarettes per day. 
There was no evidence of an interaction for infant geno-
types that included the rare *2 allele.
Hartsfield and colleagues (2001) did not observe 
any significant interaction between maternal smoking 
and EPHX1 (codon 113) or null GSTM1 genotypes in a 
case-control study of isolated cleft lip and cleft palate 
(Table 8.13). van Rooij and colleagues (2001) examined the 
association of maternal prenatal smoking and the mater-
nal GSTT1 genotype. The researchers found that mothers 
who smoked and carried the GSTT1 null genotype had a 
marginally higher risk for delivering an infant with oral 
clefting than that of nonsmokers who carried the wild-type 
genotype. Although the RR was not statistically significant, 
it was almost five times greater when both mothers and 
their infants carried the GSTT1 null genotype. There was 
no evidence of an interaction between maternal smoking 
and the CYP1A1 genotype with a recessive allele in rela-
tion to oral clefting. In a case-control study, the CYP1A1, 
GSTT1, and GSTM1 polymorphisms were also examined 
as risk factors for hypospadias, a congenital anomaly of 
the male reproductive organs (Kurahashi et al. 2005). 
The study did not observe any increased risk of hypospa-
dias among children born to mothers who smoked and 
had various genotypes, including CYP1A1 *MSPI variant 
allele genotype or the GSTT1 null genotype or GSTM1 
null genotype. In a case-only, haplotypic analysis of an 
intronic CA repeat of the MSX1 gene in 206 infants with 
oral clefting, there was evidence for an interaction with 
maternal prenatal smoking (Fallin et al. 2003). In the Iowa 
study (Romitti et al. 1999), infants whose MSX1 X1.3 or 
MSX1 X2.4 genotype contained the *2 allele and whose 
mothers smoked 10 or more cigarettes per day also had 
a significantly elevated risk of cleft palate (Table 8.13). In 
a study of limb deficiency defects, Carmichael and col-
leagues (2004) did not observe any significantly elevated 
risk for infants with MSX1 intronic CA repeat genotype 
whose mothers smoked during pregnancy. In another 
case-control study from the California Birth Defects Moni-
toring Program, the NAT1 1088 genotype *A/*A and the 
NAT1 1095 genotype *A/*A, but not NAT2 polymorphisms, 
were strongly associated with isolated oral clefting in 
infants whose mothers had smoked during pregnancy 
(Table 8.13) (Lammer et al. 2004).
Other Reproductive Endpoints
Several studies have also examined the potential 
interaction among phase I and II toxins, genes for drug 
metabolism, and prenatal exposure to tobacco smoke in 
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Table 8.13 Studies of interactions between genotype and exposure to tobacco related to oral clefting
Study Study period Population Definition of smoking Key results
Hwang et al. 
1995
1984–1992 69 case infants 
with CP
114 case infants 
with CL/P
284 control infants 





Light smokers: ≤10 ciga-
rettes/day
Heavy smokers: >10 
cigarettes/day
• Among White infants with TGFα genotype 
containing the *A2 (rare) allele at the TAQ1 
site whose mothers were heavy smokers, 
risks of CP and CL/P were significantly 
elevated (OR = 5.60 [95% CI, 1.36–22.9]) 
in infants with no family history of birth 
defects
• By amount smoked, risk for CP was elevated 
among infants with *A2 allele born to light 
smokers (OR = 6.16 [95% CI, 1.09–34.7]) as 
well as infants whose mothers were heavy 
smokers (OR = 8.69 [95% CI, 1.57-47.7])
Shaw et al. 
1996
1987–1989 731 case infants 
with orofacial 
clefting
348 with isolated 
CL/P
141 with isolated 
CP
99 with multiple 
CL/P
74 with multiple 
CP
69 with known 
cause






day, ≥20 cigarettes/day 
Nonsmokers exposed to 
secondhand smoke from 
anyone inside mother’s 
home who smoked daily 
during 4 months after 
conception or from 
regularly frequented 
places where others 
smoked
• White infants whose TGFα genotype 
contained the *A2 allele born to maternal 
heavy smokers had increased risk of isolated 
CL/P (OR = 6.1 [95% CI, 1.1–36.6])
• Risks were also elevated in the same group 
for isolated CP (OR = 9.0 [95% CI, 1.4–
61.9]) and for “known etiology clefts”  
(OR = 10.8 [95% CI, 1.2–111.7])
• Sample size in non-White racial groups was 














• No evidence was found for increased risk of 
CP or CL/P among infants with the *rare 
allele for TGFα whose mothers had smoked 
while pregnant
Romitti et al. 
1999











• For infants whose genotype contained the 
*rare allele for TGFα or TGFß3, maternal 
smoking did not increase risk of having CP 
or CL/P
• Infants whose genotype contained common 
*1 allele for TGFß3 (X5.1 or 5’UTR.1 sites) 
were at increased risk of having CP or CL/P 
• With maternal smoking of ≥10 cigarettes/
day, infants whose MSX1 X1.3 genotype 
contained *A2 allele had elevated risk of CP 
(OR = 2.7 [95% CI, 1.1–6.3])
• Similar results were found among infants 
whose MSX1 X2.4 genotype contained *A2 
allele (OR = 2.8 [95% CI, 1.1–6.9])
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Table 8.13  Continued
Study Study period Population Definition of smoking Key results











of passive exposure to 
cigarette smoke)
• No evidence was found for increased risk of 
isolated CL, CP, or CL/P among infants with 




1987–1989 85 case infants 
with CL/P 
110 control infants 
Pregnant smokers • With maternal smoking, infants whose 
genotype was homozygous for EPHX1 
codon 113 *H allele were not at higher 
risk of CL/P than were infants with EPHX1 
codon 113 wild-type allele  
(OR = 0.4 [95% CI, 0.1–1.3])
van Rooij et 
al. 2001










• Attributable fraction for oral clefting 
in maternal smokers with GSTT1 null 
genotype was 7.3%, increased to 7.7% when 
both mother and infant had GSTT1 null 
genotype
• No interaction was observed with maternal 
smoking and CYP1A1 polymorphism 
(maternal or infant) associated with risk of 
oral clefting
Fallin et al. 
2003








of passive exposure to 
secondhand smoke)
• Case-only (combined CP and CL/P) tests of 
association between MSX1 haplotypes and 
maternal smoking during first trimester 
showed excess cases of haplotype containing 




1987–1989 437 case infants
309 with isolated 
CL/P 






day or ≥20 cigarettes/day 
Nonsmokers exposed to 
secondhand smoke from 
anyone inside mother’s 
home who smoked daily 
during 4 months after 
conception or from 
regularly frequented 
places where others 
smoked
• NAT1 1088 homozygous *A/*A genotype 
among infants whose mothers smoked was 
strongly associated with CL/P  
(OR = 3.9 [95% CI, 1.1–17.2]) 
• NAT1 1095 homozygous *A/*A genotype 
was also strongly associated with CL/P  
(OR = 4.2 [95% CI, 1.2–18.0]) 
• No significant interaction was observed 
for NAT2 polymorphisms and maternal 
smoking in relation to CL/P or CP




of data from  
5 studies












• Meta-analysis results indicated that with 
maternal smoking at any level during 
pregnancy, risk of CP increased for infants 
whose TGFα genotype contained *A2 allele 
(OR = 1.95 [95% CI, 1.22–3.10])
• No significant interaction for maternal 
smoking and infant carrying TGFα *A2 
allele was associated with CL/P
Note: CI = confidence interval; CL/P = cleft lip with or without cleft palate; CP = cleft palate; OR = odds ratio.
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Table 8.14 Decreased birth weight, preterm delivery, intrauterine growth retardation, and neonatal oxidative 
damage: interactions between host genotype and exposure to tobacco smoke
Study Study period Population Definition of smoking Key results
Hong et 
al. 2001













• Urinary concentrations of neonatal oxidative damage 
from 8-OH-dG were correlated with maternal 
exposure to secondhand smoke 
• Infants of mothers with GSTM1 null genotype and 
exposure to secondhand smoke had significantly 
higher concentrations of 8-OH-dG than did infants 
of mothers with GSTM1 present genotype and no 
exposure to secondhand smoke
Wang et 
al. 2002










• Mothers with CYP1A1 MSPI genotype containing 
the *a allele who smoked throughout pregnancy had 
infants with mean birth weight decrements of -520 g 
compared with mothers with CYP1A1 MSPI *A/*A 
genotype who never smoked (from stratified models: 
LBW OR = 3.2 [95% CI, 1.6–6.4]; from interaction 
term model: LBW OR = 3.1 [95% CI, 1.2–7.8])
• Infants of mothers with GSTT1 null genotype 
who smoked throughout pregnancy had mean 
birth weight decrements of -642 g compared with 
mothers with the GSTT1 present genotype who 
never smoked (from stratified models: LBW  
OR = 3.5 [95% CI, 1.5–8.3]; from interaction term 
model: LBW OR = 2.4 [95% CI, 0.9–6.6])
• Among mothers with CYP1A1 MSPI *Aa/*aa and 
GSTT1 null genotypes, infants of mothers who 
smoked throughout pregnancy had mean birth 
weight decrements of -1,285 g (test of interaction: 
-1086 g, p <0.001) 
• Interaction between maternal GSTT1 genotype and 
maternal smoking in relation to preterm birth was 
significant (OR = 2.9 [95% CI, 1.0–8.2])
• Interaction between maternal CYP1A1 MSPI 
genotype and maternal smoking in relation to 
intrauterine growth retardation was significant  
(OR = 3.0 [95% CI, 1.2–7.8])
Hong et 
al. 2003












• Mothers exposed to secondhand smoke during 
pregnancy and having GSTM1 null genotype 
delivered infants with mean birth weight 
decrements of -158 g compared with unexposed 
women with GSTM1 present genotype, after 
adjustment for gestational age
• Similarly, women exposed to tobacco as secondhand 
smoke and having GSTT1 null genotype delivered 
infants with mean birth weight decrements of -203 g 
compared with unexposed women with GSTT1 
present genotype, after adjustment for gestational 
age
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• Placental specimens from maternal smokers who 
did not have PLAP *1/*1 genotype were associated 
with elevated risk of LBW infants (OR = 6.02 [95% 
CI, 1.65–23.02])










day for first and third 
trimesters)
Nonsmokers (hours of 
exposure to secondhand 
smoke)
• Maternal smokers during third trimester and their 
infants, both with GSTT1 null genotype, had higher 
risk of premature birth than did mothers and infants 
with GSTT1 present genotype among nonsmokers in 
third trimester (OR = 4.0 [95% CI, 1.7–9.5])
• When both mother and infant had GSTT1 null 
genotype, the risk of premature birth was elevated 
for smokers and nonsmokers and their infants
Note: 8-OH-dG = 8-hydroxy-2’-deoxyguanosine; CI = confidence interval; g = grams; LBW = low birth weight; NR = data not reported; 
OR = odds ratio.
relation to other outcomes, such as LBW, preterm birth, 
IUGR, and neonatal oxidative damage (Table 8.14).
A large case-control study described an interaction 
between self-reported smoking during pregnancy and 
maternal genetic polymorphisms for CYP1A1 MSPI and 
GSTT1, which were associated with reduced birth weight, 
preterm delivery, reduced gestation, and IUGR (Table 
8.14) (Wang et al. 2002). Mothers who had smoked con-
tinuously during pregnancy and who were heterozygous 
variant type (*A/*a) or homozygous variant type (*a/*a) 
for CYP1A1 MSPI, were at a threefold higher risk of hav-
ing a LBW (<2,500 g) infant compared with lifetime non-
smokers who were homozygous wild type (*A/*A). In these 
genotype-exposure groups, gestation was reduced on aver-
age by 1.5 weeks among smokers who were CYP1A1 MSPI 
*A/*a or *a/*a. Smokers with the GSTT1 null genotype 
gave birth to infants with significant decrements in birth 
weight compared with birth weight of infants of non-
smokers who carried at least one GSTT1 allele. The risk of 
growth retardation, defined as less than 85 percent of the 
ratio of observed birth weight to mean birth weight for 
gestational age, was associated with smoking in mothers 
who carried the CYP1A1 MSPI *A/*a or *a/*a. This study 
was unique because it presented regression models that 
evaluated interaction terms along with analyses stratified 
by gene variant and smoking status, but it lacked an objec-
tive measure of smoking.
In a study conducted in Korea, Hong and colleagues 
(2003) examined the potential interaction of the GST fam-
ily gene variants and exposure to secondhand smoke in 
association with mean birth weight (Table 8.14). Women 
classified as exposed to secondhand smoke, as determined 
by assays of urinary levels of cotinine, who carried the 
GSTM1 null genotype delivered infants with a mean birth 
weight decrement of -158 g, after adjustment for gesta-
tional age. A similar pattern was observed among mothers 
with the GSTT1 null genotype (decrement of -203 g). In 
a subsample of 81 women in the same study population, 
Hong and colleagues (2001) examined the effect of expo-
sure to secondhand smoke and maternal GST family geno-
types in relation to measurements of neonatal oxidative 
damage as urinary levels of 8-hydroxy-2’-deoxyguanosine 
(8-OH-dG). Infants born to women classified as exposed to 
secondhand smoke who carried the GSTM1 null genotype 
had significantly higher levels of log urinary 8-OH-dG 
(geometric mean level = 4.03 [95 percent CI, 2.13–7.61]) 
than did women classified as unexposed who carried the 
GSTM1 wild type. Significant differences in 8-OH-dG 
remained after adjusting for confounders.
One study evaluated phase I and II metabolic 
enzyme gene variants (Table 8.14) (Nukui et al. 2004). The 
authors reported that the most significantly elevated risk 
of premature birth occurred when both mother and infant 
carried the GSTT1 null genotype. The results were the 
same for smokers and nonsmokers, so no interaction was 
observed. Phase I genetic polymorphisms (e.g., CYP1A1) 
were not associated with an elevated risk of a premature 
birth. A study that examined PLAP polymorphisms found 
an elevated risk of LBW when the PLAP *1/*1 genotype 




The evidence of a causal relationship between smok-
ing during pregnancy and increased risk for adverse 
pregnancy outcomes is sufficient to warrant promoting 
smoking cessation among women early in pregnancy or 
before they become pregnant, because the critical period 
may be quite early. For example, the impact of smoking on 
oral clefts could be lessened by 5 to 22 percent if women 
stopped smoking before pregnancy. Thus, there is a need 
for widespread implementation of interventions for effec-
tive smoking cessation that target all women of childbear-
ing age. 
Smoking may have several ramifications of altera-
tions in fertility, menstrual cycle function, or sperm qual-
ity, including a burden on the health care system and loss 
of work productivity. These changes may affect a woman’s 
ability to conceive and maintain a pregnancy at a desired 
time in a couple’s life. The reproductive life span may be 
shortened, and early menopause is associated with other 
hormone-related health problems such as osteoporosis and 
cardiovascular disease (Harlow and Ephross 1995; Sowers 
and La Pietra 1995; Cooper and Sandler 1998). Women 
with short menstrual cycles may also be at a higher risk 
of breast cancer (Kelsey et al. 1993). Such effects warrant 
smoking cessation early in the reproductive age span, or 
ideally, prevention of smoking initiation among youth.
Smoking Prevention and Cessation
Smoking cessation is one of the most important 
actions a woman can take to improve the outcome of her 
pregnancy, and most women who stop smoking during 
pregnancy do so on their own. Because women know about 
the adverse effects of smoking on their health and that of 
a fetus, pregnancy may be a time when smoking cessation 
efforts and interventions are potentially more effective 
(Mullen 1999; Fiore et al. 1996, 2008). Nevertheless, most 
smokers do not stop smoking during pregnancy. Tobacco 
addiction is progressive and chronic and, in consequence, 
smoking cessation interventions focusing on the prenatal 
period have failed to achieve long-term abstinence among 
most pregnant smokers. Two-thirds of women who smoke 
during the first pregnancy also smoke during the second, 
exposing the first infant to tobacco smoke both in utero 
and postnatally (Dietz et al. 1997).
Population-based, cross-sectional surveys have been 
widely used to monitor prenatal smoking rates (Connor 
and McIntyre 1999; Owen and Penn 1999; Ebrahim et al. 
2000). However, such data do not provide information 
on changes in smoking behaviors during pregnancy, in 
contrast to data collected during prenatal care, in which 
smoking behaviors are recorded on more than one occa-
sion, as described by Kirkland and colleagues (2000). Such 
longitudinal data can usefully supplement survey data 
to monitor progress in control of prenatal exposure to 
tobacco smoke. Because of the social desirability of non-
smoking status, which is greater during pregnancy, the 
actual prevalence of smoking may be even higher than 
is self-reported. In the United Kingdom, 16 percent of 
respondents to a survey reported that they did not 
admit to their physicians that they smoked (Bulletin of the 
World Health Organization 1999). A study in the United 
States found nondisclosure rates of 28 percent at enroll-
ment into prenatal care and 35 percent at follow-up (Ken-
drick et al. 1995). Therefore, biochemical verification of 
smoking status of each woman during each contact with 
a clinician is needed to evaluate cessation interventions. 
Clinicians who provide health care to women have 
an important role in reducing the burden of smoking 
among women. Clinically proven programs for smoking 
cessation that can be delivered in primary care settings 
are now available. However, there is a dearth of informa-
tion specifically addressing the most effective smoking 
prevention and cessation interventions for women of 
childbearing age, especially those of low socioeconomic 
status. For this reason NC1 has implemented the TReND: 
Low SES Women and Girls Project. This project was cre-
ated to strategically address and examine the effects of 
multiple tobacco control policies on diverse populations 
of low SES women and girls. In addition, the USDHHS 
Office of Women’s Health has developed an interagency 
work group to address this issue. The FDA Office of Wom-
en’s Health has also developed a guide for providers to 
educate women about medications available to assist them 
if they are ready to quit smoking.
Experts attending the 1998 Consensus Workshop 
on Smoking Cessation During Pregnancy reviewed the 
evidence related to counseling on smoking cessation dur-
ing pregnancy, including the U.S. Public Health Service 
Clinical Practice Guideline, Treating Tobacco Use and 
Dependence (Fiore et al. 1996; Mullen 1999). This group 
concluded that brief cessation counseling (5 to 15 min-
utes), delivered by a trained provider with pregnancy-
specific self-help materials, significantly increases rates 
of cessation among pregnant smokers. The 5A strategy 
of smoking intervention—Ask, Advise, Assess, Assist, and 
Arrange—and recommended procedures are outlined in 
the one-page form, Brief Smoking Cessation Counseling 
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for Pregnant Patients. More intense efforts may be needed 
for groups of women who are less likely to stop smok-
ing and more likely to relapse (Connor and McIntyre 
1999). Smoking cessation interventions should be con-
tinued after delivery to prevent relapse, and partners 
who smoke should be included in such interventions. 
More than 50 percent of women do not recognize that 
they are pregnant until after the fourth week of gesta-
tion. Therefore, efforts to prevent exposure to tobacco 
smoke should begin before conception to avoid pregnancy 
complications or to avoid exposing the fetus to tobacco 
smoke. Furthermore, to prevent subfertility, cessation 
efforts should begin even earlier in the reproduc- 
tive period. 
Despite evidence that provider-administered cessa-
tion counseling significantly increases rates of cessation 
among pregnant smokers, evidence suggests that such 
interventions may do little to decrease overall prenatal 
smoking prevalence. It has been estimated that universal 
implementation of a provider-administered psychosocial 
cessation intervention on a national level would result in 
only a modest decline (0.8 percentage points) in the over-
all prevalence of smoking among pregnant women (Kim 
et al. 2009). Larger reductions in prenatal smoking preva-
lence will likely require implementation of comprehensive 
tobacco control policies that effectively decrease smoking 
prevalence among women of reproductive age.
Unfortunately, pregnant women who smoke most 
heavily do not appear to respond to the type of behavioral 
intervention indicated here. The U.S. Public Health Ser-
vice has suggested, as have others, the need to explore 
the use of pharmacologic approaches to achieve cessa-
tion in women who are unable to stop smoking (Fiore et 
al. 1996, 2000, 2008). These approaches include nicotine 
replacement therapy (e.g., gum, patch, inhaler, or spray); 
nonnicotine products, such as varenicline and bupropion 
hydrochloride; and second-line pharmacotherapies, such 
as clonidine and nortriptyline. However, the efficacy and 
safety of these approaches during pregnancy are not well 
documented. Pharmacologic interventions should be con-
sidered on an individual basis as an adjunct to behavioral 
interventions. These interventions should be considered 
for pregnant women only if the increased likelihood of 
smoking cessation outweighs the harmful effects on the 
fetus of nicotine replacement therapy and possible con-
tinued smoking.
To minimize the effects of smoking among all 
women and to foster effective perinatal tobacco control, 
focus and efforts should expand beyond prenatal care to 
include both the whole family and the entire reproduc-
tive life span of women. The complexities associated with 
smoking cessation among established smokers are under-
scored by reports of persistent high smoking rates among 
pregnant women in Canada, the United Kingdom, and 
the United States (Connor and McIntyre 1999; Owen and 
Penn 1999; Ebrahim et al. 2000). Long-term reduction in 
tobacco exposure during pregnancy can be achieved only 
by encouraging adolescent girls and young women not to 
start smoking.
Regulation and Policy
Ranking of infant mortality rates in established mar-
ket economies placed the United States twenty-eighth in 
2005 compared with twelfth in 1960. Rates of smoking 
remain high among women in three categories related 
to pregnancy—pregnant, planning a pregnancy, and at 
risk of pregnancy. Substantial efforts would be needed to 
reduce known risks to pregnancy and infant health, to 
reverse the stagnant trends in infant mortality rates in the 
near future. Because only about 20 percent of women suc-
cessfully control tobacco dependence during pregnancy, 
smoking cessation is recommended before pregnancy 
(U.S. Preventive Services Task Force [USPSTF] 2003). 
National recommendations to support preconception care 
as an opportunity to reduce maternal risks during preg-
nancy have been introduced (USPSTF 2003). Therefore, 
high rates of smoking in the preconception period, almost 
the same as that among all women of childbearing age, 
pose both a challenge and an opportunity to the imple-
mentation of the preconception care initiative. After child-
birth, smoking does not usually decline below the level 
achieved during pregnancy (USPSTF 2003). Therefore, 
further challenges to preventing smoking-related harm to 
infant health include continued postnatal exposure to sec-
ondhand tobacco smoke from maternal smoking. 
Intervention tools to aid smoking cessation among 
pregnant women are now available. One report estimated 
that the costs of implementing such interventions range 
from $24 to $34 per pregnant smoker counseled (Ayadi 
et al. 2006). Potential neonatal cost savings that could be 
accrued for women who stop smoking during pregnancy 
were estimated at $881 per maternal smoker (Ayadi et al. 
2006). A woman’s contact with the health care system 
during and after pregnancy provides enough opportuni-
ties to engage women for smoking cessation and provide 
follow-up and support services to prevent relapse dur-
ing the interconception period. Furthermore, women of 
childbearing age in the United States have on average 6.4 
health care visits per year (Adams and Marano 1995), and 
such opportunities can be used to improve access to the 
5A strategy of smoking intervention. 
Smoking behaviors of partners of women who smoke 
are important considerations for achieving cessation and 
prevention of relapse. Extension of services or facilitation 
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of use of services by the partners would be needed to main-
tain the benefit from smoking cessation services provided 
to the women. Because men have fewer contacts with the 
health care system than do women (Everett et al. 2005), 
smoking cessation efforts among women provide an 
opportunity for access to health care for their male part-
ners also for cessation efforts. 
Efforts to reduce smoking in the United States have 
shifted from a primary focus on smoking cessation for 
individuals to more population-based interventions that 
emphasize prevention of smoking initiation, reduction 
of exposure to secondhand tobacco smoke, and policy 
changes in health care systems to promote cessation. Par-
allel to these efforts, concerted efforts are needed to reduce 
the disparity in smoking rates among socially disadvan-
taged women and White women; targeted efforts aimed 
at women in the preconception period and those at risk 
for pregnancy; and efforts to promote smoking cessation 
among women who are pregnant. One report indicated 
that bundling of services to address common prevent-
able risks, such as tobacco and alcohol use and risks for 
sexually transmitted diseases, through a preconceptional 
approach, would benefit about one-half of all women of 
childbearing age in the United States (CDC 2006). Tobacco 
use in women coexists with other risk behaviors or mor-
bidities, including mental health disorders and substance 
use. Some factors, such as illicit drug use or alcohol use, 
may synergistically elevate the risk from other factors 
such as tobacco use or acquisition of sexually transmit-
ted infections, requiring intervention approaches through 
case management that address more than one risk fac-
tor. Use of tobacco and alcohol are comorbidities that 
can benefit from many efforts to provide several interven-
tions to a woman simultaneously. Such case-management 
approaches may help to increase adherence to treatment 
and reduce relapse to smoking after delivery. 
Earlier data have indicated that the observed 
declines during the past four decades in the United States 
in smoking rates among pregnant women reflect declines 
that occurred in general among women and were not spe-
cific to pregnancy. Therefore, efforts to close the gaps in 
the diffusion of smoking cessation intervention to individ-
ual smokers are still needed and should be a priority. How-
ever, large reductions in smoking rates among pregnant 
women over time are more likely to come from efforts to 
reduce smoking initiation by young women. 
Evidence Summary
Health professionals have long considered expo-
sure to tobacco smoke harmful to reproduction, affecting 
aspects from fertility to fetal and child development and 
pregnancy outcome. Tobacco smoke contains thousands 
of compounds, some of which are known toxicants to 
reproductive health, such as CO, nicotine, and metals. 
About 10 percent of couples who want to conceive a child 
experience infertility or reduced fertility, approximately 
10 to 20 percent of women who do conceive have miscar-
riage or stillbirth before delivery, and others have preg-
nancy complications and adverse outcomes that affect 
infant health and survival (CDC 2005). 
In 2007, 17.4 percent of women and approxi-
mately 19 percent of women of reproductive age (18 
through 44 years) smoked cigarettes (CDC 2008). 
From 2002 to 2005, 17.3 percent of pregnant women 
reported smoking cigarettes in the past month (NSDUH 
Report 2007). Because smoking rates have declined, per-
sons involuntarily exposed to tobacco smoke probably 
now outnumber active smokers and they are exposed to 
some of the same toxins to which smokers are exposed. 
Previous Surgeon General’s reports and subsequent 
studies have found that smoking is related to several 
reproductive health endpoints. The 2001 report on women 
and smoking and the 2004 report on the health conse-
quences of smoking noted a causal link between smoking 
and reduced fertility in women. Smoking may contribute 
to reduced fertility and other related reproductive end-
points, including earlier menopause or altered menstrual 
cycle parameters, through similar mechanisms such as 
by producing alterations in hormone function. Study 
findings suggest effects of smoking on estrogen and other 
hormones, which may vary by gender and the stage of life. 
Researchers have suggested that smoking has antiestro-
genic effects, but more recent data are less consistent, at 
least for nonpregnant, premenopausal women. Studies 
implicate smoking and its effects on other hormones, such 
as progesterone, gonadotropins (FSH), and androgens 
(including in men). In animal studies, cells treated with 
alkaloids found in tobacco smoke, including nicotine, 
showed a dose-dependent inhibition of progesterone 
production, whereas estradiol production showed little 
effect or was slightly stimulated (Bódis et al. 1997; Gocze 
et al. 1999; Gocze and Freeman 2000; Miceli et al. 2005). 
Other scientists concluded that nicotine affects the men-
strual cycle by inhibiting progesterone release just after 
ovulation. In animal models, nicotine acts on the HPG 
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axis, which is involved in normal sexual development and 
control of reproductive function (Matta et al. 1998). Stud-
ies show that prenatal exposure to nicotine is related to 
decreased testosterone levels in adult male rats and that 
cotinine, but not nicotine, inhibits testosterone synthesis 
in testes of neonatal rats (Sarasin et al. 2003). 
Spermatogenesis is also affected by the hormonal 
milieu. Recent studies have provided more evidence that 
tobacco smoke exposure is associated with reduced sperm 
quality, which, in turn, may be a mechanism leading to 
reduced fertility in couples. Smoking-associated DNA 
damage in sperm could also be related to birth defects in 
offspring or producing nonviable gametes, resulting in 
apparent infertility or early fetal loss.
Many epidemiologic studies have related mater-
nal smoking to reproductive problems that can origi-
nate in the oviduct (e.g., fallopian tube) (Stillman et al. 
1986; Buck et al. 1997), including infertility and ectopic 
pregnancy. Studies have shown that exposure to tobacco 
smoke diminishes oviductal functioning. Exposure to 
cigarette smoke and its components has been shown to 
alter contraction in human and rabbit oviducts (Neri and 
Eckerling 1969; Ruckebusch 1975) and to form blebs on 
the oviductal epithelium in hamsters (Magers et al. 1995). 
In other studies of hamster oviducts, effects included 
decreased smooth muscle contractions and changed the 
ratio of ciliated to secretory cells, both of which would 
affect transit time of the egg through the oviduct (Huang 
et al. 1997; Knoll and Talbot 1998; DiCarlantonio and 
Talbot 1999; Riveles et al. 2003). Adhesion between the 
extracellular matrix of the oocyte cumulus complex and 
the tips of the cilia is essential for pickup of the oocyte and 
transport through the oviduct (Talbot et al. 1999; Lam et 
al. 2000). Exposure to both mainstream and sidestream 
smoke increases adhesion, which could account for 
decreased pickup rates even when cilia beat at normal or 
accelerated rates. 
Ectopic pregnancy occurs when a fertilized egg is 
implanted outside the uterus, usually in the fallopian 
tube; it is estimated to occur in 1 to 2 percent of pregnan-
cies. This condition accounts for approximately 6 percent 
of pregnancy-related deaths in the United States (Chow et 
al. 1987; Goldner et al. 1993; Berg et al. 2003; Chang et 
al. 2003; Van Den Eeden et al. 2005). Affected women are 
at increased risk of subsequent infertility and recurrent 
ectopic pregnancy, as would be expected among women 
with tubal damage (Chow et al. 1987; Coste et al. 1991; 
Washington and Katz 1993; Skjeldestad et al. 1998). 
The 2004 Surgeon General’s report found the evidence 
suggestive but not sufficient to infer a causal relation-
ship between smoking and ectopic pregnancy (USDHHS 
2004) on the basis of a number of studies with significant 
associations between smoking and increased risk of 
ectopic pregnancy, yielding a pooled OR of 1.8 or an 
80-percent increase with smoking (Castles et al. 1999). 
Two subsequent methodologically strong studies also 
indicate an increased risk with dose-response effects, fur-
ther strengthening the evidence.
Studies have found evidence of a dose-response 
relationship even after adjustment for important poten-
tial confounders such as a history of sexually transmitted 
diseases and infertility (Bouyer et al. 2003; Karaer et al. 
2006). In addition, plausible mechanisms for a relation-
ship between smoking and ectopic pregnancy exist. As 
noted, the oviduct plays a critical role in the pickup and 
transport of the oocyte, and failure of this function can 
result in ectopic pregnancy (Talbot and Riveles 2005). 
Spontaneous abortion, the involuntary termination 
of an intrauterine pregnancy before 20 weeks of gestation, 
has been reported in approximately 12 percent of recog-
nized pregnancies; the majority occur before 12 weeks of 
gestation. Including very early pregnancy loss that may 
be unreported suggests an estimated 30 to 45 percent of 
conceptions actually end in pregnancy loss, some before 
implantation (Wilcox et al. 1988; Eskenazi et al. 1995). In 
addition to fetal abnormalities, other factors that likely 
contribute to SAB include maternal anatomic abnormali-
ties of the uterus, immunologic disturbances, thrombotic 
disorders, and endocrine abnormalities (Christianson 
1979; Cramer and Wise 2000; Regan and Rai 2000), some 
of which are affected by tobacco smoke. The 2004 Sur-
geon General’s report (USDHHS 2004) found the evidence 
suggestive but not sufficient to infer a causal relationship 
between tobacco and SAB. Additional studies have shown 
positive associations, including two with measurement 
of cotinine (Ness et al. 1999; George et al. 2006) and two 
showing associations with secondhand smoke (Venners et 
al. 2004; George et al. 2006). Proposed mechanisms for 
an effect from tobacco smoke include vasoconstrictive and 
antimetabolic effects resulting in placental insufficiency 
and the subsequent demise of the embryo or fetus, fetal 
hypoxia from CO exposure, and direct toxic effects of ciga-
rette smoke constituents. 
Preeclampsia, marked by proteinuria, hypertension, 
and dysfunction of the cells lining the uterus, is a leading 
cause of pregnancy-related mortality in the United States 
(Berg et al. 2003). The 2004 Surgeon General’s report 
found the evidence sufficient to infer a causal relation-
ship between smoking and a reduced risk of preeclampsia 
(USDHHS 2004). Smoking has been proposed to reduce 
the risk of preeclampsia by effects of exposure to thiocya-
nate, which has a hypotensive effect (Andrews 1973), by 
changing the thromboxane A2 to prostacyclin ratio, which 
would alter the way blood vessels constrict and dilate 
(Ylikorkala et al. 1985; Davis et al. 1987; Marcoux et al. 
1989; Lindqvist and Maršál 1999), or by stimulating the 
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growth of new blood vessels in the placenta (Maynard et 
al. 2003; Fisher 2004; Jeyabalan et al. 2008). 
Numerous studies have demonstrated the imme-
diate effect of smoking one or two cigarettes on mater-
nal heart rate and blood pressure (Lindblad et al. 1988; 
Morrow et al. 1988; Castro et al. 1993; Kimya et al. 1998; 
Ates et al. 2004). The clinical significance of a transiently 
elevated maternal heart rate on pregnancy is unknown. 
Studies that examined the acute effects of smoking after 
abstinence reported a transient increase in diastolic blood 
pressure and, to a lesser extent, systolic blood pressure. 
The release of catecholamine may trigger the elevations 
in maternal heart rate and blood pressure reported in 
these studies. However, smoking was also associated with 
an acute rise in plasma levels of norepinephrine, epi-
nephrine, and dopamine, which could mediate the rise in 
maternal heart rate and blood pressure (Quigley et al. 
1979). The literature indicates a transient increase in 
fetal heart rate with acute maternal smoking that was 
not statistically significant, although fetal heart rate vari-
ability, used to assess fetal well-being, was significantly 
transiently decreased (Graca et al. 1991; Ates et al. 2004). 
The clinical significance of these transient changes is not 
known. Studies on uterine and placental blood flow did 
not indicate basal differences between smokers and non-
smokers and results were inconsistent with respect to 
acute changes from smoking, so this mechanism is not 
supported as a possible cause of the well-documented fetal 
growth retardation among smokers.
Maintenance of pregnancy and fetal growth and 
development are dependent on normal formation of the 
placenta for exchange of nutrients and metabolic prod-
ucts between the mother and fetus. Studies have consis-
tently shown that maternal smoking is associated with a 
thickening of the villous membrane of the placenta, which 
would decrease the ability of nutrients to pass through the 
placenta by diffusion (Burton et al. 1989; Jauniaux and 
Burton 1992; Demir et al. 1994; Bush et al. 2000; Larsen 
et al. 2002). The thickening of the villous membrane could 
contribute to fetal growth restriction. Researchers have 
hypothesized that toxic effects of maternal smoking on 
the placenta are responsible for the thickening of the vil-
lous membrane, perhaps caused by the accumulation of 
cadmium that is associated with a reduction in fetal capil-
lary volume (Burton et al. 1989; Bush et al. 2000). Smok-
ing appears to interfere with transformation of uterine 
spiral arteries, which is critical for the formation of the 
high-capacitance system that allows increased blood flow 
from the mother to the fetus. Such interference could 
lead to increased risk of adverse pregnancy outcomes such 
as miscarriage.
Epidemiologic studies have consistently found 
an increased risk of partial obstruction of the cervix by 
the placenta (placenta previa) among maternal smokers, 
which may lead to preterm delivery or maternal or fetal or 
neonatal death (Meyer et al. 1976; Zhang and Fried 1992; 
Monica and Lilja 1995). One mechanism commonly pro-
posed to explain this association is the lower blood levels 
of O2 and reduced blood flow that result from smoking, 
with compensatory placental enlargement. 
Premature separation of the placenta from the 
uterus (placental abruption) increases the risk of perina-
tal mortality, and although several factors are involved 
(Misra and Ananth 1999), studies have consistently associ-
ated smoking with an increased risk (Raymond and Mills 
1993; Ananth et al. 1999; Castles et al. 1999; Andres and 
Day 2000). The 2004 Surgeon General’s report found the 
evidence sufficient to infer a causal relationship (USDHHS 
2004), and researchers have observed a dose-response 
relationship (Raymond and Mills 1993; Ananth et al. 1999). 
One researcher has hypothesized that smoking-related 
degenerative and/or inflammatory changes in the placenta 
are factors related to abruption (Cnattingius 2004). Other 
hypotheses include low levels of vitamin C in maternal 
smokers (Faruque et al. 1995), leading to impaired col-
lagen synthesis (Cnattingius 2004), microinfarcts, and 
accumulation of fatty deposits in placental vessels (Naeye 
1979; Andres and Day 2000).
The 2004 Surgeon General’s report found that 
the evidence was sufficient to infer a causal relationship 
between smoking and preterm delivery, a leading cause of 
neonatal morbidity and mortality in developed countries 
(USDHHS 2004). Smoking appears to increase the risk of 
both medically indicated and spontaneous preterm deliv-
ery (Kyrklund-Blomberg and Cnattingius 1998). Mecha-
nisms through which smoking may contribute to preterm 
delivery include placental abruption or effects on the 
integrity of collagen, leading to a weakening and rupture 
of the membranes and increased risk of infections.
The same Surgeon General’s report found sufficient 
evidence to infer a causal relationship between smoking 
and preterm premature rupture of membranes (PPROM) 
(USDHHS 2004). Researchers have hypothesized that 
smoking increases the risk of PPROM through several 
pathways. The effects of smoking on the immune system 
could increase the risk of genital tract infection or disrupt 
the cytokine system (French and McGregor 1996). Smok-
ing could also increase the inflammatory response and 
reduce the availability of nutrients such as vitamin C or 
decrease the uptake of nutrients by the placenta (French 
and McGregor 1996; Lykkesfeldt et al. 1996, 2000), which 
would affect collagen content and membrane structure.
Maternal smoking has also been investigated for an 
association with birth defects, and although the 2004 Sur-
geon General’s report (USDHHS 2004) found inadequate 
evidence for birth defects in general, maternal smoking 
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was considered suggestive for oral clefts. Evidence accu-
mulated since the studies in that report is even stronger 
in supporting an association with smoking and cleft lip 
and/or palate (Little et al. 2004a), with some dose-response 
effects noted (Little et al. 2004b). Animal studies sup-
port these findings with evidence that nicotine can alter 
embryonic movements that are important during embryo-
genesis for the differentiation and maturation of organ 
systems, including palate closure (Panter et al. 2000; Ejaz 
et al. 2005). Other possible mechanisms include smoking-
induced reductions in supply of essential nutrients for 
embryonic tissues, such as multivitamins and folate, fetal 
hypoxia from CO, or DNA damage from PAHs.
Deficiencies of micronutrients may contribute to 
adverse pregnancy outcomes, and smoking may contrib-
ute to this relationship. Vitamin C is required for colla-
gen formation in amnion epithelial cells, and studies have 
noted reduced vitamin C levels in women with PPROM 
(Wideman et al. 1964; Casanueva et al. 1993). A decrease 
in the amount of collagen III likely leads to a weakening 
of the tensile strength of amniotic membranes, which 
could increase the risk of PPROM. Studies consistently 
show that smokers consume less and metabolize more 
vitamin C than do nonsmokers and thus have lower levels 
of vitamin C in plasma (Preston 1991; Lykkesfeldt et al. 
2000; Cogswell et al. 2003) and in amniotic fluid (Barrett 
et al. 1991). Vitamin C is important for normal immune 
functioning, and a vitamin C deficiency in maternal smok-
ers could contribute to adverse pregnancy outcomes by 
impairing maternal immune responses to genital tract 
infections. Because the placenta is impermeable to most 
proteins, proteins are usually synthesized by the fetus 
from amino acids supplied by the mother. Abnormalities 
in amino acid transport across the placenta can contrib-
ute to impaired fetal growth. Compared with nonsmokers, 
smokers have reduced levels of several amino acids in fetal 
plasma, umbilical plasma, and placental villi (Jauniaux et 
al. 1999, 2001).
CO forms as a by-product of combustion and is the 
toxin found in the highest concentration in cigarette 
smoke—10 to 20 times the dose of nicotine (Hoffman et 
al. 1997). The toxic effects of CO result predominantly 
from its binding to hemoglobin (Longo 1976, 1977), 
which is more than 200 times that of O2 to hemoglobin 
(Hsia 1998). Fetal hemoglobin binds CO more tightly than 
does adult hemoglobin, so the fetus of a smoking mother 
has much higher levels of carboxyhemoglobin than those 
of the mother. The fetus experiences chronic hypoxia of 
fetal tissue, which persists for five or six hours of maternal 
smoking abstinence, such as during sleeping (Cole et al. 
1972; Longo 1977; Bureau et al. 1982). CO from cigarette 
smoke deprives the fetus of O2, which is essential for the 
aerobic metabolism that produces ATP, a coenzyme that 
stores the energy to fuel cellular activity throughout the 
body. Chronic mild O2 deprivation in the fetus is likely a 
major underlying mechanism of smoking-associated fetal 
growth retardation, one of the most consistent and earliest 
identified adverse effects in infants of maternal smokers 
(Longo 1976, 1977; USDHHS 1980, 2004). Furthermore, 
infants of maternal smokers showed a decrease in birth 
weight nearly five times lower than that in infants of snuff 
users, even after adjustment for variables, implicating 
CO as the likely hazard (Longo 1976, 1977; England et 
al. 2003). Reduced fetal growth is associated with adverse 
effects on other endpoints, including perinatal mortality, 
birth defects, and neurodevelopment, which may also be 
directly affected by CO exposure.
Other components of tobacco smoke, includ-
ing nicotine (see Chapter 3, “Chemistry and Toxicology 
of Cigarette Smoke and Biomarkers of Exposure and 
Harm”); heavy metals such as cadmium, lead, and mer-
cury; and PAHs have been found to be causally associated 
with several adverse reproductive outcomes described 
here. Furthermore, levels of these components are found 
to be higher in smokers than in nonsmokers. It is more 
difficult to determine whether the levels generated from 
tobacco smoke are sufficient to cause these outcomes, but 
the evidence is suggestive for several of the components. 
The metabolism of these toxic constituents likely varies 
by genetic polymorphisms that reflect differential induc-
tion of drug- or toxin-metabolizing enzymes, such as 
cytochrome P-450s and GSTs, which, in turn, may 
modify the relationship between maternal smoking and 
birth outcomes, such as LBW or congenital anomalies. 
Genetic polymorphisms coding for the expression of tissue 
damage, inflammatory response, and immune mediator 
enzymes have been examined for interaction with mater-
nal smoking in several studies of oral facial clefts, with 




1. There is consistent evidence that links smoking in 
men to chromosome changes or DNA damage in 
sperm (germ cells), affecting male fertility, pregnancy 
viability, and anomalies in offspring.
2. There is consistent evidence for association of peri-
conceptional smoking to cleft lip with or without 
cleft palate. 
3. There is consistent evidence that increases in follicle-
stimulating hormone levels and decreases in estrogen 
and progesterone are associated with cigarette smok-
ing in women, at least in part due to effects of nicotine 
on the endocrine system. 
4. There is consistent evidence that maternal smoking 
leads to transient increases in maternal heart rate and 
blood pressure (primarily diastolic), probably medi-
ated by the release of norepinephrine and epinephrine 
into the circulatory system.
5. There is consistent evidence that links maternal 
smoking to interference in the physiological transfor-
mation of spiral arteries and thickening of the villous 
membrane in forming the placenta; placental prob-
lems could lead to fetal loss, preterm delivery, or low 
birth weight.
6. There is consistent evidence of the presence of histo-
pathologic changes in the fetus from maternal smok-
ing, particularly in the lung and brain.
7. There is consistent evidence that suggests smoking 
leads to immunosuppressive effects, including dys-
regulation of the inflammatory response, that may 
lead to miscarriage and preterm delivery. 
8. There is consistent evidence that suggests a role 
for polycyclic aromatic hydrocarbons from tobacco 
smoke in the adverse effects of maternal smoking on a 
variety of reproductive and developmental endpoints.
9. There is consistent evidence that tobacco smoke 
exposure leads to diminished oviductal functioning, 
which could impair fertilization. 
10. There is consistent evidence that links prenatal smoke 
exposure and genetic variations in metabolizing 
enzymes such as GSTT1 with increased risk of adverse 
pregnancy outcomes such as lowered birth weight 
and reduced gestation.
11. There is consistent evidence that genetic polymor-
phisms, such as variants in transforming growth fac-
tor-alpha, modify the risks of oral clefting in offspring 
related to maternal smoking.
12. There is consistent evidence that carbon monoxide 
leads to birth weight deficits and may play a role in 
neurologic deficits (cognitive and neurobehavioral 
endpoints) in the offspring of smokers.
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Table 8.2 Association between maternal smoking and spontaneous abortion (SAB), 1998–2006




782 cases of SAB by 12 weeks’ 
gestation, confirmed pathologic 
examination
1,543 women who delivered term 




vs. women who smoked 
during pregnancy
None, 1–4, 5–9, ≥10 
cigarettes/day
Any smoking 1.3 (1.0–1.6) 
No association with 
smoking before 
pregnancy or with 
paternal smoking; 
adjustment for center, 
age, marital status, 
history of SAB, 





782 cases of SAB by 12 weeks’ 
gestation, confirmed pathologic 
examination
1,543 women who delivered term 




vs. women who smoked 
during pregnancy
None, 1–4, 5–9, ≥10 
cigarettes/day
≥10 cigarettes/day 1.4 (1.0–2.1)
No association with 
smoking before 
pregnancy or with 
paternal smoking; 
adjustment for center, 
age, marital status, 
history of SAB, 
nausea, and use of 
alcohol and coffee
Ness et al. 
1999
Case-control study
400 adolescents or women with SAB 
<22 weeks’ gestation at initial visit or 
during follow-up
570 adolescents or women with 
pregnancies beyond 22 weeks’ 





>500 ng/mL used to 
identify heavy smokers
1.8 (1.3–2.6)
Adjustment for use of 
cocaine, marijuana, 
and alcohol, and living 
with partner, weeks of 
gestation at interview, 
and prenatal care; 
stronger among SABs 
during follow-up  
(OR 2.4)
Ness et al. 
1999
Case-control study
400 adolescents or women with SAB 
<22 weeks’ gestation at initial visit or 
during follow-up
570 adolescents or women with 
pregnancies beyond 22 weeks’ 









Adjustment for use of 
cocaine, marijuana, 
and alcohol, and living 
with partner, weeks of 
gestation at interview, 
and prenatal care; 
stronger among SABs 
during follow-up  
(OR 2.4)
Table 8.2 Continued
Study Design/population Definition of smoking OR (95% CI) Comments
Windham et 
al. 1999c
Prospective study of women seeking 
prenatal care at large health 
maintenance organization (Kaiser) by 
12 weeks’ gestation
 
499 SABs by 20 weeks’ gestation, from 
medical records
 
5,144 pregnancies after excluding 
therapeutic abortions
California
Smoking at 8 weeks of 
gestation and amount 
vs. nonsmoking
≥5 cigarettes/day 1.3 (0.9–1.9)
Adjustment for age, 
previous fetal loss, 
gestational age at 
interview, use of 
alcohol and caffeine; 
effect modification 
with high use of 




Prospective study of women seeking 
prenatal care at large health 
maintenance organization (Kaiser) by 
12 weeks’ gestation
 
499 SABs by 20 weeks’ gestation, from 
medical records
 
5,144 pregnancies after excluding 
therapeutic abortions
California
Smoking at 8 weeks of 
gestation and amount 
vs. nonsmoking
Spouse smoking status No association
Adjustment for age, 
previous fetal loss, 
gestational age at 
interview, use of 
alcohol and caffeine; 
effect modification 
with high use of 




Prospective study of women seeking 
prenatal care at large health 
maintenance organization (Kaiser) by 
12 weeks’ gestation
 
499 SABs by 20 weeks’ gestation, from 
medical records
 
5,144 pregnancies after excluding 
therapeutic abortions
California
Smoking at 8 weeks of 
gestation and amount 
vs. nonsmoking
Hours of exposure to 





of caffeine or 
alcohol OR ~3 
for any exposure 
to SHS
Adjustment for age, 
previous fetal loss, 
gestational age at 
interview, use of 
alcohol and caffeine; 
effect modification 
with high use of 
caffeine or alcohol  
(>3 drinks/week)
Table 8.2 Continued
Study Design/population Definition of smoking OR (95% CI) Comments
Mishra et al. 
2000
Prospective study





vs. current and former 
smokers 
Amount (cigarettes/day)
   Former smokers 1.6 (1.3–2.2)
Adjustment for parity, 
therapeutic abortion, 
age, education, 
marital status, and 
area of residence; 
higher risk for 
smoking initiation at 
younger age
Mishra et al. 
2000
Prospective study





vs. current and former 
smokers 
Amount (cigarettes/day)
   Current smokers
      1–9 1.7 (1.1–2.5)
Adjustment for parity, 
therapeutic abortion, 
age, education, 
marital status, and 
area of residence; 
higher risk for 
smoking initiation at 
younger age
Mishra et al. 
2000
Prospective study





vs. current and former 
smokers 
Amount (cigarettes/day)
   Current smokers
      10–19
1.6 (1.6–2.3)
Adjustment for parity, 
therapeutic abortion, 
age, education, 
marital status, and 
area of residence; 
higher risk for 
smoking initiation at 
younger age
Mishra et al. 
2000
Prospective study





vs. current and former 
smokers 
Amount (cigarettes/day)
   Current smokers
      ≥20
2.0 (1.5–2.8)
Adjustment for parity, 
therapeutic abortion, 
age, education, 
marital status, and 
area of residence; 
higher risk for 
smoking initiation at 
younger age
Table 8.2  Continued
Study Design/population Definition of smoking OR (95% CI) Comments
Rasch 2003 Case-control study
330 women with  SAB ascertained by 
evacuation procedure at hospital, 6–16 
weeks’ gestation
1,168 pregnant women receiving 
prenatal care in weeks 6–16
Denmark
Smoking during 
pregnancy and amount 
vs. none






Large effect of 
adjustment for age, 
parity, occupation, 




40% of original 
eligible subjects not 
included in study
Rasch 2003 Case-control study
330 women with  SAB ascertained by 
evacuation procedure at hospital, 6–16 
weeks’ gestation
1,168 pregnant women receiving 
prenatal care in weeks 6–16
Denmark
Smoking during 
pregnancy and amount 
vs. none






Large effect of 
adjustment for age, 
parity, occupation, 




40% of original 
eligible subjects not 
included in study
Wisborg et al. 
2003
Prospective study among women 
seeking prenatal care
24,608 pregnant women who 
completed questionnaire by 28 weeks’ 
gestation
321 SABs by 28 weeks (104 first 
trimester, 217 second trimester) from 
Danish patient registry
Denmark
Smoking before or 
during pregnancy 
(and amount) vs. 
nonsmokers
≥10 cigarettes/day 





no difference; very 
low SAB rate (~1%), 
especially with 
extended definition 
(28 weeks); median 
entry time was second 
trimester, so most 
earlier SABs were 
missed
Wisborg et al. 
2003
Prospective study among women 
seeking prenatal care
24,608 pregnant women who 
completed questionnaire by 28 weeks’ 
gestation
321 SABs by 28 weeks (104 first 
trimester, 217 second trimester) from 
Danish patient registry
Denmark
Smoking before or 
during pregnancy 
(and amount) vs. 
nonsmokers
First trimester 0.92 (0.55–1.54)
Crude estimates; 
adjustment made 
no difference; very 
low SAB rate (~1%), 
especially with 
extended definition 
(28 weeks); median 
entry time was second 
trimester, so most 
earlier SABs were 
missed
Table 8.2  Continued
Study Design/population Definition of smoking OR (95% CI) Comments
George et al. 
2006
Case-control population-based study
463 women with SAB at 6–12 weeks’ 
gestation, interviewed after SAB (most 
within 2 weeks)
864 pregnant women with viable 




>15.0 ng/mL = active 
smoking
2.1 (1.4–3.3)
Adjustment for age, 
country of birth, 
education, marital 
status, shift work, 
parity, previous SAB, 
caffeine intake, folate 
level, change of eating 
habits, pregnancy 
symptoms; SHS 
exposed may include 
light smokers
George et al. 
2006
Case-control population-based study
463 women with SAB at 6–12 weeks’ 
gestation, interviewed after SAB (most 
within 2 weeks)
864 pregnant women with viable 




0.1–15.0 ng/mL for 
exposure to SHS vs. 
<0.1 ng/mL
1.7 (1.2–2.4)
Adjustment for age, 
country of birth, 
education, marital 
status, shift work, 
parity, previous SAB, 
caffeine intake, folate 
level, change of eating 
habits, pregnancy 
symptoms; SHS 
exposed may include 
light smokers
George et al. 
2006
Case-control population-based study
463 women with SAB at 6–12 weeks’ 
gestation, interviewed after SAB (most 
within 2 weeks)
864 pregnant women with viable 




No exposure to 
cigarette smoke
   Adjustment for age, 
country of birth, 
education, marital 
status, shift work, 
parity, previous SAB, 
caffeine intake, folate 
level, change of eating 
habits, pregnancy 
symptoms; SHS 
exposed may include 
light smokers
Table 8.2  Continued
Study Design/population Definition of smoking OR (95% CI) Comments
Nielsen et al. 
2006
Nested case-control study from 
population-based cohort of 11,088 
women with baseline survey and 
2-year follow-up
343 SAB or fetal loss by 28 weeks’ 
gestation, self-reported or in Danish 
registry
1,578 women with pregnancy of >28 
weeks during follow-up period
Denmark
Smoking at baseline, 
before pregnancy, by 






age, marital status, 
previous SAB, oral 
contraceptive use, 
IUD use, and smoking 
status and duration 
of smoking—but 
did not affect ORs; 
no association for 
former smokers or by 
duration of smoking; 
odd reference group
Nielsen et al. 
2006
Nested case-control study from 
population-based cohort of 11,088 
women with baseline survey and 
2-year follow-up
343 SAB or fetal loss by 28 weeks’ 
gestation, self-reported or in Danish 
registry
1,578 women with pregnancy of >28 
weeks during follow-up period
Denmark
Amount (cigarettes/day)
   1–14 Reference group
Adjustment for 
age, marital status, 
previous SAB, oral 
contraceptive use, 
IUD use, and smoking 
status and duration 
of smoking—but 
did not affect ORs; 
no association for 
former smokers or by 
duration of smoking; 
odd reference group
Nielsen et al. 
2006
Nested case-control study from 
population-based cohort of 11,088 
women with baseline survey and 
2-year follow-up
343 SAB or fetal loss by 28 weeks’ 
gestation, self-reported or in Danish 
registry
1,578 women with pregnancy of >28 
weeks during follow-up period
Denmark
Amount (cigarettes/day) 
   15–19 1.4 (0.9–2.1)
Adjustment for 
age, marital status, 
previous SAB, oral 
contraceptive use, 
IUD use, and smoking 
status and duration 
of smoking—but 
did not affect ORs; 
no association for 
former smokers or by 
duration of smoking; 
odd reference group
Table 8.2  Continued
Study Design/population Definition of smoking OR (95% CI) Comments
Nielsen et al. 
2006
Nested case-control study from 
population-based cohort of 11,088 
women with baseline survey and 
2-year follow-up
343 SAB or fetal loss by 28 weeks’ 
gestation, self-reported or in Danish 
registry
1,578 women with pregnancy of >28 
weeks during follow-up period
Denmark
Amount (cigarettes/day)
   ≥20 1.6 (1.1–2.5)
Adjustment for 
age, marital status, 
previous SAB, oral 
contraceptive use, 
IUD use, and smoking 
status and duration 
of smoking—but 
did not affect ORs; 
no association for 
former smokers or by 
duration of smoking; 
odd reference group
Nielsen et al. 
2006
Nested case-control study from 
population-based cohort of 11,088 
women with baseline survey and 
2-year follow-up
343 SAB or fetal loss by 28 weeks’ 
gestation, self-reported or in Danish 
registry
1,578 women with pregnancy of >28 
weeks during follow-up period
Denmark
Amount (cigarettes/day) 
   Each additional 5 1.2 (1.0–1.4)
Adjustment for 
age, marital status, 
previous SAB, oral 
contraceptive use, 
IUD use, and smoking 
status and duration 
of smoking—but 
did not affect ORs; 
no association for 
former smokers or by 
duration of smoking; 
odd reference group
Note: CI = confidence interval; IUD = intrauterine device; ng/mL = nanograms per milliliter; OR = odds ratio; SES = socioeconomic 
status; SHS = secondhand smoke.
Table 8.3 Association between maternal smoking and orofacial clefts (OFCs), 1999–2009a 
 
Study Design/population
Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
van Rooij et al. 
2001
Case-control study 
113 infants with nonsyndromic OFCs
104 infants with no defects 
White, aged 9 months–3 years
The Netherlands
Study period not specified
Smokers (20.2%) vs. 
nonsmokers
•	 Maternal smoking not associated with 
oral clefting
1.1 (0.6–2.2) See Table 8.13 for 
polymorphism 
results
Shaw et al. 2002 Case-control study
489 infants and fetal deaths with OFCs
734 control infants with no malformation





before to 3 months after 
conception —(24%) vs. 
none
•	 Association of maternal smoking with 





maternal body mass 
index, education, 
race, and ethnicity
Shaw et al. 2002 Case-control study
489 infants and fetal deaths with OFCs
734 control infants with no malformation





before to 3 months after 
conception —(24%) vs. 
none
•	 Association of maternal smoking with 





maternal body mass 
index, education, 
race, and ethnicity
Shaw et al. 2002 Case-control study
489 infants and fetal deaths with OFCs
734 control infants with no malformation





before to 3 months after 
conception —(24%) vs. 
none
•	 Association of maternal smoking with 





maternal body mass 
index, education, 
race, and ethnicity
Shaw et al. 2002 Case-control study
489 infants and fetal deaths with OFCs
734 control infants with no malformation





before to 3 months after 
conception —(24%) vs. 
none
•	 Association of maternal smoking with 











Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Shaw et al. 2002 Case-control study
489 infants and fetal deaths with OFCs
734 control infants with no malformation





before to 3 months after 
conception —(24%) vs. 
none
•	 Relationship marginally significant for 
isolated CP
    Vitamins/Smoking
Yes/No 1.0
Adjustment for 
maternal body mass 
index, education, race, 
and ethnicity
Shaw et al. 2002 Case-control study
489 infants and fetal deaths with OFCs
734 control infants with no malformation





before to 3 months after 
conception —(24%) vs. 
none
•	 Relationship marginally significant for 
isolated CP
    Vitamins/Smoking
No/Yes 2.0 (1.0–3.9)
Adjustment for 
maternal body mass 
index, education, race, 
and ethnicity
Shaw et al. 2002 Case-control study
489 infants and fetal deaths with OFCs
734 control infants with no malformation





before to 3 months after 
conception —(24%) vs. 
none
•	 Relationship marginally significant for 
isolated CP
    Vitamins/Smoking
No/No 1.6 (1.0–2.6)
Adjustment for 
maternal body mass 
index, education, race, 
and ethnicity
Shaw et al. 2002 Case-control study
489 infants and fetal deaths with OFCs
734 control infants with no malformation





before to 3 months after 
conception —(24%) vs. 
none
•	 Relationship marginally significant for 
isolated CP
    Vitamins/Smoking
Yes/Yes 1.7 (1.0–2.9)
Adjustment for 
maternal body mass 
index, education, race, 
and ethnicity
van Rooij et al. 
2002
Case-control study
45 mothers of children with OFCs
39 mothers of children with spina bifida
75 control mothers 
DNA for possible effect modification
The Netherlands
1997–1999






•	 Association with OFCs 
•	 No association between maternal NAT2 
acetylator status and OFCs
•	 No interaction between NAT2 
acetylator status and maternal 
smoking 





Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Wyszynski and Wu 
2002
Case-control study
2,029 births with nonsyndromic oral clefts
4,050 control infants with no malformation, 
matched on maternal and paternal race and 
child’s gender, county of birth, and month 
of birth
United States Natality database 
1997
Smoking
Any (16.9%) vs. none
•	 Maternal	smoking	associated	with	CL/P 
in infants Any vs. none
 
1.16 (1.01–1.33)












Wyszynski and Wu 
2002
Case-control study
2,029 births with nonsyndromic oral clefts
4,050 control infants with no malformation, 
matched on maternal and paternal race and 
child’s gender, county of birth, and month 
of birth





•	 Number	of	cigarettes/day vs. none
1–10 1.10 (0.93–1.30)












Wyszynski and Wu 
2002
Case-control study
2,029 births with nonsyndromic oral clefts
4,050 control infants with no malformation, 
matched on maternal and paternal race and 
child’s gender, county of birth, and month 
of birth





•	 Number	of	cigarettes/day vs. none
11–20 1.11 (0.87–1.41)















Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Wyszynski and Wu 
2002
Case-control study
2,029 births with nonsyndromic oral clefts
4,050 control infants with no malformation, 
matched on maternal and paternal race and 
child’s gender, county of birth, and month 
of birth





•	 Number	of	cigarettes/day vs. none
>20 1.55 (0.88–2.70) 












Jugessur et al. 
2003
Case-parent triad study




Smoking in last year or 




•	 Risk for smoking alone not stated
•	 No interaction between maternal 
smoking and TGFa gene TAQ1 
*A2/*A2 genotype in infant  
   None
Little et al. 2004a Meta-analysis of data from 24 case-control 
and cohort studies  
9 studies addressed only OFCs
15 studies assessed CL/P and CP separately
Studies published between 1974 and 2001
Smokers vs. 
nonsmokers varied by 
study 
•	 Consistent, moderate, and statistically 
significant associations between 
maternal smoking and CL/P
1.34 (1.25–1.44) None
Little et al. 2004a Meta-analysis of data from 24 case-control 
and cohort studies  
9 studies addressed only OFCs
15 studies assessed CL/P and CP separately
Studies published between 1974 and 2001
Smokers vs. 
nonsmokers varied by 
study 
•	 Evidence	of	a	dose-response	






Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Little et al. 2004b Case-control study
190 children with OFCs
248 children with no malformation





Active smoking and 








Exposure to cigarette 
smoke among mothers 
who did not smoke 
(28.2%)
Exposure to cigarette 




Any vs. none 1.9 (1.1–3.1)
Adjustment for 





Little et al. 2004b Case-control study
190 children with OFCs
248 children with no malformation





Active smoking and 








Exposure to cigarette 
smoke among mothers 
who did not smoke 
(28.2%)
Exposure to cigarette 
















Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Little et al. 2004b Case-control study
190 children with OFCs
248 children with no malformation





Active smoking and 








Exposure to cigarette 
smoke among mothers 
who did not smoke 
(28.2%)
Exposure to cigarette 




>10 cigarettes/day 2.5 (1.1–5.6)
Adjustment for 





Little et al. 2004b Case-control study
190 children with OFCs
248 children with no malformation





Active smoking and 








Exposure to cigarette 
smoke among mothers 
who did not smoke 
(28.2%)
Exposure to cigarette 




Any vs. none 2.5 (1.3–4.1)
Adjustment for 








Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Little et al. 2004b Case-control study
190 children with OFCs
248 children with no malformation





Active smoking and 








Exposure to cigarette 
smoke among mothers 
who did not smoke 
(28.2%)
Exposure to cigarette 




≤10 cigarettes/day 2.1 (1.1–3.9)
Adjustment for 





Little et al. 2004b Case-control study
190 children with OFCs
248 children with no malformation





Active smoking and 








Exposure to cigarette 
smoke among mothers 
who did not smoke 
(28.2%)
Exposure to cigarette 




>10 cigarettes/day 3.1 (1.2–7.8)
Adjustment for 








Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Little et al. 2004b Case-control study
190 children with OFCs
248 children with no malformation





Active smoking and 








Exposure to cigarette 
smoke among mothers 
who did not smoke 
(28.2%)
Exposure to cigarette 
smoke among mothers 
who smoked (31.0%)
•	 An	effect	of	involuntary	smoking	could	
not be excluded in mothers who did 
not smoke
   Adjustment for 





Honein et al. 2007 Case-control study
933 CL/P
528 CPO
3,390 controls with no defects
8 sites in the United States
Oct 1997–Dec 2001 births
Periconceptual smoking 
(1 month before 
to 3 months after 
conception)
20% controls exposed
•	 CL/P 1.3 (1.0–1.6) Strong effects for 
bilateral CL/P and 
heavy smoking
Honein et al. 2007 Case-control study
933 CL/P
528 CPO
3,390 controls with no defects
8 sites in the United States
Oct 1997–Dec 2001 births
Periconceptual smoking 
(1 month before 
to 3 months after 
conception)
20% controls exposed
•	 CPO 1.2 (0.9–1.5) Strong effects for 





Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Shi et al. 2007 Case-control study
DNA samples from 1,244 children with CL/P, 
CPO
4,183 parents, siblings, and unrelated 
population controls
Danish samples from two independent case-
control studies (Dec 1991–Aug 1994; born 
between 1981–1990)
Iowa samples from cases in Iowa Registry for 
Congenital and Inherited Disorders
Control children born without major 
anomalies were matched by birth month, 
year, and gender 
Number of cigarettes/
day
    0
    1–9
    10–19
     ≥20
•	 Maternal	smoking	was	associated	with	





of variants in 
the NAT2 and 
CYP1A1 genes 
were observed in 
both the Iowan 
and Danish 
participants
Shi et al. 2007 Case-control study
DNA samples from 1,244 children with CL/P, 
CPO
4,183 parents, siblings, and unrelated 
population controls
Danish samples from two independent case-
control studies (Dec 1991–Aug 1994; born 
between 1981–1990)
Iowa samples from cases in Iowa Registry for 
Congenital and Inherited Disorders
Control children born without major 




    0
    1–9
    10–19
     ≥20
•	 Maternal	smoking	was	associated	with	





of variants in 
the NAT2 and 
CYP1A1 genes 
were observed in 






Definition of smoking 
(smoking rate in 
controls)
 
Findings OR (95% CI) Comments
Shi et al. 2007 Case-control study
DNA samples from 1,244 children with CL/P, 
CPO
4,183 parents, siblings, and unrelated 
population controls
Danish samples from two independent case-
control studies (Dec 1991–Aug 1994; born 
between 1981–1990)
Iowa samples from cases in Iowa Registry for 
Congenital and Inherited Disorders
Control children born without major 




    0
    1–9
    10–19
     ≥20
•	 Maternal	smoking	was	associated	with	





of variants in 
the NAT2 and 
CYP1A1 genes 
were observed in 
both the Iowan 
and Danish 
participants
Shi et al. 2007 Case-control study
DNA samples from 1,244 children with CL/P, 
CPO
4,183 parents, siblings, and unrelated 
population controls
Danish samples from two independent case-
control studies (Dec 1991–Aug 1994; born 
between 1981–1990)
Iowa samples from cases in Iowa Registry for 
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Shi et al. 2007 Case-control study
DNA samples from 1,244 children with CL/P, 
CPO
4,183 parents, siblings, and unrelated 
population controls
Danish samples from two independent case-
control studies (Dec 1991–Aug 1994; born 
between 1981–1990)
Iowa samples from cases in Iowa Registry for 
Congenital and Inherited Disorders
Control children born without major 




    0
    1–9
    10–19
     ≥20
•	 There	was	an	interaction	between	
maternal smoking and fetal 
inheritance of a GSTT1 null deletion 
(Fisher combined p value <0.001)
   Suggestive effects 
of variants in 
the NAT2 and 
CYP1A1 genes 
were observed in 
both the Iowan 
and Danish 
participants
Shaw et al. 2009 Case-control study nested within a cohort 
of pregnancies with mid-pregnancy serum 
specimens
89 pregnancies with CL/P
409 pregnancies without malformations
Mid-pregnancy serum 
cotinine levels
No smoke exposure: 
cotinine value  
<2 µg/mL
Any exposure: cotinine 
value ≥2 µg/mL
•	 Association	of	maternal	serum	mid-
pregnancy cotinine levels with CL/P
2.1 (1.0–4.4) Exposure 
assessment based 
on biomarker
Note: CI = confidence interval; CL/P = cleft lip with or without cleft palate; CP = cleft palate; CPO = cleft palate only; mL = milliliter; OR = odds ratio; µg = micrograms.
aNot included in 2004 Surgeon General’s report on the health consequences of smoking.
Table 8.4 Association between maternal smoking and cardiovascular malformations, by phenotype, 1999–2008
Study Design/population
Definition of smoking 
(prevalence of 







687 infants with Down syndrome
385 case infants with cardiac defects also
302 control infants with no heart defects and 
no other specific defect 







12% of all 
participants  




2.1 (1.2–3.5) Adjustment for 
maternal race; all 





687 infants with Down syndrome
385 case infants with cardiac defects also
302 control infants with no heart defects and 
no other specific defect 







12% of all 
participants  
8% of controls for 
cardiac defects
•	 Maternal	smoking	associated	with
 Atrioventricular septal defects 2.3 (1.2–4.5)
Adjustment for 
maternal race; all 





687 infants with Down syndrome
385 case infants with cardiac defects also
302 control infants with no heart defects and 
no other specific defect 







12% of all 
participants  
8% of controls for 
cardiac defects
•	 Maternal	smoking	associated	with
 Tetralogy of Fallot 4.6 (1.2–17.0)
Adjustment for 
maternal race; all 





687 infants with Down syndrome
385 case infants with cardiac defects also
302 control infants with no heart defects and 
no other specific defect 







12% of all 
participants  
8% of controls for 
cardiac defects
•	 Maternal	smoking	associated	with
 Atrial septal defects 2.2 (1.1–4.3)
Adjustment for 
maternal race; all 




Definition of smoking 
(prevalence of 




Woods and Raju 
2001
Retrospective cohort study of 18,016 
live births in TriHealth Hospital System 
(Cincinnati, Ohio)
Congenital defects grouped in 22 categories, 




Cohort included 1,943 
mothers who were 
smokers
•	 Smoking	associated	with	increased	risk	
of cardiovascular system abnormalities
•	 Patent	ductus	arteriosus	(n	=	153)	and	




1.56 (1.12–1.82) Adjustment for 
maternal age, 
race, and diabetes 
mellitus but not 
for gestational age













Data not reported Different 






Shaw et al. 2002 Case-control study
207 infants and fetal deaths with 
conotruncal defects
489 infants and fetal deaths with orofacial 
clefts
265 infants and fetal deaths with neural tube 
defects
734 control infants with no malformation




period (1 month before 
to 3 months after 
conception)  





defects among infants of women who 
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defects
734 control infants with no malformation




period (1 month before 
to 3 months after 
conception)  
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734 control infants with no malformation




period (1 month before 
to 3 months after 
conception)  





defects among infants of women who 








Steinberger et al. 
2002
Case-control study
48 infants with single ventricle and 
abnormal situs
3,572 infants without cardiac defects
Baltimore-Washington Infant Study 
(Maryland; northern Virginia; and 
Washington, DC)
1981–1989
Parental smoking of 
>1 pack/day (maternal 
4.9%, paternal 9%) vs. 
no smoking
Exposure period during 
gestation not stated 




small case sample 
size; estimates 







Definition of smoking 
(prevalence of 




Steinberger et al. 
2002
Case-control study
48 infants with single ventricle and 
abnormal situs
3,572 infants without cardiac defects
Baltimore-Washington Infant Study 
(Maryland; northern Virginia; and 
Washington, DC)
1981–1989
Parental smoking of 
>1 pack/day (maternal 
4.9%, paternal 9%) vs. 
no smoking
Exposure period during 
gestation not stated
•	 Increased	risk	with	paternal	smoking	
of >1 pack/day 




small case sample 
size; estimates 





Steinberger et al. 
2002
Case-control study
48 infants with single ventricle and 
abnormal situs
3,572 infants without cardiac defects
Baltimore-Washington Infant Study 
(Maryland; northern Virginia; and 
Washington, DC)
1981–1989
Parental smoking of 
>1 pack/day (maternal 
4.9%, paternal 9%) vs. 
no smoking
Exposure period during 
gestation not stated
•	 Increased	risk	with	paternal	smoking	









small case sample 
size; estimates 





Steinberger et al. 
2002
Case-control study
48 infants with single ventricle and 
abnormal situs
3,572 infants without cardiac defects
Baltimore-Washington Infant Study 
(Maryland; northern Virginia; and 
Washington, DC)
1981–1989
Parental smoking of 
>1 pack/day (maternal 
4.9%, paternal 9%) vs. 
no smoking
Exposure period during 
gestation not stated
•	 Increased	risk	with	paternal	smoking	
of increasing number of cigarettes/day
20–39 1.9





small case sample 
size; estimates 







Definition of smoking 
(prevalence of 




Steinberger et al. 
2002
Case-control study
48 infants with single ventricle and 
abnormal situs
3,572 infants without cardiac defects
Baltimore-Washington Infant Study 
(Maryland; northern Virginia; and 
Washington, DC)
1981–1989
Parental smoking of 
>1 pack/day (maternal 
4.9%, paternal 9%) vs. 
no smoking
Exposure period during 
gestation not stated
•	 Increased	risk	with	paternal	smoking	
of increasing number of cigarettes/day
≥40 3.7





small case sample 
size; estimates 








36 infants with single l-transposition of 
great arteries
3,495 infants without cardiac defects
Baltimore-Washington Infant Study 




Prevalence of maternal 
smoking for control 
infants not mentioned
•	 Maternal	cigarette	smoking	associated	
with increased risk of l-transposition 
of great arteries
1.6 (1.1–2.4) Maternal smoking 
highly correlated 
with use of hair 
dyes; adjustment 
for maternal 






Malik et al. 2008 Case-control study
3,067 infants with congenital heart defects
3,947 controls without defects
Those who reported 
smoking any time 
from 1 month before 
conception and 
through each month of 
pregnancy <1 cigarette/
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smoking any time 
from 1 month before 
conception and 
through each month of 
pregnancy <1 cigarette/
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(prevalence of 




Malik et al. 2008 Case-control study
3,067 infants with congenital heart defects
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smoking any time 
from 1 month before 
conception and 
through each month of 
pregnancy <1 cigarette/






Malik et al. 2008 Case-control study
3,067 infants with congenital heart defects
3,947 controls without defects
Those who reported 
smoking any time 
from 1 month before 
conception and 
through each month of 
pregnancy <1 cigarette/






Table 8.5 Association between maternal smoking and noncardiovascular congenital malformations, by type of malformation, 1998–2008
Study Design/population
Definition of smoking 
(prevalence of 




Hwang et al. 1998 Case-control study
34 infants with isolated LDD
482 control infants with other isolated 
defects





(27.5% among all 
participants)
Any vs. none
Effect modification by 
MSX1 gene
•	 Interaction	with	MSX1 *rare alleles 











Hwang et al. 1998 Case-control study
34 infants with isolated LDD
482 control infants with other isolated 
defects





(27.5% among all 
participants)
Any vs. none
Effect modification by 
MSX1 gene
•	 Interaction	with	MSX1 *rare alleles 
and risk of isolated limb deficiency










Hwang et al. 1998 Case-control study
34 infants with isolated LDD
482 control infants with other isolated 
defects





(27.5% among all 
participants)
Any vs. none
Effect modification by 
MSX1 gene
•	 Interaction	with	MSX1 *rare alleles 
and risk of isolated limb deficiency










Reefhuis et al. 
1998
Case-control study
3,662 children with foot deformities
7,829 control children with chromosomal or 
monogenic disorder




Any (18.1%) vs. none
•	 Maternal	smoking	during	pregnancy	
associated with increased risk of foot 
deformities
1.2 (1.1–1.3) Adjustment for 
maternal age, 
registry, parity, 





Definition of smoking 
(prevalence of 




Akre et al. 1999 2 population-based case-control studies
2,782 boys operated on for cryptorchidism
1,220 boys operated on for hypospadias (5 
matched controls per case)
Linkage of Inpatient and Birth Registries
Sweden birth cohort 
1983–1993
Prenatal clinic record on 
maternal smoking
Yes (38.1%) vs. no
•	 Maternal	smoking	associated	with	
increased risk of cryptorchidism











Akre et al. 1999 2 population-based case-control studies
2,782 boys operated on for cryptorchidism
1,220 boys operated on for hypospadias (5 
matched controls per case)
Linkage of Inpatient and Birth Registries
Sweden birth cohort 
1983–1993
Prenatal clinic record on 
maternal smoking
Yes (38.1%) vs. no
•	 Maternal	smoking	not	associated	with	
increased risk of hypospadias











Chen et al. 1999 Case-control study
775 children with Down syndrome
7,750 control children with no 
malformation, matched by birth year
Washington State Birth Events Records 
Database
1984–1994
Any maternal smoking 





not associated with Down syndrome
1.00 (0.82–1.24) Adjustment for 
exact year of 
maternal age, 
race, and parity 
Källén 1999 Case-control studies
304 infants with craniosynostosis, no 
information available on type or number of 
controls
Linkages of Swedish Registry of Congenital 
Malformations and National Board of Health 
Medical Birth Registry 
Sweden
1983–1996
Smoking at first prenatal 
visit 






•	 Associated	with	craniosynostosis 1.45 (1.13–1.87) Adjustment for 









Definition of smoking 
(prevalence of 




Källén 1999 Case-control studies
304 infants with craniosynostosis, no 
information available on type or number of 
controls
Linkages of Swedish Registry of Congenital 
Malformations and National Board of Health 
Medical Birth Registry 
Sweden
1983–1996
Smoking at first prenatal 
visit 








1.67 (1.27–2.19) Adjustment for 







Källén 1999 Case-control studies
304 infants with craniosynostosis, no 
information available on type or number of 
controls
Linkages of Swedish Registry of Congenital 
Malformations and National Board of Health 
Medical Birth Registry 
Sweden
1983–1996
Smoking at first prenatal 
visit 






•	 Not	associated	with	syndromes 0.61 (0.29–1.30) Adjustment for 







Källén 1999 Case-control studies
304 infants with craniosynostosis, no 
information available on type or number of 
controls
Linkages of Swedish Registry of Congenital 
Malformations and National Board of Health 
Medical Birth Registry 
Sweden
1983–1996
Smoking at first prenatal 
visit 








 <10 cigarettes/day 1.48 (1.04–2.02)
Adjustment for 







Källén 1999 Case-control studies
304 infants with craniosynostosis, no 
information available on type or number of 
controls
Linkages of Swedish Registry of Congenital 
Malformations and National Board of Health 
Medical Birth Registry 
Sweden
1983–1996
Smoking at first prenatal 
visit 








 ≥10 cigarettes/day 2.12 (1.50–2.99)
Adjustment for 









Definition of smoking 
(prevalence of 




Källén 1999 Case-control studies
304 infants with craniosynostosis, no 
information available on type or number of 
controls
Linkages of Swedish Registry of Congenital 
Malformations and National Board of Health 
Medical Birth Registry 
Sweden
1983–1996
Smoking at first prenatal 
visit 








1.48 (1.02–2.14) Adjustment for 







Yang et al. 1999 Population-based case-control study
285 children with Down syndrome
329 control children with no defects 
Cases ascertained from Metropolitan Atlanta 
Congenital  
Defects Program









Effect modification by 
timing and origin of 
meiotic error and OC 
use
•	 No	association	in	presence	of	maternal	







action of smoking 
with type of non-
disjunction error 
and OC use
Yang et al. 1999 Population-based case-control study
285 children with Down syndrome
329 control children with no defects 
Cases ascertained from Metropolitan Atlanta 
Congenital  
Defects Program









Effect modification by 
timing and origin of 
meiotic error and OC 
use
•	 No	association	in	presence	of	maternal	







action of smoking 





Definition of smoking 
(prevalence of 




Yang et al. 1999 Population-based case-control study
285 children with Down syndrome
329 control children with no defects 
Cases ascertained from Metropolitan Atlanta 
Congenital  
Defects Program









Effect modification by 
timing and origin of 
meiotic error and OC 
use
•	 Associated	with	Down	syndrome	








action of smoking 
with type of non-
disjunction error 
and OC use
Yang et al. 1999 Population-based case-control study
285 children with Down syndrome
329 control children with no defects 
Cases ascertained from Metropolitan Atlanta 
Congenital  
Defects Program









Effect modification by 
timing and origin of 
meiotic error and OC 
use
•	 Associated	with	Down	syndrome	
in young mothers with meiosis II 
nondisjunction error
Ever smoked (age)
≥35 years 0.37 (0.07–1.87)
60–63% participa-
tion rates; inter-
action of smoking 
with type of non-
disjunction error 
and OC use
Yang et al. 1999 Population-based case-control study
285 children with Down syndrome
329 control children with no defects 
Cases ascertained from Metropolitan Atlanta 
Congenital  
Defects Program









Effect modification by 
timing and origin of 
meiotic error and OC 
use
•	 Associated	with	Down	syndrome	
in young mothers with meiosis II 
nondisjunction error
Current smoker (age)
<35 years 2.98 (1.01–8.87)
60–63% participa-
tion rates; inter-
action of smoking 





Definition of smoking 
(prevalence of 




Yang et al. 1999 Population-based case-control study
285 children with Down syndrome
329 control children with no defects 
Cases ascertained from Metropolitan Atlanta 
Congenital  
Defects Program









Effect modification by 
timing and origin of 
meiotic error and OC 
use
•	 Associated	with	Down	syndrome	
in young mothers with OC use and 
maternal meiosis II nondisjunction 
error
OC use alone 0.38 (0.05–3.01)
60–63% participa-
tion rates; inter-
action of smoking 
with type of non-
disjunction error 
and OC use
Yang et al. 1999 Population-based case-control study
285 children with Down syndrome
329 control children with no defects 
Cases ascertained from Metropolitan Atlanta 
Congenital  
Defects Program









Effect modification by 
timing and origin of 
meiotic error and OC 
use
•	 Associated	with	Down	syndrome	
in young mothers with OC use and 
maternal meiosis II nondisjunction 
error
Smoking without OC use 1.54 (0.45–5.27)
60–63% participa-
tion rates; inter-
action of smoking 
with type of non-
disjunction error 
and OC use
Yang et al. 1999 Population-based case-control study
285 children with Down syndrome
329 control children with no defects 
Cases ascertained from Metropolitan Atlanta 
Congenital  
Defects Program









Effect modification by 
timing and origin of 
meiotic error and OC 
use
•	 Associated	with	Down	syndrome	
in young mothers with OC use and 
maternal meiosis II nondisjunction 
error
Smoking with OC use 7.92 (1.63–35.6)
60–63% participa-
tion rates; inter-
action of smoking 





Definition of smoking 
(prevalence of 




Honein et al. 2000 Population-based case-control study
346 infants with isolated clubfoot
3,029 infants with no defects
Frequency matched to cases by year and 
hospital of birth
Atlanta Birth Defects Case-Control Study
1968–1980 
First trimester
Any (28.6%) vs. none
•	 Interaction	between	maternal	smoking	







Honein et al. 2000 Population-based case-control study
346 infants with isolated clubfoot
3,029 infants with no defects
Frequency matched to cases by year and 
hospital of birth
Atlanta Birth Defects Case-Control Study
1968–1980
First trimester
Any (28.6%) vs. none
•	 Interaction	between	maternal	smoking	
and family history of clubfoot






Honein et al. 2000 Population-based case-control study
346 infants with isolated clubfoot
3,029 infants with no defects
Frequency matched to cases by year and 
hospital of birth
Atlanta Birth Defects Case-Control Study
1968–1980
First trimester
Any (28.6%) vs. none
•	 Interaction	between	maternal	smoking	







Källén 2002b Case-control study
3,262 infants with hypospadias
1,413,811 infants with no malformation
Linkages of Swedish Registry of Congenital 
Malformations, National Board of Health 








0.83 (0.76–0.90) Stratification by 
maternal age, 
parity, educational 




Definition of smoking 
(prevalence of 




Källén 2002b Case-control study
3,262 infants with hypospadias
1,413,811 infants with no malformation
Linkages of Swedish Registry of Congenital 
Malformations, National Board of Health 






Smokers vs. nonsmokers 






level, and year of 
birth
Källén 2002b Case-control study
3,262 infants with hypospadias
1,413,811 infants with no malformation
Linkages of Swedish Registry of Congenital 
Malformations, National Board of Health 






Smokers vs. nonsmokers 




level, and year of 
birth
Shaw et al. 2002 Case-control study
265 infants and fetal deaths with neural tube 
defects
165 infants with LDD
734 control infants with no malformation




period (1 month before 
to 3 months after 
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265 infants and fetal deaths with neural tube 
defects
165 infants with LDD
734 control infants with no malformation




period (1 month before 
to 3 months after 













Definition of smoking 
(prevalence of 
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265 infants and fetal deaths with neural tube 
defects
165 infants with LDD
734 control infants with no malformation
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to 3 months after 











Skelly et al. 2002 Case-control study
239 children with clubfoot
365 control children with no malformation
Western Washington State
1986–1994
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Definition of smoking 
(prevalence of 
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(prevalence of 




Skelly et al. 2002 Case-control study
239 children with clubfoot
365 control children with no malformation
Western Washington State
1986–1994

















Skelly et al. 2002 Case-control study
239 children with clubfoot
365 control children with no malformation
Western Washington State
1986–1994

















van Rooij et al 
2002
Case-control study
45 case mothers of children with orofacial 
clefts




Smokers (18.1%) vs. 
nonsmokers
Cigarettes/day





acetylator status and spina bifida
•	 No	interaction	
Data not reported Adjustment 
for maternal 
education
Werler et al. 2003 Population-based case-control study
Mothers of 205 case children with 
gastroschisis
127 case children with small intestinal 
atresia
381 malformed control children
416 control children with no malformation






Control children with 
malformation




















Definition of smoking 
(prevalence of 




Werler et al. 2003 Population-based case-control study
Mothers of 205 case children with 
gastroschisis
127 case children with small intestinal 
atresia
381 malformed control children
416 control children with no malformation






Control children with 
malformation











    1–9 1.3 (0.7–2.2)
Adjustment for 
vasoconstrictive 
drug use and 
maternal age
Werler et al. 2003 Population-based case-control study
Mothers of 205 case children with 
gastroschisis
127 case children with small intestinal 
atresia
381 malformed control children
416 control children with no malformation






Control children with 
malformation











    10–19 1.4 (0.9–2.4)
Adjustment for 
vasoconstrictive 




Definition of smoking 
(prevalence of 




Werler et al. 2003 Population-based case-control study
Mothers of 205 case children with 
gastroschisis
127 case children with small intestinal 
atresia
381 malformed control children
416 control children with no malformation






Control children with 
malformation











    >19 1.8 (1.1–2.8)
Adjustment for 
vasoconstrictive 
drug use and 
maternal age
Werler et al. 2003 Population-based case-control study
Mothers of 205 case children with 
gastroschisis
127 case children with small intestinal 
atresia
381 malformed control children
416 control children with no malformation






Control children with 
malformation
























Definition of smoking 
(prevalence of 
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Mothers of 205 case children with 
gastroschisis
127 case children with small intestinal 
atresia
381 malformed control children
416 control children with no malformation






Control children with 
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Mothers of 205 case children with 
gastroschisis
127 case children with small intestinal 
atresia
381 malformed control children
416 control children with no malformation
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Werler et al. 2003 Population-based case-control study
Mothers of 205 case children with 
gastroschisis
127 case children with small intestinal 
atresia
381 malformed control children
416 control children with no malformation






Control children with 
malformation

























92 infants with LDD
180 control infants with no malformation
California Birth Defects Monitoring Program
1987–1988
Maternal and paternal 












92 infants with LDD
180 control infants with no malformation
California Birth Defects Monitoring Program
1987–1988
Maternal and paternal 












92 infants with LDD
180 control infants with no malformation
California Birth Defects Monitoring Program
1987–1988
Maternal and paternal 
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Pierik et al. 2004 Population-based nested case-control study
78 case children with cryptorchidism
56 case newborns with hypospadias
















to solvents, and 
time to pregnancy 
Pierik et al. 2004 Population-based nested case-control study
78 case children with cryptorchidism
56 case newborns with hypospadias
















to solvents, and 
time to pregnancy
Pierik et al. 2004 Population-based nested case-control study
78 case children with cryptorchidism
56 case newborns with hypospadias
















to solvents, and 
time to pregnancy
Pierik et al. 2004 Population-based nested case-control study
78 case children with cryptorchidism
56 case newborns with hypospadias




















Definition of smoking 
(prevalence of 




Carmichael et al. 
2008
Case-control study
531 cases of craniosynostosis
5,008 control children without 
malformation matched by birth cohort




pregnancy, 1st, 2nd, and 
3rd month of pregnancy
2nd and 3rd trimesters 
Categories
    None
    Smoked <5 cigarettes/
day
    Smoked 5–14 
cigarettes/day
    Smoked ≥15 
cigarettes/day
•	 Smoking	during	first	month	of	
pregnancy was not associated with 
craniosynostosis
•	 Smoking	later	in	pregnancy	(2nd	or	
3rd trimester) was associated with 
increased risk but only among mothers 






parity, folic acid 
supplement 
intake, BMI, and 
study center
Carmichael et al. 
2008
Case-control study
531 cases of craniosynostosis
5,008 control children without 
malformation matched by birth cohort




pregnancy, 1st, 2nd, and 
3rd month of pregnancy
2nd and 3rd trimesters 
Categories
    None
    Smoked <5 cigarettes/
day
    Smoked 5–14 
cigarettes/day
    Smoked ≥15 
cigarettes/day
•	 Smoked	≥15	cigarettes/day






parity, folic acid 
supplement 
intake, BMI, and 
study center
Carmichael et al. 
2008
Case-control study
531 cases of craniosynostosis
5,008 control children without 
malformation matched by birth cohort




pregnancy, 1st, 2nd, and 
3rd month of pregnancy
2nd and 3rd trimesters 
Categories
    None
    Smoked <5 cigarettes/
day
    Smoked 5–14 
cigarettes/day
    Smoked ≥15 
cigarettes/day
•	 Smoked	≥15	cigarettes/day






parity, folic acid 
supplement 




Definition of smoking 
(prevalence of 




Carmichael et al. 
2008
Case-control study
531 cases of craniosynostosis
5,008 control children without 
malformation matched by birth cohort




pregnancy, 1st, 2nd, and 
3rd month of pregnancy
2nd and 3rd trimesters 
Categories
    None
    Smoked <5 cigarettes/
day
    Smoked 5–14 
cigarettes/day
    Smoked ≥15 
cigarettes/day





parity, folic acid 
supplement 
intake, BMI, and 
study center
Note: Apgar = appearance, pulse, grimace, activity, respiration; BMI = body mass index; LDD = limb deficiency defects; OC = oral contraceptive.
aPack-years = the number of years of smoking multiplied by the number of packs of cigarettes smoked per day.
Table 8.6 Association between smoking and reproductive hormones in women
Study Population Sample/period
Definition of smoking
(number of smokers) Findings in smokers
Estimate of effect 











Former smokers (n = 23)




levels in FP similar to 
those in nonsmokers 
•		All	3	decreased	in	LP
•		Little	difference	from	
levels in former smokers
LP decreased 29% 
(10–43%)
Stronger effects in 
ovulatory cycles; 
adjustment for age; 
data on progesterone 
not presented
Michnovicz et al. 
1986
27 nonobese women with 
normal cycle length
Mean age ~30 years
Blood and urine 
samples over 48 hours 
after administration of 
radiolabeled estradiol
FP (days 1–10) in 
morning







Increased 50%, p 
<0.001 
Decreased 40%, p 
<0.01
No difference in 
FP vs. LP; age and 
BMI similar in 
nonsmokers and 
smokers,  




88 women (47 
premenopausal)
Mean age 50 years
Radiolabeled steroid 
infusion
Blood and urine 
samples at baseline
Smokers (23) 












estradiol or conversion 
from  
androgens
p <0.05 for 
metabolic 
clearance rates
NS in only 
premenopausal 
women 
No difference with 
adjustment for 
weight
Zumoff et al. 
1990
16 volunteers with normal 
ovulatory and luteal function
Aged 25–35 years
Blood samples on 17 













Increased 37% (p 
<0.0001) 
Increased 23% (p 













(number of smokers) Findings in smokers
Estimate of effect 
(95% CI or 
p value) Comments
Key et al. 1991 147 women with cycle 
lengths of 21–35 days tested 
for estradiol and progesterone 
Aged ≥35 years
Guernsey Breast Cancer 
Study
105 women tested for urinary 
steroids
24-hour urine and 1 
blood sample
Current smokers (1–10, 
11–20, ≥21 cigarettes/
day)
69 smokers tested 
for estradiol and 
progesterone 20 smokers 







NS Adjustment of serum 
values for cycle 
day, age, and BMI; 
adjustment of urine 
values for age, BMI, 
and parity
Berta et al. 1992 684 nonobese fertile women
Aged 25–52 years
24-hour urine sample 
and 3 blood samples on 
days 21–24 of LP
Smokers (237)







estradiol, FSH, and LH
Decreased 15% (p 
<0.05) 
Decreased 20% (p 
<0.002)
Results not affected 
by age




Some with family history of 
ovarian cancer
1 blood sample in early 
FP (days 1–3)









Effect of smoking 
still significant after 
adjustment for age




1 blood sample in early 
FP (days 2–4)
Self-reports on 
current smoking (31), 
former smoking, and 
involuntary and prenatal 
exposure
•		Mean	FSH	increased	in	
current smokers and 
those exposed to SHS
•		No	difference	in	FSH	in	




Increased 57% at 
<10 cigarettes/day 















(number of smokers) Findings in smokers
Estimate of effect 
(95% CI or 
p value) Comments
Key et al. 1996 167 women 
Aged ≥34 years 
Guernsey Breast Cancer 
Study
24-hour urine sample 
with timing known and 
periovulatory period 
excluded









30% for estriol in 
early FP
5–22% for estriol 
later in cycle
NS after adjustment 
for time of cycle, age, 
and BMI
Westhoff et al. 
1996
175 parous women with 
normal cycles
Aged 21–36 years
Urine sample on day 10 
to menses
Blood sample 3 times 
in LP
Self-reports, not defined 
(48)
•		No	difference	in	mean	LP	





21% decreased,  
p = 0.04




in estradiol); some 
dose-response effects
Backer et al. 
1999
3,114 women
Aged 35–60 years 
National Health and Nutrition 
Examination Survey (U.S. 
national sample)
1 convenient blood 
sample
Smoking during 5 days 
before examination
•		FSH	increased p <0.001 Cycle timing 
unknown, but tried 
to exclude samples 
obtained close to 
time of ovulation on 
basis of LH to FSH 
ratio
Lucero et al. 
2001
498 women not in depressive 
state 
Aged 36–44 years
Harvard Study of Moods and 
Cycles
1 blood sample in early 
FP (days 1–5)
Smoking not defined; 







12% increased,  
p <0.05
8% increased,  
p <0.05
42% increased, NS
No difference with 
former smoking; 
estradiol NS in 
adjusted model, 
but FSH values not 
adjusted; adjustment 
for age, BMI, calories, 






(number of smokers) Findings in smokers
Estimate of effect 
(95% CI or 
p value) Comments




1 blood sample in FP 
(days 3–7) annually for 
3 years
Lifetime nonsmokers, 











BMI, year, and 
reproductive status




Morning blood sample 
on random day (timing 
calculated)
Current smoker (yes/no) •		2a- and 16a-hy-
droxyestrone slightly 
increased before adjust-




19% increased,  
p = 0.06 
unadjusted, 
p = 0.76 adjusted
Adjustment for age, 
race, and cycle day
Windham et al. 
2005
403 women in reproductive 
years
Aged 18–39 years 
Members of Kaiser 
Permanente health 
maintenance organization
Daily urine collection 
through 2–7 cycles
Adjustment of hormone 
values for creatinine
Cigarettes/day from daily 
diary, averaged over cycle
Validated by cotinine








Adjustment for age, 
race, pregnancy 
history, BMI, and 
use of alcohol and 
caffeine; some dose-
response effects
Windham et al. 
2005
403 women in reproductive 
years
Aged 18–39 years 
Members of Kaiser 
Permanente health 
maintenance organization
Daily urine collection 
through 2–7 cycles
Adjustment of hormone 
values for creatinine
Cigarettes/day from daily 
diary, averaged over cycle
Validated by cotinine
100–150 cycles of 
smokers
•		Estrone	and	progesterone	
metabolites increased in 
early FP in smokers of 
≥10 cigarettes/day
25% and 35% 
increased, p <0.05
Adjustment for age, 
race, pregnancy 
history, BMI, and 
use of alcohol and 
caffeine; some dose-
response effects
Windham et al. 
2005
403 women in reproductive 
years
Aged 18–39 years 
Members of Kaiser 
Permanente health 
maintenance organization
Daily urine collection 
through 2–7 cycles
Adjustment of hormone 
values for creatinine
Cigarettes/day from daily 
diary, averaged over cycle
Validated by cotinine
100–150 cycles of 
smokers
•		Progesterone	decreased	
in LP in smokers of ≥20 
cigarettes/day
25% decreased,  
p = 0.06
Adjustment for age, 
race, pregnancy 
history, BMI, and 
use of alcohol and 
caffeine; some dose-
response effects
Table 8.7 Association between smoking and reproductive hormones in healthy men
Study Population Study period Definition of smoking Findings
Odds ratio/
response rate 
and 95% CI or  
p value Comments
Briggs 1973 6 healthy smokers
6 healthy nonsmokers
7 days >30 cigarettes/day •		Serum	testosterone	
lower in smokers (5.15 
+ 0.7 ng/mL) than in 
nonsmokers (7.47 + 0.53 
ng/mL) 
NR No men obese
Briggs 1973 6 healthy smokers
6 healthy nonsmokers
7 days >30 cigarettes/day •		Mean	increase	in	
testosterone after 7 days 
abstinence for smokers 
(1.65 + 0.5 ng/mL) but no 
change for nonsmokers
p <0.005 No men obese
Dotson et al. 
1975
91 university students 
attending  
simulated party
4 hours Number of cigarettes 
smoked
•		Testosterone	positively	
correlated with number 
of cigarettes smoked,  
r = 0.24
p <0.05 Study designed to 
look at testosterone 
levels, aggressive 




17 long-term male smokers 2 days smoking followed 
by day not smoking
8 cigarettes
2.8 mg of nicotine within 




hormone showed no 







All fathers of ≥2 children
3 consecutive days >20 cigarettes/day •		Smokers	had	higher	








All fathers of ≥2 children
3 consecutive days >20 cigarettes/day •		Serum	testosterone	was	
lower in smokers than in 







All fathers of ≥2 children




Study Population Study period Definition of smoking Findings
Odds ratio/
response rate 
and 95% CI or  
p value Comments
Wilkins et al. 
1982
10 long-term male smokers 
(≥1 pack/day  
of cigarettes with 1.0 mg of 
nicotine) 
2 days 2 cigarettes
2.0 mg vs. 0.2 mg of 
nicotine in 10 minutes
•		Prolactin	concentrations	
were significantly higher 
with high- vs. low-nico-
tine cigarettes 
•		150%	increase	in	pro-
lactin concentrations 30 
minutes after smoking 
cigarette with 2 mg of 
nicotine and remained 








Single blood sample >5 cigarettes/day for >2 
years
•		Plasma	testosterone	and	
free testosterone levels 
were higher in smokers 




Aged 20–39 years, 
p <0.001
Aged 40–59 years, 
p <0.01
Aged 60–80 years, 
p <0.05
Decrease in difference 
in plasma levels of 
testosterone and 
free testosterone 
in smokers vs. 
nonsmokers with 
increasing age
Klaiber et al. 
1984
Group I
23 healthy smokers  





Single fasting blood 
sample for estradiol
Not defined •		Higher	mean	serum	




ated with estradiol con-
centrations in smokers
•		Positive	correlation	with	
number of cigarettes 
smoked/day in analysis of 
pooled data from smokers 
and nonsmokers
Group I: p <0.03
Group II: p <0.001
Group I: r = 0.35, 
p <0.03
Group II: r = 0.73, 
p <0.001
Adjustment for age 
and alcohol intake





with blood sample 
obtained 120 minutes 
after smoking first 
cigarette
2 unfiltered cigarettes 
smoked in 10 minutes
•		Mean	prolactin	concen-
trations of 8.3 ng/mL for 









Study Population Study period Definition of smoking Findings
Odds ratio/
response rate 
and 95% CI or  
p value Comments
Seyler et al. 1986 4 healthy smokers
Average 22.5 cigarettes/day
2 experimental sessions 15 hours with no 
smoking followed by 
2 low-dose (0.48 mg) 
cigarettes smoked 5 
minutes apart or 2 high-
dose (2.87 mg) nicotine 
cigarettes smoked in 
rapid succession
•		No	differences	in	FSH,	
LH, prolactin, or thyroid-
stimulating hormone 
concentrations between 
baseline and either 






No history of heart disease or 
stroke
Rancho Bernardo, California
Enrollment 1972–1974 Lifetime nonsmokers, 





between groups in con-
centrations of testoster-
one or SHBG
   Adjustment for age, 
BMI, alcohol and 





No history of heart disease or 
stroke
Rancho Bernardo, California
Enrollment 1972–1974 Lifetime nonsmokers, 






p <0.001 Adjustment for age, 
BMI, alcohol and 





No history of heart disease or 
stroke
Rancho Bernardo, California
Enrollment 1972–1974 Lifetime nonsmokers, 






p <0.001 Adjustment for age, 
BMI, alcohol and 





No history of heart disease or 
stroke
Rancho Bernardo, California
Enrollment 1972–1974 Lifetime nonsmokers, 






p <0.02 Adjustment for age, 
BMI, alcohol and 





No history of heart disease or 
stroke
Rancho Bernardo, California
Enrollment 1972–1974 Lifetime nonsmokers, 






day for androstenedione, 
estrone, and estradiol, 
but not for testosterone 
and SHBG
p <0.001 Adjustment for age, 
BMI, alcohol and 
caffeine intake, and 
exercise
Table 8.7 Continued
Study Population Study period Definition of smoking Findings
Odds ratio/
response rate 
and 95% CI or  
p value Comments
Dai et al. 1988 121 men
Pittsburgh Multiple Risk 
Factor Intervention Trial







associated with number 
of cigarettes/day




pressure, and relative 
weight
Dai et al. 1988 121 men
Pittsburgh Multiple Risk 
Factor Intervention Trial







positively associated with 
number of cigarettes/day




pressure, and relative 
weight
Meikle et al. 
1989
75 healthy monozygotic twins
85 healthy dizygotic twins
1 set of healthy triplets
   Nonsmokers, former 
smokers, current 
smokers  
Packs/day for current 
smokers
•		Higher	DHT	concentra-
tions for current smokers 
than for nonsmokers
•		No	adjusted,	indepen-
dent effect of smoking 
for estrone, estradiol, 
testosterone, SHBG, LH, 
and FSH
p = 0.03 Study of effects 
of smoking on 
concentrations of 
sex steroid hormone 
through BMI




48 hours Lifetime nonsmokers vs. 
≥15 cigarettes/day
•		Estradiol	2-hydroxyl-
ation increased ~70% in 
smokers
p <0.001 None




48 hours Lifetime nonsmokers vs. 
≥15 cigarettes/day
•		Urinary	catechol	estrogen	
index significantly higher 
for smokers
p = 0.006 None
Field et al. 1994 1,241 healthy men
Boston area
341 male smokers
Enrollment 1987–1989 Cigarettes smoked/day •		Higher	androstenedione,	










Adjustment for age 
and BMI
Table 8.7 Continued
Study Population Study period Definition of smoking Findings
Odds ratio/
response rate 
and 95% CI or  
p value Comments
Sofikitis et al. 
1995










≥20 cigarettes/day for  
>3 years
•		Testicular	androgen-
binding protein lower in 
smokers
p <0.05 Included examination 
of testicular biopsy 
specimens
Sofikitis et al. 
1995










≥20 cigarettes/day for  
>3 years
•		Testicular	venous	testos-
terone lower in smokers
p <0.05 Included examination 
of testicular biopsy 
specimens
Sofikitis et al. 
1995










≥20 cigarettes/day for  
>3 years
•		Circulating	serum	FSH,	
LH, and testosterone con-
centrations not statisti-
cally different between 
smokers and nonsmokers
   Included examination 
of testicular biopsy 
specimens




NR Self-reported ≥10 
cigarettes/day
•		Cotinine	correlated	with	
SHBG (r = 0.49)
p <0.05 Matched on age and 
BMI




NR Self-reported ≥10 
cigarettes/day
•		Free	testosterone	and	
total testosterone higher 
in smokers
p = 0.03 Matched on age and 
BMI




NR Self-reported ≥10 
cigarettes/day
•		Bioavailable	testosterone	
did not differ between 
groups
   Matched on age and 
BMI




NR Self-reported ≥10 
cigarettes/day
•		17-β estradiol did not 
differ between group
p = 0.01 Matched on age and 
BMI
Table 8.7 Continued
Study Population Study period Definition of smoking Findings
Odds ratio/
response rate 
and 95% CI or  
p value Comments






1993–2000 Self-reported number of 
cigarettes/day
•  Increased LH and tes-
tosterone and decreased 
prolactin in smokers 










Testosterone lower in 
men who were able to 
stop smoking
Note: BMI = body mass index; CI = confidence interval; DHT = dihydrotestosterone; FSH = follicle-stimulating hormone; 
LH = luteinizing hormone; mg = milligrams; ng/mL = nanograms per milliliter; NR = not reported; NS = no significant difference; SHBG = sex hormone binding globulin.
Risk of IUGR with level of exposure to pollutant in first month
Pollutant/location Comparison by exposure AOR 95% CI
PM10          
Teplice Medium : low 1.44 1.03–2.02
Teplice High : low 2.14 1.42–3.23
Prachatice Medium : low 1.59 1.06–2.39
Prachatice High : low 1.09 0.49–2.46
PAH         
Teplice Medium : low 1.59 1.06–2.39
Teplice High : low 2.15 1.27–3.63
Prachatice Medium : low 1.49 0.81–2.73
Prachatice High : low 1.26 0.60–2.63
Increase in AOR for IUGR for each 10 µg of PM10 or 10 ng of PAH during first month*







*ORs adjusted for parity, maternal age and height, prepregnancy weight, education, marital status, season, year of study, and  
maternal smoking per month 
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A Vision for the Future  647
How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease
The Global Tobacco Epidemic
Tobacco use remains the leading preventable cause 
of premature death in the United States, and the World 
Health Organization (WHO) has called tobacco use “the 
single most preventable cause of death in the world today” 
(WHO 2008, p. 8). Predictions based on large population 
studies indicate that one-half of all long-term smokers, 
particularly those who began smoking in adolescence, 
will eventually die from their use of tobacco. Further-
more, one-half of the deaths caused by smoking will 
occur in middle age (35 through 69 years), resulting in 
the loss of 20 to 25 years of normal life expectancy (Peto 
et al. 1992, 2006; Doll et al. 1994). In the 45 years since 
the first U.S. Surgeon General’s report on smoking and 
health was published in 1964 (U.S. Department of Health, 
Education, and Welfare [USDHEW] 1964), smoking has 
been the primary underlying cause of more than 12 mil-
lion U.S. deaths. Each year since 2004, more than 430,000 
additional smoking-attributable deaths have been add-
ed to the national total (U.S. Department of Health and 
Human Services [USDHHS] 2004; Bonnie et al. 2007; 
Centers for Disease Control and Prevention [CDC] 2008a). 
It has been estimated that worldwide, tobacco use caused 
100 million deaths during the twentieth century, and that 
tobacco use may cause as many as 1 billion deaths in the 
twenty-first century, unless urgent and effective action is 
taken (WHO 2008).
Understanding the health consequences and dis-
eases caused by tobacco use has provided the scientific 
foundation for public health actions aimed at tobacco use 
prevention, cessation, and protection from secondhand 
smoke exposure. Since the first Surgeon General’s report, 
this series has considered research findings on mecha-
nisms of disease production in assessing the biologic plau-
sibility of associations observed in epidemiologic studies. 
The important contribution of evidence on biologic plau-
sibility and coherence in evaluation of causality has been 
reviewed in recent reports (USDHHS 2004, 2006). For 
example, evidence regarding the biologic plausibility of the 
observed relationship between exposure to secondhand 
smoke and coronary heart disease (CHD) has been very 
important in the evaluation of causality (USDHHS 2001, 
2006). In initial studies (e.g., Hirayama 1984; Garland 
et al. 1985), the estimated magnitude of the association 
between exposure to secondhand smoke and CHD seemed 
large compared with the association between active smok-
ing and CHD. However, further findings on mechanisms 
linking tobacco smoke exposure to CHD risk—in par-
ticular, the impact of tobacco smoke exposure on platelet 
aggregation and acute endothelial dysfunction—provided 
plausible and quantitatively consistent mechanisms for 
the observed nonlinear relationship with exposure levels 
to tobacco smoke (Glantz and Parmley 1991, 1995; Law 
et al. 1997). More recently, the potential effect of active 
smoking and exposure to secondhand smoke on breast 
cancer risk is an area for which data on biologic plausibil-
ity and mechanisms are critically needed in the evalua-
tion of potential causality (USDHHS 2006; International 
Agency for Research on Cancer [IARC] 2004; Miller et al. 
2007; Phillips and Garte 2008).
Despite the wealth of scientific evidence on the 
adverse health effects of exposure to tobacco smoke, many 
gaps remain in our understanding of the molecular and cel-
lular mechanisms of tobacco-induced diseases. It has been 
suggested that “given the obvious dangers of tobacco and the 
associated imperative to eliminate it, research undertaken 
purely to unravel mechanisms of tobacco-related cancer 
is difficult to justify” (Carlsten and Burke 2006, p. 2481). 
However, as discussed in Chapter 1, research to further 
understand the biologic mechanisms by which exposure 
to tobacco smoke causes disease has several important 
applications beyond assisting in the determination of 
causal relationships, including
	 •	 developing	biomarkers	of	injury	to	identify	smokers	
at early stages of disease development;
	 •	 providing	a	basis	for	preventive	therapies	that	block	
or reverse the underlying process of injury; 
	 •	 identifying	the	contribution	of	exposure	to	tobacco	
smoke to causation of diseases with multiple etio-
logic factors; and
	 •	 assessing	 tobacco	 products	 for	 their	 potential	 to	
cause injury through a particular mechanism.
Expanding our knowledge of several common 
molecular and cellular mechanisms underlying seemingly 
diverse smoking-induced diseases—such as dysregulation 
of inflammatory and immune processes (including oxida-
tive stress, altered antibody production, endothelial cell 
dysfunction, suppression of T cells) and the dysregulation 
of inflammatory cells—could have important implications 
in the potential development of novel therapeutic targets 
for various environmentally induced diseases (Wang and 
Scott 2005). For example, with growing understanding 
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of genetic and epigenetic mechanisms, opportunities are 
expanding to address the broader applications of disease 
mechanisms related to exposure to tobacco smoke (Estell-
er 2008; Herbst et al. 2008; Caporaso et al. 2009; Breton et 
al. 2009; National Cancer Institute [NCI] 2009). As noted 
in the 2007–2008 Annual Report of the President’s Cancer 
Panel, “…even if all current smokers cease using tobacco 
today and no new smokers take up the habit, the latency 
of tobacco-caused cancer and other diseases dictates that 
cancer and other morbidity and mortality from tobacco 
will still be affecting our population for at least another 
two decades” (Reuben 2008, p. 57). A list of research pri-
orities identified in this report is provided in Appendix 9.1.
A key feature of tobacco use is the development of 
nicotine addiction, which often leads to chronic, daily 
exposure to tobacco that typically persists for many years. 
As reviewed in Chapter 4 of this report, addiction, or more 
technically the diseases of dependence and withdrawal, 
make it essential to ensure that effective behavioral and 
pharmacological cessation treatments are widely available 
and accessible to diverse populations of smokers (Zaza et 
al. 2005; National Institutes of Health [NIH] State-of-the-
Science Panel 2006). The various treatments for tobacco 
use have targeted different aspects of nicotine addiction, 
such as reinforcement, withdrawal, and cue-associated 
learning. Pharmacologic treatments have included nico-
tinic acetylcholine receptor ligands (nicotine replace-
ment, and varenicline, a partial α4β2 agonist) or have 
involved alterations in signal transduction to stimulate 
the release of the same neurochemicals that are released 
by nicotine (e.g., bupropion and nortriptyline). Ideally, 
those who smoke would find it as easy to access cessation 
services as they do commercial tobacco products (Fiore et 
al. 2008). 
Effective public health and clinical approaches to 
increase smoking cessation rates have been developed 
(USDHHS 2000; Zaza et al. 2005; Bonnie et al. 2007; Reu-
ben 2007; Fiore et al. 2008). These public health strategies 
and the clinical treatments need to be more fully imple-
mented. 
Significant progress has been achieved in the United 
States during the last 50 years in reducing smoking initia-
tion and increasing smoking cessation (Bonnie et al. 2007; 
Reuben 2007; Cokkinides et al. 2009). After 30 years of 
declining rates of smoking, particularly among men, the 
total U.S. cancer deaths began to decline in the late 1990s, 
driven largely by a reduction in male lung cancer deaths 
(Cokkinides et al. 2009). Moreover, the declines in lung 
cancer death rates among men and women in Califor-
nia declined more rapidly than in the rest of the country 
after the implementation of a comprehensive and sus-
tained statewide tobacco control program (Barnoya and 
Glantz 2004; Jemal et al. 2008).
Today, an estimated one-half of all Americans who 
have ever smoked have quit (CDC 2008a, 2009a), and the 
benefits of cessation have been documented for smokers 
of all ages (USDHHS 1990; IARC 2007a). However, as a 
group, smokers who successfully quit early in life can 
avoid a large proportion of the excess mortality caused 
by smoking (USDHHS 1990; IARC 2007a). Data from the 
British Doctors’ Study have been used to demonstrate the 
lifetime risks of smoking and the amount of that risk that 
can be avoided by sustained cessation at various ages (Doll 
et al. 2004). Figure 9.1 contrasts the cumulative survival 
curves for all-cause mortality of continuing smokers (blue 
lines), with never smokers (red lines), and with smokers 
who quit by various ages (e.g., effect from sustained quit-
ting at ages 35, 40, 50, and 60 years). The survival curves 
demonstrate that even at older ages, a substantial and 
important fraction of the excess all-cause mortality due to 
smoking can be averted by sustained quitting. Nonethe-
less, smokers who quit after the age of 44 years continue 
to have excess risk for tobacco-related diseases. 
As noted in Chapter 6, cigarette smoking is a 
major cause of cardiovascular disease (CVD) and has 
multiplicative interactions with the other major risk fac-
tors for CHD. Importantly, although there is a strong 
dose-response relationship between the number of 
cigarettes smoked per day and cardiovascular risk, 
the relationship is not linear, with those who smoke 
few cigarettes per day or who do not smoke every day 
remaining at significantly elevated risk for CVD. It has 
been estimated that one-fifth of U.S. smokers are inter-
mittent or occasional smokers (CDC 2008a), and this 
pattern of use is more common among some racial and 
ethnic groups, including Blacks and Hispanics, and smok-
ers living below the poverty level (Fagan and Rigotti 
2009). This emphasizes the importance of increasing our 
understanding of the process of smoking and quitting and 
of providing appropriate cessation services to this group 
of smokers.
The time course of reduction of risk after quitting 
smoking varies substantially across disease outcomes, 
with the risk of CHD declining more rapidly than the 
risk of tobacco-related cancers, particularly among those 
with a longer duration of smoking before sustained quit-
ting (USDHHS 1990; IARC 2007a). The continued excess 
risk of lung cancer among former smokers has focused 
attention on the need to better identify those at greatest 
risk and to develop effective methods of early detection 
(Black and Baron 2007; Dubey and Powell 2008; Field and 
Duffy 2008). More than one-half of all cases of lung can-
cer are diagnosed at an advanced stage, and the five-year 
survival rate for lung cancer remains at about 15 percent 
(Jemal et al. 2008). At present, the efficacy of screening 
for lung cancer with low-dose computed tomography or 
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other methodologies remains controversial (Black and 
Baron 2007). A better understanding of the molecular and 
cellular pathways involved in respiratory carcinogenesis 
could increase the feasibility of chemoprevention trials or 
of more cost-effective application of lung cancer screening 
(Alberg et al. 2005; Dubey and Powell 2008; Field 2008).
Recent advances in the understanding of the molec-
ular origins of lung cancer have focused attention on the 
possibility that molecular profiling of genes and proteins 
could lead to the development of biomarkers for defining 
cancer risk, prognosis, and potentially improved treat-
ment for some of the even more difficult to manage 
types of lung cancer (Herbst et al. 2008). The evidence 
reviewed in Chapter 5 on the major established pathways 
of cancer causation by cigarette smoking identifies impor-
tant steps along these mechanistic pathways that could 
be used in potential biomarkers for defining cancer risk, 
prognosis, and potentially improved treatment. Figure 9.2 
graphically presents how molecular profiling and assess-
ments of genes and proteins could influence decisions 
regarding lung cancer treatment options for individ- 
ual patients.
Chronic obstructive pulmonary disease (COPD) 
remains a leading cause of death in the United States, and 
in 2005, approximately 1 in 20 deaths in the United States 
had COPD as the underlying cause, with an estimated 75 
percent of these COPD deaths attributable to smoking 
(CDC 2008b). While the U.S. trend in COPD deaths has 
remained fairly stable from 2000 to 2005 (CDC 2008b), the 
global burden of COPD is increasing (Mannino and Buist 
2007; Barnes 2007). Importantly, the evidence indicates 
that in the United States, COPD could be almost com-
pletely prevented by the elimination of smoking (USDHHS 
2004). Although the risks for COPD morbidity and mortal-
ity decline with smoking cessation, they may not return to 
the levels of nonsmokers (USDHHS 2004). The U.S. Lung 
Health Study documented the benefits of substantially 
reduced mortality among individuals with asymptomatic 
airway obstruction who quit smoking (Anthonisen et al. 
2005). The U.S. Lung Health Study also documented the 
benefits of providing an intensive 10-week smoking cessa-
tion program to this at-risk population; nearly 22 percent 
of intervention participants succeeded in quitting smok-
ing compared with only 5.4 percent of participants who 
received usual care (Anthonisen et al. 2005). These results 
emphasize that rates of smoking cessation among patients 
most at risk of COPD could be increased up to fourfold 
if current available smoking cessation treatment options 
were delivered more routinely. 
Figure 9.1 Effects on survival of stopping smoking 
cigarettes at ages 25–34 years (effect 
from age 35), ages 35–44 years (effect 
from age 40), ages 45–54 years (effect 
from age 50), and ages 55–64 years  
(effect from age 60) 
Source: Doll et al. 2004. Reprinted with permission from BMJ 
Publishing Group Ltd., © 2004.
Numerous studies have shown that COPD is asso-
ciated with lung cancer risk; this association may be 
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attributed to shared exposure to cigarette smoke, to 
shared genetic susceptibility, and/or to facilitation of 
tumor initiation and promotion by inflammation (Dubey 
and Powell 2008). The growing global burden of COPD 
emphasizes the need for research to develop biomark-
ers of injury to identify smokers at early stages of disease 
development and to provide a basis for preventive ther-
apies that block or reverse the underlying process of 
injury, particularly among former smokers. Research 
in this area may be guided by the evidence reviewed in 
Chapter 7, which identifies the two major mechanisms 
underlying the causation of COPD by cigarette smoking, 
oxidative stress (injury) and protease-antiprotease imbal-
ance, and the strong association between COPD occur-
rence and a specific genetic disorder: AAT deficiency.
As noted in Chapter 8, health professionals have 
long known that exposure to tobacco smoke during 
pregnancy poses serious risks to fetal development. 
Figure 9.2 Molecular-profiling approaches to the development of personalized therapy
Source: Herbst et al. 2008. Reprinted with permission from Massachusetts Medical Society, © 2008.
Note: Host profiling involves innate characteristics of the cancer patient. All markers that are involved in profiling lung cancer can 
apply to the tumor or its local environment. Predictive markers identify groups of patients who are likely to have increased sensitivity 
or resistance to a given therapy, a critical step in personalizing treatment. It has been traditional to assess individual genetic or pro-
tein prognostic or predictive markers (e.g., HER2 for breast cancer), but emerging techniques permit global analyses of the genomic, 
gene-expression, epigenetic, and protein profiles of the host (innate), including markers in blood and in tumor or nonmalignant lung 
tissue. These methods include SNP arrays to assess genomic alterations, bisulfite sequencing, and methylation-specific PCR to assess 
epigenetic changes, microarrays for assessing gene expression or microRNA levels, and proteomic methods (such as mass spectros-
copy, reverse-phase protein arrays, and multiplex beads) to assess intracellular signaling in tumor tissue and cytokines and angiogenic 
factors in blood. Blood-based profiling includes markers derived from the host (e.g., lymphocytes) and the tumor and local  
environment (e.g., circulating tumor cells and tumor-derived cytokines) (red arrows); IHC = immunohistochemical analysis;  
PCR = polymerase chain reaction; SNP = single nucleotide polymorphism.
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Despite this, approximately 19 percent of women of 
reproductive age smoke cigarettes, and based on birth 
certificate data, more than 1 in 10 (11.4 percent) wom-
en reported smoking during pregnancy (CDC 2004, 
2008a). However, birth certificate data often underre-
port smoking during pregnancy. In survey data from 
2002 to 2005, 17.3 percent of pregnant women reported 
smoking cigarettes in the month preceding the survey 
(NSDUH Report 2007). In addition, many pregnant wom-
en who do not smoke are exposed to secondhand smoke in 
workplaces, public places, and in their own homes. Rec-
ommendations have been made regarding the types of 
smoking cessation services that should be provided to all 
pregnant smokers (Fiore et al. 2008). Despite the docu-
mented costs of poor infant outcomes caused by smoking 
during pregnancy, and the higher prevalence of prenatal 
tobacco use found among lower income women, in 2006 
only 27 states covered tobacco cessation counseling ser-
vices for pregnant women in their Medicaid populations 
(CDC 2008e). 
Reducing the Risks from Smoking
The benefits of quitting have been shown for smok-
ers of all ages (USDHHS 1990, 2004; IARC 2007a). Smok-
ers who quit completely and permanently early in life 
have a risk of premature death very similar to lifetime 
nonsmokers (Figure 9.1) (USDHHS 1990, 2004; IARC 
2007a). However, for lung cancer, there is a persistent 
elevated risk in former smokers compared with lifetime 
nonsmokers of the same age even after a long abstinence 
(IARC 2007a). Evidence indicates that lung cancer risk 
increases far more strongly with each additional year 
of smoking than it increases for a higher average num-
ber of cigarettes smoked per day (Flanders et al. 2003; 
IARC 2007a). Although sustained smoking cessation 
at any age produces substantial reductions in risk, sig-
nificant health benefits (other than for the fetus during 
pregnancy) from reducing the amount smoked or from 
short-term cessation have not been demonstrated (Ben-
hamou et al. 1989; Godtfredsen et al. 2002; Anthonisen et 
al. 2005; Tverdal and Bjartveit 2006; IARC 2007a; Bjart-
veit and Tverdal 2009). The evidence presented in this 
report on the biologic mechanisms by which exposure to 
tobacco smoke causes cancers, cardiovascular and chron-
ic obstructive pulmonary diseases, and reproductive and 
developmental effects document the importance of smok-
ers quitting completely early in life and avoiding even 
occasional or infrequent smoking.
As reviewed in Chapter 2, in recent years a range 
of new products have been introduced and marketed to 
smokers as an alternative to conventional cigarettes, 
sometimes accompanied by messages, explicit or implied, 
that they offer reduced exposure to toxic substances or 
risk of disease. Evidence reviewed in this and previous 
reports indicates that five decades of evolving cigarette 
design have not reduced overall disease risk among smok-
ers, and new designs can be used to undermine prevention 
and cessation efforts. It is now recognized that substantial 
risks may be associated with new tobacco products:
1. Smokers who might have otherwise stopped smoking 
may continue to smoke because of perceived reduc-
tion in risk with use of new products.
2. Former smokers may resume smoking because of 
perceived reduction in risk with use of new products.
3. Nonsmokers, particularly youth, may start to use new 
products because of their perceived safety.
The evidence reviewed in this report highlights 
many of the scientific challenges that will be faced in eval-
uating new cigarette products presented as alternatives to 
conventional cigarettes, because of the diversity of such 
products, the multitude of smoking-related diseases, the 
impact of these products on nonusers, and the dearth of 
empirical data on their effects. The Institute of Medicine 
(IOM) Committee to Assess the Science Base for Tobacco 
Harm Reduction (Stratton et al. 2001) and more recent 
reviews (Gray et al. 2005; Royal College of Physicians of 
London 2007; European Commission 2008) have discussed 
the potential role in tobacco control of a wider range of al-
ternatives to the current cigarette. Several questions need 
to be carefully considered when proposing novel tobacco 
products as strategies to reducing smoking-attributable 
mortality: Do these products decrease individual risk? Do 
they increase initiation of tobacco use or promote relapse? 
Do they delay cessation? Do they lead to dual product use? 
How does their use compare to cessation? As discussed in 
Chapter 2, in the absence of a sound science base to sup-
port such alternative strategies, the primary public health 
approaches remain prevention and cessation of all forms 
of tobacco products. 
Chapter 4 in this report documents the impor-
tance of nicotine as the drug causing the addiction that 
is the fundamental reason that individuals persist in 
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using tobacco products. However, other constituents in 
tobacco and tobacco smoke may also be reinforcing or may 
facilitate the reinforcing effects of nicotine. The factors 
contributing to the high addiction potential of tobacco 
products are multiple and complex. Understanding these 
relationships is critical in developing better treatments for 
cessation and for determining appropriate strategies to 
reduce use of tobacco products (Benowitz and Henning-
field 1994; Henningfield et al. 1998, 2004; Gray et al. 2005; 
Benowitz et al. 2006; Royal College of Physicians of Lon-
don 2007; Benowitz 2008; Zeller et al. 2009).  
The evidence on the CVD risks of low levels of 
tobacco smoke exposure in Chapter 6 of this report clearly 
demonstrate that the dose response for CVD is not linear, 
with risk rising rapidly at low doses and then plateauing 
at relatively low levels of exposure. The data on CVD also 
demonstrates the potential for dual tobacco product use 
resulting in a greater risk of disease than either prod-
uct alone (Teo et al. 2006). Additional research to iden-
tify those toxicants in tobacco products that are most 
responsible for acute cardiac risks is critically needed 
(Boffetta and Straif 2009).
As reviewed in this and prior reports, the risk of 
lung and other cancers, as well as COPD, increases dra-
matically with greater duration of smoking. In addition, 
dual use of cigarettes along with other tobacco products 
could not only result in delays in sustained smoking ces-
sation but may also increase the risk of disease more than 
cigarette smoking alone. If the use of alternative tobacco 
products hinders tobacco prevention and cessation efforts 
and results in longer durations of smoking among some 
smokers, the population burden of tobacco-related mor-
bidity and mortality would be higher than for an approach 
focused on helping these smokers quit completely. In 
addition, tobacco products used in places where smoking 
is not allowed may defeat public health efforts to reduce 
smoking rates. Thus, there are continuing concerns about 
the population health impact of tobacco product modifi-
cation or alternatives to cigarettes (Stratton et al. 2001; 
European Commission 2008). 
Ending the Tobacco Epidemic
Since the health risks of tobacco use were first 
identified, the public health response has focused on pre-
venting initiation of tobacco use, encouraging cessation 
among existing users, and more recently, protecting non-
smokers from exposure to secondhand smoke. Although 
the primary focus of previous Surgeon General’s reports 
has been a review of scientific evidence related to health 
effects of tobacco use, numerous reports have provided 
specific recommendations to reduce the use of tobacco and 
exposure to secondhand smoke (Lynch and Bonnie 1994; 
USDHHS 2000; Zaza et al. 2005; NIH State-of-the-Science 
Panel 2006; Bonnie et al. 2007; Reuben 2007; Fiore et al. 
2008). Effective public health and clinical approaches to 
increase smoking cessation rates have been developed 
and need to be more fully implemented (USDHHS 2000; 
Zaza et al. 2005; Bonnie et al. 2007; Reuben 2007; Fiore et 
al. 2008). 
The IOM report, Ending the Tobacco Problem: A 
Blueprint for the Nation, concluded that the ultimate 
goal is “to reduce smoking so substantially that it is no 
longer a significant public health problem” (Bonnie et 
al. 2007, p. 1). The report proposed a two-pronged strat-
egy to accomplish this goal: first, to strengthen and fully 
implement traditional tobacco control measures known 
to be effective, and second, to change the regulatory 
landscape to permit policy innovations such as strong fed-
eral regulation of tobacco products and their marketing 
and distribution (Bonnie et al. 2007). A complete list of 
the 42 recommendations made by the IOM report is pro-
vided in Appendix 9.2. In addition, the President’s Cancer 
Panel has highlighted the critical importance of reducing 
tobacco use stating that “ridding the nation of tobacco is 
the single most important action needed to dramatically 
reduce cancer mortality and morbidity” (Reuben 2008, p. 
iii) and that “if the population ceased smoking, this single 
behavior change would be tantamount to a vaccine against 
one-third of cancer deaths” (Reuben 2007, p. vi). 
In its 2006–2007 Annual Report, the President’s 
Cancer Panel provided a detailed review of the status of 
tobacco control efforts in this country to address tobac-
co use prevention and treatment (Chapter 4) and envi-
ronmental tobacco smoke exposure (Chapter 5). In this 
review, the President’s Cancer Panel outlined the impor-
tant roles in reducing tobacco-caused death and disease 
that could be undertaken by federal, state, and local gov-
ernments; nongovernmental organizations and other 
partners; the educational system; employers, insurance, 
and the health care system; and individuals and families 
(Reuben 2007). Many of these actions are very consistent 
with the 42 recommendations made by IOM (Appendix 
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9.2) and emphasize the evidence-based methods identi-
fied by the 2006 NIH State-of-the-Science consensus con-
ference (NIH State-of-the-Science Panel 2006). The 15 
recommendations from the President’s Cancer Panel are 
provided in Appendix 9.3.
Since the release of the recommendations from 
IOM (Bonnie et al. 2007) and the President’s Cancer Panel 
review of the status of tobacco control in this country 
(Reuben 2007), additional actions have been taken at the 
federal, state, and local levels. Below is a summary of the 
status of tobacco control efforts in this country within the 
WHO MPOWER framework (WHO 2008):
	 •	 Monitor tobacco use and prevention policies.
	 •	 Protect people from tobacco smoke.
	 •	 Offer help to quit tobacco use.
	 •	 Warn about the dangers of tobacco use.
	 •	 Enforce comprehensive restrictions on tobacco 
advertising, promotion, and sponsorship.
	 •	 Raise taxes on tobacco.
MONITOR. The monitoring of the population pat-
tern of tobacco use and the status of prevention and con-
trol policies and programs has been defined as essential 
in national efforts to counter the tobacco epidemic (WHO 
2008; Giovino et al. 2009). Current efforts to monitor 
the tobacco use epidemic and identify additional steps to 
optimize measurement of tobacco use and factors influ-
encing use in the United States have been reviewed (Cruz 
2009; Delnevo and Bauer 2009; Farrelly 2009; Giovino 
et al. 2009; Stellman and Djordjevic 2009). These papers 
provide detailed analysis of national tobacco monitoring, 
research, and evaluation under the classic Agent, Host, 
Vector, and Environment framework. These reviews indi-
cate that many of the most important basic elements of a 
national monitoring system are in place but that several 
key elements are needed to improve the system. 
PROTECT. This report provides additional scien-
tific evidence that there is no risk-free level of exposure 
to tobacco smoke. Although progress has been made to 
increase protection of nonsmokers in the United States 
from secondhand smoke exposure since the release of 
the 2006 Surgeon General’s report on the health conse-
quences of involuntary exposure to tobacco smoke (CDC 
2008f), biomonitoring of exposure indicates that almost 
one-half of nonsmokers, and more than 60 percent of 
young children, continue to be exposed (CDC 2008c). 
Wide geographic, occupational, and demographic dis-
parities remain (CDC 2008c,f). It has been estimated that 
only about one in three residents of the United States live 
under state or local laws that make worksites, restaurants, 
and bars completely smoke-free (CDC 2008f).
OFFER. The U.S. Tobacco Use and Dependence 
Guideline Panel has identified the most effective interven-
tions to assist tobacco users to successfully quit (Fiore et 
al. 2008). Moreover, a systematic review and analysis of 
recommended clinical preventive services has identified 
clinical smoking cessation services as one of the most 
successful and cost-effective recommendations (Maciosek 
et al. 2006). However, data indicate that less than 30 per-
cent of smokers are offered assistance in quitting annu-
ally (Partnership for Prevention 2008). Both IOM and the 
President’s Cancer Panel address this issue in their recom-
mendations (Appendices 9.2 and 9.3).
WARN. WHO recommends that national efforts to 
warn about the dangers of tobacco should create high lev-
els of awareness of the health risks of tobacco use across 
age groups, genders, and places of residence so all people 
understand that the result of tobacco use is often suf-
fering, disfigurement, and early death (WHO 2008). The 
President’s Cancer Panel noted that the warning labels 
on tobacco products in many other countries are larger 
and more graphic than those on U.S. cigarette packages 
(see figure 17, page 74, Reuben 2007). The Federal Ciga-
rette Labeling and Advertising Act of 1965 (the Cigarette 
Act) and the Comprehensive Smokeless Tobacco Health 
Education Act of 1986 (the Smokeless Act), as amended 
by the Family Smoking Prevention and Tobacco Control 
Act (Tobacco Control Act) (2009), require new, stronger 
warning statements on cigarette and smokeless tobacco 
packages and advertising and require color graphics 
depicting the negative health consequences of smok-
ing on cigarette packages and advertising. The Tobacco 
Control Act further amends the Cigarette Act and the 
Smokeless Act to give the U.S. Food and Drug Admin-
istration the authority to revise the warning label state-
ments and the color graphics for both cigarettes and 
smokeless tobacco through rulemaking. In addition to 
potential changes in package warning labels, evidence 
supports the effectiveness of health communication and 
countermarketing strategies employing a wide range of 
efforts, including paid television, radio, billboard, print, 
and Web-based advertising at the national, state, and 
local levels; media advocacy through public relations 
efforts; and efforts to reduce or replace tobacco industry 
sponsorship and promotions (CDC 2007; NCI 2008). Rec-
ommendations 15 and 16 from IOM address the need for 
a national, youth-oriented, countermarketing campaign 
as well as increased mass media and other general and 
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targeted public education programs to promote effective 
cessation programs and activities (Appendix 9.2) (Bonnie 
et al. 2007).
ENFORCE. Both the 2007 IOM and 2006–2007 Pres-
ident’s Cancer Panel reports have identified the sophisti-
cated strategies used by the tobacco industry to counter 
policies and programs to reduce tobacco consumption 
(Bonnie et al. 2007; Reuben 2007). Cigarettes remain one 
of the most heavily marketed products in the United States, 
with more than $250 billion (in 2006 dollars) expended 
between 1940 and 2005 on cigarette advertising and 
promotion (NCI 2008). The influence of these tobacco 
industry efforts in shaping tobacco-related knowledge, 
opinions, attitudes, and behavior was reviewed in detail, 
and it was concluded that the total weight of evidence 
demonstrated a causal relationship between tobacco 
advertising and promotion and increased tobacco use 
(NCI 2008). The Tobacco Control Act will enable new 
actions to be taken at the federal, state, and local levels to 
counteract the influence of tobacco advertising, promo-
tions, and sponsorship.
RAISE. With the increase in the federal excise tax 
on cigarettes from $0.24 to $1.01 on April 1, 2009, the 
combined federal and average state cigarette excise tax 
increased to $2.21 per pack (CDC 2009b). Evidence-based 
reviews have concluded that increases in the price of 
cigarettes through excise taxes or other strategies are an 
effective policy intervention to prevent smoking initia-
tion among adolescents and young adults, reduce ciga-
rette consumption, and increase the number of smokers 
who quit (USDHHS 2000; Zaza et al. 2005; NIH State-of-
the-Science 2006; Bonnie et al. 2007; CDC 2007; Reuben 
2007). Additionally, the WHO MPOWER recommendations 
emphasize the importance of ensuring that the tax rates 
on tobacco products are adjusted periodically to keep pace 
with inflation and rise faster than consumer purchasing 
power. WHO also stresses that implementation of effec-
tive strategies to limit smuggling and the availability of 
untaxed tobacco products is essential to maximizing the 
effectiveness of higher taxes in reducing tobacco use 
(WHO 2008). 
Concluding Remarks
In 1964, the Surgeon General’s Advisory Commit-
tee concluded: “Cigarette smoking is a health hazard of 
sufficient importance in the United States to warrant 
appropriate remedial action” (USDHEW 1964, p. 33). 
Evidence-based recommendations have helped to define 
appropriate remedial actions, including those from the 
2000 Surgeon General’s report on reducing tobacco use 
(USDHHS 2000), NIH (NIH State-of-the-Science Panel 
2006), the Task Force on Community Preventive Servic-
es (Zaza et al. 2005), IOM reports (Stratton et al. 2001; 
Bonnie et al. 2007), and President’s Cancer Panel reports 
(Reuben 2007, 2008). The specific scientific conclusions 
from this report may provide further guidance for devel-
oping additional remedial actions. 
Despite significant progress, tobacco use remains 
the single most preventable cause of death and disease 
in the United States. It is worth noting that lung cancer 
was once a very rare disease. Primary Malignant Growths 
of the Lungs and Bronchi, published in 1912, reviewed 
the worldwide scientific literature and was able to identify 
only 374 verified cases of lung cancer (Adler 1912; Spi-
ro and Silvestri 2005). In stark contrast, lung cancer is 
today the nation’s leading cause of cancer death among 
both men and women, killing an estimated 160,000 people 
in the United States, and an estimated 1.34 million people 
worldwide each year (Jemal et al. 2008; WHO 2008). An 
estimated 90 percent of U.S. lung cancer deaths in men 
and 80 percent of U.S. lung cancer deaths in women are 
caused by smoking and exposure to secondhand smoke 
(CDC 2009c). In addition, more than 100,000 deaths from 
pulmonary diseases and more than 140,000 deaths from 
heart disease and stroke in the United States are caused 
each year by active smoking and exposure to secondhand 
smoke (CDC 2008d). 
Since the publication of the 1964 Surgeon General’s 
report on smoking and health, this series of reports has 
provided an incontrovertible body of research evidence 
documenting the burden of sickness and death caused by 
tobacco use. Faced with these facts, it is appropriate to 
restate the challenge issued by a former Director-General 
of WHO, Dr. Gro Harlem Brundtland, at the start of the 
international negotiations that led to the landmark 
Framework Convention on Tobacco Control:
If we do not act decisively today, a hundred years 
from now our grandchildren and their children 
will look back and seriously question how people 
claiming to be committed to public health and 
social justice allowed the tobacco epidemic to  
unfold unchecked (Brundtland 1999).
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Appendix 9.1  
Recommendations for Future Research
The evidence reviewed within this report identified 
important gaps in our scientific knowledge that merit 
greater attention in future research. Below is a listing of 
areas of research that can substantially contribute to a 
better understanding of how tobacco use causes disease.
Nicotine Addiction
With the emerging science base for understand-
ing the physiological, behavioral, and cognitive bases for 
addiction and for identifying the genetics and other 
host factors that may moderate the effects of nicotine, 
new types of interventions are being developed that are 
expanding the treatment armamentarium, thus provid-
ing more effective interventions for those who continue 
to have difficulty in quitting smoking. For example, phar-
macologic treatments are being marketed that target 
specific nicotinic receptors responsible for the reinforc-
ing effects of nicotine, such as varenicline (Gonzales et 
al. 2006; Jorenby et al. 2006; Nides et al. 2006; Oncken 
et al. 2006). Nicotine immunotherapies (vaccines) under 
development also offer potential treatments for nicotine 
addiction. Nicotine immunotherapies stimulate the 
immune system to develop antibodies to nicotine that 
reduce the level and speed of nicotine entering the brain, 
potentially changing the pharmacokinetics of nicotine and 
thereby reducing the reinforcing effects of nicotine (Pentel 
2004; Hatsukami et al. 2005). Another area of major devel-
opment in the treatment of smokers, as with the treatment 
of other diseases, involves tailoring treatments to the phe-
notype and genotype of the individuals to select the most 
efficacious treatments (Lerman and Niaura 2002). All of 
these treatment developments have been aided by greatly 
expanded understanding of the mechanisms of depen-
dence and withdrawal during the past two decades.
Valid indicators and biomarkers of addiction are 
needed to assess future “less addictive” or “less toxic” 
tobacco products and treatments and to provide a better 
understanding of the addictive process. Many subjective 
and behavioral measures and some cognitive measures 
have been developed and used to test addiction to tobacco. 
However, fundamental gaps in knowledge exist, and other 
areas need to be more vigorously pursued.
Biomarkers for Addiction Potential
Table 9.1 summarizes the methods used for ani-
mal and human testing to assess the addiction potential 
of a nicotine product. Most of these methods have been 
referred to in Chapter 4 of this report. Although there 
are many subjective and behavioral methods, researchers 
have devoted little attention to cognitive and neurophysi-
ological measures of addiction through the use of func-
tional magnetic resonance imaging or positron emission 
tomography. Using more precise tools to assess and bet-
ter understand learning processes, decision making, and 
brain changes associated with addiction will lead to the 
development of measurements in these areas. The limita-
tions and questions associated with the measures listed in 
Table 9.1 are similar to those concerning the diagnosis of 
tobacco addiction or, for that matter, biomarkers for dis-
ease in general. That is, other than relative terms (e.g., 
product A has a greater abuse potential than does prod-
uct B) or the occurrence of addiction, the threshold or 
criterion that determines the extent of abuse potential is 
unknown. 
Future Directions in Understanding Addiction
Several areas of research that can substantially con-
tribute to a better understanding of nicotine addiction 
include—but are not limited to—the following:
	 •	 Improve	understanding	of	the	criteria	for	and	mea-
sures of nicotine addiction or dependence and how 
they might differ across various populations, includ-
ing youth and ethnic minorities.
	 •	 Adapt	commonly	used	measures	of	assessing	addic- 
tion to cigarettes to other tobacco products as dem-
onstrated by preliminary efforts to develop and 
validate scales for smokeless tobacco dependence 
and, most recently, to waterpipe smoking.
	 •	 Develop	 a	 better	 understanding	 of	 the	 contribu-
tion of the design features of tobacco products 
and of constituents other than nicotine that play 
an important role in all aspects of nicotine addic-










 − Somatic signs








 − Negative affect
 − Performance
 − Physiological (e.g., heart rate, weight)
 − Acoustic startle response
•	 Physiological	reactivity	toward	smoking-related	stimuli
•	 Cue-induced	craving





Biochemical measures of addiction
•	 Cotinine/nicotine	level
Cognitive indications of addiction 
•	 Attentional	bias	toward	smoking-related	stimuli
Neurophysiological biomarkers of addiction potential or addiction
•	 Extent	of	brain	activity	in	response	to	nicotine
•	 Extent	of	brain	activity	in	response	to	cues
	 •	 Use	 current	 knowledge	 of	 the	 neurosystems	 
associated with the reinforcement, withdrawal, 
and conditioning effects of nicotine addiction to 
develop a strategic road map for future discoveries 
in this area.
	 •	 Move	toward	a	better	understanding	of	the	role	and	
neurobiology of associative learning and cognitive 
processing in the development of and recovery from 
nicotine addiction.
	 •	 Foster	 an	 interdisciplinary	 effort	 to	 develop	 links	
among genotypes, endophenotypes, phenotypes, 
and the neurobiologic effects of nicotine.
	 •	 Explore	 the	 differences	 between	 adolescents	 and	
adults in their sensitivity to nicotine and to other 
factors associated with tobacco use, and find out 
which factors contribute to these differences (e.g., 
stage of neurodevelopment, sex hormones).
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	 •	 Increase	understanding	of	the	relationship	between	
comorbid disorders and nicotine addiction, includ-
ing the common neural pathways and psychosocial 
vulnerabilities, and the mechanisms associated with 
an increased risk of nicotine addiction. 
Cancer
Even though the evidence has long been sufficient 
to infer that both active and involuntary smoking cause at 
least 15 types of cancer, the long latency of tobacco-caused 
cancers emphasizes the need for further research on the 
mechanisms by which exposure to tobacco causes cancer. 
Several areas of research that can substantially contribute 
to a better understanding of these mechanisms include—
but are not limited to—the following:
	 •	 Investigate	genetic	polymorphisms	and	phenotypic	
variations among smokers in critical aspects of the 
carcinogenic process that may lead to variations in 
susceptibility to the carcinogens in tobacco smoke. 
Examples include differences in carcinogen- and 
nicotine-metabolizing enzymes and their prod-
ucts, DNA repair genes, and cell cycle genes. This 
research could lead to the identification of individu-
als who are particularly susceptible to the effects of 
tobacco smoke and who could be targeted for preven- 
tive interventions.
	 •	 Develop	 a	 panel	 of	 quantitative	 biomarkers	 of	 car-
cinogens or their metabolites in blood or urine. 
Apply this panel of biomarkers to determine carcin-
ogen dose in smokers and its relationship to cancer. 
Such a panel could be extremely useful in determin-
ing individual risk of tobacco-induced cancer and 
potentially useful for regulation.
	 •	 Develop	 quantitative	 reproducible	 and	 reliable	
methods for assessing levels of DNA adducts spe-
cific to all major carcinogens in tobacco smoke, and 
carry out biomarker studies to investigate the rela-
tionship between DNA adducts and cancer in smok-
ers. This approach could potentially identify highly 
susceptible smokers and further define mechanisms 
of cancer induction in general, beyond the effects of 
tobacco products.
	 •	 Further	study	the	role	of	nicotine,	4-(methylnitros-
amino)-1-(3-pyridyl)-1-butanone, and other toxi-
cants in tobacco smoke in the activation of nicotinic 
acetylcholine receptors in lung epithelial cells, as 
well as similar key intracellular proteins and related 
epigenetic events that can lead to tumor promotion, 
cocarcinogenesis, progression, and maintenance 
of cancer.
	 •	 Conduct	additional	studies	of	the	potential	mecha-
nisms by which carcinogens in tobacco smoke affect 
breast tissue, and how various other effects from 
tobacco smoke exposure, including possible anties-
trogenic effects, could modulate or reduce the carci-
nogenic effects of tobacco smoke exposure.
	 •	 Develop	a	predictive	algorithm—including	tobacco	
carcinogen and DNA biomarker data and related 
parameters such as polymorphisms in DNA repair 
genes—to identify those smokers most suscep-
tible to cancer induction by cigarette smoke. This 
algorithm would be analogous to the Gail model for 
breast cancer susceptibility.
	 •	 Investigate	the	mechanisms	by	which	alcohol	con-
sumption and asbestos exposure enhance the risk 
for tobacco-related cancers.
	 •	 Study	the	major	pathway	by	which	tobacco	smoke	
induces cancer through DNA adduct formation by 
tobacco smoke carcinogens and other contributing 
factors such as tumor promotion, cocarcinogen-
esis, direct receptor binding effects of nicotine and 
tobacco-specific nitrosamines, and hypermethyl-
ation of tumor suppressor gene promoter regions 
that clearly contribute. Further research is neces-
sary to elucidate the relevant mechanisms involved 
in these pathways.
Cardiovascular Diseases
Even though the evidence has long been sufficient 
to infer that both active and involuntary smoking cause 
coronary heart disease, the observed risks from exposure 
to toxicants in combustible and noncombustible tobacco 
products emphasize the need for further research on 
the mechanisms by which exposure to tobacco adversely 
affects the cardiovascular system. Several areas of research 
that can substantially contribute to a better understand-
ing of these mechanisms include—but are not limited 
to—the following:
	 •	 Conduct	further	study	of	the	role	of	oxidizing	chem-
icals, nicotine, or other toxicants in tobacco smoke 
in the development of endothelial dysfunction.
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	 •	 Promote	 additional	 study	 of	 the	 role	 of	 specific	
toxicants in tobacco smoke in the development 
of acute and chronic inflammatory reactions and 
the development of reliable biomarkers of these 
reactions predictive of acute cardiovascular events 
and atherosclerosis.
	 •	 Identify	 the	 toxicants	 in	 tobacco	 smoke	 most	 re-
sponsible for the nonlinear dose response between 
exposure dose to tobacco smoke (including second-
hand smoke) and indicators of acute cardiovascular 
risk and related cardiovascular events.
	 •	 Identify	 the	 toxicants	 in	 tobacco	 smoke	 most	 re-
sponsible for platelet activation effects.
	 •	 Analyze	the	toxicants	in	various	forms	of	smokeless	 
tobacco products that could produce acute or 
chronic changes in mechanisms related to cardio-
vascular risk.
	 •	 Conduct	 further	 study	of	 the	differential	 effects	 of	
alveolar deposition of particulate constituents from 
tobacco smoke and other ambient air sources on 
biochemical and physiological acute and chronic 
reactions related to cardiovascular risk and related 
cardiovascular events. 
	 •	 Further	explore	the	role	of	nicotine	and	other	toxi-
cants in tobacco smoke in the development of insu- 
lin resistance.
Pulmonary Diseases
Chronic obstructive pulmonary disease (COPD) 
remains a major public health problem that is increas-
ing, but evidence indicates that COPD could be almost 
completely prevented with the elimination of smoking 
(U.S. Department of Health and Human Services 2004). 
Although there are substantial and rapid benefits to lung 
function after smoking cessation, evidence indicates that 
morbidity related to COPD persists long after cessation of 
smoking (International Agency for Research on Cancer 
2007a). Several areas of research that can substantially 
contribute to a better understanding of the mechanisms 
by which exposure to tobacco smoke increase the risk of 
COPD include—but are not limited to—the following:
	 •	 Promote	 further	 research	 in	 characterizing	 the	 
genetic basis of susceptibility to tobacco smoke in 
the causation of COPD.
	 •	 Further	 explore	 the	 role	 of	 oxidative	 stress	 in	 the	
pathogenesis of COPD and the potential to modulate 
this mechanism of disease production.
	 •	 Investigate	 more	 deeply	 the	 role	 of	 protease-anti-
protease imbalance in the pathogenesis of COPD 
and the potential to modulate this mechanism of 
disease production. 
Reproductive and  
Developmental Effects
Epidemiologic Studies
Numerous adverse pregnancy outcomes or maternal 
complications have been causally associated with 
maternal smoking. Research to better define dose- 
response relationships, especially for preeclampsia, pre-
term delivery, and premature rupture of membranes, 
would be informative. This information could be used to 
establish more accurate estimates of individual risk and 
of population-attributable risk percentage. In general, 
research is needed to better define the effects of smoking 
cessation (before or during pregnancy) on risk of pregnancy 
complications or outcomes such as spontaneous abortion, 
placenta previa, placental abruption, preterm delivery, and 
premature rupture of membranes. This information could 
be used to help refine public health strategies for decreas-
ing the contribution of maternal smoking to adverse preg- 
nancy outcomes.
Smoking should continue to be examined in studies 
of birth defects, particularly in geographic areas in which 
smoking during pregnancy remains prevalent, as the evi-
dence so far is suggestive, but not conclusive. These stud-
ies would be most beneficial if they also examine interac-
tions with genetic polymorphisms (see below), requiring 
additional subjects and funding. Animal studies that bet-
ter simulate smoke exposure would also be very useful in 
this regard.
Evidence is increasing that exposures during preg- 
nancy may have long-lasting effects on offspring. Fur-
thermore, developmental delays and disabilities are 
increasing in the population, so additional studies of 
smoking effects (in utero and postnatal exposure) on 
neurobehavioral endpoints, including cognition and 
behavior, are needed, perhaps as large cohort studies. 
In the context of some suggestive or early studies, it is 
important to pursue examination of in utero exposure to 
smoking and later reproductive effects in the offspring, 
including pubertal development, sperm quality, and 
female fertility. Studies of in utero exposure in offspring, 
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either as children or adults, are difficult to carry out 
logistically because of long follow-up times or lack of ret-
rospective data on parental tobacco use or secondhand 
smoke exposure during pregnancy if adults are studied. 
Such studies should also consider postnatal secondhand 
smoke exposure. Studies in adult offspring would need 
to be limited to nonsmokers, while considering second-
hand smoke exposure in adults as well, requiring larger 
numbers of study subjects for stratification. In addition, 
numerous other factors may affect these endpoints after 
birth. Because of some of these methodological difficul-
ties, further studies on mechanisms related to endo-
crine function would help support causal relationships 
(see below).
Research on humans would be improved with mea-
surement of a biomarker of exposure, such as cotinine. 
Studies tend to show higher cotinine levels in young 
children exposed to secondhand smoke relative to older 
children and adults, so studying the pharmacokinetics 
of cotinine in the very young (birth to five years) would 
be of interest to determine whether this is attributable to 
slower metabolism of nicotine and cotinine or to greater 
exposure to secondhand smoke.
Pathophysiological and Cellular/Molecular 
Mechanisms
Effects on Organ Systems
1. Smoking has often been considered antiestrogenic, 
but studies measuring hormone levels in nonpreg-
nant women or in men do not support this hypoth-
esis. Therefore, studies of effects of smoking and 
secondhand smoke exposure on levels of other hor-
mones in males and females would help elucidate 
the mechanism of effects of smoking on reproductive 
function and some pregnancy outcomes.
2. Research is needed to better understand mechanisms 
underlying causal relationships between maternal 
smoking and placental damage such as placenta 
previa, placental abruption, preeclampsia, preterm 
delivery, and premature rupture of membranes. Spe-
cifically needed are studies
	 •	 to	 better	 characterize	 the	 effects	 of	 maternal	
smoking on physiological transformation and on 
the development of the villous capillary system of 
the placenta;
	 •	 of	the	effects	of	maternal	smoking	on	the	balance	
between pro- and antiangiogenic factors; and
	 •	 of	 the	 effects	 of	 maternal	 smoking	 on	 nutri-
ent transport in uteroplacental circulation and 
the potential consequences for fetal growth 
and development.
3. The possible mechanisms of smoke exposure affecting 
organogenesis that may lead to birth defects require 
more research, particularly on the histopathologic 
changes in the brain and lung.
4. Research is needed to better define effects of active 
smoking on immunoregulation in general. In addi-
tion, research is needed to better understand the 
contribution of tobacco-related dysregulation of the 
immune response to adverse pregnancy outcomes, 
such as preterm delivery and preterm premature 
rupture of membranes, and to determine what mech-
anisms are involved, such as increased risk of infec-
tion of the upper genital tract or modification of the 
inflammatory response.
Molecular Mechanisms and  
Specific Toxicants
1. Cigarette smoke contains thousands of toxicants, but 
more data documenting exposure to toxicants in the 
fetus of maternal active and involuntary smokers are 
necessary to link effects of smoking to specific toxic 
mechanisms or models. Some of the primary toxicants 
of interest are heavy metals (e.g., lead, mercury, cad-
mium, arsenic), polycyclic aromatic hydrocarbons, 
solvents, and other less studied compounds such as 
pyrazines and phenols. Additional media could be 
used as substrate, including placenta, umbilical cord, 
amniotic fluid, urine excretion in the first days, and 
meconium for metals only (atomic absorption).
2. In addition, the bioavailability and bioaccumulation 
of these compounds (particularly metals) from inha-
lation of smoke in adults or children should be stud-
ied, including animal studies to interpret toxicologic 
data on these compounds.
3. Research is needed to establish whether deficiencies 
of micronutrients such as vitamin C and zinc con-
tribute to adverse pregnancy outcomes and if mecha-
nisms exist to compensate for the deficiencies, lead-
ing to better pregnancy outcomes.
4. Research on the effects of smoking and its compo-
nents on DNA damage should be conducted.
Surgeon General’s Report
660 Chapter 9
5. Further studies that include information on genetic 
polymorphisms affecting drug- and carcinogen- 
metabolizing enzymes are critical to uncovering 
mechanisms of smoking effects in many areas, in-
cluding birth defects, other adverse pregnancy out-
comes, and developmental effects.
6. In addition, a potential genetic basis for the popula-
tion of women who have difficulty quitting smok-
ing during pregnancy, including polymorphisms for 
nicotine-metabolizing enzymes or for central nervous 
system receptors, should be investigated to develop 
new pharmacologic treatments.
Appendix 9.2 
Ending the Tobacco Problem: A Blueprint for the Nation
Committee on Reducing Tobacco Use: Strategies, Barriers, and Consequences
Institute of Medicine, 2007
Richard J. Bonnie, Kathleen Stratton, and Robert B. Wallace, editors
Complete List of 
Recommendations
Strengthening Traditional Tobacco Control 
Measures
Recommendation 1: Each state should fund state tobacco 
control activities at the level recommended by the CDC 
[Centers for Disease Control and Prevention]. A reason-
able target for each state is in the range of $15 to $20 per 
capita, depending on the state’s population, demography, 
and prevalence of tobacco use. If it is constitutionally per-
missible, states should use a statutorily prescribed portion 
of their tobacco excise tax revenues to fund tobacco con-
trol programs.
Recommendation 2: States with excise tax rates below the 
level imposed by the top quintile of states should also sub-
stantially increase their own rates to reduce smuggling 
and tax evasion. State excise tax rates should be indexed 
to inflation.
Recommendation 3: The federal government should sub-
stantially raise federal tobacco excise taxes, currently 
set at 39 cents a pack. Federal excise tax rates should be 
indexed to inflation.
Recommendation 4: States and localities should enact 
complete bans on smoking in all nonresidential indoor 
locations, including workplaces, malls, restaurants, and 
bars. States should not preempt local governments from 
enacting bans more restrictive than the state ban.
Recommendation 5: All health care facilities, including 
nursing homes, psychiatric hospitals, and medical units 
in correctional facilities, should meet or exceed JCAHO 
[Joint Commission on the Accreditation of Healthcare 
Organizations] standards in banning smoking in all 
indoor areas.
Recommendation 6: The American Correctional Associa-
tion should require through its accreditation standards 
that all correctional facilities (prisons, jails, and juvenile 
detention facilities) implement bans on indoor smoking.
Recommendation 7: States should enact legislation 
requiring leases for multiunit apartment buildings and 
condominium sales agreements to include the terms gov-
erning smoking in common areas and residential units. 
States and localities should also encourage the owners of 
multiunit apartment buildings and condominium devel-
opers to include nonsmoking clauses in these leases and 
sales agreements and to enforce them.
Recommendation 8: Colleges and universities should ban 
smoking in indoor locations, including dormitories, and 
should consider setting a smoke-free campus as a goal. 
Further, colleges and universities should ban the promo-
tion of tobacco products on campus and at all campus-
sponsored events. Such policies should be monitored and 
evaluated by oversight committees, such as those associ-
ated with the American College Health Association.
Recommendation 9: State health agencies, health care 
professionals, and other interested organizations should 
undertake strong efforts to encourage parents to make 
their homes and vehicles smoke free.
Recommendation 10: States should not preempt local 
governments from restricting smoking in outdoor public 
spaces, such as parks and beaches.
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Recommendation 11: All states should license retail sales 
outlets that sell tobacco products. Licensees should be 
required to (1) verify the date of birth, by means of pho-
tographic identification, of any purchaser appearing to be 
25 years of age or younger; (2) place cigarettes exclusively 
behind the counter and sell cigarettes only in a direct 
face-to-face exchange; and (3) ban the use of self-service 
displays and vending machines. Repeat violations of laws 
restricting youth access should be subject to license sus-
pension or revocation. States should not preempt local 
governments from licensing retail outlets that sell 
tobacco products.
Recommendation 12: All states should ban the sale and 
shipment of tobacco products directly to consumers 
through mail order or the Internet or other electronic sys-
tems. Shipments of tobacco products should be permitted 
only to licensed wholesale or retail outlets.
Recommendation 13: School boards should require all 
middle schools and high schools to adopt evidence-based 
smoking prevention programs and implement them with 
fidelity. They should coordinate these in-school programs 
with public activities or mass media programming, or 
both. Such prevention programs should be conducted 
annually. State funding for these programs should be 
supplemented with funding from the U.S. Department of 
Education under the Safe and Drug-Free School Act or by 
an independent body administering funds collected from 
the tobacco industry through excise taxes, court orders, or 
litigation agreements.
Recommendation 14: All physicians, dentists, and other 
health care providers should screen and educate youth 
about tobacco use during their annual health care visits 
and any other visit in which a health screening occurs. 
Physicians should refer youth who smoke to counseling 
services or smoking cessation programs available in the 
community. Physicians should also urge parents to keep 
a smoke-free home and vehicles, to discuss tobacco use 
with their children, to convey that they expect their chil-
dren to not use tobacco, and to monitor their children’s 
tobacco use. Professional societies, including the Ameri-
can Medical Association, the American Nursing Asso-
ciation, the American Academy of Family Physicians, the 
American College of Physicians, and the American Acad-
emy of Pediatrics, should encourage physicians to adopt 
these practices.
Recommendation 15: A national, youth-oriented 
media campaign should be funded on an ongoing basis 
as a permanent component of the nation’s strategy to 
reduce tobacco use. State and community tobacco con-
trol programs should supplement the national media 
campaign with coordinated youth prevention activities. 
The campaign should be implemented by an established 
public health organization with funds provided by the 
federal government, public-private partnerships, or the 
tobacco industry (voluntarily or under litigation settle-
ment agreements or court orders) for media development, 
testing, and purchases of advertising time and space.
Recommendation 16: State tobacco control agencies 
should work with health care partners to increase the 
demand for effective cessation programs and activities 
through mass media and other general and targeted pub-
lic education programs.
Recommendation 17: Congress should ensure that stable 
funding is continuously provided to the national quit- 
line network.
Recommendation 18: The Secretary of the U.S. Depart-
ment of Health and Human Services [HHS], through the 
National Cancer Institute, the Centers for Disease Control 
and Prevention, and other relevant federal health agen-
cies, should fund a program of developmental research 
and demonstration projects combining media techniques, 
other social marketing methods, and innovative approach-
es to disseminating smoking cessation technologies.
Recommendation 19: Public and private health care sys-
tems should organize and provide access to comprehen-
sive smoking cessation programs by using a variety of 
successful cessation methods and a staged disease man-
agement model (i.e. stepped care), and should specify the 
successful delivery of these programs as one criterion for 
quality assurance within those systems.
Recommendation 20: All insurance, managed care, and 
employee benefit plans, including Medicaid and Medicare, 
should cover reimbursement for effective smoking cessa-
tion programs as a lifetime benefit.
Recommendation 21: While sustaining their own valuable 
tobacco control activities, state tobacco control programs, 
CDC, philanthropic foundations, and voluntary organiza-
tions should continue to support the efforts of community 
coalitions promoting, disseminating, and advocating for 
tobacco use prevention and cessation, smoke-free envi-
ronments, and other policies and programs for reducing 
tobacco use.
Recommendation 22: Tobacco control programs should 
consider populations disproportionately affected by 
tobacco addiction and tobacco-related morbidity and 
mortality when designing and implementing prevention 
and treatment programs. Particular attention should be 
paid to ensuring that health communications and other 
materials are culturally-appropriate and that special out-
reach efforts target all high-risk populations. Standard 
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prevention or treatment programs that are modified 
to reach high-risk populations should be evaluated 
for effectiveness.
Changing the Regulatory Landscape
Recommendation 23: Congress should repeal the existing 
statute preempting state tobacco regulation of advertis-
ing and promotion “based on smoking and health” and 
should enact a new provision that precludes all direct state 
regulation only in relation to tobacco product character-
istics and packaging while allowing complementary state 
regulation in all other domains of tobacco regulation, 
including marketing and distribution. Under this 
approach, federal regulation sets a floor while allowing 
states to be more restrictive.
Recommendation 24: Congress should confer upon the 
FDA [U. S. Food and Drug Administration] broad regu-
latory authority over the manufacture, distribution, mar-
keting, and use of tobacco products.
Recommendation 25: Congress should empower the 
FDA to regulate the design and characteristics of tobacco 
products to promote the public health. Specific authority 
should be conferred
	 •	 to	 require	 tobacco	 manufacturers	 to	 disclose	 to	
the agency all chemical compounds found in both 
product and the product’s smoke, whether added 
or occurring naturally, by quantity; to disclose to 
the public the amount of nicotine in the product 
and the amount delivered to the consumer based 
on standards established by the agency; to disclose 
to the public research on their product, as well as 
behavioral aspects of its use; and to notify the agen-
cy whenever there is a change in a product;
	 •	 to	 prescribe	 cigarette	 testing	 methods,	 including	
how the cigarettes are tested and which smoke con-
stituents must be measured;
	 •  to promulgate tobacco product standards, including 
reduction of nicotine yields and reduction or elimi-
nation of other constituents, wherever such a stan-
dard is found to be appropriate for protection of the 
public health, taking into consideration the risks 
and benefits to the population as a whole, including 
users and non-users of tobacco products; and
	 •  to develop specific standards for evaluating novel 
products that companies intend to promote as 
reduced-exposure or reduced-risk products, and to 
regulate reduced-exposure and reduced-risk health 
claims, assuring that there is a scientific basis for 
claims that are permitted.
Recommendation 26: Congress    should strengthen the 
federally mandated warning labels for tobacco products 
immediately and should delegate authority to the FDA 
to update and revise these warnings on a regular basis 
upon finding that doing so would promote greater pub-
lic understanding of the risks of using tobacco products 
or reduce tobacco consumption. Congress should require 
or authorize the FDA to require rotating color graphic 
warnings covering 50 percent of the package equivalent to 
those required in Canada.
Recommendation 27: Congress should empower the FDA 
to require manufacturers to include in or on tobacco pack-
ages information about the health effects of tobacco use 
and about products that can be used to help people quit.
Recommendation 28: Congress should ban, or empower 
the FDA to ban, terms such as “mild,” “lights,” “ultra-
lights,” and other misleading terms mistakenly interpret-
ed by consumers to imply reduced risk, as well as other 
techniques, such as color codes, that have the purpose or 
effect of conveying false or misleading impressions about 
the relative harmfulness of the product.
Recommendation 29: Whenever a court or administra-
tive agency has found that a tobacco company has made 
false or misleading communications regarding the effects 
of tobacco products, or has engaged in conduct promot-
ing tobacco use among youth or discouraging cessation 
by tobacco users of any age, the court or agency should 
consider using its remedial authority to require manufac-
turers to include corrective communications on or with 
the tobacco package as well as at the point of sale.
Recommendation 30: Congress and state legislatures 
should enact legislation regulating the retail point of sale 
of tobacco products for the purpose of discouraging con-
sumption of these products and encouraging cessation. 
Specifically:
	 •	 All	retail	outlets	choosing	to	carry	tobacco	products	
should be licensed and monitored. (See also youth 
access section in Chapter 5.)
	 •  Commercial displays or other activity promoting 
tobacco use by or in retail outlets should be banned, 
although text-only informational displays (e.g., price 
or health-related product characteristics) may be 
permitted within prescribed regulatory constraints.
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	 • Retail outlets choosing to carry tobacco products 
should be required to display and distribute pre-
scribed warnings about the health consequences 
of tobacco use, information regarding products 
and services for cessation, and corrective mes-
sages designed to offset misstatements or implied 
claims regarding the health effects of tobacco use 
(e.g., that “light” cigarettes are less harmful than 
other cigarettes).
	 •	 Retail	 outlets	 choosing	 to	 carry	 tobacco	 prod-
ucts should be required to allocate a proportion-
ate amount of space to cessation aids and nicotine 
replacement products and, after regulatory clear-
ance by the FDA or a designated state agency, to 
“qualifying” exposure-reduction products. (The FDA 
or a suitable state health agency should promulgate 
a list of “qualifying” exposure-reducing products.)
Recommendation 31: Congress should explicitly and 
unmistakably include production, marketing, and dis-
tribution of tobacco products on Indian reservations by 
Indian tribes within the regulatory jurisdiction of FDA. 
Authority to investigate and enforce the Jenkins Act should 
be transferred to the Bureau of Alcohol, Tobacco, Firearms 
and Explosives. State restrictions on retail outlets should 
apply to all outlets on Indian reservations.
Recommendation 32: State governments should develop 
and, if feasible, implement and evaluate legal mechanisms 
for restructuring retail tobacco sales and restricting the 
number of tobacco outlets.
Recommendation 33: Congress should empower the FDA 
to restrict outlets in order to limit access and facilitate 
regulation of the retail environment, and thereby protect 
the public health.
Recommendation 34: If most states fail to increase 
tobacco control funding and reduce variations in tobacco 
excise tax rates as proposed in Recommendations 1 and 
2, Congress should enact a National Tobacco Control 
Funding Plan raising funds through a per-pack remedial 
assessment on cigarettes sold in the United States. Part 
of the proceeds should be used to support national 
tobacco control programs and the remainder of the funds 
should be distributed to the states to subsidize state 
tobacco control programs according to a formula based on 
the level of state tobacco control expenditures and state 
tobacco excise rates. The plan should be designed to give 
states an incentive, not only to increase state spending on 
tobacco control, but also to raise cigarette taxes, espe-
cially in low-tax states. Congress should assure that any 
federal coordination mechanism affecting the cover-
age and collection of state tobacco excise taxes applies 
to Indian tribes.
Recommendation 35: Congress and state legislatures 
should enact legislation limiting visually displayed tobac-
co advertising in all venues, including mass media and at 
the point-of-sale, to a text-only, black-and-white format.
Recommendation 36: Congress and state legislatures 
should prohibit tobacco companies from targeting youth 
under 18 for any purpose, including dissemination of mes-
sages about smoking (whether ostensibly to promote or 
discourage it) or to survey youth opinions, attitudes and 
behaviors of any kind. If a tobacco company wishes to 
support youth prevention programs, the company should 
contribute funds to an independent non-profit organiza-
tion with expertise in the prevention field. The indepen-
dent organization should have exclusive responsibility for 
designing, executing, and evaluating the program.
Recommendation 37: The Motion Picture Association 
of America (MPAA) should encourage and facilitate the 
showing of anti-smoking advertisements before any film 
in which smoking is depicted in more than an inciden-
tal manner. The film rating board of the MPAA should 
consider the use of tobacco in the movies as a factor in 
assigning mature film ratings (e.g., an R-rating indicating 
Restricted: no one under age 17 admitted without parent 
or guardian) to films that depict tobacco use.
Recommendation 38: Congress should appropriate the 
necessary funds to enable the U.S. Department of Health 
and Human Services to conduct a periodic review of a 
representative sample of movies, television programs, 
and videos that are offered at times or in venues in which 
there is likely to be a significant youth audience (e.g., 15 
percent) in order to ascertain the nature and frequency of 
images portraying tobacco use. The results of these 
reviews should be reported to Congress and to the public.
Recommendation 39: State tobacco control agencies 
should conduct surveillance of tobacco sales and use and 
the effects of tobacco control interventions in order to 
assess local trends in usage patterns; identify special 
groups at high risk for tobacco use; determine compliance 
with state and local tobacco-related laws, policies, and 
ordinances; and evaluate overall programmatic success.
Recommendation 40: The Secretary of HHS, through FDA 
or other agencies, should establish a national comprehen-
sive tobacco surveillance system to collect information 
on a broad range of elements needed to understand and 
track the population impact of all tobacco products and 
Surgeon General’s Report
664 Chapter 9
the effects of national interventions (such as attitudes, 
beliefs, product characteristics, product distribution and 
usage patterns, and marketing messages and exposures 
to them).
New Frontiers in Tobacco Control
Recommendation 41: Congress should direct the Centers 
for Disease Control and Prevention to undertake a major 
program of tobacco control policy analysis and develop-
ment and should provide sufficient funding to support 
the program. This program should develop the next gen-
eration of macro-level simulation models to project the 
likely effects of various policy innovations, taking into 
account the possible initiatives and responses of the 
tobacco industry as well as the impacts of the innovations 
on consumers.
Recommendation 42: Upon being empowered to regulate 
tobacco products, the FDA should give priority to explor-
ing the potential effectiveness of a long-term strategy for 
reducing the amount of nicotine in cigarettes and should 
commission the studies needed to assess the feasibility of 
implementing such an approach. If such a strategy appears 
to be feasible, the agency should develop a long-term plan 
for implementing the strategy as part of a comprehensive 
plan for reducing tobacco use.
Appendix 9.3  
Promoting Healthy Lifestyles: Policy, Program, and  
Personal Recommendations for Reducing Cancer Risk
President’s Cancer Panel
2006–2007 Annual Report
Recommendations Addressing Tobacco Use Prevention and Treatment; 
Environmental Tobacco Smoke Exposure 
1. Ratify and fully implement the Framework Convention for 
Tobacco Control. Key provisions include: comprehensive bans 
on tobacco advertising, promotion, and sponsorship, larger 
and stronger warning labels on tobacco product packaging, 
provision of tobacco addiction treatment, disclosure of tobacco 
product ingredients, and public protection against environ-
mental tobacco smoke exposure.
•			President
•			Congress
2. Authorize the Food and Drug Administration (FDA) to strictly 
regulate tobacco products and product marketing. FDA must 




3. Increase the Federal excise tax on tobacco products. •			Congress
4. Require all Federal facilities to be smoke-free. •			Congress
•			Federal	agencies
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5. Reallocate existing National Cancer Institute, Centers for Dis-
ease Control and Prevention, and other Federal resources to 
better mirror the tobacco-related disease burden and capitalize 
on opportunities for progress.
•			Congress
•			Department	of	Health	and	Human	Services	
(National Institutes of Health, Centers for 
Disease Control and Prevention, Health 
Resources and Services Administration, 
Substance Abuse and Mental Health Ser-
vices Administration)
•			Veterans	Administration
6. Add the conduct of meaningful tobacco-related activities to 
the evaluation criteria for NCI-designated Cancer Centers.
•			National	Cancer	Institute
7. Reduce the influence of the tobacco industry:
	 •	 U.S.	political	parties	and	individual	candidates	should	 
refuse campaign contributions from the tobacco industry 
or its subsidiaries.
	 •	 Prohibit	recipients	of	National	Cancer	Institute	grants	and	
contracts from accepting money from tobacco companies 




8. Strengthen anti-tobacco efforts at the state and local levels:
	 •	 Increase	state	commitment	of	Master	Settlement	Agree-
ment funds and/or tobacco tax funds for tobacco control 
programs to at least the minimum level recommended by 
the Centers for Disease Control and Prevention for each 
state.
	 •	 Pass	smoke-free	ordinances	for	all	public	and	private	work-
places and public spaces.
	 •	 Encourage	state	governments	to	further	increase	tobacco	









9. Develop and provide evidence-based multimedia curricula and 
educational materials in grades K-12 on the dangers of  
tobacco use and tobacco smoke exposure and the role of 
the tobacco industry in promoting tobacco use. Encourage 
colleges and universities to disseminate tested anti-tobacco 
messages for the 18 to 24 year-old age group through campus 
radio and television stations, Web sites, and print publications.
•			Department	of	Health	and	Human	Services	
(National Institutes of Health, Centers for 




10. Cease including images of smoking in movies, television, 
music videos, video games, and other visual media with 




11. Prohibit smoking in and around the workplace. Support 
worker efforts to quit smoking; provide incentives for cessa-
tion.
•			Employers
12. Make coverage of tobacco use cessation services and medica-






     Uniformed Services
•			Indian	Health	Service
13. Incorporate smoking cessation services into the compre-




     medical centers
•			Private	oncology	offices/practices
•			All	publicly-funded	clinics	and	health	
     centers
14. Adopt the Agency for Healthcare Research and Quality 
Guidelines for Clinicians Treating Tobacco Use and  
Dependence as part of the standard of care for all health care 
providers.
•			Primary	and	other	health	care	providers
15. Quit smoking and use of any smokeless tobacco products. 
Prohibit smoking in the home and car. Protect children from 
exposure to smoking in movies and smoking role models. 
Patronize only smoke-free restaurants and other businesses.
•			Individuals	and	families
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AHH aryl hydrocarbon hydroxylase
AKT protein kinase B
AOR adjusted odds ratio
AP apurinic/apyrimidinic
AP-1 activator protein-1
APA American Psychiatric Association
APO apolipoprotein
APO A-I apolipoprotein A-I
APO B apolipoprotein B






BER base excision repair
BH BCL-2 homology
BMI body mass index 
BPDE benzo[a]pyrene-7,8-diol-9,10-epoxide
BSID Bayley Scales of Infant Development 
Ca2+ calcium ion
Cal/EPA California Environmental Protection Agency
CAM chorioallantoic membrane
CaMKII Ca2+ calmodulin-dependent protein kinase II
CAN Canadian Intense
CAT chloramphenicol acetyltransferase
CB1 cannabinoid subtype 1
CDC Centers for Disease Control and Prevention
CDK cyclin-dependent kinase
CETP cholesterol ester transfer protein
CHD coronary heart disease
CI confidence interval
CNS central nervous system
CO carbon monoxide
CO2 carbon dioxide
COPD chronic obstructive pulmonary disease
CPS-I Cancer Prevention Study I
CPS-II Cancer Prevention Study II




CSE cigarette smoke extract
CT computed tomography
CUZNSOD copper zinc superoxide dismutase
CVD cardiovascular disease
DEB diepoxybutane




DRC DNA repair capacity
DRZ diagonal radioactive zone
DSB double-strand break
DSBR double-strand break repair
DSM-III-R Diagnostic and Statistical Manual of Mental 
Disorders, 3rd ed. (rev)
DSM-IV Diagnostic and Statistical Manual of Mental 
Disorders, 4th ed.
EB 3,4-epoxybutene
ECSOD extracellular superoxide dismutase
EF etiologic fraction
ELF epithelial lining fluid
ENOS endothelial nitric oxide synthase
EPA U.S. Environmental Protection Agency
EPC endothelial progenitor cell
EPO eosinophil-specific peroxidase




FDA U.S. Food and Drug Administration
Fe2+ ferrous ion
Fe3+ ferric ion
FEV1 forced expiratory volume in one second
FFA free fatty acid
FR fecundability ratio
FSH follicle-stimulating hormone
FTC U.S. Federal Trade Commission
FTND Fagerström Test for Nicotine Dependence
FTQ Fagerström Tolerance Questionnaire




GCL glutamate cysteine ligase
GGR global genomic nucleotide excision repair
GLu-P-1 2-amino-6-methyldipyrido[1,2-a:3’,2’-d] 
imidazole















HBEC human bronchial epithelial cell
HCA heterocyclic amine
hCG human chorionic gonadotropin
HCN hydrogen cyanide
HCR  host cell reactivation
HDAC histone deacetylase
HDL high-density lipoprotein
HDLc high-density lipoprotein cholesterol
Hg mercury
HIV human immunodeficiency virus
HONC Hooked on Nicotine Checklist
HOX hypohalous acids
HPG hypothalamic-pituitary-gonadal
HPLC high-performance liquid chromatography
HR23B homologous recombinational repair group 
23B
IARC International Agency for Research on Cancer
IBF intervillous blood flow
ICAM intercellular adhesion molecule
ICD-10 International Statistical Classification of 





INOS inducible nitric oxide synthase
IOM Institute of Medicine
ISO International Organization for  
Standardization
IUGR intrauterine growth restriction




LBW low birth weight
LC liquid chromotography
LDL low-density lipoprotein
LDLc low-density lipoprotein cholesterol
LH luteinizing hormone
LMPCR ligation-mediated polymerase chain reaction





MAPK mitogen-activated protein kinase
MDM2 murine double minute 2
MDPH Massachusetts Department of Public Health
MEK mitogen-activated protein kinase kinase
mg milligram
mGluR2/3 metabotropic glutamate receptor subtype 2/3
mGluR5 metabotropic glutamate receptor subtype 5
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MMR mismatch repair
MMS methyl methanesulfonate















nAChR nicotinic acetylcholine receptor




NCI National Cancer Institute
NDMA N-nitrosodimethylamine
NER nucleotide excision repair
NF-κB nuclear factor-kappa B
ng nanogram
NHLBI National Heart, Lung, and Blood Institute
NIH National Institutes of Health
NK natural killer
nmol nanomole









NOS nitric oxide synthase
NPRO N-nitrosoproline
NRC National Research Council 
NRT nicotine replacement therapy
NSCLC non-small-cell lung cancer
NST nonstress test








p short arm of chromosome
PAD peripheral arterial disease
PAF platelet-activating factor
PAH polycyclic aromatic hydrocarbon
PAI-1 plasminogen activator inhibitor-1
PARP poly (adenosine diphosphate–ribose)  
polymerase
PAT poly AT insertion/deletion polymorphism
PCASRM Practice Committee of the American Society 
for Reproductive Medicine
PCNA proliferating cell nuclear antigen
p-CREB phosphorylated CREB
PdG 1,N2-propanodeoxyguanosine
PDK1 3-phosphoinositide–dependent protein 
kinase-1









PKA protein kinase A
PKB protein kinase B (also known as AKT)
PKC protein kinase C
PKcs protein kinase catalytic subunit







ppm parts per million
PPROM preterm premature rupture of membranes
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PREP potential reduced-exposure product
PRX peroxiredoxin
q long arm of chromosome
Q•− semiquinone radical
RCT reverse cholesterol transport
REC homologous recombination
RI resistance index 
RNS reactive nitrogen species




SARS severe acute respiratory syndrome
SCC squamous cell carcinoma
SCE sister chromatid exchange
SCENIHR Scientific Commission on Emerging and 
Newly Identified Health Risks
SCLC small-cell lung cancer
SD standard deviation
SES socioeconomic status
sFlt-1 soluble vascular endothelial growth factor 
receptor Flt-1
SGA small for gestational age
sICAM soluble intercellular adhesion molecule
SIDS sudden infant death syndrome
SNO S-nitrosothiol
SNP single nucleotide polymorphism
SOD superoxide dismutase 
S-PMA S-phenylmercapturic acid
STR short tandem repeat
sVCAM soluble vascular cell adhesion molecule
TBARS thiobarbituric acid reactive substances
TCR transcription-coupled repair
TFIIH transcription initiation factor IIH
TGFβ transforming growth factor-beta
TGRL triglyceride-rich lipoprotein
Th1 helper T-cell subset 1
Th2 helper T-cell subset 2
TIMP tissue inhibitor of metalloproteinase
Tmax time to reach maximum blood concentrations 
of nicotine
TNFα tumor necrosis factor-alpha
tPA tissue plasminogen activator














USDHEW U.S. Department of Health, Education, and 
Welfare
USDHHS  U.S. Department of Health and Human  
Services
USPSTF U.S. Preventive Services Task Force
UV ultraviolet
VCAM vascular cell adhesion molecule
VEGF  vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
VLDL very-low-density lipoprotein
Vmax maximum velocity
VOC volatile organic compound
VTA ventral tegmental area
WHO World Health Organization
XP (A–G) xeroderma pigmentosum (groups A–G)
γGT γ-glutamyltranspeptidase
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Definitions and Alternative Nomenclature of Genetic Symbols Used in This Report
Throughout this report, genes are represented by their abbreviations in italics. In many cases, proteins and enzymes related to these 
genes have the same abbreviation, presented in roman type. Definitions, alternative genetic symbols, related proteins and enzymes, 
and polymorphisms and variant genotypes are listed alphabetically by gene abbreviation.
Gene symbol 
used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
5HTT serotonin transporter SLC6A4, 
5HTTLPR
5HTT, SERT, SLC6A4 LPR; VNTR; 5HTTLPR
ADPRT poly (ADP-ribose) polymerase 
family, member 1 




   AGT ILE143VAL; GLY160ARG
ANKK1 ankyrin repeat and kinase 
domain containing 1  
   ANKK1, protein kinase PKK2 GLU713LYS (caused by 
DRD2 *TAQ1A system)
APAF1 apoptotic peptidase activating 
factor 1 
   APAF1   
APEX1 APEX nuclease 
(multifunctional DNA repair 
enzyme) 1 
   APEX1 GLU148ASP (T11865G)
AREG amphiregulin (schwannoma-
derived growth factor) 




ARP arginine-rich protein ARMET ARP, ARMET (arginine-
rich mutated in early stage 
tumors)
  
ATM ataxia telangiectasia mutated TEL1 ATM; TEL1 (telomere 
maintenance 1)
  
BAX BCL2-associated X protein    BAX   
BRAF v-raf murine sarcoma viral 
onco homolog B1 








C-FOS v-fos FBJ murine osteosarcoma 
viral oncogene homolog
FOS FOS, C-FOS   
C4A complement component 4A 
(Rodgers blood group) 
   C4A haplotype
C4B complement component 4B 
(Childo blood group) 
   C4B haplotype
CASPASE-3 cysteine-aspartic acid 
protease-3
   CASPASE-3   






used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
CCK cholecystokinin    CCK C-45T promoter 
polymorphism in SP1 
binding region of CCK 
gene
CCKAR cholecystokinin A receptor CCK1-R CCKAR, CCK1-R 
(cholecystokinin-1 receptor)
T779C, VAL365ILE
CCND1 G1/S-specific cyclin D1    CCND1 G870A, *A/*A, *G/*A, 
*G/*G
CCNH cyclin H    CCNH, cyclin-dependent 
kinase-activating kinase
VAL270ALA 




CDK4 cyclin-dependent kinase 4    CDK4, cell division kinase 4   
CDKN2A cyclin-dependent kinase 
inhibitor 2A 
   CDKN2A, P16   







CHFR checkpoint with forkhead and 
ring finger domains
   CHFR, mitotic checkpoint 
protein
  
CHRNA3 cholinergic receptor, nicotinic, 
a3
   CHRNA3   
CHRNA4 cholinergic receptor, nicotinic, 
a4 
   CHRNA4, a4 nAChR, 
nicotinic acetylcholine 
receptor a4 subunit
SNP RS3746372 (*1); 
haplotype
CHRNA5 cholinergic receptor, nicotinic, 
a5 
   CHRNA5, nicotinic 




RS8023462 and RS1948 
(CHRNA5/A3/B4 cluster)
CHRNA7 cholinergic receptor, nicotinic, 
a7
   CHRNA7, nicotinic 
acetylcholine receptor a7 
subunit, a7 nAChR
D15S1360 (a microsatellite 
polymorphic marker in 
INTRON 2) exhibited seven 
different dinucleotide 
repeat lengths (99, 109, 
111, 113, 115, 117, and 125 
bp), the major alleles are 
*113 and *115 (*113/*113, 
*113/*115, *115/*115)
CHRNB2 cholinergic receptor, nicotinic, 
b2 (neuronal) 
   CHRNB2, nicotinic 
acetylcholine receptor b2 
subunit, b2 nAChR
multiple SNPs; haplotype




How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease
Gene symbol 
used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
CHRNB4 cholinergic receptor, nicotinic, 
b4
   CHRNB4   
C-MYC avian myelocytomatosis viral 
oncogene homolog
MYC C-MYC, myc proto-oncogene 
protein
  
COMT catechol-O-methyltransferase    COMT A1947G, *A, *G, 
VAL158MET
COX-1 cyclooxygenase-1    COX-1   
COX-2 cyclooxygenase-2    COX-2   
CYP17A1 cytochrome P-450, family 17, 
subfamily A, polypeptide 1 
   CYP17A1   
CYP1A1 cytochrome P-450, family 1, 
subfamily A, polypeptide 1 
   CYP1A1, MSPI *MSPI (*A/*a, *a/*a), 
ILE462VAL
CYP2A13 cytochrome P-450, family 2, 
subfamily A, polypeptide 13 
   CYP2A13 ARG257CYS (C3375T, 
*C/*T, *T/*T)
CYP2A6 cytochrome P-450, family 2, 
subfamily A, polypeptide 6
   CYP2A6 *1 (wild type), *1A, *1B, 
*2, *3, *4, *4A, *4B, *4C, 
*4D, *5, *6, *7, *8, *9, 
*10, *12, *16, *NULL, 
*DEL
CYP2B6 cytochrome P-450, family 2, 
subfamily B, polypeptide 6
   CYP2B6 *5 (C1459T=ARG487CYS); 
*6 (G516T=GLN172HIS); 
*2 (C64T=ARG22CYS);  
*3 (C777A=SER259ARG); 
*4 (A785G=LYS262ARG)
CYP2D6 cytochrome P-450, family 2, 
subfamily D, polypeptide 6 
   CYP2D6 *3, *4A, *5
CYP2E1 cytochrome P-450, family 2, 
subfamily E, polypeptide 1 
   CYP2E1 *1C, *1D, *DRA1, *RSA1
DAPK1 death-associated protein  
kinase 1 
DAPK DAPK1, DAPK   
DAT dopamine transporter DAT1 DAT, DAT1 VNTR
DDC dopa decarboxylase (aromatic 
l-amino acid decarboxylase) 
AADC DDC, AADC haplotype
DLC1 deleted in liver cancer 1    DLC1   
DRD1 dopamine receptor D1    DRD1 *DDE1
DRD2 dopamine receptor D2    DRD2 *TAQ1A (*A), *TAQ1B, 





used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
DRD4 dopamine receptor D4    DRD4 VNTR
DRD5 dopamine receptor D5    DRD5 haplotype
DßH dopamine beta hydroxylase    DbH G1368A, C1021T, *A allele 
(G444A)
E-CADHERIN cadherin 1, type 1, E-cadherin 
(epithelial) 
    E-CADHERIN, calcium-
dependent adhesion protein, 
epithelial
  
EGFR epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) onco 
homolog, avian)
   EGFR   
ELA2 elastase, neutrophil expressed ELANE ELA2   
EN2 engrailed homeobox 2 EN-2 EN2   
ENOS endothelial nitric oxide 
synthase 
NOS3 ENOS, NOS3 *A allele (a quadruple 
repeat of a 27 base-pair 
sequence in INTRON 4), 
GLU298ASP (*ASP298)
EPHX1 gene of epoxide hydrolase 1, 
microsomal (xenobiotic)
MEH EPHX1, MEH microsomal 
epoxide hydrolase
EXON 3 SNP, EXON 4 
SNP, EXONs 3-4 SNP 
haplotypes,  (T → C) 
TYR113HIS (*H), (A → G) 
HIS139ARG
ERCC1 excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 1 (includes overlapping 
antisense sequence)
   ERCC1   
ESR1 estrogen receptor 1    estrogen receptor a *XBAL (c.454-351A → G), 
*PVULL (c.454-397T → C)
FAS Fas (TNF receptor superfamily, 
member 6)  
   FAS   
FHIT fragile histidine triad     FHIT, FRA3B   






CSF1R, C-FMS, CD115, 
FIM2, CSFR
  
GABARAP GABA receptor-associated 
protein  
   GABARAP   
GABAB2 γ-aminobutyric acid type B 
receptor 2  
   GABAB2 haplotype
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Gene symbol 
used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
GC group-specific component 
(vitamin D binding protein) 
   GC *1S (416GLU, 420THR), 
*1F (416ASP, 420THR), 
*1S/*1F, *2 (416ASP, 
420LYS), haplotype
GPX glutathione peroxidase    GPX   
GSTA1 glutathione-S-transferase 1a    GSTA1   
GSTM1 glutathione-S-transferase µ1    GSTM1 *NULL, *DEL
GSTP1 glutathione-S-transferase p1    GSTP1 ILE105VAL, *ILE/*ILE, 
*ILE/*VAL, ALA114VAL, 
*ALA/*ALA, *ALA/*VAL
GSTT1 glutathione-S-transferase q1    GSTT1 *NULL, *DEL
H-CADHERIN cadherin 13, H-cadherin 
(heart) 
CDH13 H-CADHERIN, CDH13   
HER-2/NEU  v-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 2, neuro/glioblastoma 
derived oncogene homolog 
(avian)
ERBB2 HER-2/NEU, erb B2 c-erb B2/
neu protein, HER-2(human 






IL-1ß interleukin-1b    IL-1b C-31T (TATA Box), *-31C, 
*-31T
JUN jun oncogene    JUN   
KRAS v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog 
    KRAS   
LAMA3 laminin, a3    LAMA3   
LAMB3 laminin, b3    LAMB3   
LAMC2 laminin,  γ2    LAMC2   
LIG1 ligase I, DNA, ATP-dependent    LIG1 ALA170ALA (A → C), 
ASP802ASP (C → T), 
ALA814ALA (C → G)
LIG4 ligase IV, DNA, ATP-dependent    LIG4 ALA3ALA (C8T, cDNA), 
THR9ILE (C27T, cDNA)
LKB1/STK11 serine/threonine kinase 11     LKB1, STK11   
LMYC v-myc myelocytomatosis viral 




L-MYC, LMYC, MYCL1   





used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
MAOB monoamine oxidase B    MAOB A644G (*A,*G)
MBD4 methyl-CpG binding domain 
protein 4 
   MBD4 SER342PRO (T → C), 
GLU346LYS (G → A)
MGMT O6-methylguanine-DNA 
methyltransferase 
   MGMT LEU84PHE, ILE143VAL
MMP-1 matrix metallopeptidase 1 
(interstitial collagenase) 
   MMP-1   
MMP-12 matrix metallopeptidase 12 
(macrophage elastase)
   MMP-12   
MPO myeloperoxidase    MPO   
MSX1 msh homeobox 1    MSX1 haplotype (intronic CA 
repeat), *X1.3/*X1.3, 
*X2.4/*X2.4, *2 (rare 
allele)
MUC5AC mucin 5AC, oligomeric 
mucus/gel-forming
   MUC5AC   
MUTYH mutY homolog (E. coli)    MUTYH, mutY DNA 
glycosylase, A/G-specific 
adenine DNA glycosylase
GLN335HIS (G → C)
MYO18B myosin XVIIIB    MYO18B   
NAT1 N-acetyltransferase 1     NAT1, arylamine 
N-acetyltransferase 1
1088 *A/*A (T1088A),  
1095 *A/*A (C1095A)
NAT2 N-acetyltransferase 2     NAT2, arylamine 
N-acetyltransferase 2
ILE114THR (T → C), 
LYS161LYS (C → T), 
LYS268ARG (A → G), 
ARG197GLN (G → A), 
TYR94TYR (C → T), 
GLY286GLU (G → A), 
*4/*4 (wild type)
NBS1 Nijmegen breakage syndrome 1 NBN  NBS1, NBN, nibrin GLN185GLU (C → G)
N-MYC v-myc myelocytomatosis 
viral related oncogene, 
neuroblastoma derived (avian)




NORE1A RAS association (RALGDS/AF-
6) domain family member 5 
RASFF5 NORE1A, RASFF5   
NRXN1 neurexin 1    NRXN1   
NRXN3 neurexin 3    NRXN3   
NTRK2 neurotrophic tyrosine kinase, 
receptor, type 2 
   NTRK2   
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Gene symbol 
used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
OGG1 8-oxoguanine DNA glycosylase    OGG1 SER326CYS (C → G),  
326*CYS/*CYS, 
326*SER/*SER 
OPRM1 opioid receptor, μ1    OPRM1 ASN40ASP (A118G), 
*ASP40, *ASN40 
P14ARF cyclin-dependent kinase 
inhibitor 2A (CDKN2A) 
P14 P14, P14ARF (the alternate 
reading frame products of 
CDKN2A gene)
  
P16 cyclin-dependent kinase 
inhibitor 2A (CDKN2A) 
P16INK4A P16, P16INK4A (the major 
product of CDKN2A gene)
  





P21, CDNK1A, CIP1, WAF1, 
SDI1
SER31ARG
P53 tumor suppressor     P53 ARG72PRO (G → C),  
72*ARG/*PRO, 
72*PRO/*PRO, *MSPI 
(INTRON 6), 16 bp 
insertion (INTRON 3)
P73 tumor protein gene 73 TP73 P73, TP73 *GC/*GC, *AT/*AT, 
*GC/*AT (G4A, C14T in 
EXON 2)
PARKIN Parkinson disease (autosomal 
recessive, juvenile) 2, parkin 
PARK2 PARKIN (ligase)   
PAX5 a paired box gene 5 BSAP (B-cell 
specific 
activator) a
PAX5 a (one of the products 
of PAX5 gene), BSAP (B-cell 
specific activator protein) a
  
PAX5 ß paired box gene 5 BSAP (B-cell 
specific 
activator) b
PAX b (one of the products 
of PAX5 gene), BSAP (B-cell 
specific activator protein) b
  
PCMVCAT a plasmid construct 
containing the reporter 
gene CAT (chloramphenicol 
acetyltransferase) driven 
by CMV (cytomegalovirus) 
promoter
   PCMVCAT, chloramphenicol 
acetyltransferase as a reporter
  




POLD1 polymerase (DNA directed), 
delta 1, catalytic subunit 
125kDa 
   POLD1 ARG19HIS (G → A), 
HIS119ARG (A → G), 




used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
PTEN phosphatase and tensin 
homolog 
   PTEN, deleted on 
chromosome 10
this gene may be deleted 
on chromosome 10 (10q23) 
with the development of 
cancers
RAD23B RAD23 homolog B 
(S. cerevisiae) 
   RAD23B, UV excision repair 
protein RAD23 homolog B, 
XP-C repair complementing 
protein
ALA249VAL (C → T)
RAD4 RAD4 gene of S. cerevisiae    RAD4, S. cerevisiae DNA 
damage recognition and 
repair protein
  
RAD50 RAD50 gene homolog  
(S. cerevisiae)
   RAD50 (human) ARG1111ILE (G3374T, 
cDNA)
RAD51 RAD51 homolog (S. cerevisiae)    RAD51   
RAD52 RAD52 homolog (S. cerevisiae)    RAD52
RAD54L RAD54 homolog (S. cerevisiae) S. cerevisiae 
RAD50 gene 
homolog
RAD54L ARG374SER (G1222C, 
cDNA)
RASSF1A Ras association (RalGDS/AF-6) 
domain family member 1 (A 
isoform) 
   RASSF1A   
RASSF2 Ras association (RalGDS/AF-6) 
domain family member 2 
   RASSF2   
RASSF4 Ras association (RalGDS/AF-6) 
domain family member 4 
   RASSF4, tumor suppressor 
protein
  
RB retinoblastoma 1 tumor 
suppressor 
RB1 RB, RB1   
SERPINA1 serpin peptidase inhibitor, 
clade A (a-1 antiproteinase, 
antitrypsin), member 1 
   SERPINA1, AAT protein *M, *S, *Z, *NULL
SERPINA3 serpin peptidase inhibitor, 
clade A (a-1 antiproteinase, 
antitrypsin), member 3 
   SERPINA3, ACT protein PRO229ALA, LEU55PRO, 
MET389VAL, ALA-
15THR (signal peptide), 
1258DELAA




A1013C, C1580T, A9306G, 
INTRON 4 variants, 
THR131ILE
STK11 serine/threonine kinase 11    STK11   
TDG thymine-DNA glycosylase    TDG   
TGFa transforming growth factor a    TGFa   
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Gene symbol 
used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
TGFß1 transforming growth factor b1     TGFb1 SNP RS1800469 
(C-509T, promoter), SNP 
RS2241712 (G-10807A, 
promoter), SNP RS6957 
(3’UTR), SNP RS224178 
(3’UTR), SNP RS1982073 
(T29C, LEU10PRO,  
EXON 1)
TGFß3 transforming growth factor b3    TGFb3   
TH tyrosine hydroxylase    TH VNTR
TIMP-3 tissue inhibitor of 
metalloproteinase 3  
   TIMP-3   
TNFa tumor necrosis factor (TNF 
superfamily, member 2) 
TNF TNFa, TNF TNF2 ( a promoter SNP, 
G-308A), SNPs G-376A and 
G-238A (promoter), 
G489A (INTRON), 
SNP RS3091257 (3’UTR), 
SNP RS769178 (3’UTR)
TP thymidine phosphorylase    TP   
TPH tryptophan hydroxylase TPH1 TPH, TPH1 C218A, A779C
TP53 tumor protein    TP53   
TRAIL-R1 TNF-related apoptosis inducing 
ligand receptor 1 
TNFRSF10A TRAIL-R1, TNFRSF10A, 
death receptor 4
  
UGT1A UDP glucuronosyltransferase 1 
family, polypeptide A1
   UGT1A   
XPC xeroderma pigmentosum, 
complementation group C 
XPCC, XP3 XPC, XPCC, XP3 ALA499VAL (C → T), 
LYS939GLN (A → C), 
*PAT (poly AT ins/del 
polymorphism)
XPD xeroderma pigmentosum, 
complementation group D 
ERCC2 XPD, ERCC2 ASP312ASN (G → A, 312 
*G/*A), LYS751GLN  
(A → C, 751 *A/*C)
XPF xeroderma pigmentosum, 
complementation group F
ERCC4 XPF, ERCC4 SER662PRO (T → C), 
ARG415GLN (G1244A, 
EXON 8 SNP RS1800067), 
SER835SER (T2505C, 
EXON 11 SNP RS1799801)
XPG xeroderma pigmentosum, 
complementation group G 
ERCC5 XPG, ERCC5 HIS1104ASP (G3507C, 
SNP RS17655), HIS46HIS 






used in this 
report Definition
Alternative 
gene symbol Related protein/enzyme
Polymorphism/variant 
genotype
XPV polymerase (DNA directed) eta  POLH XPV POLH, human DNA 
polymerase h 
  
XRCC1 x-ray repair complementing 
defective repair in Chinese 
hamster cells 1 
    XRCC1 ARG194TRP (C → T), 
ARG280HIS (G → A), 
ARG399GLN (G → A)
XRCC2 x-ray repair complementing 
defective repair in Chinese 
hamster cells 2
   XRCC2   
XRCC3 x-ray repair complementing 
defective repair in Chinese 
hamster cells 3 
   XRCC3 THR241MET (T → C)
XRCC4 x-ray repair complementing 
defective repair in Chinese 
hamster cells 4 
   XRCC4 ALA247SER (G → T)
XRCC5 x-ray repair complementing 
defective repair in Chinese 
hamster cells 5 (double-strand-
break rejoining)
KU80 XRCC5, KU80   
XRCC6 x-ray repair complementing 
defective repair in Chinese 
hamster cells 6
KU70 XRCC6, KU70   
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